array(1010) { [0]=> object(stdClass)#63 (35) { ["journals_id"]=> string(3) "532" ["journals_xml"]=> string(0) "" ["journals_volume"]=> string(2) "15" ["journals_issue"]=> string(7) "Archive" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(0) "" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(10) "bm-archive" ["journals_article_id_doi"]=> string(4) "none" ["journals_article_pubdate"]=> string(10) "2005-02-15" ["journals_article_title"]=> string(19) "Archive (1991-2005)" ["journals_article_author"]=> string(0) "" ["journals_article_author_country"]=> string(0) "" ["journals_article_categories_heading"]=> string(15) "Original papers" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(0) "" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3875" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(190) "

Old issues of Biochemia Medica can be accessed here

" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(11) "CC-BY-NC-ND" ["vrstni"]=> string(1) "0" ["meta_title"]=> string(0) "" ["meta_desc"]=> string(0) "" ["meta_keyw"]=> string(0) "" ["created"]=> string(19) "2018-08-07 08:13:15" ["modified"]=> string(19) "2018-08-07 08:14:52" } [1]=> object(stdClass)#62 (35) { ["journals_id"]=> string(4) "1273" ["journals_xml"]=> string(0) "" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(6) "Suppl1" ["journals_fpage"]=> string(2) "S1" ["journals_lpage"]=> string(4) "S193" ["journals_elocationID"]=> string(0) "" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(10) "bm-36-supl" ["journals_article_id_doi"]=> string(4) "none" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(118) "12th Congress of the Croatian Society of Medical Biochemistry and Laboratory Medicine with international participation" ["journals_article_author"]=> string(0) "" ["journals_article_author_country"]=> string(0) "" ["journals_article_categories_heading"]=> string(19) "Symposium abstracts" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(0) "" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(3) "886" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(10384) "

Biochemia Medica

THE JOURNAL OF CROATIAN SOCIETY FOR MEDICAL BIOCHEMISTRY AND LABORATORY MEDICINE

ČASOPIS HRVATSKOG DRUŠTVA ZA MEDICINSKU BIOKEMIJU I LABORATORIJSKU MEDICINU

UDC 577.1      ISSN 1849-820

 

12th Congress of the Croatian Society of Medical Biochemistry and  Laboratory Medicine with international participation

October 15-18, 2026 Srebreno, Croatia

Organizer

 Croatian Society of Medical Biochemistry and Laboratory Medicine

 

Auspices

President of the Republic of Croatia

International Federation of Clinical Chemistry and Laboratory Medicine – IFCC

European Federation of Clinical Chemistry and Laboratory Medicine – EFLM

Ministry of Science, Education and Youth Of the Republic of Croatia

Ministry of Health of the Republic of Croatia

 University of Zagreb

 Faculty of Pharmacy and Biochemistry

 

Scientific Committee

Jasenka Wagner Kostadinović, president

Tanja Antunović

Ivana Ćelap

Željko Debeljak

Adrijana Dorotić

Mila Lovrić

Ivanka Mikulić

Marija Milić

Vanja Radišić Biljak

 

Organizing Committee

 Ivana Lapić, president

 Andrea Čeri

 Josipa Kuleš

 Marina Njire Bratičević

 Vladimira Rimac

 

Congress Secretariat

 Jasna Đogić, secretary

 Croatian Society of Medical Biochemistry and Laboratory Medicine

 Boškovićeva 18

10000 Zagreb, Croatia

tel/fax: +385 1 48 28 133

Contents

 Pre-congress symposium 

 Artificial intelligence in laboratory medicine

 PCS-1 From text to tables: using large language models-generated structured outputs to answer scientific questions - 5

 PCS-2 The 21st century biochemist: how practical AI applications improve and simplify laboratory work - 6

 PCS-3 Large language models-based clinical decision support - 7

 PCS-4 False discovery rate corrections in routine laboratory diagnostics and biomarker discovery  - 8

 PCS-5 Deep learning-based classification of urinary sediment particles - 9

 PCS-6 Single-cell analysis via machine and statistical learning of mass spectrometry images - 10

 

Honorary lecture 

Biochemistry and the philosophy of man - 11

 

Plenary lectures 

PL-1 Research vs. clinical laboratory methods and regulations: understanding the key differences - 12

PL-2 Medical biochemist in the educational system - 13

PL-3 Genetics and epigenetics: where are we today in translational research and clinical application - 14

 

Symposium lectures 

 S1 Life-threatening bleeding: diagnosis and contemporary management - 15

 S2 Modern approach to therapeutic drug monitoring - 19

 S3 Allergic diseases – pandemics of the future  - 23

 S4 Women in sports – a multidisciplinary challenge - 27

 S5 MicroRNA in germ cell tumors– joint symposium with Horizon Project Attract Adria  - 31

 

 Working groups sessions 

 WG-1 Symposium of the Working group for laboratory hematology  - 35

 WG-2 Symposium of the Working group for laboratory endocrinology -  36

 WG-3 Symposium of the Working group for tumor markers  - 37

 

Poster abstract

A Hematology -  39

B Hemostasis - 60

C Cardiovascular diseases  -67

D Endocrinology and bone diseases - 70

F Autoimmune diseases - 79

H Pediatric laboratory medicine - 84

I Laboratory toxicology - 90

J Molecular diagnostics  - 95

K Point-of-care testing  - 111

L Sports medicine  - 115

M New biomarkers - 121

N New technologies - 126

O Case report - 130

P Pre- and postanalytical phase of laboratory work  -143

R Biostatistics - 160

S Laboratory management - 163

T Method and test validation - 167

U Other - 188

" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "0" ["meta_title"]=> string(0) "" ["meta_desc"]=> string(0) "" ["meta_keyw"]=> string(0) "" ["created"]=> string(19) "2026-10-08 14:06:48" ["modified"]=> string(19) "2026-10-08 14:20:05" } [2]=> object(stdClass)#61 (35) { ["journals_id"]=> string(4) "1225" ["journals_xml"]=> string(0) "" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(0) "" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(7) "bm-36-r" ["journals_article_id_doi"]=> string(4) "none" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(17) "List of reviewers" ["journals_article_author"]=> string(0) "" ["journals_article_author_country"]=> string(0) "" ["journals_article_categories_heading"]=> string(38) "Index of authors and list of reviewers" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(0) "" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2115" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(10774) "

List of reviewers

The Editorial Board would like to thank the reviewers for their critical assessment of the manuscripts submitted to Biochemia Medica in 2025.

 A

 Ab Rahim Siti Nadirah (Malaysia)

 Adeli Khosrow (Canada)

 Anžej Doma Saša (Slovenia)

 B

 Badrick Tony (Australia)

 Barbir Rinea (Germany)

 Baršić Lapić Ivana (Croatia)

 Bartakova Vendula (Czech Republic)

 Bayat Hassan (Iran)

 Block Darci (United States)

 Boehm Emma (Australia)

 Bokulic Adriana (Croatia)

 Bozic Mojca (Slovenia)

 Buchta Cristoph (Austria)

 C

 Cacic Melita (Denmark)

 Cavalier Etienne (Belgium)

 Ciaccio Marcello (Italy)

 Coen Herak Desiree (Croatia)

 Çolak Samsum Emel (Türkiye)

 Cornes Michael (United Kingdom)

 Coskun Abdurrahman (Türkiye)

 Coucke Wim (Belgium)

 Crnogorac Matija (Croatia)

 Çuhadar Serap (Türkiye)

 Cuk Ana (Bosnia and Herzegovina)

 D

 Daves Massimo (Italy)

 de Geus-Bosma Madeleen (The Netherlands)

 Debeljak Zeljko (Croatia)

 Dobreanu Minodora (Romania)

 Dolci Alberto (Italy)

 Dorizzi Romolo M(Italy)

 F

 Freidkin Lev (Israel)

 G

 Grankvist Kjell (Sweden)

 Grdic Rajkovic Marija (Croatia)

 Grgurevic Ivica (Croatia)

 Guzonjić Azra (Serbia)

 H

 Hayden Joshua (United States)

 I

 Ialongo Cristiano (Italy)

 J

 Jadric Radivoj (Bosnia and Herzegovina)

 Jalavu Thumeka (South Africa)

 Jokic Anja (Croatia)

 Jones Graham (Australia)

 Jovicic Snezana (Serbia)

 Juricic Gordana (Croatia)

 K

 Kajic Matekovic Katarina (Croatia)

 Kallner Anders (Sweden)

 Karlovic Dalibor (Croatia)

 Kalinic Darko (Croatia)

 Khine Aye-Aye (South Africa)

 Klarić Thomas Stephen (Croatia)

 Kocijan Irena (Croatia)

 Kocijancic Marija (Germany)

 Kotur-Stevuljevic Jelena (Serbia)

 Kozmar Ana (Croatia)

 L

 Lapic Ivana (Croatia)

 Lee Sun Min (Korea)

 Lenicek Krleza Jasna (Croatia)

 Lippi Giuseppe (Italy)

 Loh Tze Ping (Singapore)

 M

 Mandic Sanja (Croatia)

 Margetic Sandra (Croatia)

 Marijancevic Domagoj (Croatia)

 Matovinović Martina (Croatia)

 Miler Marijana (Croatia)

 Milevoj Kopcinovic Lara (Croatia)

 Muck Seler Dorotea (Croatia)

 N

 Nikler Ana (Croatia)

 Nikolac Gabaj Nora (Croatia)

 Nożewski Jakub (Poland)

 Njire Braticevic Marina (Croatia)

 O

 Omazic Jelena (Croatia)

 Oosterhuis Wytze P. (Netherlands)

 Oprea Oana Roxana (Romania)

 P

 Palicka Vladimir (Czech Republic)

 Pasalic Daria (Croatia)

 Pereira Paulo (Portugal)

 Perica Dražen (Croatia)

 Perovic Antonija (Croatia)

 Perovic Edi (Croatia)

 Podgornik Helena (Slovenia)

 Potocki Slavica (Croatia)

 R

 Radisic Biljak Vanja (Croatia)

 Radman Anita (Croatia)

 Rajdl Daniel (Czech Republic)

 Rodríguez-Romero Brenda Ivonn (Mexico)

 Rolić Tara (Croatia)

 S

 Sáenz-Flor Klever Vinicio (Ecuador)

 Senes Mehmet (Türkiye)

 Serdar Muhittin A. (Türkiye)

 Sharma Hariom (India)

 Sieminski Mariusz (Poland)

 Sonntag Oswald (Germany)

 Sonsok Sirawich (Thailand)

 Stankov Karmen (Serbia)

 Stefańska Anna (Poland)

 Stonys Ricardas (Lithuania)

 Supak Smolcic Vesna (Croatia)

 Supraha Goreta Sandra (Croatia)

 Szewczyk-Golec Karolina (Poland)

 Š

 Šegulja Dragana (Croatia)

 Štefanović Mario (Croatia)

T

 Thelan Marc (The Netherlands)

 Turčić Ana (Croatia)

 Turudić Daniel (Croatia)

 U

 Unić Adriana (Croatia)

 V 

Vanstapel Florent (Belgium)

Vekić Jelena (Serbia)

Vermeersch Pieter (Belgium)

Vidali Matteo (Italy)

Vogrinc Zeljka (Croatia)

 von Meyer Alexander (Germany)

 Vrtaric Alen (Croatia)

 Vujaklija Brajkovic Ana (Croatia)

 W

 Wan Azman Wan Norlina (Malaysia)

 Wan Nik Wan Nor Fazila Hafizan (Malaysia)

 Weicheng Xu (The Netherlands)

 Wosniok Werner (Germany)

Y

Yucel Dogan (Türkiye)

Z

Zec Ivana (Croatia

 

 

 

" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "17" ["meta_title"]=> string(0) "" ["meta_desc"]=> string(0) "" ["meta_keyw"]=> string(0) "" ["created"]=> string(19) "2026-03-06 13:19:18" ["modified"]=> string(19) "2026-03-06 13:26:34" } [3]=> object(stdClass)#60 (35) { ["journals_id"]=> string(4) "1226" ["journals_xml"]=> string(0) "" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(0) "" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(7) "bm-36-r" ["journals_article_id_doi"]=> string(4) "none" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(16) "Index of authors" ["journals_article_author"]=> string(0) "" ["journals_article_author_country"]=> string(0) "" ["journals_article_categories_heading"]=> string(38) "Index of authors and list of reviewers" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(0) "" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2050" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(24433) "

Index of authors

Index of authors in Biochemia Medica journal in 2025

 

 A

 Andrasic P Biochem Med (Zagreb) 2025;35(1):011002

 Alegre E Biochem Med (Zagreb) 2025;35(2):020802

 Antonic T Biochem Med (Zagreb) 2025;35(1):010708

 Aparicio-Pelaz D Biochem Med (Zagreb) 2025;35(2):020707

 Arbiol-Roca A Biochem Med (Zagreb) 2025;35(1):010705

 Ardalic D Biochem Med (Zagreb) 2025;35(1):010708

 B

 Banjari I Biochem Med (Zagreb) 2025:35(3):030703

 Bao G Biochem Med (Zagreb) 2025;35(2):020702

 Bayat H Biochem Med (Zagreb) 2025;35(2):020401

 Begolli G Biochem Med (Zagreb) 2025;35(1):010702, Biochem Med (Zagreb) 2025;35(1):011201

 Blanco-Vaca F Biochem Med (Zagreb) 2025:35(3):030704

 Bobetić-Vranić T Biochem Med (Zagreb) 2025;35(1):010703

 Bokulić A Biochem Med (Zagreb) 2025;35(3):030505

 Božović M Biochem Med (Zagreb) 2025;35(1):010707

 Busquets-Carmona N Biochem Med (Zagreb) 2025;35(2):020703

 C

 Cano-Corres R Biochem Med (Zagreb) 2025;35(2):020703

 Canyelles M Biochem Med (Zagreb) 2025:35(3):030704

 Chen SY Biochem Med (Zagreb) 2025;35(3):031002

 Cho E Biochem Med (Zagreb) 2025;35(1):010704

 Chou CY Biochem Med (Zagreb) 2025;35(3):031002

 Chung J Biochem Med (Zagreb) 2025;35(1):010704

 Claeyssens C Biochem Med (Zagreb) 2025;35(2):020901

 Cortes-Bosch de Basea A Biochem Med (Zagreb) 2025;35(1):010705

 Costa-Pallaruelo M Biochem Med (Zagreb) 2025:35(3):030704

 Cristelli L Biochem Med (Zagreb) 2025;35(1):010701

 Č

Čepelak I Biochem Med (Zagreb) 2025;35(1):010501, Biochem Med (Zagreb) 2025;35(2):020501

 Čeprnja M Biochem Med (Zagreb) 2025;35(1):010703

 Černiauskas L Biochem Med (Zagreb) 2025;35(3):030506

 Čorak L Biochem Med (Zagreb) 2025;35(1):010702, Biochem Med  (Zagreb) 2025;35(1):011201

 Ć

 Ćeriman Krstić V Biochem Med (Zagreb) 2025;35(2):020705

 D

 Daves M Biochem Med (Zagreb) 2025;35(1):010701

 de Koster J Biochem Med (Zagreb) 2025;35(2):020901

 De Luisi A Biochem Med (Zagreb) 2025;35(1):010701

 Debeljak Ž Biochem Med (Zagreb) 2025;35(1):010702, Biochem Med (Zagreb) 2025;35(1):011201

 Demet Arslan F Biochem Med (Zagreb) 2025;35(1):010706

 Denimal D Biochem Med (Zagreb) 2025;35(1):010502

 Dib A Biochem Med (Zagreb) 2025;35(1):010502

 Ding W Biochem Med (Zagreb) 2025;35(2):020801

 Distante S Biochem Med (Zagreb) 2025:35(3):030703

 Dodig M Biochem Med (Zagreb) 2025;35(1):010501

 Dodig S Biochem Med (Zagreb) 2025;35(1):010501, Biochem Med  (Zagreb) 2025;35(2):020501

 Dot-Bach D Biochem Med (Zagreb) 2025;35(1):010705

 Dragila Ž Biochem Med (Zagreb) 2025;35(3):030504

 Drvar V Biochem Med (Zagreb) 2025;35(2):020706

 Duvillard L Biochem Med (Zagreb) 2025;35(1):010502

 Đ

 Đerek L Biochem Med (Zagreb) 2025;35(2):020706, Biochem Med  (Zagreb) 2025;35(2):021001

 Đuras A Biochem Med (Zagreb) 2025;35(3):030505

 Đurić K Biochem Med (Zagreb) 2025;35(1):010703, Biochem Med  (Zagreb) 2025;35(3):030505

 E

 Er TK Biochem Med (Zagreb) 2025;35(3):031002

 Ercan Ş Biochem Med (Zagreb) 2025;35(2):020704

 Erika J Biochem Med (Zagreb) 2025;35(1):010701

 Escribano-Tembleque R Biochem Med (Zagreb) 2025;35(2):020703

 F

 Fabre M Biochem Med (Zagreb) 2025;35(2):020707

 Ferenac Kiš M Biochem Med (Zagreb) 2025:35(3):030703

 Ferrer-Perez R Biochem Med (Zagreb) 2025:35(3):030704

 Friščić I Biochem Med (Zagreb) 2025;35(1):011001

 G

 García-Miralles C Biochem Med (Zagreb) 2025;35(2):020703

 García-Osuna A Biochem Med (Zagreb) 2025:35(3):030704

 Gojkovic T Biochem Med (Zagreb) 2025;35(1):010708

 González A Biochem Med (Zagreb) 2025;35(2):020802

 Goreta S Biochem Med (Zagreb) 2025;35(3):030505

 Gugo K Biochem Med (Zagreb) 2025;35(2):020706

 Guiñón L Biochem Med (Zagreb) 2025:35(3):030704

 Guo K Biochem Med (Zagreb) 2025;35(3):030901

 Guzonjić A Biochem Med (Zagreb) 2025;35(2):020705

 Gvozdanović L Biochem Med (Zagreb) 2025;35(3):030504

 

H

 Habibzadeh F Biochem Med (Zagreb) 2025;35(1):010101

 Honović L Biochem Med (Zagreb) 2025;35(1):010503

 Hu G Biochem Med (Zagreb) 2025;35(3):030901

 Hu Y Biochem Med (Zagreb) 2025;35(2):020801

 I

 Ialongo C Biochem Med (Zagreb) 2025;35(2):020701, Biochem Med  (Zagreb) 2025;35(3):030501

 Imširović I Biochem Med (Zagreb) 2025;35(2):021001

 Ivanisevic J Biochem Med (Zagreb) 2025;35(1):010708

 J

 Jakopović M Biochem Med (Zagreb) 2025;35(1):010702, Biochem  Med (Zagreb) 2025;35(1):011201

 Jakšić Jurinjak S Biochem Med (Zagreb) 2025;35(2):021001

 Jani E Biochem Med (Zagreb) 2025;35(1):010701

 Jelisavac Ćosić S Biochem Med (Zagreb) 2025;35(3):030505

 Jeras J Biochem Med (Zagreb) 2025;35(3):030503

 Jerković Raguž M Biochem Med (Zagreb) 2025;35(3):030702

 Jokić A Biochem Med (Zagreb) 2025;35(1):010503

 Jovanović D Biochem Med (Zagreb) 2025;35(2):020705

 Jovicic S Biochem Med (Zagreb) 2025;35(1):010708

 Jukić T Biochem Med (Zagreb) 2025;35(1):010703

 K

Kačkov S Biochem Med (Zagreb) 2025;35(2):021001

Karčiauskaitė D Biochem Med (Zagreb) 2025;35(3):030506

Kardum Paro MM Biochem Med (Zagreb) 2025;35(1):011001

Karlović H Biochem Med (Zagreb) 2025;35(3):030702

Kim S Biochem Med (Zagreb) 2025;35(1):010704

Klapan D Biochem Med (Zagreb) 2025;35(3):030504

Klhůfek J Biochem Med (Zagreb) 2025;35(3):030902

Knežević J Biochem Med (Zagreb) 2025;35(1):010702, Biochem Med (Zagreb) 2025;35(1):011201

Kocijančić M Biochem Med (Zagreb) 2025;35(3):030505

Köseoğlu M Biochem Med (Zagreb) 2025;35(1):010706

Kotur Stevuljević J Biochem Med (Zagreb) 2025;35(2):020705

Kozmar A Biochem Med (Zagreb) 2025;35(2):020706

Kraljević Šmalcelj M Biochem Med (Zagreb) 2025;35(1):010703

 L

Ladika Davidović B Biochem Med (Zagreb) 2025;35(3):030701

Lapić I Biochem Med (Zagreb) 2025;35(2):021001

Lazić A Biochem Med (Zagreb) 2025;35(2):020502

Leleu D Biochem Med (Zagreb) 2025;35(1):010502 Lemaire S Biochem Med (Zagreb) 2025;35(1):010502

Lenicek Krleza J Biochem Med (Zagreb) 2025;35(1):010503, Biochem Med (Zagreb) 2025;35(1):011002

Levtchenko E Biochem Med (Zagreb) 2025;35(2):020901 Li J Biochem Med (Zagreb) 2025;35(2):020702

Li C Biochem Med (Zagreb) 2025;35(3):030506

Lu KC Biochem Med (Zagreb) 2025;35(3):030502

Lu CL Biochem Med (Zagreb) 2025;35(3):030502

Lukić M Biochem Med (Zagreb) 2025;35(1):010702, Biochem Med  (Zagreb) 2025;35(1):011201

Lukić I Biochem Med (Zagreb) 2025;35(3):030505

 M

Ma C Biochem Med (Zagreb) 2025;35(2):020801

Madurga A Biochem Med (Zagreb) 2025;35(1):010705

Manav A Biochem Med (Zagreb) 2025;35(2):020704

Mandić S Biochem Med (Zagreb) 2025:35(3):030703

Marc J Biochem Med (Zagreb) 2025;35(2):020705

Marijančević D Biochem Med (Zagreb) 2025;35(3):030505

Markeljević J Biochem Med (Zagreb) 2025;35(3):030701

Maršić L Biochem Med (Zagreb) 2025;35(3):030504

Martínez-Bru C Biochem Med (Zagreb) 2025:35(3):030704 

Martínez-Sevilla E Biochem Med (Zagreb) 2025;35(2):020703

Mazgelytė E Biochem Med (Zagreb) 2025;35(3):030506

 Ménégaut L Biochem Med (Zagreb) 2025;35(1):010502

 Mihaljević Z Biochem Med (Zagreb) 2025;35(3):030504

 Mikovic Z Biochem Med (Zagreb) 2025;35(1):010708

 Mikulić I Biochem Med (Zagreb) 2025;35(3):030702

 Mikulić V Biochem Med (Zagreb) 2025;35(3):030702

 Miler M Biochem Med (Zagreb) 2025;35(1):010707

 Milevoj Kopčinović L Biochem Med (Zagreb) 2025;35(1):010707

 Miljkovic-Trailovic M Biochem Med (Zagreb) 2025;35(1):010708

 Mrsić F Biochem Med (Zagreb) 2025;35(3):030701

 Muñoz T Biochem Med (Zagreb) 2025;35(2):020802

 Munjas J Biochem Med (Zagreb) 2025;35(1):010708

 Musil P Biochem Med (Zagreb) 2025;35(3):031001

 N

 Nan N Biochem Med (Zagreb) 2025:35(3):030704

 Navarro-Badal MR Biochem Med (Zagreb) 2025;35(1):010705

 Nesek-Adam V Biochem Med (Zagreb) 2025;35(3):030504

 Nikler A Biochem Med (Zagreb) 2025;35(2):020502

 Nikolac Gabaj N Biochem Med (Zagreb) 2025;35(1):010707

 O

Occhipinti F Biochem Med (Zagreb) 2025;35(1):010701

Ostanek B Biochem Med (Zagreb) 2025;35(2):020705

Özkanay H Biochem Med (Zagreb) 2025;35(1):010706

 P

 Pavić I Biochem Med (Zagreb) 2025;35(1):011002, Biochem Med  (Zagreb) 2025;35(2):020501

 Pekas D Biochem Med (Zagreb) 2025;35(2):020502

 Perales-Afán JJ Biochem Med (Zagreb) 2025;35(2):020707

 Perkov S Biochem Med (Zagreb) 2025;35(1):011001

 Pezo A Biochem Med (Zagreb) 2025;35(3):030505

 Podolar S Biochem Med (Zagreb) 2025;35(1):010503

 Pšenčík M Biochem Med (Zagreb) 2025;35(3):030902

 Puente-Lanzarote JJ Biochem Med (Zagreb) 2025;35(2):020707

 

Q

 Qiu L Biochem Med (Zagreb) 2025;35(2):020801

 R

Radišić Biljak V Biochem Med (Zagreb) 2025;35(2):020502

Radman A Biochem Med (Zagreb) 2025;35(1):010707

Rimac V Biochem Med (Zagreb) 2025;35(1):010503 

Rogić D Biochem Med (Zagreb) 2025;35(2):021001

Rolić T Biochem Med (Zagreb) 2025:35(3):030703

Ruiz L Biochem Med (Zagreb) 2025;35(2):020802

Rumora L Biochem Med (Zagreb) 2025;35(1):010702, Biochem Med  (Zagreb) 2025;35(1):011201

 S

Samardzić N Biochem Med (Zagreb) 2025;35(2):020705

Samardžić J Biochem Med (Zagreb) 2025;35(3):030504

Samaržija M Biochem Med (Zagreb) 2025;35(1):010702, Biochem Med (Zagreb) 2025;35(1):011201

Saračević A Biochem Med (Zagreb) 2025;35(2):020502

Saric-Matutinovic M Biochem Med (Zagreb) 2025;35(1):010708

Segers H Biochem Med (Zagreb) 2025;35(2):020901

Serdar Hiršl T Biochem Med (Zagreb) 2025;35(1):010703, Biochem  Med (Zagreb) 2025;35(3):030505

Shin S Biochem Med (Zagreb) 2025;35(1):010704

Simić I Biochem Med (Zagreb) 2025;35(2):020705

Siter Kuprešanin M Biochem Med (Zagreb) 2025;35(3):030505

Smaić F Biochem Med (Zagreb) 2025;35(2):021001

Solé-Enrech G Biochem Med (Zagreb) 2025;35(2):020703

Somborac-Bačura A Biochem Med (Zagreb) 2025;35(1):010703

Sopić M Biochem Med (Zagreb) 2025;35(2):020705

Stanišić L Biochem Med (Zagreb) 2025;35(3):030505

Stefanović A Biochem Med (Zagreb) 2025;35(1):010708

 Š

Šálek T Biochem Med (Zagreb) 2025;35(3):030902, Biochem Med (Zagreb) 2025;35(3):031001

Šarić-Matutinović M Biochem Med (Zagreb) 2025;35(1):010708

Šebeštjen M Biochem Med (Zagreb) 2025;35(3):030503

Šegulja D Biochem Med (Zagreb) 2025;35(2):021001

Šupe-Domić D Biochem Med (Zagreb) 2025;35(3):030505

T

Tešija Kuna A Biochem Med (Zagreb) 2025;35(2):020706, Biochem Med (Zagreb) 2025;35(3):030701

Tomaš I Biochem Med (Zagreb) 2025;35(1):010702, Biochem Med (Zagreb) 2025;35(1):011201

Tomić V Biochem Med (Zagreb) 2025;35(3):030702

Tomić Sremec N Biochem Med (Zagreb) 2025;35(2):020706

Trajković N Biochem Med (Zagreb) 2025;35(2):020502

Tsai KW Biochem Med (Zagreb) 2025;35(3):030502

Tseng Y Biochem Med (Zagreb) 2025;35(3):031002

Tumiatti D Biochem Med (Zagreb) 2025;35(1):010701

 U

 Ugovšek S Biochem Med (Zagreb) 2025;35(3):030503

 Unić A Biochem Med (Zagreb) 2025;35(1):010707

 V

 Vekic J Biochem Med (Zagreb) 2025;35(1):010708

 Vermeersch P Biochem Med (Zagreb) 2025;35(2):020901

 Vladimirov S Biochem Med (Zagreb) 2025;35(1):010708

 Vlašić Tanasković J Biochem Med (Zagreb) 2025;35(1):010503

 Vodička M Biochem Med (Zagreb) 2025;35(3):030902

 Vogrinc Ž Biochem Med (Zagreb) 2025;35(2):021001

 Vrtarić A Biochem Med (Zagreb) 2025;35(1):010707

 Vukasović I Biochem Med (Zagreb) 2025;35(3):030701

 Vukić Dugac A Biochem Med (Zagreb) 2025;35(1):010702, Biochem Med (Zagreb) 2025;35(1):011201

 W

 Wang J Biochem Med (Zagreb) 2025;35(3):030502

 Wayne Jones A Biochem Med (Zagreb) 2025;35(3):030501

 Westgard S Biochem Med (Zagreb) 2025;35(2):020401

 Witters P Biochem Med (Zagreb) 2025;35(2):020901

 X

Xia L Biochem Med (Zagreb) 2025;35(2):020801

Xu L Biochem Med (Zagreb) 2025;35(3):030901

Y

Yazdani M Biochem Med (Zagreb) 2025:35(3):030703

Yeh CC Biochem Med (Zagreb) 2025;35(3):031002

Yıldız R Biochem Med (Zagreb) 2025;35(1):010706

Yoo S Biochem Med (Zagreb) 2025;35(1):010704

Yu S Biochem Med (Zagreb) 2025;35(1):010704

Z

Zec I Biochem Med (Zagreb) 2025;35(1):010703, Biochem Med  (Zagreb) 2025;35(3):030505

Zeljkovic A Biochem Med (Zagreb) 2025;35(1):010708

Zhang Q Biochem Med (Zagreb) 2025;35(2):020801

Zlatníková I Biochem Med (Zagreb) 2025;35(3):031001

Zrinski Topić R Biochem Med (Zagreb) 2025;35(1):011002

Zupan J Biochem Med (Zagreb) 2025;35(3):030503

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "16" ["meta_title"]=> string(0) "" ["meta_desc"]=> string(0) "" ["meta_keyw"]=> string(0) "" ["created"]=> string(19) "2026-03-06 13:28:40" ["modified"]=> string(19) "2026-03-06 13:43:03" } [4]=> object(stdClass)#59 (35) { ["journals_id"]=> string(4) "1261" ["journals_xml"]=> string(27723) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-031001 10.11613/BM.2026.031001 Preanalytical mysteries Spurious life-threatening hypermagnesemia caused by a preanalytical error in an intensive care unit: a case report RolićTara12PavlićInja*12SarićIvana12 Faculty of Medicine, University of Osijek, Osijek, Croatia Institute of Clinical Laboratory Diagnostics, Osijek University Hospital Centre, Osijek, Croatia Corresponding author: pavlicinja@gmail.com

Author contributions

T Rolić: Conceptualization, Writing; I Pavlić: Conceptualization, Writing, Visualisation; I Sarić: Writing, Supervision, Writing - review and editing.

10082026 15102026 36 3 031001 2801202628062026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Spurious hypermagnesemia from preanalytical error

• Blood drawn during ongoing magnesium infusion

• Critical values discordant with clinical condition

• Repeat sampling resolved the diagnostic dilemma

• Communication prevents inappropriate patient treatment

Accurate measurement of electrolytes is essential in critically ill patients. Magnesium (Mg) concentrations are particularly vulnerable to preanalytical errors, which may lead to life-threatening misinterpretation. A 57-year-old woman was admitted to the intensive care unit (ICU) due to acute decompensated heart failure and atrial fibrillation. On the second day of ICU hospitalization, serum samples analyzed in the emergency laboratory revealed critically low sodium (Na), potassium (K), and chloride (Cl) concentrations, accompanied by extremely elevated Mg concentrations that were considered incompatible with life. Given the discrepancy between life-threateningly high Mg concentrations and the patient’s stable clinical condition, as confirmed by clinicians, who reported no signs of hyporeflexia, respiratory depression, or other symptoms of Mg toxicity, the laboratory medicine professional (LMP) initiated urgent communication with the clinical staff and recommended repeating the blood draw and all analyses. A reflex glucose measurement revealed a markedly elevated concentration (55.4 mmol/L), indicating contamination with a glucose infusion. The repeated analysis showed Mg and other electrolyte concentrations within reference ranges. Further investigation confirmed that blood sampling had been performed from the same arm and venous catheter through which infusion was being administered. The abnormal laboratory findings were explained by a preanalytical error caused by blood sampling during active infusion. This case emphasizes the importance of appropriate documentation of ongoing intravenous therapy and blood sampling conditions, as well as communication between the LMP and clinical staff. Awareness of preanalytical variables is essential to prevent misinterpretation of laboratory results and inappropriate patient treatment.

Keywords: case reporthypermagnesemiapreanalytical errorsample re-collectionelectrolyte imbalance
Introduction

Errors in the preanalytical phase, which encompasses the whole period including test ordering, patient preparation, specimen collection, handling, transport, and processing, represent the largest source of laboratory inaccuracies and have been reported to account for over 60% of total testing errors (1). Such errors can lead to spurious test results that, if unrecognized, may provoke inappropriate clinical decisions or unnecessary interventions.

Accurate laboratory measurement and interpretation of serum electrolytes, including calcium (Ca) and magnesium (Mg), are essential in the management of critically ill patients, particularly those admitted to intensive care units (ICUs). Electrolyte disturbances are frequent in this population and have direct implications for hemodynamic stability, cardiac rhythm, neuromuscular function, and overall prognosis. Consequently, laboratory medicine professionals (LMP) must ensure that reported laboratory values are both analytically and clinically valid and must exercise particular vigilance when critical values are detected.

Magnesium plays a pivotal, but often underappreciated role in many physiological processes, including its role as one of the major intracellular cations, particularly in muscle and skeletal cells, as well as in cardiac conduction, vascular tone regulation, ion channel function, and numerous enzymatic processes (2, 3). Hypermagnesemia, defined as a serum Mg concentration above the reference interval, is relatively uncommon and may be found in diabetic acidosis, Addison’s disease, atherosclerosis, oxalate poisoning, antacid use, and especially in chronic renal failure, or iatrogenically, through Mg-containing infusions (4). However, spurious hypermagnesemia may arise from preanalytical issues such as sample collection timing relative to intravenous fluid administration, sample contamination, or inadvertent inclusion of samples drawn during Mg infusion (2).

Given these considerations, accurate documentation of specimen collection time and clinical context is crucial; failure to do so may result in misinterpretation of laboratory results and subsequent errors in clinical interpretation and patient management.

Case presentation

A 57-year-old female was admitted to the Osijek University Hospital Centre at the Emergency Department in January 2026 for acute decompensated heart failure with atrial fibrillation. Due to the need for continuous monitoring and advanced cardiac care, she was transferred to the cardiology ICU during the night following admission. On the following day in the ICU, a blood specimen was collected by ICU clinical staff according to routine ward procedures for evaluation of serum electrolyte status, including Ca and Mg. The sample was received in the Institute of Clinical Laboratory Diagnostics at the Department for Emergency Laboratory Medicine at 12:00 h with a request for an electrolyte panel including Ca and Mg measurements. The requisition form documented the time of sample receipt but did not clarify the exact time of phlebotomy or whether any intravenous infusions were ongoing at the time of sampling.

Laboratory analysis revealed critical elevations in Mg, which were immediately communicated to the attending clinical staff according to national recommendations for critical value reporting. All assay results are summarized in Table 1.

Measured electrolyte, calcium, and magnesium concentrations in initial and repeated patient serum samples
Analyte Concentration at sample admission(mmol/L)(12.00 h) Critical value Reference interval (mmol/L) Re-sampling(mmol/L)(13.30 h)
Mg 21.52 > 2.00 0.65-1.05 0.98
Ca 2.38 > 3.50 2.14-2.53 2.43
Na 108 < 120 137-146 139
K 2.5 < 2.8 3.9-5.1 2.9
Cl 73 < 75 97-108 97
Mg - magnesium. Ca - calcium. Na - sodium. K - potassium. Cl - chloride.
Laboratory analyses

Venous blood samples were collected according to routine clinical practice and processed in accordance with national laboratory recommendations (5). Blood was drawn into an anticoagulant free tube, and centrifuged within the time and under the conditions recommended by the tube manufacturer. Electrolyte concentrations were measured from the primary tube on a biochemical analyzer DxC700 (Beckman Coulter, Brea, USA) using the manufacturer’s standard spectrophotometric methods for electrolyte, Ca and Mg measurements.

The first laboratory analysis revealed critically decreased concentrations of sodium, potassium and chloride, accompanied by an extremely elevated Mg concentration, inconsistent with the patient’s clinical presentation and incompatible with life. According to standard laboratory procedures, the critical results were repeated using the primary tube sample prior to communication with the clinical staff. These critical values were reported by the LMP from the emergency laboratory to the responsible ICU clinician immediately by telephone.

Given the discordance between the laboratory results and the patient’s clinical condition, the LMP initiated prompt communication with the clinical staff and requested additional information regarding the exact time of blood sampling, sampling site, and recent or ongoing intravenous therapy. Based on this phone discussion, the laboratory recommended immediate recollection of the blood sample. In addition, a reflex glucose measurement performed on the original sample revealed a markedly elevated glucose concentration (55.4 mmol/L), further supporting contamination by glucose-containing infusion fluid.

Investigation of the preanalytical error

Further investigation revealed that blood sampling had been performed while an intravenous infusion containing 2 g magnesium sulfate (MgSO4) diluted in 100 mL of 5% glucose was still running. The infusion had not been discontinued prior to blood collection. The sample was collected from the same arm and venous access used for infusion administration. In addition, a delay occurred during transport of the sample to the emergency laboratory, coinciding with a clinical shift change in the ICU (6). The shift change did not directly influence the laboratory results; however, it contributed to delayed recognition of the preanalytical error due to incomplete transfer of information regarding ongoing infusion therapy. These circumstances resulted in contamination of the blood sample and spurious critical electrolyte results. Repeat blood sampling performed under appropriate conditions demonstrated electrolyte and Mg concentrations within the reference range, confirming the preanalytical origin of the initial abnormal results.

Discussion

This case illustrates how preanalytical errors remain the most frequent source of laboratory testing inaccuracies, particularly in intensive care settings. In the ICU, rapid therapeutic interventions, frequent infusions, and shift changes increase the risk of incomplete information transfer and inappropriate blood sampling practices. Serum Mg measurement is especially vulnerable to such errors, as intravenous administration can cause falsely elevated serum concentrations if blood is drawn from the same or adjacent venous access site.

Unexplained, life-threatening laboratory values must always be communicated to clinicians without delay; however, critical reporting should be accompanied by immediate verification of preanalytical conditions. Key questions include: Who collected the sample? When was it collected? From which site? Was any infusion ongoing at the time of sampling? Effective communication between laboratory professionals, nurses, and clinicians is essential to rapidly identify potential sources of error and prevent inappropriate clinical interventions.

In this case, the transport delay itself did not directly affect Mg stability; however, it contributed to incomplete transfer of clinical information during ICU shift change, thereby delaying recognition of the preanalytical error.

The educational value of this case lies in reinforcing that accurate interpretation of laboratory results requires full insight into the preanalytical phase. Both junior and senior laboratory medicine professionals must remain vigilant and proactive in questioning unexpected results, while clinical staff should be continuously educated on correct sampling practices, particularly during intravenous therapy.

Take-home message

Clear and timely communication regarding preanalytical conditions, especially the timing and site of blood sampling relative to ongoing therapy, is essential for reliable laboratory interpretation. Awareness and documentation of these factors can prevent misinterpretation of laboratory results, errors in clinical interpretation, and ultimately avoid inappropriate or harmful clinical management.

Recommendations for laboratory practice

Always repeat blood sampling when laboratory results are incompatible with life or inconsistent with the clinical condition

Always communicate laboratory results with clinicians and nurses

Educate non-laboratory staff about the potential consequences of preanalytical errors and misinterpretation of laboratory results

Organize lectures with presentations of real cases

Pay particular attention to communication regarding ongoing therapies, recent blood sampling procedures, and critical laboratory results during clinical and laboratory shift changes

Potential conflict of interes

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References PlebaniM. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med. 2006;44:750–9. 10.1515/CCLM.2006.12316729864 Ab RahimSNNordinNWan OmarWFAZulkarnainSKumarSSinhaS The Laboratory and Clinical Perspectives of Magnesium Imbalance. Cureus. 2023;15:e49835. 10.7759/cureus.4983538045630 Thomas L, editor. Clinical Laboratory Diagnostics: Use and Assessment of Clinical Laboratory Results [Internet]. Frankfurt am Main: TH-Books Verlagsgesellschaft; [cited 2025 December 20]. Available from: https://clinical-laboratory-diagnostics.com/ Aal-HamadAHAl-AlawiAMKashoubMSFalhammarH. Hypermagnesemia in Clinical Practice. Medicina (Kaunas). 2023;59:1190. 10.3390/medicina5907119037512002 SimundicAMBoleniusKCadamuroJChurchSCornesMPvan Dongen-LasesEC Joint EFLM-COLABIOCLI Recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56:2015–38. 10.1515/cclm-2018-060230004902 BaruahAGoyalPSinhaSRameshKLDattaR. Delay in specimen processing-major source of preanalytical variation in serum electrolytes. J Clin Diagn Res. 2014;8:CC01–03. 10.7860/JCDR/2014/10150.528525653938
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "031001" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-031001" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.031001" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(114) "Spurious life-threatening hypermagnesemia caused by a preanalytical error in an intensive care unit: a case report" ["journals_article_author"]=> string(39) "Tara Rolić, Inja Pavlić, Ivana Sarić" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(23) "Preanalytical mysteries" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(94) "case report, hypermagnesemia, preanalytical error, sample re-collection, electrolyte imbalance" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1640" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "13" ["meta_title"]=> string(114) "Spurious life-threatening hypermagnesemia caused by a preanalytical error in an intensive care unit: a case report" ["meta_desc"]=> string(114) "Spurious life-threatening hypermagnesemia caused by a preanalytical error in an intensive care unit: a case report" ["meta_keyw"]=> string(94) "case report, hypermagnesemia, preanalytical error, sample re-collection, electrolyte imbalance" ["created"]=> string(19) "2026-08-10 10:38:16" ["modified"]=> string(19) "2026-10-02 11:02:58" } [5]=> object(stdClass)#58 (35) { ["journals_id"]=> string(4) "1260" ["journals_xml"]=> string(50911) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030901 10.11613/BM.2026.030901 Case reports Analytical interference by IgM paraprotein causing platform-dependent electrolyte discrepancies: a case-based laboratory investigation WangSheng1DuanXiaoyong1ZouYulin1GuiJianxiong*2 The Third Clinical Medical College of China Three Gorges University, Gezhouba Central Hospital of Sinopharm, Yichang, Hubei, China The Eighth Hospital of Wuhan, Wuhan, Hubei, China Corresponding author: 1090561703@qq.com

Author contributions

S Wang: Conceptualization, Investigation, Methodology, Validation, Visualization, Writing – original draft; X Duan: Data curation, Investigation, Resources, Validation; Y Zou: Resources, Formal analysis, Writing – review & editing; J Gui: Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing.

10082026 15102026 36 3 030901 0204202602072026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• IgM-κ paraprotein caused marked platform-dependent interference in electrolyte and total calcium measurements

• Total calcium differed by 71% between Hitachi and Beckman despite the same Arsenazo III reagent

• Direct ion-selective electrode analysis excluded true hyponatremia and hypercalcemia

• Platform-specific mixing dynamics determined the extent of paraprotein interference

• Recognition of marked inter-platform discrepancies prompted targeted laboratory investigation, leading to identification of IgM paraprotein and diagnosis of occult Waldenström macroglobulinemia

Accurate measurement of serum electrolytes and calcium is essential for clinical management; however, monoclonal immunoglobulins, particularly IgM paraproteins, may cause misleading analytical interference. We report the case of an 85-year-old man admitted for low back pain whose serum sample showed marked inter-platform discordance in sodium and total calcium results. The Hitachi platform reported a “hypercalcemic crisis” (total calcium 4.95 mmol/L) and severe hyponatremia (125 mmol/L), whereas the Beckman Coulter AU platform showed only mildly elevated total calcium (2.89 mmol/L) and milder hyponatremia (133 mmol/L). This corresponded to a 71.3% difference in total calcium, despite both platforms using the Arsenazo III method. Direct ion-selective electrode measurements excluded true hyponatremia and hypercalcemia. Dilution studies, polyethylene glycol precipitation, reaction-curve inspection, and simulation experiments confirmed that IgM-related precipitation and optical scattering were the underlying mechanisms. Specifically, platform-specific mixing dynamics determined the magnitude of interference. Recognition of biochemical-clinical discordance and targeted method comparison prompted hematological evaluation and led to a diagnosis of Waldenström macroglobulinemia. This case highlights that unexplained analytical discrepancies may delay recognition of underlying disease if analytical interference is not appropriately investigated.

Keywords: paraprotein interferencepseudohypercalcemiapseudohyponatremiaplatform-dependent discrepancyWaldenström macroglobulinemia
Introduction

Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoproliferative disorder characterized by monoclonal IgM paraproteinemia and bone marrow infiltration (1-3). Its clinical manifestations are diverse and often nonspecific, frequently resulting in delayed diagnosis (4-6). High concentrations of IgM paraprotein are a well-recognized source of analytical interference and may produce spurious laboratory abnormalities (7-10). Although pseudohyponatremia and pseudohypercalcemia attributable to IgM have been reported, few studies have systematically evaluated the magnitude of such interference across major analytical platforms.

Here, we describe a patient whose serum sample showed a striking dual pattern of platform-dependent interference on Hitachi and Beckman Coulter platforms. Notably, one platform yielded only clinically subtle abnormalities, which could easily have escaped clinical attention. This case illustrates the importance of correlating laboratory results with clinical findings and pursuing targeted verification when analytical interference is suspected.

Case report

An 85-year-old man with a 20-year history of hypertension was admitted for low back pain and left thigh pain of 1 year’s duration, with worsening over the preceding week. Lumbar magnetic resonance imaging showed lumbar disc herniation. Vital signs were stable, and physical examination revealed localized tenderness in the left L4–S1 region. On the day of admission, the first venous blood sample was collected from the antecubital vein in the morning in a non-fasting state using a plain vacuum blood collection tube without additives (Zhejiang Gongdong Medical Technology Co., Ltd., China). Initial routine biochemical testing of this sample on a Beckman Coulter AU5811 analyzer (Beckman Coulter, Brea, USA) showed the following results: total calcium (TCa), 2.89 mmol/L (reference interval 2.11-2.52 mmol/L); sodium (Na), 133 mmol/L (137-147 mmol/L); chloride (Cl), 96 mmol/L (99-110 mmol/L); and creatinine, 126 μmol/L (57-111 μmol/L). Although sodium and chloride were only mildly decreased, the unexplained elevation in total calcium was inconsistent with the clinical presentation and was questioned by the clinicians; consequently, they requested a repeat fasting panel, which was collected the following morning and analyzed via the laboratory’s routinely available Hitachi LABOSPECT 008α workflow.

The morning after admission, a second fasting venous blood sample was collected from the antecubital vein using the same type of collection tube. Repeated testing on a Hitachi LABOSPECT 008α analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan) revealed a markedly different biochemical profile: TCa 4.95 mmol/L, reaching the threshold for hypercalcemic crisis; Na 125 mmol/L; and Cl 92 mmol/L. Total protein was 78 g/L, albumin was 36 g/L, and globulin was 42 g/L. Despite the extreme abnormalities reported by the Hitachi platform, the patient had no clinical manifestations consistent with severe hypercalcemia, strongly suggesting analytical interference.

Comparison of the initial AU5811 results with the next-day Hitachi results revealed substantial discrepancies in sodium and chloride. Chronologically, the initial biochemical screening (Sample A) was performed on the AU5811 analyzer upon admission. The subsequent LABOSPECT 008α analysis utilized a separate fasting sample (Sample B) collected the following morning. To investigate the profound instrument discordance, Sample B was subjected to multi-platform analysis, including remeasurement on the AU5811 and direct potentiometry on a blood gas analyzer. The AU5811 results displayed in Table 1 represent this re-analysis of Sample B, which exactly matched the index finding from Sample A (yielding a TCa of 2.89 mmol/L). Using the albumin concentration of 36 g/L measured in Sample B, the albumin-corrected total calcium values were calculated as 2.97 mmol/L for the AU5811 remeasurement and 5.03 mmol/L for the LABOSPECT 008α result (11). The corrected values remained markedly discrepant, suggesting that albumin adjustment alone was insufficient to account for the observed findings. Importantly, total calcium measured with the same brand and lot of Arsenazo III reagent (Medicalsystem Biotechnology Co., Ltd., Ningbo, China) differed by 2.06 mmol/L, corresponding to a 71.3% inter-platform difference. Given the lack of compatible clinical features, the sample was remeasured on additional platforms and subjected to dilution and confirmatory testing. The results of electrolyte and calcium measurements across analytical platforms, together with dilution and confirmatory testing, are summarized in Table 1.

Laboratory results of the second-day fasting sample on multiple platforms
Parameter AU5811 (iISE) LABOSPECT 008α (iISE) ABL90 FLEX (dISE) Reference Interval
K+ 3.82 3.73 3.9 3.50–5.30 mmol/L
Na+ 133 125 138 137–147 mmol/L
Cl– 96 92 100 99–110 mmol/L
Ca2+ - - 0.90 1.10–1.35 mmol/L
TCa 2.89 4.95 - 2.11–2.52 mmol/L
TCa (DW 1:1) 1.98 2.00 - 2.11–2.52 mmol/L
TCa (DW 1:3) 2.02 1.96 - 2.11–2.52 mmol/L
TCa (NS 1:1) 2.78 4.56 - 2.11–2.52 mmol/L
TCa (NS 1:3) 2.39 3.32 - 2.11–2.52 mmol/L
TCa (PEG 1:1) 2.00 2.00 - 2.11–2.52 mmol/L
All results shown in this table were obtained from the same fasting serum sample collected on the morning of the second day of admission. Albumin concentration in this sample was 36.1 g/L. The corresponding albumin-corrected total calcium values were 2.97 mmol/L and 5.03 mmol/L for the AU5811 and LABOSPECT 008α results, respectively. Albumin-corrected total calcium was calculated using the formula: corrected TCa (mmol/L) = measured TCa + 0.02 × (40 - albumin (g/L)) (11). Blood gas analysis was performed on an ABL90 FLEX analyzer (Radiometer, Copenhagen, Denmark). For distilled-water dilution and PEG precipitation experiments, measurements were performed on the supernatant obtained after centrifugation. iISE - indirect ion-selective electrode. dISE - direct ion-selective electrode. TCa - total calcium. DW - distilled water. NS - normal saline. PEG - polyethylene glycol 6000, 25%.

Dilution with distilled water induced immediate opalescence (a positive Sia water test), indicating a high paraprotein concentration susceptible to precipitation under reduced ionic strength (10). After 1:1 dilution with distilled water, dilution-adjusted total calcium decreased substantially and approached a level physiologically consistent with the ionized calcium concentration measured by direct ion-selective electrode (dISE, 0.90 mmol/L), confirming analytical interference. With normal saline dilution, paraprotein did not precipitate; however, the interference decreased in a concentration-dependent manner. On the basis of the positive Sia water test and previous reports, macromolecular protein interference affecting sodium, chloride, and total calcium was confirmed (10). Polyethylene glycol (PEG 6000, 25%) precipitation was then performed, after which total calcium measured approximately 2.00 mmol/L on the Hitachi platform, supporting the absence of true hypercalcemia demonstrated by the ionized calcium result from the blood gas analyzer.

Manual simulation experiments further elucidated the mechanism underlying the platform differences. When serum was mixed with the Hitachi ISE diluent, spontaneous flocculent precipitation developed in the patient sample upon static contact (Figure 1A). In contrast, no precipitation was observed with the Beckman Coulter ISE diluent. Similarly, marked turbidity occurred when the patient’s serum contacted Arsenazo III reagent 1 (Figure 1B). Reaction-curve analysis demonstrated pronounced platform-dependent differences (Figure 2). On the Hitachi platform, absorbance showed a continuous upward drift, reflecting persistent optical scattering from suspended precipitates generated by ultrasonic mixing. In contrast, the Beckman Coulter AU platform showed relatively stable kinetics. Nevertheless, the final reported total calcium concentrations on the Beckman Coulter AU platform were 2.89 mmol/L for the patient sample and 2.25 mmol/L for the representative non-paraproteinemic control serum sample.

Visual demonstration of paraprotein-related precipitation during assay mixing. (A) Mixture of Hitachi ion-selective electrode (ISE) diluent and serum at the routine testing ratio. From left to right: a representative non-paraproteinemic control serum sample mixed with Hitachi diluent without visible precipitation; the patient’s serum mixed with Hitachi diluent approximately 30 s after addition; and the patient’s serum mixed with Hitachi diluent 10 min after addition, showing progressive turbidity. (B) Mixture of Arsenazo III reagent 1 (R1) and serum at the routine testing ratio. The representative non-paraproteinemic control serum sample remained clear, whereas the patient sample developed immediate and marked turbidity on contact with reagent 1.

Reaction curve profiles for total calcium (Arsenazo III method) on two analytical platforms. (A) Patient sample on the Hitachi platform showing a progressive upward absorbance drift after reagent addition, indicating ongoing paraprotein-induced microprecipitation. (B) Representative non-paraproteinemic control serum sample on the Hitachi platform showing a stable reaction plateau. (C) Patient sample on the Beckman Coulter platform (reported value, 2.89 mmol/L); despite the slight elevation, the kinetic profile remained relatively stable compared with that shown in panel A. (D) Representative non-paraproteinemic control serum sample on the Beckman Coulter platform (reported value, 2.25 mmol/L) showing a normal, stable reaction curve.

Based on these findings, immunoglobulin testing was subsequently requested and revealed markedly elevated IgM (25.43 g/L), identifying IgM paraprotein as the principal cause of the observed analytical interference. A comprehensive hematological evaluation was therefore initiated. Bone marrow examination revealed lymphoplasmacytic infiltration, and bone marrow cytology was concordant with the histological findings. Immunophenotypic analysis by flow cytometry demonstrated a clonal population of kappa light chain-restricted B cells with a phenotype consistent with lymphoplasmacytic lymphoma. Molecular testing further demonstrated MYD88 L265P positivity, whereas no CXCR4 mutation was detected. Taken together with the markedly elevated serum IgM concentration, these findings established the diagnosis of WM.

Given the presence of renal dysfunction and light-chain involvement, the patient subsequently received targeted therapy with the Bruton tyrosine kinase inhibitor ibrutinib (420 mg once daily). After treatment initiation, he showed a favorable clinical and laboratory response. After 3 months of treatment, he reported marked relief of back and lower limb pain. At 6 months of follow-up, hematological parameters indicated a substantial response: serum IgM had decreased from 25.43 g/L to 2.08 g/L, and the M-protein fraction had declined to 2.7%. Renal function and metabolic parameters improved concurrently, with serum creatinine normalizing to 76 μmol/L and estimated glomerular filtration rate increasing to 92.7 mL/min/1.73 m2. Total calcium returned to the normal range and stabilized at approximately 2.35 mmol/L. These findings indicate that early laboratory recognition of analytical interference not only prevented misinterpretation of biochemical results, but also facilitated timely diagnosis and appropriate management of the underlying hematological disorder. Unfortunately, the patient later died of COVID-19-related complications. Written informed consent for the publication of this case report and the accompanying images was obtained from the patient’s next of kin.

Discussion

A particularly important feature of this case is that total calcium on the Beckman Coulter AU5811 was only mildly elevated at 2.89 mmol/L. Such values often receive limited clinical attention and would rarely be attributed to severe paraprotein-related interference. In contrast, the spurious “hypercalcemic crisis” reported by the Hitachi platform was not clinically plausible and therefore triggered verification for analytical interference. This finding emphasizes that any discrepancy between laboratory metrics and clinical presentation demands immediate investigation. The 71% inter-platform discrepancy prompted further investigation that ultimately led to diagnosis.

With respect to the electrolyte discrepancies, indirect ion-selective electrode results differed markedly between platforms. On the Beckman Coulter AU5811, macroglobulins occupy plasma volume during dilution, causing underestimation of sodium and chloride through the electrolyte exclusion effect (12-15). On the Hitachi platform, this interference was further amplified by precipitation and reduced water availability, resulting in more pronounced pseudohyponatremia.

The extreme discrepancy between the Hitachi and Beckman Coulter platforms, together with similar observations reported between Hitachi and Siemens systems, supports the existence of a platform-dependent interference gradient for Arsenazo III methods (16). Crucially, standard albumin correction did not materially alter this discrepancy, indicating that albumin adjustment alone could not explain the observed findings and that the discrepancy was unlikely to reflect altered protein-binding physiology alone. Instead, differences in mixing methodology, particularly the high-energy ultrasonic mixing used by the Hitachi platform, likely determine the extent to which precipitates remain suspended within the optical path, thereby substantially influencing absorbance and the final reported calcium concentration (17, 18). Thus, despite use of the same Arsenazo III principle, platform-specific mixing and reaction conditions appear to critically modulate the magnitude of paraprotein-induced optical interference.

This case extends previous observations by showing that unexplained analytical abnormalities may delay recognition of underlying disease if analytical interference is not considered. Multiple reports have described combined pseudohyponatremia and pseudohypercalcemia caused by monoclonal paraproteins, particularly IgM (19-22). Paraproteins may also interfere with numerous other assays, including enzymes, creatinine, hemolysis indices, and bicarbonate (23-27).

Implications for laboratory practice

The practical lesson from this case is not that all samples should be routinely tested on multiple chemistry platforms. Rather, when laboratory results are unexplained or inconsistent with clinical expectations, even mild abnormalities should prompt consideration of analytical interference. To avoid misdiagnosis in similar settings, identifying the cause of major discrepancies between analytical platforms is essential. In addition, when mild abnormalities are unexplained, inspection of reaction curves may help identify interference that might otherwise be overlooked.

When the clinical presentation is discordant with biochemical findings, for example in an asymptomatic patient with an apparent “hypercalcemic crisis”, visual inspection of the reaction curve and the sample itself, including the Sia water test, may be informative. Furthermore, standard automated flags on a routine chemistry panel, such as an elevated globulin fraction and an inverted albumin-to-globulin (A/G) ratio, serve as critical, universally accessible clues signaling the potential presence of high-concentration monoclonal immunoglobulins. Hemolysis, icterus, and lipemia indices may also provide useful clues to abnormal sample properties. Simple mixing tests with water or saline can reveal precipitation in selected high-paraprotein samples, although precipitation may depend on ionic strength and reagent composition. Use of direct ISE or dilution-based approaches provides an important verification step when high protein concentrations are suspected. For laboratories operating a single routine chemistry platform, a blood gas analyzer equipped with direct ISE serves as a practical alternative for electrolyte verification. If such testing is not available locally, external verification, dilution studies, PEG precipitation, and close clinical-laboratory communication should be considered.

Ultimately, proactive communication between the laboratory and clinicians plays a pivotal role in the diagnosis of occult hematological disorders. Laboratory professionals should interpret results from a clinical perspective and actively discuss unexpected or clinically inconsistent findings with clinicians to seek a reasonable explanation.

Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References GertzMA. Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management. Am J Hematol. 2025;100:1061–73. 10.1002/ajh.2766640095219 BibasMSarosiekSCastilloJJ. Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems. Mediterr J Hematol Infect Dis. 2024;16:e2024061. 10.4084/MJHID.2024.06138984103 KumarSKCallanderNSAdekolaKAndersonLDJrBaljevicMBazR Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:e240001. 10.6004/jnccn.2024.000138244272 PrattGEl-SharkawiDKothariJD’SaSAuerRMcCarthyH Diagnosis and management of Waldenström macroglobulinaemia - A British Society for Haematology guideline. Br J Haematol. 2022;197:171–87. 10.1111/bjh.1803635020191 YoshidaI. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma3. Lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM). Int J Hematol. 2025;121:740–5. 10.1007/s12185-025-03948-839998797 Kaseb H, Gonzalez-Mosquera LF, Parsi M, Mewawalla P. Lymphoplasmacytic Lymphoma. Treasure Island: StatPearls Publishing; 2026. Available at: https://www.statpearls.com/point-of-care/31289. Assessed on January 15th 2026. YilmazNSSenBGulbaharO. Contribution of the laboratory to a diagnosis process by sequential reflective testing: Paraprotein interference on a direct bilirubin assay. Biochem Med (Zagreb). 2021;31:020801. 10.11613/BM.2021.02080133927558 WhittleEde WaalEHuynhTTreacyOMortonA. Pre-analytical mysteries: A case of severe hypervitaminosis D and mild hypercalcaemia. Biochem Med (Zagreb). 2021;31:011001. 10.11613/BM.2021.01100133380896 OliverasLColomaAEscartínTCastroMJVicenteNGomàM False positive elevation in serum creatinine: a case report. Front Med (Lausanne). 2024;11:1375173. 10.3389/fmed.2024.137517338500956 MassonPChutovaEOrisCDannusLTSapinVBouvierD. Waldenstrom’s macroglobulinemia highlighted by turbidity interference: a case report. Ann Biol Clin (Paris). 2022;80:487–93.36453737 PayneRBCarverMEMorganDB. Interpretation of serum total calcium: effects of body posture and plasma albumin concentration. BMJ. 1973;4:643–6. 10.1136/bmj.4.5893.6434758544 DattaSKChopraP. Interference in Ion-Selective Electrodes Due to Proteins and Lipids. J Appl Lab Med. 2022;7:589–95. 10.1093/jalm/jfab12534751739 AzizFSamRLewSQMassieLMisraMRoumeliotiME Pseudohyponatremia: Mechanism, Diagnosis, Clinical Associations and Management. J Clin Med. 2023;12:4076. 10.3390/jcm1212407637373769 VeraMASutphinAHansenLEl-KhouryJM. Resolving Pseudohyponatremia: Validation of Plasma Sodium on Radiometer ABL800 Blood Gas Analyzers for Immediate Reflex Testing. Lab Med. 2022;53:e105–8. 10.1093/labmed/lmab11435015890 DimeskiGBadrickTJohnAS. Ion Selective Electrodes (ISEs) and interferences--a review. Clin Chim Acta. 2010;411:309–17. 10.1016/j.cca.2009.12.00520004654 MennensSFBJVan der SpekERuinemans-KoertsJVan BorrenMMGJ. Hematologists/Physicians Need to Be Aware of Pseudohypercalcemia in Monoclonal Gammopathy: Lessons from a Case Report. Case Rep Hematol. 2024;2024:8844335. 10.1155/2024/884433539189035 YuTLiXHuangBGuJLiuJChenM The identification and correction of pseudohypercalcemia. Front Oncol. 2024;14:1441851. 10.3389/fonc.2024.144185139544294 SunusiUChenLLiNLeeJKYSiddiquiIGoodhueE Prevalence and Clinical Impact of Pseudohypercalcemia in Paraproteinemia: A Case and Cohort Study. J Clin Med. 2025;14:7676. 10.3390/jcm1421767641227076 LordeNPrattGGeberhiwotTAyukJGittoesN. Paraprotein-induced spurious hypercalcaemia: diagnostic pitfalls in two cases. Eur J Endocrinol. 2025;193:K1–4. 10.1093/ejendo/lvaf15140712044 ChowdhuryRTurcotteAERondon-BerriosHWorkenehBT. Spurious Electrolyte and Acid-Base Disorders in the Patient With Cancer: A Review. Am J Kidney Dis. 2023;82:237–42. 10.1053/j.ajkd.2023.01.44136906215 WangDLiPSuWHouLHanJZhangY From interference to insight: pseudo-lipidemia led to the diagnosis of Waldenström macroglobulinemia. BMC Cardiovasc Disord. 2025;25:170. 10.1186/s12872-025-04588-w40065247 FortgensPPillayTS. Pseudohyponatremia revisited: a modern-day pitfall. Arch Pathol Lab Med. 2011;135:516–9. 10.5858/2010-0018-RS.121466372 SamKMSchneiderHGChoyKWLamQT. Falsely decreased Abbott Alinity-c gamma-glutamyl transferase-2 result from paraprotein and heparin interference: case report and subsequent laboratory experiments. Clin Chem Lab Med. 2024;62:e126–8. 10.1515/cclm-2024-001538439680 LiBThompsonSIgotKKingRDoogueMFlorkowskiC. Artefactually low creatinine by Beckman Coulter enzymatic method due to immunoglobulin M paraprotein interference. Ann Clin Biochem. 2023;60:423–7. 10.1177/0004563223119050737482625 CapaldoCEveillardJRKerspernHIanottoJCLevenC. A new pitfall in potassium testing: A case series of false elevation of hemolysis index in the presence of monoclonal protein. Clin Chim Acta. 2025;571:120224. 10.1016/j.cca.2025.12022440054713 NelsonHAGenzenJRDelgadoJCRudolfJW. An Interference in an Automated HCO3- Assay Leads to an Unexpected IgG Monoclonal Gammopathy Diagnosis. J Appl Lab Med. 2022;7:622–5. 10.1093/jalm/jfab12634849974 SarkarR. Paraprotein Interferences: Insights from a Short Study Involving Multiple Platforms and Multiple Measurands. EJIFCC. 2024;35:120–31. 10.21203/rs.3.rs-3355321/v139247662
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030901" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030901" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030901" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(134) "Analytical interference by IgM paraprotein causing platform-dependent electrolyte discrepancies: a case-based laboratory investigation" ["journals_article_author"]=> string(51) "Sheng Wang, Xiaoyong Duan, Yulin Zou, Jianxiong Gui" ["journals_article_author_country"]=> string(5) "China" ["journals_article_categories_heading"]=> string(12) "Case reports" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(129) "paraprotein interference, pseudohypercalcemia, pseudohyponatremia, platform-dependent discrepancy, Waldenström macroglobulinemia" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1918" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "12" ["meta_title"]=> string(134) "Analytical interference by IgM paraprotein causing platform-dependent electrolyte discrepancies: a case-based laboratory investigation" ["meta_desc"]=> string(134) "Analytical interference by IgM paraprotein causing platform-dependent electrolyte discrepancies: a case-based laboratory investigation" ["meta_keyw"]=> string(129) "paraprotein interference, pseudohypercalcemia, pseudohyponatremia, platform-dependent discrepancy, Waldenström macroglobulinemia" ["created"]=> string(19) "2026-08-10 10:36:26" ["modified"]=> string(19) "2026-10-02 11:02:40" } [6]=> object(stdClass)#57 (35) { ["journals_id"]=> string(4) "1259" ["journals_xml"]=> string(55896) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030801 10.11613/BM.2026.030801 Short communications What do laboratories know about the pneumatic tube delivery systems they depend on? JayanettiAnushkaBadrickTony Royal College of Pathologists of Australasia Quality Assurance Programs, St Leonards, New South Wales, Australia Corresponding author: tony.badrick@rcpaqap.com.au

Author contributions

A Jayanetti: Conceptualization, Methodology, Investigation, Writing – original draft, review & editing; T Badrick: Conceptualization, Methodology, Investigation, Writing – original draft, review & editing.

10082026 15102026 36 3 030801 1702202604062026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Survey of laboratories on pneumatic tube system governance

• Half of the respondents were unsure how often their pneumatic tube systems were serviced

• Total of 63% didn’t know if the systems were validated before installation

• Laboratories may not realise whether their systems are functioning correctly

Introduction

Pneumatic tube systems (PTS) are a key component of many laboratory sample delivery systems. However, they can be a source of preanalytical error, particularly when samples are lost or damaged. The Key Incident Monitoring and Management (KIMMS) program of the Royal College of Pathologists Australasia Quality Assurance Programs (RCPAQAP) conducted a survey to gather information on the maintenance of these systems.

Materials and methods

The categories of questions included general information, service, maintenance and validation of systems, and incident reporting. The responses were compiled and reviewed using Microsoft Forms.

Results

The survey found a lack of awareness of servicing and validation records, as well as of the PTS’s functionality. Most sites reported incidents with their pneumatic tube systems (37/45, 80%), mainly system failures rather than samples being lost, delayed, or damaged.

Conclusions

Greater oversight of laboratories is needed, and relationships with system vendors must be strengthened to ensure quality service.

Keywords: quality assurancepreanalytic errorspecimen quality
Introduction

Pneumatic tube systems (PTS) are extensively used within clinical laboratories to transport patient samples, paperwork, and pharmacy items within or between organisations, and, to a lesser extent, blood products (1). Compared to manual transport, PTS have been shown to improve turnaround times and do not increase hemolysis (2-4). Some measurands may be impacted by the rapid acceleration in the PTS, such as platelet-related tests (5). Lactate dehydrogenase (LD), potassium, D-dimer, and prothrombin time have been shown to be affected by PTS (1, 6, 7). Also, blood gas samples should not be transported in PTS, and contradicting data exists on the transport of cerebrospinal fluid specimens for the diagnosis of hemorrhage. Adequate centrifugation of samples is essential, or any cells left above the gel plug can hemolyse, dependent on time and speed of the PTS (4). However, all these papers assume that the PTS is operating optimally and regularly serviced.

Methods for validating PTS have been proposed using the relationship between analyte concentrations in plasma, such as LD and potassium, and the PTS forces recorded by 3-axis accelerometers, or by more formal procedures that are not widely used in Australia (6, 8). There has been little in the literature on the governance of PTS, which is important when the system may be shared between a laboratory and other hospital units.

Feedback from the 2023 Royal College of Pathologists Australasia Quality Assurance Programs (RCPAQAP) The Key Incident Monitoring and Management (KIMMS) workshop indicated that the maintenance and performance of pneumatic tube systems are not always optimal and may lead to preanalytical errors, such as hemolysed or leaked samples. In the KIMMS program, incidents related to PTS can be reported under the general transport delay category, but there is no specific PTS category. This research sought to identify issues relating to the governance and maintenance of PTS used by clinical laboratories. Therefore, for this project, we aimed to collect information on pneumatic tube systems utilised by, and often shared by, clinical laboratories to assess how they were validated and managed.

Materials and methods

We circulated a Microsoft Forms (Microsoft Corporation, Redmond, USA) audit via email to 89 quality managers across Australia/New Zealand. The survey is included in the Supplementary data. The audit was developed under the guidance of the RCPAQAP KIMMS advisory committee. Responses were anonymous, but an email address was requested. No ethical approval or institutional oversight was required. The categories of questions included general information, service, maintenance and validation of systems, and incident reporting. The responses were compiled and reviewed using Microsoft Forms. There was no statistical analysis – the data and graphs were produced by the Microsoft Forms software.

Results

Forty-five responses (51% response rate) were received from public and private pathology, with some respondents submitting multiple forms if their site had several PTS. Most of the laboratories (78%, 35/45) were part of networks of clinical laboratories, while 16% (7/45) operated as stand-alone laboratories. The remaining 6% (3/45) were laboratories that were part of a larger non-laboratory organisation. Regarding the age of these systems, 30% (14/45) had been in use for 11-20 years, 22% (10/45) for 6-10 years, 15% (7/45) for over 21 years, and 11% (5/45) for under 5 years. Only 4% (1/45) of respondents had systems with sections of varying ages, and the remaining 18% (8/45) were unsure. Most respondents (31/45) had Lamson (Kings Park, NSW, Australia) systems, while others had systems from Benchmark Systems (Willetton, WA, Australia), Aerocom (Thornleigh, NSW, Australia), Airlink Systems (Kilsyth, VIC, Australia), Telecom (Zwijndrecht, The Netherlands) and Swisslog (Redditch, United Kingdom). Hospitals were the primary managers of these systems, overseeing 73% (33/45), with pathology organisations managing 22% (10/45). Regarding transported items, blood samples were the most common at 96% (43/45), followed by paperwork at 93% (42/45), urine samples at 91% (41/45), blood cultures at 89% (40/45), and swabs at 89% (40/45). Although these are the totals, it should be remembered that a container may often contain mixtures of these.

Half of the respondents (23/45) were unsure how often their pneumatic tube systems were serviced (Table 1), and 63% (29/45) didn’t know if the systems were validated before installation (Table 2). Some validation methods included time-to-delivery, reliability, sample damage, and transport of different blood components and products. Some respondents referred to guidelines for validating systems, such as the AABB guidelines for pneumatic tube systems (6).

Number and percentage of audit responses on how often the PTS is serviced
How often is the pneumatic tube system serviced? Responses (N = 45) % Response
Weekly 0 0
Never 2 4
Biannually 2 4
Monthly 6 13
Yearly 6 13
Quarterly 6 13
Unsure 23 51
PTS – pneumatic tube system.
Number and percentage of audit responses on whether the system has been validated as part of its installation
Was your organization’s pneumatic tube system been validated as part of installation? Responses (N = 45) % Response
Yes 14 31
No 2 4
Unsure 29 64

Most sites reported incidents involving their PTS (37/45, 80%), mainly system failures rather than sample loss, delays, or damage (Table 3). There was no relation between system age and incidents, though some respondents said ageing systems failed more often. There was also no trend between incident frequency and servicing (Table 4).

Audit responses on the frequency of incidents involving pneumatic tube systems
Responses (N = 45)
< 5 5 to 10 > 10 Unsure Other
How many times has the pneumatic tube system failed in the past 6 months? 19 9 8 5 3
How many times have specimens been lost, misdirected or delayed when transported by the pneumatic tube system in the past 6 months? 26 2 5 10 0
Comparison of responses on the frequency of servicing of pneumatic tube systems <italic>versus</italic> the number of incidents reported
Response Service interval of PTS Failure of PTS in the past 6 months Number of lost, misdirected or delayed specimens in the PTS in the past 6 months Frequency of specimen transport delay through PTS, causing them to age (in the past 6 months) Specimens have been going to the wrong location through PTS in the past 6 months Number of specimens damaged in the PTS in the past 6 months (i.e. hemolyzed, clotted) Frequency of specimen leakage in the system in the past 6 months
1 3 monthly < 5 < 5 < 5 < 5
2 6 monthly Unsure Unsure < 5 < 5 Unsure < 5
3 6 monthly < 5 < 5
4 Approx monthly? 42 Unsure Unsure Unsure Unsure < 5
5 Lamson service monthly, hospital staff do daily maintenance Never fails, do have issues that are dealt with by the service team < 5
6 Monthly 5 to 10 5 to 10 5 to 10 Unsure < 5
7 Monthly > 10 < 5 < 5 < 5 Unsure 5 to 10
8 Monthly Just around 40 times where the shift engineer was called in to fix (April- October > 10
9 Monthly
10 Never < 5 < 5
11 Never < 5 < 5
12 Quarterly 5 to 10 < 5
13 Quarterly 5 to 10 5 to 10 < 5 < 5 < 5 < 5
14 Quarterly > 10 > 10 < 5 > 10 < 5 > 10
15 Quarterly < 5 < 5 Unsure Unsure
16 Quarterly < 5 < 5 Unsure Unsure
Discussion

The lack of awareness of servicing and validation records suggests that laboratories may not have sufficient oversight of their operating systems. Instead, others often handle these responsibilities, such as hospital administration. Because of this, laboratories may not realise whether their systems are functioning correctly or can easily investigate issues such as turnaround times, which are crucial for improving their services. While the harm of delayed paperwork is not as severe as that of delayed blood samples or CSF, it may still impact patient care.

Something to note is that many respondents who were unsure whether their systems were validated or serviced also could not identify related incidents, further indicating the need for greater surveillance of laboratories.

Pneumatic tube systems pose a potential patient risk due to preanalytical errors, which can be mitigated through maintenance and vendor servicing adjustments tailored to each site (1). Greater oversight of laboratories is needed, and relationships with system vendors must be strengthened to ensure quality service. The results of the study primarily indicate that many laboratory respondents were unaware of servicing frequency, validation status and incident records, and that governance of PTS may be fragmented. However, another major finding of the study is that validation of the PTS has not been conducted, and that maintenance of these systems is not being undertaken. This is noted as anecdotal, based on the descriptive survey findings as represented in the individual responses in the Supplementary data.

There were limitations to this survey. As this was a survey-based audit, the results were subject to self-reporting bias and differences in respondents’ access to information on PTS servicing, validation and incident records. Also, access to service records, particularly shared PTS records, was not always available to respondents. For some incident categories, the numbers were small, reducing the statistical power of the findings. Finally, we acknowledge potential selection and response bias, as only 45 of 89 invited quality managers responded.

Acknowledgement

The pneumatic tube system audit was developed and reviewed with the guidance of the RCPAQAP KIMMS Advisory Committee.

Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article (and its supplementary files).

References PlebaniMZaninottoM. Pneumatic tube delivery systems for patient samples: evidence of quality and quality of evidence. Clin Chem Lab Med. 2011;49:1245–6. 10.1515/CCLM.2011.21621663463 FernandesCMBWorsterAEvaKHillSMcCallumC. Pneumatic tube delivery system for blood samples reduces turnaround times without affecting sample quality. J Emerg Nurs. 2006;32:139–43. 10.1016/j.jen.2005.11.01316580476 Ausmolo AJT, Pua JFD, Abiog MDH, Alberto BC, Bilo ELM, De Leon CIL, et al. A Systematic Review of the Impact of Pneumatic Tube System Transport on Blood Chemistry and Hematology Parameters. Res Sq [Internet]. 2022;1-35. Available from: 10.21203/rs.3.rs-2274742/v2. Assessed on January 15th 2026. EvliyaoğluOToprakGTekinABaşaraliMKKilinçCÇolpanL. Effect of Pneumatic Tube Delivery System Rate and Distance on Hemolysis of Blood Specimens. J Clin Lab Anal. 2012;26:66–9. 10.1002/jcla.2148422467320 GlasMMauerDKassasHVolkTKreuerS. Sample transport by pneumatic tube system alters results of multiple electrode aggregometry but not rotational thromboelastometry. Platelets. 2013;24:454–61. 10.3109/09537104.2012.71838322931353 SubbarayanDChoccalingamCLakshmiCKA. The Effects of Sample Transport by Pneumatic Tube System on Routine Hematology and Coagulation Tests. Adv Hematol. 2018;2018:6940152. 10.1155/2018/694015230079089 FarnsworthCWWebberDMKrekelerJABudelierMMBartlettNLGronowskiAM. Parameters for validating a hospital pneumatic tube system. Clin Chem. 2019;65:694–702. 10.1373/clinchem.2018.30140830808643 Karp JK, Harach M, Mohammed M, Richard R, Uhl L, van der Hoop J. AABB Guide to Pneumatic Tube Delivery Systems: Validation and Use to Transport Blood Components. Association for the Advancement of Blood & Biotherapies; 2020. Available at: https://www.aabb.org/aabb-store/product/aabb-guide-to-pneumatic-tube-delivery-systems-validation-and-use-to-transport-blood-components---digital-15175121. Assessed on January 15th 2026.
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030801" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030801" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030801" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(83) "What do laboratories know about the pneumatic tube delivery systems they depend on?" ["journals_article_author"]=> string(31) "Anushka Jayanetti, Tony Badrick" ["journals_article_author_country"]=> string(9) "Australia" ["journals_article_categories_heading"]=> string(20) "Short communications" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(54) "quality assurance, preanalytic error, specimen quality" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1205" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "11" ["meta_title"]=> string(83) "What do laboratories know about the pneumatic tube delivery systems they depend on?" ["meta_desc"]=> string(83) "What do laboratories know about the pneumatic tube delivery systems they depend on?" ["meta_keyw"]=> string(54) "quality assurance, preanalytic error, specimen quality" ["created"]=> string(19) "2026-08-10 10:35:18" ["modified"]=> string(19) "2026-10-02 11:02:32" } [7]=> object(stdClass)#56 (35) { ["journals_id"]=> string(4) "1272" ["journals_xml"]=> string(72159) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030705 10.11613/BM.2026.030705 Original articles Determination of method-specific reference intervals for vitamin B12 and its correlation with holotranscobalamin MadenciOzlem C.1ErtugEbru*1AladagNazire2IsmanFerruh K.3YılmazIbrahim4 Department of Clinical Biochemistry, Kartal Dr Lutfi Kirdar City Hospital, Istanbul, Turkey Department of Internal Medicine, Kartal Dr Lutfi Kirdar City Hospital, Istanbul, Turkey Department of Clinical Biochemistry, Medeniyet University, Istanbul, Turkey Department of Clinical Biochemistry, Haseki Training and Research Hospital, Istanbul, Turkey Corresponding author: ebruertug@yahoo.com

Author contributions

O Madenci: Conceptualization, Investigation, Methodology, Visualization, Writing – original draft, Formal analysis; E Ertug: Conceptualization, Investigation, Methodology, Visualization, Writing – review & editing; N Aladag: Data collection, Investigation; FK Isman: Data collection, Investigation; I Yılmaz: Data collection, Investigation.

15102026 15102026 36 3 030705 1809202528072026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Fixed vitamin B12 cut-offs can misclassify deficiency due to method differences

• Laboratories should use method-specific and locally validated reference intervals

• Holotranscobalamin shows low to moderate correlation with total B12

Introduction

We aimed to compare total serum vitamin B12 measurements across four immunoassay platforms, establish method-specific reference intervals, evaluate the clinical impact of a uniform deficiency cut-off, and assess associations between total vitamin B12 and holotranscobalamin (holoTC).

Materials and methods

Residual serum samples from 220 apparently healthy adults undergoing routine health check-ups were analyzed. Total vitamin B12 was measured on Beckman, Abbott, Siemens, and Roche platforms. Beckman analyses used the updated Access Vitamin B12 II calibrator introduced in December 2024. Holotranscobalamin was measured on the Abbott system. Reference intervals were derived using non-parametric methods according to CLSI EP28-A3c guidelines. Method comparison was performed using Passing-Bablok regression and concordance correlation coefficients (CCC), and associations between total vitamin B12 and holoTC were assessed using Spearman correlation analysis.

Results

Total vitamin B12 concentrations differed significantly across platforms, with moderate to good agreement (CCC: 0.81-0.91). Study-derived lower reference limits (LRLs) varied substantially between assays and differed from manufacturer-provided values, most prominently for the Beckman platform. Application of a fixed deficiency cut-off of 148 pmol/L resulted in marked method-dependent differences in deficiency classification. Correlations between total vitamin B12 and holoTC were low to moderate across analytical platforms.

Conclusions

Serum vitamin B12 results vary across platforms, causing method-dependent LRLs and inconsistent classification with uniform cut-offs, underscoring the need for method-specific interpretation and improved harmonization. Low-to-moderate correlations reflect that holoTC and total vitamin B12 represent different components of vitamin B12 status and that total vitamin B12 assays differ by platform in reflecting the active fraction.

Keywords: reference rangestranscobalaminsvitamin B 12vitamin B 12 deficiency
Introduction

Vitamin B12 is an essential micronutrient involved in DNA synthesis, erythropoiesis, and neurological function, and its deficiency may lead to clinically significant conditions such as megaloblastic anemia, peripheral neuropathy, and cognitive impairment (1). Accurate laboratory assessment of vitamin B12 status is therefore critical for appropriate diagnosis and patient management. However, there is currently no universally accepted gold standard test for diagnosing vitamin B12 deficiency, and available laboratory assays primarily serve as supportive tools rather than definitive tests for diagnosis (2).

In routine clinical practice, total serum vitamin B12 remains the most widely used first-line test owing to its analytical feasibility, compatibility with automated platforms, and cost-effectiveness, while biomarkers such as methylmalonic acid (MMA) and holotranscobalamin (holoTC) are mainly used as second-line or complementary tests (2-4).

In circulation, approximately 80% of vitamin B12 is bound to haptocorrin and is biologically inactive, whereas only the transcobalamin-bound fraction (holoTC), accounting for about 20% of total circulating vitamin B12, is available for cellular uptake. Consequently, total serum vitamin B12 concentrations may not reliably reflect early or functional deficiency. In this context, holoTC has been proposed as a more sensitive and specific biomarker in selected clinical settings, particularly among individuals with borderline vitamin B12 concentrations, older adults, pregnant women, and patients with impaired absorption (e.g., post-gastrectomy). Nevertheless, the routine use of holoTC as a first-line test remains limited due to higher costs and insufficient evidence supporting its cost-effectiveness (2, 4-6).

Consequently, total serum vitamin B12 measurement remains the mainstay of laboratory assessment. However, its analytical determination is inherently challenging due to low circulating concentrations, complex binding characteristics, and the absence of a fully harmonized reference measurement procedure (2). Although the introduction of the WHO International Reference Reagent (IRR 03/178) marked an important step toward standardization, substantial inter-assay variability persists among commercially available immunoassays, primarily driven by differences in calibration, antibody specificity, and assay design, limiting the comparability of results across platforms (1, 7, 8). Moreover, traceability to the WHO International Standard (IS 03/178) has not been fully implemented across all commercially available total vitamin B12 immunoassays. Comparative studies evaluating the performance of current total vitamin B12 assays using patient serum samples remain limited (9, 10).

In addition to analytical variability, there is no universal consensus on clinical decision thresholds for vitamin B12 deficiency. National Institute for Health and Care Excellence (NICE) defines total vitamin B12 concentrations < 133 pmol/L as deficiency and 133-258 pmol/L as possible deficiency requiring confirmatory testing, while slightly higher thresholds (148 pmol/L) have also been applied in clinical practice (2, 11, 12). National Institute for Health and Care Excellence permits the use of locally validated lower reference limits (LRLs) when substantial method-related variability is present (2). Accordingly, guideline-recommended diagnostic cut-offs should be applied only when an assay’s LRL is broadly comparable; otherwise, result interpretation should rely on assay-specific or locally validated reference limits with careful clinical judgment. Fixed diagnostic cut-offs fail to account for method-dependent analytical differences and may therefore result in inconsistent clinical classification across platforms. Although manufacturer-reported LRLs vary across the evaluated assays, Beckman Coulter applies the highest manufacturer-reported lower reference limit, highlighting persistent inter-assay variability (7, 8). However, comparative data evaluating the impact of platform-specific reference intervals on clinical classification in routine laboratory practice remain limited. Moreover, reference intervals derived from healthy populations reflect statistical distributions rather than functional vitamin B12 sufficiency and may miss early or subclinical deficiency (1, 2, 6).

In December 2024, Beckman Coulter introduced the Access Vitamin B12 II Calibrators (REF D06116), traceable to internal standards aligned with the WHO IRR 03/178 in accordance with EN ISO 17511. Although an average recovery of 111% relative to the WHO-assigned concentration of 354 pmol/L has been reported, suggesting improved analytical alignment, the extent to which this recalibration improves inter-platform clinical comparability has not yet been established (13). It therefore remains uncertain whether such recalibration efforts are sufficient to enable uniform application of vitamin B12 deficiency cut-offs across immunoassay platforms, or whether method-specific analytical characteristics continue to influence LRLs and deficiency classification.

We hypothesized that total serum vitamin B12 measurements differ across commonly used immunoassay platforms (Beckman, Abbott, Siemens, and Roche), resulting in method-specific reference intervals and platform-dependent differences in clinical classification when a uniform deficiency cut-off is applied. We further hypothesized that correlations between total vitamin B12 and holoTC vary across analytical platforms.

Materials and methods

This retrospective study was conducted in the Biochemistry Laboratory between February 1 and June 1, 2025. A total of 220 adults (≥ 18 years) attending the internal medicine outpatient clinic for routine health check-ups were included. Clinical records and laboratory data were reviewed in collaboration with an internal medicine specialist. Individuals with conditions known to affect vitamin B12 status were excluded, including chronic systemic or gastrointestinal diseases, malignancy, pregnancy or lactation, and vitamin supplementation within the preceding 3 months. Patients using medications known to interfere with vitamin B12 metabolism, such as metformin, proton pump inhibitors, H2-receptor antagonists, antiepileptic drugs, or those with a history of nitrous oxide exposure were also excluded, as were individuals with clinical or laboratory findings that could confound the assessment of vitamin B12 status (1). Laboratory-based exclusion criteria included anemia (hemoglobin < 120 g/L for women and < 130 g/L for men), macrocytosis (mean corpuscular volume > 100 fL), depleted iron stores (serum ferritin < 15 µg/L), and folate deficiency (serum folate < 6.8 nmol/L) (14-17).

Fasting venous blood samples were collected in serum separator tubes (SST) (Vacusera, Disera A.Ş., Izmir, Turkey; lot no. 235305) and centrifuged within 1 hour at 3000xg for 10 minutes. At the end of each day, residual serum samples from eligible individuals were identified, aliquoted, and stored at - 80 °C for up to two months under controlled conditions to ensure sample stability prior to analysis. All measurements were performed on the same thawed aliquots using four automated immunoassay platforms, in accordance with CLSI EP09c guidelines (18): Beckman DXi 800 Unicel (REF no. 33000) (Beckman Coulter, Brea, USA), Abbott Alinity i 1000 (REF no. 07P6732) (Abbott Laboratories, Abbott Park, USA), Siemens Atellica IM Analyzer (REF no. 57258298) (Siemens Healthineers, Erlangen, Germany), and Roche Cobas e801 (REF no. 806567702) (Roche Diagnostics, Basel, Switzerland). Holotranscobalamin measurements were performed simultaneously on the Abbott Alinity i 1000 system (REF no. 10995088).

All platforms employ competitive assay designs with chemical pretreatment to release vitamin B12, generating signals inversely proportional to analyte concentration. Intrinsic factor-mediated binding is a common feature of all assays; however, methodological differences exist in signal detection. The Abbott Alinity i 1000, Siemens ADVIA Centaur XP/Atellica IM, and Roche Cobas e801 assays are intrinsic factor-based protein-binding methods without direct antibody recognition of vitamin B12, using chemiluminescent microparticle immunoassay (CMIA), direct chemiluminescent immunoassay (CLIA), and electrochemiluminescence immunoassay (ECLIA) principles, respectively. In contrast, the Beckman Coulter Access assay is a competitive immunoenzymatic method in which vitamin B12 binds to an intrinsic factor-enzyme conjugate and detection is achieved through antibody-mediated capture of intrinsic factor-bound complexes.

As this study was retrospective and based on existing laboratory results and residual serum samples, no additional intervention was performed and individual informed consent was not required. The study was approved by the institutional ethics committee of Dr. Lütfi Kırdar Kartal City Hospital (Decision No: 2025/010.99/18/13.

Statistical analysis

Data distribution was assessed using the Kolmogorov-Smirnov test. As the data were non-normally distributed, results are presented as the median and interquartile range (IQR). Reference intervals were calculated using the non-parametric quantile method, defined by the 2.5th and 97.5th percentiles of values obtained from the healthy population, together with 90% confidence intervals (CI), in accordance with CLSI EP28-A3c guidelines (19).

Outliers were identified using the Tukey fence method. Sex-related differences were evaluated using the standard normal deviation (z) test, with calculated z-values compared against the critical z-value. Age-related partitioning was assessed by stratifying participants into four age groups (18-39, 40-59, 60-69, and ≥ 70 years), and differences in vitamin B12 concentrations among age groups were analyzed using the Kruskal-Wallis test (20).

Method comparison was performed using Passing-Bablok regression analysis and the CCC. Comparisons were based on the mean vitamin B12 concentration derived from the four analytical platforms, as no single reference measurement procedure was available. Proportional systematic error was considered significant when the 95% confidence interval for the slope did not include 1.0, and constant systematic error when the 95% CI for the intercept did not include 0.

The relationship between holoTC and total vitamin B12 concentrations measured across platforms was evaluated using Spearman correlation analysis. All statistical analyses were performed using MedCalc Statistical Software version 12 (MedCalc Software, Mariakerke, Belgium).

Results

Analytical performance characteristics of the four vitamin B12 assays, based on manufacturer specifications, are summarized in Table 1. Demographic characteristics and laboratory parameters used for population characterization and vitamin B12 assessment are presented in Table 2, while reference interval data for total vitamin B12 and holoTC are shown in Table 3. Initially, 225 apparently healthy individuals were included for reference interval analysis; five were identified as outliers and excluded, yielding a final study population of 220 individuals.

Analytical performance characteristics of vitamin B12 assays by manufacturer claims
BeckmanVitamin B12 AbbottVitamin B12 SiemensVitamin B12 RocheVitamin B12
Test name B12 II Alinity i B12 Atellica IM B12 Elecsys B12 II
Imprecision across measuring range(total CV %) < 12% < 7.9% < 10% < 8.1%
Analytical sensitivity(pmol/L) LoB < 58LoD < 77LoQ < 77 LoB < 61LoD < 80LoQ < 109 LoB < 33LoD < 66LoQ < 66 LoB < 37LoD < 74LoQ < 111
Linearity(pmol/L) 75-1549 109-1476 33-1476 74-1476
Reference intervals (pmol/L) 164-1062 138-652 156-672 145-569
CV - coefficient of variation. LoB - limit of blank. LoD - limit of detection. LoQ - limit of quantification.
Demographic and laboratory characteristics of the study population
Parameters Median(N = 220) 2.5-97.5thpercentile
Age (median, range) (years) 43 (18-89) 18-75
Sex, N (%) Female 128 (58%)Male 92 (42%)
Hemoglobin (g/L) 135 128-145
Hematocrit (L/L) 0.399 0.298-0.493
MCV (fL) 85.7 61.67-95.72
Folate (nmol/L) 16.61 7.79-38.93
Ferritin (µg/L) 218 23.9-1341
MCV - mean corpuscular volume.
Reference intervals for vitamin B12 and holotranscobalamin
Parameters Median(N = 220) 2.5-97.5thpercentile Lower limit90% CI Upper limit90% CI
BeckmanVitamin B12 (pmol/L) 203 110–522 95-118 413-784
AbbottVitamin B12 (pmol/L) 278 141–517 124-156 452-579
SiemensVitamin B12 (pmol/L) 234 125–430 97-137 407-472
RocheVitamin B12 (pmol/L) 227 120–470 101-128 401-523
HoloTC (pmol/L) 53 21-117 19-23 108-120
HoloTC - holotranscobalamin. CI - confidence interval.

Sex-based partitioning was evaluated using the Harris-Boyd Z test. The calculated Z values for Beckman, Abbott Alinity, Siemens, and Roche assays (1.25, 1.39, 2.27, and 0.96, respectively) were all below the critical value (Z* = 2.87); therefore, sex-specific reference intervals were not warranted, and combined reference intervals were applied across all platforms. Age-related differences in vitamin B12 concentrations were assessed using the Kruskal-Wallis test and were not statistically significant for any platform (Beckman, P = 0.103; Abbott, P = 0.060; Siemens, P = 0.743; Roche, P = 0.136). Accordingly, age-specific reference intervals were not established.

Passing-Bablok regression analyses comparing each analytical platform with the mean vitamin B12 concentration are provided in Supplementary Figure 1. Concordance correlation coefficients demonstrated moderate to good agreement between individual platforms and the reference mean, with values ranging from 0.81 to 0.91 (Table 4).

Method comparison results of four vitamin B12 assays
Passing-Bablok regression analysis Concordance correlation coefficient
Method Slope (CI)* Intercept (CI) CCC (CI) ρ Cb
BeckmanVitamin B12 II 0.99(0.94 to 1.03) - 26.3*(- 38.0 to - 16.2) 0.87(0.84 to 0.89) 0.94 0.92
AbbottVitamin B12 1.16*(1.10 to 1.24) - 3.3(- 19.0 to 13.0) 0.81(0.77 to 0.84) 0.92 0.88
SiemensVitamin B12 1.01(0.95 to 1.08) - 3.8(- 20.0 to 9.1) 0.91(0.88 to 0.93) 0.91 0.99
RocheVitamin B12 1.10*(1.06 to 1.15) - 33.8*(- 43.7 to - 24.4) 0.91(0.88 to 0.93) 0.92 0.98
Comparisons were based on the mean vitamin B12 concentration across four platforms. *A systematic error was considered significant if the 95% confidence interval excluded 1.0 for the slope or 0 for the y-intercept. CCC - concordance correlation coefficient. CI - confidence interval. ρ - Pearson correlation coefficient. Cb - bias correction factor.

Method-specific reference intervals for serum vitamin B12 were established and compared with manufacturer-reported limits. The study-derived LRLs were lower than the manufacturer-provided values for Beckman (110 vs. 164 pmol/L), Roche (120 vs. 145 pmol/L), and Siemens (125 vs. 156 pmol/L), whereas Abbott was the only platform for which the study-derived LRL exceeded the manufacturer’s reported value (141 vs. 138 pmol/L).

Using manufacturer-provided reference intervals, the proportion of individuals classified as having low vitamin B12 concentrations differed markedly between platforms, being highest for Beckman (29.1%), intermediate for Roche (8.6%) and Siemens (8.2%), and lowest for Abbott (1.8%).

When a uniform deficiency threshold of 148 pmol/L was applied, the proportion of samples below the cut-off varied across platforms, ranging from 2.7% for Abbott to 15.0% for Beckman, with intermediate rates for Siemens (6.8%) and Roche (9.5%) (11, 12). Spearman’s correlation analysis showed that the association between total vitamin B12 and holoTC was moderate for Roche (r = 0.48) and Beckman Coulter (r = 0.47), and low for Abbott (r = 0.33) and Siemens (r = 0.26) (Table 5).

Correlation of total B12 with holotranscobalamin
System r (CI)
Beckman Vitamin B12 0.47 (0.35-0.57)
Abbott Vitamin B12 0.33 (0.20-0.45)
Siemens Vitamin B12 0.26 (0.12-0.38)
Roche Vitamin B12 0.48 (0.37-0.58)
r - Spearman correlation coefficient. CI - confidence interval.
Discussion

Persistent inter-assay variability and incomplete harmonization limit the clinical comparability of total vitamin B12 results, while uncertainty over whether clinical classification should be based on fixed diagnostic cut-offs, manufacturer-provided reference intervals, or locally derived reference limits further complicates result interpretation. In line with these challenges, method comparison analyses in the present study indicate that total vitamin B12 measurements are not fully interchangeable across analytical platforms. Although concordance analysis indicated overall moderate to good agreement with the reference mean, Passing-Bablok regression revealed assay-dependent systematic differences, with Beckman showing a constant negative bias, Abbott exhibiting proportional bias, Roche showing both proportional and constant negative bias, whereas Siemens showed minimal systematic bias. Differences in assay design and detection principles (CLIA, CMIA, and ECLIA) may underlie the observed inter-assay variability and should be considered when interpreting vitamin B12 results, particularly when fixed diagnostic cut-offs are applied or results are compared across platforms. These findings are consistent with previous reports demonstrating assay-dependent variability in vitamin B12 measurement. İspir et al. evaluated serum vitamin B12 concentrations using four automated immunoassays-Beckman Coulter DxI 800 UniCel, Siemens ADVIA Centaur XP, Roche Cobas e801, and Abbott Architect i2000sr-and reported high overall correlations among methods. The Beckman Coulter DxI 800 UniCel assay yielded lower vitamin B12 concentrations than the other platforms, with a mean bias of - 90 pmol/L, in line with our observation of a constant negative bias for the Beckman assay. Notably, despite these analytical differences, all four methods showed comparable performance in reflecting functional vitamin B12 status, as indicated by similar correlations with methylmalonic acid and homocysteine (21).

These assay-dependent analytical differences directly influence the clinical interpretation of vitamin B12 results, particularly when uniform cut-offs are applied across different analytical platforms. In this context, our findings highlight the distinct roles of clinical decision limits and reference intervals, as well as the need to apply them in a method-dependent manner when interpreting vitamin B12 results. For vitamin B12, clinical decision limits are outcome-based values derived from external clinical evidence and define concentrations associated with an increased risk of deficiency, whereas reference intervals are method-dependent and reflect the analytical characteristics of individual assays (22).

Analysis of identical samples from our clinically healthy cohort showed that application of a fixed vitamin B12 cut-off (148 pmol/L) resulted in markedly different deficiency classifications across assays, reflecting incomplete inter-assay harmonization. Especially when vitamin B12 concentrations are close to diagnostic decision limits, use of a universal cut-off may lead to inconsistent clinical interpretation across analytical platforms. Assay-dependent differences also persisted when manufacturer-provided reference intervals were applied, with Beckman identifying the highest and Abbott the lowest proportion of results below the lower limit, while Roche and Siemens showed intermediate patterns. This finding indicates a mismatch between manufacturer-defined reference limits and the LRLs observed in our study population. Importantly, method-specific reference intervals should not be regarded as direct substitutes for clinical decision limits, as their isolated use may obscure biochemical deficiency in the absence of appropriate clinical context (2).

In line with our findings, Jassam et al. reported assay-dependent differences in vitamin B12 reference intervals across Roche, Siemens, and Beckman DXi platforms, with the Beckman assay showing a lower reference limit (81 pmol/L) compared with the others. These differences were attributed to the lack of standardized reference materials and the absence of higher-order reference measurement procedures (8). To address whether NICE-recommended vitamin B12 cut-offs can be applied across different analytical platforms, Cesana et al. evaluated inter-assay variability in total vitamin B12 measurements, with particular focus on concentrations close to clinical decision thresholds. Agreement among commonly used total vitamin B12 immunoassays was assessed using 19 external quality assessment exercises and 97 serum samples measured on Abbott, Beckman, Siemens, and Roche platforms, with Roche serving as a WHO International Standard–traceable reference. The authors demonstrated substantial inter-method variability, with Abbott consistently yielding higher and Beckman yielding lower vitamin B12 concentrations relative to Roche; notably, Beckman exhibited both proportional and constant systematic errors. These findings challenge the interchangeability of fixed diagnostic thresholds across assays and support the need for assay-aware interpretation of vitamin B12 results (10). The NICE-recommended 133 pmol/L threshold for absolute vitamin B12 deficiency is method-dependent and based on earlier analytical methodologies that may not be fully harmonized with contemporary standardized assay platforms, potentially limiting cross-platform comparability. Notably, studies using Abbott-based assays have suggested higher deficiency thresholds (~180 pmol/L), indicating that strict adherence to the 133 pmol/L cut-off may underestimate the prevalence of vitamin B12 deficiency in individuals who could benefit from supplementation (2, 9, 23). In the study by Cesana et al., Roche traceable to the WHO International Standard was used as the reference method, and regression-based conversion was applied to estimate corresponding cut-off values for other platforms. Using this approach, a markedly lower threshold of approximately 109 pmol/L was estimated for Beckman, and recalibration of the Beckman system was recommended before reliable application of fixed cut-offs. In our study, conducted after implementation of the WHO-traceable Access Vitamin B12 II calibrator (IS 03/178), method-dependent differences in LRLs persisted, with Siemens and Roche showing closely aligned values, Beckman yielding the lowest (110 pmol/L), and Abbott the highest. These findings indicate that inter-assay variability continues to influence vitamin B12 classification even in a clinically healthy cohort, despite recent calibration updates (7, 10).

In a Roche-based reference interval study including over 27,000 individuals, a higher lower reference limit (140 vs. 120 pmol/L) was reported compared with our study, likely reflecting population differences and the inability to exclude vitamin B12 supplementation in retrospective designs, underscoring the importance of locally derived, population-based reference intervals (24). A study in healthy young adults reported vitamin B12 reference intervals differing from manufacturer-provided ranges and found no gender-related differences, in line with our findings (25). National Health and Nutrition Examination Survey (NHANES) analyses indicate that the higher vitamin B12 concentrations observed with increasing age are largely attributable to greater supplement use; accordingly, no age-related variation was observed in our healthy cohort, from which supplement users were excluded (20).

According to NICE recommendations, holoTC provides complementary information in selected clinical contexts and should not be used as a substitute for total vitamin B12 measurement (2). In our healthy adult cohort, holoTC showed low-to-moderate correlations with total vitamin B12 across all analytical platforms, consistent with previous reports (1, 3). This is expected, as holoTC represents the biologically active fraction of vitamin B12 rather than total circulating concentrations. Accordingly, holoTC and total vitamin B12 assess different aspects of vitamin B12 status and are not interchangeable. The platform-dependent variability in correlation strength further suggests that total vitamin B12 assays differ in how well they reflect the biologically active fraction.

This study evaluated a limited number of immunoassay platforms, while other systems used in different regions were not assessed, which may limit generalizability. Nevertheless, the included assays represent the most widely used and up-to-date platforms available in our laboratory at the time of the study. As none of the evaluated assays constitutes a reference measurement procedure, method comparisons were based on the consensus mean of the four platforms. Due to its retrospective design, only prescribed and documented vitamin B12 supplementation recorded in hospital electronic medical records could be evaluated, whereas undocumented over-the-counter vitamin use could not be completely assessed. Importantly, reference intervals were derived from a carefully selected healthy population, minimizing bias related to vitamin B12 supplementation that cannot be excluded in retrospective studies and thereby enhancing the clinical relevance of the lower reference limits.

In conclusion, this study demonstrates that total serum vitamin B12 concentrations differ substantially across commonly used immunoassay platforms, resulting in method-dependent variation in LRLs and underscoring the need for improved assay harmonization. Application of a uniform deficiency cut-off does not adequately account for these analytical differences and leads to variable deficiency classification, even among apparently healthy individuals. Accordingly, total vitamin B12 cut-offs should not be assumed to be universally applicable across analytical platforms. Accurate assessment of vitamin B12 status requires interpretation beyond fixed cut-offs, incorporating method-specific, locally derived reference limits within the appropriate clinical context. Finally, the low-to-moderate correlations observed indicate that holoTC and total vitamin B12 reflect different components of vitamin B12 status and are not interchangeable, with total vitamin B12 assays differing by platform in their reflection of the biologically active fraction.

Acknowledgments

We gratefully acknowledge the assistance provided in the separation of samples and the valuable contribution to the technical editing of the graphical abstract.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References WolffenbuttelBHOwenPJWardMGreenR. Vitamin B12. BMJ. 2023;383:e071725. 10.1136/bmj-2022-07172537984968 National Institute for Health and Care Excellence (NICE). Vitamin B12 deficiency in over 16s: diagnosis and management. Evidence review for diagnostic tests. NG239. 2024. HannibalLLysneVBjørke-MonsenALBehringerSGrünertSCSpiekerkoetterU Biomarkers and algorithms for the diagnosis of vitamin B12 deficiency. Front Mol Biosci. 2016;3:27. 10.3389/fmolb.2016.0002727446930 Jarquin CamposARischLNydeggerUWiesnerJVazquez Van DyckMRenzH Diagnostic accuracy of holotranscobalamin, vitamin B12, methylmalonic acid, and homocysteine in detecting vitamin B12 deficiency in a large, mixed patient population. Dis Markers. 2020;2020:7468506. 10.1155/2020/746850632089757 NexoEHoffmann-LückeE. Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility. Am J Clin Nutr. 2011;94:359S–65S. 10.3945/ajcn.111.01345821593496 Bjørke-MonsenALLysneV. Vitamin B12 – a scoping review for Nordic Nutrition Recommendations 2023. Food Nutr Res. 2023;67:10257. 10.29219/fnr.v67.1025738084149 CesanaBMPorterKTosiMZuccottiGFerraroS. Changing the bar for B12 deficiency: possible clinical impact of NICE’s thresholds revisions. J Lab Precis Med. 2025;10:49. 10.21037/jlpm-25-49 JassamNBancroftTLuvaiAMbagayaWBarthJH. Vitamin B12 reference intervals on Beckman, Roche and Siemens analytical platforms. Ann Clin Biochem. 2023;60:417–22. 10.1177/0004563223120221137669635 FerraroSDa MolinSCeredaCZuccottiGMarcovinaSCesanaBM. Vitamin B12 Deficiency and New Recommendations by the National Institute for Health and Care Excellence: A Challenging Clinical and Laboratory Topic. Clin Chem. 2025;71:1102–4. 10.1093/clinchem/hvaf03740152469 CesanaBMda MolinSJassamNBarthJHBuoroSTosiM Assessing the harmonization of current total vitamin B12 measurement methods: relevance and implications. Clin Chem Lab Med. 2025;63:2433–41. 10.1515/cclm-2025-093940828910 DevaliaVHamiltonMSMolloyAMBritish Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166:496–513. 10.1111/bjh.1295924942828 de BenoistB. Conclusions of a WHO Technical Consultation on folate and vitamin B12 deficiencies. Food Nutr Bull. 2008;29:S238–44. 10.1177/15648265080292S12918709899 Beckman Coulter. Access Vitamin B12 II assay: instructions for use. Brea (CA): Beckman Coulter; 2024. Available from: https://www.beckmancoulter.com. Accessed August 15th 2025. World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva: World Health Organization; 2024. Hoffbrand AV, Moss PAH. Essential haematology. 7th ed. Oxford: Wiley-Blackwell; 2016. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: World Health Organization; 2020. O’LearyFSammanS. Vitamin B12 and folate deficiency. Nutrients. 2010;2:299–316. 10.3390/nu203029922254022 Clinical and Laboratory Standards Institute (CLSI). Measurement procedure comparison and bias estimation using patient samples; Approved Guideline. CLSI document EP09c. 3rd ed. Wayne: CLSI; 2018. Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved Guideline. CLSI document EP28-A3c. 3rd ed. Wayne: CLSI; 2010 (reaffirmed April 2020). MinevaEMSternbergMRZhangMAokiYStorandtRBaileyRL Age-specific reference ranges are needed to interpret serum methylmalonic acid concentrations in the US population. Am J Clin Nutr. 2019;110:158–68. 10.1093/ajcn/nqz04531127807 İspirESerdarMAOzgurtasTGulbaharOAkınKOYesildalF Comparison of four automated serum vitamin B12 assays. Clin Chem Lab Med. 2015;53:1205–13. 10.1515/cclm-2014-084325720078 OzardaYSikarisKStreichertTMacriJIFCC Committee on Reference Intervals and Decision Limits (C-RIDL). Distinguishing reference intervals and clinical decision limits: a review by the IFCC committee on reference intervals and decision limits. Crit Rev Clin Lab Sci. 2018;55:420–31. 10.1080/10408363.2018.148225630047297 HeilSGde JongeRde RotteMCvan WijnenMHeiner-FokkemaRMKoboldAC Screening for metabolic vitamin B12 deficiency by holotranscobalamin in patients suspected of vitamin B12 deficiency: a multicentre study. Ann Clin Biochem. 2012;49:184–9. 10.1258/acb.2011.01103922302152 MadurgaAArbiol-RocaANavarro-BadalMRCortes-Bosch de BaseaADot-BachD. Strategic use of Big Data: implementing reference intervals for serum folate and serum cobalamin. Biochem Med (Zagreb). 2025;35:010705. 10.11613/BM.2025.01070539974199 AlneesMKharrazLAwwadMNajajraDAbu HamdehNDarwishA The reference value of serum vitamin B12 among An-Najah National University students. J Family Med Prim Care. 2024;13:4035–40. 10.4103/jfmpc.jfmpc_422_2439464998
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030705" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030705" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030705" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(112) "Determination of method-specific reference intervals for vitamin B12 and its correlation with holotranscobalamin" ["journals_article_author"]=> string(77) "Ozlem C. Madenci, Ebru Ertug, Nazire Aladag, Ferruh K. Isman, Ibrahim Yılmaz" ["journals_article_author_country"]=> string(6) "Turkey" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(72) "reference ranges, transcobalamins, vitamin B 12, vitamin B 12 deficiency" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1282" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "10" ["meta_title"]=> string(112) "Determination of method-specific reference intervals for vitamin B12 and its correlation with holotranscobalamin" ["meta_desc"]=> string(112) "Determination of method-specific reference intervals for vitamin B12 and its correlation with holotranscobalamin" ["meta_keyw"]=> string(72) "reference ranges, transcobalamins, vitamin B 12, vitamin B 12 deficiency" ["created"]=> string(19) "2026-10-01 11:15:13" ["modified"]=> string(19) "2026-10-02 11:02:24" } [8]=> object(stdClass)#55 (35) { ["journals_id"]=> string(4) "1258" ["journals_xml"]=> string(66396) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030704 10.11613/BM.2026.030704 Original articles Forensic integrity of blood alcohol sampling in the emergency department, Part II: Establishing quality goals of turnaround time with Monte Carlo simulation IalongoCristiano* Department of Clinical Pathology, University Hospital Policlinico Umberto I, Rome, Italy Corresponding author: c.ialongo@policlinicoumberto1.it

Author contributions

CI conceived and designed the study, performed the statistical analysis and drafted the manuscript.

10082026 15102026 36 3 030704 1304202628062026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Monte Carlo simulation reveals a 7.0% risk of false negatives in the emergency department (ED)

• Optimal quality goal for intra-ED sampling is set at 134 minutes (95% reliability)

• Acceptable and minimum performance goals are 214 and 273 minutes, respectively

• Every 1% increase in assay imprecision erodes the forensic window by 3 minutes

• The Index of Logistic Reliability (ILR) validates transport forensic performance

Introduction

In the emergency department (ED), the turnaround time (TAT) for forensic blood alcohol sampling is a critical determinant of legal admissibility. Due to the pharmacokinetics of ethanol, delays in sampling lead to metabolic decay, potentially resulting in pharmacokinetic false negatives (FNpk). This study aims to establish objective, evidence-based quality goals for intra-ED TAT using Monte Carlo simulation to preserve forensic reliability.

Materials and methods

Data were collected from 121 forensic cases at a major metropolitan university hospital in 2025. A Monte Carlo simulation (N = 50,000 iterations) was performed to model the probability of FNpk based on ethanol elimination rate (β), analytical imprecision (CV), and extra-ED versus intra-ED TAT components. Probability density functions (PDFs) were fitted using Weibull and Gamma distributions to characterize observed clinical and logistical data.

Results

The simulation revealed a baseline P(FNpk) of 7.0% for the intra-ED phase, increasing to 7.6% when including extra-ED transport. Quality goals were derived for three tiers: optimal (TAT95%) at 134 minutes, acceptable (TAT80%) at 214 minutes, and minimum (TAT60%) at 273 minutes. Regression analysis showed that for every 1% increase in assay CV, the TAT quality goal erodes by 2.7 to 3.3 minutes. The logistic process was found efficient, with an Index of Logistic Reliability (ILR) of 86.4%.

Conclusions

Monte Carlo simulation effectively translates pharmacokinetic variables into actionable forensic quality goals. Current ED performance requires process improvement, particularly in the request-transmission phase, to minimize FNpk and ensure forensic equity.

Keywords: blood alcohol concentrationMonte Carlo methodhealthcare quality indicatorsforensic toxicologycomputer simulation
Introduction

In the high-pressure environment of the emergency department (ED), timeliness is synonymous with life-saving care. However, in cases involving suspected drink-driving or substance-facilitated crimes, timeliness is critical during the intra-ED preanalytical phase for blood samples collected for forensic purposes. Indeed, together with the integrity of the chain of custody (CoC), the rapidity in blood sampling preserves the significance of the toxicological evidence and thus is inextricably linked to the “legal admissibility” in judicial proceedings (1).

Central to monitoring this efficiency is the turnaround time (TAT). Traditionally defined as the interval from the initial diagnostic request to the final validation of results, TAT serves as a primary key performance indicator (KPI) for laboratory and emergency services (2). In the forensic context, the narrow window for specimen collection dictated by the pharmacokinetics of ethanol and other drugs entails shortest TAT for avoiding altering evidence due to delay.

To drive process improvement through KPIs, organizations must establish clear quality goals and performance specifications (3). Within the ED, however, there is a notable absence of objective benchmarks specifically tailored for forensic sampling. To bridge this gap, an evidence-based model is required to define the relationship between pharmacokinetic variables and statistical metrics of timeliness, such as the median and the 95th percentile of TAT.

This study is a second part of a two-part investigation and directly builds upon the empirical evidence established in Part I (4). In the preceding epidemiological paper, a retrospective analysis of 115 forensic cases demonstrated that the median intra-ED preanalytical turnaround time was 139 minutes. Crucially, this workflow velocity remained exceptionally stable and unaffected by operational stressors such as emergency department overcrowding, shifts, or weekends, suggesting a fixed or potentially “degraded” operational baseline. When factoring in transit delays from the scene of the accident, the overall median preanalytical lag reached 204 minutes.

To translate these descriptive findings into actionable clinical and legal quality goals, the present study utilizes the exact data parameters and structural definitions derived from the Part I cohort. Specifically, the empirical probability density functions (PDFs) describing serum alcohol concentrations at admission (SACED), intra-ED logistical intervals (TATintra), and extra-ED transit timelines (TATextra) are extracted directly from Part I’s dataset to ground our simulation in real-world clinical behavior. By merging these real workflows with established kinetic behaviors of ethanol metabolic decay and assay imprecision, this work aims to execute a Monte Carlo simulation. The objective is to define precise math-driven quality goals for timeliness, establishing clear thresholds where the probability of a pharmacokinetic decay of the sample is minimized to safeguard the legal admissibility of forensic evidence.

Materials and methods Materials

The data used for this simulation were collected from January 1st to December 31st, 2025, at the Azienda Ospedaliero-Universitaria Policlinico Umberto I of Rome (ethical committee approval on laboratory data retrospective analysis nr.0518/2024). They pertain to drivers involved in road accidents for whom forensic toxicological testing was requested, in compliance with the provisions of the Italian Highway Code (Codice della Strada). All the specimens were collected and processed in the CoC. Data were presented and discussed in Part I of this series (4).

The blood alcohol values used in this study refer to serum alcohol concentration (SAC), in accordance with forensic sample screening procedures performed using the enzymatic method with the alcohol dehydrogenase (ADH) reagent, as described in Part I (4). To this regard, according to the Italian Highway Code, as sample testing SAC < 0.5 g/L is considered legally “negative”, and undergone no further confirmatory analysis by headspace-gas chromatography (HS-GC), except for the novice drivers (driving license < 3 years) for whom it is applied the zero-tolerance.

Methods General principle

The objective of a Monte Carlo simulation is to characterize the behavior of an unknown output variable Y based on N uncertain input variables Xn. Given a general functional model:

the simulation generates synthetic data to approximate the probability density function (PDF) of Y. The process begins by defining the deterministic relationship between variables and assigning a specific PDF to each input X. During each of the N iterations, a stochastic value is sampled for each input form the PDF and propagated through the model to calculate a point value for Y. Collectively, these N iterations constitute the empirical realization of Y. If N is sufficiently large (e.g., N >10,000), the resulting empirical distribution converges toward the true PDF of the output.

Simulation model

If SAC0 and SAC1 are two concentration values measured at a time interval t from each other, then for SAC1 > 0.21 g/L and a known elimination rate β, the relationship can be expressed as:

If SAC0 = SACcrit is the concentration value at the time of the event of interest (e.g., the car accident) and SAC1 = SACED is the concentration value measured at the ED, then t = TAT, and we can write:

Since SACED is subject to measurement error ε due to analytical imprecision (represented by the coefficient of variation, CV) of the assay, the term must be adjusted for each simulation iteration “i” as follows:

where SACED(i) is the i-th simulated value of SACED, Z represents the standard normal deviate, i.e., a Gaussian distribution with a mean of 0 and unit variance (corresponding to a given level of probability). See Appendix A for further explanation.

Similarly, TAT can be adjusted for the i-th simulation by decomposing into an extra- (TATextra) and an intra-ED (TATintra) component, namely:

Hence, it follows that:

Probability of false negatives

Given L as the legal limit for alcohol intoxication (LLI), the i-th subject with a SAC greater than L at the moment of blood sampling in the ED is defined as:

However, an individual with SAC greater than L at the time of the event is defined by Eq.3 as:

Therefore, an individual rendered “negative” due to an extended TAT satisfies both Eq. 4 and Eq. 5, by definition. Thus, for a pharmacokinetic false negative (FNpk), we can write:

The conditional probability of an FNpk can then be calculated as the ratio of subjects who were formerly positive but are currently negative to the total number of subjects who were formerly positive:

The function I(…) represents the indicator function, which returns 1 if the condition within the brackets is met and 0 otherwise. Obviously, the term TAT can be treated according to Eq. 3c.

To provide an objective assessment of FNpk, a predefined acceptability threshold (α) can be established:

Quality goal of turnaround time

If C0 = Croad is a known or assumed population characteristic (e.g., blood alcohol by roadside breath testing) and C1 = L, the quality goal for TAT can be defined based on the “erosion” (metabolic degradation) of ethanol measured in the ED sample:

To account for the analytical imprecision of the measurement method in the ED, Eq. 9a can be modified by incorporating the CV, as seen in Eq. 3b:

In this case, the random Z is replaced by a constant k, chosen to represent a specific coverage probability for L to provide a “protected” LLI (Lprot). This serves as a safety threshold to ensure that - net of instrumental error - the subject’s SAC (or BAC) is truly above the legal limit (see Appendix B for further details).

Since Eq. 9b represents the total TAT from the time of the event to the completion of sample collection, it includes both extra-ED and intra-ED time. Therefore, if the PDF of the extra-ED TAT is known, it follows that:

Based on Eq. 9c, quality specifications can be derived from the percentiles of the generated TAT distribution. Consequently, the p-th percentile represents the maximum allowable time to prevent Croad from eroding below the legal threshold for 100 x (1-p)% of subjects:

Alternatively, to represent the worst-case scenario (i.e., considering subjects with the highest metabolic degradation rate), the 95th percentile of β can be used in place of the stochastic value:

Consequently, quality goals can be directly derived from the 5th (optimal or TAT95%), 20th (acceptable or TAT80%), and 40th (minimum or TAT60%) percentiles of the TATgoal. Specifically, the p-th percentile represents the TAT value ensuring that 100 x (1-p)% of the Croad distribution remains above the limit L at the time of ED sampling. This value also corresponds to a threshold Croad value, which represents the minimum concentration guaranteed to avoid the risk of FNpk.

Benchmark of extra-ED turnaround time

If TATextra and Croad are known, based on Eq. 9a, an Index of Logistic Reliability (ILR) can be derived relative to the average logistic quality:

As shown, ILR > 0.5 indicates an efficient logistic service, as at least 50% of TATL(CV) is available to the ED to complete blood sampling. Conversely, ILR > 0.5 indicates logistic inefficiency, as transport leaves less than 50% of TATL(CV) for blood sampling. Notably, if TATextra is so delayed that it exceeds TATL(CV), then ILR ≤ 0. In such cases, a logistic failure occurs because the patient arrives at the ED when the alcohol level in blood is already below L.

Finally, given Eq. 11, the probability of logistic success (PLS) can be calculated as follows:

This index returns the probability that the TATextra is short enough to leave at least 100 x ω% of the TATL(CV) to the ED personnel to complete the blood sampling before the concentration falls below L(CV).

Probability density function estimation

To model the SACED, TATintra, TATextra, we utilized 3-parameter Lognormal, Weibull, and Gamma distributions. These specific PDFs were selected to accommodate the positive lower bounds and long right tails characteristic of the observed data. The optimal PDF fit was determined by minimizing the sum of squared differences (SSQ) between the empirical and calculated 5th, 10th, 25th, 50th, 75th, 90th percentiles, as defined by:

To ensure the distributions respected physical and physiological constraints, a minimum threshold θ) was assigned during parameter optimization. For PDF of SACED, θ ≥ 0.21 g/L to represent the transition between zero- and first-order kinetics, accounting for a 15% inherent overestimation in SAC measurement (1.15 x 0.18 g/L ≈ 0.21 g/L). Based on empirical evidence, the thresholds for the PDF of TATintra and the PDF of TATextra were set at θ ≥ 60 and θ ≥ 30 minutes, respectively.

Conversely, the PDF of β was directly modeled using a Normal distribution based on established literature, with a mean (μ) of 0.15 g/L and a standard deviation (SD) of 0.03 g/L (5). The PDF of Croad distribution was modeled using a truncated Normal distribution, consistent with established literature on roadside alcohol control (6, 7). The parameters were adjusted to yield a SAC with μ = 1.6 g/L (equivalent to 1.36 g/L BAC), with a SD = 0.30 g/L and θ = 0.30 g/L (0.26 g/L BAC).

Statistical analysis

Fitting of PDFs and Monte Carlo simulations were conducted using Microsoft Excel 2013 (Microsoft Corporation, Redmond, USA), using Visual Basic macros (which can be provided as add-ins on request). All simulations were performed with N = 50,000 iterations, for CV = 5% and L = 0.5g/L.

The temporal erosion rate of the TAT quality goals relative to the assay CV was determined using ordinary least-squares (OLS) linear regression. To generalize this relationship across different tiers, each quality goal dataset (TAT95%, TAT80%, and TAT60%) was normalized via zero-centering. Specifically, the calculated intercept was subtracted from each observed value to force the regression through the origin (i.e., setting the intercept c = 0).

Results

For the 2025 calendar year, the total caseload consisted of N = 121 forensic toxicological cases performed under chain of custody. The epidemiological characteristics of this cohort have been previously described in Part I of this study (4). From this total, N = 39 (32%) cases were selected based on a SACED = 0.21 g/L. Figure 1 illustrates the stratification of SACED and intra-ED TAT relative to sample selection. Regarding the estimation of PDFs, Table 1 summarizes the fitting results.

Distribution of serum alcohol concentration (SAC) and turnaround time (TAT) of data selected for Monte Carlo simulations (shaded bars) and excluded data (white bars), based on the eligibility threshold of SAC ≥ 0.21 g/L; panel “A” shows SAC values across the dataset and panel “B” of TAT values, measured in minutes, categorized by the same SAC threshold.

Best fit of probability density functions
Variable Lognormal(SSQ) Weibull(SSQ) Gamma(SSQ)
SACED 0.168050 0.036837 0.073868
TATintra 159.0934 157.5233 143.5628
TATextra 20.64071 9.151448 8.955764
SSQ – sum of squared differences. ED – emergency department. SACED – serum alcohol concentrations at admission. TATintra – intra-ED turnaround time. TATextra – extra-ED turnaround time.

Analysis of the deciles for the estimated SACED PDF (with θ = 0.21 g/L) revealed a sub-optimal fit in the left tail of the distribution - the region most significantly associated with the generation of FNpk. Consequently, a compromise was applied by setting θ = 0.15 g/L. This corresponds to approximately 0.13 g/L after adjusting for SAC bias - a value where the elimination constant is roughly 80% of the ADH saturation point - resulting in an SSQ = 0.028957 (8). Final parameter details are provided in Table 2.

Parameters of fitted probability density functions
Variable Distribution location scale shape
SACED Weibull 0.15 1.431 1.808
TATintra Gamma 65.4 52.912 1.319
TATextra Gamma 30 13.766 1.591
ED – emergency department. SACED - serum alcohol concentrations at admission. TATintra - intra-ED turnaround time. TATextra - extra-ED turnaround time.

Based on the parameters in Table 2, Monte Carlo simulations indicate a P(FNpk) = 7.0% when considering TATintra alone, and P(FNpk) = 7.6% when including TATextra. Figure 2 shows the impact of CV values ranging from 2% to 25% on P(FNpk).

Effect of assay imprecision, measured as the coefficient of variation (CV), on the probability of pharmacokinetic false negatives (P(FNpk)). P(FNpk) was calculated based on either the intra-emergency department turnaround time (TATintra) alone or the combined intra- and extra-ED TAT (TATtotal).

The quality goals obtained assuming a legal positivity limit of 0.541 g/L (after adjustment for a CV of 5% uncertainty) are shown in Table 3. Figure 3 depicts the correlation between TATintra and P(FNpk) for a subject whose SACroad is unknown at the time of ED admission.

Quality goals for the intra-emergency department turnaround time calculated for subjects with rapid elimination kinetic (β<italic><sub>95th</sub></italic>) or random population value (β<italic><sub>stochastic</sub></italic>)
Quality goal Level of protection (%) against FNpk Minimum serum alcohol at the scene (SACroad, g/L) protected from FNpk TATintra (minutes)
β95th βstochastic
50 1.61 298 375
Minimum (TAT60%) 60 1.53 273 342
70 1.45 245 306
Acceptable (TAT80%) 80 1.35 214 266
90 1.22 169 213
Optimal (TAT95%) 95 1.12 134 171
99 0.91 65 89
FNpk -pharmacokinetic false negative, i.e. a subject which is negativized by the prolonged waiting for the blood sampling in the emergency department. TATintra - intra-ED turnaround time. A legal limit of intoxication of 0.5 g/L adjusted for analytical imprecision of CV = 5% (final value 0.541 g/L) was applied.

Relationship between the probability of false negatives (P(FNpk)) and the intra-Emergency Department turnaround time, calculated against a legal limit of alcohol intoxication of 0.5 g/L and an assay imprecision of 5% (TATL(CV)). The graphic shows how short the TATL(CV) needs to be to ensure a given P(FNpk). P(FNpk) was calculated based on either the stochastic value (open circles) or the 95th percentile (open triangles) of the distribution of the elimination rate (β) of ethanol. The horizontal dotted line represents P(FNpk) = 5%.

Regression analysis indicates that for every one-percent increase in assay CV, the TAT quality goal is reduced by approximately 2.7 to 3.3 minutes. This variability depends on whether the calculation is based on the 95th percentile of the ethanol elimination rate (β95th ≈ 0.2 g/L/h, a fixed value representing rapid metabolizers) or the stochastic population elimination (representing the random variation around the population mean μstochastic ≈ 0.15 g/L/h). This relationship is illustrated in Figure 4.

Effect of assay imprecision, measured as the coefficient of variation (CV), on the temporal erosion of the turnaround time (TATintra) quality goal, calculated against a legal limit of alcohol intoxication of 0.5 g/L and an assay imprecision of 5%. Temporal erosion (measured in minutes) was calculated based on either the stochastic value (open circles; μstochastic ≈ 0.15 g/L/h) or the 95th percentile (open triangles; β95th ≈ 0.2 g/L/h) of the ethanol elimination rate (β) distribution. Linear regression analysis reveals that for any TAT goal, there is a temporal erosion ranging from - 2.7 to - 3.3 minutes for every one-percentage-point increase in assay imprecision, depending on whether β is used to simulate a random individual (the stochastic value) or a rapid metabolizer (the 95th percentile of β).

Regarding the efficiency of the extra-ED TAT phase, the ILR = 86.4% (Figure 5). Therefore, based on a minimum target ILR of 70%, the PLS = 96.6%,

Graphical representation of the Index of Logistic Reliability (ILR). The full circle represents the average time elapsed from the car accident—the moment the subject was putatively positive - to the point of negativization relative to the legal limit of alcohol intoxication (LLI) of 0.5 g/L. The dark-gray shaded area indicates the time window available to perform blood sampling in the emergency department (ED) following the subject’s arrival at the hospital. The dashed white line represents the acceptability threshold of ILR = 70%.

Discussion

The Monte Carlo simulation provides a robust framework for defining objective quality goals of timelines in forensic testing for drink-driving. Numerical simulations become indispensable when experimental evidence is neither ethical nor practically feasible. This makes them an essential tool in the investigation of extra-analytical quality, where outcome studies - while highly desirable for producing high-value information to define quality goals - remain extremely difficult to implement (9, 10).

By modeling the stochastic nature of ethanol pharmacokinetics and the analytical uncertainty of the laboratory assay, we have translated TAT into measures of forensic reliability. Therefore, TAT is not merely a KPI of efficiency but a critical determinant of legal admissibility. This completes the characterization of the reliability paradigm for forensic procedures in medical emergency settings, alongside preanalytical procedures and assay robustness (11, 12).

The simulation analysis of epidemiological findings from Part I revealed that P(FNpk) was as much as 7.0% when considering the intra-ED phase alone and increased marginally to 7.6% when the extra-ED phase was included. This suggests that approximately one in thirteen drivers, despite being above the legal limit at the time of the incident, may test negative at the time of sampling due to metabolic decay. We may consider this result satisfactory if we assume an arbitrary goal of 5% (recalling Eq. 8), although there is no evidence in the literature establishing such a value as an objective quality goal.

Thus, to drive process improvement through truly objective criteria, we defined three tiers of quality goals for the TATintra based on SACroad data from a population of drivers whose blood alcohol content was known through roadside controls. In this manner, ED performance is calibrated against the specific composition of the individuals potentially prompting a CoC. For the evaluation of ED performance, we compared these goals with the 95th percentile calculated for the TATintra. While this percentile is certainly more representative of execution performance, it is also more susceptible to the influence of extreme values, given that the TAT PDF is strongly right-skewed. Consequently, further investigation is warranted to assess the stability of different percentiles relative to their ability to represent process performance, particularly regarding P(FNpk).

Notwithstanding, our current 95th percentile of 294 minutes observed in Part I (95% CI: 271–320 minutes) rests entirely between the TAT80% and the TAT60%. We can therefore state that our performance falls within an acceptability range that guarantees coverage of a SACroad of at least 1.53 g/L, which is slightly above the median of 1.48 g/L observed in Part I. This figure appears as acceptable as a SAC of 1.53 g/L in the ED was certainly higher at the time of the incident, that is SACroad. However, it must be recalled that in our case series, 7.4% of subjects had a SAC between 0.1 and 0.5 g/L and 64.5% had values below 0.1 g/L. Therefore, bearing in mind that the logic of this “protection” is to ensure that operating within such a maximum TATintra (i.e., the 95th percentile) guarantees an 80% to 60% probability that a random subject remains above the legal limit at the time of sampling, it is evident that a significant portion of the observed negatives are likely false negatives. It must be also considered that under the most stringent quality goal parameters, our performance significantly exceeds the minimum acceptable TAT60% of 273 minutes. Therefore, process improvement is clearly necessary.

To develop an improvement plan, the TATintra stratification from Part I (Table 1) indicates that the most actionable phase is the transmission of the request for CoC testing. This phase alone can account for up to nearly 150 minutes, which is likely to be merely a waiting time for almost 50% of CoC of drink-driving cases that are represented by lower-severity triage codes. Importantly, establishing these quality goals does not imply that forensic sampling should ever compete with active medical resuscitation. Patient care and stabilization remain the absolute ethical and clinical priorities in the ED. Instead, these performance benchmarks target systemic, administrative bottlenecks - such as the request-transmission phase - which often leave stable, lower-severity patients waiting unnecessarily, thereby inadvertently degrading vital forensic evidence.

Regarding the extra-ED phase, another part of potential improvement, our benchmark indices show that with an ILR of 86.4%, patient transport consumes less than 20% of the “metabolic time” to reach L. Thus, the ED has over 80% of the available time to perform the blood draw before the subject tests negative. If we set a minimum quality goal for transport at an ILR of 70%, the PLS of 96.6% indicates that the transport process is fully capable of meeting this requirement. These data align well with the 0.6 percentage point increase in P(FNpk) observed when adding TATextra to TATintra, objectively excluding the logistical process from the primary improvement path.

A key advantage of numerical simulations is the ability to model diverse clinical and analytical scenarios, which enabled us to investigate the relationship between TAT and the assay CV. Our results demonstrate that higher CV values necessitate shorter sampling times to maintain an equivalent level of forensic certainty. Indeed, the CV acts as a “hidden delay” that erodes the quality goal by raising the ‘protected’ LLI or, equivalently, by blurring the measured SAC. Given an erosion rate of 2.7 to 3.3 minutes for every one-percent increase in CV, a 2% CV (typical of chromatographic methods) offers no substantial advantage over the 5% CV afforded by modern, fully automated ADH assays. In contrast, a 10% CV reduces the TAT quality goals by approximately 30 minutes across all tiers, while a 20% CV results in a nearly 60-minute reduction. Beyond the analytical uncertainty introduced by the assay CV, the model is similarly sensitive to individual metabolic variations, particularly in the “worst-case biological scenario” of rapid clearers simulated by the 95th percentile of the elimination rate (β95th). As shown in Table 3, when shifting from a stochastic population distribution (μstochastic ≈ 0.15 g/L/h) to a rapid clearance rate (β95th ≈ 0.20 g/L/h), the allowable time window to capture evidence shrinks significantly from 171 to 134 minutes. This explicitly demonstrates how an increasing β compounds the “hidden delay” of analytical error and drastically escalates the P(FNpk). These findings are of particular relevance given that current regulations do not distinguish between the clinical and forensic applications of enzymatic ADH assays (12). Indeed, even though the enzymatic ADH testing is not acceptable for forensic confirmation due to its known limitations, nevertheless, establishing strict operational timelines remains vital to safeguard the reliability of the initial screening phase within the clinical laboratory framework before eventual chromatographic confirmation (12).

The critical need for workflow timeliness is further amplified by regional legal frameworks. In countries like Italy, retrograde extrapolation (back-calculation) is judicially inadmissible, meaning that a delayed sample cannot be legally reconstructed. Consequently, any screening result where SAC < 0.5 g/L is strictly dismissed as legally negative and is not sent for confirmation, unless a zero-tolerance policy applies. Conversely, in jurisdictions where retrograde extrapolation is permitted, achieving a rapid intra-ED TAT remains scientifically vital. Ensuring the blood draw occurs before the blood alcohol levels decay into non-linear elimination kinetics SAC < 0.21 g/L is a prerequisite for executing a mathematically valid and safe back-calculation.

Concerning the limitations of this study, as a simulation its power primarily depends on the goodness-of-fit of the PDFs to the observed data. Given the relatively small sample size, the accuracy of the PDF modeling may have been constrained, particularly within the left tail of the distribution where P(FNpk) cases originate. Consequently, the defined quality goals may lack perfect centering. To address this concern, it must be noted that P(FNpk) and TAT quality goals do not necessarily coincide. The reason is that these two measures approach the same issue from opposite perspectives. Specifically, P(FNpk) is a backward estimation based on “aftermath” data; at this stage, it is difficult to determine which samples falling below the LLI (especially if also below the limit of quantitation) were originally positive but turned negative due to waiting times. Conversely, quality goals are established via forward calibration on the actual population expected during roadside controls - the population most likely to generate CoC events. The same applies when considering the difference between P(FNpk) calculated on TATintra and TATtotal, respect to the ILR. Therefore, the suggested strategy is to use P(FNpk) as a starting point to evaluate the forensic reliability of the ED and subsequently rely on calibrated quality goals once the population has been characterized for prediction.

Finally, a fundamental limitation of the present study concerns its single-center retrospective design and the specific dataset used to configure the simulation model. While the Monte Carlo framework incorporates a massive number of stochastic iterations to capture analytical and physiological variability, the underlying PDFs are fundamentally reflective of the specific operational workflows, logistical bottlenecks, and patient demographics of a single metropolitan university hospital. Consequently, the validity, predictive power, and target thresholds (TAT95%, TAT80%, TAT60%) of this quality-goal model must be rigorously evaluated on an independent set of samples. External validation using discrete data matrices collected from diverse emergency frameworks and geographical jurisdictions is essential. Testing the model against such independent datasets will confirm whether these algorithmic quality definitions can be safely generalized as standard performance indicators across the broader clinical and forensic toxicology community.

In conclusion, this two-part study provides a quantitative framework for assessing forensic equity in the ED. Based on numerical simulations of collected epidemiological data, this offers an unprecedented approach in laboratory medicine literature that merges medico-legal reliability with patient safety. Future research should expand upon this model, ideally through prospective multi-center studies integrating extensive data from both roadside controls and diverse hospital settings.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References JonesAW. Pharmacokinetics of ethanol - Issues of forensic importance. Forensic Sci Rev. 2011;23:91–136.26231237 HawkinsRC. Laboratory turnaround time. Clin Biochem Rev. 2007;28:179–94.18392122 SimundicAMTopićE. Quality indicators. Biochem Med (Zagreb). 2008;18:311–9. 10.11613/BM.2008.027 SapioMCrinitiAGiglioSGalardoGGandiniOAngeloniA Forensic integrity of blood alcohol sampling in the Emergency Department, Part I: Epidemiology and factors affecting turnaround time. Biochem Med (Zagreb). 2026;36:030703. 10.11613/BM.2026.030703 JonesAW. Evidence-based survey of the elimination rates of ethanol from blood with applications in forensic casework. Forensic Sci Int. 2010;200:1–20. 10.1016/j.forsciint.2010.02.02120304569 JonesAW. Evaluation of breath-alcohol instruments. IV. Roadside tests with Alcolmeter pocket model. Forensic Sci Int. 1985;28:157–65. 10.1016/0379-0738(85)90126-44065780 KriikkuPWilhelmLJenckelSRintataloJHurmeJKramerJ Comparison of breath-alcohol screening test results with venous blood alcohol concentration in suspected drunken drivers. Forensic Sci Int. 2014;239:57–61. 10.1016/j.forsciint.2014.03.01924747668 HøisethGWiikEKristoffersenLMørlandJ. Ethanol elimination rates at low concentrations based on two consecutive blood samples. Forensic Sci Int. 2016;266:191–6. 10.1016/j.forsciint.2016.05.03927295074 HorvathARBossuytPMSandbergSJohnASMonaghanPJVerhagen-KamerbeekWD Setting analytical performance specifications based on outcome studies - is it possible? Clin Chem Lab Med. 2015;53:841–8. 10.1515/cclm-2015-021425996384 HorvathARBellKJLCeriottiFJonesGRDLohTPLordS Outcome-based analytical performance specifications: current status and future challenges. Clin Chem Lab Med. 2024;62:1474–82. 10.1515/cclm-2024-012538836433 IalongoC. Blood alcohol concentration in the clinical laboratory: a narrative review of the preanalytical phase in diagnostic and forensic testing. Biochem Med (Zagreb). 2024;34:010501. 10.11613/BM.2024.01050138107001 IalongoCJonesAW. The enzymatic analysis of alcohol (ethanol) in serum and plasma with the alcohol dehydrogenase reagent: focus on intra-analytical and post-analytical aspects. Biochem Med (Zagreb). 2025;35:030501. 10.11613/BM.2025.03050140822841
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030704" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030704" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030704" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(156) "Forensic integrity of blood alcohol sampling in the emergency department, Part II: Establishing quality goals of turnaround time with Monte Carlo simulation" ["journals_article_author"]=> string(17) "Cristiano Ialongo" ["journals_article_author_country"]=> string(5) "Italy" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(120) "blood alcohol concentration, Monte Carlo method, healthcare quality indicators, forensic toxicology, computer simulation" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "9703" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "9" ["meta_title"]=> string(156) "Forensic integrity of blood alcohol sampling in the emergency department, Part II: Establishing quality goals of turnaround time with Monte Carlo simulation" ["meta_desc"]=> string(156) "Forensic integrity of blood alcohol sampling in the emergency department, Part II: Establishing quality goals of turnaround time with Monte Carlo simulation" ["meta_keyw"]=> string(120) "blood alcohol concentration, Monte Carlo method, healthcare quality indicators, forensic toxicology, computer simulation" ["created"]=> string(19) "2026-08-10 10:31:42" ["modified"]=> string(19) "2026-10-02 11:02:11" } [9]=> object(stdClass)#54 (35) { ["journals_id"]=> string(4) "1257" ["journals_xml"]=> string(60018) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030703 10.11613/BM.2026.030703 Original articles Forensic integrity of blood alcohol sampling in the emergency department, Part I: Epidemiology and factors affecting turnaround time SapioMaria1CrinitiAnna2GiglioSimona1GalardoGioacchino3GandiniOrietta4AngeloniAntonio2IalongoCristiano1 Department of Clinical Pathology, University Hospital Policlinico Umberto I, Rome, Italy Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, Italy Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy Corresponding author: c.ialongo@policlinicoumberto1.it

Author contributions

M Sapio: Conceptualization, Writing – original draft, Writing – review & editing; A Criniti: Methodology, Formal analysis, Writing – review & editing; S Giglio: Methodology, Formal analysis, Writing – review & editing; G. Galardo: Methodology, Formal analysis, Writing - review & editing; O Gandini: Methodology, Formal analysis, Writing – review & editing; A Angeloni: Investigation, Writing – review & editing; C Ialongo: Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing

10082026 15102026 36 3 030703 1304202628062026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Median intra- emergency departments (ED) turnaround time for forensic alcohol sampling is 139 minutes

• The primary bottleneck is the 57-minute delay in requesting toxicological tests

• Intra-ED sampling delays are independent of triage priority and duty shifts

• Total preanalytical delay from accident to sampling reaches a median of 204 min

• Sampling delays remain stable regardless of hospital workload or time of day

Introduction

Drink-driving remains a leading global cause of road traffic fatalities. In Italy, the determination of blood alcohol concentration (BAC) in injured drivers relies on coordination between law enforcement and emergency departments (ED) to ensure legally admissible evidence. Because ethanol undergoes continuous metabolic decay, any delay in blood sampling can lead to underestimated values or “pharmacokinetic false negatives”.

Materials and methods

A retrospective study was conducted throughout 2025 on 115 drivers admitted to a major university hospital following road accidents. Preanalytical turnaround time (TAT), categorized into intra-ED and extra-ED intervals, was assessed against variables like clinical severity (triage code), temporal patterns (duty shifts/weekends), and licensure status. Serum alcohol concentration (SAC) that is used to screen BAC was measured with the enzymatic methods.

Results

The population was predominantly male (77.4%) with a median age of 36 years. While the median intra-ED TAT was 139 minutes and remained stable across various clinical and temporal factors, the overall preanalytical TAT (from accident to sampling) reached a median of 204 minutes. The only statistically significant association concerned SAC at ED admission with ED duty shift (P = 0.045), and with day of the week (P = 0.035).

Conclusions

The observed TAT appears insensitive to environmental stressors, potentially indicating a “degraded” baseline performance. This study emphasizes that objective quality goals for TAT cannot rely solely on administrative averages. Instead, they must be grounded in a quantitative relationship between sampling delay and metabolic decay using pharmacokinetic models to mitigate the risk of forensic evidence loss.

Keywords: blood alcohol contenthospital emergency servicepreanalytical phasesubstance abuse detectionretrospective study
Introduction

Drink-driving is one of the leading causes of death and serious injury worldwide, affecting drivers, passengers, and pedestrians alike. It is well documented that alcohol impairs the cognitive and motor functions essential for safe driving, leading to a markedly increased risk of road traffic crashes even at relatively low blood alcohol concentration (BAC) (1, 2). Globally, it is estimated that 5% to 35% of all road traffic fatalities are attributable to driving under the influence of alcohol, with substantial regional variability related to legislation, cultural factors, and the enforcement of traffic safety laws (3, 4).

In Europe, approximately 25% of all road traffic deaths are alcohol-related (5). In response, the European Union (EU) has identified drink-driving as a key target for prevention and enforcement, setting since 2011 the objective of reducing road fatalities by 50% (6). These policy orientations have reinforced the need for effective legal and clinical procedures to ensure timely and reliable assessment of alcohol impairment.

In Italy, the enforcement of drink-driving laws in traffic accidents resulting in injured drivers relies on close coordination among law enforcement agencies, emergency medical services, and hospital emergency departments (EDs). This integrated framework is designed to ensure both timely and appropriate medical care and the legally admissible determination of BAC as close as possible to the time of the incident. Such timing is crucial because, due to the pharmacokinetics of ethanol, delayed blood sampling may lead to falsely negative or underestimated BAC values (7).

While playing a pivotal role in this process, the ED is frequently burdened by high workloads, time pressure, and overcrowding, factors that can compromise the timeliness of blood sampling. Additionally, the legal requirements for BAC testing necessitate a rigorous and time-consuming chain of custody (CoC) protocol. In cases involving severe offenses, such as ‘vehicular homicide’, blood testing results must be provided strictly within 48 hours of the blood draw. Consequently, the burden of the CoC process extends beyond the ED to the hospital’s clinical laboratory. To expedite the overall turnaround time (TAT), the CoC workflow may involve an initial screening phase of serum alcohol concentration (SAC) measured with the enzymatic alcohol dehydrogenase (ADH) reagent on clinical chemistry analyzers (8). Thereafter, confirmatory analysis via headspace gas-chromatography (HS-GC) is performed, sometimes directly within the same laboratory setting.

Against this background, this research has been developed as two-part study. The present article (Part I) aims to provide epidemiological data on drink-driving cases at a major metropolitan university hospital, and to identify the factors influencing timely blood sampling for SAC analysis within the CoC framework. Part II of this study (published separately) assess TAT for SAC within CoC in the ED to establish evidence-based quality goals of performance (9).

Materials and methods Study population and data collection

Data were collected retrospectively from January 1st to December 31st, 2025 (ethical committee approval on laboratory data retrospective analysis nr.0518/2024). The study included drivers involved in road accidents and admitted to the ED of Azienda Ospedaliero-Universitaria Policlinico Umberto I of Rome, for whom a forensic toxicological determination of alcohol concentration was requested in compliance with the provisions of the Italian Highway Code (Codice della Strada). Since the Italian Highway Code defines legal limits in terms of BAC, but an initial screening phase of SAC measured with the ADH method is performed for CoC, all analytical measurements and data stratifications within this study are reported strictly as SAC.

Newly licensed drivers and professional drivers, for whom Italian law mandates a zero-tolerance policy for the use of any psychotropic substances, were also included. All the specimens were collected and processed in the CoC.

Demographic variables

Descriptive epidemiological analyses included patient age at the time of ED admission and sex, and driving status, with particular attention to newly licensed drivers (< 3 years vs. ≥ 3 years of licensure), in accordance with the Italian Highway Code.

Preanalytical turnaround time and influencing variables

For the assessment of preanalytical TAT, the following time points were considered: (a) presumed time of the accident; (b) time of ED admission; (c) time of receipt of the toxicological testing request issued by prosecutorial or law enforcement authorities; and (d) the start and (e) end times of sample collection within the chain of custody. Accordingly, the following intra-ED TAT intervals were calculated: b–c, c–d, d–e, as well as the total intra-ED preanalytical TAT (TATintra) was defined b–e. The extra-ED preanalytical TAT (TATextra) was defined as a–b; therefore, the overall preanalytical TAT (TATintra+ TATextra) was defined as a–e. The time points are represented in Figure 1.

Schematic flowchart of the preanalytical turnaround time (TAT) workflow and intervals. For the assessment of preanalytical TAT, the following definitive time points were considered: (a) presumed time of the accident; (b) time of emergency department (ED) admission; (c) time of receipt of the toxicological testing request issued by prosecutorial or law enforcement authorities; and (d) the start and (e) end times of biological sample collection within the chain of custody (CoC).

Variables potentially influencing TAT included the severity of the patient’s clinical condition at admission, classified according to the triage numerical/color code (1–2–3; red–yellow–green); temporal patterns of ED arrival time according to duty shifts, categorized as daytime (08:00–14:00), afternoon (14:00–20:00), or nighttime (20:00–08:00); and the day of the week (weekday vs. weekend/holiday).

Toxicological analysis

Serum alcohol concentration testing was performed on Ilab Taurus chemistry analyzer (Instrumentation Laboratory S.p.A., Milan, Italy). Where appropriate, SAC values were categorized as < 0.1 g/L (limit of quantitation of the ADH method), 0.1-0.5 g/L (below the legal limit of intoxication), 0.5-0.8 g/L (first grade of intoxication above the legal limit), 0.8-1.5 g/L (second grade) and > 1.5 g/L (third grade).

Statistical analysis

Outliers in the TAT were identified using the available CoC information and were then excluded from the analysis. All data were preliminarily assessed for normality using the Anderson-Darling test. In the absence of a normal distribution, continuous variables were reported as the median and interquartile range (IQR). Differences in medians were evaluated using either the Mann-Whitney test or the Kruskal-Wallis test, depending on the number of groups compared, while associations between categorical variables were assessed using Fisher’s or Fisher-Freeman-Halton’s exact test. All analyses were performed on the total sample size, unless otherwise specified. Confidence intervals on percentiles were computed using the bias-corrected accelerated (BCa) bootstrap. Statistical significance was set at P < 0.05. All statistical analyses were conducted using Minitab software (version 22.1; Minitab, LLC, State College, USA).

Results Epidemiological data

The study population consisted of 121 individuals, 115 of whom were included in the final analysis as they were associated with known cases of prolonged delay (e.g., incorrect name in the first toxicological analysis request which caused a resubmission of the request). Data are summarized in Table 1. Age distribution did not differ significantly between the genders (P = 0.970). No professional drivers were present.

Summary data of the case series demographics and driving experience
Variable Males (N = 89) Females (N = 26) Total (N = 115)
Median age (IQR) 36.2 (28.3) 35.6 (27.6) 36.2 (26.6)
License < 3 years, N (%) 11 (12.4%) 4 (15.4%) 15 (13.0%)
License > 3 years, N(%) 78 (87.6%) 22 (84.6%) 100 (87.0%)

With regard to trauma severity, 61 individuals (53%; 50 males and 11 females) were classified as triage code 1 (immediate), 34 (29.6%; 24 males and 10 females) as triage code 2 (delayed), and 20 (17.4%; 15 males and 5 females) as triage code 3 (minor). The distribution of patient age stratified by sex and triage code is shown in Figure 2.

Box-plot representing the age distribution of drivers (N = 115) admitted to the emergency department for forensic toxicological analysis following road traffic accidents, stratified by gender and clinical severity (triage-assigned code).

Regarding temporal patterns of ED admissions, 10.7% occurred during the daytime shift (08:00–14:00), 19.8% during the afternoon shift (14:00–20:00), and 69.4% during the nighttime shift (20:00–08:00). Overall, 62.8% of admissions occurred on weekdays (Monday–Friday), while 37.2% occurred on weekends or public holidays.

Overall, 28.1% of subjects presented with a SAC > 0.5 g/L, corresponding to the legal limit of intoxication (LLI) in Italy for non-professional drivers holding a driving license for more than 3 years. Within this subgroup, the median SAC was 1.48 g/L (IQR = 0.5 g/L). By contrast, subjects with SAC < 0.1 g/L (limit of quantitation of the ADH method) were 64.5%. The distribution of SAC is summarized in Figure 3. Since almost two-third of the SAC values were below the limit of quantitation, statistical tests were performed on the data categorized as shown in Figure 3. The association between SAC at ED admission and study variables is summarized in Table 2.

Distribution of serum alcohol concentrations (SAC) among drivers (N = 115) admitted to the emergency department for forensic toxicological analysis following road traffic accidents. The limit of quantitation for the automated enzymatic method was 0.1 g/L. In accordance with the Italian Highway Code, 0.5 g/L represents the legal limit of intoxication (LLI), while 0.8 g/L and 1.5 g/L represent the second and third grades of intoxication, respectively.

Association between serum alcohol concentration (SAC) at emergency department (ED) admission, trauma severity and age of driving licence with demographic/temporal variables
Independent Variable Dependent Variable P-value (Fisher-Freeman-Halton exact test)
SAC at ED admission Driver sex 0.794
Age of driving license 0.949
Trauma severity (triage code) 0.340
ED duty shift 0.045
Day of the week 0.035*
Trauma severity (Triage Code) Driver sex 0.567
ED duty shift 0.329
Day of the week 0.634
Age of driving license Trauma Severity 0.536
ED duty shift 0.569
Day of the week 0.138
*Computed with Kruskal-Wallis test.

Independently of the day of the week, the peak of ED admissions (11.6%) occurred during the 01:00–01:59 time interval, within which 28.6% of patients had a SAC > 0.5 g/L. Conversely, during the 03:00–03:59 interval, accounting for 7.4% of total admissions, the proportion of patients with SAC > 0.5 g/L reached 88.9%. Detailed hourly distributions of ED admissions and cases with SAC > 0.5 g/L are shown in Figure 4. The association between severity of trauma according to the triage-assigned code, license experience and study variables is summarized in Table 2.

Hourly distribution of serum alcohol concentrations (SAC) and cases exceeding the Italian legal limit of alcohol intoxication (SAC > 0.5 g/L) among drivers (N = 115) admitted to the emergency department following road traffic accidents for forensic toxicological analysis.

Turnaround time data

The median TATintra was 139 minutes (IQR = 88 minutes). The stratification of TAT values for the individual intervals within the preanalytical phase is reported in Table 3. In 16 cases for which the presumed time of the accident could be retrieved from the toxicological testing request documentation, the median TATextra was 46 minutes (IQR = 19 minutes).

Stratification of turnaround time (TAT) of the intra- and extra-emergency department (ED) preanalytical phases for sample collection within the chain of custody
TAT interval Median IQR 95th percentile 95%CI
Intra-ED TAT Minutes
(b–c) From ED admission to toxicological tests request 59 57 149 120-159
(c–d) From toxicological tests request to start of the chain of custody 50 45 168 144-228
(d–e) From start to end of the chain of custody 25 26 71 60-111
(b–e) Total intra-ED preanalytical TAT (TATintra) 139 88 294 271-320
Extra-ED* Minutes
(a–b) From time of accident to ED admission (TATextra) 46 21 86 61-88
(a–e) Overall pre-analytical TAT (TATintra + TATextra) 204 99 420 280-510
*Computed in 16 out of 121 cases. CI – confidence interval.

With respect to influencing variables, the median TATintra did not differ significantly according to trauma severity as assessed by triage code (P = 0.372), ED duty shift (P = 0.519), or day of the week (P = 0.981). Table 4 summarizes the results of the statistical analyses performed on the individual TATintra intervals. Notably, TAT and SAC were not significantly associated (P = 0.934). The distribution of TATintra according to the level of SAC is shown in Figure 5.

Statistical significance of factors influencing intra-emergency department (ED) turnaround time (TAT) intervals for sample collection within the chain of custody, assessed using the Kruskal-Wallis test
Factors
TAT interval Severity of trauma ED duty shift Day of the week
Intra-ED TAT (TATintra) P-value
(b-c) From ED admission to toxicological test request 0.541 0.927 0.694
(c-d) From toxicological test request to start of the chain of custody 0.173 0.455 0.094
(d-e) From start to end of the chain of custody 0.814 0.645 0.957

Heatmap of intra-emergency department turnaround time (TATintra) according to serum alcohol concentration (SAC) among drivers (N = 115) admitted for forensic toxicological analsis following road traffic accidents.

Discussion

This single-center one-year retrospective evaluation of the epidemiology of drink-driving cases admitted to the ED of a large metropolitan hospital shows an epidemiological framework made up predominantly composed by males, with a ratio of nearly 4:1 relative to females and a median age of approximately 40 years in both groups. This gender gap aligns with national and global statistics, which consistently identify middle-aged males as being significantly more involved in alcohol-related road accidents (10, 11).

Cases of high clinical severity (triage code 1) accounted for half of the recorded instances. Interestingly, novice drivers (licensed < 3 years), who represented approximately 15% of the total, did not show an association with increased trauma severity. Unexpectedly, trauma severity did not vary significantly with SAC. This finding may be due either to the unaccounted consumption of other substances of abuse that impair driving performance, or by the large prevalence of cases with SAC below the limit of quantitation of the ADH method (12).

The temporal distribution of events shows that two-thirds of admissions occurred on weekends or holidays, and two-thirds during the night shift, reflecting the prevalence of recreational ethanol consumption (13). Notably, the level of SAC peaked during the night and in the weekends or holidays. A peculiar misalignment exists between the peak of total driver admissions (01:00–01:59) and the peak of drivers exceeding the legal limit of 0.5 g/L (03:00–03:59). It is hypothesized that this reflects a distinct pattern of alcohol consumption: the 03:00–03:59 peak likely involves accidents occurring in recreational contexts where alcohol abuse is a central feature and drinking is concentrated within a short interval (14, 15). These individuals face higher alcohol levels and a hazardous interaction between psychotropic effects, fatigue, and the high cognitive load required by night driving.

As such, the ED’s peak forensic activity coincides with its most challenging operational hours (16). Nevertheless, the median TATintra was influenced neither by the severity of injuries nor by the specific time slot in which the CoC was executed. This result contrasts with recent evidence from a large cohort study (N = 8923), where drivers admitted during the night shift and patients with the most severe injuries experienced longer TATs (17).

High-severity traumas requiring urgent clinical intervention typically lead to significant delays in forensic sampling due to the prioritization of medical stabilization (17). In contrast, our setting demonstrated exceptional stability, the interpretation of which is puzzling. On one hand, this could be viewed as a positive outcome, demonstrating the ED medical team’s proficiency and standardized mastery of CoC protocols that ensures “forensic equity” for all drivers. On the other hand, it allows for a more critical interpretation: such stability might indicate a “degraded” baseline TAT, one so high that it remains insensitive to additional environmental or clinical stressors.

Quantitatively, literature indicates that an average preanalytical TAT of 1.8 hours (108 minutes) is expected, with approximately 44% of forensic samples collected within 2 hours (roughly corresponding to a median of slightly more than 120 minutes) of the accident and 81.3% within 3 hours (17, 18). Recalling that the TAT has usually a skewed distribution which makes the average useless, our median TATintra of 139 minutes was reasonably consistent with the state of the art. This is especially relevant considering that a median of 57 minutes was consumed by the waiting for the toxicological test request alone, a process which can be easily improved. However, accounting for the TATextra (from the presumed time of the accident to ED admission) increased the median TAT to 204 minutes (approximately 3.4 hours), which conversely appears unacceptably long.

Regardless of the underlying cause (e.g., ED overcrowding, staffing shortages, or communication difficulties with law enforcement), an objective judgment on whether the observed TAT is truly degraded or forensically “safe” requires evidence-based criteria. Quality goals must be grounded in a quantitative relationship between sampling delay and the potential loss of forensic evidence due to metabolic decay, a risk we may term “pharmacokinetic false negatives.”

While this study provides valuable real-world insight into the operational workflow of forensic blood alcohol sampling within a major metropolitan emergency department, several limitations must be acknowledged.

First, a key finding is the substantial overall preanalytical delay between the accident and blood sampling, which yielded a median time of 204 minutes. However, because the exact time of the road accident was missing or unrecorded in the vast majority of law enforcement requests, this specific interval could only be analyzed for a small subset of the study population (N = 16 out of 121 cases). This small sub-cohort may not be fully representative of the entire study population, and the calculated TATextra should be interpreted with caution.

Second, the statistical evaluations rely exclusively on univariate analyses. Given the complex environment of an overcrowded emergency department, multiple clinical, demographic, and temporal variables likely interact dynamically (e.g., triage severity, night shifts, and weekend staffing). A multivariable regression model could provide stronger evidence regarding independent predictors of prolonged TAT. However, due to the modest final sample size N = 115) and the heavily skewed distributions of categorical data (e.g., nearly 70% of admissions occurring during night shifts), a multivariable approach risked overfitting the statistical models. Therefore, univariate tests were prioritized as a more reliable baseline analysis.

Finally, the study is limited by its retrospective, single-center design, which may reflect local operational habits or institutional arrangements that restrict direct generalizability to other clinical settings. Additionally, the analysis did not screen for the potential co-ingestion of illicit psychotropic substances or prescription medications, which frequently co-occur in traffic accidents and can heavily influence clinical triage prioritization.

In conclusion, establishing an evidence-based extra-analytical quality criterion requires a probabilistic and statistical framework since a direct experimental approach is ethically and practically unfeasible. Specifically, the known pharmacokinetics of ethanol provides a quantitative model suitable for determining performance specifications via Monte Carlo numerical simulations. Due to the complexity of this method and its significant implications, this simulation-based approach is addressed separately in the Part II of this work (9).

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References HurstPMHarteDFrithWJ. The grand rapids dip revisited. Accid Anal Prev. 1994;26:647–54. 10.1016/0001-4575(94)90026-47999209 ZadorPLKrawchukSAVoasRB. Alcohol-related relative risk of driver fatalities and driver involvement in fatal crashes in relation to driver age and gender: an update using 1996 data. J Stud Alcohol. 2000;61:387–95. 10.15288/jsa.2000.61.38710807209 World Health Organization (WHO), International Federation of Red Cross and Red Crescent Societies (IFRC), Global Road Safety Partnership (GRSP). Drink-driving: A road safety manual for decision-makers and practitioners. 2nd ed. Geneva: WHO; 2022. Available from: https://cdn.who.int/media/docs/default-source/documents/health-topics/road-traffic-injuries/ifrc-drink-driving-2022-final.pdf. Accessed Feb 27th 2026. KassymLKussainovaASemenovaYKussainovAMarapovDZhanaspayevM Worldwide prevalence of alcohol use in non-fatally injured motor vehicle divers: a systematic review and meta-analysis. Healthcare (Basel). 2023;11:758. 10.3390/healthcare1105075836900763 European Commission (EC). Alcohol and drugs: Road safety thematic report. Brussels: European Road Safety Observatory (ERSO), Directorate General for Transport; 2023. Available from: https://road-safety.transport.ec.europa.eu/system/files/2023-10/ERSO-TR-alcohol_drugs_2023.pdf. Accessed Feb 27th 2026. European Commission (EC). Policy Orientations on road safety 2011–2020 (COM/2010/0389). Brussels: European Commission; 2010. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52010DC0389. Accessed Feb 27th 2026. JonesAW. Pharmacokinetics of ethanol - Issues of forensic importance. Forensic Sci Rev. 2011;23:91–136.26231237 IalongoCJonesAW. The enzymatic analysis of alcohol (ethanol) in serum and plasma with the alcohol dehydrogenase reagent: focus on intra-analytical and post-analytical aspects. Biochem Med (Zagreb). 2025;35:030501. 10.11613/BM.2025.03050140822841 IalongoC. Forensic integrity of blood alcohol sampling in the emergency department, Part II: Establishing quality goals of turnaround time with Monte Carlo simulation. Biochem Med (Zagreb). 2026;36:030704. 10.11613/BM.2026.030704 Istituto Nazionale di Statistica (ISTAT). Incidenti stradali in Italia - Anno 2024. Roma: Istituto Nazionale di Statistica; 2025. Available from: https://www.istat.it/wp-content/uploads/2025/07/REPORT_INCIDENTI_STRADALI_2024.pdf. Accessed Feb 27th 2026. Peden M, Sleet D, Hyder AA, Jarawan E, Mathers C. World report on road traffic injury prevention. Geneva: World Health Organization; 2004. Available from: https://iris.who.int/bitstream/handle/10665/42871/9241562609.pdf. Accessed Feb 27th 2026. BlandinoACotroneoRTambuzziSDi CandiaDGenoveseUZojaR. Driving under the influence of drugs: correlation between blood psychoactive drug concentrations and cognitive impairment. A narrative review taking into account forensic issues. Forensic Sci Int Synerg. 2022;4:100224. 10.1016/j.fsisyn.2022.10022435330981 RoomRMäkeläPBenegalVGreenfieldTKHettigeSTumwesigyeNM Times to drink: cross-cultural variations in drinking in the rhythm of the week. Int J Public Health. 2012;57:107–17. 10.1007/s00038-011-0259-321553132 WardeASassoAHolmesJHernández AlavaMStevelyAKMeierPS. Situated drinking: The association between eating and alcohol consumption in Great Britain. Nordisk Alkohol Nark. 2023;40:301–18. 10.1177/1455072523115722237255611 HolmesJSassoAHernández AlavaMBorges NevesRStevelyAKWardeA How is alcohol consumption and heavy episodic drinking spread across different types of drinking occasion in Great Britain: An event-level latent class analysis. Int J Drug Policy. 2024;127:104414. 10.1016/j.drugpo.2024.10441438588637 RichardsJRStaytonTLWellsJAParikhAKLaurinEG. Night shift preparation, performance, and perception: are there differences between emergency medicine nurses, residents, and faculty? Clin Exp Emerg Med. 2018;5:240–8. 10.15441/ceem.17.27029706053 PriceJMSmithRCMilesAKKayagilTA. Delays in blood collection and drug toxicology results among crash-involved drivers arrested for impaired driving. Traffic Inj Prev. 2024;25:667–72. 10.1080/15389588.2024.233391838648016 VernichFRomaniLMineoFMannocchiGStefaniLPallocciM The crime of vehicular homicide in Italy: trends in alcohol and drug use in fatal road accidents in Lazio region from 2018 to 2024. Toxics. 2025;13:607. 10.3390/toxics1307060740711051
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030703" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030703" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030703" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(132) "Forensic integrity of blood alcohol sampling in the emergency department, Part I: Epidemiology and factors affecting turnaround time" ["journals_article_author"]=> string(114) "Maria Sapio, Anna Criniti, Simona Giglio, Gioacchino Galardo, Orietta Gandini, Antonio Angeloni, Cristiano Ialongo" ["journals_article_author_country"]=> string(5) "Italy" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(118) "blood alcohol content, hospital emergency service, preanalytical phase, substance abuse detection, retrospective study" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2282" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "8" ["meta_title"]=> string(132) "Forensic integrity of blood alcohol sampling in the emergency department, Part I: Epidemiology and factors affecting turnaround time" ["meta_desc"]=> string(132) "Forensic integrity of blood alcohol sampling in the emergency department, Part I: Epidemiology and factors affecting turnaround time" ["meta_keyw"]=> string(118) "blood alcohol content, hospital emergency service, preanalytical phase, substance abuse detection, retrospective study" ["created"]=> string(19) "2026-08-10 10:29:35" ["modified"]=> string(19) "2026-10-02 11:01:59" } [10]=> object(stdClass)#53 (35) { ["journals_id"]=> string(4) "1267" ["journals_xml"]=> string(90744) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030702 10.11613/BM.2026.030702 Original articles Matrix metalloproteinase 9 and dipeptidyl peptidase-4/cluster of differentiation 26 are better performing biomarkers than matrix metalloproteinase 3 in stratifying mild and moderate activity of the ulcerative colitis Banković RadovanovićPatricija*1DetelDijana2Cetina ŽgrablićJadranka3ČičakHelena4StanićGabrijela5JuričićGordana6LabinacLoredana7PerkovićManuela7Troskot PerićRosana89 Department of transfusion medicine, General hospital Pula, Pula, Croatia Department of medical chemistry, biochemistry and clinical chemistry, Faculty of Medicine, Rijeka, Croatia Department of gastroenterology, General hospital Pula, Pula, Croatia Department of medical laboratory diagnostics, University hospital “Sveti Duh”, Zagreb, Croatia Department of pathology and cytology, University hospital “Sveti Duh”, Zagreb, Croatia Department of medical laboratory diagnostics, General hospital Pula, Pula, Croatia Department of pathology and cytology, General hospital Pula, Pula, Croatia Department of gastroenterology and hepatology, University hospital “Sveti Duh”, Zagreb, Croatia Faculty of health studies, University of Rijeka, Rijeka, Croatia

The first two authors contributed equally to this work.

Corresponding author: patricijaqm@gmail.com

Author contributions

P Banković Radovanović: Conceptualization, Data duration, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualisation, Writing-original draft, Writing-review and editing; D Detel: Conceptualization, Funding acquisition, Investigation, Methodology, Resources, Supervision, Validation, Visualisation, Writing-review and editing; J Cetina Žgrablić: Investigation, Writing-review and editing; H Čičak: Formal analysis, Investigation, Writing-review and editing; G Stanić: Formal analysis, Writing-review and editing; G Juričić: Formal analysis, Writing-review and editing; L Labinac: Formal analysis, Writing-review and editing; M Perković: Formal analysis, Writing-review and editing; R Troskot Perić: Investigation, Writing-review and editing.

10082026 15102026 36 3 030702 3101202618062026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Matrix metalloproteinase (MMP) 9 and dipeptidyl peptidase-4/cluster of differentiation 26 (DPP4/CD26) showed better discrimination of the mild and moderate ulcerative colitis than MMP3

• MMP9 had the highest area under the curve and largest effect size, but DPP4/CD26 demonstrated comparable discriminatory ability

• DPP4/CD26 and MMP3 demonstrated no correlations with disease severity, MMP9 showed weak correlation

• Disease severity was only partially explained by biomarkers

Introduction

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory bowel disease with an unpredictable clinical course. Reliable biomarkers reflecting intestinal inflammation remain a clinical priority. The aim is to evaluate the matrix metalloproteinase’s (MMP) 3, MMP9 and peptidase-4/cluster of differentiation 26 (DPP4/CD26) discriminative ability between different stages of the UC and assess their association with disease activity.

Material and methods

This cross-sectional study enrolled 40 patients with mild and moderate UC. Disease activity was assessed using Truelove-Witts, Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and Mayo score, as well as histological evaluation. Biomarker concentrations were measured in serum samples. Discriminative ability was evaluated using receiver operating characteristic (ROC) analysis with area under the curve (AUC) and Youden-derived cut-off values. The association between biomarker concentrations and disease activity was assessed using Spearman’s rank correlation coefficient.

Results

MMP9 and DPP4/CD26 demonstrated comparable discriminative ability (AUC = 0.76, 95% confidence interval (CI): 0.60 to 0.88, P < 0.001; Cohen’s d = 1.09 and AUC = 0.71, 95%CI: 0.54 to 0.84, P = 0.015; Cohen’s d = 0.86, respectively). At the Youden-derived cut-off, MMP9 showed high sensitivity (80%) and moderate specificity (60%) to discriminate, whereas DPP4/CD26 showed lower sensitivity (45%) and high specificity (90%). MMP9 demonstrated statistically significant weak-to-moderate correlations with all disease activity tests (ρ = 0.41-0.49; P = 0.001-0.008), while MMP3 and DPP4/CD26 showed limited or inconsistent correlations.

Conclusion

MMP9 and DPP4/CD26 displayed a significant difference between mild and moderate UC activity and demonstrated comparable discriminatory potential, although their combination does not enhance this feature. MMP9 showed a weak but significant association with disease activity, whereas MMP3 showed no clinical relevance.

Keywords: biomarkersulcerative colitisROC curvedisease progression
Introduction

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory bowel disease with an unpredictable course. Its diagnosis is primarily based on invasive diagnostic procedures, including endoscopic examination and mucosal biopsy, as well as histopathological tissue analysis along with clinical assessment of laboratory indicators (1). Although the etiology of this disease has not yet been fully understood, it is believed to be driven by an inappropriate immune response of the intestinal mucosa to dietary antigens and/or commensal microbiota, induced by a complex interaction of genetic changes and various environmental factors, such as stress. This is followed by an inflammatory reaction and increased production of reactive oxygen and nitrogen species, leading to tissue injury and impairment of intestinal function (2).

Ulcerative colitis has intrigued the scientific and professional public for decades with respect to its etiopathogenesis, diagnostics and disease monitoring as well as therapeutic strategies. Since periods of remission and relapse alternate abruptly and unpredictably during the disease, it is essential to find reliable predictors of disease progression. Such predictors would also facilitate therapy-related decisions contributing to its more rational application, as well as reducing the potential harmful effects of the administered drugs (3). The goal of treatment is to achieve and maintain remission with complete mucosal healing, to eliminate inflammation and improve immune status (4). Although the algorithm for determining therapy is well established, treatment is generally applied individually and depends on the extent and location of the inflammatory process, disease activity, clinical course of the disease and patient response to the applied therapy (4). Therefore, to establish a good therapeutic regimen, apart from a differential diagnosis, it is very important to be able to predict the course of the disease and the risk of relapse, preferably by a non-invasive method or procedure (5). In this regard, circulating biomarkers represent promising tools. The role of a range of circulating markers in serum, urine and the intestinal mucosa has been investigated to date.

Previous research has indicated a connection between C-reactive protein (CRP) and therapy outcomes as well as disease activity, although there are also studies in which CRP has proven to be an unreliable marker of activity (6, 7). However, CRP as a marker of inflammation lacks disease specificity, as it is elevated in a broad spectrum of pathological conditions and is not specific to UC. Nevertheless, it still plays an important role in clinical management of many inflammatory diseases (8).

Furthermore, several prospective studies have investigated the prognostic potential of fecal calprotectin (fCal) in a sample of patients with UC in clinical remission, showing that a twofold increase in fCal concentrations over 3 months increases the risk of relapse and that low fCal concentrations are associated with long-term remission and mucosal healing (9, 10). It has also been observed that fCal correlates with the clinical status of UC and endoscopic findings, but it can also predict remission in the patient with refractive UC (11, 12).

Among other potential biomarkers, which are not routinely examined, are a group of proteolytic enzymes with diagnostic potentials. Matrix metalloproteinase (MMP) and peptidase-4/cluster of differentiation 26 (DPP4/CD26) are part of this large family of proteolytic enzymes, initially shown to play an important role in the remodelling of the extracellular matrix (13, 14). Experimental models of inflammatory bowel disease (IBD) have demonstrated that these proteolytic enzymes participate in the development of various pathological conditions, especially those underpinned by inflammatory and/or malignant processes (15, 16). Within MMP family, MMP3 and MMP9 have been extensively investigated as potential predictive and prognostic biomarkers of IBD (17-19). It has also been shown that MMP3 plays a critical role in the formation of fibrosis and fistulas. Therefore, the level of expression of this protease in inflamed tissue could indicate the further advancement of the disease and the risk of developing complications (16). Additionally, experimental evidence indicates that inhibition of metalloproteinase impair wound healing, further underscoring the crucial role of MMPs in tissue remodelling and damage (20).

Over the past two decades, studies have shown that DPP4/CD26, through its proteolytic effects on a wide range of substrates, is involved in the modulation and thus regulation of the immune response in UC (14). Studies in patients with UC have suggested that DPP4/CD26 may serve as a potential biomarker for monitoring disease activity and inflammatory burden (21, 22).

However, despite promising findings, only a limited number of studies have directly linked circulating concentrations of these proteolytic enzymes with degree of inflammatory activity within intestinal tissue.

Accordingly, we hypothesized that serum concentrations of MMP3, MMP9 and DPP4/CD26 reflect ongoing inflammatory process in the bowel tissue of patients with UC. Therefore, the primary aim of the study is to explore whether the concentration of these biomarkers in blood differs in distinct stages of the UC activity (mild, moderate and severe). The second aim is to determine whether the concentration of these biomarkers in blood is correlated with different stages of the disease. The third aim is to identify which of these biomarkers show the strongest correlation with the disease stage or has better discriminative ability.

Material and methods Subjects

This cross-sectional study was conducted as part of a larger prospective study, in two centres: General Hospital Pula and University Hospital “Sveti Duh” Zagreb, Croatia, between January 2020 and August 2025, with a gap of three years during the COVID-19 pandemic, when sampling was suspended and actually started in May 2023. Ethical committees of both institutions approved the study (1224/18-2 and 01-949/16) in accordance with the Helsinki Declaration.

Participants were selected by a gastroenterologist according to the established inclusion criteria after setting the diagnosis of UC based on clinical examination, medical history, endoscopic evaluation, and histological analysis of colonic biopsies. In the process of inclusion, the gastroenterologist informed the participants about the purpose of the study, study procedures, their role and rights, as well as any information that they considered relevant. Only fully informed participants who provided written informed consent were included. The aforementioned inclusion criteria were confirmed diagnosis of UC, age above 18 years, and signed informed consent. Persons with Crohn’s disease, irritable bowel syndrome, intestinal infections or indeterminate colitis, as well as pregnant women, were not included in the study.

Based on the collected data and disease activity, participants were stratified according to clinical and endoscopic classification into three groups: i) 20 participants with mild activity, ii) 20 participants with moderate activity and iii) 20 participants with severe activity.

Blood samples for biochemical analyses were collected to assess general and nutritional status (complete blood count, iron, ferritin and albumin) and inflammatory factors (white blood cell (WBC), erythrocyte sedimentation rate (ESR), CRP, ferritin) of the subjects. Three mL of K3EDTA venous blood, 8 mL of venous blood with Z Serum Separator Clot Activator tube and 1.5 mL of citrated (4NC ESR sodium citrate 3.2% tube) venous blood were collected. All the tubes used in the study were Vacuette, Greiner Bio-One Kremsmuenster, Austria. On the day of the blood collection, patients also provided a stool specimen in a sterile container for the determination of the fCal concentration.

Methods

For the clinical assessment of the disease severity, Truelove-Witts index was used which classifies UC into three categories: mild, moderate and severe activity, based on the number of bloody stools per day, pulse, body temperature, hemoglobin concentration and ESR (23). Classification criteria are described in Supplementary table 1.

Ulcerative colitis endoscopic index for severity (UCEIS) was used for the endoscopic assessment of the disease activity (23). Ulcerative colitis endoscopic index for severity evaluates vascular patterns, bleeding, erosions and ulcers, with a total score ranging from 0 to 8, and it is described in Supplementary table 2. A score of 0-1 is considered a remission, 2-4 a mild activity, 5-6 a moderate and 7-8 a severe activity (24).

Mayo endoscopic subscore (MES) was also used for endoscopic assessment of the disease activity (23). With MES, gastroenterologists described the mucosal appearance at endoscopy as normal (score 0), mild activity (score 1), moderate activity (score 2) and severe activity (score 3). Classification details are presented in Supplementary table 3.

Since the original scoring systems differed in their numerical ranges, prior to analysis all scores were recoded into a unified ordinal classification based on clinically defined disease activity categories: 0 = no disease activity, 1 = mild activity, 2 = moderate activity, and 3 = severe activity. This harmonization was performed using clinically established interpretative thresholds for each scoring system (presented in Supplementary material). Following this recoding procedure, the analysed variable represented an ordinal outcome with four ordered categories consistently shared across all methods.

Biopsy samples obtained during colonoscopy were fixed in 10% buffered formalin. The collected and fixed samples were embedded in paraffin blocks and sectioned at 3.5 μm. The resulting slides were stained with hematoxylin and eosin (Merck, Sigma-Aldrich, Darmstadt, Germany) using the GEMINI AS automated stainer (Thermo Fisher Scientific, Waltham, USA). Histological analysis was performed on the colon tissue biopsies, by establishing: i) the presence of chronic inflammatory infiltrate defined by lymphocytes, plasmocytes, or eosinophils in the lamina propria; ii) the presence of acute inflammatory cell infiltrate defined by neutrophils in the lamina propria, in epithelium or the destruction of crypt by neutrophils; iii) the presence of ulceration. Findings were expressed as the Nancy histological index that is presented in Supplementary figure 1 (25).

Parameters of inflammation, general and nutritional status were determined from blood by using photometry (albumin) and immunoturbidimetry (CRP, iron) on the Roche Cobas c503 analyzer (Roche Diagnostics, Meinheim, Germany), CMIA (ferritin) on the Abbott Allinity I (Abbott Laboratories, Abbott Park, USA). Erythrocyte sedimentation rate was determined with the modified Westergren method on the Sed Rate Screener 100/II (SRS 100/II) (Greiner Bio-One GmBH, Kremsmünster, Austria) and complete blood count with optical flow cytometry and cytochemical method on the Sysmex XN-1000 analyzer (Sysmex Corporation, Kobe, Japan). To obtain serum samples, tubes were centrifuged for 10 min at 1800xg. For determining the concentration of MMP3, MMP9 and DPP4/CD26, serum aliquots were separated and stored at - 80°C until analysis. Serum concentrations of MMP3, MMP9, and DPP4/CD26 were determined using sandwich enzyme-linked immunosorbent assay (ELISA) kits (Proteintech, Manchester, UK). The assays were performed according to the manufacturer’s instructions using capture antibody coated on the wells, conjugate (detection antibody labelled with biotin-streptavidin-horseradish peroxidase), and tetramethylbenzidine substrate. Analytical specification for MMP3, MMP9 and DPP4/CD26 ELISA tests are provided in Supplementary table 4. Each sample was run in duplicate. A microplate reader (Bio-Tek EL808, Winooski, USA) measured the absorbance of the final product at 450 nm with the correction wavelength set at 630 nm. The concentration of MMP3, MMP9 and DPP4/CD26 in each sample was calculated from the four-parameter logistic standard curve and expressed in nanograms per millilitre (ng/mL).

Concentrations of fecal calprotectin were determined on the BIO-FLASH instrument (Inova Diagnostics, San Diego, USA) with QUANTA Flash Chemiluminescence Immunoassay (CLIA) and Buhlmann fCal turbo (Buhlmann Laboratories AG, Shonenbuch, Switzerland) following fecal extraction under the procedure described by the manufacturer.

Because two different fCal assay methods used in the same study could introduce method-related variability on results, we searched for similar cases. Published comparative data indicate that systematic bias between methods can be observed; in fact, constant and proportional differences between these two methods have been reported, with the following equation of regression line (26):

y = - 19.73 (- 37.26 to - 7.25) + 2.21 (2.02 to 2.55) x.

However, despite these discrepancies at the absolute quantitative level, agreement in clinically relevant interpretative categories remains high, with a reported kappa coefficient of 0.885 (95% confidence interval (CI): 0.76 to 1.00), indicating excellent concordance.

Statistical analysis

The sample size was determined based on a statistical power analysis with α = 0.05 and β = 0.20. Data from previous studies on MMP3 and MMP9 as well as DPP4/CD26 in patient samples with UC were used for the power analysis. In the MedCalc spreadsheet calculator for the sample size data for each parameter were entered, specifically: the difference in the values of the observed parameter during the active phase of the disease and remission as well as the standard deviations for these data. The analysis indicated that a minimum of 19 participants per group was required.

To assess the normality of distribution, Kolmogorov-Smirnov test for all variables was used. However, due to the sample size bellow 30, non-parametric tests were used and data were presented as median (interquartile range). Age was presented as median and range. Differences between groups were analyzed using the Mann-Whitney U test.

With Friedman ANOVA, differences between ordinal measurements (clinical, endoscopic and histological results) were evaluated, which are presented as median and interquartile range (IQR). Associations between biomarker concentrations and disease severity scores were assessed using Spearman rank correlation test.

The discriminative ability of MMP3, MMP9 and DPP4/CD26 as well as fCal was evaluated using receiver operating characteristic (ROC) curve analysis. The optimal cut-off value for discrimination between disease stages was determined using the Youden index. Areas under the curve (AUC) were compared using DeLong test. Effect size was calculated using Cohen’s d.

We defined the level of significance as a P value less than 0.05. We performed the statistical analyses by using MedCalc 12.5.0.0 statistical software (MedCalc Software, Ostend, Belgium).

Results

A total of 40 patients were included in the final analysis and were stratified into two groups according to disease activity: 20 patients with mild UC and 20 patients with moderate UC. Although a third group with severe disease activity was initially planned, only six patients met the inclusion criteria for this category; therefore, this group was excluded from further analysis due to insufficient sample size for reliable statistical evaluation.

The demographic data of two groups of subjects as well as laboratory results along with the assessment of the disease activity are presented in Table 1.

Summary statistics of demographic data, clinical and laboratory results in patients with UC
UC activity*
Mild(N = 20) Moderate(N = 20) P-value†
Age (years) 55 (24-85) 47 (19-76) 0.561
BMI (kg/m2) 25.3 (23.5-28.6) 25.7 (23.8-26.5) 0.725
WBC (x109/L) 6.70 (5.52-7.75) 7.55 (6.11-8.80) 0.181
Hb (g/L) 149 (135-153) 136 (122-152) 0.168
ESR (mm/3.6 ks) 8 (5-15) 11 (7-27) 0.207
CRP (mg/L) 2.8 (0.9-5.3) 5.2 (2.2-11.1) 0.053
Ferritin (µg/L) 87.0 (52.3-169) 89.7 (26.7-134.9) 0.448
Iron (µmol/L) 12.4 (9.0-20.3) 11.6 (7.2-14.4) 0.169
Albumin (g/L) 45.0 (43.5-46.0) 45.5 (40.8-47.0) 0.914
fCal (mg/kg) 79 (36-201) 727 (275-1500) < 0.001
MMP3 (ng/mL) 16.7 (6.1-98.4) 23.5 (14.3-55.0) 0.317
MMP9 (ng/mL) 1820.0(733.1-2038.2) 2038.2(2038.2-3231.1) 0.003
DPP4/CD26 (ng/ml) 798.5(598.7-1078.2) 1051.4(808.3-1768.5) 0.026
*The activity was determined according to the clinical and endoscopic classifications, confirmed with histopathological Nancy index (25). †Mann-Whitney for independent samples. UC - ulcerative colitis. BMI - body mass index. WBC - white blood cells. Hb - hemoglobin. ESR - erythrocyte sedimentation rate. CRP - C-reactive protein. fCal - fecal calprotectin. MMP - matrix metalloproteinase. DPP4/CD26 - dipeptidyl peptidase-4/cluster of differentiation 26. P < 0.05 was considered statistically significant.

Friedman ANOVA did not show a statistically significant difference among the four paired disease classification (P = 0.136), indicating good concordance between these methods in defining UC activity in this cohort (Table 2).

Results of comparison of clinical and endoscopic scores with histological findings to assess the ability of the scores and their fitness in defining the activity of the ulcerative colitis
Classification tools(median (IQR)) P-value(Friedman ANOVA)
Clinical scores 0.136
Truelove-Witts1.5 (1.0-2.0)
Endoscopic scores
UCEIS1.0 (0-2.0)
MES1.0 (0-2.0)
Histological findings2.0 (1.0-2.0)
IQR - interquartile range. UCEIS - Ulcerative colitis endoscopicindex of severity. MES - Mayo endoscopic sub score. P < 0.05 was considered statistically significant.

Correlation analysis between serum biomarker concentrations and disease activity indices is presented in Table 3. None of the biomarkers showed strong linear correlation with disease activity, even though significant weak to moderate correlations were observed for some of them. Furthermore, ROC analysis revealed that MMP9 and DPP4/CD26 discriminated between mild and moderate disease with an AUC of 0.76 (95% CI: 0.60 to 0.88) and 0.71 (95% CI: 0.54 to 0.84), respectively (Table 4). DeLong pairwise comparison of ROC curves MMP9-DPP4/CD26 showed ΔAUC 0.06 (95% CI: - 0.16 to 0.27), P = 0.599. For MMP9, the Youden index identified an optimal cut-off value of > 1993.4 yielding a sensitivity of 80% and specificity of 60% for discrimination between mild and moderate disease. For DPP4/CD26, the optimal cut-off was > 12667.4 (sensitivity 45%, specificity 90%). Large effect size was shown for both MMP9 and DPP4/CD26 (Cohen’s d = 1.09 and 0.86, respectively). Comparable results for fCal in terms of correlation with the disease activity are presented in Table 4. DeLong pairwise comparison of ROC curves fCal-MMP9 and fCal-DPP4/CD26 showed ΔAUC 0.07 0.07 (95% CI: - 0.14 to 0.27), P = 0.520 and 0.13 (95% CI: - 0.10 to 0.35), P = 0.271, respectively.

Correlation of MMP3, MMP9 and DPP4/CD26 with disease severity in patients with ulcerative colitis
Truelove-WittsSp ρ(P-value) UCEISSp ρ(P-value) MayoSp ρ(P-value) NancySp ρ(P-value)
MMP3 (ng/mL) 0.16(0.323) 0.14(0.377) 0.11(0.516) 0.42(0.007)
MMP9 (ng/mL) 0.48(0.002) 0.47(0.002) 0.41(0.008) 0.49(0.001)
DPP4/CD26 (ng/mL) 0.36(0.025) 0.09(0.572) 0.02(0.893) 0.14(0.404)
fCal (mg/kg) 0.57(< 0.001) 0.54(< 0.001) 0.52(< 0.001) 0.57(< 0.001)
Disease severity was established with clinical (Truelove-Witts), endoscopic scores (UCEIS, Mayo) and histological Nancy index (25), with addition of comparable data for fecal calprotectin. MMP - matrix metalloproteinase. DPP4/CD26 - dipeptidyl peptidase-4/cluster of differentiation 26. fCal - fecal calprotectin. UCEIS - Ulcerative colitis endoscopic Index of severity. Sp ρ - Spearman’s rank correlation coefficient. P < 0.05 was considered statistically significant.
Group comparison and discriminative ability of disease severity of MMP3, MMP9 and DPP4/CD26 in patients with ulcerative colitis (with addition of the comparable data for fecal calprotectin)
UCmild(N = 20) Activity*moderate(N = 20) P-value† AUC(95% CI)P-value Youden cut-off Se (%) Sp (%) Cohen’s d‡ Interpretationof cut-off
MMP 3 (ng/mL) 16.7(6.1-98.4) 23.5(14.3-55.0) 0.317 0.59 (0.43-0.78)0.337 - - - - No discrimination
MMP9(ng/mL) 1820.0(733.1-2038.2) 2038.2(2038.2-3231.1) 0.003 0.76 (0.60-0.88)< 0.001 > 1993.4 80 60 1.09 Good for detecting moderate disease
DPP4/CD26(ng/mL) 798.5(598.7-1078.2) 1051.4(808.3-1768.5) 0.026 0.71 (0.54-0.84)0.015 > 1267.4 45 90 0.86 Good for confirming mild disease
fCal(mg/kg) 79(36-201) 727(275-1500) < 0.001 0.83 (0.68-0.93)< 0.0001 > 254 75 90 - Good for confirming mild disease with added detection value
*The activity was determined according to the clinical and endoscopic classifications, confirmed with histopathological Nancy index (25). †Mann-Whitney for independent samples. ‡Calculated on socsistatistics.com/effectsize/deault3.aspx; accessed January 8th 2026. UC - ulcerative colitis. MMP - matrix metalloproteinase. DPP4/CD26 - dipeptidyl peptidase-4/cluster of differentiation 26. fCal - fecal calprotectin. AUC - area under the curve. Se - sensitivity. Sp - specificity. P < 0.05 was considered statistically significant.
Discussion

In our study, MMP9 and DPP4/CD26 demonstrated comparable discriminative ability in differentiating between mild and moderate UC. This is supported by relatively large AUC obtained for both biomarkers and at the same time the absence of the statistically significant difference between their AUC values. In addition, MMP9 showed particular utility in identifying patients with moderate disease activity and in detecting progression from mild to moderate UC. Furthermore, the large effect size observed for both biomarkers further suggests their clinical relevance in distinguishing between two stages of disease activity. In contrast, MMP3 showed no discriminative ability and association with disease severity was limited to the histological score only, indicating low utility for disease stratifications.

Among the evaluated biomarkers, MMP9 showed the strongest overall performance with significant group differences, the highest AUC, large effect size and consistent correlations with disease severity across multiple ordinal tests, including the Truelove-Witts clinical score, UCEIS, Mayo endoscopic sub score, and the Nancy histological index. However, despite statistical significance, the magnitude of these correlations was only weak to moderate. The coefficients of determination indicate that less than one quarter of the variability in disease severity could be explained by serum MMP9 concentrations. This suggests that MMP9 reflects disease severity only partially and that additional clinical, immunological, and molecular factors substantially contribute to disease progression in UC.

Dipeptidyl peptidase-4/cluster of differentiation 26 also demonstrated significant concentration difference in mild and moderate UC, along with adequate discriminative ability and large effect size. However, its correlations with disease severity indices were inconsistent and limited to the clinical score only. This finding suggests that DPP4/CD26 may be useful for differentiating disease stages without reflecting gradual disease progression.

Moreover, results for sensitivity and specificity obtained at the cut-off values for both MMP9 and DPP4/CD26 suggest that they perform well at detecting moderate disease and confirming mild disease, respectively.

By observing demographic and laboratory data in mild and moderate group of the UC activity, it was noticed that the two groups were comparable in terms of age, body mass index, and most laboratory parameters, with no statistically significant differences observed for WBC, hemoglobin, ESR, ferritin, iron, albumin, or CRP. A pronounced and statistically significant difference was observed for fCal, which was markedly higher in the moderate activity group compared to the mild group, confirming its strong association with intestinal inflammatory burden and supporting the correct stratification of patients according to disease activity. In addition, fCal demonstrated moderate positive correlation with all applied measures of disease activity, including the Truelove-Witts clinical score, Mayo endoscopic sub score and the Nancy histological index. This is in concordance with the results of Ryu et al. who also demonstrated moderate positive correlation of fCal with endoscopic activity in UC assessed with Mayo end UCEIS endoscopic scores (27).

Due all these characteristics of the fCal, it would be anticipated that fCal, in combination with MMP9 or DPP4/CD26, could enhance the stratification between mild and moderate UC. However, the results of the further evaluation did not support this assumption. Although numerical differences in AUCs were observed between certain biomarker pairs, DeLong’s test did not demonstrate statistically significant improvements in discrimination. These findings suggest that the biomarkers provide largely overlapping diagnostic information, and that their combined use does not meaningfully enhance stratification between mild and moderately active disease. This may be explained by the fact that both MMP9 and DPP4/CD26 participate in closely related inflammatory pathways, thereby reflecting overlapping aspects of mucosal inflammation rather than distinct biological processes.

Individual results for the fCal ROC analysis in our study are in concordance with the results from the study of Swaminathan et al. Their results of AUC and 95%CI for fCal at the cut-off value of ≥ 250mg/kg, being associated with the active endoscopic disease, as well as the sensitivity and specificity at the derived cut-off are comparable to those in our study (28).

Even though there are relatively small number of similar studies of MMPs and DPP4/CD26 in UC to be compared with, some studies are partially consistent with our results. In their study, Siloşi et al. demonstrated statistically significant differences in MMP3 and MMP9 serum concentrations between moderate and mild activity in UC patients, although they did not test discriminatory ability of these biomarkers (18). Furthermore, Pinto-Lopes et al. reported that serum DPP4/CD26 concentrations were able to discriminate between active disease and remission in UC patients, supporting its potential role as a biomarker of disease activity (21).

The main limitations of this study include the small sample size despite the results of the power analysis, the exclusion of patients with severe disease activity as well as the exploratory nature of derived cut-off values. Nevertheless, the consistency of findings across multiple analytical approaches, including group comparisons, ROC analysis, effect size estimation, and correlation with independent disease activity indices, support the robustness of the observed differences.

The use of two different analytical methods for fCal should be mentioned as possible limitation. Although this reflects real-world clinical practice, inter-method variability cannot be entirely excluded. However, available evidence indicates high agreement in clinically relevant interpretative categories between assays, and in our dataset fCal values obtained with both methods showed consistent and significant correlations with clinical, endoscopic and histological findings. It should also be noted that fCal was not the primary focus of this study, but rather served as a complementary biomarker within a broader analytical framework. Therefore, potential inter-method variability is unlikely to have materially influenced the main study outcomes or overall conclusions. Nevertheless, the use of multiple analytical platforms may have introduced a degree of measurement variability that could not be fully controlled for and represents a potential source of bias. Future studies using a single standardized assay or direct head-to-head method comparison within the same cohort would be valuable to further validate these findings. Despite these limitations, we believe that the strong and consistent associations with independent markers of disease activity support the robustness and clinical relevance of our conclusions.

Furthermore, the cut-off values derived using the Youden index should be interpreted with caution, as they were obtained in a relatively small cohort and are intended only as exploratory mean for classification of disease severity. Validation in larger and independent patient populations is required before their potential clinical implementation.

In conclusion, significant differences in serum biomarker concentration between mild and moderate UC activity were observed for MMP9 and DPP4/CD26, whereas MMP3 did not demonstrate meaningful discriminatory potential. With respect to the association between biomarker concentrations and disease activity, no consistent correlation across disease stages was identified, except for MMP9, which demonstrated a weak but statistically significant association with the disease activity. Finally, both MMP9 and DPP4/CD26 exhibited comparable discriminative ability in distinguishing mild and moderate UC activity, supporting their potential utility in disease activity stratification. However, their combined use does not enhance this stratification. In contrast, MMP3 appears to have no clinical relevance in this context.

Potential conflict of interest

None declared.

Data availability statement

The data will be shared on reasonable request to the corresponding author.

References KaenkumchornTWahbehG. Ulcerative Colitis: Making the Diagnosis. Gastroenterol Clin North Am. 2020;49:655–69. 10.1016/j.gtc.2020.07.00133121687 BiasiFLeonarduzziGOteizaPIPoliG. Inflammatory Bowel Disease: mechanisms, redox considerations, and therapeutic targets. Antioxid Redox Signal. 2013;19:1711–47. 10.1089/ars.2012.453023305298 NowakJKKallaRSatsangiJ. Current and emerging biomarkers for ulcerative colitis. Expert Rev Mol Diagn. 2023;23:1107–19. 10.1080/14737159.2023.227961137933807 AdamsSMBornemannPH. Ulcerative colitis. Am Fam Physician. 2013;87:699–705.23939448 SakuraiTSarutaM. Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. Digestion. 2023;104:30–41. 10.1159/00052784636404714 IwasaRYamadaASonoKFurukawaRTakeuchiKSuzukiY. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterol. 2015;15:103. 10.1186/s12876-015-0333-z26271624 PapamichaelKRivals-LereboursOBillietTVande CasteeleNGilsAFervanteM Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohns Colitis. 2016;10:1015–23. 10.1093/ecco-jcc/jjw06727022161 BrayCBellLNLiangHHaykalRKaiksowFMazzaJJ Erythrocyte Sedimentation Rate and C-reactive Protein Measurements and Their Relevance in Clinical Medicine. WMJ. 2016;115:317–21.29094869 ZhulinaYCaoYAmcoffKCarlsonMTyskCHalfvarsonJ. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016;44:495–504. 10.1111/apt.1373127402063 ZittanEKellyOBKirschRMilgromRBurnsJNguyenGC Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s disease. Inflamm Bowel Dis. 2016;22:623–30. 10.1097/MIB.000000000000065226829408 D’HaensGFerranteMVermeireSBaertFNomanMMoortgatL Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–24. 10.1002/ibd.2291722344983 HassanEARamadanHKIsmaelAAMohamedKFEl-AltarMMAlhelaliI. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. Saudi J Gastroenterol. 2017;23:238–45. 10.4103/sjg.SJG_599_1628721978 de BruynMVandoorenJUgarte-BerzalEArijsIVermeireSOpdenakkerG. The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. Crit Rev Biochem Mol Biol. 2016;51:295–358. 10.1080/10409238.2016.119953527362691 MeloFJPinto-LopesPEstevinhoMMMagroF. The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2021;27:1153–65. 10.1093/ibd/izaa32433295607 ZhuFYangTNingMLiuYXiaWFuY MiR-146a alleviates inflammatory bowel disease in mice through systematic regulation of multiple genetic networks. Front Immunol. 2024;15:1366319. 10.3389/fimmu.2024.136631938799464 KirkegaarTHansenABruunEBrynskovJ. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease. Gut. 2004;53:701–9. 10.1136/gut.2003.01744215082589 ShamseyaAMHusseinWMElnelyDAAdelFHeaderDA. Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021;33:e803–9. 10.1097/MEG.000000000000226434678857 SiloşiIBoldeanuMVMogoantăSSGhiluşiMCojocaruMBiciuşcăV Matrix metalloproteinases (MMP-3 and MMP-9) implication in the pathogenesis of inflammatory bowel disease (IBD). Rom J Morphol Embryol. 2014;55:1317–24.25611261 MatusiewiczMNeubauerKMierzchala-PasierbMGamianAKrzystek-KorpackaM. Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases. Dis Markers. 2014;2014:643645. 10.1155/2014/64364524803722 CastanedaFEWaliaBVijay-KumarMPatelNRRoserSKolachalaVL Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005;129:1991–2008. 10.1053/j.gastro.2005.09.01716344067 Pinto-LopesPAfonsoJPinto-LopesRRochaCLagoPGonçalvesR. Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26:1707–19. 10.1093/ibd/izz31931912883 JaenischSEAbbottCAGorellMDBamptonPButlerRNYazbekR. Circulating Dipeptidyl Peptidase activity is a potential biomarker for inflammatory bowel disease. Clin Transl Gastroenterol. 2022;13:e00452. 10.14309/ctg.000000000000045235060938 TezelHAKurtI. Clinical and Endoscopic Classification and Activity Indices of Inflammatory Bowel Diseases. J Enterocolitis. 2025;4:S28–34. 10.14744/Jenterocolitis.2025.03924 Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Score Calculator. Available from: https://www.mdapp.co/ulcerative-colitis-endoscopic-index-of-severity-uceis-score-calculator-608/#. Accessed December 26th 2025. Marchal-BressenotASalleronJBoulagnon-RombiCBastienCCahnVCadiotG Development and validation of the Nancy histological index for UC. Gut. 2017;66:43–9. 10.1136/gutjnl-2015-31018726464414 Beljan A. Kvantitativna analiza fekalnog kalprotektina novom kemiluminiscentnom metodom na analizatoru Bio-Flash (Inova Diagnostics). Master thesis (in Croatian), 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:163:840166. Accessed December 28th 2025. RyuDGKimHWParkSBKangDHChoiCWKimSJ Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis. Medicine (Baltimore). 2019;98:e17080. 10.1097/MD.000000000001708031490411 SwaminathanABorichevskyGMFramptonCMDayASHamptonMBKettleAJ Comparison of fecl calprotectin and myeloperoxidase in predicting outcomes in inflammatory bowel disease. Inflamm Bowel Dis. 2025;31:28–36. 10.1093/ibd/izae03238417068
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030702" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030702" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030702" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(216) "Matrix metalloproteinase 9 and dipeptidyl peptidase-4/cluster of differentiation 26 are better performing biomarkers than matrix metalloproteinase 3 in stratifying mild and moderate activity of the ulcerative colitis" ["journals_article_author"]=> string(188) "Patricija Banković Radovanović, Dijana Detel, Jadranka Cetina Žgrablić, Helena Čičak, Gabrijela Stanić, Gordana Juričić, Loredana Labinac, Manuela Perković, Rosana Troskot Perić" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(62) "biomarkers, ulcerative colitis, ROC curve, disease progression" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(3) "887" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "7" ["meta_title"]=> string(116) "Matrix metalloproteinase 9 and dipeptidyl peptidase-4/cluster of differentiation 26 are better performing biomarkers" ["meta_desc"]=> string(116) "Matrix metalloproteinase 9 and dipeptidyl peptidase-4/cluster of differentiation 26 are better performing biomarkers" ["meta_keyw"]=> string(62) "biomarkers, ulcerative colitis, ROC curve, disease progression" ["created"]=> string(19) "2026-09-14 11:42:36" ["modified"]=> string(19) "2026-10-02 11:01:45" } [11]=> object(stdClass)#52 (35) { ["journals_id"]=> string(4) "1255" ["journals_xml"]=> string(84771) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030701 10.11613/BM.2026.030701 Original articles Moving percentage of failed delta checks: a novel patient-based quality control model YilmazNiyazi Samet*1SenBayram2TurkmenSena1ÇubukçuHikmet Can3GulbaharOzlem1 Department of Medical Biochemistry, Gazi University Faculty of Medicine, Ankara, Turkey Department of Clinical Biochemistry, Recep Tayyip Erdogan University Training and Research Hospital, Rize, Turkey Rare Diseases Department, General Directorate of Health Services, Turkish Ministry of Health, Ankara, Turkey Corresponding author: dr.sametyilmaz.0653@gmail.com

Author contributions

NS Yilmaz: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. B Sen: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. S Turkmen: Software, Resources, Methodology, Investigation, Data curation. HC Çubukçu: Writing – review & editing, Visualization, Validation, Supervision, Software, Resources, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. O Gulbahar: Writing – review & editing, Supervision, Project administration, Methodology, Investigation, Formal analysis.

10082026 15102026 36 3 030701 2910202519052026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Moving percentage of failed delta checks (MPFDC) is a novel patient-based quality control model based on reference change value, and suitable for measurands with low index of individuality

• MPFDC may be integrated with the laboratory information system and middleware

• MPFDC evaluates analytical performance by considering biological variation

• Appyling errors of ± 15%, median number of patients affected before error detection was 34/29 respectively and median time until error detection was 18 minutes

Introduction

For measurands with a low index of individuality (II), delta check is crucial. If delta percentage change (DPC) values in different patients consecutively exceed the reference change value (RCV), it may indicate an analytical problem. Similarly to moving sum (MovSuM), percentage of DPCs exceeding RCV can be used as a quality control model by comparing it with a certain threshold. This study aimed to develop a novel patient-based quality control (PBQC) model using delta checks and evaluate its performance.

Materials and methods

The study was performed at Gazi University Biochemistry Laboratory. The model was tested on creatinine (measured on Advia Chemistry Systems using the alkaline picrate method), with pooled-CVa = 2.5%, CVi = 4.7%, and RCV = 19%. If DPC > RCV, it was counted as a violation, i.e. failed delta check (FDC). The percentage of violations was calculated for every 20 consecutive patients with previous results over the past year. Similarly to MovSuM, when a new result is added, moving percentage of failed delta checks (MPFDC) removes the oldest data and calculates the percentage of violations continuously. Moving percentage of failed delta checks thresholds determined as 35%/30% (for positive/negative direction). After excluding dialysis patients and patients without previous results, and previous results measured with different systems, we applied truncation (truncation limits: < 27 and > 362 μmol/L). The remaining 5484 results were divided into 55 batches.

Results

After applying positive and negative errors of 15%, median number of patients affected before error detection (MNPed) was 34 and 29, respectively. Median time until error detection was 18 minutes. Sensitivity and specificity were 96% and 86%, respectively.

Conclusions

Moving percentage of failed delta checks, a novel RCV-based PBQC model, has high sensitivity and rapid error detection, suitable for measurands with low II.

Keywords: patient-based quality controldelta checksystematic errorquality assurancequality controlbiological variation
Introduction

With extremely significant improvements in technical and workflow processes in the laboratory, the frequency of analytical errors has decreased over the years. However, it still has not been minimized to the desired level, and it still occurs (1, 2). To cope with analytical errors, traditional quality control (QC) strategies are applied in almost all laboratories today. During traditional QC intervals, laboratories release hundreds of results; therefore, QC strategies are needed to monitor analytical quality continuously. Regarding this issue, patient-based quality control (PBQC) may be a solution. The use of PBQC is particularly important for systematic error detection and patient safety, especially for laboratories that release patient results via autoverification.

Recently, we have witnessed a paradigm shift and an increase in the implementation of PBQC methods (3, 4). Patient-based quality control has several advantages over traditional QC including cost, commutability, and the ability to perform near real-time monitoring (5). Patient-based quality control approaches such as moving average (MA), moving median (MM), average of normal, moving sum (MovSum) and delta check implementations are helpful in detecting errors, whether systematic or not (6-9). However, each PBQC technique has several advantages and drawbacks. For example, MA may not perform efficiently when the data is skewed (5).

Delta checks, which apply for different purposes in laboratories, can also be integrated into PBQC methods (9). Harnessing delta check, simple and rational methods can be designed to detect systematic errors. Recently, such approaches have been developed through delta checks to detect analytical errors in the laboratory. Concepts such as average of delta (AoD), average of patient deltas, and the delta plus-minus even distribution check have been mentioned recently (10-12).

During verification of test results, one of the data that guides a clinical biochemist most is the previous results of the patients, indeed. Especially in tests with a low index of individuality (II) such as creatinine, the previous results of the patients are more important than population-based reference intervals (popRIs). The II for many measurands is lower than 0.6. When a measurand’s II is low, it is useful to follow up patients with the personalized reference intervals (prRI) rather than popRIs (13). For the measurands suitable for prRI, delta check implementation will be important in determining whether the person’s steady state has changed or not. Moreover, if the delta change value of a measurand consecutively exceeds the reference change value (RCV) in different patients, it may indicate an analytical problem (14). At this point, we can state that our study begins where delta check (i.e. biological variation) meets MovSum. In our model named moving percentage of failed delta checks (MPFDC), first as in the rationale of the MovSum method, binarization is applied to delta check failures (violations) in both directions. Then, the percentages of failures (delta change exceeding the RCV) in an estimated block size is used as a quality control model by constantly monitoring and comparing it with a certain threshold/cut-off. However, it needs a dynamic approach such as MovSum or MA, for monitoring the analytical quality in a timely manner.

Delta change values in some tests (such as creatinine, troponin, sodium) are important in the diagnosis and clinical course of the disease. In the College of American Pathologists (CAP) Q-Probes Study, 78% of laboratories reported using delta check for creatinine (15). In this study, it was seen that creatinine ranked second after sodium in terms of delta check usage frequency (15). To date, Risk, Injury, Failure, Loss of Kidney Function, and End-Stage Kidney Disease (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications have been defined for acute kidney injury. In the definitions made by RIFLE, AKIN and KDIGO delta change value of creatinine is emphasized (16). In this context, with a low II value, creatinine is a very suitable test for our model. Therefore, the model was tested on creatinine.

In this study, we aimed to develop a PBQC model that enables the detection of analytical or preanalytical systematic errors using delta check and to demonstrate its performance criteria on real patient data.

Materials and methods

The study was conducted at Gazi University Health Research and Application Hospital (GUHRAH), Core Biochemistry Laboratory, between September 2023 and November 2023. The Gazi University Health Research and Application Hospital is a tertiary care academic medical centre, which has approximately 1000 beds. Approximately 1400 creatinine test results are released in the GUHRAH Core Laboratory in a day. For the study, ethical approval was obtained from the Gazi University Faculty of Medicine Clinical Research Ethics Committee (Date: 21.03.2025, Number: 031).

The creatinine was analysed using the alkaline picrate method using the ADVIA Chemistry XPT System (Siemens Healthineers, Erlangen, Germany). For creatinine, the pooled coefficient of analytical variation (CVa) of four autoanalysers generating creatinine results was 2.5%. All the four analysers were calibrated just before the start of the study. Analyser comparability was not evaluated, however, median values for each analyser during the study period and strafied by day is provided at Supplementary data (Supplementary Table 1 and 2).

Choosing the appropriate within-subject biological variation value and reference change value calculation

To determine the within-subject biological variation (CVi) value, all publications on creatinine were evaluated in the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) biological variation database (17). The publications from the last 20 years, which included serum as the sample type, mixed gender, and non-enzymatic methods were particularly examined. Since the analyser, method, gender and sample type of our laboratory are the same, CVi was chosen from the EuBIVAS study as 4.7% (18).

The formula originally proposed by Harris and Yasaka was used to calculate RCV: RCV = 21/2 x Z x (CVA2 + CVI2) ½ (19). Delta check limits were established using bidirectional Z-score (2.58 for 99% probability to achieve a ≤ 1% false rejection rate). The CVa value in the formula was calculated using the results of the internal QC, with a pooled standard deviation approach. Finally, the RCV value was calculated as RCV = 19% with CVa = 2.5% and CVi = 4.7%.

Editing the raw data for the model

For PBQC models, some data should be excluded to yield better performance from the model. Thus, we performed several data processing steps on the raw data. The truncation limits were defined by excluding results below the 2nd percentile and above the 98th percentile of the data. Truncation limits were set < 27 μmol/L and > 362 μmol/L (< 0.31 mg/dL and > 4.1 mg/dL). The flowchart regarding editing the raw data is given in Figure 1.

The flowchart of editing the raw data.

Exclusion criteria were: 1) results from dialysis clinic; 2) current or past results outside the analytical measurement range; 3) data from patients without previous results; 4) data from patients whose previous results were measured with a different analytical system and 5) results outside of truncation limits.

Except for the exclusion criteria, all results from all autoanalysers over a one-week period were considered as inclusion criteria. No exclusions were made based on age. In the model applied for creatinine, for delta percentage change (DPC) calculation we included the patients’ previous results of up to one year, because recent studies shown CVi for creatinine does not change significantly up to one year (20, 21).

The model: moving percentage of failed delta checks

The distribution of patient results for creatinine was evaluated (whether the patient results’ distribution was symmetrical or skewed) before applying the model. It was seen a skewed distribution of patient results.

Our model is inspired by an original study from Jones (10). Also, MPFDC is inspired by the MovSum and moving rate of positive patient results methods for the binarization process after checking whether the delta check value was greater than RCV or not (6, 22).

In our model, DPC values were used to determine the change between patients’ current and previous results. If DPC > RCV for a measurand (i.e. creatinine), this was counted as a violation; i.e. failed delta check (FDC). If the violation was in the increasing direction, it was counted as + 1 point; however, if there was a decreasing direction, it was counted as - 1 point. In cases where |DPC| < |RCV| (the absolute value of DPC < RCV), it was counted as 0 point. The model was implemented with a block size of 20 consecutive patients with previous result over the past year. For each block, the arithmetic sum of violation scores (DPC > RCV) was calculated and converted into a percentage. When a new result was added, the oldest data were removed, and the moving sum of violations (moving sum of failed delta checks) was recalculated and converted into percentage accordingly. We named our method moving percentage of failed delta checks (MPFDC). The Excel implementation of the model is shown in Figure 2 and Supplementary Figure 1.

Moving percentage of failed delta checks (MPFDC) Excel sheet. Current results above the reference range are highlighted in red. The red, green dashed, and blue boxes represent different blocks. The color variation is used to distinguish between the blocks. AdviaChemistryXPT_1 (autoanalyser 1) is not presented in the figure, because this autoanalyser started to perform at 10:10 in that day.

Continuously, MPFDC calculates the percentage of the number of violations in the system. Our model is based on within-subject biological variation and can reveal systematic errors.

Establishing the model’s control limits

After designing the model, we wanted to explore the range in which our MPFDC values oscillate during a time period when analytical quality is acceptable. To prove no analytical error was present while establishing the MPFDC control limits, QC material was run for creatinine every two hours on all four autoanalysers for one week. In this way, it was proved that all the analysers were in acceptable analytical condition. Under both day-shift and night-shift conditions, QC was performed every two hours, and creatinine data for that week were evaluated. With this data generated from four autoanalysers, for the week to which the strict quality control protocol applied, the maximum MPFDC values naturally observed in the data were analysed. Afterwards, we calculated the MPFDC control limits (MPFDC thresholds/cut-offs) from this data. After evaluating the data, the control limits were specified as +35% and -30% of every 20 consecutive patients with previous result over the past year, for positive and negative directions, respectively. The data retrieved from GUHRAH’s laboratory information system were analysed via Microsoft Excel.

Error simulation and moving percentage of failed delta checks’s performance of error detection

After establishing control limits, the model’s performance was evaluated using erroneous results. The performance of MPFDC was assessed by applying an error of 15% in both directions (positive and negative directions) to real patient data. To demonstrate how the model works, a visual of how the model detects error after applying a 15% error in the positive direction (for a random batch) was presented (Supplementary figure 1). Error has been added to the creatinine results, in accordance with the analytical performance specifications of Clinical laboratory improvement amendments (CLIA) in effect at the time the study was conducted (23).

All results (5484 patient results) were divided into 55 batches. Then, we introduced total allowable error (TEa; 15% error) in both positive and negative directions to every batch. Afterwards, our model’s sensitivity and specificity were checked. According to the simulations, the most appropriate control limits for the MPFDC model with the highest error detection sensitivity and specificity were + 35% and - 30% in the positive and negative direction, respectively. An important point to note here is that the system was designed to give a warning (alarm) when the model exceeded the MPFDC control limits (specified as + 35% and - 30%) at least three times in a row. In this way, the possibility of false alarms was reduced, and the specificity of the system was increased.

Error were introduced to the patient data, and the number of patient results falling between the error introduction and MPFDC alarm (i.e. MPFDC exceeding the established control limit three times in a row) was calculated as average number of patients affected before error detection (ANPed) and median number of patients affected before error detection (MNPed). In addition, average time until error detection in minutes (ATed), median time until error detection in minutes (MTed), average number of deltas to error detection (ANDed) and median number of deltas to error detection (MNDed) were calculated as performance metrics. For these calculations, also for sensitivity and specificity analyses, MPFDC’s performance was analysed in 55 batches spaced at 100-sample intervals. The error was applied starting from the first patient at the beginning of each batch. After detecting the error using the MPFDC, model’s performance metrics were calculated on the raw data.

Statistical analysis

Normality of the data was evaluated for each statistical analysis. On every occasion, after Kolmogorov-Smirnov test, it was seen none of the groups had normal distribution, so nonparametric tests were performed. Kruskal-Wallis test is used for comparing the groups, and pairwise comparisons were performed with post-hoc Dunn test after Bonferroni correction. Descriptive values are given as number (N), median and interquartile range (IQR). Significance was assumed for all values where P < 0.05.

Results

The raw data consisted of 8171 patient results. A total of 5987 (73%) of the raw data had previous results within the last year. In the raw data, 1239 (15%) results were above the reference interval. There were 164 results with critical values, corresponding to 2% of the total results.

There were four autoanalysers in our laboratory and so in the study. For each analyser, QC results are presented as mean (SD) for Level 1 and Level 2, respectively: analyser 1: 215 (5.1) and 506 (6.2) μmol/L; analyser 2: 210 (6.3) and 498 (11.3) μmol/L; analyser 3: 216 (6.1) and 510 (11.6) μmol/L; analyser 4: 215 (6.0) and 500 (13.3) μmol/L.

Analyser 1 yielded CVs of 2.4% and 1.2% for level 1 and level 2, respectively, whereas analyser 2 showed 3.0% and 2.3%. Similarly, analyser 3 demonstrated CVs of 2.8% and 2.3%, and analyser 4 showed 2.8% and 2.7% at the respective levels. The combined analysis of all analysers resulted in an overall pooled CV of 2.5%, representing the overall within-laboratory imprecision of the analytical system.

Patient results were obtained over a period of one week (five working days and night shifts, besides two weekend days). If Analyser 4 was not malfunctioning, only Analyser 4 (emergency device) was operational during night shifts from 17:00 to 08:00 and on weekends. The number of patients analysed on each autoanalyser during this one-week period was 1915 (23%), 2210 (27%), 1787 (22%) and 2259 (28%) for analyser 1, analyser 2, analyser 3 and analyser 4, respectively. Median (IQR) values of emergency department, outpatients, and inpatients were 66 (34), 66 (26) and 75 (28) μmol/L, respectively. The results of inpatients were higher than both patients from emergency department and outpatients (P < 0.001). No difference was found between the emergency department and outpatients. For delta check interval it was seen the median delta check interval was 14 days. Minimum delta check interval was 0 days (i.e. 8 hours) and maximum delta check interval was 365 days. The 25th-75th percentile of delta interval was 2-87 days.

After applying positive and negative errors of 15% to each batch, the model’s performance metrics were calculated on the raw data. Median number of patients affected before error detection (MNPed) was 34 and 29, respectively (Table 1). Median time until detection of error (MTed) was 18 minutes. Sensitivity of the model was 96%; whereas specificity was 86% (Table 1). Besides MNPed and MTed, all the other performance metrics such as ANPed, ATed, ANDed and MNDed are presented in Table 1. In addition, Table 2 shows the MPFDC application rates and delta check violation ratios in patient data where no errors were applied.

Moving percentage of failed delta checks’ performance when 15% error was applied
Positive error applied Negative error applied
ANPed* 37 39
MNPed* 34 29
ATed (minutes)† 41 63
MTed (minutes)† 18 18
ANDed 20 24
MNDed 16 17
Total Number of Batches 55 55
Number of False Negative Batches 4 0
Number of False Positive Batches‡ 8
Sensitivity (%) 96
Specificity (%) 86
*The performance of the MPFDC calculated for raw data. †Time represented as minutes, and calculated for raw data. ‡In the normal patient data without any errors applied, there are eight false positive batches. Six of which were in the positive direction, and two were in the negative direction. Control limit positive cut-off 35% and control limit negative cut- off - 30% were applied. ANPed - average number of patients affected before error detection. MNPed - median number of patients affected before error detection. ATed - average time until error detection. MTed - median time until error detection. ANDed - average number of deltas to error detection. MNDed - median number of deltas to error detection.
Moving percentage of failed delta checks application rates and delta check violations by patient type
Outpatient Inpatient Total
All patients in raw data, N(%) 5694 (70%) 2477 (30%) 8171 (100%)
MPFDC (delta check) appliedpatients, N(%) 3302 (58%) 2182 (88%) 5484 (67%)
DPC (delta check) violations in MPFDCmodel when there is no error, N(%) 479 (15%) 458 (21%) 937 (17%)
Data presented in this table are raw patient data before errors were applied to the patient results. MPFDC - moving percentage of failed delta checks. DPC - delta percentage change.
Discussion

Here, we assessed the ability of the MPFDC model’s performance in detecting simulated errors in the real patient data. The model’s performance is quite good to detect an error of 15% in creatinine. Our model is based on within-subject biological variation and inspired by MovSum and MA methods (6-8). A key point in our study is that the model’s performance on raw patient data (real patient data) has been determined. This allowed us to see the model’s true performance across the whole patient data, regardless of whether the patient’s previous results were available. This is a valuable aspect of our study.

Indeed, there are two similar studies to our work in the PBQC literature. One of the studies similar to our study is from Cembrowski et al. (11). In their study, they combined delta check and MA to develop an average of deltas (AoD) strategy that monitors the mean delta of consecutive, intrapatient results. However, our study differs from their study because we were not interested in AoD values. Instead, after applying binarization to delta check failures (violations) and calculating the sum of violations, we used the failed delta check ratios in every 20 patients. Our study is distinct because we combined and summed delta check failures and calculated failure ratios dynamically, similar to MovSum and moving average, rather than using AoD. To our knowledge, our work is the first study to integrate the concept of MovSum with delta check (i.e. integrating the MovSum concept with biological variation). In this study, from delta check failures, we first tried to obtain a moving sum value considering both positive and negative directions and then calculated the percentage of this sum value in every 20 patients in a moving way.

Another similar study to ours is from Hatanaka et al. (12). They developed a dynamic PBQC model based on the variation in the distribution of delta check values in positive and negative directions. However, their model does not employ any binarization process based on the RCV value, as in our study. They based their design on positive and negative delta check values and did not compare them with a cutoff such as RCV. To our knowledge, there is no other study that applies binarization to delta check failures, then arithmetically sums the violation counts to account for the effects of both positive and negative aspects similar to MovSum, and then dynamically applies this to every 20 patients as in MA or MovSum logic. We believe that our publication synthesizes and integrates the rationale of biological variation, MA, and MovSum.

Determining the maximum time interval for applying delta checks can be estimated by considering whether physiological biological variation of the measurand is stable or not during the selected period (21). In general, patients’ previous results from a maximum of three months ago are used for delta check calculation. However, based on a recently published study, no significant change is detected in the CVi values of some analytes (including creatinine) between 18-365 days (20). In another publication, it was revealed that delta check rule performance is not affected by the time interval and error detection capacity can be increased by expanding the time period (21). Therefore, in our study, when operating delta checks, patients whose previous results were up to one year were included for DPC calculation. As designed in our study, the delta check time interval can be extended up to one year for analytes with low II. Since we used the same method and autoanalyser one year ago, we were able to determine the delta check period as one year to include more patient results in our MPFDC model considering the data in the literature. Patients whose previous results exceeded the one-year period were not included in the model. Since we set the duration to one year, we have reached a quite good number of patients for delta check in our model (67% of patients). As expected, there is some difference between ANDed-ANPed and MNDed-MNPed, but considering the one-year delta check period, we believe this difference appears to be reasonable.

For PBQC applications to be effective, false alarms should not be excessive, and false negatives also should be minimized. In addition, each laboratory should have a scheme for what to do when a PBCQ alarm arises. If the delta check limits or control limits are set low, they may give numerous false alarms (24). On the other hand, if the limits are set too high, some errors may not be detected. Therefore, delta check limits and the model’s control limits should be designed well for effective performance. Excessive false alarms may increase workload and turnaround times; it may also be challenging for the staff (25). So, we set the bidirectional Z score for RCV calculation as 2.58 to minimize false alarms. If further specificity is desired, optimizations can be attempted by selecting a Z-score of 99.9% instead of 99%, or by requiring the control limit to be reached five times in a row rather than three times to trigger the MPFDC alarm. In our study, for adequate sensitivity, we determined the MPFDC alarm should be triggered by the MPFDC reaching the control limits three times in a row.

When a 15% error was applied in the positive direction, errors were not detected in four batches. These false negatives may have been because of slight negative shifts in these batches that were not detected by internal quality control. We also think the false negatives may have occurred because of the effect of the patient population. Blood may have been predominantly drawn after treatment/hydration in hospitalized patients. When we examined the eight alarms that occurred in 55 batches due to false positive batches, we observed no problems. We suspected the false positives were due to oscillations observed in the data related to the patient population. We carefully reviewed the patient results and the information in the patient files and did not detect any analytical errors in the false alarms.

In our study, for calculating RCV, the CVi value in healthy individuals was used, which may be considered as a limitation. A substantial part of biological variation studies has been conducted with healthy individuals. Some studies have observed that the CVi values of analytes in chronic stable diseases are close to the values of healthy patients (14, 26). However, it has also been shown that CVi values for creatinine may vary in some populations, and disease conditions (26-29). Our hospital is a tertiary referral center, and there are various subpopulations in our study, such as pediatric, older adult, pregnant, transplantation, intensive care and even nephrology department’s patients. Individuals with the disease, except dialysis patients, were included in our study. Therefore, pathologic changes in creatinine results are commonly seen in our patient population. This may have caused the cutoff we determined for MPFDC to be high. Indeed, using data from biological variation studies that include patient data will make the models more suitable for real settings. Recently, in a striking study, RCV values were created from real patient results by evaluating laboratory data from middleware for nearly two years (30). In the study, the RCV value for creatinine obtained from patient data expressed as RCV alternate was found to be 25.3% (30). It would be useful for each laboratory to calculate similar data by exhibiting this approach in the studies to be performed in the laboratory.

Laboratories are like factories. Large-scale laboratories may have multiple production lines (i.e. instruments) to produce the same product (i.e. a measurand). The laboratories are responsible for ensuring the quality of the tests coming out of each analyser in real time and without producing too many problematic results at the time of error detection. If a laboratory applies the MPFDC model by including data from several analysers, an error affecting all instruments can be detected faster as the data stream to the system will increase. However, if just one device from multiple devices produces erroneous results, the erroneous results may be diluted in the data generated from the whole devices, causing the error detection time to extend (31). In our study, data flowed from four autoanalysers. Using our error simulation, we simulated a situation that could affect the results across all four devices, namely, an analytical variation, such as deterioration in water quality, inappropriate ambient temperature, improper operating temperatures, use of inappropriate calibrators or internal quality control, problems with reagent preparation, dilution errors, issues with the reagent lot, changes in reagent formulations by the manufacturer, analytical shifts such as drift or shift in calibration, using buffers with the wrong pH, or deterioration in reagents and calibrators during storage or use. The model can also detect preanalytical issues such as inappropriate centrifugation and the detection of incompatible blood samples from external centers (e.g., delayed centrifugation). However, a common situation is that only one of the four devices produces erroneous results, which can lead to dilution of the erroneous results (31). This is one of the major limitations of our study. We did not perform the study on an analyser basis. A key point here is that if the MPFDC is operated without distinguishing between all devices in the laboratory, erroneous results from only one device may be diluted, leading to relatively late detection of the error. The number of autoanalysers included in the model may also be important in determining the desired cutoff value for warnings. In the MPFDC model, the cutoffs when the model is run individually for each device may differ from those when all devices in the laboratory are operated together. Similarly, if data flows from multiple devices, increasing the block size for error detection might be a consideration. In fact, we believe that implementing our model on a device-by-device basis would be more beneficial, as it would allow for earlier error detection and could also directly point to the source of the error (the analyser producing the erroneous results). We have not yet tested this in our study, but it could be tested in future studies.

We implemented the MPFDC model in our hospital to the laboratory information system (LIS) (Nucleus, Monad Software and Consultancy, Ankara, Turkey), without the use of a middleware. Information technology staff implemented the model into the LIS within one month. In our hospital, the MPFDC model operates independently of conventional internal quality control as a supplementary tool. A specificity of 86% equals to a false rejection rate of 14% may be considered high for PBQC studies. However, that performance is at level of 15% error. High sensitivity (96%) ensures minimal risk of missing critical problematic events. In our setting, this trade-off provides safer and more clinically relevant performance. Moving percentage of failed delta checks operates continuously in the background, and when an alarm is triggered, a notification is sent to mobile phones of three laboratory specialists. Upon receiving an alert via SMS notification, patient results are immediately evaluated by the in-charge laboratory specialist for that day. Data are retrieved via LIS in one minute, and we can transfer it to Excel and filter by analyser to see if violations are arising from one analyser. Totally, this process is completed in 5 minutes. After evaluating the patient results on a device-specific basis, and, if deemed necessary, quality control is performed on the relevant device or devices. Also, in future we are planning to do separate analyser monitoring from LIS. Now, we only do separate monitoring by filtering the data, after alarm arises.

The reasons for our ATed being relatively high compared to MTed might be the lower frequency of blood sample arrivals at the laboratory during the night shifts and the skewed distribution of time until error detection. In addition, patients presenting at night and weekends are more probable to be emergent first time-presenting patients and therefore less probable to have previous results and caused higher detection times. In fact, considering that we receive a continuous flow of patient results from four devices, and that approximately 1100 creatinine tests are processed within an 8-hour period, we believe that the ANPed, MNPed, ATed, and MTed values are quite good. The number of samples received per hour decreases significantly during the night shift, particularly between 1:00 AM and 6:00 AM. The difference between ATed and MTed stems from the longer error detection times during periods of relatively low sample flow, such as after midnight.

An interesting finding of our study is the differences were observed in the model’s performance when positive and negative errors were applied. This may be due to interventions such as treatment or hydration, patients coming in groups from specific clinics, or shifts too small to be detected by internal quality control, which minimally impact the data. The literature also notes that whether the applied error is positive or negative can affect error detection in various parameters (5).

However, there are several limitations of applying PBQC. There is growing interest in PBQC; nevertheless, there are currently still several drawbacks to widespread implementation of PBQC (32). Knowledge of statistics and particular abilities of LIS and middlewares are crucial to optimise and implement a PBQC model. Therefore, when designing models, it is important that they are relatively simple, feasible and pragmatic. Another limitation is that our model might have suffered from the “population problem” like any other PBQC techniques (5). Variations in the population by time of day, week or month according to specific clinics (nephrology, oncology, pediatrics) due to phlebotomy schedules may not be distinguished from analytical shifts. When applying PBQC, data from particular clinics may be excluded, but this approach may cause a reduction in the data, thus may lag the detection of error. In our study, there were no exclusions based on age or location/ward except dialysis clinic. Thus, we enabled the system to evaluate more patient results. Methods such as truncation limits may reduce the impact of population variation (5). Since the number of patients arriving daily is quite high, meaning we are a large-scale hospital, we had the opportunity to perform truncation for those with creatinine results < 27 and > 362 μmol/L. A limitation of this study is the lack of daily inter-instrument comparability assessment. Although identical analytical platforms, reagents, and methods were used, a formal inter-instrument comparison was not performed. Therefore, potential minor instrument-specific biases related to calibration, maintenance conditions, or operator variability could not be excluded. Nevertheless, analytical performance was continuously monitored through internal QC materials run at two-hour intervals for each analyser. In addition, for each instrument, internal quality control means and SD values, instrument CVs, and median values of patient results were presented as supportive indicators of analytical stability.

For measurands, the PBQC models are not one-size-fits-all (33). It would be useful to develop unique and distinct PBQC models for each measurand considering factors such as the measurand’s analytical performance, II, and whether the analyte results are normally distributed (5, 33). If delta check is used in a PBQC model, the performance of the model may be affected by the patient population characteristics of the laboratory. In choosing a PBQC model for an analyte, one must first determine how the results for that measurand are distributed. For instance, the MA method performs inadequately for creatinine and ALT, which have right-skewed distributions (5). Moreover, for measurands with a low II the delta check implementation is substantial (14). Therefore, for these measurands, a PBQC model that includes delta check practices and is based on biological variation may be valuable and should be implemented in laboratories (32). Creatinine with a skewed distribution and a low II is suitable for our model. In addition, an advantage of our model is that it does not require a transformation of the patient data. A limitation was that we could not compare the performance of our model with another model, such as MA or MM. Because the creatinine data were already skewed, applying MA without transformation was clearly not feasible.

Particularly for the laboratories performing autoverification, our model may be used as an alarm system for detecting systematic errors in time. If algorithms that enable the detection of irregular analytical errors is already included in the autoverification model, it may be possible to integrate MPFDC into the autoverification plan additionally. In this way, under the guarantee of early awareness of systematic error thanks to our model, this may help broaden the autoverification range, autoverify the patients without previous results and improve autoverification performance. Soon the laboratory users will get more advanced PBQC options. In this context, we call on LIS and middleware vendors to implement PBQC literature and carefully evaluate the documents and spreadsheets shared in literature (34). This will allow for maximum security in autoverification applications, thus improving patient safety.

In conclusion, MPFDC a novel RCV-based PBQC model, has high sensitivity and rapid error detection. It evaluates the sustainability of analytical performance quality by considering within-subject biological variation and detecting systematic analytical errors. MPFDC may help as a gatekeeper to support and assist autoverification systems for detecting analytical errors. Particularly, the measurands with a low II are suitable for this model.

Acknowledgements

We would like to thank Ediz BAYKAL and Zeynep Başak AYDEMİR from Nucleus, Monad Software and Consultancy, and Dr. Yunus DURSUN from Gazi University Faculty of Medicine, Department of Medical Biochemistry for their worthwhile efforts on integration of MPFDC to the laboratory information system.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References PlebaniMLippiG. Improving diagnosis and reducing diagnostic errors: the next frontier of laboratory medicine. Clin Chem Lab Med. 2016;54:1117–8. 10.1515/cclm-2016-021727101552 LippiGCervellinG. From laboratory instrumentation to physician’s brain calibration: the next frontier for improving diagnostic accuracy. J Lab Precis Med. 2017;2:74–74. 10.21037/jlpm.2017.08.11 BadrickTBietenbeckAKatayevAvan RossumHHLohTPCervinskiMA Implementation of patient-based real-time quality control. Crit Rev Clin Lab Sci. 2020;57:532–47. 10.1080/10408363.2020.176573132486872 BadrickTBietenbeckACervinskiMAKatayevAvan RossumHHLohTP. Patient-based real-time quality control: review and recommendations. Clin Chem. 2019;65:962–71. 10.1373/clinchem.2019.30548231263035 SmithJDBadrickTBowlingF. A direct comparison of patient-based real-time quality control techniques: The importance of the analyte distribution. Ann Clin Biochem. 2020;57:206–14. 10.1177/000456322090217431910640 LimCYBadrickTPing LohT. Patient-based quality control for glucometers: using the moving sum of positive patient results and moving average. Biochem Med (Zagreb). 2020;30:020709. 10.11613/BM.2020.02070932550817 LiuJTanCHBadrickTLohTP. Moving sum of number of positive patient result as a quality control tool. Clin Chem Lab Med. 2017;55:1709–14. 10.1515/cclm-2016-095028328525 LiuJTanCHBadrickTLohTP. Moving standard deviation and moving sum of outliers as quality tools for monitoring analytical precision. Clin Biochem. 2018;52:112–6. 10.1016/j.clinbiochem.2017.10.00929107011 RandellEWYeniceS. Delta checks in the clinical laboratory. Crit Rev Clin Lab Sci. 2019;56:75–97. 10.1080/10408363.2018.154053630632840 JonesGR. Average of delta: a new quality control tool for clinical laboratories. Ann Clin Biochem. 2016;53:133–40. 10.1177/000456321558140025800407 CembrowskiGSXuQCervinskiMA. Average of patient deltas: patient-based quality control utilizing the mean within-patient analyte variation. Clin Chem. 2021;67:1019–29. 10.1093/clinchem/hvab05733993233 HatanakaNYamamotoYShiozakiYKuramuraENagaiNKondoA Development and Evaluation of “The Delta Plus-Minus Even Distribution Check”: A Novel Patient-Based Real-Time Quality Control Method for Laboratory Tests. J Appl Lab Med. 2024;9:316–28. 10.1093/jalm/jfad11638170846 CoşkunASandbergSUnsalICavusogluCSerteserMKilercikM Personalized reference intervals in laboratory medicine: a new model based on within-subject biological variation. Clin Chem. 2021;67:374–84. 10.1093/clinchem/hvaa23333188412 Clinical and Laboratory Standards Institute (CLSI). Use of Delta Checks in the Medical Laboratory. 2nd ed. CLSI guideline EP33. Wayne:CLSI;2023. SchifmanRBTalbertMSouersRJ. Delta check practices and outcomes: a Q-probes study involving 49 health care facilities and 6541 delta check alerts. Arch Pathol Lab Med. 2017;141:813–23. 10.5858/arpa.2016-0161-CP28402169 GarnerAELewingtonAJBarthJH. Detection of patients with acute kidney injury by the clinical laboratory using rises in serum creatinine: comparison of proposed definitions and a laboratory delta check. Ann Clin Biochem. 2012;49:59–62. 10.1258/acb.2011.01112522130632 Aarsand AK, Webster C, Fernandez-Calle P, Jonker N, Diaz-Garzon J, Coskun A, et al. The EFLM Biological Variation Database. Available from: https://biologicalvariation.eu/. Accessed October 20th 2025. CarobeneAMarinoICoşkunASerteserMUnsalIGuerraE The EuBIVAS project: within-and between-subject biological variation data for serum creatinine using enzymatic and alkaline picrate methods and implications for monitoring. Clin Chem. 2017;63:1527–36. 10.1373/clinchem.2017.27511528720681 HarrisEKYasakaT. On the calculation of a” reference change” for comparing two consecutive measurements. Clin Chem. 1983;29:25–30. 10.1093/clinchem/29.1.256848276 JonesGRD. Estimates of within-subject biological variation derived from pathology databases: an approach to allow assessment of the effects of age, sex, time between sample collections, and analyte concentration on reference change values. Clin Chem. 2019;65:579–88. 10.1373/clinchem.2018.29084130692116 TanRZMarkusCLohTP. Impact of delta check time intervals on error detection capability. Clin Chem Lab Med. 2020;58:384–9. 10.1515/cclm-2019-100431734649 LiTCaoSWangYXiongYHeYKeP Moving rate of positive patient results as a quality control tool for high-sensitivity cardiac troponin T assays. Ann Lab Med. 2021;41:51–9. 10.3343/alm.2021.41.1.5132829579 CLIA Requirements for Analytical Quality. 1992. Available from: https://westgard.com/clia-a-quality/quality-requirements/125-clia.html. Accessed May 10th 2024. LeeJKimS-YKwonHJLeeHKKimYKimY. Usefulness of biological variation in the establishment of delta check limits. Clin Chim Acta. 2016;463:18–21. 10.1016/j.cca.2016.08.00727524506 GruenbergJMSteinTAKargerAB. Determining the utility of creatinine delta checks: a large retrospective analysis. Clin Biochem. 2018;53:139–42. 10.1016/j.clinbiochem.2018.01.02329402415 RicósCIglesiasNGarcía-LarioJ-VSimónMCavaFHernándezA Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem. 2007;44:343–52. 10.1258/00045630778094563317594781 LohTPMetzMP. Indirect estimation of pediatric between-individual biological variation data for 22 common serum biochemistries. Am J Clin Pathol. 2015;143:683–93. 10.1309/AJCPB7Q3AHYLJTPK25873502 Pineda-TenorDLaserna-MendietaEJTimón-ZapataJRodelgo-JiménezLRamos-CorralRRecio-MontealegreA Biological variation and reference change values of common clinical chemistry and haematologic laboratory analytes in the elderly population. Clin Chem Lab Med. 2013;51:851–62. 10.1515/cclm-2012-070123518452 BioscaCRicósCJiménezCVLauzuricaRGalimanyR. Model for establishing biological variation in nonhealthy situations: renal posttransplantation data. Clin Chem. 1997;43:2206–8. 10.1093/clinchem/43.11.22069365419 CembrowskiGSLyonAWMcCuddenCQiuYXuQMeiJ Transformation of sequential hospital and outpatient laboratory data into between-day reference change values. Clin Chem. 2022;68:595–603. 10.1093/clinchem/hvab27135137000 ZhouQLohTPBadrickTLimCY. Impact of combining data from multiple instruments on performance of patient-based real-time quality control. Biochem Med (Zagreb). 2021;31:020705. 10.11613/BM.2021.02070533927555 DeanPSmithJBadrickT. Are we there yet? - why is the adoption of patient-based real-time quality control taking so long? J Lab Precis Med. 2025;10:10. 10.21037/jlpm-24-54 LukićVIgnjatovićS. Integrating moving average control procedures into the risk-based quality control plan in small-volume medical laboratories. Biochem Med (Zagreb). 2022;32:020711. 10.11613/BM.2022.02071135799981 LowHQKimHKKimSBadrickTLohTPLimCY Spreadsheet for patient based quality control analysis and evaluation. EJIFCC. 2025;36:26–36.40061063
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030701" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030701" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030701" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(85) "Moving percentage of failed delta checks: a novel patient-based quality control model" ["journals_article_author"]=> string(83) "Niyazi Samet Yilmaz, Bayram Sen, Sena Turkmen, Hikmet Can Çubukçu, Ozlem Gulbahar" ["journals_article_author_country"]=> string(6) "Turkey" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(118) "patient-based quality control, delta check, systematic error, quality assurance, quality control, biological variation" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1390" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "4" ["meta_title"]=> string(85) "Moving percentage of failed delta checks: a novel patient-based quality control model" ["meta_desc"]=> string(85) "Moving percentage of failed delta checks: a novel patient-based quality control model" ["meta_keyw"]=> string(118) "patient-based quality control, delta check, systematic error, quality assurance, quality control, biological variation" ["created"]=> string(19) "2026-08-10 10:25:20" ["modified"]=> string(19) "2026-10-02 11:01:13" } [12]=> object(stdClass)#51 (35) { ["journals_id"]=> string(4) "1271" ["journals_xml"]=> string(130219) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030504 10.11613/BM.2026.030504 Reviews Challenges in PT/INR harmonization across the total testing process ZouJia-min1LiTian-ji1LiuQi*2HuYong-gang*3 Department of Clinical Laboratory, Luzhou Mental Hospital, Luzhou, China Department of Orthopedics, People’s Hospital of Naxi District, Luzhou, China Department of Clinical Laboratory, People’s Hospital of Naxi District, Luzhou, China Corresponding authors: 1056630675@qq.com, 572758784@qq.com

Author contributions

J-m Zou: Conceptualization, Writing – original draft, Writing- review and editing; T-j Li: Conceptualization, Data collection, Analysis, Writing – original draft, Writing- review and editing; Y-g Hu: Conceptualization, Data collection, Analysis, Writing – original draft, Writing- review and editing; Q Liu: Conceptualization, Writing – original draft, Writing- review and editing.

15102026 15102026 36 3 030504 1605202606082026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Prothrombin time/international normalized ratio (PT/INR) non-equivalence persists despite thromboplastin calibration due to variability across the total testing process

• INR does not reliably harmonize results in liver disease or direct oral anticoagulant exposure

• Reagent–instrument combinations introduce system-dependent biases not fully corrected by standard calibration

• Commutable external quality assessment materials and patient-based real-time quality control are essential for detecting clinically relevant bias

• True PT/INR harmonization requires management of the entire vein-to-report pathway

The International Normalized Ratio (INR), introduced by the World Health Organization in 1983, is central to vitamin K antagonist (VKA) therapy monitoring. However, thromboplastin standardization alone does not ensure harmonized prothrombin time (PT)/INR results. Residual variability arises throughout the testing continuum. In this narrative review, we examine the principal sources of residual PT/INR non-equivalence across the “vein-to-report” pathway. Particular attention is devoted to clinical settings in which the assumptions underlying INR calibration are only partially satisfied, including advanced liver disease and exposure to direct oral anticoagulants. We further discuss postanalytical factors, such as determination of the mean normal prothrombin time and system-specific verification of the International Sensitivity Index, as well as quality assurance strategies, including the use of commutable external quality assessment materials and patient-based real-time quality control. Prothrombin time/INR harmonization requires integrating preanalytical practices, recognizing reagent-instrument dependencies, and quality strategies reflecting real-world testing conditions.

Keywords: prothrombin timeinternational normalized ratioharmonizationstandardizationdirect oral anticoagulants
Introduction

The most well-established preanalytical determinants of prothrombin time/international normalized ratio (PT/INR) reliability originate from specimen collection. Proper venipuncture technique is essential to avoid local activation or contamination. Prolonged tourniquet application, traumatic venipuncture, incorrect collection order, and sampling through indwelling lines may compromise sample quality and introduce variability in clot-based assays (1, 2).

The International Normalized Ratio, introduced by the World Health Organization (WHO) in 1983, uses the International Sensitivity Index (ISI) to reduce thromboplastin-related differences and establish metrological traceability (3, 4). Despite being one of the most influential standardization tools in laboratory medicine, “standardization” has not fully translated into “harmonization” - clinically equivalent results across all methods and settings (5-8).

Analytical variability also stems from how clot formation is detected. Prothrombin time systems rely on mechanical or viscosity detection, or optical monitoring of light transmission changes during fibrin formation. These methods differ not only in physical basis but also in sensitivity to hemolysis, lipemia, icterus, hypofibrinogenemia, and other matrix abnormalities (9, 10). Even when the same specimen is analyzed with closely related reagent systems, inconsistencies may persist because the clotting endpoint is operationally assigned rather than universally observed. In optical systems, the reported PT may depend on signal thresholds, clotting-curve processing rules, and platform-specific endpoint algorithms (11-13). Such differences may have clinical consequences when PT/INR results are used for vitamin K antagonist dose adjustment, interpretation of direct oral anticoagulant exposure, liver-disease severity assessment, or comparison of results across institutions.

The aim of this narrative review is therefore to critically examine residual PT/INR non-equivalence across the total testing process. We focus on how preanalytical conditions, reagent-instrument interactions, endpoint-detection principles, postanalytical INR parameters, external quality assessment materials, and clinical context influence the degree to which PT/INR results can be considered clinically interchangeable. By linking these sources of variability to patient-management consequences, we seek to clarify why PT/INR harmonization requires more than correct application of the INR formula and why system-specific verification and context-aware interpretation remain necessary.

Prothrombin time and International Normalized Ratio

The expanding use of direct oral anticoagulants (DOACs) illustrates an important boundary of PT/INR harmonization beyond the vitamin K antagonist (VKA) model. Unlike VKAs, which reduce multiple vitamin K-dependent factors in a relatively coordinated manner, DOACs produce target-specific effects that reflect drug class, plasma concentration, and reagent-dependent analytical responsiveness rather than biologically standardized patterns (14-16). Accordingly, PT/INR results in DOAC-exposed samples should not be interpreted as standardized measures of anticoagulant intensity. The clinical magnitude of this divergence is substantial. Tripodi and colleagues demonstrated that plasma from patients with advanced liver disease produced INR differences of 15-20% when tested with reagents at opposite ends of the ISI spectrum (ISI 0.9 vs. ISI 1.7), despite equivalent calibration traceability (17).

International Normalized Ratio was introduced to reduce PT variability by transforming it into a standardized expression: INR = (PTpatient / MNPT)ISI, where MNPT denotes the mean normal prothrombin time and ISI denotes the International Sensitivity Index (3, 4). This transformation improves comparability mainly in patients receiving VKAs, in whom vitamin K-dependent coagulation factors decrease in a relatively coordinated manner. However, INR standardization remains conditional. When this biological assumption is not met, clinically relevant non-equivalence may persist (18). To this end, we examine the harmonization of PT/INR from a preanalytical, analytical, and postanalytical perspective, which is primarily structured around a five-tier framework: patient-related biological context and non-parallel factor abnormalities; procedural preanalytical variation; reagent-instrument and endpoint-detection dependence; postanalytical INR parameters, including MNPT determination and ISI verification; and external quality assessment (EQA) commutability and reporting practice.

Preanalytical phase

The preanalytical phase is a major source of coagulation testing variability. Preanalytical errors and unsuitable samples can account for up to 70-77% of all laboratory errors. In coagulation testing specifically, specimen rejection rates are significantly higher than for other test groups (19, 20). This review distinguishes procedural preanalytical variables (directly affecting specimen quality) from patient-related biological conditions (altering the clinical context of PT/INR interpretation). Only procedural variables are cross-institutional standardization targets; biological modifiers define the limits of interpretive comparability (21-23).

Patient-related biological determinants beyond procedural preanalytics

Not all influences preceding PT measurement are procedural. Before venipuncture, the patient’s biological state may already affect both the generation and interpretation of PT prolongation. Unlike classical preanalytical variables, these factors do not primarily impair specimen integrity, but alter the biological context in which PT/INR is produced and interpreted.

This distinction is important because the INR model was developed in VKA-treated patients (24). In other conditions, PT prolongation reflects heterogeneous and often overlapping pathophysiological mechanisms. In chronic liver disease, including cirrhosis, alterations involve not only reduced synthesis of procoagulant factors but also concomitant changes in anticoagulant and fibrinolytic pathways; therefore, PT/INR captures only a limited component of the rebalanced hemostatic system. Moreover, because the INR was standardized primarily for monitoring vitamin K antagonist therapy, it does not reliably harmonize PT results across thromboplastin reagents in patients with chronic liver disease. Inter-reagent differences can reach approximately 0.7 INR units in this setting, underscoring that INR should not be used as a stand-alone measure of global coagulopathy or bleeding risk in cirrhosis (25). In sepsis, by contrast, PT prolongation is more closely related to inflammation-driven coagulation activation, factor consumption, endothelial dysfunction and consumptive coagulopathy, while reduced vitamin K availability in critical illness may provide a partially overlapping and potentially modifiable contribution (26, 27).

From a harmonization perspective, these patient-related determinants may therefore amplify residual differences between reagents and analytical systems even when procedural preanalytics are well controlled (21). They should therefore be considered biological modifiers of PT/INR interpretability rather than conventional preanalytical errors. This distinction is essential, because it explains why optimized collection and processing alone cannot ensure full PT/INR comparability across all clinical settings (3, 8).

Blood collection and phlebotomy-related variables

Proper venipuncture technique is fundamental to the reliability of PT/INR assays. Preanalytical errors occur in roughly 5% of coagulation specimen collections (28). Although the exact proportions reported in different studies differ, insufficient fill volume and clot formation consistently remain the predominant issues (29, 30). In accordance with Clinical and Laboratory Standards Institute (CLSI) guidance, the recommended order of draw positions sodium citrate tubes (light blue, 3.2% citrate) immediately after blood culture bottles and before any serum, heparin, EDTA, or glycolytic inhibitor tubes (31). When a winged (“butterfly”) collection set is used, a discard tube (non-additive or citrate) must be drawn first to offset tubing dead space and avert under-filling; this discard remains mandatory even if only a coagulation tube is collected. No discard is required for standard evacuated tubes without a winged set.

Tourniquet application should not exceed one minute and must be released as soon as blood flow is established (32). Sodium citrate tubes must be filled to at least 90% of the nominal volume to maintain the critical 9:1 blood-to-anticoagulant ratio; under-filling leads to relative citrate excess and consequent falsely prolonged PT/INR values. Studies demonstrate that underfilling 3.8% sodium citrate collection tubes significantly prolongs PT (33). However, when using the 3.2% sodium citrate currently recommended by CLSI, no statistically significant difference in PT results was observed between 60% and 100% fill volumes (31). Immediately after collection, the tube should be gently inverted four to five times to ensure thorough mixing, whereas vigorous shaking should be avoided to prevent hemolysis (34). A clean, minimally traumatic venipuncture minimises tissue factor contamination, and severely hemolyzed samples are considered unacceptable (35). Collectively, strict adherence to these standardised procedures and to the correct order of draw effectively minimises collection-related variability (36).

Anticoagulant ratio, processing, and sample stability

After collection, the in vitro specimen environment is critical. Prothrombin time depends on accurate reversal of citrate-mediated calcium chelation. In markedly elevated hematocrit (> 55%), reduced plasma fraction produces relative anticoagulant excess. Guidelines recommend adjusted citrate volumes, yet the evidence base derives predominantly from indirect studies of underfilled tubes or artificially constructed hematocrit values rather than direct patient data (31). A study demonstrated that the impact of citrate adjustment depends critically on reagent type: recombinant tissue factor thromboplastin showed strong agreement between adjusted and unadjusted INRs (R2 = 0.823; median 2.25 vs 2.22), with > 10% deviation only when hematocrit exceeded 62%, whereas rabbit brain thromboplastin exhibited only moderate correlation (R2 = 0.427) and a clinically significant median INR difference (2.51 vs 3.45), challenging the universal application of current guidelines (37). From a practical standpoint, manual CLSI H21 adjustment is burdensome in high-throughput laboratories, requiring individual patient hematocrit values, manual tube preparation, and careful labeling, each step introducing potential human error, while automation strategies such as pre-labeled adjusted tubes or barcode-integrated calculation systems remain underutilized in most routine settings. Laboratories thus face a trade-off between theoretical accuracy and operational reality.

Prothrombin time/INR stability is time- and temperature-dependent: CLSI recommends up to 24 hours at room temperature, though refrigerated storage data are nuanced (plasma PT/INR is stable for up to 24 hours at 4 °C in some studies; whole blood PT/INR can also be refrigerated for up to 24 hours per the updated guideline, which supersedes previous recommendations against refrigeration (31, 38). For patients receiving unfractionated heparin, whole blood specimens must be centrifuged within 1 hour at room temperature, and plasma analysis completed within 4 hours of collection; delays beyond these thresholds may compromise reliability due to platelet factor 4 mediated heparin neutralization (39). Ultimately, adequate centrifugation, defined as centrifugation of capped citrated whole blood at 1500xg for no less than 15 minutes at room temperature (15-25 °C), preferably using a swing-out bucket rotor with the brake deactivated, to achieve platelet-poor plasma with a residual platelet count < 10,000/μL, and strict adherence to standardized collection, processing, and timing protocols remain essential prerequisites for inter-laboratory comparability (40, 41). Major procedural sources of preanalytical variability affecting PT/INR are shown in Table 1.

Major procedural sources of preanalytical variability affecting PT/INR
Variation category Source Mechanism Effect on PT/INR Controllability
Blood collection Prolonged or difficult venipuncture (41) Partial activation during sampling; specimen quality compromise Unreliable PT/INR High
Blood collection Incorrect order of draw in open systems / line contamination (41) Carry-over of anticoagulants or other additives Prolonged or unreliable PT/INR, especially when contamination occurs High
Sample processing Underfilled citrate tube (41,42) Excess citrate ® calcium over-chelation Prolonged PT / elevated INR High
Sample processing Extreme hematocrit (> 55%) without citrate adjustment (42) Relative excess of citrate in reduced plasma volume Prolonged PT / elevated INR Medium
Sample processing Inadequate centrifugation (40,42) Residual cellular components and platelet phospholipid Potentially altered or less reliable PT/INR (direction assay-dependent) High
Transport / storage Delay in processing or inadequate temperature control (42) Time- and condition-dependent alteration of coagulation factor/activity stability Usually prolonged or less reliable PT/INR High
PT/INR - prothrombin time/international normalized ratio. PT – prothrombin time.
Analytical phase

The analytical phase is a critical determinant of PT/INR comparability. Although the ISI framework was introduced to reduce variability attributable to differences in thromboplastin responsiveness, analytical harmonization remains incomplete in routine practice. Residual non-comparability may persist because differences in reagent composition, analyzer-specific clot detection principles, and context-dependent sample behavior are only partially corrected by INR transformation (1-4). Analytical disagreement should therefore be understood not simply as the result of isolated technical imperfections, but as the combined consequence of biological complexity and system-dependent measurement design. This issue is particularly important in multi-center clinical trials, transplant networks involving cross-border organ allocation, or regions with high population diversity. Laboratories should consider local MNPT establishment or formal transfer validation when patient demographics or analytical systems differ substantially from reference conditions (41).

Thromboplastin reagents and analytical sensitivity

The limitations of the ISI model’s foundational assumptions become especially evident outside the classic vitamin VKA setting. The model presupposes coordinated declines in vitamin K-dependent factors, thereby allowing universal calibration correction. When factor abnormalities are non-parallel, the PT prolongation-to-deficiency relationship becomes reagent- and system-dependent. In advanced liver disease, disproportionate factor VII reduction produces reagent-dependent PT responses that cannot be fully corrected by a single ISI conversion (17, 42).

Current guidelines recommend evaluating at least 20 normal plasmas and 60 stable VKA-treated samples spanning INR approximately 1.5-4.5, with log-transformed PT results compared to the reference system via orthogonal regression (43, 44). To address method-dependent bias, Tripodi and colleagues developed INR calibrated for cirrhosis (INR(liver)), using a cirrhosis-specific ISI derived from chronic liver disease patients (45). Independent validation yielded mixed results: Bechmann et al. reported that INR(liver) reduced but did not eliminate method-related Model for End-Stage Liver Disease (MELD) variation, with residual 8-12% disagreement at INR > 2.0 (46). White et al. confirmed improvement was most pronounced at lower INR ranges (1.5-2.5) but diminished with severe factor VII depletion. These data indicate INR(liver) is a partial solution; clinical harmonization requires complementary strategies including ISI optimization and thrombin generation assay (TGA) integration (47, 48). Similar divergence has been documented in sepsis-associated coagulopathy and other non-VKA conditions where factor consumption patterns are heterogeneous (49).

Another issue concerns MNPT sourcing. Laboratories may locally determine MNPT from healthy donors or, in some settings, rely on manufacturer assignments. The latter assumes manufacturer reference conditions match the local reagent-instrument combination, an assumption that may not hold in practice (41, 50). Direct adoption of manufacturer-assigned MNPT may introduce systematic bias if local normal PT values differ. Postanalytical harmonization requires not only correct formula application but validation that the MNPT is suitable for the local measurement system.

Detection principles and endpoint definition

Analytical variability also arises from the way clot formation is detected and translated into a reportable endpoint. Clotting time is assigned through platform-specific detection principles (Table 2). Prothrombin time systems use mechanical, viscosity-based, or optical methods. These differ in susceptibility to interference from hemolysis, lipemia, bilirubin, and hypofibrinogenemia (13).

Detection principles in coagulation analyzers and their relevance to PT/INR
Analytical aspect Mechanical/viscosity-based detection Optical detection Selected magnetic bead-based platforms Relevance to PT/INR comparability
Physical principle Detects changes in sample movement, oscillation, or viscosity as fibrin polymerization progresses Detects changes in light transmission, absorbance, or turbidity during clot formation Detects clot-related changes in magnetic particle motion using platform-specific sensing systems Different detection principles may translate the same coagulation reaction into different PT seconds, which are not always fully normalized by INR conversion
Endpoint definition Endpoint is assigned when movement attenuation or viscosity-related threshold criteria are reached Endpoint is assigned from optical curve thresholds and platform-specific signal-processing algorithms Endpoint is assigned from changes in magnetic particle behavior together with platform-specific threshold algorithms Endpoint assignment is operational rather than universal, and may therefore contribute to inter-system variability
Susceptibility to hemolysis/lipemia/icterus Less susceptible to purely optical interference, although biological and matrix-related effects may still influence results More susceptible to optical interference, although modern HIL checks and correction algorithms may mitigate some effects In some comparative studies, showed lower susceptibility to optical interference than photo-optical systems; performance remains platform-dependent Matrix-dependent bias differs across systems and may reduce comparability in visually compromised samples
Performance in low fibrinogen states Weak clot formation may still impair endpoint recognition, particularly in severe hypofibrinogenemia Weak or shallow optical clotting curves may reduce signal robustness Performance may remain acceptable on some platforms, but depends on assay design and signal-processing rules Severe hypofibrinogenemia can accentuate system-dependent differences in clot endpoint assignment
Additional analytical output Usually limited to endpoint-based clotting results May provide full clotting curves and derived waveform parameters; clot waveform analysis is primarily associated with photo-optical systems Usually limited in routine PT output, depending on platform implementation Additional algorithmic output may improve interpretation, but also increases platform dependence
Practical implication Often advantageous in optically compromised samples, but not inherently interchangeable with other systems Informative and waveform-capable, but more sensitive to optical artifacts Potentially useful in selected optically compromised specimens, but not inherently interchangeable with other systems PT/INR harmonization should evaluate the reagent–instrument pair as the analytical unit rather than the reagent alone
PT/INR - prothrombin time/international normalized ratio. HIL - hemolysis/icterus/lipemia index. PT – prothrombin time.

Traditional internal quality control (IQC) and EQA remain laboratory quality assurance foundations. However, satisfactory performance in traditional quality systems does not guarantee clinically equivalent results across laboratories, because PT/INR comparability depends not only on analytical precision but also on whether quality assessment materials behave like real patient plasma across different reagent-instrument systems (51).

Analytical non-comparability is therefore not reducible to reagent sensitivity alone. Instead, PT/INR performance should be understood at the level of the integrated analyzer–reagent system, in which the same biological reaction may be translated into different clotting times depending on how endpoint formation is detected and processed. For PT/INR harmonization, the relevant unit of comparison is thus not the reagent in isolation, but the full measurement system through which coagulation is measured and converted into reportable data (see Table 2).

Pharmacodynamic interference from direct oral anticoagulants

The increasing use of DOACs illustrates an important boundary of PT/INR harmonization outside the VKA model. Unlike VKAs, which reduce several vitamin K-dependent clotting factors in a relatively coordinated manner, DOACs exert target-specific effects on coagulation assays (14). Their influence on PT therefore reflects drug-specific and reagent-dependent analytical effects rather than a biological pattern that can be reliably normalized through conventional INR transformation. A systematic review by Samuelson et al. demonstrated that the performance of standard anticoagulation tests varies across DOACs and reagents, with most assays showing insufficient correlation to provide a reliable assessment of DOAC effects (16).

However, recent developments include the MRX PT DOAC assay, which generates a DOAC Normalised Ratio (DNR) from a DOAC-sensitive PT and an INR from a DOAC-insensitive PT, with the Clot Time Ratio (CTR) calculated as DNR/INR (52). In a 2024 evaluation, the MRX PT DOAC assay demonstrated 100% sensitivity and 100% negative predictive value for edoxaban concentrations > 50 ng/mL, and can be run on widely available coagulation analyzers (53). This suggests that reagent-dependent DOAC effects may be harnessed for detection purposes rather than dismissed solely as confounding variability. Direct oral anticoagulant stop reagents, such as DOAC Stop and DP-Filter, offer another pathway: these products can effectively neutralize the in vitro effect of all DOACs, including rivaroxaban, enabling accurate baseline PT/INR determination in DOAC-exposed samples (54, 55). Future guidelines may evolve to incorporate DOAC-specific verification protocols, particularly for emergency settings where rapid exclusion of clinically relevant DOAC concentrations is required. Typical effects of selected DOACs on PT assays and associated interpretation risks are shown in Table 3.

Typical effects of selected DOACs on PT assays and associated interpretation risks
Drug class/example Typical effect on PT Inter-reagent variability Main interpretation risk Recommended reporting implication References
Direct factor Xa inhibitor (rivaroxaban) Often moderate to marked PT prolongation High PT prolongation may be misread as a standardized estimate of anticoagulant intensity PT/INR should not be used to estimate rivaroxaban intensity; if assessment is clinically required, use a drug-appropriate assay ((14,15,56))
Direct factor Xa inhibitor (apixaban) Usually minimal, absent, or inconsistent effect in many PT systems High A normal PT may falsely reassure clinicians despite clinically relevant drug exposure A normal PT does not exclude clinically relevant apixaban exposure ((14,15,57))
Direct thrombin inhibitor (dabigatran) Usually weak and inconsistent PT effect; prolongation is more likely at higher concentrations Moderate to high PT is relatively insensitive and may underestimate drug presence PT is not suitable for excluding dabigatran; dilute thrombin time or ecarin-based assays are preferred when assessment is required ((14,56,57))
Direct factor Xa inhibitor (edoxaban) Moderate PT prolongation, greater than apixaban but less than rivaroxaban in most systems (1.5-2.5 x control at peak) Moderate to high INR may appear falsely elevated; edoxaban-specific anti-Xa assay preferred for quantitative assessment PT/INR should not be used to estimate edoxaban intensity; anti-Xa assay recommended if quantitative data required ((14,56))
DOACs overall Drug-specific and reagent-dependent PT effects that do not conform to the VKA calibration model High INR reporting may give a misleading impression of standardization and comparability PT results in DOAC-treated patients should not be interpreted within the conventional VKA-oriented INR framework ((14,56,57))
DOACs - direct oral anticoagulants. PT – prothrombin time. PT/INR - prothrombin time/international normalized ratio. VKA - vitamin K antagonist.
Artificial intelligence and machine learning in PT/INR quality assurance

Artificial intelligence (AI) and machine learning (ML) approaches have recently been explored in laboratory quality systems, particularly for patient-based real-time quality control (PBRTQC) and coagulation waveform analysis (58-60). Existing studies using ensemble learning and rule-based hybrid models suggest that ML may improve the early detection of analytical drift; however, the magnitude of improvement is strongly dependent on dataset structure, local patient mix, and calibration strategy, and cannot be generalized as a fixed performance gain across laboratories (58). For example, reported improvements in drift detection sensitivity vary widely across simulation-based and retrospective datasets, and are influenced by baseline analytical stability and signal-to-noise ratio rather than algorithm type alone (58, 59). Consequently, performance estimates should be interpreted as context-specific rather than transferable metrics, and prospective multicenter validation remains limited.

Deep learning models applied to optical clot waveform data have demonstrated promising capability in identifying preanalytical interference such as hemolysis, lipemia, and icterus. Nevertheless, most published studies remain retrospective or single-platform in design, and clinical implementation requires validation across heterogeneous analyzer-reagent systems before routine adoption (61). Importantly, current evidence supports AI as an adjunctive interpretive layer rather than a replacement for standardized analytical quality systems. Integration into routine laboratory workflows will require resolution of key barriers, including model transparency, regulatory validation, interoperability with laboratory information systems, and dataset harmonization across institutions (60, 62).

Point-of-care testing INR devices and clinical harmonization implication

The expansion of point-of-care testing (POCT) has extended the PT/INR harmonization challenge beyond centralized laboratories into decentralized clinical settings (63). While POCT INR devices improve care accessibility and enable rapid feedback for outpatient and home VKA monitoring, they cannot be assumed analytically interchangeable with central laboratory assays without formal verification (64). Point-of-care testing systems adopt strip- or cartridge-based whole-blood detection, whereas laboratory assays use platelet-poor plasma with optical or mechanical clot detection, creating inherent gaps in detection principle and matrix susceptibility (65, 66).

Agreement between the two methods is generally acceptable within conventional therapeutic INR ranges, but bias progressively increases at higher values, driven by analytical non-linearity and intrinsic matrix effects of whole-blood testing (67). Discordance risk is further amplified in patients with advanced liver disease or abnormal hematocrit and fibrinogen concentrations. This carries clinical relevance: MELD scores are standardized to laboratory INR, while POCT results commonly seen in emergency or ambulatory settings may lead to misclassification of disease severity (63, 68).

Regular comparative verification against local central laboratory systems is essential. Current guidance recommends method comparison in stable VKA-treated patients, with an acceptable paired deviation of approximately 0.5 INR units (69). Venous laboratory confirmation should be prioritized before major clinical decisions at high INR levels (65). U.S. Food and Drug Administration (FDA) recalls of INRatio devices further underscore the necessity of device-specific validation, even as newer platforms show improved performance (67, 70). Point-of-care testing does not undermine the broader INR framework, but clarifies that cross-system comparability remains conditional on measurement method, specimen matrix, and clinical context.

Owren-Quick Divergence and Fiix-PT Calibration

The persistent methodological divergence between Owren and Quick PT systems remains a relevant source of inter-laboratory variability despite shared ISI-based calibration (71). Although INR transformation improves comparability, residual bias has been consistently demonstrated at higher INR ranges and in complex patient populations, particularly in the context of liver disease and intensive anticoagulation regimens (68).

The Fiix-PT concept offers an innovative approach to reducing analytical variability by selectively prioritizing factor II and X activity while attenuating sensitivity to factor VII-driven fluctuations (72). This strategy may enhance analytical stability in VKA monitoring; however, its clinical adoption remains at an early validation stage, with current evidence largely derived from observational and regionally confined studies (73). Notably, while the Icelandic nationwide cohort study demonstrated improved VKA stability and reduced bleeding events, these findings were obtained within a relatively homogeneous healthcare system with centralized laboratory standardization, which may limit their direct extrapolation to more heterogeneous international settings (74).

Accordingly, Fiix-PT should currently be regarded as a promising yet context-sensitive calibration strategy, requiring robust multicenter validation across diverse reagent–instrument systems before broad implementation can be recommended (73). From a harmonization perspective, it is more appropriately viewed as part of a broader conceptual evolution toward mechanism-informed coagulation assessment rather than as a direct substitute for conventional PT/INR. Future research should prioritize: (i) multicenter validation across different reagent classes; (ii) head-to-head comparisons with standardized INR in diverse populations; and (iii) integration into clinical decision algorithms, rather than relying on isolated numerical substitution.

Postanalytical phase

Postanalytical variability in PT/INR testing arises mainly from the parameters used to convert PT seconds into INR, the compatibility of those parameters with the local reagent–instrument system, and the way INR results are subsequently interpreted or incorporated into clinical decision tools (43). Although these factors occur after clot detection, they can introduce clinically relevant bias because INR is a calculated result rather than a directly measured analyte.

Determination of the mean normal prothrombin time

Mean normal prothrombin time serves as the baseline denominator in the INR formula, and systematic bias in this value propagates directly into all patient INR results (43). Manufacturers typically provide a default MNPT value established under reference conditions, but this value may not transfer reliably to local reagent-instrument combinations or patient populations. Population-related variation in normal PT values represents an often-overlooked source of systematic bias: reference intervals for coagulation tests established in Western cohorts may not be appropriate for non-Western populations, and direct adoption of imported MNPT values can introduce consistent offset across all patient results (75).

Current CLSI guidelines recommend that laboratories establish or verify MNPT locally using at least 20 plasma samples from healthy donors matched to the local patient demographic (43). For open analytical systems where reagents are used on non-validated instrument platforms, local MNPT determination is not optional but a methodological requirement to maintain metrological traceability. Field evidence indicates that laboratories performing local MNPT verification exhibit significantly lower between-laboratory INR bias than those relying exclusively on manufacturer-assigned values (76). In multinational clinical trials or cross-border organ allocation networks, formal transfer validation of MNPT is particularly critical, as even small deviations in baseline PT can produce clinically meaningful INR differences near therapeutic or prognostic thresholds.

International Sensitivity Index verification and postanalytical system compatibility

The ISI is the core calibration parameter that normalizes thromboplastin sensitivity differences across reagents. However, manufacturer-assigned ISI values are validated only for specific reagent-instrument combinations; when reagents are deployed on alternative platforms in open systems, the ISI may no longer be accurate, introducing systematic bias into INR calculations (3, 77).

Per CLSI H54-A guidelines, local ISI calibration or verification requires testing at least 20 normal plasmas and 60 stable VKA-treated samples spanning an INR range of approximately 1.5-4.5, with orthogonal regression applied to log-transformed PT results against a reference measurement system (43). This procedure corrects for platform-specific differences in clot endpoint detection, optical signal processing, and reagent-instrument interaction that cannot be captured by a generic reagent ISI. Multi-center evaluation data demonstrate that local ISI calibration reduces between-laboratory INR bias compared with using manufacturer-assigned values alone, particularly at higher INR values (78). Despite this well-documented benefit, local calibration remains underimplemented in routine practice, contributing to persistent postanalytical variability across institutions.

Postanalytical harmonization therefore requires recognition that INR is generated by an integrated reagent-instrument-calculation system, not by reagent sensitivity alone. Regulatory frameworks increasingly emphasize that manufacturers should provide system-specific ISI values for each certified reagent-instrument pair, rather than a single generic reagent ISI, to reduce the burden on individual laboratories and improve baseline standardization.

Clinical amplification of INR variability

The clinical impact of postanalytical INR variability is disproportionately magnified when INR values are incorporated into validated prognostic scoring systems, most notably the MELD score (68). The MELD algorithm uses a log-transformed INR term, meaning that even small absolute differences in INR (0.2-0.3 units) can alter calculated disease severity and shift patient priority near liver transplantation eligibility thresholds (79).

This amplification effect is particularly consequential in advanced liver disease, where INR itself is already subject to substantial reagent-dependent analytical bias due to non-parallel factor deficiency (25). Postanalytical errors in MNPT or ISI thus compound pre-existing analytical non-equivalence, leading to clinically significant misclassification of cirrhosis severity. To minimize this cumulative variation, laboratories serving liver transplant centers are advised to prioritize thromboplastin reagents with ISI values closest to 1.0, implement local ISI/MNPT calibration, and participate in EQA programs using commutable human plasma materials (25, 80).

Future outlooks

Although the INR system has substantially improved comparability of PT results for monitoring vitamin K antagonist therapy, complete harmonization across laboratories remains difficult (5, 8). Future research should focus on four areas: local verification of MNPT and ISI in open reagent-instrument systems; broader use of commutable EQA materials; indication-specific interpretation for clinical settings in which conventional INR assumptions are not fulfilled; and prospective validation of complementary approaches such as Fiix-PT, thrombin generation assays, PBRTQC, and AI-assisted quality surveillance. These priorities require multicentre studies including diverse patient populations, different thromboplastin reagents, Quick and Owren methods, central-laboratory and decentralized testing environments, and clinically relevant outcomes.

Conclusion

The INR remains one of the most influential standardization tools in laboratory medicine, but its success should not obscure its limitations. As this review shows, calibration of thromboplastin responsiveness alone does not ensure full PT comparability across the total testing process or across all clinical settings. Residual variability may arise from patient-related biological context, specimen handling, reagent-instrument interactions, postanalytical parameter validity, and decentralized testing conditions. Prothrombin time/INR harmonization should therefore be understood not as a completed achievement, but as an ongoing process requiring integrated control across preanalytical, analytical, and postanalytical phases together with quality systems that reflect real-world patient samples and routine practice.

Acknowledgments

This work was supported by the Luzhou Medical Association (Grant No. 2024-YXXM-120). During the preparation of this manuscript, the authors used Kimi (Moonshot AI) for the purposes of polishing the language and style. The authors have reviewed and edited the output and take full responsibility for the content of this publication.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References GosselinRC. Review of coagulation preanalytical variables with update on the effect of direct oral anticoagulants. Int J Lab Hematol. 2021;43 Suppl 1:109–16. 10.1111/ijlh.1358534288452 KitchenSAdcockDMDauerRKristoffersenAHLippiGMackieI International Council for Standardization in Haematology (ICSH) recommendations for processing of blood samples for coagulation testing. Int J Lab Hematol. 2021;43:1272–83. 10.1111/ijlh.1370234581008 PollerL. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost. 2004;2:849–60. 10.1111/j.1538-7836.2004.00775.x15140114 DorgalalehAFavaloroEJBahrainiMRadF. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). Int J Lab Hematol. 2021;43:21–8. 10.1111/ijlh.1334932979036 van den BesselaarAMStavelinAKitchenSBryantMTripodiAScalambrinoE Defining a metrologically traceable and sustainable calibration hierarchy of international normalized ratio for monitoring of vitamin K antagonist treatment in accordance with International Organization for Standardization (ISO) 17511:2020 standard: communication from the International Federation of Clinical Chemistry and Laboratory Medicine-SSC/ISTH working group on prothrombin time/international normalized ratio standardization. J Thromb Haemost. 2024;22:1236–48. 10.1016/j.jtha.2023.12.01338128762 van den BesselaarAMvan RijnCJJAbdoelCFChantarangkulVScalambrinoEKitchenS Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: Harmonizing the manual tilt tube method. J Thromb Haemost. 2020;18:1986–94. 10.1111/jth.1487332356308 KirkwoodTB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost. 1983;49:238–44. 10.1055/s-0038-16573716879511 PlebaniMLippiG. Standardization and harmonization in laboratory medicine: not only for clinical chemistry measurands. Clin Chem Lab Med. 2022;61:185–7. 10.1515/cclm-2022-112236368011 BaiBChristieDJGormanRTWuJR. Comparison of optical and mechanical clot detection for routine coagulation testing in a large volume clinical laboratory. Blood Coagul Fibrinolysis. 2008;19:569–76. 10.1097/MBC.0b013e328307087218685440 TekkesinNKılıncC. Optical and mechanical clot detection methodologies: a comparison study for routine coagulation testing. J Clin Lab Anal. 2012;26:125–9. 10.1002/jcla.2149722628225 GeensTVertessenFMalfaitRDeiterenKMaesMB. Validation of the Sysmex CS5100 coagulation analyzer and comparison to the Stago STA-R analyzer for routine coagulation parameters. Int J Lab Hematol. 2015;37:372–81. 10.1111/ijlh.1229525233923 ÜlferG. A comparison of the optical method with the mechanical method in routine coagulation tests. J Med Biochem. 2025;44:479–85. 10.5937/jomb0-5610040821639 WoolleyAGolmardJLKitchenS. Effects of haemolysis, icterus and lipaemia on coagulation tests as performed on Stago STA-Compact-Max analyser. Int J Lab Hematol. 2016;38:375–88. 10.1111/ijlh.1249827306848 DouxfilsJAgenoWSamamaCMLessireSTen CateHVerhammeP Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16:209–19. 10.1111/jth.1391229193737 GosselinRCAdcockDMBatesSMDouxfilsJFavaloroEJGouin-ThibaultI International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018;118:437–50. 10.1055/s-0038-162748029433148 SamuelsonBTCukerASiegalDMCrowtherMGarciaDA. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. Chest. 2017;151:127–38. 10.1016/j.chest.2016.08.146227637548 LismanTvan LeeuwenYAdelmeijerJPereboomITHaagsmaEBvan den BergAP Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int. 2008;28:1344–51. 10.1111/j.1478-3231.2008.01783.x18482269 WinterWEFlaxSDHarrisNS. Coagulation Testing in the Core Laboratory. Lab Med. 2017;48:295–313. 10.1093/labmed/lmx05029126301 AquinoJBDamianKB. Pre-analytical Factors Influencing Blood Sample Rejection Rate in the Hematology Laboratory of the Philippine General Hospital from 2018 to 2022: A Cross-sectional Study. Acta Med Philipp. 2025;59:30–6.40950533 GoswamiBMahajanBChawlaRMallikaV. Evaluation of errors in a clinical laboratory: A one-year experience. Clin Chem Lab Med. 2010;48:63–6. 10.1515/CCLM.2010.00620047530 LismanTHernandez-GeaVMagnussonMRobertsLStanworthSThachilJ The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost. 2021;19:1116–22. 10.1111/jth.1523933792172 DahlbergSSchöttUKanderT. The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study. J Intensive Care. 2021;9:11. 10.1186/s40560-020-00517-533461606 IbaTLeviMLevyJH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost. 2020;46:89–95. 10.1055/s-0039-169499531443111 ZivelinARaoLVRapaportSI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest. 1993;92:2131–40. 10.1172/JCI1168148227329 TripodiAChantarangkulVMannucciPM. The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. J Thromb Haemost. 2008;6:243–8. 10.1111/j.1538-7933.2008.02827.x17988228 van VughtLAUhelFDingCVan’t VeerCSciclunaBPPeters-SengersH Consumptive coagulopathy is associated with a disturbed host response in patients with sepsis. J Thromb Haemost. 2021;19:1049–63. 10.1111/jth.1524633492719 PaulusMCDrentMKouwIWKBalversMGJBastAvan ZantenARH. Vitamin K: a potential missing link in critical illness-a scoping review. Crit Care. 2024;28:212. 10.1186/s13054-024-05001-238956732 KitchenSAdcockDMDauerRKristoffersenAHLippiGMackieI International Council for Standardisation in Haematology (ICSH) recommendations for collection of blood samples for coagulation testing. Int J Lab Hematol. 2021;43:571–80. 10.1111/ijlh.1358434097805 GaurKPuriVShuklaSSharmaSSumanSSinghR. Finish before the start: Analyzing preanalytical sample errors in a tertiary care hematology laboratory. Indian J Pathol Microbiol. 2020;63:435–40. 10.4103/IJPM.IJPM_191_1932769334 IqbalMSTabassumAArbaeenAFQasemAHElshemiAGAlmasmoumH. Preanalytical Errors in a Hematology Laboratory: An Experience from a Tertiary Care Center. Diagnostics (Basel). 2023;13: 10.3390/diagnostics1304059136832079 Clinical and Laboratory Standards Institute. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays. 6th ed. CLSI guideline H21. Wayne, PA: Clinical and Laboratory Standards Institute; 2024. GosselinRCMarlarRA. Preanalytical Variables in Coagulation Testing: Setting the Stage for Accurate Results. Semin Thromb Hemost. 2019;45:433–48. 10.1055/s-0039-169270031291676 KimHKParkSLimJHJeongJLeeS. Validation of pre-analytical stability of specimens requested for various routine coagulation tests. Clin Exp Thromb Hemost. 2021;7:7–13. 10.14345/ceth.21002 Adcock FunkDMLippiGFavaloroEJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost. 2012;38:576–85. 10.1055/s-0032-131976822706973 BakerPPlattonSGibsonCGrayEJenningsIMurphyP Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Br J Haematol. 2020;191:347–62. 10.1111/bjh.1677632537743 PlebaniMSciacovelliLAitaAPadoanAChiozzaML. Quality indicators to detect pre-analytical errors in laboratory testing. Clin Chim Acta. 2014;432:44–8. 10.1016/j.cca.2013.07.03324012653 SilvaVMRezendeDCGarciaESCavalheiroCStrunzCC. Effect of anticoagulant adjustment on prothrombin time test using two different PT reagents in patients with elevated hematocrit. Pract Lab Med. 2020;22:e00177. 10.1016/j.plabm.2020.e0017733134464 NakanishiRSakayoriTMatsuiDKonoMMakiMDunoisC Effects of storage time and temperature on coagulation factor and natural anticoagulant activities in healthy individuals. Sci Rep. 2025;15:10797. 10.1038/s41598-025-95389-w40155424 BakerPPlattonSArachchillageDJKitchenSPatelJRiatR Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology Guideline. Br J Haematol. 2024;205:1302–18. 10.1111/bjh.1972939223697 GosselinRC. Ultracentrifugation for Coagulation Testing. Methods Mol Biol. 2023;2663:63–70. 10.1007/978-1-0716-3175-1_437204704 FavaloroEJAdcockDM. Standardization of the INR: how good is your laboratory’s INR and can it be improved? Semin Thromb Hemost. 2008;34:593–603. 10.1055/s-0028-110453819085760 LeeJHKweonOJLeeMKLeeHWKimHJKimHR. Clinical usefulness of international normalized ratio calibration of prothrombin time in patients with chronic liver disease. Int J Hematol. 2015;102:163–9. 10.1007/s12185-015-1820-226068391 Adcock DM, Brien WF, Duff SL, Johnston M, Marlar RA, Ng VL, et al. Procedures for validation of INR and local calibration of PT/INR systems; approved guideline. CLSI document H54-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. World Health Organization Expert Committee on Biological Standardization. Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy with vitamin K antagonists. WHO Technical Report Series. 2013;979:271–316. TripodiAChantarangkulVPrimignaniMFabrisFDell’EraASeiC The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology. 2007;46:520–7. 10.1002/hep.2173217659574 BechmannLPSichauMWichertMGerkenGKrögerKHilgardP. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int. 2011;31:75–82. 10.1111/j.1478-3231.2010.02358.x20958919 HemkerHCGiesenPAl DieriRRegnaultVde SmedtEWagenvoordR Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15. 10.1159/00007163612853707 TripodiASalernoFChantarangkulVClericiMCazzanigaMPrimignaniM Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41:553–8. 10.1002/hep.2056915726661 TaylorFBJrTohCHHootsWKWadaHLeviM. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30. 10.1055/s-0037-161606811816725 CritchfieldGCBennettST. The influence of the reference mean prothrombin time on the international normalized ratio. Am J Clin Pathol. 1994;102:806–11. 10.1093/ajcp/102.6.8067801896 International Organization for Standardization. ISO 15189:2022. Medical laboratories - Requirements for quality and competence. 4th ed. Geneva: International Organization for Standardization; 2022. FavaloroEJPasalicL. Innovative Diagnostic Solutions in Hemostasis. Diagnostics (Basel). 2024;14:2521. 10.3390/diagnostics1422252139594185 MithoowaniSSiegalD. DOACs: role of anti-Xa and drug level monitoring. Hematology (Am Soc Hematol Educ Program). 2024;2024:178–85. 10.1182/hematology.202400066639643984 WangJLimHYNandurkarHHoP. DOAC-stop can remove direct oral anticoagulants and allow analysis by global coagulation assays. Int J Lab Hematol. 2023;45:360–7. 10.1111/ijlh.1402036691357 SavolaPLemponenMJoutsi-KorhonenLHelinTA. Novel Ex Vivo DOAC Removal Methods Reduce Interference in Lupus Anticoagulant Testing. Diagnostics (Basel). 2022;12:2520. 10.3390/diagnostics1210252036292209 DouxfilsJAdcockDMBatesSMFavaloroEJGouin-ThibaultIGuillermoC 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2021;121:1008–20. 10.1055/a-1450-817833742436 SteffelJCollinsRAntzMCornuPDestegheLHaeuslerKG 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23:1612–76. 10.1093/europace/euab06533895845 LordeNMahapatraSKalariaT. Machine Learning for Patient-Based Real-Time Quality Control (PBRTQC), Analytical and Preanalytical Error Detection in Clinical Laboratory. Diagnostics (Basel). 2024;14:1808. 10.3390/diagnostics1416180839202296 ZhouBLiXChengSZhouZKangH. Patient-based pre-classified real-time quality control with neural network (PCRTQC-NN). Pract Lab Med. 2025;47:e00506. 10.1016/j.plabm.2025.e0050641080614 YangHSÇubukçuHCDel BenFDuanXFengJFransG Implementation of AI systems in the clinical laboratory: insights from an expert survey and recommendations for best practice. Clin Chem Lab Med. 2026;64:1513–26. 10.1515/cclm-2025-132241630421 TanJYDe GuzmanMRTWongWHYeoCKGohGHNgHJ Decoding Clot Waveform Analysis: Toward Better Understanding and Harmonization. Semin Thromb Hemost. 2026;52:460–75. 10.1055/a-2778-981041506647 ÇubukçuHCBoursierGLinkoSBernabeu-AndreuFAMeško BrguljanPTosheska-TrajkovskaK Regulating the future of laboratory medicine: European regulatory landscape of AI-driven medical device software in laboratory medicine. Clin Chem Lab Med. 2025;63:1891–914. 10.1515/cclm-2025-048240440607 KardjadjM. Regulatory Approved Point-of-Care Diagnostics (FDA & Health Canada): A Comprehensive Framework for Analytical Validity, Clinical Validity, and Clinical Utility in Medical Devices. J Appl Lab Med. 2025;10:1622–37. 10.1093/jalm/jfaf10640794850 WoolGD. Benefits and Pitfalls of Point-of-Care Coagulation Testing for Anticoagulation Management: An ACLPS Critical Review. Am J Clin Pathol. 2019;151:1–17. 10.1093/ajcp/aqy08730215666 Clinical and Laboratory Standards Institute. Point-of-Care Coagulation Testing and Anticoagulation Monitoring. 2nd ed. CLSI guideline POCT14. Wayne, PA: Clinical and Laboratory Standards Institute; 2020. FitzmauriceDAGeersingGJArmoiryXMachinSKitchenSMackieI. ICSH guidance for INR and D-dimer testing using point of care testing in primary care. Int J Lab Hematol. 2023;45:276–81. 10.1111/ijlh.1405136882063 MunirRSchapkaitzENobleLLoonatSMcCreeMAliN A Comprehensive Clinical Assessment of the LumiraDx International Normalized Ratio (INR) Assay for Point-of-Care Monitoring in Anticoagulation Therapy. Diagnostics (Basel). 2024;14:2683. 10.3390/diagnostics1423268339682591 Shikdar S, Vashisht R, Zubair M, Bhattacharya PT. International Normalized Ratio: Assessment, Monitoring, and Clinical Implications. StatPearls. Treasure Island (FL): StatPearls Publishing; 2026. BhatMAbuziedYFagihZWaniTGawanIAndalayEM Efficacy of Point-of-Care for INR Testing Compared to Standard Laboratory Methods at a Tertiary Care Hospital in Saudi Arabia. Glob J Qual Saf Healthc. 2020;3:98–104. 10.36401/JQSH-19-3637275600 U.S. Food and Drug Administration. Class 1 Device Recall: INRatio/INRatio2 PT/INR Test Strips. Silver Spring, MD: U.S. Food and Drug Administration; 2014. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=126845. Accessed July 3, 2026. NilssonCUStrandbergKReinstrupP. Warfarin monitoring with viscoelastic haemostatic assays, thrombin generation, coagulation factors and correlations to Owren and Quick prothrombin time. Scand J Clin Lab Invest. 2018;78:358–64. 10.1080/00365513.2018.147449229792060 JonssonPILetertreLJuliussonSJGudmundsdottirBRFrancisCWOnundarsonPT. During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time. J Thromb Haemost. 2017;15:131–9. 10.1111/jth.1354927774726 OnundarsonPTPalssonRWittDMGudmundsdottirBR. Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article. Thromb J. 2021;19:72. 10.1186/s12959-021-00327-134654442 OskarsdottirARGudmundsdottirBRJensdottirHMFlygenringBPalssonROnundarsonPT. Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study. Blood. 2021;137:2745–55. 10.1182/blood.202000869833512454 KelemAEngidayeGAddisuBMandefroBTeketelewBBBertaDM Coagulation parameters reference interval for adult population of Debre Berhan town, Northeast Ethiopia. Thromb J. 2025;23:115. 10.1186/s12959-025-00808-741275213 PollerLKeownMIbrahimSvan den BesselaarAMRobertsCStevensonK Comparison of local International Sensitivity Index calibration and ‘Direct INR’ methods in correction of locally reported International Normalized Ratios: an international study. J Thromb Haemost. 2007;5:1002–9. 10.1111/j.1538-7836.2007.02452.x17367490 FavaloroEJMcVickerWLayMAhujaMZhangYHamdamS Harmonizing the International Normalized Ratio (INR): standardization of methods and use of novel strategies to reduce interlaboratory variation and bias. Am J Clin Pathol. 2016;145:191–202. 10.1093/ajcp/aqv02226800763 PollerLIbrahimSKeownMPattisonAJespersenJ. Simplified method for international normalized ratio (INR) derivation based on the prothrombin time/INR line: an international study. Clin Chem. 2010;56:1608–17. 10.1373/clinchem.2009.14193720798354 KimWRMannalitharaAHeimbachJKKamathPSAsraniSKBigginsSW MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161:1887–95.e4. 10.1053/j.gastro.2021.08.05034481845 BuchtaCSalleBDMarringtonRAlbarèdeSBadrickTBickerW Behind the scenes of EQA–characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part IV – Benefits for participant laboratories. Clin Chem Lab Med. 2025;63:879–97. 10.1515/cclm-2024-129239754494
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030504" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030504" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030504" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(67) "Challenges in PT/INR harmonization across the total testing process" ["journals_article_author"]=> string(45) "Jia-min Zou, Tian-ji Li, Qi Liu, Yong-gang Hu" ["journals_article_author_country"]=> string(5) "China" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(108) "prothrombin time, international normalized ratio, harmonization, standardization, direct oral anticoagulants" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1413" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "6" ["meta_title"]=> string(67) "Challenges in PT/INR harmonization across the total testing process" ["meta_desc"]=> string(67) "Challenges in PT/INR harmonization across the total testing process" ["meta_keyw"]=> string(108) "prothrombin time, international normalized ratio, harmonization, standardization, direct oral anticoagulants" ["created"]=> string(19) "2026-10-01 11:13:20" ["modified"]=> string(19) "2026-10-02 11:01:33" } [13]=> object(stdClass)#50 (35) { ["journals_id"]=> string(4) "1270" ["journals_xml"]=> string(341412) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030503 10.11613/BM.2026.030503 Reviews Interference of iron deficiency in glycated hemoglobin testing and its clinical implications: a systematic review and meta-analysis SouzaEmanuele Maria CoimbraDominguetiCaroline Pereira* Federal University of São João del-Rei, West Center Campus, Divinópolis, Brazil Corresponding author: caroldomingueti@ufsj.edu.br

Author contributions

EM Coimbra Souza - Conceptualization, Methodology, Writing – original draft; Formal analysis; C Pereira Domingueti - Conceptualization, Methodology, Writing – review & editing; Project administration; Formal analysis.

15102026 15102026 36 3 030503 1012202531072026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• There is a false increase in glycated hemoglobin (HbA1c) concentrations in patients with iron deficiency anemia

• There is a false increase in HbA1c concentrations in patients with latent iron deficiency

• Iron deficiency anemia and latent iron deficiency interfere with the HbA1c test

Introduction

Concentration of glycated hemoglobin (HbA1c) may be influenced by different types of anemia. This systematic review and meta-analysis aimed to evaluate the effect of iron deficiency anemia (IDA) and latent iron deficiency (LID) on HbA1c concentrations.

Materials and methods

A search was conducted in Medline/PubMed, Web of Science, Embase, and LILACS up to May 2026. Eligible studies included cross-sectional, cohort, case-control, non-randomized intervention studies and clinical trials assessing the impact of IDA or LID on HbA1c concentrations. Methodological quality was evaluated using the ROBINS-I V2 tool for intervention studies and the Newcastle-Ottawa Scale for cross-sectional studies. Meta-analyses were performed using Review Manager 5 (The Cochrane Collaboration, Copenhagen, Denmark).

Results

Among 43 studies evaluating IDA, 33 reported falsely elevated HbA1c concentrations. Of six studies assessing LID, two observed increased HbA1c concentrations. All four studies evaluating iron deficiency regardless of anemia status found elevated HbA1c. Among 19 intervention studies, 14 showed a reduction in HbA1c following iron supplementation. Meta-analyses including 30 studies confirmed increased HbA1c concentrations in patients with IDA (0.66% (0.31 to 1.00) or 7.21 mmol/mol (3.39 to 10.93), P < 0.001). Meta-analysis of four studies verified increased HbA1c in individuals with LID (0.66% (0.01 to 1.32) or 7.21 mmol/mol (0.11 to 14.43), P = 0.05). Meta-analysis of 14 intervention studies demonstrated a reduction in HbA1c following iron therapy (- 0.50% (- 0.92 to - 0.09) or 5.46 mmol/mol (- 10.05 to - 0.98), P = 0.02). Heterogeneity was mainly related to HbA1c assay methods and diagnostic criteria for anemia and iron deficiency.

Conclusions

Iron deficiency anemia interferes with HbA1c measurement, leading to falsely elevated values, while LID may also increase HbA1c concentrations.

Keywords: anemiairon-deficiencyglycated hemoglobinclinical laboratory techniques
Introduction

According to the World Health Organization (WHO), anemia is defined by low hemoglobin concentration in the bloodstream (1). Gardner et al. 2020 estimated that the global prevalence of anemia in 2019, considering all age groups, was 22.8%, equivalent to 1.74 billion people, with children under five being the most affected group, and that iron deficiency was the most common cause of anemia (2). Iron deficiency anemia (IDA) may result from gastrointestinal bleeding and menstruation in women, as well as from inadequate dietary iron intake and impaired iron absorption (3).

Laboratory diagnosis of IDA is made through hematological and biochemical tests, and there are three stages of iron deficiency. The first is iron depletion, which consists of a decrease in the body’s reserves. The best method for identifying this stage is a serum ferritin test, which is responsible for iron storage in the body. In the second stage, iron deficiency occurs, leading to iron-deficient erythropoiesis generated by the reduction of circulating minerals, resulting in decreased production of iron components and hemoglobin, but without decreasing their concentration. The tests that may be requested at this stage are serum iron and transferrin saturation. Finally, there is IDA, characterized by reduced hemoglobin concentrations that can be observed in the blood count (4).

There is substantial evidence indicating that IDA can interfere with glycated hemoglobin (HbA1c) measurements, leading to falsely elevated results (5). This effect is primarily attributed to the prolonged lifespan of erythrocytes observed in IDA, which increases their exposure time to circulating glucose and consequently enhances hemoglobin glycation. In addition, iron deficiency may alter the structure of hemoglobin and promote oxidative processes, such as hemoglobin peroxidation, further accelerating non-enzymatic glycation (6). This falsely elevated HbA1c could suggest poor glycemic control for patients with diabetes mellitus (DM) or lead to an incorrect diagnosis. Some studies have demonstrated that the clinical use of HbA1c, especially for diagnosis, should be associated with a complete blood count and markers of iron metabolism to assess whether the increase was being induced by iron deficiency (7, 8).

In this context, it is important to conduct a systematic review and meta-analysis to carefully assess the interference of latent iron deficiency (LID) and IDA on HbA1c concentrations and the real impact of this deficiency on the interpretation of HbA1c test results for the diagnosis of DM and for monitoring glycemic control in patients with DM. Therefore, the PICOS-based research question is whether patients with IDA or LID exhibit higher HbA1c concentrations compared to those without iron deficiency.

Materials and methods

Systematic review and meta-analysis conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) recommendations (9). This systematic review was not registered in the international PROSPERO database.

Selection of articles in Medline/PubMed, Web of Science, Embase, and LILACS using the descriptors “glycated hemoglobin” and their respective entry terms, in combination with the descriptors “anemia, iron- deficiency” and “iron deficiencies” and their respective entry terms using “AND” between the terms (Appendix) until May 2, 2026.

The eligibility criteria were established in accordance with the PRISMA recommendation and consist of observational cross-sectional, cohort, case-control, clinical trial or non-randomized intervention studies that evaluate the interference of LID or IDA in HbA1c testing (9).

Only studies whose experimental design allowed for the distinction of the following points, according to the acronyms PECOS (Table 1) and PICOS (Table 2), were included in the systematic review.

PECOS strategy for study selection in the systematic review
Patients Patients with LID or IDA
Exposure Iron deficiency
Control Patients without LID or IDA
Outcome Interference in the HbA1c test
Study design Cross-sectional observational, cohort, or case-control
LID - latent iron deficiency. IDA - iron deficiency anemia. HbA1c - glycated hemoglobin.
PICOS strategy for study selection in the systematic review
Patients Patients with LID or IDA
Intervention Iron supplementation
Control Patients with LID or IDA before intervention
Outcome Interference in the HbA1c test
Study design Clinical trial or non-randomized intervention study
LID - latent iron deficiency. IDA - iron deficiency anemia. HbA1c - glycated hemoglobin.

We also included studies comparing patients with different severities of IDA (severe, moderate and mild IDA). Studies that were not cross-sectional observational, cohort, case-control, non-randomized intervention or clinical trial were excluded, including systematic reviews, narrative reviews, conference abstracts, letters, editorials, case reports, notes, meta-analyses, and preclinical studies. Studies that did not assess at least one marker of iron metabolism (ferritin, transferrin saturation, serum iron, or total iron-binding capacity (TIBC)) to define IDA or LID were also excluded. In addition, studies evaluating the association between elevated ferritin concentrations and HbA1c were excluded. Articles published in Russian were also excluded.

The selection of studies was performed in two stages, both of which were carried out independently by two people. In the first stage, duplicate articles were excluded, and then a preliminary reading of the title and abstract of the articles was performed with the aim of including only those that are observational cross-sectional, cohort, case-control, clinical trials or non-randomized intervention studies and that assessed the interference of LID or IDA in the HbA1c test. In the second stage, the preselected articles were read in full to assess their inclusion in the study according to the eligibility criteria. A flowchart was then constructed summarizing the number of articles included and excluded in each stage according to the established criteria, in accordance with the PRISMA recommendation (9).

The following data were extracted from the selected articles to construct tables: author, year of publication, country, study design, administered iron dose, method used to measure HbA1c, main exclusion criteria, diagnostic criteria for anemia, biomarkers/diagnostic criteria for iron deficiency, sample size, patient characteristics (gender, age group, presence or absence of diabetes mellitus, etc.), main results, effect of iron supplementation on HbA1c, interference of IDA or LID in HbA1c testing, interference in the risk of classification as prediabetes or diabetes mellitus by HbA1c testing.

The methodological quality of the non-randomized studies included in the systematic review was assessed using the ROBINS-I V2 tool (10). This tool assesses the following domains of bias: confounding, classification of interventions, selection of participants into the study, missing data, measurement of outcomes, selection of the reported result. An overall risk of bias judgment was formulated based on the weakest component principle: the overall risk followed the ranking of the domain with the highest level of bias identified. Studies were categorized as having low, moderate, serious or critical risk.

The methodological quality of the cross-sectional studies included in this systematic review was assessed using the Newcastle-Ottawa Scale (NOS) adapted for cross-sectional studies (11). According to the NOS, a maximum of nine stars can be awarded to each study. One star could be assigned for each of the following criteria: representativeness of the sample, selection of controls, sample size, diagnosis, and statistical test. Up to two stars could be awarded for comparability and for the accuracy of the method used to measure HbA1c concentrations. Studies were classified as low quality if they received up to three stars, as moderate quality if they received four to six stars, and as high quality if they received seven or more stars.

Statistical analysis

Meta-analyses were performed on studies that: (i) compared HbA1c concentrations before and after iron supplementation; (ii) compared HbA1c concentrations between patients with and without IDA; and (iii) compared HbA1c concentrations between patients with and without LID. Studies that did not report mean values, standard deviations, or sample sizes were excluded from the meta-analyses. Studies were also excluded if they did not include an appropriate control group.

The mean, standard deviation, and sample size before and after iron supplementation, or of patients with and without IDA or patients with and without LID in each study were used in the meta-analyses, and the difference between the means was calculated, P ≤ 0.05 was considered statistically significant. Some studies reported results exclusively as subclassifications; therefore, overall combined mean and standard deviation estimates were calculated to enable their inclusion in the analysis. Heterogeneity between studies was assessed using the I2 test, with studies presenting I2 > 50% and P < 0.10 being considered heterogeneous. Fixed-effect and random-effect models were used in the meta-analysis calculations in the presence of homogeneity and heterogeneity, respectively. The statistical program Review Manager (RevMan) version 5 (The Cochrane Collaboration, Copenhagen, Denmark) was used to perform the meta-analyses.

Subgroup analyses were performed to explore potential sources of heterogeneity among the included studies and to assess the consistency of the results across different clinical and methodological contexts. The predefined subgroups included sex (studies including both sexes, those restricted to nonpregnant women, and those including pregnant women), age group (children and adolescents vs. adults), and diabetes status (presence of DM vs. exclusion of patients with DM). Additional subgroup analyses considered studies excluding patients with chronic kidney disease (CKD), those excluding individuals with inflammation and/or elevated C-reactive protein (CRP) and those excluding patients with anemia not caused by iron deficiency. Methodological subgroups were defined according to the laboratory method used for HbA1c measurement (high-performance liquid chromatography (HPLC) vs. immunoturbidimetry), the criteria used to define anemia according to the WHO, and the criteria used to define iron deficiency according to the WHO (12, 13). Publication bias was assessed by visual inspection of funnel plots.

Results

Figure 1 shows the flowchart of article selection for this systematic review. After evaluating the eligibility criteria, 61 articles were included in the systematic review. Table 3 shows the location, study design, main exclusion criteria, HbA1c measurement method, diagnostic criteria for anemia and biomarkers/diagnostic criteria for iron deficiency in the studies included in the systematic review.

Flowchart of the selection of articles evaluating the interference of iron deficiency in glycated hemoglobin (HbA1c) measurement that were included in the systematic review

Location, study design, main exclusion criteria, HbA1c measurement method, diagnostic criteria for anemia and biomarkers/diagnostic criteria for iron deficiency in the studies included in the systematic review
Author, year Country Study design/ Iron doseadministered Main exclusion criteria HbA1c measurement method Diagnostic criteria for anemia Biomarkers/diagnostic criteria for iron deficiency
Mukasa et al., 2026 (14) Uganda Cross-sectional/ NA Anemia, hemoglobinopathies, CKD Enzymatic method NI Ferritin < 70 μg/L
Tedong et al., 2026 (15) Cameroon Cross-sectional/ NA Hemolytic anemia, hemoglobinopathies, G6PD deficiency, thalassemia, malaria, infections, inflammation, elevated CRP concentrations Immuno-turbidimetry Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 30 μg/L (M), ferritin < 15 μg/L (F), serum iron, TIBC
Deepali et al., 2025 (16) India Cross-sectional/ NA DM, hemoglobinopathies, recent blood transfusion, severe non-IDA anemia, CKD HPLC NI Ferritin, serum iron, TIBC
Koga and Ishibashi, 2025 (17) Japan Cross-sectional/ NA NI HPLC and enzymatic method Hb < 80 g/L Ferritin, serum iron, TIBC
Dutta et al., 2024 (18) India Cross-sectional/ NA DM, hemolytic anemia, hemoglobinopathies, acute blood loss, vitamin B12/folate deficiency, treatment with erythropoietin, CKD Latex agglutination Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 15 µg/L, serum iron > 30 µg/dL, TIBC > 360 µg/dL, transferrin saturation < 15%
Firat et al., 2024 (19) Turkey Cross-sectional/ NA Hemoglobinopathies, vitamin B12/folate deficiency, chronic inflammatory diseases, elevated CRP concentrations HPLC Hb < 110 g/L Ferritin < 15 μg/L
Haseena et al., 2024 (20) India Cross-sectional/ NA DM, Anemia not caused by iron deficiency, hemoglobinopathies, vitamin B12/folate deficiency, acute blood loss, CKD Immuno-turbidimetry NI Ferritin
Kanojia et al., 2024 (21) India Non-randomized intervention/ NI DM, hemolytic anemia, hemoglobinopathies NI NI Ferritin
Kesharwani et al., 2024 (22) India Cross-sectional/ NA DM, hemoglobinopathies, blood transfusion, CKD HPLC Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 30 μg/L, serum iron, TIBC
Krishnan et al., 2024 (23) India Cross-sectional/ NA DM, acute blood loss, hemolytic anemia, hemoglobinopathies Immuno-turbidimetry Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 15 µg/L
Kumar et al., 2024 (24) India Cross-sectional/ NA DM, anemia not caused by iron deficiency, sickle cell disease, thalassemia, prolonged blood loss, CKD Cation exchange chromatography Hb < 130 g/L (M) or < 120 g/L (F) Ferritin, serum iron
Nakum et al., 2024 (25) India Cross-sectional/ NA NI NI NI Ferritin < 22 µg/L (M), ferritin < 10 µg/L (F), serum iron, TIBC
Patel et al., 2024 (26) India Non-randomized intervention/ 100 mg/day of iron for 3 months DM NI NI Ferritin
Suvethasri et al., 2024 (27) India Cross-sectional/ NA DM, hemoglobinopathies, hemolytic anemia, CKD NI Hb < 100 g/L Ferritin
Shubham et al., 2024 (28) India Non-randomized intervention/ 160 mg/day of ferric ammonium citrate for 3 months DM, hemolytic anemia, hemoglobinopathies, acute or chronic blood loss, recent blood transfusion, CKD NI Hb < 130 g/L (M) or < 120 g/L (F) Ferritin
Taati et al., 2024 (29) Iran Clinical trial/ 100 mg/day of ferrous sulfate for 8 or 16 weeks Anemia not caused by iron deficiency NI Hb < 130 g/L (M) or < 120 g/L (F) Ferritin
Thakker et al., 2024 (30) India Non-randomized intervention/ 100 mg/day of iron for 4 weeks DM, bleeding disorders, CKD Immuno-turbidimetry Hb < 110 g/L Serum iron, TIBC, transferrin saturation
Alzahani et al., 2023 (31) Saudi Arabia Non-randomized intervention/ NI Anemia not caused by iron deficiency, recent blood loss, recent blood transfusion, CKD HPLC Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 30 µg/L
Elsheikh et al., 2023 (32) Egypt Cross-sectional/ NA Acute or chronic blood loss, hemolytic anemia, hemoglobinopathies, CKD NI Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 15 µg/L
Gharde et al., 2023 (33) India Cross-sectional/ NA DM, anemia not caused by iron deficiency, sickle cell disease, thalassemia, acute or chronic blood loss, CKD NI Hb < 130 g/L (M) or < 120 g/L (F) Ferritin, serum iron, TIBC
Kumar et al.,2023 (34) Pakistan Cross-sectional/ NA Acute blood loss, hemolytic anemia, hemoglobinopathies, CKD HPLC NI Serum iron < 59 μg/dL, transferrin saturation < 15%
Nosheen etal., 2023 (35) Pakistan Non-randomized intervention/ NI NI NI Hb < 140 g/L (M) or < 120 g/L (F) Ferritin, serum iron, TIBC
Aydin et al., 2022 (36) Turkey Non-randomized intervention/ 270 mg/day of ferrous sulfate for 3 months Elevated CRP concentrations, anemia not caused by iron deficiency, recent blood transfusion, CKD HPLC Hb < 120 g/L Ferritin < 15 μg/L
El-Agouza et al., 2022 (37) Palestine Non-randomized intervention/ 325 mg/day of ferrous sulfate NI Cation exchange chromatography NI Ferritin
Estrella et al., 2022 (38) United States Cross-sectional/ NA CKD HPLC Hb < 137 g/L (M 20 to 49 years) or < 133 g/L (M 50 to 69 years) or < 124 g/L (M ≥ 70 years) or < 120 g/L (F 20 to 69 years) or < 118 g/L (F ≥ 70 years) Ferritin < 27 μg/L, serum iron < 10.7 μmol/L, TIBC > 77 μmol/L, transferrin saturation < 15%
Janice et al., 2022 (39) India Cross-sectional/ NA Acute blood loss, CKD Nephelometry Hb < 100 g/L Ferritin < 90 μg/L
Jyothsna et al., 2022 (40) India Cross-sectional/ NA DM, inflammatory disease, acute illness, anemia not caused by iron deficiency, CKD HPLC Hb < 137 g/L (M 20 to 49 years) or < 133 g/L (M 50 to 69 years) or < 124 g/L (M ≥ 70 years) or < 120 g/L (F 20 to 69 years) or < 118 g/L (F ≥ 70 years) Ferritin < 12 µg/L, transferrin saturation < 15%
Pradeepa et al., 2022 (41) India Cross-sectional/ NA Acute or chronic blood loss, hemoglobinopathies HPLC LID: Hb ≥ 130 g/L (M) or ≥ 120 g/L (F), IDA: Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 70 μg/L
Rao et al.,2022 (42) United States Cross-sectional/ NA NI Enzymatic method NI Ferritin, serum iron, transferrin saturation, TIBC
Altuntas et al., 2021 (43) Turkey Non-randomized intervention/ 100 mg/day of iron for 3 months DM, hemoglobinopathies, hemolytic anemia, CKD HPLC Hb < 120 g/L (F) or < 130 g/L (M) Ferritin
Bindayel, 2021 (44) Saudi Arabia Cross-sectional/ NA DM, anemia not caused by iron deficiency, CKD HPLC Hb ≤ 120 g/L Ferritin < 15 μg/L
Kanchana and Pushpa, 2021 (45) India Cross-sectional/ NA DM, hemolytic anemia, CKD Immuno-turbidimetry Hb < 110 g/L Ferritin < 15 μg/L (M) or < 9 μg/L (F)
Lyons et al.,2020 (46) Netherlands Cross-sectional/ NA Hb variants HbAS and HbAC, CKD HPLC NI Ferritin < 15 μg/L if CRP < 5 mg/mL or ferritin < 30 μg/L if CRP ≥ 5 mg/mL
Mahgoob and Moussa, 2020 (47) Egypt Cross-sectional/ NA Anemia not caused by iron deficiency, recent blood loss, hemoglobinopathies Colorimetric NI Ferritin < 12 μg/L (< 5 years) or < 15 μg/L (≥ 5 years)
Pilla et al., 2020 (48) India Non-randomized intervention/ NI DM, hemolytic anemia, aplastic anemia, anemia of chronic diseases NI Hb < 120 g/L (F) or < 130 g/L (M) Ferritin, serum iron
Purbey et al., 2020 (49) India Non-randomized intervention/ 160 mg/day of ferric ammonium citrate for 3 months DM, hemoglobinopathies, hemolytic anemia, acute or chronic blood loss, recent blood transfusion, CKD NI Hb < 120 g/L (F) or < 130 g/L (M) Ferritin
Sabitha et al., 2020 (50) India Cross-sectional/ NA Inflammatory disease HPLC NI Serum iron < 50 ng/dL and transferrin saturation < 14%
Intra et al., 2019 (51) Italy Cross-sectional/ NA DM, infectious disease, hematological disease, blood transfusion, CKD HPLC Hb ≤ 130 g/L (M) or ≤ 110 g/L (F) Ferritin ≤ 17 μg/L (M) or ≤ 10 μg/L (F)
Silva et al., 2019 (52) Brazil Cross-sectional/ NA DM HPLC and Immuno-turbidimetry Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 15 μg/L
Wei et al., 2019 (53) China Cross-sectional/ NA NI HPLC NI Quartile of transferrin and transferrin saturation concentrations
Akkermans et al., 2018 (54) Netherlands Non-randomized intervention/ 9 mg/kg/day of ferrous fumarate for 2 months Acute infection and/or inflammation (CRP ≥ 10 mg/L), hemoglobinopathies, recent blood transfusion HPLC IDA: Hb 2 standard deviations below the mean for children of the same age, LID: Hb normal IDA/Absolute LID: Ferritin < 12 μg/L (< 5 years) or < 15 μg/L (≥ 5 years)Functional LID: zinc protoporphyrin > 61 μmol/mol heme (< 5 years) or 70 μmol/mol heme (≥ 5 years) or RDW-CV > 14% or RDW-SD > 43.39 fL
Eser et al., 2018 (55) Turkey Non-randomized intervention/ NI DM, hemoglobinopathies Enzymatic method Hb < 110 g/L in the first and third trimesters of pregnancy or < 105 g/L in the second trimester of pregnancy Ferritin < 30 μg/L
Hashimoto and Koga, 2018 (56) Japan Cross- sectional/ NA Elevated CRP concentrations, CKD HPLC NI Ferritin < 15 μg/L
Intra et al., 2018 (57) Italy Cross- sectional/ NA DM, infectious disease, hematological disease, anemia not caused by iron deficiency, CKD HPLC Hb ≤ 130 g/L (M) or ≤ 115 g/L (F) Ferritin ≤ 17 μg/L (M) or ≤ 10 μg/L (F)
Urrechaga, 2018 (58) Spain Cross- sectional/ NA Acute phase reaction (CRP > 5.0 mg/L), macrocytic anemia HPLC IDA: Hb < 130 g/L (M) or < 120 g/L (F), LID: Hb ≥ 130 g/L (M) or ≥ 120 g/L (F) Ferritin < 50 μg/L (M) or < 30 μg/L (F)
Madhu et al., 2017 (59) India Non-randomized intervention/ 100 mg/day of Fe for 3 months DM, chronic inflammatory disease (CRP > 0.6 mg/dL), hemolytic anemia, hemoglobinopathies, CKD HPLC Hb < 100 g/L Ferritin ≤ 15 μg/L, serum iron ≤ 7.17 μmol/L, TIBC ≥ 71.6 μmol/L, transferrin saturation ≤ 16%
Nasli-Esfagani et al., 2017 (60) Iran Clinical trial/ 200 mg/day of ferrous sulfate for 3 months Hemoglobinopathies, treatment with erythropoietin, active infection, recent blood loss or blood transfusion, hemolytic anemia, CKD HPLC Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 9 μg/L (M) or < 15 μg/L (F)
Rajagopal et al., 2017 (61) India Cross-sectional/ NA DM, hemolytic anemia, blood loss, CKD HPLC Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 15 μg/L, serum iron < 60 μg/dL
Attard et al.,2015 (62) China Cross-sectional/ NA NI HPLC Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 15 μg/L
Hong et al.,2015 (63) South Korea Cross-sectional/ NA NI HPLC Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 15 μg/L, transferrin saturation < 10%
Christy et al.,2014 (64) India Cross-sectional/ NA DM, hemoglobinopathies, hemolytic anemia, CKD HPLC Hb < 120 g/L (M) or < 110 g/L (F) Ferritin < 29 μg/L (M) or < 20 μg/L (F)
Shanthi et al., 2013 (8) India Cross-sectional/ NA DM, hemoglobinopathies, hemolytic anemia, CKD Immuno-turbidimetry Hb < 110 g/L Ferritin < 15 μg/L (M) or < 9 μg/L (F)
Hardikar et al., 2012 (65) India Cross-sectional/ NA NI HPLC Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 15 μg/L
Rafat et al.,2012 (66) India Cross-sectional/ NA DM, blood transfusion, acute blood loss, hemolytic anemia, Hb variants HPLC NI Ferritin, serum iron, TIBC
Satriawibawa et al., 2012 (67) Indonesia Cross-sectional/ NA Chronic inflammation, chronic bleeding, hemolytic anemia, thalassemia, CKD Immuno-turbidimetry NI Serum iron < 50 μg/dL
Sinha et al., 2012 (68) India Non-randomized intervention/ NI DM, acute blood loss, hemolytic anemia, hemoglobinopathies, CKD Cation exchange chromatography Hb < 130 g/L (M) or < 120 g/L (F) Ferritin < 30 μg/L
Ford et al., 2011 (69) United States Cross-sectional/ NA NI HPLC Hb < 137 g/L (M 20 to 49 years) or < 133 g/L (M 50 to 69 years) or < 124 g/L (M ≥ 70 years) < 120 g/L (F 20 to 69 years) or < 118 g/L (F ≥ 70 years) At least two of: ferritin < 12.1 μg/L, transferrin saturation < 15%, erythrocyte protoporphyrin > 1.24 μmol/L
Kim et al.,2010 (70) United States Cross-sectional/ NA CKD HPLC NI At least two of: ferritin ≤ 15 µg/L, erythrocyte protoporphyrin > 70 µg/dL, transferrin saturation < 16%
Koga et al.,2010 (71) Japan Cross-sectional/ NA NI HPLC LID: Hb ≥ 114 g/LIDA: Hb < 114 g/L Ferritin < 15 μg/L
Coban et al.,2004 (72) Turkey Non-randomized intervention/ 100 mg/day of ferrous sulfate for 3 months DM, hemoglobinopathies, hemolytic anemia, CKD Immuno-turbidimetry NI Ferritin < 15 μg/L (M) or < 9 μg/L (F)
Tarim et al., 1999 (73) Turkey Non-randomized intervention/ 6 mg/kg/day of oral Fe for 3 months NI HPLC NI Ferritin, serum iron, transferrin saturation, TIBC
HbA1c - glycated hemoglobin. CKD - chronic kidney disease. CRP - C-reactive protein. DM - diabetes mellitus. F - female. Fe - elemental iron. Hb - hemoglobin. HPLC - high performance liquid chromatography. ID - iron deficiency. IDA - iron deficiency anemia. LID - latent iron deficiency. M - male. NI - not informed. NA - not applicable. RDW-CV - red cell distribution width. CV - coefficient of variation. RDW-SD - red cell distribution width. SD - standard deviation. TIBC - total iron-binding capacity.

Among the 61 studies included in the systematic review, most were cross-sectional (N = 42, 0.69), followed by non-randomized intervention studies (N = 17, 0.28), with only two clinical trials (N = 2, 0.03). The included studies were conducted across diverse geographic regions, with the highest representation from India (N = 27, 0.44), followed by Turkey (N = 6, 0.10), the United States (N = 4, 0.06), and Japan (N = 3, 0.05). Regarding the methods used for HbA1c measurement, most studies employed HPLC (N = 33, 0.54), immunoturbidimetry (N = 9, 0.15), enzymatic assays (N = 3, 0.05), and cation exchange chromatography (N = 3, 0.05).

The main exclusion criteria reported across studies included CKD (N = 34, 0.56), DM (N = 29, 0.48), hemoglobinopathies or hemoglobin variants, including thalassemia and sickle cell disease (N = 30, 0.49), hemolytic anemia (N = 21, 0.34), and acute or chronic blood loss (N = 17, 0.28), recent blood transfusion (N = 10, 0.16), non-IDA (N = 10, 0.16), inflammatory diseases (N = 7, 0.11), infectious or acute conditions (N = 6, 0.10), elevated CRP concentrations (N = 6, 0.10), macrocytic anemia or vitamin B12/folate deficiency (N = 4, 0.06). Notably, 12 studies (0.20) did not report exclusion criteria necessary to rule out anemia unrelated to iron deficiency or inflammation or DM.

The criteria used to diagnose anemia varied across studies. Twenty-four studies (0.39) applied the WHO definition, while 18 (0.30) used alternative criteria (12). Nineteen studies (0.31) did not report the diagnostic criteria. The biomarkers used to assess IDA and LID also varied across studies. Ferritin was the most frequently reported marker (N = 53, 0.87), followed by serum iron (N = 20, 0.33), TIBC (N = 14, 0.23), and transferrin saturation (N = 13, 0.21). The WHO criteria for defining iron deficiency based on ferritin concentrations were applied in 17 studies (0.28) (13).

The methodological quality of the intervention studies included in the systematic review, as assessed using the ROBINS-I V2 tool, is presented in Supplementary Table 1. Of the 19 studies, five were classified as having a moderate risk of bias, while 14 were classified as having a serious risk of bias.

The methodological quality of the cross-sectional studies, as assessed using the NOS adapted for cross-sectional studies, is presented in Supplementary Table 2. Of the 42 articles, 24 (0.57) received four to six stars and were therefore classified as having moderate quality, 17 (0.40) received one to three stars and were classified as having low quality, and only one (0.02) received seven or more stars and was classified as having high quality.

Table 4 shows sample size and characteristics of the patients, main results, and effect of iron supplementation on HbA1c concentrations in the studies included in the systematic review that assessed HbA1c concentrations before and after iron supplementation. Among the 19 studies, most included adults (15/19), two included pregnant women, one children and adolescents, and another adults and adolescents. Some studies included patients with type 1 diabetes mellitus (T1DM) (3/19) and type 2 diabetes mellitus (T2DM) (3/19). Overall, HbA1c concentrations decreased following iron supplementation in the majority of studies (14/19), increased in two studies - reflecting normalization of initially low HbA1c concentrations - and remained unchanged in three studies.

Sample size and characteristics of patients, main results, and effect of iron supplementation on HbA1c concentrations in studies included in the systematic review that assessed HbA1c concentrations before and after iron supplementation
Author, year Sample size and characteristics of patients HbA1c before iron supplementation HbA1c after supplementation P Effect of iron supplementationon HbA1c test
Kanojia et al., 2024 (21) 50 adults without DM with IDA 7.16 ± 0.88% 5.48 ± 0.31% < 0.001 Decreased in adults without DM
Patel et al., 2024 (26) 92 adults without DM with IDA 4.63 ± 0.32% 5.82 ± 0.34% < 0.001 Increased in adults without DM
Shubham et al., 2024 (28) 50 adults without DM with IDA 5.92 ± 0.37% 5.49 ± 0.42% < 0.001 Decreased in adults without DM
Taati et al., 2024 (29) 27 adults with T2DM with IDA (16 weeks)28 adults with T2DM with IDA (8 weeks) 8.123 ± 1.791%7.122 ± 1.612% 7.989 ± 2.201%7.311 ± 2.106% > 0.05> 0.05 No change in adults with T2DM
Thakker et al., 2024 (30) 155 pregnant women without DM with IDA 5.53 ± 0.48% 5.23 ± 0.44% < 0.001 Decreased in pregnant women without DM
Alzahrani et al., 2023 (31) 104 adults with IDA 5.75% 5.44% < 0.001 Decreased in adults
Nosheen et al., 2023 (35) 60 adults with T1DM with IDA(30 women and 30 men) 8.603%Women: 9.43%Men: 7.79% 7.608%Women: 8.09%Men: 7.12% < 0.010< 0.010< 0.010 Decreased in adults (women and men) with T1DM
Aydin et al., 2022 (36) 146 adults with T2DM with IDA 7.09 ± 0.51% 6.69 ± 0.53% < 0.001 Decreased in adults with T2DM
El-Agouza et al., 2022 (37) 730 adults with IDA 6.15 ± 0.62% 5.25 ± 0.45% < 0.001 Decreased in adults
Altuntas et al., 2021 (43) 131 adults without DM with IDA 5.4 ± 0.5% 5.5 ± 0.3% 0.057 No change in adults without DM
Pilla et al., 2020 (48) 100 adults without DM with IDA (mild and moderate IDA x severe IDA) Mild and moderate IDA: 6.1 ± 0.23%Severe IDA: 5.5 ± 0.24% Mild and moderate IDA: 5.1 ± 0.14%Severe IDA: 4.6 ± 0.2% < 0.001< 0.001 Decreased in adults without DM
Purbey et al., 2020 (49) 50 adults without DM with IDA 5.92 ± 0.37% 5.49 ± 0.42% < 0.001 Decreased in adults without DM
Akkermans et al., 2018 (54) 13 children and adolescents withT1DM with LID NI Mean HbA1c difference= -0.12 ± 0.58% 0.611 No change in children and adolescents with T1DM
Eser et al., 2018 (55) 37 pregnant women without DM with IDA 5.01 ± 0.39% 4.69 ± 0.38% < 0.05 Decreased in pregnant women without DM
Madhu et al., 2017 (59) 60 adults without DM with IDA 5.5 ± 0.7% 5.0 ± 0.6% (decrease of 0.47%) < 0.05 Decreased in adults without DM
Nasli-Esfagani et al., 2017 (60) 45 adults with T2DM with IDA who received iron supplementation and 45 who received placebo Iron supplementation: 7.59 ± 1.16%Placebo: 7.40 ± 1.01% Iron supplementation: 6.80 ± 0.85%Placebo: 7.14 ± 0.95% < 0.001< 0.001 Decreased in adults with T2DM (iron supplementation reduced more HbA1c than placebo, p = 0.005)
Sinha et al., 2012 (68) 50 adults and adolescents without DM with IDA 4.6% 5.9% < 0.001 Increased in adults and adolescents without DM
Coban et al., 2004 (72) 50 adults without DM with IDA 7.4 ± 0.8% 6.2 ± 0.6% 0.001 Decreased in adults without DM
Tarim et al., 1999 (73) 11 adults with T1DM with ID and 11 adults without DM with ID 9,15 ± 2,47%WithT1DM: 10.6 ± 2.6%Without DM: 7.7 ± 1.3% 7,35 ± 2,27%WithT1DM: 8.3 ± 2.6%Without DM: 6.4 ± 1.2% < 0.001< 0.05< 0.05 Decreased in adults with T1DM and without DM
DM - diabetes mellitus. Hb - hemoglobin. HbA1c - glycated hemoglobin. ID - iron deficiency. IDA - iron deficiency anemia. LID - latent iron deficiency. T1DM - type 1 diabetes mellitus. T2DM - type 2 diabetes mellitus. P ≤ 0.05 was considered statistically significant.

Table 5 shows sample size and characteristics of patients, main results, and interference of IDA or LID in the HbA1c test in the studies included in the systematic review that evaluated HbA1c concentrations in patients with and without IDA or LID.

Sample size and characteristics of patients, main results, and interference of iron deficiency anemia or latent iron deficiency in the HbA1c test of the studies included in the systematic review that evaluated the HbA1c concentrations of patients with and without iron deficiency anemia or latent iron deficiency
Author, year Sample size and characteristics of patients HbA1c of IDA/LID/ID group HbA1c of control group P Interference in HbA1c testing
Tedong et al., 2026 (15) 135 adults with DM with IDA75 adults with DM without IDA 9.11 ± 2.72% 9.08 ± 2.05% 0.91 IDA did not alter HbA1c in adults with DM
Deepali et al., 2025 (16) 50 adults without DM with IDA50 adults without DM without IDA 6.1 ± 0.4% 5.7 ± 0.3% < 0.05 IDA increased HbA1c in adults without DM
Koga and Ishibashi, 2025 (17) 15 adults with IDA12 adults without IDA 6.2% (5.3–9.1) 7.8% (7.2–8.4) 0.157 IDA did not alter HbA1c in adults
Dutta et al., 2024 (18) 60 adults without DM with IDA60 adults without DM without IDA 6.5 ± 0.5% 5.13 ± 0.8% <0.001 IDA increased HbA1c in adults
Firat et al., 2024 (19) 240 pregnant women with DM (67 with IDA and 173 without IDA)430 pregnant women without DM (103 with IDA and 327 without IDA) 5.67 ± 1.03%With DM: 6.4 ± 0.7%Without DM: 5.2 ± 0.9% 5.41 ± 0.83%With DM 6.0 ± 0.4%Without DM: 5.1 ± 0.8% < 0.010< 0.010> 0.05 IDA increased HbA1c in pregnant women with DM, but not in those without DM
Haseena et al., 2024 (20) 50 pregnant women without DM with IDA50 pregnant women without DM without IDA 6.21 ± 0.36% 4.54 ± 0.66% < 0.001 IDA increased HbA1c in pregnant women without DM
Kanojia et al., 2024 (21) 50 adults without DM with IDA50 adults without DM without IDA 7.16 ± 0.88% 5.49 ± 0.27% < 0.001 IDA increased HbA1c in adults without DM
Kesharwani et al., 2024 (22) 100 adults without DM with IDA100 adults without DM without IDA 6.0 ± 0.5% 5.4 ± 0.4% < 0.001 IDA increased HbA1c in adults without DM
Krishnan et al., 2024 (23) 50 adults without DM with IDA50 adults without DM without IDA 4.67 ± 0.39% 5.42 ± 0.29% < 0.001 IDA decreased HbA1c in adults without DM
Kumar et al., 2024 (24) 60 adults without DM with IDA and without IDA 6.8 ± 1.1% 5.6 ± 0.9% 0.003 IDA increased HbA1c in adults without DM
Nakum et al., 2024 (25) 88 adults with T2DM with IDA88 adults with T2DM without IDA 6.17 ± 1.58% 7.75 ± 1.82% < 0.001 IDA decreased HbA1c in adults with T2DM
Suvethasri et al., 2024 (27) 100 adults without DM with IDA100 adults without DM without IDA 5.87 ± 1.25% 4.97 ± 1.59% < 0.001 IDA increased HbA1c in adults without DM
Shubham et al., 2024 (28) 50 adults without DM with IDA50 adults without DM without IDA 5.92 ± 0.37% 5.11 ± 0.3% < 0.001 IDA increased HbA1c in adults without DM
Thakker et al., 2024 (30) 155 pregnant women without DM with IDA (120 mild IDA x 30 moderate IDA x 5 severe IDA)155 pregnant women without DM without IDA 5.44 ± 0.65%Moderate IDA: 6.24%Severe IDA: 6.52% 4.87 ± 0.42%Mild IDA: 5.31%Mild IDA: 5.31% < 0.010< 0.001< 0.001 IDA increased HbA1c in pregnant women without DM, and the worsening of IDA severity increased HbA1c
Alzahani et al., 2023 (31) 103 adults with IDA104 adults without IDA 5.75 ± 0.35% 5.32 ± 0.48% 0.001 IDA increased HbA1c in adults
Elsheikh et al., 2023 (32) 41 with DM (11 with IDA and 30 without IDA)404 without DM (130 with IDA and 274 without IDA) With DM: 7.9%Without DM: 5.46% With DM: 6.91%Without DM: 5.1% < 0.0010.249 IDA increased HbA1c in adults with DM, but not in adults without DM
Gharde et al., 2023 (33) 55 adults without DM with IDA56 adults without DM without IDA 6.04 ± 0.74% 4.91 ± 0.65% < 0.001 IDA increased HbA1c in adults without DM
Janice et al., 2022 (39) 31 women with moderate IDA8 women with severe IDA Severe IDA: 4.50 ± 0.34% Moderate IDA: 5.18 ± 0.35% < 0.001 Greater severity of IDA increased HbA1c in women
Jyothsna et al., 2022 (40) 30 adults without DM with IDA30 adults without DM without IDA 5.8 ± 0.40% 4.9 ± 0.55% < 0.001 IDA increased HbA1c in adults without DM
Rao et al., 2022 (42) 12,320 adults with IDA21,440 adults without IDA Men 5.7%Women: 6.0% Men: 5.4%Women: 5.6% < 0.001 IDA increased HbA1c in both men and women
Altuntas et al., 2021 (43) 131 adults without DM with IDA (29 mild IDA x 31 moderate IDA x 2 severe IDA)132 adults without DM without IDA 5.4 ± 0.5% 5.9 ± 0.5%HbA1c did not alter as the severity of anemia worsened < 0.001> 0.05 IDA decreased HbA1c in adults without DM
Bindayel, 2021 (44) 21 women aged 20 to 50 years without DM with IDA (9 mild IDA x 12 moderate and severe IDA)38 women aged 20 to 50 years without DM without IDA 5,40 ± 0,36%Mild IDA: 5.39 ± 0.38%Moderate and severe IDA: 5.40 ± 0.35% Without IDA 5.15 ± 0.36% > 0.05 IDA did not alter HbA1c in women < 50 years of age without DM
Kanchana and Pushpa, 2021 (45) 50 adults without DM with IDA50 adults without DM without IDA 7.4 ± 0.5% 5.2 ± 0.8% < 0.001 IDA increased HbA1c in adults without DM
Mahgoob and Moussa, 2020 (47) 72 children with T1DM with IDA75 children with T1DM without IDA 8.04 ± 1.59% 7.21 ± 1.47% < 0.001 IDA increased HbA1c in children with T1DM
Purbey et al., 2020 (49) 50 adults without DM with IDA50 adults without DM without IDA 5.92 ± 0.37% 5.11 ± 0.2% < 0.001 IDA increased HbA1c in adults without DM
Intra et al., 2019 (51) 86 adults and adolescents without DM with IDA2,745 adults and adolescents without DM without IDA 5.59% 5.34% < 0.001 IDA increased HbA1c in adults and adolescents without DM
Silva et al., 2019 (52) 61 adults without DM with IDA (19 mild IDA x 26 moderate IDA x 16 severe IDA)61 adults without DM without IDA IDA: 5.6 ± 0.4% (HPLC) and 5.7 ± 0.4%Mild IDA: 5.5 ± 0.4% (HPLC) and 5.5 ± 0.3% (turbidimetry)Moderate IDA: 5.6 ± 0.4% (HPLC) and 5.7 ± 0.4% (turbidimetry)Severe IDA: 5.7 ± 0.4% (HPLC) and 5.9 ± 0.4% (turbidimetry) 5.3 ± 0.4% (HPLC) and 5.3 ± 0.3% (turbidimetry) < 0.001< 0.001> 0.05> 0.05 IDA increased HbA1c in adults without DM
Hashimoto and Koga,2018 (56) 42 pregnant women with IDA and without IDA42 pregnant and nonpregnant women with IDA and without IDA NINI NINI < 0.001> 0.05 IDA increased HbA1c in pregnant women, but not in nonpregnant women
Intra et al., 2018 (57) 109 adults and adolescents without DM with IDA2,516 adults and adolescents without DM without IDA 5.53% 5.34% < 0.001 IDA increased HbA1c in adults without DM
Madhu et al., 2017 (59) 62 adults without DM with IDA60 adults without DM without IDA 5.5 ± 0.7% 4.9 ± 0.5% < 0.001 IDA increased HbA1c in adults without DM
Rajagopal et al., 2017 (61) 75 adults without DM with IDA (40 mild IDA x 30 moderate IDA x 5 severe IDA)75 adults without DM without IDA 6.84 ± 0.07% 5.12 ± 0.04%HbA1c increased as the severity of anemia worsened < 0.001< 0.05 IDA increased HbA1c concentrations in adults
Hong et al., 2015 (63) 476 adults with IDA414 adults without IDANormoglycemia (FPG < 100 mg/dL)Prediabetes (100 ≤ FPG < 126 mg/dL)DM (FPG ≥ 126 mg/dL) 5.70 ± 0.02%5.59 ± 0.02%6.00 ± 0.05%7.40 ± 0.46% 5.44 ± 0.03%5.40 ± 0.03%5.75 ± 0.06%6.81 ± 0.23% < 0.001< 0.0010.0050.003 IDA increased HbA1c in adults with normoglycemia, prediabetes and DM
Christy et al., 2014 (64) 120 adults (70 women and 50 men) without DM with IDA and without IDANormoglycemia (FPG < 100 mg/dL)Prediabetes (100 ≤ FPG < 126 mg/dL) 6.87 ± 1.4%Women: 7.02 ± 1.58%Men: 6.67 ± 1.06%Normoglycemia: 6.43 ± 1.07%Prediabetes: 7.33 ± 1.55%Normoglycemia: 6.47 ± 1.19% (women) and 6.36 ± 0.88% (men)Prediabetes: 7.63 ± 1.76% (women) and 6.95 ± 1.15% (men) 5.65 ± 0.69%Women: 5.82 ± 0.53%Men: 5.59 ± 0.85%Normoglycemia: 5.46 ± 0.62%Prediabetes: 5.89 ± 0.75%Normoglycemia: 5.61 ± 0.58% (women) and 5.45 ± 0.67% (men)Prediabetes: 5.96 ± 0.46% (women) and 5.83 ± 1.00% (men) < 0.05< 0.05< 0.05< 0.05< 0.05< 0.05< 0.05< 0.05< 0.05 IDA increased HbA1c concentrations in women and men with normoglycemia and prediabetes
Shanthi et al., 2013 (8) 50 adults without DM with IDA50 adults without DM without IDA 7.6 ± 0.5% 5.5 ± 0.8% < 0.001 IDA increased HbA1c in adults without DM
Rafat et al., 2012 (66) 30 pregnant women without DM with IDA90 pregnant women without DM without IDA (30 in the first, 30 in the second, 30 in the third trimester) 5.19 ± 0.32% 4,58 ± 0.33%4.56 ± 0.36% (first trimester)4.48 ± 0.34% (second trimester)4.69 ± 0.28% (third trimester) < 0.001< 0.001< 0.001< 0.001 IDA increased HbA1c in pregnant women without DM
Satriawibawa et al., 2012 (67) 6 children and adolescents with T1DM with IDA27 children and adolescents with T1DM without IDA 11.3 ± 2.5% 10.2 ± 2.4% 0.373 IDA did not alter HbA1c in children and adolescents with T1DM
Sinha et al., 2012 (68) 50 adults and adolescents without DM with IDA50 adults and adolescents without DM without IDA 4.6% 5.5% < 0.001 IDA decreased HbA1c in adults and adolescents
Coban et al., 2004 (72) 50 adults without DM with IDA50 adults without DM without IDA NI NI < 0.001 IDA increased HbA1c in adults
Pradeepa et al., 2022 (41) 447 adults with T2DM with IDA123 adults with T2DM with LID117 adults with T2DM without IDA/LID LID: 9.4 ± 2.0%IDA: 9.1 ± 1.7% 8.7 ± 0.8% < 0.001< 0.001 IDA and LID increased HbA1c in adults with T2DM
Akkermans et al., 2018 (54) 13 children and adolescents with T1DM with absolute LID 211 without absolute LID100 children and adolescents with T1DM with functional LID 104 without functional LID7 children and adolescents with T1DM with IDA and 220 without IDA Absolute LID: 7.7 ± 3.1%Funcional LID: 8.2 ± 3.6%IDA: 8.2 ± 3.1% Without absolute LID: 8.1 ± 3.7%Without funcional LID: 8.1 ± 3.7%Without IDA: 8.2 ± 3.7% 0.3600.6180.947 IDA and LID did not alter HbA1c in children and adolescents with T1DM
Urrechaga, 2018 (58) 136 adults with T2DM with IDA157 adults with T2DM with LID368 adults with T2DM without LID/IDAM > 50 and < 50 years and F > 50 and < 50 yearsFPG < 7.0 mmol/L and > 7.0 mmol/L IDA (women ≤ 50 years and FPG < 7.0 mmol/L): 6.4 ± 1.4%IDA (women > 50 years old and FPG < 7.0 mmol/L): 7.0 ± 1.2%IDA (women ≤ 50 years old and FPG > 7.0 mmol/L): 7.5 ± 1.5%IDA (women > 50 years old and FPG > 7.0 mmol/L): 8.5 ± 1.5%LID (women), IDA (men), LID (men) Women ≤ 50 years and FPG < 7.0 mmol/L: 5.5 ± 0.9%Women > 50 years old and FPG < 7.0 mmol/L: 6.0 ± 0.8%Women ≤ 50 years old and FPG > 7.0 mmol/L: 6.6 ± 1.2%Women > 50 years old and FPG > 7.0 mmol/L: 7.8 ± 1.3%Without LID/IDA (women and men) 0.005< 0.001< 0.0010.004> 0.05 IDA increased HbA1c in women with T2DM, but not in men with T2DMLID did not alter HbA1c in women or men with T2DM
Ford et al., 2011 (69) 818 adults with DM with LID, with IDA, and without LID/IDA7,478 adults without DM with LID, with IDA, and without LID/IDA With DM: 7.85% (IDA)With DM: 7.54% (LID)Without DM: 5.30% (IDA)Without DM: 5.39% (LID) With DM: 7.71%Without DM: 5.31% > 0.05> 0.05 IDA and LID did not alter HbA1c in adults with and without DM
Koga et al., 2010 (71) 50 women aged 20 to 50 years with LID17 women aged 20 to 50 years with IDA57 women aged 20 to 50 years without LID/IDA IDA: 5.1 ± 0.2%LID: 5.0 ± 0.2% 4.8 ± 0.2% < 0.001< 0.05 IDA and LID increased HbA1c in women < 50 years of age
Mukasa et al., 2026 (14) 43 adults with T2DM with LID103 adults with T2DM without LID 7.82% (6.36-9.74) 8.46% (6.82-9.93) > 0.05 LID did not alter HbA1c in adults with T2DM
Kumar et al., 2023 (24) 230 adults with and without ID 5.89 ± 0.43% 5.52 ± 0.50% < 0.001 ID increased HbA1c in adults
Lyons et al., 2020 (46) 520 women with ID and 1,612 without ID68 men with ID and 1,177 without ID 5.61 ± 0.53%5.6 ± 0.5% (women)5.7 ± 0.7% (men) 5.50 ± 0.64%5.5 ± 0.6% (women)5.5 ± 0.7% (men) < 0.0010.0020.088 ID increased HbA1c in women, but not in men
Sabitha et al., 2020 (50) 53 adults with DM and good glycemic control (33 with LID and 20 without LID)33 with DM and poor glycemic control (20 with LID and 13 without LID)50 without DM (10 with LID and 40 without LID) 6.80 ± 1.82%With DM: 8.74 ± 1.82%DM (poor glycemic control): 9.90 ± 1.10%DM (good glycemic control): 6.82 ± 0.63%Without DM: 5.46 ± 0.38% 6.40 ± 1.33%With DM: 8.07 ± 1.25%DM (poor glycemic control): 8.90 ± 0.98%DM (good glycemic control): 6.80 ± 0.44%Without DM: 5.38 ± 0.49% < 0.010.040.030.920.63 ID increased HbA1c in patients with DM with poor glycemic control, but not in patients with DM with good glycemic control or without DM
Tarim et al., 1999 (73) 37 adults with T1DM (11 with ID and 26 without ID)31 adults without T1DM (11 with ID and 20 without ID) 9.15 ± 2.41%With T1DM: 10.6 ± 2.6%Without T1DM: 7.7 ± 1.3% 8.39 ± 3.82%With T1DM: 10.3 ± 3.9%Without T1DM: 5.9 ± 1.3% 0.050.050.05 ID increased HbA1c in adults without T1DM, but not in those with T1DM
DM - diabetes mellitus. F - female. FPG - fasting plasma glucose. GDM - gestational diabetes mellitus. Hb - hemoglobin. HbA1c - glycated hemoglobin. ID - iron deficiency. IDA - iron deficiency anemia. LID - latent iron deficiency. M - male. NI - not informed. TS - transferrin saturation. TIBC - total iron-binding capacity. T1DM - type 1 diabetes mellitus. T2DM - type 2 diabetes mellitus. FPG - fasting plasma glucose. P ≤ 0.05 was considered statistically significant.

Among the 43 studies evaluating the interference of IDA on HbA1c, most included adults of both sexes (31/43), with smaller proportions assessing pregnant women (5/43), women only (3/43), children and adolescents (3/43), or adults and adolescents (1/43). Diabetes status varied, with some studies including patients with T1DM (3/43), T2DM (3/43), or unspecified DM (5/43). Overall, IDA was associated with increased HbA1c concentrations in the majority of studies (33/43), while a few reported decreased (4/43) or unchanged values (6/43). Additional findings indicated that greater anemia severity was linked to higher HbA1c, and that the effect of IDA on HbA1c may vary according to factors such as pregnancy status, glycemic status and sex.

Among the 10 studies evaluating the effect of LID (without anemia) (6/10) or iron deficiency (with or without anemia) (4/10) on HbA1c, most included adults of both sexes (8/10), with smaller proportions assessing women only (1/10), and children and adolescents (1/10). Diabetes status varied, with some studies including patients with T2DM (3/10), T1DM (2/10), and unspecified DM (2/10). Overall, LID was associated with increased HbA1c concentrations in two studies (2/6), whereas four studies (4/6) reported no significant effect. In contrast, iron deficiency was consistently associated with increased HbA1c concentrations across all four studies. Notably, the effect of LID and iron deficiency on HbA1c may vary according to factors such as glycemic status and sex.

Table 6 shows sample size and characteristics of patients, main results, and interference in the risk of classification as prediabetes or DM by HbA1c test in the studies included in the systematic review that assessed this risk.

Sample size and characteristics of patients, main results, and interference in the risk of classification as prediabetes or diabetes mellitus by HbA1c testing in the studies included in the systematic review that assessed this risk
Author, year Sample size and characteristics of patients Main results Interference in the risk of classification as prediabetes and DM by HbA1c test
Dutta et al., 2024 (18) 60 adults without DM with IDA and without IDA Each unit decrease in Hb increased the likelihood of HbA1c values in the prediabetic and diabetic range by 2.61 (1.65-3.50) times and 2.40 (1.81-3.77) times, respectively (P < 0.001)Each unit decrease in serum ferritin increased the likelihood of HbA1c values in the prediabetic and diabetic range by 1.02 (1.01-1.04) times and 1.01 (1.01-1.05) times, respectively (P < 0.001) IDA increased the risk of classification as prediabetes and DM in adults
Estrella et al., 2022 (38) 12,151 adults with DM, prediabetes and normoglycemia with LID, with IDA, and without LID/IDA Women with IDA had a higher risk of classification as prediabetes (OR = 2.35 (1.68-3.28)) and DM [OR= 3.60 (1.60-8.08)] by HbA1cThe increased risk of classification as prediabetes and DM was not observed in women with LID or in men with IDA or LID IDA increased the risk of classification as prediabetes and DM by HbA1c in women, but not in menLID did not alter the risk of classification as prediabetes and DM by HbA1c in women or men
Lyons et al., 2020 (46) 3,088 adults with DM or normoglycemia with and without LID Women with ID had a higher risk of HbA1c ≥ 5.5% to <6.5% than women without ID [OR: 1.43 (1.08-1.87), P < 0.01]There was no association between ID and increased risk of HbA1c ≥ 5.5% to <6.5% in men, and there was no association between ID and increased risk of HbA1c ≥ 6.5% in men or women ID increased the risk of classification as prediabetes by HbA1c in women, but not in men ID did not alter the risk of classification as DMby HbA1c in women or men
Purbey et al.,2020 (49) 50 adults with prediabetes or normoglycemia with IDA before and after iron supplementation50 adults with prediabetes or normoglycemia without IDA The proportion of patients with prediabetes by HbA1c was higher in those with IDA (80%) than in those without IDA (0%) (P < 0.001)In the group of patients with IDA, the proportion of prediabetic patients decreased from 80% to 30% after iron supplementation (P < 0.001) IDA increased the risk of classification as prediabetic by HbA1c in adults
Wei et al.,2019 (53) 689 children and adolescents with DM or prediabetes or normoglycemia Regression analysis demonstrated that transferrin concentrations and transferrin saturation were significantly associated with HbA1c concentrations (P < 0.05)The highest risk of HbA1c > 5.7% was found in the highest serum transferrin quartile and lowest transferrin saturationquartile in girls and boys ID increased the risk of classification as DM or prediabetes by HbA1c in children and adolescents
Attard et al.,2015 (62) 227 adults with DM or prediabetes or normoglycemia with LID, with IDA and without LID/IDA The proportion of individuals diagnosed with DM by HbA1c was lower in those with LID (M: 12.9% and W: 19.1%) than in those without LID (M: 25.1% and W: 38.3%) (P < 0.05)The proportion of individuals diagnosed with prediabetes by HbA1c was higher in those with LID (H: 63% and M: 55.2%) than in those without LID (F: 42.6% and M: 49.0%) (P < 0.05)Women with LID had a lower relative risk of being classified as having DM by HbA1c than by FPG [RRR =0.37 (0.15-0.88)] after adjusting for covariatesAmong women with LID, a lower percentage was predicted to have DM by HbA1c (0.5%) than by FPG (1.5%) LID decreased the risk of classification as DM by HbA1c in women, but not in men
Hong et al.,2015 (63) 9,775 adults with DM or normoglycemia with IDA and 476 without IDA The weighted proportions of HbA1c concentrations ≥ 5.7% and ≥ 6.1% were higher in patients with IDA than in those without IDA after adjusting for confounding factors (P < 0.001 and P < 0.012, respectively)The weighted proportion of an HbA1c level ≥ 6.5% did not differ between patients with and without IDA after adjusting for confounding factors IDA increased the risk of classification as prediabetes by HbA1c in adultsIDA did not alter the risk of classification as DM by HbA1c in adults
Hardikar et al., 2012 (65) 116 adults aged 21 years with DM or prediabetes or normoglycemia The prevalence of prediabetes was 7.8% by OGTT and 23.3% by HbA1c, and the prevalence of DM was 2.6% by OGTT and 2.6% by HbA1cTwenty-four patients who were normoglycemic by OGTT were misclassified as having prediabetes or DM by HbA1c, and six patients with prediabetes or DM by OGTT were misclassified as normoglycemic by HbA1cPatients classified as having prediabetes or DM by HbA1c had lower ferritin concentrations (23.2 (6.6-46.7)) ng/mL] than those classified as normoglycemic by HbA1c (25.8 (7.9–53.8)) ng/mL].Lower ferritin concentrations were significantly associated with higher HbA1c concentrations in the multivariate analysis LID increased the risk of classification as prediabetes and DM by HbA1c in adults aged 21 years
Kim et al., 2010 (70) 1,225 adults with DM or prediabetes or DMwith ID and 9310 adults without ID ID was associated with an increased risk of HbA1c ≥ 5.5% and ≥ 6.5% in women before and after adjustment for covariatesID was not associated with an increased risk of HbA1c ≥ 5.5% in men after adjusting for covariates The difference in the predicted prevalence of HbA1c ≥ 5.5% between women with and without ID was significant after adjusting for covariates (P < 0.05)The difference in the predicted prevalence of HbA1c ≥ 6.5% between women with and without ID and ofHbA1c ≥ 5.5% between men with and without ID was not significant after adjusting for covariates ID increased the risk of classification as prediabetes and DM by HbA1c in women, but not in men
DM - diabetes mellitus. F - female. HbA1c - glycated hemoglobin. ID - iron deficiency. IDA - iron deficiency anemia. LID - latent iron deficiency. M - male. FPG - fasting plasma glucose. OGTT - oral glucose tolerance test.

Among these nine studies, most were conducted in adults of both sexes (8/9), with only one including children and adolescents. Overall, IDA was associated with an increased risk of HbA1c-based classification as prediabetes in all four studies that assessed this outcome and as DM in two of these studies. Latent iron deficiency was associated with an increased risk of classification as both prediabetes and DM in two studies (2/3). Similarly, iron deficiency was associated with an increased risk of classification as prediabetes in two studies (2/3) and as DM in one study (1/3). Some studies reported an increased risk limited to prediabetes, whereas others observed elevated risks for both prediabetes and DM, with certain findings suggesting sex-specific effects, particularly among women.

The results of the meta-analyses are shown in Figures 2A, 3A, and 4A and funnel plots in Figures 2B, 3B, and 4B. Fourteen studies were included in the meta-analysis that compared HbA1c concentrations before and after iron supplementation (Figure 2A). The random model was used to perform the meta-analysis, as the studies were heterogeneous (P < 0.001 and I2 = 99%). The meta-analysis showed that HbA1c concentrations decreased by an average of - 0.50% (- 0.92 to - 0.09) or 5.46 mmol/mol (- 10.05 to - 0.98) after iron supplementation (P = 0.02). HbA1c concentrations decreased after iron supplementation across multiple subgroup analyses (Table 7), including both sexes, pregnant women, studies including patients with DM, and those excluding individuals with CKD, anemia not caused by iron deficiency, or inflammation and/or elevated CRP, as well as when HbA1c was measured using HPLC and when anemia was defined according to the WHO (12). However, this effect was not observed in the subgroup in which HbA1c was measured by immunoturbidimetry, or in studies that excluded patients with DM.

A) Meta-analysis of studies evaluating glycated hemoglobin (HbA1c) concentrations before and after iron supplementation. B) Funnel plot

A) Meta-analysis of studies evaluating the interference of iron deficiency anemia in glycated hemoglobin (HbA1c) concentration. B) Funnel plot

A) Meta-analysis of studies that evaluated the interference of latent iron deficiency on glycated hemoglobin (HbA1c) concentrations. B) Funnel plot

Subgroup analysis of the meta-analysis that compared HbA1c concentrations before and after iron supplementation
Subgroup Mean difference of HbA1c(95% CI) P
Both sexes - 0.54% (- 1.05 to - 0.04) 0.04
Pregnant women - 0.31% (- 0.39 to - 0.22) < 0.001
Only patients with DM - 0.56% (- 0.94 to - 0.18) 0.004
Patients with DM were excluded - 0.46% (- 1.02 to 0.09) 0.10
HbA1c was determined by HPLC - 0.45% (- 0.81 to - 0.08) 0.02
HbA1c was determined by immunoturbidimetry - 0.74% (- 1.62 to 0.14) 0.10
Patients with anemia not caused by iron deficiency were excluded - 0.35% (- 0.52 to - 0.18) < 0.001
Patients with CKD were excluded - 0.36% (- 0.56 to - 0.17) < 0.001
Patients with inflammation or elevated CRP were excluded - 0.42% (- 0.53 to - 0.32) < 0.001
Anemia was defined by Hb < 120 g/L (F) and < 130 g/L (M) - 0.34% (- 0.68 to 0.00) 0.05
CI - confidence interval. CKD - chronic kidney disease. CRP - C-reactive protein. DM - diabetes mellitus. F - female. Hb - hemoglobin. HbA1c - glycated hemoglobin. HPLC - high performance liquid chromatography. M - male. P ≤ 0.05 was considered statistically significant.

Thirty studies were included in the meta-analysis comparing HbA1c concentrations in patients with and without IDA (Figure 3A). A random model was used to perform the meta-analysis, as the studies were heterogeneous (P < 0.001 and I2 = 100%). The meta-analysis showed that HbA1c concentrations were higher in patients with IDA than in those without IDA, with a mean difference of 0.66% (0.31 to 1.00) or 7.21 mmol/mol (3.39 to 10.93) (P < 0.001). Concentrations of HbA1c were higher in patients with IDA compared with controls across several subgroup analyses (Table 8), including adults, children and adolescents, both sexes, nonpregnant women, pregnant women, and studies excluding individuals with DM, CKD, anemia not caused by iron deficiency, or inflammation and/or elevated CRP, as well as when HbA1c was measured by immunoturbidimetry. In contrast, this association was not observed in subgroups in which HbA1c was measured by HPLC, when iron deficiency and anemia were defined according to WHO criteria, or in studies including patients with DM (12, 13).

Subgroup analysis of the meta-analysis that compared HbA1c concentrations in patients with and without iron deficiency anemia
Subgroup Mean difference of HbA1c(95% CI) P
Adults 0.66% (0.31 to 1.01) < 0.001
Children and adolescents 0.81% (0.34 to 1.28) < 0.001
Both sexes 0.67% (0.27 to 1.06) 0.001
Nonpregnant women 0.29% (0.19 to 0.38) < 0.001
Pregnant women 0.77% (0.30 to 1.24) 0.001
Only patients with DM 0.09% (- 0.45 to 0.62) 0.75
Patients with DM were excluded 0.85% (0.37 to 1.32) < 0.001
HbA1c was determined by HPLC 0.45% (- 0.04 to 0.95) 0.07
HbA1c was determined by immunoturbidimetry 0.91% (0.17 to 1.65) 0.02
Patients with anemia not caused by iron deficiency were excluded 0.69% (0.32 to 1.06) < 0.001
Patients with CKD were excluded 0.94% (0.53 to 1.34) < 0.001
Patients with inflammation or elevated CRP were excluded 0.63% (0.33 to 0.93) < 0.001
Anemia was defined by Hb < 120 g/L (F) and < 130 g/L (M) 0.49% (- 0.02 to 1.00) 0.06
Iron deficiency was defined by ferritin < 15 µg/L (≥ 5 years old) and < 12 µg/L (< 5 years old) 0.44% (- 0.17 to 1.05) 0.16
CKD - chronic kidney disease. CRP - C-reactive protein. DM - diabetes mellitus. F - female. Hb - hemoglobin. HbA1c - glycated hemoglobin. HPLC - high performance liquid chromatography. M - male. P ≤ 0.05 was considered statistically significant.

Four studies were included in the meta-analysis comparing HbA1c concentrations in patients with and without LID (Figure 4A). The random model was used to perform the meta-analysis, as the studies were heterogeneous (P < 0.001 and I2 = 89%). The meta-analysis showed that HbA1c concentrations were higher in patients with LID or iron deficiency than in those without these conditions, with a mean difference of 0.66% (0.01 to 1.32) or 7.21 mmol/mol (0.11 to 14.43) (P = 0.05).

Discussion

Iron deficiency anemia interferes with HbA1c measurement, leading to elevated HbA1c concentrations, as reported in most studies included in this systematic review, and corroborated by meta-analysis. Latent iron deficiency may also be associated with increased HbA1c concentrations, as indicated by meta-analysis (8, 16, 18-22, 24, 27, 28, 30-33, 39-42, 45, 47, 49, 51, 52, 56-59, 61, 63, 64, 66, 71, 72). However, few studies evaluated this issue, and this finding was not consistently observed across the studies included in the systematic review, since only two of the six studies reported an association between LID and increased HbA1c concentrations (41, 71). Furthermore, all studies that evaluated the interference of iron deficiency, regardless the presence of anemia, on HbA1c found increased HbA1c concentrations (24, 46, 50, 73).

The elevation of HbA1c concentrations observed in patients with IDA or LID may be attributed to prolonged red blood cell survival. In iron deficiency, erythropoiesis is reduced, leading to an increased lifespan of circulating erythrocytes. Because the red blood cell membrane is highly permeable to glucose, this prolonged exposure enhances hemoglobin glycation, resulting in falsely elevated HbA1c concentrations (6, 74). Additionally, iron deficiency may alter the structure of hemoglobin and promote hemoglobin peroxidation, accelerating hemoglobin glycation (6). This interference of IDA and LID on HbA1c concentrations was corroborated by studies showing that treatment of iron deficiency reduced HbA1c concentrations, a finding that was confirmed by meta-analysis (21, 28, 30, 31, 35-37, 48, 49, 55, 59, 60, 72, 73).

Among the eleven studies included in this systematic review that evaluated the interference of IDA on HbA1c testing in patients with DM, six reported falsely elevated HbA1c concentrations (19, 32, 41, 47, 58, 63). The remaining five studies did not report falsely elevated HbA1c concentrations (15, 25, 54, 60, 67). Among the four studies that evaluated the interference of LID on HbA1c testing in patients with DM, only one reported falsely elevated HbA1c concentrations (41). The remaining three studies did not report falsely elevated HbA1c concentrations (14, 54, 58). Furthermore, both studies that evaluated the interference of iron deficiency, regardless of the presence of anemia, on HbA1c testing in patients with DM found increased HbA1c concentrations (50, 73). Therefore, while IDA appears to interfere with HbA1c test in patients with DM, leading to falsely elevated results, LID does not appear to result in significant interference in these patients. Some studies have also shown that the severity of IDA can intensify the false increase in HbA1c concentrations (30, 39, 61).

The false elevation of HbA1c caused by interference from IDA has important implications for clinical practice, as HbA1c values may not accurately represent actual glycemic status (75). The American Diabetes Association and the European Association for the Study of Diabetes recommend that HbA1c remain below the target of 7.0% for patients with T1DM and T2DM in order to avoid long-term complications (76). When HbA1c concentrations remain ≥ 7% despite treatment with oral antidiabetic drug or insulin, clinicians often intensify therapy by increasing dosages or introducing additional medications to achieve adequate glycemic control. However, in the presence of falsely elevated HbA1c values, this approach may lead to overtreatment and a higher risk of hypoglycemia (75). Therefore, HbA1c results in patients with DM and IDA should be interpreted with caution. In clinical scenarios where HbA1c reliability is compromised, alternative glycemic markers, such as self-monitoring of blood glucose, continuous glucose monitoring, fructosamine, or glycated albumin, are recommended (77).

Overestimation of HbA1c may also affect individuals without DM, leading to potential misdiagnosis of DM or prediabetes when values are falsely elevated due to IDA or LID. This issue was evaluated in nine studies (18, 38, 46, 49, 53, 62, 63, 65, 70). Among these, four studies reported that IDA increased the risk of classification as prediabetes (18, 38, 49, 63). Two of these studies also reported an increased risk of classification as DM (18, 38). Latent iron deficiency was associated with an increased risk of classification as both prediabetes and DM in one study (65). Iron deficiency, regardless of the presence of anemia, was associated with an increased risk of classification as prediabetes in three studies (46, 53, 70). Two of these studies also reported an increased risk of classification as DM (53, 70). These findings indicate that HbA1c testing may lead to misdiagnosis of DM and prediabetes in individuals with IDA or LID. Given the high prevalence of these conditions, caution is warranted when interpreting HbA1c values. In patients with suspected iron deficiency, evaluation with a complete blood count to detect anemia, along with biomarkers of iron metabolism, preferably serum ferritin, should be considered. When iron deficiency is present, its correction and the use of alternative glycemic markers may be appropriate before establishing a definitive diagnosis (7, 8). According to the American Diabetes Association, in clinical conditions associated with an altered relationship between HbA1c and glycemia, including disorders affecting red blood cell turnover, such as IDA, the diagnosis of DM should be based on plasma glucose criteria rather than HbA1c (77).

Furthermore, some studies have shown that IDA and LID increased the risk of classification as prediabetes and/or DM only in women, but not in men (38, 46, 70). In addition, two studies reported that women with iron deficiency had higher HbA1c concentrations compared to the control group, whereas no significant difference was observed among men (46, 58). This may be explained by higher prevalence of IDA and LID in women, which is related to menstrual blood loss and nutritional deficiencies, particularly among those of reproductive age, and is associated with shifts in HbA1c distribution to higher concentrations (38, 46, 70).

Although most studies report falsely elevated HbA1c concentrations in IDA, some investigations have observed lower HbA1c values and increased concentrations after iron supplementation (23, 25, 26, 43, 68). These conflicting findings may be explained by differences in the diagnostic criteria used to define IDA, laboratory methods used for HbA1c measurement, and the presence of associated conditions, such as CKD, hemoglobinopathies, and other non-IDAs, which may reduce HbA1c concentrations, as well as inflammatory conditions, which may increase ferritin concentrations and interfere with the diagnosis of iron deficiency (78, 79).

The assessment of publication bias, conducted through visual inspection of the funnel plots (Figures 2B, 3B, and 4B), demonstrated patterns of dispersion that suggest potential biases, with the analysis of Figure 4B being particularly limited by the small number of studies included in the meta-analysis of LID. This perception is corroborated by the methodological quality analysis, which revealed that most intervention studies (14/19) have a serious risk of bias according to the ROBINS-I V2 tool, while cross-sectional studies were mostly of moderate (24/42) or low (17/42) quality according to the NOS. Among the main factors that compromised the scientific rigor of the included studies were the absence of rigorous control for confounding variables, such as the presence of CKD and anemia not caused by iron deficiency, the non-strict adherence to the WHO diagnostic criteria for anemia and iron deficiency, and the use of laboratory methods for HbA1c without National Glycohemoglobin Standardization Program (NGSP) certification. These methodological weaknesses explain the high statistical heterogeneity detected in the meta-analyses and impose caution in generalizing the findings.

The American Diabetes Association recommends that HbA1c should be measured in a laboratory using methods certified by the NGSP and traceable to the International Federation of Clinical Chemistry (IFCC) reference system, ensuring alignment with the Diabetes Control and Complications Trial (DCCT) assay (77). However, the NGSP recognize that HbA1c results may be affected by biological factors, regardless of the analytical method used (78). Thirty-three studies used HPLC to measure HbA1c (16, 17, 19, 22, 31, 34, 36, 38, 40, 41, 43, 44, 46, 50-54, 56-66, 69-71, 73). However, only eight studies reported using an NGSP-certified method (18, 51, 52, 56, 57, 59, 65, 70). Subgroup analysis suggested that immunoturbidimetric methods may be more susceptible to interference from IDA, resulting in more pronounced elevations in HbA1c compared to HPLC. One possible explanation is that turbidimetric methods rely on antibodies to recognize the glycated fraction of hemoglobin. In the presence of IDA, structural alterations in hemoglobin may promote cross-reactivity or exaggerated antibody binding, potentially leading to falsely elevated results. In contrast, HPLC separates hemoglobin fractions based on ionic charge, which may make it less sensitive to certain structural changes that do not significantly affect the isoelectric point of the molecule (6, 80).

According to the WHO, anemia is defined by hemoglobin concentrations < 120 g/L in nonpregnant women and < 130 g/L in men aged 15-65 years, with specific reference values also established for children and pregnant women (12). Iron deficiency is defined by serum ferritin concentrations < 12 µg/L in children under 5 years of age and < 15 µg/L in individuals aged 5 years or older (13). However, only a subset of the included studies applied these criteria for the diagnosis of anemia and/or iron deficiency, which contributed to the heterogeneity observed across studies (15, 18, 19, 22-24, 28, 29, 31-33, 36, 41, 43, 44, 46-49, 51, 52, 54-56, 58-63, 65, 68, 71). This finding was supported by subgroup analysis, which showed that the associations between IDA and increased HbA1c was not observed in studies that strictly applied the WHO criteria to define anemia and iron deficiency. This indicates that HbA1c elevation may be less consistent when more stringent diagnostic criteria are employed.

Another limitation of this systematic review is that exclusion criteria varied widely across the included studies. Several studies excluded patients with anemia not caused by iron deficiency, such as hemoglobinopathies, hemoglobin variants, thalassemia, hemolytic anemia, acute or chronic blood loss, which is important since these can result in falsely reduced HbA1c concentrations (8, 14-16, 18-24, 27-34, 36, 39-41, 43-49, 51, 54, 55, 57-61, 64, 66-68, 72, 78). Patients with CKD were also excluded in many studies, which is relevant because CKD may lead to anemia of chronic disease and falsely reduced HbA1c concentrations (8, 14, 16, 18, 20, 22, 24, 27, 28, 30-34, 36, 38-40, 43-46, 49, 51, 56, 57, 59-61, 64, 67, 68, 70, 72, 81). Subgroup analysis demonstrated that IDA was associated with increased HbA1c concentrations, and iron supplementation was associated with a reduction in HbA1c concentrations in studies that excluded patients with CKD or anemia not caused by iron deficiency. However, these findings should be interpreted with caution, given the considerable heterogeneity across studies in the definition of anemia not caused by iron deficiency.

Some studies excluded patients with inflammatory or infectious conditions and/or elevated CRP concentrations (15, 19, 36, 40, 50, 51, 54, 56-60, 67). This is an important consideration, as ferritin is an acute-phase reactant, and its concentration increase in the presence of inflammation, potentially interfering with the diagnosis of IDA and LID when assessed by ferritin concentrations (13, 79). Subgroup analysis demonstrated that IDA was associated with increased HbA1c concentrations, and iron supplementation was associated with a reduction in HbA1c concentrations in studies that excluded patients with inflammation and/or elevated CRP.

Subgroup analysis also showed that the association between IDA and elevated HbA1c remained significant across various population groups, including adults of both sexes, nonpregnant and pregnant women, children and adolescents, and individuals without DM. Therefore, the findings of this study consolidate and expand the evidence on the interference of iron deficiency in HbA1c measurement, demonstrating, based on a meta-analysis of 30 studies, that IDA is associated with a significant increase in HbA1c concentrations, in contrast to previous systematic reviews that included a smaller number of studies (82, 83). Furthermore, these results corroborate prior evidence that iron supplementation reduces HbA1c concentrations (5, 84). However, the methodological quality assessment and subgroup analyses indicate that these findings should be interpreted with caution, as the methods used to measure HbA1c and the diagnostic criteria for anemia and iron deficiency represent important sources of bias.

Some additional relevant aspects of this study include the analysis of the effect of LID on HbA1c concentrations, which may also be associated with increased HbA1c concentrations. However, this finding is limited by the small number of available studies. Another relevant aspect was the assessment of the risk of diagnostic error, suggesting that iron deficiency may increase the likelihood of misclassifying individuals as prediabetic or diabetic, although the current evidence remains inconclusive.

In conclusion, IDA interferes with HbA1c measurement, leading to falsely elevated HbA1c concentrations. This effect was observed in most of the studies included in the systematic review and was corroborated by the meta-analysis results. However, these findings should be interpreted with caution, particularly because the HbA1c assay used, including NGSP-certified HPLC methods, and the diagnostic criteria for anemia and iron deficiency, such as WHO definitions, may influence the magnitude of this effect. Latent iron deficiency may also be associated with increased HbA1c concentrations, as indicated by meta-analysis. However, this finding is limited by the small number of available studies.

Given the high prevalence of IDA and LID in the general population, it is important that HbA1c testing be accompanied by a complete blood count and assessment of iron status, preferably ferritin. This approach may help ensure a more accurate interpretation of HbA1c results in individuals with iron deficiency.

APPENDIX

The articles were selected using the following combination of descriptors, which were defined according to Medical Subject Headings (MeSH): (“Glycated hemoglobin” or “Hemoglobin, Glycated” or “Glycohemoglobin” or “Glycohemoglobins” or “Glycated Hemoglobins” or “Hemoglobins, Glycated” or “Hemoglobin, Glycosylated” or “Glycosylated Hemoglobin” or “Glycated Hemoglobin A1c” or “Hemoglobin A1c, Glycated” or “Glycosylated Hemoglobin A1c” or “Hemoglobin A1c, Glycosylated” or “Hb A1a-2” or “Hemoglobin, Glycated A1a-2” or “A1a-2 Hemoglobin, Glycated” or “Glycated A1a-2 Hemoglobin” or “Hemoglobin, Glycated A1a 2” or “Glycated Hemoglobin A” or “Hemoglobin A, Glycated” or “Hb A1a+b” or “Hb A1c” or “HbA1” or “Glycosylated Hemoglobin A” or “Hemoglobin A, Glycosylated” or “Hb A1” or “Glycohemoglobin A” or “Hemoglobin A(1)” or “Hemoglobin, Glycosylated A1a-1” or “A1a-1 Hemoglobin, Glycosylated” or “Glycosylated A1a-1 Hemoglobin” or “Hemoglobin, Glycosylated A1a 1” or “Hb A1a-1” or “Hemoglobin, Glycated A1b” or “A1b Hemoglobin, Glycated” or “Glycated A1b Hemoglobin” or “Hb A1b” or “Hemoglobin, Glycosylated A1b” or “A1b Hemoglobin, Glycosylated” or “Glycosylated A1b Hemoglobin” or “Fructated Hemoglobins” or “Hemoglobins, Fructated”) and (“anemia, iron-deficiency” or “Anemia, Iron Deficiency” or “Iron-Deficiency Anemia” or “Iron Deficiency Anemia” or “Anemias, Iron-Deficiency” or “Anemias, Iron Deficiency” or “Iron-Deficiency Anemias” or “Iron Deficiency Anemias” or “Iron Deficiencies” or “Deficiencies, Iron” or “Deficiency, Iron” or “Sideropenia” or “Sideropenias” or “Iron Deficiency” or “Hypoferritinemia” or “Hypoferritinemias” or “Latent Iron Deficiency” or “Deficiencies, Latent Iron” or “Deficiency, Latent Iron” or “Iron Deficiencies, Latent” or “Iron Deficiency, Latent” or “Latent Iron Deficiencies”).

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References World Health Organization. The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015. GardnerWKassebaumN. Global, regional, and national prevalence of anemia and its causes in 204 countries and territories, 1990-2019. Curr Dev Nutr. 2020;4:830. 10.1093/cdn/nzaa053_035 KumarASharmaEMarleyASamaanMABrookesMJ. Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterol. 2022;9:e000759. 10.1136/bmjgast-2021-00075934996762 PaivaAARondóPHGuerra-ShinoharaEM. Parâmetros para avaliação do estado nutricional de ferro [Parameters for the assessment of iron status]. Rev Saude Publica. 2000;34:421–6. 10.1590/S0034-8910200000040001910973166 EnglishEIdrisISmithGDhatariyaKKilpatrickESJohnWG. The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia. 2015;58:1409–21. 10.1007/s00125-015-3599-325994072 GuoWZhouQJiaYXuJ. Increased Levels of Glycated Hemoglobin A1c and Iron Deficiency Anemia: A Review. Med Sci Monit. 2019;25:8371–8. 10.12659/MSM.91671931696865 SimmonsDHlaingT. Interpretation of HbA1c: association with mean cell volume and haemoglobin concentration. Diabet Med. 2014;31:1387–92. 10.1111/dme.1251824910286 ShanthiBRevathyCManjula DeviAJ. Subhashree. Effect of iron deficiency on glycation of haemoglobin in nondiabetics. J Clin Diagn Res. 2013;7:15–7. 10.7860/JCDR/2012/4881.265923449741 PageMJMcKenzieJEBossuytPMBoutronIHoffmannTCMulrowCD The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71): 10.1136/bmj.n7133782057 Cochrane Bias Methods Group. ROBINS-I V2: Risk Of Bias In Non-randomized Studies of Interventions. Version 2, 2025. Available from: https://www.riskofbias.info/welcome/robins-i-v2. Accessed November 10th 2025. WellsGASheaBO’ConnellDPetersonJWelchVLososM The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Ottawa Hospital Research Institute. Canada: University of Ottawa, Department of Epidemiology and Community Medicine. Publications. 2026;14:4. World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. World Health Organization, Geneva, 2024. World Health Organization. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. World Health Organization, Geneva, 2020. MukasaRJMubiruNSekitolekoIMakangaRNkaburaHOngariaT Comparative assessment of the impact of iron deficiency on HbA1c accuracy in non-anaemic individuals with type 2 diabetes: A secondary data analysis. PLoS One. 2026;21:e0323034. 10.1371/journal.pone.032303441628151 TedongLDe ManfouoRTDjeukamgangMMTchoumkeMMKoulPBWWMekiejeMPT Prevalence and Determinants of Anemia and Iron Deficiency Anemia Among Patients With Diabetes Mellitus in Cameroon: An Analytical Cross-Sectional Study. Health Sci Rep. 2026;9:e71999. 10.1002/hsr2.7199941804491 DeepaliPKumarD. Impact of Iron Deficiency Anemia on Hemoglobin A1c Levels: A Cross-Sectional Study. IJPQA. 2025;16:268–72. 10.25258/ijpqa.16.1.40 KogaMIshibashiM. Effect of sampling position of erythrocytes on HbA1c levels in iron deficiency anemia: Comparison between enzymatic assay and HPLC. Diabetol Int. 2025;16:86–91. 10.1007/s13340-024-00769-839877454 DuttaNKhatunBDasIGhoshARoyS. Effect of iron deficiency anemia on HbA1c in non-diabetics: an analytical study from eastern India. Endocrinol Res Pract. 2024;28:216–3. 10.5152/erp.2024.507 FiratAKatlanDCUzunayN. Impact of Iron Deficiency Anemia on Hemoglobin A1c Levels in Diabetic and Non-Diabetic Pregnant Women. Clin Exp Obstet Gynecol. 2024;51:24. 10.31083/j.ceog5101024 HassenaCArunaYSireeshaTDurgaT. Amulya. A Comparative Study of HbA1c Levels and Serum Ferritin among Iron Deficient Anemic Pregnant Women and Normal Pregnant Women in a Tertiary Hospital. Int J Toxicol Pharmacol Res. 2024;14:146–51. KanojiaSCSinghSMittalAPatelAKausarH. Iron deficiency anemia and its effect on HbA1c levels in patients above 30 years. PJMHS. 2024;18:14–7. 10.53350/pjmhs020241812.14 KesharwaniAPatoudiVHVishwakarmaNSasmalP. Unveiling the Impact of Iron Deficiency Anemia on HbA1c in Non-Diabetics: Insights from a Case-Control Study. IJPCR. 2024;16:479–83. KrishnanNRGeethaPAJu NathMEranhikkalHRaseemaAK. To estimate the HbA1c levels in patients with iron deficiency anemia and to compare this with healthy individuals. JAMP. 2024;6:885–9. KumarSMuzaffarMAAhmadI. Cross-Sectional Investigation on Haemoglobin HbA1c Levels in Iron-Deficiency Anemia. Int J Curr Pharm Rev Res. 2024;16:91–5. NakumDChokshiJHaideriSParikhUGohilMRajguruH Effect of iron deficiency anemia on HbA1c levels in diabetic patients at tertiary care centre. J Cardiovasc Dis Res. 2024;15:1375–84. PatelAPundkarAAgarwalAGadkariCVasavadaY. Association Between Glycated Hemoglobin (HbA1c) Levels in Patients With Iron Deficiency Anemia in a Tertiary Care Hospital in Central India. Cureus. 2024;16:e66121. 10.7759/cureus.6612139229395 SuvethasriSKPrasadMKBanthaviSPSivakumarK. A study of effect of iron deficiency anemia on glycosylated hemoglobin in non-diabetic patients. Natl J Physiol Pharm Pharmacol. 2024;14:1708–11. ShubhamLabrezMZPrasadR. Study on the Effect of Iron Deficiency Anaemia on HbA1c Levels in Non-Diabetic Adults. Int J Pharm Clin Res. 2024;16:19–224. TaatiBGanjiRMoradiLVosoughiTGisoueiA. Therapeutic effect of ferrous sulfate in diabetic patients with iron deficiency anaemia: a randomised controlled trial. Ann Med Surg (Lond). 2024;86:1989–96. 10.1097/MS9.000000000000183838576965 ThakkerKSMohanapuSSenM. A comparative study to assess Hba1c levels in antenatal non diabetic women with anemia and without anemia. Clin Epidemiol Glob Health. 2024;30:101777. 10.1016/j.cegh.2024.101777 AlzahraniBASalamatullahHKAlsharmFSBaljoonJMAbukhodairAOAhmedME The effect of different types of anemia on HbA1c levels in non-diabetics. BMC Endocr Disord. 2023;23:24. 10.1186/s12902-023-01280-y36709277 ElsheikhEAljohaniSSAlshaikhmubarakMMAlsubaieAWAlhawlMAAlsultanNH Effect of iron deficiency anemia on HbA1c in diabetic and non-diabetic patients. JPTCP. 2023;30:732–47. GhardeCAtkarCMTayadeAKungarT. To study the effect of iron deficiency anaemia on HbA1c levels in non diabetics at Tertiary Care Centre of Central India: A cross sectional study. JAMP. 2023;5:1446–50. KumarDRasheedTZuberiBFSadafRAliFS. Correlation of HbA1c with Serum Iron & Transferrin Saturation in Non-Diabetic Patients with Iron Deficiency. Pak J Med Sci. 2023;39:956–60. 10.12669/pjms.39.4.696437492295 NosheenAAhmadSAFayyazMMohydinMZaidiWHMalikMHBA Effect of Iron Supplementation on HbA1c levels in Type 1 Diabetic patients. Pak J Med Health Sci. 2023;17:149. 10.53350/pjmhs2023174149 AydınBÖzçelikSKilitTPEraslanSÇelikMOnbaşıK. Relationship between glycosylated hemoglobin and iron deficiency anemia: A common but overlooked problem. Prim Care Diabetes. 2022;16:312–7. 10.1016/j.pcd.2022.01.00235000894 El-AgouzaIAbu ShahlaASirdahM. The effect of iron deficiency anaemia on the levels of haemoglobin subtypes: possible consequences for clinical diagnosis. Clin Lab Haematol. 2002;24:285–9. 10.1046/j.1365-2257.2002.00464.x12358889 EstrellaMLPérezCMSuárezEFuentes-PayánWThyagarajanBGoldsmithJC Sex-Specific Associations of Iron-Anemia Status With Hemoglobin A1C Levels Among Hispanics/Latinos Without Self-Reported Diabetes Mellitus: The Hispanic Community Health Study/Study of Latinos. Endocr Pract. 2022;28:282–91. 10.1016/j.eprac.2021.11.08634896297 JaniceDPrathimaMBSushithSNarayananRReshmaSNairS Effect of iron deficiency anaemia over glycated hemoglobin in non-diabetic women. Int J Biochem Mol Biol. 2022;13:23–7.35891642 JyothsnaPSuchitraMMKusuma KumariMChandrasekharCRukmangadhaNAlokS Effect of Iron Deficiency Anemia on Glycated Albumin Levels: A Comparative Study in Nondiabetic Subjects with Iron Deficiency Anemia. J Lab Physicians. 2022;15:253–8. 10.1055/s-0042-175758937323601 PradeepaRShreyaLAnjanaRMJebaraniSRajNKKumarM Frequency of iron deficiency anemia in type 2 diabetes-Insights from tertiary diabetes care centres across India. Diabetes Metab Syndr. 2022;16:102632. 10.1016/j.dsx.2022.10263236343394 RaoLVPrattGWBiCKrollMH. Large-scale retrospective analyses of the effect of iron deficiency anemia on hemoglobin A1c concentrations. Clin Chim Acta. 2022;529:21–4. 10.1016/j.cca.2022.02.00535167841 Çetinkaya AltuntaşSEvranMGürkanESertMTetikerT. HbA1c level decreases in iron deficiency anemia. Wien Klin Wochenschr. 2021;133:102–6. 10.1007/s00508-020-01661-632377869 BindayelIA. Influence of iron deficiency anemia on glycated hemoglobin levels in non-diabetic Saudi women. J Int Med Res. 2021;49:300060521990157. 10.1177/030006052199015733641472 KanchanaRPushpaK. Vitamin D and glycated hemoglobin levels in non-diabetic anemic patients. Natl J Physiol Pharm Pharmacol. 2021;11:904–7. 10.5455/njppp.2021.11.06191202120062021 LyonsJvan der LindenELMeeksKBeuneESmeethLBahendekaS Inverse Association between Iron Deficiency and Glycated Hemoglobin Levels in Ghanaian Adults-the RODAM Study. J Nutr. 2020;150:1899–908. 10.1093/jn/nxaa10932433726 MahgoobMHMoussaMM. Glycated albumin versus HbA1c as indicators of glycemic control in type I diabetic children with iron deficiency anemia. Clin Pediatr Endocrinol. 2020;29:151–7. 10.1297/cpe.29.15133088014 PillaRPalletiSKRayanaRSkssSRRazzackAAKallaS. Glycated haemoglobin (HbA1c) variations in nondiabetics with nutritional anemia. Cureus. 2020;12:e11479. 10.7759/cureus.1147933329975 PurbeyRAgrawalBKKaushalPKelaRThomasA. A Study on the Effect of Iron Deficiency Anaemia on Haemoglobin A1c Levels in Non-Diabetic Adults. J Evol Med Dent Sci. 2020;9:1649–54. 10.14260/jemds/2020/362 SabithaDDawsonETiwariSNKSwethaPNaushadSMBabaKS Study of Glycation of Transferrin and its Effect on Biomarkers of Iron Status in Uncontrolled Diabetes Mellitus Patients. J Clin Diagn Res. 2020;14:BC06–09. 10.7860/JCDR/2020/44506.13909 IntraJLimontaGCappelliniFBertonaMBrambillaP. Glycosylated Hemoglobin in Subjects Affected by Iron-Deficiency Anemia. Diabetes Metab J. 2019;43:539–44. 10.4093/dmj.2018.007230604593 SilvaJFPimentelALCamargoJL. Effect of iron deficiency anaemia on HbA1c levels is dependent on the degree of anaemia. Clin Biochem. 2016;49:117–20. 10.1016/j.clinbiochem.2015.09.00426365695 WeiJLuoXZhouSHeXZhengJSunX Associations between iron status and insulin resistance in Chinese children and adolescents: findings from the China Health and Nutrition Survey. Asia Pac J Clin Nutr. 2019;28:819–25.31826380 AkkermansMDMieke HoudijkECABakkerBBoersACvan der KaayDCMde VriesMC Iron status and its association with HbA1c levels in Dutch children with diabetes mellitus type 1. Eur J Pediatr. 2018;177:603–10. 10.1007/s00431-018-3104-329396628 EserCDenizENeslihanYAytacTOmerKSerdarY. The effect of iron supplementation on HBA1c levels in non-diabetic pregnant women. Biomed Res. 2020;29:1033–6. 10.4066/biomedicalresearch.29-17-3550 HashimotoKKogaM. Influence of Iron Deficiency on HbA1c Levels in Pregnant Women: Comparison with Non-Pregnant Women. J Clin Med. 2018;7:34. 10.3390/jcm702003429461483 IntraJLimontaGCappelliniFBertonaMBrambillaP. Glycated haemoglobin and iron deficiency anaemia: a case‐control study. Pract Diabetes. 2018;35:90–6a. 10.1002/pdi.2170 UrrechagaE. Influence of iron deficiency on HbA1c levels in type 2 diabetic patients. Diabetes Metab Syndr. 2018;12:1051–5. 10.1016/j.dsx.2018.06.02430042079 MadhuSVRajAGuptaSGiriSRusiaU. Effect of iron deficiency anemia and iron supplementation on HbA1c levels - Implications for diagnosis of prediabetes and diabetes mellitus in Asian Indians. Clin Chim Acta. 2017;468:225–9. 10.1016/j.cca.2016.10.00327717800 Naslı-EsfahaniELarijaniBAminiP. GHASEMABADI RG, Razmandeh R. Effect of treatment of iron deficiency anemia on hemoglobin A1c in type 2 diabetic patients. Turk J Med Sci. 2017;47:1441–6. 10.3906/sag-1601-2729151315 RajagopalLGanapathySArunachalamSRajaVRamrajB. Does Iron Deficiency Anaemia and its Severity Influence HbA1C Level in Non Diabetics? An Analysis of 150 Cases. J Clin Diagn Res. 2017;11:EC13–5. 10.7860/JCDR/2017/25183.946428384869 AttardSMHerringAHWangHHowardAGThompsonALAdairLS Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutr Diabetes. 2015;5:e166. 10.1038/nutd.2015.1626098445 HongJWKuCRNohJHKoKSRheeBDKimDJ. Association between the presence of iron deficiency anemia and hemoglobin A1c in Korean adults: the 2011-2012 Korea National Health and Nutrition Examination Survey. Medicine (Baltimore). 2015;94:e825. 10.1097/MD.000000000000082525997055 ChristyALManjrekarPABabuRPHegdeARukminiMS. Influence of iron deficiency anemia on hemoglobin A1c levels in diabetic individuals with controlled plasma glucose levels. Iran Biomed J. 2014;18:88–93.24518549 HardikarPSJoshiSMBhatDSRautDAKatrePALubreeHG Spuriously high prevalence of prediabetes diagnosed by HbA(1c) in young indians partly explained by hematological factors and iron deficiency anemia. Diabetes Care. 2012;35:797–802. 10.2337/dc11-132122323413 RafatDRabbaniTKAhmadJAnsariMA. Influence of iron metabolism indices on HbA1c in non-diabetic pregnant women with and without iron-deficiency anemia: effect of iron supplementation. Diabetes Metab Syndr. 2012;6:102–5. 10.1016/j.dsx.2012.05.01123153978 SatriawibawaIWEArimbawaIMAriawatiKSuparyathaIBGPutraIGNSHartawanINB. Serum iron is negatively correlated with the HbA1c level in children and adolescents with type 1 diabetes mellitus. Clin Pediatr Endocrinol. 2022;31:242–9. 10.1297/cpe.2022-001236405436 SinhaNMishraTKSinghTGuptaN. Effect of iron deficiency anemia on hemoglobin A1c levels. Ann Lab Med. 2012;32:17–22. 10.3343/alm.2012.32.1.1722259774 FordESCowieCCLiCHandelsmanYBloomgardenZT. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011;3:67–73. 10.1111/j.1753-0407.2010.00100.x20942846 KimCBullardKMHermanWHBecklesGL. Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care. 2010;33:780–5. 10.2337/dc09-083620067959 KogaMSaitoHMukaiMMatsumotoSKasayamaS. Influence of iron metabolism indices on glycated haemoglobin but not glycated albumin levels in premenopausal women. Acta Diabetol. 2010;47:65–9. 10.1007/s00592-009-0123-619404566 CobanEOzdoganMTimuragaogluA. Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol. 2004;112:126–8. 10.1159/00007972215345893 TarimOKüçükerdoğanAGünayUEralpOErcanI. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int. 1999;41:357–62. 10.1046/j.1442-200X.1999.t01-1-01083.x10453183 RadinMS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014;29:388–94. 10.1007/s11606-013-2595-x24002631 DaviesMJArodaVRCollinsBSGabbayRAGreenJMaruthurNM Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753–86. 10.2337/dci22-003436148880 American Diabetes Association Professional Practice Committee for Diabetes. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49:S132–49. 10.2337/dc26-S00641358894 American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49:S27–49. 10.2337/dc26-S00241358893 National Glycohemoglobin Standardization Program. Factors that interfere with HbA1c test results, 2024. Available from https://ngsp.org/factors.asp. Accessed 25th April 2026. RuschJAvan der WesthuizenDJGillRSLouwVJ. Diagnosing iron deficiency: controversies and novel metrics. Best Pract Res Clin Anaesthesiol. 2023;37:451–67. 10.1016/j.bpa.2023.11.00139764832 WeykampC. HbA1c: a review of analytical and clinical aspects. Ann Lab Med. 2013;33:393–400. 10.3343/alm.2013.33.6.39324205486 Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98:1–115. 10.1016/j.kint.2020.06.019 CavagnolliGPimentelALFreitasPACGrossJLCamargoJL. Factors affecting A1C in non-diabetic individuals: Review and meta-analysis. Clin Chim Acta. 2015;445:107–14. 10.1016/j.cca.2015.03.02425818244 KuangLLiWXuGYouMWuWLiC. Systematic review and meta-analysis: influence of iron deficiency anemia on blood glycosylated hemoglobin in diabetic patients. Ann Palliat Med. 2021;10:11705–13. 10.21037/apm-21-294434872295 AlQarniAMAlghamdiAAAljubranHJBamalanOAAbuzaidAHAlYahyaMA. The effect of iron replacement therapy on HbA1c levels in diabetic and nondiabetic patients: a systematic review and meta-analysis. J Clin Med. 2023;12:7287. 10.3390/jcm1223728738068338
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030503" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030503" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030503" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(131) "Interference of iron deficiency in glycated hemoglobin testing and its clinical implications: a systematic review and meta-analysis" ["journals_article_author"]=> string(57) "Emanuele Maria Coimbra Souza, Caroline Pereira Domingueti" ["journals_article_author_country"]=> string(6) "Brazil" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(76) "anemia, iron-deficiency, glycated hemoglobin, clinical laboratory techniques" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2450" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "5" ["meta_title"]=> string(131) "Interference of iron deficiency in glycated hemoglobin testing and its clinical implications: a systematic review and meta-analysis" ["meta_desc"]=> string(131) "Interference of iron deficiency in glycated hemoglobin testing and its clinical implications: a systematic review and meta-analysis" ["meta_keyw"]=> string(76) "anemia, iron-deficiency, glycated hemoglobin, clinical laboratory techniques" ["created"]=> string(19) "2026-10-01 11:08:14" ["modified"]=> string(19) "2026-10-02 11:01:25" } [14]=> object(stdClass)#49 (35) { ["journals_id"]=> string(4) "1269" ["journals_xml"]=> string(137248) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030502 10.11613/BM.2026.030502 Reviews Viral triggers of Guillain-Barré syndrome: implications for laboratory diagnostics KłodnickaKarolina1JanuszewskiJacek*12TyczyńskaMagdalena2TeresińskaBarbara1TrzaskaczPaulina1FormaAlicja3FliegerJolanta4BajJacek1 Department of Correct, Clinical and Imaging Anatomy, Medical University of Lublin, Lublin, Po-land Doctoral School, Medical University of Lublin, Lublin, Poland Department of Forensic Medicine, Medical University of Lublin, Lublin, Poland Department of Analytical Chemistry, Medical University of Lublin, Lublin, Poland Corresponding author: jacek.januszewski000@gmail.com

Author contributions

K Kłodnicka: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualisation, Writing - original draft preparation, Writing - review & editing. J Januszewski: Conceptualization, Data curation, Formal analysis, Inves-tigation, Resources, Software, Visualisation, Writing - original draft preparation, Writing - review & editing. M Tyczyńska: Conceptualization, Data curation, Formal analysis, Investigation, Methodolo-gy, Resources, Writing - original draft preparation. B Teresińska: Conceptualization, Data curation, Formal analysis, Investigation, Resources, Writing - original draft preparation. P Trzaskacz: Con-ceptualization, Data curation, Formal analysis, Investigation, Resources, Visualisation, Writing - original draft preparation. A Forma: Conceptualization. J Flieger: Supervision. J Baj: Supervision.

15102026 15102026 36 3 030502 0701202628072026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Viral infections can trigger Guillain-Barré syndrome (GBS) through immune mechanisms

• Molecular mimicry between viral antigens and nerves plays a key pathogenic role

• Different viruses may induce distinct GBS subtypes with varied clinical features

• Laboratory tests support diagnosis by detecting antibodies and viral markers

• Early recognition of viral triggers improves management and patient outcomes

Guillain-Barré syndrome (GBS) is a leading cause of acquired acute neuromuscular paralysis and is an immune-mediated disorder of the peripheral nervous system (PNS). Accumulating evidence indi-cates that GBS is often preceded by infectious events that trigger autoimmune responses through mechanisms such as molecular mimicry and autoantibody production. Campylobacter jejuni remains the most common bacterial agent, but viral pathogens also contribute to the development of GBS. This review summarizes the current evidence regarding viruses as triggers of GBS, including herpes-viruses, hepatotropic viruses (A, B, C, and E), human immunodeficiency virus, Zika virus, influenza virus, varicella-zoster virus, and the coronavirus SARS-CoV-2. Emphasis is placed on laboratory test results related to viral GBS, including antiganglioside antibodies, serological markers of recent in-fection, molecular diagnostic methods, and cerebrospinal fluid analysis. From the standpoint of la-boratory medicine, both the clinical diagnosis and the distinction of GBS subtypes can be supported by the identification of recent viral infections and the detection of immunological biomarkers. How-ever, cross-reactivity, extended antibody persistence, and inadequate assay standardization frequently make it difficult to interpret laboratory test results. In patients with probable viral GBS, this review shows the diagnostic significance and limitations of routine laboratory testing. It also highlights the significance of close coordination between laboratory professionals and clinicians.

Keywords: antibodiesantigangliosideGuillain-Barré syndromelaboratory diagnosticsviral in-fection
Introduction

Guillain-Barré syndrome (GBS) is a postinfectious, monophasic polyradiculoneuropathy caused by immune-mediated damage to the peripheral nervous system (PNS) (1). It is the leading cause of ac-quired neuromuscular paralysis, often preceded by infectious events such as Campylobacter jejuni, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and, more recently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2, 3). While bacterial triggers are well characterized, the contribution of viral pathogens to GBS pathogenesis remains incompletely understood, representing a critical gap in both clinical and laboratory diagnostics.

Guillain-Barré syndrome manifests in different subtypes, including primary demyelinating and ax-onal variants, the latter comprising acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) (4). Miller-Fisher syndrome (MFS), a rare variant of GBS, is characterized by ataxia, areflexia, and ophthalmoparesis, with anti-ganglioside GQ1b antibodies de-tected in approximately 85% of patients (5). These features highlight the immunological heterogene-ity of GBS and the potential role of virus-induced autoimmunity.

The main objective of this review is to summarize current evidence on viral triggers of GBS, with particular emphasis on their implications for laboratory diagnostics. We hypothesize that identifying viral infections and associated immunological biomarkers can improve subtype differentiation and clinical management. By providing an updated overview of viral contributions to GBS pathogenesis, this review aims to support laboratory professionals and clinicians in interpreting serological, mo-lecular, and cerebrospinal fluid (CSF) findings in suspected viral GBS cases. In order to clearly pre-sent the complexity of the phenomena discussed, a synthetic pathophysiological model illustrating the sequence of events leading from viral infection to damage to the structures of the peripheral nerve (PN) is presented in Figure 1.

Pathomechanism of virus-associated Guillain-Barré syndrome. The figure depicts the cas-cade from viral infection to immune activation, subsequent production of autoantibodies via molec-ular mimicry, and resulting peripheral nerve damage. TNF-α - tumor necrosis factor-alpha. IL-6 - interleukin-6.

Materials and methods

A comprehensive review of the available literature regarding viral pathogens and GBS was conduct-ed. The literature search was performed across PubMed, Google Scholar, and Scopus databases in March 2025 by two independent reviewers. Both reviewers conducted the search strategy concur-rently. The initial broad search utilized the terms: (“Guillain-Barré Syndrome” OR “Guillain Barre Syndrome”) AND “virus”. To ensure exhaustive coverage of specific pathogens, a supplementary targeted search was performed within the same timeframe using the terms: (“Guillain Barre Syn-drome” OR “Guillain-Barré Syndrome”) AND (“CMV” OR “Epstein-Barr virus” OR “Zika virus” OR “SARS-CoV-2” OR “Influenza virus” OR “Hepatitis A” OR “Hepatitis B” OR “Hepatitis C” OR “Hepatitis E” OR “HIV” OR “Herpes simplex virus” OR “Varicella zoster virus”). The search pri-marily targeted English-language articles published within the last 5 years, encompassing both hu-man and animal studies. However, seminal papers, highly relevant historical case reports, and foun-dational clinical guidelines published prior to this period were also included to provide essential context and mechanistic insights. Inclusion criteria comprised a confirmed viral infection preceding or associated with GBS and the availability of sufficient clinical or laboratory data. Exclusion crite-ria included duplicate reports across databases, off-topic studies, and articles lacking specific rele-vant information. The initial broad search yielded 1386 previously published articles. Following the removal of duplicates and a rigorous screening of titles, abstracts, and full texts against the prede-fined criteria, irrelevant and redundant studies were progressively excluded. Ultimately, 95 articles met all criteria and were included in the final review.

Herpes simplex virus

This herpesvirus primarily affects the skin and mucous membranes and may lead to a variety of dis-eases, such as cold sores, genital herpes, herpes stromal keratitis, meningitis, and encephalitis. Her-pes simplex virus type 1 (HSV-1) is a neurotropic virus that causes a life-long latent infection in sensory ganglia following an initial epithelial infection (6). The association between MFS and an underlying HSV-1 infection has been recognized in a reported case of a 48-year-old man who devel-oped diplopia, bilateral ptosis, and unstable gait after an acute diarrheal illness and recurring cold sores. While the patient presented with a history of a preceding acute Campylobacter jejuni infection, the recurrent nature of the HSV-1 infection was identified as the primary precipitant for the MFS episode. The diagnosis was supported by the presence of anti-GQ1b ganglioside IgG antibodies and abnormal magnetic resonance imaging (MRI) findings in the bilateral cranial nerves III and VI. This case highlights the complex interplay between multiple pathogens and autoimmunity, suggesting that HSV-1 may provoke the formation of cross-reactive autoantibodies toward gangliosides via molecu-lar mimicry, even in the setting of prior gastrointestinal illness (7). This abnormal immune activity causes the development of antibodies that cross-react with ganglioside components of PNs, leading to demyelination and axonal damage typical of GBS and MFS (8). Another reported case involves an 80-year-old male who, after an upper respiratory tract infection, developed dysarthria, dysphonia, ophthalmoplegia, areflexia, and unstable posture. Herpes simplex virus type 1 DNA was detected in CSF analysis (9). This highlights the importance of detecting HSV reactivation in CSF to guide rou-tine laboratory diagnostics and combined antiviral and immunomodulatory treatment. Cross-reactivity between human herpesviruses has been suggested in previous studies (10). Although HSV-1 has been proposed as a potential trigger or exacerbating factor in GBS/MFS, the available evidence is limited to case reports, and no direct mechanistic link, including molecular mimicry, has been conclusively demonstrated (11). It is worth noting, however, that GBS as a consequence of HSV-1 infection is uncommon, with most HSV infections not leading to autoimmune neuropathy. In conclusion, HSV-1 infection can trigger GBS/MFS through complex immunological processes such as molecular mimicry and immune modulation. Early detection via laboratory testing and prompt initiation of combined antiviral and immunotherapy can improve patient outcomes (12).

Varicella Zoster virus

Varicella Zoster virus (VZV) is a common human-restricted pathogen. After primary varicella infec-tion, VZV enters latency in the sensory ganglia and can later reactivate to cause herpes zoster (HZ), a disease with significant morbidity but low mortality. Both varicella and zoster are generally self-limiting, but in immunocompromised patients, they may cause serious complications, including encephalitis, myelitis, and in rare cases GBS (13). Herpes zoster typically presents as a localized ve-sicular rash along a dermatome and may be accompanied by sensory and motor deficits. Current evi-dence suggests that VZV can trigger GBS through molecular mimicry, where viral antigens such as glycoproteins gB, gH, and gL structurally resemble PN gangliosides (8). This molecular similarity may provoke an autoimmune response, leading to antibody production against host neurons. Proin-flammatory cytokines induced by the infection, particularly tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), may weaken the blood-nerve barrier and facilitate leukocyte infiltration into PNs (12, 14). Although GBS after VZV infection is uncommon, HZ should be considered a potential trigger. A systematic review identified 29 cases of GBS following primary VZV infection, with a median age of 37 years and a male predominance. Most patients exhibited sensory-motor deficits, including tetraparesis and cranial nerve involvement, especially the facial nerve. Intravenous immu-noglobulin (IVIG) was used as first-line therapy in all cases, with favorable outcomes in most pa-tients (14). There are also reports of axonal GBS variants, such as, following zoster AMAN infection, highlighting immune response heterogeneity and the possibility of seronegative presentations. In conclusion, GBS following varicella or zoster can lead to severe illness, particularly in adults, and is often associated with cranial nerve involvement (15). Early recognition and prompt immunotherapy are essential to improve clinical outcomes.

Cytomegalovirus

Cytomegalovirus (CMV), a member of the Herpesviridae family, is a common viral trigger of GBS, especially in adults (16). CMV-associated GBS is often characterized by the presence of IgM an-ti-ganglioside antibodies, particularly anti-GM2, indicating a virus-specific immune mechanism. Laboratory confirmation typically includes CMV IgM serology, detection of viral DNA by polymer-ase chain reaction (PCR) in blood or CSF, and antiganglioside antibody assays, which can guide di-agnosis and prognosis (17).

For example, a 9-year-old patient developed axonal sensory-motor GBS after CMV infection, con-firmed by positive anti-CMV IgM and elevated antiganglioside antibodies. Follow-up revealed com-plete neurological recovery (17). Epidemiological data suggest that CMV-GBS more frequently af-fects younger individuals, with sensory deficits and facial palsy. The underlying mechanism involves molecular mimicry, where CMV antigens resemble host gangliosides, triggering cross-reactive hu-moral responses (18, 19). Although CMV infection alone does not always result in GBS, immune dysregulation in susceptible hosts promotes PN injury via both humoral (anti-ganglioside antibodies) and cellular (CD8+ T-cell mediated) pathways (19). In summary, CMV can precipitate GBS through virus-specific immune mechanisms, and routine laboratory testing serology, PCR, and antibody de-tection plays a pivotal role in diagnosis, subtype classification, and monitoring recovery (16-21).

Epstein-Barr virus

Epstein-Barr virus is a cause of infectious mononucleosis and has been implicated as a rare but probable trigger of GBS (22-24). Although EBV associated with GBS is uncommon, serological and immunological evidence supports a potential link. Cytomegalovirus and Campylobacter jejuni are better known as triggers of GBS because of well-defined molecular mimicry mechanisms. Ep-stein-Barr virus can cause GBS via alternative immune pathways. Proposed mechanisms include EBV-induced polyclonal B-cell activation and bystander PN components. Laboratory identification of EBV as a trigger is well established in clinical practice, including confirmed primary infection in immunocompetent patients and EBV-associated manifestations in immunocompromised individuals, such as kidney transplant recipients. Detection of EBV-specific antibodies may support the diagnosis in suspected post-infectious GBS cases, although clinical presentations may vary (22-24).

SARS-CoV-2

The 2019 pandemic was caused by the novel coronavirus SARS-CoV-2, responsible for COVID-19, primarily affecting the respiratory system (25). Early reports indicated neurological involvement, both central and peripheral, including anosmia, ageusia, headache, fever, fatigue and myalgia (26). SARS-CoV-2 can reach the nervous system via the olfactory nerve, transsynaptic transfer, leukocyte migration across the blood-brain barier, or direct endothelial infection (27). Mechanisms of neural injury include direct neurotropism, immune-mediated damage, cytokine storm, coagulopathy, and molecular mimicry between viral antigens and PN components (28, 29). Guillain-Barré syndrome and variants such as MFS have been reported following COVID-19 infection. A systematic review of 23 COVID-19-associated GBS cases in 2021 showed a median age of 61 years, equal gender distribu-tion, and predominance of the acute inflammatory demyelinating polyradioculopathy (AIDP) subtype over AMSAN (30). Severe demyelination and ICU admission were more common in these patients, highlighting the clinical significance of even rare postinfectious neuropathies (26, 29). Epidemiolog-ical data also indicate an increase in GBS incidence during the pandemic compared with the previous 30 years (31).

Zika virus

There are several reports describing the Zika virus (ZIKV) as a potential trigger for GBS. Detection of ZIKV RNA in serum, CSF, urine, and saliva by RT-PCR confirms viral infection and supports la-boratory diagnosis (32). Epidemiological studies in Colombia and Puerto Rico reported a rise in GBS cases during ZIKV outbreaks, with most patients showing neurological symptoms within four weeks after ZIKV infection (33). Laboratory analyses also revealed anti-glycolipid antibodies in some pa-tients, indicating a potential mechanism of molecular mimicry between viral antigens and neuronal components, especially in the AMAN subtype of GBS (34). Routine laboratory tests, including RT-PCR and serological assays, are essential for confirming ZIKV infection and monitoring immu-nological responses in suspected GBS cases. These findings highlight the role of laboratory diagnos-tics in identifying ZIKV-associated neurological complications (32-34).

Influenza virus

Most epidemiological data show only occasional cases of GBS linked to influenza infection or vac-cination, though some studies suggest possible correlations (35). Molecular mimicry is the most widely accepted mechanism, in which gangliosides on peripheral neurons structurally resemble in-fluenza virus antigens (36). Immune activation during infection can generate cross-reactive antibod-ies targeting neural structures, leading to axonal damage or demyelination (37, 38). During the 2009-2011 H1N1 pandemic in Norway, influenza infection but not vaccination was associated with an increased risk of GBS (39). Comprehensive laboratory diagnostics, including serological and im-munological assays, are essential for identifying influenza infection and monitoring immune re-sponses in patients with suspected GBS (40).

Hepatitis A virus

Hepatitis A virus (HAV) is a non-cytopathic RNA virus transmitted via the fecal-oral route, causing acute hepatitis of varying severity (41-45). Although HAV is not neurotropic, several cases of GBS have been reported in temporal association with HAV infection (46, 47). Molecular mimicry, where HAV antigens share epitopes with gangliosides or other PN components, is proposed to trigger cross-reactive antibodies leading to demyelination or axonal injury (5, 47, 48). Guillain-Barré syn-drome typically develops within six weeks of infection, often involving facial palsy and axonal vari-ants such as AMAN (49-53). Routine laboratory testing, including serology and immunological as-says, is essential to confirm HAV infection and to monitor immune responses in suspected GBS cas-es (46-48, 54).

Hepatitis B virus

Hepatitis B virus (HBV) is a hepatotropic DNA virus transmitted vertically or via contaminated body fluids (55). Although primarily affecting the liver, HBV infection has been rarely associated with GBS and other immune-mediated neuropathies (56-59). Mechanisms include molecular mimicry, immune complex formation, and T-cell dysregulation, which may lead to production of cross-reactive antibodies against PNs (60–63). Immune complexes containing HBsAg have been de-tected in both serum and CSF of the HBV infection-associated GBS case, supporting laborato-ry-based diagnosis and monitoring of immune-mediated damage (59-63). Awareness of this rare as-sociation is important, as early interventions such as IVIG or plasma exchange (PLEX) can improve neurological outcomes (64).

Hepatitis C virus

Hepatitis C virus (HCV) chronically infects approximately 58 million people worldwide and is transmitted via blood and high-risk sexual contact (65, 66). Hepatitis C virus exerts immunomodula-tory effects that can predispose to autoimmune complications, including GBS (66, 67). Immuno-pathogenic mechanisms involve persistent activation of innate and adaptive immunity, B-cell-driven autoimmunity, molecular mimicry, and immune complex deposition (68-70). Deposition of immune complexes in small vessels supplying PNs may result in vascular and demyelinating neuropathies. Laboratory tests, including serology and detection of immune complexes, are critical in assessing infection status and monitor autoimmune responses in HCV-infected patients with neurological complications. Long-lasting immune activation triggered on by chronic HCV infection is character-ized by persistent inflammatory signals and changes in humoral and cellular immune responses. Furthermore, persistent immunological abnormalities such as continuous macrophage activation fol-lowing viral elimination, suggest that HCV may have prolonged immunomodulatory effects that may promote immune-mediated issues resulting from infection (69-71).

Hepatitis E virus

Hepatitis E virus (HEV) infection has been linked to GBS through aberrant immune responses (72). Molecular mimicry, with antibodies or T cells targeting viral antigens cross-reacting with PN com-ponents such as gangliosides, contributes to inflammatory and demyelinating nerve damage (73-75). Hepatitis E virus genotype 1 is most commonly associated with neurological complications, with autoantibodies targeting nodal and paranodal proteins, disrupting nerve conduction and promoting demyelination and axonal degeneration via complement activation (75, 76). Laboratory detection of HEV infection and monitoring of immunopathogenic markers are important for identifying patients at risk of HEV-associated GBS (72-76).

Human immunodeficiency virus

Guillain-Barré syndrome has been reported in association with human immunodeficiency virus (HIV) infection, primarily in case reports since the 1980s (77-79). Guillain-Barré syndrome usually occurs early during acute retroviral syndrome or seroconversion, but can also develop during chronic HIV infection (80-82). Proposed mechanisms include autoimmune responses triggered by molecular mimicry between viral antigens and PN components, bystander activation of immune cells, and im-paired regulation of autoreactive T cells, which may lead to demyelination and axonal damage (83, 84). Immune reconstitution inflammatory syndrome (IRIS) after initiation of highly active antiretro-viral therapy (HAART) may also contribute to GBS onset. Routine laboratory testing, including CSF analysis showing elevated protein concentrations and immunological assays - such as markers of intrathecal immune activation, the assessment of anti-ganglioside antibodies and CD4+ T cell counts - is essential for diagnosis and monitoring of HIV-associated GBS (85, 86). CD4+ T cell depletion, chronic immune activation, and endothelial dysfunction in untreated HIV infection may further pre-dispose to autoimmune neuropathies (87-92). The British HIV Association (BHIVA) recommends HIV screening in all patients presenting with GBS (93).

Laboratory diagnostics

Accurate laboratory diagnostics is critical in confirming virus-associated GBS and its variants, in-cluding MFS, and in guiding immunotherapy and antiviral interventions. Routine laboratory ap-proaches combine serological, molecular, and immunological methods to provide a comprehensive assessment of viral exposure, immune activation, and PN involvement.

In alignment with current international consensus guidelines, CSF analysis remains a cornerstone of the diagnostic workup for GBS, where a separate evaluation of biochemical and cellular parameters is required (2, 8). The expected laboratory findings in patients with GBS are characterized by albu-minocytologic dissociation, defined as an elevated CSF protein concentration (> 0.45 g/L) accompa-nied by a normal CSF leukocyte count (< 10 cells/μL) or, less commonly, a mildly elevated leuko-cyte count (< 50 cells/μL) (1). According to current diagnostic criteria and management frameworks, this classical pattern supports the clinical diagnosis but its absence, particularly during the first week of symptom onset when protein concentrations can still be normal, does not exclude GBS (2).

For example, serological assays detecting virus-specific IgM and IgG antibodies are central in diag-nosing infections such as CMV, EBV, HSV-1, and hepatitis viruses, and in differentiating acute from past infections (6, 9, 11, 14, 16, 17, 20, 22-24, 46, 55, 57, 62, 65, 69, 94). Molecular diagnostics, par-ticularly PCR, enhance detection sensitivity by identifying viral DNA or RNA in serum, CSF, urine, or saliva. PCR-based confirmation is especially valuable in cases with atypical serological results, early infection before seroconversion, or reactivation of latent viruses such as HSV-1 or VZV (6-9, 13). In CSF, PCR detection of viral nucleic acids, together with protein concentration assessment, cell count, and immunoglobulin indices, can clarify whether neuropathy is driven primarily by direct viral neurotropism or post-infectious autoimmune mechanisms (9, 85, 86). For instance, HSV-1 DNA detected in CSF in GBS patients supports combined antiviral and immunomodulatory treatment (9). Similarly, detection of Zika virus RNA by RT-PCR confirms infection and supports the identification of molecular mimicry driven AMAN subtype GBS (32-34). Laboratory testing is also essential for early detection of viral reactivation or co-infections, which may modulate the risk of autoimmune neuropathy. For example, CMV IgM and IgG positivity alongside transient EBV IgM positivity sug-gests that multiple viral exposures can contribute synergistically to disease onset (94). Similarly, in SARS-CoV-2-associated GBS, serological and molecular analyses can differentiate post-infectious autoimmune neuropathy from direct viral neurotropism, guiding the use of immunomodulatory ther-apy in critically ill patients (26, 29, 30).

In laboratory diagnosis, antiganglioside antibody tests play a key role. They reflect the immunologi-cal mechanisms triggered by various pathogens, including viruses and bacteria (8). A key aspect of the pathophysiology of GBS is the development of antiganglioside antibodies. They arise through molecular mimicry between viral or bacterial antigens and PN components (3, 8, 76). These antibod-ies are typically detected in serum using enzyme-linked immunosorbent assay (ELISA) or im-munoblot techniques (5, 70). Viral infections can trigger production of antibodies against ganglioside components of PNs, including GM1, GM2, and GQ1b, through molecular mimicry (3, 8, 34). Sero-logical detection of these antibodies allows classification of GBS subtypes (AIDP, AMAN, AMSAN) and helps predict clinical outcomes. Their clinical significance lies in their clear association with specific clinical variants of GBS. Anti-GQ1b antibodies are highly specific for MFS, whereas anti-bodies against GM1 or GD1a gangliosides are often associated with axonal forms of GBS, such as AMAN (5, 18, 75). Identification of these antibody profiles is a key diagnostic tool for subtyping and prognostic assessment (5, 18, 69). Moreover, sequential measurement of antibody titers can monitor immune response dynamics and treatment efficacy during IVIG or plasma exchange therapy (8, 10, 15, 95). In EBV-associated GBS, polyclonal B-cell activation may lead to the production of diverse autoantibodies, while detection of EBV capsid-specific antibodies may support diagnosis when con-sidered alongside clinical findings (22-24). Additional biochemical analyses, including measurement of inflammatory cytokines, chemokines, and complement components in serum and CSF, may fur-ther characterize immune activation and peripheral nerve injury (10, 13, 95). Regarding the position-ing of serological biomarkers within current diagnostic algorithms, antiganglioside antibody testing is officially recognized as a supportive, secondary diagnostic tool rather than a mandatory criterion (2, 17). While their routine screening is highly recommended to narrow down specific clinical phe-notypes and differentiate GBS variants from other acute neuropathies, current management guide-lines emphasize that therapeutic interventions (such as IVIG or plasma exchange) should never be delayed while awaiting antibody test results (2, 5, 17). Interpretation of the results of these tests, however, requires careful consideration of diagnostic sensitivity and specificity, which vary dramat-ically depending on the GBS subtype (5). IgG anti-GQ1b antibodies demonstrate exceptional diag-nostic sensitivity (approximately 85%) and high specificity for MFS (5). In the case of primary de-myelinating variants, such as acute inflammatory demyelinating polyradiculopathy (AIDP), the clin-ical sensitivity of standard antiganglioside panels remains relatively low (approximately 40-60%). This means that a negative serological result cannot completely exclude the diagnosis of GBS (5, 69). However, when specific IgM anti-GM2 antibodies are detected in acute CMV infection or IgG an-ti-GM1/GD1a in axonal variants, such as AMAN, their diagnostic specificity confirms the GBS sub-type and helps determine the clinical prognosis (5, 17, 69). Modern laboratory diagnostics rely on integrating serological test results with patient clinical profiles. The complex relationships between viral etiology, clinical phenotype of GBS, and antiganglioside antibody profiles require a systematic diagnostic approach.

Complementary biochemical assays enhance diagnostic accuracy. Measurement of inflammatory cytokines, chemokines, and complement components in serum and CSF can provide mechanistic in-sight into virus-induced immune activation and PN injury (10, 13, 95). Elevated proinflammatory cytokines may facilitate leukocyte infiltration across the blood-nerve barrier and exacerbate demye-lination in VZV or influenza-associated GBS (15, 36). Immune complex deposition, particularly in hepatitis B and C infections, can be identified through laboratory detection of HBsAg or HCV-antigen complexes in serum and CSF, elucidating the pathway of T-cell dysregulation and an-tibody-mediated nerve injury (59, 69-71). Furthermore, the acute inflammatory cascade triggered by viral pathogens induces robust generation of reactive oxygen species (ROS), leading to significant oxidative stress that accelerates mitochondrial dysfunction and lipid peroxidation within peripheral myelin and axonal membranes (5, 8). New clinical studies highlight the significant role of structural biomarkers that reflect direct damage to PNs and axons in viral GBS (5, 8, 69). Among these, neuro-filaments, and especially tau protein, have gained importance as surrogate markers of axonal degen-eration and cytoskeletal damage resulting from intense autoimmune insults (17, 69). In patients with AMAN, significantly elevated concentrations of neurofilament light chain and tau in both CSF and serum correlate with the degree of PN damage and may serve as valuable indicators of long-term clinical outcome (2, 5, 69). Similarly, changes in peripherin, an intermediate filament protein ex-pressed primarily in peripheral neurons, reflect structural remodeling and stress responses of axonal networks during acute demyelinating or axonal attacks (7, 17). These structural biomarkers are now viewed as powerful research tools. Assessment of neurofilaments, peripherins, and tau protein pro-vides pathobiological information on the severity of virus-induced neurodegeneration and gives hope for the development of personalized prognostic algorithms in the future (2, 17, 69).

Finally, integrating laboratory findings into clinical decision-making is vital for optimizing patient outcomes. Combined interpretation of serology, PCR, antiganglioside antibodies, CSF biochemistry, and immune markers provides a robust framework for identifying virus-specific triggers, confirming GBS subtypes, and guiding timely interventions (16-21, 32-34, 85, 86). Early and precise laboratory evaluation allows clinicians to anticipate potential complications, select appropriate antiviral or im-munomodulatory therapy, and monitor neurological recovery, ultimately improving prognosis and reducing long-term disability. A summary of key biomarkers, recommended analytical methods, and diagnostic limitations for individual viral pathogens is presented in Table 1.

Associations between viral triggers, GBS clinical subtypes, and key anti-ganglioside anti-body profiles
Viral trigger Associated GBS subtype(s) Key antiganglioside antibodies
CMV AIDP, AMAN, Sensory GBS Anti-GM2 (IgM)
EBV AIDP, MFS Anti-GM1, Anti-GD1a
VZV AIDP, AMAN Anti-GM1, Anti-GD1b
HSV-1 AIDP, MFS Anti-GD1a, Anti-GQ1b (rare)
SARS-CoV-2 AIDP, AMAN, MFS Anti-GD1a, Anti-GM1
ZIKV AMAN (frequent autonomic dysfunction) Anti-GA1, Anti-GM1
Influenza virus AMAN, AIDP Anti-GM1, Anti-GD1a
HBV / HCV AIDP (associated with vasculitis) Anti-GM1 (rare)
HIV AIDP (seroconversion or IRIS) Anti-GM1, Anti-glycolipid complexes
CMV – Cytomegalovirus. EBV - Epstein-Barr virus. VZV - Varicella-zoster virus. HSV-1 - Herpes simplex virus type 1. SARS-CoV-2 - Severe acute respiratory syndrome coronavirus 2. ZIKV - Zika virus. HBV - Hepatitis B virus. HCV - Hepatitis C virus. HIV - Human immunodeficiency virus. AIDP - Acute inflammatory demyelinating polyneuropathy. AMAN - Acute motor axonal neuropathy. GBS - Guillain-Barré syndrome. MFS - Miller Fisher syndrome. IRIS - Immune reconstitution inflammatory syndrome. IgM - Immunoglobulin M. GM1, GM2, GD1a, GD1b, GQ1b, GA1 - Gangliosides (standard nomenclature).

In summary, laboratory diagnostics in virus-associated GBS are multifaceted, encompassing serolo-gy, molecular detection, antibody profiling, and immunochemical analysis. These methods not only confirm viral triggers but also elucidate the biochemical and immunopathogenic mechanisms under-lying PN injury, emphasizing their central role in research and clinical management of virus-induced neuropathies.

Discussion

The reviewed evidence suggests that viral infections can trigger GBS (7, 9, 12). However, a critical review of the current literature has shown that the clinical utility of laboratory markers remains in-consistent (11, 37, 49). Molecular mimicry is a widely accepted mechanism. A key challenge is the high heterogeneity of antibody responses. CMV-associated GBS often presents with IgM anti-GM2 antibodies, which strongly correlate with sensorimotor deficits and facial nerve paralysis, providing a reliable diagnostic link (9, 15, 51). In contrast, EBV-associated GBS lacks a single pathognomonic marker. It often demonstrates polyclonal B-cell activation, complicating differentiation from other postinfectious neuropathies (23, 94). Although SARS-CoV-2 has been associated with GBS, the role of direct neurotropism remains debated. Laboratory results often demonstrate elevated protein con-centrations in CSF (1, 58, 80). Unlike C. jejuni or CMV infections, antiganglioside antibody profiles are much less predictable in COVID-19 (67, 90).

Our analysis highlights the importance of identifying virus-specific markers and antiganglioside pro-files for differentiating GBS subtypes. The presence of anti-GQ1b antibodies in patients with oph-thalmoplegia and ataxia confirms the diagnosis of MFS, regardless of whether the trigger is HSV-1 or other pathogens (2, 5, 12). Axonal variants (AMAN/AMSAN) are more frequently associated with infections triggering anti-GM1 or anti-GD1a antibodies, often associated with ZIKV or CMV (37, 49, 80). However, clinical interpretation of these findings is often hampered by cross-reactivity and the transient nature of antibody titers. Future studies should focus on long-term monitoring of these bi-omarkers to determine their predictive value for treatment response (1, 58, 94). Integrating structural markers such as neurofilaments with traditional serological testing may provide a more robust framework for the treatment of patients with GBS, moving beyond a simple “positive/negative” di-agnosis towards a personalized, subtype-specific treatment strategy (1, 49, 67).

In conclusion, the primary finding of this review is that the viruses discussed can function as triggers for GBS. Impairment of the immune response, production of autoantibodies, molecular mimicry, and oxidative stress are likely mechanisms contributing to GBS onset. Several of the presented pathogens also exhibit neurotropic capabilities, facilitating direct or indirect nervous system injury. These ob-servations highlight the importance of considering recent viral infections in patients presenting with early neurological symptoms, enabling timely initiation of appropriate treatment, and potentially reducing the need for intensive care and complications such as respiratory failure. Although our un-derstanding of virus-associated GBS has advanced, many pathophysiological mechanisms remain incompletely elucidated, and optimal therapeutic strategies are still under investigation. Future re-search, including well-designed clinical studies, is essential to refine laboratory diagnostics, clarify immunopathogenic mechanisms, and improve prevention and management of GBS worldwide.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References ShahrizailaNLehmannHCKuwabaraS. Guillain-Barré syndrome. Lancet. 2021;397:1214–28. 10.1016/S0140-6736(21)00517-133647239 HughesRACCornblathDR. Guillain-Barré syndrome. Lancet. 2005;366:1653–66. 10.1016/S0140-6736(05)67665-916271648 YuRKUsukiSArigaT. Ganglioside molecular mimicry and its pathological roles in Guil-lain-Barré syndrome and related diseases. Infect Immun. 2006;74:6517–27. 10.1128/IAI.00967-0616966405 MalekpourMKhanmohammadiSMeybodiMJEShekouhDRahmanianMRKardehS COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism. Immun Inflamm Dis. 2023;11:e875. 10.1002/iid3.87537249286 WillisonHJJacobsBCvan DoornPA. Guillain-Barré syndrome. Lancet. 2016;388:717–27. 10.1016/S0140-6736(16)00339-126948435 VerzosaALMcGeeverLABharkSJDelgadoTSalazarNSanchezEL. Herpes Simplex Virus 1 Infection of Neuronal and Non-Neuronal Cells Elicits Specific Innate Immune Responses and Immune Evasion Mechanisms. Front Immunol. 2021;12:644664. 10.3389/fimmu.2021.64466434135889 BiesJJHassanMPrakashSPorres-AguilarMPeraltaDP. A Rare Association Between Herpes Simplex Virus Type 1 and Miller-Fisher Syndrome. Cureus. 2023;15:e38163. 10.7759/cureus.3816337252484 LamanJDHuizingaRBoonsGJJacobsBC. Guillain-Barré syndrome: expanding the con-cept of molecular mimicry. Trends Immunol. 2022;43:296–308. 10.1016/j.it.2022.02.00335256276 AlbertiCMolitiernoNIacobelliVVelardoDComiGPCortiS A rare association of Guillain-Barré syndrome/Miller-Fisher syndrome overlap syndrome and Herpes Simplex Virus Type 1 infection: trigger or exacerbating factor? Ther Adv Neurol Disord. 2024;17:17562864241297086. 10.1177/1756286424129708639628849 BalachandranNObaDEHutt-FletcherLM. Antigenic cross-reactions among herpes sim-plex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. J Virol. 1987;61:1125–35. 10.1128/jvi.61.4.1125-1135.19873029407 AlbertiCMolitiernoNIacobelliVVelardoDComiGPCortiS A rare association of Guillain-Barré syndrome/Miller-Fisher syndrome overlap syndrome and Herpes Simplex Virus Type 1 infection: trigger or exacerbating factor? Ther Adv Neurol Disord. 2024;17:17562864241297086. 10.1177/1756286424129708639628849 DiggikarPMPancholiTYammanuruBMundadaMRJ. Exploring Treatments for a Rare Guillain-Barré Variant: A Case Report of Miller-Fisher Syndrome. Cureus. 2024;16:e65561. 10.7759/cureus.6556139192912 AndreiGSnoeckR. Advances and Perspectives in the Management of Varicella-Zoster Virus Infections. Molecules. 2021;26(4):1132. [Pub-Med]10.3390/molecules2604113233672709 NerabaniYAtliAAHamdanOHajjar MwaffakAHaj HammadhNAHMarstawiH Guillain-Barré syndrome following varicella-zoster virus infection: a case report and systematic review. Ann Med Surg (Lond). 2023;85:5621–8. 10.1097/MS9.000000000000137037915710 OliverSLZhouMArvinAM. Varicella-zoster virus: molecular controls of cell fu-sion-dependent pathogenesis. Biochem Soc Trans. 2020;48:2415–35. 10.1042/BST2019051133259590 PomeroyCEnglundJA. Cytomegalovirus: epidemiology and infection control. Am J Infect Control. 1987;15:107–19. 10.1016/0196-6553(87)90164-73039875 SpagnoliCIodiceASalernoGGFrattiniDBertaniGPisaniF CMV-associated axonal sensory-motor Guillain-Barré syndrome in a child: Case report and review of the literature. Eur J Paediatr Neurol. 2016;20:168–75. 10.1016/j.ejpn.2015.11.00426621312 RodríguezYRojasMPachecoYAcosta-AmpudiaYRamírez-SantanaCMonsalveDM Guillain–Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol. 2018;15:547–62. 10.1038/cmi.2017.14229375121 Khalili-ShiraziAGregsonNGrayIReesJWinerJHughesR. Antiganglioside antibod-ies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry. 1999;66:376–9. 10.1136/jnnp.66.3.37610084538 SilvaCTSilvaSSilvaMJAlmeidaAFFonsecaJMeloC Guillain-Barré Syn-drome in a Teenage Girl: A Severe Case With Anti-GM2 Antibodies Associated With Acute CMV Infection and Literature Review. Clin Pediatr (Phila). 2020;59:300–4. 10.1177/000992281989818631888351 OrlikowskiDPorcherRSivadon-TardyVQuincampoixJCRaphaëlJCDurandMC Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis. 2011;52:837–44. 10.1093/cid/cir07421427390 KimSYChoeKWParkSYoonDOckCYHongSW Mild form of Guillain-Barré syndrome in a patient with primary Epstein-Barr virus infection. Korean J Intern Med. 2016;31:1191–3. 10.3904/kjim.2015.03326837010 Masajtis-ZagajewskaAMurasKMochecka-ThoelkeAKurnatowskaINowickiM. Guil-lain-Barré syndrome in the course of EBV infection after kidney transplantation--a case report. Ann Transplant. 2012;17:133–7. 10.12659/AOT.88346823018266 DowlingPCCookSD. Role of infection in Guillain-Barré syndrome: laboratory confirma-tion of herpesviruses in 41 cases. Ann Neurol. 1981;9 Suppl:44–55. 10.1002/ana.4100907096261680 JhaNKOjhaSJhaSKDurejaHSinghSKShuklaSD Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations. J Mol Neurosci. 2021;71:2192–209. 10.1007/s12031-020-01767-633464535 SriwastavaSKatariaSTandonMPatelJPatelRJowkarA Guillain Barré Syn-drome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series. J Neurol Sci. 2021;420:117263. 10.1016/j.jns.2020.11726333321326 MauryALyoubiAPeiffer-SmadjaNde BrouckerTMeppielE. Neurological manifesta-tions associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. Rev Neurol (Paris). 2021;177:51–64. 10.1016/j.neurol.2020.10.00133446327 SavelieffMGFeldmanELStinoAM. Neurological sequela and disruption of neuron-glia homeostasis in SARS-CoV-2 infection. Neurobiol Dis. 2022;168:105715. 10.1016/j.nbd.2022.10571535364273 AladawiMElfilMAbu-EshehBAbu JazarDArmoutiABayoumiA Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review. Can J Neurol Sci. 2022;49:38–48. 10.1017/cjn.2021.10233949300 AgostiEGiorgianniAD’AmoreFVinacciGBalbiSLocatelliD. Is Guillain-Barrè syn-drome triggered by SARS-CoV-2? Case report and literature review. Neurol Sci. 2021;42:607–12. 10.1007/s10072-020-04553-932643136 GigliGLBaxFMariniAPellitteriGScaliseASurcinelliA Guillain-Barré syn-drome in the COVID-19 era: just an occasional cluster? J Neurol. 2021;268:1195–7. 10.1007/s00415-020-09911-332430572 DirlikovEMajorCGMedinaNALugo-RoblesRMatosDMuñoz-JordanJL Clin-ical Features of Guillain-Barré Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016. JAMA Neurol. 2018;75:1089–97. 10.1001/jamaneurol.2018.105829799940 da SilvaIRFFronteraJABispo de FilippisAMdo NascimentoOJMRIO-GBS-ZIKV Re-search Group. Neurologic Complications Associated With the Zika Virus in Brazilian Adults. JAMA Neurol. 2017;74:1190–8. 10.1001/jamaneurol.2017.170328806453 Cao-LormeauVMBlakeAMonsSLastèreSRocheCVanhomwegenJ Guil-lain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387:1531–9. [Pub-Med]10.1016/S0140-6736(16)00562-626948433 CunninghamMW. Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae. Microbiol Spectr. 2019;7:10. 10.1128/microbiolspec.GPP3-0045-201831373269 CutilloGSaariahoAHMeriS. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cell Mol Immunol. 2020;17:313–22. 10.1038/s41423-020-0388-932152553 DiamondBHonigGMaderSBrimbergLVolpeBT. Brain-reactive antibodies and dis-ease. Annu Rev Immunol. 2013;31:345–85. 10.1146/annurev-immunol-020711-07504123516983 HughesRAC. Guillain-Barré syndrome: History, pathogenesis, treatment, and future direc-tions. Eur J Neurol. 2024;31:e16346. 10.1111/ene.1634638752584 GhaderiSGunnesNBakkenIJMagnusPTrogstadLHåbergSE. Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwe-gian population-based cohort study. Eur J Epidemiol. 2016;31:67–72. 10.1007/s10654-015-0047-026008750 LeeHKangHYJungSYLeeYM. Incidence of Guillain-Barré Syndrome Is Not Associated with Influenza Vaccination in the Elderly. Vaccines (Basel). 2020;8:431. 10.3390/vaccines803043132752037 AndaniAMellouKDewdaPEeuwijkJKassianosGVan DammeP Evolution and Impact of Hepatitis A Epidemiology in Europe-Systematic Literature Review of the Last 20 Years. J Viral Hepat. 2025;32:e14030. 10.1111/jvh.1403039526433 CastanedaDGonzalezAJAlomariMTandonKZervosXB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol. 2021;27:1691–715. 10.3748/wjg.v27.i16.169133967551 SalajeghehFShafieipourSNajminejadZPourzandPNakhaieMJahangiriS HAV-induced acalculous cholecystitis: A case report and literature review. Clin Case Rep. 2023;11:e7254. 10.1002/ccr3.725437113636 HofmeisterMGXingJFosterMAAugustineRJBurkholderCCollinsJ Factors Associated With Hepatitis A Mortality During Person-to-Person Outbreaks: A Matched Case-Control Study-United States, 2016-2019. Hepatology. 2021;74:28–40. 10.1002/hep.3164533217769 McMichaelAJBorrowPTomarasGDGoonetillekeNHaynesBF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010;10:11–23. 10.1038/nri267420010788 KadanaliAKizilkayaMTanHErolSTasyaranMAParlakM. An unusual presentation of hepatitis A virus infection: Guillain-Barré syndrome. Trop Doct. 2006;36:248. 10.1258/00494750677860470617034710 HuangCZhangYDengSRenYLuW. Trauma-Related Guillain-Barré Syndrome: Sys-tematic Review of an Emerging Concept. Front Neurol. 2020;11:588290. 10.3389/fneur.2020.58829033240210 DimachkieMMBarohnRJ. Guillain-Barré Syndrome and Variants. Neurol Clin. 2013;31:491–510. 10.1016/j.ncl.2013.01.00523642721 GhasemiABroomand LomerNSaberiA. Is there a link between Hepatitis A virus and Guillain-Barré syndrome? A systematic review of case reports. eNeurologicalSci. 2025;38:100551. 10.1016/j.ensci.2025.10055139866833 LeonhardSEMandarakasMRGondimFAABatemanKFerreiraMLBCornblathDR Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15:671–83. 10.1038/s41582-019-0250-931541214 VermaRChaudhariTSGiriP. Unilateral facial palsy in Guillain-Barre syndrome (GBS): a rare occurrence. BMJ Case Rep. 2012;2012:bcr2012007077. 10.1136/bcr-2012-00707723087283 OnoSChidaKTakasuT. Guillain-Barré syndrome following fulminant viral hepatitis A. Intern Med. 1994;33:799–801. 10.2169/internalmedicine.33.7997718965 ChitambarSDFadnisRSJoshiMSHabbuABhatiaSG. Case report: Hepatitis A preced-ing Guillain-Barré syndrome. J Med Virol. 2006;78:1011–4. 10.1002/jmv.2065616789022 AngCWJacobsBCLamanJD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol. 2004;25:61–6. 10.1016/j.it.2003.12.00415102364 di Filippo VillaDNavasMC. Vertical Transmission of Hepatitis B Virus-An Update. Microorganisms. 2023;11:1140. 10.3390/microorganisms1105114037317114 MaHYanQZMaJRLiDFYangJL. Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies. World J Gastroenterol. 2024;30:1295–312. 10.3748/wjg.v30.i10.129538596493 LoombaRLiangTJHepatitisB. Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152:1297–309. 10.1053/j.gastro.2017.02.00928219691 KongQXGaoZKLiuYJiangLLLiuYJLianZY. Explore genetic susceptibility associ-ation between viral infections and Guillain-Barré syndrome risk using two-sample Mendelian ran-domization. J Transl Med. 2024;22:890. 10.1186/s12967-024-05704-839358724 YimamKKMerrimanRBTodd FrederickR. A rare case of acute hepatitis B virus infec-tion causing guillain-barré syndrome. Gastroenterol Hepatol (N Y). 2013;9:121–3.23983658 ChenYZhangJChuXXuYMaF. Vaccines and the risk of Guillain-Barré syndrome. Eur J Epidemiol. 2020;35:363–70. 10.1007/s10654-019-00596-131858323 LubetzkiCStankoffB. Demyelination in multiple sclerosis. Handb Clin Neurol. 2014;122:89–99. 10.1016/B978-0-444-52001-2.00004-224507514 WeiJDuanS. Severe Guillain-Barré syndrome associated with chronic hepatitis B: A case report and literature review. Medicine (Baltimore). 2021;100:e27989. 10.1097/MD.000000000002798935049206 WekerleHLassmannH. The immunology of inflammatory demyelinating dis-ease. McAlpine’s. Mult Scler. 2006;491–555. 10.1016/B978-0-443-07271-0.50013-6 BaliliKLouhabNAdarmouchLChraaMHachimiABelbachirA Guillain–Barre syndrome: small-volume plasmapheresis versus intravenous immunoglobulin - 3rd level hospital experience. Egypt J Neurol Psychiatr Neurosurg. 2024;60:45. 10.1186/s41983-024-00820-0 ElgretliWChenTKronfliNSebastianiGHepatitisC. Virus-Lipid Interplay: Pathogene-sis and Clinical Impact. Biomedicines. 2023;11:271. 10.3390/biomedicines1102027136830808 MolokwuOYoungBMSinghMMenezesKMianR. Reactivation of Chronic Hepatitis C as a Potential Trigger for Guillain-Barré Syndrome. Cureus. 2019;11:e5244. 10.7759/cureus.524431565642 ComarmondCLorinVMarquesCMaciejewski-DuvalAJoherNPlanchaisC TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor au-toantibody responses. J Hepatol. 2019;71:908–19. [Pub-Med]10.1016/j.jhep.2019.06.02931279905 LingalaSGhanyMG. NATURAL HISTORY OF HEPATITIS C. Gastroenterol Clin North Am. 2015;44:717–34. 10.1016/j.gtc.2015.07.00326600216 van den BergBWalgaardCDrenthenJFokkeCJacobsBCvan DoornPA. Guil-lain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–82. 10.1038/nrneurol.2014.12125023340 BaileyJRBarnesECoxAL. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology. 2019;156:418–30. 10.1053/j.gastro.2018.08.06030268785 GorinJBMaloneDFGStrunzBCarlssonTAlemanSBjörkströmNK Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection. Sci Rep. 2020;10:2081. 10.1038/s41598-020-58768-z32034167 van den BergBvan der EijkAAPasSDHunterJGMaddenRGTio-GillenAP Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology. 2014;82:491–7. 10.1212/WNL.000000000000011124415572 ZhengXYuLXuQGuSTangL. Guillain-Barre syndrome caused by hepatitis E infec-tion: case report and literature review. BMC Infect Dis. 2018;18:50. 10.1186/s12879-018-2959-229357816 YukiNHartungHP. Guillain-Barré syndrome. N Engl J Med. 2012;366:2294–304. 10.1056/NEJMra111452522694000 KaidaKSonooMOgawaGKamakuraKUeda-SadaMAritaM GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome. Neurology. 2008;71:1683–90. 10.1212/01.wnl.0000335160.72184.7d19015484 KomagamineTYukiN. Ganglioside mimicry as a cause of Guillain-Barré syndrome. CNS Neurol Disord Drug Targets. 2006;5:391–400. [Pub-Med]10.2174/18715270677795076516918391 VarshneyANAnandRBhattacharjeeAPrasadPKumarNSinghNK. HIV seroconver-sion manifesting as Guillian-Barre syndrome. Chin Med J (Engl). 2014;127:396. 10.3760/cma.j.issn.0366-6999.2013133824438640 Bani-SadrFNeuvilleSCrassardIGuihotAMolinaJM. Acute Guillain-Barré syndrome during the chronic phase of HIV infection and dramatic improvement under highly active an-tiretroviral therapy. AIDS. 2002;16:1562. 10.1097/00002030-200207260-0001712131198 SchreiberALNorburyJWDe SousaEA. Functional recovery of untreated human immu-nodeficiency virus-associated Guillain-Barré syndrome: a case report. Ann Phys Rehabil Med. 2011;54:519–24. 10.1016/j.rehab.2011.09.00922036304 EkenzeOSOnwuekweIOEzeala AdikaibeBA. Profile of neurological admis-sions at the University of Nigeria Teaching Hospital Enugu. Niger J Med. 2010;19:419–22. 10.4314/njm.v19i4.6196721526631 SchleicherGKBlackAMochanARichardsGA. Effect of human immunodeficiency virus on intensive care unit outcome of patients with Guillain-Barré syndrome. Crit Care Med. 2003;31:1848–50. 10.1097/01.CCM.0000069516.81522.F412794429 HellmuthJFletcherJLKValcourVKroonEAnanworanichJIntasanJ Neurologic signs and symptoms frequently manifest in acute HIV infection. Neurology. 2016;87:148–54. 10.1212/WNL.000000000000283727287217 CoyleSCormackIS. Refractory HIV-Associated Guillain-Barré Syndrome Responsive to Antiretroviral Therapy: A Case Report. Case Rep Infect Dis. 2024;2024:7292001. 10.1155/crdi/729200139619280 VidalJEGuedesBFGomesHRMendonçaRH. Guillain-Barré syndrome spectrum as manifestation of HIV-related immune reconstitution inflammatory syndrome: case report and literature review. Braz J Infect Dis. 2022;26:102368. 10.1016/j.bjid.2022.10236835605654 PontaliEFeasiMCrisalliMPCassolaG. Guillain-Barré Syndrome with Fatal Outcome during HIV-1-Seroconversion: A Case Report. Case Rep Infect Dis. 2011;2011:972096. 10.1155/2011/97209622567484 KokotisPSchmelzMPapadimasGKSkopelitisEEAroniKKordossisT Poly-neuropathy induced by HIV disease and antiretroviral therapy. Clin Neurophysiol. 2013;124:176–82. 10.1016/j.clinph.2012.05.02222766629 WeiXDeckerJMWangSHuiHKappesJCWuX Antibody neutralization and escape by HIV-1. Nature. 2003;422:307–12. 10.1038/nature0147012646921 KanmogneGD. HIV Infection, Antiretroviral Drugs, and the Vascular Endothelium. Cells. 2024;13:672. 10.3390/cells1308067238667287 KanmogneGDPrimeauxCGrammasP. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun. 2005;333:1107–15. 10.1016/j.bbrc.2005.05.19815979050 CysiqueLABrewBJ. Comorbid depression and apathy in HIV-associated neurocognitive disorders in the era of chronic HIV infection. Handb Clin Neurol. 2019;165:71–82. 10.1016/B978-0-444-64012-3.00006-X31727231 BernelliCDanziGBCerratoEPieriniSOrnaghiMGBottaL Cardiovascular Events Recurrence and Coronary Artery Disease in HIV Patients: The Price We Have to Pay for the Chronicization of the Disease. Can J Cardiol. 2020;36:127–34. 10.1016/j.cjca.2019.07.63631813674 BicharaBRoutyJPEzerNCostiniukCT. Primary lung cancer diagnoses in people living with HIV in a large clinical centre in Montreal, Canada over 3 decades. AIDS Care. 2020;32:979–83. 10.1080/09540121.2020.175861432372653 ShepherdSJBlackHThomsonECGunsonRN. HIV positive patient with GBS-like syn-drome. JMM Case Rep. 2017;4:e005107. 10.1099/jmmcr.0.00510729026634 NtzioraFEuthimiouATektonidouMAndreopoulosAKonstantopoulosK. Guil-lain-Barre syndrome presenting with sensory disturbance following a herpes virus infection: a case report. J Med Case Rep. 2011;5:563. 10.1186/1752-1947-5-56322136568 WanninayakeLRajapakshaDNairNGunarathneKRanawakaU. Guillain-Barre syn-drome of acute motor axonal neuropathy (AMAN) type associated with herpes zoster: a case report. BMC Neurol. 2024;24:109. 10.1186/s12883-024-03607-138570806
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030502" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030502" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030502" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(83) "Viral triggers of Guillain-Barré syndrome: implications for laboratory diagnostics" ["journals_article_author"]=> string(142) "Karolina Kłodnicka, Jacek Januszewski, Magdalena Tyczyńska, Barbara Teresińska, Paulina Trzaskacz, Alicja Forma, Jolanta Flieger, Jacek Baj" ["journals_article_author_country"]=> string(6) "Poland" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(95) "antibodies, antiganglioside, Guillain-Barré syndrome, laboratory diagnostics, viral in-fection" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1008" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "3" ["meta_title"]=> string(83) "Viral triggers of Guillain-Barré syndrome: implications for laboratory diagnostics" ["meta_desc"]=> string(83) "Viral triggers of Guillain-Barré syndrome: implications for laboratory diagnostics" ["meta_keyw"]=> string(95) "antibodies, antiganglioside, Guillain-Barré syndrome, laboratory diagnostics, viral in-fection" ["created"]=> string(19) "2026-10-01 11:05:36" ["modified"]=> string(19) "2026-10-02 11:00:56" } [15]=> object(stdClass)#29 (35) { ["journals_id"]=> string(4) "1254" ["journals_xml"]=> string(256448) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030501 10.11613/BM.2026.030501 Reviews Laboratory diagnostics in personalised medicine - 36th Symposium of the Croatian society of medical biochemistry and laboratory medicine RogićDunja12ŠimičevićLivija*23ŽigmanTamara34BambirIvan45Vukić DugacAndrea356Tješić-DrinkovićDuška345 FumićKsenija12LehmanIvan45RakoIvana2PopovićMarina37GanociLana23ŽivkovićMaja38Mihaljević-PelešAlma38 Faculty of Pharmacy and Biochemistry, Zagreb, Croatia Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia School of Medicine, University of Zagreb, Zagreb, Croatia Department of Pediatrics, University Hospital Centre Zagreb, Zagreb, Croatia Cystic Fibrosis Centre for Children and Adults, University Hospital Centre Zagreb, Zagreb, Croatia Clinic for respiratory diseases Jordanovac, University Hospital Centre Zagreb, Croatia Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia Department of Psychiatry and Psychological Medicine, Zagreb University Hospital Centre, Zagreb, Croatia Corresponding author: livija.simicevic@kbc-zagreb.hr

Author contributions

D Rogić: Conceptualization, Supervision, Writing – review & editing; L Šimičević, T Žigman, I Bambir, A Vukić Dugac, D Tješić - Drinković, K Fumić, I Lehman, I Rako, M Popović, L Ganoci, M Živković, A Mihaljević-Peleš: Writing – Original Draft, Conceptualization, Writing – Review & Editing.

10082026 15102026 36 3 030501 0312202504062026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Personalised medicine tailors prevention, diagnosis, monitoring of disease progression, treatment, and treatment response to each patient

• Identifying genetic variants enables early detection and targeted therapy

• Gene-based therapies and newborn screening transform disease outcomes

• Advances in cancer genetics and pharmacogenomics guide safer and more precise care

• Laboratory diagnostics translates genomics into real clinical benefits

Personalised medicine has become a central paradigm in modern healthcare, aiming to tailor prevention, diagnosis, and therapy to each patient’s unique molecular and clinical profile. This paper provides a comprehensive overview of the lectures presented at the 36th annual Symposium of the Croatian society of medical biochemistry and laboratory medicine. It highlights key topics including the role of disease-causing variants in hereditary disorders, the development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, the evolution of newborn screening programs and spinal muscular atrophy diagnostics, emphasizing early detection and timely initiation of therapy, advances in cancer genetics, pharmacogenetics, and the translation of other laboratory-based innovations into clinical practice. Altogether, these advances reaffirm the central role of laboratory diagnostics as the cornerstone of personalised medicine, bridging genetic discovery with clinical translation and transforming modern healthcare into a predictive, preventive, and truly patient-centred discipline.

Keywords: precision medicinegenetic diseases, neoplastic syndromespharmacogenomicsnewborn screening
Introduction

Personalised medicine has become a central paradigm in modern healthcare, aiming to tailor prevention, diagnosis, and treatment to each patient’s unique molecular and clinical profile (1). Hereditary disorders clearly illustrate this progress: detecting disease-causing variants allows precise risk assessment, presymptomatic diagnosis, and targeted therapeutic strategies (2). In terms of outcome modifications, an excellent example is development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators which shows how innovative therapies can fundamentally alter a disease’s course-turning cystic fibrosis from an inevitably fatal childhood disorder into a manageable chronic condition (3). Traditionally based on biochemical assays, newborn screening programs are now adopting genomic technologies. This shift enables presymptomatic diagnosis and treatment of conditions such as spinal muscular atrophy, where early intervention markedly improves survival and motor function (4, 5). Similarly, advances in cancer genetics have revealed how germline mutations in cancer susceptibility genes are associated with cancer risk, enabling risk-appropriate screening and management recommendations, and how the synergy between germline and somatic mutations drives hereditary malignancies.

Precision oncology now applies molecular profiling to match patients with targeted therapies and innovative clinical trials (6, 7). Pharmacogenomics further advances personalization by guiding therapy selection, predicting drug response and toxicity, and integrating complex drug-gene-environment interactions into routine clinical practice (8, 9).

Hereditary disorders – Yesterday, today, and tomorrow

Over the past few decades, rapid advances in gene analysis technologies have transformed research into genetic disorders-uncovering their molecular mechanisms and enabling precise diagnostic and prognostic testing. Our understanding of these conditions has deepened in parallel with advances in genetics and molecular biology. Key milestones in the development of genetic technologies are shown in Table 1. The study of hereditary disorders dates back to the 19th century, when Gregor Mendel, often regarded as the father of genetics, described the principles of inheritance through experiments on pea plants. However, a real understanding of the molecular basis of inheritance emerged in the mid-20th century. A key milestone was the discovery of deoxyribonucleic acid (DNA) structure in 1953 by James Watson and Francis Crick. This breakthrough was based on X-ray crystallography data previously obtained by Rosalind Franklin (10, 11). Watson and Crick received the Nobel Prize in Physiology for this discovery. Uncovering the double-helix DNA structure made it possible to understand how genetic information is stored and transmitted. In the following decades, scientists identified numerous genes related to hereditary diseases, such as cystic fibrosis, Huntington’s disease, thalassemia, sickle cell disease, phenylketonuria, and spinal muscular atrophy. Traditional methods such as Sanger sequencing, while accurate, were slow and limited in throughput (12). At the beginning of the 21st century, a revolution in genetics came with next-generation sequencing (NGS), which allows millions of DNA fragments to be read simultaneously. This made it technically feasible and financially accessible to analyse parts of the genome or even whole genomes. As a result, diagnosing rare hereditary diseases, discovering new genes and mutations, and understanding the genetic basis of complex disorders became much more achievable. The speed, sensitivity, and decreasing costs of these methods have made them the foundation of modern genetic diagnostics and research (13). Today, hereditary disorders are recognized as an important public health issue. People with a genomic predisposition to certain diseases, such as hereditary breast cancer, can take preventive measures early. Prenatal diagnostics and preimplantation genetic testing also allow for the detection of hereditary diseases even before birth. Gene therapy has emerged as one of the most promising areas of development, aiming to correct or replace faulty genes. New technologies, for example, clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) offer the potential for precise genome editing but also raise important ethical questions (14). For now, treatments using these technologies are not part of routine clinical practice and remain largely within the realm of scientific research. Genomic newborn screening (gNBS) is also on the horizon, allowing for the detection of genetic variants associated with serious but potentially treatable hereditary diseases before clinical symptoms appear. While it improves diagnostic sensitivity compared to standard techniques, its implementation requires careful consideration of legal, ethical, and social issues. This includes informed consent, protection of genetic data, and especially the clinical interpretation of variants of uncertain significance (15). Looking ahead, further advancements in personalised medicine are expected, with therapies tailored to patients’ individual genetic profiles. The digital analysis of large genetic datasets, combined with artificial intelligence, will help predict disease risk and guide the selection of the most effective therapies for newly diagnosed patients (16). Through real-world examples of diagnostics and treatment, this review highlights the benefits achieved through the remarkable progress in genetics over the past two decades.

Key milestones in the development of genetic technologies
Time Period Technology / Discovery Significance
1860s Mendel’s laws of inheritance Foundation of modern genetics
1953 Discovery of DNA structure Understanding storage and transmission of genetic information
1977 Sanger DNA sequencing First accurate method for reading DNA sequences
1990 – 2003 Human Genome Project Complete mapping of the human genome
2005 – present NGS Fast, cost-effective genome analysis
From 2012 CRISPR-Cas9 genome editing Precise genome modification; potential therapeutic applications
2020s gNBS, AI in genomics Early diagnosis, personalised medicine, data-driven treatment decisions
AI - Artificial intelligence. CRISPR-Cas9 - clustered regularly interspaced short palindromic repeats-associated protein 9. DNA - deoxyribonucleic acid. gNBS - genomic newborn screening. NGS - next-generation sequencing.
Cystic fibrosis and CFTR modulators – New drugs, new disease?

Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by pathogenic variants in the CFTR gene which encodes the CFTR chloride channel protein. This defect leads to abnormal mucus production and results in a multisystem disease, with progressive lung failure being the leading cause of mortality among CF patients. Cystic fibrosis transmembrane conductance regulator dysfunction produces thickened secretions that primarily affect the lungs but also involve the pancreas and other organs (12).

Until recently, CF therapy focused on symptomatic treatment without targeting the underlying protein defect. Symptomatic treatment, including airway clearance techniques, pancreatic enzyme replacement, and antibiotics, has significantly improved survival but could not fully prevent ongoing lung damage and disease progression (13).

Following the discovery of the CFTR gene and its pathogenic variants, years of research led to the development of targeted therapies known as CFTR modulators. Cystic fibrosis transmembrane conductance regulator modulators are innovative therapies that act directly on the defective CFTR protein to restore its function, addressing the root cause of the disease rather than its consequences. Key CFTR modulators include ivacaftor, the dual combinations lumacaftor-ivacaftor and tezacaftor-ivacaftor, and the triple combinations elexacaftor-tezacaftor-ivacaftor and vanzacaftor-tezacaftor-deutivacaftor (Table 2). The triple combination therapy has been a major breakthrough, showing efficacy in approximately 90% of CF patients with eligible CFTR mutations, especially those with the CFTR F508del variant (NM_000492.4:c.1521_1523delCTT; p.Phe508del). Clinical trials and real-world data have demonstrated significant improvements in lung function, a decrease in pulmonary exacerbations, better nutritional status, and enhanced quality of life. Decreased sweat chloride levels, an important biomarker, indicate restored CFTR function. Moreover, early introduction of therapy may alter the natural course of CF and improve long-term outcomes (14, 15).

Overview of cystic fibrosis transmembrane conductance regulator modulators: mechanism of action, target mutations and European medicines agency - approved age indications
CFTR modulator Type Mechanism of action Targeted mutations Indicated age for therapy (EU/EMA)*
Ivacaftor (Kalydeco) Potentiator Increases CFTR channel opening probability Gating mutations (e.g. G551D) > 4 months
Lumacaftor–Ivacaftor (Orkambi) Corrector + potentiator† Improves CFTR foldingand channel gating Homozygous F508del‡ > 2 years
Tezacaftor–Ivacaftor (Symkevi) Corrector + potentiator Improves CFTR processing and gating Homozygous F508del or one responsive mutation > 6 years
Elexacaftor–Tezacaftor–Ivacaftor (Kaftrio) Tripletherapy Two correctors plus one potentiator;significantly improves CFTR function ≥ 1 F508del allele > 2 years
Vanzacaftor–Tezacaftor–Deutivacaftor(in clinical trials) Tripletherapy(next-generation) Enhanced potency and improved pharmacokinetics ≥ 1 F508del and other mutations(pending approval) In clinicaltrials
Commercial brand names are provided in parentheses. *Indicated age refers to the minimum approved age for therapy according to the European medicines agency (EMA). †Potentiators increase the open probability of the CFTR channel at the cell surface, whereas correctors improve CFTR protein folding, processing and trafficking to the plasma membrane. ‡F508del refers to the CFTR variant NM_000492.4:c.1521_1523delCTT (p.Phe508del), the most common pathogenic mutation in cystic fibrosis. CFTR - cystic fibrosis transmembrane conductance regulator.

The remarkable improvements in clinical outcomes achieved with CFTR modulators have led some experts to define cystic fibrosis as a “new disease”. Although the prognosis of CF has improved significantly, new challenges have emerged, such as long-term drug safety, high treatment costs, and treatment adherence (16).

Croatia is among European countries with a high prevalence of CFTR F508del variant, present in approximately 70-80% of CF alleles, making the majority of Croatian patients eligible for CFTR modulator triple therapy. These modulators have been introduced into clinical practice in Croatia since autumn 2021. According to national data, patients on triple therapy have shown significant improvements in both clinical outcomes and quality of life (17-19). Current national priorities for CF therapy include expanding eligibility for the triple combination of elexacaftor, tezacaftor, and ivacaftor to younger age groups and introducing vanzacaftor/tezacaftor/deutivacaftor into Croatian clinical practice.

Newborn screening in the era of personalised medicine

A novel approach in medicine is focused on the specific needs of each patient and is described by the term “P4 medicine” (predictive, preventive, personalised, participatory). This concept is based on understanding an individual’s genetic features, biomarkers, environmental, and lifestyle factors (20). This knowledge enables clinicians to select the most appropriate preventive or therapeutic approach at the optimal time. At the same time, an increasing number of novel therapeutic options are becoming available for rare diseases, including gene therapies that are already in routine use for certain diseases. However, these therapies are most effective when started early-ideally during the presymptomatic phase of the disease (21).

Newborn screening (NBS) from dried blood spots (DBS) is a diagnostic approach widely recognized as one of the greatest achievements of modern public health, particularly in rare diseases (22). The fundamental goal of NBS is the early identification of newborns with rare monogenic disorders for which treatment exists and where early intervention reduces morbidity and mortality. For decades, Wilson and Jungner’s principles guided decisions on which diseases to include in NBS programs (23). However, advances in technology and clinical practice have required modifications to these historic criteria (24, 25). The number of disorders included in NBS programs differs between countries and may now reach up to 50, depending on local policies (26). In Croatia, NBS was first introduced in 1978 with screening for phenylketonuria, followed by congenital hypothyroidism seven years later. Since 2017, tandem mass spectrometry (MS/MS) has been used in the Croatian NBS program, expanding screening to eight rare diseases. In 2023, molecular technologies were introduced, enabling screening for spinal muscular atrophy (SMA). An overview of the development of NBS in Croatia is presented in Table 3.

Milestones in the implementation of newborn screening in Croatia
Year Test/Condition introduced* Technology used†
1978 Phenylketonuria Biochemical test from DBS
1985 Congenital hypothyroidism Hormone analysis
2017 Eight rare diseases Tandem mass spectrometry
2023 Spinal muscular atrophy Molecular methods (PCR)
2023 Expanded Croatian NBS panel Customized NGS panel(confirmatory testing)
*Refers to the condition(s) newly included in the national newborn screening (NBS) programme in the specified year. †Technology primarily used for screening or confirmatory testing at the time of implementation. DBS - dried blood spots. NBS - newborn screening. NGS - next-generation sequencing. PCR - polymerase chain reaction.

Tandem mass spectrometry enables rapid detection of numerous metabolites in DBS and has transformed NBS from single-disease testing into a platform capable of identifying more than 40 conditions simultaneously. Today, MS/MS is widely used as a first-tier test for inborn errors of metabolism (IEM). Nevertheless, it has well-known limitations, including sensitivity to sample quality, the risk of false-positive and false-negative results, and the inability to detect disorders without measurable metabolite changes in blood (27). The strengths and limitations of different NBS technologies are summarized in Table 4.

Technologies in newborn screening – advantages, limitations and clinical applications
Technology Advantages Limitations* Application
MS/MS Rapid multi-metabolite analysis;detects > 40 conditions simultaneously Sample-quality sensitive;risk of FP/FN results;limited to metabolite-detectable disorders IEM,first-tier NBS
gNBS (PCR, MLPA, ddPCR) Direct variant detection;fast and precise Limited to predefined target genes; requires prior assay validation SMA, SCID
NGS Wide gene–disease coverage (~480 genes) High cost;challenges in VUS interpretation;requires advanced bioinformatics expertise Confirmatory testing after positive NBS results
Untargeted metabolomics Discovery of novel biomarkers; deeper phenotypic insight Lack of standardization; requires extensive clinical validation Potential future application
*These represent potential limitations of screening technologies, reflecting the possibility of incorrect classification due to analytical constraints, biological variability, or incomplete genomic coverage. ddPCR - droplet digital polymerase chain reaction. FP - false positive. FN - false negative. gNBS - genomic newborn screening. IEM - inborn errors of metabolism. MLPA - multiplex ligation-dependent probe amplification. MS/MS - tandem mass spectrometry. NBS - newborn screening. NGS - next-generation sequencing. PCR - polymerase chain reaction. SCID - severe combined immunodeficiency. SMA - spinal muscular atrophy. VUS - variant of uncertain significance.

The extraction of genetic material from DBS has enabled gNBS, now widely adopted in Europe as a first- or second-tier test for SMA and severe combined immunodeficiency. Methods used include real-time polymerase chain reaction (PCR), digital droplet PCR, and multiplex ligation-dependent probe amplification (28). In parallel, the development of NGS has accelerated progress in genetics. Following positive biochemical screening results, a customized NGS panel is now used as a confirmatory diagnostic test for all disorders included in the Croatian NBS program (29).

In the current era of genomic medicine, NBS faces new challenges. The gNBS could significantly expand the number of screened conditions if used as a first-tier test, while reducing false positives, shortening diagnostic times, improving predictive values, and broadening clinical utility (30). Several international pilot studies are evaluating the feasibility of gNBS panels, which typically include a median of 480 gene-disease associations (31). However, broader screening does not automatically mean a better NBS program. Integration of molecular technologies into NBS offers numerous advantages, but also raises questions such as legal and ethical concerns, interpretation of results, and infrastructural requirements, as summarized in Table 5. There is also a need for effective systems for long-term follow-up and care for persons diagnosed with a genetic condition through NBS (32).

Challenges in integrating genomic newborn screening into clinical practice in Croatia
Category Key challenges
Ethical and legal Data privacy in Croatia; informed consent procedures; potential psychological impact on families; long-term storage and secondary use of genomic data
Interpretation Need for additional training of healthcare professionals; standardization of sequencing workflows; quality control; interpretation of VUS; reporting of predisposition genes
Infrastructure Investment in laboratory and bioinformatics capacity; establishment of multidisciplinary teams; development of long-term clinical follow-up systems
Societal Public and patient engagement; acceptance of genomic technologies; cost considerations and equity of access
The listed challenges reflect current organizational, regulatory and infrastructural aspects relevant to the implementation of genomic newborn screening within the Croatian national healthcare system, based on available national programme data and implementation experience. VUS - variant of uncertain significance.

At the same time, untargeted metabolomics using quadrupole time-of-flight (Q-TOF) or tandem Orbitrap instruments is emerging as a complementary approach. This approach offers greater insights into phenotypes of disease and can detect novel and known disease biomarkers. However, current methods still need comprehensive validation and careful selection of clinically significant biomarkers for examination (33).

Today and in the near future, designing an effective NBS demands strategic combination of advanced metabolomics with biochemical methods, and genomic technologies in standardized protocols. Such approaches also require the availability of appropriate therapeutic options for the screened diseases. Current consensus suggests that the introduction of genomic methods into NBS should be justified only for disorders with early childhood onset and for diseases with effective treatments that can cure, prevent, or slow disease progression (34, 35). The future direction of NBS is closely linked to personalised medicine, integrating genetic findings into individualized treatment and follow-up strategies for each infant. It will require integration of NBS with health information systems, artificial intelligence systems, and longitudinal follow-up of infants identified through NBS to track their long-term health outcomes and treatment effectiveness. The multi-omics approach offers exciting potential to expand the scope of NBS programs in the future (36).

Along with this new potential, sustaining, and advancing NBS programs present an ongoing challenge. Despite all current and future technological possibilities, the benefits of NBS for the child must always outweigh the risks. Any revision of NBS criteria should include medical, legal, ethical, and social considerations. Furthermore, it should engage patients, key stakeholders, and the wider community.

Spinal muscular atrophy in newborn screening - Treatment advantages

Spinal muscular atrophy shows how NBS programmes can improve disease outcomes through early treatment initiation (29, 37). It is a severe neuromuscular disorder most often caused in about 95% of cases by homozygous deletion of the SMN1 gene, and is characterized by high morbidity and mortality, particularly in its most severe form – Type 1 (38, 39). The introduction of disease-modifying therapies has revolutionised the therapeutic landscape of SMA, shifting the focus from palliative care to a promising curative strategy when treatment begins before symptom onset (40, 41). Implementing NBS for SMA enables early identification of affected infants before symptoms appear, providing a unique opportunity for early medical intervention (29, 37). Presymptomatic therapy yields the best outcomes, as motor neurons remain responsive to therapy before irreversible damage occurs (42, 43).

Revolutionary therapeutic landscape

Three ground-breaking therapies have transformed outcomes for SMA patients: nusinersen, onasemnogene abeparvovec, and risdiplam (40, 42, 43). Each therapy targets the core pathophysiology of SMA. Nusinersen, administered intrathecally, is an antisense oligonucleotide that modulates SMN2 pre-mRNA splicing to enhance the synthesis of functional SMN protein (40, 44). Clinical studies show remarkable efficacy when initiated presymptomatically, with patients achieving motor milestones that sharply contrast with the natural history (40, 42). The NURTURE study reported 100% survival without permanent ventilation and near-normal motor development in most participants treated presymptomatically (40, 45). Onasemnogene abeparvovec, the first gene therapy for SMA, delivers a functional SMN1 gene copy via an adeno-associated virus vector; when administered presymptomatically, infants reach milestones typically unattainable in untreated SMA Type 1 (43). Risdiplam is an orally administered small molecule that enhances SMN2 pre-mRNA splicing and increases production of functional SMN protein. Its oral bioavailability and favourable safety profile support long-term therapy, with best results when started presymptomatically (40, 43). The three available disease-modifying therapies are summarised in Table 6.

Disease-modifying therapies for spinal muscular atrophy
Therapy Type Drug administration* Mechanismof action Keyevidence†
Nusinersen Antisense oligonucleotide Intrathecal injection Modification of SMN2 pre-mRNA splicing leading to increased production of functional SMN protein NURTURE study: presymptomatically treated infants showed survival and attainment of motor milestones not typically observed in untreated SMA type 1
Onasemnogene abeparvovec Gene therapy Intravenous infusion (single dose)‡ AAV9-mediated delivery of a functional SMN1 gene resulting in increased SMN protein expression Presymptomatic infants achieved major motor milestones rarely observed in untreated SMA type 1
Risdiplam Small molecule Oral administration Modification of SMN2 splicing resulting in increased systemic SMN protein levels Demonstrated sustained motor function improvement, with greatest benefit when initiated presymptomatically
*Drug administration indicates the route and mode of delivery used in clinical practice. †Key evidence summarizes findings from pivotal clinical trials supporting the efficacy of early or presymptomatic treatment. ‡ “Single dose” refers to one-time systemic gene replacement therapy administered as a single intravenous infusion. AAV9 - adeno-associated virus vector 9. SMA - Spinal muscular atrophy. SMA type 1 - most severe early-onset form of SMA characterized by symptom onset in infancy and rapid motor neuron degeneration. SMN - Survival motor neuron.

The advantage of presymptomatic over symptomatic treatment is substantial and consistent across all available therapies (40, 42). Natural history studies show that patients with SMA Type 1 rarely achieve independent sitting, with a median survival without ventilatory support of ~10.5 months (38). In contrast, presymptomatically treated patients frequently achieve independent sitting, standing, and even walking (40, 42, 43). Long-term follow-up confirms durable benefits: treated patients show normal growth, preserved swallowing, fewer respiratory complications, and markedly improved quality of life (43, 46, 47). While symptomatic patients may respond, they seldom reach the developmental milestones seen with presymptomatic treatment (40, 42). The therapeutic window is therefore critical; delays in therapy initiation can compromise outcomes (41-43). A comparison of natural history versus presymptomatic outcomes is shown in Table 7.

Clinical outcomes in spinal muscular atrophy: natural history <italic>vs.</italic> presymptomatic treatment
Outcome Natural history(SMA Type 1) Presymptomatictreatment*
Survival Median survival 10.5 months without permanent ventilatory support > 95% survival without need for permanent ventilation
Motor milestones Independent sitting rarely achieved Independent sitting, standing and walking frequently achieved when treatment is initiated presymptomatically
Respiratory function Recurrent infections and early respiratory failure Preserved respiratory function with fewer complications
Quality of life Severe motor disability and high caregiver burden Improved growth and swallowing, reduced disease burden and better family well-being
This comparison summarizes published evidence on the natural history of untreated SMA type 1 and outcomes observed in infants receiving disease-modifying therapy initiated during the presymptomatic stage (46,47). Outcomes are based on clinical trial and observational cohort data demonstrating substantially improved survival and motor development with early treatment. SMA - spinal muscular atrophy.

The Croatian SMA NBS pilot study, conducted at the University Hospital Centre Zagreb, established a clinical pathway from screening-to-treatment (29). During one year of the study, five SMA patients were identified among 32,655 screened newborns. All five patients immediately received specialised neuromuscular evaluation and rapid therapy introduction. The success of the pilot study is reflected both in analytical performance and in the clinical outcomes achieved through early therapy initiation. All infants identified in the first year began treatment before symptom onset, with constant monitoring demonstrating preserved motor function and age-appropriate milestones (29). This real-world experience verifies the benefits of presymptomatic treatment observed in clinical trials (40, 42, 43). The multidisciplinary approach ensures a seamless transition from screening to treatment and serves as an outline for effective clinical implementation (29). The Croatian pilot results are summarised in Table 8.

Croatian spinal muscular atrophy newborn screening pilot study (2022–2023)
Parameter Results
Period 1 year
Number of newborns screened 32,655
SMA patients identified 5
Time of diagnosis Before symptom onset
Intervention Immediate specialist evaluation plus early therapy
Outcome Preserved motor function; age-appropriate milestones
This table summarizes the initial real-world outcomes of implementing newborn screening for spinal muscular atrophy, demonstrating early identification of affected infants and timely initiation of therapy prior to symptom onset, which is associated with improved motor development and clinical prognosis. The data reflect results from the national newborn screening programme in Croatia during the first year of SMA screening implementation (29). SMA - spinal muscular atrophy.

Furthermore, newborn screening supports a personalised-medicine approach that integrates genetic and clinical factors. Examination of SMN2 gene copy number leads treatment intensity, as fewer copies generally predict more severe disease type (39, 44). Newly developed assessment tools, including motor scales for presymptomatic infants and biomarkers such as compound muscle action potentials, enable accurate monitoring of treatment response and disease progression (40, 42).

Economic and societal impact

Patients treated presymptomatically require fewer hospitalisations, fewer respiratory interventions, and less supportive care than those treated after symptom onset (40, 46). Preservation of motor function mitigates long-term disability-related costs and extends productive years of life. Family quality of life improves substantially with presymptomatic therapy, reducing caregiver burden and enhancing family functioning (46).

Addition of SMA to the existing national screening programme in Croatia, together with modern SMA treatments, demonstrates precision medicine in action: early recognition leads to transformative clinical outcomes (40, 41, 43). The results of the Croatian pilot study confirm that well-organised screening-to-treatment pathways deliver the benefits of presymptomatic intervention in real-world clinical practice (29). The body of evidence supports NBS for SMA as a vital component of comprehensive care, ensuring affected infants receive life-changing therapies at the optimal time (40, 42, 43).

Hereditary malignant diseases

Hereditary malignant diseases often present as hereditary cancer syndromes (HCSs), groups of cancers caused by inherited, germline pathogenic variants that typically follow recognizable clinical patterns and affect multiple organs. Rare congenital disorders, such as Bloom syndrome, Fanconi anemia, and ataxia-telangiectasia, show broader multi-organ involvement and are usually inherited in an autosomal-recessive pattern, caused by biallelic mutations in DNA-repair genes. These often present with immunodeficiency and early-onset cancers (48, 49). In contrast, most individuals with HCSs appear clinically healthy, except for an increased lifetime cancer risk due to inherited germline pathogenic variants (GPVs) in key genes such as tumour suppressors, oncogenes, or mismatch repair (MMR) genes. These GPVs typically follow autosomal dominant inheritance, with a 50% chance of transmission. Although a single inherited GPV does not directly cause cancer because cellular repair mechanisms remain intact, only a few additional somatic mutations are needed to trigger malignant transformation, leading to earlier cancer onset than in the general population.

Hereditary cancer syndromes account for about 10% of all malignancies, yet many remain undiagnosed. Common indicators include early-onset cancers, multiple primary tumours, family history, and rare presentations like male breast cancer (50-52).

Most HCS-related genes are tumour suppressors (e.g., BRCA1 – breast cancer 1; BRCA2 – breast cancer 2; MLH1 – mutL homolog 1; MSH2 – mutS homolog 2; RB1 – RB transcriptional corepressor 1), where cancer typically develops after a “second hit” inactivates the remaining functional allele. A smaller number of HCSs involve inherited activating mutations in oncogenes, such as RET (ret proto-oncogene receptor tyrosine kinase) in multiple endocrine neoplasia types 2A and 2B (53). A single gene can predispose to several cancer types, while the same cancer may arise from mutations in different genes (Table 9). For example, GPVs in MMR genes cause Lynch syndrome (colorectal, endometrial, ovarian, gastric cancers), while TP53 (tumour protein p53) and CHEK2 (checkpoint kinase 2) genes are linked to Li-Fraumeni syndrome (leukaemia, breast cancer, sarcoma, brain tumours). Pathogenic variants in the BRCA1 and BRCA2 gene are responsible for hereditary breast and ovarian cancer syndrome, increasing the risk of breast, ovarian, prostate, and pancreatic cancers. Beyond BRCA1 and BRCA2, variants in genes like ATM (ataxia-telangiectasia mutated), PALB2 (partner and localizer of BRCA2), BRIP1 (BRCA1 interacting helicase 1), STK11 (serine/threonine kinase 11), and NBN (nibrin) also contribute to a moderate hereditary predisposition for breast cancer (51, 52).

Hereditary cancer predisposition syndromes in clinical oncology
Syndrome Tumour type Mode of inheritance Genes
Hereditary breast cancer and ovarian cancer syndrome Breast cancerOvarian cancerProstate cancerPancreatic cancer Dominant BRCA1BRCA2
Fanconi anemia/medulloblastoma Recessive BRCA2
HNPCC,including ‘‘Lynch II’’ syndrome Colon cancerEndometrial cancerOvarian cancerRenal pelvis cancersUreteral cancersPancreatic cancerStomach and small bowel cancersHepatobiliary cancers Dominant MLH1MSH2MSH6
Li-Fraumeni Syndrome Soft tissue sarcomaBreast cancerOsteosarcomaLeukaemia,Brain tumoursAdrenocortical carcinoma Dominant TP53CHEK2
Cowden Syndrome Breast cancerThyroid cancerEndometrial and other cancers Dominant PTEN
FAP, AFAP Colon cancer Dominant APC
MAP Colon cancer Recessive MUTYH
Hereditary gastric cancer Stomach cancers Dominant CDH1
Juvenile polyposis Gastrointestinal cancersPancreatic cancer Dominant SMAD4BMPR1A
Peutz-Jeghers syndrome Colon cancerSmall bowel cancerBreast cancerOvarian cancerPancreatic cancer Dominant STK11
Familial gastrointestinal stromal tumour Gastrointestinal stromal tumours Dominant KIT
Hereditary melanoma pancreatic cancer syndrome Pancreatic cancerMelanoma Dominant CDKN2A
Bloom syndrome LeukaemiaCarcinoma of the tongueSquamous cancersWilms’ tumourColon cancer Recessive BLM
Nijmegen breakage syndrome LymphomaGliomaMedulloblastoma Rhabdomyosarcoma Recessive NBS1
Retinoblastoma RetinoblastomaOsteosarcoma Dominant RB1
Hereditary paraganglioma Paraganglioma Pheochromocytoma Dominant SDHDSDHCSDHB

This table provides a selective overview of clinically relevant hereditary cancer predisposition syndromes in oncology and is not intended to represent an exhaustive list of all known syndromes.

AFAP - attenuated familial adenomatous polyposis. APC - adenomatous polyposis coli. BLM - Bloom syndrome RecQ like helicase. BMPR1A - bone morphogenetic protein receptor type 1A. BRCA1 - breast cancer 1. BRCA2 - breast cancer 2. CDH1 - cadherin 1. CDKN2A - cyclin-dependent kinase inhibitor 2A. CHEK2 - checkpoint kinase 2. FAP - familial adenomatous polyposis. HNPCC - hereditary nonpolyposis colorectal cancer. KIT - KIT proto-oncogene receptor tyrosine kinase. MAP - MUTYH-associated polyposis. MLH1 - mutL homolog 1. MSH2 - mutS homolog 2. MSH6 - mutS homolog 6. MUTYH - mutY DNA glycosylase. NBN (NBS1) - nibrin. PTEN - phosphatase and tensin homolog. RB1 - RB transcriptional corepressor 1. SDHB - succinate dehydrogenase complex iron sulfur subunit B. SDHC - succinate dehydrogenase complex subunit C. SDHD - succinate dehydrogenase complex subunit D. SMAD4 - SMAD family member 4. STK11 - serine/threonine kinase 11. TP53 - tumour protein p53.

It is important to emphasize that individuals do not inherit cancer itself but rather GPVs in specific genes that increase susceptibility to certain tumour types. These variants are classified according to their penetrance into high, moderate and low-risk categories. High-risk (highly penetrant) genes, such as BRCA1, BRCA2, MLH1, MSH2, MSH6, APC and TP53, are linked with HCSs such as HBOC, Lynch syndromes, FAP and Li-Fraumeni syndrome. Individuals with GPVs in these genes may have a 5 to 50-fold increased risk compared to the general population. Moderate-risk genes, including ATM, BRIP1, CHEK2 and PALB2, give a 1.5 to 5-fold increased cancer risk. Low-risk variants, while individually associated with only a slight increase in risk (up to 1.5-fold), are common in the population, and their cumulative effect may be clinically relevant (54).

The molecular basis of hereditary malignant diseases lies in GPVs within the genome that affect gene function or expression. The American college of medical genetics (ACMG) has established a five-tier system classifying genetic variants: pathogenic (P), likely pathogenic (LP), of uncertain significance (VUS), likely benign (LB), and benign (B) (55). In oncology, the International Agency for research on cancer (IARC) further refines this by applying quantitative probability thresholds to assess disease causality (Table 10) (56). These classification schemes lead the clinical interpretations of genetic results. Gene variants graded as P or LP are counted as clinically actionable, they give information about treatment and disease-specific surveillance. However, VUSs are still a key challenge due to their doubtful impact on gene function and risk of disease. Continuous follow-up and genetic counselling are therefore essential for such patients so determination of VUS clinical relevance over time can be done. The cancer development has a multifactorial basis, individuals with suspected HCSs are recommended to take genetic testing (NGS and multi-gene panels focused on cancer susceptibility genes). Compared to traditional methods, NGS is faster, broader, and more cost-effective. It can be used for single-genes, targeted panels, whole exomes, or even whole genomes, giving complete genetic information but keeping controllable costs (57, 58). In oncology, multi-gene panel NGS testing is favoured due to its higher analytical sensitivity and specificity. By focusing on disease-relevant genes, it simplifies interpretation and improves diagnostic accuracy. Genetic testing identifies GPVs that increase cancer risk and has several key clinical applications (59). First, certain variants predict treatment response, for example, BRCA1 and BRCA2 gene variants indicate potential benefit from PARP inhibitors, while MMR gene variants can guide immunotherapy decisions (60, 61). Second, confirming a HCS at the molecular level enables tailored preventive strategies, including enhanced surveillance or prophylactic surgery, which can significantly improve outcomes (62, 63). Third, identifying a GPV in a patient allows for cascade testing in family members, facilitating individualized preventive or therapeutic plans (64, 65).

Classification system of genetic variants according to the International agency for research on cancer
Class* Description† Probability ofbeing pathogenic Counseling consequences‡
1 Benign < 0.001 Considered equivalent to “no pathogenic variant detected”; routine population-based screening recommended
2 Likely benign 0.010-0.049 Managed as negative test result; standard clinical surveillance based on general risk
3 VUS 0.050-0.949 Clinical management guided by personal and family history; periodic variant re-evaluation
4 Likely pathogenic 0.950-0.990 Genetic counselling and intensified surveillance according to high-risk management guidelines
5 Pathogenic > 0.990 Full high-risk management including tailored surveillance, preventive strategies and cascade testing of relatives
*Classes refer to the IARC five-tier classification of germline genetic variants in cancer susceptibility genes (56). †Description indicates the clinical interpretation of the variant classification. ‡Counselling consequences refer to recommendations for genetic counselling, clinical surveillance and risk management of the proband and at-risk family members. IARC - International agency for research on cancer. VUS - variant of uncertain significance.

All genetic testing candidates must take pre-test counselling and give informed consent. Counselling should cover the purpose and limitations of the genetic test, likely outcomes, implications for family members and privacy concerns.

The discovery of cancer-predisposing genes and improved diagnosis of hereditary malignancies represent significant progress in translational medicine today, in the current era of personalised medicine. Future investigations should spotlight strategies for tumour development prevention and progression prevention in germline pathogenic variants carriers.

From genetics to treatment: a personalised approach to oncology

Precision oncology moves beyond the one-size-fits-all model of cancer care. It emphasises therapies customized to the patient’s genetic and molecular features and directed toward cancer-specific mutations (66, 67). This approach is driven by the recognition that the same mutations can occur in tumours from different organs, allowing treatment efficacy to be independent of tumour origin. The goal is to improve outcomes by using treatments tailored to each patient’s unique genetic changes.

Cancer is a disease of cellular evolution. Over time, cancer cells acquire mutations that confer a survival advantage, enabling uncontrolled growth and resistance to cell death. This reflects a loss of control over the cell cycle, which is regulated by two major gene classes: proto-oncogenes and tumour-suppressor genes. Proto-oncogenes promote normal cell growth, in the case of the mutation, they become oncogenes, with a “gain of function” which leads to uncontrolled cell proliferation. A single mutated allele can be enough to alter gene function. These mutations are typically acquired. Tumour suppressor genes suppress cell growth and programmed cell death. Mutations in these types of genes result in a “loss of function” and commonly require both mutated alleles to be deactivated, often through loss of heterozygosity (LOH). A subclass, DNA repair genes, are tumour suppressors since their loss of function increases the overall mutation rate in other genes. The variations between proto-oncogenes, tumour suppressor, and DNA repair genes are summarised in Table 11.

Gene categories in cancer
Gene type Normal role Effect of mutation Example genes Inheritance pattern
Proto-oncogenes Promote growth/division Gain of function → oncogene activation, and uncontrolled proliferation KRAS, BRAF,EGFR Somatic (predominantly)
Tumour suppressor genes Inhibit growth, trigger apoptosis Loss of function → uncontrolled cell growth TP53, RB1,APC Germline with somatic “second hit” or somatic only
DNA repair genes Maintain genomic stability and DNA integrity Loss of function → accumulation of mutations BRCA1, BRCA2, MSH2, MLH1 Germline or somatic
APC - adenomatous polyposis coli. BRAF - B-Raf proto-oncogene, serine/threonine kinase. BRCA1 - breast cancer 1. BRCA2 - breast cancer 2. EGFR - epidermal growth factor receptor. KRAS - Kirsten rat sarcoma viral oncogene homolog. MLH1 - mutL homolog 1. MSH2 - mutS homolog 2. RB1 - RB transcriptional corepressor 1. TP53 - tumour protein p53.

Key mutations, critical for a tumour’s growth and progression, are referred to as driver mutations. They are often point mutations and are rarely lost due to weak negative selection (68). Tumours typically have about four driver mutations, though this varies by cancer type (69). Driver mutations are characterized by their recurrence across many patients and at specific “hotspots” (70). Most other mutations are passenger mutations, which are not critical for tumour growth, but recent research suggests they can have a cumulative effect on the tumour’s characteristics (71).

Most tumour mutations are somatic (acquired) due to environmental factors or aging; only 5-10% are germline (inherited) (72). Unlike germline mutations, which are in every cell, somatic mutations are only in the cells where they occurred, leading to clonal heterogeneity. As a tumour grows, different subpopulations of cells, or subclones, develop unique mutations (73).

Cancer treatments act as a powerful selective force (74). A drug may kill the dominant, “naive” cancer cells, but it selects for and promotes the growth of a small fraction of cells that have acquired resistance mutations. This resistant subclone then becomes the dominant population, explaining why subsequent therapies are often less effective.

Mutations can be detected using tissue biopsy or a non-invasive liquid biopsy, which identifies tumour-derived DNA fragments circulating in the bloodstream (75). Liquid biopsies can detect mutations from multiple subclones.

Today, NGS is the primary method for analysing cancer genomics (76). It can detect various mutations, for example, single nucleotide polymorphisms (SNPs), small deletions and insertions (indels), and larger changes like copy number variations (CNVs). The variant allele frequency (VAF) helps differentiate between germline and somatic mutations; a high VAF (50-100%) suggests a germline mutation, while somatic mutations can have a very low VAF (77).

Somatic mutations leave characteristic patterns called mutational signatures, with more than 80 identified by COSMIC (78). These signatures fall into three types:

Type 1: caused by exogenous or endogenous processes (e.g., UV radiation).

Type 2: linked to defective DNA repair mechanisms (e.g., BRCA1/BRCA2 mutations).

Type 3: caused by unknown processes.

The classification of mutational signatures and their therapeutic implications is presented in Table 12.

Mutational signatures and their therapy implications
Signature type Main cause Example Therapy relevance
Type 1 Exogenous and endogenous mutational processes UV-induced mutations May predict response to immunotherapy in melanoma
Type 2 DNA repair defects BRCA1/2deficiency Increased sensitivity to platinum-based chemotherapy and PARP inhibitors
Type 3 Unknown mechanisms – Currently under research
Signature types represent simplified categories of mutational processes associated with specific biological mechanisms and therapeutic vulnerabilities. BRCA1 - breast cancer 1. BRCA2 - breast cancer 2. PARP - poly(ADP-ribose) polymerase. UV - ultraviolet.

Understanding these signatures is clinically valuable as a predictor of therapeutic response. For example, tumours with a specific signature indicating a defect in homologous recombination are sensitive to platinum-based therapies or PARP inhibitors. A high tumour mutational burden (TMB) signature or a defect in the mismatch repair (MMR) system that leads to high microsatellite instability (MSI-H) are both excellent predictors of response to immunotherapy, regardless of the tumour’s location (79).

Different to conventional chemotherapy, precision oncology drugs have high specificity for molecular targets (80). These drugs fall into two main categories: small-molecule drugs and biologics. Chemically synthesized small-molecule drugs act on intracellular or extracellular targets (e.g., kinase inhibitors), while biologic drugs, typically antibodies, target extracellular targets (e.g., cell receptor inhibitors). Although precision oncology has potential, it faces challenges such as tumour heterogeneity, considerable healthcare costs, and limited access to genetic testing (81). Consequently, to address these concerns, innovative clinical trial designs have been developed to better evaluate targeted therapies and enable their implementation in precision oncology (82, 83). Table 13 summarizes contemporary adaptive clinical trial designs used in precision oncology to match targeted therapies with specific genomic alterations either across or within tumour types.

Innovative clinical trial designs in precision oncology
Trial design Inclusion criteria Purpose Example
N-of-1* Single patient with a defined molecular alteration Evaluation of individualized targeted therapy in a single patient Rare tumours with unique actionable mutations
Basket Different tumour types sharing the same molecular alteration Assessment of efficacy of mutation-targeted therapy across cancer types NTRK inhibitor trials
Umbrella Single tumour type withdifferent molecular subgroups Allocation of targeted therapies based on molecular profiling Lung cancer umbrella trials
Super-umbrella Hybrid design combining basket and umbrella approaches Large adaptive master protocol evaluating multiple targets and therapies Master protocols in precision oncology
This table summarizes contemporary adaptive clinical trial designs used in precision oncology to match targeted therapies with specific genomic alterations across or within tumour types. *N-of-1 trial refers to a single-patient clinical study in which treatment is selected based on the individual molecular profile, allowing direct assessment of therapeutic benefit in that specific patient. NTRK - Neurotrophic tyrosine receptor kinase.

All multifaceted decisions are often reached by a multidisciplinary team of experts.

Results of molecular profiling precisely direct the selection of targeted drugs that work on specific molecular pathways. Key patterns include:

Kinase and receptor mutations: tumours with BRAF, EGFR, and ALK gene mutations exhibit constant growth signals and can be treated with kinase inhibitors. Amplification of the ERBB2 (HER2) gene is targeted with monoclonal antibodies (trastuzumab).

DNA repair mutations: tumours with BRCA1/BRCA2 mutations have damaged DNA repair, and consequently are sensitive to PARP inhibitors. Tumours with a defect in the MMR system respond well to immunotherapy.

Other targets: mutations in genes such as IDH1, PIK3CA, KRAS G12C, NTRK, and RET can be treated with specific inhibitors.

Detailed molecular profiling, from driver mutations and mutational signatures to understanding tumour heterogeneity, is the foundation of personalised cancer treatment. As our knowledge of tumour genetics progresses, new targeted treatments continue to emerge. These advances have turned precision oncology into standard practice, allowing clinicians to tailor therapy decisions according to the patient’s unique genetic characteristics.

Pharmacogenetics and individualisation of therapy

The concept of individualising drug therapy based on genetic information is one of the key implementations of personalised medicine today. Pharmacogenetics, the study of how genetic variation affects individual responses to therapy, aims to optimise drugs selection and minimise adverse drug reactions (ADRs). As early as the mid-20th century, discoveries of inherited enzyme insufficiencies, for example, glucose-6-phosphate dehydrogenase (G6PD) deficiency and N-acetyltransferase polymorphisms revealed that genetics significantly modulates drug metabolism and toxicity (84, 85). Today, with the advent of NGS and bioinformatics, pharmacogenetics has expanded from single gene-drug interactions to pharmacogenomics, genome-wide approaches that consider the complex interplay of multiple genes and pathways (86, 87). Currently, pharmacogenomics is clinically relevant for a growing number of medications, with actionable pharmacogenes guiding drug selection and dosing to improve efficacy and reduce ADRs. Implementation is supported by expert societies such as the Dutch pharmacogenetics working group (DPWG) and the clinical pharmacogenetics implementation consortium (CPIC), which have published evidence-based guidelines for more than 160 gene-drug pairs (88-91). Integrating pharmacogenetic data into clinical workflows has been associated with improved safety, efficacy, and greater cost-effectiveness, particularly for medicines with narrow therapeutic index or high ADR risk (92).

At the core of pharmacogenomics are inherited variants, especially in genes encoding drug-metabolising enzymes, transporters, receptors, drug targets, and immune modulators, that influence how individuals process and respond to medications throughout their lives (86, 87, 93). Therefore, pharmacogenomic testing focuses on germline sequence variants that influence individual variability in drug response, covering pharmacokinetics (drug metabolism) and pharmacodynamics (drug targets and sensitivity) (94). It is estimated that variations in genes involved in pharmacokinetics and pharmacodynamics explain about 20-30% of variability in drug response (92). Unlike inherited disease genetics, in pharmacogenetics germline sequence variants are not classified by the traditional pathogenicity categories used in medical genetics, because they primarily describe the impact on drug response and not disease causation. Major pharmacogenetics resources, such as PharmGKB (Pharmacogenomics knowledgebase), and newly established ClinPGx (Clinical pharmacogenomics), as well as CPIC and DPWG, classify gene-drug interactions by systematically evaluating drug-gene pair clinical relevance and actionability for drug prescribing decisions (88, 95, 96). These resources provide evidence-based recommendations regarding drug selection, dosage adjustment, or consideration of alternative therapies based on genotype-predicted phenotypes such as poor, intermediate, normal, or ultra-rapid metabolizer status, as well as enzyme activity scores and drug transporter functionality.

Genetic polymorphisms of cytochrome P450 (CYP) enzymes significantly influence individual responses to drugs, susceptibility to toxicity, and cancer risk. They are crucial for metabolising endogenous substances, xenobiotics, and carcinogens. Variants in CYP genes may lead to loss of enzyme function, reduced expression, altered substrate specificity, or increased enzyme activity (97, 98). A key step in pharmacogenomics is translating genotype into phenotype, enabling functional predictions that guide drug therapy. For drug-metabolising enzymes such as CYPs, allele combinations define metabolic phenotypes of individuals, ranging from three to five categories depending on the specific enzyme and functional allele composition. These phenotypes include poor metabolizers (PMs; two nonfunctional alleles); intermediate metabolizers (IMs; one normal function and one nonfunctional allele, or two decreased function alleles), normal metabolizers (NMs; two normal function alleles, or one normal function and one decreased function allele), rapid metabolizers (RMs; one normal function and one increased function allele), and ultrarapid metabolizers (UMs; multiple active gene copies or two increased function alleles) (94, 99). A similar genotype-to-phenotype translation applies to drug transporters (ABCG2, SLCO1B1), where variants alter substrate transport rather than metabolism. Functional categories range from poor, decreased, normal, to increased function phenotypes, influencing drug exposure and toxicity risk (99, 100).

The most relevant pharmacogenomic markers are those with high-level evidence for clinical actionability by CPIC and DPWG, and those recognised by regulatory agencies such as the European medicines agency (EMA) and the United States Food and drug administration (FDA). The key pharmacogenomic genes include ABCG2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, HLA-B, NUDT15, SLCO1B1, TPMT, UGT1A1, VKORC1 and others (85, 86, 88, 89, 91, 95). These genes are involved in the metabolism of numerous drugs, with common clinical applications across multiple therapeutic areas: psychiatry (selective serotonin reuptake inhibitors (SSRIs): CYP2B6, CYP2C19, CYP2D6); cardiology (clopidogrel: CYP2C19; mavacamten: CYP2C19; statins: ABCG2, SLCO1B1; warfarin: CYP2C9, VKORC1); oncology (fluoropyrimidines: DPYD; tamoxifen: CYP2D6; irinotecan: UGT1A1); pain management (opioids: CYP2D6); infectious diseases (HLA-B57:01 predicts abacavir hypersensitivity); immunosuppressive therapy (tacrolimus: CYP3A5; azathioprine: NUDT15, TPMT); and neurology (carbamazepine: HLA-B15:02; siponimod: CYP2C9), among others. Given the wide range of gene-drug interactions, transitioning from single-gene tests to pre-emptive pharmacogenomic panels is a logical next step. Recent large trials support this approach. The PREPARE study demonstrated that implementing a 12-gene pharmacogenetic panel significantly reduces ADRs across diverse European healthcare systems (89, 91). This aligns with recent finding that 98.8% of individuals carry at least one actionable pharmacogenetic variant with therapeutic implications, and 23.3% have at least one specific gene-drug pair for which a therapy adjustment is recommended (101). This is particularly important for older adults and patients with polypharmacy, where pharmacogenetic testing can help to safely manage complex medication regimens and minimise ADRs in these vulnerable populations (102).

Pharmacogenetic information is increasingly incorporated into drug labels and clinical decision support tools, with more than 300 drug-gene pairs recognised by regulatory agencies FDA and EMA (103). Discrepancies exist between agencies in the level and specificity of pharmacogenetic recommendations, but harmonisation efforts are ongoing (92, 94). The consensus of actionable pharmacogenomic labelling between the FDA and the EMA is about 50%, and guidelines provided by CPIC and DPWG are only partly implemented into the summary of product characteristics (SmPCs) (104). Pharmacogenomic actionable labelling is the most common classification, and CYP2D6 most frequent gene in FDA pharmacogenomic labelling (105).

Both the efficacy and the safety of drug therapy vary among populations due to ethnogeographic differences in pharmacogenetic variants. These differences have direct implications for public health, supporting population-specific genotyping strategies and cost-effectiveness models for pharmacogenomic testing. However, there are significant inequities in global pharmacogenomic research coverage, with African and some Asian populations being underrepresented, despite their high genetic diversity and unique variant profiles (92, 106). Recognising and integrating these differences is crucial for pharmacogenomic implementation in diverse patient groups (86).

While challenges remain in the implementation of pharmacogenomics into health-care systems – a knowledge gap in the health-care workforce, variability in reimbursement, integration with clinical decision systems, interpretation of rare variants - progress is steadily advancing (90, 92). Beyond clinical use, pharmacogenomics also informs drug discovery and development (86). Expanding beyond single-gene testing to comprehensive, population-tailored strategies, supported by clinical guidelines, regulatory frameworks, and international collaboration, is essential for personalised medicine advancement.

Antidepressant treatment in breast cancer patients using tamoxifen

Depression is a common and serious concern among breast cancer patients, affecting roughly one-third of women worldwide (107). Not only can depression arise from the psychological burden of having a life-altering and life-threatening illness, but the biological effects of cancer and its treatment can also cause depression. Among women in Croatia, breast cancer is the most frequently diagnosed cancer according to the Croatian Institute for Public Health. Almost 80% of patients with breast cancer have hormone receptor-positive disease, and in these patients, anti-oestrogen therapies are indicated as adjuvant treatment (108).

Tamoxifen, a weak anti-oestrogen prodrug, is metabolized into active metabolites, including 4-hydroxy-tamoxifen, N-desmethyltamoxifen, and 4-hydroxy-N-desmethyl-tamoxifen (endoxifen). The response to tamoxifen may vary among patients and depends partly on the CYP2D6 genotype (109, 110). The CYP2D6 gene is highly polymorphic and is classified into four metabolic phenotypes: PM, IM, NM, and UM (111, 112). The consequences of impaired tamoxifen metabolism are particularly significant in patients carrying decreased-function alleles (CYP2D6 *9, *10, *41) or no-function alleles (*3, *4, *5, *6). The distribution of these variants differs across populations (113, 114). Patients categorised as PM with inactivating alleles tend to have inferior survival versus carriers of the wild-type allele (115). Nevertheless, recent studies show inconsistent results regarding associations between CYP2D6 alleles and clinical outcomes (116, 117).

Individuals with low CYP2D6 enzyme activity, either due to genetic variants or concomitant usage of strong CYP2D6 inhibitors, show significantly decreased endoxifen concentrations during tamoxifen therapy (118, 119). Some antidepressants, such as SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs), are substrates of CYP2D6 but also inhibit CYP2D6, thereby reducing the creation of active tamoxifen metabolites and potentially its anticancer effect. Table 14 summarizes the inhibitory potential of different antidepressants on CYP2D6. Inhibitors can convert normal or ultrarapid metabolizers into intermediate or poor metabolizers. This is known as phenoconversion (120). Phenoconversion arises from drug-drug interactions, and when combined with the genetic background, it is referred to as drug-drug-gene interactions. Given its importance, the CPIC guidelines recommend considering CYP2D6 inhibitors when calculating the activity score (AS) for the CYP2D6 enzyme (121). Potent CYP2D6 inhibitors such as paroxetine and fluoxetine substantially reduce endoxifen concentrations in plasma (122). Weaker inhibitors like sertraline and citalopram may also reduce concentrations, but to a lesser extent (123). Based on this, the application of potent inhibitors should be avoided in patients with tamoxifen therapy (124). Nevertheless, the impact of weak-to-moderate inhibitors remains less clear, and interactions with other CYP enzymes involved in tamoxifen metabolism should also be considered (125).

Antidepressants and their inhibitory effect on cytochrome P450 2D6
Antidepressant CYP2D6 inhibition strength* Effect on endoxifen concentration† Clinical recommendation
Paroxetine, fluoxetine,bupropion Strong Markedly reduced Avoid concomitant use with tamoxifen
Sertraline, citalopram, duloxetine Moderate to weak Slightly reduced Use with caution and monitor clinical response
Venlafaxine, vortioxetine, escitalopram Minimal or none No relevant effect Considered safer alternatives with tamoxifen
*Inhibition strength refers to the degree of cytochrome P450 2D6 enzyme inhibition, categorized according to in vivo effects on CYP2D6 metabolic activity and drug–drug interaction potential. †Endoxifen is the main active metabolite of tamoxifen formed predominantly via CYP2D6-mediated metabolism; reduced CYP2D6 activity may lead to lower endoxifen plasma concentrations and potentially decreased therapeutic efficacy of tamoxifen. CYP2D6 - cytochrome P450 2D6.

There has been much debate about whether antidepressant use affects breast cancer recurrence. Current evidence does not support the hypothesis that antidepressants worsen prognosis, although some data suggest a potential increased risk that requires further research (126).

According to CPIC and the DPWG, pharmacogenomic testing for CYP2D6 is recommended to guide tamoxifen dosing, as well as to inform antidepressant prescribing (121, 127). Considering the relevance of phenoconversion, CPIC guidelines also recommend including the effect of CYP2D6 inhibitors in activity score calculation. A recently developed CYP2D6 phenoconversion calculator allows manual prediction of CYP2D6 phenotype by integrating genotype, allele count, and concomitant medications, and is summarized in Table 15 (128). In conclusion, depression is a common condition among women with breast cancer receiving tamoxifen and should not be ignored. A conservative management approach emphasizes thoughtful choice of antidepressants to minimize the risk of clinically significant interactions, especially strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion). Weak inhibitors, such as venlafaxine and vortioxetine, are generally safe to use with tamoxifen. Pharmacogenomics has an increasingly important role in optimizing therapy and improving outcomes in these patients.

Cytochrome P450 2D6 phenoconversion calculator – Inputs and outputs
Input required Description Output
Genotype Number and functional status of CYP2D6 alleles Base AS
Concomitant medications List of co-administered CYP2D6 inhibitors Adjusted AS
Final predicted phenotype PM, IM, NM, UM (after considering inhibitors) Guides dosing of tamoxifen and antidepressants dosing
Activity score (AS) represents a quantitative measure of CYP2D6 enzymatic function derived from the sum of allele activity values (e.g. 0 for no function, 0.5 for decreased function, 1 for normal function) (128). The adjusted AS accounts for phenoconversion due to concomitant CYP2D6 inhibitors, resulting in a modified predicted metabolizer phenotype. CYP2D6 - cytochrome P450 2D6. IM - intermediate metaboliser. NM - normal metaboliser. PM - poor metaboliser. UM - ultrarapid metaboliser.
Conclusion

Altogether, these advances confirm the position of laboratory diagnostics as the cornerstone of personalised medicine-bridging genetic discovery with clinical translation and transforming modern healthcare into a predictive, preventive, and truly patient-centred discipline.

Potential conflict of interest

None declared.

Data availability statement

Not applicable.

References RedekopWKMladsiD. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health. 2013;16:S4–9. 10.1016/j.jval.2013.06.00524034312 GinsburgGSWillardH. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154:277–87. 10.1016/j.trsl.2009.09.00519931193 StenzingerAMoltzenEKWinklerEMolnar-GaborFMalekNCostescuA Implementation of precision medicine in healthcare—A European perspective. J Intern Med. 2023;294:437–54. 10.1111/joim.1369837455247 JørgensenJT. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. Oncologist. 2019;24:e432–40. 10.1634/theoncologist.2019-005430940745 Di SanzoMDCipolloniLBorroMRussaRLSanturroAScopettiM Clinical Applications of Personalized Medicine: A New Paradigm and Challenge. Curr Pharm Biotechnol. 2017;18:194–203. 10.2174/138920101866617022410560028240172 ChanISGinsburgGS. Personalized Medicine: Progress and Promise. Annu Rev Genomics Hum Genet. 2011;12:217–44. 10.1146/annurev-genom-082410-10144621721939 ChernyNIde VriesEGEEmanuelLFallowfieldLFrancisPAGabizonA Words Matter: Distinguishing “Personalized Medicine” and “Biologically Personalized Therapeutics”. J Natl Cancer Inst. 2014;106:dju321. 10.1093/jnci/dju32125293984 HoraJRambhiaNManiI. Drug repurposing for personalized medicine. Prog Mol Biol Transl Sci. 2024;207:107–22. 10.1016/bs.pmbts.2024.02.00738942534 Visvikis-SiestSTheodoridouDKontoeMSKumarSMarschlerM. Milestones in Personalized Medicine: From the Ancient Time to Nowadays—the Provocation of COVID-19. Front Genet. 2020;11:569175. 10.3389/fgene.2020.56917533424917 WatsonJDCrickFHC. Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid. Nature. 1953;171:737–8. 10.1038/171737a013054692 FranklinREGoslingRG. Molecular Configuration in Sodium Thymonucleate. Nature. 1953;171:740–1. 10.1038/171740a013054694 OngTRamseyBW. Cystic Fibrosis: A Review. JAMA. 2023;329:1859–71. 10.1001/jama.2023.812037278811 RatjenFBellSCRoweSMGossCHQuittnerALBushA. Cystic fibrosis. Nat Rev Dis Primers. 2015;1:15010. 10.1038/nrdp.2015.1027189798 BurgelPRDurieuIChironRRamelSDanner-BoucherIPrevotatA Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021;204:64–73. 10.1164/rccm.202011-4153OC33600738 DainesCLTullisECostaSLinnemannRWMallMAMcKoneEF Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J. 2023;62:2202029. 10.1183/13993003.02029-202237945033 FajacIBurgelPRMartinC. New drugs, new challenges in cystic fibrosis care. Eur Respir Rev. 2024;33:240045. 10.1183/16000617.0045-202439322262 Tješić-DrinkovićDOmerzaLBambirITodorićIAničićMNSenečić-ČalaI Cistična fibroza – nove terapijske mogućnosti. Lijec Vjesn. 2022;144:27–35. Tješić-DrinkovićDBambirITješić-DrinkovićDVukić DugacABambiarIBaretićM Cistična fibroza – ishodi liječenja u Hrvatskoj uz CFTR modulatore. Lijec Vjesn. 2023;145:121–30. Zolin A, Adamoli A, Bakkeheim E. ECFSPR Annual Report 2023. European Cystic Fibrosis Society [Internet]. [cited 2025 Oct 3]. Available from: https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports HoodLFloresM. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol. 2012;29:613–24. 10.1016/j.nbt.2012.03.00422450380 YuTWKingsmoreSFGreenRCMacKenzieTWassersteinMCagganaM Are we prepared to deliver gene-targeted therapies for rare diseases? Am J Med Genet C Semin Med Genet. 2023;193:7–12. 10.1002/ajmg.c.3202936691939 GroseljUTansekMZBattelinoT. Fifty years of phenylketonuria newborn screening - A great success for many, but what about the rest? Mol Genet Metab. 2014;113:8–10. 10.1016/j.ymgme.2014.07.01925174964 WilsonJMGJungnerG. Principles and practice of screening for disease. J R Coll Gen Pract. 1968;16:318.4234760 AndermannABlancquaertIBeauchampSDéryV. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86:317–9. 10.2471/BLT.07.05011218438522 Schnabel-BessonEMützeUDikowNHörsterFMorathMAAlexK Wilson and Jungner Revisited: Are Screening Criteria Fit for the 21st Century? Int J Neonatal Screen. 2024;10:62. 10.3390/ijns1003006239311364 TherrellBLPadillaCDBorrajoGJCKhneisserISchielenPCJIKnight-MaddenJ Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023). Int J Neonatal Screen. 2024;10:38. 10.3390/ijns1002003838920845 HoffmannGFLindnerMLoeberJG. 50 years of newborn screening. J Inherit Metab Dis. 2014;37:163–4. 10.1007/s10545-014-9688-524526389 BhattacharjeeASokolskyTWymanSKReeseMGPuffenbergerEStraussK Development of DNA confirmatory and high-risk diagnostic testing for newborns using targeted next-generation DNA sequencing. Genet Med. 2015;17:337–47. 10.1038/gim.2014.11725255367 ŠimićDŠarićAŠkaričićALehmanIBunozaBRakoI One-Year Pilot Study Results of Newborn Screening for Spinal Muscular Atrophy in the Republic of Croatia. Int J Neonatal Screen. 2024;10:50. 10.3390/ijns1003005039051406 SpiekerkoetterUBickDScottRHopkinsHKronesTGrossES Genomic newborn screening: Are we entering a new era of screening? J Inherit Metab Dis. 2023;46:778–95. 10.1002/jimd.1265037403863 BetzlerIRHempelMMützeUKölkerSWinklerEDikowN Comparative analysis of gene and disease selection in genomic newborn screening studies. J Inherit Metab Dis. 2024;47:945–70. 10.1002/jimd.1275038757337 RahimzadehVFriedmanJMde WertGKnoppersBM. Exome/Genome-Wide Testing in Newborn Screening: A Proportionate Path Forward. Front Genet. 2022;13:865400. 10.3389/fgene.2022.86540035860465 GertsmanIBarshopBA. Promises and pitfalls of untargeted metabolomics. J Inherit Metab Dis. 2018;41:355–66. 10.1007/s10545-017-0130-729536203 HuangXWuDZhuLWangWYangRYangJ Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates. Orphanet J Rare Dis. 2022;17:66. 10.1186/s13023-022-02231-x35193651 DownieLBoufflerSEAmorDJChristodoulouJYeungAHortonAE Gene selection for genomic newborn screening: Moving toward consensus? Genet Med. 2024;26:101077. 10.1016/j.gim.2024.10107738275146 AshendenAJChowdhuryAAnastasiLTLamKRozekTRanieriE The Multi-Omic Approach to Newborn Screening: Opportunities and Challenges. Int J Neonatal Screen. 2024;10:42. 10.3390/ijns1003004239051398 PriorTWSnyderPJRinkBDPearlDKPyattREMihalDC Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A. 2010;152A:1608–16. 10.1002/ajmg.a.3347420578137 D’AmicoAMercuriETizianoFDBertiniE. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71. 10.1186/1750-1172-6-7122047105 ButchbachMER. Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development. Int J Mol Sci. 2021;22:7896. 10.3390/ijms2215789634360669 ChaytowHFallerKMEHuangYTGillingwaterTH. Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med. 2021;2:100346. 10.1016/j.xcrm.2021.10034634337562 FarrarMAKiernanMC. Spinal muscular atrophy - the dawning of a new era. Nat Rev Neurol. 2020;16:593–4. 10.1038/s41582-020-00410-732978515 FarrarMAParkSBVucicSCareyKATurnerBJGillingwaterTH Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355–68. 10.1002/ana.2486428026041 AngillettaIFerranteRGiansanteRLombardiLBaboreADell’EliceA Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies. Int J Mol Sci. 2023;24:14873. 10.3390/ijms24191487337834320 Costa-RogerMBlasco-PérezLCuscóITizzanoEF. The Importance of Digging into the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy. Int J Mol Sci. 2021;22:9029. 10.3390/ijms2216902934445733 De VivoDCBertiniESwobodaKJHwuWLCrawfordTOFinkelRSNURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842–56. 10.1016/j.nmd.2019.09.00731704158 KölbelHModlerLBlaschekASchara-SchmidtUVillKSchwartzO Parental Burden and Quality of Life in 5q-SMA Diagnosed by Newborn Screening. Children (Basel). 2022;9:1829. 10.3390/children912182936553273 ErdosJWildC. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. Eur J Paediatr Neurol. 2022;39:1–10. 10.1016/j.ejpn.2022.04.00635533607 WalshMFChangVYKohlmannWKScottHSCunniffCBourdeautF Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders. Clin Cancer Res. 2017;23:e23–31. 10.1158/1078-0432.CCR-17-046528572264 SharmaRLewisSWlodarskiMW. DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns. Front Pediatr. 2020;8:570084. 10.3389/fped.2020.57008433194896 JahnARumpAWidmannTJHeiningCHorakPHutterB Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. Ann Oncol. 2022;33:1186–99. 10.1016/j.annonc.2022.07.00835988656 GarberJEOffitK. Hereditary Cancer Predisposition Syndromes. J Clin Oncol. 2005;23:276–92. 10.1200/JCO.2005.10.04215637391 ImyanitovENKuliginaESSokolenkoAPSuspitsinENYanusGAIyevlevaAG Hereditary cancer syndromes. World J Clin Oncol. 2023;14:40–68. 10.5306/wjco.v14.i2.4036908677 McDonnellJEGildMLClifton-BlighRJRobinsonBG. Multiple endocrine neoplasia: an update. Intern Med J. 2019;49:954–61. 10.1111/imj.1439431387156 StadlerZKThomPRobsonMEWeitzelJNKauffNDHurleyKE Genome-Wide Association Studies of Cancer. J Clin Oncol. 2010;28:4255–67. 10.1200/JCO.2009.25.781620585100 RichardsSAzizNBaleSBickDDasSGastier-FosterJ Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24. 10.1038/gim.2015.3025741868 PlonSEEcclesDMEastonDFoulkesWDGenuardiMGreenblattMS Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91. 10.1002/humu.2088018951446 ShendureJJiH. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–45. 10.1038/nbt148618846087 LevySEMyersRM. Advancements in Next-Generation Sequencing. Annu Rev Genomics Hum Genet. 2016;17:95–115. 10.1146/annurev-genom-083115-02241327362342 GaruttiMFoffanoLMazzeoRMichelottiADa RosLVielA Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool. Genes (Basel). 2023;14:1025. 10.3390/genes1405102537239385 AndréTShiuKKKimTWJensenBVJensenLHPuntC Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N Engl J Med. 2020;383:2207–18. 10.1056/NEJMoa201769933264544 RobsonMImSASenkusEXuBDomchekSMMasudaN Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523–33. 10.1056/NEJMoa170645028578601 PeltomäkiPNyströmMMecklinJPSeppäläTT. Lynch Syndrome Genetics and Clinical Implications. Gastroenterology. 2023;164:783–99. 10.1053/j.gastro.2022.08.05836706841 RooneyMMMillerKNPlichtaJK. Genetics of Breast Cancer: Risk Models, Who to Test, and Management Options. Surg Clin North Am. 2023;103:35–47. 10.1016/j.suc.2022.08.01636410352 SchmidlenTJBristowSLHatchellKEEsplinEDNussbaumRLHaverfieldEV. The Impact of Proband Indication for Genetic Testing on the Uptake of Cascade Testing Among Relatives. Front Genet. 2022;13:867226. 10.3389/fgene.2022.86722635783293 FreyMKAhsanMDBergeronHLinJLiXFowlkesRK Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis. J Clin Oncol. 2022;40:4129–43. 10.1200/JCO.22.0030335960887 VogelsteinBPapadopoulosNVelculescuVEZhouSDiazLAJrKinzlerKW. Cancer genome landscapes. Science. 2013;339:1546–58. 10.1126/science.123512223539594 GarrawayLALanderES. Lessons from the Cancer Genome. Cell. 2013;153:17–37. 10.1016/j.cell.2013.03.00223540688 AaltonenLAAbascalFAbeshouseAAburataniHAdamsDJAgrawalN Pan-cancer analysis of whole genomes. Nature. 2020;578:82–93. 10.1038/s41586-020-1969-632025007 MartincorenaIRaineKMGerstungMDawsonKJHaaseKVan LooP Universal Patterns of Selection in Cancer and Somatic Tissues. Cell. 2017;171:1029–41.e21. 10.1016/j.cell.2017.09.04229056346 BányaiLTrexlerMKerekesKCsukaOPatthyL. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes. eLife. 2021;10:e59629. 10.7554/eLife.5962933427197 KumarSWarrellJLiSMcGillivrayPDMeyersonWSalichosL Passenger mutations in 2500 cancer genomes: Overall molecular functional impact and consequences. Cell. 2020;180:915–927.e16. 10.1016/j.cell.2020.01.03232084333 PDQ® Cancer Genetics Editorial Board. PDQ Genetics of Breast and Gynecologic Cancers. Bethesda, MD: National Cancer Institute. Updated 03/06/2025. [Internet]. [cited 2025 Oct 15]. Available at: https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq GerlingerMRowanAJHorswellSMathMLarkinJEndesfelderD Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92. 10.1056/NEJMoa111320522397650 Jamal-HanjaniMWilsonGAMcGranahanNBirkbakNJWatkinsTBKVeeriahS Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376:2109–21. 10.1056/NEJMoa161628828445112 SiravegnaGMarsoniSSienaSBardelliA. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48. 10.1038/nrclinonc.2017.1428252003 GoodwinSMcPhersonJDMcCombieWR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17:333–51. 10.1038/nrg.2016.4927184599 KonnickEQPritchardCC. Germline, hematopoietic, mosaic, and somatic variation: interplay between inherited and acquired genetic alterations in disease assessment. Genome Med. 2016;8:100. 10.1186/s13073-016-0350-827716394 AlexandrovLBNik-ZainalSWedgeDCAparicioSAJRBehjatiSBiankinAV Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. 10.1038/nature1247723945592 StricklerJHHanksBAKhasrawM. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? Clin Cancer Res. 2021;27:1236–41. 10.1158/1078-0432.CCR-20-305433199494 SmithCEPPrasadV. Targeted Cancer Therapies. Am Fam Physician. 2021;103:155–63.33507053 YinJShenSShiQ. Challenges, opportunities, and innovative statistical designs for precision oncology trials. Ann Transl Med. 2022;10:1038. 10.21037/atm-22-35636267789 MooreDCGuinigundoAS. Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine. J Adv Pract Oncol. 2023;14:9–13. 10.6004/jadpro.2023.14.3.1637206904 FountzilasETsimberidouAMVoHHKurzrockR. Clinical trial design in the era of precision medicine. Genome Med. 2022;14:101. 10.1186/s13073-022-01102-136045401 MeyerUAZangerUM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997;37:269–96. 10.1146/annurev.pharmtox.37.1.2699131254 RodenDMMcLeodHLRellingMVWilliamsMSMensahGAPetersonJF Pharmacogenomics. Lancet. 2019;394(10197):521–32. 10.1016/S0140-6736(19)31276-031395440 PirmohamedM. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24:350–62. 10.1038/s41576-022-00572-836707729 SadeeWWangDHartmannKTolandAE. Pharmacogenomics: Driving Personalized Medicine. Pharmacol Rev. 2023;75:789–814. 10.1124/pharmrev.122.00081036927888 Caudle KE, Whirl-Carrillo M, Relling MV, Hoffman JM, Donnelly RS, Haidar CE, et al. Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium (CPIC). Clin Pharmacol Ther. 2025 Jul 18 [cited 2025 Oct7] [Epub ahead of print]. HaidarCECrewsKRHoffmanJMRellingMVCaudleKE. Advancing Pharmacogenomics from Single-Gene to Preemptive Testing. Annu Rev Genomics Hum Genet. 2022;23:449–73. 10.1146/annurev-genom-111621-10273735537468 KabbaniDAkikaRWahidADalyAKCascorbiIZgheibNK. Pharmacogenomics in practice: a review and implementation guide. Front Pharmacol. 2023;14:1189976. 10.3389/fphar.2023.118997637274118 SwenJJvan der WoudenCHMansonLEAbdullah-KoolmeesHBlagecKBlagusT A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347–56. 10.1016/S0140-6736(22)01841-436739136 LauschkeVMZhouYIngelman-SundbergM. Pharmacogenomics Beyond Single Common Genetic Variants: The Way Forward. Annu Rev Pharmacol Toxicol. 2024;64:33–51. 10.1146/annurev-pharmtox-051921-09120937506333 WeinshilboumRMWangL. Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clin Proc. 2017;92:1711–22. 10.1016/j.mayocp.2017.09.00129101939 TayehMKGaedigkAGoetzMPKleinTELyonEMcMillinGA Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022;24:759–68. 10.1016/j.gim.2021.12.00935177334 SwenJJNijenhuisMde BoerAGrandiaLMaitland-van der ZeeAHMulderH Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011;89:662–73. 10.1038/clpt.2011.3421412232 ThornCFKleinTEAltmanRB. PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol. 2013;1015:311–20. 10.1007/978-1-62703-435-7_2023824865 BozinaNBradamanteVLovrićM. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol. 2009;60:217–42. 10.2478/10004-1254-60-2009-188519581216 RendicSPGuengerichFP. Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update. Arch Toxicol. 2021;95:395–472. 10.1007/s00204-020-02971-433459808 CaudleKEDunnenbergerHMFreimuthRRPetersonJFBurlisonJDWhirl-CarrilloM Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19:215–23. 10.1038/gim.2016.8727441996 Cooper-DeHoffRMNiemiMRamseyLBLuzumJATarkiainenEKStrakaRJ The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111:1007–21. 10.1002/cpt.255735152405 LitoniusKKullaNFalkenbachPKristianssonKTarkiainenEKUkkola-VuotiL Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data. Clin Pharmacol Ther. 2025;117:278–88. 10.1002/cpt.345839365028 BožinaNVrkić KirhmajerMŠimičevićLGanociLMirošević SkvrceNKlarica DomjanovićI Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. Croat Med J. 2020;61:147–58. 10.3325/cmj.2020.61.14732378381 ChengCMSoTWBubpJL. Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations. Ann Pharmacother. 2021;55:1185–94. 10.1177/106002802098304933384014 ShekhaniRSteinacherLSwenJJIngelman-SundbergM. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. Clin Pharmacol Ther. 2020;107:1240–55. 10.1002/cpt.172031715018 DebSHopeflRReevesAACvetkovicD. ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with Clinical Pharmacogenetics Implementation Consortium (CPIC) Evidence Levels. Medicines (Basel). 2024;11:6. 10.3390/medicines1103000638535119 ZhouYLauschkeVM. Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. Hum Genet. 2022;141:1113–36. 10.1007/s00439-021-02385-x34652573 PilevarzadehMAmirshahiMAfsargharehbaghRRafiemaneshHHashemiSMBalouchiA. Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;176:519–33. 10.1007/s10549-019-05271-331087199 HowladerNChenVWRiesLAGLochMMLeeRDeSantisC Overview of breast cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010. Cancer. 2014;120:3771–80. 10.1002/cncr.2905925412389 ZembutsuHNakamuraSAkashi-TanakaSKuwayamaTWatanabeCTakamaruT Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. Clin Cancer Res. 2017;23:2019–26. 10.1158/1078-0432.CCR-16-177927797974 KiyotaniKMushirodaTImamuraCKHosonoNTsunodaTKuboM Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients. J Clin Oncol. 2010;28:1287–93. 10.1200/JCO.2009.25.724620124171 GaedigkASimonSDPearceREBradfordLDKennedyMJLeederJS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234–42. 10.1038/sj.clpt.610040617971818 JiYSkierkaJMBlommelJHMooreBEVanCuykDLBruflatJK Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol Diagn JMD. 2016;18:438–45. 10.1016/j.jmoldx.2016.01.00326947514 NishidaYFukudaTYamamotoIAzumaJ. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics. 2000;10:567–70. 10.1097/00008571-200008000-0001010975611 BradfordLD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–43. 10.1517/14622416.3.2.22911972444 LuJLiHGuoPShenRLuoYGeQ The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis. Onco Targets Ther. 2017;10:5429–37. 10.2147/OTT.S14919729180876 SchrothWAntoniadouLFritzPSchwabMMuerdterTZangerUM Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes. J Clin Oncol. 2007;25:5187–93. 10.1200/JCO.2007.12.270518024866 MayerSEWeissNSChubakJDoodyDRCarlsonCSMakarKW CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. Cancer Causes Control. 2019;30:103–12. 10.1007/s10552-018-1117-x30542984 StearnsVJohnsonMDRaeJMMorochoANovielliABhargavaP Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758–64. 10.1093/jnci/djg10814652237 SchrothWWinterSMürdterTSchaeffelerEEcclesDEcclesB Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. Front Pharmacol. 2017;8:582. 10.3389/fphar.2017.0058228955222 NahidNAJohnsonJA. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. Expert Opin Drug Metab Toxicol. 2022;18:769–85. 10.1080/17425255.2022.216031736597259 GoetzMPSangkuhlKGuchelaarHJSchwabMProvinceMWhirl-CarrilloM Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018;103:770–7. 10.1002/cpt.100729385237 JinYDestaZStearnsVWardBHoHLeeKH CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30–9. 10.1093/jnci/dji00515632378 BorgesSDestaZLiLSkaarTCWardBANguyenA Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80:61–74. 10.1016/j.clpt.2006.03.01316815318 SiderasKIngleJNAmesMMLoprinziCLMrazekDPBlackJL Coprescription of Tamoxifen and Medications That Inhibit CYP2D6. J Clin Oncol. 2010;28:2768–76. 10.1200/JCO.2009.23.893120439629 SafgrenSLSumanVJLeon FerreRAKoselMLStearnsVHenryNL The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen. Breast Cancer Res Treat. 2025;211:261–70. 10.1007/s10549-025-07644-340011368 ChubakJBowlesEJAYuOBuistDSMFujiiMBoudreauDM. Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control. 2016;27:125–36. 10.1007/s10552-015-0689-y26518198 ClinPGx [Internet]. [cited 2025 Oct 15]. The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group. Annotation of DPWG Guideline for tamoxifen and CYP2D6. November 2018 Update. Available from: https://www.clinpgx.org/guidelineAnnotation/PA166104966/annotation CYP2D6 Phenoconversion Calculator. Precision Medicine Program. UF Health. University of Florida [Internet]. [cited 2025 Oct 15]. Available from: https://precisionmedicine.ufhealth.org/how-to-interpret-results/phenoconversion-calculator/.
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030501" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030501" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030501" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(136) "Laboratory diagnostics in personalised medicine - 36th Symposium of the Croatian society of medical biochemistry and laboratory medicine" ["journals_article_author"]=> string(224) "Dunja Rogić, Livija Šimičević, Tamara Žigman, Ivan Bambir, Andrea Vukić Dugac, Duška Tješić-Drinković, Ksenija Fumić, Ivan Lehman, Ivana Rako, Marina Popović, Lana Ganoci, Maja Živković, Alma Mihaljević-Peleš" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(95) "precision medicine, genetic diseases, neoplastic syndromes, pharmacogenomics, newborn screening" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1237" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "2" ["meta_title"]=> string(136) "Laboratory diagnostics in personalised medicine - 36th Symposium of the Croatian society of medical biochemistry and laboratory medicine" ["meta_desc"]=> string(136) "Laboratory diagnostics in personalised medicine - 36th Symposium of the Croatian society of medical biochemistry and laboratory medicine" ["meta_keyw"]=> string(95) "precision medicine, genetic diseases, neoplastic syndromes, pharmacogenomics, newborn screening" ["created"]=> string(19) "2026-08-10 10:23:22" ["modified"]=> string(19) "2026-10-02 11:00:48" } [16]=> object(stdClass)#65 (35) { ["journals_id"]=> string(4) "1268" ["journals_xml"]=> string(58001) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-3-030101 10.11613/BM.2026.030101 Lessons in biostatistics Beyond accuracy: how often and in which direction diagnostic tests err HabibzadehFarrokh Department of Medical Journalism, Shiraz University of Medical Sciences, Shiraz, Iran Corresponding author: Farrokh.Habibzadeh@gmail.com

Author contributions

F Habibzadeh: Conceptualization, Methodology, Writing – review & editing.

15102026 15102026 36 3 030101 0305202603092026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Conventional accuracy metrics do not quantify error frequency or direction

• Number needed to misdiagnose (NNM) shows how often one misdiagnosis occurs

• Misdiagnosis direction index (MDI) shows whether errors are mainly false positive or false negative

• Weighted MDI incorporates unequal clinical consequences

• NNM and MDI complement conventional diagnostic indices

Diagnostic tests are commonly evaluated using sensitivity, specificity, predictive values, likelihood ratios, and receiver operating characteristic (ROC) curve analysis. Although essential, these measures do not fully answer two practical questions frequently raised in clinical medicine: how often a test makes mistakes, and whether those mistakes are predominantly false positive or false negative. This article introduces two complementary measures that address these questions: the number needed to misdiagnose (NNM), which expresses the frequency of diagnostic error in intuitive clinical terms, and the misdiagnosis direction index (MDI), which indicates whether errors are mainly false positive or false negative. A weighted MDI is also introduced for unequal clinical harms of errors. Together with conventional indices such as Youden’s index, these measures provide a broader framework for interpreting diagnostic performance.

Keywords: sensitivityspecificitydiagnostic errorsfalse positive reactionsfalse negative reactionsbiostatistics
Introduction

Diagnostic tests are integral to screening, diagnosis, prognosis, therapeutic monitoring, and clinical decision-making (1-3). Their results often determine whether further investigations are pursued, treatment is initiated, or disease is ruled out. Accordingly, understanding how test performance is measured and interpreted is fundamental to evidence-based medicine.

Conventional performance measures and their limitations

The common performance indices used to evaluate diagnostic tests include sensitivity (Se), specificity (Sp), predictive values, likelihood ratios, and receiver operating characteristic (ROC) curve features (4, 5). Each of these measures addresses a different clinical or methodological question (1, 5-8). A detailed overview of these conventional indices has recently been published and will not be repeated here (1).

Briefly, Se estimates the probability that a diseased person has a positive test result; and Sp, the probability that a non-diseased person has a negative result (6). Positive and negative predictive values estimate the probability of presence or absence of a disease after the test result is known, and therefore depend strongly on disease prevalence (1). Likelihood ratios quantify how strongly a positive or negative result changes disease odds and are particularly useful in Bayesian interpretation of test results (8, 9). Receiver operating characteristic curves summarize the trade-off between Se and Sp across different cut-off values; they are widely used for tests with continuous results (5, 7).

Youden’s index (calculated as Se + Sp – 1) can be interpreted as the net probability of correct classification beyond chance, representing the difference between the probabilities of a positive test result in diseased and non-diseased individuals; the index ranges from 0 (useless test) to 1 (perfect test) (10). However, it does not indicate how many errors occur in a specific population because that depends on disease prevalence. Nor does it indicate whether errors are mainly false positive (FP) or false negative (FN). Therefore, Youden’s index, while useful for overall discrimination, shares similar limitations regarding error frequency and direction.

Although indispensable, the conventional performance measures do not directly answer two practical questions frequently raised by clinicians and policy-makers: 1) How often does this test make mistakes in the population where it is used?; 2) Are those mistakes mainly FP or FN?

These questions are paramount for clinicians because the consequences of the two error types may differ substantially. A FP result may lead to anxiety, unnecessary investigations, overtreatment, labeling, and increased healthcare costs. In contrast, a FN result may delay diagnosis, postpone treatment, worsen prognosis, or facilitate disease transmission.

Traditional indices address these concerns only partially. Sensitivity reflects the ability to minimize FN results, whereas Sp reflects the ability to minimize FP results; however, neither directly quantifies the overall population burden of diagnostic error (6). Similarly, Youden’s index summarizes discriminatory performance but does not indicate whether the remaining errors are predominantly FP or FN (10).

The number needed to misdiagnose (NNM) was proposed as a clinically intuitive summary of error frequency: the number of persons who need to be tested for one misdiagnosis (either FP or FN) to occur (11). While useful, NNM, however, does not indicate the direction of those errors.

This article therefore presents a practical framework that complements conventional diagnostic indices by focusing on two additional dimensions of test performance: the frequency of misdiagnosis and the direction of misdiagnostic error.

How often does a test err? Number needed to misdiagnose

The population false-negative rate (FNR) and false-positive rate (FPR) are derived from the data presented in Table 1 using the following equations (Eqs):

Four possible outcomes when the results of a diagnostic test are compared with the results of a gold-standard (reference standard) test
Disease
Present Absent
Test Result Positive TPn pr Se FPn (1–pr) (1–Sp) TP + FP
Negative FNn pr (1–Se) TNn (1–pr) Sp FN + TN
TP + FNn pr FP + TNn (1–pr) n
In each cell, the expected frequencies in a population of n tested individuals, assuming disease prevalence, and test sensitivity and specificity. The expected number of true positives (TP) is n pr Se; false positives (FP), n (1 − pr)(1 − Sp); false negatives (FN), n pr (1 − Se); and true negatives (TN), n (1 – pr) Sp. These quantities form the basis for calculating the population false-negative rate (FNR), false-positive rate (FPR), number needed to misdiagnose (NNM), and misdiagnosis direction index (MDI). TP – true-positive. FP – false-positive. FN – false-negative. TN – true-negative. Se – sensitivity. Sp – specificity. pr – prevalence. n – total number of tested individuals.

where pr represents prevalence; Se, sensitivity; and Sp, specificity. The NNM, by definition, is (11):

Number needed to misdiagnose is analogous to the number needed to treat in therapeutic studies. Rather than describing treatment benefit, it expresses diagnostic error in intuitive clinical units. The higher the NNM, the better the test performs (1, 11).

Example

If the overall population error rate (FNR  +  FPR) is 0.05:

This means that, on average, one misdiagnosis occurs for every 20 tested individuals. Number needed to misdiagnose is clinically intuitive, but it does not indicate whether those errors are mainly FP or FN.

In which direction does a test err? Addressing the limitation of NNM

To address the above-mentioned limitation of NNM, I define the misdiagnosis direction index (MDI) as follows:

Misdiagnosis direction index measures the net population imbalance between FP and FN rates rather than the proportion of one error type among all misdiagnoses. Consequently, its magnitude reflects both the predominance of one error type and the overall burden of diagnostic error. The theoretical range of MDI is from −1 to +1. The absolute value reflects the degree of imbalance. A positive value shows FP predominance; a negative value, FN predominance; and zero, balanced error direction.

Why the direction matters clinically

Two tests may have similar overall accuracy yet very different clinical implications. For example, in cancer screening, FNs may delay life-saving treatment; in infectious disease control, FNs may facilitate transmission; in low-risk population screening, FPs may cause more aggregate harm than FNs. Therefore, knowing the direction of diagnostic error may be as important as knowing its frequency.

Weighted misdiagnosis direction index

Under certain circumstances, an FN result may be substantially more harmful than a FP result. Let C denote the relative harm of one FN compared with one FP, then:

where wMDI represents the weighted MDI; a positive value indicates that the weighted FP burden predominates; a negative value, weighted FN burden predominates; and zero, weighted harms are balanced.

The value of C is not fixed and depends on the clinical context. It reflects the relative clinical, economic, or societal consequences of an FN result compared with a FP result. Selection of C should preferably be based on expert consensus, decision analysis, health-economic evaluation, or clinical guidelines (7, 12).

Example

Suppose a test has a population FPR of 0.04 and a population FNR of 0.01; then, the MDI is 0.03 (Eq. 3), reflecting FP dominance. Suppose that, in this example, a FN result is considered approximately five times more harmful than a FP result (C=5); then:

The wMDI is a weighted population error rate, expressed as a proportion of all tested individuals; it is not a relative risk or a percentage of misdiagnoses. After weighting, FNs become the dominant concern. Therefore, wMDI may help inform diagnostic threshold selection when the relative consequences of FP and FN results are unknown (7).

Statistical uncertainty and confidence intervals

Like all estimates derived from sample data, NNM and MDI are subject to sampling variability. Therefore, point estimates should ideally be accompanied by confidence intervals (CIs).

Confidence interval for NNM

Because NNM is a function of three estimated quantities, pr, Se, and Sp (Eq. 2), its sampling variability cannot be obtained directly from standard variance formulas. An approximate variance (Var) can be derived using the first-order Taylor series expansion (also termed ‘delta method’), which approximates a nonlinear function locally by a linear function in the neighborhood of the estimated values (13). This approximation expresses the variance of the derived measure in terms of the variances of its component estimates, weighted by the corresponding partial derivatives. From Eq. 2, the partial derivatives of NNM with respect to pr, Se, and Sp are:

The approximate variance of NNM, using delta method, is (13):

We have:

where n is the total number of tested individuals. Substituting the values into Eq. 7 and simplifying yield:

Because the variance of NNM is proportional to NNM4, variance increases dramatically as errors become rare (high NNM). Accordingly, an approximate 95% CI for NNM is:

Because NNM is bounded below by zero and its variance increases rapidly as the misdiagnosis rate approaches zero, the resulting confidence interval may be asymmetric in practice; therefore, negative lower limits, if obtained, should be truncated at zero; in such cases, bootstrap-based intervals may provide more reliable estimates (14).

Confidence interval for MDI

Misdiagnosis direction index is also a function of pr, Se, and Sp. From Eq. 3, the partial derivatives of MDI with respect to pr, Se, and Sp are:

Using delta method, the approximate variance of MDI is:

Substituting values from Eq. 7 in Eq. 11 and simplifying give:

The 95% CI of MDI is therefore:

As before, when sample size is small or proportions are extreme, bootstrap confidence intervals may be preferable (14).

The following example is hypothetical and is intended solely to illustrate the proposed indices. Nevertheless, the situation reflects a common problem in laboratory medicine, where two competing assays or diagnostic strategies may exhibit similar overall discriminatory performance while differing substantially in the balance between Se and Sp. Such differences may have important clinical consequences that are not apparent from Youden’s index alone but are captured by the NNM and MDI.

Worked example: complete calculation of NNM, MDI and their 95% CI

Consider two hypothetical diagnostic tests evaluated in a population of 1000 individuals with a disease prevalence of 20%. Thus, 200 individuals are diseased and 800 are disease-free.

The two tests were selected intentionally to demonstrate different error profiles. Suppose Test A has a Se of 0.95 and a Sp of 0.80, hence a Youden’s index of 0.75 (0.95 + 0.80 – 1). The expected outcome values of the test are presented in Table 2. The population FNR and FPR are then 0.01 and 0.16, respectively (Eq. 1). The total misdiagnosis rate is thus 0.17 (FNR + FPR), translating to an NNM of 5.9 (95% CI, 5.1 to 6.7) (Eqs. 2, 8 and 9). The corresponding MDI is 0.15 (0.13 to 0.17) (Eqs. 3, 12 and 13). On average, one misdiagnosis occurs for approximately every six tested individuals. The positive MDI and its 95% CI excluding zero indicate that diagnostic errors are predominantly FP.

Expected classification table for Test A (sensitivity 0.95, specificity 0.80) in a hypothetical population of 1000 individuals with disease prevalence 20%
Disease
Present Absent
Test Result Positive 190 160 250
Negative 10 640 650
200 800 1000
Of the 1000 individuals, 200 are expected to have the disease and 800 are expected to be disease-free. Applying a sensitivity of 0.95 yields 190 true-positive and 10 false-negative results. Applying a specificity of 0.80 yields 640 true-negative and 160 false-positive results. The corresponding population false-negative rate is 0.01 (10/1000), the false-positive rate is 0.16 (160/1000), the total misdiagnosis rate is 0.17 (170/1000), and the number needed to misdiagnose is 5.9. This example illustrates a test with relatively frequent false-positive results.

Now suppose another test, Test B, having a Se of 0.80 and a Sp of 0.95, hence a Youden’s index of 0.75 (0.80 + 0.95 – 1). Table 3 shows the classification table. Given the population FNR of 0.04, and a FPR of 0.04, the NNM is 12.5 (95% CI, 9.9 to 15.1); the MDI is 0 (-0.02, +0.02). This test produces one misdiagnosis for every 12.5 tested individuals, substantially outperforming Test A in overall error frequency. The MDI is zero, indicating no evidence of directional imbalance between FP and FN errors.

Expected classification table for Test B (sensitivity 0.80, specificity 0.95) in a hypothetical population of 1000 individuals with disease prevalence 20%.
Disease
Present Absent
Test Result Positive 160 40 200
Negative 40 760 800
200 800 1000
Of the 1000 individuals, 200 are expected to have the disease and 800 are expected to be disease-free. Applying a sensitivity of 0.80 yields 160 true-positive and 40 false-negative results. Applying a specificity of 0.95 yields 760 true-negative and 40 false-positive results. The corresponding population false-negative rate is 0.04 (40/1000), the false-positive rate is 0.04 (40/1000), the total misdiagnosis rate is 0.08 (80/1000), and the number needed to misdiagnose is 12.5. This example illustrates a test with substantially fewer overall errors and a balanced distribution of false-positive and false-negative results.

Both tests have identical Youden’s indices of 0.75 (Table 4), indicating similar overall discriminatory ability (10). However, NNM and MDI reveal clinically important differences in error frequency and direction. Test A misdiagnoses one in every six patients (predominantly FPs), while Test B misdiagnoses one in every 12.5 patients with balanced error distribution. This demonstrates that Youden’s index alone cannot capture the clinical utility differences between tests with similar discrimination but different error profiles.

Summary of the diagnostic performance measures for two hypothetical diagnostic tests evaluated at disease prevalence of 20% and 30%
Index Prevalence 20% Prevalence 30%
Test A Test B Test A Test B
Sensitivity 0.95 0.80 0.95 0.80
Specificity 0.80 0.95 0.80 0.95
False-negative rate 0.010 0.040 0.015 0.060
False-positive rate 0.160 0.040 0.140 0.035
Youden’s index 0.75 0.75 0.75 0.75
NNM (95% CI) 5.9 (5.1 to 6.7) 12.5 (9.9 to 15.1) 6.5 (5.5 to 7.4) 10.5 (8.5 to 12.5)
MDI (95% CI) 0.15 (0.13 to 0.17) 0.00 (-0.02 to 0.02) 0.13 (0.10 to 0.15) -0.03 (-0.04 to -0.01)
Both tests have identical sensitivities, specificities, and Youden’s indices at each prevalence, indicating equivalent overall discriminatory performance. However, changing disease prevalence alters the population false-negative and false-positive rates and, consequently, the NNM and the MDI. The results illustrate that tests with identical Youden’s indices may differ substantially in the frequency and direction of diagnostic errors and that these differences vary with disease prevalence. NNM – number needed to misdiagnose. MDI – misdiagnosis direction index. CI – confidence interval.

As a real-world laboratory example, consider measurement of prostate-specific antigen (PSA) for prostate cancer screening. Lowering the PSA decision threshold generally increases Se but reduces Sp, leading to more FP results and unnecessary prostate biopsies. Conversely, raising the threshold improves Sp but increases FN results, potentially delaying cancer diagnosis. Conventional measures such as Se, Sp, and Youden’s index summarize diagnostic discrimination, whereas the NNM additionally quantifies how frequently misdiagnoses (either FP or FN) occur in the screened population and the MDI indicates whether the remaining errors predominantly represent FP or FN classifications. These complementary measures may therefore facilitate selection of clinically appropriate PSA decision thresholds. Furthermore, because the clinical consequences of missing an aggressive prostate cancer differ from those of performing an unnecessary biopsy, different healthcare systems or clinical guidelines may reasonably assign different relative weights to FN and FP results when using the wMDI (Eq. 4).

Comparison of two diagnostic tests

Although both tests would generally be considered diagnostically acceptable, they differ substantially in their clinical implications. Test A has higher Se and therefore minimizes FN results (more appropriate for ruling out a disease), but this occurs at the expense of frequent FP results (1, 6, 15). Its positive MDI indicates a strong tendency toward over-diagnosis. Test B, on the other hand, has lower Se but substantially higher Sp (more appropriate for ruling in a disease), resulting in fewer overall errors and balanced misclassification (Table 4).

This example illustrates how NNM and MDI together provide clinically relevant information not conveyed by conventional test performance measures alone. Number needed to misdiagnose answers how often does the test make mistakes; MDI answers in which direction are those mistakes occurring.

To further illustrate the influence of disease prevalence, Table 4 compares the two tests when the prevalence increases from 20% to 30%, while Se and Sp remain unchanged. Although both tests continue to have identical Youden’s indices of 0.75, their NNM and MDI values change appreciably. For Test A, the NNM increases modestly because the reduction in FP results outweighs the increase in FN results, while the MDI remains positive, indicating continued predominance of FP errors. In contrast, Test B shows a decrease in NNM and a shift of the MDI from approximately zero to a negative value, indicating that FN errors become more frequent than FP errors as disease prevalence increases. These findings demonstrate that, unlike Youden’s index, NNM and MDI incorporate the effect of disease prevalence and provide clinically relevant information regarding both the frequency and direction of diagnostic errors.

Number needed to misdiagnose and MDI vary as disease prevalence changes for tests with different Se and Sp profiles. Number needed to misdiagnose is strongly prevalence-dependent (Figure 1). Even when Se and Sp remain fixed, overall diagnostic performance may vary substantially across populations with different disease prevalence. Tests optimized for high Se often exhibit reduced NNM at low prevalence because FP results dominate (Figure 1).

Effect of disease prevalence on the number needed to misdiagnose (NNM) and misdiagnosis direction index (MDI) for three tests with different sensitivity (Se) and specificity (Sp) profiles in 1000 tested individuals. Upper panel: NNM. Lower panel: MDI. Shaded areas represent approximate 95% confidence intervals (delta method). Note strong prevalence dependence of NNM and potential sign change in MDI.

Misdiagnosis direction index may change sign as prevalence changes. At low prevalence, FP errors often predominate, resulting in positive MDI values. As prevalence increases, FN errors become increasingly influential, potentially shifting MDI below zero (Figure 1, lower panel). The prevalence at which MDI crosses zero represents the equilibrium point where FP and FN misclassifications are equally frequent. This behavior highlights the importance of interpreting diagnostic performance in the clinical population of intended use.

For a given test under certain circumstances (constant Se, Sp, and disease prevalence), both MDI and NNM 95% CI widths decrease approximately in proportion to 1/√n as sample size increases (Figure 2). However, because Var (NNM) µ NNM4 (Eq. 8), tests with very low error rates (large NNM values) require considerably larger sample sizes to achieve precise estimates than tests with moderate NNM values. When comparing across different tests, those with larger NNM will show wider confidence intervals for the same sample size. Consequently, even modest uncertainty in Se, Sp, or prevalence may translate into substantial uncertainty in NNM when diagnostic errors are rare. This property emphasizes the importance of reporting confidence intervals alongside point estimates, particularly when very large NNM values are observed.

For the test (sensitivity of 0.95 and specificity of 0.80) and disease prevalence of 20%, the 95% confidence interval (CI) widths of both number needed to misdiagnose (NNM) and the misdiagnosis direction index (MDI) decrease as sample size (n) increases. Both follow approximately 1/√n relationships (note the different Y-axis scales). Both curves follow the same 1/√n decay because, at fixed prevalence, sensitivity, and specificity, the variances of NNM and MDI are each a constant divided by n; the distinctive property of NNM – its variance is proportional to NNM4 – becomes apparent only when comparing tests with different NNM values (Figure 1), not when varying sample size for a single test.

Relationship with ROC curves and cut-off values

Changing the cut-off value of a quantitative test usually changes Se and Sp in opposite directions (5-7). Consequently, NNM and MDI also change. A lower cut-off often increases Se and reduces FNs but may increase FPs. A higher cut-off often increases Sp and reduces FPs, but may increase FNs (5, 15). Therefore, cut-off selection should ideally consider not only ROC characteristics, but also the expected frequency and direction of errors in the intended population (3, 7, 15).

Practical recommendations for reporting

When presenting diagnostic studies, authors should report Se, Sp, predictive values, likelihood ratios, and area under the ROC curve (AUC) as core measures. Where the clinical population prevalence is known or estimable, reporting NNM and MDI with their 95% CIs is also recommended. When the clinical consequences of FP and FN errors differ substantially, the wMDI should be reported alongside the clinical consequence ratio used.

Conclusion

No single metric captures all aspects of diagnostic performance. Conventional indices such as Se, Sp, likelihood ratios, and ROC analysis remain essential, but they do not directly quantify how often a test errs or whether those errors are predominantly FP or FN. The NNM provides an intuitive measure of error frequency, while the MDI indicates the direction of diagnostic error. Together with established measures, these indices may provide a broader and more clinically meaningful understanding of test performance.

Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References HabibzadehF. Diagnostic tests performance indices: an overview. Biochem Med (Zagreb). 2025;35:010101. 10.11613/BM.2025.01010139974192 HabibzadehPYadollahieMHabibzadehF. What is a “Diagnostic Test Reference Range” Good for? Eur Urol. 2017;72:859–60. 10.1016/j.eururo.2017.05.02428558944 Sox HC, Higgins MC, Owens DK, Schmidler GS. Medical decision making. Hoboken: John Wiley & Sons; 2024. 10.1002/9781119627876 FlorkowskiCM. Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Clin Biochem Rev. 2008;29 Suppl 1:S83–7.18852864 AltmanDGBlandJM. Diagnostic tests 3: receiver operating characteristic plots. BMJ. 1994;309(6948):188. 10.1136/bmj.309.6948.1888044101 AltmanDGBlandJM. Diagnostic tests. 1: Sensitivity and specificity. BMJ. 1994;308(6943):1552. 10.1136/bmj.308.6943.15528019315 HabibzadehFHabibzadehPYadollahieM. On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med (Zagreb). 2016;26:297–307. 10.11613/BM.2016.03427812299 HabibzadehFHabibzadehP. The likelihood ratio and its graphical representation. Biochem Med (Zagreb). 2019;29:020101. 10.11613/BM.2019.02010131015780 GoligherECHeathAHarhayMO. Bayesian statistics for clinical research. Lancet. 2024;404:1067–76. 10.1016/S0140-6736(24)01295-939277290 YoudenWJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5. 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-315405679 HabibzadehFYadollahieM. Number Needed to Misdiagnose. Epidemiology. 2013;24:170. 10.1097/EDE.0b013e31827825f223232619 VickersAJElkinEB. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models. Med Decis Making. 2006;26:565–74. 10.1177/0272989X0629536117099194 Cox C. Delta method. In: Armitage P, Colton T, editors. Encyclopedia of Biostatistics. 2nd ed. Chichester: John Wiley & Sons; 2005. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993. 10.1007/978-1-4899-4541-9 Newman TB, Kohn MA. Evidence-Based Diagnosis. New York: Cambridge University Press; 2009. 10.1017/CBO9780511759512
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030101" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-3-030101" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.030101" ["journals_article_pubdate"]=> string(10) "2026-10-15" ["journals_article_title"]=> string(70) "Beyond accuracy: how often and in which direction diagnostic tests err" ["journals_article_author"]=> string(18) "Farrokh Habibzadeh" ["journals_article_author_country"]=> string(4) "Iran" ["journals_article_categories_heading"]=> string(24) "Lessons in biostatistics" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(110) "sensitivity, specificity, diagnostic errors, false positive reactions, false negative reactions, biostatistics" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2633" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "1" ["meta_title"]=> string(70) "Beyond accuracy: how often and in which direction diagnostic tests err" ["meta_desc"]=> string(70) "Beyond accuracy: how often and in which direction diagnostic tests err" ["meta_keyw"]=> string(110) "sensitivity, specificity, diagnostic errors, false positive reactions, false negative reactions, biostatistics" ["created"]=> string(19) "2026-10-01 10:51:00" ["modified"]=> string(19) "2026-10-02 11:00:35" } [17]=> object(stdClass)#66 (35) { ["journals_id"]=> string(4) "1237" ["journals_xml"]=> string(111887) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-021201 10.11613/BM.2026.021201 Corrigendum Corrigendum to: Refining quality control strategies in highly automated laboratories: experience in the integration of multistage statistical designs and risk management Costa-PallarueloMaria*12Garcia-OsunaAlvaro12CanyellesMarina12Martinez-BruCecilia2NanNicoleta1Ferrer-PerezRosa12Blanco-VacaFrancisco1GuinonLeonor123 Biochemistry Department, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain Core Laboratory, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Quality Department Laboratories, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Corresponding author: mcostap@santpau.cat 15042026 15062026 36 2 021201 0202202610032026 ©Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

This is a correction of Biochem Med (Zagreb) 2025;35(3):030704. DOI: https://doi.org/10.11613/BM.2025.030704.

Since the publication of the article, the authors have noticed an error in the calculation of the sigma metric. The corrected calculations are presented below. We apologize to the readers for any inconvenience this error may have caused.

During a post-publication review of the calculations, an error was identified in the formula used for the calculation of the sigma metric. Specifically, the calculations were performed without considering the absolute value in the formula: Sigma (σ) = (TEa − |SE|) / CV (where TEa represents the allowable total error, SE the systematic error and CV the coefficient of variation).

Consequently, the sigma values reported for the evaluated parameters were affected. After identifying this issue, the sigma metrics were recalculated using the correct formula including the absolute value of SE. Subsequently, all related analyses and procedures based on these sigma values were repeated using the corrected calculations.

All corrections are underlined to facilitate identification of the changes from the previously published version.

Corrections in the Abstract

Results: Additionally, to streamline management, the QCP covering the greatest number of parameters per analyzer was prioritized, which ultimately resulted in the adoption of only three general QCP. Only 4 individualized QCP were required to cover 9 parameters with lower sigma values.

Corrections in the Methods section

For each quality control level in each analyzer, the sigma value was calculated using the equation: Sigma (σ) = (TEa - |SE|) / CV.

Corrections in the Results section

The mean sigma values obtained for each parameter in each of the analyzers are shown in Tables 2 and 3, respectively. All Alinity systems showed 9 to 14 parameters with sigma values ≥ 6, 4 to 8 parameters with sigma between 5 and 6, 3 to 5 parameters with sigma between 4 and 5 and up to 2 parameters with sigma < 4.

This resulted in the adoption of only three QC plans (QCP 1, 2 and 3) out of the seven initially defined. As shown in Table 8, only nine parameters with lower sigma values required individualized QC plans due to their need for stricter QC rules. These nine parameters were effectively covered by four individual QCPs.

Corrections in the Discussion section

Second, for measurement procedures with sigma values between 4.65 and 6, QC rules can be selected based on the desired run size, while maintaining an acceptable Max E(Nuf). For measurement procedures with sigma values between 4 and 4.65, achieving an acceptable Max E(Nuf) requires applying more complex QC rules, such as multiple control rules 13s/22s/R4s/41s (MR N4), in the “startup” stage to reach an appropriate Ped, regardless of the desired run size.

Corrections in Tables Mean sigma values for the parameters measured in Alinity c systems
Parameter σ, mean
Alinity c1 Alinity c2 Alinity c3 Alinity c4
Albumin ≥ 6 ≥ 6 5.56 5.39
AP ≥ 6 5.30 ≥ 6 5.94
ALT 4.75 4.68 5.81 5.16
Amylase na ≥ 6 ≥ 6 na
AST ≥ 6 na 4.97 ≥ 6
Calcium 5.84 5.66 5.14 5.82
Cholesterol na 5.06 4.51 4.96
Chloride 4.14 3.31 4.63 na
CK na ≥ 6 ≥ 6 ≥ 6
Creatinine ≥ 6 ≥ 6 ≥ 6 ≥ 6
Direct Bilirubin ≥ 6 na ≥ 6 na
GGT ≥ 6 4.19 ≥ 6 ≥ 6
Glucose 5.61 ≥ 6 ≥ 6 ≥ 6
HDL na na na 4.21
LD ≥ 6 na ≥ 6 ≥ 6
Magnesium 3.00 na 2.45 3.31
CRP ≥ 6 ≥ 6 ≥ 6 ≥ 6
Potassium 5.77 5.81 5.32 na
Sodium 3.12 3.49 3.22 na
Total Bilirubin ≥ 6 ≥ 6 ≥ 6 5.14
Total Protein ≥ 6 ≥ 6 ≥ 6 ≥ 6
Triglyceride ≥ 6 na ≥ 6 ≥ 6
Urea ≥ 6 ≥ 6 4.78 5.69
Uric Acid na ≥ 6 4.55 na
Albumin U na 5.54 na na
Calcium U na ≥ 6 na na
Creatinine U ≥ 6 ≥ 6 na na
Glucose U na ≥ 6 na na
Phosphorus U na 5.23 na na
Potassium U ≥ 6 ≥ 6 na na
Sodium U 4.61 5.00 na na
Urea U 5.62 5.21 na na
σ - sigma. AP - alkaline phosphatase. ALT - alanine aminotransferase. AST - aspartate aminotransferase. CK - creatine kinase. HDL - high density lipoprotein. LD - lactate dehydrogenase. GGT - gamma-glutamyl transferase. CRP - C-reactive protein. U - urine. na - parameter not available.
Quality control plans for the parameters measured in Alinity c systems
Parameter Alinity c1 Alinity c2 Alinity c3 Alinity c4
QCP Category QCP Category QCP Category QCP Category
Albumin 1 B 1 C 1 C 1 D
AP 1 B 1 C 1 C 1 D
ALT 5 B 5 B 1 C 2 D
Amylase na na 1 D 1 E na na
AST 1 C na na 3 C 1 D
Calcium 1 B 1 C 2 C 1 D
Cholesterol na na 2 C 4 E 2 D
Chloride 4 E - E 7 E na na
CK na na 1 D 1 E 1 E
Creatinine 1 A 1 B 1 C 1 C
D Bil 1 E na na 1 E na na
GGT 1 B 6 C 1 C 1 D
Glucose 1 B 1 B 1 C 1 D
HDL na na na na na na 4 D
LD 1 C na na 1 E 1 E
Magnesium - C na na - E - E
CRP 1 C 1 C 1 C 1 D
Potassium 1 B 1 B 2 A na na
Sodium - B - B - A na na
T Bil 1 B 1 C 1 C 2 D
Total Protein 1 C 1 C 1 C 1 D
Triglyceride 1 C na na 1 E 1 D
Urea 1 A 1 A 5 C 1 C
Uric Acid na na 1 E 4 E na na
Albumin U na na 1 D na na na na
Calcium U na na 1 E na na na na
Creatinine U 1 E 1 E na na na na
Glucose U na na 1 E na na na na
Phos U na na 1 E na na na na
Potassium U 1 E 1 E na na na na
Sodium U 7 E 2 E na na na na
Urea U 1 E 1 E na na na na
AP - alkaline phosphatase. ALT - alanine aminotransferase. AST - aspartate aminotransferase. CK - creatine kinase. D Bil – direct bilirubin. HDL - high density lipoprotein. LD - lactate dehydrogenase. GGT - gamma-glutamyl transferase. CRP - C reactive protein. Phos – phosphorus. QCP - quality control plan. T Bil - total bilirubin. U - urine. na - not available. “-“ - sigma < 4.
Framework for selecting a quality control plan based on the sigma level of measurement procedures
Sigma level “Startup” stage “Monitor” stage
≥ 6 12.5s N1 QC rules could be selected based on the desired run size*
4.65-6 QC rules could be selected based on the workload* QC rules could be selected based on the desired run size*
4-4.65 MR N4 QC rules could be selected based on the desired run size*
< 4 na† na†
*QC rule could be selected based on the “sigma metric statistical QC run size nomogram” proposed by Westgard et al (1). †No QC strategy is available, as no “startup” QC rule achieves a Ped ≥ 0.9. Improvement of the analytical performance is needed. QC - quality control. N - number of quality control measurements per QC event.
Quality control plan implemented by analyzer and individualized quality control plans for specific parameters
Analyzer QCP Individualized QCP, parameter
Alinity1 c1 1 5, ALT; 4, chloride; 7, sodium U
Alinity1 c2 2 5, ALT; 6, GGT
Alinity2 c3 3 4, cholesterol and uric acid; 5, urea; 7, chloride
Alinity3 c4 2 4, HDL
Cobas Pro1 3 -
Cobas Pro2 3 4, NT-proBNP
ALT - alanine aminotransferase. HDL - high density lipoprotein. NT-proBNP - N-terminal pro brain natriuretic peptide. QCP - quality control plan.
Allowable total error (and source of the analytical performance specification) applied to each parameter measured in Alinity c systems
TEa Source
Albumin 8.25 p90 SEQC
AP 21.00 MCS
ALT 18.70 EFLM des
Amylase 13.10 EFLM des
AST 18.70 EFLM min
Calcium 9.10 MCS
Cholesterol 8.30 EFLM des
Chloride 6.00 MCS
CK 8.50 p90 SEQC
Creatinine 22.00 MCS
D Bil 23.40 EFLM des
GGT 9.20 EFLM opt
Glucose 9.30 EFLM min
HDL 14.90 EFLM min
LD 21.00 MCS
Magnesium 9.40 MCS
CRP 26.00 EFLM opt
Potassium 7.30 EFLM min
Sodium 3.20 MCS
T Bil 37.00 EFLM min
Total Protein 9.00 MCS
Triglyceride 26.20 EFLM des
Urea 17.10 EFLM des
Uric Acid 12.50 EFLM des
Albumin U 14.00 MCS
Calcium U 16.00 MCS
Creatinine U 13.00 MCS
Glucose U 8.40 MCS
Phos U 11.00 MCS
Potassium U 8.60 MCS
Sodium U 7.20 MCS
Urea U 13.00 MCS
AP - alkaline phosphatase. ALT - alanine aminotransferase. AST - aspartate aminotransferase. CK - creatine kinase. CRP - C-reactive protein. D Bil - direct bilirubin. EFLM des - desirable analytical performance specification (APS) according to the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) biological variation database (10). EFLM min - minimum APS according to the EFLM biological variation database (10). EFLM opt - optimal APS according to the EFLM biological variation database (10). HDL - high density lipoprotein. LD - lactate dehydrogenase. GGT - gamma-glutamyl transferase. MCS - Spanish minimum consensus specification, based on state-of-the-art performance (12). p90 SEQC - 90th percentile of measurement errors provided by the Spanish Society of Laboratory Medicine (SEQCML) from the external quality assessment schemes, used as a state-of-the-art APS. Phos – phosphorus. QCP - quality control plan. SOTA - state-of-the-art. T Bil - total bilirubin. TEa - allowable total error. U – urine.
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "021201" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-021201" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.021201" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(169) "Corrigendum to: Refining quality control strategies in highly automated laboratories: experience in the integration of multistage statistical designs and risk management" ["journals_article_author"]=> string(154) "Maria Costa-Pallaruelo, Alvaro Garcia-Osuna, Marina Canyelles, Cecilia Martinez-Bru, Nicoleta Nan, Rosa Ferrer-Perez, Francisco Blanco-Vaca, Leonor Guinon" ["journals_article_author_country"]=> string(5) "Spain" ["journals_article_categories_heading"]=> string(11) "Corrigendum" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(0) "" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1912" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "19" ["meta_title"]=> string(85) "Corrigendum to: Refining quality control strategies in highly automated laboratories:" ["meta_desc"]=> string(85) "Corrigendum to: Refining quality control strategies in highly automated laboratories:" ["meta_keyw"]=> string(0) "" ["created"]=> string(19) "2026-04-07 11:17:34" ["modified"]=> string(19) "2026-06-11 09:03:33" } [18]=> object(stdClass)#67 (35) { ["journals_id"]=> string(4) "1253" ["journals_xml"]=> string(29598) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-021001 10.11613/BM.2026.021001 Preanalytical mysteries A challenging laboratory case due to inappropriate sampling through an antiseptic barrier cap IntrocasoGiovanni*1PirasGiorgia1MandelliGiorgia2FrisoliSabrina2BottariFabio1 Clinical Laboratory Unit, Centro Cardiologico Monzino IRCCS, Milan, Italy Intensive Care Unit, Centro Cardiologico Monzino IRCCS, Milan, Italy Corresponding author: giovanni.introcaso@ccfm.it

Author contributions

G Introcaso: Conceptualization, Methodology, Writing – review & editing; G Piras: Formal analysis, Investigation; G Mandelli: Formal analysis, Investigation; S Frisoli: Visualization, Supervision. F. Bottari: Review and editing.

15062026 15062026 36 2 021001 0509202510042026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Blood sampling is a process that can generate preanalytical errors

• Isopropanol contamination alters red blood morphology and cytometry

• Preanalytical error detected by hematology analyzers could be confirmed by peripheral blood smear

• Collaborative work between nurse and laboratory teams improves quality results

Antiseptic barrier caps are currently used as novel tools in critically ill patients to achieve sterility of the blood sampling site and to prevent central line-associated bloodstream infections in the intensive care unit. A clinical and laboratory case of analytical interferences on erythrocytes, platelets and leukocytes due to the isopropyl alcohol contained in the antiseptic barrier cap is described. An aged man with history of heart valve disease was monitored for hematological parameters after surgery of mitral and tricuspid valve replacement. Leukocyte scattergrams changes on the Sysmex XN 2000 analyzer with the suspicion of platelet clumps were observed. After investigation on sampling procedure, antiseptic barrier cap of an arterial access (BD PureHub disinfecting cap) was used. Another sample has been requested, and the analysis of complete blood count and peripheral blood smear confirmed the presence of clumped microerythrocytes and erythrocytes with damaged membranes. In addition, differential leukocyte count revealed an overestimation of eosinophils by 10%. A new sample taken from venous access provided accurate results without alterations. The preanalytical error generated during blood sampling highlights the importance of correct use of biomedical devices. Furthermore, hematology analyzer technology represents a promising tool for assessing sample quality.

Keywords: alcohol contaminationanalytical interferenceshematological analyzerinappropriate samplingpreanalytical phase
Introduction

The present case report describes a laboratory challenge in identifying a preanalytical error and an example of effective collaboration between the clinical laboratory and the inpatient departments. Antiseptic barrier caps are currently used as novel tools in critically ill patients to achieve sterility of the blood sampling site then to prevent central line-associated bloodstream infections in the intensive care unit (ICU) (1). Recommendations and guidelines have been formulated by the Centers for Disease Control and Prevention (CDC) to prevent the common problem of hospital-acquired infections (2). Patients are treated in critical care settings such as ICUs, where bundled protocols are increasingly required, such as the septic bundle protocol. Furthermore, bedside care and treatment for critically ill patients requires special attention among healthcare workers, and standardization of therapeutic and care procedures is required.

Hematological analyzers provide a large amount of potentially useful data with the main parameters (i.e. complete blood count (CBC), leukocyte differential count, and hemoglobin (Hb) measurement). These parameters, called “research use only” (RUO), can provide useful information not only for pathologies but also about sample quality (3-6).

In this clinical case we demonstrated analytical interferences on the analyses of erythrocytes, platelets and leukocytes due to the isopropyl alcohol contained in the antiseptic cap of a luer connector. Instrumental flags along with analysis of scattergrams allowed detection of interferences in the ethylenediaminetetraacetic acid (EDTA) blood sample. An aged man with a history of heart valve disease was hospitalized for mitral and tricuspid valve replacement surgery. However, the patient underwent coronary artery bypass grafting under normothermic extracorporeal circulation and cardioplegic arrest. Two units of packed red blood cells were transfused. Biochemical and hematological tests were requested daily showing postsurgical anemia and high inflammatory markers. On the fourth day of ICU monitoring, an EDTA sample was processed in the laboratory for CBC. This common laboratory test allows monitoring the immunological response, the state of anemia and hemostasis in the post-operative period.

In addition, modern analyzers can be useful to define preanalytical conditions of anticoagulated blood samples that could influence diagnostic test results. Our clinical case highlights the role of new analytical technologies and laboratory procedure in improving the quality of diagnosis or clinical monitoring in hematology.

Laboratory analyses

During routine work, the technician and the laboratory specialist observed changes in leukocyte scattergrams of the patient sample on the Sysmex XN 2000 analyzer (Sysmex Corporation, Kobe, Japan) (Figure 1). Afterwards, a peripheral blood smear (PBS) on fresh whole blood and May-Grünwald Giemsa staining was scheduled for the suspicion of platelet (PLT) clumps highlighted by the PLT flag: PLT clumps? on the analyzer screen. The EDTA sample was macroscopically inspected and showed no abnormalities; a repeated PLT count on the fluorescent channel (PLT-F) confirmed the previous PLT count without instrumental flags. No platelet aggregation was detected with this channel. However, analysis of PBS excluded the presence of PLT agglutinates or aggregates. A careful evaluation of the smear revealed damaged erythrocytes and microerythrocytes that agglutinated and simulated on the analyzer agglutinated platelets (Figure 2). The damaged red blood cells produced hemolysis which however did not cause a significant change in the patient’s hemoglobin concentration (Figure 1 and Figure 3). Fresh whole blood smear allowed us to quickly highlight anomalous morphological features and to recognize the alterations of the red blood cells. A blood smear with May-Grünwald Giemsa technique confirmed the previous criticisms (Figure 2). Alterations of leukocyte scattergrams generated the PLT clump flag on the white cell differential (WDF) and white cell nucleated red (WNR) channels and the suspicion of leukocyte misclassification. For this reason, we prompted the control of leukocyte differential count by manual microscope method revealing an analytical overestimation of eosinophils of 10%. A complete blood count on a new sample from the ICU showed these data without quantitative and qualitative alterations (Figure 3).

Complete blood count results of the isopropanol contaminated sample. The scattergrams show interferences in both the White cell differential (WDF) and White cell nucleated red (WNR) channels (blue color). Eosinophils were not well separated (red color) determining an overestimation. Scattergram dispersion generated the false platelet clumps (PLT Clumps?) flag.

Red blood cells with alterations and membrane damage (red arrows). Microerythrocytes agglutination resulted as effect of isopropanol 70% (blue arrows). Above, the fresh blood smear. Below, the May-Grünwald smear (1000X).

Complete blood count results of the second sample. Leukocyte populations are well separated without interferences and instrumental flags.

What happened?

During daily post-surgery patient monitoring in ICU, blood samples for hematological tests were obtained from a luer connector. In the laboratory, scattergram analysis of differential leukocyte and instrumental flags suggested the presence of PLT agglutinates or the possible infection due to fungi or microorganisms. However, a PBS as additional investigation was performed. We called the ICU asking for clinical information and if there were any problems with the sampling. A variation of the sampling procedure has been reported: the cap has been used directly without the backflow valve (BD PureHub disinfecting cap, Becton, Dickinson and Company, Franklin Lakes, USA). This procedure may have generated sample contamination. The disinfectant may therefore have been accidentally aspirated into the EDTA tube during collection and a small amount of 70% isopropanol could have therefore contaminated the sample, causing cytological damage of red blood cells. At this point, to verify the contamination hypothesis, a new blood sample taken from another access route was then requested. Results on a new EDTA sample with normal outcomes (Figure 3) confirmed the preanalytical hypothesis. The information obtained by a phone call with the ICU nurse asking for explanations on the sampling procedures has been very important. It allowed us to suppose a variation of the sampling procedure used in ICU clarifying that the observed analytical anomalies could be due to the sampling phase. The explanation of the use of the luer connector and the cap with 70% isopropanol disinfectant allowed us to resolve this challenging case due to a preanalytical error of inappropriate sampling. A careful team evaluation of the analytical and preanalytical data allowed us to correct the sampling error before the clinical results validation and reporting.

Discussion

Technology of modern hematological analyzers using laser beam on a biological sample by light scattering allowed us to obtain important clinical information along with PBS evaluation (6, 7). These analyzers automatically provide new data defined cell population data (CPD) or leukocyte CPD (5-8). However, recent studies aimed to determine the accuracy of instrumental flags on Sysmex analyzers for detecting platelet clumps (9-11). Therefore, preanalytical evaluation of the blood sample from which the quality of the results derives is increasingly investigated. Flow cytometry used in hematology analyzers could provide automated analysis of sample suitability prior to analytical parameter analysis. Our work underlines the possibility of preanalytical error detection using instrumental flags with biological interferences; then, the instrument highlights the possible issue that requires further investigation. Indeed, in this case report, we described the detection of errors during a blood sampling through carefully evaluated platelet flags and leukocyte scattergrams. To date, microscopic analysis using a PBS evaluation was essential to clarify the analyzer flags: a suspicion of morphological alteration or sample artefacts requires a PBS confirmation. In fact, red blood cell damage and related parameter alterations due to sample contamination by isopropyl alcohol were highlighted. In literature there are numerous cases of contamination of samples for microbiological and genetic tests. Our report first reported a case of preanalytical error due to contamination through an antiseptic barrier, although many cases of red blood cell alterations are known. For instance, the effects of cephalosporins on red blood cells are well known. Ceftriaxone, a widely used antibiotic, is one of the most common drugs to cause drug-induced immune hemolytic anemia with alterations of RBC derived-parameters (11, 12). Today, antiseptic barrier caps are currently used as biomedical devices to optimize blood sampling while reducing bacterial infections. Here, we have shown an occasionally improper use of these devices determining an inappropriate sampling with potential incorrect results and patient misclassification. In our laboratory, there is currently a procedure for preanalytical evaluation but it is operator dependent. As a corrective action, standardization of sampling procedures in the department and a careful validation of the preanalytical phase by the analyzer might be implemented. Flow cytometry seems to be a promising technique for identifying inappropriate samples.

What YOU should do in your laboratory to prevent such errors

The BD PureHub disinfectant cap is currently used as novel biomedical device, designed to provide high-level protection for needle-free luer connectors. These devices are cornerstones for care reducing the risk of bacterial contamination, both as a rapid disinfectant and as a protective barrier between catheter access points. Although rare events, inappropriate use of these biomedical devices can occur in clinical practice, especially in critical conditions. For this reason, shared procedures between operators and protocols aimed at standardizing healthcare are essential. Collaboration between laboratory and ICU was crucial in detecting non-conformity. For this, continuous education for both laboratory technicians and ICU staff can help prevent errors. Besides, specific protocols for preanalytical evaluation in clinical laboratories are required. In this sense, the definition of instrumental flags to detect preanalytical errors will be increasingly important. Fluorescent platelet channel on Sysmex analyzers detecting PLT aggregation or PLT agglutination is promising. Careful sample evaluation remains crucial to increase the quality of clinical data. Standardization of preanalytical phase through new technological insights is required to improve the total quality. Furthermore, implementation of validation rules on hematology analyzers may improve the detection of preanalytical errors helping laboratory teamwork.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References GillisVELMvan EsMJWoutersYWantenGJA. Antiseptic barrier caps to prevent central line-associated bloodstream infections: A systematic review and meta-analysis. Am J Infect Control. 2023;51:827–35. 10.1016/j.ajic.2022.09.00536116679 Guidelines for the Prevention of Intravascular Catheter-Related Infections. 2011. Available from: https://www.cdc.gov/infection-control/hcp/intravascular-catheter-related-infection/index.html Accessed January 15th 2026. DavesMRoccaforteVLombardiFPanellaRPastoriSSpreaficoM Modern hematology analyzers: beyond the simple blood cells count (with focus on the red blood cells). J Lab Precis Med. 2024;9:4. 10.21037/jlpm-23-32 La GioiaABasileMFioriniFAndreoliESalamoneDFioriniM. Pseudoerythroblastosis on Sysmex XN hematology analyzers: a clue to Candida sepsis. Case report and literature review. Clin Chem Lab Med. 2022;60:e210–2. 10.1515/cclm-2022-048635730140 ParkDHParkKParkJParkHHChaeHLimJ Screening of sepsis using leukocyte cell population data from the Coulter automatic blood cell analyzer DxH800. Int J Lab Hematol. 2011;33:391–9. 10.1111/j.1751-553X.2011.01298.x21338473 UrrechagaEBovedaOAguirreU. Role of leucocytes cell population data in the early detection of sepsis. J Clin Pathol. 2018;71:259–66. 10.1136/jclinpath-2017-20452428821583 IntrocasoGGalottaASalviniLFaioniEMBonomiAAssanelliE Leukocyte cell population data as potential markers of Covid-19 disease characterization. J Med Biochem. 2023;42:454–9. 10.5937/jomb0-4158937790201 SheanRCWilliamsMCRetsAV. Advances in Hematology Analyzers Technology. Clin Lab Med. 2024;44:377–86. 10.1016/j.cll.2024.04.00139089744 WooSKimBHun HeoNKimMSYoonYAChoiYJ. Definition of Significant Platelet Clumping: Should We Review All Samples With a Platelet Clumping Flag From Automated Hematology Analyzer? Int J Lab Hematol. 2025;47:79–86. 10.1111/ijlh.1438739434430 XuPFangKChenXLiuYDongZZhuJ The Flagging Features of the SysmexXn-10 Analyser for Detecting Platelet Clumps and the Impacts of Platelet Clumps on Complete Blood Count Parameters. Clin Chem Lab Med. 2022;60:748–55. 10.1515/cclm-2021-122635212492 AndrasicPZrinski TopicRPavicIJasna Lenicek KrlezaJ. Red blood cell agglutination caused by ceftriaxone and its effect on erythrocyte parameters: a case report. Biochem Med (Zagreb). 2025;35:011002. 10.11613/BM.2025.01100239703758 BarcelliniWZaninoniAGiannottaJAFattizzoB. New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy. J Clin Med. 2020;9:3859. 10.3390/jcm912385933261023
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "021001" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-021001" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.021001" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(93) "A challenging laboratory case due to inappropriate sampling through an antiseptic barrier cap" ["journals_article_author"]=> string(83) "Giovanni Introcaso, Giorgia Piras, Giorgia Mandelli, Sabrina Frisoli, Fabio Bottari" ["journals_article_author_country"]=> string(5) "Italy" ["journals_article_categories_heading"]=> string(23) "Preanalytical mysteries" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(116) "alcohol contamination, analytical interferences, hematological analyzer, inappropriate sampling, preanalytical phase" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2838" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "18" ["meta_title"]=> string(93) "A challenging laboratory case due to inappropriate sampling through an antiseptic barrier cap" ["meta_desc"]=> string(93) "A challenging laboratory case due to inappropriate sampling through an antiseptic barrier cap" ["meta_keyw"]=> string(116) "alcohol contamination, analytical interferences, hematological analyzer, inappropriate sampling, preanalytical phase" ["created"]=> string(19) "2026-06-01 10:59:28" ["modified"]=> string(19) "2026-06-11 09:03:24" } [19]=> object(stdClass)#68 (35) { ["journals_id"]=> string(4) "1236" ["journals_xml"]=> string(59594) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020902 10.11613/BM.2026.020902 Case reports Extrapyramidal and anticholinergic reactions in an adolescent patient: a case for pharmacogenetic consideration Žunić IšasegiIris*1StefanovićIvana1Okružnik ŽelalićMarta1ŠimičevićLivija23GanociLana23ŽivkovićMaja34BegovacIvan13BožinaNada3 Department of Child and Adolescent Psychiatry, University Hospital Centre Zagreb, Zagreb, Croatia Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia School of Medicine, University of Zagreb, Zagreb, Croatia Department of Psychiatry and Psychological Medicine, University Hospital Centre Zagreb, Zagreb, Croatia Corresponding author: iris.zunic.isasegi1@kbc-zagreb.hr

Author contributions

I Žunić Išasegi and I Begovac: conceptualized the principal ideas and developed the outline of the proof; L Šimičević and L Ganoci: conducted the pharmacogenetic testing and performed the interpretation of the results; I Begovac, M Živković. and N Božina: participated in the planning process and oversaw all stages of the work; N Božina: supervised pharmacogenetic testing and interpretation of results; I Stefanović. and M Okružnik Želalić: contributed to the interpretation of the findings, including aspects related to clinical practice; All authors provided critical feedback and played an integral role in shaping the research, analysis, and writing manuscript.

15042026 15062026 36 2 020902 0909202502022026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• The more polymorphic the symptoms, the more complex the treatment of adolescent patients

• An adolescent patient developed extrapyramidal symptoms after fluphenazine

• Patient developed anticholinergic syndrome after biperiden, following extrapyramidal symptoms from fluphenazine

• Pharmacogenetic testing showed CYP2C9 poor and CYP2D6 normal–intermediate metabolism

• Pharmacogenetic findings reveal patient characteristics, supporting genotype-guided therapy.

Adolescent patients with borderline personality traits present a significant clinical challenge due to their polymorphic symptomatology occurring together with ongoing psychological and physiological development. While psychotherapy remains the first-line treatment, it is often combined with different psychopharmacological medications. This case report presents a 17.5-year-old female adolescent who developed extrapyramidal symptoms (EPS) following the addition of fluphenazine to her therapy, which had been modified due to deteriorating psychiatric symptoms. After the resolution of the EPS, the patient developed anticholinergic syndrome within a few days. Pharmacogenetic testing showed genetic variations associated with modified drug and dopamine metabolism, which may have contributed to her increased predisposition to drug adverse effects. This case highlights the complexity of psychopharmacological management in adolescents with multidimensional symptomatology and emphasizes the potential value of integrating pharmacogenetic data to guide optimal treatment strategies.

Keywords: borderline personality traitschild and adolescent psychiatryextrapyramidal symptomsanticholinergic syndromepharmacogenetics
Introduction

Treatment of patients with borderline personality disorder (BPD) traits in adolescence represents a great challenge because of their polymorphous symptomatology. Although psychotherapy remains the first line of treatment, an additional psychopharmacological approach, unfortunately often off label, is also required. In adolescents, off-label use of medications - prescribing drugs outside approved indications, age ranges, or dosages - is often necessary and considered ethically appropriate when guided by evidence, careful risk-benefit assessment, proper monitoring, and informed parental involvement. The greater the polymorphic nature of symptomatology, the more complex the treatment approach is required in adolescents. In cases of polymorphic symptomatology, priority is given to addressing the most severe and dangerous symptoms first. For example, in BPD traits, these include suicidality, poor self-image, and related manifestations. It is also common in clinical practice to implement a combination of therapeutic approaches and to adjust or change pharmacological treatments as needed. Many physiological changes take place during childhood and adolescence, which may affect the pharmacokinetics of psychotropic drugs (1-4). Consequently, adolescent psychopharmacotherapy warrants caution during treatment initiation and adjustment. Pharmacogenetic testing facilitates personalized and efficacious treatment strategies by elucidating inter-individual variability in drug effects attributable to genetic differences, thereby mitigating empirical prescribing, diminishing adverse effects, expediting therapeutic response, and enhancing the likelihood of remission.

The patient’s parents provided written informed consent during her treatment for the potential use and publication of clinically relevant data. This was done in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments, ensuring full protection of the patient’s identity and the confidentiality of all related data.

Case description

This is a case report about 17.5-year-old girl with a history of psychiatric treatment since she was 13.5 years old. The patient presented with restrictive anorexia nervosa, which later expanded to polymorphous symptomatology. It included non-suicidal self-harm behavior often accompanied with high suicidal risk, gender dysphoria elements, bulimic behavior, and dissociative phenomena. Furthermore, she suffered from affective instability, unstable interpersonal relationships, chronic feelings of emptiness, and an intense fear of abandonment.

The clinical presentation of our patient required intensive psychotherapy sessions combined with psychopharmacological treatment. Over the course of four years, she experienced multiple inpatient stays, received care at a day hospital and recurrent outpatient treatment approximately every two weeks. Standard examinations were often performed, including monitoring the dynamics of blood tests, electrocardiograms, electroencephalograms, brain magnetic resonance imaging, and psychological testing. She was also continuously followed in pediatric care due to the potential somatic consequences of eating disorder symptoms.

From January, the therapy included fluoxetine, quetiapine, and diazepam. The timeline of therapy changes, including daily doses, along with the occurrence of side effects, is presented in Figure 1. During an outpatient treatment session in April 2024, when she was 17.5 years old, she admitted to having experienced paranoid ideations for a long time, which caused her significant distress. At that time, her pharmacotherapy regimen included fluoxetine at daily dose (DD) of 20 mg, quetiapine XR (extended release) 50 mg, quetiapine IR (immediate release) 25 mg (administered at noon), clonazepam as needed at 0.5 mg. with a maximum dose of three tablets per day. Due to the observed anxious-related paranoid ideation and the evident progressive deterioration in her clinical presentation, mostly regarding BPD traits, pharmacotherapy was revised. The revised therapy included a gradual discontinuation of fluoxetine (20 mg administered every other day for 10 days, followed by complete cessation), an increase of quetiapine XR dose to 100 mg daily, quetiapine IR 25 mg on an as-needed basis (up to 2-3 times per day) and the introduction of fluphenazine in DD of 1mg. The clonazepam dosage remained unchanged (Figure 1).

Timeline of administered medications and associated adverse drug reactions. DD - daily dose. (Icons from Phosphor Icons, licensed under the MIT License).

Five days after the introduction of the new pharmacotherapy regimen, the patient and her mother contacted us by telephone, reporting symptoms indicative of acute dystonia. The patient was immediately invited and examined in our outpatient clinic the same day. She described muscle rigidity in the back, neck, and the thighs, with intermittent blurred vision, which had begun the previous day. Her legal guardian confirmed regular intake of the prescribed therapy and reported that she had difficulty walking with occasional backward movements of the neck. Our patient skipped her morning dose that day and her symptoms gradually improved by the time she arrived at our department. Physical examination revealed normal vital signs, with no symptoms of significant muscle rigidity or laryngeal spasm/dysphonia.

At the examination, a 2 mg dose of biperiden was administered, after which the patient reported subjective relief from muscle rigidity. Her pharmacotherapy was promptly revised: fluphenazine and fluoxetine were immediately discontinued, biperiden was initiated at 2 mg once daily for the following two days, the quetiapine XR dose was increased to 150 mg daily, and clonazepam was maintained at the current dose.

Two days later, patients mother contacted us again, and we recommended a pediatric evaluation through the emergency department because our patient was experiencing the following symptoms: headache, nausea without vomiting, alternating constipation and diarrhea, an intermittent feeling of suffocation with blurred vision when looking down and straight ahead, mydriasis, diplopia, difficulty urination. At the emergency department, the patient was examined by an ophthalmologist due to suspected narrow-angle glaucoma. The patient’s vital signs were within normal limits. Supportive somatic treatment was initiated, including the discontinuation of the current psychopharmacotherapy and the introduction of diazepam instead. The patient continued psychiatric treatment and was admitted to our department five days after the pediatric evaluation for pharmacological modification under inpatient conditions. Aripiprazole was gradually introduced during the inpatient stay, reaching daily dose of 7.5 mg, at which point the patient reported blurry vision. A follow-up ophthalmological examination suggested possible side effects of aripiprazole, after which aripiprazole was excluded from therapy. The patient was maintained on diazepam monotherapy. Considering the patient’s adverse drug reactions, a comprehensive pharmacogenetic panel was performed, targeting common functional polymorphisms in genes encoding drug-metabolizing enzymes and transporters. The analyzed pharmacogenes included CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, NAT2, ABCB1 (MDR1), ABCG2, as well as variants in the serotonin transporter gene promoter region (5-HTTLPR), catechol-O-methyltransferase (COMT), dopamine receptor D2 (DRD2), and the dopamine transporter variable number tandem repeat (DAT1 VNTR). Pharmacogenetic testing was performed using a targeted panel, including TaqMan DME and SNP assays on a 7500 Real-Time polymerase chain reaction (PCR) System (Applied Biosystems, Thermo Fisher Scientific, Waltham, USA), while PCR and PCR- restriction fragment length polymorphism (RFLP) methods were used for the analysis of 5-HTTLPR, DRD2, and DAT1 VNTR. Genomic DNA was isolated from 3 mL of EDTA-anticoagulated peripheral blood using the QIAcube automated system (QIAGEN, Hilden, Germany).

Pharmacogenetics findings

The genotyping results indicated the presence of genetic variations associated with altered drug metabolism as well as dopamine signaling. All pharmacogenetic findings are summarized in Table 1, presenting the patient’s pharmacogenetic profile and including polymorphisms of cytochrome P450 enzymes, transporter genes, and neurotransmitter-related genes, relevant for psychopharmacological treatment. Genotype-derived phenotypes are shown alongside known substrates or inhibitors of the listed enzymes or transporters. According to pharmacogenetic findings, both drug-metabolism and dopamine-related genetic factors, played a role in the patient’s response to treatment.

Pharmacogenetic profile of the patient and related pharmacotherapy
Gene/allele Genotype Phenotype Drug substrate Drug inhibitor
CYP1A2*1F(-163C>A, rs762551) *1F/*1F Normal/Rapidmetaboliser Fluoxetine Fluoxetine
CYP2B6 *4,*6, *9 *1/*1 Normal metaboliser FluoxetineDiazepam
CYP2C9 *2,*3 *2/*2 Poor metaboliser FluoxetineDiazepam Fluoxetine
CYP2C19 *2, *17 *1/*1 Normal metaboliser FluoxetineQuetiapineDiazepam FluoxetineDiazepam
CYP2D6 xN, *3, *4, *5, *6, *9, *10, *41 *1/*41 Normal/Intermediate metaboliser FluoxetineQuetiapineFluphenazineBiperidenAripiprazole FluoxetineFluphenazine
CYP3A4 *1B, *22 *1/*1 Normal metaboliser FluoxetineQuetiapineClonazepamDiazepamAripiprazole FluoxetineDiazepam
CYP3A5 *3 *1/*3 Intermediatemetaboliser FluoxetineQuetiapineDiazepamAripiprazole
NAT2 *4, *5, *6 *5/*5 Poor metaboliser Clonazepam
ABCB1 c.3435C>T C/C Normal function QuetiapineDiazepam FluoxetineFluphenazineAripiprazole
ABCG2 c.421C>A C/A Decreased function Quetiapine
SLCO1B1 *5 (c.521T>C) *1/*1 Normal function
5-HTTLPR(LA, LG, SA) LA/LA High expression
COMT c.472G>A(p.Vall58Met, rs4680) G/G Higher enzymaticactivity
DAT1 VNTR (6-12) 9/10 Intermediate expression
DRD2(Taq1A, A1, A2) A2/A2 Normal expression
Variant alleles are bolded. 5-HTTLPR - Serotonin transporter gene promoter region. ABCB1 - ATP-binding cassette subfamily B member 1. ABCG2 - ATP-binding cassette subfamily G member 2. COMT - Catechol-O-methyltransferase gene. DRD2 - Dopamine receptor D2 gene. DAT1 VNTR - Dopamine transporter gene variable number tandem repeat. NAT2 - N-acetyltransferase 2. SLCO1B1 - Solute carrier organic anion transporter family member 1B1.
Discussion

This case report describes an adolescent patient with polymorphous psychic symptoms treated with low doses of antipsychotics but who at first developed EPS, and after biperiden treatment in combination with quetiapine developed elements of anticholinergic syndrome.

Extrapyramidal symptoms are common adverse effects of antipsychotics, and the development of acute EPSs could depend on the activity of dopaminergic system and its gene variants (5).

Our patient’s pharmacogenetic profile may clarify factors that contributed to the development of EPS following the introduction of fluphenazine to fluoxetine, quetiapine, and clonazepam treatment. The patient is a homozygous for the CYP2C9*2 allele and is predicted to be CYP2C9 poor metabolizer and heterozygous for the CYP2D6*41 allele, indicating CYP2D6 normal-to-intermediate metabolizer. Specifically, fluphenazine is metabolized by CYP2D6; moreover, fluoxetine is a potent inhibitor of both CYP2C9 and CYP2D6 (6-9). Moreover, the presence of the CYP2D6*41 allele with reduced enzymatic function, and concurrent fluoxetine therapy may have caused phenoconversion, a functional inhibition of CYP2D6 activity, actually changing the patients’ metabolizer status closer to poor metabolizer phenotype. This functional reduction in CYP2D6 activity may have secondarily impaired fluphenazine clearance, increasing the risk of adverse drug reactions (10-12).

This combination of genetic predisposition and drug-drug interaction plausibly reduced the metabolism of fluphenazine, resulting in elevated fluphenazine plasma concentrations increasing the risk of dopaminergic blockade and EPS development (13, 14).

In addition to the pharmacokinetics factors described above, genetic variability may further modify the dopaminergic pharmacodynamic profile, contributing to dopaminergic hypoactivity. Predicted higher COMT activity (COMT c.472GG genotype) may lead to more rapid dopamine clearance in the prefrontal cortex, potentially lowering baseline dopaminergic tone and therefore increasing predisposition to EPS development (15). Furthermore, intermediate DAT1 expression (linked with DAT1 9/10 repeat) may enhance dopamine reuptake and thereby diminish dopamine availability at postsynaptic receptors (16, 17). Finally, normal D2 receptor density (DRD2 Taq1A A2/A2 genotype) may not stimulate compensatory upregulation of receptor and may consequently further reduce dopaminergic signaling together with dopamine-blocking agents (18). These pharmacogenetic findings highlight both pharmacokinetic and pharmacodynamic characteristics of the patient and support the implementation of genotype-guided psychopharmacological therapy. In this case, future treatment should avoid potent CYP2C9/CYP2D6 inhibitors and antipsychotics with high affinity for the D2 receptor.

The underwent anticholinergic syndrome was anticipated, considering the pharmacological profiles of the administered therapy, quetiapine and biperiden, followed by aripiprazole. Quetiapine is primarily metabolized by the CYP3A4 enzyme and is also a substrate of the ABCG2 transporter. Patient’s decreased transport function of ABCG2 may increase quetiapine concentrations, potentially exacerbating anticholinergic side effects (19, 20).

In this patient, the occurrence of blurred vision during the initiation of aripiprazole therapy aligns with previously reported cases in the literature, although the underlying mechanisms remain incompletely understood. Potential explanations include acute transient myopia secondary to ciliary body and choroidal effusion and swelling, anterior displacement of the ciliary processes, narrowing of the ciliary sulcus, anterior movement of the iris and lens, or direct drug penetration into the lens resulting in osmotic swelling (21). Given that aripiprazole is metabolized primarily via CYP2D6, and the patient is a normal to intermediate CYP2D6 metabolizer, these adverse effects may also be related to metabolic variability. This further highlights the importance of pharmacogenetic testing in cases of such side effects, as it allows for a more precise assessment of potential correlations and, possibly, causal relationships. BPD traits in adolescence are still topics of discussion in child and adolescent psychiatry, particularly considering that adolescence per se is a turbulent and emotionally challenging period. Nevertheless, the stability and reliability of symptoms and features (such as identity disturbance, affective instability, relationship difficulties, impulsivity) are high, and these traits interfere with normal developmental processes in adolescence. Hence, if neglected or unrecognized, they can evolve into chronic patterns with poor psychosocial outcomes in adulthood. Therefore, timely intervention is crucial for adolescents coping with these difficulties (22-24). Although psychotherapy remains the first-line treatment, medications are commonly prescribed for patients with BPD. Negative attitudes toward both psychotherapy and drug treatment are common among patients/parents, especially considering that clinical entity, which makes it even more important to select medications that relieve psychological difficulties without causing side-effects (25, 26).

Although pharmacogenetics is not yet part of standard practice in child and adolescent psychiatry, it can considerably affect the adverse drug reactions. While pharmacogenetic guidelines for prescribing antidepressants and antipsychotics in the pediatric population are missing, it is hypothetically possible to implement Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) guidelines in pediatric psychiatry clinical practice to enhance therapeutic result and decrease adverse reactions risk, ultimately leading to better treatment outcomes (11, 27-29). This clinical case illustrates how both drug-metabolism and dopamine-related genetic factors had a significant role in the patient’s response to treatment, highlighting the potential benefits of genotype-guided therapy in everyday clinical practice.

Our study has some limitations. The interpretation of the reported adverse drug reactions and pharmacogenetic findings is limited by the lack of drug blood concentration data. Therapeutic drug monitoring was not performed because the adverse effects appeared very soon after treatment initiation, at a stage when such measurements would have been unlikely to add meaningful clinical insight.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References BatchelorHKMarriottJF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79:395–404. 10.1111/bcp.1226725855821 Begovac I. Borderline poremećaj ličnosti. In: Dječja i adolescentna psihijatrija. 1st ed. Zagreb: University of Zagreb, School of Medicine; 2021. p. 908-20. LiangJRingelingLTHermansRABayraktarIBoschTMEgbertsKM Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen. Expert Opin Drug Metab Toxicol. 2023;19:501–9. 10.1080/17425255.2023.225234037668177 MalikSVermaPRuañoGAl SiaghyADilawarABishopJR Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications. J Child Adolesc Psychopharmacol. 2024;34:4–20. 10.1089/cap.2023.007438377525 ZivkovićMMihaljević-PelesABozinaNSagudMNikolac-PerkovicMVuksan-CusaB The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol. J Clin Psychopharmacol. 2013;33:593–9. 10.1097/JCP.0b013e31829abec923963056 Gene-specific Information Tables for CYP2C9 [Internet]. Available from: https://www.pharmgkb.org/page/cyp2c9RefMaterials. Accessed May 22nd 2025. Gene-specific Information Tables for CYP2D6 [Internet]. Available from: https://www.pharmgkb.org/page/cyp2d6RefMaterials. Accessed May 22nd 2025. Whirl‐CarrilloMHuddartRGongLSangkuhlKThornCFWhaleyR An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021;110:563–72. 10.1002/cpt.235034216021 Fluoxetine Pathway. Pharmacokinetics [Internet]. Available from: https://www.pharmgkb.org/pathway/PA161749012. Accessed May 22nd 2025. BaharMASetiawanDHakEWilffertB. Pharmacogenetics of Drug–Drug Interaction and Drug–Drug–Gene Interaction: A Systematic Review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics. 2017;18:701–39. 10.2217/pgs-2017-019428480783 BousmanCAStevensonJMRamseyLBSangkuhlKHicksJKStrawnJR Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114:51–68. 10.1002/cpt.290337032427 HicksJKBishopJSangkuhlKMüllerDJiYLeckbandS Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98:127–34. 10.1002/cpt.14725974703 UpToDateInc. Drug interactions [Internet]. n.d. Available from: https://www.uptodate.com/drug-interactions/#di-druglist. Accessed May 22nd 2025. Siragusa S, Bistas K, Saadabadi A. Fluphenazine [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459194/. Accessed May 22nd 2025. AntypaNDragoASerrettiA. The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes. Neurosci Biobehav Rev. 2013;37:1597–610. 10.1016/j.neubiorev.2013.06.00623792050 FukeSSuoSTakahashiNKoikeHSasagawaNIshiuraS. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 2001;1:152–6. 10.1038/sj.tpj.650002611911442 MillJAshersonPBrowesCD’SouzaUCraigI. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: Evidence from brain and lymphocytes using quantitative RT‐PCR. Am J Med Genet. 2002;114:975–9. 10.1002/ajmg.b.1094812457396 ThompsonJThomasNSingletonAPiggotMLloydSPerryEK D2 dopamine receptor gene (DRD2) Taql A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 1997;7:479–84. 10.1097/00008571-199712000-000069429233 WangJSZhuHMarkowitzJSDonovanJLYuanHDeVaneCL. Antipsychotic Drugs Inhibit the Function of Breast Cancer Resistance Protein. Basic Clin Pharmacol Toxicol. 2008;103:336–41. 10.1111/j.1742-7843.2008.00298.x18834354 ZubiaurPFernández-CamposPNavares-GómezMSoria-ChacarteguiPVillapalos-GarcíaGRománM Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics. Pharmaceutics. 2021;13:1573. 10.3390/pharmaceutics1310157334683865 Kavak SinanoğluGYavrumF. Aripiprazole-Related Acute Myopia: A Case Report. J Clin Psychopharmacol. 2025;45:520–1. 10.1097/JCP.000000000000203640511867 LarrivéeMP. Borderline personality disorder in adolescents: the He-who-must-not-be-named of psychiatry. Dialogues Clin Neurosci. 2013;15:171–9. 10.31887/DCNS.2013.15.2/mplarrivee24174891 MillerALMuehlenkampJJJacobsonCM. Fact or fiction: Diagnosing borderline personality disorder in adolescents. Clin Psychol Rev. 2008;28:969–81. 10.1016/j.cpr.2008.02.00418358579 SteppSD. Development of borderline personality disorder in adolescence and young adulthood: introduction to the special section. J Abnorm Child Psychol. 2012;40:1–5. 10.1007/s10802-011-9594-322116635 KalamanCRIbrahimNShakerVChamCQHoMCVisvalingamU Parental Factors Associated with Child or Adolescent Medication Adherence: A Systematic Review. Healthcare (Basel). 2023;11:501. 10.3390/healthcare1104050136833035 Mirhaj MohammadabadiMSMohammadsadeghiHEftekhar AdrebiliMPartovi KolourZKashaninasabFRashediV Factors associated with pharmacological and psychotherapy treatments adherence in patients with borderline personality disorder. Front Psychiatry. 2022;13:1056050. 10.3389/fpsyt.2022.105605036582255 CrewsKRMonteAAHuddartRCaudleKEKharaschEDGaedigkA Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110:888–96. 10.1002/cpt.214933387367 HicksJKSangkuhlKSwenJEllingrodVMüllerDShimodaK Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37–44. 10.1002/cpt.59727997040 Pharmacogenetic Guidelines [Internet]. Netherlands; Available from: https://www.knmp.nl/dossiers/farmacogenetica/pharmacogenetics. Accessed May 22nd 2025.
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020902" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020902" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020902" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(111) "Extrapyramidal and anticholinergic reactions in an adolescent patient: a case for pharmacogenetic consideration" ["journals_article_author"]=> string(146) "Iris Žunić Išasegi, Ivana Stefanović, Marta Okružnik Želalić, Livija Šimičević, Lana Ganoci, Maja Živković, Ivan Begovac, Nada Božina" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(12) "Case reports" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(131) "borderline personality traits, child and adolescent psychiatry, extrapyramidal symptoms, anticholinergic syndrome, pharmacogenetics" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2209" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "17" ["meta_title"]=> string(111) "Extrapyramidal and anticholinergic reactions in an adolescent patient: a case for pharmacogenetic consideration" ["meta_desc"]=> string(111) "Extrapyramidal and anticholinergic reactions in an adolescent patient: a case for pharmacogenetic consideration" ["meta_keyw"]=> string(131) "borderline personality traits, child and adolescent psychiatry, extrapyramidal symptoms, anticholinergic syndrome, pharmacogenetics" ["created"]=> string(19) "2026-04-07 11:06:33" ["modified"]=> string(19) "2026-06-11 09:03:16" } [20]=> object(stdClass)#69 (35) { ["journals_id"]=> string(4) "1235" ["journals_xml"]=> string(48332) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020901 10.11613/BM.2026.020901 Case reports Tumour lysis syndrome in the setting of a high-grade B-cell lymphoma with primary bone marrow localization – a case report IvankoIva*12JosipovićJosipa23ĆelapIvana45Novaković CohaSabina1MatijacaHana1BrblićTomislav1Kojić KatovićSandra6GaćinaPetar17 Department of Haematology, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia School of Medicine, Catholic University of Croatia, Zagreb, Croatia Department of Nephrology and Arterial Hypertension, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia Department of Clinical Chemistry, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia Department of Pathology and Cytology, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia School of Dental Medicine, University of Zagreb, Zagreb, Croatia Corresponding author: iva.ivanko@kbcsm.hr

Author contributions

I Ivanko: Conceptualization, Methodology, Writing; J Josipović: Writing – Review & Editing; S Novaković Coha: Technical Help, Translation Assistance; H Matijaca: Data Collecting, Technical Help; T Brblić: Writing, Translation Assistance; I Ćelap: Critical Review, Revision; P Gaćina: Supervision.

15042026 15062026 36 2 020901 0409202525012026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Tumour lysis syndrome (TLS) is a grave concern in aggressive lymphoma treatment

• High-grade B-cell lymphoma is amongst leading cause of TLS

• Laboratory parameters can predict the magnitude of TLS

• Extreme cases of TLS may require management beyond standard treatment guidelines

Tumour lysis syndrome (TLS) is an oncologic emergency usually arising after chemotherapy administration, caused by a massive tumour breakdown and characterized by a specific laboratory and clinical findings. We present a case of TLS, both spontaneous and treatment related, in a 59-year-old woman with high grade B-cell lymphoma without apparent bulky disease on radiologic scans. The patient presented with acute kidney failure with marked hyperuricemia (2764 µmol/L) and extremely high lactate dehydrogenase (LD) activity (13,770 U/L). She was treated with rasburicase, corticosteroid pre-phase therapy, sequential chemotherapy and renal replacement therapy tailored to electrolytic disturbances. After initial resolution of spontaneous TLS, at the start of chemotherapy administration, she experienced systemic inflammatory response (SIRS) and therapy related TLS which included, amongst else, vast hyperphosphatemia (6.12 mmol/L). Despite all intensive care treatment, patient went into multiorgan failure preceding lethal outcome. This case report confirms the value of laboratory parameters in establishing the diagnosis of TLS with LD as an indicator of massive tumour turnover. Due to a high risk of deleterious complications, management of extreme TLS cases challenges the current guidelines of TLS therapy. Modern treatment options such as targeted anticytokine therapy could potentially bring benefit in these specific circumstances.

Keywords: tumour lysis syndromeacute kidney failurenon-Hodgkin lymphoma
Introduction

Tumour lysis syndrome (TLS) is an oncologic emergency characterized by a specific laboratory abnormalities (hyperkalemia, hyperphosphatemia, hyperuricemia and hypocalcemia) often coupled with clinical signs of multiple organ dysfunction (kidney damage, cardiac arrythmia, sudden death, seizure) because of a fast tumor degradation (1). In most cases, TLS occurs during or immediately after delivery of a targeted tumor therapy, although spontaneous events have been described (2, 3). Predominately, malignant hematological neoplasms such as high-grade lymphoproliferative neoplasms (Burkitt lymphoma) carry significant risk of TLS but other non-hematologic, solid tumors can pose a serious threat (4).

Here, we describe a case of TLS occurring in the setting of high-grade B-cell non-Hodgkin lymphoma characterized with a profound, life-threatening electrolytic disturbances and ominous clinical course.

Case presentation

Fifty-nine-year-old female patient with a history of a well-controlled arterial hypertension and insulin non-dependent diabetes mellitus, was admitted to the Department of Hematology, Clinical Hospital Centre Sestre milosrdnice, Zagreb, Croatia, in April 2025, under the suspicion of acute leukemia. The patient was transferred to our unit from a local hospital. Initial laboratory findings revealed leukocytosis, anemia and thrombocytopenia requiring transfusion therapy, marked elevation of lactate dehydrogenase (LD) activity and signs of acute renal injury with hyperuricemia (Table 1). Peripheral blood smear (obtained in the local hospital) revealed 30% blasts. Upon admission to our hospital the patient presented with uncompromised vital signs (temperature, heart rate, respiration, blood pressure) with preserved diuresis. She reported worsening malaise for several days. During the first 24 hours of hospitalization, the patient’s renal function continued to decline with the development of anuria. After consulting the Department of Dialysis, the patient underwent continuous veno-venous hemodiafiltration (CVVHDF) in the Intensive Care Unit (ICU). Rasburicase treatment (0.20 mg per kg of total body weight, on day 2 and day 3, intravenously) commenced alongside dialysis in order to minimize further renal deterioration caused by extreme hyperuricemia. Cytological smear of the bone marrow, performed on the 2nd day of hospitalization, showed almost a 100% infiltration of atypical blasts without peroxidase and periodic acid-Schiff coloration arousing suspicion of an acute lymphoblastic leukemia (Figure 1). However, flow cytometry of the bone marrow aspirate indicated a diagnosis of a mature CD10+ B-lymphoproliferative disorder.

Laboratory findings in a patient with high-grade B-cell lymphoma and tumour lysis syndrome
Day of hospitalization
Laboratory parameter, unit(reference interval) 1st 2nd 6th 11th 12th(6 a.m.) 12th(6 p.m.)
Creatinine, µmol/L (49-90) 488 541 145 282 255 189
Uric acid, µmol/L (134-337) 2764 2709 235 1379 668 /
Phosporus, mmol/L (0.79-1.42) 1.92 / 1.2 3.24 4.76 6.12
Potassium, mmol/L (3.9-5.1) 4.7 4.5 3.3 5.1 6.1 7.4
Calcium, mmol/L (2.14-2.53) 2.69 / 2.30 1.9 1.75 1.56
LD, U/L 37 °C (124-241) > 7325 > 7325 > 7325 13,770 > 7325 > 7325
Leukocytes, x109/L (3.4-9.7) 25.9 23.3 38.5 3.7 0.8 1.0
Hemoglobin, g/L (119-157) 80 80 88 68 85 94
Platelets, x109/L (158-424) 22 44 14 11 11 54
CRP, mg/L (< 5) 42.4 38.3 12.5 86.4 174 /
1st day - parameters reflect spontaneous tumor lysis syndrome, 11th day - parameters reflect onset of therapy related tumor lysis syndrome. LD - lactate dehydrogenase (for LD values greater than 7325 U/L to be expressed, the blood specimen requires additional technical method of blood specimen dilution). CRP - C-reactive protein.

Cytologic smear of the bone marrow aspirate (May-Grünwald Giemsa stain) of a patient with high-grade B-cell lymphoma. Red arrows indicate an example of the high-grade B-cell lymphoma cell (malignant transformation of B-lymphocytes).

CD10+ non-Hodgkin lymphomas, predominately follicular lymphoma, were known to cause a high tumor burden but due to the clinical and laboratory findings, a transformation to a higher-grade lymphoma was anticipated from the bone marrow biopsy. Due to technical reasons this part of diagnostic evaluation was still ongoing.

While waiting for a definitive diagnosis, corticosteroid pre-phase treatment was initiated with the aim of preparing the patient for a definitive chemotherapy treatment. To assess lymphoma staging, a computed tomography (CT) scan was performed, and no large tumor masses were found in the mediastinum nor abdomen, which translated to a conclusion that the entire tumor burden was within the bone marrow. There were no findings of renal pathology nor post-renal obstruction. Over the next few days, CVVHDF was continued and methylprednisolone (100 mg intravenously per day for 9 days). Hyperuricemia was resolved; however, the patient was still anuric. The patient was also treated with parenteral antibiotic therapy (piperacillin/tazobactam) due to positive blood culture for Clostridium perfringens and urine culture for Klebsiella pneumoniae. Approximately one week into hospitalization bone marrow biopsy evaluation was completed, resulting in a diagnosis of a high-grade B-cell lymphoma with almost 100 percent of bone marrow infiltration.

After pre-phase corticosteroid treatment and the resolution of laboratory signs of TLS, the next step was introduction of sequential chemotherapy with intermittent dialysis support due to anuria. On the 10th day of hospitalization, anti-CD20 monoclonal antibody (rituximab) was slowly delivered during 12-hours interval (375 mg/m2) followed by a single attenuated dose of vincristine (1 mg intravenously), without of the rest planned cytostatic therapy. Usually after pre-phase corticosteroid treatment, chemotherapy is applied in full dose and regimen, but in this particular case with extreme tumor burden, we decided to apply more conservative approach. While receiving immunotherapy, the patient experienced hypotension, chills and temperature rise. The immunotherapy was temporarily stopped and patient received corticosteroid and anti-inflammatory treatment (paracetamol) with fluids. After stabilization, rituximab was started at lower infusional rate. During chemoimmunotherapy therapy administration diuresis was established (more than 1000 mL of urine output). However, laboratory evaluation on the 11th day revealed renal function worsening with rising hyperuricemia, hyperphosphatemia and hypocalcemia. Leukocyte count dropped from 30x109/L to 3.7x109/L in less than 24 hours indicating a fast tumor breakdown (Table 1). To comprehend the magnitude of TLS, we kindly asked Department of Clinical Chemistry for a definitive LD measure. On the 11th day of hospitalization, after nine days of pre-phase corticosteroid therapy, LD was 13,770 IU/L. The patient was clinically stable, and a course of intermittent hemodialysis was performed to obtain a fast control over electrolytic disturbances. Rasburicase was also repeated on the 11th day in a standard dose.

Unfortunately, progressive electrolyte and metabolic disturbances within the context of TLS developed, including extreme hyperphosphatemia along with hyperkalemia and hypocalcemia, ultimately leading to full-blown clinical TLS manifested by dyspnea and hypotension.

The patient was intubated; mechanically ventilated and arterial blood pressure was maintained by vasopressors. Continuous renal replacement therapy was commenced once again in the hope that continuous clearance of degrading products from the tumor cells would ease electrolyte disturbances. Despite all intensive care methods, the patients succumbed to multi-organ failure on the 12th day of hospitalization.

Permission for this case report to be published was given by the patient’s children.

Laboratory methods

Venous blood for routine analysis was drawn according to patient management protocol in vacutainers with gel (for biochemistry tests, volume 5 mL) and with EDTA anticoagulant (for full blood count, volume 3 mL) (Greiner Bio-One, Kremsmünster, Austria). Biochemistry parameters (creatinine, LD, C-reactive protein, uric acid, phosphorus, potassium and calcium) were measured on biochemistry analyzer Alinity c (Abbott Diagnostics, Abbott Park, USA) using original reagents and according to manufacturer instructions. Full blood count was determined on Sysmex XN1000 (Sysmex Co, Kobe, Japan). Cytological bone marrow and peripheral blood analysis was done with May-Grünwald Giemsa stain on Olympus BX 41 microscope (Olympus, Hamburg, Germany).

Discussion

We have presented a patient with high-grade B lymphoma whose illness encompassed two clinical and laboratory entities – spontaneous and treatment related TLS. While spontaneous TLS was characterized by extreme hyperuricemia, hallmark of treatment related TLS were extreme electrolytic disturbances, predominately hyperphosphatemia.

Tumor lysis syndrome is a well-known oncologic emergency with a high mortality rate (5, 6). The hallmark of TLS is the release of massive quantities of cellular breakdown products leading to hyperuricemia which may contribute to acute kidney injury through intratubular urate crystal precipitation and obstruction (7).

The diagnosis is based on Cairo-Bishop definition of TLS which includes laboratory criteria of electrolyte abnormalities (hyperkalemia, hyperphosphatemia, hypocalcemia) with uric-acid elevation and clinical criteria (kidney damage, cardiac arrythmia, sudden death, seizure) (1).

Current treatment guidelines place focus on the use of hyperuricemia lowering agents, maintaining electrolyte equilibrium and fluid balance (8, 9).

Rasburicase (recombinant urate oxidase), in the context of TLS, is a superior method of hyperuricemia management than allopurinol due to the uric acid degradation into much more water-soluble compound allantoin (8). It is worth mentioning that the blood specimen for uric acid monitoring after the usage of rasburicase should be collected in a prechilled tube, placed on ice, and the assay completed within four hours (10). Continuous degradation of uric acid ex-vivo can result in a falsely low concentration and affect the clinical decision for the rasburicase reusage.

Unlike hyperuricemia, severe hyperphosphatemia can only be resolved by a renal replacement therapy, especially CVVHDF due to better tolerance and hyperphosphatemia rebound avoidance (8, 11).

Lactate dehydrogenase activity is not included in diagnostic criteria of TLS, however it points to a rapid tumor turnover which is hallmark of aggressive hematological malignancies. Tumor lysis syndrome risk stratification does acknowledge LD elevation as a high risk for TLS occurrence (8).

Our patient presented with spontaneous TLS based on hyperuricemia and hyperphosphatemia as the laboratory criterion and kidney failure as the clinical criterion by the Cairo-Bishop definition. Treatment related TLS was diagnosed also based on a Cairo-Bishop definition with a new onset of hyperuricemia and hyperphosphatemia, emerging hypocalcemia and hyperkalemia and clinical deterioration, both directly related to chemoimmunotherapy administration (Table 1).

The patient was treated according to the current guidelines for TLS management (8, 12). The rasburicase was chosen over allopurinol due to the extreme hyperuricemia. Volume overload, suggested by the guidelines, was not applied due to anuria. Instead, kidney replacing therapy, both intermittent and continuous, was administered as a method of correction of electrolyte disturbances and metabolic acidosis arising from renal injury while preserving fluid balance. Continuous renal replacement therapy was specifically directed to suppress immunochemotherapy related vast hyperphosphatemia which is in accordance with guidelines and treatment approach used in real clinical practice (13, 14). Pre-phase corticosteroid treatment was initiated before introducing targeted immunochemotherapy to minimize the risk of treatment related TLS. Immunochemotherapy itself was administered sequentially for the same reason. Recent study of Mohamad et al. implies that even immunotherapy alone applied in fractionated manner (during several days) can lower the risk of therapy related TLS in highly aggressive lymphomas (15).

However, this case has proved to be an extreme presentation of TLS, where standard treatment methods, suggested by the guidelines, failed to suppress ominous circle of tumor degradation and organ injury. What is interesting is that only laboratory changes – hyperuricemia and severe hyperphosphatemia foreshadowed the magnitude of TLS with extreme LD elevation being an ominous sign of a rapid tumor turnover. Diagnostic radiology workup, commonly used as a measure of a tumor burden in lymphomas, had no value in this case due to the fact that there was no visible bulky disease. Dynamic of uric acid concentrations clearly indicate two phases of disease trajectory – spontaneous and treatment related TLS (Figure 2).

Dynamics of changes in acid uric concentration in patient with high-grade B-cell lymphoma by hospitalization day.

Further, patient’s reaction at the start of immunotherapy (hypotension, high fever) was in fact systemic inflammatory syndrome (SIRS) based on cytokine releasing syndrome (CRS). Although we did not measure IL-6 at the time, clinical presentation and symptoms amelioration to corticosteroid therapy support our theory. Interleukine-6 antagonists, such as tocilizumab are not a part of guidelines for TLS and are reserved for management of CRS caused by chimeric antigen receptor T-cell therapy (CAR-T) and bispecific antibody therapy (16). In the context of these novel therapies, IL-6 antagonist is used as anti-inflammatory agent directed at the systemic response to the massive tumor breakdown. It has been shown that high IL-6 concentrations in aggressive B non-Hodgkin lymphoma correlate with high LD, bone marrow involvement and poor outcome (17). Cytokine profile determination, including IL-6, could be of use for acknowledging patients in high risk of TLS and CRS directed therapy could potentially bring benefit in the management of extreme TLS.

In conclusion, although treatment of this patient was according to the current guidelines of TLS management, it failed to prevent lethal outcome. This case highlights the continuous need for expanding and upgrading standard treatment guidelines, starting from early recognition of the magnitude of TLS to introducing possible novel therapies which could potentially be beneficial in lowering high complication rates in extreme TLS cases.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are not publicly available to preserve individuals’ privacy, but are available from the corresponding author on request which will not include patient’s personal informations.

References CairoMSBishopM. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11. 10.1111/j.1365-2141.2004.05094.x15384972 WesemüllerWTavernaC. Spontaneous Tumor Lysis Syndrome. Case Rep Oncol. 2020;13:1116–24. 10.1159/00050964333082757 RoqueWRehmanASuero-AbreuGADanekBAColaoJFayngershA Spontaneous tumor lysis syndrome in T-cell malignancy: two case reports. Stem Cell Investig. 2019;6:24. 10.21037/sci.2019.07.0131559311 AlqurashiRMTamimHHAlsubhiZDAlzahraniAATashkandiE. Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases. Cureus. 2022;14:e30652. 10.7759/cureus.3065236439565 DuraniUShahNDGoRS. In-hospital outcomes of tumor lysis syndrome: a population-based study using the National Inpatient Sample. Oncologist. 2017;22:1506–9. 10.1634/theoncologist.2017-014728904174 DarmonMGuichardIVincentFSchlemmerBAzoulayÉ. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma. 2010;51:221–7. 10.3109/1042819090345695920001238 DuLZongYLiHWangQXieLYangB Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:212. 10.1038/s41392-024-01916-y39191722 ChanYLEl‐SharkawiDShahPChanouzasDO’ConnorDMarksSD British Society for Haematology updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children with haematological malignancies: A focus on patient safety. Br J Haematol. 2025;207:1248–58. 10.1111/bjh.7009240903841 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas – Supportive Care Section. Version 3.2025 [Internet]. 2025 Aug [cited 2025 Nov 04]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Kent and Medway Cancer Collaborative. Guidelines for use of rasburicase in adult haematology and oncology patients [Internet]. 2024 [cited 2025 Nov 4]. Available from: https://www.kmcc.nhs.uk/s3/assets/pharmacy/guidelines-for-use-of-rasburicase-v7.pdf Larson RA, Pui CH. Tumor lysis syndrome: Prevention and treatment. UpToDate [Internet]. 2025 Jul [cited 2025 Nov 04]. Available from: https://www.uptodate.com/contents/tumor-lysis-syndrome-prevention-and-treatment Croatian Cooperative Group for Hematologic Diseases. Recommendations for systemic treatment of lymphoma Version 4.4. [Internet]. 2022 [cited 2025 Nov 4]. Available from: https://www.krohem.hr/dijagnosticko-terapijske-smjernice/ PanSShenQZhouJLiT. Spontaneous tumor lysis syndrome (STLS) during biopsy for burkitt lymphoma: a case report. BMC Pediatr. 2024;24:209. 10.1186/s12887-024-04679-138521927 KikuchiSMuroMKamiharaYWadaAMurakamiJNabeY Massive hyperphosphatemia in clinical tumor lysis syndrome during prophylactic rasburicase use: risk factors and treatment options. Int Cancer Conf J. 2022;12:69–74. 10.1007/s13691-022-00580-936605847 MohamadJBouroumeauAMcKeeTAMachNSamiiKChamuleauM Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma: Insights from real-life clinical practice. Cancer Rep (Hoboken). 2024;7:e1983. 10.1002/cnr2.198339410860 CrombieJLGraffTFalchiLKarimiYHBannerjiRNastoupilL Consensus recommendations on the management of toxicity associated with CD3× CD20 bispecific antibody therapy. Blood. 2024;143:1565–75. 10.1182/blood.202302243238252906 BaoCGuJHuangXYouLZhouZJinJ. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes. Cytokine. 2023;169:156289. 10.1016/j.cyto.2023.15628937453327
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020901" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020901" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020901" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(124) "Tumour lysis syndrome in the setting of a high-grade B-cell lymphoma with primary bone marrow localization – a case report" ["journals_article_author"]=> string(139) "Iva Ivanko, Josipa Josipović, Ivana Ćelap, Sabina Novaković Coha, Hana Matijaca, Tomislav Brblić, Sandra Kojić Katović, Petar Gaćina" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(12) "Case reports" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(65) "tumour lysis syndrome, acute kidney failure, non-Hodgkin lymphoma" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2734" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "16" ["meta_title"]=> string(124) "Tumour lysis syndrome in the setting of a high-grade B-cell lymphoma with primary bone marrow localization – a case report" ["meta_desc"]=> string(124) "Tumour lysis syndrome in the setting of a high-grade B-cell lymphoma with primary bone marrow localization – a case report" ["meta_keyw"]=> string(65) "tumour lysis syndrome, acute kidney failure, non-Hodgkin lymphoma" ["created"]=> string(19) "2026-04-07 11:05:19" ["modified"]=> string(19) "2026-06-11 09:03:05" } [21]=> object(stdClass)#70 (35) { ["journals_id"]=> string(4) "1252" ["journals_xml"]=> string(93938) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020709 10.11613/BM.2026.020709 Original articles Factors associated with Gla-rich protein serum concentrations in healthy adults MarreirosCatarina1ViegasCarla12NunesSelene3SilvaAna Paula45FaíscaMarília6SchurgersLeon7SimesDina Costa*12 Centre of Marine Sciences (CCMAR/CIMAR LA), Universidade do Algarve, Faro, Portugal GenoGla Diagnostics, Centro de Ciências do Mar do Algarve (CCMAR/CIMAR LA), Universidade do Algarve, Faro, Portugal Department of Imunology, Unidade Local de Saúde do Algarve (ULSA), Faro, Portugal Department of Nephology, Unidade Local de Saúde do Algarve (ULSA), Faro, Portugal Faculty of Medicine and Biomedical Sciences, Universidade do Algarve, Faro, Portugal SYNLAB Algarve, Faro; Portugal Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands Corresponding author: dsimes@ualg.pt

Author contributions

C. Marreiros - conceptualization, methodology, software, formal analysis, resources, writing-original draft preparation, writing-review and editing; C. Viegas - conceptualization, validation, resources, writing-review and editing, supervision funding acquisition; S. Nunes - validation and writing-review and editing; A.P. Silva - validation and writing-review and editing; M. Faísca - resources and writing-review and editing; L. Schurgers - validation, writing-review and editing, supervision; D. Costa Simes - conceptualization, validation, resources, writing-review and editing, supervision, funding acquisition.

15062026 15062026 36 2 020709 1605202525042026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Age had a weak negative association with total Gla-rich protein (tGRP)

• No significant sex differences were observed in tGRP concentrations

• Highest tGRP concentrations observed in the 18-30 age group

• Age and calcium were the main factors influencing serum tGRP variability

Introduction

Gla-rich protein (GRP) is a vitamin K-dependent protein involved in the regulation of ectopic calcification and inflammatory processes. However, data on circulating GRP concentrations in healthy adults remain limited.

Materials and methods

This cross-sectional observational study evaluated serum total GRP (tGRP) concentrations in 254 healthy adult blood donors (48% male), aged 18-65 years, using a sandwich enzyme-linked immunosorbent assay (ELISA) (GenoGla Diagnostics, Faro, Portugal). Participants were stratified by age tertiles, and associations between serum tGRP concentrations and demographic and laboratory parameters were assessed using non-parametric statistical tests, Spearman correlation, and stepwise linear regression.

Results

The median serum tGRP concentration in the overall population was 1809.5 pg/mL (interquartile range: 1197.4-2476.0 pg/mL). Serum tGRP concentrations differed significantly across age tertiles (P = 0.038), with higher concentrations observed in younger adults. Serum tGRP concentrations showed a weak but statistically significant inverse correlation with age (r = - 0.30, P = 0.001), while no significant differences were observed between sexes (P = 0.420). In multivariable analysis, age and serum calcium concentration remained independently associated with serum tGRP concentrations, jointly explaining approximately 7% of their variability.

Conclusion

This study establishes robust reference data for circulating tGRP concentrations in healthy adults, providing a foundation for the interpretation of GRP measurements in future clinical and epidemiological research.

Keywords: Gla-rich proteinserum concentrationshealthy adultsage factors
Introduction

Gla-rich protein (GRP), also known as upper zone of growth plate and cartilage matrix associated protein (UCMA), is a circulating vitamin K-dependent protein with calcium- and mineral-binding properties (1-3). Gla-rich protein has been implicated in biological processes related to extracellular matrix organization mineral homeostasis, inflammatory responses, and mechanisms driving malignant transformation (4-8).

Most available knowledge regarding GRP derives from studies conducted in pathological contexts, particularly conditions characterized by inflammation and ectopic calcification (9-11). Accordingly, circulating GRP concentrations have been reported in several diseases cohorts, including chronic kidney disease and cardiovascular disease (12-16).

However, data on circulating GRP concentrations in well-characterized healthy adult populations remain limited. To date, GRP concentrations have mainly been reported in control groups, not specifically designed to represent healthy individuals and therefore provides limited insight into GRP concentrations in this context (15, 16).

Reliable characterization of circulating GRP concentrations in healthy populations requires analytical robustness. Our group has previously reported GRP concentrations in several clinical cohorts using a sandwich enzyme-linked immunosorbent assay (ELISA) for total GRP (tGRP). Since its initial description this assay has undergone technical optimization, aimed at improving analytical robustness and long-term performance while preserving the original assay principle and analytical target (17). Importantly, all previously reported clinical GRP measurements from our group were generated using this optimized assay version; however, its formal analytical validation is reported for the first time in the present study (12-14).

Establishing descriptive data on GRP concentrations in healthy adults is essential for contextualizing findings from disease-based studies and for supporting future clinical and translational research. In healthy individuals, demographic characteristics such as age and sex, as well as routinely measured laboratory parameters reflecting renal function, lipid metabolism, and low-grade inflammation, may plausibly influence circulating protein concentrations and therefore warrant systematic evaluation.

Therefore, the aim of the present study was to describe serum tGRP concentrations in a cohort of healthy adult blood donors using a sandwich ELISA and to explore their associations with demographic characteristics and selected routine laboratory parameters.

Materials and methods Subjects

This cross-sectional observational study evaluated serum tGRP concentrations in healthy adult blood donors. Participants were recruited at the Immunology Department of Algarve Local Health Unit (ULSA), Faro, Portugal, between May and August 2024. A total of 363 blood donors were selected prior to blood collection using a standardized health questionnaire and medical interview, mandatory for all blood donation units in Portugal and regulated by the Portuguese Institute of Blood and Transplantation (IPST). This screening procedure follows national legislation transposing European Union directives on blood quality and safety (Directive 2002/98/EC and subsequent implementing directives) and includes evaluation of medical history, medication use, recent infections, and transfusion-relevant risk factors. As part of routine blood donor eligibility screening, hemoglobin concentration was assessed by trained nursing staff using a point-of-care capillary finger-prick hemoglobin test (Werfen, Carnaxide, Portugal). Individuals not meeting blood donation hemoglobin requirements were excluded as viable blood donors. Only donors fulfilling all eligibility requirements for blood donation were selected for posterior biochemical analysis (Table 1).

Inclusion criteria and parameters obtained for the selection of apparently healthy subjects
Parameter (unit) Inclusion criteria Participant values
Age, years 18-65* 19-65
BMI, kg/m2 < 30* 24.90 ± 3.14
Creatinine, µmol/L 62-115† 73 (64.5-86.6)
eGFR, mL/min/1.73 m2 ≥ 90† 112 (108-124)
Total cholesterol, mmol/L < 5.70† 4.64 (4.03-5.20)
HDL cholesterol, mmol/L > 0.91† 1.45 (1.19-1.57)
LDL cholesterol, mmol/L < 3.37† 2.69 (2.16-3.03)
Total protein, g/L 60-83† 72.50 ± 5.80
Calcium, mmol/L 2.12-2.62† 2.39 ±0.13
Phosphate, mmol/L 1.10-1.45† 1.24 ±0.08
Magnesium, mmol/L 0.70-0.90† 0.77 ± 0.05
Sodium, mmol/L 136-145† 139.2 ± 2.65
Potassium, mmol/L 3.7-5.2† 4.28 ± 0.39
Total bilirubin, µmol/L < 20† 9.75 (3.72-12.45)
AST, U/L < 40† 22.80 (17.24-26.12)
hsCRP, mg/L ≤ 3† 0.40 (0.26-0.45)
Characteristics and inclusion criteria. Data are represented mean ± standard deviation or median (interquartile range), according to data distribution. Age is presented as minimum-maximum. *Inclusion criteria applied during blood donor selection according to ULSA institutional blood donation eligibility requirements. †Biochemical reference ranges used to exclude participants with values outside the normal laboratory range (Synlab, Portugal).. BMI - body mass index. eGFR - estimated glomerular filtration rate. C-HDL - high density lipoprotein. C-LDL - low density lipoprotein. AST - aspartate aminotransferase. hsCRP - high sensitivity C-reactive protein.

Exclusion criteria comprised obesity (body mass index ≥ 30 kg/m2), known pregnancy, non-Caucasian ancestry, a previous or current diagnosis of diabetes mellitus (type 1 or type 2), thyroid, liver or kidney disease, anemia, osteoarthritis or other articular disease, and cardiovascular disease (including hypertension, coronary artery disease, previous myocardial infarction, coronary angioplasty, coronary bypass surgery, varicose veins, congestive cardiac failure, or stroke). Individuals with a first-degree family history of hypertension, neoplasia, or diabetes mellitus (type 1 or type 2), and/or laboratory parameters outside predefined eligibility ranges for the present study (Table 1) were excluded. These reference ranges correspond to routine clinical chemistry parameters measured as part of the study and were used to ensure inclusion of individuals without biochemical abnormalities. In addition, participants receiving coumarin derivatives, systemic glucocorticoids or other anti-inflammatory therapy, or calcium/phosphate binders were excluded. Information on prescription medication use was systematically collected during donor eligibility assessment. The use of over-the-counter dietary supplements, such as vitamins or mineral preparations, was not systematically recorded. Body mass index (BMI) was calculated as weight divided by height squared (kg/m2). Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation. The study was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent for the use of blood samples and associated data for research purposes, according to ULSA blood donation procedures. Ethical approval for sample collection, storage, and use in this study was obtained from the Ethics Committee of ULSA (approval code UAIF063/2021).

Venous blood was collected from the antecubital vein under resting conditions during routine blood donation procedures. Because sampling occurred throughout the day, participants were not required to fast. Blood was collected into serum tubes without anticoagulant (Greiner Bio-One, São Paulo, Brasil). Samples were allowed to clot for 30-60 minutes at room temperature and centrifuged for 10 minutes at 2000xg at room temperature. Serum samples were anonymized using a coded identification system and stored at - 80 °C at ULSA.

After completion of participant recruitment, serum samples were transported in a single batch to the Centre of Marine Sciences (CCMAR), University of Algarve, under temperature-controlled conditions on dry ice and stored at - 80 °C until analysis. All samples underwent two freeze-thaw cycles: the first for routine biochemical analysis, and the second for serum tGRP quantification.

Routine clinical chemistry parameters were measured in September 2024 using standard automated methods at SYNLAB facilities (Faro, Portugal) on an ADVIA 1800 Clinical Chemistry System (Siemens Healthineers, Erlangen, Germany). Parameters included high-sensitivity C-reactive protein (hsCRP), creatinine, calcium, phosphate, magnesium, potassium, sodium, total bilirubin, aspartate aminotransferase (AST), total protein, total cholesterol, HDL-cholesterol, and LDL-cholesterol.

Methods

Serum tGRP concentrations were measured in December 2024 using a proprietary in-house sandwich ELISA developed by GenoGla Diagnostics (Faro, Portugal), based on the assay originally described (17). The assay uses an affinity-purified goat polyclonal antibody, as capture antibody, directed against the N-terminal region of GRP (N-TermGRP), designed to recognize the GRP-F1 isoform.

Minor protocol adjustments relative to the original assay were introduced while maintaining the same analytical principle (17).

Calibration curves were generated using serial dilutions of RP-HPLC-purified recombinant GRP-F1 standards (18). The validated quantitative range of the assay was 240-1600 pg/mL. Analytical performance was evaluated according to standard validation procedures.

Linearity was assessed by least-squares linear regression, with acceptance criterion defined as R2 ≥ 0.99.

Intra-assay precision was assessed by calculating the coefficient of variation (CV, %) for replicate measurements within a single assay run. Inter-assay precision was assessed using in-house quality control (QC) serum samples at two concentration levels (QC Low and QC High), QC samples were analyzed across independent assay runs performed within the same year. Inter-assay precision is expressed as the coefficient of variation (CV, %) for each QC level on an annual basis.

Analytical sensitivity was determined by calculating the limit of detection (LOD) as the mean blank signal plus three standard deviations. The lower limit of quantification (LLOQ) was defined as the lowest concentration meeting predefined accuracy and precision criteria.

Statistical analysis

Statistical analysis were performed using SPSS (version 26; IBM, Chicago, IL, USA). Normality of continuous variables was assessed using the Shapiro-Wilk test. Variables with a non-Gaussian distribution are presented as median with interquartile range (IQR, 25th-75th percentiles). Variables with a Gaussian distribution are presented as mean ± standard deviation (SD). Categorical variables are presented as absolute and relative frequencies. Participants were stratified into three age groups based on tertiles of the age distribution (18-30, 31-46, and 47-65 years). For descriptive and comparative analyses, serum tGRP concentrations were also dichotomized using the population median value. Comparisons between two independent groups (sex groups) were performed using the Mann–Whitney U test. Differences across age groups were assesed using the Kruskal-Wallis test with Dunn’s post hoc correction for multiple comparisons. Exploratory associations of continuous variables were made using Spearman’s rank correlation coefficient, and results are reported with corresponding 95% confidence intervals. For categorical comparisons between age subgroups, the chi-square test was used, followed by post hoc pairwise comparisons using the z-test for proportions with Bonferroni correction. To identify independent predictors of circulating tGRP concentrations, a stepwise linear regression analysis was performed. As serum tGRP concentrations were continuously distributed but showed a non-normal distribution, logarithmic transformation was applied prior to regression analysis to approximate normality and satisfy model assumptions. Variables showing a statistically significant association with tGRP concentrations in univariable analyses (ρ < 0.05) were eligible for inclusion in the multivariable model. All statistical tests were two-sided, and a P value ≤ 0.05 was considered statistically significant.

Results Analytical performance of the optimized Gla-rich protein ELISA

The analytical performance of the optimized sandwich ELISA for serum tGRP was evaluated.

The assay demonstrated good linearity over the evaluation period (2018-2025), with high goodness of fit across the measuring range (R2 ≥ 0.993), Table 2. Assay precision was acceptable, with intra-assay CV ranging from 1.4% to 3.2% and inter-assay CV ranging from 2.5% to 9.4%. The lower limit of quantification (LLOQ) remained stable across years (240-280 pg/mL), supporting reliable quantification of circulating tGRP.

Long-term precision and analytical sensitivity parameters of the total Gla-rich protein ELISA
Year Intra-assay CV(%) Inter-assay CV (%) - QC Low Inter-assay CV (%) - QC High LOD(pg/mL) LLOQ(pg/mL)
2018 2.7 (2.0-4.6) 9.1 5.9 55.8 (8.4-105.2) 240 (240-240)
2019 2.5 (2.0-3.3) 9.0 4.8 27.1(0-61.0) 280 (240-320)
2021 2.4 (2.2-5.0) 8.6 2.5 0 (0-5.1) 240 (240-320)
2022 2.0 (1.5-3.2) 7.6 5.4 47.5 (17.4-102.5) 240 (240-320)
2023 2.1 (0.7-4.2) 8.8 4.8 48.6 (10.8-132.6) 240 (240-240)
2024 1.5 (0.9-1.8) 8.8 3.4 51.1(50.3-106.6) 240 (240-240)
2025 1.5 (1.0-4.1) 9.4 5.3 15.1 (0-55.9) 240 (240-280)
Data are presented as mean ± standard deviation for intra-assay coefficient of variation (CV) and as absolute values for inter-assay CV (QC Low and QC High). LOD and LLOQ values are presented as median (minimum-maximum). QC - quality control. LOD - limit of detection. LLOQ - lower limit of detection. IQR - interquartile range.
Circulating total Gla-rich protein concentrations in healthy individuals

From an initial recruitment of 363 volunteer blood donors, 254 participants met all eligibility criteria and were included in the final analyses. Exclusions were due to high-sensitivity C-reactive protein (hsCRP) concentrations > 3 mg/L (N = 49), estimated glomerular filtration rate < 90 mL/min/1.73 m2 (N = 2), total cholesterol > 5.7mmol/L (N = 27), LDL-cholesterol > 3.4 mmol/L (N = 11), and body mass index ≥ 30 kg/m2 (N = 3). The final study population included 121 men (47.6%). Median age was 41 (18-65) years. Descriptive demographic and biochemical characteristics of the study population are summarized in Table 1. The median serum tGRP concentration in the overall population was 1809.5 pg/mL (IQR: 1197.4-2476.0 pg/mL), Table 3. When participants were stratified into age tertiles (18-30, 31-46, and 47-65 years), serum tGRP concentrations differed across age groups, (Figure 1a; Kruskal-Wallis test, P = 0.038). Median tGRP concentrations were 2069.5 pg/mL (IQR: 1509.5-2816.0 pg/mL for 18-30 years, 1783.0 pg/mL (IQR: 1273.4-2435.6 pg/mL for 31-46 years, and 1516.0 pg/mL (IQR: 996.3-2121.0 pg/mL for 47-65 years, Table 3. No statistically significant differences in serum tGRP concentrations were observed between men and women in the overall population (Mann–Whitney U test, P = 0.420), nor within individual age groups (all P > 0.05) (Figure 1b). In healthy participants, serum tGRP concentrations showed a weak inverse correlation with age (Spearman r = − 0.30, P = 0.002). Although several additional associations reached statistical significance with tGRP, such as hsCRP (r = - 0.20, P = 0.004) and LDL-cholesterol (r = - 0.16, P = 0.003), and weakly positively correlated with estimated glomerular filtration rate (eGFR; r = 0.11, P = 0.025), serum creatinine (r = 0.14, P = 0.028), calcium (r = 0.16, P = 0.011), and phosphate (r = 0.14, P = 0.027, correlation coefficients were < 0.25 and therefore not considered meaningful. No statistically significant correlations were observed between tGRP concentrations and BMI, total cholesterol, HDL-cholesterol, total protein, magnesium, sodium, potassium, total bilirubin, or AST. When tGRP concentrations were dichotomized using the population median, differences in distribution across age groups were observed (χ2 test, P = 0.013; Table 4). Post hoc analysis using the z-test for comparison of proportions with Bonferroni correction showed that the proportion of individuals with higher tGRP concentrations was significantly greater in the youngest age group compared with the oldest age group, while no significant differences were observed between the intermediate group and the other age groups. Variables showing significant univariable associations with serum tGRP concentrations were further evaluated using stepwise multivariable linear regression. In the final model, age and serum calcium concentration remained independently associated with tGRP concentrations. Age showed an inverse association with tGRP concentrations, whereas serum calcium was positively associated. The final model explained approximately 7% of the variability in serum total GRP concentrations (Table 5).

Serum total Gla-rich protein concentrations according to age groups and sex in healthy adults.
Group N Median (pg/mL) IQR (pg/mL)
Overall population
Total 254 1809.5 1197.4-2476.0
Male 121 1799.5 1185.3-2616.1
Female 133 1761.0 1227.0-2265.3
Age 18-30 years
Total 71 2069.5 1509.5-2816.0
Male 24 2263.6 1594.8-3077.0
Female 47 2004.5 1479.5-2624.3
Age 31-46 years
Total 96 1783.0 1273.4-2435.6
Male 52 1799.5 1205.8-2652.0
Female 44 1644.3 1278.4-2229.5
Age 47-65 years
Total 87 1516.0 996.3-2121.0
Male 45 1571.0 1012.9-2226.0
Female 42 1506.2 948.8-2100.7
IQR - interquartile range.

Total GRP (tGRP) serum concentrations across age groups (a) and segmented by sex (b), for the 254 individuals meeting the inclusion criteria (i.e., 18-30 years vs. 31-46 years vs. 47-65 years). Data are presented as individual values with median and range for tGRP serum concentrations. (a) Kruskal-Wallis with Dunn’s post hoc analysis to determine differences in total GRP serum concentrations between age subgroups. (b) Mann-Whitney U-Test to determine differences in tGRP serum concentrations between sexes (female vs. male) in each age group. tGRP - total Gla-rich protein. F - female. M - male.

Comparison of age subgroups between lower and higher total Gla-rich protein serum concentrations
Age subgroups (years) P Total individuals (N)
18-30N (%) 31-46N (%) 47-65N (%)
Median for tGRP serum concentrations (pg/mL) ≤ 1809.5 27(20.8%)a 50(38.5%)a,b 53(40.8%)b < 0.001 130
> 1809.5 44(35.8%)a 46(37.4%)a,b 33(26.8.%)b 123
Total Individuals (N) 71 96 86 254
Data are presented as frequency of the observation found between higher tGRP concentrations (> 1809.5 pg/mL) and lower tGRP concentrations (≤ 1809.5 pg/mL) along the 3 age subgroups. Chi-squared test for differences between groups are given. Post hoc comparisons between age subgroups were performed using the z-test for comparison of proportions with Bonferroni correction. a,bindicate statistically significant differences between groups. tGRP - total Gla-rich protein.
Factors associated with serum total Gla-rich protein concentrations
Variable B (unstandardized) 95% CI for B β (standardized)
Age (years) - 18.3 - 27.5 to - 9.1 - 0.238
Serum calcium (mmol/L) 937.5 102.2 to 1773.1 0.134
Model statistics: Adjusted R2 = 0.073. F-change = 4.886. P = 0.028. N = 254. Multivariable linear regression analysis of factors associated with serum total Gla-rich protein (tGRP) concentrations in healthy adults. Age and serum calcium concentration were retained in the final stepwise linear regression model. Unstandardized (B) and standardized (β) regression coefficients with 95% confidence intervals and P values are shown. CI - confidence interval.
Discussion

In this cross-sectional study, we characterized circulating tGRP serum concentrations in a cohort of healthy adult blood donors and explored their associations with demographic and selected laboratory parameters. By focusing on a well-defined population and samples collected and stored under comparable conditions, this study provides consistent descriptive data on serum tGRP concentrations in healthy adults. These data contribute to the interpretation of GRP measurements in future population-based and clinical studies. The most consistent finding was the inverse association between serum tGRP concentrations and age. Serum tGRP concentrations differed significantly across age tertiles, with higher concentrations observed in younger adults, whereas no significant differences were detected between sexes. Post hoc comparisons further showed that this difference was primarily driven by higher tGRP concentrations in the youngest age group compared with the oldest group, while the intermediate group showed no significant differences. These findings indicate that age is an important factor to consider when interpreting circulating tGRP concentrations in healthy individuals.

Age-related changes have been described for other vitamin K-dependent such as Matrix Gla Protein, supporting the biological plausibility of this observation (19, 20). Nevertheless, the cross-sectional design of the study does not allow conclusions regarding causality, and longitudinal studies will be required to determine whether changes in tGRP concentrations reflect aging-related physiological processes or other age-associated factors.

In univariable analyses, serum tGRP concentrations were associated with several laboratory parameters. Although some associations reached statistical significance, their correlation coefficients were low and therefore not considered clinically meaningful. In the final stepwise regression model, age and serum calcium concentration remained independently associated with serum tGRP concentrations, jointly explaining a modest proportion of their variability. This finding suggests that circulating tGRP concentrations in healthy adults are influenced by multiple determinants, and that a substantial proportion of interindividual variability remains unexplained.

The independent association between serum calcium concentration and circulating tGRP concentrations is consistent with the known biochemical properties of GRP. Gla-rich protein is a vitamin K–dependent protein with a high density of γ-carboxylated glutamate residues, which confer calcium- and mineral-binding capacity (1). Experimental and clinical studies have demonstrated that GRP can interact with calcium-containing mineral phases and is present in calcified tissues and extracellular matrix structures (9, 11, 14, 21). Although the present study does not allow mechanistic inferences, the observed association between serum calcium and tGRP concentrations in healthy individuals is biologically plausible and supports the concept that circulating tGRP may be linked to systemic mineral homeostasis, even within physiological ranges (17). Previous studies have reported circulating GRP concentrations in control groups included in cardiovascular disease-focused studies (15, 16). However, these control populations were not specifically selected to represent healthy adults and were characterized by moderate-to-high cardiovascular risk. Although similar analytical approaches were used, the reported total GRP concentration ranges differ substantially between these studies. In addition, limited clarity in the description of the biological sample matrix, with inconsistent reporting of serum versus plasma, further limits direct comparison and interpretation of absolute GRP concentrations (15). Accordingly, the present study provides, for the first time, consistent descriptive data generated using a well-characterized sandwich ELISA applied to a characterized healthy cohort. This approach enables a more robust interpretation of circulating tGRP concentrations and supports the future development of evidence-based reference frameworks, as well as clinical and epidemiological studies involving this biomarker.

The analytical validation and long-term stability assessment reported here provide methodological support for the population-based findings and strengthen confidence in the reported serum tGRP concentrations. This study has several limitations that should be acknowledged. First, participants were recruited among voluntary blood donors, and blood collection was performed without standardized fasting conditions or a fixed time window, which may have introduced additional biological variability. Second, the study population consisted exclusively of Portuguese adults of European ancestry, limiting the generalizability of the findings to other ethnic or geographic populations. Third, although age and serum calcium concentration were independently associated with serum tGRP concentrations, the explained variability was relatively modest, indicating that other factors, such as dietary habits, vitamin K status, genetic variability, or unmeasured preanalytical variables, may contribute to circulating tGRP concentrations. Finally, the cross-sectional design precludes assessment of intra-individual temporal changes.

In conclusion, this study provides robust data on circulating total GRP serum concentrations in healthy adults and demonstrates an age-associated pattern that should be considered in the interpretation of GRP measurements. The findings highlight the importance of well-characterized healthy populations and analytically validated assays in biomarker research. Future studies in larger and more diverse populations, ideally using longitudinal designs, are warranted to further elucidate the determinants and clinical relevance of circulating GRP concentrations.

Acknowledgements

This research was funded by Portuguese National Funds from FCT—Foundation for Science and Technology, through the PhD grant 2020.07476.BD, project EXPL/BTM-TEC/0990/2021, contracts UID/04326/2025, UID/PRR/04326/2025 and LA/P/0101/2020 (DOI:10.54499/LA/P/0101/2020), from MarPlus project, by AAC n 41/ALG/2020—Project n 072583—NUTRISAFE, by the Portuguese Society of Nephrology (SPN) through projects funding 2019, and by Portuguese Pharmaceutical Order through BiNOV Award 2024.

Potential conflict of interest

Dina C. Simes and Carla Viegas are cofounders of GenoGla Diagnostics. The tools and methods described in this manuscript are included in a PCT patent application PCT/PT2009000046, which is owned by University of Algarve and the Centre of Marine Sciences (CCMAR) and the exclusive rights are licensed to GenoGla Diagnostics. Marília Faísca is the Technical Director of the SYNLAB Algarve Laboratory, with full hierarchical autonomy and technical-scientific independence in the exercise of her functions, conferred by the Management of SYNLAB Algarve. Leon Schurgers receives grants to institutions from Gnosis by Lesaffre, Bayer, Boehringer Ingelheim, is a consultant for IDS and is shareholder of Coagulation Profile. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Data availability statement

The data that support the findings of this study are not openly available due to reasons of sensitivity, privacy restrictions and because they are in the process of analysis for results publication, but are available from the corresponding author upon reasonable request.

References ViegasCSBSimesDCLaizeVWilliamsonMKPricePACancelaML. Gla-rich Protein (GRP), A New Vitamin K-dependent Protein Identified from Sturgeon Cartilage and Highly Conserved. J Biol Chem. 2008;283:36655–64. 10.1074/jbc.M80276120018836183 Surmann-SchmittCDietzUKirevaTAdamNParkJTagarielloA Ucma, a Novel Secreted Cartilage-specific Protein with Implications in Osteogenesis. J Biol Chem. 2008;283:7082–93. 10.1074/jbc.M70279220018156182 TagarielloALutherJStreiterMDidt-kozielLWuellingMSurmann-schmittC Ucma — A novel secreted factor represents a highly specific marker for distal chondrocytes. Matrix Biol. 2008;27:3–11. 10.1016/j.matbio.2007.07.00417707622 StockMMengesSEitzingerNGeßleinMBotschnerRWormserL A Dual Role of Upper Zone of Growth Plate and Cartilage Matrix–Associated Protein in Human and Mouse Osteoarthritic Cartilage: Inhibition of Aggrecanases and Promotion of Bone Turnover. Arthritis Rheumatol. 2017;69:1233–45. 10.1002/art.4004228086000 CavacoSViegasCSBRafaelMSRamosAMagalhãesJBlancoFJ Gla-rich protein is involved in the cross-talk between calcification and inflammation in osteoarthritis. Cell Mol Life Sci. 2016;73:1051–65. 10.1007/s00018-015-2033-926337479 ViegasCSRúbenCMLúciaSVideiraPASilvaZAraújoN Gla-rich protein function as an anti-inflammatory agent in monocytes/ macrophages: Implications for calcification-related chronic inflammatory diseases. PLoS One. 2017;12:e0177829. 10.1371/journal.pone.017782928542410 LeeSHLeeYJParkSIKimJE. Unique cartilage matrix-associated protein inhibits the migratory and invasive potential of triple-negative breast cancer. Biochem Biophys Res Commun. 2020;530:680–5. 10.1016/j.bbrc.2020.07.11432768190 ParkNRLeeYJLeeSHKimJE. Anti-cancer Effect of Unique Cartilage Matrix-associated Protein in Breast Cancer Cells Depends on γ-Carboxylation. Anticancer Res. 2023;43(5):1959–65. 10.21873/anticanres.1635537097656 ViegasCSBRafaelMSEnriquezJLTeixeiraAVitorinoRLuísIM Gla-rich protein acts as a calcification inhibitor in the human cardiovascular system. Arterioscler Thromb Vasc Biol. 2015;35:399–408. 10.1161/ATVBAHA.114.30482325538207 GökdemirCEOkuyanHMKaraboğaİTerziMYKalacıA. Comparison of the protective effect of the upper zone of the growth plate and unique cartilage matrix-associated protein with hyaluronic acid and corticosteroids on an experimental rat osteoarthritis model. Arch Rheumatol. 2024;39:81–8. 10.46497/ArchRheumatol.2024.10066 SeuffertFWeidnerDBaumWSchettGStockM. Upper zone of growth plate and cartilage matrix associated protein protects cartilage during inflammatory arthritis. Arthritis Res Ther. 2018;20:88. 10.1186/s13075-018-1583-229720262 SilvaAPViegasCSBMendesFMacedoAGuilhermePTavaresN Gla-Rich Protein (GRP) as an Early and Novel Marker of Vascular Calcification and Kidney Dysfunction in Diabetic Patients with CKD: A Pilot Cross-Sectional Study. J Clin Med. 2020;9:365. 10.3390/jcm903063532120910 SilvaAPViegasCSBGuilhermePTavaresNDiasCRatoF Gla-Rich Protein, Magnesium and Phosphate Associate with Mitral and Aortic Valves Calcification in Diabetic Patients with Moderate CKD. Diagnostics (Basel). 2022;12:496. 10.3390/diagnostics1202049635204586 MarreirosCViegasCGuedesAMSilvaAPÁguasACFaíscaM Gla-Rich Protein Is Associated with Vascular Calcification, Inflammation, and Mineral Markers in Peritoneal Dialysis Patients. J Clin Med. 2024;13:1–12. 10.3390/jcm1323742939685887 VankovaDPashevaMAngelovAYotovYGalunskaB. Is Circulating Gla-Rich Protein Linked With Coronary Calcium And Cardiovascular Pathology In Patients With Atrial Fibrillation Or Heart Failure? A Pilot Study. Scripta Sci Med. 2021;53:21–7. 10.14748/ssm.v0i0.7374 Zhelyazkova-SavovaMDYotovYTNikolovaMNNazifova-TasinovaNFVankovaDGAtanasovAA Statins, vascular calcification, and vitamin K-dependent proteins: Is there a relation? Kaohsiung J Med Sci. 2021;37:624–31. 10.1002/kjm2.1237333634559 ViegasCSSantosLMacedoALMatosAASilvaAPNevesPL Chronic Kidney Disease Circulating Calciprotein Particles and Extracellular Vesicles Promote Vascular Calcification: A Role for GRP (Gla-Rich Protein). Arterioscler Thromb Vasc Biol. 2018;38:575–87. 10.1161/ATVBAHA.117.31057829301790 RafaelMSCavacoSViegasCSBSantosSRamosAWillemsBAG Insights into the association of Gla-rich protein and osteoarthritis, novel splice variants and γ-carboxylation status. Mol Nutr Food Res. 2014;58:1636–46. 10.1002/mnfr.20130094124867294 CranenburgECMVermeerCKoosRBoumansMLHackengTMBouwmanFG The Circulating Inactive Form of Matrix Gla Protein (ucMGP) as a Biomarker for Cardiovascular Calcification. J Vasc Res. 2008;45:427–36. 10.1159/00012486318401181 SilaghiCNFodorDGheorgheSRCrAM. Serum total matrix Gla protein : Reference interval in healthy adults and variations in patients with vascular and osteoarticular diseases. Clin Chim Acta. 2019;490:128–34. 10.1016/j.cca.2018.12.029 WillemsBAFurmanikMCaronMMJChatrouMLLKustersDHMWeltingTJM Ucma/GRP inhibits phosphate-induced vascular smooth muscle cell calcification via SMAD-dependent BMP signalling. Sci Rep. 2018;8:4961. 10.1038/s41598-018-23353-y29563538
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020709" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020709" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020709" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(79) "Factors associated with Gla-rich protein serum concentrations in healthy adults" ["journals_article_author"]=> string(115) "Catarina Marreiros, Carla Viegas, Selene Nunes, Ana Paula Silva, Marília Faísca, Leon Schurgers, Dina Costa Simes" ["journals_article_author_country"]=> string(25) "Portugal, The Netherlands" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(67) "Gla-rich protein, serum concentrations, healthy adults, age factors" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1768" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "15" ["meta_title"]=> string(79) "Factors associated with Gla-rich protein serum concentrations in healthy adults" ["meta_desc"]=> string(79) "Factors associated with Gla-rich protein serum concentrations in healthy adults" ["meta_keyw"]=> string(67) "Gla-rich protein, serum concentrations, healthy adults, age factors" ["created"]=> string(19) "2026-06-01 10:54:52" ["modified"]=> string(19) "2026-06-11 09:02:50" } [22]=> object(stdClass)#71 (35) { ["journals_id"]=> string(4) "1246" ["journals_xml"]=> string(43769) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020708 10.11613/BM.2026.020708 Original articles Cross-interference of hemolysis, icterus and lipemia: A study with real patient samples Bozkurt YavuzHatice*TünerSoycan Department of Clinical Chemistry, Uşak University Faculty of Medicine, Uşak, Turkey Corresponding author: haticebozkurtyavuz@gmail.com

Author contributions

H Bozkurt Yavuz: Conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software – programming, supervision, validation, visualisation, writing – original draft, writing – review & editing; S Tüner: data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, supervision, validation, visualisation, writing – review & editing.

15062026 15062026 36 2 020708 0611202514042026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Hemolysis, icterus and lipemia (HIL) are among the most common errors encountered in the preanalytical phase

• Cross-interference among HIL indices can cause misinterpretation

• Hemolysis falsely increased lipemia and decreased icterus measurements

• Lipemia led to false increases in icterus and reduced mild hemolysis

• Icterus caused a false reduction in low levels of hemolysis

Introduction

Hemolysis, icterus, and lipemia (HIL) are frequent preanalytical interferences, leading to erroneous results or sample rejection. While individual effects of these indices have been studied, their interferences on each other remain largely unexplored. This study aimed to evaluate the cross-interference of HIL parameters using endogenous patient-derived samples, thereby ensuring clinically relevant conditions, and to propose a decision algorithm for improved sample quality assessment.

Materials and methods

Following the CLSI-EP07 guideline, high-concentration icterus and lipemia pools from leftover clinical samples and hemolizate pool have been prepared. These pools were serially diluted with low-index serum (HIL0) to obtain defined combinations. Indices were measured using the Abbott Alinity c system. Cross interferences were calculated as percentage bias compared to baseline values.

Results

High level hemolysis remained largely unaffected by other indices. Hemolysis in the range of 2.5-10.0 g/L caused a 20-150% false increase in lipemia and a 10-60% false decrease in icterus. Conversely, lipemia in the range of 25-100 index led to a 20-150% false increase in icterus and reduced low level of hemolysis by 10-30%. Similarly, icterus at 42.75-171 µmol/L resulted in a 15-45% false reduction in low levels of hemolysis. No concentration-dependent systematic bias was observed for lipemia and icterus, whereas hemolysis showed level-dependent effects.

Conclusions

Cross-interference among HIL indices can lead to misinterpretation if indices are assessed independently. A rule-based, threshold-dependent algorithm incorporating these interactions is proposed to enhance accuracy in sample rejection decisions. Implementation of such integrated approaches, along with manufacturer transparency may significantly improve laboratory reliability.

Keywords: hemolysisicteruslipemiapreanalytical phaseinterferencesample handling
Introduction

Hemolysis, icterus, and lipemia (HIL) are frequent preanalytical issues that can interfere with routine test results and lead to misinterpretation (1). Hemolysis, icterus, and lipemia were previously assessed visually based on color and turbidity, but this method was time-consuming, subjective, and lacked standardization (2, 3). The Clinical and Laboratory Standards Institute (CLSI) C56A guideline recommends the use of a detection system for HIL serum indices to ensure reliable assessment of sample quality (4).

Hemolysis, icterus, and lipemia are among the primary rejection criteria used in clinical laboratories. Moreover, in vitro hemolysis is the most common error, affecting up to 3.3% of routine blood samples and representing 40-70% of all unsuitable specimens (1). The cut-off values provided by reagent manufacturers are commonly used in test rejection protocols; however, reagent package inserts generally do not include information on the mutual interference between HIL parameters (5, 6). This may lead to the performance of a test that should have been rejected or the rejection of a test that should have been analyzed. There are studies showing that hemolysis affects icterus and that lipemia increases hemolysis (7, 8). However, to the best of our knowledge, no study has evaluated the mutual interference of all three parameters - hemolysis, icterus, and lipemia. Recent research emphasizes the importance of using natural lipemic samples in interference studies to improve the accuracy of results and facilitate effective patient management (9). The purpose of this study is to assess the cross-interference of HIL parameters under clinically relevant conditions by using only endogenous patient samples and to develop a decision algorithm for improving sample quality evaluation.

Materials and methods

This experimental analytical interference study was conducted in accordance with the CLSI EP07 guideline. This guideline recommends evaluating the effect of hemolysis, icterus, and lipemia at five different concentrations (including zero) on two different concentrations of the target analyte (10). While this approach is relatively straightforward for a standard analyte routinely measured in laboratories, our study aimed to investigate the mutual effects of hemolysis, icterus, and lipemia on each other. Therefore, a modified approach was adopted to align with this objective. The reason for this adjustment is that the added interfering substances themselves affect the measured outcome. To address this, serial dilutions of the interfering substances were performed, their recoveries calculated, and comparisons were made using these target values. The analyses were performed using the Abbott Alinity c system (Abbott Laboratories, Chicago, USA). The study was conducted with the approval of the Uşak University non-interventional studies ethics committee (778-778-20).

Sample selection and sample preparation

A serum pool with hemolysis < 0.02 g/L, lipemia < 2 index and icterus < 20 µmol/L was prepared from leftover samples to be used as a diluent and was designated as HIL0. The HIL0 pool was prepared using samples from 10 patients. To create lipemic and icteric serum pools, sera from patients with high lipemia and icterus levels were used. For the icterus pool, sufficient serum was obtained from two patients with cholestasis, whereas the lipemia pool was prepared using sera from three different patients. The hemolysate-containing pool was prepared by generating hemolysate from the complete blood count samples of a patient whose serum sample was used in the HIL0 pool, thereby ensuring the absence of lipemia and icterus, with freezing/thawing of whole blood followed by the osmotic shock protocol (11). Because the hemolysis level was very high (> 100 g/L), the hemolysate was diluted with HIL0 serum to achieve the desired (2 g/L) hemoglobin concentration.

Samples were considered eligible for the high-lipemia pool if they showed a lipemia index of 300 with hemolysis < 0.02 g/L and icterus < 20 µmol/L. Similarly, samples were included in the high-icterus pool if they had an icterus level of 228 µmol/L with hemolysis < 0.02 g/L and lipemia < 2 index. Samples showing concurrent elevation of more than one HIL parameter were excluded from pool preparation.

The HIL-0 and high-concentration pools were prepared from fresh samples that had completed analysis on the day of the study, and no freezing, thawing, or prolonged storage was performed. Serial dilutions of these high-concentration HIL pools with the HIL0 pool showed no significant deviation, which simplified the study; the results obtained from the serial dilutions, with each sample analyzed in five replicates, are presented in Table 1. As the obtained values were closely clustered, no outliers were identified. This allowed for the calculation of expected HIL values in serum pools mixed in known ratios, enabling comparison with measured HIL values. For example, to obtain a pool containing 5 H and 171 I, 1 mL of the H 20 pool and 3 mL of the I 228 pool were mixed, resulting in a 4 mL sample with 5 H, 171 I, and L < 2. The H value was measured in this sample, allowing the interference of 171 icterus on 5 H to be determined.

Serial dilution results of high index pools with HIL0 serum sample
High-index: HIL0 ratio Number of replicates Expected H index(g/L) Measured H index (g/L) Expected I index(µmol/L) Measured I index (µmol/L) Expected L index(index) Measured L index (index)
1:0 5 20 20 ± 0.6 228 228 ± 6.9 300 300 ± 10
1:1 5 10 10 ± 0.38 114 114 ± 6.7 150 151 ± 6
1:3 5 5 5.02 ± 0.18 67 66.7 ± 2.6 75 74 ± 3
1:5 5 3.33 3.29 ± 0.10 38 38.1 ± 2.4 50 51 ± 2.5
1:9 5 2 2.01 ± 0.06 23 22.8 ± 1.7 30 29 ± 1.5
H - hemolysis. I - icterus. L - lipemia. HIL0 - hemolysis, icterus, lipemia free serum sample. The measured H, I and L index are presented as mean and standard deviation.

The prepared interference tubes were labeled and briefly vortex-mixed, then arranged in a random order on the analyzer racks. Prior to each analytical run, vortexing was repeated, and the tubes were re-randomized to ensure that the order of analysis differed from the previous run.

Acceptable interference limit

The guideline recommends the use of total allowable error when defining acceptable interference limits; however, such limits are not defined for hemolysis, icterus, and lipemia indices in the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Biological Variation database. In practice, reagent package inserts commonly apply an arbitrary threshold of 10% as the allowable amount of interference (6). In the present study, the outcome variables were the serum indices themselves (hemolysis, icterus, and lipemia) rather than patient-reportable analytes. Therefore, analyte-specific clinical interference limits based on total allowable error were not directly applicable in this context, and the analysis focused on the analytical interaction between the indices. In our study, considering that hemolysis can affect clinically critical analytes such as potassium even at low levels, we predefined an allowable difference of 10%. Accordingly, results showing changes exceeding ± 10% and demonstrating a consistent directional pattern in accordance with the monotonicity concept described in the guideline were interpreted as false-positive or false-negative results.

Number of replicates

According to CLSI EP07, when the ratio of the allowable difference (δ) to within-run imprecision (σ) exceeds 2, a minimum of five replicates is recommended. In this study, the allowable interference was predefined as 10%, the coefficient of variation (CV) for hemolysis, icterus, and lipemia were 3.0%, 3.7%, and 4.2%, yielding δ/σ ratios of 3.33, 2.7, and 2.4, respectively. As all ratios exceeded 2, five replicate measurements were performed for each dilution level and index.

Statistical analysis

Cross interferences were calculated as percentage bias compared to baseline values using the formula: Bias (%) = [(Measured Value - Expected Value) / Expected Value] x 100. Within-run imprecision was evaluated using CV (%). Data points from the five replicates were expressed as mean percentage differences, and descriptive statistics (mean ± standard deviation) were calculated using Microsoft Excel .

Results

An increase in hemolysis leads to an increase in lipemia results, while a decrease is observed in the icterus. Figure 1 summarizes the percentage increases and decreases relative to the baseline value. The low level of icterus is the index level most positively affected by lipemia, with an observed increase of up to 150%. In contrast to icterus, lipemia decreases hemolysis. The effect of increasing lipemia on hemolysis and icterus is summarized in Figure 2. Although icterus does not have a significant effect on the results in the presence of lipemia and high-level hemolysis (bias < 10%), it causes a nearly 50% decrease in low-level hemolysis when the icterus level reaches 171 µmol/L. The effect of icterus on hemolysis and lipemia is summarized in Figure 3. Lipemia was not influenced by icterus, and false increases in the lipemia index occurred only at hemolysis levels above 2.5 g/L, while no false decrease was observed, indicating that low lipemia index values remain reliable.

Percent difference of icterus and lipemia indices under hemolysis interference. Each sample was analyzed in five replicates; data points represent mean percentage differences.

Percent difference of icterus and hemolysis indices under lipemia interference. Each sample was analyzed in five replicates; data points represent mean percentage differences.

Percent difference of hemolysis and lipemia indices under icterus interference. Each sample was analyzed in five replicates; data points represent mean percentage differences.

Discussion

In this study, we proposed a decision algorithm based on HIL indices, taking into account the mutual interactions among them. High hemolysis values are considered reliable, as no interference from other indices leads to a false increase in the hemolysis index. Similarly, low lipemia index values are deemed accurate, as they are not subject to falsely decreased results due to other indices.

For lipemia and icterus, we observed no concentration-dependent systematic shift in interference and therefore developed a rule-based algorithm grounded in individual test-specific rejection thresholds for Abbott Alinity c system. However, a different approach was necessary for hemolysis, since high and low levels of hemolysis were not equally affected by icterus and lipemia interference. Based on this observation, we stratified hemolysis using a threshold of 5 g/L, and created a conditional algorithm accordingly. This was particularly relevant for analytes sensitive to even low-level hemolysis. The final step of the proposed algorithm requires expert review, as introducing a fixed correction factor was not feasible due to the concentration-dependent nature of HIL effects. Therefore, instead of applying a universal mathematical correction, we prioritized a structured interpretive approach that integrates both laboratory thresholds and expert opinion. A summary of the proposed algorithm is presented in Figure 4.

Hemolysis, icterus, lipemia - based decision algorithm incorporating cross-interference effects on Abbott Alinity c systems. Platform-specific hemolysis-, icterus and lipemia-based decision algorithm incorporating cross-interference effects for Abbott Alinity c systems.

In tests that are affected even by low levels of hemolysis, the simultaneous presence of hemolysis and icterus may lead to the unintentional reporting of a result that should have been rejected. For instance, in a patient presenting with hyperbilirubinemia (total bilirubin concentration: 171 µmol/L), if the hemolysis index is measured as 0.9 g/L by the analyzer, the result may be reported since it falls below the rejection threshold of 1.25 g/L hemoglobin, defined in the kit insert for the potassium assay (12). However, considering that the icterus index is 171 µmol/L in this case, our findings indicate that the actual hemolysis may exceed the rejection threshold, 1.25 g/L hemoglobin, and thus the result should not be reported. This may lead to an artificially elevated potassium concentration, potentially altering and prolonging the course of treatment.

The need for greater transparency from manufacturers regarding HIL interference has previously been emphasized by the EFLM Working group for preanalytical phase (13). However, upon reviewing the Abbott Alinity c package inserts, we found that certain reagent inserts do not provide detailed information on how lipid interference studies are conducted, and some do not even specify the hemolysis concentrations that affect the result (14, 15). In our view, this transparency should include detailed diagrams explaining both the units used and the methodology of the study, and the evaluations should be applicable to real patient samples rather than being based solely on artificial substances such as Intralipid.

On the other hand, the use of Intralipid solution is common in lipemia studies, and certain Abbott kit package inserts also evaluate lipemic interference using Intralipid (5). In a study evaluating the effects of HIL on analytes, the measured concentrations of hemoglobin and total bilirubin were used to represent hemolysis and icterus, respectively, while the calculated concentration of Intralipid was used for lipemia, and serial dilutions of the Intralipid solution were reported to align with Abbott index values when expressed in mg/dL (2). The degree of turbidity does not always correlate well with triglyceride concentration; although a strong linear relationship has been shown using standardized lipid emulsions, this correlation is much weaker in real patient samples (16). Kit manufacturers may report interference evaluations for lipemia up to 10 g/L Intralipid concentration in their package inserts (5). However, in the lipemia part of our study, the highest achievable lipemia value was 300 index, and the leftover samples used to prepare this pool had triglyceride concentrations exceeding 20 g/L. These values were among the highest identified when we retrospectively reviewed the laboratory information system. The difference between Intralipid and native lipemia may be attributed to the fact that the refractive index of Intralipid particles differs from that of lipoproteins (9). Therefore, in our study, we chose to use g/L units for hemoglobin and µmol/L for icterus, while using unit of ‘index’ for lipemia, as it did not correlate with real triglyceride concentration.

This study has certain limitations. While preparing the HIL0 pool, it was not possible to identify a sample in which the HIL indices were all simultaneously zero. As a result, there may be minimal interference present in the baseline pool. However, considering the very high concentrations of the added interferents, we believe that such a small magnitude of variation in any index would have a negligible impact on the overall results. In addition, during the preparation of the hemolysate, the selected samples were processed with distilled water. Thus, the only artificial substance used throughout the study was distilled water. Regarding the lipemia effect on hemolysis, although the patient sample used in the hemolysate preparation was not lipemic, the L index was found to be elevated, in line with our study hypothesis. Since there was no lipemia in the sample, L < 2 was accepted in the hemolysate without additional lipemia and the increase due to lipemia addition was calculated accordingly. Also, all measurements were performed on a single analytical platform (Abbott Alinity c); therefore, the observed HIL index behavior and the proposed decision algorithm are platform-specific, and the findings may not be directly generalizable to other analytical systems.

In conclusion, this study highlights that HIL indices can influence not only test results but also each other’s measurements. These mutual interferences indicate that evaluating HIL indices in isolation may lead to misinterpretation, especially in borderline cases. Therefore, integrated algorithms that consider cross-interference effects and provide expert-based interpretation are essential for improving the accuracy and reliability of laboratory test processes.

Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References TianGWuYJinXZengZGuXLiT The incidence rate and influence factors of hemolysis, lipemia, icterus in fasting serum biochemistry specimens. PLoS One. 2022;17:e0262748. 10.1371/journal.pone.026274835045128 HoCKMChenCSetohJWSYapWWTHawkinsRCW. Optimization of hemolysis, icterus and lipemia interference thresholds for 35 clinical chemistry assays. Pract Lab Med. 2021;25:e00232. 10.1016/j.plabm.2021.e0023234095417 SimundicAMTopicENikolacNLippiG. Hemolysis detection and management of hemolyzed specimens. Biochem Med (Zagreb). 2010;20:154–9. 10.11613/BM.2010.018 Clinical Laboratory Standards Institute (CLSI). Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline. CLSI C56-A document. Wayne:CLSI;2012. Abbott Diagnostics, Glucose, Alinity c, Abbott Laboratories Abbott Park, IL 60064 USA; Revised 2022. VrtaricAMilerMNikolac GabajNCelapIVidranskiVBocanM Hemolysis index. Can we uncritically trust manufacturer declarations? Clin Chem Lab Med. 2025;64:698–705. 10.1515/cclm-2025-130241126781 Bozkurt YavuzH. The relationship between hemolysis and I-index: investigating its use as a screening test in hyperbilirubinemia. Scand J Clin Lab Invest. 2025;85:64–9. 10.1080/00365513.2025.246020139903684 DimeskiGMolleePCarterA. Increased lipid concentration is associated with increased hemolysis. Clin Chem. 2005;51:2425. 10.1373/clinchem.2005.05864416306120 Çolak SamsumESürerHBolatSŞeneşMYücelD. Comparison of lipemia interference created with native lipemic material and intravenous lipid emulsion in emergency laboratory tests. Biochem Med (Zagreb). 2024;34:020701. 10.11613/BM.2024.02070138665874 Clinical Laboratory Standards Institute (CLSI). Interference Testing in Clinical Chemistry; Approved Guideline. CLSI EP07 document. Wayne:CLSI;2018. DimeskiG. Interference testing. Clin Biochem Rev. 2008;29 Suppl 1:S43–8.18852856 Abbott Diagnostics Integrated Chip Technology (ICT) Sample Diluent Alinity c, Abbott Laboratories Abbott Park, IL 60064 USA; Revised 2018. . von MeyerACadamuroJLippiGSimundicAM. Call for more transparency in manufacturers declarations on serum indices: On behalf of the Working Group for Preanalytical Phase (WG-PRE), EFLM. Clin Chim Acta. 2018;484:328–32. 10.1016/j.cca.2018.03.04329617625 Abbott Diagnostics, Uric acid, Alinity c, Abbott Laboratories Abbott Park, IL 60064 USA; Revised 2022. Abbott Diagnostics, Iron2, Alinity c, Abbott Laboratories Abbott Park, IL 60064 USA; Revised 2022. NikolacN. Lipemia: causes, interference mechanisms, detection and management. Biochem Med (Zagreb). 2014;24:57–7. 10.11613/BM.2014.00824627715
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020708" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020708" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020708" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(87) "Cross-interference of hemolysis, icterus and lipemia: A study with real patient samples" ["journals_article_author"]=> string(35) "Hatice Bozkurt Yavuz, Soycan Tüner" ["journals_article_author_country"]=> string(6) "Turkey" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(79) "hemolysis, icterus, lipemia, preanalytical phase, interference, sample handling" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3270" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "14" ["meta_title"]=> string(87) "Cross-interference of hemolysis, icterus and lipemia: A study with real patient samples" ["meta_desc"]=> string(87) "Cross-interference of hemolysis, icterus and lipemia: A study with real patient samples" ["meta_keyw"]=> string(79) "hemolysis, icterus, lipemia, preanalytical phase, interference, sample handling" ["created"]=> string(19) "2026-05-28 12:28:22" ["modified"]=> string(19) "2026-06-11 09:02:24" } [23]=> object(stdClass)#72 (35) { ["journals_id"]=> string(4) "1251" ["journals_xml"]=> string(99074) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020707 10.11613/BM.2026.020707 Original articles Optimization of icterus interference thresholds for 45 parameters on the Atellica analyzers CH930 and IM1300 LeleuDamienDenimalDamienDuvillardLaurence* Université Bourgogne Europe, CHU Dijon Bourgogne, Service de Biochimie, INSERM UMR 1231, Dijon, France Corresponding author: laurence.duvillard@chu-dijon.fr

Author contributions

D Leleu: Investigation, Writing – original draft; D Denimal: Conceptualization, Methodology, Writing – review & editing; L Duvillard: Conceptualization, Methodology, Formal analysis, Supervision, Writing – review & editing.

15062026 15062026 36 2 020707 1311202531032026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Data from the supplier for icterus-induced interference on Atellica are very partial

• We evaluated it for 45 parameters by spiking samples with conjugated or unconjugated bilirubin

• The measured biases were compared to EFLM recommendations

• Icterus index threshold warrants to be revised for 38 among the 45 parameters tested

• Our data enable a more reliable interpretation of results for icteric samples on Atellica

Introduction

The data provided by the manufacturer regarding icterus interference on the various parameters measured on Atellica analyzers are very incomplete, potentially leading to erroneous result interpretation. We aimed to evaluate icterus interference on Atellica CH930 and IM1300 for 45 parameters and to suggest revised icterus indexes for a better interpretation of results.

Materials and methods

Pools of serum or plasma were spiked with various concentrations of either conjugated or unconjugated bilirubin. Analytes were measured in triplicate on bilirubin-spiked and native samples. Biases were calculated as the difference between the mean results of both samples. We compared the observed biases to the threshold of 10% similar to the manufacturer, and also to the total allowable errors recommended by the European Biological Variation Study (EuBIVAS).

Results

Based on significant bias above 10%, revised icterus index thresholds were higher than manufacturer recommendations for 33 parameters, and lower for 3 parameters. Based on the EuBIVAS criteria, the thresholds were higher than manufacturer recommendations for 33 parameters, and lower for 5 parameters. The revised thresholds differed between the 2 evaluation methods in 13 cases, being less strict for some parameters with the EuBIVAS criteria, and stricter for other ones. For some parameters, the magnitude of interference differed for conjugated and unconjugated bilirubin, or depended on the concentration of the analyte.

Conclusions

This work provides important data that can be used to improve the interpretation of results for 45 parameters on Atellica analyzers CH930 and IM1300 in patients with hyperbilirubinemia.

Keywords: Atellica analyzersicterus interferenceicterus index
Introduction

Icterus is frequent for serum or plasma samples, especially in hospitalized patients (1). It is likely to interfere with the quantification of different biochemical parameters (2). Several mechanisms are likely to explain icterus interference in biochemistry assays (2). Firstly, since bilirubin absorbs light between 400 and 540 nm, it can interfere with colorimetric assays taking absorbance measurement at these wavelengths. Secondly, bilirubin can interfere with oxidoreduction reactions like Trinder reaction. Bilirubin is likely to reduce hydrogen peroxide in Trinder reaction, decreasing the reduction of the chromogen, resulting in a negative bias, which amount depends on the efficiency of hydrogen peroxide acceptor. But, for unclear reasons, the conjugated and unconjugated forms of bilirubin may induce interference in opposite directions.

It is highly important to understand the extent to which icterus interferes with the measurement of the concentration of an analyte. Indeed, laboratory professionals can either decide to cancel a result in case of significant icterus interference, or to transmit the result with either an indication of the direction or the approximate magnitude of the bias (3). Current analyzers are now able to evaluate icterus levels in samples through spectrophotometric measurement, with results reported as the icterus index (I-index). Unfortunately, some manufacturers have not always evaluated icterus interference across the full range of bilirubin concentrations encountered in patients (4). For the sake of caution, they recommend suppressing the results for samples whose I-index is above the threshold for which they stopped interference assays, even if there is no significant interference for that threshold. The problem described here above concerns Atellica analyzers (Siemens, Erlangen, Germany) for both chemistry and immunoassays (5). For some parameters, icterus interference is specific to one analytical platform and the I-index scale is heterogeneous among analytical platforms (6). As a result, data cannot be generalized from one platform to another.

The aim of the present study was to evaluate on the recently launched Atellica analyzers the icterus interference on the 45 parameters routinely quantified in our laboratory for which the manufacturer recommends to flag results from an icterus index between 1 and 5, suggesting a potential interference, whereas for most of these parameters, no significant interference was evidenced for the recommended thresholds (i.e. no interference higher than 10%, which is the criteria chosen by the manufacturer). We conducted interference experiments using both conjugated and unconjugated bilirubin since the two forms of bilirubin are likely to have varying effects on the results (2). For the parameters biased by icterus, we estimated the amount of interference for different I-index values to guide laboratory professionals in interpreting and potentially transmitting the result.

Materials and methods

This analytical interference study was conducted between January 2024 and March 2025 in the Biochemistry department of the Dijon Bourgogne University Hospital.

Materials

The effect of icterus was evaluated on 45 parameters using pools of serum, heparinized plasma, or plasma with sodium fluoride (from blood collected in BD Vacutainer SST™, PST™, and fluoride tubes with gel separator, respectively), which were kept at + 4 °C after routine analysis, for less than 36h. The nature of the biological matrix depended on the usual practices of our laboratory and was validated by the Atellica manufacturer as indicated in the technical sheets (5). Ethics committee approval and informed consent were not required in compliance with our institutional guidelines for the use of pools of anonymized leftover patient samples that were scheduled for disposal. Hemolysis, icterus and lipemia indices of plasma or serum pools were equal to 0 before spiking.

Interference was tested at concentrations whose choice is precised in Supplementary table 1. A specific pool (3 to 5 mL) was constituted just before experiments for each analyte and each concentration, from 3 to 5 samples. Interference was first tested for a low concentration of the analyte, and then on a higher concentration, when a bias higher than the recommended thresholds was observed on the first concentration. On the Atellica system, icterus is expressed as an index ranging from 0 to 6 (Table 1) (5). Lyophilized unconjugated bilirubin (> 98%; Merck, Fontenay sous Bois, France) was dissolved in 0.1 N NaOH, just before each interference testing (7-10). This sample was vortexed, protected from light by aluminium foil, let stand 5 minutes and vortexed again before the next step. It was added to a fraction of the plasma or serum pool with a dilution factor 1:10 (v/v), and the tube was protected from light until being used for the preparation of spiked samples. Bilirubin concentration was measured on the native pool and on this unconjugated bilirubin-enriched sample on Atellica with dedicated reagent, and, based on these results, we prepared different dilutions in the native pool, to achieve a set of 5 samples with the desired bilirubin concentrations (1 sample per icterus index level). For each level of the icterus index, bilirubin concentration was adjusted to a concentration just below the threshold for the above index level indicated in Table 1 (maximum 10 µmol/L below). At the end, 0.1 N NaOH solution always represented less than 5% (v/v) of the final samples. For each parameter, we checked that 5% (v/v) 0.1 N NaOH did not influence results on native samples (data not shown). For conjugated bilirubin, we purchased bilirubin conjugate ditaurate disodium salt from Merck as described in previous studies (6, 11-13). We directly mixed it in a fraction of the plasma or serum pool. This sample was vortexed, let stand 5 minutes and vortexed again before the next step. It was protected from light by aluminium foil until being used for the preparation of spiked samples. Bilirubin concentration was measured on the conjugated bilirubin-enriched pool and then we processed as described for unconjugated bilirubin.

Correspondence between the icterus index values and bilirubin concentrations on the Atellica system, according to the manufacturer’s specifications (5)
Index value Bilirubin concentration (µmol/L)
0 < 34.2
1 34.2-170
2 171-342
3 342-513
4 513-684
5 684-1026
6 > 1027
Methods

Analyte measurements were performed using an Atellica automated platform equipped with a chemistry module CH930 and an immunoanalysis module IM1300. The methods for the different parameters are detailed in Table 2. Measurements for each analyte were performed in triplicate, as previously done in similar works, within the shortest possible timeframe using the same analyzer and reagent batches (9, 14). Samples were loaded on the analyzer just after their preparation in the following order: native pool, conjugated bilirubin enriched samples from I = 1 to 5, and unconjugated bilirubin enriched samples from I = 1 to 5. Experiments were conducted at a time when activity was low in our department, so analysis were performed very quickly after sample loading. All assays were conducted in accordance with the manufacturer’s instructions, with routine internal and external quality control procedures in place, including for hemolysis, icterus and lipemia indexes (Probioqual, Lyon, France). Our laboratory is accredited according to ISO 15189:2022 standards.

Methods and wavelengths used for the quantification of the parameters evaluated in this study
Methods Wavelengths (nm)
CHEMISTRY MODULE
Alanine aminotransferase, P5P Conversion NADH to NAD 340/410
Albumin, bromocresol purple Complex albumin-bromocresol purple 596/694
Apolipoprotein AI Immunoturbidimetry 340/694
Apolipoprotein B Immunoturbidimetry 340/694
Aspartate aminotransferase, P5P Conversion NADH to NAD 340/410
Calcium Complex calcium-arsenazo III 658/694
Carbon dioxide Conversion NADH analog to NAD analog 410/478
Ceruloplasmin Immunoturbidimetry (Sentinel reagent) 340
Cholesterol, HDL Trinder, substrate: 4 aminoantipyrine + NNbis-(4-sulfobutyl)-m-toluidine 596/694
Cholesterol, LDL Trinder, substrate: 4 aminoantipyrine + DSBmT (NNbis-(4-sulfobutyl)-m-toluidine) 545/694
Cholesterol, total Trinder, substrate: 4 aminoantipyrine + phenol 505/694
Creatinine Trinder, substrate: 4 aminoantipyrine + N-ethyl-N-(3-methylphenyl)-N’-succinyl-ethylenediamine 545/694
Gamma-glutamyl transferase Transfer of g-glutamyl group from g-glutamyl-3-carboxy-4-nitroanilide to glycylglycine 410/478
Glucose, hexokinase Conversion NAD to NADH 340/410
Haptoglobin Immunoturbidimetry 340/694
Immunoglobulin A Immunoturbidimetry 340/596
Immunoglobulin G Immunoturbidimetry 340/694
Lactic acid Trinder, substrate: 4 aminoantipyrine + proton donor
Lipase Product of the substrate transformed by lipase 571/694
Lipoprotein (a) Immunoturbidimetry 694
Magnesium Complex with xylitlyl blue 505/694
Phosphorus Complex phosphomolybdate 340/658
Prealbumin Immunoturbidimetry 410
Protein, total Complex with CuSO4 545
Transferrin Immunoturbidimetry 340/596
Triglyceride Trinder, substrate: 4 aminoantipyrine + 4 chlorophenol 505/694
Urea Conversion NADH to NAD 340/410
Uric acid Trinder, substrate: 4 aminophenazone + N-ethyl-N-[2 hydroxy-3 sulfopropyl]-3 methylaniline] 545/694
IMMUNOANALYSIS MODULE
AFP Sandwich immunoassay, chemiluminescence, acridinium ester 596
CA 125 Sandwich immunoassay, chemiluminescence, acridinium ester 596
CA 15-3 Sandwich immunoassay, chemiluminescence, acridinium ester 596
CEA Sandwich immunoassay, chemiluminescence, acridinium ester 596
Cortisol Competitive immunoassay, chemiluminescence, acridinium ester 596
C-peptide Sandwich immunoassay, chemiluminescence, acridinium ester 596
Folate Competitive immunoassay, chemiluminescence, acridinium ester 596
FSH Sandwich immunoassay, chemiluminescence, acridinium ester 596
fT3 Competitive immunoassay, chemiluminescence, acridinium ester 596
fT4 Competitive immunoassay, chemiluminescence, acridinium ester 596
Insulin Sandwich immunoassay, chemiluminescence, acridinium ester 596
LH Sandwich immunoassay, chemiluminescence, acridinium ester 596
Oestradiol Competitive immunoassay, chemiluminescence, acridinium ester 596
Progesteron Competitive immunoassay, chemiluminescence, acridinium ester 596
Prolactin Sandwich immunoassay, chemiluminescence, acridinium ester 596
TSH Sandwich immunoassay, chemiluminescence, acridinium ester 596
Vitamin B12 Competitive immunoassay, chemiluminescence, acridinium ester 596
The informations are issued from the technical sheets (5). AFP - alpha fetoprotein. CA - carbohydrate antigen. CEA - carcinoembryonic antigen. FSH - follicle stimulating hormone. fT4 - free thyroxin. fT3 - free triiodothyronine. HDL - high density lipoprotein. LDL - low density lipoprotein. LH - luteinizing hormone. P5P - pyridoxal-5-phosphate. TSH - thyroid stimulating hormone.
Statistical analysis

The mean of the three replicate values was used for analysis. A correction by the dilution factor was applied for the samples enriched with unconjugated bilirubin. The difference in concentration between each bilirubin-spiked sample and no spiked native pool was expressed in percentage, thereafter referred to as “bias”. In a first approach, we considered that interference was significant when the absolute bias exceeded 10%, in accordance with the process described by Siemens. In addition to this generic threshold, analyte specific acceptability criteria based on biological variation were also applied. Specifically, we evaluated whether the bias exceeded the desirable total allowable analytical error defined by the European Biological Variation Study (EuBIVAS) conducted by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) (15, 16).

Results Estimation of bilirubin-induced interference

All the results are summarized in Table 3 and the results showing an interference higher than EuBIVAS threshold are graphically represented on Supplementary figures 1 and 2. For 29 of the 45 parameters tested, no bias above 10% was observed up to I = 5, for conjugated or unconjugated bilirubin. For 26 of these 29 parameters, the bias was also lower than EuBIVAS threshold (no recommendation for C-peptide). For the 16 remaining parameters a bias higher than 10% was observed for I-index ≤ 5, either for conjugated bilirubin, unconjugated bilirubin or both. For all of these parameters except for progesteron, similar results were observed with EuBIVAS thresholds. For aspartate aminotransferase, low density lipoprotein (LDL) cholesterol, uric acid, creatinine, total protein, folate, and estradiol, the bias was higher with conjugated bilirubin compared to unconjugated bilirubin. On the contrary, for calcium, total cholesterol, triglycerides, free triiodothyronine (fT3), free thyroxine (fT4), follicle - stimulating hormone (FSH), progesteron and vitamin B12, the bias was higher with unconjugated bilirubin. For lactate, both forms of bilirubin had similar effects. On the other hand, for the different parameters cited above, except for creatinine and uric acid, the bias decreased when the concentration of the analyte increased, falling well below 10% in some cases.

Biases induced by interference of conjugated and unconjugated bilirubin
Analyte (matrix) Baseline concentration Bias relative to baseline following spiking (%)Conjugated bilirubinUnconjugated bilirubin EuBIVAS acceptable bias (desirable performance) (%) (14, 15)
I = 1 I = 2 I = 3 I = 4 I = 5
CHEMISTRY MODULE
Alanine aminotransferase, P5P (Ph) 49.3 IU/l + 4.8- 3.8 + 4.8- 5.7 + 4.1- 7.8 + 1.4- 7.6 - 0.6+ 3.9 18.7
Albumin, bromocresol purple (Ph) 25.7 g/L + 1.2- 0.4 + 1.2+ 0.4 - 2.7+ 3.8 - 2.7+ 2.0 + 1.2+ 2.4 3.3
Apolipoprotein AI (S) 1.20 g/L NPNP NPNP - 1.1+ 0.4 - 1.1- 0.3 - 0.8+ 1.1 6.2
Apolipoprotein B (S) 0.74 g/L NPNP NPNP + 0.5- 0.5 - 0.50.0 0.0+ 1.6 10.6
Aspartate aminotransferase, P5P(Ph) 46.3 IU/L + 10.2+ 1.1 + 18.1+ 3.1 + 30.3+ 1.4 + 38.2- 0.4 + 48.3+ 2.4 12.4
187 IU/L + 3.7+ 0.5 + 6.00.0 + 8.3- 1.0 + 12.8- 1.4 + 16.4+ 0.4
Calcium (Ph) 1.93 mmol/L + 1.9- 0.1 + 1.1- 4.6 - 0.7- 6.1 + 0.2- 7.2 + 0.4- 13.1 2.3
2.63 mmol/L - 0.3- 2.0 + 0.9- 2.3 - 0.4- 2.5 + 0.1- 3.9 - 0.9- 4.2
Carbon dioxide (Ph) 16 mmol/L 0.0- 1.1 - 2.1- 0.1 - 2.1- 2.3 - 2.1- 3.0 - 6.3- 4.2 4.9
28 mmol/L - 1.2+ 1.1 - 1.2+ 3.4 0.0+ 2.7 0.0+ 3.8 0.0- 0.4
Ceruloplasmin (S) 0.20 g/L - 1.7- 0.7 0.0+ 0.3 - 1.7+ 3.1 - 1.7+ 4.2 - 5.0+ 5.0 8.1
Cholesterol, HDL (S) 0.76 mmol/L - 0.4+ 3.7 + 3.1+ 5.6 + 2.2+ 6.7 - 4.8+ 6.5 - 5.3+ 6.2 9.9
Cholesterol, LDL (S) 1.68 mmol/L - 3.6+ 0.2 - 8.9- 1.6 - 15.1- 6.5 - 19.8- 8.2 - 30.0-11.2 11.8
3.19 mmol/L - 2.1- 0.7 - 5.0- 0.9 - 7.4- 4.3 - 9.9- 5.3 - 17.2- 7.5
Cholesterol, total (S) 2.87 mmol/L + 3.7+ 13.1 + 5.3+ 23.3 + 5.6+ 34.4 + 6.3+ 40.8 + 7.2+ 48.9 8.3
4.90 mmol/L + 0.5+ 3.0 - 1.0+ 7.5 - 1.5+ 13.0 - 1.6+ 14.1 - 2.7+ 17.9
Creatinine (Ph) 67.7 µmol/L - 4.0+ 1.5 - 7.4- 0.7 - 7.9- 5.6 - 14.8- 4.2 - 18.3- 9.8 7.8
213 µmol/L - 2.2+ 0.2 - 6.1- 0.6 - 8.9- 2.1 - 13.3- 4.1 - 15.8- 4.1
Gamma-glutamyl transferase (Ph) IU/L - 0.7- 2.2 - 0.7- 4.8 0.0- 3.9 - 2.2- 6.6 - 5.1- 6.4 18.3
Glucose (Ph) 4.59 mmol/L - 0.1+ 0.4 - 1.3+ 0.5 - 1.5- 0.5 - 2.2+ 1.5 - 2.5+ 0.4 6.1
Haptoglobin (Ph) 0.30 g/L - 1.10.0 - 2.2- 1.0 - 2.2- 2.7 - 2.2- 2.0 - 3.30.0 17.1
Immunoglobulin A (S) 0.72 g/L - 0.5- 0.4 - 0.9- 1.7 - 3.2- 2.1 - 4.9- 1.1 - 2.8+ 1.5 14.5
Immunoglobulin G (S) 6.70 g/L - 0.0+ 0.3 + 3.4+ 1.1 + 3.3+ 4.4 + 0.3+ 5.1 + 0.1+ 2.3 7.3
Lactic acid (Pf) 1.88 mmol/L - 11.0- 9.7 - 12.8- 11.0 - 51.1- 33.5 - 51.8- 41.8 - 53.2- 59.7 36.2
8.51 mmol/L - 1.3- 0.6 - 2.2- 2.2 - 3.4- 4.7 - 4.6- 4.6 -7.6- 8.9
Lipase (Ph) 48.7 IU/L - 0.3+ 0.7 - 1.7+ 0.3 - 3.1- 1.3 - 0.3+ 0.6 - 2.1- 4.5 12.9
Lipoprotein (a) (S) 157 mg/L + 1.0+ 1.3 + 0.8+ 2.8 + 1.5+ 1.2 + 0.8+ 1.8 + 0.6+ 4.5 29.8
Magnesium (Ph) 0.75 mmol/L - 1.3- 0.3 - 1.8- 1.1 - 3.6- 3.4 - 4.9- 4.7 - 6.2- 6.0 3.8
1.16 mmol/L - 0.6+ 0.8 - 0.9- 0.2 - 1.7- 2.9 - 2.9- 2.7 - 4.9- 1.1
Phosphorus (Ph) 1.08 mmol/L 0.0+ 0.7 + 1.9- 0.8 + 2.5- 0.9 + 4.0- 0.1 + 7.4- 1.9 9.6
Prealbumin (Ph) 0.19 g/L + 1.8+ 2.0 1.81.0 - 3.5+ 0.5 - 3.5- 2.1 - 5.3+ 0.8 14.5
Total protein (Ph) 49.6 g/L - 4.8- 4.5 - 10- 8.4 - 17.3- 12.2 - 22.3- 16.0 - 34.2- 22.0 3.8
72.8 g/L - 3.3- 2.0 - 5.3- 4.1 - 9.0- 6.0 - 11.3- 7.9 - 17.0- 11.6
Transferrin (S) 1.86 g/L + 0.5+ 0.8 + 0.2+ 2.6 + 0.9+ 2.5 - 0.2+ 1.5 + 1.6+ 1.6 6.8
Triglycerides (S) 1.12 mmol/l + 2.1+ 5.5 + 3.6+ 17.8 + 3.3+ 34.9 + 5.1+ 40.1 + 6.5+ 53.8 25.8
2.80 mmol/L - 0.1+ 7.0 2.6+ 11.8 4.3+ 18.3 - 6.5+ 20.4 - 9.6+ 25.6
Urea (Ph) 6.3 mmol/L + 1.6+ 1.0 + 2.6+ 1.2 + 2.1+ 0.9 + 1.1- 3.1 + 4.2- 1.5 17.1
Uric acid (Ph) 310 mmol/l - 6.8- 0.3 - 14.2- 0.8 - 24.6- 0.4 - 32.5- 0.5 - 55.3- 1.0 11.6
508 mmol/L - 6.3- 1.0 - 14.6- 0.9 - 25.7- 0.7 - 31.1- 1.0 - 45.5- 0.6
IMMUNOANALYSIS MODULE
AFP (S) 10.9 µg/L NPNP NPNP + 3.4+ 1.2 + 2.8+ 8.0 + 0.9- 2.8 17,6
CA125 (S) 37.2 kIU/L NPNP NPNP + 7.5- 1.5 +7.8- 1.1 + 8.6- 3.1 13,9
CA15-3 (S) 37.3 kIU/L NPNP NPNP + 3.6- 1.3 + 5.5- 0.8 + 7.0+ 0.7 12,9
CEA (S) 4.4 µg/L NPNP NPNP 0.0- 4.7 + 6.1+ 2.1 + 2.3- 2.4 26,9
Cortisol (S) 5.69 µg/dL NPNP NPNP NPNP + 4.2+ 4.7 + 9.8+ 4.7 22.2
C-peptide (S) 0.41 ng/mL NPNP NPNP + 3.3- 0.9 + 2.4+ 1.0 + 4.1+ 10.1 none
Folate (S) 3.14 ng/mL + 8.0NP + 10.0NP + 15.6- 5.1 + 18.2- 3.6 + 16.7- 4.8 15.5
5.48 ng/mL +1.0NP + 5.8NP + 9.4- 4.5 + 13.1- 3.2 + 10.1- 2.4
FSH (S) 4.8 IU/L 0.0+ 3.8 - 1.4- 2.5 + 3.5+ 23.1 + 2.8+ 22.9 - 2.8+ 20.6 17.6
71 IU/L NPNP NPNP + 8.5+ 4.3 + 9.4+ 3.5 + 2.8+ 6.7
fT4 (Ph) 9.4 pmol/L + 0.7+ 4.6 - 1.1+ 7.2 - 1.1+ 12.2 0.0+ 17.3 + 3.2+ 27.1 6.3
15.0 pmol/L + 0.9+ 2.6 + 0.4+ 3.8 + 1.1+ 9.9 + 6.2+ 7.2 + 2.7+ 12.7
fT3 (Ph) 2.83 pmol/L - 1.1+ 3.4 + 1.3+ 6.9 + 0.1+ 9.0 - 3.4+ 10.9 - 6.9+ 16.5 11.3
5.7 pmol/L - 1.8- 0.2 - 4.1+ 1.1 - 5.3+ 5.4 - 9.4+ 5.3 - 10.5+ 7.7
Insulin (S) 3.00 mIU/L NPNP NPNP NPNP NPNP + 1.1+ 2.4 31.5
LH (S) 2.9 IU/L NPNP NPNP 0.0+ 3.0 - 2.3+ 2.3 - 6.9- 0.8 29.1
Oestradiol (S) 135 ng/L + 3.7- 1.7 + 5.7- 5.3 + 12.6- 9.0 + 23.2- 8.0 + 25.4- 8.9 18.3
1294 ng/L + 1.4+ 2.8 - 1.2+ 3.9 - 5.8+ 3.6 - 4.8+ 6.1 - 7.3+ 5.1
Progesteron (S) 1.16 µg/L + 0.6+ 2.2 - 1.7- 0.9 - 3.4- 0.4 - 4.3- 2.7 - 12.1- 11.4 26.2
9.74 µg/L - 1.4- 1.3 - 1.0- 4.6 - 3.8- 7.8 - 5.5- 19.1 - 8.0- 22.3
Prolactin (S) 246 mIU/L NPNP NPNP - 5.1- 7.7 - 4.2- 8.2 - 5.3- 5.4 56.7
TSH (Ph) 2.08 mIU/L NPNP NPNP + 0.3- 3.3 + 0.6- 2.0 + 1.0+ 1.0 24.8
Vitamin B12 (S) 244 ng/L NPNP NPNP + 3.3+ 2.7 + 3.6+ 5.1 + 3.6+ 13.3 15.4
1376 ng/L NPNP NPNP + 0.7- 1.5 +1.0+ 1.0 + 2.3+ 4.3
Results are from measurements performed in triplicate and averaged. Biases are calculated as the difference between spiked and native samples and expressed in %. AFP - alpha fetoprotein. CA carbohydrate antigen. CEA - carcinoembryonic antigen. FSH - follicle stimulating hormone. fT4 - free thyroxin. fT3 - free triiodothyronine. HDL - high density lipoprotein. I - icterus index. LDL - low density lipoprotein. LH - luteinizing hormone. NP - not performed. P5P - pyridoxal-5-phosphate. Ph - heparinized plasma. Pf - sodium fluoride plasma. S - serum. TSH - thyroid stimulating hormone.
Revised I-index thresholds

Table 4 lists the manufacturer-suggested I-index thresholds. An icterus-induced bias was proven to be higher than 10% only for a few of the parameters. For most of parameters, the bias was below 10%, but tests were not performed for higher bilirubin concentrations. In this case, as a precaution, the manufacturer considered that the bias could be more than 10% above the tested threshold. We suggest new thresholds for I-index, based on our experimental results, firstly considering bias above 10% as significant. For 29 parameters, I-index threshold can be increased to 6 instead of 2 to 5 (Table 4). For creatinine, fT3 and progesteron, it can be increased from 3 to 4, and for vitamin B12 it can be set at 5 instead of 3. At the opposite, based on a significant interference for bias higher than 10%, the threshold for aspartate aminotransferase, total cholesterol, and lactate should be stricter than those suggested by the manufacturer. Based on EuBIVAS desirable recommended performance limits reported in Table 3, the index threshold can be maintained at 6 for parameters with an icterus-induced interference below 10%, except for carbon dioxide (I = 5) and magnesium (I = 4). For parameters with a bias exceeding 10%, we also suggested I-index thresholds related to EuBIVAS recommended performance limits. These indexes were less strict than those based on a bias higher than 10% for 7 parameters, similar for 5 and stricter for 4.

Suggested revised index thresholds for icterus interference
Index suggested by Siemens Revised index for bias ≤ 10% Revised index for bias ≤ EuBIVAS thresholds
CHEMISTRY MODULE
Alanine aminotransferase, P5P 3* 6 6
Albumin, bromocresol purple 4* 6 6
Apolipoprotein AI 4* 6 6
Apolipoprotein B 4* 6 6
Aspartate aminotransferase, P5P 3* 1 2
Calcium 5* 5 2
Carbon dioxide 4* 6 5
Ceruloplasmin 4* 6 6
Cholesterol, HDL 4* 6 6
Cholesterol, LDL 3 3 3
Cholesterol, total 3 1 1
Creatinine 3* 4 3
Gamma-glutamyl transferase 2* 6 6
Glucose 4* 6 6
Haptoglobin 3* 6 6
Immunoglobulin A 3* 6 6
Immunoglobulin G 5* 6 6
Lactic acid 2 1 3
Lipase 3* 6 6
Lipoprotein (a) 3* 6 6
Magnesium 4* 6 4
Phosphorus 4* 6 6
Prealbumin 3* 6 6
Total protein 3* 3 1
Transferrin 4* 6 6
Triglycerides 2* 2 3
Urea 3* 6 6
Uric acid 2* 2 2
IMMUNOANALYSIS MODULE
AFP 3*† 6 6
CA125 3*† 6 6
CA15-3 3*† 6 6
CEA 3*† 6 6
Cortisol 3*† 6 6
C-peptide 3*† 6 none
Folate 3 3 3
FSH 3*† 3 3
fT4 3*† 3 2
fT3 3* 4 5
Insulin 3*† 6 6
LH 3* 6 6
Oestradiol 3*† 3 4
Progesteron 3* 4 6
Prolactin 3*† 6 6
TSH 5* 6 6
Vitamin B12 3*† 5 6
*indicates that the manufacturer did not show significant interference for the index below but that interference assays for that index and higher have not been reported in the technical sheets. †indicates that information has been extrapolated from the Centaur analyzer (Siemens), without any experiment performed on Atellica. AFP - alpha fetoprotein. CA - carbohydrate antigen. CEA - carcinoembryonic antigen. FSH - follicle stimulating hormone. fT4 - free thyroxin. fT3 - free triiodothyronine. HDL - high density lipoprotein. LDL - low density lipoprotein. LH - luteinizing hormone. P5P - pyridoxal-5-phosphate. TSH - thyroid stimulating hormone.
Discussion

The present study performed on the Atellica platform (Siemens) highlights the need for revised thresholds for significant icterus-induced interference in most of the parameters studied. Among the 45 tested parameters, a new threshold was suggested for 36 of them using the 10% limit method, and for 38 using the EuBIVAS limit method. In addition, our findings highlight the differential impact of conjugated and unconjugated bilirubin, and possibly the dependence of icterus-induced interference on the concentration of the measured parameter on Atellica analyzers. To the best of our knowledge, no similar work has been previously reported for the Atellica platform, in contrast to published studies on the Alinity (Abbott) and Cobas (Roche) analyzers (13, 17).

Acceptability limits have been defined by different ways throughout the literature (6, 8, 14). The Atellica manufacturer chose 10% for all parameters, and we initially kept the same criteria in line with this choice, so that our work could be seen as the extension of manufacturer’s work. However, as suggested by Von Meyer et al., a single 10% threshold does not take into account within-subject and within-group biological variability, and is not always the most appropriate approach in a context of medical decision (4). Several acceptability limits are often proposed for one parameter, as can be seen in the synthetic document on the Westgard Quality Control site, which may make the certain choice difficult (15). We also proposed revised I-index thresholds based on the allowable total errors issued from EuBIVAS conducted by the European Federation of Clinical Chemistry and Laboratory Medicine. Although the revised I-index threshold is similar for both evaluations for many parameters, it differs for others. For biochemical parameters such as magnesium and calcium which have a narrow biological variation and a weak icterus interference, the proposed I-index is lower with EuBIVAS threshold compared to the 10% threshold. On the contrary, for hormonal parameters impacted by icterus, I-index threshold is likely to be higher based on EuBIVAS criteria due to considerable biological variations.

In most cases, the threshold for significant icterus-induced interference was increased, while it was reduced for a few analytes. Knowing the precise impact of interferences on laboratory results is essential for interpretation and patient care. The major issue for Atellica users is that the manufacturer did not evaluate icterus interference across the full range of the bilirubin concentrations likely to be encountered in patients and suggests, as a precautionary measure, to consider that a significant interference may occur above the tested threshold. In addition, the range of bilirubin concentration tested is highly variable from one parameter to another, stopping sometimes at very low concentrations. Very interestingly, our work demonstrated that for many parameters reliable results can be released for all patients, since no bias higher than 10% or EuBIVAS recommended threshold was observed for bilirubin concentration reaching 1000 µmol/L, which is almost never encountered in clinical practice. Not releasing these results from I-index equal to 3 or 4 (equivalent to a bilirubin concentration equal to 340 or 510 µmol/L, respectively), or releasing them with a doubt about a potential interference is an issue especially in hospital where patients with an icterus are frequent. In addition, we suggested revised I-index thresholds lower than 6 but with a value higher than that suggested by the manufacturer for some parameters. Replacing the manufacturer’s thresholds by the thresholds based on our results allows to release much more results with confidence without any doubt about a potential bilirubin-induced interference. In case of a significant icterus interference, laboratory professionals choose between cancelling the result or releasing it with a comment. Our work provides further insight for formulating a potential comment with the sense of interference and an estimation of it.

We performed assays with both conjugated and unconjugated bilirubin which showed that interference may be very different for the two forms of bilirubin. This has previously been reported for different parameters, underlying the importance of performing tests with both forms of bilirubin (11, 18). In practice, the measurement of icterus indices does not allow to tell the difference between them, and in an automated work process, some results are wrongly tagged or even cancelled. For these parameters, a further analysis of the results including the measurement of each of the two forms of bilirubin could lead to the release of reliable results not biased by any interference, in case of the increase in the bilirubin fraction without any interference. Thus, our data are also important for guiding the transmission of results in patients with a broad predominance of one form of bilirubin. The reasons for the differential interference of conjugated and unconjugated bilirubin are not clear. Interestingly, Table 2 shows that, among the methods with the Trinder reaction, those using phenol or a derivative as a chromogen with a reading at 505/694 nm, present a positive interference mainly with unconjugated bilirubin. On the contrary, those using another chromogen with reading at 545/694 nm present a negative interference mainly with conjugated bilirubin. Negative interference of bilirubin is frequently mentioned in line with its reducing power. The sense of interference and the form of interfering bilirubin appears to depend on the nature of chromogen in the Trinder reaction. Thus, for a single parameter, interference may be variable and cannot always be anticipated, which is the case for triglycerides for example (6, 7). As far as immunoassays are concerned, icterus-induced interference occurs mainly with competitive assays. Again, the mechanism of interference is not clear since it is alternatively observed with conjugated or unconjugated bilirubin. Exposure of an acridinium ester label to an alkaline hydrogen peroxide solution triggers a flash of light, and bilirubin may reduce hydrogen peroxide. The bias is usually positive. For competitive immunoassays, this may be consistent with the reducing power of bilirubin which interferes with the oxidoreduction reaction of acridinium ester. Another explanation may be that bilirubin disrupts the binding of the competitor to the antibody.

The main limitation of this study concerns parameters for which icterus-induced interference is very different for conjugated and unconjugated bilirubin. Indeed, analyzers do not differentiate both forms of bilirubin and the recommended I-index thresholds, based on the bilirubin form with the highest interference, may lead to flag results in an abusive manner. However, in patients with a broad predominance of one form, results may be reinterpreted by the laboratory professionals.

In conclusion, this study provides many relevant additional data concerning bilirubin-induced interference on the quantification of 45 parameters on Atellica analyzers CH930 and IM1300. Our findings can be used to improve the interpretation of results in patients with increased blood bilirubin concentration and are of major importance for the daily practice of clinical laboratories equipped with Atellica analyzers. Indeed, much more results can be released with confidence without any doubt about a potential bilirubin-induced interference. In addition, knowing the differential impact of both forms of bilirubin on some parameters gives the opportunity to interpret more specifically the impact on results for the patients with a hyperbilirubinemia with a broad predominance of one form of bilirubin. Also, knowing that bilirubin-induced interference is modulated by the concentration of the analyte for some parameters may differentially guide the release of results.

Acknowledgments

We would like to thank Suzanne Rankin for the language revision of the manuscript.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References MainaliSMerrillAEKrasowskiMD. Frequency of icteric interference in clinical chemistry laboratory tests and causes of severe icterus. Pract Lab Med. 2021;27:e00259. 10.1016/j.plabm.2021.e0025934761095 FarrellCJLCarterAC. Serum indices: managing assay interference. Ann Clin Biochem. 2016;53:527–38. 10.1177/000456321664355727147624 CadamuroJLippiGvon MeyerAIbarzMvan DongenELases. European survey on preanalytical sample handling - Part 2: Practices of European laboratories on monitoring and processing haemolytic, icteric and lipemic samples. On behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE). Biochem Med (Zagreb). 2019;29:020705. 10.11613/BM.2019.02070531223259 von MeyerACadamuroJLippiGSimundicAM. Call for more transparency in manufacturers declarations on serum indices: On behalf of the Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). Clin Chim Acta. 2018;484:328–32. 10.1016/j.cca.2018.03.04329617625 Document Library - Siemens Healthineers [Internet]. [cited 2025 Sept 30]; Available from: https://doclib.siemens-healthineers.com/home VrtaricAMilerMGabajNNVidranskiVBocanMFilipiP Icteria interference for 34 clinical chemistry analytes on different analytical platforms: Method or analyzer dependent? Clin Chim Acta. 2025;565:119993. 10.1016/j.cca.2024.11999339389215 HoCKMChenCSetohJWSYapWWTHawkinsRCW. Optimization of hemolysis, icterus and lipemia interference thresholds for 35 clinical chemistry assays. Pract Lab Med. 2021;25:e00232. 10.1016/j.plabm.2021.e0023234095417 Cano-CorresRSole-EnrechGAparicio-CalventeMI. Definition of icteric interference index for six biochemical analytes. Biochem Med (Zagreb). 2023;33:020702. 10.11613/BM.2023.02070237324113 AlvarezYFKelliherMTHubbardJANerenzRDCervinskiMA. Reevaluating the Icterus Index Cutoff of a Jaffé Creatinine Method. J Appl Lab Med. 2022;7:1151–7. 10.1093/jalm/jfac04535899580 AgarwalSVargasGNordstromCTamEBuffoneGJDevarajS. Effect of interference from hemolysis, icterus and lipemia on routine pediatric clinical chemistry assays. Clin Chim Acta. 2015;438:241–5. 10.1016/j.cca.2014.08.00825128720 AlvarezFWhalenKScottMG. Conjugated, but not unconjugated, bilirubin negatively interferes in Hitachi 747 assay of inorganic phosphorus. Clin Chem. 1993;39:2345–6. 10.1093/clinchem/39.11.2345a8222236 SteenGKlerkALaanKVDEppensEF. Evaluation of the interference due to haemoglobin, bilirubin and lipids on Immulite 2500 assays: a practical approach. Ann Clin Biochem. 2011;48:170–5. 10.1258/acb.2010.01018721355012 KarinAHigginsVMillerJBrincDKulasingamVSelvaratnamR. Evaluation of hemolysis, lipemia, and icterus interference with common clinical immunoassays. Clin Chem Lab Med. 2023;61:1035–45. 10.1515/cclm-2022-092436635939 KnezevicCENessMATsangPHTTenneyBJMarzinkeMA. Establishing hemolysis and lipemia acceptance thresholds for clinical chemistry tests. Clin Chim Acta. 2020;510:459–65. 10.1016/j.cca.2020.08.00432771484 Consolidated Comparison of Chemistry Performance Specifications - Westgard QC [Internet]. [cited 2025 Sept 30]; Available from: https://westgard.com/clia-a-quality/quality-requirements/consolidated-comparison-of-chemistry-performance-specifications Consolidated Comparison of Immunoassay Performance Specifications - Westgard QC [Internet]. [cited 2025 Oct 31]; Available from: https://westgard.com/clia-a-quality/quality-requirements/consolidated-comparison-of-immunoassay-performance-specifications.html JiJZMengQH. Evaluation of the interference of hemoglobin, bilirubin, and lipids on Roche Cobas 6000 assays. Clin Chim Acta. 2011;412:1550–3. 10.1016/j.cca.2011.04.03421575617 BeynePLettéronPHervéCRoulletJBDelacouxE. Bilirubin interference with determination of creatinine, lactate, phosphorus, and uric acid on Beckman Synchron CX7. Clin Chem. 1996;42:988–90. 10.1093/clinchem/42.6.9888665703
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020707" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020707" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020707" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(108) "Optimization of icterus interference thresholds for 45 parameters on the Atellica analyzers CH930 and IM1300" ["journals_article_author"]=> string(48) "Damien Leleu, Damien Denimal, Laurence Duvillard" ["journals_article_author_country"]=> string(6) "France" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(55) "Atellica analyzers, icterus interference, icterus index" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1584" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "13" ["meta_title"]=> string(108) "Optimization of icterus interference thresholds for 45 parameters on the Atellica analyzers CH930 and IM1300" ["meta_desc"]=> string(108) "Optimization of icterus interference thresholds for 45 parameters on the Atellica analyzers CH930 and IM1300" ["meta_keyw"]=> string(55) "Atellica analyzers, icterus interference, icterus index" ["created"]=> string(19) "2026-06-01 10:52:21" ["modified"]=> string(19) "2026-06-11 09:02:13" } [24]=> object(stdClass)#73 (35) { ["journals_id"]=> string(4) "1250" ["journals_xml"]=> string(160395) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020706 10.11613/BM.2026.020706 Original articles Verification of harmonized reference intervals in Croatia: is it time for a change? FriščićIva*1BurazerIda1RadeljakAndrea2PerkovSonja1Kardum ParoMirjana Mariana1 Department of Medical Biochemistry and Laboratory Medicine, Merkur University Hospital, Zagreb, Croatia Department for Clinical Laboratory Diagnostics, Children’s Hospital Srebrnjak, Zagreb, Croatia Corresponding author: iva.friscic@gmail.com

Author contributions

I Friščić: Conceptualization, Data duration, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation – Verification, Visualisation, Writing – original draft; I Burazer: Conceptualization, Data duration, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation – Verification, Visualisation, Writing – review & editing; A Radeljak: Conceptualization, Investigation, Writing – review & editing; S Perkov: Conceptualization, Investigation, Resources, Supervision, Writing – review & editing; MM Kardum Paro: Conceptualization, Investigation, Project administration, Resources, Supervision, Writing – review & editing.

15062026 15062026 36 2 020706 1607202524032026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Harmonized reference intervals were verified in healthy adults in Croatia

• Most tested reference intervals were confirmed in a single sample set

• International harmonized reference intervals were adopted for total calcium and alkaline phosphatase

• Periodic re-evaluation of harmonized reference intervals is needed

Introduction

The study of harmonized reference intervals (RIs) in Croatia was published in 2004. Since then, notable methodology and population characteristics changes have occurred in the Croatian population, highlighting the need for re-evaluation. This study aimed to verify harmonized RIs for hematology, coagulation, and clinical chemistry laboratory tests and assess their applicability in one clinical hospital center.

Materials and methods

This verification study included 100 apparently healthy adults (40 males, 60 females; aged 22 to 75 years), selected using both a priori and a posteriori exclusion criteria following CLSI EP28-A3c guidelines. Blood samples were collected under standardized preanalytical conditions. Hematology analysis was performed on the Sysmex XN1000 analyzer (Sysmex, Kobe, Japan), coagulation testing on the Sysmex CS2500 analyzer (Siemens Healthcare Diagnostics Inc., Marburg, Germany), and clinical chemistry analysis on the Beckman Coulter DxC700AU (Beckman Coulter, Brea, USA) and Radiometer ABL90 FLEX (Radiometer, Brønshøj, Denmark) analyzers. Reference intervals were considered verified if at least 90% of results (18/20) fell within the predefined RIs.

Results

All tested hematology and coagulation RIs were successfully verified. Among 27 tested biochemical analytes, 25 RIs were verified in the first sample set. Total calcium and alkaline phosphatase RIs required additional verification. International harmonized RIs were adopted and successfully verified for both tests using two independent sample sets.

Conclusions

Most harmonized RIs in use in Croatia remain applicable to the adult population of one clinical hospital center. However, periodic re-evaluation is needed due to changes in analytical methods and population characteristics. Reference intervals from international harmonization projects can provide a valid alternative when local verification fails.

Keywords: reference valuesverificationharmonizationCLSI
Introduction

Reference intervals (RIs) are a fundamental tool for the assessment of laboratory test results. The use of appropriate RIs provides clinicians with the proper context for interpreting laboratory test results and has a significant impact on the clinical decision-making process (1, 2). The establishment of direct RIs is a time-consuming and financially demanding process, and the derivation of indirect RIs requires advanced informatics infrastructure and expertise (1-4). Furthermore, the derivation of indirect RIs has additional limitations related to reference population selection and the exclusion of pathological results, as well as to the standardization of preanalytical conditions and analytical methods (1, 4, 5). Consequently, most laboratories routinely transfer and verify RIs from literature sources, which mostly include manufacturers’ test instructions, national or international expert group recommendations, and harmonized RIs derived using direct single- or multicenter studies or indirect approaches (1, 2, 4-7). In the context of harmonization, international initiatives coordinated by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have played a key role. The IFCC Committee on Reference Intervals and Decision Limits (C-RIDL) and the IFCC Task Force on Global Reference Interval Database (TF-GRID) have emphasized the use of standardized protocols, multicenter data, and large-scale datasets to improve the comparability and transferability of RIs across populations and analytical platforms. The primary objective of the TF-GRID is the development of an IFCC-hosted platform serving as a centralized global RI database for clinical chemistry and hematology (1, 2, 4, 5). Despite these efforts, local verification remains essential before routine implementation due to population- and laboratory-specific factors (1). In Croatia, the national RI harmonization project was initiated in 2003 by the Croatian Chamber of Medical Biochemists (CCMB). It resulted in publications released in 2004 and 2007, which include RIs in general, specialized and highly specialized medical biochemistry (8, 9). These RIs were based on data obtained from the population of Zagreb and its surrounding area, whose demographic characteristics most closely align with those of the Croatian population (10). Samples used for the establishment of RIs were collected across multiple centers, while laboratory analyses and statistical data processing were performed in a single center, which also serves as the national Reference Centre for the development and implementation of RIs. Current national recommendations are primarily based on previously published data (8-10). For the pediatric population, the use of RIs from international literature sources is recommended, primarily those from the Canadian Laboratory Initiative on Pediatric Reference Intervals database (CALIPER database) (11). Following the initial publications, verification of RIs was performed for serum creatinine (CREA) measured using the enzymatic method, as well as for aspartate aminotransferase (AST) and alanine aminotransferase (ALT), whose catalytic activities are determined using the IFCC reference methods with pyridoxal-5-phosphate (PLP) activation. Given the high degree of standardization of these methods, the internationally harmonized RIs are considered suitable for the studied population (12, 13). The study by Flegar-Meštrić et al., published in 2016, represents the most recent publication in Croatia to provide a critical review of harmonized RIs for the adult population (13). Verification of RIs for the neonatal population in Croatia was conducted in 2024, demonstrating minimal differences compared to the evaluated RIs (14). Since the last verification of RIs for the adult population (12, 13), significant methodological, dietary, and demographic changes have occurred within the Croatian population. On this basis, we aimed to verify the harmonized RIs for routine hematology, coagulation, and clinical chemistry laboratory tests in adults aged 20 years and older currently in use in clinical laboratories in Croatia (8, 9, 13). To this end, a single-center university hospital with a large urban catchment area, serving approximately one fifth of the population of the city of Zagreb, Croatia, provided the case study for this investigation.

Materials and methods Subjects

This study was approved by the Ethical Committee of Mekur University Hospital, Zagreb, Croatia (approval number: 03/1-4884/4). All subjects signed an informed consent form. The study was conducted between July 2024 and June 2025. The study population consisted of adults aged 20 years and older. Reference individuals were selected from a larger group of apparently healthy volunteers recruited from hospital staff and the general population, using both a priori and a posteriori sampling methods. The a priori selection included the use of a standardized questionnaire developed following the international CLSI EP28-A3c guidelines, designed to assess medical history, lifestyle factors, and medication use (15). Exclusion criteria included self-reported disease, regular alcohol consumption, the use of addictive substances, and blood sampling under non-fasting conditions. Self-reported disease was defined as a positive response to questionnaire items 6-9. In addition, hypertension was considered an exclusion criterion when it required regular medication, as indicated by a positive response to questionnaire items 11 and 12. Alcohol consumption was assessed by self-report, where “occasional” referred to infrequent, social alcohol intake, while “regular” consumption indicated habitual alcohol use; individuals reporting regular consumption were excluded. The questionnaire is shown in Table 1.

Standardized questionnaire used for selection of reference individuals
Number Question Answer format
1 Full name Free text
2 Age Numeric
3 Sex Male / Female
4 Height (cm) Numeric
5 Weight (kg) Numeric
6 Do you consider yourself a healthy person? Yes / No
7 Do you suffer from any chronic diseases? Free text
8 Have you been hospitalized in the past 3 months? Yes (specify) / No
9 Have you had any serious illnesses in the last 3 years? Yes (specify) / No
10 Hereditary or chronic diseases in the family Yes (specify) / No
11 Hypertension Yes / No
12 Regular medication, including dietary supplements Free text
13 Physical activity Regular (≥ 3x/week) / Occasional / Never
14 When did you last exercise? Free text
15 Smoking Yes / No
16 Alcohol consumption Never / Occasionally / Regularly
17 Use of addictive substances Yes / No
18 Special diet Free text
19 Other Free text
20 Blood sampling in accordance with professional guidelines (filled by lab staff) Yes / No

A posteriori exclusion criteria included the presence of an acute inflammatory process, indicated by elevated C-reactive protein (CRP) concentration (> 5 mg/L) and total leukocyte count (> 9.4×109/L), and specific reasons stated under the questionnaire item “Other”. For certain laboratory tests, specific exclusion criteria were applied, including the use of medication and dietary supplements for liver enzymes and total and direct bilirubin concentrations, and physical exercise within three days before blood sampling for creatine kinase (CK). Serum and plasma samples with hemolysis, icterus, or lipemia index (HIL) ≥ 1 were also excluded.

Methods

The verification was conducted at the Department of Medical Biochemistry and Laboratory Medicine, Merkur University Hospital, Zagreb, Croatia, designated as the national Reference Centre for the development and implementation of RIs. All analytical methods used in this study are accredited according to the International Organization for Standardization (ISO) standard 15189:2022, which requires continuous internal quality control and participation in external quality assessment schemes (16).

Blood sampling was performed following the Joint EFLM-COLABIOCLI Recommendation for venous blood sampling (17). All samples were collected between 7:00 and 9:00 a.m. After completing the questionnaire, each subject was identified by stating their full name and date of birth. The phlebotomist verified and recorded the fasting status, which required at least 12 hours without food intake, no alcohol consumption within the previous 24 hours, and refraining from caffeine-containing beverages and smoking on the morning of blood collection. For each subject, three blood tubes were collected. Blood for hematology analysis was drawn into K3EDTA vacuum tubes (BD Vacutainer K3EDTA, K3E, Franklin Lakes, USA), blood for coagulation analysis into sodium citrate vacuum tubes (3.2% [0.109 M], BD Vacutainer 9NC, Franklin Lakes, USA), and blood for clinical chemistry analysis into red-cap vacuum tubes containing micronized silica particles as a clot activator, without gel (BD Vacutainer Serum, clot activator, no gel, Franklin Lakes, USA). Blood collection followed the recommended order of draw: citrate tube-clot activator tube-EDTA tube. Hematology analysis was performed on whole blood within 30 minutes of blood collection. Vacuum tubes intended for coagulation and clinical chemistry analyses were centrifuged before analysis at 2100×g for 15 and 10 minutes, respectively. All analyses were completed within 90 minutes of blood collection. The serum sample for clinical chemistry analysis was divided into two aliquots: one was immediately analyzed on the blood gas analyzer Radiometer ABL90 FLEX (Radiometer, Brønshøj, Denmark) for ionized calcium, while the other was analyzed for all remaining analytes on the clinical chemistry analyzer Beckman Coulter DxC700AU (Beckman Coulter, Brea, USA). Hematology analyses were performed on the Sysmex XN1000 analyzer (Sysmex, Kobe, Japan), erythrocyte sedimentation rate (ESR) was measured on the iSED analyzer (Alcor Scientific, Smithfield, USA), and coagulation testing was performed on the Sysmex CS2500 analyzer (Siemens Healthcare Diagnostics Inc., Marburg, Germany). For each sample, HIL indices were determined using a Beckman Coulter photometric test and assessed semi-quantitatively based on the approximate concentration of the interferent, with HIL ≥ 1 corresponding to ≥ 0.5 g/L hemoglobin, ≥ 0.025 g/L (42,8 µmol/L) bilirubin, or ≥ 0.4 g/L Intralipid, according to the Beckman Coulter manufacturer’s instructions for use. Detailed information on analytical methods, reagents, instruments, and traceability is provided in Supplementary Table 1.

Statistical analysis

Reference interval partitioning by age and/or sex for individuals aged 20 years and older was performed according to the harmonized RIs currently in use in Croatia (8-10, 12, 13). According to international CLSI EP28-A3c guidelines, RI verification was performed using 20 reference individuals per subgroup (15). For age- and sex-independent RIs, the sample set included 10 males and 10 females. A RI was considered verified if at least 18 out of 20 results (90%) fell within the predefined RI. If this criterion was not met in the first set, a second set of 20 samples was analyzed under the same conditions. If the criterion was still not met, RIs from alternative literature sources were considered for further verification. All data were tabulated and analyzed using Microsoft Excel (Microsoft Corporation, Redmond, USA) and MedCalc for Windows, version 17.9.2 (MedCalc Software, Ostend, Belgium).

Results

Baseline characteristics of the study population are summarized in Table 2. A total of 136 individuals presented for blood sampling. Out of these, 53 (39%) were male, and 83 (61%) were female. The age range was 26 to 75 years for men and 22 to 68 years for women. Applying the a priori exclusion criteria, 2 male and 4 female individuals were excluded due to self-reported chronic diseases and hospitalization within the previous 3 months. An additional 11 male and 19 female individuals were excluded based on a posteriori exclusion criteria. One male participant was excluded for a reason stated under the questionnaire item “Other” (voluntary blood donation within 30 days before blood sampling), while all others were excluded due to parameters indicating an acute inflammatory process. Due to specific exclusion criteria for liver enzymes and bilirubin, which included the use of medication and dietary supplements, 1 male and 6 female individuals were excluded. Based on the CK-specific exclusion criterion involving physical exercise within 3 days before blood sampling, 13 male and 18 female individuals were excluded. Analyte-specific exclusion criteria resulted in minor differences in age distribution. No samples had hemolysis, lipemia, or icterus index ≥ 1.

Baseline characteristics of the study population used for reference interval verification
Initial population Final RI population Bilirubin/liver enzymes population* CK population†
Total 136 100 93 69
M, N (%) 53 (39) 40 (40) 39 (42) 27 (39)
F, N (%) 83 (61) 60 (60) 54 (58) 42 (61)
Age range, years (M) 26-75 26-75 26-75 29-75
Age range, years (F) 22-68 22-68 22-68 25-68
*Exclusion based on medication and dietary supplement use. †Exclusion based on physical exercise within 3 days before blood sampling. M - male. F - female. RI - reference interval. CK - creatine kinase.
Hematology reference intervals

Reference intervals for red blood cells (RBC), hemoglobin (Hb), and hematocrit (Hct) are sex-dependent, while RIs for erythrocyte sedimentation rate (ESR) are both age- and sex-dependent (with separate intervals for males and females under and over 50 years of age). All other hematology RIs are age- and sex-independent. The sample set for age- and sex-independent RIs included 10 male and 10 female individuals, aged 22 to 75 years. Male-specific RIs included individuals aged 26 to 75 years (age-independent), 26 to 48 years (under 50), and 50 to 75 years (over 50), while female-specific RIs included individuals aged 22 to 68 years (age-independent), 22 to 46 years (under 50), and 51 to 68 years (over 50). All tested RIs were confirmed in the first set of samples. Verification results for all analytes, including RI partitioning, current RIs, sample size, median, interquartile range (IQR), and the number of results within the RI, are summarized in Table 3.

Hematology reference interval verification results
Analyte (unit) RI partitioning Current RI* Median (IQR) N Results within the harmonized RI, N (%)
RBC (×1012/L) M 4.34-5.72 4.81(4.27-5.63) 20 20 (100)
F 3.86-5.08 4.47 (4.24-4.72) 20 20 (100)
Hb (g/L) M 138-175 144 (128-155) 20 20 (100)
F 119-157 136 (125-139) 20 20 (100)
Hct (L/L) M 0.415-0.530 0.416 (0.382-0.439) 20 20 (100)
F 0.356-0.470 0.390 (0.370-0.406) 20 20 (100)
MCV (fL) All 83.0-97.2 86.5 (84.9-88.7) 20 20 (100)
MCH (pg) All 27.4 - 33.9 29.8 (29.1-30.6) 20 20 (100)
MCHC (g/L) All 320-345 342 (338-344) 20 18 (90)
RDW (%) All 9.0-15.0 12.7 (12.3-13.1) 20 20 (100)
Plt (×109/L) All 158-424 241 (217-268) 20 20 (100)
MPV (fL) All 6.8-10.4 9.9 (9.5-10.1) 20 19 (95)
Rtc (×109/L) All 22-97 62.6 (57.2-70.7) 20 19 (95)
Rtc (Rel/103 RBC) All 5.0-21.6 12.9 (11.7-14.8) 20 19 (95)
WBC (×109/L) All 3.4-9.7 6.11 (5.43-7.15) 20 20 (100)
Neutrophils (×109/L) All 2.06-6.49 3.34 (2.72-4.24) 20 20 (100)
Neutrophils (%) All 44-72 54.6 (49.5-61.5) 20 20 (100)
Lymphocytes (×109/L) All 1.19-3.35 2.01 (1.67-2.46) 20 20 (100)
Lymphocytes (%) All 20-46 32.9 (26.9-38.4) 20 20 (100)
Monocytes (×109/L) All 0.12-0.84 0.55 (0.42-0.60) 20 20 (100)
Monocytes (%) All 2-12 8.3 (7.2-9.7) 20 20 (100)
Eosinophils (×109/L) All 0.00-0.43 0.14 (0.09-0.24) 20 19 (95)
Eosinophils (%) All 0-7 2.2 (1.3-4.0) 20 20 (100)
Basophils (×109/L) All 0.00-0.06 0.04 (0.03-0.06) 20 20 (100)
Basophils (%) All 0-1 0.7 (0.5-0.9) 20 20 (100)
M, < 50 y 2-13 4 (3-7) 20 20 (100)
ESR (mm/3.6 ks) M, ≥ 50 y 3-23 9 (6-14) 20 20 (100)
F, < 50 y 4-24 6 (5-9) 20 20 (100)
F, ≥ 50 y 5-28 12 (9-16) 20 20 (100)
*RIs were adopted from harmonized RIs currently in use in Croatia (8). RI - reference interval. IQR - interquartile range. M - male. F - female. RBC - red blood cells. Hb - hemoglobin. Hct - hematocrit. MCV - mean cell volume. MCH - mean cell haemoglobin. MCHC - mean cell haemoglobin concentration. RDW - red cell distribution width. Plt - platelets. MPV - mean platelet volume. Rct - reticulocytes. WBC - white blood cells. ESR - erythrocyte sedimentation rate.
Coagulation reference intervals

All coagulation RIs are age- and sex-independent. The sample set included 10 male and 10 female individuals, aged 22 to 75 years. All tested RIs were confirmed in the first set of samples. Verification results for all analytes, including RI partitioning, current RIs, sample size, median, IQR, and the number of results within the RI, are summarized in Table 4.

Coagulation reference interval verification results
Analyte (unit) RI partitioning Current RI* Median (IQR) N Results within the harmonized RI, N (%)
PT (% activity) All ≥ 0.70 1.04 (0.97 - 1.13) 20 20 (100)
APTT (s) All 20 - 30 26 (24 - 26) 20 20 (100)
APTT (ratio) All 0.8 - 1.2 1.0 (1.0 - 1.0) 20 20 (100)
Fbg (g/L) All 1.8 - 3.5 2.6 (2.4 - 2.9) 20 20 (100)
*RIs were adopted from harmonized RIs currently in use in Croatia (8). RI - reference interval. IQR - interquartile range. M - male. F - female. PT - prothrombin time. APTT - activated partial thromboplastin time. Fbg - fibrinogen.
Clinical chemistry reference intervals

Reference intervals for total bilirubin (TBIL), direct bilirubin (DBIL), urea, aspartate aminotransferase (AST), amylase (AMY), lactate dehydrogenase (LD), lipase (Lip), potassium (K), sodium (Na), chloride (Cl), total calcium (Ca), ionized Ca, magnesium (Mg), inorganic phosphate (Phos), and CRP are age- and sex-independent. The initial sample set included 10 male and 10 female individuals, aged 22 to 75 years. All tested RIs were verified in the first set of samples, except for total Ca. A second set of 20 samples, including 10 male and 10 female individuals aged 23 to 73 years, was analyzed for total Ca, but the verification criteria were still not met.

Reference intervals for albumin (Alb), total protein (TP), and glucose (Glc) are age-dependent. Due to an insufficient number of participants, verification of RIs for Alb and TP in individuals over 70 years of age was not performed. The sample set for verification of RIs between 20 and 70 years included 10 male and 10 female individuals, aged 22 to 63 years. Both tested RIs were verified in the first set of samples. The sample sets for Glc RIs included 10 male and 10 female individuals in each age group: 22 to 29 years and 30 to 75 years. Both RIs were verified in the first set of samples.

Reference intervals for creatinine (CREA), uric acid, alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), CK, iron (Fe), unsaturated iron-binding capacity (UIBC), and total iron-binding capacity (TIBC) are sex-dependent. The male sample set included individuals aged 26 to 75 years, and the female sample set included individuals aged 22 to 68 years. All tested RIs were verified in the first set of samples.

Reference intervals for alkaline phosphatase (ALP) are both age- and sex-dependent. The first sample set included male individuals aged 26 to 75 years, female individuals aged 22 to 46 years, and female individuals aged 52 to 68 years. In this set, the RIs for males of all ages and for females under 50 years of age were not verified, while the RI for females over 50 years was confirmed. A second set of 40 samples was collected, consisting of 20 male individuals aged 28 to 73 years and 20 female individuals aged 22 to 49 years; however, the verification criteria still were not met.

Verification results for all analytes, including RI partitioning, current RIs, sample size, median, IQR, and the number of results within the RI, are summarized in Table 5.

Clinical chemistry reference interval verification results
Analyte (unit) RI partitioning Current RI* Median (IQR) N Results within the harmonized RI, N (%)
TBIL (µmol/L) All 3-20 13 (10-15) 20 20 (100)
DBIL (µmol/L) All < 5 2 (1-3) 20 20 (100)
Glc (mmol/L) All; < 30 y 4.2-6.0 4.5 (4.3-4.8) 20 20 (100)
All; ≥ 30 y 4.4-6.4 4.7 (4.5-4.9) 20 19 (95)
CREA† (µmol/L) M 64-104† 85 (82-94) 20 20 (100)
F 49-90† 69 (64-77) 20 20 (100)
Uric acid (µmol/L) M 182-403 326 (298-346) 20 19 (95)
F 134-337 252 (237-275) 20 20 (100)
Urea (mmol/L) All 2.8-8.3 5.4 (4.1-6.2) 20 20 (100)
AST (U/L)‡ All 11-34‡ 23 (20-26) 20 20 (100)
ALT (U/L)‡ M 9-59‡ 26 (22-31) 20 20 (100)
F 8-41‡ 19 (16-24) 20 20 (100)
AMY (U/L) All 23-91 63 (52-70) 20 20 (100)
M 60-142 70 (60-78)§ 40 15 (75)§
68 (53-73)║ 13 (65)║
ALP (U/L) F; < 50 y 54-119 54 (40-67)§ 40 10 (50)§
55 (40-66)║ 11 (55)║
F; ≥ 50 y 64-153 77 (72-96) 20 19 (95)
GGT (U/L) M 11-55 28 (18-34) 20 20 (100)
F 9-35 17 (14-20) 20 20 (100)
CK (U/L) M < 177 109 (69-130) 20 20 (100)
F < 153 81 (67-113) 20 20 (100)
LD (U/L) All < 241 166 (156-179) 20 20 (100)
Lip (U/L) All 13-60 19 (16-23) 20 19 (95)
K (mmol/L) All 3.9-5.1 4.2 (4.1-4.4) 20 20 (100)
Na (mmol/L) All 137-146 141 (140-141) 20 20 (100)
Cl (mmol/L) All 97-108 104 (103-105) 20 20 (100)
Ca, total (mmol/L) All 2.14-2.53 2.46 (2.38-2.53)§ 40 15 (75)§
2.47 (2.40-2.52)║ 16 (80)║
Ca, ionized (mmol/L) All 1.18-1.32 1.25 (1.23-1.27) 20 19 (95)
Mg (mmol/L) All 0.65-1.05 0.83 (0.81-0.85) 20 20 (100)
Phos (mmol/L) All 0.79-1.42 1.17 (1.08-1.23) 20 19 (95)
Fe (µmol/L) M 11-32 21 (16-25) 20 20 (100)
F 8-30 15 (13-19) 20 20 (100)
UIBC (µmol/L) M 25-54 39 (34-44) 20 19 (95)
F 26-59 46 (39-53) 20 20 (100)
TIBC (µmol/L) M 49-72 60 (57-64) 20 20 (100)
F 49-75 64 (55-66) 20 20 (100)
Alb (g/L) All, < 70 y 40.6-51.4 45.5 (43.8-49.1) 20 19 (95)
All, ≥ 70 y 39.6-48.4 NA 2 NA¶
CRP (mg/L) All < 5.0 0.9 (0.5-1.7) 20 20 (100)
TP (g/L) All, < 70 y 66-81 72 (70-76) 20 19 (95)
All, ≥ 70 y 66-80 NA 2 NA¶
*RIs were adopted from harmonized RIs currently in use in Croatia (8), unless otherwise specified. †RIs according to reference (12). ‡RIs according to reference (13). §First set of samples. ║Second set of samples. RIs for individuals aged ≥ 70 years were not verified due to an insufficient number of reference individuals in this age group. RI - reference interval. IQR - interquartile range. M - male. F - female. TBIL - bilirubin, total. DBIL - bilirubin, direct. Glc - glucose. CREA - Creatinine. AST - aspartate aminotransferase. ALT - alanine aminotransferase. AMY - amylase. ALP - alkaline phosphatase. GGT - gamma-glutamyltransferase. CK - creatine kinase. LD - lactate dehydrogenase. Lip - lipase. K - potassium. Na - sodium. Cl - chloride. Ca - calcium. Mg - magnesium. Phos - inorganic phosphate. Fe - iron. UIBC - unsaturated iron-binding capacity. TIBC - total iron-binding capacity. Alb - albumin. CRP - C-reactive protein. TP - total protein.

The verification results for total Ca and ALP in males of all ages and in females under 50 years of age did not meet verification criteria in either sample set. For total Ca, all out-of-range results were observed above the upper reference limit, whereas for ALP, all out-of-range results were below the lower reference limit. The distribution of total Ca and ALP results relative to the applied RIs is illustrated in Figures 1 and 2. Further verification was performed using RIs from alternative literature sources and RIs provided by the reagent manufacturer (Beckman Coulter). For total Ca, RIs from the UK Pathology Harmony harmonization project were verified, while for ALP, RIs from the IFCC primary reference procedure were verified (18, 19). Verification using both data sets met the predefined verification criteria for both analytes for RIs derived from harmonized literature sources, as well as those provided by the reagent manufacturer. Results for all data sets are presented in Table 6.

Distribution of total calcium (Ca) results relative to the evaluated reference interval in the first and second set of samples. Individual results are shown as dots. Dashed horizontal lines represent the lower and upper reference limits.

Distribution of alkaline phosphatase (ALP) results relative to the evaluated reference interval in the first and second set of samples for males of all ages (M) and females under 50 years of age (F < 50). Individual results are shown as dots. Dashed horizontal lines represent the lower and upper reference limits.

Alternative sources reference interval verification results for total calcium and alkaline phosphatase
International harmonized RI Reagentmanufacturer RI
Analyte (unit) RI partitioning Median (IQR) RI Results within the RI, N (%) RI Results within the RI, N (%)
Ca, total (mmol/L) All 2.46 (2.38-2.53)‡ 2.20-2.60* 19 (95) 2.20-2.65 19 (95)
2.47 (2.40-2.52)§ 20 (100) 20 (100)
M 70 (60 - 78)‡ 43-115† 20 (100) 43-115 20 (100)
68 (53 - 73)§ 19 (95) 19 (95)
ALP (U/L) F; < 50 y 54 (40 - 67)‡ 33-98† 19 (95) 33-98 19 (95)
55 (40 - 66)§ 20 (100) 20 (100)
F; ≥ 50 y 77 (72 - 96) NA║ NA║ NA║ NA║
*RIs according to reference (18). †RIs according to reference (19). ‡First set of samples. §Second set of samples. ║Verification of RIs for females aged ≥ 50 years was not performed because no literature-based (19) or manufacturer-provided RIs are available for this age group. RI - reference interval. IQR - interquartile range. M - male. F - female. Ca - calcium. ALP - alkaline phosphatase.
Discussion

The results of this study indicate that the harmonized RIs recommended by the CCMB for hematology, coagulation, and clinical chemistry laboratory tests are suitable for the population of apparently healthy volunteers from one clinical hospital center. The findings suggest that the existing harmonized RIs, derived from a population with demographic characteristics comparable to those of our study cohort, remain clinically relevant despite methodological and population changes in recent years. However, the recommended Croatian harmonized RIs for total Ca and ALP could not be verified in this study. Harmonized RIs from alternative literature sources were considered for further verification, including RIs for total Ca from the UK Pathology Harmony project and IFCC-recommended RIs for the IFCC traceable method for ALP determination. The RIs from these two literature sources were verified, confirming the high degree of standardization and harmonization of both methods. Differences in verification outcomes between previously recommended and alternative harmonized RIs may reflect differences in RI derivation methodology and reference population characteristics. This highlights the relevance of RI origin and derivation methodology when interpreting verification results. In addition to international harmonized RIs, manufacturer-provided RIs for total Ca and ALP were also evaluated during the verification process, in accordance with routine laboratory practice. Both the first and the second verification sets fulfilled the manufacturer-recommended RIs for these analytes. Although manufacturer RIs may be applied when appropriate and are commonly used in the absence of published reference data, they represent the lowest level of currently available evidence, as they are typically derived from limited or insufficiently described reference populations. In contrast, harmonized RIs proposed by international initiatives or professional societies are based on systematically designed studies, transparent methodologies, and broader population data, representing a higher level of scientific evidence (1, 6). It should be noted that the manufacturer-recommended RIs for ALP were identical to those proposed by international harmonized sources (19). However, the original harmonized publication was preferred, as it provided detailed information on study design and population characteristics, which are not available in reagent package inserts. On this basis, harmonized RIs from international literature were considered more appropriate for routine use and verification. The fact that not all RIs were verified highlights the need for periodic review, verification, and revision of RIs, which is also one of the requirements of the CLSI EP28-A3c guidelines and the ISO standard 15189:2022 (12, 16). However, neither CLSI nor ISO standards define a fixed time interval for RI verification. Instead, RI verification should be performed when relevant changes occur that may affect the applicability of existing RIs (16). Such changes include modifications of analytical methods or platforms, reagent reformulations, changes in calibration or traceability, or significant changes in the demographic or clinical characteristics of the reference population. In addition, RI verification is recommended when introducing new tests or when clinically relevant discrepancies between patient results and expected distributions are observed (1, 12, 16).

This study has several limitations, including the selection and size of the study population and the analytical methods used. The population size, which included 20 individuals per subgroup for each RI, is sufficient for the verification of RIs according to the CLSI EP28-A3c guidelines. However, this number is insufficient for de novo establishment of RIs should such a need arise. For this reason, in cases where the harmonized RIs currently recommended in Croatia were not successfully verified, international harmonized RIs were adopted instead of establishing de novo RIs. An additional limitation relates to the statistical nature of RI verification. The pass/fail outcome of RI verification depends on the number of tested reference individuals and assumes independence between individual analytes. However, some laboratory parameters are biologically and analytically correlated, such as RBC indices, liver enzymes, and TP and Alb. Therefore, some non-verified RIs should be interpreted with caution, particularly when biologically related analytes are considered. Additionally, the age distribution of the study population did not permit verification of age-partitioned RIs for individuals over 70 years (for Alb and TP), limiting conclusions for that demographic. The study population consisted of apparently healthy volunteers, including hospital staff and individuals from the general population. However, the population was relatively homogeneous, as all participants were affiliated with a single clinical hospital center. Due to this homogeneity, there is a possibility that the selected population does not fully represent the biological variability of the broader Croatian population. This may limit the generalizability of the obtained results to other regions of the country with potentially different demographic characteristics. Regarding analytical methods, hematology parameters, ESR, coagulation assays, clinical chemistry tests, and ionized Ca were each measured on a single analytical platform per test group (Sysmex XN1000 for hematology, iSED for ESR, Sysmex CS2500 for coagulation, Beckman Coulter DxC700AU for clinical chemistry, and Radiometer ABL90 FLEX for ionized Ca). This may limit the applicability of the results to laboratories using other analytical systems. These limitations highlight the importance of conducting multicenter studies with larger and more diverse populations, as well as cross-platform analytical comparisons, in order to ensure the broader applicability of verified RIs across different laboratory settings and regions.

In conclusion, our findings support the continued use of most harmonized RIs currently recommended in Croatia for adults over the age of 20, while also emphasizing the importance of regular RI verification, especially in light of changing demographic and methodological conditions.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References OzardaY. Reference intervals: current status, recent developments and future considerations. Biochem Med (Zagreb). 2016;26:5–16. 10.11613/BM.2016.00126981015 DoyleKBunchDR. Reference intervals: past, present, and future. Crit Rev Clin Lab Sci. 2023;60:466–82. 10.1080/10408363.2023.219674637036018 MaSYuJQinXLiuJ. Current status and challenges in establishing reference intervals based on real-world data. Crit Rev Clin Lab Sci. 2023;60:427–41. 10.1080/10408363.2023.219549637038925 BohnMKBaileyDBalionCCembrowskiGCollierCDe GuireV Reference interval harmonization: harnessing the power of big data analytics to derive common reference intervals across populations and testing platforms. Clin Chem. 2023;69:991–1008. 10.1093/clinchem/hvad09937478022 CeriottiFVidaliM. Reference interval harmonization: will big data provide a solution? Clin Chem. 2023;69:945–7. 10.1093/clinchem/hvad09837428457 TateJRYenTJonesGRD. Transference and validation of reference intervals. Clin Chem. 2015;61:1012–5. 10.1373/clinchem.2015.24305526089382 XuPZhouQXuJ. Reference interval transference of common clinical biomarkers. Scand J Clin Lab Invest. 2021;81:264–71. 10.1080/00365513.2021.190785833819111 Commission for Laboratory Results Harmonization of the Croatian Chamber of Medical Biochemists. Harmonizacija laboratorijskih nalaza u području opće, specijalne i visokodiferentne medicinske biokemije. Zagreb: Croatian Chamber of Medical Biochemists; 2004. Available at: https://homunizam.wordpress.com/wp-content/uploads/2020/03/harmonizacija-laboratorijskih-nalaza.pdf. Accessed June 22nd 2025. (in Croatian) Stavljenić Rukavina A, Čvorišćec D, editors. Harmonizacija laboratorijskih nalaza u području opće, specijalne i visokodiferentne medicinske biokemije. Zagreb: Medicinska naklada; 2007. (Croatian Chamber of Medical Biochemists). (in Croatian) Flegar-MeštrićZTadejDVrhovski-HebrangD. Reference intervals of 56 haematological and biochemical constituents of blood and serum for reference individuals corresponding to reference state - population of Zagreb, Croatia. Croat Med J. 1993;34:163–9. AdeliKHigginsVTrajcevskiKWhite-Al HabeebN. The Canadian laboratory initiative on pediatric reference intervals a CALIPER white paper. Crit Rev Clin Lab Sci. 2017;54:358–413. 10.1080/10408363.2017.137994529017389 Flegar-MeštrićZPerkovSSimonovićBJuretićD. Applicability of common reference intervals for serum creatinine concentrations to the Croatian population. Clin Chem Lab Med. 2010;48:231–5. 10.1515/CCLM.2010.05419943808 Flegar-MeštrićZPerkovSRadeljakA. Standardization in laboratory medicine: Adoption of common reference intervals to the Croatian population. World J Methodol. 2016;6(1):93–100. 10.5662/wjm.v6.i1.9327019800 FriščićIPerkovSRadeljakAStipanović-KastelićJKardum ParoMM. CLSI-based verification and de novo establishment of reference intervals for common biochemical assays in Croatian newborns. Biochem Med (Zagreb). 2024;34:020705. 10.11613/BM.2024.02070538665867 Clinical and Laboratory Standards Institut (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline – third edition; Approved Guideline. CLSI document C28-A3c. Wayne:CLSI;2008. International Organization for Standardization (ISO). ISO 15189:2022 – Medical laboratories – Requirements for quality and competence. Geneva:ISO;2022. SimundicAMBöleniusKCadamuroJChurchSCornesMPvan Dongen-LasesEC Working Group for Preanalytical Phase (WG-PRE), of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and Latin American Working Group for Preanalytical Phase (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOCLI). Joint EFLM-COLABIOCLI Recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56:2015–38. 10.1515/cclm-2018-060230004902 BergJ. Lane, V. Pathology Harmony; a pragmatic and scientific approach to unfounded variation in the clinical laboratory. Ann Clin Biochem. 2011;48:195–7. 10.1258/acb.2011.01107821555538 SchumannGKlaukeRCanaliasFBossert-ReutherSFranckPFHGellaFJ IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 9: Reference procedure for the measurement of alkaline phosphatase activity. Clin Chem Lab Med. 2011;49:1439–46. 10.1515/CCLM.2011.62121702699
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020706" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020706" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020706" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(83) "Verification of harmonized reference intervals in Croatia: is it time for a change?" ["journals_article_author"]=> string(87) "Iva Friščić, Ida Burazer, Andrea Radeljak, Sonja Perkov, Mirjana Mariana Kardum Paro" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(51) "reference values, verification, harmonization, CLSI" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2297" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "12" ["meta_title"]=> string(83) "Verification of harmonized reference intervals in Croatia: is it time for a change?" ["meta_desc"]=> string(83) "Verification of harmonized reference intervals in Croatia: is it time for a change?" ["meta_keyw"]=> string(51) "reference values, verification, harmonization, CLSI" ["created"]=> string(19) "2026-06-01 10:46:55" ["modified"]=> string(19) "2026-06-11 09:02:01" } [25]=> object(stdClass)#74 (35) { ["journals_id"]=> string(4) "1234" ["journals_xml"]=> string(63850) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020705 10.11613/BM.2026.020705 Original articles Evaluation of analytical performance and clinical applicability of the UriSed Mini, a semi-automated urine analyzer for cell counting in cerebrospinal fluid OpreaOana Roxana12FotacheAna-Maria*12MănescuIon Bogdan12DobreanuMinodora12 Department of Laboratory Medicine, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania Clinical Laboratory, Emergency County Clinical Hospital of Targu Mures, Targu Mures, Romania Corresponding author: fotache.anamaria@yahoo.com

Author contributions

OR Oprea: Conceptualization, Methodology, Validation, Formal analysis, Resources, Project administration, Writing - original draft, Preparation, Writing - review & editing; A Fotache.: Conceptualization, Data curation, Validation, Investigation, Writing - review & editing; IB Mănescu.: Conceptualization, Data curation, Validation, Investigation, Writing - review & editing; M Dobreanu.: Conceptualization, Validation, Formal analysis, Resources, Visualisation, Supervision, Writing - review & editing.

15042026 15062026 36 2 020705 2102202524022026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• This study first shows that the UriSed Mini aligns with optical microscopy for cerebrospinal fluid

• The inter-rater test showed a weighted kappa of 0.96, indicating strong agreement

• Further validation studies are recommended for broader clinical application

Introduction

Cerebrospinal fluid (CSF) analysis is essential in diagnosing central nervous system pathologies. While manual cell counting by optical microscopy is the gold standard, it is labor-intensive and time-consuming, posing challenges particularly in urgent cases, automated hematology analyzers offer alternatives but come with limitations. The aim of the study was to evaluate the performance of the UriSed Mini instrument for CSF in accordance with ICSH guidelines.

Materials and methods

A total of 77 CSF patient samples were analyzed by both methods from September 2023 to September 2024. Following the International Council for Standardization in Hematology guidelines, the UriSed Mini was evaluated for short- and long-term imprecision, limit of blank, limit of detection and analytical measurement range. Quantitative comparison between the two methods was conducted using Bland-Altman and Passing-Bablok analyses. Qualitative agreement was assessed through inter-rater agreement testing.

Results

The UriSed Mini successfully met all performance criteria, both in comparison to the manufacturer’s claims and in the context of practical clinical requirements. While statistically significant differences were observed in the quantitative comparison (0.6 cells/µL), these discrepancies are unlikely to have clinical significance at the medical decision-making level. The qualitative comparison demonstrated excellent agreement, with a weighted kappa coefficient of 0.96 (95% confidence interval: 0.89-1.00).

Conclusions

This study demonstrates that the UriSed Mini meets analytical standards for CSF cell counting and aligns closely with optical microscopy at clinically relevant thresholds.

Keywords: cerebrospinal fluid (CSF)UriSed Minicell countingWBC counting
Introduction

In emergency settings, cerebrospinal fluid (CSF) collection and biochemical/cellular analysis are recommended for patients suspected of acute bacterial or viral meningitis and other types of neurological diseases, as these represent the most crucial steps in confirming or excluding the diagnosis (1-3). In the United States alone, over 300,000 lumbar punctures are performed annually in both adult and pediatric populations (4). This high volume of samples translates into a substantial workload for laboratories, requiring significant resources in terms of both sample handling and time. Although manual cell counting by optical microscopy is the gold standard, it is labor-intensive and time consuming, presenting challenges especially in emergency cases (5). Automated hematology analyzers offer an alternative but come with limitations, such the need for microscopic review, depending on their characteristics and limitations (6). Thus, an automated method for cell counting in CSF (and other body fluids) is highly advantageous, as it minimizes variability and, crucially, reduces the time needed to obtain results. According to the International Council for Standardization in Hematology (ICSH) guidelines, validation of a new automated cell counting method for body fluids necessitates an extensive performance evaluation and comparison with the manual gold standard (7).

The aim of the study was to evaluate the performance of the UriSed Mini instrument for CSF in accordance with ICSH guidelines.

Materials and methods

The study was conducted from September 2023 to September 2024 in the clinical laboratories of a tertiary hospital, using residual CSF samples. Prior to initiation, ethical approval was obtained from the hospital’s Ethics Committee (18062/30.06.2023).

All samples underwent initial assessment by manual microscopic evaluation and were subsequently analyzed within two hours of collection using the UriSed Mini (77 Elektronika, Budapest, Hungary). Samples were collected in clear tubes (Beckton Dickinson, Franklin Lakes, USA), 2 ml from each patient. All samples were collected by the clinicians in our hospital through lumbar punction. Imprecision, both within-run and between-run, was evaluated, and additional parameters were assessed, including the limit of blank (LoB), limit of detection (LoD), and analytical measurement range (AMR) for both white blood cells (WBCs) and red blood cells (RBCs). Furthermore, a comparative analysis was performed between the UriSed Mini and the manual counting method for the CSF samples.

The UriSed Mini (77 Elektronika, Hungary) is a semi-automated instrument for analyzing urinary sediment, requiring only a small sample volume (170 µL), which can be directly pipetted into the test cuvette. According to manufacturer’s protocol, the cuvette undergoes centrifugation at 2000 rpm for 10 seconds. In RUO (research use only) body fluid mode, sample analysis occurs in two stages. In the first stage, which parallels urinary sediment analysis, 170 µL of the sample is processed, generating 45 microscopic images. In the second stage, the sample is manually diluted with a Body Fluid Stain, and another 170 µL of the mixture is analyzed in a second cuvette, producing an additional 45 images. These 90 images per sample are then analyzed to calculate final results in cells/µL. The instrument quantifies WBCs, RBCs and other nucleated cells. For samples with more than 1.5 WBC/µL after staining, the instrument also reports the percentages of polymorphonuclear cells (PMN) and mononuclear cells. Using the Research Only Software, the UriSed Mini may analyze five types of body fluids: CSF, pleural fluid (PLE), ascitic fluid (ASC), pericardial fluid (PER), continuous ambulatory peritoneal dialysis (CAPD). However, the software has not yet been validated for clinical use.

Microscopic evaluation

For the manual microscopic evaluation of body fluids, samples were analyzed by two experienced laboratory technicians using Fuchs-Rosenthal counting chambers. In samples with a high RBC count, Turk solution was applied to lyse the RBCs, and the final result was adjusted based on the dilution factor.

Imprecision assessment

For the short-term imprecision study, 10 replicates of the quality control (QC) material (both negative and positive controls) were measured on the same day. The QC material for body fluids is a synthetic product provided by the instrument manufacturer (Spinalscopics, Quantimetrix, Irvine, USA; Body fluid stain, 77 Elektronika, Budapest, Hungary). In addition, the short-term imprecision was also assessed on patient samples by performing 10 replicates of a CSF sample within two hours of sample collection. The patient samples were analyzed using 90 images per sample, following the manufacturer’s protocol.

For the long-term imprecision study, 20 replicates of the QC material were measured over the course of one month, following the body fluid protocol (90 images per determination). Due to the inability to store patient samples without risk of cell degradation, patient samples were not included in the long-term imprecision assessment. For leukocyte and erythrocyte counts in body fluids, no biological variation–based quality specifications are available. According to CLSI H56-A, laboratories are expected to establish their own performance goals during method validation (6). In line with Westgard’s recommendations, an imprecision of up to 20% is considered acceptable for analytes with inherently high variability, provided clinical decision-making is not compromised (8).

Limit of blank and limit of detection

To determine the LoB, a CSF patient sample with no detectable WBCs or RBCs on manual examination was measured 11 times on the same day. The sample diluent, considered an acellular fluid, was also measured 10 times over three days.

For the LoD, four CSF patient samples with low counts of WBCs and RBCs (< 2 WBC/µL and < 3 RBC/µL), as determined by manual examination, were tested in six replicates each. The results were then compared to the LoD specified by the manufacturer to evaluate alignment with the stated performance criteria.

Analytical measurement range

To establish the AMR, two CSF samples were selected: one with a high RBC count and one with a high WBC count, in alignment with the manufacturer’s declared AMR range of 2-1200 WBC/µL and 3-1800 RBC/µL. Acceptable precision criteria were set as follows: for points around 15 particle/µL, a standard deviation (SD) of < 5% was considered acceptable. For about 150 particle/µL, a coefficient of variation (CV) of < 15% was required. These acceptability criteria were the manufacturer’s claim stated by the manufacturer.

Each sample was diluted with saline to obtain three distinct concentration levels, with three replicate measurements performed at each concentration. The mean, SD and CV% were calculated for each point, and the data were analyzed using a correlation test to assess linearity across the concentration range. For the correlation test performed, the mean of the three replicates was used.

Comparison with manual method

Each sample was counted manually using Fuchs-Rosenthal chambers and subsequently measured on the UriSed Mini, with both assessments completed within two hours of sample collection. A quantitative comparison was conducted to evaluate numerical consistency, alongside a qualitative comparison for clinical relevance. For the qualitative analysis, WBC results were categorized into two groups: samples with ≤ 5 WBC/µL and those with > 5 WBC/µL. Agreement between methods was assessed using the kappa coefficient.

Statistical analysis

Descriptive statistics were applied to determine the LoB and LoD. For the analytical measurement range, data sets were compared using Pearson’s correlation test. The distribution of variables was assessed using the D’Agostino-Pearson test. To compare UriSed Mini results with manual counts, Bland-Altman analysis and Passing-Bablok regression were conducted, alongside an inter-rater agreement test (kappa) with linear weights for the qualitative assessment. All statistical analyses were performed using MedCalc Statistical Software, version 20.104 (MedCalc Software Ltd, Ostend, Belgium), with statistical significance set at P < 0.05.

Results

The results of the imprecision assessment are shown in Table 1 (short-term imprecision) and Table 2 (long-term imprecision). For WBCs in CSF, we obtained a within-run SD of 0.35 (CV 19.45%), though this was at a mean count of 1.8 WBC/µL, below the LoQ specified by the UriSed Mini manufacturer; and a SD of 2.1 (CV 8.18%) with mean values of 25 RBC/µL. As anticipated, CV% values decreased as cell counts increased in both samples and controls. In an internal study of the manufacturer (unpublished data), the imprecision results were: SD 0.9 (CV 11%) at 8.4 WBC/µL, SD 5.0 (CV 7%) at 74.8 WBC/µL.

Results of short-term imprecision for UriSed Mini with quality control material and patient sample
Body fluid type Mean SD CV (%)
Negative control (RBC/µL) 12.80 1.59 12.46
Positive control (RBC/µL) 75.62 5.93 7.85
Negative control (WBC/µL) 4.29 0.77 17.86
Positive control (WBC/µL) 50.45 4.17 8.27
Patient CSF (RBC/µL) 25.62 2.10 8.18
Patient CSF (WBC/µL) 1.80 0.35 19.45
Negative control and positive control - synthetic QC sample Spinalscopics, Quantimetrix (10 replicates each). The accepted criteria for imprecision were < 20%. The target mean and range of the QC samples are the same as for the long-term imprecision study (see Table 2). RBC - red blood cell. WBC - white blood cell. SD - standard deviation. CV - coefficient of variation. CSF - cerebrospinal fluid.
Results of long-term imprecision evaluation for UriSed Mini with quality control material
Body fluid type Mean SD CV (%) Target mean (range)
Negative control (RBC/µL) 12.28 2.41 19.64 6.60 (0.00-13.30)
Positive control (RBC/µL) 70.73 13.70 19.32 64.40 (27.70-101.10)
Negative control (WBC/µL) 5.23 0.82 15.71 8.88 (0.00-17.70)
Positive control (WBC/µL) 47.39 4.50 9.41 58.80 (12.20-105.00)
Negative control and positive control - synthetic QC sample Spinalscopics, Quantimetrix (20 replicates each). The accepted criteria for imprecision were < 20%. RBC - red blood cell. WBC - white blood cell. SD - standard deviation. CV - coefficient of variation.

For the LoB, across all replicates, no WBCs or RBCs were found in the CSF patient sample that was negative on manual investigation, and neither in the sample diluent. It is important to note that in the UriSed Mini, each sample is analyzed in a single-use cuvette, and sampling is performed manually by the user using a disposable pipette tip. Additionally, the dilution and staining of the sample are done separately in single-use laboratory tubes, eliminating the risk of sample diluent contamination. As a result, we did not perform a carry-over study. For the LoD, the results of the initial examination and of consequent diluted samples, are shown in Table 3 for RBCs and WBCs.

Limit of detection for RBC-CSF and WBC-CSF
RBC-CSF
Sample Mean (RBC/µL) SD 95% CI Manufacturer claim
A 0.66 0.90 0.13-1.18
B 1.7 0.98 0.73-2.66
C 0.75 0.51 0.01-1.02 0.93
D 0.97 0.66 0.32-1.62
WBC-CSF
Sample Mean (WBC/µL) SD 95% CI Manufacturer claim
A 0.46 0.33 0.19-0.72
B 0.40 0.38 0.06-0.73
C 0.90 0.60 0.41-1.38 0.68
D 0.90 0.88 0.22-1.50
RBC - red blood cell. WBC - white blood cell. SD - standard deviation. CI - confidence interval. CSF - cerebrospinal fluid.

A wide variety of samples (N = 77) were used for the comparison between UriSed Mini and the manual investigation, with values ranging between 0-2100 WBC/µL and 0-4718/µL for RBCs. The distribution test had the following results: manual RBC count, P < 0.001; UriSed Mini RBC count, P < 0.001; manual WBC count, P < 0.001; and UriSed Mini WBC count, P < 0.001. Result of the Bland-Altman analysis is shown in Figures 1 and 2.

Bland-Altman plots comparing RBC counts obtained with the UriSed Mini (test method) and manual microscopic counting (reference method), shown in absolute units (RBC/µL, left) and percentages (%, right). Upper panels: full RBC range (N = 65); lower panels: 0-20 WBC/µL range (N = 52).

Bland-Altman plots comparing WBC counts obtained with the UriSed Mini (test method) and manual microscopic counting (reference method), shown in absolute units (WBC/µL, left) and percentages (%, right). Upper panels: full WBC range (N = 77); lower panels: 0-20 WBC/µL range (N = 68).

The Passing Bablok regression for RBC (y = 0 + 1.25 x), WBC - whole range of samples (y = - 0.23 + 1.15 x) and WBC < 20 cells/µl (y = - 0.44 + 1.34 x) results are shown in Figure 3. Before the regression analysis, linearity was tested and no significant deviation was found for either WBCs (P = 0.810) or RBCs (P = 0.310).

Passing-Bablok regression plots obtained by comparing cell counts obtained from UriSed Mini (test method) and manual microscopic counting (reference method). A) RBC count (whole range, N = 65). B) WBC count (whole range, N = 77). C) WBC count (range 0-20 WBC/µL, N = 68).

For the qualitative comparison, out of the 77 CSF samples, 59 were included in the negative category (≤ 5 WBC/µL) by both methods, 17 were included in the positive category (> 5 WBC/µL) by both methods, and one sample was discordant, being classified as positive by the automated count and negative by the manual count. The inter-rater agreement test showed a weighted kappa of 0.96 (95% CI: 0.89-1.00), which shows a very good agreement between methods.

Discussion

In this study, an evaluation of the UriSed Mini urine analyzer for CSF samples was performed. The instrument’s imprecision (CV < 20%) was assessed using both patient samples and QC material. For LoB, LoD and AMR patient samples were used. Agreement between UriSed Mini and the manual method (gold standard) was evaluated with 77 patient samples.

The within-run imprecision observed for RBC and WBC counts in both QC materials and body fluid samples remained below the predefined 20% limit, consistent with acceptable performance ranges reported for automated body fluid counting on hematology analyzers. Previous evaluations of Sysmex XN-series instruments and other automated platforms have documented similarly low imprecision values for total nucleated cell and RBC counts, supporting the analytical stability seen in our study (9-11). As commonly reported, higher CVs occurred at low cell concentrations; however, the corresponding absolute variation was too small to affect clinical interpretation, particularly around the established CSF decision thresholds where the presence of any RBCs or a WBC count above 5/µL is clinically meaningful (1).

Between-run imprecision was likewise < 20% across QC levels, consistent with findings for the UriSed3 in urinary sediment analysis and aligned with the study’s predefined criteria (12).

The limits of blank observed in the literature for automated analyzers vary widely but generally fall within low ranges for both RBCs and WBCs (5). The manufacturer’s LoD for the UriSed Mini also fit within the 95% confidence intervals obtained in our CSF sample measurements and were comparable to LoD values reported for Sysmex instruments, while some analyzers such as Iris did not report LoD for body fluids (5). These concordances support the reliability of the UriSed Mini at the low cell concentrations most relevant for CSF analysis.

Analytical measurement range assessment showed performance compatible with the manufacturer’s specifications, and correlation coefficients were similar to those previously reported for automated body fluid analyzers (Table 4) (5). Agreement analyses using Bland-Altman and Passing-Bablok regression indicated small, systematic differences between methods. For RBCs, the UriSed Mini showed a slight proportional overestimation compared with manual counting, most evident at low concentrations, although the magnitude of the bias remained below clinically relevant levels. For WBCs, a systematic underestimation at higher counts and a slight overestimation at low counts were observed, but again without compromising clinical interpretation, particularly in the critical 0-5 WBC/µL range.

Analytical measurement range for RBC-CSF and WBC-CSF
RBC-CSF
Sample Mean (RBC/µL) SD (RBC/µL) CV (%)
Undiluted 1568.87 46.78 2.98
Dilution 1 779.63 25.36 3.25
Dilution 2 503.23 2.79 0.56
Dilution 3 379.40 5.54 1.46
Manufacturer claim Analytical measurement range: 3-1800 RBC/µL
Results r = 1.00 (95% CI 0.99-1.00), P < 0.001
WBC-CSF
Sample Mean (WBC/µL) SD (WBC/µL) CV (%)
Undiluted 1206.00 27.79 2.26
Dilution 1 805.40 10.51 1.31
Dilution 2 240.67 7.20 2.99
Dilution 3 28.07 5.18 18.47
Manufacturer claim Analytical measurement range: 2-1200 WBC/µL
Results r = 1.00 (95% CI 0.99-1.00), P < 0.001
RBC - red blood cell. WBC - white blood cell. SD - standard deviation. CV - coefficient of variation. CSF - cerebrospinal fluid.

Given that CSF interpretation relies primarily on categorical thresholds-especially the cut-off of > 5 WBC/µL to indicate potential CNS pathology-the high categorical agreement observed between manual counts and the UriSed Mini is clinically reassuring (1, 2). Only one discordant sample was identified among 77 tested, and the weighted kappa coefficient (0.96) demonstrated near-perfect agreement, comparable to performance levels reported for other automated body fluid analyzers.

Automated hematology instruments provide reliable overall performance but may show limited accuracy at low cell counts, a limitation noted in previous evaluations. In contrast, the UriSed Mini demonstrated strong performance in this range, likely aided by its low detection limits and integrated optical verification function. The ability to visually confirm cell morphology and detect bacteria directly on the instrument provides an additional advantage compared with analyzers lacking optical microscopy capabilities.

In summary, the UriSed Mini showed analytical performance comparable to that reported for established automated body fluid analyzers, with reliable agreement in the clinically critical low-count range (5, 9-12). These findings support its suitability as an alternative to manual microscopy for routine CSF cell counting.

While numerous studies have explored the performance of automated hematology analyzers for body fluid cell counting, this study uniquely utilized a urine analyzer for this purpose. This novel approach, coupled with the adherence to ICSH guidelines for performance evaluation, represents a key strength of the study. Last but not least, the use of disposable cuvettes in the case of UriSed equipment, compared to the extensive washing in BF mode of the hematology instrument is less time consuming. The primary limitation was the relatively small sample size. However, these findings serve as a preliminary investigation, providing a foundation for a subsequent study with a larger cohort of CSF samples to further validate the method. Because of the low numbers of WBC in our samples we were not able to evaluate the performances of the instrument for differentiated leukocyte count (neutrophils, mononuclear etc.). To evaluate this, a high number of WBCs in BF are needed.

To fully evaluate the performances of the analyzer, a multicentric study should be performed in which multiple body fluid types and samples from a wide range of pathologies may be included.

Automated cell counters offer a compelling alternative or complement to traditional manual methods, bringing increased speed and consistency to cell counting in body fluids. This study is the first to demonstrate that the UriSed Mini, an automated urine analyzer, not only meets all analytical performance criteria for body fluid cell counting but also aligns closely with optical microscopy, the gold standard, regarding clinically relevant thresholds. Further validation studies are recommended for broader clinical application, and laboratories are advised to conduct their own performance evaluations. Nevertheless, the UriSed Mini, which functions as a “hybrid” between automated counting and optical microscopy, appears to be a viable method for CSF cell counting in both routine and especially emergency testing.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References TunkelARHartmanBJKaplanSLKaufmanBARoosKLScheldWM Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–84. 10.1086/42536815494903 HrishiAPSethuramanM. Cerebrospinal fluid (CSF) analysis and interpretation in neurocritical care for acute neurological conditions. Indian J Crit Care Med. 2019;23 Suppl 2:S115–9. 10.5005/jp-journals-10071-2318731485118 Dyckhoff-ShenSKoedelUPfisterHWKleinM. SOP: emergency workup in patients with suspected acute bacterial meningitis. Neurol Res Pract. 2021;3:2. 10.1186/s42466-020-00098-633499920 VickersADonnellyJMooreJBarnumSScheinTWangH. Epidemiology of lumbar punctures in hospitalized patients in the United States. PLoS One. 2018;13:e0208622. 10.1371/journal.pone.020862230543645 Clinical and Laboratory Standards Institute (CLSI). Body fluid analysis for cellular composition; Approved guideline. CLSI document H-56a. Wayne: CLSI; 2006. Alcaide MartínMJAltimira QueralLSahuquillo FríasLValiña AmadoLMerinoAGarcía de Guadiana-RomualdoL. Automated cell count in body fluids: a review. Adv Lab Med. 2021;2:149–77. 10.1515/almed-2021-001137363326 BournerGde la SalleBGeorgeTTabeYBaumHCulpN ICSH guidelines for the verification and performance of automated cell counters for body fluids. Int J Lab Hematol. 2014;36:598–612. 10.1111/ijlh.1219624628711 Westgard JO. Desirable specifications for total error, imprecision, and bias, derived from intra- and inter-individual biologic variation. Westgard QC [Internet]. Available from: https://westgard.com/clia-a-quality/quality-requirements/biodatabase1.html. Accessed August 14th 2025. RoccaforteVDavesMProserpioVSciariniFSangiorgioRCostanzoA Evaluation of body fluid mode of Sysmex XN-9000 for white blood cell counts in cerebrospinal fluid. J Lab Precis Med. 2018;3:22. 10.21037/jlpm.2018.02.01 DanisePMaconiMRovettiAAvinoDDi PalmaAGerardo PirofaloM Cell counting of body fluids: comparison between three automated haematology analysers and the manual microscope method. Int J Lab Hematol. 2013;35:608–13. 10.1111/ijlh.1209323647736 ChoJOhJLeeSGLeeYHSongJKimJH. Performance Evaluation of Body Fluid Cellular Analysis Using the Beckman Coulter UniCel DxH 800, Sysmex XN-350, and UF-5000 Automated Cellular Analyzers. Ann Lab Med. 2020;40:122–30. 10.3343/alm.2020.40.2.12231650728 LaiwejpithayaSWongkrajangPReesukumalKBuchaCMeepanyaSPattanavinC UriSed 3 and UX-2000 automated urine sediment analyzers vs manual microscopic method: a comparative performance analysis. J Clin Lab Anal. 2018;32:e22249. 10.1002/jcla.2224928464263
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020705" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020705" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020705" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(156) "Evaluation of analytical performance and clinical applicability of the UriSed Mini, a semi-automated urine analyzer for cell counting in cerebrospinal fluid" ["journals_article_author"]=> string(76) "Oana Roxana Oprea, Ana-Maria Fotache, Ion Bogdan Mănescu, Minodora Dobreanu" ["journals_article_author_country"]=> string(7) "Romania" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(67) "cerebrospinal fluid (CSF), UriSed Mini, cell counting, WBC counting" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1876" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "11" ["meta_title"]=> string(156) "Evaluation of analytical performance and clinical applicability of the UriSed Mini, a semi-automated urine analyzer for cell counting in cerebrospinal fluid" ["meta_desc"]=> string(156) "Evaluation of analytical performance and clinical applicability of the UriSed Mini, a semi-automated urine analyzer for cell counting in cerebrospinal fluid" ["meta_keyw"]=> string(67) "cerebrospinal fluid (CSF), UriSed Mini, cell counting, WBC counting" ["created"]=> string(19) "2026-04-07 11:03:10" ["modified"]=> string(19) "2026-06-11 09:01:40" } [26]=> object(stdClass)#75 (35) { ["journals_id"]=> string(4) "1233" ["journals_xml"]=> string(161170) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020704 10.11613/BM.2026.020704 Original articles Effects of different blood storage conditions on leukocytes cell population data using the Sysmex XN hematological analyzer RoccaforteVincenzo*12PanellaRossella1DavesMassimo3De MartinoAntonella1JaniErika3SabbatiniGiovanni4AgostiniPierfrancesco2De FilippiFloriana1FormentiPaolo4LippiGiuseppe5VidaliMatteo6PezziAngelo4PastoriStefano1 S.C. Analisi Chimico Cliniche e Microbiologiche, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo, Italy UOSVD Patologia Clinica, ASL Bari, Ospedale San Paolo, Bari, Italy Laboratory of Clinical Biochemistry (SABES-ASDAA), Hospital of Bolzano, Bolzano, Italy S.C. Anestesia, Rianimazione e Terapia Intensiva, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo, Italy Section of Clinical Biochemistry, University of Verona, Verona, Italy Clinical Pathology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy Corresponding author: vincenzo.roccaforte@asl.bari.it

Author contributions

V Roccaforte: Conception and design of the study, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of the manuscript; R Panella: Provision of study materials or patients, collection and assembly of data, manuscript writing, final approval of the manuscript; M Daves: Collection and assembly of data, manuscript writing, final approval of the manuscript; M Vidali: Data analysis and interpretation, manuscript writing, final approval of the manuscript; Lippi: Data analysis and interpretation, manuscript writing, final approval of the manuscript.

15042026 15062026 36 2 020704 1811202519022026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• The present evaluation of 18 experimental hematology parameters under three different storage temperatures consistently demonstrated a predominant pattern of instability at 37 °C, with intermediate changes at 4 °C and the highest stability at room temperature

• Across both the three complementary analytical approaches and the regression-based European Federation of Clinical Chemistry and Laboratory Medicine protocol, this temperature gradient was evident, with several parameters exceeding the maximum permissible error within hours when exposed to heat stress

• Parameters such as neutrophils complexity (NE-SSC), neutrophils size (NE-FSC), monocytes complexity (MO-X), and lymphocytes complexity (LY-X) emerged as consistently stable in both frameworks, maintaining values within stability limits across all conditions up to 24 h

Introduction

The aim of this study was to investigate the stability of leukocyte cell population data (CPD) assessed on Sysmex XN-3000 hematological analyzer in samples stored for up to 24 h at different temperatures.

Materials and methods

Whole-blood samples from 25 donors were analyzed for 18 CPD parameters at baseline and after storage at room temperature (RT), 4 °C, or 37 °C for 3, 6, 12, and 24 h. Stability was assessed using three complementary approaches: paired Wilcoxon tests with Bonferroni correction, percent difference between medians > 10%, and per-sample percent change > 10% in ≥ 2 samples. In addition, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) stability protocol was applied, modelling percent differences over time using linear regression through the origin to estimate the rate of change and the stability limit (SL), defined as the time required to exceed a maximum permissible error of 10%.

Results

According to predefined stability criteria, several CPD parameters exceeded stability limits within 24 h, particularly under storage at 37 °C. Parameters related to neutrophil, lymphocyte and monocyte complexity and size (e.g., neutrophils complexity (NE-SSC), neutrophils size (NE-FSC), monocytes complexity (MO-X), lymphocytes complexity (LY-X); where SSC = side scatter, FSC = forward scatter) showed slow rates of change with estimated stability limits beyond 24 h across storage conditions. In contrast, fluorescence- and dispersion-related parameters (e.g., neutrophils fluorescence intensity (NE-SFL), width of dispersion of neutrophils complexity (NE-WX), width of dispersion of lymphocytes fluorescence (LY-WY), width of dispersion of monocytes size (MO-WZ); where SFL = side fluorescence, W = width of dispersion) reached the stability limit within 24 h, most frequently at 37 °C. Lymphocyte size (LY-Z) exceeded the stability limit at 17 h also under storage at 4 °C.

Conclusions

Leukocyte CPD stability is strongly temperature- and parameter-dependent. Exposure to elevated temperature (37 °C) leads to early exceedance of predefined stability limits for several CPD parameters, whereas storage at RT preserves stability for longer time intervals. Avoiding prolonged exposure to high temperatures is therefore essential for reliable CPD assessment in routine laboratory practice.

Keywords: cell population data (CPD)Sysmexsample stabilityexperimental hematology parameterspre-analytical variability
Introduction

Up to 70% laboratory errors are attributable to extra-analytical issues, especially to inaccurate or inappropriate procedures for management of biological specimens (1). The analytical assessment of unsuitable samples represents a major challenge for the quality of diagnostic testing and poses serious hazards to patient safety. The complete blood cell count (CBC) is an essential test for diagnosis and management of a variety of hematological diseases. It is essential that blood samples are always collected, managed, transported and stored under appropriate conditions for obtaining accurate tests results.

Several studies have been published on the stability of whole blood samples for CBC testing with often controversial conclusions, which were mostly attributable to the use of different hematological analyzers (2, 3). Delays in analyzing specimens are not rare occurrences in clinical laboratory practice, because samples may arrive even from very distant peripheral laboratories, or due to technical and organizational issues.

The cell population data (CPD) parameters, that can be obtained from a standard CBC test, have been recently implemented for providing useful information for diagnosis and prognosis in many diseases (4-6). The CPD describe multiple physical and functional characteristics of leukocytes in the analyzed sample, which may be altered under various pathological conditions, including hematological malignancies, solid tumors, and severe infections (7). Nonetheless, preanalytical influences on these parameters have not been comprehensively assessed to the best of our knowledge, while limited evidence has been provided that blood storage may have an impact on their measurement (7-9). For example, a study by Martens et al., referring to unpublished results, reported that CPD results may be stable up to for 6 hours after sample collection (10).

Preanalytical factors remain largely unexplored in CPD research and may represent a critical aspect in obtaining reliable results. The effects of EDTA on blood cell morphology are well documented (7, 8). Since CPD fundamentally reflect cellular morphological and functional features, factors such as storage time and temperature are very likely to significantly influence CPD measurements. Several studies on CPD were retrospective in nature, generating a theoretical risk that poorly controlled preanalytical conditions may have led to inaccurate results and potentially inappropriate conclusions (7-9).

Therefore, the aim of the study was to investigate the reliability of CPD measured on Sysmex XN hematological analyzer in samples stored for up to 24 h at different temperatures.

Materials and methods

This prospective study was designed to investigate the influence of preanalytical variables on CPD parameters measured with the XN-3000 series automated hematology analyzer, that employs a technology based on fluorescence flow cytometry (Sysmex XN, Kobe, Japan). The study population consisted of 25 ostensibly healthy subjects. The inclusion criteria were being apparently healthy men or women aged ≥ 18 years.

All blood samples were drawn by a single experienced nurse. For each participant, three evacuated blood tubes containing dipotassium ethylenediamine tetraacetic acid (K2ETDA) (Greiner Bio-One Vacuette, Kremsmunster, Austria) were collected. The filling volume of the test tubes used in this study is 2 mL and we used an integrated venous blood collection systems that comprise a blood collection needle of 19 Gauges, tube holder and the evacuated blood collection tube.

The CPD are automatically measured by XN-3000 and test results are available in a dedicated working window of the instrumental software. All samples were analyzed on the same analyzer using an identical lot of reagents.

The Sysmex XN-3000 hematological analyzer used in this study was calibrated in accordance with the manufacturer’s recommendations and the laboratory’s standard operating procedures. The last full calibration was performed before the initiation of the study, and no recalibration was required during the study period, as instrument performance remained stable. Internal quality control (IQC) was carried out daily at the beginning of each working day using manufacturer-provided control materials (XN-CHECK, Sysmex Corporation) at multiple concentration levels (low, normal, and high). Quality control results were evaluated against the target ranges provided by the manufacturer and monitored using routine laboratory acceptance criteria (including Westgard multirule principles). Throughout the study period, all QC results were within acceptable limits, ensuring the analytical reliability of the measurements. Samples stored under varying conditions were consistently equilibrated to room temperature for approximately 30 minutes prior to analysis, in accordance with the manufacturer’s recommendations.

The values of CPD parameters measured in the current study were: neutrophils complexity (NE-SSC), lymphocytes complexity (LY-X), monocytes complexity (MO-X), width of dispersion of neutrophils complexity (NE-WX), width of dispersion of lymphocytes complexity (LY-WX), width of dispersion of monocytes complexity (MO-WX), neutrophils fluorescence intensity (NE-SFL), lymphocytes fluorescence intensity (LY-Y), monocytes fluorescence intensity (MO-Y), width of dispersion of neutrophils fluorescence (NE-WY), width of dispersion of lymphocytes fluorescence (LY-WY), width of dispersion of monocytes fluorescence (MO-WY), neutrophils size (NE-FSC), lymphocytes size (LY-Z), monocytes size (MO-Z), width of dispersion of neutrophils size (NE-WZ), width of dispersion of lymphocytes size (LY-WZ) and the width of dispersion of monocytes size (MO-WZ) (11).

Cell population data

In the Sysmex XN3000, the white blood cell (WBC) differential count is performed in the white differential channel (WDFc). White blood cells are treated with a lysing reagent that permeabilizes the cell membrane before analysis, followed by staining of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) with a specific fluorochrome (11). The CPD parameters provide quantitative information on the morphological and functional characteristics of neutrophils, monocytes, and lymphocytes, and are derived from the characteristics of the cell clusters identified in the WDFc. Optical signals along the X-axis (side scatter) reflect internal cellular complexity, fluorescence along the Y-axis corresponds to nucleic acid content, and forward scatter (Z-axis) indicates cell size. For each subset, the mean and standard deviation of these parameters are recorded.

The width of dispersion (WDF) of the values is a heterogeneous signal. This parameter is calculated according to the distribution width, as it represents the range of the distribution of the major populations, excluding outliers below 20% peak height in the distribution curve (10). The following CPD are reported along the X-axis of the WDFc: NE-SSC, LY-X, MO-X, NE-WX, LY-WX and MO-WX; CPD on the y-axis: NE-SFL, LY-Y, MO-Y, NE-WY, LY-WY and MO-WY; and CPD reported on the z-axis: NE-FSC, LY-Z, MO-Z, NE-WZ, LY-WZ and MO-WZ (10-12).

Study design and analytical conditions

For each parameter, whole-blood samples were measured at baseline (T0) and after storage under three temperatures, i.e. room temperature (RT), 4 °C, and 37 °C, at four time points: 3 h (T3), 6 h (T6), 12 h (T12), and 24 h (T24). This yielded 12 experimental conditions (3 temperatures × 4 times) plus the baseline. The 37 °C condition was included as an intentional heat stress model to explore the upper limits of temperature-related preanalytical variability, rather than to reflect routine storage practices. Samples assigned to the 37 °C condition were maintained in a thermostatic to ensure stable and reproducible temperature conditions throughout the storage period.

All comparisons were performed within each parameter, with each condition evaluated relative to its corresponding baseline measurement.

Ethical approval, informed consent and data protection

This study was approved by the Ethics Committee of Milano Area 3 (Reference No. 5725/2025, April 16, 2025) in accordance with the Declaration of Helsinki (2013 revision). Written informed consent was obtained from all study participants and data were processed anonymously in compliance with the General Data Protection Regulation-GDPR EU 679/2016.

Statistical analysis

Since no established maximum allowable differences were available for these experimental hematology parameters, we adopted three complementary analytical approaches to assess stability.

Approach 1 - Paired non-parametric testing: for each parameter, we ran 12 paired Wilcoxon signed-rank tests comparing baseline (T0) to each condition (RT/4 °C/37 °C at 3 h, 6 h, 12 h, 24 h). To control the family-wise error rate across the 12 comparisons, Bonferroni’s correction was applied. A condition was classified as non-stable if the adjusted P was < 0.05.

Approach 2 - Percent difference between medians > 10%: for each parameter and condition, we computed the percent difference between medians of the 25 sample results as PD% = (median at Tx − median at T0) / (median at T0) × 100%. A condition was classified as non-stable if the absolute percent difference between medians was greater than 10%. This threshold was selected as a pragmatic criterion in the absence of established analytical performance specifications for CPD parameters.

Approach 3 - Per-sample percent change thresholding: for each parameter and condition, we computed each sample’s percent change relative to baseline as PD% = (value at Tx − value at T0) / (value at T0) × 100%. We then counted the number of samples with an absolute percent difference between conditions > 10%. A condition was then classified as non-stable when > 1 sample (out of 25) exceeded the 10% threshold (i.e. ≥ 2 samples). This criterion was adopted to reduce the influence of isolated outliers and to identify changes affecting more than a single sample, thereby reflecting instability at the population level rather than individual variability.

These approaches provided distinct but complementary perspectives, allowing the identification of parameters and conditions that consistently met or failed the stability criteria (statistical testing and criteria reflecting potential clinical impact). For each parameter, stability was summarized separately by approach (Wilcoxon/medians/per-sample) and temperature (RT, 4 °C, 37 °C), considering all time points or only up to 12h.

In addition to the three approaches described above, stability was also evaluated according to the recently proposed European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) protocol for sample stability assessment (13). The same convention for percent difference calculation was applied across all analytical approaches to ensure methodological consistency. For each parameter and temperature condition, percentage differences from baseline were calculated for each sample and each time point as: PD% = (Tx - T0) / T0 x 100%, where Tx corresponds to the value of the analyte at 3 h, 6 h, 12 h, and 24 h, while T0 the value at 0 h. This yielded 100 data points per analyte–temperature combination (25 samples × 4 time points). Linear regression was then performed forcing the intercept through the origin, producing estimates of the slope (percentage change per hour), the corresponding p-value, and the coefficient of determination (R2). For each analyte–temperature pair, the stability limit was calculated as the time point at which the fitted regression line crossed the maximum permissible error (MPE), set at 10% in this study. This value was selected as a pragmatic threshold in the absence of established analytical performance specifications for CPD parameters and to ensure internal consistency across analytical approaches. A representative example of this EFLM-based stability assessment, including the regression line, MPE threshold, and stability limit, is shown in Figure S1.

The classification followed the adapted EFLM criteria used in this analysis as “Stable”: non-significant slope (P ≥ 0.050), “Unstable”: significant slope (P < 0.050) with R2 > 0.500, “To be confirmed”: significant slope (P < 0.050) with R2 ≤ 0.500. It should be noted that, in accordance with the EFLM protocol, linear regression was forced through the origin, assuming zero percent difference at baseline. Under this modelling assumption, very small but consistent slopes may reach statistical significance when a large number of observations is available. In such cases, statistical significance reflects the presence of a systematic temporal trend rather than clinically meaningful instability within the investigated time window. Therefore, the estimated stability limit, representing the time required to reach the maximum permissible error, should be considered together with the slope and its significance when interpreting practical sample stability.

All analyses were performed by R software ver. 4.5.1. Comparisons between quantitative variables were evaluated by Wilcoxon signed-rank tests and p values were adjusted using the Bonferroni’s correction.

Results

The study population consisted of 25 donors (12 males and 13 females), with a median age of 43 (21-56) years.

Stability assessment using three analytical approaches

The differences from baseline and overall stability were assessed using the three complementary analytical approaches described in the previous Methods section.

Tables 1 and 2 provide a summary of stability assessment for the three analytical approaches. Table 1 includes all time points up to 24 h, whereas Table 2 is restricted to the time window up to 12 h. The latter was designed to highlight stability patterns within time intervals more representative of routine laboratory workflows.

Summary of stability assessment results for the three analytical approaches across all time points (up to 24 h)
Parameter Statistical significance(P corrected value) %difference between medians > 10% > 2 samples with %difference > 10%
RT 4 °C 37 °C RT 4 °C 37 °C RT 4 °C 37 °C
NE-SSC * * * * * *
NE-SFL * *
NE-FSC * * * * *
NE-WX *
NE-WY * * *
NE-WZ * *
LY-X * * * * *
LY-Y * * * *
LY-Z * * *
LY-WX * * * * *
LY-WY * *
LY-WZ * * *
MO-X * * * * * * *
MO-Y * * *
MO-Z * *
MO-WX * * *
MO-WY *
MO-WZ * * * *
Each row corresponds to one parameter and each column to one of the three approaches, paired Wilcoxon test after Bonferroni correction (P < 0.05), absolute percent difference between medians > 10%, and ≥ 2 samples with an absolute percent change from baseline > 10%, reported separately for each storage temperature (RT, 4 °C, and 37 °C). An asterisk (*) indicates that, for that specific combination of analytical approach and storage temperature, the parameter met the predefined stability criteria at all evaluated time points. Stability criteria were defined as a percentage difference between medians < 10% (Approach 2) and fewer than two samples (out of 25) showing an absolute percent change > 10% (Approach 3). RT - room temperature. NE-SSC - neutrophils complexity. NE-SFL - neutrophils fluorescence intensity. NE-FSC - neutrophils size. NE-WX - width of dispersion of neutrophils complexity. NE-WY - width of dispersion of neutrophils fluorescence. NE-WZ - width of dispersion of neutrophils size. LY-X - lymphocytes complexity. LY-Y - lymphocytes fluorescence intensity. LY-Z - lymphocytes size. LY-WX - width of dispersion of lymphocytes complexity. LY-WY - width of dispersion of lymphocytes fluorescence. LY-WZ - width of dispersion of lymphocytes size. MO-X - monocytes complexity. MO-Y - monocytes fluorescence intensity. MO-Z - monocytes size. MO-WX - width of dispersion of monocytes complexity. MO-WY - width of dispersion of monocytes fluorescence. MO-WZ - width of dispersion of monocytes size.
Summary of stability assessment results for the three analytical approaches, considering only time points up to 12 h.
Parameter Statistical significance(P corrected value) %difference between medians > 10% > 2 samples with %difference > 10%
RT 4 °C 37 °C RT 4 °C 37 °C RT 4 °C 37 °C
NE-SSC * * * * * * *
NE-SFL * * *
NE-FSC * * * * * *
NE-WX * * * *
NE-WY * * * *
NE-WZ * * *
LY-X * * * * * * *
LY-Y * * * * *
LY-Z * * * *
LY-WX * * * * * *
LY-WY * * *
LY-WZ * * *
MO-X * * * * * * *
MO-Y * * * *
MO-Z * * *
MO-WX * * * *
MO-WY * * *
MO-WZ * * * *
Each row corresponds to one parameter and each column to one of the three approaches, paired Wilcoxon test after Bonferroni correction (P < 0.05), absolute percent difference between medians > 10%, and ≥ 2 samples with an absolute percent change from baseline > 10%, reported separately for each storage temperature (RT, 4 °C, and 37 °C). An asterisk (*) indicates that, for that specific combination of analytical approach and storage temperature, the parameter met the predefined stability criteria at all evaluated time points. Stability criteria were defined as a percentage difference between medians < 10% (Approach 2) and fewer than two samples (out of 25) showing an absolute percent change > 10% (Approach 3). RT - room temperature. NE-SSC - neutrophils complexity. NE-SFL - neutrophils fluorescence intensity. NE-FSC - neutrophils size. NE-WX - width of dispersion of neutrophils complexity. NE-WY - width of dispersion of neutrophils fluorescence. NE-WZ - width of dispersion of neutrophils size. LY-X - lymphocytes complexity. LY-Y - lymphocytes fluorescence intensity. LY-Z - lymphocytes size. LY-WX - width of dispersion of lymphocytes complexity. LY-WY - width of dispersion of lymphocytes fluorescence. LY-WZ - width of dispersion of lymphocytes size. MO-X - monocytes complexity. MO-Y - monocytes fluorescence intensity. MO-Z - monocytes size. MO-WX - width of dispersion of monocytes complexity. MO-WY - width of dispersion of monocytes fluorescence. MO-WZ - width of dispersion of monocytes size.

Across the three analytical approaches, no parameter remained entirely stable under all conditions when the full 24 h window was considered. Across the three analytical approaches, NE-SSC, NE-FSC, MO-X, and LY-X met the predefined stability criteria more frequently than other parameters, particularly within the first 12 h (Tables 1, 2).

For these parameters, deviations beyond the 10% threshold or statistically significant Wilcoxon results were infrequent within the first 12 h.

According to the predefined criteria, a higher number of non-stable conditions was observed at 37 °C compared with 4 °C and RT across the evaluated time points (Tables 1, 2). At room temperature, several parameters met the predefined stability criteria at 24 h according to the applied analytical approaches (Tables 1, 2, Figure 1).

Median values of experimental hematology parameters at different storage times and temperatures. Each panel represents one of the 18 investigated parameters, arranged in three rows by cell lineage: neutrophil-related (row 1), lym-phocyte-related (row 2), and monocyte-related parameters (row 3). The x-axis shows storage time points (0, 3, 6, 12, and 24 hours), and the y-axis shows the corresponding measured value for each parameter. Data points represent the median across all the 25 samples for the given time-temperature condition, connected by lines to illustrate trends over time. Colors indicate storage temperature: blue for room temperature (RT), red for 4 °C, and green for 37 °C. Differences in line slope and vertical displacement reflect the degree of deviation from baseline over time, with steeper slopes or larger shifts indi-cating reduced stability. NESSC - neutrophils complexity. NESFL - neutrophils fluorescence intensity. NEFSC - neutrophils size. NEWX - width of dispersion of neutrophils complexity. NEWY - width of dispersion of neutrophils fluorescence. NEWZ - width of dispersion of neutrophils size. LYX - lymphocytes complexity. LYY - lymphocytes fluorescence intensity. LYZ - lymphocytes size. LYWX - width of dispersion of lymphocytes complexity. LYWY - width of dispersion of lymphocytes fluo-rescence. LYWZ - width of dispersion of lymphocytes size. MOX - monocytes complexity. MOY - monocytes fluorescence intensity. MOZ - monocytes size. MOWX - width of dispersion of monocytes complexity. MOWY - width of dispersion of monocytes fluorescence. MOWZ - width of dispersion of monocytes size.

Stability evaluation using the EFLM protocol

The summary outcomes of this regression-based analysis for all analytes and temperature conditions are presented in Tables 3 and 4, with Table 4 providing an aggregated overview across the entire dataset. Specifically, Table 4 summarizes the EFLM-based stability limits with respect to a 24 h operational time window, indicating whether each parameter exceeded this threshold across all storage temperatures or, when this was not the case, the specific temperature(s) at which the stability limit was reached within 24 h.

Summary of regression-based stability evaluation according to the EFLM protocol for all 18 experimental hematology parameters under three storage temperatures (room temperature, 4 °C, 37 °C)
Parameter Condition Slope P Signif R2 R2 > 0.7 Conclusion SL, h
NE-SSC RT - 0.112 < 0.001 * 0.721 + Unstable 89
4 °C - 0.018 0.087 0.029 Stable
37 °C - 0.235 < 0.001 * 0.842 + Unstable 43
NE-SFL RT 0.104 < 0.001 * 0.117 To be confirmed 96
4 °C 0.530 < 0.001 * 0.618 +/- Unstable 19
37 °C - 0.531 < 0.001 * 0.528 +/- Unstable 19
NE-FSC RT 0.120 < 0.001 * 0.210 To be confirmed 83
4 °C 0.226 < 0.001 * 0.142 To be confirmed 44
37 °C 0.073 0.010 * 0.066 To be confirmed 136
NE-WX RT 0.446 < 0.001 * 0.554 +/- Unstable 22
4 °C 0.426 < 0.001 * 0.449 To be confirmed 23
37 °C 0.932 < 0.001 * 0.783 + Unstable 11
NEWY RT 0.155 < 0.001 * 0.134 To be confirmed 64
4 °C - 0.220 < 0.001 * 0.244 To be confirmed 45
37 °C 1.838 < 0.001 * 0.640 +/- Unstable 5
NE-WZ RT 0.746 < 0.001 * 0.460 To be confirmed 13
4 °C 0.200 0.023 * 0.051 To be confirmed 50
37 °C 1.113 < 0.001 * 0.684 +/- Unstable 9
LY-X RT 0.065 < 0.001 * 0.389 To be confirmed 154
4 °C 0.075 < 0.001 * 0.404 To be confirmed 133
37 °C 0.341 < 0.001 * 0.766 + Unstable 29
LY-Y RT - 0.283 < 0.001 * 0.572 +/- Unstable 35
4 °C - 0.008 0.729 0.001 Stable
37 °C - 1.271 < 0.001 * 0.880 + Unstable 8
LY-Z RT - 0.104 0.122 0.024 Stable
4 °C 0.581 < 0.001 * 0.718 + Unstable 17
37 °C 0.716 < 0.001 * 0.692 +/- Unstable 14
LY-WX RT - 0.005 0.937 0.000 Stable
4 °C 0.096 0.204 0.016 Stable
37 °C 0.331 < 0.001 * 0.117 To be confirmed 30
LY-WY RT 1.682 0.034 * 0.045 To be confirmed 6
4 °C 0.261 < 0.001 * 0.181 To be confirmed 38
37 °C 0.799 < 0.001 * 0.253 To be confirmed 13
LYWZ RT 0.367 < 0.001 * 0.173 To be confirmed 27
4 °C 0.642 0.316 0.010 Stable
37 °C 1.386 < 0.001 * 0.611 +/- Unstable 7
MO-X RT 0.011 0.386 0.008 Stable
4 °C 0.073 < 0.001 * 0.190 To be confirmed 137
37 °C 0.021 0.269 0.012 Stable 471
MO-Y RT 1.887 0.118 0.024 Stable
4 °C 2.247 0.066 0.034 Stable
37 °C 0.651 0.545 0.004 Stable
MO-Z RT 0.078 0.113 0.025 Stable
4 °C 0.652 < 0.001 * 0.515 +/- Unstable 15
37 °C 0.920 < 0.001 * 0.587 +/- Unstable 11
MO-WX RT 0.235 < 0.001 * 0.129 To be confirmed 43
4 °C 0.234 0.012 * 0.062 To be confirmed 43
37 °C 2.382 < 0.001 * 0.700 + Unstable 4
MO-WY RT 0.597 < 0.001 * 0.213 To be confirmed 17
4 °C - 0.146 0.059 0.036 Stable
37 °C 2.127 < 0.001 * 0.612 +/- Unstable 5
MO-WZ RT 0.620 0.402 0.007 Stable
4 °C 0.310 0.012 * 0.062 To be confirmed 32
37 °C 1.229 < 0.001 * 0.394 To be confirmed 8
For each parameter-temperature combination, the regression slope (% change per hour), corresponding P-value, statistical significance (Signif), coefficient of determination (R2), and classification outcome (“Stable”, “Unstable”, “To be confirmed”) are reported. The stability limit in hours (SL, h) represents the estimated time to reach the maximum permissible error (MPE = 10%) based on the fitted regression line. In the column “Signif”, “*” indicates a statistically significant slope (P < 0.05). In the column “R2 > 0.7”, “+” denotes R2 values exceeding 0.7, whereas “±” denotes 0.5 < R2 ≤ 0.7 (see EFLM criteria in the text). RT - room temperature. NE-SSC - neutrophils complexity. NE-SFL - neutrophils fluorescence intensity. NE-FSC - neutrophils size. NE-WX - width of dispersion of neutrophils complexity. NE-WY - width of dispersion of neutrophils fluorescence. NE-WZ - width of dispersion of neutrophils size. LY-X - lymphocytes complexity. LY-Y - lymphocytes fluorescence intensity. LY-Z - lymphocytes size. LY-WX - width of dispersion of lymphocytes complexity. LY-WY - width of dispersion of lymphocytes fluorescence. LY-WZ - width of dispersion of lymphocytes size. MO-X - monocytes complexity. MO-Y - monocytes fluorescence intensity. MO-Z - monocytes size. MO-WX - width of dispersion of monocytes complexity. MO-WY - width of dispersion of monocytes fluorescence. MO-WZ - width of dispersion of monocytes size.
Aggregated overview of EFLM protocol-based stability classification outcomes across all 18 experimental hematology parameters and three storage temperatures
Parameter All conditions: Stable, OR Unstable/To be confirmed with limit > 24h ≥ 1 condition: Unstable/To be confirmed with limit < 24h
NE-SSC X
NE-SFL 4 °C: 19h, 37 °C: 19h
NE-FSC X
NE-WX RT: 22 h, 4 °C: 23 h, 37 °C: 11 h
NE-WY 37 °C: 5 h
NE-WZ RT: 13 h, 37 °C: 9 h
LY-X X
LY-Y 37 °C: 8 h
LY-Z 4 °C: 17 h, 37 °C: 14 h
LY-WX X
LY-WY 37 °C: 13 h
LY-WZ 37 °C: 7 h
MO-X X
MO-Y X
MO-Z 4 °C: 15 h, 37 °C: 11 h
MO-WX 37 °C: 4 h
MO-WY RT: 17 h, 37 °C: 5 h
MO-WZ 37 °C: 8 h
For each temperature, the table reports the number and percentage of parameters classified as Stable, Unstable, or To be confirmed. This overall summary provides a comparative perspective on the effect of temperature on stability across the entire dataset. X indicates stability or instability but with limit > 24h. Summary of European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)-based stability limits (SL) with respect to a 24 h operational time window. For each experimental hematology parameter, the first column indicates whether the estimated stability limit exceeded 24 h across all storage temperawtures (SL > 24 h). The second column, populated only for parameters not meeting this criterion, reports the specific storage temperature(s) at which the stability limit was reached within 24 h (SL < 24 h). For parameters listed in the second column, the absence of a given temperature indicates that the stability limit exceeded 24 h under that storage condition. The two columns are mutually exclusive and provide complementary information on the practical time-temperature dependence of parameter stability according to the EFLM protocol. NE-SSC - neutrophils complexity. NE-SFL - neutrophils fluorescence intensity. NE-FSC - neutrophils size. NE-WX - width of dispersion of neutrophils complexity. NE-WY - width of dispersion of neutrophils fluorescence. NE-WZ - width of dispersion of neutrophils size. LY-X - lymphocytes complexity. LY-Y - lymphocytes fluorescence intensity. LY-Z - lymphocytes size. LY-WX - width of dispersion of lymphocytes complexity. LY-WY - width of dispersion of lymphocytes fluorescence. LY-WZ - width of dispersion of lymphocytes size. MO-X - monocytes complexity. MO-Y - monocytes fluorescence intensity. MO-Z - monocytes size. MO-WX - width of dispersion of monocytes complexity. MO-WY - width of dispersion of monocytes fluorescence. MO-WZ - width of dispersion of monocytes size.

Figure S1 shows a representative example of the EFLM-based stability assessment.

For some analytes, the regression analysis yielded statistically significant slopes associated with estimated stability limits exceeding the maximum investigated storage time (24 h). In these cases, the significant slope reflects the presence of a slow and consistent temporal trend, while the corresponding stability limit indicates that the maximum permissible error would not be reached within the studied time window.

Among the six neutrophil-related parameters, NE-SSC and NE-FSC showed slow rates of change with estimated stability limits exceeding 24 h across all storage conditions, whereas NE-SFL, NE-WX, NE-WY and NE-WZ reached the stability limit within 5-23 h, particularly at 37 °C.

Similar behavior was observed for lymphocyte-related parameters, with LY-X and LY-WX showing stability limits beyond 24 h, while LY-Y, LY-Z, LY-WY and LY-WZ showed progressive deterioration at 37 °C, reaching the stability limit within 7-14 h. LY-Z reached the stability limit at 17 h also when samples were kept at 4 °C, representing the only lymphocyte-related parameter showing instability within 24 h under refrigerated storage. Among the monocyte-related parameters, MO-Z, MO-WX, MO-WY and MO-WZ reached the stability limit within 4-11 h at 37 °C. In contrast, MO-X and MO-Y showed stability limits exceeding the 24 h time window across all storage conditions (Tables 3, 4).

Discussion

The preanalytical influence on CPD has received little attention in the current scientific literature to the best of our knowledge. Although preanalytical factors remain largely unexplored in CPD research, they are likely to be of substantial clinical significance. Moreover, it is conceivable that the specific technology employed by a hematology analyzer may influence its sensitivity to preanalytical effects, implying that these effects should be evaluated for each analytical platform individually.

Figure 1 shows the temporal profiles of 18 experimental hematology parameters, revealing heterogeneous stability patterns depending on both the analyte and storage temperature. For several parameters, values remained relatively stable over the first 12 hours, particularly at room temperature and 4 °C, whereas storage at 37 °C often resulted in more pronounced changes over time. Some parameters displayed gradual shifts, while others showed abrupt deviations at later time points. The direction of change also varied between parameters, with some increasing and others decreasing compared to baseline. For parameters like NE-SSC and MO-X, the variability remained low up to 12 h across all temperatures.

Taken together, the observed results demonstrated a predominant pattern of instability at 37 °C, with intermediate changes at 4 °C and the highest stability at room temperature.

Across both the three complementary analytical approaches and the regression-based EFLM protocol, this temperature gradient was evident, with several parameters exceeding the maximum permissible error within hours when exposed to heat stress. Parameters such as NE-SSC, NE-FSC, MO-X, and LY-X showed slow rates of change with estimated stability limits exceeding the investigated 24 h time window across storage conditions, indicating preservation of analytical integrity within routine laboratory timeframes. In contrast, several parameters, including NE-SFL, NE-WX, NE-WY, NE-WZ, LY-Y, LY-Z, LY-WY, LY-WZ, MO-Z, MO-WX, MO-WY, and MO-WZ, reached the maximum permissible error within 24 h, particularly under exposure to 37 °C.

When interpreting EFLM-based stability results, statistical significance of the regression slope should not be considered in isolation. In accordance with the EFLM protocol, regression was forced through the origin, which may lead to statistically significant slopes even for very small rates of change when a large number of observations is available. In such cases, the estimated stability limit provides a more informative measure of practical relevance, as it reflects the time required to exceed the predefined maximum permissible error.

In another study the stability of CPD has been assessed. Specifically, Sun et al used a Beckman Coulter hematology analyzer for measuring CPD by means of a rather different approach (i.e., VCS technology) (8). Although their results are not directly comparable to ours due to the use of a fundamentally different analytical approach, they nonetheless warrant discussion. In brief, the study assessed the effects of storing peripheral blood at room temperature on CPD values using samples from 17 healthy donors analyzed up to 48 hours. Neutrophils showed increased mean volume after 8 hours and decreased mean conductivity, suggesting nuclear condensation or cytoplasmic expansion. Light scatter parameters in neutrophils decreased as early as 6 hours, indicating cytoplasmic degranulation and nuclear hypo-segmentation. Lymphocytes exhibited increased mean volume only at 48 hours, while mean conductivity rose earlier, reflecting cytoplasmic contraction. Their light scatter parameters changed within 2-3 hours, suggesting membrane irregularities and chromatin condensation. Monocytes showed stable mean volume and conductivity but significant decreases in light scatter parameters, indicating reduced granularity and nuclear condensation. Standard deviations for all cell types increased over time, reflecting greater population variability. Notably, CPD alterations appeared earlier than morphological changes observed microscopically. Some neutrophil CPD changes mimic pathological conditions such as myelodysplastic syndrome. It was therefore concluded that, consistent with our findings, RT storage significantly impacts leukocyte CPD values in a time- and cell-type-dependent manner.

A key strength of our study is the substantial sample size, the inclusion of four distinct time points, and the comprehensive assessment of 18 parameters across three temperature conditions. To our knowledge, this study is among the few to fully implement the new EFLM stability protocol in parallel with other analytical approaches, enabling direct comparison and methodological validation.

Overall, a clear gradient of instability was observed across all parameter series (RT < 4 °C < 37 °C). Taken together, these findings highlight that samples appear to become instable most rapidly at 37 °C for the majority of the CPD parameters investigated, often within the first 12 h, whilst storage at 4 °C generally delays deterioration but does not fully prevent instability for some parameters. The storage at RT showed the best preservation overall. From a practical standpoint, the key message is that avoiding prolonged exposure to high temperatures is critical to maintaining the integrity of these experimental hematology parameters.

Some limitations of this study should be acknowledged. First, duplicate measurements were not performed at each time point, which may limit the assessment of analytical imprecision over time. Second, the study was conducted on samples from ostensibly healthy subjects, and stability patterns may differ in pathological conditions. Third, the stability assessment was limited to a single analytical platform, and therefore the findings cannot be directly extrapolated to other hematology analyzers employing different technologies. Finally, the 37 °C condition was included as a heat-stress model rather than a routine storage scenario, and its results should be interpreted accordingly. Despite these limitations, the use of multiple complementary analytical approaches and the application of the EFLM protocol provide a robust framework for evaluating CPD stability.

In conclusion, this study demonstrates a clear time- and temperature-dependent instability of leukocyte cell population data (CPD) measured on the Sysmex XN hematological analyzer. Across all analytical approaches, a consistent gradient of instability was observed, with the highest stability at room temperature, intermediate stability at 4 °C, and the most rapid deterioration at 37 °C. Several parameters, including NE-SSC, NE-FSC, MO-X, and LY-X, maintained stability within a 24 h time window across storage conditions, whereas others exceeded predefined stability limits within 24 h, particularly under heat-stress conditions. These findings indicate that CPD are sensitive to preanalytical storage conditions and highlight the importance of controlling temperature exposure to preserve analytical integrity in routine laboratory practice.

Potential conflict of interest

None declared.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References LippiGGuidiGCMattiuzziCPlebaniM. Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med. 2006;44:358–65. 10.1515/CCLM.2006.07316599826 DavesMZaglerEMCeminRGnechFJoosAPlatzgummerS Sample stability for complete blood cell count using the Sysmex XN haematological analyser. Blood Transfus. 2015;13:576–82.26057491 ZiniG. International Council for Standardization in Haematology. Stability of complete blood count parameters with storage: toward defined specifications for different diagnostic applications [Editorial]. Int J Lab Hematol. 2014;36:111–3. 10.1111/ijlh.1218124373157 RoccaforteVSabbatiniGPanellaRDavesMFormentiPGottiM The potential role of leukocytes cell population data (CPD) for diagnosing sepsis in adult patients admitted to the intensive care unit. Clin Chem Lab Med. 2025;63:1031–42. 10.1515/cclm-2024-120239851139 MantovaniEMAFormentiPPastoriSRoccaforteVGottiMPanellaR The Potential Role of Neutrophil-Reactive Intensity (NEUT-RI) in the Diagnosis of Sepsis in Critically Ill Patients: A Retrospective Cohort Study. Diagnostics (Basel). 2023;13:1781. 10.3390/diagnostics1310178137238265 FormentiPIsidoriLPastoriSRoccaforteVMantovaniEAIezziM A Secondary Retrospective Analysis of the Predictive Value of Neutrophil-Reactive Intensity (NEUT-RI) in Septic and Non-Septic Patients in Intensive Care. Diagnostics (Basel). 2024;14:821. 10.3390/diagnostics1408082138667467 HoffmannJJML. Cell population data: much more to explore. Clin Chem Lab Med. 2022;61:377–9. 10.1515/cclm-2022-117336622868 SunTLiJWuBHuangHLuoJXuD Effects of blood storage on cell population data. Clin Lab. 2020;66:1501–8. 10.7754/Clin.Lab.2020.19113532776740 BordignonJCBueno GardonaRGVasconcellosLDSIachinskiJSDambrosRHArrudaG Thermal and chronological stability of monocyte distribution width (MDW), the new biomarker for sepsis. Clin Chem Lab Med. 2022;60:e232–4. 10.1515/cclm-2022-048535857658 MartensRJHvan AdrichemAJMattheijNJABrouwerCGvan TwistDJLBroerseJ Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the Sysmex XN-10 hematology analyzer. Clin Chem Lab Med. 2020;59:783–93. 10.1515/cclm-2020-152933554540 UrrechagaEBóvedaOAguirreU. Role of leucocytes cell population data in the early detection of sepsis. J Clin Pathol. 2018;71:259–66. 10.1136/jclinpath-2017-20452428821583 DavesMRoccaforteVLombardiFPanellaRPastoriSSpreaficoM Modern hematology analyzers: beyond the simple blood cells count (with focus on the red blood cells). J Lab Precis Med. 2024;9:4. 10.21037/jlpm-23-32 Gomez-RiojaRVon MeyerACornesMCostelloeSVermeerschPSimundicAM European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group Preanalytical Phase (WG-PRE). Recommendation for the design of stability studies on clinical specimens. Clin Chem Lab Med. 2023;61:1708–18. 10.1515/cclm-2023-022137021544
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020704" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020704" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020704" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(123) "Effects of different blood storage conditions on leukocytes cell population data using the Sysmex XN hematological analyzer" ["journals_article_author"]=> string(229) "Vincenzo Roccaforte, Rossella Panella, Massimo Daves, Antonella De Martino, Erika Jani, Giovanni Sabbatini, Pierfrancesco Agostini, Floriana De Filippi, Paolo Formenti, Giuseppe Lippi, Matteo Vidali, Angelo Pezzi, Stefano Pastori" ["journals_article_author_country"]=> string(5) "Italy" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(116) "cell population data (CPD), Sysmex, sample stability, experimental hematology parameters, pre-analytical variability" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1875" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "10" ["meta_title"]=> string(123) "Effects of different blood storage conditions on leukocytes cell population data using the Sysmex XN hematological analyzer" ["meta_desc"]=> string(123) "Effects of different blood storage conditions on leukocytes cell population data using the Sysmex XN hematological analyzer" ["meta_keyw"]=> string(116) "cell population data (CPD), Sysmex, sample stability, experimental hematology parameters, pre-analytical variability" ["created"]=> string(19) "2026-04-07 11:01:15" ["modified"]=> string(19) "2026-06-11 09:00:52" } [27]=> object(stdClass)#76 (35) { ["journals_id"]=> string(4) "1232" ["journals_xml"]=> string(82303) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020703 10.11613/BM.2026.020703 Original articles Preanalytical study concerning the influence of tube type and centrifugation conditions on the concentration of calprotectin in ascites DorotićAdrijana*1Siter-KuprešaninMarija1ČičakHelena1SaračevićAndrea1VuljanićDora1Troskot PerićRosana23AlfirevićIgor456 Department of Medical Laboratory Diagnostics, University Hospital “Sveti Duh”, Zagreb, Croatia Department of Gastroenterology and Hepatology, Referral Center for Functional Gastrointestinal Disorders of the Ministry of Health of Republic Croatia, University Hospital “Sveti Duh”, Zagreb, Croatia Faculty of Health Studies, University of Rijeka, Rijeka, Croatia University Department of Surgery, University Hospital “Sveti Duh”, Zagreb, Croatia Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia University North, Varaždin, Croatia

The first two authors contributed equally to this work.

Corresponding author: adorotic@kbsd.hr

Author contributions

A Dorotić: Conceptualization, Formal analysis, Investigation, Methodology, Visualisation, Writing – original draft, Project administration; M Siter Kuprešanin: Conceptualization, Formal analysis, Investigation, Methodology, Visualisation, Writing – original draft; H Čičak: Conceptualization, Formal analysis, Investigation, Methodology, Visualisation, Writing – original draft, Project administration, Resources; A Saračević: Conceptualization, Formal analysis, Investigation, Methodology, Visualisation, Writing – original draft, Project administration; D Vuljanić: Conceptualization, Formal analysis, Investigation, Methodology, Visualisation; R. Troskot Perić: Conceptualization, Investigation, Visualisation, Project administration; I. Alfirević: Project administration, Resources, Supervision, Writing – review & editing

15042026 15062026 36 2 020703 1607202525012026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Calprotectin in ascites is a possible marker of spontaneous bacterial peritonitis

• Preanalytical conditions for calprotectin in ascites are not clearly defined

• For determining calprotectin in ascites, red tube with clot activator (1500xg,15 min) should be used

Introduction

Concentration of calprotectin in ascitic fluid has been proposed as the possible diagnostic marker for spontaneous bacterial peritonitis. This study aimed to choose the optimal preanalytical conditions for the determination of the concentration of calprotectin in ascitic fluid.

Materials and methods

Study was performed using 20 samples of ascitic fluid of inflammatory etiology. Number of total nucleated (TNC) and polymorphonuclear cells (PMN) were determined on Advia 2120i (Siemens Healthineers). Ascitic samples were collected into three tube types (K2EDTA, tubes with clot activator and Li-heparin tubes) and centrifuged under three different conditions (400xg, 1500xg and 3000xg 15 minutes). Concentration of calprotectin was determined using Bühlmann’s turbidimetric assay and potassium and lactate dehydrogenase using standard laboratory methods on Atellica Solution (Siemens Healthineers). Data was evaluated by Friedman test and Spearman’s correlation coefficient.

Results

The highest concentration of calprotectin was observed in red tubes with clot activator (centrifuged 1500xg 15 minutes; median 0.349 mg/L, IQR 0.094-1.129 mg/L) and the lowest in lavender tubes (centrifuged 3000xg 15 minutes; median 0.109 mg/L, IQR: 0.037-0.850 mg/L). Friedman test showed statistically significant difference between concentration of calprotectin in different preanalytical conditions (P < 0.001). According to the desirable biological variation criteria, differences in calprotectin concentration were clinically significantly different for different preanalytical conditions.

Conclusions

To determine the concentration of calprotectin in ascites, we suggest using a test tube with a red cap and centrifugation conditions of 1500xg 15 minutes which is consistent with the relevant national and international guidelines.

Keywords: ascitesbiochemistrycalprotectininflammationvalidation/evaluation
Introduction

Peritoneal effusion, widely known as ascites is a pathological accumulation of fluid in the peritoneal cavity due to the increased production or decreased fluid removal. It is a common complication in patients with liver cirrhosis that indicates progression of the disease. In patients with advanced disease stage, ascites accumulation can lead to life-threatening bacterial infection of ascitic fluid, also known as spontaneous bacterial peritonitis (SBP) (1-3). According to the American Association for the Study of Liver Disease (AASLD) and European Association for the Study of the Liver Disease (EASL) guidelines, the diagnosis of SBP is based on diagnostic paracentesis, the number of polymorphonuclear cells (PMN) in ascites with more than 250x106/L PMN cells and/or a positive finding of ascites culture on exclusively one bacterial strain (4, 5). With the aim to find additional diagnostic marker for SBP, concentration of numerous inflammatory parameters in samples of ascitic fluid, including calprotectin, have been the center of various research studies (6-8).

Calprotectin is a calcium and zinc-binding protein which is detected almost exclusively in neutrophils. It is secreted or passively released from neutrophils during inflammatory processes and hence it has been investigated as a marker of disease activity in many inflammatory and autoimmune diseases (9). Therefore, calprotectin is of particular significance in being accurately reflective of PMN count and their activity in ascitic fluid and has also often been in the center of various research studies as a possible diagnostic and prognostic marker for SBP (6-8, 10, 11).

It has been reported that calprotectin measurement in blood-derived matrices could be affected by preanalytical factors such as sample type, collection and storage conditions (such as temperature), and the presence and type (if any) of used anticoagulants. Some studies have demonstrated higher concentration of calprotectin in serum samples compared to plasma, which makes blood calprotectin concentrations matrix dependent. Although, the dependence of calprotectin concentration on preanalytical factors has been very well investigated in blood-derived matrices and stool samples – commonly used samples in clinical practice, a review of the literature showed that there is no consensus regarding the choice of tube type and centrifugation conditions for determining the concentration of the calprotectin in ascites (12, 13). Considering the dependence of calprotectin on preanalytical conditions in samples derived from blood and stool, our research group hypothesize the same dependence for ascitic fluid samples.

According to the document Laboratory testing of extravascular body fluids: National recommendations on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine Part I – Serous fluids, to determine the total and differential cell count in extravascular body fluids, tubes with ethylenediaminetetraacetic acid (EDTA) should be used, while samples of ascites for biochemical analysis should be collected in tubes with heparin as anticoagulant, with the alternative option of using a tube without additives if transport conditions are met (14). On the other hand, according to the document of the Clinical and Laboratory Standards Institute (CLSI) C49: A Analysis of Body Fluids in Clinical Chemistry; Approved Guideline, it is recommended that the analysis of body fluids is carried out in the same containers and under the same preanalytical conditions as the comparative blood sample, which is usually tube with red top (15).

According to our knowledge, so far, no study has been conducted that examined different preanalytical conditions and their influence on the concentration of calprotectin in ascites. Therefore, the aim of this study was to investigate whether there is a significant difference between the concentration of calprotectin in ascitic fluid using different test tubes and under different conditions of centrifugation. Also, additional aim of the study was to choose the optimal preanalytical conditions for the determination of the concentration of calprotectin in ascitic fluid (using Bühlmann’s turbidimetric assay) for further studies of diagnostic accuracy.

Materials and methods Subjects

The study was performed from June 2023 to February 2024 in the Department of Medical Laboratory Diagnostics, University Hospital Sveti Duh, Zagreb, Croatia. Ascitic fluid samples were collected from patients who were admitted to Emergency Department at University Hospital Sveti Duh, Zagreb, Croatia and Department of Gastroenterology and Hepatology at University Hospital Sveti Duh, Zagreb, Croatia. Inclusion criteria for participation in the study were patients with suspected or advanced liver cirrhosis or malignancy-relates ascites requiring diagnostic paracentesis with abdominal pain, fever, encephalopathy, hypotension, renal failure, acidosis or peripheral leukocytosis. These patients are expected to have a high concentration of leukocytes in ascites, and consequently high number of PMN and therefore elevated concentration of calprotectin. Patients under 18 years of age, as well as patients with traumatic abdominal injuries and a proven intra-abdominal source of infection where not included in the study. The exclusion criteria related to samples included small sample volumes, hemorrhagic, milky appearance or purulent ascites.

Study was approved by the Ethics committee of the University Hospital Sveti Duh. The respondents were familiar with the study procedures and expressed their consent to participate in the study by signing an informed consent form. The study was conducted within the research project „Diagnostic value of calprotectin in early recognition of inflammation“ (KK.01.1.1.04.0055) funded by the European Fund for Regional Development.

Methods

Patients were subjected to diagnostic and therapeutic paracentesis, a simple bedside procedure in which a needle is inserted into the peritoneal cavity and ascitic fluid is being removed. Paracentesis was performed under aseptic conditions from a puncture site in the left or right lower quadrant with the patient in the supine position. All samples were immediately collected at the bedside and processed by laboratory personnel without further delay. Ascitic fluid was immediately transferred into three types of tubes: (1) tubes with lavender top that use potassium salt of ethylenediaminetetraacetic acid (K2EDTA) as an anticoagulant which is sprayed onto the interior surface of tube (2 mL, lot 3122664, Becton, Dickinson and Company, Franklin Lakes, USA); (2) tubes with red top that use clot activator (4 mL, lot 3086919, Becton, Dickinson and Company, Franklin Lakes, USA) and (3) tubes with green top that contain lithium heparin as an anticoagulant (2 mL, lot 3058240, Becton, Dickinson and Company, Franklin Lakes, USA). Each type of tube was filled in triplicate, meaning we had nine tubes in total - three tubes with a lavender top, three tubes with a red top, and three tubes with a green top. All three tube types, in total nine different tubes, containing ascitic fluid were mixed according to the manufacturers’ specifications to ensure thorough mixing of the sample with the additive. Each of the tube type was centrifuged using bench top VWR Mega Star 1.6 centrifuge (VWR International, Radnor, USA), under following different conditions: (1) at 400xg for 15 minutes, (2) at 1500xg for 15 minutes and (3) at 3000xg for 15 minutes. Following the above, nine different preanalytical conditions were taken into the account for each sample, as shown in Figure 1.

Different preanalytical conditions for testing calprotectin concentration in ascites.

Prior to centrifugation, according to the national guidelines for extravascular body fluids, the number of total nucleated cells (TNC) was measured in tubes with K2EDTA anticoagulant using body fluid application on Advia 2120i hematology analyzer (Siemens Healthineers, Erlangen, Germany) (13). For the determination of PMN, additionally, cytocentrifuge smear was prepared using cytocentrifuge Rotofix 32A (Hettich Zentrifugen, Tuttlingen, Germany). Cytocentrifugation, a common technique for the capture of cells on microscopic slides, was performed for 8 minutes at 800 rounds per minute (RPM), and afterwards, slides were stained in May-Grünwald solution for 3 minutes and Giemsa solution for 12 minutes following the established laboratory protocol. The number of PMN was determined using light microscopy using Olympus BX53 (Olympus, Tokyo Japan), with magnification of 100 times and with immersion oil. To avoid variability in the determination of number of PMN, one experienced specialist in laboratory medicine examined all of the smears and estimated the PMN number. The aforementioned hematology analyzer, Advia 2120i using Body Fluid Application has the ability for the enumeration of TNC count and red blood cells count for pleural, peritoneal, and peritoneal dialysis specimens collected in EDTA tubes. The TNC count is derived from the Basophil/Lobularity channel using BASO reagent containing surfactant and phthalic acid (16).

After centrifugation, in all three tube types (nine tubes in total), concentration of calprotectin was determined using automated in vitro diagnostic test for the quantitative determination of calprotectin in human stool specimens (Bühlmann fCAL turbo, Bühlmann Laboratories AG, Schönenbuch, Switzerland), with the dilution factor adjusted for ascitic fluid measurements on Atellica Solution automated biochemistry analyzer (Siemens Healthineers, Erlangen, Germany). The aforementioned reagent has been validated and routinely verified by users for the determination of calprotectin concentration in stool samples on Atellica Solution automated biochemistry analyzer. In the manufacturer’s protocol, it is suggested to dilute the stool samples in a ratio of 1:500 with 5 mL of extraction buffer. Subsequently, the raw data from the analyzer is multiplied by a factor of 500 for the mentioned diluted stool extracts in order to obtain the final concentration of calprotectin in stool samples (17). Considering that the same dilution was not used in the pre-preparation of ascites samples, and is included in the method application, we applied the division of all results of calprotectin concentration in ascites with a correction factor of 500. A similar protocol was used in the study conducted by Čičak et al. to determine the stability of calprotectin concentration with the same reagent on the same analyzer in synovial fluid samples (18). Considering the change in sample type, compared to that determined by the manufacturer, and the fact that the protocol has been changed in the context of not diluting samples, the expression of calprotectin concentration has been changed from concentration per sample mass (µg/g) to concentration per liter of sample (expressed in SI units as mg/L).

As cell integrity markers, potassium concentration (K) and lactate dehydrogenase (LD) activity were selected, widely known as parameters highly sensitive to cell structural integrity. Under the assumption that during more intense centrifugation force the cellular structures disintegrate and the mentioned markers come out of the cells, by determining their concentration and activity in ascites samples, we wanted to notice subtle differences in K concentrations and LD activity as well as cell disintegration and choose optimal centrifugal force and time. Markers of cell integrity, K concentration and LD activity were determined on the same automatic analyzer. Cells were considered intact at the lowest concentration of K and lowest activity of LD, considering that the mentioned parameters are primarily of intracellular origin, and do not originate from overly aggressive centrifugation of the sample. Concentration of K was measured using potentiometric measurements with integrated indirect multi-sensor technology (IMT) and LD activity was measured using standardized enzymatic method. Due to the structure of K2EDTA anticoagulant, K was not determined in samples collected in K2EDTA tubes. Internal quality control was run daily for all analytes as a part of standard laboratory work. In order to reduce the impact of method imprecision, all biochemistry analytes were measured in duplicate. Also, to reduce the impact of possible instability of the analytes, all preanalytical procedures were made within maximum 10 minutes after sample collection, which is approximate time for transport of the samples to the laboratory.

Statistical analysis

Statistical analysis was performed using MedCalc statistical software version 12.5.0.0 (MedCalc, Ostend, Belgium). Experiment generated quantitative (numerical) data in paired samples. Since the sample size was relatively small and according to Kolmogorov-Smirnov test for testing the normality of data; they did not follow a normal distribution, a non-parametrical statistical test, Friedman test, was used for testing the difference between the parameters in different preanalytical conditions. For parameters that showed statistically significant difference using Friedman test, post-hoc multiple comparison was done. Statistically significant difference was set to 5% and consequently P < 0.05 were considered as statistically significant.

For defining clinically significant difference between concentration of calprotectin in different preanalytical conditions, means of the calculated absolute values of biases were compared with the clinically significant difference criteria. Mentioned criteria was set using biological variation concept. Using the mean value of the biological variability data (e.g. within-subject biological variation (CVI) and between-subject (CVG) biological variation) in females and males for serum calprotectin concentration established by Briers et al., and using the formula for calculation the desirable bias (< 0.25 x (CVi2 + CVg2)1/2) clinically significant difference was set at 14% (19). The impact of analytical imprecision was minimized by determining the concentration of all parameters in duplicate and therefore was not considered. The reference point for calculating the bias was the calprotectin concentrations obtained in the red tube centrifuged at 1500xg for 15 minutes because under these conditions the mean calprotectin concentration was highest, and it also corresponds to the conditions under which the accompanying serum sample was centrifuged, as suggested by the CLSI guidelines (15).

Results

Study was performed using 20 samples of ascitic fluid of inflammatory etiology. The results of calprotectin concentrations and other tested biochemistry parameters, as well as cell analysis in different preanalytical conditions are summarized in Table 1. Cell analysis confirmed that some of the samples (N = 4/20) met the diagnostic criteria for SBP (PMN count > 250 x106/L).

Concentration of calprotectin and other tested parameters in ascites depending on different preanalytical conditions
Tube type Lavender tube top(K2EDTA additive)(N = 20) Red tube top(clot activator)(N = 20) Green tube top(lithium heparin additive)(N = 20)
Centrifugation conditions 400xg15 min 1500xg15 min 3000xg15 min 400xg15 min 1500xg15 min 3000xg15 min 400xg15 min 1500xg15 min 3000xg15 min
Calprotectin (mg/L) 0.121 (0.048-0.864) 0.162 (0.043-0.824 0.109 (0.037-0.850) 0.277 (0.058-1.076) 0.349 (0.094-1.129) 0.345 (0.071-1.014) 0.186(0.066-0.900) 0.187(0.073-0.715) 0.193(0.090-0.802)
Total nucleated cells (x106/L) 162(69-611) n.a. n.a. n.a. n.a. n.a. n.a.
Polymorphonuclear cells (x106/L) 43(17-48) n.a. n.a. n.a. n.a. n.a. n.a.
Lactate dehydrogenase (U/L) 68(58-108) 66(58-100) 67(55-109) 68(60-104) 69(58-111) 68(58-115) 70(59-103) 69(59-101) 68(58-115)
Potassium (mmol/L) n.a. n.a. n.a. 3.8(3.5-4.3) 3.9(3.4-4.5) 3.9(3.5-4.5) 3.9(3.4-4.6) 3.9(3.4-4.5) 3.9(3.5-4.5)
Data are expressed as median and interquartile range (IQR). IQR – interquartile range. n.a. – not applicable.

Results in Table 1 indicate that the highest concentration of calprotectin in ascites is in red tubes that have been centrifuged at 1500xg for 15 minutes (median concentration 0.349 mg/L, IQR: 0.094-1.129 mg/L) and the lowest concentration of calprotectin is obtained in lavender tubes that have been centrifuged at 3000xg for 15 minutes (median concentration 0.109 mg/L IQR: 0.037-0.850 mg/L).

Statistical analysis showed that there is a statistically significant difference between concentration of calprotectin in different preanalytical conditions (P < 0.001) and that there are at least two groups of calprotectin concentrations obtained in different preanalytical conditions statistically significantly different. A more detailed presentation of the preanalytical conditions in which calprotectin concentrations differ significantly is presented in Table 2.

Testing statistical difference in the concentration of calprotectin in ascites depending on different preanalytical conditions
Tube number Tube type and centrifugation conditions Statistical difference P-value
1 Lavender top tube (K2EDTA additive) at 400xg 15 min (1) vs. (5) (6) (9) P < 0.001
2 Lavender top tube (K2EDTA additive) at 1500xg 15 min (2) vs. (5) (6) (9)
3 Lavender top tube (K2EDTA additive) at 3000xg 15 min (3) vs. (4) (5) (6) (8) (9)
4 Red top tube (clot activator) at 400xg 15 min (4) vs. (3)
5 Red top tube (clot activator) at 1500xg 15 min (5) vs. (1) (2) (3) (7)
6 Red top tube (clot activator) at 3000xg 15 min (6) vs. (1) (2) (3) (7)
7 Green top tube (lithium heparin additive) at 400xg 15 min (7) vs. (5) (6)
8 Green top tube (lithium heparin additive) at 1500xg 15 min (8) vs. (3)
9 Green top tube (lithium heparin additive) at 3000xg 15 min (9) vs. (1) (2) (3)
Statistical analysis was performed using Friedman test. P < 0.05 was considered statistically significant.

For defining clinically significant difference, according to the desirable biological variation criteria, differences in concentration of calprotectin were clinically significantly different for all tested tubes vs. red tube centrifuged at 1500xg for 15 minutes. Results of testing clinically significant difference are presented in Table 3.

Testing clinical difference in the concentration of calprotectin in ascites depending on different preanalytical conditions
Tube number Tube type and centrifugation conditions Bias (%)
1 Red top tube (clot activator) at 400xg 15 min 24
2 Red top tube (clot activator) at 1500xg 15 min 0
3 Red top tube (clot activator) at 3000xg 15 min 34
4 Lavender top tube (K2EDTA additive) at 400xg 15 min 45
5 Lavender top tube (K2EDTA additive) at 1500xg 15 min 54
6 Lavender top tube (K2EDTA additive) at 3000xg 15 min 48
7 Green top tube (lithium heparin additive) at 400xg 15 min 30
8 Green top tube (lithium heparin additive) at 1500xg 15 min 26
9 Green top tube (lithium heparin additive) at 3000xg 15 min 35
Absolute mean biases for the calprotectin concentration were calculated for all tube types and centrifugation conditions vs. calprotectin concentration in tubes with red top that use clot activator centrifuged at 1500xg for 15 min.

Statistical analysis indicated that there was no significant difference between the K concentration in the two used tubes types – red top tube vs. green top tube regardless of the centrifugation conditions (P = 0.540). On the contrast to the K concentration, there was a statistically significant difference in the LD activity between all tested preanalytical conditions (P = 0.046). Results for statistical analysis of LD activity difference are presented in Table 4.

Testing statistical difference in the lactate dehydrogenase activity in ascites depending on different preanalytical conditions
Tube number Tube type and centrifugation conditions Statistical difference P-value
1 Lavender top tube (K2EDTA additive) at 400xg 15 min P = 0.046
2 Lavender top tube (K2EDTA additive) at 1500xg 15 min (2) vs. (4) (5) (6)
3 Lavender top tube (K2EDTA additive) at 3000xg 15 min (3) vs. (4) (5) (6)
4 Red top tube (clot activator) at 400xg 15 min (4) vs. (2) (3)
5 Red top tube (clot activator) at 1500xg 15 min (5) vs. (2) (3)
6 Red top tube (clot activator) at 3000xg 15 min (6) vs. (2) (3)
7 Green top tube (lithium heparin additive) at 400xg 15 min
8 Green top tube (lithium heparin additive) at 1500xg 15 min
9 Green top tube (lithium heparin additive) at 3000xg 15 min
Statistical analysis was performed using Friedman test. P < 0.05 was considered statistically significant.
Discussion

The most significant result of our study is the established statistically and clinically significant difference in calprotectin concentrations in ascites depending on the various test tubes and centrifugation conditions. The highest concentration of calprotectin in ascites was in a red top tubes and the lowest concentration was obtained in a lavender top tube. As expected, the question of further selection of the test tube for determining the concentration of calprotectin in ascites arises.

A review of the literature did not find any studies that attempted to define preanalytical factors for determining calprotectin concentration in ascites. Despite this, various authors try to define diagnostic and prognostic role of calprotectin in ascites for individual clinical entities, very often SBP, without clearly established and referenced preanalytical factors. In study conducted by Fernandes et al., ascitic fluid samples were centrifuged during 15 minutes at 3500 RPM, without mentioning the centrifugation force nor collection tube type (20). On the other hand, Burri et al. centrifugated ascitic fluid samples for 15 minutes at 500xg, also without mentioning the tube type (21). Kassem et al. in their study stated that ascitic fluid was centrifuged for 15 minutes, but the information about centrifugation force is missing (22). Another possibility that has also been observed in the literature is that authors do not mention preanalytical conditions at all, as in the study of the Egyptian authors Abdel Rahman et al. (8). Given the fact that our study showed a clear influence of the mentioned preanalytical factors on the concentration of calprotectin in ascites, the need to standardize and to understand these conditions for further studies of diagnostic accuracy is clearly justified.

The observed differences in calprotectin concentrations in different tube types can be explained by differences in the molecular structures of the additives in individual tubes. EDTA anticoagulant has the ability to chelate divalent cations, and therefore also chelate calcium and zinc ions, which are crucial for the optimal structure and consequently also for the function of the calprotectin molecule. Studies of structural analysis, performed by Imani et al., of calprotectin molecule with fluorescence spectroscopy which included alteration in concentration of calcium, zinc and manganese, showed a remarkable change in secondary and tertiary structure of tested protein depending on the metal ions (23). Therefore, a result showing a significantly statistically and clinically lower concentration of calprotectin in a tube which have the ability to chelate crucial metal ions, is not surprising. Considering presented results; authors strongly discourage the use of lavender top tubes in determining the concentration of calprotectin in ascitic fluid samples. Similar to our results, but analyzing a different sample type, in their preanalytical study, Pedersen et al. found significantly higher calprotectin concentrations in serum and Li-heparin plasma samples vs. EDTA samples (24). The explanation for the differences in calprotectin concentrations obtained in red and green tubes may be found in the sensitivity of neutrophils to the blood clotting process. Calprotectin is detected almost exclusively in neutrophils that are in vitro highly dependent on platelet activation and coagulation process which may induce release of intracellular calprotectin into the extracellular medium and lead to higher concentrations of calprotectin in serum, as proposed by study conducted by Honap et al. (25).

According to our results, there is no statistically significant difference between the K concentration, in the different preanalytical conditions. Lactate dehydrogenase activity has been the lowest in the lavender tube top centrifuged for 15 minutes at 1500xg; indicating that these centrifugation conditions affect cell structure to the smallest extent. In their short communication, Veena et. al showed that K and LD levels in serum were found to be raised by increasing the centrifugal force up to 3000xg (26).

Considering the highest calprotectin concentration in ascites was observed in red tube and the lowest LD activity with the centrifugation conditions of 15 minutes at 1500xg, authors suggest using red tube centrifuged for 15 minutes at 1500xg for determining the concentration of calprotectin in ascites.

A possible limitation of our study could be a relatively small number of samples included in the study. The authors believe that the nature of the samples used justifies their small number. A more significant possible limitation of the study concerns the fact that most of the samples included in the study did not meet the criteria for diagnosing SBP and the obtained calprotectin concentrations are relatively small (smaller than in similar studies). Question arises whether the same results would be extrapolated to the higher calprotectin concentrations.

On the other hand, there are numerous novelties of our study. Presented study was performed on an automated biochemical analyzer using an automated method that significantly speeds up the time required for making laboratory test results unlike most literature examples that report the use of ELISA or point of care tests for determining the calprotectin concentration in ascites. Also, automated method is not subject to variability related to laboratory personnel, as is the case with smear examination, which is still the suggested diagnostic method in case of SBP assessment. According to our knowledge, this kind of preanalytical study in ascitic fluid samples has not been conducted yet. The proven influence of different preanalytical conditions on the concentration of calprotectin in ascitic fluid samples once again irrefutably confirms the importance of preanalytical processes in laboratory medicine. This study provides comprehensive analysis of different preanalytical conditions and their influence on the concentration of calprotectin in ascites for future studies.

Extravascular body fluids are a relatively unexplored area in the laboratory medicine and therefore provide wide possibilities in the diagnostic field in the future. However, before being introduced into the routine clinical practice, these new sample types require the satisfaction of clearly set quality criteria in the area of method validation. Clearly defining the basic preanalytical conditions, such as the type of test tubes and centrifugation conditions, are one of them. We would like to emphasize that there is a significant difference between the concentration of calprotectin in ascitic fluid using different test tubes and under different conditions of centrifugation. In conclusion, considering the observed difference between the concentration of calprotectin in various preanalytical conditions, to determine the concentration of calprotectin in ascites, we suggest sampling in a test tube with a red cap and centrifugation conditions of 15 minutes and 1500xg which is in accordance with relevant national and international guidelines (14, 15).

Acknowledgments

The study was carried out as part of the research project „Diagnostic value of calprotectin in early recognition of inflammation“ (KK.01.1.1.04.0055) funded by the European Fund for Regional Development.

The authors kindly thank all respondents who expressed their approval for participating in the study. Authors also thank to all the employees of the University Hospital Sveti Duh, Zagreb, Croatia – Department of Gastroenterology and Hepatology, Emergency Department and Department of Medical Laboratory Diagnostics who participated in the collection and in the analytical part of the sample processing.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References LiBGaoYWangXQianZMengZHuangY Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study. Liver Int. 2020;40:1447–56. 10.1111/liv.1441832128975 SongDS. Spontaneous Bacterial Peritonitis. Korean J Gastroenterol. 2018;72:56–63. 10.4166/kjg.2018.72.2.5630145857 LataJStiburekOKopacovaM. Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis. World J Gastroenterol. 2009;15:5505–10. 10.3748/wjg.15.550519938187 BigginsSWAngeliPGarcia-TsaoGGinèsPLingSCNadimMK Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1014–48. 10.1002/hep.3188433942342 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417. 10.1016/j.jhep.2010.05.00420633946 FahmyMMNosairNAEAhmedMH. Ascitic fluid calprotectin and ratio of calprotectin to total protein in spontaneous bacterial peritonitis. J Pak Med Assoc. 2023;73:S43–6. 10.47391/JPMA.EGY-S4-637482828 HeiklAAEl-NokeetyMMRoshdyEMoheyA. Ascitic calprotectin as a diagnostic marker for spontaneous bacterial peritonitis in hepatitis C virus cirrhotic Egyptian patients. Egypt J Intern Med. 2018;30:1–7. 10.4103/ejim.ejim_41_17 Abdel RahmanEMAttiaFAAlsebaeyAKhalik ElkadyMASayedMMAwadAR Ascitic calprotectin as a useful marker in the diagnosis of spontaneous bacterial peritonitis in adults. Egypt Liver J. 2020;10:14. 10.1186/s43066-020-0022-7 JukićABakiriLWagnerEFTilgHAdolphTE. Calprotectin: from biomarker to biological function. Gut. 2021;70:1978–88. 10.1136/gutjnl-2021-32485534145045 HonarNNezamabadipourNDehghaniSMHaghighatMImaniehMHAtaollahiM An evaluation of ascitic calprotectin for diagnosis of ascitic fluid infection in children with cirrhosis. BMC Pediatr. 2022;22:382. 10.1186/s12887-022-03433-935773636 NasereslamiMKhamnianZMoaddabYJalaliZ. Diagnostic and prognostic role of ascitic fluid calprotectin level: six-month outcome findings in cirrhotic patients. Scand J Gastroenterol. 2020;55:1093–8. 10.1080/00365521.2020.179402332715845 HamerHMMulderAHLde BoerNKCrouwelFvan RheenenPFSpekleM Impact of Preanalytical Factors on Calprotectin Concentration in Stool: A Multiassay Comparison. J Appl Lab Med. 2022;7:1401–11. 10.1093/jalm/jfac05735856861 InfantinoMManfrediMAlbesaRGrossiVLariBBenucciM Critical role of pre-analytical aspects for the measurement of circulating calprotectin in serum or plasma as a biomarker for neutrophil-related inflammation. Clin Chem Lab Med. 2021;59:e317–21. 10.1515/cclm-2021-017233641273 Milevoj KopčinovićLNikolac GabajNCulejJJokićAKocijanINjegovanM Laboratory testing of extravascular body fluids: National recommendations on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Part I – Serous fluids. Biochem Med (Zagreb). 2020;30:010502. 10.11613/BM.2020.01050231839720 Clinical and Laboratory Standards Institute (CLSI). Analysis of body fluids in clinical chemistry. Approved guideline. Document C49-A. CLSI, Wayne, USA: 2007. Siemens Healthcare Diagnostics. Customer Bulletin: Body Fluid Application. Rev A. USA: Siemens Healthcare Diagnostics Inc.; 2010. BÜHLMANN fCAL turbo. Calprotectin turbidimetric assay for professional use. Reagent Kit (Version A2). Buhlmann Laboratories AG, Schönenbuch, Switzerland, 2020. ČičakHBulatSJeličićJIvkovićAMaštrović RadončićKRadišić BiljakV Short- and long-term stability of synovial fluid calprotectin. Biochem Med (Zagreb). 2024;34:030704. 10.11613/BM.2024.03070439435164 BriersMMassaBVander CruyssenBVan Den BremtSHofmanLVan LangenhoveL Discriminating signal from noise: the biological variation of circulating calprotectin in serum and plasma. Clin Chem Lab Med. 2023;62:e113–5. 10.1515/cclm-2023-112638081590 FernandesSRSantosPFatelaNBaldaiaCTato MarinhoRProençaH Ascitic calprotectin is a novel and accurate marker for spontaneous bacterial peritonitis. J Clin Lab Anal. 2016;30:1139–45. 10.1002/jcla.2199427184969 BurriESchulteFMuserJMeierRBeglingerC. Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count. World J Gastroenterol. 2013;19:2028–36. 10.3748/wjg.v19.i13.202823599621 KassemASalah ShabanaHAAboeleninMMSalahHE. Comparative study of ascitic fluid and serum levels of calprotectin, procalcitonin and endocan in patients with liver cirrhosis for early diagnosis and prediction of spontaneous bacterial peritonitis. Azhar Med J. 2018;47:257–69. 10.12816/0052252 ImaniMBahramiYJalianiHZArdestaniSK. In solution cation-induced secondary and tertiary structure alterations of human calprotectin. Protein J. 2014;33:465–73. 10.1007/s10930-014-9578-625213023 PedersenLBirkemoseEGilsCSafiSNyboM. Sample Type and Storage Conditions Affect Calprotectin Measurements in Blood. J Appl Lab Med. 2018;2:851–6. 10.1373/jalm.2017.02477833636827 HonapSAimone-GastinISalignacSFlayacJPaoliJ Plasma Concentration of Calprotectin, but Not Serum Concentration, Is a Predictive Biomarker for Clinical Remission in Ulcerative Colitis. Inflamm Intest Dis. 2025;10:104–14. 10.1159/00054572240365553 MinderEISchibliAMahrerDNesicPPlüerK. Effects of different centrifugation conditions on clinical chemistry and Immunology test results. BMC Clin Pathol. 2011;11:6. 10.1186/1472-6890-11-621569233
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020703" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020703" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020703" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(135) "Preanalytical study concerning the influence of tube type and centrifugation conditions on the concentration of calprotectin in ascites" ["journals_article_author"]=> string(135) "Adrijana Dorotić, Marija Siter-Kuprešanin, Helena Čičak, Andrea Saračević, Dora Vuljanić, Rosana Troskot Perić, Igor Alfirević" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(72) "ascites, biochemistry, calprotectin, inflammation, validation/evaluation" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1578" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "9" ["meta_title"]=> string(135) "Preanalytical study concerning the influence of tube type and centrifugation conditions on the concentration of calprotectin in ascites" ["meta_desc"]=> string(135) "Preanalytical study concerning the influence of tube type and centrifugation conditions on the concentration of calprotectin in ascites" ["meta_keyw"]=> string(72) "ascites, biochemistry, calprotectin, inflammation, validation/evaluation" ["created"]=> string(19) "2026-04-07 10:59:12" ["modified"]=> string(19) "2026-06-11 09:00:33" } [28]=> object(stdClass)#77 (35) { ["journals_id"]=> string(4) "1231" ["journals_xml"]=> string(73264) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020702 10.11613/BM.2026.020702 Original articles Development and validation of a HPLC method for therapeutic monitoring of brivaracetam KomljenovićSven1ZovkoSara2Bujan KovačAndreja34Petelin GadžeŽeljka34SertićMiranda5LovrićMila*14 5 Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia Department of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina Department of Neurology, University Hospital Centre Zagreb, Referral Centre of the Ministry of Health of the Republic of Croatia for Epilepsy, Affiliated Member of the ERN EpiCARE, Zagreb, Croatia School of Medicine, University of Zagreb, Zagreb, Croatia Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia Corresponding author: mila.lovric@kbc-zagreb.hr

Author contributions

S Komljenović: Formal analysis, Investigation, Validation, Methodology, Writing – original draft; S Zovko: Formal analysis, Investigation, Writing – original draft; A Bujan Kovač: Investigation, Project administration, Writing – original draft; Ž Petelin Gadže: Conceptualization, Visualisation, Writing – review & editing; M Setić: Conceptualization, Methodology, Writing – review & editing; M Lovrić: Conceptualization, Supervision, Visualisation, Writing – review & editing.

15042026 15062026 36 2 020702 1406202515012026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• A novel chromatography method developed for brivaracetam monitoring

• Satisfactory analytical characteristics, cost-effective and accessible

• Method greenness presented for environmental impact and future method development

• Improved laboratory approach and contribution for epilepsy patients

Introduction

Brivaracetam belongs to antiepileptic drugs and due to the interindividual variability, therapeutic drug monitoring is recommended, especially when used in polytherapy and in patients with altered pharmacokinetics. The aim of this study is to develop and validate a high-performance liquid chromatography (HPLC) method with a diode array detector (HPLC-DAD) that is suitable for therapeutic monitoring of brivaracetam and assess method’s greenness.

Materials and methods

High-performance liquid chromatography method was validated according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and Clinical and Laboratory Standards Institute (CLSI) guidelines. Preparation of serum samples was performed by liquid–liquid extraction using ethyl acetate:hexane (1:1) with chloramphenicol as internal standard. Separation was achieved using a 5 µm 4.6 x 250 mm C18 Shim-pack GIST column with the mobile phase consisting of a 50 mM phosphate buffer (pH = 4.5) and organic mixture of acetonitrile and methanol (8/3; v/v). Brivaracetam is quantified at 210 nm. AGREEprep was utilized for the method’s greenness scoring.

Results

The developed HPLC-DAD method is linear over a concentration range of 0.25-20.00 µmol/L. Repeatability was lower than 7.20%, intermediate precision was lower than 8.30%, and within-laboratory precision was lower than 10.50%, except for the values at the lower limit of quantification (0.25 µmol/L) which were still below 20.00%. Bias was lower than ± 10.60%. The method displays very high specificity at 210 nm. The result for method greenness was 0.4.

Conclusions

The validation parameters were within the acceptance criteria of the ICH and CLSI guidelines. The developed method is simple, selective, reproducible, more sensitive than other published HPLC methods and suitable for the therapeutic drug monitoring of brivaracetam.

Keywords: method validationliquid chromatographybrivaracetamtherapeutic drug monitoring
Introduction

Epilepsy is a chronic neurological disorder that affects about 50 million people worldwide, and even though there are numerous anticonvulsant drugs with different mechanisms of action for the treatment of epilepsy, one of the main challenges is drug resistance in patients, which affects about 30% of them (1, 2). Brivaracetam (BRV; UCB 34714; 2-(2-oxo-4-propylpyrrolidin-1-yl) butanamide) is a third generation of antiepileptic drug. In the European Union, the European Medicines Agency has approved BRV as an adjunctive therapy for focal (partial onset) seizures, with or without secondary generalization in adults, adolescents and children from 2 years of age. In the United States, the Food and Drug Administration has approved BRV as either monotherapy or adjunctive therapy for partial seizures in patients from one month and older (3, 4). Brivaracetam is available in three different pharmaceutical formulations: tablets, oral solution and intravenous injection solution (3).

Like its structural analogue levetiracetam (LEV), BRV acts by binding to synaptic vesicle glycoprotein 2A (SV2A), which is located in the presynaptic membrane and is expressed primarily in the brain, and has an important function in epileptogenesis (5, 6). It is believed that due to its higher lipophilicity (LogD 1.04) compared to LEV (LogD 0.64), BRV passes more easily through the blood-brain barrier and achieves its effect more quickly (7). Furthermore, BRV has as much as 15-30 times higher affinity for SV2A than LEV (8).

Brivaracetam has linear pharmacokinetics, it is rapidly absorbed from the gastrointestinal tract and is weakly bound to plasma proteins (9, 10). In the liver, it is metabolized mostly by hydrolysis that is not dependent on cytochrome P450 (CYP), but also via cytochrome P450, where the enzyme CYP2C19 plays the most important role, and its metabolites are mainly excreted in the urine (11, 12). The most common side effects that occur with the use of BRV are headache, fatigue, somnolence and dizziness (13). Brivaracetam can be considered as an alternative replacement for LEV, as overnight switching from LEV to BRV has been shown in clinical practice to be a quick and safe option and is mainly performed due to psychiatric or behavioral side effects associated with LEV (6, 14-19).

Due to the narrow therapeutic index and large interindividual variability in BRV elimination rate, therapeutic drug monitoring (TDM) is recommended, especially when used in polytherapy (20, 21). For the determination of BRV by chromatographic methods, several publications are available in the literature, including reverse phase high performance liquid chromatography (RP-HPLC) for the determination of BRV and its stereoisomers and the determination of BRV in pharmaceutical forms (22, 23). Ultra performance liquid chromatography (UPLC) methods have been developed for the determination of impurities and degradation products of BRV, but also for the determination of BRV and other antiepileptic drugs in biological fluids (24-27). Liquid chromatography tandem mass spectrometry (LC-MS/MS) and a simple high performance liquid chromatography with ultraviolet spectroscopy (HPLC-UV) methods were also used for determination in pharmaceutical forms and biological fluids (21, 28, 29). LC-MS/MS are sensitive and reliable methods; however, they are too expensive and often unavailable to some researchers. HPLC is considered a cheaper and more readily available method for TDM. Due to the growing clinical need for TDM of BRV, the aim of this study is to develop and verify an HPLC method with a diode array detector (HPLC-DAD) that is cheap, available and suitable for simple quantification of BRV concentration in serum.

Green analytical chemistry (GAC) aims to reduce or eliminate the use of chemicals that are potentially hazardous to the environment or human health. To make chemical processes greener, it is necessary to use less harmful and cleaner chemicals (30). Our goal is to develop an environmentally friendly method that will respect the principles of GAC.

Materials and methods

Method validation for brivaracetam quantification was done by combining International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines from 2022 for method validation in collaboration with European Medical Agency (EMA) and Clinical and Laboratory Standards Institute (CLSI) guidelines (31, 32).

Chemicals and reagents

The gradient mobile phase was prepared using an organic mixture of HPLC-grade acetonitrile and methanol obtained from Merck (Merck Millipore, Darmstadt, Germany) and a buffer solution prepared by dissolving sodium dihydrogen phosphate monohydrate obtained from Merck (Merck Millipore, Darmstadt, Germany) in HPLC-grade water obtained using NW Ultra-pure Water System (Nirosta, Osijek, Croatia). Chemicals used for extraction were ethyl acetate, hexane, sodium hydroxide (NaOH) obtained from Merck (Merck Millipore, Darmstadt, Germany) and a chloramphenicol standard obtained from Sigma (Sigma-Aldrich, Burlington, USA), used as an internal standard (IS).

Instruments and chromatography conditions

The analysis was performed using a Prominence HPLC system (Shimadzu Corporation, Kyoto, Japan) with a diode array detector (DAD). Chromatographic separation was achieved using a 5 µm 4.6 x 250 mm C18 Shim-pack GIST column (Shimadzu Corporation, Kyoto, Japan) as the stationary phase, while the mobile phase consists of 2 solutions: the first solution contains a 50 mM sodium dihydrogen phosphate solution (pH = 4.5), and the second an organic mixture of acetonitrile and methanol (ratio 8:3). Efficient chromatographic separation was achieved with a 20-minute analysis by applying a linear gradient mobile phase (from 30 to 60% organic mixture in 16 minutes) until the end of the analysis.

Calibrators and quality control samples

The calibration curve was constructed using commercially available four-point calibrators from Recipe (RECIPE Chemicals + Instruments GmbH, Munich, Germany). Four points consisted of blank calibrator (matrix without BRV), a 1.33 µmol/L concentration point, a 6.70 µmol/L concentration point and a 19.4 µmol/L concentration point. Commercially available control samples in two levels (RECIPE Chemicals + Instruments GmbH, Munich, Germany) were used to assess precision and accuracy. The lower-concentration control sample was manually diluted with blank serum pool and used to estimate the limit of detection (LOD) and the lower limit of quantification (LLOQ).

Sample preparation

Samples were prepared using a liquid-liquid extraction (LLE) procedure. A 500 μL aliquot of the sample (patient serum, control, or calibrator) was pipetted into a tube. Subsequently, 25 μL of internal standard (IS) (chloramphenicol, 0.1 mg/mL) and 50 μL of NaOH were added, followed by vortexing. For LLE, 3 mL of an ethyl acetate:hexane (1:1) mixture was added, the tube was capped, vortexed, mixed for 15 minutes on a horizontal shaker and centrifuged to separate the organic and aqueous phases. A 2.5 mL aliquot of the organic phase (upper layer) was transferred to a new tube and evaporated to dryness under air flow. The residue was reconstituted in 150 μL of a mobile phase and transferred to an autosampler vial for chromatographic analysis.

Selectivity/specificity

The selectivity of the method was evaluated by analyzing 20 random patient samples from residues of serum sample (morning, fasting) of patients treated with another psychotropic drug, but not with BRV. UV spectra were also used to confirm the selectivity of the method.

Analytical sensitivity

Analytical sensitivity parameters of the method: limit of detection, the lowest concentration that can be detected with statistical significance and lower limit of quantitation, the lowest analyte concentration that can be quantified with a predefined accuracy and precision, were based on a standard deviation of the noise response from blank samples at retention time of BRV. The values obtained from the selectivity/specificity assessment were used. To define LOD and LLOQ, the arithmetic mean of the 20 mentioned samples was used and the triple or tenfold value of the standard deviation was added, respectively. The calculated LLOQ obtained was assessed by other approach based on precision and accuracy, provided that the specified value meets the criterion of coefficient of variation (CV) ≤ 20% (ICH guideline M10 on bioanalytical method validation). The LLOQ confirmation sample was prepared by diluting the control sample with blank serum pool.

Linearity

The linearity of the method for BRV determination was evaluated using a one-point available commercial calibrator with concentration of 20.00 µmol/L (RECIPE Chemicals + Instruments GmbH, Munich, Germany). Linearity was verified by serial dilution of the calibrator with a blank serum pool to achieve six concentration levels (0.63, 1.25, 2.50, 5.00, 10.00, and 20.00 µmol/L), with a total of 29 measurements performed across the range. The acceptance criterion from the target value was CV ≤ 15%, BIAS ≤ ± 15% while the criterion at the LLOQ was CV ≤ 20%, BIAS ≤ ± 20%.

Precision and accuracy

Precision and accuracy data were obtained by running control samples in quintuplicate over 5 days. To assess precision, repeatability (Sr), intermediate precision (Sb), and within-laboratory precision (SWL) were calculated along with their corresponding coefficients of variation. The acceptance criterion for the listed parameters was CV ≤ 15%, while the criterion at the limit of quantification was CV ≤ 20% (ICH guideline M10 on bioanalytical method validation). Control samples had declared values of 4.12 and 9.61 µmol/L while at the LLOQ concentrations were diluted with blank serum pool to target values of 0.40 and 0.25 µmol/L.

Method greenness

To evaluate the environmental and occupational health impact of the method, the AGREEprep software was employed (33). This tool quantifies various factors such as sample preparation procedures, chemicals, energy consumption, and safety measures. The resultant score, ranging from 0 (least green) to 1 (greenest), provides a quantitative assessment of the method’s environmental sustainability.

Clinical application

We evaluated the applicability of the newly developed HPLC-DAD method by processing routine serum samples for TDM of patients with epilepsy on chronic brivaracetam therapy in combination with other antiepileptic drugs. Therapeutic drug monitoring was a part of the patients’ routine clinical management. The clinical study has been positively assessed and approved by the Ethics Committee University Hospital Center Zagreb on March 6, 2023, in Zagreb (Class: 8.1-23/62-4; Number: 02/21 AG). To evaluate therapeutic intervals for BRV, patients’ results from two separate periods were compared to the suggested range of 1.00-10.00 µmol/L. The first period included 50 samples collected from March to October 2023, and the second period also included 50 patients’ samples, collected from May to October 2024. Fasting blood samples, used for therapeutic interval evaluation, were taken in the morning at a 12-hour distance from the evening brivaracetam dose. Blood samples were collected at the Department of Laboratory Diagnostics, University Hospital Center Zagreb, in various Greiner Bio-One VACUETTE serum (Greiner Bio-One, Kremsmünster, Austria) tubes without anticoagulant. The blood samples were rested for a minimum of 30 minutes (depending on the transport time between the sampling site and the central lab) and then centrifuged at 3000 rpm for 5 minutes to separate the serum. The separated serum was immediately frozen at - 20 °C and stored for later analysis, unless the BRV analysis was scheduled for the same day. Samples were kept stored for up to 28 days after collection, after which they were thawed at room temperature for 1 hour and subsequently vortexed before analysis. These storage conditions are consistent with the manufacturer’s specifications for the QC materials and calibrators.

Statistical analysis

Statistical analysis was performed using Microsoft Excel (Microsoft, Redmond, U.S.) and MedCalc Statistical Software version 23.2.6 (MedCalc Software Ltd., Ostend, Belgium). Normality of distribution was assessed using the Shapiro-Wilk test. Data following a normal distribution are presented as mean ± standard deviation, while non-normally distributed data are expressed as median and interquartile range (IQR). Linearity was evaluated using Weighted Least Squares (WLS) linear regression (1/x2 weighting factor) to mitigate the effect of heteroscedasticity. The line equation, slope, intercept, and coefficient of determination (R2) were calculated. To further assess the association between theoretical and measured values, Spearman’s rank correlation (rs) was applied on the full linearity dataset (N = 29). Comparison of brivaracetam concentrations between the two clinical periods was performed using the Mann-Whitney test. In all analyses, P-values < 0.05 were considered statistically significant.

Results Chromatograms and specificity

After adjusting the chromatographic conditions, the BRV peak was eluated at the retention time of 6.9 min and detected at 210 nm (Figure 1), free from any overlapping peaks. The method demonstrated high specificity, as injection of the blank serum pool showed no interfering peaks at the retention time of BRV (6.9 min) and at 210 nm (Figure 2). This was further confirmed by the chromatogram analysis of 20 blood samples that did not contain BRV. No interferences on BRV separation were observed after injecting quality control samples containing commonly co-prescribed antiepileptics, their metabolites, and other relevant co-medication drugs (Figure 3).

Chromatogram of a patient’s sample with brivaracetam therapy.

Chromatogram of blank sample demonstrating lack of brivaracetam peak at 6.9 min.

Chromatogram of quality control sample showcasing brivaracetam peak at 6.9 min, observed at 210 nm.

At the chosen chromatographic conditions, IS has a retention time of 7.5 min and at a wavelength of 210 nm, there is an overlap with the unknown substance from the blank sample pool and QC material. Because of this interference, we chose another wavelength (306 nm) for detection and quantification of IS, where detected substance has no absorption (Figure 4).

Chromatogram of quality control sample showcasing internal standard peak at 7.5 min, observed at 306 nm.

Analytical sensitivity

Analytical sensitivity parameters LOD and LLOQ, calculated from blank sample analyses, were 0.02 µmol/L and 0.05 µmol/L, respectively. However, subsequent validation showed that the LLOQ of 0.05 µmol/L did not meet the criteria for precision and accuracy. Therefore, the working range was extended to 0.25 µmol/L, a level which met the criteria for precision and accuracy.

Linearity

The method exhibited satisfactory linearity over the tested range. The regression equation was: y = 0.963 x (95% CI: 0.927 to 0.999, P < 0.001) - 0.032 (95% CI: - 0.088 to 0.025, P = 0.194). The results showed proportional, but no constant difference (Figure 5). The coefficient of determination (R2) was 0.9993 (P < 0.001). A strong correlation was confirmed between measured and target values (rs = 0.99, P < 0.001). Coefficients of variation for replicates ranged from 5.89% to 8.98%, and the bias ranged from - 2.10% to - 10.32% at the lowest concentration (Table 1).

Brivaracetam method linearity. Data points represent the mean of replicates at each level.

Summary of concentrations, CVs, and BIAS for linearity of an HPLC method for therapeutic monitoring of brivaracetam
Target value (µmol/L) Average measured value (µmol/L) CV (%) BIAS (%)
20.00 18.82 5.89 - 5.90
10.00 9.40 6.60 - 5.99
5.00 4.90 5.98 - 2.10
2.5 2.44 6.49 - 2.61
1.25 1.19 8.98 - 5.06
0.63 0.56 8.32 - 10.32
CV - coefficient of variation.
Precision and accuracy

Results for repeatability, intermediate precision and intra-laboratory precision were within acceptable limits of 15% (overall) and 20% at the LLOQ (Table 2). As expected, CVs were higher at lower concentrations, consistent with the expected decrease in precision closer to the LLOQ (CV 16.38%). Accuracy results were also satisfactory (BIAS - 10.58 to 4.29%) and showed a similar trend of increasing variability at lower concentrations.

Repeatability, intermediate precision, intra-laboratory precision and accuracy results of an HPLC method for therapeutic monitoring of brivaracetam
Target value (µmol/L) Average measured value (µmol/L) Sr (CV%) Sb (CV%) SWL (CV%) BIAS (%)
4.12 4.20 3.04 6.15 6.73 2.04
9.61 10.02 1.48 5.98 6.13 4.29
0.40 0.38 7.17 8.22 10.42 - 4.01
0.25 0.22 6.57 15.28 16.38 - 10.58
Sr – repeatability. Sb - intermediate precision. SWL - within-laboratory precision.
Method greenness

Using the AGREEprep software, a value of 0.4 was obtained (Figure 6). Since strict guidelines for acceptable GAC scores and published papers on HPLC BRV method validation with GAC assessment are rare, we conclude that, under these conditions, the obtained score is acceptable.

AGREEprep scoreboard showcasing score and weight for each variable in analytical method.

Clinical application

The HPLC method for therapeutic monitoring of brivaracetam was introduced at the request of physicians who prescribed BRV for the treatment of resistant epilepsy. Initial doses were 50 mg twice a day and we used therapeutic range of 2.40-4.30 µmol/L (0.50-0.90 mg/L) which has been suggested in Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology (34). After a certain time, the doses were raised to 100 mg twice a day, which required a correction of the therapeutic range. In accordance with clinicians, we implemented another preliminary therapeutic range of 1.00-10.00 µmol/L, which has been proposed based on clinical trials (35).

The utility of the suggested therapeutic interval was assessed by comparing results from two periods. In the first period, March-October 2023, 3 out of 50 samples were excluded from calculations due to falsely ordered BRV, resulting in concentrations below the LLOQ. The data from the samples analyzed were not normally distributed (P < 0.001). The median concentration (IQR) was 6.10 (5.70) µmol/L. The percentage of agreement with the therapeutic interval was 85%. In the second period, May–October 2024, all 50 patient samples were used. One sample showed a concentration below the LLOQ, and a value of 0 was used in the calculation. The percentage of agreement in the second period with the therapeutic interval was 70%. The data from the second period showed a normal distribution (P = 0.198). The average concentration was 7.44 ± 3.77 µmol/L. No difference in concentrations between the two periods was observed (P = 0.130).

Discussion

In this study, an HPLC-DAD method was developed and validated for the determination of BRV concentration in serum. This is particularly important for patients who do not exhibit an adequate response to therapeutic doses, have impaired renal function, or possess an altered CYP2C19 genotype. A diode array detector was employed due to its sufficient sensitivity and specificity in quantifying a variety of drugs. Given the structural similarity between BRV and its analog, LEV, chromatographic conditions were adopted to harmonize the procedure with existing analytical procedures.

The use of chloramphenicol as an internal standard ensured adequate compensation for matrix effects and extraction variations, aligning with ICH recommendations for bioanalytical methods. Furthermore, the choice of LLE proved to be an effective strategy to enhance sensitivity and obtain cleaner extracts without the complexity and costs associated with solid-phase extraction.

The developed method demonstrated satisfactory specificity, where minor interference observed at the retention time of the IS was successfully addressed by wavelength adjustment, without compromising the reliability of quantification.

The initially estimated LLOQ did not fulfill the acceptance criteria for precision and accuracy. Therefore, a higher LLOQ was established to ensure reliable and reproducible measurements, which is essential for TDM. The slight negative bias observed during linearity assessment remained within acceptable limit. Conversely, regression and correlation confirmed linear relationship. The achieved LLOQ and confirmed linearity successfully complement the reported therapeutic range (1.00-10.00 µmol/L). This enables the accurate detection of underdosed and overdosed patients, as well as stratification from non-compliant patients.

Several HPLC and LC-MS/MS methods for the determination of the BRV in biological fluids have been reported in the literature. The developed HPLC-DAD method provides adequate sensitivity for the quantification of BRV concentrations, and the validation parameters obtained in this study are comparable to those reported. The established performance surpassed previously published HPLC method with an LLOQ around 10 µmol/L and is in line with some published LC-MS/MS methods with an LLOQ around 0.50 µmol/L (25, 28, 29). Although other LC-MS/MS methods demonstrate superior sensitivity (LLOQ around 9 and 3 nmol/L), this enhanced sensitivity was primarily utilized for pharmacokinetic studies or drug abuse monitoring and not for TDM (24, 27). At the similar concentration (2.36 µmol/L), the latter LC-MS/MS method achieved CV ≤ 5.68% and BIAS ≤ - 11.98%, which we found comparable to our results (27).

The greenness evaluation indicates that the environmental impact of the method is influenced by the non-automated sample preparation and utilization of hazardous chemicals. Although several methods reported scores around 0.7, they were either developed for BRV measurement in pharmaceutical formulations or utilized different methodologies for TDM (36-38). The transition to automated systems or commercial kits would likely lower the negative environmental contribution; however, the high investment costs associated with such improvements pose a significant challenge for financially strained facilities.

Clinical application was established through cooperation with physicians who prescribed BRV for the treatment of resistant epilepsy. While BRV concentrations in both monitoring periods were within the suggested therapeutic interval, neither period met the 90% agreement requirement, suggesting that these intervals may require further refinement in clinical practice.

In conclusion, results of the validation of the chromatographic method using a diode array detector displayed that the method is simple to use and exhibits a good signal response. It covers the suggested therapeutic range, significantly improving the clinical approach to patient’s TDM.

Acknowledgments

The authors sincerely thank Predrag Donat Švaljek and other hospital staff from the University Hospital Centre Zagreb involved in the study. The authors also acknowledge the use of Gemini AI for language editing and proofreading of the manuscript.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References StrianoPMinassianBA. From Genetic Testing to Precision Medicine in Epilepsy. Neurotherapeutics. 2020;17:609–15. 10.1007/s13311-020-00835-431981099 LöscherWPotschkaHSisodiyaSMVezzaniA. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol Rev. 2020;72:606–38. 10.1124/pr.120.01953932540959 Brivaracetam, EMA summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/briviact-epar-product-information_en.pdf. Acessed April 22nd 2024. UCB, Inc. Briviact US prescribing information; 2018. Available from: https://www.briviact.com/briviact-PI.pdf. Acessed June 13th 2024. LattanziSChiesaVDi GennaroGFerlazzoELabateALa NeveA Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond. Neurol Sci. 2024;45:4519–27. 10.1007/s10072-024-07485-w38558319 CoppolaGIapadreGOpertoFFVerrottiA. New developments in the management of partial-onset epilepsy: role of brivaracetam. Drug Des Devel Ther. 2017;11:643–57. 10.2147/DDDT.S10346828293101 NicolasJMHannestadJHoldenDKervynSNabulsiNTytgatD Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57:201–9. 10.1111/epi.1326726663401 FeyissaAM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data. Neuropsychiatr Dis Treat. 2019;15:2587–600. 10.2147/NDT.S14354831571877 RolanPSargentini-MaierMLPigeoletEStockisA. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66:71–5. 10.1111/j.1365-2125.2008.03158.x18341673 Sargentini-MaierMLRolanPConnellJTytgatDJacobsTPigeoletE The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007;63:680–8. 10.1111/j.1365-2125.2006.02829.x17223857 Sargentini-MaierMLEspiePCoquetteAStockisA. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36:36–45. 10.1124/dmd.107.01712917908923 Dean L. Brivaracetam Therapy and CYP2C19 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, eds. Medical Genetics Summaries. Bethesda (MD) 2012. StockisAHartstraJMolletMHadiS. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. Epilepsia. 2016;57:1288–93. 10.1111/epi.1343327346728 SteinhoffBJStaackAM. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord. 2019;12:1756286419873518. 10.1177/175628641987351831523280 ZahnertFKrauseKImmischIHabermehlLGornyIChmielewskaI Brivaracetam in the Treatment of Patients with Epilepsy-First Clinical Experiences. Front Neurol. 2018;9:38. 10.3389/fneur.2018.0003829467714 VillanuevaVLaloyauxCD’SouzaWFaughtEKleinPReuberM Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records. CNS Drugs. 2023;37:819–35. 10.1007/s40263-023-01033-437684497 AbrairaLSalas-PuigJQuintanaMSeijo-RaposoIMSantamarinaEFonsecaE Overnight switch from levetiracetam to brivaracetam. Safety and tolerability. Epilepsy Behav Rep. 2021;16:100504. 10.1016/j.ebr.2021.10050434901817 LercheHKnakeSRosenowFSchulze-BonhageAHellotSLeunikavaI Brivaracetam substituting other antiepileptic treatments: Results of a retrospective study in German epilepsy centers. Epilepsia Open. 2020;5:451–60. 10.1002/epi4.1241532913953 MenzlerKMrossPMRosenowFSchubert-BastSWillemsLMZahnertF First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study. BMJ Open. 2019;9:e030746. 10.1136/bmjopen-2019-03074631690606 PatsalosPNSpencerEPBerryDJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit. 2018;40:526–48. 10.1097/FTD.000000000000054629957667 HentschelMStoffel-WagnerBSurgesRvon WredeRDolscheid-PommerichRC. Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy. Epilepsia. 2024;65:620–9. 10.1111/epi.1787338158709 PalaniappanIMuruganMParamasivamP. Simultaneous determination of Brivaracetam and its isomers in the Brivaracetam drug by RP-HPLC. J Appl Pharm Sci. 2022;12:127–38. DalalATegeliVWaghmodeR. RP-HPLC method development and validation for the estimation of brivaracetam in bulk and formulation. Int J Adv Sci Res. 2022;13:79–83. 10.55218/JASR.202213709 IqbalMEzzeldinEAl-RashoodKA. UPLC-MS/MS assay for identification and quantification of brivaracetam in plasma sample: Application to pharmacokinetic study in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1060:63–70. 10.1016/j.jchromb.2017.05.03928600961 MohamedSRivaRContinM. Development and Validation of an UHPLC-MS/MS Assay for the Therapeutic Monitoring of Brivaracetam Plasma Concentrations in Patients with Epilepsy. Ther Drug Monit. 2020;42:445–51. 10.1097/FTD.000000000000072631934942 VishweshwarVBabuJMMuralikrishnaR. Development and validation of stability-indicating UPLC method for the determination of brivaracetam, its related impurities and degradation products. Int J Pharm Sci Res. 2018;9:2315–27. IqbalMKhalilNYEzzeldinEAl-RashoodKA. Simultaneous Detection and Quantification of Three Novel Prescription Drugs of Abuse (Suvorexant, Lorcaserin and Brivaracetam) in Human Plasma by UPLC-MS-MS. J Anal Toxicol. 2019;43:203–11. 10.1093/jat/bky07830295849 MansourNMEl-SherbinyDTIbrahimFAEl SubbaghHI. Development of an Inexpensive, Sensitive and Green HPLC Method for the Simultaneous Determination of Brivaracetam, Piracetam and Carbamazepine; Application to Pharmaceuticals and Human Plasma. Microchem J. 2021;163:105863. 10.1016/j.microc.2020.105863 HagemannAKlimpelDBienCGBrandtCMayTW. Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy. Epilepsia. 2020;61:e43–8. 10.1111/epi.1650032304097 SajidMPlotka-WasylkaJ. Green analytical chemistry metrics: A review. Talanta. 2022;238:123046. 10.1016/j.talanta.2021.12304634801903 ICH guideline M10 on bioanalytical method validation and study sample analysis. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf Acessed January 25th 2023. Clinical and Laboratory Standards Institute (CLSI) guidelines. Available at: https://clsi.org/standards/products/method-evaluation/documents/. Acessed January 25th 2023. WojnowskiWTobiszewskiMPena-PereiraFPsillakisE. AGREEprep - Analytical Greenness Metric for Sample Preparation. TrAC. 2022;149:116553. 10.1016/j.trac.2022.116553 HiemkeCBergemannNClementHWConcaADeckertJDomschkeK Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51:9–62. 10.1055/s-0043-11649228910830 ReimersABergJABurnsMLBrodtkorbEJohannessenSIJohannessen LandmarkC. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Des Devel Ther. 2018;12:271–80. 10.2147/DDDT.S15438829467570 PalaniappanIManiavannanMParthibanP. Simultaneous determination of Brivaracetam and its isomers in the Brivaracetam drug by RP-HPLC. J Appl Pharm Sci. 2022;12:127–38. NouraMMDinaTEFawziaAIHusseinIES. Validation of a specific Reversed-Phase HPLC method for the quantification of three racetams; Piracetam, Levetiracetam, and brivaracetam in the presence of Co-administered drugs in their pharmaceuticals; greenness assessment and application to biological fluid and in-vitro dissolution testing. Microchem J. 2022;181:107703. 10.1016/j.microc.2022.107703 AlnemariRAbduljabbarMAlthobaitiYAlshehriSAlmutairiFMAl ShmranyH Development and validation of a green spectrofluorimetric method for brivaracetam determination using N-doped graphene quantum dots: Mechanistic insights and bioanalytical applications. J Photochem Photobiol Chem. 2025;465:116357. 10.1016/j.jphotochem.2025.116357
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020702" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020702" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020702" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(86) "Development and validation of a HPLC method for therapeutic monitoring of brivaracetam" ["journals_article_author"]=> string(106) "Sven Komljenović, Sara Zovko, Andreja Bujan Kovač, Željka Petelin Gadže, Miranda Sertić, Mila Lovrić" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(83) "method validation, liquid chromatography, brivaracetam, therapeutic drug monitoring" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3996" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "8" ["meta_title"]=> string(86) "Development and validation of a HPLC method for therapeutic monitoring of brivaracetam" ["meta_desc"]=> string(86) "Development and validation of a HPLC method for therapeutic monitoring of brivaracetam" ["meta_keyw"]=> string(83) "method validation, liquid chromatography, brivaracetam, therapeutic drug monitoring" ["created"]=> string(19) "2026-04-07 10:56:02" ["modified"]=> string(19) "2026-06-11 08:44:10" } [29]=> object(stdClass)#78 (35) { ["journals_id"]=> string(4) "1230" ["journals_xml"]=> string(57365) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020701 10.11613/BM.2026.020701 Original articles Urinary placental growth factor stability as a critical factor in the reliability of preeclampsia diagnosis Martinez-MarzoEva*12PeranMaria12Lerma-IruretaJuan1Medel-MartinezAna1PaulesCristina1345OrosDaniel1345FabreMarta124 Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain Biochemistry Department, University Clinical Hospital Lozano Blesa, Zaragoza, Spain Obstetrics Department, University Clinical Hospital Lozano Blesa, Zaragoza, Spain Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, Madrid, Spain University of Zaragoza, Zaragoza, Spain Corresponding author: emartinezmarz@salud.aragon.es

Author contributions

E Martinez-Marzo: Conceptualization, Methodology, Investigation, Writing – original draft; M Peran: Writing – original draft; J Lerma-Irureta: Formal analysis, Data curation, Investigation; A Medel-Martinez: Resources, Data curation; C Paules: Supervision, Writing – review & editing; D Oros: Supervision, Writing – review & editing; M Fabre: Conceptualization, Methodology, Supervision, Writing – review & editing.

15042026 15062026 36 2 020701 0808202515012026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Urinary placental growth factor (PlGF) may support diagnosis and prediction of preeclampsia

• First structured study assessing PlGF stability in urine samples

• The stability protocol used improves consistency across laboratories

• Urinary PlGF is stable for up to 48 hours when stored at 2-8 °C

• Urinary PlGF remains stable after two freeze-thaw cycles

Introduction

Placental growth factor (PlGF) is a key biomarker for diagnosing and predicting preeclampsia (PE). While serum-based PlGF assays are well established, urine has emerged as a promising non-invasive alternative matrix. However, the absence of urinary PlGF stability data remains a major preanalytical limitation. This study aimed to assess urinary PlGF stability under common preanalytical conditions, including refrigerated storage and a double freeze-thaw cycle.

Materials and methods

A prospective study was conducted using urine samples from ten pregnant women. Each sample was processed under standard laboratory conditions and aliquoted into five tubes. One aliquot was immediately frozen at - 80 °C (T0), three were stored at 2-8 °C for 48, 96, and 168 hours before freezing, and one underwent a double freeze-thaw cycle. Urinary PlGF concentrations were measured using the Elecsys PlGF immunoassay on Roche Cobas e801 analyzer. Percent degradation (PD%) was calculated relative to baseline. A linear regression model was applied to estimate the time to exceed a maximum permissible instability (MPI) of ± 10%.

Results

Urinary PlGF remained stable at 2-8 °C for up to 48 hours, with a mean PD% of - 6% (95% confidence interval (CI): - 9.1 to - 2.8). The regression model (PD% = - 0.0834 x Time (h)) estimated the - 10% threshold at approximately 120 hours. After a double freeze-thaw cycle, the mean PD% was - 1.5% (95% CI: - 3.4 to 0.4%).

Conclusions

Urinary PlGF shows acceptable stability for up to 48 hours under refrigeration and is stable over two freeze-thaw cycles. These findings provide essential preanalytical data supporting its potential use in clinical and research settings.

Keywords: placental growth factorpreanalytical phasepreeclampsiastabilityurine
Introduction

Preeclampsia (PE) is a leading cause of maternal and perinatal morbidity and mortality worldwide (1). It is characterized by placental dysfunction and typically manifests after 20 weeks of gestation with new-onset hypertension and proteinuria (2). Early and accurate diagnosis is essential to reduce associated complications. The pathophysiology of PE has been strongly linked to an imbalance between angiogenic and antiangiogenic factors. Serum concentrations of soluble fms-like tyrosine kinase-1 (sFlt-1), an antiangiogenic molecule, are elevated in women with PE, while free circulating concentrations of placental growth factor (PlGF), a proangiogenic protein, are decreased (3). The serum sFlt-1/PlGF ratio has been incorporated into clinical algorithms and is recommended by international guidelines due to its high negative predictive value for PE diagnosis (4, 5). Additionally, serum PlGF alone has demonstrated notable diagnostic performance (6, 7).

While serum remains the standard matrix for angiogenic markers (sFlt-1 and PlGF), urine has gained increasing attention as a promising alternative sample. Its non-invasive and spontaneous collection, greater patient acceptability, and feasibility for repeated testing make it especially suitable for use in non-specialized or low-resource settings (8, 9). Several studies have investigated urinary biomarkers for PE diagnostic. Proteomic analyses have identified candidates such as SERPINA1, uromodulin, albumin fragments and fibrinogen-derived peptides, which reflect endothelial and renal dysfunction in PE (10). Other analytes like activin A, inhibin A and sFlt-1 have also shown potential, particularly in multimarker models. However, PlGF has emerged as one of the most promising urinary biomarkers, showing consistent diagnostic performance even without creatinine adjustment (11).

A thorough understanding of an analyte’s properties is essential prior to its clinical application. Assessing its stability under real-world preanalytical conditions is critical to ensure reliable measurement. Clinical laboratories often depend on published literature and manufacturer specifications to define acceptable storage times (12). Multiple studies have evaluated the stability of PlGF in serum over periods ranging from 48 hours to 30 days; however, their findings vary depending on storage conditions, analytical methods, and stability criteria (13-15). To our knowledge, no study has systematically assessed the stability of PlGF in urine, highlighting a key preanalytical gap that must be addressed before this matrix can be reliably implemented in clinical or research settings.

The aims of this study were to assess the stability of PlGF in urine samples stored refrigerated at 2-8 °C for up to seven days as well as after a double freeze-thaw cycle, reflecting typical preanalytical conditions encountered in hospital settings.

Materials and methods Subjects

This prospective study was carried out at the University Clinical Hospital Lozano Blesa (Zaragoza, Spain) within the framework of project PI22/143, supported by the Instituto de Salud Carlos III (ISCIII), Government of Spain. Following the protocol published by the Spanish Society of Laboratory Medicine (SEQC-ML) for the stability testing of biochemical analytes, ten urine samples were collected from pregnant women with suspected PE at various gestational ages (16). Sample collection was conducted between January and February 2025 and laboratory analysis was performed in April 2025.

The study was approved by the Research Ethics Committee of the Community of Aragón (C.I. PI19/346 and PI23/102) and all patients provided written informed consent.

Methods

From each participant, 10 mL of midstream urine was collected in sterile, additive-free VACUETTE Z urine no additive 10 mL tubes (Greiner Bio-One GmbH, Kremsmünster, Austria). All urine samples were centrifuged at 3500 rpm for five minutes at room temperature and the supernatant was aliquoted into five sterile round-bottom polystyrene tubes (500 μL each) (Deltalab, Barcelona, Spain). One aliquot was immediately frozen at - 80 °C (T0), while the remaining three were stored refrigerated at 2-8 °C for 48, 96 and 168 hours, respectively, before being frozen at - 80 °C. An additional aliquot from each participant underwent a double freeze-thaw cycle to simulate a common preanalytical condition in research. All double freeze-thaw aliquots were frozen at - 80 °C immediately after collection (T0). Four days later, each aliquot was completely thawed at room temperature for approximately 30 minutes, ensuring full homogenization, and subsequently refrozen at - 80 °C, completing the first freeze–thaw cycle. The second thaw occurred on the day of laboratory analysis, when all aliquots were thawed simultaneously and analyzed in a single batch within two hours to minimize analytical variability. Because samples were collected on different dates, the interval between the second freezing and final thaw varied from 38 to 80 days. A flowchart illustrating the sample processing workflow is presented in Figure 1.

Flowchart of the stability study process from sampling to analysis. The figure was created using BioRender.com.

Urinary PlGF concentrations were measured using the Elecsys PlGF immunoassay (lot 796564), run on Roche Cobas e801 analyzer (Roche Diagnostics, Basel, Switzerland). As no immunoassay is currently validated for urinary PlGF measurement, analytical performance of the system was monitored using routine serum internal quality controls at low (≈ 50 pg/mL) and high (≈ 100 pg/mL) concentration levels, showing inter-assay coefficients of variations (CVs) of 3.1% and 3.3%, respectively. All samples were analyzed in duplicate, and the average of both replicates was used in all calculations.

Statistical analysis

For each time point, the percent degradation (PD%) was calculated relative to baseline using the following formula: PD% = ((Tx – T0) / T0) x 100, where T0 is the baseline PlGF concentration and Tx the concentration at the specified time point. The mean PD%, standard deviation (SD) and 95% confidence interval (CI) were calculated for each storage condition. According to the SEQC-ML protocol, an analyte was considered stable if the mean PD% ± 95% CI remained within the maximum permissible instability (MPI) (16). An MPI threshold of ± 10% was adopted for defining analyte stability.

To model the degradation trend over time, a linear regression analysis was performed using the PD% values. The regression line was constrained to pass through the origin, in accordance with the SEQC-ML comprehensive stability protocol, reflecting the biological assumption of no degradation at time zero (16). The resulting regression equation was: PD% = - 0.0834 x Time (h), with a coefficient of determination R2 = 0.97.

All statistical analyses were performed using Jamovi v2.6 (The jamovi project, Sydney, Australia) and Microsoft Excel 365 MSO version 2505 (Microsoft Corporation, Redmond, USA).

Results

Urinary stability of PlGF was evaluated in samples obtained from ten pregnant women. Baseline concentrations ranged from 97 to 371 pg/mL. The mean PlGF concentration for each individual sample at every storage time point is shown in Figure 2, allowing a visual comparison of analyte behavior over time.

Urinary PLGF concentrations for all samples at each time point. PIGF - placental growth factor.

To assess analyte stability, the PD% relative to the baseline value was calculated for each sample after 48, 96 and 168 hours of refrigerated storage at 2-8 °C with the corresponding average PD% and 95% CI (Table 1).

Individual percent degradation (PD%) values and group means with 95% confidence intervals for urinary PlGF concentrations
Individual PD% 48 hours 96 hours 168 hours
Sample 1 - 9.5% - 16.7% - 24.3%
Sample 2 - 6.5% - 7.2% - 7%
Sample 3 - 1.3% - 3.4% - 4.8%
Sample 4 - 5.8% - 7.6% - 10.8%
Sample 5 - 3.2% - 6.8% - 8.2%
Sample 6 - 0.3% - 3.5% - 5.1%
Sample 7 - 1.2% - 3.3% - 3.3%
Sample 8 - 12.2% - 18.1% - 20.9%
Sample 9 - 7.5% - 9.9% - 14.9%
Sample 10 - 12.1% - 19% - 26.4%
Average PD% (95% CI) - 6%(- 9.1 to - 2.8) - 9.6%(- 14 to - 5.1) - 12.6%(- 18.7 to - 6.4)
PIGF - placental growth factor.

At 48 hours, mean degradation remained within the acceptable MPI threshold of - 10%, indicating adequate analyte stability. At 96 hours, however, the lower bound of the 95% CI crossed this threshold, suggesting that analyte stability may no longer be guaranteed. By 168 hours, a marked increase in degradation was observed and most samples exceeded the instability limit (Figure 3A).

(A) Average PD% with 95% confidence intervals at each storage time point for PIGF stability measurement; (B) Individual PD% trajectories for each sample. The dashed line indicates the regression model and the solid black line marks the MPI threshold of - 10%. PIGF - placental growth factor. PD% - percent degradation. MPI - maximum permissible instability.

Based on the linear regression equation, the estimated time at which PD% reaches the - 10% MPI threshold is approximately 120 hours (5 days) (Figure 3B).

Finally, the effect of a double freeze-thaw cycle on PlGF stability was evaluated. The mean PD% following the second thaw was - 1.5%, with a 95% CI of - 3.4% to 0.4%, indicating minimal impact on stability (Figure 4).

Individual PD% values after a double freeze-thaw cycle. PIGF - placental growth factor. PD% - percent degradation.

Discussion

This study provides the first structured assessment of urinary PlGF stability under conditions that simulate typical hospital workflows. Our results show that PlGF remains adequately stable at 2-8 °C for up to 48 hours, with the mean PD% and its 95% CI remaining within the predefined MPI of ± 10%. Beyond this time point, progressive degradation was observed, with the 95% CI at 96 hours exceeding the MPI threshold and most samples surpassing it at 168 hours. Additionally, PlGF remained stable after two freeze-thaw cycles, with a mean PD% of - 1.5% (95% CI: - 3.4% to 0.4%).

Stability studies on biomarkers have often used heterogeneous acceptance criteria, which limit comparability and reproducibility of results across laboratories (15, 17, 18). To improve consistency, the SEQC-ML proposed a structured protocol using MPI, PD% and regression modeling, which was followed in our study (16).

According to the consensus of the Milan Strategic Conference, clinical outcome-based specifications (model 1) could not be applied because no established clinical decision limits are available for urinary PlGF (19). Likewise, the biological variation-based approach (model 2) was not applicable due to the absence of urine-specific biological variation data. Although biological variation data exist for serum PlGF (intra-individual CV = 7.9%, inter-individual CV = 12.9%), suggesting an allowable bias of approximately 5.7%, these data were derived from non-pregnant women and PlGF concentrations are known to fluctuate with gestational age during pregnancy (20, 21). Moreover, they refer to a different biological matrix, further limiting their relevance for the present study. Finally, the state-of-the-art approach (model 3) was also not applicable because no validated method is currently available for urinary PlGF measurement, as all existing immunoassays are designed for serum. Therefore, a pragmatic MPI threshold of ± 10% was adopted in the absence of previously reported urinary PlGF stability data and in line with previous thresholds used in serum PlGF stability studies (13, 14, 22, 23).

The evidence available on PlGF stability is limited exclusively to studies performed in serum, which cannot be extrapolated to urine due to the fundamentally different biochemical composition of both matrices. Based on our results, urinary PlGF appears stable for at least 48 hours when stored at 2-8 °C. Beyond this period, degradation becomes more pronounced, with several samples exceeding the predefined instability limit, likely reflecting the intrinsic variability of urine, including differences in pH, ionic strength and the presence of proteases or bacterial enzymes. The degradation pattern observed is comparable to that of other urinary biomarkers, such as inflammatory proteins, which have also shown similar stability limitations at 4 °C (9, 24). Overall, these findings highlight the need for further research on urinary PlGF stability, as no prior data exists and current knowledge from serum-based studies cannot inform urine-specific preanalytical behavior.

Recent studies have investigated urinary PlGF as a potential biomarker for PE, including its correlation with serum concentrations. Hebert-Schuster et al. reported a very strong correlation between urinary and serum PlGF concentrations (ρ = 0.983, P < 0.05), particularly when serum PlGF exceeded 100 pg/mL, suggesting that urinary PlGF may reliably reflect circulating concentrations (25). Similarly, Martín-Palumbo et al. found that urinary PlGF showed the strongest correlation with its serum counterpart (R2 = 0.73) among all markers studied and demonstrated high predictive value for PE (area under curve (AUC) = 0.866), comparable to that of serum PlGF (AUC = 0.853) (26). Although these studies support the clinical potential of urinary PlGF, none have addressed analyte stability, a key preanalytical requirement for reliable measurement. Demonstrating stability during refrigerated storage and over two freeze-thaw cycles is essential for its future implementation in both research and clinical workflows. The analyte’s acceptable performance under typical storage conditions supports its suitability for use in outpatient and non-specialized healthcare settings, where sample transport and delayed processing are common.

One of the main strengths of this study is its real-world applicability, as sample collection and handling were conducted under standard clinical laboratory conditions, reflecting typical preanalytical variability. Furthermore, applying a validated and structured stability protocol (SEQC-ML model) reinforces the methodological consistency and reliability of the results (16). All samples were processed in a single analytical batch, using the same reagent lot, minimizing analytical variability as much as possible. However, several limitations must be acknowledged. First, while the time-to-instability estimation (≈ 120 hours) derived from regression modeling provides useful insight, only the 48-hour time point showed consistent stability across all samples. Two of the ten aliquots exceeded the 10% MPI at 48 hours; however, according to the SEQC protocol, stability is determined by the mean PD% and its 95% CI rather than individual sample variability, reinforcing that the maximum acceptable stability is up to 48 hours. Second, there is currently no commercially available immunoassay and material controls for measuring urinary PlGF concentrations; available tests are validated only for serum. Lastly, although the sample size was sufficient for preliminary conclusions, a larger cohort would be necessary to confirm these findings.

In conclusion, urinary PLGF exhibits good stability under refrigerated conditions and shows minimal impact from freeze-thaw events, supporting its utility in clinical and translational research. Nevertheless, the sharp decline in stability beyond 48 hours and the high inter-sample variability emphasize the need for prompt processing and consistent preanalytical procedures. Our findings provide new preanalytical evidence on urinary PlGF stability, which is essential for its reliable implementation in clinical practice.

Acknowledgments

We are grateful to all pregnant women who provided urine samples at the Biochemistry Department of the University Clinical Hospital Lozano Blesa (Zaragoza, Spain). This study was supported by grants from the Government of Aragon, Spain, co-financed by FEDER (“Una manera de hacer Europa, Construyendo Europa desde Aragón” / European Social Funds: B46_20R and B46_23R), and by project PI22/143 funded by the Instituto de Salud Carlos III, Government of Spain. A.M.-M. and M.F. were supported by research grants from the Instituto de Salud Carlos III (FI21/00224 and CM22/00045, respectively).

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References DuleyL. The Global Impact of Pre-eclampsia and Eclampsia. Vol. 33, Seminars in Perinatology. 2009. p. 130–7. Duley L. The Global Impact of Pre-eclampsia and Eclampsia. Semin Perinatol. 2009;33:130–7. 10.1053/j.semperi.2009.02.01019464502 YoungBCLevineRJKarumanchiSA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173–92. 10.1146/annurev-pathol-121808-10214920078220 MaesaJMRomero-TabaresABenot-LópezS. Diagnostic validity of the sFlt-1/PlGF ratio in the identification of preeclampsia: A systematic review. Clin Invest Ginecol Obstet. 2020;47:30–7. 10.1016/j.gine.2019.04.001 ZeislerHLlurbaEChantraineFVatishMStaffACSennströmM Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374:13–22. 10.1056/NEJMoa141483826735990 National Institute for Health and Care Excellence (NICE). PLGF-based testing to help diagnose suspected preterm pre-eclampsia Diagnostics guidance [Internet]. London; 2022 Jul. Available from: www.nice.org.uk/guidance/dg49. Accessed May 15th 2025. ChappellLCDuckworthSSeedPTGriffinMMyersJMackillopL Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: A prospective multicenter study. Circulation. 2013;128:2121–31. 10.1161/CIRCULATIONAHA.113.00321524190934 ZhangLLiWChiXSunQLiYXingW Predictive performance of sFlt-1, PlGF and the sFlt-1/PlGF ratio for preeclampsia: A systematic review and meta-analysis. J Gynecol Obstet Hum Reprod. 2025;54:102925. 10.1016/j.jogoh.2025.10292539947348 SaudeEJSykesBD. Urine stability for metabolomic studies: Effects of preparation and storage. Metabolomics. 2007;3:19–27. 10.1007/s11306-006-0042-2 ChangCObeidWThiessen-PhilbrookHParikhCR. Sample Processing and Stability for Urine Biomarker Studies. J Appl Lab Med. 2021;6:1628–34. 10.1093/jalm/jfab08234414423 KolialexiAMavreliDTountaGMavrouAPapantoniouN. Urine proteomic studies in preeclampsia. Proteomics Clin Appl. 2015;9:501–6. 10.1002/prca.20140009225644222 WuJYaoYWangTXuTJiangR. Pregnancy urine biomarkers for effectively preeclampsia prediction: a systematic review and meta-analysis. Hypertens Pregnancy. 2025;44: 10.1080/10641955.2025.248779440199719 Gomez-RiojaRVon MeyerACornesMCostelloeSVermeerschPSimundicAM Recommendation for the design of stability studies on clinical specimens. Clin Chem Lab Med. 2023;61:1708–18. 10.1515/cclm-2023-022137021544 Armstrong-BuisseretLKHaslamSJamesTBradshawLHeazellAEP. Verification of placental growth factor and soluble-fms-like tyrosine kinase 1 assay performance in late pregnancy and their diagnostic test accuracy in women with reduced fetal movement. Ann Clin Biochem. 2020;57:223–33. 10.1177/000456322091199332081030 CowansNJAlfthanHStenmanUHSpencerK. Stability of first trimester placental growth factor in serum and whole blood. Prenat Diagn. 2011;31:1193–7. 10.1002/pd.289422028208 LianIADypdalsbakkTÅsbergA. Stability of serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1). Scand J Clin Lab Invest. 2024;84:160–7. 10.1080/00365513.2024.234003738669234 Gómez-RiojaRAmaroMSDiaz-GarzónJBauçàJMEspartosaDMFernández-CalleP A protocol for testing the stability of biochemical analytes. Technical document. Clin Chem Lab Med. 2019;57:1829–36. 10.1515/cclm-2019-058631348756 RowsonSReddyMRolnikDLDa Silva CostaFPalmerKR. Stability of placental growth factor, soluble fms-like tyrosine kinase 1, and soluble fms-like tyrosine kinase 1 e15a in human serum and plasma. Placenta. 2019;86:1–3. 10.1016/j.placenta.2019.08.00131476387 ČičakHBulatSJeličićJIvkovićARadončićKMRadišić BiljakV Short-and long-term stability of synovial fluid calprotectin. Biochem Med (Zagreb). 2024;34:030704. 10.11613/BM.2024.03070439435164 SandbergSFraserCGHorvathARJansenRJonesGOosterhuisW Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med. 2015;53:833–5. 10.1515/cclm-2015-006725719329 BragaFFerraroSBorilleSPanteghiniM. Biological variation of two serum markers for preeclampsia prediction. Clin Chem Lab Med. 2020;58:e27–8. 10.1515/cclm-2019-064931377736 SchiettecatteJRusscherHAnckaertEMeesMLeeserBTirelliAS Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem. 2010;43:768–70. 10.1016/j.clinbiochem.2010.02.01020206155 HigginsVMaLRagosnigBLMelamedNHladunewichMJamesT Analytical Performance and Quality Indicators of Fully Automated Immunoassays for sFlt-1 and PlGF. J Appl Lab Med. 2022;7:555–67. 10.1093/jalm/jfab13535233636 LawLWSahotaDSWai ChanLChenMKin LauTLeungTY. Effect of long-term storage on placental growth factor and fms-like tyrosine kinase 1 measurements in samples from pregnant women. J Matern Fetal Neonatal Med. 2010;23:1475–80. 10.3109/1476705100367824220230323 ParikhCRButrymowiczIYuAChinchilliVMParkMHsuCY Urine stability studies for novel biomarkers of acute kidney injury. Am J Kidney Dis. 2014;63:567–72. 10.1053/j.ajkd.2013.09.01324200462 Hebert-SchusterMRanaweeraTFraichardCGaudet-ChardonnetATsatsarisVGuibourdencheJ Urinary sFlt-1 and PlGF levels are strongly correlated to serum sFlt-1/PlGF ratio and serum PlGF in women with preeclampsia. Pregnancy Hypertens. 2018;12:82–3. 10.1016/j.preghy.2018.03.01129674205 Martín-PalumboGAlcortaMDde AguadoMPAntolínEBarthaJL. Urinary sFlt-1 and PlGF as preeclampsia predictors: sFlt-1/creatinine ratio improves the prediction value. Eur J Obstet Gynecol Reprod Biol. 2024;298:53–60. 10.1016/j.ejogrb.2024.05.00238728842
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020701" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020701" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020701" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(107) "Urinary placental growth factor stability as a critical factor in the reliability of preeclampsia diagnosis" ["journals_article_author"]=> string(114) "Eva Martinez-Marzo, Maria Peran, Juan Lerma-Irureta, Ana Medel-Martinez, Cristina Paules, Daniel Oros, Marta Fabre" ["journals_article_author_country"]=> string(5) "Spain" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(76) "placental growth factor, preanalytical phase, preeclampsia, stability, urine" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2785" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "7" ["meta_title"]=> string(107) "Urinary placental growth factor stability as a critical factor in the reliability of preeclampsia diagnosis" ["meta_desc"]=> string(107) "Urinary placental growth factor stability as a critical factor in the reliability of preeclampsia diagnosis" ["meta_keyw"]=> string(76) "placental growth factor, preanalytical phase, preeclampsia, stability, urine" ["created"]=> string(19) "2026-04-07 10:54:10" ["modified"]=> string(19) "2026-06-11 08:44:01" } [30]=> object(stdClass)#79 (35) { ["journals_id"]=> string(4) "1249" ["journals_xml"]=> string(185528) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020505 10.11613/BM.2026.020505 Reviews Homovanillic acid and vanillylmandelic acid as neuroblastoma biomarkers in children KavalakattSina1IvicaJosko*2 Custom Biologics, Toronto, Canada McMaster University, Department of Pathology and Molecular Medicine, Hamilton, Canada Corresponding author: joskoi@mcmaster.ca

Author contributions

S Kavalakatt: Writing - review & editing, Literature review, Visualization. J Ivica: Conceptualization, Writing - review & editing, Literature review.

15062026 15062026 36 2 020505 2508202501052026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Neuroblastoma is a fatal tumor diagnosed in children

• It is characterized by high concentration of urine homovanillic and vanillylmandelic acid

• Although diagnosis is complex, early diagnosis is crucial for survival rate

• Various analytical methods have been developed, such as HPLC-ECD and LC-MS/MS

• Laboratories performing these tests should establish their own reference intervals

Neuroblastoma (NBL) is the most common pediatric tumor with the highest fatality rate. The survival rate is improved when NBL is diagnosed in children under 1 year of age, but the diagnosis is complex due to the heterogeneity of the disease. This tumor type is characterized by elevated catecholamines and their metabolites, particularly homovanillic acid (HVA) and vanillylmandelic acid (VMA). Numerous analytical methods measuring urinary HVA and VMA have been developed to support the early NBL diagnosis. However, it is difficult to establish age-related reference ranges for these tests in children. To support the diagnostic process, the aim of this review is to provide up-to-date published age-related HVA and VMA reference intervals with focus on neuroblastoma development, catecholamine metabolism and possible interferences in the analytical methods used.

Keywords: homovanillic acidneuroblastomareference intervalsvanillylmandelic acid
Introduction

Neuroblastoma (NBL) is the most common extracranial solid tumor in the pediatric population with a 5-year survival rate of 50% (1). Neuroblastoma accounts for 8% of pediatric cancer and contributes to 15% of cancer-related deaths in children. The disease has a highly diverse prognosis depending on the location of the tumor and age at diagnosis (1). If diagnosed when the child is less than a year old, the 5-year survival rate is significantly higher compared to those who were diagnosed at greater than one year of age. Early detection is possible through screening of biomarkers excreted in detectable quantities.

Neuroblastoma originates in the neural crest cells and is commonly located in the adrenal medulla or sympathetic chain. The tumor can arise anywhere from the abdomen, regional lymph nodes, bone marrow, cortex, and liver. Uncommonly, obstruction of facial and ophthalmic veins can occur due to the tumor leading to an appearance of “raccoon eyes” (2). Furthermore, disparities in risk and survival rates depend on race and ethnicity in the pediatric population (3). Genetic differences were thought to be one of the main causes for the higher prevalence of high-risk NBL in black and Native American subjects (3).

This neuroendocrine tumor is the most common catecholamine-producing tumor of the sympathetic nervous tissue (4). The major catecholamines are noradrenaline (nor-epinephrine), adrenaline (epinephrine), and dopamine, with the latter being most elevated in NBL. Most catecholamines produced by neuroblastoma cells are metabolized to vanillylmandelic acid (VMA) by hepatic alcohol dehydrogenase. Dopamine is metabolized completely to homovanillic acid (HVA). These catecholamine metabolites are excreted into urine in relatively large amounts with micromolar concentrations allowing ease of measurement (5).

The recommended criteria for diagnosis of NBL are either unequivocal pathologic diagnosis from tumor tissue with/without immunohistology, electron microscopy, increased urine or serum catecholamines or metabolites; or bone marrow aspirate biopsy containing unequivocal tumor cells and increased urine or serum catecholamines or metabolites. Homovanillic acid and VMA have served as valuable clinical biomarkers since the 1970s for diagnosing and follow up NBL (6, 7).

The combined biochemical detection of urinary HVA and VMA allows NBL diagnosis with high sensitivity (66-100%) and high specificity (> 99%) (8). In Vietnamese children, aged less than 6 months up to 15 years, sensitivity of random spot urine HVA was 88% and 82% for VMA, meaning that 12% and 18% will have falsely negative HVA and VMA, respectively, even though these children had NBL. Specificity for both random spot urine HVA and VMA was similar (98% vs. 97%), meaning that only 2% and 3% were falsely negative for HVA and VMA, respectively. Positive (LR+) and negative likelihood (LR-) ratio for a random spot urine HVA was 39.85 and 0.12, respectively, while LR+ and LR- for a random spot urine VMA was 37.1 and 0.18, respectively (9). In another study from France, the authors concluded that the specificity and sensitivity for spot urine HVA at the cut-off of 23 nmol/µmol creatinine was 99% and 82%, respectively, with the area under the curve (AUC) of 0.90. Meanwhile, the specificity and sensitivity for VMA, at the cut-off of 12 nmol/µmol creatinine, was 95% and 91%, respectively, with the AUC of 0.936. This diagnostic performance was seen in children aged less than 1 year of age. The authors also did test accuracy in children aged between 1-5 years of age. In this group, the specificity and sensitivity for HVA at the cut-off of 13 nmol/µmol creatinine was 99% and 100%, respectively, with the AUC of 1.00. For the same age group, VMA at the cut-off of 6 nmol/µmol creatinine the specificity was slightly lower at 97% with the same sensitivity and the overall AUC being 0.99. The oldest age group, 5-10 years of age, had both specificity and sensitivity for HVA at the cut-off of 19 nmol/µmol creatinine 100% with AUC of 1.00, while VMA at the cut-off of 5 nmol/µmol creatinine specificity was lower with 96% and the same sensitivity as HVA (i.e. 100%). The AUC for VMA in this age group, i.e. 5-10 years old, was 0.991 (10).

Homovanillic acid and VMA have similar characteristics making it convenient to quantitate both analytes from the same specimen. Different specimens have been used for quantification including 24-hour urine and spot urine, which always must be corrected or normalized for creatinine excretion (HVA/Cr and VMA/Cr). The standard practice requires the use of urine samples obtained from 24-hour collections to account for the effect of the circadian cycle variations in metabolite secretion. Studies have demonstrated the interchangeability between samples from 24-hour collections and single spot urine (11). The difficulty of obtaining a 24-hour collection from a young child, studies supporting that the variations in excretion of HVA and VMA during different times of the day is due to renal excretion variation, and the ease of spot urine collection increases the popularity of spot urine samples (12). The detection of NBL patients with positive HVA and/or VMA depends on the stage of the disease with abnormal concentration at later stages of the tumor (13). In this review, we have explored the published reference interval data for urinary HVA and VMA in children from birth to 19 years of age, the analytical methods used for these analytes, preanalytical considerations, and possible analytical interferences with special attention to main pathway of NBL development and catecholamine metabolism.

Neuroblastoma development and molecular pathogenesis

The cells of origin are mostly from the sympathoadrenal cells of the neural crest that differentiate into catecholamine-secreting chromaffin cells and ganglion cells (14). Several biomarkers have been assessed to enable accurate diagnosis and follow-up for NBL. Disialoganglioside (GD2) is one such well investigated surface antigen, abundantly expressed in the outer membrane of all neuroblastomas. Disialoganglioside has been suggested to be integral in the formation and maintenance of membrane microdomains in neural tissues. Histological detection of GD2 can be used to detect NBL; however, the promising utilization has been as an antigen for immunotherapy (15). The receptor tyrosine kinases, TrkA, TrkB and TrkC are neurotrophin receptors that are critical for development and maintenance of the peripheral nervous system. While elevated expression of TrkA indicates low-grade NBL to spontaneous regression or differentiation, high expression of TrkB has been correlated with high-risk NBL and low patient survival rates (16).

Elevated expression of Myelocytomatosis oncogene neuroblastoma-derived homolog gene (MycN) is integral for ventral migration and cell expansion within neural crest during normal sympathoadrenal development in murine models (Figure 1). It has been suggested that sympathoadrenal maturation happens independent of MycN expression. The sympathoadrenal precursor cells matures into neural or chromaffin cells. In absence of signals or response to signals determining neuronal and chromaffin cell fate, preneoplastic lesions in sympathoadrenal precursor cells can develop into NBL (17). Controlled apoptosis occurs in the maturation stages to circumvent effects of the excess precursor cells produced. The persistent high concentration of MycN, a master transcription factor, in the maturation phase could result in sustained proliferation and eventual development of NBL (18).

Development of neuroblastoma from neural crest cells. Neural crest cells undergo epithelial to mesenchymal transition, delaminating, migrating and differentiating to somites or towards dorsal aorta. Dorsal aorta neural crest cells start to differentiate into sympathoadrenal progenitor cells or Schwann cell progenitors, eventually giving rise to sympathetic neurons or chromaffin cells respectively. This process is regulated by complex signaling pathways. Dysregulation of factors such as MYCN, ALK, PHOX2A, LIN2B and TRX, induce changes in cell specification, migration and cell differentiation resulting in hyperneoplastic lesions resulting in neuroblastoma.

Other common genetic markers studied are the MYCN gene amplification, anaplastic lymphoma kinase (ALK) mutations, paired-like homeobox 2B (PHO2XB) loss of function, mutations, and inactivating transcriptional regulator ATRX mutations (19). An accumulation of these mutations also adds further complexity to the pathogenesis of the disease. Although numerous markers have been studied, no single marker has been able to provide an accurate diagnosis. A combination of imaging, cell surface markers, genetic analysis and measurement of secreted catecholamine metabolites are used for diagnosis and monitoring of NBL treatments in patients.

Vanillylmandelic and homovanillic acid metabolism and secretion

Neuroblastoma is characterized by the synthesis, metabolism, and secretion of catecholamines and related metabolites - HVA and VMA. The pathways involved in biosynthesis, metabolism, storage, and secretion of these biomarkers highlight their diagnostic value.

The biosynthesis of catecholamines starts with the conversion of tyrosine, by tyrosine hydroxylase to 3,4-dihydroxyphenylalanine (DOPA). Aromatic- L-amino acid decarboxylase converts DOPA to dopamine, which is then transported into storage granules by vesicular monoamine transporters. Dopamine is further converted to norepinephrine by dopamine β-hydroxylase, an enzyme exclusively present in the storage granules. Norepinephrine is converted to epinephrine depending on the presence of phenylethanolamine N-methyltransferase (PNMT) in the adrenal chromaffin cells (20). This enzyme is present in the cytosol; hence this conversion depends on the transfer of norepinephrine from the storage granules to the cytoplasm. Epinephrine is then translocated back into the storage granule and actively secreted as a hormone.

The secretion of catecholamines is initiated by exocytotic secretion of the vesicular stores into the surrounding extracellular space. The secretion of norepinephrine from sympathetic neurons occurs locally and neuronal uptake takes place releasing only a small proportion into the bloodstream (20). 3,4-dihydroxyphenylglycol (DHPG) is converted by monoamine oxidase (MAO) from norepinephrine. Further metabolism of DHPG is performed by catechol-O-methyltransferase (COMT) to 3-methoxy-4-hydroxyphenylglycol (MHPG) and most MHPG is converted to VMA in the liver by alcohol dehydrogenase (21). Dopamine is metabolized to HVA by the combined actions of COMT and MAO. The pathways are detailed in Figure 2. LaBrosse et al. showed that neuroblastomas lacked catecholamine storage vesicles, a characteristic of mature chromaffin cells (22). As these tumors do not generally present with hypertension or with varied urinary catecholamine metabolites, hence measurement of catecholamine metabolites particularly HVA and VMA have been used for diagnosis.

Catecholamine metabolism and secretion. Initial biosynthesis of dopamine, norepinephrine and epinephrine occur in chromaffin cells of the adrenal medulla. Catecholamines are synthesized from tyrosine derived from the food consumed or phenylalanine in the liver. Tyrosine conversion to dihydroxyphenylalanine (DOPA) is catalyzed by tyrosine hydroxylase. Enzyme DOPA decarboxylase converts DOPA to dopamine. Dopamine is converted to noradrenaline by hydroxylation of the dopamine side chain catalyzed by dopamine-β-hydroxylase. Noradrenaline is converted to adrenaline by phenylethanolamine N-methyltransferase (PNMT). 90% of the catecholamines are taken up by the nerve endings after which it is utilized or deaminated by monoamine oxidase (MAO). Monoamine oxidase and catechol-O-methyltransferase (COMT) are responsible for converting dopamine and norepinephrine/epinephrine to homovanillic acid (HVA) and vanillylmandelic acid (VMA). The main metabolic pathways take place in different compartments followed by entry into the bloodstream, clearance and metabolism by kidneys for elimination in urine.

Sample pretreatment and preanalytical considerations

In individuals without NBL, activation of the sympathetic nervous system is a factor responsible for higher concentrations of catecholamine metabolites. Other confounding factors including acute illness, diet, exercise, medication, patient posture during sampling, accuracy of sampling time and sample stability have been shown to influence catecholamine and related metabolite concentrations (23).

Effect of diet and exercise

Ingestion of dopamine rich foods such as bananas, pineapples, nuts, beans and tomatoes have been suggested to impact the concentrations of catecholamine and their metabolites in urine samples (24). The enzymatic activity of sulphotransferase enzyme (SULT1A3), is known to influence the impact of dietary catecholamines in urine. Sulphotransferase found in the gastrointestinal tract, liver, platelets and nervous tissue, rapidly sulfates dietary catecholamines before systemic absorption. A reduced or variable SULT1A3 activity can result in increased circulating catecholamines thereby increasing the risk of false positive results in urinary catecholamine as well as HVA/VMA testing. Hence, although avoiding catecholamine rich food is recommended, an overnight fast can be a solution to circumvent the dietary effects.

Increased HVA/VMA secretion has been studied in cases of acute illness; hence such an episode requires documentation and confirmation from the patient. Supine position of the patient has been shown to significantly reduce catecholamine secretion and consequently urinary HVA and VMA concentration in comparison to sample collection in seated position (25). Physical activity has been correlated to increased HVA/VMA concentrations; hence it has been recommended to avoid intense exercise before sample collection. Another confounding factor for high concentration of metanephrine metabolites, i.e. HVA and VMA, is renal failure. Pamporaki et al. have reported a 50% increase in metanephrine metabolites in patients requiring dialysis (26).

Effect of medication

A common interfering factor in test interpretation is the interference of various medications in the analytical method used and pharmacological effects. While paracetamol and sulfasalazine have been reported to interfere with high-performance liquid chromatography coupled with electrochemical detection (HPLC-ECD), 3-O-methyldopa and midodrine interfere with liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods. Various medications have been implicated in false results and are summarized in Table 1.

Medication interference and type of effects
Medications(reference) Type of effect Impact
Atypical antipsychotics (Quetiapine, clozapine, risperidone) (27) Pharmacophysiological Clozapine and Quetiapine block α2-adrenoreceptors and Risperidone blocks D2 and serotonin 5-HT2A receptors; altering dopamine pathways and increasing VMA secretion
Monoamine oxidase inhibitors (28) Pharmacophysiological Inhibits oxidative deamination of catecholamines impairing HVA and VMA metabolism
α-adrenoreceptor blockers (doxazosin) (29) Pharmacophysiological α- adrenoreceptor antagonism; possible norepinephrine increase
Phenoxybenzamine (30) Pharmacophysiological α- adrenoreceptor antagonism; Increases norepinephrine/ normetanephrine concentration
Tricyclic antidepressants (Venlafaxine) (30) Pharmacophysiological Increases norepinephrine/ normetanephrine concentration; reduced norepinephrine neuronal uptake
3-O-methydopa (23) LC-MS/MS Interferes with L-dopa and dopamine metabolic pathway; decreases HVA and VMA concentration
Paracetamol (31) Analytical interference Interferes with oxidation/ colorimetric reactions in HPLC-ECD measurements
Amoxicillin (32) Analytical interference Co-elutes with urinary normetanephrine resulting in false positive HPLC-ECD results
Sulfasalazine (33) Analytical interference Interferes with current affecting accurate HPLC-ECD measurements
Labetalol (30) Analytical interference Labetalol metabolites could produce false signals leading to spurious elevation of HVA/VMA concentrations in HPLC-ECD
VMA - vanillylmandelic acid. HVA- homovanillic acid. HPLC-ECD - high performance liquid chromatography coupled with electrochemical detection. LC-MS/MS - liquid chromatography tandem mass spectrometry.

Significantly elevated concentration of metanephrine metabolites have been reported due to pharmacological interferences. Medications such as tricyclic antidepressants and serotonin and norepinephrine reuptake inhibitors that reduce catecholamine uptake result in significantly increased VMA via increasing normetanephrine concentration. β- Blockers such as propranolol and atenolol have been suggested to be correlated with increased false positive results (34). Sympathomimetics and Parkinson’s medication L-Dopa may falsely increase HVA and VMA through stimulation of catecholamine production and consequently increased production of their end products i.e. HVA and VMA. On the other hand, monoamine oxidase inhibitors can cause decreased concentration of both HVA and VMA through inhibition of MAO, which in turn inhibits production of their precursors – catecholamines (23).

It is of prime importance that clinicians are aware of these interferences to avoid potential misdiagnosis of patients and suggest further testing in case of possible false positives.

Sample collection and patient preparation

Twenty-four-hour urine or random urine, normalized by urine creatinine, collections are usually used for HVA/VMA measurement. However, the recommended specimen is 24-hour urine since NBL may not secrete the hormone (epinephrine and norepinephrine for VMA and dopamine for HVA) metabolites constantly over a day. The impact of diet and medications on HVA/VMA concentrations should be communicated to the patient. The patients should avoid intake of food that stimulates catecholamines synthesis and consequently HVA and/or VMA production, such as coffee, tea, especially green tea, bananas, citrus fruits, phenylethylamine from dark chocolate, cocoa and vanilla. It is also important that samples are collected under conditions of minimal physiological or emotional stress. The impact of acute illness and stressful situations on increased metanephrine and consequently increased VMA concentrations have been well studied (35). The reliability of the test is dependent on the timing of sample collection; hence the patient should ensure that all urine is collected in the 24-hour time frame. However, NBL is a pediatric cancer, and it is sometimes difficult to collect preferred specimens so for that reason clinical laboratories tend to accept random spot urine specimens. The quality of the urine collection can be improved by issuing clear instructions to clinicians and the patient prior to the collection.

Improved diagnostic performance was observed in urine samples collected at night due to the possible circadian effect resulting in lower excretion of catecholamines and consequently their end-products i.e. HVA and VMA (36).

Analyte stability

Both HVA and VMA were assessed for their stability in the refrigerated conditions (between 2-8 °C) and pH between 1 and 4 with 6M HCl, 6M HNO3, or 50% acetic acid (37). The authors found that both analytes were stable for up to 7 days in these conditions (38). In another study, the authors performed the percent recoveries to assess the stability of HVA and VMA in native, acidified with HCl and citrate urines and found that both analytes were stable for up to 4 weeks at the ambient temperature, + 4 ºC, and - 20 ºC degrees (39). Another study, done on filter paper, assessed the stability of urinary HVA and VMA and concluded that both analytes were stable for up to 2 years frozen and refrigerated. On the other hand, both analytes were only stable for up to 3 weeks at room temperature (40).

Analytical testing methods

The quantification of HVA and VMA has been performed using thin – layer chromatography (TLC), HPLC-ECD or coupled with fluorescence detection (FLD), gas chromatography-mass spectrometry (GC-MS), gas chromatography-flame ionization detector (GC-FID), enzyme immunoassay (EIA) and LC-MS/MS. Measurements have evolved over the past several decades with each methodology having advantages and disadvantages.

Thin – layer chromatography

Historically, TLC was used to test for urinary HVA and VMA in confirmed cases of NBL. Takada et al. used TLC in ten Japanese children with established diagnosis of NBL, where both HVA and VMA were increased, and decreased after the cancer was either removed surgically or after chemotherapy treatment (41). In a paper by Takeda et al. the TLC method was also used for mass screening of neuroblastoma in Japanese children from 1981 until 1984 (42). Thin – layer chromatography was also used in investigation of circadian rhythms of HVA and VMA urinary excretion in healthy and depressed study participants (43).

High-performance liquid chromatography

High-performance liquid chromatography coupled with ECD is the most commonly used technique for quantification of biogenic amines, not only HVA and VMA. Most amines are prone to oxidation with inherent fluorescence properties. Extensive sample preparation and a long time are required, although the design is straightforward enabling development and improvement of the method. In that regard, in the corresponding author’s laboratory urinary HVA and VMA were measured on HPLC-ECD. The method was extremely laborious with using solid phase extraction, using separate columns and mobile phases and was time consuming. Many published articles validated the analysis of not only HVA and/or VMA but also a few other tumor markers on HPLC-ECD (44-46). High-performance liquid chromatography coupled with FLD was also used in several publications, either to compare to a newer LC-MS/MS method, or to assess urine HVA and VMA, simultaneously with 5-hydroxyindoleacetic acid (5-HIAA) and 3, 4-dihydroxyphenylacetic acid (DOPAC) by HPLC-FLD (47, 48).

Gas chromatography

Owing to high identification, sensitivity, and separation power, GC-MS is an integral tool in clinical chemistry. Before the invention of mass spectrometry and its application with GC, GC-FID was used to measure various catecholamine metabolites (49). Lavreri et al. used GC-FID to confirm the analytical interference of the over-the-counter analgesic, antipyretic and anti-inflammatory medication ibuprofen. They determined that the ibuprofen metabolite, hydroxy-ibuprofen, interfered with urinary VMA (50). Beals et al. published a robust protocol for GC-MS method for simultaneous measurement of HVA and VMA (51). The Austrian neuroblastoma program developed the secondary stable isotope dilution GC-MS for HVA and VMA to help reduce unnecessary retesting of the primary HPLC method. Implementation of the GC-MS method reduced retesting from 11% (HPLC alone) to approximately 5% (52). In Vietnamese children, urinary HVA and VMA reference intervals (RI) were established by GC-MS. The authors optimized and validated a classic GC-MS method with derivatization (9). It has been used in the quantification of several amines including HVA and VMA. Although this technique allows the profiling of related compounds simultaneously, most analytes require extensive derivatization to become amenable to ionization. Consequent to low practicality, GC-MS application has been limited to only certain specialized endocrinology laboratories (24).

Enzyme immunoassay

Enzyme immunoassay is based on the competitive reaction between catecholamine metabolites and corresponding monoclonal antibodies, labelled by HVA or VMA. Immunoassays enable full automation, high throughput and limited operator technical expertise. Thus, Yokomori et al. developed a mass screening of NBL in young Japanese infants. In their paper, they used two different monoclonal antibodies for HVA and VMA. The EIA measurement correlated well with the HPLC HVA and VMA measurement, providing the possibility of automation (53). Other countries that used EIA for HVA and VMA for the NBL screening were Austria and the state of Texas in the USA (54, 55). In another study, a competitive EIA for urinary VMA was produced, where polyclonal antibody against VMA with a VMA-acetylcholinesterase labelled conjugate. Again, the EIA correlated well with HPLC method (56). Although immunoassays have the highest analytical sensitivity of all quantitation techniques, there are several limitations including specificity, accuracy, cross-reactivity and interference with other compounds. Further, different assays are required to assess related compounds. The high cost involved in developing the assay in-house limits the dependency on the diagnostic industry (57).

Liquid chromatography-tandem mass spectrometry

Liquid chromatography-tandem mass spectrometry is a combination of separation capabilities of HPLC with high sensitivity, specificity and accuracy of mass spectrometric detection. It is the method of choice in several pharmaceutical and related industries for measurement of drugs. It is used to assess a wide range of compounds such as biogenic amines, steroids, thyroid hormones, thyroglobulin and vitamin D (58). Stable isotopes of analytes are used as internal controls to correct losses with sample pre-treatment, analyte separation and detection. Recently, LC-MS/MS has been replacing HPLC, GC-MS and immunoassay due to improved specificity, less runtimes and less intensive sample preparation. A difficulty with this technique is compound specific matrix effects (59). LC-MS/MS has been a method of choice since many clinical laboratories started acquiring this powerful but quite costly instrumentation. One article describes application of automation using solid liquid extraction for urinary HVA and VMA (59). Yu et al. described a development of a candidate reference measurement procedure for urinary HVA and VMA using the isotope dilution (ID) ID-LC-MS/MS (60). Many others developed and optimized an LC-MS/MS method in their laboratories, where this method replaced the older HPLC-ED method (61-63). Some other published methods also included 5-hydroxyindoleacetic acid (5-HIAA) to HVA and VMA (64, 65). Another method by Xie et al. included urinary fractionated catecholamines (epinephrine, norepinephrine, dopamine), fractionated metanephrines (metanephrine, normetanephrine, 3-methoxythyramine), serotonin, 5-HIAA as well as HVA and VMA (66).

Reference intervals

Reference intervals are considered as a benchmark to compare individual patient test results and therefore play a central role in evaluation of laboratory results. Reliable and accurate RI are critical for accurate interpretation of laboratory results. Reference intervals should be established using a large number of samples from healthy volunteers tiered for covariates including age, gender and ethnicity. Homovanillic acid and VMA excretion is known to increase with age while creatinine excretion increases with muscle mass. Hence, it is critical to correct both analytes’ values for creatinine excretion. No differences have been reported in HVA and VMA concentration in relation to gender. Hence, age-related reference intervals and decision limits must take into account these variations. It is recommended that each laboratory maintain local RI related to the observed population (67). For the adult population, it is relatively easier to collect blood or urine samples. This approach, however, is difficult in the pediatric population due to limitations in obtaining samples from healthy participants. An alternative is to utilize a large number of laboratory results and analyze them with specific statistical methods (68).

Diagnosis of catecholamine producing pediatric tumors has been historically assessed in urine, hence RI for this matrix is most studied. Although 24-hour collection of urine is preferred, this becomes difficult for children. Hence, spot urine collection is preferred with correction using excreted creatinine concentrations. This, however, introduces a new variable as creatinine output varies with diet, exercise and muscle mass (69). Data from published studies are compiled into Table 2 and 3 depending on units of reference ranges, as shown below. The reference ranges vary based on the analytical testing method used, population size and selection method.

Reference ranges for HVA and VMA in mmol/mol creatinine
Reference and method used Sample size (N) Age group HVA(mmol/mol Cr) VMA (mmol/mol Cr)
926 All < 13.97 < 7.82
Barco, 2014 (68)HPLC-ECD All < 18 months < 16.46 < 11.48
All > 18 months < 9.87 < 5.54
*Healthy = 314;With suspected NET = 36 < 1 yr < 20.27
1 yr < 17.7
Tohmola, 2015 (70)LC-MS/MS 2-4 yrs < 9.48
5-9 yrs < 8.68
10-15 yrs < 6.74
1658 Under 1 yr < 23.1 < 12.9
1 or 2 yrs < 18 < 12.3
3 or 4 yrs < 12 < 8.9
Davidson, 2011 (71)HPLC-ECD 5 to 7 yrs < 10.5 < 7.9
8 to 10 yrs < 9.8 < 5
11 to 13 yrs < 5.9 < 5.6
14 to 19 yrs < 5.0 < 5.5
367 <1 yrs < 16.8 < 13
Kellie, 1986 (72)HVA: on-column gas chromatography 1-5 yrs < 13.8 < 7.7
VMA: Method by Pisano et al. extraction and spectrophotometric determination 5-10 yrs < 11 < 5.3
10-15 yrs < 7 > 4.1
12 < 3 months < 21.7
28 3 - 12 months < 27.9
Tuchman, 1985 (73)capillary GC 15 1 - 2 yrs < 19.7
22 2 - 5 yrs < 19.9
21 5 - 10 yrs < 14.7
13 10 - 15 yrs < 8.4
10 0 - 1 months < 17.6
12 1 - 4 months < 13.2
Ito, 1985 (74)HPLC 10 4 - 7 months < 8.3
10 7 - 10 months < 5
9 10 - 16 months < 3.4
35 3-6 months < 9.63 < 6.17
Premel- cabic, 1986 (75)HPLC 17 6-10 months < 7.14 < 4.28
24 10 - 16 months < 6.4 < 5.02
181 for HVA163 for VMA <1 months (N=38) < 16.8 < 13
1-5 months (N=67) < 13.8 < 7.7
Kellie, 1986 (72)GC and spectrophotometry 5-10 months (N=45) < 11 < 5.3
10-15 months (N=31) < 7 < 4.1
140 ≤ 14 months <1 months to 26
2 months to 18
Henderson, 1992 (76)capillary GC 4 months to 15
6 months to 14.5
10 months to 14
14 months to 12
Mathieu, 1996 (77)HPLC-ECD 105,293 4 months - 1 yr < 20.56 < 13.82
Craft, 1989 (78)GC with flame ionization detection and GC-MS 1st phase: 95 6 months < 25.15 < 16.27
2nd phase: 2304 6 months < 24.22 < 14.28
Parker, 1992 (79)GC and Flame ionization detection 20,829 6 months < 24 < 15
Cole,1995 (80)GC-MS 10,000 6 months < 24.2 < 14.7
33 0 - 12 m < 23.99 < 13.67
44 1 yrs < 23.18 < 14.5
Shen, 2019 (81)LC-MS/MS 125 2 - 4 yrs < 45.42 < 10.58
339 5 - 9 yrs < 43.13 < 7.61
195 10 - 14 yrs < 21.16 < 6
39 15 - 18 yrs < 16.18 < 5.99
57 <1 yrs < 25
43 1<3 yrs < 15
Fitzbibbon, 1992 (82)HPLC-ECD 46 >3<5 yrs < 15
45 >5<8 yrs < 14
41 >8<11 yrs < 10
51 >11-14 yrs < 5
Cr – creatinine. VMA – vanillylmandelic acid. HVA- homovanillic acid. HPLC-ECD - high performance liquid chromatography coupled with electrochemical detection. LC-MS/MS – liquid chromatography tandem mass spectrometry. HPLC - high performance liquid chromatography. GC-Gas chromatography. LC-Liquid chromatography. MS-mass spectrometry. m-month. yrs-years. *The authors did not differentiate between healthy individuals and suspected NET, with regards to total N (sample population). 1st phase indicates “pilot study” and 2nd phase indicates “clinical trial”.
Reference ranges for HVA and VMA in µmol/24 hours
Reference and method used Sample Size (N) Age group HVA(µmol/24 hrs) VMA(µmol/24 hrs)
35 3-6 months < 23.607 < 13.12
Premel- Cabic, 1986 (75)HPLC 17 6-10 months < 25.803 < 16.15
24 10-16 months < 47.763 < 26.24
De Schaepdryver, 1978 (83)HPLC 17 0-6 months < 4.94 /
Nishi, 1986 (84)HPLC 24 6-11 months < 12.41 < 8.78
VMA - vanillylmandelic acid. HVA- homovanillic acid. HPLC - high performance liquid chromatography.
Laboratory interpretation and follow-up

Potential impact of analytical and preanalytical interferences needs to be considered by clinicians and laboratories providing the tests, for appropriate interpretation of results. Accurate interpretation depends on patient presentation, symptoms and medical history, while also depending on the patient’s population and background. Patients being tested due to non-specific symptoms such as hypertension, sweating and headache could arise from other conditions like primary hypertension and migraine. In this patient group, while specificity and positive predictive value are limited, the diagnostic sensitivity and negative predictive value are relatively high (85). Measurement of O-methylated catecholamine metabolites can provide insights into location, size, type of disease mutation and aggressiveness of the disease, by assessing the patterns of increase of these metabolites above the reference intervals (86). Neuroblastoma can be ruled in or out depending on repeated measurements of VMA/HVA concentration along with clinical findings, abdominal mass symptoms and magnetic resonance imaging (MRI) findings to decide if a biopsy is necessary (10). However, a small percentage of NBL tumors are non-secretory, hence, repeated measurements will not increase detection rate in these cases (87).

Catecholamines and metabolites are not helpful in detection of relapse for patients who have previously been treated for NBL. In these cases, local recurrence or progression of the disease was established by ultrasound, computed tomography or magnetic resonance imaging (88).

Future perspectives

There is large variation in reporting of test results from different laboratories. This variability could arise from several factors including sample collection, inadequate sample sizes, age groups of the population and the statistical methods used. Recent studies use graphical representation of data identifying outliers and complementing statistical analysis. Although quantifying urine HVA and VMA aids in diagnosis and follow up of NBL, these tests are not 100% specific or sensitive. This could also signify that neuroblastoma is a heterogeneous disease.

Early detection of NBL may provide improved survival chances. This premise led to several mass-screening programs; however, the results have not been promising. Although the screening led to increased cases of diagnosis, a decrease in mortality rates was not observed. This could be due to the high tendency of spontaneous regression or due to difficulty in the screening system used (88). The difference in pattern of neuroblastoma growth also arises from the stage of the disease and hence factors such as analytical system used, age of the population and repeated sampling should be considered (89). While HVA and VMA are the foundational biochemical markers for diagnosis and risk stratification of NBL, their prognostic utility is limited by heterogeneity and variable secretion across tumor subtypes. This underscores the need for complementary biomarkers that capture tumor burden, metabolic programming, oxidative stress and microenvironmental interactions (19, 90).

The predictive power and detection accuracy of HVA and VMA could be substantially improved through combination with emerging metabolites such as vanillactic acid (VLA), 3-methoxytyramine sulfate (MTS), lactate dehydrogenase (LDH) neuron-specific enolase (NSE), and CA125 (90). Serum LDH and NSE reflect proliferative activity and neuroendocrine differentiation (91, 92). Further, CA125 has emerged as a potential indicator of tumor-host interactions in high risk NBL (93, 94). Alterations in lipid metabolism, including dysregulated very-long-chain fatty acids (VLCFA) profiles, are increasingly recognized as hallmarks of pediatric tumors offering novel prognostic insights when combined with catecholamine metabolism (94). High LDH values positively correlated with a worse prognosis (95).

Future efforts should prioritize multivariate modeling approaches - including machine-learning-based composite scores - to validate multi-marker panels that outperform single-analyte testing for risk stratification, early relapse detection, and response assessment. Prospective multicenter validation and integration with clinical and molecular risk factors will be essential to enable clinical translation of these combined metabolite signatures into precision-based NBL care (89, 96).

Variability can be reduced through improved assays, increased standardization of sample preparation, methods and values, using harmonized reference intervals and establishing local reference ranges with appropriate healthy age groups. Use of age-adjusted reference intervals could circumvent variability arising from differences in age of population groups. The reference ranges should be established according to the International Federation of Clinical Chemistry (IFCC) recommendations. Although the incidence of NBL is very low, mass screening of infants for the disease should be established at different time intervals to enable improved prognosis.

In conclusion, NBL remains a clinically heterogenous pediatric malignancy in which early detection is critical to improving outcomes. Urinary catecholamine metabolites, HVA and VMA, play central role in the biochemical evaluation of this disease. The high specificity and sensitivity across age groups make them valuable biomarkers for diagnosis and monitoring NBL.

This review highlights that accurate interpretation of HVA and VMA is dependent on age-specific reference intervals, normalization to creatinine and consideration of pre-analytical variables such as specimen type, collection method and sample stability. While 24-hour urine collections have traditionally been recommended, increasing evidence supports the clinical utility and practicality of spot urine samples in pediatric populations.

Advances in analytical methodologies have further improved the reliability and precision of HVA and VMA measurements, especially LC-MS/MS, which is virtually free of analytical interferences. Overall, integrating robust analytical practices with clinically appropriate interpretation of urinary HVA and VMA supports their use as key biomarkers in the management of NBL.

Acknowledgements

We thank Meriam Smadi for her help in data organization and literature review. We also thank McMaster University for their help throughout the study.

Potential conflict of interest

None declared.

Data availability statement

No data was generated since this is a literature review manuscript.

References DuBoisSGMacyMEHendersonTO. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book. 2022;42:1–13. 10.1200/EDBK_34978335522915 PollardZFGreenbergMFBordencaMLangeJ. Atypical acquired pediatric Horner syndrome. Arch Ophthalmol. 2010;128:937–40. 10.1001/archophthalmol.2010.11920625060 HendersonTOBhatiaSPintoNLondonWBMcGradyPCrottyC Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children’s Oncology Group study. J Clin Oncol. 2011;29:76–82. 10.1200/JCO.2010.29.610321098321 FitzgibbonMCTormeyWP. Paediatric reference ranges for urinary catecholamines/metabolites and their relevance in neuroblastoma diagnosis. Ann Clin Biochem. 1994;31:1–11. 10.1177/0004563294031001018154845 LaBrosseEH. Catecholamine metabolism in neuroblastoma: kinetics of conversion of 3H-3-methoxy-4-hydroxyphenylglycol to 3H-3-methoxy-4-hydroxymandelic acid. J Clin Endocrinol Metab. 1970;30:580–9. 10.1210/jcem-30-5-5804910525 BrodeurGMPritchardJBertholdFCarlsenNLCastelVCastelberryRP Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77. 10.1200/JCO.1993.11.8.14668336186 PritchardJBarnesJGermondSHartmanOde KrakerJLewisI Stage and urinary catecholamine metabolite excretion in neuroblastoma. European Neuroblastoma Study Group. Lancet. 1989;2:514–5. 10.1016/S0140-6736(89)92135-12570230 HwangNChongEOhHChoHWLeeJWSungKW Application of an LC-MS/MS Method for the Simultaneous Quantification of Homovanillic Acid and Vanillylmandelic Acid for the Diagnosis and Follow-Up of Neuroblastoma in 357 Patients. Molecules. 2021;26:3470. 10.3390/molecules2611347034200415 TranMTBaglinJTranTTHoangKTPhungLTReadA Development of a new biochemical test to diagnose and monitor neuroblastoma in Vietnam: homovanillic and vanillylmandelic acid by gas chromatography-mass spectrometry. Clin Biochem. 2014;47:206–15. 10.1016/j.clinbiochem.2013.11.01624296288 MonsaingeonMPerelYSimonnetGCorcuffJB. Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma. Eur J Pediatr. 2003;162:397–402. 10.1007/s00431-003-1175-112684897 GregianinLJMcGillACPinheiroCMBrunettoAL. Vanilmandelic acid and homovanillic acid levels in patients with neural crest tumor: 24-hour urine collection versus random sample. Pediatr Hematol Oncol. 1997;14:259–65. 10.3109/088800197090094959185210 CangemiGBarcoSReggiardoGViscardiEDi CataldoAGaraventaA Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma. Pediatr Blood Cancer. 2013;60:E170–2. 10.1002/pbc.2467123813598 StrengerVKerblRDornbuschHJLadensteinRAmbrosPFAmbrosIM Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer. 2007;48:504–9. 10.1002/pbc.2088816732582 L’AbbateAMacchiaGD’AddabboPLonoceATolomeoDTrombettaD Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer. Nucleic Acids Res. 2014;42:9131–45. 10.1093/nar/gku59025034695 YuALGilmanALOzkaynakMFLondonWBKreissmanSGChenHX Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34. 10.1056/NEJMoa091112320879881 NakagawaraAArima-NakagawaraMScavardaNJAzarCGCantorABBrodeurGM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993;328:847–54. 10.1056/NEJM1993032532812058441429 MarshallGMCarterDRCheungBBLiuTMateosMKMeyerowitzJG The prenatal origins of cancer. Nat Rev Cancer. 2014;14:277–89. 10.1038/nrc367924599217 RickmanDSSchulteJHEilersM. The Expanding World of N-MYC-Driven Tumors. Cancer Discov. 2018;8:150–63. 10.1158/2159-8290.CD-17-027329358508 MarisJM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–11. 10.1056/NEJMra080457720558371 EisenhoferGKopinIJGoldsteinDS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56:331–49. 10.1124/pr.56.3.115317907 EisenhoferGAnemanAHooperDRundqvistBFribergP. Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. J Neurochem. 1996;66:1565–73. 10.1046/j.1471-4159.1996.66041565.x8627312 LaBrosseEHComoyEBohuonCZuckerJMSchweisguthO. Catecholamine metabolism in neuroblastoma. J Natl Cancer Inst. 1976;57:633–8. 10.1093/jnci/57.3.63310450 BootCS. A Laboratory Medicine Perspective on the Investigation of Phaeochromocytoma and Paraganglioma. Diagnostics (Basel). 2023;13:2940. 10.3390/diagnostics1318294037761307 de JongWHPostWJKerstensMNde VriesEGKemaIP. Elevated urinary free and deconjugated catecholamines after consumption of a catecholamine-rich diet. J Clin Endocrinol Metab. 2010;95:2851–5. 10.1210/jc.2009-258920382681 DärrRPamporakiCPeitzschMMiehleKPrejbiszAPeczkowskaM Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf). 2014;80:478–86. 10.1111/cen.1232724102244 PamporakiCPrejbiszAMałeckiRPistroschFPeitzschMBishoffS Optimized Reference Intervals for Plasma Free Metanephrines in Patients With CKD. Am J Kidney Dis. 2018;72:907–9. 10.1053/j.ajkd.2018.06.01830146420 BortolozziAMasanaMDíaz-MataixLCortésRScorzaMCGingrichJA Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors. Int J Neuropsychopharmacol. 2010;13:1299–314. 10.1017/S146114571000009X20158933 OstadkarampourMPutninsEE. Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action. Front Pharmacol. 2021;12:676239. 10.3389/fphar.2021.67623933995107 RichardsonCSAtassiDKhanABernardiniAShahPP. Doxazosin for the treatment of mental health disorders: A scoping review. PLOS Ment Health. 2025;2:e0000494. 10.1371/journal.pmen.000049441662109 LendersJWDuhQYEisenhoferGGimenez-RoqueploAPGrebeSKMuradMH Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42. 10.1210/jc.2014-149824893135 DavidsonFD. Paracetamol-associated interference in an HPLC-ECD assay for urinary free metadrenalines and catecholamines. Ann Clin Biochem. 2004;41:316–20. 10.1258/000456304120162615298744 BarcoSAlpigianiMGGhiggeriGMTalioMMaffiaATripodiG Amoxicillin-associated interference in an HPLC-EC assay for urinary fractionated metanephrines: potential pitfall in pheochromocytoma biochemical diagnosis. Clin Biochem. 2014;47:119–21. 10.1016/j.clinbiochem.2014.07.00925038424 ZulingETDebonoMRabEBalasubramanianS. Sulfasalazine as a cause of false-positive elevation of urinary normetanephrine in patients with adrenal mass and suspected phaeochromocytoma: a diagnostic challenge. BMJ Case Rep. 2023;16:e253597. 10.1136/bcr-2022-25359737730424 EisenhoferGGoldsteinDSWaltherMMFribergPLendersJWKeiserHR Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003;88:2656–66. 10.1210/jc.2002-03000512788870 KlineGABoydJSadrzadehHSMLeungAA. Inpatient Measurements of Urine Metanephrines are Indistinguishable from Pheochromocytoma: Retrospective Cohort Study. Am J Med. 2021;134:1039–46.e3. 10.1016/j.amjmed.2021.03.01533864763 KawanoYKawasakiTKawazoeNAbeIUezonoKUenoM Circadian variations of urinary dopamine, norepinephrine, epinephrine and sodium in normotensive and hypertensive subjects. Nephron. 1990;55:277–82. 10.1159/0001859752370928 Urine Preservatives - Collection and Transportation for 24-Hour Urine Specimens. Available from: https://www.mayocliniclabs.com/-/media/it-mmfiles/Special-Instructions/9/6/7/Urine_Preservatives-Collection_and_Transportation_for_24-Hour_Urine_Specimens. Accessed 30th August, 2025. JuniorLFPauloBFZauliDA. A-103 Stability Study of the Biogenic Amines 5-Hydroxyindoleacetic Acid (5-HIAA), Vanillylmandelic Acid (VMA), and Homovanillic Acid (HVA) in Acidified Vs Non-acidified Human Urine Samples. Clin Chem. 2023;69(Supplement 1):hvad097.094. 10.1093/clinchem/hvad097.094 EugsterPJCentenoCDunandMSeghezziCGrouzmannE. Stabilization of urinary biogenic amines measured in clinical chemistry laboratories. Clin Chim Acta. 2021;514:24–8. 10.1016/j.cca.2020.12.00933333038 CyrDGiguèreRTuchmanMLemieuxB. Stability of urinary HVA and VMA on filter paper. Early Hum Dev. 1997;49:149–52. 10.1016/S0378-3782(97)01886-09226122 Takada H, Inui A, Imashuku S, Sawada T, Nakamura T. A Serial and Simultaneous Determination of Urinary VMA and HVA in Ten Cases of Neuroblastoma. Proceedings of the Symposium on Chemical Physiology and Pathology. 1972;11:188-93. TakedaTHataeYNakadateNHatayamaY. Change in Diagnostic Methods for Massscreening of Neuroblastoma. Japanese Journal of National Medical Services. 1987;41:420–4. RiedererPBirkmayerWNeumayerEAmbroziLLinauerW. The daily rhythm of HVA, VMA, (VA) and 5-HIAA in depression-syndrome. J Neural Transm. 1974;35:23–45. 10.1007/BF012453334824677 ManickumT. Simultaneous analysis of neuroendocrine tumor markers by HPLC-electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:4140–6. 10.1016/j.jchromb.2009.09.04119926540 Němečková-MakrlíkováABarekJNavrátilTFischerJVyskočilVDejmkováH. Simultaneous determination of tumour biomarkers homovanillic acid, vanillylmandelic acid, and 5-hydroxyindole-3-acetic acid in human urine using single run HPLC with a simple wall-jet glassy carbon electrochemical detector. J Electroanal Chem (Lausanne). 2020;878:114629. 10.1016/j.jelechem.2020.114629 CaoGMHoshinoT. Simultaneous determination of 3,4-dihydroxymandelic acid, 4-hydroxy-3-methoxymandelic acid, 3,4-dihydroxyphenylglycol, 4-hydroxy-3-methoxyphenylglycol, and their precursors, in human urine by HPLC with electrochemical detection. Chromatographia. 1998;47:396–400. 10.1007/BF02466470 MatserYAHVerlyIRNvan der HamMde Sain-van der VeldenMGMVerhoeven-DuifNMAshS Optimising urinary catecholamine metabolite diagnostics for neuroblastoma. Pediatr Blood Cancer. 2023;70:e30289. 10.1002/pbc.3028937010353 JiangKWuHQinWGuGYuS. Determination of four biogenic amine metabolites in urine by high-performance liquid chromatography. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2014;32:140–2. [In Chinese]24630022 WadmanSKKettingDVoûtePA. Gas chromatographic determination of urinary vanilglycolic acid, vanilglycol, vanilacetic acid and vanillactic acid-chemical parameters for the diagnosis of neurogenic tumours and the evaluation of their treatment. Clin Chim Acta. 1976;72:49–68. 10.1016/0009-8981(76)90036-X184988 LevreriICarusoUDeianaFBuoncompagniADe BernardiBMarcheseN The secretion of ibuprofen metabolites interferes with the capillary chromatography of urinary homovanillic acid and 4-hydroxy-3-methoxymandelic acid in neuroblastoma diagnosis. Clin Chem Lab Med. 2005;43:173–7. 10.1515/CCLM.2005.02915843212 Beals M, Ramoo B, Clinton Frazee C, Garg U. Quantitation of Neuroblastoma Markers Homovanillic Acid (HVA) and Vanillylmandelic Acid (VMA) in Urine by Gas Chromatography–Mass Spectrometry (GC/MS). In: Garg U, (ed.). Clinical Applications of Mass Spectrometry in Biomolecular Analysis. Methods in Molecular Biology. New York: Humana; 2022. vol 2546. 10.1007/978-1-0716-2565-1_17 FaulerGLeisHJHuberESchellaufCKerblRUrbanC Determination of homovanillic acid and vanillylmandelic acid in neuroblastoma screening by stable isotope dilution GC-MS. J Mass Spectrom. 1997;32:507–14. 10.1002/(SICI)1096-9888(199705)32:5<507::AID-JMS503>3.0.CO;2-99180052 YokomoriKHoriTTsuchidaYKurodaMYoshiokaM. A new urinary mass screening system for neuroblastoma in infancy by use of monoclonal antibodies against VMA and HVA. J Pediatr Surg. 1989;24:391–4. 10.1016/S0022-3468(89)80278-72659761 KerblRUrbanCEAmbrosPFLacknerHLadensteinRSpullerE Screening for neuroblastoma in late infancy by use of EIA (enzyme-linked immunoassay) method: 115000 screened infants in Austria. Eur J Cancer. 1996;32A:2298–305. 10.1016/S0959-8049(96)00361-99038613 AterJLGardnerKLFoxhallLETherrellBLJrBleyerWA. Neuroblastoma screening in the United States: results of the Texas Outreach Program for neuroblastoma screening. Cancer. 1998;82:1593–602. 10.1002/(SICI)1097-0142(19980415)82:8<1593::AID-CNCR23>3.0.CO;2-Z9554539 TaranFBernardHValleixACréminonCGrassiJOlichonD Competitive enzyme immunoassay for urinary vanillylmandelic acid. Clin Chim Acta. 1997;264:177–92. 10.1016/S0009-8981(97)00092-29293376 UngerNDeutschbeinTWalzMKMannKPetersennS. The value of immunoassays for metanephrines in the biochemical diagnosis of pheochromocytomas. Horm Metab Res. 2009;41:676–9. 10.1055/s-0029-122413319557670 HigashiTShibayamaYFujiMShimadaK. Liquid chromatography-tandem mass spectrometric method for the determination of salivary 25-hydroxyvitamin D3: a noninvasive tool for the assessment of vitamin D status. Anal Bioanal Chem. 2008;391:229–38. 10.1007/s00216-007-1780-318087693 SunDMcLeanD-MMPalatyJKonforteD. Leveraging supported liquid extraction and automated workflow for high efficiency and high quality clinical LC-MS/MS method for quantification of urinary 5-hydroxyindoleacetic acid (5-HIAA), vanillylmandelic acid (VMA) and homovanillic acid (HVA). Clin Chim Acta. 2025;566:120057. 10.1016/j.cca.2024.12005739571774 YuLKangSChengLZhangQOuyangFHanL Establishment and clinical application of a candidate reference measurement procedure for quantification of urinary vanillylmandelic acid and homovanillic acid using ID-LC-MS/MS method. J Pharm Biomed Anal. 2024;248:116311. 10.1016/j.jpba.2024.11631138901157 HwangNChongEOhHChoHWLeeJWSungKW Application of an LC–MS/MS Method for the Simultaneous Quantification of Homovanillic Acid and Vanillylmandelic Acid for the Diagnosis and Follow-Up of Neuroblastoma in 357 Patients. Molecules. 2021;26:3470. 10.3390/molecules2611347034200415 RossiLMatserYAHBarcoSCafaroAPigliascoFBiondiM Validation of an LC-MS/MS method for urinary homovanillic and vanillylmandelic ACIDS and application to the diagnosis of neuroblastoma. J Mass Spectrom Adv Clin Lab. 2025;36:73–81. 10.1016/j.jmsacl.2025.04.00740421176 ClarkZDCutlerJMPavlovIYStrathmannFGFrankEL. Simple dilute-and-shoot method for urinary vanillylmandelic acid and homovanillic acid by liquid chromatography tandem mass spectrometry. Clin Chim Acta. 2017;468:201–8. 10.1016/j.cca.2017.03.00428263737 LionettoLLostiaAMStiglianoACardelliPSimmacoM. HPLC–mass spectrometry method for quantitative detection of neuroendocrine tumor markers: Vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid. Clin Chim Acta. 2008;398:53–6. 10.1016/j.cca.2008.08.00318760269 GrouzmannECentenoCEugsterPJ. Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method. Clin Chem Lab Med. 2018;56:1533–41. 10.1515/cclm-2017-112029708876 XieZLorkiewiczPRiggsDWBhatnagarASrivastavaS. Comprehensive, robust, and sensitive UPLC-MS/MS analysis of free biogenic monoamines and their metabolites in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1099:83–91. 10.1016/j.jchromb.2018.09.01230248561 OzardaY. Reference intervals: current status, recent developments and future considerations. Biochem Med (Zagreb). 2016;26:5–16. 10.11613/BM.2016.00126981015 BarcoSGennaiIReggiardoGGalleniBBarbagalloLMaffiaA Urinary homovanillic and vanillylmandelic acid in the diagnosis of neuroblastoma: report from the Italian Cooperative Group for Neuroblastoma. Clin Biochem. 2014;47:848–52. 10.1016/j.clinbiochem.2014.04.01524769278 WangZMGallagherDNelsonMEMatthewsDEHeymsfieldSB. Total-body skeletal muscle mass: evaluation of 24-h urinary creatinine excretion by computerized axial tomography. Am J Clin Nutr. 1996;63:863–9. 10.1093/ajcn/63.6.8638644679 TohmolaNItkonenOTurpeinenUJoenvääräSRenkonenRHämäläinenE. Preanalytical validation and reference values for a mass spectrometric assay of serum vanillylmandelic acid for screening of catecholamine secreting neuroendocrine tumors. Clin Chim Acta. 2015;446:206–12. 10.1016/j.cca.2015.03.04125896957 DavidsonDFHammondPJMurphyDCarachiR. Age-related medical decision limits for urinary free (unconjugated) metadrenalines, catecholamines and metabolites in random urine specimens from children. Ann Clin Biochem. 2011;48:358–66. 10.1258/acb.2011.01102321670092 KellieSJClagueAEMcGearyHMSmithPJ. The value of catecholamine metabolite determination on untimed urine collections in the diagnosis of neural crest tumours in children. Aust Paediatr J. 1986;22:313–5. 10.1111/j.1440-1754.1986.tb02156.x3566681 TuchmanMMorrisCLRamnaraineMLBowersLDKrivitW. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: comparison with 24-hour urine collections. Pediatrics. 1985;75:324–8. 10.1542/peds.75.2.3243969335 ItoSKatoTMarutaKJimbowKFujitaK. “Total” acidic metabolites of catecholamines in urine as determined by hydrolysis with hydriodic acid and liquid chromatography: application to patients with neuroblastoma and melanoma. Clin Chem. 1985;31:1185–8. 10.1093/clinchem/31.7.11854006189 Prémel-CabicATurcantAAllainP. Normal reference intervals for free catecholamines and their acid metabolites in 24-h urines from children, as determined by liquid chromatography with amperometric detection. Clin Chem. 1986;32:1585–7. 10.1093/clinchem/32.8.15853731457 HendersonMJHeneyDMcGinlayJMLewisIBaileyC. Measurement of dopamine, HVA and HMMA in untimed urine samples: establishment of age-related reference data in children. Ann Clin Biochem. 1992;29:162–7. 10.1177/0004563292029002071626919 MathieuPFrappazDChauvinFCombaretVVercheratMBrunat-MentignyM A 5-year (1990-1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observations. Early Hum Dev. 1996;46:177–96. 10.1016/0378-3782(96)01763-X9019414 CraftAWDaleGMcGillASeviourJSpenceEM. Biochemical screening for neuroblastoma in infants: a feasibility study. Med Pediatr Oncol. 1989;17:373–8. 10.1002/mpo.29501705052796853 ParkerLCraftAWDaleGBellSColeMMcGillAC Screening for neuroblastoma in the north of England. BMJ. 1992;305:1260–3. 10.1136/bmj.305.6864.12601303649 ColeMCraftAWParkerLBellSSeviourJAMcGillAC Urinary creatinine adjusted reference ranges for homovanillic and vanillylmandelic acid in children and adults. Clin Chim Acta. 1995;236:19–32. 10.1016/0009-8981(95)06031-17664463 ShenYLiHLuJLuoXGuanQChengL. Analytical validation and clinical application of urinary vanillylmandelic acid and homovanillic acid by LC-MS/MS for diagnosis of neuroblastoma. Biomed Chromatogr. 2019;33:e4484. 10.1002/bmc.448430632178 FitzgibbonMFitzGeraldRJTormeyWPO’MearaAKennyD. Reference values for urinary HMMA, HVA, noradrenaline, adrenaline, and dopamine excretion in children using random urine samples and HPLC with electrochemical detection. Ann Clin Biochem. 1992;29:400–4. 10.1177/0004563292029004051642445 De SchaepdryverAFHooftCDelbekeMJden NoortgaeteMV. Urinary catecholamines and metabolites in children. J Pediatr. 1978;93:266–8. 10.1016/S0022-3476(78)80516-2566789 NishiMMiyakeHTakedaTTakasugiNSatoYHanaiJ. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old. Jpn J Clin Oncol. 1986;16(4):351–5.3795531 EisenhoferGPrejbiszAPeitzschMPamporakiCMasjkurJRogowski-LehmannN Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clin Chem. 2018;64:1646–56. 10.1373/clinchem.2018.29136930097498 EisenhoferGLendersJWSiegertGBornsteinSRFribergPMilosevicD Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48:1739–49. 10.1016/j.ejca.2011.07.01622036874 SimonTHeroBHunnemanDHBertholdF. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer. 2003;39:1899–903. 10.1016/S0959-8049(03)00376-912932669 BrodeurGMBagatellR. Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol. 2014;11:704–13. 10.1038/nrclinonc.2014.16825331179 AmanoHUchidaHHaradaKNaritaAFuminoSYamadaY Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations. Cancer Sci. 2024;115:1634–45. 10.1111/cas.1611638411285 MassaronSSeregniELukschRCasanovaMBottiCFerrariL Neuron-specific enolase evaluation in patients with neuroblastoma. Tumour Biol. 1998;19:261–8. 10.1159/0000300169679736 MorozVMachinDHeroBLadensteinRBertholdFKaoP The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020;67:e28359. 10.1002/pbc.2835932472746 HirokawaSYamashitaIKurokiYYamashitaYFujimakiMAoyamaK Neuroblastoma in an adult with a high serum level of carbohydrate antigen, CA125: report of a case. Surg Today. 1998;28:349–54. 10.1007/s0059500501399548327 LiJQiZChenMWangJLiuX. Clinical value of combined serum CA125, NSE and 24-hour urine VMA for the prediction of recurrence in children with neuroblastoma. Ital J Pediatr. 2023;49:102. 10.1186/s13052-023-01508-637620978 PavlovaNNThompsonCB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016;23:27–47. 10.1016/j.cmet.2015.12.00626771115 CangemiGReggiardoGBarcoSBarbagalloLConteMD’AngeloP Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther. 2012;5:417–23. 10.2147/OTT.S3636623226699 Lozano-MontoyaJJimenez-PastorAFuster-MatanzoAWeissGCerdá AlberichLVeiga-CanutoD Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort. Front Oncol. 2025;15:1528836. 10.3389/fonc.2025.152883640061893
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020505" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020505" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020505" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(83) "Homovanillic acid and vanillylmandelic acid as neuroblastoma biomarkers in children" ["journals_article_author"]=> string(28) "Sina Kavalakatt, Josko Ivica" ["journals_article_author_country"]=> string(6) "Canada" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(76) "homovanillic acid, neuroblastoma, reference intervals, vanillylmandelic acid" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2049" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "6" ["meta_title"]=> string(83) "Homovanillic acid and vanillylmandelic acid as neuroblastoma biomarkers in children" ["meta_desc"]=> string(83) "Homovanillic acid and vanillylmandelic acid as neuroblastoma biomarkers in children" ["meta_keyw"]=> string(76) "homovanillic acid, neuroblastoma, reference intervals, vanillylmandelic acid" ["created"]=> string(19) "2026-06-01 10:44:13" ["modified"]=> string(19) "2026-06-11 08:43:36" } [31]=> object(stdClass)#80 (35) { ["journals_id"]=> string(4) "1248" ["journals_xml"]=> string(138594) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020504 10.11613/BM.2026.020504 Reviews Proteomics in myelodysplastic syndromes: towards novel prognostic and diagnostic biomarkers NovakRuđer12Mandac SmoljanovićInga*3GrgurevićLovorka124 Centre for translational and clinical research, Department of Proteomics, School of Medicine, University of Zagreb, Zagreb, Croatia BIMIS – Biomedical research center Šalata, School of Medicine, University of Zagreb, Zagreb, Croatia Division of Hematology, Clinical Hospital Merkur, Zagreb, Croatia Department of Anatomy “Drago Perović”, School of Medicine, University of Zagreb, Zagreb, Croatia Corresponding author: imandac@yahoo.com

Author contributions

L Grgurević and R Novak contributed to the conceptualization of ideas, manuscript writing, figure design, and supervision; I Mandac Smoljanović. contributed to manuscript writing.

15062026 15062026 36 2 020504 0110202514042026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Myelodysplastic neoplasms are syndrome is defined by cytopenias and ineffective hematopoiesis

• Dysregulated signaling proteins involved in immune evasion are linked to poor outcome

• Bone marrow microenvironment remodeling drives disease progression and adhesion defects

• Proteomics biomarkers may guide therapy and improve patient outcomes

Myelodysplastic neoplasms (MDS) are clonal hematopoietic disorders defined by ineffective hematopoiesis, cytopenias, and variable risk of progression to acute myeloid leukemia. Although genomic and epigenomic studies have provided insight into disease pathogenesis, reliable biomarkers for diagnosis and prognosis remain limited. Proteomics offers an important advantage because it reflects the functional protein state and captures post-translational modifications, making it highly relevant for risk assessment and therapy guidance. Recent studies have identified several groups of candidate biomarkers. Kinases and signal transduction proteins such as CAMK1D, PRKCZ, KIT, MAST4, PAK6, PTK7, and NTRK1 are dysregulated in MDS and associated with poor outcomes, immune evasion, and aberrant stem cell signaling. Oncofetal proteins like IGF2BP3 and signaling regulators such as RBP4 further highlight proteomic signatures linked to chemoresistance and subtype specificity. In the transplant setting, immune regulators including CSK, FGR, CRTAM, GP1BA, UBE2N, and STAT1 may serve as predictors of graft rejection and relapse. Cytoskeletal and extracellular matrix proteins such as CEP55, Talin-1, Kindlin-3, Vinculin, THBS1, LRG1, SPARC, SAA1, Clusterin, and PRDM16 underscore the role of bone marrow microenvironmental remodeling and adhesion defects in disease progression. Finally, metabolic enzymes such as LDHA reflect altered energy metabolism and correlate with more aggressive disease biology. Collectively, these proteomic candidates illustrate the complex interplay of signaling, immune regulation, bone microenvironment, and metabolism in MDS. Their validation in clinical cohorts could enable early detection, refined risk stratification, and new therapeutic avenues, positioning proteomics as a central tool in the future management of MDS.

Keywords: myelodysplastic neoplasmsacute myeloid leukemiabiomarkerproteomics
Myelodysplastic neoplasms

Myelodysplastic neoplasms (MDS) are a group of malignant clonal hematological disorders characterized by ineffective hematopoiesis and dysplasia affecting cell lineages of the bone marrow. It typically presents with nonspecific symptoms related to cytopenias, including fatigue from anemia, infections from neutropenia, and bleeding or bruising from thrombocytopenia. The annual incidence of MDS is approximately 4.9 per 100,000. Although it is rare before age 40, it rises sharply after 70, with a median age at diagnosis of 65 years and a slightly higher incidence in men (1). Congenital, environmental and life-style factors contribute to the risk of developing MDS. Hereditary bone marrow failure syndromes are well-established predisposing conditions, while environmental risks include benzene exposure from cigarette smoke and occupational exposure to solvents, paints, and pesticides. Epidemiological studies also link higher body mass index (BMI) to increased risk of MDS, with relative risks of 1.15 for overweight, 2.18 for obese adults, and a particularly elevated risk for people with BMI > 35 kg/m2 (2). The increased risk might stem form obesity-related inflammation, immune dysregulation, and adipocyte-driven alterations of the bone marrow microenvironment (3, 4). Myelodysplastic neoplasms may also arise as a secondary condition from pre-existing hematologic disorders or following cytotoxic chemotherapy and/or radiotherapy. Therapy-related MDS is linked to alkylating agents, topoisomerase II inhibitors and autologous stem cell transplantation (ASCT). It accounts for up to 15% of cases, and carries a markedly increased risk of myeloid neoplasms (5, 6). Elevated MDS incidence has also been observed after solid organ transplantation, likely due to prolonged immunosuppression, with agents such as azathioprine conferring a particularly high risk through impaired DNA repair and chromosomal instability (7-10).

Pathogenesis of myelodysplastic neoplasms

Despite extensive study, the exact “cell of origin” in MDS remains unclear. Early MDS is marked by hypercellular bone marrow, coupled with peripheral cytopenias that are driven by increased apoptosis and impaired differentiation of affected cells. This apoptosis may reflect immune responses against MDS antigens, but it also arises from mitochondrial dysfunction and the activation of pro-apoptotic pathways, exacerbated by a raise in pro-inflammatory cytokines. The paradox of high apoptosis in early MDS versus reduced apoptosis reported during clonal expansion in advanced disease, suggests a dynamic shift in cellular programs. These insights position apoptosis as both a hallmark of MDS-related bone marrow failure and a potential biomarker and therapeutic target (11-13).

Recent advances in molecular profiling have reshaped our understanding of MDS pathogenesis, revealing a complex interplay between multiple factors. Genetic and cytogenetic abnormalities influence disease phenotype, progression, and treatment response, thus defining different MDS subtypes and carrying major prognostic value. Cytogenetic lesions occur in roughly half of de novo cases, while recurrent mutations that affect RNA splicing, epigenetic regulation, transcription and signaling, are detected in over 90% of cases (14).

Myelodysplastic neoplasms incidence rises sharply after age 70, which centers aging in its pathogenesis. Age-related defects in DNA repair, epigenetic regulation, metabolism, and chronic inflammation create a permissive environment for somatic mutations, particularly in DNMT3A, TET2, and ASXL1, that are considered hallmarks of age-related clonal hematopoiesis (15, 16). These processes drive clonal selection and hematopoietic imbalance, providing insight into early MDS evolution and guiding the search for predictive genetic biomarkers (11, 12, 17). Somatic mutations in genes regulating RNA splicing (SF3B1, SRSF2, U2AF1), DNA methylation (TET2, DNMT3A), and histone modification (ASXL1, EZH2) are common early events in MDS, disrupting gene expression and differentiation to drive clonal hematopoiesis (18). Additional mutations in signaling pathways (NRAS, JAK2), transcription factors (RUNX1), or tumor suppressors (TP53) promote clonal dominance, genomic instability, and leukemic transformation (19, 20). Through the stepwise accumulation of such genetic and epigenetic alterations that drive clonal expansion, impaired differentiation, and increased blast proliferation, MDS can progress to acute myeloid leukemia (AML) (21).

Myelodysplastic neoplasms was classified in 2022 by the World Health Organisation (WHO) 5th Edition, which replaced “syndromes” with “neoplasms” and defined entities based on morphology and specific genetic markers, including MDS with low blasts and isolated chromosome deletion del(5q), MDS with low blasts and SF3B1 mutation, and MDS with biallelic TP53 inactivation (22). Similarly, the International Consensus Classification (ICC) recognizes the mentioned genetically defined entities, but classifies patients with 10-19% blasts as „MDS/AML“, whereas WHO retains them as MDS with increased blasts-2 (23). Both systems rely on morphologic criteria (≥ 10% dysplasia in one or more lineages, blast counts in marrow and blood, and ring sideroblasts) alongside genetic abnormalities to define subtypes (24).

Several pre-MDS indolent myeloid disorders have also been recognized: idiopathic cytopenia of undetermined significance (ICUS), idiopathic dysplasia of undetermined significance (IDUS), clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenia of undetermined significance (CCUS) (25-27). Idiopathic cytopenia of undetermined significance involves persistent cytopenia without MDS-related dysplasia or cytogenetic/molecular abnormalities (17, 28, 29). Idiopathic dysplasia of undetermined significance features morphological dysplasia with minimal or no cytopenia and lacks clonal mutations or cytogenetic changes. Clonal hematopoiesis of indeterminate potential is defined by age-related mutations in genes involved in myeloid malignancies, without cytopenias or neoplastic features. Clonal cytopenia of undetermined significance combines unexplained cytopenia with clonal mutations, often with minimal dysplasia but without MDS-defining abnormalities. These entities provide a valuable model for developing and validating diagnostic and prognostic biomarkers (11, 26-29).

Diagnostic and therapeutic approaches

Given the marked biological heterogeneity of MDS, accurate classification is essential for diagnosis and therapeutic decision-making. Recent WHO and ICC updates integrate morphology and genetic aberrations since cytogenetic or molecular alterations are detectable in approximately 90% of cases. Myelodysplastic neoplasms diagnosis thus requires evidence of dysplastic changes in ≥ 10% of cells in at least one hematopoietic lineage, fewer than 20% myeloblasts in peripheral blood or bone marrow, and presence of clonal genetic abnormalities. However, caution is needed, as many of these mutations also occur in healthy individuals or in related conditions (21). Some patients exhibit cytopenias without meeting full MDS criteria, often with stable blood counts for years (26). Myelodysplastic neoplasms is further characterized by its inherent risk of progression to AML. The risk was initially stratified by the International Prognostic Scoring System-Revised (IPSS-R) based on marrow blast percentage, cytogenetic risk group, hemoglobin concentration, platelet count, and absolute neutrophil count (30). This framework was expanded in 2022 by the International Prognostic Scoring System-Molecular (IPSS-M), by incorporating the mutational status of relevant genes (i.e. TP53, SF3B1, TET2, ASXL1, RUNX1) (31). This refines risk stratification and enables treatment adapted to patient age, comorbidities, and genetic profile, thus improving quality of life and delaying the progression to AML.

Therapeutic options for MDS currently range from conventional therapies, such as hypomethylating agents and lenalidomide, to intensive myeloablative regimens. Although these approaches may induce clinical responses, they fail to fully eradicate MDS stem cells (32-34). Current research in MDS increasingly focuses on common genetic abberations, like targeting TP53 using its reactivator Eprenetapopt, or IDH1/2 inhibitors and luspatercept for patients with SF3B1 mutations (21, 35). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative therapy for MDS (36, 37). However, the disease is sustained by diverse and adaptable stem cell populations, which complicates their eradication, and relapse remains the leading cause of treatment failure. Maintenance and pre-emptive therapies following HSCT are, therefore, also areas of active investigation (38, 39). Ultimately, the development of new approaches like digital diagnostics and peripheral blood omics may change future diagnostic practices. Effective management of MDS will likely depend on rational combinations of classical supportive and non-targeted treatments with individualized, mutation-directed therapies (40, 41).

Protein biomarkers of myelodysplastic neoplasms

As classification systems increasingly integrate molecular features, proteomic profiling offers an opportunity to refine these categories by capturing the functional consequences of genetic lesions and microenvironmental alterations of MDS. This highlights the need to evaluate protein-level biomarkers alongside established genomic markers. Proteomic studies in MDS have utilized several sample types, capturing distinct layers of disease biology. Peripheral blood offers a minimally invasive source suitable for longitudinal monitoring and reflects systemic inflammatory and metabolic alterations. Bone marrow provides a more direct view of the dysplastic niche and microenvironmental remodeling. Finally, stem and progenitor cell-enriched fractions allow the identification of protein signatures specifically associated with clonal hematopoiesis and early leukemogenic events.

Despite significant advances, robust and clinically applicable biomarkers capable of predicting disease course and stratifying high-risk patients remain a major unmet need (42-46). The purpose of this review is to integrate and evaluate candidate protein biomarkers with potential prognostic relevance and therapeutic value in MDS. These proteins can be categorized according to their predominant biological functions into: kinases and signal transduction molecules, proteins implicated in graft rejection, cytoskeletal and extracellular matrix (ECM) regulators, and metabolic enzymes. Such classification facilitates a clearer understanding of their roles in disease pathogenesis and also highlights potential therapeutic avenues. These molecules were selected via a comprehensive literature review and are proposed for future validation of their diagnostic and prognostic utility in MDS.

1. Kinases/Signal transduction molecules

Protein kinases have a critical role in cell signaling and regulation. Through phosphorylation, they modify the function, activity, localization, or interactions of their target proteins. Dysregulated kinase activity is proposed as a defining feature of MDS progression and is closely associated with poor prognosis in patients. Individual kinase alterations are well characterized in other cancers (e.g., KIT in systemic mastocytosis, neurotrophic tropomyosin kinase receptors fusions in solid tumors, but their collective dysregulation in MDS suggests a unique pathogenic network (47, 48). While individual biomarkers may not be relevant, their collective expression, synthesized into a diagnostic panel, has proven useful for stratifying patients into subgroups based on disease severity. The expression profiles and activity of several kinases has recently been characterized and annotated to MDS patient subgroups using the Kinase Stratification Score (KISS) (42). These proteins converge on three significant pathways: immune evasion, stem cell dysregulation and therapeutic resistance. Immune evasion is a hallmark of cancer development. It allows malignant cells to avoid detection by the host immune system, a process that is often orchestrated through dysregulated signaling pathways. Aberrant calcium/calmodulin and Wnt signaling pathway were suggested to be of particular importance to MDS. A notable example is a calcium/calmodulin-dependent kinase (CAMK1D) that modulates the differentiation and apoptosis of haematopoetic cells (49). Yao et al. associated high expression of CAMK1D in MDS patients with poor overall survival rate, likely due its suppression of caspase-mediated apoptosis, which permits leukemic clone survival. Another member of this signaling pathway is protein kinase C zeta (PRKCZ) whose elevated expression was linked to poor prognosis (42). The cluster of Wnt-related kinases were also implicated in the pathology of this disease. Namely, elevated expression of the transmembrane receptor tyrosine kinase KIT appears to further disrupt stem cell signaling and to increase blast counts, thus potentially intersecting functionally with CAMK1D activity in the progression of MDS (50). Elevated expression levels of several other Wnt-related kinases have been proposed as potential prognostic biomarkers within the KISS model, although their mechanisms of contribution to MDS pathogenesis are largely unknown. In particular, overexpression of microtubule-associated serine/threonine kinase 4 (MAST4), p21-activated kinase 6 (PAK6), and protein tyrosine kinase 7 (PTK7) have been linked to adverse outcomes. Moreover, while mutations in neurotrophic receptor tyrosine kinase 1 (NTRK1) are commonly associated with solid tumours, they have also been correlated with poor overall survival (42). NTRK1 mutations in MDS often result in constitutive kinase activation, analogous to gain-of-function mutations in solid tumours, implicating a shared “hyperactive signaling” phenotype despite divergent mutational spectra (51). Functionally, patients classified as KISS-high exhibit concurrent overexpression of all seven kinases. This implies that the kinases are not in direct biochemical interaction and that they act in additive manner in pathogenesis of MDS.

Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) exerts broadly detrimental effects on patient prognosis. This oncofetal protein, typically low in healthy adults, is frequently re-expressed in cancers. In MDS and AML patients, elevated plasma concentrations of IGF2BP3 are associated with chemotherapy resistance and reduced survival. These effects are thought to result from the stabilization of survival-promoting mRNAs, including modulators of the PI3K-AKT and MAPK pathways, thereby inhibiting apoptosis (52).

Retinol-Binding Protein 4 (RBP4) is increasingly recognized not only as a transporter of retinol but also as a signaling molecule that modulates metabolic and inflammatory pathways. Through its endocrine-like effects, RBP4 can influence cellular communication and immune responses, placing it among proteins with signaling functions. The RBP4 is a blood transporter of retinol (vitamin A), with a role in multiple metabolic and inflammatory pathways (53). Elevated concentrations of RBP4 expression have been observed in certain subtypes of MDS, such as refractory anemia with excess blasts-1 (54). However, RBP4 concentrations remain normal in MDS subtype, anemia with ringed sideroblasts, suggesting that RBP4 may serve as a potential biomarker specific to certain MDS subgroups (55).

Kinases are among the most important drug targets in the human proteome, with a long history of being targeted for an expanding range conditions (56). Understanding the kinase activation patterns driving MDS is a crucial insight into the mechanisms underlying disease progression. Targeting these dysregulated pathways holds the potential to modulate ineffective hematopoiesis or reduce malignant cell survival. With the exception of PTK7, for which inhibitory strategies have shown only limited success in phase 1 clinical trials, inhibitors of other potential immune evasion mediators have yet to be evaluated in the context of MDS (Table 1) (51, 57-61). Table 1 summarizes the most frequently reported proteomic biomarkers in MDS. To aid interpretation, the column ‘Validation potential’ reflects an assessment based on several criteria: (i) reproducibility across independent cohorts; (ii) availability of orthogonal confirmation (e.g., ELISA, flow cytometry, targeted MS); (iii) demonstrated association with clinically relevant endpoints such as survival, progression, or treatment response; and (iv) feasibility of measurement in routine clinical samples such as peripheral blood, bone marrow plasma, or CD34+ fractions. These criteria collectively indicate the likelihood that each biomarker could progress toward clinical validation.

Candidate protein biomarkers in myelodysplastic neoplasms (MDS) with potential prognostic and therapeutic relevance.
Molecule Pathway/Category Reported effect in MDS Prognostic implication Validation potential Reference
CAMK1D Calcium/calmodulin signaling kinase Suppresses caspase-mediated apoptosis, modulates hematopoietic differentiation High expression linked to poor overall survival Strong candidate biomarker; warrants functional and clinical validation (42, 49)
PRKCZ Protein kinase C family Dysregulated expression contributes to immune evasion Associated with poor prognosis Promising, requires further mechanistic studies (42)
KIT Receptor tyrosine kinase (Wnt-related) Alters stem cell signaling, increases blast counts Overexpression linked to disease progression Targetable kinase, potential therapeutic biomarker (50)
MAST4 Serine/threonine kinase (Wnt-related) Mechanism unclear, implicated via KISS model Overexpression associated with adverse outcome Candidate for exploratory validation (42)
PAK6 Serine/threonine kinase (Wnt-related) Mechanism unclear, implicated via KISS model Overexpression associated with adverse outcome Candidate for exploratory validation (42, 61)
PTK7 Pseudokinase, Wnt signaling modulator Implicated in MDS via KISS model; limited therapeutic inhibition tested High expression linked to poor prognosis Limited clinical trial data; further validation needed (42, 57)
NTRK1 Neurotrophic receptor tyrosine kinase Activating mutations cause constitutive signaling Mutations correlated with reduced survival Potential shared oncogenic driver; promising biomarker (42, 51)
IGF2BP3 RNA-binding oncofetal protein Stabilizes pro-survival mRNAs (PI3K-AKT, MAPK pathways); promotes chemoresistance Elevated concentrations linked to reduced survival and therapy resistance Strong candidate for clinical validation (52)
RBP4 Retinol-binding protein, signaling modulator Alters metabolic and inflammatory signaling; subtype-specific expression Elevated in RAEB-1 but not in RARS; potential subgroup biomarker Promising subtype-specific biomarker for stratification (53-55)
For each candidate biomarker, it is crucial to distinguish whether clinical implementation would require detection of somatic mutations (e.g., NTRK1) or quantification of protein overexpression (e.g., KIT, PTK7), as the analytical platforms and clinical significance differ accordingly.
2. Proteins related to graft rejection

Graft rejection is a transplant failure in which the recipient’s immune system attacks the transplanted bone marrow or blood-forming cells, preventing engraftment and recovery. Disruption of the kinase signaling pathways can trigger dysregulated innate and adaptive immune responses. This imbalance promotes inflammation and immune cell infiltration, processes that can ultimately lead to graft rejection. This is of high importance to MDS since HSCT is the only curative option currently available for patients. Therefore, identifying proteins that predict allograft rejection at an early stage of treatment is of great importance for monitoring graft function and assessing relapse risk. Several of these candidate proteins converge on common signalling pathways like NF-κB, and Src kinase pathways implicated in inflammatory signaling and immune cell activation (62, 63).

A likely candidate is C-terminal Src kinase (CSK), which regulates immune homeostasis by preventing the overactivation of inflammatory pathways. Elevated CSK was associated with MDS by post-transplant immune activity and is potentially predictive of disease relapse (46). CSK is a known regulator that can control the activity of tyrosine-protein kinase Fgr (FGR), a non-receptor tyrosine kinase primarily expressed in hematopoietic cells (64). In physiologic conditions, FGR expression is largely restricted to macrophage subsets; however, during inflammation, it is produced by most hematopoietic cell types. As FGR regulates inflammatory cytokine secretion and immune cell activation, the combined activity of these two modulators could exacerbate the chronic immune dysregulation and ineffective hematopoiesis characteristic of MDS (46, 65). Similarly, dysregulation of Lck/yes-related novel (LYN) kinase in hematopoietic cells has been reported in chronic myelomonocytic leukemia and AML (66).

Graft rejection is largely driven by cytotoxic T cells that recognize donor antigens, trigger inflammation, and destroy graft tissue. This process is amplified by class I-restricted T cell-associated molecule (CRTAM), which is expressed on activated cytotoxic immune cells and is overexpressed in patients with MDS. Its overexpression could contribute to enhanced graft rejection and disease relapse. Glycoprotein Ib alpha chain (GP1BA) is a component of the platelet receptor complex von Willebrand factor that is essential for hemostasis and vascular immunity (46). Although GP1BA is not mutated in MDS, the characteristic dysfunction of megakaryocytes and abnormal platelet activation that present in MDS patients, may reflect its altered levels.

Finally, ubiquitin-conjugating enzyme E2N (UBE2N) mediates the attachment of ubiquitin to target proteins, a key mechanism regulating NF-κB-dependent DNA repair (67). Unlike the previously discussed immune modulators, UBE2N primarily influences malignant cell survival. It is overexpressed in leukemic stem and progenitor cells in both MDS and AML, where it supports the maintenance and persistence of these malignant cell populations (68). The roles of other immune modulators, such as oxidized LDL receptor 1 (OLR1), S100 calcium-binding protein A12 (S100A12), and signal transducer and activator of transcription 1 (STAT1), have also been implicated in post-transplant complications, though their contributions require further investigation (46).

Similar to therapeutic approaches linked to immune evasion, efforts to target graft rejection-related mediators or their pathways in MDS remain in the earliest stages of development. For instance, modulating STAT1 activity is being tested in various disease settings such as myelofibrosis, myeloproliferative neoplasms, thrombocytopenia, and hematologic malignancies, including MDS (69-73). Such inhibitors may potentially help restore normal hematopoiesis by dampening the overactive JAK-STAT signaling observed in MDS, offering an altrenative therapeutic alley. Similarly, inhibition of UBE2N has been shown to suppress the function and viability of MDS/AML cell lines as well as patient derived samples (74, 75).

Beyond these, multiple other conceptually promising mediators represent druggable targets, however most evidence is limited to early-stage studies or to different disease contexts and their clinical relevance in MDS is yet to be established (Figure 1) (76-78).

Schematic representation of post-transplant mechanisms in MDS, illustrating the distinction between relapse biology and immunologic transplant complications. Chronic inflammation and immune infiltration activate dysregulated kinase pathways (NF-κB, Src, JAK–STAT), which support leukemic stem cell persistence and ultimately lead to post-transplant relapse. In contrast, graft-versus-host disease (GVHD) arises from alloimmune activation of cytotoxic T and NK cells, exemplified by CRTAM-mediated effector responses. Graft rejection reflects failure of donor engraftment, primarily driven by host innate immune activation. These pathways represent biologically and clinically distinct processes, and only the kinase-driven axis contributes to malignant relapse rather than GVHD or graft rejection.

3. Bone marrow microenvironment and cytoskeletal/ECM regulators

The bone marrow cytoskeleton orchestrates the regulation of cell morphology, migratory capacity, intracellular signaling, and mitotic division. Several proteins related to impaired cytoskeletal dysfunction have thus emerged as promising therapeutic targets in acute leukemias (79). Centrosomal Protein 55 (CEP55) is a cell division modulator whose overexpression is considered to promote tumorigenesis (80). Talin-1 (TLN1) is a cytoskeletal protein that plays a role in linking integrins to the actin cytoskeleton, facilitating cell adhesion and migration (81). The concentrations of both proteins were elevated in bone marrow plasma of patients with MDS, particularly those with ring sideroblasts. Indeed, increased CEP55 expression has been associated with abnormal karyotypes which strengthens it as a potential for chromosomal instability (43). Kindlin-3 has strengthened the understanding of problematic leukocyte adhesion in AML. Its epigenetic suppression (hypermethylation) leads to dysfunctional blood cell adhesion and cell viability in both MDS and AML, potentially exacerbating the bone marrow failure observed in MDS (82). Furthermore, kindlin-3 deficiency may contribute to the defective hematopoietic microenvironment of MDS by disrupting integrin signaling. Its mutations may overlap with inflammatory mechanisms that involved in the MDS pathogenesis (83). Vinculin is another cytoskeletal modulator involved in cell adhesion and mechano-transduction whose expression levels are altered in MDS. Reduced expression of vinculin in peripheral blood mononuclear cells from MDS patients may contribute to impaired cell adhesion, thereby disrupting hematopoiesis - a hallmark of the disease (84). Additionally, its reduced expression in plateletes derived from MDS patients may impair integrin αIIbβ3 activation, resulting in defective platelet aggregation and contributing to the bleeding complications commonly observed in MDS patients (85). Finally, increased levels of posttranslational modifications of vinculin have also been suggested as promising cadidate diagnostic biomarkers (86).

The cytoskeleton is in constant crosstalk with the ECM, coordinating adhesion, signaling, and microenvironmental remodeling (87). Low concentrations of thrombospondin-1 (THBS1), an ECM glycoprotein that plays a role in angiogenesis, apoptosis and tumor progression have been observed in patients with MDS. Those exhibiting reduced THBS1 expression tend to have shorter overall survival, suggesting its potential utility as a prognostic biomarker (88). Pathological angiogenesis has also been associated with leucine-rich α-2-glycoprotein 1 (LRG1), a glycoprotein primarily secreted by hepatocytes and neutrophils. Elevated plasma concentrations of LRG1 in MDS patients are believed to influence the bone marrow microenvironment through its expression and secretion from neutrophil granules. LRG1 promotes aberrant angiogenesis by modulating TGF-β signaling, resulting in the formation of immature and dysfunctional blood vessels (44, 89). Another important mediator of ECM remodelling is secreted protein acidic and rich in cysteine (SPARC, osteonectin). Implicated in several hematologic malignancies, particularly MDS, it is of growing interest due to its dual functions as both a tumor suppressor and tumor promotor. SPARC is located on chromosome 5q31.3-q32, a region frequently deleted in MDS, particularly in the 5q-syndrome, a distinct subtype of MDS defined by the deletion of chromosome 5q which has a more favourable prognosis. Similarly, the transcription factor PR domain containing 16 (PRDM16) has recently been implicated in hematologic malignancies. The PRDM16 gene is located on chromosome 1p36, a region frequently involved in chromosomal translocations in patients with MDS and AML. Translocations of this gene are linked to its overexpression, which is associated with poor prognosis in affected patients (90). Secreted by the bone marrow stroma microenvironment, serum amyloid A1 (SAA1) is known to regulate the ECM through matrix metalloprotineases (91). Emerging evidence also implicates SAA1 in the pathogenesis of both MDS and AML (92). It has been shown to promote the proliferation of malignant clones in these disorders, regardless of cytogenetic or mutational profiles. Targeting SAA1 using IL-6 inhibitors or small peptides could mitigate clonal expansion in MDS (93, 94). Aditionally, as elevated concentrations of SAA1 were correlated with increased disease severity in MDS and its progression to AML, it could have potential as a biomarker for disease monitoring (Figure 2).

Schematic representation of the bone marrow microenvironment showing cytoskeletal regulators (CEP55, Talin-1, Kindlin-3, Vinculin) and ECM proteins (THBS1, LRG1, SPARC, SAA1, Clusterin), together with PRDM16, illustrating disrupted adhesion, signaling, and remodeling processes driving MDS/AML progression. ECM - extracellular matrix. HSC - hematopoietic stem cell. MSC - mesenchymal stem cell.

One of the most prominent chaperons of the ECM is clusterin. Overexpression of secreted clusterin (CLU) has been linked to resistance to chemotherapy and radiotherapy in various types of cancer (95). In patients with MDS, CLU proteoforms in plasma-derived exosomes were compared to “free” plasma CLU concentrations. The observed altered distribution of CLU proteoforms suggests their potential utility as a biomarker for MDS progression (45).

4. Metabolic enzymes

Increased activity of lactate dehydrogenase A (LDHA) in MDS patients, as indicated by their elevated plasma LDH, may serve as a potential prognostic factor (96). LDHA is a glycolytic enzyme that catalyzes the conversion of pyruvate to lactate, thereby sustaining glycolytic flux and supporting energy production under hypoxic conditions. The involvement of this enzyme in tumorigenesis is well-established, reflecting its importance in the metabolic reprogramming of malignant cells (97). A wide array of LDHA inhibitors, ranging from synthetic molecules and natural compounds to antisense oligonucleotides, RNA interference, and N-terminal mimetic peptides, are currently under investigation in various cancers (98-100). However, their role in MDS remains uncertain.

In conclusion, a deeper understanding of the cellular composition of the normal, dysplastic, and leukemic marrow niche, as well as the complex network of intercellular interactions, is expected to provide novel insights into therapeutic approaches in the coming years.

Genomics is an integral part of routine diagnostic and prognostic assessment in MDS. However, despite advances in genomic profiling, MDS remains a therapeutic challenge due to its striking molecular heterogeneity, with patients exhibiting diverse mutational landscapes, epigenetic dysregulation, and metabolic adaptations. Future management will rely increasingly on strategies that integrate disease pathophysiology, biology, and their molecular underpinnings. Proteomics enables the identification of disease-specific protein expression patterns and post-translational modifications, and can uncover novel biomarkers of diagnosis, prognosis, and therapeutic response. Integration of clinical proteomic data into existing diagnostic frameworks may thus lead to improved molecular classification, optimized therapeutic decision-making, and the development of protein-targeted therapies in MDS (46).

Acknowledgements

The authors sincerely acknowledge Tomislav Balen, MD for his assistance in the initial collection of literature data, carried out during his education within the course “Basic Concepts of Scientific Work Preparation” at the Department of Proteomics.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References Garcia-ManeroG. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1307–25. 10.1002/ajh.2698437288607 MaXLimUParkYMayneSTWangRHartgeP Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol. 2009;169:1492–9. 10.1093/aje/kwp07419395696 GregorMFHotamisligilGS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–45. 10.1146/annurev-immunol-031210-10132221219177 Veldhuis-VlugAGRosenCJ. Clinical implications of bone marrow adiposity. J Intern Med. 2018;283:121–39. 10.1111/joim.1271829211319 KondeASSrivastavaPPuppalaMWongSPingaliSRIyerSP. Risk of myelodysplasia in patients post solid organ transplant: A review of recent trends from a tertiary transplantation center. J Clin Oncol. 2016;34:7064. 10.1200/JCO.2016.34.15_suppl.7064 Ertz-ArchambaultNKosiorekHTaylorGEKelemenKDueckACastroJ Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol. 2017;3:936–43. 10.1001/jamaoncol.2016.643528152123 ChuaCCFlemingSWeiAH. Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. Best Pract Res Clin Haematol. 2019;32:3–12. 10.1016/j.beha.2019.02.00730927972 AhmadOFKeaneMGMcCartneySKhwajaABloomSL. Azathioprine-associated myelodysplastic syndrome in two patients with ulcerative colitis. Frontline Gastroenterol. 2013;4:205–9. 10.1136/flgastro-2012-10027628839727 VisconteVTiuRVRogersHJ. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res. 2014;49:216. 10.5045/br.2014.49.4.21625548754 SperlingASGibsonCJEbertBL. The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17:5–19. 10.1038/nrc.2016.11227834397 HeuserMYunHTholF. Epigenetics in myelodysplastic syndromes. Semin Cancer Biol. 2018;51:170. 10.1016/j.semcancer.2017.07.00928778402 ItzyksonRKosmiderOFenauxP. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. Best Pract Res Clin Haematol. 2013;26:355–64. 10.1016/j.beha.2014.01.00124507812 OsterHSvan de LoosdrechtAAMittelmanM. Diagnosis of myelodysplastic syndromes: the classic and the novel. Haematologica. 2025;110:300–11. 10.3324/haematol.2023.28493739445407 CazzolaMDella PortaMGMalcovatiL. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122:4021–34. 10.1182/blood-2013-09-38166524136165 SatoNGoyamaSKitamuraT. ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights. Int J Hematol. 2025;122:327–40. 10.1007/s12185-025-04038-540773119 DunnWGMcLoughlinMAVassiliouGS. Clonal hematopoiesis and hematological malignancy. J Clin Invest. 2024;134:e180065. 10.1172/JCI18006539352393 ChungSSParkCY. Aging, hematopoiesis, and the myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2017;2017:73–8. 10.1182/asheducation-2017.1.7329222239 ChangYH. Myelodysplastic syndromes and overlap syndromes. Blood Res. 2021;56:S51–64. 10.5045/br.2021.202101033935036 DelioMBrykeCMendezLJosephLJassimS. JAK2 Mutations Are Rare and Diverse in Myelodysplastic Syndromes: Case Series and Review of the Literature. Hematol Rep. 2023;15:73–87. 10.3390/hematolrep1501000836810551 MaslahNKaciNRouxBAlexeGMarieRPasquerH JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms. Nat Commun. 2025;16:6270. 10.1038/s41467-025-60884-140623967 PlatzbeckerUKubaschASHomer-BouthietteCPrebetT. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35:2182–98. 10.1038/s41375-021-01265-734045662 Li W. The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. Leukemia. 2022;1-21. 10.36255/exon-publications-leukemia-who-5th-edition-hematolymphoid-tumors ArberDAOraziAHasserjianRPBorowitzMJCalvoKRKvasnickaHM International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. 10.1182/blood.202201585035767897 HasserjianRPGermingUMalcovatiL. Diagnosis and classification of myelodysplastic syndromes. Blood. 2023;142:2247–57. 10.1182/blood.202302007837774372 SteensmaDPBejarRJaiswalSLindsleyRCSekeresMAHasserjianRP Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16. 10.1182/blood-2015-03-63174725931582 ValentP. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. Pathobiology. 2019;86:30–8. 10.1159/00048904229860246 TanakaTNBejarR. MDS overlap disorders and diagnostic boundaries. Blood. 2019;133:1086–95. 10.1182/blood-2018-10-84467030670443 MalcovatiLCazzolaM. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). Hematology. 2015;2015:299–307. 10.1182/asheducation-2015.1.29926637737 Montalban-BravoGGarcia-ManeroG. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93:129–47. 10.1002/ajh.2493029214694 GreenbergPLTuechlerHSchanzJSanzGGarcia-ManeroGSoléF Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012;120:2454–65. 10.1182/blood-2012-03-42048922740453 BernardETuechlerHGreenbergPLHasserjianRPOssaJEANannyaY Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence. 2022;1:a2200008. 10.1056/EVIDoa220000838319256 NakamuraRSaberWMartensMJRamirezAScottBOranB Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021;39:3328–39. 10.1200/JCO.20.0338034106753 ScottBLPasquiniMCLoganBRWuJDevineSMPorterDL Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017;35:1154–61. 10.1200/JCO.2016.70.709128380315 OranBAhnKWFrethamCBeitinjanehABasheyAPawarodeA Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplant Cell Ther. 2021;27:921.e1–10. 10.1016/j.jtct.2021.08.00734403791 OsterHSvan de LoosdrechtAAMittelmanM. Diagnosis of myelodysplastic syndromes: the classic and the novel. Haematologica. 2025;110:300–11. 10.3324/haematol.2023.28493739445407 ZhanDParkCY. Stem Cells in the Myelodysplastic Syndromes. Front Aging. 2021;2:719010. 10.3389/fragi.2021.71901035822030 BewersdorfJPZeidanAM. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Cancers (Basel). 2021;13:1610. 10.3390/cancers1307161033807279 SallmanDAAschASAl MalkiMMLeeDJDonnellanWBMarcucciG The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results. Blood. 2019;134:569. 10.1182/blood-2019-126271 ChungSSEngWSHuWKhalajMGarrett-BakelmanFETavakkoliM CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci Transl Med. 2017;9:eaaj2025. 10.1126/scitranslmed.aaj202528123069 CluzeauTLoschiMFenauxPKomrokjiRSallmanDA. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. Int J Mol Sci. 2021;22:10105. 10.3390/ijms22181010534576266 BergTSalterBRadfordMChenHTTLeberB. Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS). Curr Oncol. 2025;32:319. 10.3390/curroncol3206031940558262 YaoCYLinCCWangYHKaoCJTsaiCHHouHA Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes. Blood Adv. 2024;8:2442–54. 10.1182/bloodadvances.202301151238527292 MouraAABezerraMJBMartinsAMABorgesDPOliveiraRTGOliveiraRM Global Proteomics Analysis of Bone Marrow: Establishing Talin-1 and Centrosomal Protein of 55 kDa as Potential Molecular Signatures for Myelodysplastic Syndromes. Front Oncol. 2022;12:833068. 10.3389/fonc.2022.83306835814389 MajekPSovovaZPecankovaKCermakJGasovaZPecherkovaP Mass spectrometry, data re-analysis, and homology modelling predict posttranslational modifications of leucine-rich alpha-2-glycoprotein as a marker of myelodysplastic syndrome. Cancer Biomark. 2022;34:485–92. 10.3233/CBM-21003335275518 PecankovaKPecherkovaPGasovaZSovovaZRiedelTJägerE Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome. PLoS One. 2022;17:e0262484. 10.1371/journal.pone.026248435007303 Guru MurthyGSZhangTBolonYTSpellmanSDongJAuerP Proteomics to predict relapse in patients with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation. Biomark Res. 2024;12:10. 10.1186/s40364-023-00550-038273355 Piris-VillaespesaMAlvarez-TwoseI. Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap. Front Pharmacol. 2020;11:443. 10.3389/fphar.2020.0044332346366 ManeaCABadiuDCPloscaruICZguraABacinschiXSmarandacheCG A review of NTRK fusions in cancer. Ann Med Surg (Lond). 2022;79:103893. 10.1016/j.amsu.2022.10389335860155 RacioppiLLentoWHuangWArvaiSDoanPLHarrisJR Calcium/calmodulin-dependent kinase kinase 2 regulates hematopoietic stem and progenitor cell regeneration. Cell Death Dis. 2017;8:e3076. 10.1038/cddis.2017.47428981105 ZhuHHJiKAldersonNHeZLiSLiuW Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood. 2011;117:5350. 10.1182/blood-2011-01-33347621450902 CoccoEScaltritiMDrilonA. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–47. 10.1038/s41571-018-0113-030333516 LinTLJaiswalAKRitterAJReppasJTranTMNeebZT Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia. Blood Adv. 2024;8:261–75. 10.1182/bloodadvances.202301113238048400 SteinhoffJSLassASchuppM. Biological Functions of RBP4 and Its Relevance for Human Diseases. Front Physiol. 2021;12:659977. 10.3389/fphys.2021.65997733790810 KimNPrieferR. Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development. Eur J Med Chem. 2021;226:113856. 10.1016/j.ejmech.2021.11385634547506 MájekPReicheltováZSuttnarJČermákJDyrJE. Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. Proteome Sci. 2012;10:31. 10.1186/1477-5956-10-3122568928 SilnitskySRubinSJSZerihunMQvitN. An Update on Protein Kinases as Therapeutic Targets—Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases. Int J Mol Sci. 2023;24:17600. 10.3390/ijms24241760038139428 MaitlandMLSachdevJCSharmaMRMorenoVBoniVKummarS First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clin Cancer Res. 2021;27:4511–20. 10.1158/1078-0432.CCR-20-375734083232 FromontCAtzoriAKaurDHashmiLGrecoGCabanillasA Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity in Vivo Mouse Model. J Med Chem. 2020;63:6784–801. 10.1021/acs.jmedchem.9b0180332433887 BogardASTavalinSJ. Protein Kinase C (PKC)ζ pseudosubstrate inhibitor peptide promiscuously binds PKC family isoforms and disrupts conventional PKC targeting and translocation. Mol Pharmacol. 2015;88:728–35. 10.1124/mol.115.09945726199377 ZhongZYaoRDuanYOuyangCDuZLiL Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia. Biomedicines. 2025 July 1;13:1652. 10.3390/biomedicines1307165240722724 GaoJHaBHLouHJMorseEMZhangRCalderwoodDA Substrate and Inhibitor Specificity of the Type II p21-Activated Kinase, PAK6. PLoS One. 2013;8:e77818. 10.1371/journal.pone.007781824204982 TakPPFiresteinGS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7–11. 10.1172/JCI1183011134171 LowellCA. Src-family kinases: rheostats of immune cell signaling. Mol Immunol. 2004;41:631–43. 10.1016/j.molimm.2004.04.01015220000 RuzzeneMJamesPBrunatiAMDonella-DeanaAPinnaLA. Regulation of c-Fgr protein kinase by c-Src kinase (CSK) and by polycationic effectors. J Biol Chem. 1994;269:15885–91. 10.1016/S0021-9258(17)40763-07515063 DuSAlvaradoJJWalesTEMorocoJAEngenJRSmithgallTE. ATP-site inhibitors induce unique conformations of the acute myeloid leukemia-associated Src-family kinase, Fgr. Structure. 2022;30:1508–17.e3. 10.1016/j.str.2022.08.00836115344 OchmanARLipinskiCAHandlerJAReaumeAGSaporitoMS. The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. J Pharmacol Exp Ther. 2012;342:23–32. 10.1124/jpet.112.19218722431203 Al-HakimAEscribano-DiazCLandryMCDonnellLPanierSSzilardRK The ubiquitous role of ubiquitin in the DNA damage response. DNA Repair (Amst). 2010;9:1229–40. 10.1016/j.dnarep.2010.09.01121056014 WangTPineARKotiniAGYuanHZamparoLStarczynowskiDT Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell. 2021;28:1074–89.e7. 10.1016/j.stem.2021.01.01133571445 O’SheaJJSchwartzDMVillarinoAVGadinaMMcInnesIBLaurenceA. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–28. 10.1146/annurev-med-051113-02453725587654 VerstovsekSMesaRAGotlibJLevyRSGuptaVDiPersioJF A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807. 10.1056/NEJMoa111055722375971 PardananiAHarrisonCCortesJECervantesFMesaRAMilliganD Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643–51. 10.1001/jamaoncol.2015.159026181658 MascarenhasJHoffmanRTalpazMGerdsATSteinBGuptaV Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652–9. 10.1001/jamaoncol.2017.581829522138 ZeidanAMCookRJBordoniRBerensonJREdenfieldWJMohanS A phase 1/2 study of the oral Janus kinase 1 inhibitors INCB052793 and itacitinib alone or in combination with standard therapies for advanced hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2022;22:523–34. 10.1016/j.clml.2022.01.01235260349 BarreyroLSampsonAMIshikawaCHuenemanKMChoiKPujatoMA Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Sci Transl Med. 2022;14:eabb7695. 10.1126/scitranslmed.abb769535263148 StubbinsRJPlatzbeckerUKarsanA. Inflammation and myeloid malignancy: quenching the flame. Blood. 2022;140:1067–74. 10.1182/blood.202101516235468199 WangXLuoYZhouQMaJ. The roles of S100A8/A9 and S100A12 in autoimmune diseases: mechanisms, biomarkers, and therapeutic potential. Autoimmun Rev. 2025;24:103920. 10.1016/j.autrev.2025.10392040876560 TianKOguraSLittlePJXuSWSawamuraT. Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. Ann N Y Acad Sci. 2019;1443:34–53. 10.1111/nyas.1398430381837 RedinEGarmendiaILozanoTSerranoDSenentYRedradoM SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. J Immunother Cancer. 2021;9:e001496. 10.1136/jitc-2020-00149633658304 Machado-NetoJAVicariHPLipreri da SilvaJCLimaK. New molecular targets in acute leukemias: cytoskeletal regulatory proteins. Biochem Soc Trans. 2025;53:1249–58. 10.1042/BST2025301740982350 TandonDBanerjeeM. Centrosomal protein 55: a new paradigm in tumorigenesis. Eur J Cell Biol. 2020;99:151086. 10.1016/j.ejcb.2020.15108632646645 WangYHuangHWengHJiaCLiaoBLongY Talin mechanotransduction in disease. Int J Biochem Cell Biol. 2024;166:106490. 10.1016/j.biocel.2023.10649037914021 McDowallASvenssonLStanleyPPatzakIChakravartyPHowarthK Two mutations in the KINDLIN3 gene of a new leukocyte adhesion deficiency III patient reveal distinct effects on leukocyte function in vitro. Blood. 2010;115:4834–42. 10.1182/blood-2009-08-23870920357244 XuZJobeSMMaYQShavitJA. A novel leukocyte adhesion deficiency type III mutation manifests functional importance of the compact FERM domain in kindlin-3. J Thromb Haemost. 2024;22:558–64. 10.1016/j.jtha.2023.10.01337866516 PecankovaKMajekPCermakJDyrJE. Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome. BioMed Res Int. 2015;2015:872983. 10.1155/2015/87298325969835 CzibereAGFröbelJHartwigSCadedduRPWilkMBrunsI Platelets derived from patients with myelodysplastic syndromes (MDS) show defective platelet aggregation and integrin αIIbβ3 receptor (GPIIb/IIIa) signaling caused by a reduced expression of proteins required for inside-out signaling. Blood. 2009;114:598. 10.1182/blood.V114.22.598.598 NardoGPozziSMantovaniSGarbelliSMarinouKBassoM Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS. Antioxid Redox Signal. 2009;11:1559–67. 10.1089/ars.2009.254819290778 GeigerBBershadskyAPankovRYamadaKM. Transmembrane extracellular matrix-cytoskeleton crosstalk. Nat Rev Mol Cell Biol. 2001;2:793–805. 10.1038/3509906611715046 ZhuLLiQWangXLiaoJZhangWGaoL THBS1 is a novel serum prognostic factor of acute myeloid leukemia. Front Oncol. 2020;9:1567. 10.3389/fonc.2019.0156732117788 PecankovaKCermakJMajekP. Proteomic case studies of MDS in progression: heterogeneity and more heterogeneity. Turk J Haematol. 2022;39:272–4. 10.4274/tjh.galenos.2022.2022.029036247531 DuhouxFPAmeyeGMontano-AlmendrasCPBahloulaKMozziconacciMJLaibeS PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. Br J Haematol. 2012;156:76–88. 10.1111/j.1365-2141.2011.08918.x22050763 WangYWWangWSWangLYBaoYRLuJWLuY Extracellular matrix remodeling effects of serum amyloid A1 in the human amnion: implications for fetal membrane rupture. Am J Reprod Immunol. 2019;81:e13073. 10.1111/aji.1307330461130 ChernakBGalan-DiezMAliAMCuesta-DominguezAChenZKoehnkeT Serum amyloid A1 (SAA1) secreted by the stromal microenvironment drives malignant clonal proliferation in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Blood. 2023;142:4118. 10.1182/blood-2023-174485 OkudaY. AA amyloidosis - benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019;29:268–74. 10.1080/14397595.2018.151514530132351 JanaAKGreenwoodABHansmannUHE. Small peptides for inhibiting serum amyloid A aggregation. ACS Med Chem Lett. 2021;12:1613–21. 10.1021/acsmedchemlett.1c0045634676044 Martín-GarcíaDGarcía-ArandaMRedondoM. Therapeutic potential of clusterin inhibition in human cancer. Cells. 2024;13:665. 10.3390/cells1308066538667280 ZhouYTanZXuePWangYLiXGuanF. High-throughput, in-depth and estimated absolute quantification of plasma proteome using data-independent acquisition/mass spectrometry (“HIAP-DIA”). Proteomics. 2021;21:e2000264. 10.1002/pmic.20200026433460299 LibertiMVLocasaleJW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211–8. 10.1016/j.tibs.2015.12.00126778478 HanJHLeeEJParkWHaKTChungHS. Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases. Front Pharmacol. 2023;14:1275000. 10.3389/fphar.2023.127500037915411 GuoLYangYShengYWangJLiWZhouX Galloflavin relieves the malignant behavior of colorectal cancer cells in the inflammatory tumor microenvironment. Front Pharmacol. 2021;12:752118. 10.3389/fphar.2021.75211834955826 LuQYZhangLYeeJKGoVLWLeeWN. Metabolic consequences of LDHA inhibition by epigallocatechin gallate and oxamate in MIA PaCa-2 pancreatic cancer cells. Metabolomics. 2015;11:71–80. 10.1007/s11306-014-0672-826246802
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020504" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020504" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020504" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(91) "Proteomics in myelodysplastic syndromes: towards novel prognostic and diagnostic biomarkers" ["journals_article_author"]=> string(58) "Ruđer Novak, Inga Mandac Smoljanović, Lovorka Grgurević" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(72) "myelodysplastic neoplasms, acute myeloid leukemia, biomarker, proteomics" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1843" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "5" ["meta_title"]=> string(91) "Proteomics in myelodysplastic syndromes: towards novel prognostic and diagnostic biomarkers" ["meta_desc"]=> string(91) "Proteomics in myelodysplastic syndromes: towards novel prognostic and diagnostic biomarkers" ["meta_keyw"]=> string(72) "myelodysplastic neoplasms, acute myeloid leukemia, biomarker, proteomics" ["created"]=> string(19) "2026-06-01 10:39:48" ["modified"]=> string(19) "2026-06-11 08:43:25" } [32]=> object(stdClass)#81 (35) { ["journals_id"]=> string(4) "1241" ["journals_xml"]=> string(142042) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020503 10.11613/BM.2026.020503 Reviews Myocardial fibrosis and viability: the role of imaging and biomarkers in patients with chronic total occlusion on coronary angiography Dragila TomašićŽeljka*12MaršićLea23MikolčićAnamaria1MaričićLana24Selthofer RelatićKristina24Šnajder MujkićDarija25 Department of Emergency Medicine, University Hospital Centre Osijek, Osijek, Croatia Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia Department of Emergency Medicine, General Hospital Našice, Našice, Croatia Division of Cardiology, Department of Internal Medicine, University Hospital Centre Osijek, Osijek, Croatia Clinical Institute for Nuclear Medicine and Radiation Protection, University Hospital Centre Osijek, Osijek, Croatia Corresponding author: zeljka.dragila5@gmail.com

Author contributions

Ž Dragila Tomašić: Conceptualization, Methodology, Supervision, Writing – original draft, Writing – review & editing; A Mikolčić: Visualisation, Writing – review & editing; L Maršić: Visualisation, Writing – review & editing; L Maričić: Visualisation, Writing – review & editing; K Selthofer Relatić: Supervision, Writing – review & editing; D Šnajder Mujkić: Conceptualization, Supervision, Writing – review & editing

15062026 15062026 36 2 020503 1810202519032026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Viable myocardium guides treatment decisions in chronic coronary disease

• Early detection of myocardial fibrosis may improve patient outcomes

• Terminal collagen propeptides are promising markers of myocardial fibrosis

• Galectin-3 links inflammation and fibrosis in the myocardium

• Identifying reliable fibrosis biomarkers could enhance viability assessment

In patients with chronic total occlusion on coronary angiography, myocardial viability assessment is an essential tool in guiding treatment decisions, especially revascularization. Current non-invasive tests are often limited by the presence of myocardial fibrosis. This narrative review incorporates evidence from 76 studies and aims to provide an updated overview of non-invasive methods for myocardial viability assessment, with emphasis on the role of myocardial fibrosis. Every imaging modality provides valuable information, even though they differ in sensitivity, specificity, availability, radiation exposure, contraindications and limitations in the presence of fibrosis. Biomarkers that provide insight into different aspects of myocardial fibrosis – including collagen synthesis (procollagen type I carboxy-terminal propeptide and procollagen type III amino-terminal propeptide), as well as inflammation and fibrotic signalling (galectin-3) – may complement imaging by reflecting myocardial remodelling. However, main limitations to this approach are no standardized reference ranges and cut-off values, analytical variability and insufficient validation for clinical outcomes prediction. Despite their potential to guide personalized revascularization decisions, circulating fibrosis biomarkers currently remain experimental tools. Further large-scale prospective clinical studies that incorporate biomarkers with imaging are needed before their implementation into clinical practice.

Keywords: biomarkerscollagencoronary artery diseasefibrosisgalectin 3
Introduction

Chronic total occlusion (CTO) is defined by the CTO Academic Research Consortium as major coronary artery occlusion without forward flow that has been present for ≥ 3 months (1). It is found in 15-20% of patients undergoing coronary angiography (2, 3). Although collateral circulation develops to compensate for reduced blood flow, it is often insufficient to fully restore myocardial perfusion (4).

The rate and severity of complications for percutaneous coronary intervention in patients with CTO are higher (1-3%) when compared to other procedures in chronic coronary syndrome (3, 5-7). However, performing percutaneous coronary intervention in patients with symptoms (angina or dyspnoea) significantly improves their quality of life compared to optimal medical therapy (8-11).

On the other hand, treatment decisions in asymptomatic patients rely on accurate myocardial viability assessment, which can predict functional recovery after revascularization (12, 13). Non-invasive imaging modalities used for myocardial viability assessment differ in specificity, sensitivity, availability, operator-dependence and radiation exposure (14, 15). Their diagnostic accuracy may also be complicated by the presence of myocardial fibrosis (16).

Circulating fibrosis biomarkers – procollagen type I carboxy-terminal propeptide (PICP), procollagen type III amino-terminal propeptide (PIIINP) and galectin-3 (Gal-3) – show promising results in viability assessment by reflecting direct tissue remodelling. They have the potential to identify fibrotic non-viable myocardium earlier and more precisely (17, 18).

The aim of this review is to summarize current non-invasive imaging modalities for myocardial viability assessment, explain the pathophysiological role of myocardial fibrosis and evaluate circulating fibrosis biomarkers as complementary tools for clinical decision-making for revascularization in patients with CTO.

Methods

This paper is a structured narrative review. A literature search was conducted and finished in May 2025 to identify publications relevant to the role of non-invasive imaging and circulating biomarkers (particularly PICP, PIIINP and Gal-3) in myocardial viability and fibrosis. The search covered publications from January 2005 to May 2025. It was performed using the PubMed/MEDLINE database because it provided the most comprehensive and peer-reviewed indexed sources in imaging and biomarker research relevant to CTO population. Non-indexed databases were excluded to improve clinical relevance and minimize heterogeneity. The following keywords and their combinations using Boolean operators (AND, OR) were used to refine the search: “myocardial viability”, “fibrosis biomarkers”, “myocardial fibrosis”, “imaging”, “chronic coronary syndrome”, “chronic total occlusion”, “PICP”, “PIIINP”, and “Galectin-3”. Titles/abstracts and full texts were screened by two independent reviewers, with disagreements resolved by a senior third reviewer.

Inclusion criteria:

Original research papers, meta-analyses, systematic reviews or guidelines

Studies including adult patients (> 18 years of age) with coronary artery disease, chronic coronary syndrome or heart failure with fibrosis related aetiology

Animal studies that provide insights relevant to fibrosis or myocardial viability

Studies evaluating non-invasive myocardial viability assessment and pathophysiology of myocardial fibrosis that are relevant to circulating fibrosis biomarkers (PICP, PIIINP, Gal-3).

Exclusion criteria:

Non-English articles

Case reports, editorials and conference abstracts

Pediatric or congenital heart disease population

Animal studies without relevance to fibrosis or myocardial viability.

After screening for eligibility, 76 studies were included as follows: 13 covering chronic total occlusion, 14 myocardial viability imaging modalities, 11 pathophysiology of myocardial fibrosis, 15 collagen biomarkers and 23 galectin-3. The study selection process is shown in Figure 1.

PRISMA-style flow diagram of the literature search and study selection process

Myocardial viability testing

In research and clinical practice, viable myocardium shows contractile cellular dysfunction at rest, which is expected to improve after coronary revascularization. Recurrent ischemia triggers myocardial hibernation – adaptive down-regulation of myocardial function – which exists on a clinical spectrum of reversible ischemic dysfunction (19). Myocardial stunning represents impaired contractility following resolution of acute ischemia, lasting for several hours or days, but recovering spontaneously (20). Both hibernating and stunned myocardium are considered viable. Viability should be considered as a spectrum, where revascularization of each component may yield diverse pathophysiological benefits (19).

The utility of a viability test is judged on its accurate prediction of contractile dysfunction reversal after revascularization using quantitative and/or qualitative measures. Improvement may occur within hours to days in areas of stunned myocardium, or months in areas of hibernating myocardium. Every imaging method focuses on a different element of pathophysiology (21). Viability imaging modalities differ in their advantages and limitations (Table 1), but they all play an essential role in the management of patients with chronic coronary syndrome and CTO. The choice should be individualized based on patient characteristics, possible contraindications, expertise and local availability (22).

Comparison of non-invasive imaging modalities for viable myocardium detection
Test Advantages Disadvantages
SPECT InexpensiveWidely available Exposure to radiationFalse negatives in the setting of multi-vessel diseaseFalse positives due to attenuation
PET Greater accuracy than SPECTAnatomical information Exposure to radiationLimited availability and facility expertise
DSE No exposure to radiation or contrastStructural informationHigher specificity in obese and female patients Dependant on technical expertise and imaging qualityLower sensitivity in the setting of single-vessel disease
CMR Higher sensitivity and specificityGives detailed structural information Expensive, limited availabilityContraindicated in advanced renal diseaseAffected by presence of arrythmia
*Adapted from (20). SPECT - single photon emission computed tomography. PET - positron emission tomography. DSE - dobutamine stress echocardiography. CMR - cardiac magnetic resonance.

Positron emission tomography (PET) assesses glucose metabolism using glucose analogues, where preserved glucose uptake indicates viable myocardium even when contractility is impaired. It demonstrates the highest sensitivity for detecting preserved metabolic activity and predicting contractile recovery. However, its accuracy depends on standardized preparations (fasting, glycemic control and insulin protocols) and does not directly quantify the scar tissue, which may lead to false positive results in acutely stunned or inflamed myocardium (23-26).

Single photon emission computed tomography (SPECT) evaluates regional blood flow by quantifying intracellular uptake of perfusion tracers (e.g., 99mTc-sestamibi). It is widely used due to its accessibility and familiarity, even though its lower spatial resolution and reduced accuracy in comparison to PET limits its use for detailed viability characterization (27, 28).

Dobutamine stress echocardiography (DSE) assesses contractile reserve by stimulating β1-adrenergic receptors with dobutamine, causing systolic thickening in viable myocardium. It has high specificity for predicting short and mid-term functional improvement after revascularization. However, image quality and interpretability depend on the acoustic window and operator expertise, which may reduce diagnostic accuracy (15).

Cardiac magnetic resonance (CMR) evaluates myocardial tissue using late gadolinium enhancement for scar quantification and quantitative mapping (native T1 and extracellular volume) for measurement of diffuse interstitial fibrosis. It provides the most comprehensive structural assessment, but its use may be limited due to availability, as well as in patients with renal dysfunction and implanted devices (29, 30).

A perfect method for myocardial viability testing has not been found. Fibrotic tissue, which results from chronic damage and remodelling, may not accurately reflect the true viability of the heart muscle. This can lead to challenges in distinguishing viable and non-viable tissue, influencing treatment plans. Therefore, it is important to understand the pathophysiology of myocardial fibrosis.

Myocardial fibrosis

Myocardial fibrosis represents a significant global health problem implicated in nearly all forms of heart disease leading to increased left ventricular stiffness and impaired contraction and relaxation (31, 32). It develops when persistent injury, such as chronic ischemia, pressure overload or neurohormonal activation, triggers sustained inflammatory and pro-fibrotic signalling (33).

The fibrotic response can be divided into three phases: the initiative, the effective and the amplificative phase (34). Sustained activation by mechanical stress stimulates the production of circulating and myocardial cytokines and pro-fibrotic growth factors which (in the effective phase) bind to their receptors triggering the activation of transcriptional factors and signalling pathways resulting in the transformation of cardiac fibroblasts into myofibroblasts (35). Activated myofibroblasts synthesize excess collagen type I and III and expand the extracellular matrix (ECM) (21, 36).

There are three main patterns of myocardial fibrosis – replacement, reactive interstitial and perivascular (Table 2). Replacement fibrosis reflects irreversible scarring after cardiomyocyte loss, while reactive interstitial and perivascular fibrosis represent diffuse remodelling that progresses despite preserved cardiomyocyte viability. Extensive fibrosis reduces the nutrient supply to the cardiomyocytes creating a vicious cycle of inflammation, cell death and ECM expansion (37).

Types of myocardial fibrosis
Type of fibrosis Characteristics Common cause Functional impact
Replacement Collagen scar formation replacing cardiomyocytesUsually reparative and protective* Myocardial infarction Systolic dysfunction
Reactive interstitial ECM accumulation without cardiomyocyte loss Chronic activation of pro-fibrotic stimuliHypertension, obesity, diabetes mellitusMicrovascular dysfunction Diastolic dysfunctionReduced left ventricular complianceImpaired myocardial perfusion
Perivascular Expansion of microvascular adventitia
*Replacement fibrosis has a critical protective role by ensuring the structural integrity of the heart and preventing mechanical complications after myocardial infarction (37). ECM - extracellular matrix.

These tissue-level changes have an impact on diagnostic testing. Expansion of the ECM increases the distribution volume for gadolinium, affecting late gadolinium enhancement patterns and T1 extracellular volume mapping on CMR (29, 30). Reduction of capillary density and alteration of mitochondrial function may impact tracer uptake in nuclear perfusion imaging, lowering the accuracy of PET and SPECT for viability assessment (28). Similarly, myocardial fibrosis limits contractile reserve, diminishing the sensitivity of DSE for identifying the potential for functional recovery (15).

Given the clinical significance of myocardial fibrosis, early detection and monitoring of its progression are crucial for improving patient outcomes. Circulating biomarkers of collagen turnover, fibrotic signalling and inflammation may serve as complementary tools and provide insight into myocardial remodelling.

Biomarkers of myocardial fibrosis

Circulating biomarkers, detected in blood or urine, should ideally reflect the underlying pathophysiological processes in the target conditions or organs (33). The investigation of myocardial fibrosis biomarkers has received increasing attention in research communities. They are often molecules that play an essential part in the complex process of fibrosis development (38). Endomyocardial biopsy with quantification of collagen volume fraction by histology remains the gold standard for the diagnosis and staging of myocardial fibrosis. However, it is an invasive procedure with a risk of sampling error which limits its use to selected patients and research settings (39). This highlights the need for non-invasive imaging and circulating fibrosis biomarkers.

Collagen synthesis biomarkers

As previously mentioned, myocardial fibrosis represents abnormal distribution and deposition of collagen, mainly increased collagen deposition and collagen turnover. Procollagen type I and III propeptides are markers of its synthesis and breakdown (38).

The ECM in the heart is composed predominantly of collagen type I (85%) and III (11%). They are both synthetized by cardiac fibroblasts as fibrillar collagen or procollagen, which is then split by proteinases in carboxy (C) and amino (N) terminal propeptides (40). Procollagen type I carboxy-terminal propeptide and procollagen type III amino-terminal propeptide are currently the only proven circulating peptides associated with proven myocardial interstitial fibrosis on endomyocardial biopsy (41).

Collagen type I is a fibrillar protein, aligned in fibres, present in almost all connective tissue structures, including bones, tendons, skin, sclera, blood vessels, as well as in other tissues providing a structural matrix. The dominant isoform is heterotrimer consisting of two α1 (I) and one α2 (I) chain (17). Its synthesis may be directly reflected by plasma concentrations of PICP because it is produced by cleavage in a ratio of 1:1 (42). On the other hand, PIIINP plasma concentrations may not be an accurate marker of collagen synthesis due to its smaller size, even though it has been linked to the amount of collagen type III fibres in the myocardium of heart failure patients (43).

Collagen type III is responsible for myocardial elasticity in reticular fibres in interstitial tissue of the heart, liver, lung and blood vessels. It is a homotrimer consisting of three α1 (III) chains overlapped in a triple helix (17). After proteases cleave propeptides of fibrillar collagen, PIIINP is released into the bloodstream by the lymphatics. It is considered to have an important role in fibril diameter, as well as having great storage capacity and stability (42).

A variety of immunoassay-based techniques are used to measure PICP and PIIINP, including enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (RIA), and electrochemiluminescence immunoassays (ECLIA). However, there is considerable analytical variability between platforms due to differences in calibration standards, antibody specificity and sample preparation requirements. This variability complicates obtaining cross-study comparisons and universal cut-off value definitions (43). The preferred sample type is serum, as plasma anticoagulants and residual fibrinogen may introduce assay interference by interfering with antibody binding (44). Even in serum samples, lipids, fibrin and inadequate centrifugation can introduce measurement error, while storage conditions differ between research and routine clinical laboratories. These factors contribute to variation between different laboratories that may exceed normal biological differences between patient groups (45, 46). Analytical performance and laboratory requirements of the most widely used assays for PICP and PIIINP are listed in Table 3 (47-51). While ECLIA-based methods show higher precision, greater automation and lower analytical variability, they are poorly harmonized across different manufacturers and reference ranges have not been standardized (51). On the other hand, ELISA kits are widely employed in research settings, but their higher inter-batch variability and operator-dependency limit clinical translation (52). Therefore, assay choice may impact study outcomes as much as underlying biological variation limiting the interpretation of PICP and PIIINP (53).

Analytical performance and laboratory requirements of the most widely used assays for procollagen type I C-terminal propeptide (PICP) and procollagen type III N-terminal propeptide (PIIINP)
Assay* Method Sample Type Detection limit Intra-assay variability Inter-assay variability Remarks‡
Takara BioPICP Sandwich ELISA Serum ~ 0.2 ng/mL < 5% < 7% Manual ELISA; widely used in research, 96-well format
Orion Diagnostica UniQPIIINP Radioimmunoassay Serum ~ 1 µg/L ~ 5% ~ 7% Historical use; requires radiation license
General† ECLIA Serum ~ 0.1-0.5 ng/mL < 3-5% < 5-8% Fully automated; high analytical precision; low sample volume; superior reproducibility
Cloud-ClonePICP Competitive ELISA Serum ~ 0.1 ng/mL < 10% < 12% Research use only; limited clinical validation
MyBioSourcePIIINP Competitive ELISA Serum 3.12 ng/ml < 15% < 15% Research-grade; manual handling
*From (47–51). †Performance values reflect the general analytical characteristics of ECLIA as standardized platform technology. Specific commercial ECLIA assays for PICP and PIIINP are not yet widely available. Values shown are based on validated ECLIA platforms reported in (51). ‡No standardized reference intervals or clinically validated cut-off values are currently available for circulating PICP or PIIINP as thresholds for myocardial viability or revascularization decision-making; reported values in the literature are assay- and disease-specific. ELISA - enzyme-linked immunosorbent assay. ECLIA - electrochemiluminescence immunoassay.

Concentrations of PIIINP are positively correlated with diastolic dysfunction in patients with heart failure with reduced ejection fraction, as well as left ventricular mass index and relative wall thickness in patients with left ventricular hypertrophy who have undergone successful coarctation of the aorta repair (54, 55). A cross-sectional study conducted by Yang et al. demonstrated that in patients with hypertrophic cardiomyopathy, plasma PICP concentrations correlated with myocardial PICP content and myocardial collagen volume fraction on histology (56). Ferreira et al. showed that PICP concentrations were significantly higher in hypertensive patients before treatment (57).

In the study by Raafs et al., fibrosis was quantified in 209 patients with dilated cardiomyopathy using endomyocardial biopsy with determination of collagen volume fraction, CMR with late gadolinium enhancement and circulating PICP and PIIINP concentrations (58). They found that circulating PICP concentrations were significantly higher in patients with myocardial fibrosis on CMR (91 (67–112) ng/mL vs. 77 (62–97) ng/mL, P = 0.02). RNA sequencing of endomyocardial biopsy tissue confirmed the increased expression of pro-inflammatory and pro-fibrotic pathways in patients with elevated PICP concentrations, and also demonstrated significant correlation with histologically proven myocardial fibrosis (R2 = 0.17, P = 0.001). Furthermore, PICP was independently associated with adverse cardiovascular events and mortality. They did not find such association or correlation with PIIINP (58).

In patients with non-ischemic dilated cardiomyopathy, elevated serum concentrations of PICP and PIIINP were associated with CMR findings of myocardial fibrosis (156 ng/mL vs. 74 ng/mL, P < 0.001; and 5.1 ng/mL vs. 3.5 ng/mL, P < 0.001, respectively). Additionally, a cut-off value of 44.4 ng/mL for PICP predicted myocardial fibrosis with 77.5% sensitivity, 76% specificity and a negative predictive value of 85.5%, while PIIINP at a cut-off value of 1.18 ng/mL had a 71.83% sensitivity, 83% specificity and a negative predictive value of 83.6% (59). However, these cut-off values were derived from a single disease and cannot be assumed for ischemic diseases or viability assessment due to different underlying mechanisms. No universally accepted diagnostic cut-offs exist for PICP or PIIINP; their values currently remain disease dependent and cannot be applied as criteria for revascularization.

The clinical diagnostic utility of PICP and PIIINP was investigated in a systematic review and meta-analysis conducted by Zhang et al. (60). They reviewed 1130 records from four databases and included 12 studies after independent screening. The results confirmed that patients with myocardial fibrosis had significantly elevated serum PICP (95% confidence interval (CI) = 0.40 to 1.40) and PIIINP (95% CI = 0.04 to 1.23) (60). A study by Ravassa et al. explored utility of PICP in differentiating patients with heart failure who would be more likely to experience myocardial recovery. They found that patients with lower PICP (< 108.1 ng/mL) showed greater left ventricular reverse remodelling and lower risk of outcome related to heart failure (61).

Patient characteristics such as age, body mass index, comorbidities and heart failure treatment (particularly spironolactone) can alter concentrations of these biomarkers by their effect on collagen turnover (62). It has been suggested that propeptides may be incorporated in the collagen fibre network, preventing them from being cleaved leading to underestimation of true PICP and PIIINP concentrations even in patients with extensive myocardial fibrosis (63). Also, circulating concentrations reflect systemic fibrosis; elevated concentrations may originate from non-cardiac fibrosis involving the liver, kidneys, bones or lungs. Therefore, increased concentration does not necessarily reflect in situ myocardial fibrosis (40). This population-dependent variability and lack of tissue specificity negatively impact the ability of PICP and PIIINP to discriminate reversible from irreversible myocardial dysfunction which is required to guide revascularization decisions.

Galectin-3

Galectin-3 regulates several cellular functions: growth, differentiation, proliferation, adhesion, apoptosis and tissue repair (64). Most commonly, it is located in the cytoplasm, as well as being expressed on the cellular surface. It is then secreted into biological fluids such as urine and blood. Additionally, injured and inflammatory cells release it under different pathological conditions (18). Galectin-3 is a potent inflammatory protein involved in acute and chronic inflammation by initiating and amplifying the inflammatory response (65, 66).

It is measured in plasma or serum using immunoassay-based techniques, most commonly ELISA or ECLIA (67). Galectin-3 concentrations do not differ significantly when measured in serum or plasma (68). Commercially available assays have different sensitivity and specificity, with reported limits of detection typically ranging from 0.1-0.3 ng/mL. Intra- and inter-assay coefficients of variation of different platforms are typically under 10% which is acceptable for clinical use, although platform-specific variability remains a major limitation to clinical interpretation (69). Consequently, Gal-3 concentrations cannot be directly compared across studies unless the same assay platform is used, while the absence of cross-platform standardization prevents establishment of universal cut-off values. Therefore, reported Gal-3 normal ranges cannot be uniformly applied and assay-specific interpretation remains necessary.

A study on rat models after myocardial infarction showed increased concentrations of Gal-3 and a later peak in non-infarcted myocardium demonstrating its role in cardiac remodelling (70). In a study by Liu et al., they infused Gal-3 into rats intrapericardially and reported its overexpression compromising the cardiomyocyte´s viability. They also noted elevated mast cell and macrophage infiltration, increased perivascular and interstitial fibrosis and cardiac hypertrophy (71).

Expression of Gal-3 is associated with increased fibroblast activity, ECM accumulation and production of collagen in the myocardium. It is also expressed in fibroblasts and macrophages after stressful events (72, 73). After activation, it forms a complex with transforming growth factor beta on the cell surface which stimulates fibrosis development. This signal, along with mechanical stress, transforms fibroblasts into active myofibroblasts that produce collagen (74).

Some recent studies investigated the Gal-3 upper reference limit in a healthy population of blood donors. They measured Gal-3 by using the Architect STAT Galectin-3 immunoassay. Median Gal-3 plasma concentration was 14.3 ng/mL (interquartile range 11.9-16.7 ng/mL), while the 97.5th percentile upper reference limit (URL) of normal in their study population (90% CI) was 26.1 (23.3-31.5) ng/mL. No sex-related differences were found. In contrast, age was a confounding variable that affected its concentration – the URL of Gal-3 was found to be higher in older (> 45 years) than in younger subjects (31.5 (26.2-51.4) vs. 21.8 (21-26.1) ng/mL, respectively) (75, 76). This indicates that population-based reference intervals are affected by age, as well as being assay-specific, limiting their routine clinical interpretation.

In a study of patients with non-ischemic dilated cardiomyopathy, elevated Gal-3 concentrations were associated with findings of myocardial fibrosis on CMR (17.7 ng/mL vs. 9.1 ng/mL, P < 0.001). Furthermore, a cut-off value of 11 ng/mL predicted myocardial fibrosis with 90.4% sensitivity, 66.1% specificity and 92% negative predictive value (59). These thresholds were derived from a single disease entity, which cannot be anticipated for viability assessment in ischemic disease due to different underlying mechanisms. For example, remodelling after myocardial infarction involves acute macrophage activation and transient sharp Gal-3 elevation, while chronic ischemic disease is characterized by lower inflammatory markers as part of chronic interstitial fibrosis. Consequently, similar Gal-3 concentrations may reflect transient and reversible inflammation in certain patients but irreversible fibrosis in others, depending on the remodelling mechanism (64, 77).

Galectin-3 measurement is endorsed by the 2017 Guidelines of the American Heart Association for assessing risk and evaluating prognosis of patients with heart failure. Different mechanisms are involved in the promotion of heart failure by Gal-3, some of which are: inflammatory cell infiltration, fibroblast proliferation and cardiomyocytes hypertrophy (64). The threshold of 17.8 ng/mL is often considered to successfully discriminate between low-risk and high-risk for clinical complications in heart failure patients (74).

Galectin-3 has also been investigated in other cardiovascular diseases, especially those initiated and stimulated by inflammation, where elevated concentrations reflect disease activity and severity, as well as adverse prognosis (78-82). In a study by Screever et al. they investigated the association of CMR-identified fibrosis with Gal-3 after myocardial infarction. Concentrations of Gal-3 were higher in patients with CMR-identified fibrosis (20 vs. 15 ng/mL, P = 0.004) (83). In another study by Asleh et al., Gal-3 concentrations above 15.1 ng/mL were associated with a higher risk of heart failure and death after myocardial infarction, even after adjustment for age, sex, comorbidities and troponin levels (84). A study by Sherpa et al. showed that elevated concentrations of Gal-3 are associated with a higher risk of myocardial fibrosis and sudden cardiac death (85). This shows the importance of larger studies that would target Gal-3 to prevent myocardial fibrosis and lower the risk of sudden cardiac death.

Limitations and clinical utility of fibrosis biomarkers in predicting myocardial viability

Even though circulating biomarkers such as PICP, PIIINP and Gal-3 reflect remodelling of the ECM, they have rarely been studied in association with functional recovery after revascularization, the clinical definition of myocardial viability. Published data mostly investigate their correlation with fibrosis burden on non-invasive imaging, without an evaluation of contractility improvement, perfusion or symptom relief after revascularization (43, 63). Additionally, elevated circulating biomarker concentrations do not indicate irreversible scar, as they may also reflect active inflammation or diffuse interstitial fibrosis without loss of function (64). Different concentrations across various cardiovascular diseases, limited tissue specificity and lack of standardized cut-offs reduce their discriminative power in distinguishing reversible from irreversible myocardial dysfunction. There is currently no biomarker cut-off that reliably differentiates myocardium capable of recovery from an irreversible scar.

They provide information on underlying biological processes of myocardial remodelling, but currently lack outcome-based validation. Consequently, their use remains primarily experimental. They should be interpreted as complementary indicators of remodelling, not as the determinants of revascularization decisions. Well-designed clinical studies incorporating biomarkers with contemporary imaging are required before their usage in routine viability assessment.

To enable comparison of the available circulating fibrosis biomarkers, Table 4 summarizes their underlying biological pathways, commonly used analytical methods, current level of clinical validation and key strengths and limitations.

Comparison of circulating fibrosis biomarkers relevant to myocardial viability assessment
Biomarker Biological pathway Analytical methods Clinical validation Strengths Limitations
PICP Collagen type I synthesisReplacement and interstitial fibrosis ELISARIAECLIA ModerateCorrelates with CMR fibrosis, biopsy collagen volume fraction, remodelling and outcomes in heart failureLimited data in ischemic viability Strongest correlation with collagen type I turnoverAutomated ECLIA platforms availableIndependent association with adverse outcomes Affected by systemic fibrosis (bone, liver)Assay variability and lack of harmonized cut-offsUnderestimates fibrosis if propeptides remain in extracellular matrix
PIIINP Collagen type III synthesisEarly interstitial fibrosis ELISARIAECLIA Low–moderateAssociated with heart failure severity and remodelling Reflects dynamic collagen turnoverUseful in heart failure and hypertrophic cardiomyopathy Less specific for myocardial fibrosisHigher biological variabilityInfluenced by liver disease, obesity, systemic inflammationLimited prognostic value
Galectin-3 Macrophage activationInflammationFibrosis signallingFibroblast proliferation ELISAECLIA ModerateValidated predictor of heart failure hospitalization and mortalityCorrelates with diffuse fibrosis on CMR Reflects upstream fibrotic signallingStable in serum/plasmaLarge body of clinical outcome data Not specific to cardiac tissueInfluenced by age and renal functionAssay variability and non-unified reference intervalsElevations may reflect inflammation
PICP - procollagen type I C-terminal propeptide. PIIINP - procollagen type III N-terminal propeptide. ELISA - enzyme-linked immunosorbent assay. RIA - radioimmunoassay. ECLIA - electrochemiluminescence immunoassay. CMR - cardiac magnetic resonance.
Telomere length determination as an emerging biomarker of myocardial fibrosis

Cellular aging and repeated inflammatory or oxidative stress progressively shorten the telomeres. These processes are also integral to fibroblast activation and ECM expansion (86). Studies have shown that shortened leukocyte telomeres correlate with the degree of cardiac aging (87).

Telomere length can be measured with fluorescence in-situ hybridization (flow-FISH), quantitative polymerase chain reaction (PCR) or Southern blot analysis, with quantitative PCR being the most widely used because of its low sample requirements and scalability. Nevertheless, lack of standardized reference ranges, assay variability and low specificity currently limit its clinical application (88).

Despite these limitations, telomere length assessment provides insight into the burden of remodelling and cellular stress. In future, it may complement other biomarkers to improve stratification of patients with chronic coronary syndrome, especially those with CTO in whom the degree of irreversible remodelling influences viability and benefit from revascularization.

Conclusion

Reliable myocardial viability evaluation represents a key step in selecting patients with chronic coronary syndrome and CTO who are most likely to benefit from revascularization. Circulating fibrosis biomarkers, such as PICP, PIIINP and Gal-3 reflect ECM remodelling and may complement non-invasive imaging modalities in identifying patients with irreversible myocardial fibrosis who are less likely to benefit from revascularization. However, these biomarkers are currently associated with fibrosis burden rather than functional recovery after revascularization. No biomarker cut-off has been prospectively validated in large-scale studies to reliably discriminate reversible dysfunction from irreversible scar.

Circulating fibrosis biomarkers should therefore be used as adjunctive tools that reflect underlying biological processes, not as standalone guides for revascularization decisions. Their integration into clinical guidelines and pathways requires large-scale prospective outcome-based studies that link biomarker concentrations with contractility recovery and perfusion improvement. Future research should focus on standardizing assays and reference intervals, finding disease-specific cut-offs that differentiate acute inflammation from established fibrosis, as well as prospective strategies that combine biomarkers with advanced non-invasive imaging modalities.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References YbarraLFRinfretSBrilakisESKarmpaliotisDAzzaliniLGranthamJA Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies: CTO-ARC Consensus Recommendations. Circulation. 2021;143:479–500. 10.1161/CIRCULATIONAHA.120.04675433523728 AzzaliniLJolicoeurEMPighiMMillánXPicardFTadrosVX Epidemiology, management strategies, and outcomes of patients with chronic total coronary occlusion. Am J Cardiol. 2016;118:1128–35. 10.1016/j.amjcard.2016.07.02327561190 SimsekBKostantinisSKaracsonyiJAlaswadKKrestyaninovOKhelimskiiD Predicting periprocedural complications in chronic total occlusion percutaneous coronary intervention: The PROGRESS-CTO complication scores. JACC Cardiovasc Interv. 2022;15:1413–22. 10.1016/j.jcin.2022.06.00735863789 KoelblCONedeljkovicZSJacobsAK. Coronary chronic total occlusion (CTO): A review. Rev Cardiovasc Med. 2018;19:33–9. 10.31083/j.rcm.2018.01.89631032601 StegPGGreenlawNTenderaMTardifJCFerrariRAl-ZaibagM Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: Data from the international observational CLARIFY registry. JAMA Intern Med. 2014;174:1651–9. 10.1001/jamainternmed.2014.377325110899 BrilakisESBanerjeeSKarmpaliotisDLombardiWLTsaiTTShunkKA Procedural outcomes of chronic total occlusion percutaneous coronary intervention: A report from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2015;8:245–53. 10.1016/j.jcin.2014.08.01425700746 GalassiARBoukhrisMTomaAElhadjZILaroussiLGaemperliO Percutaneous coronary intervention of chronic total occlusions in patients with low left ventricular ejection fraction. JACC Cardiovasc Interv. 2017;10:2158–70. 10.1016/j.jcin.2017.06.05829055762 YehRWTamezHSecemskyEAGranthamJASapontisJSpertusJA Depression and angina among patients undergoing chronic total occlusion percutaneous coronary intervention: The OPEN-CTO registry. JACC Cardiovasc Interv. 2019;12:651–8. 10.1016/j.jcin.2018.12.02930878475 ObedinskiyAAKretovEIBoukhrisMKurbatovVPOsievAGIbn ElhadjZ The IMPACTOR-CTO trial. JACC Cardiovasc Interv. 2018;11:1309–11. 10.1016/j.jcin.2018.04.01729976368 JuricicSATesicMBGalassiARPetrovicONDobricMROrlicDN Randomized controlled comparison of optimal medical therapy with percutaneous recanalization of chronic total occlusion (COMET-CTO). Int Heart J. 2021;62:16–22. 10.1536/ihj.20-42733518655 WernerGSMartin-YusteVHildick-SmithDBoudouNSianosGGelevV A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39:2484–93. 10.1093/eurheartj/ehy22029722796 EliasJVan DongenIMHoebersLPOuweneelDMClaessenBEPMRåmunddalT Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial. J Cardiovasc Magn Reson. 2017;19:53. 10.1186/s12968-017-0369-z28724418 MegalyMSaadMTajtiPBurkeMNChavezIGösslM Meta-analysis of the impact of successful chronic total occlusion percutaneous coronary intervention on left ventricular systolic function and reverse remodeling. J Interv Cardiol. 2018;31:562–71. 10.1111/joic.1253829974508 CantonLSumaNAmiconeSImpellizzeriABodegaFMarinelliV Clinical impact of multimodality assessment of myocardial viability. Echocardiography. 2024;41:e15854. 10.1111/echo.1585438940225 GarciaMJKwongRYScherrer-CrosbieMTaubCCBlanksteinRLimaJ State of the art: Imaging for myocardial viability: A scientific statement from the American Heart Association. Circ Cardiovasc Imaging. 2020;13:e000053. 10.1161/HCI.000000000000005332833510 BingRDweckMR. Myocardial fibrosis: why image, how to image and clinical implications. Heart. 2019;105:1832–40. 10.1136/heartjnl-2019-31556031649047 NikolovAPopovskiN. Extracellular matrix in heart disease: Focus on circulating collagen type i and iii derived peptides as biomarkers of myocardial fibrosis and their potential in the prognosis of heart failure: A concise review. Metabolites. 2022;12:297. 10.3390/metabo1204029735448484 HaraANiwaMNoguchiKKanayamaTNiwaAMatsuoM Galectin-3 as a next-generation biomarker for detecting early stage of various diseases. Biomolecules. 2020;10:389. 10.3390/biom1003038932138174 RyanMMorganHChiribiriANagelEClelandJPereraD. Myocardial viability testing: all STICHed up, or about to be REVIVED? Eur Heart J. 2022;43:118. 10.1093/eurheartj/ehab72934791132 Vaidya Y, Cavanaugh SM, Dhamoon AS. Myocardial stunning and hibernation. StatPearls [Internet]. 2023 Aug [cited 2024 Nov 3]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK537026/. BengelFMDiekmannJHessAJerosch-HeroldM. Myocardial fibrosis: Emerging target for cardiac molecular imaging and opportunity for image-guided therapy. J Nucl Med. 2023;64:49S–58S. 10.2967/jnumed.122.26486737918842 BabesEETitDMBungauAFBusteaCRusMBungauSG Myocardial viability testing in the management of ischemic heart failure. Life (Basel). 2022;12:1760. 10.3390/life1211176036362914 LiDLKronenbergMW. Myocardial perfusion and viability imaging in coronary artery disease: clinical value in diagnosis, prognosis, and therapeutic guidance. Am J Med. 2021;134:968–75. 10.1016/j.amjmed.2021.03.01133864764 MadsenSDiasAHLauritsenKMBoucheloucheKTolbodLPGormsenLC. Myocardial viability testing by positron emission tomography: Basic concepts, mini-review of the literature and experience from a tertiary PET center. Semin Nucl Med. 2020;50:248–59. 10.1053/j.semnuclmed.2020.02.01032284111 LeeYJangJLimSNaSJ. Evaluation of clinical variables affecting myocardial glucose uptake in cardiac FDG PET. Diagnostics (Basel). 2024;14:1705. 10.3390/diagnostics1416170539202193 SinghVDorbalaS. Normal variants and pitfalls in cardiac PET/CT. Semin Nucl Med. 2021;51:441–57. 10.1053/j.semnuclmed.2021.04.00434049686 ManapragadaPPAndrikopoulouEBajajNBhambhvaniP. PET cardiac imaging (perfusion, viability, sarcoidosis, and infection). Radiol Clin North Am. 2021;59:835–52. 10.1016/j.rcl.2021.05.00934392922 KatikireddyCKSamimA. Myocardial viability assessment and utility in contemporary management of ischemic cardiomyopathy. Clin Cardiol. 2022;45:152–61. 10.1002/clc.2377935077580 SohnSHKangYKimJSParkEALeeWHwangHY. Impact of myocardial viability on long-term outcomes after surgical revascularization. Thorac Cardiovasc Surg. 2024;72:441–8. 10.1055/a-2228-710438092064 YangXTianJZhangLDongWMiHLiJ Myocardial viability, functional status, and collaterals of patients with chronically occluded coronary arteries. Front Cardiovasc Med. 2021;8:754826. 10.3389/fcvm.2021.75482634869665 TraversJGKamalFARobbinsJYutzeyKEBlaxallBC. Cardiac fibrosis: The fibroblast awakens. Circ Res. 2016;118:1021–40. 10.1161/CIRCRESAHA.115.30656526987915 MaZGYuanYPWuHMZhangXTangQZ. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci. 2018;14:1645. 10.7150/ijbs.2810330416379 SuthaharNMeijersWCSilljéHHWde BoerRA. From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities. Curr Heart Fail Rep. 2017;14:235–50. 10.1007/s11897-017-0343-y28707261 KongPChristiaPFrangogiannisNG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71:549–74. 10.1007/s00018-013-1349-623649149 SaadatSNoureddiniMMahjoubin-TehranMNazemiSShojaieLAschnerM Pivotal role of TGF-β/Smad signaling in cardiac fibrosis: Non-coding RNAs as effectual players. Front Cardiovasc Med. 2021;7:588347. 10.3389/fcvm.2020.58834733569393 FrangogiannisNG. Cardiac fibrosis. Cardiovasc Res. 2021;117:1450–88. 10.1093/cvr/cvaa32433135058 PiekAde BoerRASilljéHHW. The fibrosis-cell death axis in heart failure. Heart Fail Rev. 2016;21:199–211. 10.1007/s10741-016-9536-926883434 AnZYangGZhengHNieWLiuG. Biomarkers in patients with myocardial fibrosis. Open Life Sci. 2017;12:337–44. 10.1515/biol-2017-0039 HahnVSYanekLRVaishnavJYingWVaidyaDLeeYZJ Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020;8:712–24. 10.1016/j.jchf.2020.04.00732653448 LijnenPJMaharaniTFinahariNSPrihadiJ. Serum collagen markers and heart failure. Cardiovasc Hematol Disord Drug Targets. 2012;12:51–5. 10.2174/18715291280182314722524171 GonzálezASchelbertEBDíezJButlerJ. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018;71:1696–706. 10.1016/j.jacc.2018.02.02129650126 DingYWangYZhangWJiaQWangXLiY Roles of biomarkers in myocardial fibrosis. Aging Dis. 2020;11:1157–74. 10.14336/AD.2020.060433014530 LópezBGonzálezARavassaSBeaumontJMorenoMUSan JoséG Circulating biomarkers of myocardial fibrosis: The need for a reappraisal. J Am Coll Cardiol. 2015;65:2449–56. 10.1016/j.jacc.2015.04.02626046739 BoltonJSChaudhurySDuttaSGregorySLockeEPiersonT Comparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination. Malar J. 2020;19:159. 10.1186/s12936-020-03225-532303235 LippiGCadamuroJVon MeyerASimundicAM. Practical recommendations for managing hemolyzed samples in clinical chemistry testing. Clin Chem Lab Med. 2018;56:718–27. 10.1515/cclm-2017-110429373316 TuckMKChanDWChiaDGodwinAKGrizzleWEKruegerKE Standard operating procedures for serum and plasma collection: Early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8:113. 10.1021/pr800545q19072545 ELISA Kit for procollagen i c-terminal propeptide (PICP) | SEA570Hu | Homo sapiens (Human) CLOUD-CLONE CORP.(CCC). Available from: https://www.cloud-clone.com/products/SEA570Hu.html. Accessed July 21st 2025. Ordering information technical information. Available from: www.oriondiagnostica.com. Accessed July 21st 2025. Procollagen type I C-peptide (PIP) detection. Available from: https://www.takarabio.com/products/antibodies-and-elisa/primary-antibodies-and-elisas-by-research-area/bone-research/procollagen-type-i-c-peptide?srsltid=AfmBOorB-PVz2IEMJ6dZ0ODHaOiKc5dlptpNtexlqpvO9t9HQ9owdrhz. Accessed July 21st 2025. PIIINP elisa kit | Human Procollagen III N-Terminal Propeptide ELISA Kit. Available from: https://www.mybiosource.com/piiinp-human-elisa-kits/procollagen-iii-n-terminal-propeptide/76351. Accessed July 21st 2025. Premnath SM, Zubair M. Electrochemiluminescence method. StatPearls [Internet]. 2023 Jun [cited 2025 Jul 21]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK594228/. AydinSEmreEUgurKAydinMASahinİCinarV An overview of ELISA: a review and update on best laboratory practices for quantifying peptides and proteins in biological fluids. J Int Med Res. 2025;53:3000605251315913. 10.1177/0300060525131591339922798 RubiśPPDziewięckaEGonzálezAClelandJGF. High variability in assays of blood markers of collagen turnover in cardiovascular disease: Implications for research and clinical practice. Eur J Heart Fail. 2025;27:901–4. 10.1002/ejhf.337538980205 LinYTLinYHWuXMKoCLYenRFChenYH The relationship between serum fibrosis markers and restrictive ventricular filling in patients with heart failure with reduced ejection fraction: A technetium-99m radionuclide ventriculography study. Oncotarget. 2017;8:2381–90. 10.18632/oncotarget.1379527924061 YamazawaHMurakamiTTakedaATakeiKFurukawaTNakajimaH. Serum concentration of procollagen type III amino-terminal peptide is increased in patients with successfully repaired coarctation of the aorta with left ventricular hypertrophy. Pediatr Cardiol. 2015;36:555–60. 10.1007/s00246-014-1049-525311763 YangCQiaoSSongYLiuYTangYDengL Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2019;43:107150. 10.1016/j.carpath.2019.10715031639652 FerreiraJPRossignolPPizardAMachuJLCollierTGirerdN Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart. 2019;105:307–14. 10.1136/heartjnl-2018-31318230121630 RaafsAGVerdonschotJAJHenkensMTHMAdriaansBPWangPDerksK The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. Eur J Heart Fail. 2021;23:933–44. 10.1002/ejhf.220133928704 RevnicRCojan-MinzatBOZlibutAOrzanRIAgostonRMuresanID The role of circulating collagen turnover biomarkers and late gadolinium enhancement in patients with non-ischemic dilated cardiomyopathy. Diagnostics (Basel). 2022;12:1435. 10.3390/diagnostics1206143535741245 ZhangTXueQZhuRJiangY. Diagnostic value of PICP and PIIINP in myocardial fibrosis: A systematic review and meta-analysis. Clin Cardiol. 2022. 10.1002/clc.2390136468277 RavassaSLupónJLópezBCodinaPDomingoMRevuelta-LópezE Prediction of left ventricular reverse remodeling and outcomes by circulating collagen-derived peptides. JACC Heart Fail. 2023;11:58–72. 10.1016/j.jchf.2022.09.00836599551 PellicoriPFerreiraJPMariottoniBBrunner-La RoccaHPAhmedFZVerdonschotJ Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. Eur J Heart Fail. 2020;22:1711–23. 10.1002/ejhf.171631950604 NikolovATzekovaMKostovK. Serum biomarkers of collagen type i and type iii turnover in heart failure – the need for reappraisal. Acta Med Croatica. 2020;74:145–52. SeropianIMCassagliaPMiksztowiczVGonzálezGE. Unraveling the role of Galectin-3 in cardiac pathology and physiology. Front Physiol. 2023;14:1304735. 10.3389/fphys.2023.130473538170009 WangXGaurMMounzihKRodriguezHJQiuHChenM Inhibition of Galectin-3 post-infarction impedes progressive fibrosis by regulating inflammatory profibrotic cascades. Cardiovasc Res. 2023;119:2536–49. 10.1093/cvr/cvad11637602717 BošnjakISelthofer-RelaticKVčevA. Prognostic value of galectin-3 in patients with heart failure. Dis Markers. 2015;2015:690205. 10.1155/2015/69020525960597 de BoerRALokDJAJaarsmaTVan Der MeerPVoorsAAHillegeHL Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60–8. 10.3109/07853890.2010.53808021189092 ChristensonRHDuhSHWuAHBSmithAAbelGdeFilippiCR Multi-center determination of Galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem. 2010;43:683–90. 10.1016/j.clinbiochem.2010.02.00120153309 LokDJAVan Der MeerPDe La PortePWBALipsicEVan WijngaardenJHillegeHL Prognostic value of Galectin-3, a novel marker of fibrosis in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323–8. 10.1007/s00392-010-0125-y20130888 Sanchez-MasJLaxAAsensio-LopezMCFernandez-Del PalacioMJCaballeroLGarridoIP Galectin-3 expression in cardiac remodeling after myocardial infarction. Int J Cardiol. 2014;172:e98–101. 10.1016/j.ijcard.2013.12.12924433619 LiuYHD’AmbrosioMLiaoTDPengHRhalebNESharmaU N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by Galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296:H404–12. 10.1152/ajpheart.00747.200819098114 BouffetteSBotezIDe CeuninckF. Targeting Galectin-3 in inflammatory and fibrotic diseases. Trends Pharmacol Sci. 2023;44:519–31. 10.1016/j.tips.2023.06.00137391294 SeropianIMEl-DiastyMEl-SherbiniAHGonzálezGERabinovichGA. Central role of Galectin-3 at the cross-roads of cardiac inflammation and fibrosis: Implications for heart failure and transplantation. Cytokine Growth Factor Rev. 2024;80:47–58. 10.1016/j.cytogfr.2024.10.00239482190 BlandaVBracaleUMDi TarantoMDFortunatoG. Galectin-3 in cardiovascular diseases. Int J Mol Sci. 2020;21:1–18. 10.3390/ijms2123923233287402 AgnelloLBelliaCLo SassoBPivettiAMuratoreMScazzoneC Establishing the upper reference limit of Galectin-3 in healthy blood donors. Biochem Med (Zagreb). 2017;27:030709. 10.11613/BM.2017.03070929180917 MuellerTEggerMLeitnerIGabrielCHaltmayerMDieplingerB. Reference values of Galectin-3 and cardiac troponins derived from a single cohort of healthy blood donors. Clin Chim Acta. 2016;456:19–23. 10.1016/j.cca.2016.02.01426920637 LeancăSACrișuDPetrișAOAfrăsânieIGenesACostacheAD Left ventricular remodeling after myocardial infarction: From physiopathology to treatment. Life. 2022;12:1111. 10.3390/life1208111135892913 LyngbakkenMNMyhrePLRøsjøHOmlandT. Novel biomarkers of cardiovascular disease: Applications in clinical practice. Crit Rev Clin Lab Sci. 2019;56:33–60. 10.1080/10408363.2018.152533530457415 BošnjakIBedekovićD. Selthofer- Relatić K, Bilić-Ćurčić I. Galectin-3: A heart failure biomarker as sign of active coronary heart disease. World J Cardiovasc Dis. 2017;7:373–9. 10.4236/wjcd.2017.711035 BošnjakIBedekovićDSelthofer-RelatićKRoguljićHBilić-ĆurčićI. Association of galectin-3 and significant atherosclerotic epicardial artery disease in patients with chronic coronary syndrome. Cardiol Croat. 2022;17:167. 10.15836/ccar2022.167 BošnjakIBedekovićDSelthofer-RelatićKRoguljićHMihaljevićIDukićD Heart failure biomarkers in revascularized patients with stable coronary heart disease as clinical outcome predictors. Front Cardiovasc Med. 2024;11:1458120. 10.3389/fcvm.2024.145812039346100 BošnjakIBedekovićDSelthofer-RelatićKRoguljićHMihaljevićIBilić-ĆurčićI. Role of galectin-3 in diagnosis and severity assessment of epicardial artery lesions in patients with suspected coronary artery disease. BMC Cardiovasc Disord. 2023;23:268. 10.1186/s12872-023-03310-y37221462 ScreeverEMGorterTMWillemsTPAboumsallemJPSuthaharNMahmoudB Diffuse myocardial fibrosis on cardiac magnetic resonance imaging is related to Galectin-3 and predicts outcome in heart failure. Biomolecules. 2023;13:410. 10.3390/biom1303041036979345 AslehREnriquez-SaranoMJaffeASManemannSMWestonSAJiangR Galectin-3 levels and outcomes after myocardial infarction: A population-based study. J Am Coll Cardiol. 2019;73:2286–95. 10.1016/j.jacc.2019.02.04631072572 SherpaMDSonkawadeSDJonnalaVPokharelSKhazaeliMYatsynovichY Galectin-3 is associated with cardiac fibrosis and an increased risk of sudden death. Cells. 2023;12:1218. 10.3390/cells1209121837174619 SagrisMTheofilisPAntonopoulosASTsioufisKTousoulisD. Telomere length: A cardiovascular biomarker and a novel therapeutic target. Int J Mol Sci. 2022;23:16010. 10.3390/ijms23241601036555658 van DuijvenbodenSNelsonCPRaisi-EstabraghZRamirezJOriniMWangQ Leucocyte telomere length and conduction system ageing. Heart. 2025;111:314–20. 10.1136/heartjnl-2024-32487539689933 Martin-RuizCMBairdDRogerLBoukampPKrunicDCawthonR Reproducibility of telomere length assessment: an international collaborative study. Int J Epidemiol. 2015;44:1673–83. 10.1093/ije/dyu19125239152
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020503" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020503" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020503" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(134) "Myocardial fibrosis and viability: the role of imaging and biomarkers in patients with chronic total occlusion on coronary angiography" ["journals_article_author"]=> string(130) "Željka Dragila Tomašić, Lea Maršić, Anamaria Mikolčić, Lana Maričić, Kristina Selthofer Relatić, Darija Šnajder Mujkić" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(67) "biomarkers, collagen, coronary artery disease, fibrosis, galectin 3" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1190" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "4" ["meta_title"]=> string(134) "Myocardial fibrosis and viability: the role of imaging and biomarkers in patients with chronic total occlusion on coronary angiography" ["meta_desc"]=> string(134) "Myocardial fibrosis and viability: the role of imaging and biomarkers in patients with chronic total occlusion on coronary angiography" ["meta_keyw"]=> string(67) "biomarkers, collagen, coronary artery disease, fibrosis, galectin 3" ["created"]=> string(19) "2026-05-28 12:00:46" ["modified"]=> string(19) "2026-06-11 08:42:11" } [33]=> object(stdClass)#82 (35) { ["journals_id"]=> string(4) "1229" ["journals_xml"]=> string(143099) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020502 10.11613/BM.2026.020502 Reviews Procollagen I carboxy-terminal propeptide: a multi-faceted biomarker JainSharon Philip*1IkkurthyNiharika2SundaraSwetha3JainShervinchris Philip4 Department of Medicine, David Tvildiani Medical University, Tbilisi, Georgia Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, USA Department of Community Medicine, Rangaraya Medical College, Kakinada, India Department of Medicine, Jubilee Mission Medical College and Research Institute, Kerala, India Corresponding author: sharon4olaseril@gmail.com

Author contributions

S Jain: Conceptualization, Methodology, Project administration, Supervision, Visualisation, Writing – original draft, Writing – review & editing. N Ikkurthy: Conceptualization, Methodology, Project administration, Supervision, Visualisation, writing- original draft, writing- review and editing. S Sundara: Conceptualization, Writing – original draft, Writing – review & editing. Sh Jain: Conceptualization, Writing – original draft, Writing – review & editing.

15042026 15062026 36 2 020502 0506202518022026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Procollagen I carboxy-terminal propeptide (PICP) is a marker of collagen production across many body systems

• It helps assess prognosis and monitor treatment across several diseases

• Emerging evidence suggests PICP could become a valuable tool across medical specialties

• Further research is required to define its role in routine diagnostics

• More studies are needed to establish PICP reference values

Procollagen I carboxy-terminal propeptide (PICP) is a cleavage product of procollagen I, the precursor of type I collagen. Type I collagen is the most abundant type of collagen in the human body and plays a central role in maintaining structural integrity across tissues such as skin, bone, vasculature, and connective organs. Procollagen I carboxy-terminal propeptide, released during collagen synthesis, has been associated with fibrotic activity and tissue remodeling in different conditions across organ systems, including the heart, lungs, liver, kidneys, skin, and musculoskeletal system. Although many studies have investigated PICP in individual diseases, ranging from cardiomyopathies to liver cirrhosis and chronic lung disorders, its overall diagnostic and prognostic value remain incompletely defined. Serum PICP is a biomarker of fibrotic activity, with potential to be a valuable screening tool or component of diagnostic risk scores before moving to invasive methods such as biopsy. The ability to monitor fibrotic progression or therapeutic response through a simple blood test presents an opportunity for earlier diagnosis, improved disease stratification, and more efficient treatment monitoring. This literature review aims to provide a comprehensive synthesis of current knowledge on PICP, focusing on its biological role in collagen metabolism and clinical applications. By critically evaluating recent advances in assay methodologies, reference ranges, and interpretation in diverse patient populations, this review highlights both the strengths and limitations of PICP as a diagnostic and prognostic tool to identify future directions for research and clinical practice.

Keywords: Procollagen I carboxy-terminal propeptidecollagenbiomarkerfibrosis
Introduction

Collagen is an extracellular structural protein whose function depends upon a triple helical structure of three polypeptide chains twisted around each other, wherein there are additional globular domains in addition to the triple helices (1, 2). Among the 28 known collagen types, type I collagen (COL1) is the most abundant in tissues such as skin, bone, tendons, and blood vessels, accounting for approximately 90% of the body’s collagen content (3, 4).

Due to its near ubiquity, the monitoring of collagen synthesis can play an important diagnostic role in multiple disease systems (2, 5, 6). Often, propeptides are used as a measure of collagen synthesis and degradation, with serum concentrations of carboxy-terminal (C-terminal) propeptide of procollagen I (PICP) used as a measure of extracellular COL1 synthesis, and C-terminal telopeptide of type I collagen (ICTP) used as a marker of extracellular COL1 degradation (5).

Since 1974, PICP has been quantified using immunoassays, and numerous biomarker utilities have been determined over the decades (7). Given its widespread distribution and structural role, dysregulation of COL1 metabolism is associated with a range of pathological conditions (2). Diagnostic uses have been discovered in wound healing, liver disease, cancer monitoring, heart disease, inflammatory bowel disease, interstitial lung disease, and many other disease processes (8-13).

This literature review synthesizes nearly five decades of research on PICP, providing an overview of its structure, biological mechanisms, and clinical relevance. By evaluating the strengths, limitations, and current applications as a diagnostic and prognostic biomarker, this review aims to objectively assess PICP’s potential role in clinical practice and acknowledge that future research may provide additional insight and expand our existing knowledge of it.

Materials and methods

A comprehensive literature search was conducted across databases PubMed, Google Scholar, Embase, and Scopus from inception to May 2025. Search terms included “Procollagen type I C-terminal propeptide”, “PICP”, combined with keywords related to its clinical role, such as “diagnosis”, “prognosis”, “fibrosis”, “biomarker”, and systemic keywords, such as “cardiology”, “oncology”, “pediatric”, “dermatology”, “bone”, “hepatic”, “respiratory”, “neurology” and “renal”, as well as suitable modifiers. Clinical studies reporting on the role of PICP in diagnosis, prognosis, or disease monitoring in humans were eligible for inclusion. Case reports, editorials, conference abstracts and animal studies were excluded.

Structure and physiological role of procollagen I C-terminal propeptide

Procollagen I C-terminal propeptide is a terminal component of the precursor molecule of COL1, with the other terminal component being procollagen I nitro-terminal (N-terminal) propeptide (PINP). Procollagen I is synthesized within the endoplasmic reticulum, and the two terminal propeptides serve to prevent premature fiber formation. After the molecule reaches the extracellular space, the C-terminal and N-terminal parts of the molecule split from the collagen molecule during the process of procollagen conversion to collagen (Figure 1) (14, 15). The splitting of PICP from procollagen is achieved by procollagen C-peptidases, after which the mature collagen molecules spontaneously assemble into stable fibers (6). Because PICP is produced in a 1:1 stoichiometric ratio to COL1, with each cleaved C-terminal propeptide molecule equivalent to one collagen molecule produced, its serum concentrations are a reliable measure of collagen activity and production (16).

Schematic representation of type I collagen synthesis and release of procollagen type I carboxy-terminal propeptide (PICP). Type I procollagen is synthesized with N- and C-terminal propeptides. While the N-terminal is removed during maturation, the C-terminal propeptide is cleaved and released into the blood and later degraded by liver endothelial cells. Mature collagen is formed from the cross-linking of fibrils. Figure created using BioRender.com.

Due to its molecular weight (100 kDa), PICP is not affected by glomerular filtration, and its clearance occurs primarily through uptake by the liver’s sinusoidal endothelial cells, making its clearance independent of renal factors (17, 18). It is important to distinguish PICP from other C-telopeptides, such as ICTP. While PICP reflects collagen synthesis, ICTP is a marker of collagen degradation, released during its breakdown and tissue remodelling, and exists between the terminal propeptides and the mature collagen molecule (3, 19).

Methods of determination

In most of the studies on PICP, serum is the primary matrix used, with the occasional use of plasma or tissue samples. Units are typically expressed in ng/mL or µg/L; a lack of consistency across the studies limit comparisons. Methods used for analysis include enzyme-linked immunosorbent assays (ELISA) and older radioimmunoassays (RIA). In earlier works using RIA, preliminary reference intervals for healthy adults (18-61 years old) were deduced as 38-202 µg/L for men and 50-170 µg/L for women (4). An ELISA assay for PICP with a detection limit of 1 ng/L, measurable range of 1-640 ng/mL, and < 10% intra- and inter-assay imprecision values was developed. The result was an efficient method to produce PICP-specific antibodies, enabling potential use in clinical diagnostic applications (20). Despite these advances, differences in calibrators and variabilities in commercial kit standards act as barriers to interpretation and clinical implementation (21). Within ELISA methods, cut-offs vary from assay to assay, and units are inconsistently reported. Other limitations include large sample volumes and long incubation times required by traditional PICP assays (20). This is a barrier to consistent interpretation and impedes accurate pooling of results to understand the biomarker and its true normal range. Although few studies have validated PICP for long-term monitoring, the absence of standardized reference ranges limits its applicability. Longitudinal use of PICP is further complicated by inter-individual differences and potential confounding factors such as hepatic dysfunction and medication use (22-24). Immunoassays dominate PICP measurement today, especially ELISA, chemiluminescence immunoassay, and electrochemiluminescence immunoassay. Radioimmunoassays and immunoradiometric assay are historically important but have now been largely phased out due to radioactivity concerns, whereas high-performance liquid chromatography is mainly research-oriented and not used clinically (4, 20). Though PICP presents itself as a promising biomarker of collagen type I synthesis and fibrosis, its clinical utility is limited by assay variability, lack of harmonized reference ranges, and confounding systemic factors. Until these issues are resolved, PICP remains more of a research tool than a widely adopted diagnostic marker.

Clinical utility and diagnostic value of procollagen I C-terminal propeptide in different systemic diseases Cardiovascular disease

Associations between PICP and cardiovascular disease have been studied for over two decades, with one of the initial connections being made between collagen scar formation after acute myocardial infarction (25). Following studies identified the role of PICP in hypertensives, where PICP was found to be a more accurate predictor of myocardial fibrosis compared to left ventricular mass index and E/A ratio (E-wave/A-wave ratio, an echocardiographic marker of left ventricular diastolic function), and a valuable tool for measuring the cardioprotective effects of antihypertensive medications (5, 11, 26). This same association makes PICP a useful biomarker of myocardial fibrosis in hypertrophic cardiomyopathy, with a strong correlation existing between plasma PICP concentrations and myocardial PICP content (27).

Procollagen I C-terminal propeptide was also found to be a sensitive and specific testing metric for detecting left ventricular ejection fraction (LVEF) heart failure (HF), with 86.2% sensitivity and 98.8% specificity in distinguishing between normal individuals and those with HF (28). Therefore, PICP can act as an additional tool for confirmatory diagnosis alongside more established biomarkers of heart failure, such as N-terminal pro-B-type natriuretic peptide (NT-proBNP), and offer insight into myocardial damage rather than the pressure or volume overload (28). Elevated serum PICP was also found to have a correlation with post-surgical atrial fibrillation in patients after cardiac surgery, which may be explained by the presence of increased left atrial myocardial fibrosis found in those with elevated PICP concentrations (29, 30).

In recent years, PICP has also been found to play a role in dilated cardiomyopathy (DCM). Studies have shown that an analysis of combinations of matrix metallopeptidase 1, PICP, and other serum biomarkers provides enough insight into DCM for risk stratification. The presence of higher concentrations of serum PICP was also associated with higher rates of adverse outcomes in those with DCM (31).

Baseline PICP concentrations were found to be higher in patients with Friedreich’s ataxia than in the general population and predictive of left ventricular dilation over time, suggesting myocardial fibrosis leading to cardiomyopathy and arrhythmias (32). Overall, although PICP is unlikely to serve as a standalone biomarker for cardiovascular disease, it holds potential, pending further validation, to become an integral component of multi-marker diagnostic scores for risk assessment and personalized cardioprotective therapy.

Bone and connective tissue disease

Women with rheumatoid arthritis had significantly reduced PICP due to the negative impact of chronic inflammation on bone formation and remodeling (33). Subsequent studies examined the effects of hormone replacement therapy on bone biochemical markers such as PICP in postmenopausal women with rheumatoid arthritis. Further, they corroborated the results with the Larsen score to check if it is predictive of bone mineral density (BMD) (34, 35). The decrease in PICP at 1 and 2 years follow-up, a consequence of reduced need for bone turnover, was associated with improved BMD and a good Larsen score; these findings reinforced previous similar studies (34-36).

Synovial fluid and suction blister fluid PICP concentrations are increased in systemic lupus erythematosus and scleroderma patients (37-39). Elevated concentrations of PICP are observed in systemic sclerosis, with higher concentrations in the diffuse type involving viscera. Procollagen I C-terminal propeptide can be used as a marker of severity and determinant of prognosis and risk of pulmonary fibrosis (40, 41). Dermatomyositis patients have significantly elevated serum PICP, which was correlated with increased creatine kinase levels, indicative of active muscle damage (42). These findings suggest that PICP can be potentially used as a follow-up marker to monitor treatment efficacy and stratify severity in various rheumatologic diseases.

Beyond autoimmune diseases, PICP can offer insight into orthopedic conditions. The conventional methods of X-ray are widely used and straightforward, whereas techniques like periprosthetic BMD measurements can be more technically challenging and often detect aseptic loosening (AL) in total hip arthroplasty only at a late stage. Whether collagen biomarkers can identify individuals at risk of AL at early stages, since biochemical changes in bone turnover can be detected before radiographic signs of loosening, was investigated. He et al. concluded that an elevation in PICP concentrations as a means of compensation can be an early indicator of altered bone turnover in patients with prosthetic implants, suggesting potential loosening (43). Serum PICP concentrations were also identified as a sensitive diagnostic indicator of skull involvement in Paget’s disease (44).

Beyond these conditions, due to the role of PICP in bone formation, it has been extensively studied in osteoporosis, with PICP being found to be a predictor of osteoporotic fracture (45). Procollagen I C-terminal propeptide release is directly related to the rate of bone collagen synthesis and can be used as a proxy measure of osteoblast activity (46). Earlier studies have shown that PICP concentrations decrease in response to antiresorptive therapy, such as estrogen, and increase in response to anabolic therapy, such as teriparatide. Correlation with BMD was also identified for PICP, hence making it useful to monitor treatment response compared to imaging-based approaches, which require a longer time period to pick up alterations in BMD (47-49). Though PICP concentrations are similar in perimenopausal and menopausal women, it is useful in distinguishing women with higher turnover (lower PICP) and women with low turnover (higher PICP) amongst menopausal women (47). The former group is at increased risk of osteoporosis and thus can be classified as potentially higher risk and could benefit from earlier initiation of hormone replacement therapy or calcium supplements. However, despite these positive results, when compared to other bone formation markers such as PINP, PICP was found to be inferior (21, 50). Though PICP provides insight into bone metabolism and connective tissue diseases, it cannot be considered a definitive and sole diagnostic measure. It may be a useful tool when used alongside PINP and imaging. Future work should focus on integration to improve clinical applicability.

Oncology

Given its role in bone formation, PICP has potential utility in oncology as a biomarker to detect and monitor bone metastases (BM). Procollagen I C-terminal propeptide reflects the rate of type I collagen synthesis and may parallel the increased bone turnover lesions seen in metastases. Prostate-specific antigen (PSA), while commonly used, lacks specificity for prostate cancer (PC). Procollagen I carboxy-terminal propeptide can act as an adjunct tool to diagnose early skeletal metastases of prostate adenocarcinoma and improve overall specificity (51-53). Procollagen I C-terminal propeptide and PSA concentrations were significantly higher in PC patients with BM compared to those with benign prostate hyperplasia (46). Lung and breast cancer (BC) are two other cancers commonly associated with BM. However, studies in BC patients had conflicting results. Two studies showed PICP is not nearly as sensitive as other collagen biomarkers in diagnosing metastasis in BC, limiting its clinical efficacy as a standalone marker (54, 55). Whereas Song et al. demonstrated statistically significant results, PICP concentrations were higher in the BC bone metastases group, and a decline was observed following 3 months of treatment. They concluded that PICP can be used to diagnose and assess treatment efficacy in BC metastases (56).

Though not specific (2.1%), PICP was highly sensitive (95.2%) in detecting BM in lung cancer patients. While it cannot replace existing superior standard modalities, it may be a valuable adjunctive tool, especially in resource-limited settings (57-59). While PICP alone was insignificant in women with epithelial ovarian cancer, a low PICP:PINP ratio was associated with faster metastatic progression and poor clinical outcome (60). Overall, although elevated PICP has been linked to BM in cancer, it lacks adequate specificity to be used alone. Nevertheless, it may improve clinical assessment and support early detection of skeletal involvement in prostate cancer, monitoring treatment response in breast cancer, and identify and assess metastatic progression in lung and ovarian cancer when combined with other routine imaging and biomarkers.

Hepatic disease

End-stage liver disease and liver cirrhosis are marked by increased collagen deposition triggered by inciting factors such as chronic alcohol use or hepatitis infections, leading to fibrosis, the precursor to cirrhosis (22, 23). Liver biopsy is considered to be the gold standard modality to evaluate the severity of fibrosis, but as it is an invasive tool, it may not be ideal for all patients or to monitor disease course on a routine basis, therefore, research has been conducted on the utility of alternative non-invasive collagen markers (23).

Two such frequently investigated markers are PICP and procollagen type III C-terminal propeptide (PIIICP). Though PIIICP is widely used as a collagen turnover biomarker, PICP offers the advantage of existing in a uniform form in the serum, without any variation, and is metabolized entirely through the liver via specific receptors and therefore remains unaffected in patients with co-existing renal diseases (61, 62). Studies on PICP were predominantly in chronic alcoholic patients and are limited in number. Studies demonstrated the presence of maximally increased PICP concentrations in chronic alcoholic patients with hepatitis and cirrhosis and adequately elevated concentrations in patients with fatty liver and non-alcoholic diseases such as primary biliary cirrhosis (23, 61, 62). A positive correlation was noted between high levels of hepatic inflammation and the severity of fibrosis with PICP (23, 61).

Lower concentrations of this biomarker cannot be used to exclude hepatic disease definitively; instead, they are best utilized as adjunctive tools in patients where liver biopsy is not feasible, and can also help monitor therapeutic response when baseline values are elevated (23). Procollagen type III N-terminal propeptide (PIIINP) is generally considered a more sensitive marker for early fibrotic changes and better reflects initial disease burden than PICP, which explains its preference as a biomarker (62). Considering the drawbacks of both PIIINP and PICP and that studies have shown that evaluating the ratio of PIIINP to PICP correlates well with both clinical and morphological severity of liver disease, rather than relying solely on PICP or PIIINP, it is more rational to focus research efforts on the PIIINP/PICP ratio as a means of assessing the extent and severity of hepatic fibrosis (23, 62). In hepatic disease, PICP shows promise as a non-invasive marker of fibrosis, especially in alcoholic liver disease and cirrhosis, but current studies are limited and require further validation.

Renal disease

The role of PICP in renal disease is often related to its role in other disease systems. Procollagen I carboxy-terminal propeptide in pre-dialysis chronic renal failure is a possible noninvasive indicator of bone turnover in both adults and children (24, 63). It is elevated in those with diabetes, but the rise in serum PICP is associated with the concurrent presence of hypertension. Procollagen I carboxy-terminal propeptide is also an indicator of potential diabetic complications, such as diabetic retinopathy or nephropathy, suggesting that PICP may reflect early microvascular damage and fibrotic progression (64).

Procollagen I carboxy-terminal propeptide is an active indicator of a pro-fibrotic state, with elevated concentrations of the biomarker being associated with subclinical fibrosis and subclinical renal disease (65, 66). In addition, PICP is a good predictor of all-cause mortality in advanced kidney disease, with one univariate analysis showing PICP above a cut-off point (PICP > 297.31 µg/L) being associated with a five-fold increased risk of mortality from chronic kidney disease (HR 5.07, 95% confidence interval (CI) 1.94-13.29, P = 0.001) (65, 67). Koh et al. also found significant associations between PICP and chronic renal failure (68). Renal and cardiac disease often go hand in hand, and elevated PICP may be an indicator of concurrent conditions and an interplay of two disease processes affecting one another (65, 66, 68). Clinically, PICP could be monitored longitudinally in high-risk patients such as those with diabetes, severe hypertension, or advanced renal disease to detect early fibrotic changes and assess therapeutic effectiveness. As a non-invasive marker of subclinical renal damage, it can help provide prognostic insight into long-term outcomes and a basis for future clinical studies.

Respiratory disease

Airway remodeling, characterized by predominantly COL1 deposition, drives the pathophysiology of chronic obstructive pulmonary disease (COPD) and asthma, leading to airway narrowing (69, 70). Zeng et al. investigated whether serum PICP concentrations were associated with the degree of inflammation in stable COPD patients and concluded that the concentrations were significantly higher in COPD cases (69). They hypothesized that a higher level could potentially translate to a poorer prognosis and increased severity, though further studies are needed to draw conclusive results (69). Another study involving asthma patients measured PICP concentrations in the sputum following inhaled steroids, and a decrease in the collagen biomarker was noted (70). The above cases suggest using PICP as a biomarker to assess the degree of ongoing inflammation and airway remodeling changes in obstructive lung diseases and identify individuals more at risk of exacerbations.

Given its role in collagen synthesis, it is logical to study its concentrations in granulomatous and interstitial diseases such as sarcoidosis, which causes progressive pulmonary fibrosis. A cross-sectional study comparing serum PICP and bronchoalveolar lavage fluid (BALF) found that the latter was a better and more sensitive indicator of pulmonary sarcoidosis. However, the concentrations were not corroborated by the standard modalities, such as serum angiotensin converting enzyme and chest radiography, and the author attributed the discrepancy to the cross-sectional nature of the study. In contrast, another study established no association between the two (71, 72). More studies are warranted on this topic.

Fibrosing alveolitis is another progressive lung disease with a poor prognosis, and no reliable predictors of progression have been established yet. One study concluded that BALF PICP concentrations are increased in this disease and can be used to assess pulmonary involvement and demonstrated a negative correlation between BALF and epithelial lining fluid (ELF) PICP and diffusing capacity of the lungs for carbon monoxide, indicating that higher concentrations of PICP imply a decreased efficiency in the transfer of gases (73). Another study demonstrated higher BALF and ELF PICP concentrations in asbestos patients with parenchymal involvement, suggesting its use as a biomarker to identify the parenchymal participation in those individuals exposed to asbestos (74). The role of PICP was studied in acute respiratory distress syndrome/acute lung injury subjects. Procollagen I carboxy-terminal propeptide was elevated in these subjects, and the balance of collagen turnover was more in favor of synthesis, promoting fibrotic changes early in the disease course. Higher concentrations could potentially mean higher degrees of fibrotic changes and poorer outcomes with increased mortality, necessitating the need for more interventions (75). Given its correlation with fibrotic activity and impaired gas exchange, studies have shown that PICP can be used as a biomarker to assess disease severity and prognosis in conditions such as fibrosing alveolitis, sarcoidosis, ARDS, etc. Elevated BALF PICP concentrations correlate with the extent of fibrosis and reduced diffusing capacity for carbon monoxide (DLCO), suggestive of both structural and functional impairment. However, current evidence is limited, so it cannot replace gold standard procedures (spirometry, chest X-ray, lung biopsy, etc). Measurement of BALF PICP can be offered as a practical alternative for patients with fibrotic lung disease where lung biopsy is contraindicated, for those who decline biopsies, or to monitor disease progression when repeated biopsies aren’t practical.

Pediatric disease

Dexa-scan and quantitative computed tomography are the gold standards for evaluating BMD due to their accuracy and low radiation exposure. However, in a pediatric setting, they are associated with challenges such as irritability, crying, and discomfort, leading to inconsistent results and not capturing real-time changes in bone metabolism. In contrast, bone turnover markers such as PICP are minimally invasive. Patients can be monitored over time, reflecting the current state of bone metabolism, making the biomarker valuable for pediatric patients (76, 77). Type I and III collagen biomarkers, especially PICP, reflect the growth velocity in the pediatric age group, and the concentrations are comparatively lower in adults (78-81). In this context, PICP serves not only as a biomarker for bone health but also as an indicator of somatic growth.

Multiple studies have investigated the potential role of PICP as a biomarker to diagnose osteogenesis imperfecta (OI) prenatally. While the lowest concentrations are seen with type 4 OI, abnormally low concentrations were seen in the other types, and a positive correlation was established between the severity of OI and PICP (78, 82). It is indicative of the role of PICP in disease stratification.

Procollagen I carboxy-terminal propeptide has shown promise in evaluating the response to treatments in conditions causing reduced BMD or stature. Since low vitamin K has been implicated in reduced BMD in children with cystic fibrosis (CF), the concentrations of bone turnover markers, such as PICP, before and after vitamin K administration in cystic fibrosis patients with defined low BMD was assessed (83). An increase in PICP, reflecting collagen biosynthesis, was observed following vitamin K treatment, concluding that long-term vitamin K supplementation may ultimately improve BMD scores in CF patients. Procollagen I carboxy-terminal propeptide can be potentially used as a marker to evaluate response to vitamin K and monitor BMD (83-85). A 3-year follow-up of prepubertal children with idiopathic short stature (ISS) treated with growth hormone (GH) therapy showed improvement in BMD and a gradual rise in PICP concentrations, reaching control numbers by the end of the study (86). Thus, it can be used to measure the effectiveness of long-term GH therapy in patients with ISS or GH-deficient individuals and help diagnose GH-deficient individuals (87-89).

In individuals with low BMD due to malabsorptive diseases such as celiac disease, PICP can be measured to check the effectiveness of a gluten-free diet in normalizing BMD (90). Procollagen I carboxy-terminal propeptide was negatively correlated with gestational age (GA) and birth weight in studies involving appropriate-for-gestational-age (AGA) neonates, implying that those born earlier with lower GA and weight have higher bone turnover, which may be harmful to bone health (91-93). However, similar concentrations were observed in small for gestational age (SGA) infants when concentrations lower than AGA infants were expected; reduced bone mineral content rather than defective collagen metabolism was proposed as the reason (94). Procollagen I carboxy-terminal propeptide was also found to be possibly affected by the baby’s gender, maternal health, and parity in some studies, whereas others found no association (92, 95).

Furthermore, maternal health conditions may indirectly influence neonatal PICP. Insulin-like growth factor-1 (IGF-1) acts as a growth regulator, and maternal conditions such as preeclampsia reduce IGF-1, reducing PINP concentrations. Based on this fact, Kanjantie et al. proposed that cord blood PINP may serve as valuable markers for both fetal growth and maturity, and could potentially be used to predict postnatal growth rates in preterm infants (93). Procollagen I carboxy-terminal propeptide may also serve as an early indicator of fibrotic complications in neonatal conditions. It was identified as a reliable predictor for bronchopulmonary dysplasia in low-birth-weight infants (96). Posthemorrhagic hydrocephalus (PHHC) is a complication seen in preterm infants following intraventricular hemorrhage (IVH). Posthemorrhagic hydrocephalus babies were observed to have high PICP concentrations compared to non-hemorrhagic hydrocephalus babies, denoting early fibrotic changes in the former case. It was inferred that higher PICP following IVH increase the risk for PHHC (97). Procollagen I carboxy-terminal propeptide provides a window into pediatric health by reflecting skeletal growth and fibrotic complications, presenting itself as a promising tool to monitor bone and developmental disorders in early life.

Other clinical associations of procollagen I carboxy-terminal propeptide

Collagen plays an important role in maintaining the structural integrity of skin by being involved in tissue remodeling and fibrosis. In dermatological conditions characterized by excessive collagen deposition, such as systemic sclerosis and scleroderma, serum PICP can be a measure of the severity of skin pathologies (37, 41, 98). Its minimally invasive feature offers a practical advantage over skin biopsies.

Beyond dermatology, PICP is also significant in neurological injury. Subdural PICP concentrations were significantly elevated following head trauma-induced subarachnoid hemorrhage, indicating increased collagen synthesis and fibrosis during the healing process. Thus, higher PICP concentrations may be associated with an increased risk of complications such as chronic subdural hematomas, effusions, or late posthemorrhagic hydrocephalus, suggesting that it can be potentially used to identify patients at risk of developing chronic fibrotic sequelae following neurological trauma (99, 100). Overall, PICP shows promise as a cross-disciplinary biomarker for monitoring fibrosis in both dermatological and neurological conditions.

Summary of evidence

Procollagen I carboxy-terminal propeptide has a clearly established biological basis as a marker for type I collagen synthesis; however, its clinical utility varies across systems. Evidence is strongest in cardiovascular remodelling, bone and connective tissue disorders, metastatic surveillance, and chronic renal disease. In these settings, PICP concentrations correlate with fibrotic burden, disease severity, and adverse outcomes but remain limited by specificity and performance compared to other markers (e.g., PINP). In contrast, evidence remains limited in hepatic and pediatric diseases, as interpretation is confounded by clearance mechanisms and physiological collagen turnover. Despite these constraints, overall across systems, PICP is best positioned as an adjunct biomarker, useful for monitoring disease progression and treatment response, and fine-tuning risk stratification, rather than as a definitive diagnostic test.

Limitations and challenges

The widespread presence of PICP is a double-edged sword, as the biomarker is elevated in a wide range of diseases, yet often lacks specificity for the same reason (19). Elevations may occur in cardiovascular, hepatic, and renal diseases, among others, making it difficult to attribute the elevated PICP to a single etiology, especially in the presence of multiple comorbidities. The mechanism by which PICP is cleared from the body may also obscure the presence of disease. In the presence of hepatic disease, the impaired clearance of PICP causes increased serum concentrations of the biomarker regardless of the rate of collagen turnover. In such states, elevations due to other concurrent disease processes, such as heart failure or chronic kidney disease, are masked by the already elevated serum concentrations of PICP (63, 67). Similarly, increases in PICP may reflect general bone turnover rather than metastasis alone, or in children, it could be part of physiologic growth development (46, 79). These examples demonstrate how, sometimes, elevations in PICP could be due to non-pathological processes.

Future potential and perspectives

Procollagen I carboxy-terminal propeptide is now being used in combination with imaging strategies such as cardiac magnetic resonance imaging with late gadolinium enhancement to improve prognostic power in conditions such as aortic stenosis, dilated cardiomyopathy, and heart failure (101, 102). This layering of diagnostic tools may help in more accurate risk stratification, prognostic estimates, and precision medicine. Exploration of ratios such as PIIINP/PICP ratio should be investigated in other key systemic diseases, such as cardiovascular and renal diseases, in the hopes that it may also improve specificity and prognostic value, as observed in hepatic fibrosis. Beyond diagnosis and prognosis, PICP also holds potential as a tool for therapeutic monitoring, especially in conditions where stabilizing or reversing fibrosis is the target. As discussed in this review, across cardiac, hepatic, respiratory diseases, etc., evidence suggests that changes in PICP concentrations parallel the responses to anti-fibrotic therapies, reflective of reduced fibrotic activity. This makes PICP a minimally invasive option to track therapeutic effectiveness over time and enables earlier detection compared to imaging methods. To counteract the challenges to standardization, mass spectrometry may be a new method of measuring PICP. While currently used in the context of research, the method may offer the added benefit of lending PICP better specificity. Mass spectrometry is currently a common practice for other biomarkers, such as PINP and procollagen type III biomarkers (103). Larger-scale studies on PICP must be done, looking at a broader range of diseases. Fibrosis occurs in numerous diseases across organ systems, and the diagnostic role of PICP should be evaluated, with disease-specific cutoffs to aid clinical decision-making and reasoning. Furthermore, the relationships between PICP and other diagnostic techniques and biomarkers must be explored.

Conclusion

Procollagen I carboxy-terminal propeptide is a promising biomarker of type I collagen synthesis with potential utility across multiple disease processes. Its characteristic of being present in a 1:1 stoichiometric ratio with COL1 production makes it an accurate and reliable measure of collagen synthesis. Coupled with its clearance independent of renal function, it becomes a potentially reliable tool in clinical practice. Due to confounding factors in clinical practice, elevated PICP concentrations should be interpreted in the context of underlying comorbidities and age, rather than as a standalone indicator.

This review highlights the diverse diagnostic and prognostic potential of PICP in several disease systems and patient populations. Evidence of PICP is most compelling and interesting in renal disease, where it predicts all-cause mortality in advanced kidney disease. Though cardiovascular and bone disorders have potential in conditions such as heart failure and monitoring treatment in osteoporosis, PICP is typically combined with other routine biomarkers and imaging, limiting its independent use here. Oncology, pediatrics, respiratory diseases, and other specialties remain of academic interest, reflecting collagen turnover without sufficient clinical evidence yet. Overall, PICP can contribute to risk stratification, disease monitoring, and severity assessment. Its integration into multimodal diagnostic strategies may yield meaningful clinical benefits. Future work must focus on assay standardization, disease-specific reference ranges, and large-scale longitudinal studies to validate existing findings. With these advances, PICP could evolve into a valuable adjunct in routine diagnostics and precision medicine.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References BurgesonRE. New Collagens, New Concepts. Annu Rev Cell Biol. 1988;4:551–77. 10.1146/annurev.cb.04.110188.0030033058166 NeculaLMateiLDraguDPiticaINeaguABleotuC Collagen Family as Promising Biomarkers and Therapeutic Targets in Cancer. Int J Mol Sci. 2022;23:12415. 10.3390/ijms23201241536293285 IvanovaVPKrivchenkoAI. A current viewpoint on structure and evolution of collagens. I. Fibrillar collagens. J Evol Biochem Physiol. 2012;48:127–39. 10.1134/S0022093012020016 MelkkoJNiemiSRisteliLRisteliJ. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990;36:1328–32. 10.1093/clinchem/36.7.13282372946 QuerejetaRVaroNLópezBLarmanMArtiñanoEEtayoJC Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729–35. 10.1161/01.CIR.101.14.172910758057 ChalikiasGKTziakasDN. Biomarkers of the extracellular matrix and of collagen fragments. Clin Chim Acta. 2015;443:39–47. 10.1016/j.cca.2014.06.02825007952 TaubmanMBGoldbergBSherrC. Radioimmunoassay for human procollagen. Science. 1974;186:1115–7. 10.1126/science.186.4169.11154478921 RasmussenLHJensenLTAvnstorpCKarlsmarkTPetersKHørslev-PetersenK. Collagen types I and III propeptides as markers of healing in chronic leg ulcers. A noninvasive method for the determination of procollagen propeptides in wound fluid--influence of growth hormone. Ann Surg. 1992;216:684–91. 10.1097/00000658-199212000-000111466622 HayasakaASchuppanDOhnishiKOkudaKHahnEG. Serum concentrations of the carboxyterminal cross-linking domain of procollagen type IV (NC1) and the aminoterminal propeptide of procollagen type III (PIIIP) in chronic liver disease. J Hepatol. 1990;10:17–22. 10.1016/0168-8278(90)90067-22307825 NakashimaJSumitomoMMiyajimaAJitsukawaSSaitoSTachibanaM The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol. 1997;157:1736–9. 10.1016/S0022-5347(01)64847-X9112516 de JongSvan VeenTABde BakkerJMTVosMAvan RijenHVM. Biomarkers of myocardial fibrosis. J Cardiovasc Pharmacol. 2011;57:522–35. 10.1097/FJC.0b013e31821823d921423029 HyamsJSCareyDELeichtnerAMGoldbergBD. Type 1 procollagen as a biochemical marker of growth in children with inflammatory bowel disease. J Pediatr. 1986;109:619–24. 10.1016/S0022-3476(86)80224-43761075 MadaharPDuprezDAPodolanczukAJBernsteinEJKawutSMRaghuG Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. Respir Med. 2018;140:108–14. 10.1016/j.rmed.2018.06.00129957270 ProckopDJKivirikkoKITudermanLGuzmanNA. The biosynthesis of collagen and its disorders (first of two parts). N Engl J Med. 1979;301:13–23. 10.1056/NEJM197907053010104449904 RisteliJNiemiSKauppilaSMelkkoJRisteliL. Collagen propeptides as indicators of collagen assembly. Acta Orthop Scand Suppl. 1995;266:183–8. 10.3109/174536795091576888553849 BonninMRGonzalezMTGriñóJMCruzadoJMMartínezJMNavarroMA. Evolution of Circulating C-Terminal Propeptide of Type I Procollagen in Patients with Chronic Renal Failure Pre and Post Renal Transplantation. Eur J Clin Chem Clin Biochem. 1996;34:897–900. 10.1515/cclm.1996.34.11.8978960463 EriksenEFCharlesPMelsenFMosekildeLRisteliLRisteliJ. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res. 1993;8:127–32. 10.1002/jbmr.56500802028442431 MelkkoJHellevikTRisteliLRisteliJSmedsrødB. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med. 1994;179:405–12. 10.1084/jem.179.2.4058294857 MartinEMChangJGonzálezAGenoveseF. Circulating collagen type I fragments as specific biomarkers of cardiovascular outcome risk: Where are the opportunities? Matrix Biol. 2025;137:19–32. 10.1016/j.matbio.2025.03.00140037418 SeoWYKimJHBaekDSKimSJKangSYangWS Production of recombinant human procollagen type I C-terminal propeptide and establishment of a sandwich ELISA for quantification. Sci Rep. 2017;7:15946. 10.1038/s41598-017-16290-929162919 DonescuOSBattiéMCVidemanTRisteliJEyreD. The predictive role of bone turnover markers for BMD in middle-aged men. Aging Male. 2006;9:97–102. 10.1080/1368553060070863116916744 ZhouWCZhangQBQiaoL. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014;20:7312–24. 10.3748/wjg.v20.i23.731224966602 SavolainenERGoldbergBLeoMAVelezMLieberCS. Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease. Alcohol Clin Exp Res. 1984;8:384–9. 10.1111/j.1530-0277.1984.tb05684.x6385761 CoenGBallantiPMazzaferroSPasqualiMBonucciE. Procollagen type 1 C-terminal extension peptide, PTH and 1,25 (OH) 2D3 in chronic renal failure. Bone. 1993;14:415–20. 10.1016/8756-3282(93)90173-88161367 UusimaaPRisteliJNiemeläMLummeJIkäheimoMJounelaA Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation. 1997;96:2565–72. 10.1161/01.CIR.96.8.25659355895 LópezBQuerejetaRVaroNGonzálezALarmanMMartínez UbagoJL Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286–91. 10.1161/01.CIR.104.3.28611457746 YangCQiaoSSongYLiuYTangYDengL Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2019;43:107150. 10.1016/j.carpath.2019.10715031639652 DemirSEdeHKaplanMYavuzFYucelCKurtIH. The novel diagnostic marker in low-LVEF heart failure patients. Bratisl Lek Listy. 2018;119:421–4. 10.4149/BLL_2018_07630160130 SwartzMFFinkGWSarwarMFHicksGLYuYHuR Elevated Pre-Operative Serum Peptides for Collagen I and III Synthesis Result in Post-Surgical Atrial Fibrillation. J Am Coll Cardiol. 2012;60:1799–806. 10.1016/j.jacc.2012.06.04823040566 RavassaSBallesterosGLópezBRamosPBragardJGonzálezA Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation. J Am Coll Cardiol. 2019;73:1398–410. 10.1016/j.jacc.2018.12.07430922470 RaafsAGAdriaansBHenkensMVerdonschotJAbdul HamidMDíezJ Biomarkers of Collagen Metabolism Are Associated with Left Ventricular Function and Prognosis in Dilated Cardiomyopathy: A Multi-Modal Study. J Clin Med. 2023;12:5695. 10.3390/jcm1217569537685762 MehtaNChackoPJinJTranTPriorTWHeX Serum versus Imaging Biomarkers in Friedreich Ataxia to Indicate Left Ventricular Remodeling and Outcomes. Tex Heart Inst J. 2016;43:305–10. 10.14503/THIJ-14-419827547137 KrögerHRisteliJRisteliLPenttiläIAlhavaE. Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis. Ann Rheum Dis. 1993;52:338–42. 10.1136/ard.52.5.3388323381 Forsblad d’EliaHChristgauSMattssonLASaxneTOhlssonCNordborgE Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]. Arthritis Res Ther. 2004;6:R457. 10.1186/ar121515380045 PulleritsRd’EliaHFTarkowskiACarlstenH. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial. Rheumatology (Oxford). 2009;48:785–90. 10.1093/rheumatology/kep07919416946 LemsWFJacobsJWvan den BrinkHRvan RijnHJBijlsmaJW. Transient decrease in osteocalcin and markers of type 1 collagen turnover during high-dose corticosteroid pulse therapy in rheumatoid arthritis. Br J Rheumatol. 1993;32:787–9. 10.1093/rheumatology/32.9.7878369888 SøndergaardKHeickendorffLRisteliLRisteliJZachariaeHStengaard-PedersenK Increased levels of type I and III collagen and hyaluronan in scleroderma skin. Br J Dermatol. 1997;136:47–53. 10.1111/j.1365-2133.1997.tb08745.x9039294 Villa-ManzanoAIGamez-NavaJISalazar-ParamoMValera-GonzalezICGarcia-GonzalezAGarcia-GonzalezG Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus. Rheumatol Int. 2006;26:712–6. 10.1007/s00296-005-0064-516231121 SchejaAWildtMWollheimFAAkessonASaxneT. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford). 2000;39:1110–3. 10.1093/rheumatology/39.10.111011035131 HeickendorffLZachariaeHBjerringPHalkier-SørensenLSøndergaardK. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol. 1995;32:584–8. 10.1016/0190-9622(95)90341-07896946 KikuchiKIhnHSatoSIgarashiASomaYIshibashiY Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis. Arch Dermatol Res. 1994;286:77–80. 10.1007/BF003707318154928 KuboMKikuchiKFujimotoMTamakiK. Serum concentrations of carboxyterminal propeptide of type 1 procollogen and tissue inhibitor of metalloproteinase 1 in patients with dermatomyositis. Arch Dermatol Res. 1998;290:253–7. 10.1007/s0040300503009681676 HeTWuWHuangYZhangXTangTDaiK. Multiple biomarkers analysis for the early detection of prosthetic aseptic loosening of hip arthroplasty. Int Orthop. 2013;37:1025–31. 10.1007/s00264-013-1837-123467893 AlvarezLPerisPPonsFGuañabensNHerranzRMonegalA Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget’s disease activity. Arthritis Rheum. 1997;40:461–8. 10.1002/art.17804003129082934 MeltonLJ3rdKhoslaSAtkinsonEJO’FallonWMRiggsBL. Relationship of Bone Turnover to Bone Density and Fractures. J Bone Miner Res. 1997;12:1083–91. 10.1359/jbmr.1997.12.7.10839200008 ZissimopoulosAStellosKMatthaiosDPetrakisGParmenopoulouVBabatsikouF Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. JBUON. 2009;14:463–72.19810140 De LeoVDittoAla MarcaALanzettaDMassafraCMorganteG. Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int. 2000;66:263–7. 10.1007/s00223001005310742442 GloverSJEastellRMcCloskeyEVRogersAGarneroPLoweryJ Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45:1053–8. 10.1016/j.bone.2009.07.09119679211 BurshellALMörickeRCorrea-RotterRChenPWarnerMRDalskyGP Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone. 2010;46:935–9. 10.1016/j.bone.2009.12.03220060081 DemeuseJMackowiakAGrifnéeEMassonnetPHuyghebaertLDubrowskiT Latest Advances in Structural Insights and Quantification Techniques for Type I Collagen Biomarkers: A path toward standardization? Biomark Insights. 2025;20:11772719251336274. 10.1177/1177271925133627440417349 ZissimopoulosAStellosCPetrakisGBaziotisN. Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma. Hell J Nucl Med. 2004;7:162–7. [in Greek]15841291 ZissimopoulosABantisAStellosKPetrakisGMatthaiosD. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients. JBUON. 2008;13:69–74.18404790 YingMMaoJShengLWuHBaiGZhongZ Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction. J [in Greek]. J Pers Med. 2023;13:705. 10.3390/jpm1305070537240875 ZissimopoulosAPetrakisGStellosKBaziotisN. Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer. Hell J Nucl Med. 2006;9:60–4. [in Greek]16617400 KeskikuruRKatajaVKosmaVMEskelinenMUusitupaMJohanssonR Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer. Anticancer Res. 1999;19:4481–4.10650796 SongBLiXZhouQYangXJiangYWangA. Application of Bone Turnover Markers PICP and β-CTx in the Diagnosis and Treatment of Breast Cancer with Bone Metastases. Clin Lab. 2018;64:11–6. 10.7754/Clin.Lab.2017.16102129479886 ChaiXYinwangEWangZWangZXueYLiB Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value. Front Oncol. 2021 October 14;11:692788. 10.3389/fonc.2021.69278834722241 YlisirniöSSassiMLRisteliJTurpeenniemi-HujanenTJukkolaA. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res. 1999;19:5577–81.10697621 EbertWMuleyTHerbKPSchmidt-GaykH. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res. 2004;24:3193–201.15510610 SimojokiMSantalaMRisteliJKauppilaA. Discrepant expression of carboxy- and aminoterminal propeptides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer. Gynecol Oncol. 2003;88:358–62. 10.1016/S0090-8258(02)00139-712648587 NiemeläOBlakeJEOrregoH. Serum type I collagen propeptide and severity of alcoholic liver disease. Alcohol Clin Exp Res. 1992;16:1064–7. 10.1111/j.1530-0277.1992.tb00700.x1471760 GuañabensNParésAAlvarezLDe OsabaMJMMonegalAPerisP Collagen-Related Markers of Bone Turnover Reflect the Severity of Liver Fibrosis in Patients with Primary Biliary Cirrhosis. J Bone Miner Res. 1998;13:731–8. 10.1359/jbmr.1998.13.4.7319580479 Polak-JonkiszDZwolińskaDBednorzROwczarekHSzymańskaANahaczewskaW. Procollagen I carboxyterminal propeptide (PICP) as a bone formation marker and carboxyterminal telopeptide of type I collagen (ICTP) as a bone degradation marker in children with chronic renal failure under conservative therapy. Med Sci Monit. 2003;9:CR19–23.12552245 InukaiTFujiwaraYTayamaKAsoYTakemuraY. Serum levels of carboxy-terminal propeptide of human type I procollagen are an indicator for the progression of diabetic nephropathy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2000;48:23–8. 10.1016/S0168-8227(99)00137-010704696 ChiuariuTȘalaruDUrecheCVasiliuLLupuALupuVV Cardiac and Renal Fibrosis, the Silent Killer in the Cardiovascular Continuum: An Up-to-Date. J Cardiovasc Dev Dis. 2024;11:62. 10.3390/jcdd1102006238392276 UrecheCDodiGCovicANedelcuAVolovățSRSascăuRA Connection between Cardiac Fibrosis Biomarkers and Echocardiography Parameters in Advanced Chronic Kidney Disease Patients. J Clin Med. 2023;12:3003. 10.3390/jcm1208300337109335 UrecheCDodiGȘerbanAMCovicASVoroneanuLHogașS Predictive Value of Collagen Biomarkers in Advanced Chronic Kidney Disease Patients. Biomolecules. 2023;13:389. 10.3390/biom1302038936830758 KohYSJungHOParkMWBaekJYYoonSGKimPJ Comparison of Left Ventricular Hypertrophy, Fibrosis and Dysfunction According to Various Disease Mechanisms such as Hypertension, Diabetes Mellitus and Chronic Renal Failure. J Cardiovasc Ultrasound. 2009;17:127–34. 10.4250/jcu.2009.17.4.12720661337 ZengYYHuWPZuoYHWangXRZhangJ. Altered serum levels of type I collagen turnover indicators accompanied by IL-6 and IL-8 release in stable COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:163–8. 10.2147/COPD.S18813930655663 KaiSNomuraAMorishimaYIshiiYSakamotoTKiwamotoT Effect of inhaled steroids on increased collagen synthesis in asthma. Respiration. 2007;74:154–8. 10.1159/00009139016465044 LammiLKinnulaVLahdeSRisteliJPaakkoPLakariE Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Eur Respir J. 1997;10:2725–30. 10.1183/09031936.97.101227259493651 BacchellaLTinelliCGilèLSPeonaVAprileCGorriniM Serum type I and type III procollagen peptide levels in sarcoidosis. Eur Respir J. 1996;9:1648–51. 10.1183/09031936.96.090816488866588 LammiLRyhänenLLakariERisteliJPääkköPKahlosK Type III and Type I Procollagen Markers in Fibrosing Alveolitis. Am J Respir Crit Care Med. 1999;159:818–23. 10.1164/ajrccm.159.3.980506010051256 LammiLRyhänenLLakariERisteliJPääkköPRuotsalainenM Carboxyterminal propeptide of type I procollagen in ELF: elevation in asbestosis, but not in pleural plaque disease. Eur Respir J. 1999;14:560–4. 10.1034/j.1399-3003.1999.14c13.x10543275 ArmstrongLThickettDRMansellJPIonescuMHoyleEBillinghurstRC Changes in collagen turnover in early acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;160:1910–5. 10.1164/ajrccm.160.6.981108410588605 BachrachLK. Dual energy X-ray absorptiometry (DEXA) measurements of bone density and body composition: promise and pitfalls. J Pediatr Endocrinol Metab. 2000;13 Suppl 2:983–8.11086651 ZhangYHuangXLiCZhangJYuXLiY Broad application prospects of bone turnover markers in pediatrics. J Clin Lab Anal. 2022;36:e24656. 10.1002/jcla.2465635949006 KauppilaSTekayARisteliLKoivistoMRisteliJ. Type I and type III procollagen propeptides in amniotic fluid of normal pregnancies and in a case of mild osteogenesis imperfecta. Eur J Clin Invest. 1998;28:831–7. 10.1046/j.1365-2362.1998.00371.x9792997 CroftonPMShrivastavaAWadeJCStephenRKelnarCJLyonAJ Bone and collagen markers in preterm infants: relationship with growth and bone mineral content over the first 10 weeks of life. Pediatr Res. 1999;46:581–7. 10.1203/00006450-199911000-0001510541322 TommasiMBacciottiniLBenucciABrocchiAPasseriASaraciniD Serum biochemical markers of bone turnover in healthy infants and children. Int J Biol Markers. 1996;11:159–64. 10.1177/1724600896011003048915711 Lieuw-A-FaMSierraRISpeckerBL. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. J Bone Miner Res. 1995;10:849–53. 10.1002/jbmr.56501006047572307 MariniJCHopkinsEGlorieuxFHChrousosGPReynoldsJCGundbergCM Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res. 2003;18:237–43. 10.1359/jbmr.2003.18.2.23712568401 NicolaidouPStavrinadisILoukouIPapadopoulouAGeorgouliHDourosK The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. Eur J Pediatr. 2006;165:540–5. 10.1007/s00431-006-0132-116622660 StreetMESpaggiariCZiveriMAVoltaCFedericoGBaroncelliGI Analysis of bone mineral density and turnover in patients with cystic fibrosis: associations between the IGF system and inflammatory cytokines. Horm Res. 2006;66:162–8. 10.1159/00009414316804317 BaroncelliGIDe LucaFMagazzúGArrigoTSferlazzasCCatenaC Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation. Pediatr Res. 1997;41:397–403. 10.1203/00006450-199703000-000169078542 LanesRGunczlerPEsaaSWeisingerJR. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study. Clin Endocrinol (Oxf). 2002;57:725–30. 10.1046/j.1365-2265.2002.01614.x12460321 KuboTTanakaHInoueMKanzakiSSeinoY. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy. Bone. 1995;17:397–401. 10.1016/S8756-3282(95)00267-78573414 CinazPHasanogluEGökçoraNDogukanSDemirA. Serum levels of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen in children with growth retardation. Mater Med Pol. 1994;26:55–8.7745984 BaroncelliGIBertelloniSCeccarelliCCupelliDSaggeseG. Dynamics of bone turnover in children with GH deficiency treated with GH until final height. Eur J Endocrinol. 2000;142:549–56. 10.1530/eje.0.142054910822216 PraticoGCaltabianoLBottaroGPalanoGMRotoloNSpinaM. Serum levels of osteocalcin and type I procollagen in children with celiac disease. J Pediatr Gastroenterol Nutr. 1997;24:170–3. 10.1002/j.1536-4801.1997.tb01730.x9106103 HeMFChenPYZhaoYFZhaoZY. Relationship between bone turnover markers and bone sound of speed in appropriate-for-gestational-age neonates. CJCP. 2013;15:678–81. [in Chinese]23965884 AlyHMoustafaMFAmerHAHassaneinSKeevesCPatelK. Gestational age, sex and maternal parity correlate with bone turnover in premature infants. Pediatr Res. 2005;57:708–11. 10.1203/01.PDR.0000160591.70409.C815774820 KajantieEHytinanttiTKoistinenRRisteliJRutanenEMSeppäläM Markers of type I and type III collagen turnover, insulin-like growth factors, and their binding proteins in cord plasma of small premature infants: relationships with fetal growth, gestational age, preeclampsia, and antenatal glucocorticoid treatment. Pediatr Res. 2001;49:481–9. 10.1203/00006450-200104000-0000811264430 NamgungRTsangRCSierraRIHoML. Normal serum indices of bone collagen biosynthesis and degradation in small for gestational age infants. J Pediatr Gastroenterol Nutr. 1996;23:224–8. 10.1002/j.1536-4801.1996.tb01526.x8890070 GourgiotisDBrianaDDGeorgiadisABoutsikouMBakaSMarmarinosA Perinatal collagen turnover markers in intrauterine growth restriction. J Matern Fetal Neonatal Med. 2012;25:1719–22. 10.3109/14767058.2012.66301922339296 BhandariVFallPRaiszLRoweJ. Potential biochemical growth markers in premature infants. Am J Perinatol. 1999;16:339–49. 10.1055/s-2007-99388210614701 HeepAStoffel-WagnerBSodittVAringCGroneckPBartmannP C-propeptide in the cerebrospinal fluid of neonates with posthaemorrhagic hydrocephalus. Arch Dis Child Fetal Neonatal Ed. 2002;87:F34–6. 10.1136/fn.87.1.F3412091288 GiornoLPMalmongeSMSantosAR. Collagen as a biomaterial for skin wound healing: From structural characteristics to the production of devices for tissue engineering. Int J Artif Organs. 2025;48:135–45. 10.1177/0391398825131643739894968 SajantiJ. High concentrations of procollagen propeptides in chronic subdural haematoma and effusion. J Neurol Neurosurg Psychiatry. 2003;74:522–4. 10.1136/jnnp.74.4.52212640081 HaoXJunwenWJiaqingLRanLZhuoZYiminH High fibrosis indices in cerebrospinal fluid of patients with shunt-dependent post-traumatic chronic hydrocephalus. Transl Neurosci. 2016;7:92–7. 10.1515/tnsci-2016-001528123828 RaafsAGVerdonschotJAJHenkensMTHMAdriaansBPWangPDerksK The combination of carboxy‐terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy – A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. Eur J Heart Fail. 2021;23:933–44. 10.1002/ejhf.220133928704 RajahMRMaraisEMaarmanGJDoubellEDoubellAFHerbstPG. Utility of Serum Biomarkers of Myocardial Fibrosis in High-Gradient Severe Aortic Stenosis: An Explorative Cardiovascular Magnetic Resonance Imaging-Based Study. Diagnostics (Basel). 2025;15:1143. 10.3390/diagnostics1509114340361961 KühleMKuhnJLyTDKnabbeCFischerB. Using targeted proteomics-based detection of collagen propeptides to quantify fibrillar collagen biogenesis in vitro. Biochimie. 2025;228:101–13. 10.1016/j.biochi.2024.09.00439278395
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020502" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020502" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020502" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(68) "Procollagen I carboxy-terminal propeptide: a multi-faceted biomarker" ["journals_article_author"]=> string(79) "Sharon Philip Jain, Niharika Ikkurthy, Swetha Sundara, Shervinchris Philip Jain" ["journals_article_author_country"]=> string(10) "USA, India" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(72) "Procollagen I carboxy-terminal propeptide, collagen, biomarker, fibrosis" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2402" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "3" ["meta_title"]=> string(68) "Procollagen I carboxy-terminal propeptide: a multi-faceted biomarker" ["meta_desc"]=> string(68) "Procollagen I carboxy-terminal propeptide: a multi-faceted biomarker" ["meta_keyw"]=> string(72) "Procollagen I carboxy-terminal propeptide, collagen, biomarker, fibrosis" ["created"]=> string(19) "2026-04-07 10:50:51" ["modified"]=> string(19) "2026-06-11 08:43:10" } [34]=> object(stdClass)#83 (35) { ["journals_id"]=> string(4) "1228" ["journals_xml"]=> string(111695) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020501 10.11613/BM.2026.020501 Reviews Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives de AlmeidaGabriel Barroso1dos SantosMariane Melo1de Oliveira BarbosaDyjaene1ConceiçãoRogério Reis1de Almeida LopesBruno2de Melo SantosHerbert Henrique1MarchioroSilvana Beutinger*1 Laboratory of Immunology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, Bahia, Brazil Laboratory of Acute Leukemia Genetics, National Cancer Institute, Rio de Janeiro, Brazil Corresponding author: silmarchioro@hotmail.com

Author contributions

GBA, MMS and SBM: writing, reviewing, and editing. DOB, RRC: reviewing and editing. MMS, BAL and HHMS: conceptualization and rewiew.

15042026 15062026 36 2 020501 2505202502022026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Classification of plasmacytoid dendritic cell-related hematologic neoplasms

• Immunomodulatory role of dendritic cells in the leukemic microenvironment

• Therapeutic advances in acute myeloid leukemia through dendritic cell-based vaccination strategies

Dendritic cells (DCs) are essential immune system sentinels, playing a key role in activating naïve T cells against leukemic cells. They have an immunomodulatory function, promoting an immune response and, at the same time, regulating immune tolerance to avoid excessive reactions. Plasmacytoid dendritic cell (pDC) neoplasms are a complex group of disorders, and among the subtypes, acute myeloid leukemia (AML) with pDC dermatosis (AML-pDC) stands out. In this context, pDCs can play an immunomodulatory role by inhibiting or promoting immune responses and acting as tumor progenitors since, in some cases, they can collaborate with the tumor microenvironment, favoring immune evasion and proliferation. However, the clinical significance of pDC in AML is not fully understood. Studies suggest that the interaction of pDCs with the leukemic microenvironment may contribute to disease progression by impairing the immune system’s ability to control tumor cells. Understanding the role of DCs in neoplasia is crucial, as it provides important insights for new studies seeking advances in innovative therapeutic strategies, such as dendritic cell vaccines. These vaccines are promising, with low toxicity and the potential to improve the prognosis of individuals affected by AML, stimulating an effective immune response.

Keywords: dendritic cellsplasmacytoid dendritic cellacute myeloid leukemia
Introduction

Immunological aspects play a crucial role in the development and progression of malignant hematological diseases, and recent research has shed increasing light on the role of innate immune cells, particularly within leukemic contexts (1, 2). Among these, dendritic cells (DCs) have received considerable attention. While they play a pivotal role in initiating and regulating immune responses against tumor cells, accumulating evidence also highlights their potential to support tumor progression, particularly through the induction of immunosuppressive microenvironments (3). This duality reinforces the complexity of DCs in leukemogenesis and underscores the need for a deeper understanding of their functional plasticity.

In parallel with functional studies, advances in immunophenotyping, molecular profiling, and genetic analyses have redefined DC-related disorders in hematologic malignancies (4, 5). The expansion of neoplastic dendritic cells has long been recognized in these diseases; however, recent classifications reflect a more refined understanding of their biology (6). Among the dendritic cell subsets, plasmacytoid dendritic cells (pDCs) have emerged as particularly relevant in myeloid neoplasms (7). Currently, three distinct types of neoplastic pDC proliferation are described: 1) blastic plasmacytoid dendritic cell neoplasm (BPDCN), 2) acute myeloid leukemia with pDC differentiation (pDC-AML), and 3) mature plasmacytoid dendritic cell proliferation (MPDCP). Each entity exhibits distinct phenotypic features that correlate with different stages of pDC maturation, and these features have significant clinical and therapeutic implications (8-10).

Given this constantly evolving scenario, this descriptive review searched databases such as PubMed and SciELO, including original articles, literature reviews and experimental studies, using descriptors such as pDC, AML, immunotherapy, and vaccine. The objective was to provide an updated overview of dendritic cells in leukemic contexts, with an emphasis on their classification, immunological functions, and functional heterogeneity. Furthermore, it sought to investigate how a deeper understanding of the biology of these cells, particularly the immunomodulatory properties of pDCs, can inform the development of targeted immunotherapeutic strategies, leading to a more precise characterization of the disease and the advancement of innovative therapeutic approaches.

Dendritic cells subsets and biology

Dendritic cells comprise a heterogeneous group characterized by diverse locations, phenotypes, and immunological functions, with a standard function in antigen presentation. These cells possess numerous pattern recognition receptors (PRRs). Known as professional antigen-presenting cells (APCs), they are most effective at activating naïve T cells through MHC-I for CD8+ T cells and MHC-II for CD4+ T cells (11, 12). The main subsets described are shown in Figure 1. This plasticity enables DCs to shape the immune response differently when encountering various pathogens (4).

Main dendritic cell (DC) subsets, their corresponding cellular markers, and the associated transcription factors that drive their development. A. Conventional DC type 1 IRF (interferon regulatory factor), and TLR (Toll-like receptors), transcription factors such as BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3), IRF8, BCL-6 (B-cell lymphoma 6); ID2 (Inhibitor DNA Binding 2); ZBTB-42 (Zinc Finger and BTB Domain Containing 42). B. Conventional DC 2 has four transcription factors: IRF4, ID2, ZBTB-46, and NOTCH2 (notch receptor 2). C. Monocyte-derived DC surface CX3CR1 (CX3C chemokine receptor), transcription factors MAFB (MAF transcription factor B), KLF4 (KLF transcription factor 4). D. Plasmacytoid DC IRF7. Figure created using Servier Medical Art resources (Servier Medical Art, CC BY 4.0 license).

Under homeostatic conditions, DCs are present in various tissues and can migrate to the T cell zones of lymph nodes during the inflammatory process. Depending on the stimulus, DCs alter their phenotypes, which can exert either immunogenic or tolerogenic effects (4). Conventional type 1 DCs (DC1) are located in the paracortex of lymph nodes and capture cellular antigens through CD205+ or TIM3 (mucin domain-containing protein 3) receptors (12). They facilitate the presentation of cross-antigens to CD4+ and CD8+ T cells. DC1 are equipped with toll-like receptors (TLR) 3, 4, 9, 11, and 13, and primarily produce interleukin (IL) 12 and interferon (IFN) III, which are critical in the responses against viruses, tumors, and intracellular bacteria (making them the most efficient antigen-presenting cells for stimulating the Th1 phenotype) as well as for regulatory T cells (12, 13). Data demonstrates that in Batf3+/+ mice, deficient in DC1, there is a failure in the migration of CD8+ T lymphocytes. Replacement with activated DCs from Batf3+/+ mice restores this response, indicating that only CD103+ DC1s are indispensable and cannot be replaced by other DC subtypes. However, their antitumor role may be limited, for example, by the action of granulocyte colony-stimulating factor (G-CSF), which suppresses the expression of interferon regulatory factor 8 (IRF8), an essential factor for the development of DC1 (14).

Conventional type 2 DCs (DC2) participate in the capture of antigens in the skin and migrates to the T zones of lymph nodes through chemoreceptors (CXCR4 and CCR7). They are cells that participate in presenting tumor-associated antigens (TAAs). In addition, DC2 expresses interferon regulatory factor 4 (IRF4), which enables them to present MHC-II efficiently and is more effective in activating CD4+ T cells compared to DC1 (4, 15). They are endowed with TLR (1, 4-7, 9, 13) and mainly express tumor necrosis factor (TNF), IL-6, and IL-23, which are associated with responses to extracellular bacteria, fungi, and allergens, and are specialized in activating T for Th2 and Th17 subtypes (15).

Conventional type 2 DCs are considered the most heterogeneous subset of DCs both phenotypically and functionally (16). Single-cell transcriptome analyses have revealed that human DC2s are subdivided into at least two main groups: cDC2 and DC3. In mice, inflammatory cDC2s (inf-cDC2s) have been identified, characterized by the expression of CD172a and CD11b. Notably, these inf-cDC2s also express CD64 and IRF8, typical markers of monocyte-derived DC (moDCs) and cDC1s, respectively. Studies demonstrate that TLRs and type I IFN promote the maturation of these inf-cDC2s in an IRF8-dependent manner (17, 18).

Recently described DC subgroups, such as immature DCs (imDCs) and regulatory DCs (DCregs), have been implicated in the formation of an immunosuppressive microenvironment that favors tumor progression. A new profile of CD11c+ MHCIIlow DCs (T-DCs) has recently been identified, accumulating in the splenic microenvironment of mice with T-cell acute lymphoblastic leukemia (T-ALL). These T-DCs exhibited an immature phenotype, characterized by low expression of MHC II, CD86, CD83, and CD40 molecules. Functionally, T-DCs promoted T-ALL progression, exhibiting reduced phagocytic capacity and limited potential for activating CD4+ T cells. Furthermore, RNA analyses demonstrated that T-DCs express low levels of genes associated with maturation and antigen processing. Single-cell RNA sequencing studies further revealed the heterogeneity of these cells, showing that they are predominantly composed of DC1s, DC2s, and DCs with macrophage-like characteristics (19). Thus, the heterogeneity observed among the DC subsets appears to reflect transcriptional profiles shaped by different immunological and environmental stimuli, highlighting the importance of understanding the differentiation factors and pathways that drive the development of these populations.

Inflammatory or moDCs arise in inflammatory contexts and are present in the blood, mucous membranes, lymphoid organs, and inflamed tissues. They express multiple TLRs (1, 2, 4, 6-9, 13), produce pro-inflammatory cytokines (TNF, iNOS, IL-12, and IL-23), and promote Th1 responses through cross-presentation of antigens to CD8+ and CD4+ T lymphocytes (4, 15). In mice, moDCs can present antigens directly in peripheral tissues, activating both naive and memory CD8+ T lymphocytes, as observed in models of acute lymphocytic choriomeningitis virus infection, where a drastic increase in moDCs is seen in secondary lymphoid organs in an IFN-γ-dependent manner. In these models, activation by moDCs enhances the differentiation of memory CD8+ T cells compared to cDC, through the upregulation of Eomesodermin (Eomes) and TCF-1 (20). Although this function is not yet fully understood in humans, evidence suggests similar mechanisms, including cross-presentation via the vacuolar pathway and activation of CD8+ T lymphocytes in non-lymphoid tissues by moDCs derived from ascites fluid (21).

Among the methodologies employed in therapeutic strategies involving DCs, the use of moDCs stands out. In various types of cancer, such as melanoma, and in leukemia, where leukemic DCs may be dysfunctional, autologous or allogeneic moDCs become a preferred alternative (22). One limitation is that moDCs do not naturally express leukemic antigens, making it necessary to load them ex vivo (23). However, data demonstrate that these moDC vaccines can induce effective antigen-specific responses against leukemic clones (24).

Plasmacytoid DCs (pDCs) are found in the bone marrow, secondary lymphoid organs, and blood but have limited antigen presentation capacity. Throughout their development, they present transcription factors such as E2-2, ZEB2, IKZF1, MTG16, and during their maturation, genes such as RUNX2, SPIB, IRF7, and NFATC3 (15). They play a crucial role in responses to RNA and DNA viruses, as they express TLRs 7, 9, and 12. When activated, they release type I and III interferons, which have activity under NK and activate the antiviral state in host cells. In addition to their well-known antiviral activities, pDCs have been shown to play a fundamental role in the development of various inflammatory diseases (4, 11).

Role of pDC in acute myeloid leukemia

Studies on the role of plasmacytoid dendritic cells (pDCs) in leukemias have gained increasing attention in recent years. Although this cell group comprises less than 1% of nucleated cells in the bone marrow and blood, it is recognized as the primary producer of type I and III interferons (25). Conventionally, pDCs are identified by the expression of CD123, HLA-DR, and CD303/BDCA2, in the absence of other lineage-specific markers (e.g., lymphoid and/or myeloid), and also express the FLT3 cytokine receptor (12, 26).

Given their potent capacity to produce interferons, particularly types I and III, pDCs have been considered key players in anti-tumor immunity. Interferons can promote the death of cancer cells via cytotoxic mechanisms; however, depending on the stimuli, pDCs may adopt a pro-tumorigenic phenotype. For instance, impaired IFN production can foster a microenvironment conducive to Treg expansion, which may support tumor growth (3, 27).

This duality in pDC function is further illustrated by their role in modulating T cell responses. In solid tumors, a higher density of dendritic cells within the tumor microenvironment is associated with enhanced activation of CD8+ T cells and, consequently, a reduction in neoplastic clones (28). Interestingly, during acute myeloid leukemia (AML), pDCs typically remain in a quiescent state. However, stimulation with TLR7 and TLR9 agonists has shown promise in reprogramming their tolerogenic profile. This reprogramming enhances endogenous type I IFN production and may facilitate the clearance of leukemic cells (29). Supporting this, murine models have demonstrated that antigens from circulating leukemic cells can be captured by a subset of splenic DCs, known as CD8α+ DCs, which facilitate the presentation of tumor antigens to CD8+ T cells, thereby promoting an anti-leukemic response (30).

In the context of myelodysplastic syndromes (MDS), the role of pDCs is also gaining prominence. Studies have shown that lower proportions of pDCs correlate with poorer prognoses, as classified by the International Prognostic Scoring System-Revised (IPSS-R), and are associated with decreased patient survival (31). These findings highlight the potential of pDCs to serve as biomarkers that complement traditional clinical risk stratification. Furthermore, reduced pDC counts in grafts have been linked to higher incidences of acute graft-versus-host disease (aGVHD) in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. In this context, low peripheral blood pDC counts may also predict transplant-related mortality, reinforcing their clinical relevance (32).

Neoplasms involving pDCs

The importance of pDCs is further emphasized by their involvement in plasmacytoid dendritic cell neoplasms, highlighting their ambiguous role in the tumor microenvironment. It is hypothesized that pDCs originate from common hematopoietic progenitors (CD34+), derived from monocytes (CD14+) and conventional dendritic cells (15, 33). However, they may also derive from leukemic clones in AML and MDS, suggesting a complex interaction between leukemic cells and the pDC progeny (26, 27). In this context, the observation that pDCs are markedly depleted in most cases of AML and other high-grade myeloid neoplasms, while their increased differentiation may point to an early hematopoietic stem cell or multipotent progenitor as the cell of origin, reinforces the notion that pDC dysregulation is intricately linked to disease pathogenesis and may serve as an indicator of adverse clinical outcomes (26).

Throughout their development, pDCs progress through three maturation stages: early, intermediate, and late, each characterized by distinct marker expression profiles. Early-stage pDCs express CD34 and CD117 while lacking CD303 and CD304. As they transition to the intermediate stage, they begin to express CD4, CD303, and CD304, while concurrently declining in CD34 and CD117 expression. In the final stage, mature pDCs express CD4, CD303, CD304, and CD45 (Figure 2). Notably, CD123 and HLA-DR are consistently expressed across all stages and serve as reliable markers for both mature and immature pDCs. Additionally, CD56 expression may appear during intermediate stages, particularly when CD2 and CD5 are co-expressed (34, 35).

Main immunophenotypic markers used in the diagnosis of malignant dendritic cell neoplasms. Positive phenotype for pDC lineage (CD123+, CD4+, HLA-DR) and common markers (CD303+, CD304+ TCF4+ TCL1+). BPDCN (Blastic plasmacytoid dendritic cell neoplasm) is identified by the expression of CD56+; MPDCP (Mature plasmacytoid dendritic cell proliferation) presents CD56- and CD34-; pDC-AML (Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation) presents CD56-. Figure created using Servier Medical Art resources (Servier Medical Art, CC BY 4.0 license).

Myeloid neoplasms with pDC differentiation, also described as pDC expansion in myeloid neoplasms (MN), are commonly associated with acute myeloid leukemia (pDC-AML). Representing approximately 3-5% of all AML cases, these neoplasms exhibit a median pDC proportion of 6.6%. Unlike other AML subtypes, pDC-AML can present with varying degrees of pDC maturation, often in early or intermediate stages (26). This feature reflects the abnormal differentiation trajectory of pDCs previously discussed. Notably, pDC-AML is also observed in AML subtypes with higher cellular differentiation, such as M4 (acute myelomonocytic leukemia) and M5 (acute monocytic leukemia), and typically affects individuals between 45 and 70 years of age (10). Clinical manifestations are diverse and may include anemia, thrombocytopenia, lymphadenopathy, and cutaneous lesions. Skin involvement appears more frequent in pDC-AML than in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Importantly, patients with pDC-AML tend to have lower complete remission rates and a reduced median overall survival of approximately 8 months, compared to other AML cases (10, 35).

Building upon the clinical profile, genetic and epigenetic studies have begun to uncover molecular characteristics of pDC-AML, although research in this area remains limited. An influential association has been identified with RUNX1 mutations, which affect the RUNT DNA-binding domain and are found in approximately 78% of pDC-AML cases. These mutations are less frequent in MPDCP and appear to drive leukemogenesis by promoting the expansion and differentiation of pDCs from leukemic blasts (36, 37). This mechanism reinforces the idea that pDCs in pDC-AML may not be reactive or bystanders but derive directly from the leukemic clone. Other recurrent mutations associated with pDC-AML include TP53, TET2, ASXL1, and DNMT3A; however, mutations in FLT3 I/D, although commonly observed, are not considered unique to this AML subtype (38).

Compared to BPDCN, it presents a distinct but overlapping molecular landscape. Recent genome-wide analyses have shown significant deregulation of key regulatory pathways in BPDCN, including a marked loss of DNA methylation, indicative of mitotic stress and epigenetic instability (39). This contrasts with the genetic profiles seen in pDC-AML, highlighting divergent pathophysiological mechanisms even among neoplasms involving pDCs. In BPDCN, differentially expressed genes include STAT5A, CDK6, CCR4, CCND2, and FOXO1, which contribute to a molecular profile distinct from other dendritic cell disorders. Structural chromosomal abnormalities, such as deletions or rearrangements in regions like 5q, 12p, 17p, and monosomy 9, further characterize BPDCN. Moreover, gene-level mutations commonly involve ASXL1, IDH1/2, TET1/2, TP53, and others (35, 38). The elevated expression of genes such as LAMP5 and CCDC50, alongside increased levels of eosinophilic chemoattractant cytokines (e.g., eotaxin, RANTES), suggests a possible pre-inflammatory microenvironment, despite pDCs in BPDCN often displaying a non-activated phenotype (35).

Immunosuppressive mechanisms

These molecular and immunological changes underscore a broader phenomenon observed across dendritic cell-related neoplasms - immune dysregulation within the tumor microenvironment (TME). In AML, for example, the TME has been shown to promote the conversion of innate immune cells to an immunosuppressive phenotype, contributing to tumor progression (3, 40). RNA-seq analyses of bone marrow samples from AML patients have revealed a highly heterogeneous and altered immune landscape, including the presence of Th17 cells, CD8+ memory T cells, exhausted T lymphocytes, regulatory T cells (Tregs), macrophages, and dysfunctional dendritic cells (41). These findings reinforce the notion that pDCs and other DC subsets, whether as part of the leukemic clone or as modulators of the immune response, play a central role in reshaping the AML microenvironment and may serve as biomarkers and potential therapeutic targets.

The obstacles to an effective immune response in AML are multifactorial and contribute significantly to the disease’s capacity to evade immune surveillance. These obstacles include: i) deficient antigen presentation due to low neoantigen load; ii) imbalance in T cell subpopulations, particularly an increase in Tregs; iii) T cell exhaustion caused by chronic inflammatory stimulation and overexpression of inhibitory ligands; iv) expansion of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs); and v) increased production of immunomodulatory factors and metabolic mediators (42).

Within this context, AML is broadly considered a malignancy of low immunogenicity (42). Neoplastic clones in AML downregulate genes and proteins related to MHC class II (such as HLA-DP and HLA-DR), impairing antigen presentation by dendritic cells (DCs) to naïve T cells (43). DC-AML fusion vaccines have emerged as a promising therapeutic approach to counteract this immunoevasive strategy. These fusion cells can present a broader array of epitopes and activate multiple T cell receptors (TCRs), potentially restoring effective immune responses.

The immunosuppressive environment in AML is further compounded by the prominent role of Tregs, which can inhibit various immune system components. Elevated levels of Tregs are commonly reported, particularly after chemotherapy, and their abundance is associated with delayed hematopoietic recovery. Consequently, strategies targeting Tregs have gained interest. Additionally, T cell exhaustion, characterized by the expression of co-inhibitory receptors such as CTLA-4, PD-1, TIM-3, and LAG-3, has been described in AML. Leukemic blasts can express PD-L1/PD-L2 in response to interferon signaling, further dampening effector T cell responses (3, 40).

This immune dysfunction is compounded by MDSCs and TAMs, both of which adopt pro-tumor phenotypes under the influence of the leukemic microenvironment. These cells, together with immunosuppressive mediators such as arginase pathway products, indoleamine 2,3-dioxygenase (IDO), and prostaglandin E2 (PGE2), contribute to the increased recruitment of Treg cells and further suppression of anti-tumor immunity (2, 44, 45). These molecules also promote programmed death-1 (PD-1) expression, reinforcing the exhausted phenotype of T cells.

At the metabolic level, AML blasts have been shown to overexpress STAT5, a transcription factor that enhances glycolytic metabolism. The resulting lactate accumulation in the bone marrow can promote nuclear translocation of E3-binding protein (E3BP), facilitating histone acetylation and upregulating programmed death-ligand 1 (PD-L1) transcription. This metabolic reprogramming has been clinically correlated with increased STAT5 and PD-L1 levels in newly diagnosed AML patients, further linking metabolic alterations with immune evasion (46).

Amid these alterations, pDCs have been implicated in immune modulation and tumor progression. Recent studies describe a unique subset termed tumor-associated pDCs (TAPDCs) or tumor-forming pDCs (TF-pDCs). Some mechanisms related to this process are illustrated in Figure 3; among them, these cells, often expanded in the AML microenvironment, exhibit a non-activated phenotype, producing low levels of IFN-α in response to TLR stimulation. The persistence of TAPDCs supports Treg expansion and the maintenance of an immunosuppressive niche (10, 47).

Main mechanisms involved in DC-mediated immunosuppression in hematologic malignancies. Produced by TM, cytokines such as PGE2, TGF-β, and TNF-α can stimulate the development of MDSC and M2 macrophages, thereby inhibiting inflammation. These cytokines lead to low IFN production in TF-pDC. TF-pDCs are associated with the development of Tregs. IL-10 produced by TM or TReg causes inhibition of the T response and low expression of Toll-like receptors in DC. The production of IDO and expression of ICOS and its ligands stimulate the differentiation of T cells in an anti-inflammatory profile.TM - tumor microenvironment. IL-10 - interleukin 10. IFN-α - interferon alpha. TGF-β - transforming growth factor beta. PGE2 - prostaglandin E2. MDSC - Myeloid-Derived Suppressor Cells. M2 - Macrophage M2. TLR - Toll-like receptors. TF-PDC - tumor-forming pDCs. ICOs - Inducible costimulator-ligands. Figure created using Servier Medical Art resources (Servier Medical Art, CC BY 4.0 license).

In pDC-AML, this immunosuppressive role becomes even more evident. TAPDCs release leukemic antigens while failing to mount an effective type I IFN response, thereby facilitating immune escape by leukemic clones. These pDCs also skew T cell differentiation toward Treg and Th2 profiles, a shift supported by their expression of IDO and PD-L1. Additionally, elevated levels of transforming growth factor (TGF) β and TNF in the leukemic microenvironment can inhibit IRF-7, a key transcription factor required for IFN-α production, thereby reinforcing the dysfunctional state of TAPDCs (10, 44, 45).

Furthermore, studies show that reduced levels of cDCs at diagnosis and a predominance of pDCs during remission are frequently observed in AML (48). This imbalance suggests a disrupted DC compartment, where a higher ratio of pDCs to moDCs may correlate with immunosuppression and poor clinical outcomes (28). According to Xiao et al., the loss of pDC differentiation is predictive of residual disease post-induction therapy, positioning pDC profiling as a potential tool for risk stratification. Notably, in AML-M4/M5, pDC infiltration has been linked to disease progression. Under the leukemic microenvironment, pDCs may differentiate into tumor-associated dendritic cells, contributing to immune evasion and treatment resistance (27).

DC-based therapies

Over the past decades, DC-based vaccines have emerged as a promising immunotherapeutic strategy in the treatment of hematologic malignancies, including AML. Continuous research has explored advanced methodologies to enhance their clinical potential and overcome immune resistance mechanisms (49). While allogeneic hematopoietic stem cell transplantation remains a valuable treatment option, its use is often limited by severe complications such as GVHD, contributing to significant morbidity and mortality (50, 51). Table 1 summarizes the main DC-based vaccination strategies currently under clinical investigation.

Relevant clinical trials available on vaccination therapy in acute myeloid leukemia
Vaccine type Vaccine antigen Doses Phases endpoint Results Authors
DC WT1 4 (2 every 2 months) Antileukemic response Relapse reduction rate of 25% Anguille S et al. (57)
Allogeneic DC WT1, PRAME 4 Phase I Tolerated treatmentIncreased overall survivalDevelopment of cellular and humoral immune response Van de Loosdrecht A et al. (58)
Genetically modified DC (gmDC) MUC1, flagellin, SOCS1 1 Phase I – IIgmDCs elicited potent TAA-specific CTL responses in vitro Phase I: safe in acute leukemia patients and yielded improved survival rate.Phase II: complete remission rate of 83% in 12 relapsed AML patients. Wang D et al. (52)
DC WT1, PRAME 4, every 6 weeks Improved immune response rate Stable disease Eckl J et al. (59)
TLR7/8-matured DCs transfected with RNA WT1, PRAME, CMVpp65 10 Phase IImmune response TLR7/8-matured DCs to AML patients in CR at high risk of relapse was feasible and safe and resulted in induction of antigen-specific immune responses. Lichtenegger FS et al. (24)
moDC autologous - 5 (days 1, 7, 14, 21, 35) Phase I/II No severe adverse event was documented.prolonged overall survival Chevallier P et al. (60)
Autologous RNA-loaded mature dendritic cell (mDC) WT, PRAME 1 (4 week, 6 week).1 monthly dose for 2 years - Treatment was well tolerated;Eleven of 20 patients (55%) remained in CR;Overall survival at five years was 75% (95% CI: 50–89), with 70% of patients ≥60 years of age being long-term survivors Floisand Y et al. (61)
Allogeneic Leukemia-Derived Dendritic Cell - 4 fortnightly;Reinforcement (week 14 and 18). Improved immune response rate Increase in the number of circulating antigen-presenting DCsVaccination improve and induce maturation of DC (cDC1, cDC2 and pDC), presentation to tumor-reactive T cells Van Zeeburg H et al. (62)
DC/AML fusion vaccine Mean fusion vaccine dose was 3,7 x106 cell2 doses with a 3-week interval. Phase IResult 20 effectively received the vaccine; adverse reactions included mild local reactions; 5 cases of GVHD possibly related to vaccination; 45% had high-risk disease, and 14 remained in complete remission, with late relapses (3–5 years); Median overall survival was 50 months after transplantation. The vaccine has proven to be safe, feasible, and potentially effective Liegel J et al. (63)
DC - dendritic cell. AML - acute myeloid leukemia. TAA - tumor-associated antigen. CTL - cytotoxic T cell. CR - complete remission. GVHD - graft-versus-host disease.

Dendritic cell vaccines can be generated from various cellular sources, commonly leukemia-derived DCs (AML-DCs) and monocyte-derived DCs (moDCs). However, a central challenge in vaccine development lies in selecting appropriate antigenic targets, due to the inherent heterogeneity of leukemic clones. To navigate this complexity, leukemic antigens are generally classified into two main categories: leukemia-associated antigens (LAAs), which are overexpressed or aberrantly expressed in leukemic cells (e.g., Wilms’ tumor protein 1 – WT1), and leukemia-specific antigens (LSAs), which result from somatic mutations and include true neoantigens, such as Nucleophosmin 1 (NPM1) (44, 52).

Despite encouraging results from preclinical and early-phase clinical trials, several barriers still hinder the complete optimization and clinical efficacy of DC vaccines in AML. These include the difficulty in identifying universal, immunogenic antigens due to disease heterogeneity, challenges in standardizing DC generation protocols, and determining the most effective routes of administration. Furthermore, the immunosuppressive nature of the AML microenvironment, characterized by Treg expansion, dysfunctional antigen presentation, and inhibitory cytokine signaling, remains a significant obstacle that may substantially diminish the vaccine’s therapeutic potential (1, 50).

The primary antigens utilized in DC-based vaccines are WT1 and PRAME, often combined with additional targets to enhance applicability across patients; however, these approaches still fail to fully address tumor heterogeneity. Several vaccine platforms are under development, including autologous, allogeneic, and genetically modified DCs, each exhibiting distinct immunogenic profiles and clinical potential. These strategies have demonstrated increased interferon production and expansion of cytotoxic CD8+ T lymphocytes, indicating effective activation of antitumor immune responses. Despite encouraging results, the lack of methodological standardization, limited sample sizes, and scarcity of advanced-phase randomized trials continue to hinder the establishment of definitive evidence of clinical efficacy. Nevertheless, DC vaccines remain a promising and safer alternative to CAR-T cell or bispecific T-cell engager antibody therapies, which, although highly effective, are frequently associated with severe toxicities such as cytokine release syndrome, neurotoxicity, and tumor lysis syndrome (53). Moreover, many CAR-T targets, including CD33, CD117, and CD123, are also expressed on hematopoietic stem cells, raising the risk of severe and potentially fatal myeloablation (54).

Among the barriers to implementing DC vaccines, one difficulty is the complexity and high cost of individualized production, which requires leukapheresis, cell culture, genetic manipulation, or fusion with leukemic blasts, in addition to rigorous quality controls, making the process time-consuming and dependent on specialized infrastructure. The time required for vaccine preparation may not coincide with the ideal therapeutic window, especially in post-transplant patients, who may experience toxicities or relapse before vaccination (55). Another relevant challenge is the risk of interference from immunosuppression and the potential for induction of GVHD, which requires a careful balance between immunological efficacy and safety. Tumor heterogeneity and antigen loss also limit the durability of the immune response, while the absence of predictive biomarkers and large-scale clinical studies prevents adequate patient selection and regulatory approval (56). Finally, the limited scalability and difficulty of integration into hospital routines reinforce the need to develop more standardized, accessible, and “off-the-shelf” platforms to enable large-scale clinical use.

Conclusion

In summary, DCs, particularly pDCs, play a central role in modulating the immune response in hematological malignancies, such as acute myeloid leukemia. Their ability to present leukemic antigens and coordinate the activation of T lymphocytes positions them as critical mediators between immunity and tumor tolerance. However, mechanisms such as the downregulation of MHC molecules, the expansion of regulatory T cells, T lymphocyte exhaustion, and immunosuppressive remodeling of the microenvironment compromise their function, favoring immune evasion and disease progression. Thus, understanding the interactions between DCs and the leukemic microenvironment is crucial for elucidating their role in both resistance and therapeutic response.

In this context, DC-based immunotherapies, especially dendritic cell vaccines, emerge as a promising alternative to conventional immunological approaches, such as CAR-T therapies, offering the potential for personalization and lower toxicity. Although challenges persist, including tumor heterogeneity, the ideal selection of antigens, and the influence of the immunosuppressive microenvironment, advances in the phenotypic and functional characterization of DCs pave the way for more effective strategies to reactivate antitumor immunity. A deeper understanding of their biology and regulatory mechanisms will be crucial to consolidating the role of DC vaccines as a viable therapeutic tool, capable of improving prognosis and clinical outcomes in AML and related hematological malignancies.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References Del PreteASalviVSorianiALaffranchiMSozioFBosisioD Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20:432–47. 10.1038/s41423-023-00990-636949244 TettamantiSPievaniABiondiADottiGSerafiniM. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 2022;36:13–22. 10.1038/s41375-021-01350-x34302116 BarakosGPHatzimichaelE. Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Diseases. 2022;10:33. 10.3390/diseases1002003335735633 Jiménez-CorteganaCPalomaresFAlbaGSanta-MaríaCde la Cruz-MerinoLSánchez-MargaletV Dendritic cells: the yin and yang in disease progression. Front Immunol. 2024;14:1321051. 10.3389/fimmu.2023.132105138239364 Motallebzadeh KhanmiriJAlizadehMEsmaeiliSGholamiZSafarzadehAKhani-EshratabadiM Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review. Cytotherapy. 2024;26:427–35. 10.1016/j.jcyt.2024.02.00938483358 BeirdHCKhanMWangFAlfayezMCaiTZhaoL Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer J. 2019;9:99. 10.1038/s41408-019-0262-031811114 YangLLiSChenLZhangY. Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity. Cancer Biol Med. 2023;20:728–47. 10.20892/j.issn.2095-3941.2023.024137817484 Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703-19. 10.1038/s41375-022-01613-1 HuangYWangYChangYYuanXHaoLShiH Myeloid Neoplasms with Elevated Plasmacytoid Dendritic Cell Differentiation Reflect the Maturation Process of Dendritic Cells. Cytom Part J Int Soc Anal Cytol. 2020;97:61–9. 10.1002/cyto.a.2395331876105 PengJHeSYangXHuangLWeiJ. Plasmacytoid dendritic cell expansion in myeloid neoplasms: A novel distinct subset of myeloid neoplasm? Crit Rev Oncol Hematol. 2023;192:104186. 10.1016/j.critrevonc.2023.10418637863402 CollinMBigleyV. Human dendritic cell subsets: an update. Immunology. 2018;154:3–20. 10.1111/imm.1288829313948 ChrisikosTTZhouYSloneNBabcockRWatowichSSLiHS. Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer. Mol Immunol. 2019;110:24–39. 10.1016/j.molimm.2018.01.01429549977 SeguraE. Human dendritic cell subsets: An updated view of their ontogeny and functional specialization. Eur J Immunol. 2022;52:1759–67. 10.1002/eji.20214963235187651 LiuPZhaoLKroemerGKeppO. Conventional type 1 dendritic cells (cDC1) in cancer immunity. Biol Direct. 2023;18:71. 10.1186/s13062-023-00430-537907944 AndersonDADutertreCAGinhouxFMurphyKM. Genetic models of human and mouse dendritic cell development and function. Nat Rev Immunol. 2021;21:101–15. 10.1038/s41577-020-00413-x32908299 LeónB. Type 2 conventional dendritic cell functional heterogeneity: ontogenically committed or environmentally plastic? Trends Immunol. 2025;46:104–20. 10.1016/j.it.2024.12.00539843310 SaitoYKomoriSKotaniTMurataYMatozakiT. The Role of Type-2 Conventional Dendritic Cells in the Regulation of Tumor Immunity. Cancers (Basel). 2022;14:1976. 10.3390/cancers1408197635454882 ShinJYWangCYLinCCChuCL. A recently described type 2 conventional dendritic cell (cDC2) subset mediates inflammation. Cell Mol Immunol. 2020;17:1215–7. 10.1038/s41423-020-0511-y32732988 CuiXLiYXieWLiRZhangDZhangS Identification of a novel immature dendritic cell subset with potential pro-leukemic effects in leukemia microenvironment. Cell Death Dis. 2025;16:571. 10.1038/s41419-025-07851-240730800 ShinKSJeonIKimBSKimIKParkYJKohCH Monocyte-Derived Dendritic Cells Dictate the Memory Differentiation of CD8+ T Cells During Acute Infection. Front Immunol. 2019;10:1887. 10.3389/fimmu.2019.0188731474983 Tang-HuauTLGueguenPGoudotCDurandMBohecMBaulandeS Human in vivo-generated monocyte-derived dendritic cells and macrophages cross-present antigens through a vacuolar pathway. Nat Commun. 2018;9:2570. 10.1038/s41467-018-04985-029967419 BoudewijnsSBloemendalMde HaasNWestdorpHBolKFSchreibeltG Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunol Immunother CII. 2020;69:477–88. 10.1007/s00262-019-02466-x31980913 O’BrienLJGuillereyCRadfordKJ. Can Dendritic Cell Vaccination Prevent Leukemia Relapse? Cancers (Basel). 2019;11:875. 10.3390/cancers1106087531234526 LichteneggerFSSchnorfeilFMRotheMDeiserKAltmannTBückleinVL Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial. Clin Transl Immunology. 2020;9:e1117. 10.1002/cti2.111732153780 FengJPucellaJNJangGAlcántara-HernándezMUpadhayaSAdamsNM Clonal lineage tracing reveals shared origin of conventional and plasmacytoid dendritic cells. Immunity. 2022;55:405–422.e11. 10.1016/j.immuni.2022.01.01635180378 XiaoWGoldbergADFamulareCADevlinSMNguyenNTSimS Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica. 2019;104:1378–87. 10.3324/haematol.2018.20301830523054 ZhuLWangPZhangWLiQXiongJLiJ Plasmacytoid Dendritic Cell Infiltration in Acute Myeloid Leukemia. Cancer Manag Res. 2020;12:11411–9. 10.2147/CMAR.S26082533192098 PerzolliAKoedijkJBZwaanCMHeidenreichO. Targeting the innate immune system in pediatric and adult AML. Leukemia. 2024;38:1191–201. 10.1038/s41375-024-02217-738459166 FatehchandKMehtaPColvinCBButeynNJSanthanamRMerchand-ReyesG Activation of plasmacytoid dendritic cells promotes AML-cell fratricide. Oncotarget. 2021;12:878–90. 10.18632/oncotarget.2794933953842 KlineDEMacNabbBWChenXChanWCFoscoDKlineJ. CD8α+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell Fates. J Immunol. 2018;201(12):3759–69. 10.4049/jimmunol.180118430420437 ChanALiuYDevlinSGaoQBaikJSiglerA Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome. HemaSphere. 2022;6:e685. 10.1097/HS9.000000000000068535136856 LiBMengLTianYLingJHuYLuQ A Low Level of Plasmacytoid Dendritic Cells at Engraftment Is a Valuable Prognostic Indicator in Children Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021;27:611.e1–12. 10.1016/j.jtct.2021.04.01233895404 NuttSLChopinM. Transcriptional Networks Driving Dendritic Cell Differentiation and Function. Immunity. 2020;52:942–56. 10.1016/j.immuni.2020.05.00532553180 El HusseinSWangW. Flow Cytometry Profiling of Plasmacytoid Dendritic Cell Neoplasms. Cancers (Basel). 2024;16:2118. 10.3390/cancers1611211838893237 LeeYJKimYParkSHJoJC. Plasmacytoid dendritic cell neoplasms. Blood Res. 2023;58:90–5. 10.5045/br.2023.202305237105563 GongXLiCWangYRaoQMiYWangM Mature plasmacytoid dendritic cells associated with acute myeloid leukemia show similar genetic mutations and expression profiles to leukemia cells. Blood Sci. 2022;4:38–43. 10.1097/BS9.000000000000009735399539 DenkerSKünstnerASchwartingJWitteHMBernardVStöltingS Clonal evolution and blastic plasmacytoid dendritic cell neoplasm: malignancies of divergent hematopoietic lineages emerging from a common founding clone. Leukemia. 2024;38:1858–61. 10.1038/s41375-024-02305-838890446 RenosiFCallananMLefebvreC. Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells. Cancers (Basel). 2022;14:4132. 10.3390/cancers1417413236077669 KünstnerASchwartingJWitteHMXingPBernardVStöltingS Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features. Leukemia. 2024;38:1086–98. 10.1038/s41375-024-02240-838600314 KhaldoyanidiSKHindoyanASteinASubkleweM. Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research. Crit Rev Oncol Hematol. 2022;175:103710. 10.1016/j.critrevonc.2022.10371035588936 GuoRLüMCaoFWuGGaoFPangH Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res. 2021;9:15. 10.1186/s40364-021-00265-033648605 MendezLMPoseyRRPandolfiPP. The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. Front Oncol. 2019;9:1162. 10.3389/fonc.2019.0116231781488 SavinoAMStuaniL. Targeting glycolysis to rescue 2-hydroxyglutarate immunosuppressive effects in dendritic cells and acute myeloid leukemia. Haematologica. 2024;109:2388–90. 10.3324/haematol.2023.28489338497144 VagoLGojoI. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130:1552–64. 10.1172/JCI12920432235097 TaghilooSAsgarian-OmranH. Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways. Crit Rev Oncol Hematol. 2021;157:103164. 10.1016/j.critrevonc.2020.10316433271388 HuangZWZhangXNZhangLLiuLLZhangJWSunYX STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct Target Ther. 2023;8:391. 10.1038/s41392-023-01605-237777506 WangPFengYDengXLiuSQiangXGouY Tumor-forming plasmacytoid dendritic cells in acute myelocytic leukemia: a report of three cases and literature review. Int J Clin Exp Pathol. 2017;10:7285–91.31966568 ZalmaïLViaillyPJBiichleSCheokMSoretLAngelot-DelettreF Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica. 2021;106:3056–66. 10.3324/haematol.2020.25374033054115 DuarteADZangirolamiABSantosINiemannFSHonmaHNAmaroEC Production of dendritic cell vaccines using different methods with equivalent results: Implications for emerging centers. Hematol Transfus Cell Ther. 2024;46:30–5. 10.1016/j.htct.2022.11.00636503996 Motallebzadeh KhanmiriJAlizadehMEsmaeiliSGholamiZSafarzadehAKhani-EshratabadiM Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review. Cytotherapy. 2024;26:427–35. 10.1016/j.jcyt.2024.02.00938483358 PalomaresFPinaADakhaouiHLeiva-CastroCMunera-RodriguezAMCejudo-GuillenM Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines. Vaccines (Basel). 2024;12:165. 10.3390/vaccines1202016538400148 WangDHuangXFHongBSongXTHuLJiangM Efficacy of intracellular immune checkpoint-silenced DC vaccine. JCI Insight. 2018;3:e98368. 10.1172/jci.insight.9836829415891 KandraPNandigamaREulBHuberMKoboldSSeegerW Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. Front Immunol. 2022;13:903562. 10.3389/fimmu.2022.90356235720364 Marvin-PeekJSavaniBNOlalekanOODholariaB. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. Cancers (Basel). 2022;14:497. 10.3390/cancers1403049735158765 NajafiSMortezaeeK. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023;164:114954. 10.1016/j.biopha.2023.11495437257227 FanTZhangMYangJZhuZCaoWDongC. Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduct Target Ther. 2023;8:450. 10.1038/s41392-023-01674-338086815 AnguilleSVan de VeldeALSmitsELVan TendelooVFJuliussonGCoolsN Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130:1713–21. 10.1182/blood-2017-04-78015528830889 van de LoosdrechtAAvan WeteringSSantegoetsSJAMSinghSKEeltinkCMden HartogY A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother CII. 2018;67:1505–18. 10.1007/s00262-018-2198-930039426 EcklJRaffegerstSSchnorfeilFPrinz-SchulzPFingerhutCFloisandY DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment. Blood. 2019;134 Supplement_1:3923. 10.1182/blood-2019-129749 ChevallierPSaiaghSDehameVGuillaumeTPeterlinPBercegeayS A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients. Hum Vaccin Immunother. 2021;17:3511–4. 10.1080/21645515.2021.194399134152898 FløisandYRembergerMBigalkeIJosefsenDVålerhaugenHInderbergEM WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia. 2023;37:1842–9. 10.1038/s41375-023-01980-337507426 Van ZeeburgHWagner DrouetEPlatzbeckerUHolderriedTAWVan ElssenCGiagounidisA Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients. Blood. 2023;142 Supplement 1:2957. 10.1182/blood-2023-188573 LiegelJCheloniGBisharatLKaragkouniDGerhardGChedidG Final Results of Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia. Transplant Cell Ther. 2025;31 Supplement:S109. 10.1016/j.jtct.2025.01.172
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020501" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020501" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020501" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(99) "Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives" ["journals_article_author"]=> string(193) "Gabriel Barroso de Almeida, Mariane Melo dos Santos, Dyjaene de Oliveira Barbosa, Rogério Reis Conceição, Bruno de Almeida Lopes, Herbert Henrique de Melo Santos, Silvana Beutinger Marchioro" ["journals_article_author_country"]=> string(6) "Brazil" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(68) "dendritic cells, plasmacytoid dendritic cell, acute myeloid leukemia" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2218" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "2" ["meta_title"]=> string(99) "Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives" ["meta_desc"]=> string(99) "Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives" ["meta_keyw"]=> string(68) "dendritic cells, plasmacytoid dendritic cell, acute myeloid leukemia" ["created"]=> string(19) "2026-04-07 10:21:31" ["modified"]=> string(19) "2026-06-11 08:43:02" } [35]=> object(stdClass)#84 (35) { ["journals_id"]=> string(4) "1240" ["journals_xml"]=> string(48488) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-2-020101 10.11613/BM.2026.020101 Lessons in biostatistics EvalTest: a web-based tool for the assessment of diagnostic test performance AyadNassim* Modeling and Biostatistics Unit, Pasteur Institute of Algeria, Algiers, Algeria Corresponding author: nassim.ayad.ph@gmail.com, Submitted: November 4, 2025 Accepted: February 11, 2026

Author contributions

N Ayad: programming, software development – conceptualization, methodology, writing – review & editing.

15042026 15062026 36 2 020101 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• EvalTest provides an open-source, web-based tool for diagnostic test evaluation

• It computes key diagnostic performance metrics and performs ROC curve analysis with transparent methods

• The application enhances reproducibility and accessibility in clinical and research diagnostics

Introduction

Accurate diagnostic tests are essential in clinical and laboratory medicine. Evaluation of diagnostic test performance requires advanced statistical expertise and the use of specialized or proprietary software. The aim of this work is to develop an open-source R Shiny application for facilitating diagnostic test evaluation by integrating statistical rigor with user-friendly interactivity.

Materials and methods

The EvalTest application was developed in the R programming language using the Shiny framework and released as an open-source package on the Comprehensive R Archive Network, with the full source code available on GitHub. In addition, the application is available on a cloud platform and accessible via web browser. Statistical formulas used to compute diagnostic performance indicators and their confidence intervals were implemented within the R environment to ensure transparency and reproducibility.

Results

The developed application provides an interactive interface for importing Excel datasets, setting test variable type, selecting test and reference variables, and specifying disease prevalence. It automatically computes key diagnostic performance indicators, including sensitivity, specificity, predictive values, likelihood ratios, accuracy, the Youden index, and the area under the curve (AUC), along with their 95% confidence intervals. EvalTest also generates confusion matrices, receiver operating characteristic (ROC) curves with confidence bands, and identifies the optimal cutoff for quantitative tests. All numerical and graphical outputs can be exported in suitable formats to facilitate reporting and documentation.

Conclusions

EvalTest provides an open and reproducible solution for diagnostic test evaluation by computing and visualizing key performance measures with their confidence intervals, supporting its use in clinical and research settings.

Keywords: accuracydiagnostic testevaluationlaboratory medicinebiostatistics
Introduction

A diagnostic test is a medical, clinical, or paraclinical examination designed to assist clinicians in establishing a diagnosis and guiding patient care decisions (1). Depending on its intended application, test performance may be evaluated by its ability to discriminate between clinical states (e.g. presence versus absence of disease) or to detect clinically meaningful changes over time, such as those defined by critical difference or reference change values. Before implementation in clinical practice or laboratory medicine, a diagnostic test requires careful performance assessment, analogous to the evaluation of a drug or therapeutic intervention, as its accuracy directly impacts diagnostic decisions, treatment choices, and patient outcomes (2). Such evaluations are typically performed by manufacturers, independent investigators, or clinical laboratories, depending on the context, and complement regulatory requirements, such as those defined by Regulation (EU) 2017/746 on the In-Vitro Diagnostic Regulation (IVDR) (3).

Performance is typically assessed by comparing the test results to those of a reference standard, defined as the best available diagnostic test for the disease of interest or, when appropriate, clinical outcomes, reasonably applicable in clinical or research settings (1). Common statistical indicators include sensitivity (ability to correctly identify diseased individuals), specificity (ability to correctly identify non-diseased individuals), positive and negative predictive values (probability that positive or negative test results reflect true disease status), likelihood ratios (ability of positive or negative tests results to increase or decrease, respectively, the probability of disease), accuracy (overall correct classification), and the area under the receiver operating characteristic (ROC) curve. These metrics provide critical insights into a test’s discriminative performance and support clinicians in selecting appropriate diagnostic strategies (4). Despite their importance, the computation and interpretation of diagnostic performance metrics often require advanced statistical expertise and reliance on specialized or proprietary software (e.g. MedCalc, Analyse-it, XLSTAT). Such tools may limit accessibility due to licensing costs, restricted platforms, or the need for advanced training, and often provide limited transparency regarding the underlying calculations, thereby hindering reproducibility and independent verification of results. These limitations can pose significant barriers for healthcare professionals and researchers, particularly in resource-limited settings.

The aim of the present work was therefore to develop an open-source, accessible, and flexible software solution for the evaluation of diagnostic test performance. To address the identified challenges, we developed EvalTest, an open-source, web-based application. By providing an interactive, user-friendly, and programming-free platform that integrates standard diagnostic performance metrics in a transparent and reproducible manner, EvalTest seeks to bridge the gap between established statistical methodology and its practical application in laboratory medicine and clinical research.

Materials and methods Materials

In this work, a synthetic dataset was generated to illustrate the functionalities and workflow of the developed application. The generated dataset, entitled data.xlsx, contained many observations distributed across three columns: Disease, Test1, and Test2. The Disease column represented the reference variable coded as binary values (1 = disease, 0 = no disease) and was generated using a binomial distribution. Test1 corresponded to a quantitative test variable generated from chi-square (χ2) distribution. The chi-square distribution was chosen for Test1 to generate a positive-valued, right-skewed quantitative variable. Test2 represented a qualitative (binary) test variable generated using a binomial distribution. Assumed disease prevalence in the population was 0.1, reflecting a realistic low-prevalence scenario commonly encountered in diagnostic testing contexts. The generated dataset consisted of a total of 113 observations, including 72 diseased and 41 non-diseased individuals, according to the reference variable. This dataset was created exclusively for testing and demonstration purposes and does not represent real patient or clinical data (Supplementary Material).

Methods

The open-source application shown here was developed within RStudio environment (version 2025.05.0) with R programming language (version 4.5.1) which are available to download for free at https://posit.co/downloads/ and https://cran.r-project.org/, respectively (5, 6). The application was built using the shiny package and relies on several established R packages to support data import, statistical analysis, visualization and outputs export (7-15). Specifically, the binom package (version 1.1) was used to compute Wilson confidence intervals for proportion-based metrics, while the pROC package (version 1.19.0.1) was employed for ROC analysis (8, 13). All packages’ versions are reported in the reference list to ensure full reproducibility. EvalTest (version 1.0.5) has been developed as an R package and officially released and publicly available through the Comprehensive R Archive Network (16). This means that the application can be installed as an R package and run from a local instance of R on a local machine running a Linux, Windows, or macOS-based operating system. It is worth noting that the performance will depend on the hardware on which you are running R and RStudio. In addition, EvalTest is available on the Shiny.io cloud platform and accessible via web browser at https://nassimayad.shinyapps.io/EvalTest/, without requiring local installation. The full codebase for the application can be found at https://github.com/NassimAyad87/EvalTest. The version used to generate the figures and results presented in this manuscript corresponds to release v1.0.5 of the repository (commit ec6306d). The application’s modularity enables interested users to fork this repository and easily develop and add new modules as they wish.

Statistical analysis

The evaluation of diagnostic tests relies on four fundamental outcomes obtained by comparing test results with the gold standard. The true positives (TP) are the number of diseased individuals which correctly identified as positives, while the true negatives (TN) correspond to the number of non-diseased individuals correctly identified as negatives. Conversely, the false positives (FP) refer to the number of non-diseased individuals incorrectly identified as positives, and the false negatives (FN) indicates the number of diseased individuals incorrectly identified as negatives (17). The open-source application implements these definitions to quantify TP, TN, FP, and FN and present them in a confusion matrix table. These outcomes form the basis for calculating statistical performance indicators such as sensitivity and specificity.

Statistical indicators implemented in the application are mathematically defined in this chapter. These measures evaluate the ability of a test to discriminate between diseased and non-diseased individuals. All estimates are reported with their corresponding confidence intervals.

Test sensitivity (Se) is the probability that a diseased individual tests positive, whereas test specificity (Sp) is the probability that a non-diseased individual tests negative (17). The formulas used in their computations are shown in equations (Eq.) 1 and 2. The accuracy of a test is its ability to differentiate the patient and healthy cases correctly. To estimate the accuracy of a test, we should calculate the proportion of true positive and true negative in all evaluated cases, as shown in Eq. 3 (18).

For proportions such as sensitivity, specificity, and accuracy, confidence intervals (CIs) were calculated using the Wilson binomial confidence interval implemented in the binom package (8). Wilson interval is recommended because it performs better than the traditional Wald interval, especially with small samples or proportions close to 0 or 1 (19). Given the observed proportion (p), its denominator (n), and the quantile of the standard normal distribution for the desired confidence level (z), the Wilson interval CIWilson is calculated as shown in Eq. 4.

The positive predictive value (PPV) is the probability that a person has a disease if his test is positive. Similarly, we can define the negative predictive value (NPV), the probability that a person does not have a certain disease when the test is negative. PPV and NPV are determined by both the sensitivity and specificity of the test, as well as the prior probability of disease. When no other information is available, this probability is represented by the population disease prevalence (pr) specified by the user in the application (17). The sample prevalence is not used, as it does not provide additional information when a population-level prevalence is known. PPV and NPV are therefore derived from Bayes’ theorem (Eq. 5 and 6) using the estimated sensitivity and specificity together with the user-defined prevalence parameter, rather than the observed sample prevalence. Their confidence intervals (CIPPV, CINPV) were derived by propagation of uncertainty using the confidence bounds of sensitivity and specificity. Since PPV and NPV are functions of Se and Sp, their uncertainty depends on the variability of Se and Sp. The lower and upper bounds of PPV and NPV were determined by evaluating all combinations of Se and Sp confidence interval limits and taking the minimum and maximum resulting values, respectively (Eq. 7 and 8). This approach provides a conservative, distribution-free estimate of uncertainty and is particularly appropriate in small samples. Analytic variance estimation of predictive values relies on asymptotic normality, which may perform poorly in small samples, whereas bootstrap-based confidence intervals may be unstable under limited resampling variability and can require substantial computational effort when a large number of resamples is required (20).

The likelihood ratios (LR+ and LR-) summarize how many times more (or less) likely patients with the disease are to have that particular test result than patients without the disease. More formally, it is the ratio of the probability of the specific test result in people who do have the disease to the probability in people who do not (21). Their calculation formulas are shown in Eq. 9 and 10. Their confidence intervals (CILR+ and CILR-) were estimated in logarithm scale, following the approach described by Simel et al. (22). They are computed as shown in Eq. 11 and 12.

The Youden index (J) is a global measure of a diagnostic test’s discriminative ability, ranging from 0 to 1, where 0 indicates no discriminative power (random classification) and 1 indicates a perfect diagnostic test (23). It is calculated as shown in Eq. 13. Under the common assumption that sensitivity, estimated from diseased subjects, and specificity, estimated from non-diseased subjects, represent independent proportions, the variance of the Youden index can be approximated by the sum of the binomial variances of sensitivity and specificity. Subsequently, confidence interval of Youden index (CIJ) is computed as shown in Eq. 14.

The receiver operating characteristic (ROC) curve was generated using the framework implemented in the pROC package and the area under the curve (AUC) was calculated accordingly (13, 24). The optimal threshold of the continuous test variable was defined as the value of (t) that minimizes the Euclidian distance d(t) between the ROC curve point (1 − Sp, Se) and the top-left corner of the ROC space, as expressed in Eq. 15 (25). In this formulation, Se(t) and Sp(t) denote the sensitivity and specificity at a given cutoff t, respectively. Using this threshold, the continuous test variable was dichotomized to classify each observation in the example dataset as test-positive or test-negative. These binary classifications were then used to construct the corresponding confusion matrix, from which sensitivity, specificity, predictive values, likelihood ratios, and other performance metrics were calculated. This stepwise procedure illustrates how the ROC analysis directly informs the computation of diagnostic performance measures for the dataset. Confidence intervals for sensitivity estimates along the ROC curve were obtained using nonparametric bootstrap resampling with 5000 iterations, as implemented in the pROC package (13). These interval estimates were used solely to construct the graphical confidence band around the ROC curve. As bootstrap procedures rely on random resampling and the application is interactive, a fixed random seed was not imposed; therefore, minor graphical variation of the confidence band may occur across runs. The confidence interval for the AUC was calculated using DeLong’s nonparametric method (24). Additional graphical enhancements, including the display of the optimal cut-off point and AUC value with its confidence interval, were implemented using the ggplot2 package (10).

To ensure computational robustness, all formulas were implemented with error-handling conditions. Whenever the denominator of a proportion was equal to zero, the function returned a missing (NA) value to prevent the application from freezing or encountering errors.

All confidence intervals were calculated at the 95% confidence level, using a standard normal quantile of z = 1.96. All estimates and confidence intervals were rounded to three decimal places.

Results Application overview

The EvalTest application provides a user-friendly graphical interface for evaluating diagnostic test performance through an interactive R Shiny environment. As shown in Figure 1, the interface is organized into clearly defined sections that guide users through the analysis workflow.

EvalTest user interface layout.

On the left panel, users can import their dataset in Excel format (.xlsx), specify the test variable type (qualitative or quantitative), select the corresponding columns for the test and reference (disease status) variables, and input the disease prevalence within the study population. Disease prevalence value can be adjusted manually by entering a number or using the up and down arrow controls. The Run analysis button initiates the computation process. The central and lower panels display the main analytical outputs, including the ROC curve, the confusion matrix (contingency table), and the diagnostic performance indicators. Each component is accompanied by a download option, allowing users to export the ROC plot, confusion matrix, and calculated metrics in appropriate formats.

This intuitive layout ensures a seamless workflow from data upload to results interpretation, making EvalTest accessible to healthcare professionals and researchers with or without advanced statistical or programming expertise.

Data input and preprocessing

The example dataset consisted of 113 observations and included one binary reference variable indicating disease status and two test variables. The reference variable defined two outcome groups, with 72 observations as disease-present and 41 as disease-absent. Test1 was a continuous variable, whereas Test2 was a binary test variable.

In the “Data import & parameters setting” panel, users can upload their dataset in Excel format (.xlsx) by clicking the ‘Browse’ button (Figure 1). Before uploading, the dataset should contain a minimum of two distinct columns: one for the test variable (either qualitative binary coded as 1/0 or quantitative) and another for the reference variable, representing the disease status (binary: 1 = diseased, 0 = non-diseased). The selected columns must not contain missing values to ensure valid computation. Once the dataset is successfully uploaded, a blue ribbon appears, indicating “Upload complete”. Then, users specify the type of test variable (Qualitative or Quantitative) and select the corresponding columns for both the test and reference variables from the drop-down menus. The disease prevalence in the study population can then be entered manually or adjusted incrementally using the up and down arrow controls within the prevalence input field. For the example analysis presented in this work, Test1 was selected as the quantitative test variable and Disease as the reference variable, with the disease prevalence parameter set to 0.1 (Figure 2A).

EvalTest parameters setting and outputs. (A) Data import and parameters setting panel showing uploaded data, variable selection, and parameter configuration. (B) Confusion matrix generated by EvalTest, illustrating the classification results for the selected quantitative test variable Test1 and the reference variable Disease, and displaying the true positives (TP = 58), false positives (FP = 15), false negatives (FN = 14), and true negatives (TN = 26). (C) Diagnostic performance indicators computed by EvalTest, derived from the analyzed dataset data. (D) ROC curve generated by EvalTest for the quantitative test variable Test1, showing the optimal cut-off point and the area under the curve (AUC) with its 95% CI. The x-axis represents specificity displayed in reversed direction (i.e. equivalent to 1-specificity). The shaded area corresponds to the 95% bootstrap confidence band.

To enhance data reliability, EvalTest automatically performs input validation and displays error messages when inconsistencies are detected. For instance, if the user selects “Qualitative” as the test variable type but uploads continuous data, an error appears indicating: “For qualitative tests, the test variable must contain only 0 and 1 values.”. Similarly, if the reference variable includes invalid entries, the application displays: “The reference variable must contain only 0 and 1 values.”. In the case of quantitative analyses, if the selected test variable is not numeric, the system halts the process and notifies the user with the message: “For quantitative tests, the test variable must be numeric.” Furthermore, after removing missing values, if the reference variable no longer includes both outcome levels (0 and 1), an additional alert is triggered stating: “The reference variable must contain both 0 and 1 after removing missing values.” These built-in checks help prevent input errors and guide users toward proper dataset formatting. This preprocessing step ensures that the uploaded dataset is correctly structured and ready for subsequent diagnostic performance analysis within the EvalTest application.

Confusion matrix

Upon activation of the “Run analysis” button (Figure 2A), EvalTest generated a detailed confusion matrix summarizing the classification of individuals according to the test and reference results. The matrix displays the counts of true positives (TP = 58), false positives (FP = 15), false negatives (FN = 14), and true negatives (TN = 26), which are automatically computed from the imported dataset and presented both in matrix form and as a summarized list (Figure 2B). For continuous test variables, such as Test1 in this example, the application first determined the optimal threshold from the ROC analysis and then dichotomized the test results into positive and negative outcomes based on this cutoff. The confusion matrix could also be downloaded in Excel format for further documentation or reporting (Figure 2B).

Diagnostic performance indicators

Based on the confusion matrix counts, EvalTest automatically computes key diagnostic performance indicators, including sensitivity, specificity, predictive values, accuracy, likelihood ratios, and the Youden index as shown in Figure 2C. Each metric is displayed together with its 95% confidence interval (CI). The availability of the underlying confusion matrix ensures transparency by allowing readers to identify the numerators and denominators used for each performance estimate. All computed results are presented in a tabular format and can be exported as an Excel file for further use.

ROC curve analysis and cutoff determination

EvalTest displayed the ROC curve, illustrating the trade-off between sensitivity and specificity across all possible thresholds. The application automatically identified and highlighted the optimal cutoff point of the test variable, annotating it on the ROC plot with its corresponding sensitivity and specificity values. In the example shown, the optimal cutoff was approximately 0.205. The AUC was 0.731 (95% CI: 0.630–0.833). The ROC plot displayed the confidence band around the curve, illustrating the uncertainty associated with the estimated ROC curve. Users can export the plot in publication-ready quality for inclusion in reports or manuscripts (Figure 2D).

Discussion

In the illustrative example, the selected cut-off resulted in high sensitivity and moderate specificity. The imbalance between sensitivity and specificity is consistent with a cut-off chosen to favor case detection. The positive predictive value was low and the negative predictive value was high, illustrating the strong influence of the low disease prevalence in the population on post-test probabilities. Bayes formulas were used to estimate predictive values to obtain more conservative and generalizable results when the sample prevalence is not representative of the target population. The likelihood ratios indicate that a positive test result produces only a modest increase in disease probability, whereas a negative test result substantially reduces the likelihood of disease. Overall performance measures, including accuracy and the Youden index, summarize moderate discriminatory effectiveness at the chosen threshold. The AUC indicates moderate discriminative ability of the continuous test. The uncertainty associated with these estimates should be carefully considered.

EvalTest provides a user-friendly and open-source tool for evaluating diagnostic test performance, integrating advanced statistical methods within an accessible web-based interface. Unlike commercial tools such as MedCalc, Analyse-it, or XLSTAT, EvalTest requires no programming skills, proprietary licenses, or software installation, facilitating broader accessibility and reproducibility. The application automatically computes key diagnostic indicators such as sensitivity, specificity, predictive values, likelihood ratios, accuracy, and the Youden index, along with 95% CI and ROC curve visualization. Built-in data validation, error handling and transparent reporting of underlying counts enhance robustness, clarity, and allow users to verify results. The application’s ability to process both binary and continuous test variables, automatically determine optimal thresholds, and generate publication-ready outputs constitutes a major practical advantage over many existing tools.

Several limitations should be acknowledged, EvalTest currently supports only single-test analyses. It does not include modules for comparative ROC analysis, multivariable adjustment, or time-dependent ROC curves. Additionally, confidence interval estimates - particularly for likelihood ratios and predictive values - may exhibit increased uncertainty in small sample sizes or in settings with extreme or zero cell counts. In such cases, the application returns NA for the affected estimates, ensuring that undefined or misleading values are not displayed. In addition, predictive values depend directly on user-specified prevalence assumptions; while this allows clinically relevant post-test probability estimation when samples are not representative, inappropriate prevalence inputs may affect interpretation. Future developments will focus on incorporating comparative and multivariate analyses, addressing uncertainty arising from user-specified prevalence, implementing continuity corrections or alternative estimation methods and extending compatibility with additional data formats.

EvalTest bridges the gap between statistical methodology and clinical application, offering an open, transparent, and reproducible tool for diagnostic test evaluation. Its accessibility and methodological rigor make it a valuable addition to the resources available for clinicians, laboratory scientists, and researchers.

Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article and its supplementary files.

References Ben HassineDChebilDMelkiSNouiraSBen AbdelazizABen SalemK Evaluation of the performance of a diagnostic test: Reproducibility, Internal validity and External validity. Tunis Med. 2022;100:1–8.35822325 Van den BruelACleemputIAertgeertsBRamaekersDBuntinxF. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J Clin Epidemiol. 2007;60:1116–22. 10.1016/j.jclinepi.2007.03.01517938052 Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU. Off J Eur Union. 2017;L117:176–332. InácioVRodríguez-ÁlvarezMXGayoso-DizP. Statistical evaluation of medical tests. Annu Rev Stat Appl. 2021;8:41–67. 10.1146/annurev-statistics-040720-022432 Posit Team. RStudio: integrated development environment for R. Boston, USA: Posit Software PBC; 2025. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R foundation for statistical computing; 2025. Chang W, Cheng J, Allaire JJ, Sievert C, Schloerke B, Xie Y, et al. shiny: web application framework for R; 2025. R package version 1.11.1. Dorai-Raj S. binom: binomial confidence intervals for several parameterizations [R package]. Version 1.1. 2022. Available from: https://CRAN.R-project.org/package=binom. Accessed November 11th 2025. Xie Y, Cheng J, Tan X, Aden-Buie GDT. a wrapper of the JavaScript library ‘DataTables’ [R package]. Version 0.34.0. 2025. Available from: https://CRAN.R-project.org/package=DT. Accessed November 11th 2025. Wickham H, Chang W, Henry L, Pedersen TL, Takahashi K, Wilke C, et al. ggplot2: create elegant data visualisations using the grammar of graphics [R package]. Version 4.0.0. 2025. Available from: https://CRAN.R-project.org/package=ggplot2. Accessed November 11th 2025. Kassambara A. ggpubr: ‘ggplot2’ based publication ready plots [R package]. Version 0.6.1. 2025. Available from: https://CRAN.R-project.org/package=ggpubr. Accessed November 11th 2025. Schauberger P, Walker A. openxlsx: read, write and edit xlsx files [R package]. Version 4.2.8. 2025. Available from: https://CRAN.R-project.org/package=openxlsx. Accessed November 11th 2025. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: display and analyze ROC curves [R package]. Version 1.19.0.1. 2025. Available from: https://CRAN.R-project.org/package=pROC. Accessed November 11th 2025. Wickham H, Bryan J. readxl: read excel files [R package]. Version 1.4.5. 2025. Available from: https://CRAN.R-project.org/package=readxl. Accessed November 11th 2025. Chang W, Borges Ribeiro B. shinydashboard: create dashboards with ‘shiny’ [R package]. Version 0.7.3. 2025. Available from: https://CRAN.R-project.org/package=shinydashboard. Accessed November 11th 2025. Ayad N. EvalTest: a Shiny app to evaluate diagnostic test performance [R package]. Version 1.0.5. 2025. Available from: https://CRAN.R-project.org/package=EvalTest. Accessed November 11th 2025. 10.32614/CRAN.package.EvalTest. HabibzadehF. Diagnostic tests performance indices: an overview. Biochem Med (Zagreb). 2025;35:010101. 10.11613/BM.2025.01010139974192 BaratlooAHosseiniMNegidaAEl AshalG. Part 1: Simple definition and calculation of accuracy, sensitivity and specificity. Emerg (Tehran). 2015;3:48–9.26495380 BrownLDCaiTTDasGuptaA. Interval Estimation for a Binomial Proportion. Stat Sci. 2001;16:101–33. 10.1214/ss/1009213286 YingGSMaguireMGGlynnRJRosnerB. Calculating Sensitivity, Specificity, and Predictive Values for Correlated Eye Data. Invest Ophthalmol Vis Sci. 2020;61:29. 10.1167/iovs.61.11.2932936302 DeeksJJAltmanDG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329:168. 10.1136/bmj.329.7458.16815258077 SimelDLSamsaGPMatcharDB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991;44:763–70. 10.1016/0895-4356(91)90128-V1941027 YoudenWJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5. 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-315405679 RobinXTurckNHainardATibertiNLisacekFSanchezJC pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. 10.1186/1471-2105-12-7721414208 HassanzadMHajian-TilakiK. Methods of determining optimal cut-point of diagnostic biomarkers with application of clinical data in ROC analysis: an update review. BMC Med Res Methodol. 2024;24:84. 10.1186/s12874-024-02198-238589814
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "2" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "020101" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-2-020101" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.020101" ["journals_article_pubdate"]=> string(10) "2026-06-15" ["journals_article_title"]=> string(76) "EvalTest: a web-based tool for the assessment of diagnostic test performance" ["journals_article_author"]=> string(11) "Nassim Ayad" ["journals_article_author_country"]=> string(7) "Algeria" ["journals_article_categories_heading"]=> string(24) "Lessons in biostatistics" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(73) "accuracy, diagnostic test, evaluation, laboratory medicine, biostatistics" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "6322" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "1" ["meta_title"]=> string(76) "EvalTest: a web-based tool for the assessment of diagnostic test performance" ["meta_desc"]=> string(76) "EvalTest: a web-based tool for the assessment of diagnostic test performance" ["meta_keyw"]=> string(73) "accuracy, diagnostic test, evaluation, laboratory medicine, biostatistics" ["created"]=> string(19) "2026-04-07 12:18:37" ["modified"]=> string(19) "2026-06-11 08:42:25" } [36]=> object(stdClass)#85 (35) { ["journals_id"]=> string(4) "1223" ["journals_xml"]=> string(55548) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-011002 10.11613/BM.2026.011002 Preanalytical mysteries Falsely decreased triglyceride concentration in a patient with acute pancreatitis due to insufficient configuration of alarm rules LiuYin1LiuQianhui1FengBin2GanWei*1 Department of Laboratory Medicine, Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University; Sichuan Clinical Research Center for Laboratory Medicine, Chengdu, Sichuan Province, China Sichuan University, West China Clinical Medical College, Chengdu, Sichuan Province, China Corresponding author: 2004ganwei@scu.edu.cn

Author contributions

Y Liu: Data curation, Funding acquisition, Investigation, Project administration, Visualization, Writing - original draft, Writing - review & editing; Q Liu: Data curation, Formal analysis, Resources, Writing - review & editing; B Feng: Data curation, Software, Validation; W Gan: Conceptualization, Funding acquisition, Project administration, Supervision, Writing - review & editing.

15022026 15022026 36 1 011002 3005202508012026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Kinetic instability in high-triglyceride (TG) samples: rapid chromogen formation followed by bleaching due to oxygen depletion

• Inadequate analyzer alarm rules failed to flag extreme TG reaction curves

• Laboratory professionals should recognize falsely low TG from abnormal curves

• Laboratory information system-based correlation monitoring: lipemic index and TG value verification

Acute pancreatitis is a potentially life-threatening complication of severe hypertriglyceridemia. The accurate measurement of triglyceride concentration is essential for diagnosis and therapeutic monitoring. This article presents a case of acute hypertriglyceridemia pancreatitis in which the patient’s triglyceride concentration appeared to drop rapidly from 128.04 mmol/L to 1.53 mmol/L within 12 hours of admission. Subsequent retesting revealed an actual triglyceride value of 88.92 mmol/L. This case underscores a critical and underreported preanalytical challenge: the failure of the analyzer to trigger “> Kin” warnings despite clear abnormalities in the reaction kinetics curve, leading to clinically significant underestimation. To mitigate such errors, we propose a novel strategy that integrates automated lipemic index-based predilution protocols with enhanced alarm configurations, including the introduction of a “>Abs” alert, adjustment of prozone detection parameters, and the implementation of correlation checks between lipemic indices and triglyceride values within the laboratory information system. These practical interventions, which can be adopted in clinical laboratories, represent a proactive approach to prevent erroneous reporting and enhance diagnostic reliability. This report highlights the necessity for increased vigilance among laboratory professionals when discordance occurs between high lipemic indices and unexpectedly low triglyceride results, suggesting possible kinetic anomalies.

Keywords: acute pancreatitisanalytical techniques and equipmentanalyzer alarmscase reporthypertriglyceridemia
Introduction

Hypertriglyceridemia (HTG), defined as a fasting triglyceride (TG) concentration exceeding 1.7 mmol/L, represents the third most common cause of acute pancreatitis after gallstones and excessive alcohol consumption (1). It is further classified as severe when TG concentrations exceed 10 mmol/L and very severe when TG concentrations reach or exceed 20 mmol/L (2). Recent studies indicate that hypertriglyceridemia-induced pancreatitis (HTGP) may account for up to 22% of all acute pancreatitis cases, particularly among patients with markedly elevated baseline triglycerides (3). Notably, HTGP is associated with higher mortality compared to other etiologies of pancreatitis, and elevated triglyceride concentrations after discharge are strongly correlated with the risk of recurrence (4, 5). This underscores the critical importance of early recognition and aggressive triglyceride-lowering therapy, with current guidelines recommending maintaining serum triglycerides below 5.65 mmol/L during acute management and under 2.27 mmol/L for long-term prevention of recurrence (6, 7).

Accurate measurement of triglyceride concentrations is therefore essential not only for diagnosis but also for guiding therapeutic interventions such as plasmapheresis, insulin infusion, and other TG-lowering treatments aimed at interrupting the vicious cycle of inflammation and hypertriglyceridemia (8). Over recent decades, the clinical measurement of triglycerides has benefited from improved analytical efficiency, quality control, and standardization through the widespread adoption of automated biochemical analyzers (9). These systems incorporate technical alarm functions to detect preanalytical and analytical errors, including sample clots, reagent insufficiency, instrument failure, and reaction abnormalities, thereby reducing the reporting of erroneous results, particularly those caused by interference (10-12). However, despite these advancements, rare but clinically significant errors persist, such as falsely low triglyceride results due to inadequately configured analytical monitoring systems, as observed with the Roche Cobas c702 analyzer (Roche Diagnostics GmbH, Mannheim, Germany).

Laboratory analyses

An older male patient presented to the emergency department of West China Hospital with left abdominal distension, pain and discomfort from a high-fat diet four hours prior, accompanied by vomiting yellow fluid 3 times. On admission to our hospital, blood samples were collected using serum collection tubes (red cap) (Becton, Dickinson & Company (BD), Franklin Lakes, USA). After clotting, the serum was separated by centrifugation at 3500xg for 10 minutes at room temperature. Serum lipids, electrolytes and pancreatitis markers were measured via a Roche Cobas c702 analyzer and matching reagents. The results were as follows: triglyceride (TG): 128.04 mmol/L; total cholesterol (TC): 29.42 mmol/L; amylase: 133 U/L; lipase: 382 U/L and pancreatic amylase: 116 U/L (Table 1). Together with an abdominal imaging report and clinical symptoms, HTGP was diagnosed, and intravenous insulin was used to lower the TG concentration along with heparin. During the following 12 hours, the pancreatic enzyme activities continued to increase (serum lipase increased to 681 U/L, pancreatic amylase to 198 U/L), and the TC decreased to 22.02 mmol/L, whereas TG sharply decreased to 1.53 mmol/L (Table 1). This TG result is perplexing because it is discordant with both the serum’s grossly turbid appearance (Figure 1A) and the objective artificial intelligence (AI)-based lipemia index analysis. The pre-analytical instrument (which automatically analyzes serum images, generates a Hemolysis, Icterus, Lipemia (HIL) index, and transmits it to the Laboratory Information System - LIS) graded the sample as ‘lipemia ++++,’ a finding that typically confirms severe lipemia.

Patient laboratory results
Parameter, unit At admission After 12 hours
Triglycerides, mmol/L(reference interval: 0.29-1.7) 128.04 1.53(88.92 after dilution)
Cholesterol total, mmol/L(reference interval: 2.8-5.17) 29.42 22.02
High-density lipoprotein cholesterol, mmol/L(reference interval: ≥ 1) 0.12 0.17
Low-density lipoprotein cholesterol, mmol/L(reference interval: < 3.4) 0.72 0.52
Amylase, U/L(reference interval: 35-135) 133 216
Lipase, U/L(reference interval: 13-60) 382 681
Pancreatic amylase, U/L(reference interval: 13-53) 116 198

Patient plasma sample and the kinetics curve. (A) Plasma sample visualization; (B) The kinetics curve of falsely result and post-dilution; (C) The kinetics curve of re-measurement; (D) Screenshots of the video in triglycerides measurement of hyperlipidemia specimens at different time points; Control: 2.20 mmol/L, Case: 88.92 mmol/L.

Further investigation

To determine the cause, we checked the kinetic curve of the TG in analyzer and found that it was obviously abnormal, but the analyzer still gave a result of 1.53 mmol/L without triggering any alarms (Figure 1B). The technician identified this inconsistency. The sample was subsequently reassayed, and the analyzer displayed a ‘> Kin’ alarm, indicating kinetic instability (Figure 1C). This triggered the analyzer’s automatic dilution function. After automatic 5-fold dilution by the analyzer, the actual value of the serum triglyceride concentration was determined to be 88.92 mmol/L, significantly higher than the initial reported value of 1.53 mmol/L (Table 1).

What happened?

To capture the dynamic measurement curve of the TG for this sample, a video was recorded (see in Supplementary material). After adding the reagent, the red products rapidly generated and reached peak intensity at 150 seconds (corresponding to approximately the 10th point on the dynamic curve). Subsequently, the color became uneven and gradually faded. However, in the normal control, the solution reached peak intensity at 90 s (approximately the 6th point) and remained stable thereafter. When the end-point (10 minutes) was reached, the red-colored solution appeared uneven, with numerous red particles floating on the surface. When the reaction time was extended to 20 minutes, the red color in the solution disappeared, leaving only a significant accumulation of color at the surface (Figure 1D). The surface, being in contact with the air, maintains a continuous supply of oxygen, allowing the reaction to proceed. As a result, an accumulation of the red-colored product (benzquinamide) is observed there. However, O2 in the solution is scarce, and the concentration of benzquinamide compounds gradually decreases. The continuous decrease in the reaction kinetics curve for the case sample is consistent with the disappearance of the red color in the video. Therefore, it is important to identify abnormal reaction by kinetic monitoring to intercept erroneous results. Why did the analyzer fail to trigger a “> Kin” alarm during the initial test?

The kinetic monitoring of triglycerides on Roche systems employs a “>Kin” alarm based on rate changes in absorbance at four prozone measuring points (pmp), a process referred to as the Prozone Check (PC). The algorithm analyzes absorbance readings at pmp2, pmp4, pmp10, and pmp14 through three sequential steps (Table 2):

Prozone check result calculation display
First Step(Calculation absorbance (Primary - Secondary))
Prozone measuringpoints Initial curve(Interception notactivated) Reassayed curve(Interception activated) Curve after dilution
pmp2 12335 12137 2594
pmp4 13024 13329 8082
pmp10 19480 19450 11098
pmp14 15021 14849 11217
Second Step(Calculation absorbance between pmp4 and pmp2 or pmp14 and pmp10)if |Apmp4 - Apmp2| < 1000, the reaction rate prozone limit check is not performed
Apmp14 - Apmp10 - 4459 - 4601 119
Apmp4 - Apmp2 689(|Apmp4 - Apmp2| < 1000limit check not performed) 1192 5488
Third Step(Prozone limit check)prozone limits from -3 to 100, out of this range triggering “>Kin” alarm
V2((Apmp14-Apmp10)/4) - 1150.25 29.75
V1((Apmp4-Apmp2)/2) Not performed 596 2744
PC = V2/V1*100 - 192.99(out of the prozonelimits(- 3 to 100)) 1.08(In the prozone limits)

Step 1: The absorbance value at each pmp is calculated by subtracting the secondary wavelength reading from the primary wavelength.

Step 2: Absorbance differences are computed. The absolute difference between pmp4 and pmp2 (|Apmp4 - Apmp2|) is evaluated to determine whether the reaction exhibits a sharp change due to high triglyceride (TG) concentration.

Step 3: Prozone limit check. This step is activated only if the difference from Step 2 reaches or exceeds 1000. The algorithm then calculates the ratio of the late-phase reaction rate (between pmp14 and pmp10, denoted as V2) to the early-phase rate (between pmp4 and pmp2, denoted as V1), multiplies the result by 100, and checks whether it falls within the range of - 3 to 100. Values within this range are considered acceptable and do not trigger an alarm, while values outside this range confirm a significant kinetic abnormality, activate the “>Kin” alarm, and invalidate the result.

In the case presented here (Table 2), the initial reaction measurement was not flagged by the “>Kin” alarm. The absorbance values at the critical points were Apmp2 = 12,335 and pmp4 = 13,024. The absolute difference |13,024 – 12,335| = 689 fell below the threshold of 1000, indicating that the reaction did not show a sufficiently sharp change to suggest a high TG concentration. As a result, the condition for initiating Step 3 was not met, and the prozone limit check was bypassed. The triglyceride concentration was subsequently calculated using the endpoint method, yielding an erroneous result of 1.53 mmol/L. Notably, although the raw reaction data showed a visually conspicuous deviation in the kinetic curve, which should have triggered the “>Kin” alarm, the analyzer’s internal monitoring algorithm failed to recognize this anomaly. Consequently, no “>Kin” flag was generated, and the analyzer transmitted the erroneous result without any critical alert to the LIS. In the absence of an error flag from the analyzer, the LIS accepted the result without further interrogation according to its standard operating procedure. The core issue, therefore, lies in the failure of the analyzer’s software algorithm to reliably detect abnormal reaction kinetics under these specific conditions, resulting in a false-negative error reporting.

Discussion

Triglycerides (TG) were quantified using a one-step enzymatic colorimetric assay (Roche Diagnostics). The method is based on a coupled enzymatic cascade leading to the formation of a chromogenic product. Specifically, serum triglycerides are enzymatically hydrolyzed to release free glycerol. The glycerol is subsequently phosphorylated by adenosine triphosphate (ATP) in a reaction catalyzed by glycerol kinase, yielding glycerol-3-phosphate. This intermediate is then oxidized by glycerol-3-phosphate oxidase, generating hydrogen peroxide (H2O2) as a byproduct. Finally, the hydrogen peroxide drives a Trinder-type endpoint reaction in the presence of peroxidase, where it oxidatively couples 4-aminophenazone and 4-chlorophenol to form a red quinoneimine dye. The intensity of this chromogen is measured spectrophotometrically at a primary wavelength of 505 nm, with a secondary reference wavelength of 700 nm to correct for background interference. Oxygen and water are essential co-substrates in this reaction sequence (13). A typical reaction curve is illustrated in Figure 1B (post-dilution curve). However, in samples with elevated triglyceride concentrations, substrates, particularly oxygen, are rapidly depleted. Under anaerobic conditions, the enzymatic pathway may be altered, and preformed chromogen can undergo reduction (a phenomenon known as “bleaching”) by serving as an alternative electron acceptor for glycerol-3-phosphate oxidase. This leads to underestimation of the true triglyceride concentration (14). Since all commercially available triglyceride assays rely on this same chemical principle, chromogen bleaching represents a universal challenge in clinical chemistry, particularly in samples with high triglyceride concentrations. Although different analytical platforms employ varying algorithms to detect abnormal reaction kinetics, those using monitoring strategies and logic similar to the Roche system, which depends primarily on prozone checking, remain prone to erroneously reporting falsely low results in hypertriglyceridemic samples. This is because the activation of alerts under such monitoring logic exhibits inherent randomness and lacks consistent reliability. As shown in Figure 1B (initial curve), absorbance changes at early time points (e.g., points 2 and 3) are discordant. The value at point 2 rises, resulting in an absorbance difference between pmp4 and pmp2 of less than 1000. Consequently, the prozone limit check is not triggered (Table 2). These findings highlight that reliance solely on the “>Kin” alarm is insufficient for reliable kinetic monitoring of high‐triglyceride samples on the Cobas c702 system.

The limitations described above are not merely theoretical. Failure to trigger triglyceride prozone checks in severely lipemic samples appears to be an underrecognized issue on the Cobas c702 platform. In addition to the case presented here, three previous studies have also documented falsely low triglyceride concentrations in lipemic plasma (15-17). While these studies discussed the causes of such inaccuracies and emphasized the clinical importance of recognizing pseudolow triglycerides in hypertriglyceridemia, none identified potential technical flaws in the front‐area inspection of the kinetic curve. Notably, we strongly suspect that at least one of these previously reported cases may have been due to a prozone check failure, given that the same analytical system (Cobas c702) was used (17). To the best of our knowledge, this is the first report to attribute pseudolow triglyceride results specifically to an alarm system loophole accompanied by significant kinetic curve abnormalities.

To mitigate errors resulting from prozone check failures in intercepting high-concentration triglyceride samples on analyzers such as the Cobas c702 or other systems with similar logic, the implementation of enhanced detection and preprocessing strategies is recommended. Based on current technological capabilities, the following multidimensional approaches should be considered:

At the LIS level:

Establish an automated correlation check between the serum lipemic index and TG values. Significant discrepancies should trigger alerts during result verification, prompting technologists to visually inspect sample appearance, evaluate reaction kinetics, and/or perform repeat testing.

Implement rule-based automatic pre-dilution protocols for samples exhibiting lipemic indices above predefined thresholds (e.g., ≥ +++), utilizing integrated HIL index data obtained from automated biochemical analyzers or image-based AI recognition systems.

At the analyzer level:

Introduce an absorbance-based alarm mechanism to identify abnormal reaction kinetics. For instance, using the Roche Cobas c702 analyzer, setting an absorbance limit (> 12,000) at the 6th measurement point can effectively flag severely lipemic samples, since their peak absorbance typically occurs later (e.g., at point 10) than in normal samples.

Optimize prozone detection parameters by expanding the number of monitoring points and refining criteria, such as setting a delta threshold between endpoint and maximum absorbance.

Develop an intelligent kinetic curve recognition system using adaptive machine learning to identify nonlinearity and interference patterns. Unlike static rule-based algorithms, adaptive AI enhances continuous pattern learning and provides greater flexibility in anomaly detection, as demonstrated in reaction monitoring and pattern recognition (18-20).

To enhance the detection and preprocessing of severely lipemic samples, our laboratory has implemented an image-based AI algorithm for serum index recognition over the past five years; however, it was only following this incident that a definitive protocol establishing a correlation between the lipemic index and triglyceride values was formally introduced. This integration has proven to be a practical and effective safeguard against the erroneous reporting of artificially low lipid concentrations in grossly lipemic specimens. Nevertheless, an automatic pre-dilution step triggered directly by lipemia index has not yet been deployed, as its implementation requires extensive validation of inter-instrument connectivity, clearly defined threshold criteria, and confirmation of optimal dilution factors to ensure analytical accuracy. Addressing these aspects remains a critical direction for future methodological refinement.

What YOU can do in your laboratory to prevent such errors

To mitigate such errors within the laboratory setting, the following measures are recommended:

Universal HIL index assessment: Implement systematic measurement of HIL indices on all samples using automated biochemical analyzers or image-based AI assessment tools.

Automated pre-dilution for lipemic samples: Establish rule-based automatic pre-dilution procedures for samples exceeding predefined lipemic index thresholds (e.g., ≥ +++), to minimize analytical interference prior to testing.

LIS-based correlation monitoring: Incorporate a real-time correlation check between the lipemic index and triglyceride values within the LIS. Significant discrepancies should automatically trigger an alert during the validation phase, prompting laboratory staff to inspect reaction kinetics curves on the analyzer to verify result reliability and identify potential procedural or instrumental deviations.

In summary, improperly configured alert rules can fail to identify severely lipemic samples, resulting in spuriously low triglyceride values. Laboratorians should acknowledge the inherent limitations of kinetic algorithms in handling such samples and develop strengthened protocols to reduce the risk of inaccurate triglyceride reporting.

Acknowledgments

We thank Sixu Lin from Roche Diagnostics for her interpretation in the monitoring algorithms of TG. We would like to express our sincere gratitude to the National Natural Science Foundation of China (No. 32200933) and the Sichuan Science and Technology Program (No. 2023NSFSC1536) for their financial support.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References TrikudanathanGYaziciCEvans PhillipsAForsmarkCE. Diagnosis and Management of Acute Pancreatitis. Gastroenterology. 2024;167:673–88. 10.1053/j.gastro.2024.02.05238759844 LaufsUParhoferKGGinsbergHNHegeleRA. Clinical review on triglycerides. Eur Heart J. 2020;41:99–109c. 10.1093/eurheartj/ehz78531764986 YangALMcNabb-BaltarJ. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020;20:795–800. 10.1016/j.pan.2020.06.00532571534 GrigoreMBalabanDVJingaMIonita-RaduFCostacheRSDumitruAL Hypertriglyceridemia-Induced and Alcohol-Induced Acute Pancreatitis-A Severity Comparative Study. Diagnostics (Basel). 2025;15:882. 10.3390/diagnostics1507088240218233 GuanLDingLWanJXiaLHeWXiongH Serum triglyceride levels are associated with recurrence in patients with acute hypertriglyceridemic pancreatitis. Front Med (Lausanne). 2023;10:1079637. 10.3389/fmed.2023.107963737007797 ChristianJBArondekarBBuysmanEKJohnsonSLSeegerJDJacobsonTA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6:450–61. 10.1016/j.jacl.2012.08.00723009781 WuBUBatechMDongEYDuanLYadavDChenW. Influence of Ambulatory Triglyceride Levels on Risk of Recurrence in Patients with Hypertriglyceridemic Pancreatitis. Dig Dis Sci. 2019;64:890–7. 10.1007/s10620-018-5226-x30094622 HinesOJPandolSJ. Management of severe acute pancreatitis. BMJ. 2019;367:16227. 10.1136/bmj.l622731791953 DurnerJ. Clinical chemistry: challenges for analytical chemistry and the nanosciences from medicine. Angew Chem Int Ed Engl. 2010;49:1026–51. 10.1002/anie.20090336320041459 SeimiyaMSuzukiYYoshidaTSawabeYMatsushitaKNomuraF. The abnormal reaction data-detecting function of the automated biochemical analyzer was useful to prevent erroneous total-bilirubin measurement and to identify monoclonal proteins. Clin Chim Acta. 2015;441:44–6. 10.1016/j.cca.2014.12.01325523191 García-GonzálezEAramendiaMGonzalez-TaranconRRomero-SanchezNRelloL. Detecting paraprotein interference on a direct bilirubin assay by reviewing the photometric reaction data. Clin Chem Lab Med. 2017;55:1178–85. 10.1515/cclm-2016-069028076302 PantV. Importance of Observing the Progress Curve During Enzyme Assay in an Automated Clinical Chemistry Analyzer: A Case Study. EJIFCC. 2022;33:56–62.35645694 FossatiPPrencipeL. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077–80. 10.1093/clinchem/28.10.20776812986 ShephardMDWhitingMJ. Falsely low estimation of triglycerides in lipemic plasma by the enzymatic triglyceride method with modified Trinder’s chromogen. Clin Chem. 1990;36:325–9. 10.1093/clinchem/36.2.3252406041 MarkotaAKnehtlMSinkovicAEkartRHojsRBevcS. Plasma exchange treatment for acute hyperlipidemic pancreatitis with falsely low levels of serum triglycerides - a case report. Transfus Apher Sci. 2014;51:178–80. 10.1016/j.transci.2014.08.01525219637 MelnickSNazirSGishDRaj AryalM. Hypertriglyceridemic pancreatitis associated with confounding laboratory abnormalities. J Community Hosp Intern Med Perspect. 2016;6:31808. 10.3402/jchimp.v6.3180827406459 Van ElslandeJHijjitSDe VusserKLangloisMMeijersBMertensA Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample. Biochem Med (Zagreb). 2021;31:021002. 10.11613/BM.2021.02100233927560 PapikKMolnarBFedorcsakPSchaeferRLangFSreterL Automated prozone effect detection in ferritin homogeneous immunoassays using neural network classifiers. Clin Chem Lab Med. 1999;37:471–6. 10.1515/CCLM.1999.07610369120 WangXZhangMLiCJiaCYuXHeH. Performance and efficiency of machine learning models in analyzing capillary serum protein electrophoresis. Clin Chim Acta. 2025;569:120165. 10.1016/j.cca.2025.12016539875052 HeHWangLWangXZhangM. Artificial intelligence in serum protein electrophoresis: history, state of the art, and perspective. Crit Rev Clin Lab Sci. 2024;61:226–40. 10.1080/10408363.2023.227432537909425
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "011002" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-011002" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.011002" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(130) "Falsely decreased triglyceride concentration in a patient with acute pancreatitis due to insufficient configuration of alarm rules" ["journals_article_author"]=> string(39) "Yin Liu, Qianhui Liu, Bin Feng, Wei Gan" ["journals_article_author_country"]=> string(5) "China" ["journals_article_categories_heading"]=> string(23) "Preanalytical mysteries" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(107) "acute pancreatitis, analytical techniques and equipment, analyzer alarms, case report, hypertriglyceridemia" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2536" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "15" ["meta_title"]=> string(130) "Falsely decreased triglyceride concentration in a patient with acute pancreatitis due to insufficient configuration of alarm rules" ["meta_desc"]=> string(130) "Falsely decreased triglyceride concentration in a patient with acute pancreatitis due to insufficient configuration of alarm rules" ["meta_keyw"]=> string(107) "acute pancreatitis, analytical techniques and equipment, analyzer alarms, case report, hypertriglyceridemia" ["created"]=> string(19) "2026-02-16 09:08:02" ["modified"]=> string(19) "2026-02-17 09:22:56" } [37]=> object(stdClass)#86 (35) { ["journals_id"]=> string(4) "1215" ["journals_xml"]=> string(57229) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-011001 10.11613/BM.2026.011001 Preanalytical mysteries Unexpected abnormal flotation of gel separator in tube of post dialysis samples: a case report highlighting the critical role of sampling site selection CroisonnierAnne*1BoisVincent1VerninGuillaume2ChiricaCarole1GuergourDorra1 Immunoanalysis Biochemistry Unit, Department of Biochemistry, Molecular Biology and Environmental Toxicology, Institute of Biology and Pathology, Grenoble Alpes University Hospital, Grenoble, France AGDUC (Association Grenobloise des Dialysés et Urémiques Chroniques), Grenoble, France

First two authors contributed equally to this work.

Corresponding author: acroisonnier@chu-grenoble.fr

Author contributions

A Croisonnier: Investigation, drafting the manuscript, critical revision and approval of the manuscript, visualisation; V Bois: Investigation, drafting the manuscrit, critical revision and approval of the manuscript, visualisation; G Vernin: Critical revision and approval of the manuscript; C Chirica: Investigation, review and editing, critical revision and approval of the manuscript; D Guergour: Project administration, investigation, critical revision and approval of the manuscript.

15122025 15022026 36 1 011001 2805202523102025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Unexplained abnormal flotation of separator gel observed during hemodiafiltration

• Biochemical results discordant with the patient’s clinical condition

• The false-hyperproteinemia warrants evaluation for a preanalytical error

• Sampling from an inappropriate site was identified as the source of the anomaly

• The correct sampling site is essential to ensure valid hemodiafiltration results

Proper preanalytical handling of blood samples is critical to ensure the reliability of laboratory results, particularly in patients undergoing hemodialysis, where biochemical monitoring is essential for assessing dialysis adequacy and guiding treatment decision. We reported three cases of abnormal post-dialysis gel separator flotation in blood collection tubes from patients undergoing hemodiafiltration: in each case, the gel migrated to the top of the tube, with plasma trapped below and blood cells remaining at the bottom. Marked hyperproteinemia and hypercalcemia were observed in the plasma, inconsistent with the patient’s clinical status and pre-dialysis values. These findings raised suspicion of a preanalytical error potentially associated with the hemodialysis procedure. On-site investigations conducted in collaboration with the dialysis center for four additional patients, combined with a better understanding of the principles of hemodiafiltration and the potential sampling sites, confirmed that the gel migration anomaly was secondary to unsuitable sampling from the venous line (outflow line) of the dialysis circuit instead of the arterial one (inflow line). In conclusion, we highlighted the critical role of adhering to the appropriate sampling site when performing post-dialysis blood tests: the arterial line was identified as the appropriate site for post-dialysis blood sampling, while the venous line should be reserved exclusively for infusion or reinjection purposes and must never be used for blood collection at the end of dialysis.

Keywords: blood specimen collectionhemodiafiltrationrenal dialysishyperproteinemiapreanalytical phase
Introduction

Assessment of dialysis adequacy is a fundamental component of patient management in hemodialysis (HD). Among the most widely used indicators is the Kt/V index, which allows to assess dialysis adequacy. Urea measurement is required for the calculation of this index, where “K” represents urea clearance (L/min), “t” the duration of the dialysis session (min), and “V” the urea distribution volume (L). A target Kt/V value above 1.2 is generally recommended to ensure effective solute removal and optimize clinical outcomes (1). Monthly pre- and post-dialysis blood tests are therefore essential to ensure reliable Kt/V calculation and to prevent misinterpretation that could compromise patient care (2). Additionally, they provide essential information for monitoring electrolyte balance through the measurement of sodium, potassium, chloride, calcium, and protein concentrations, as well as for maintaining acid-base homeostasis by assessing bicarbonate (3). Rigorous control of preanalytical variables is crucial to ensure the reliability of laboratory results and to support optimal clinical decision-making (4). In our laboratory, blood samples from dialysis patients are collected using lithium heparin tubes with a gel separator. The separator gel is an inert, thixotropic polymer that alters its viscosity during centrifugation without interacting with blood components. Due to its specific density, intermediate between plasma and packed red blood cells, the gel typically forms a stable barrier between these two layers after centrifugation (5). These tubes offer several advantages: they eliminate the need for specimen aliquoting, provide a larger volume of usable plasma post-centrifugation, and minimize the risk of contamination from the cellular fraction due to the presence of the gel barrier. Moreover, samples collected in gel-containing tubes are more stable, ensuring proper preservation conditions of the specimens (6). Although infrequent, abnormal gel flotation due to an increase in plasma density may be observed. In cases such as hyperproteinemia or following administration of a contrast dye, analytical errors may result (7, 8). We reported an unexpected flotation of the separator gel in blood samples from three patients, observed exclusively after hemodialysis. This anomaly was associated with discrepancies between pre- and post-dialysis laboratory results: marked, unexplained hyperproteinemia and severe hypercalcemia were detected post-dialysis, inconsistent with pre-dialysis values and the patients’ asymptomatic clinical status. This case report aimed to identify the potential causes of abnormal gel migration following centrifugation, as well as the aberrant biochemical values observed in post-dialysis blood samples.

The three patients were undergoing hemodiafiltration (HDF) suggesting a dialysis-related issue that warrants further investigation. Conventional HD uses diffusion and convection across a semi-permeable membrane to facilitate renal clearance of waste products. Hemodiafiltration, in contrast, enhances the convection mechanism by applying positive pressure to the blood compartment, increasing filtration and promoting the elimination of medium molecular weight uremic toxins, including inflammatory proteins (9, 10). However, this process also results in a significant loss of water and plasma electrolytes, necessitating reinfusion of an isovolumic substitution fluid to compensate for these hydro electrolytic losses before returning the purified blood to the patient (Figure 2). We therefore hypothesized that blood sampling performed at the end of dialysis, before the reinfusion of the replacement fluid, could explain the observed hyperproteinemia, due to hemoconcentration induced by hemodiafiltration. The objective of our study was to demonstrate that the anomalies of gel migration and discrepancies between pre- and post-dialysis samples originate from a previously undescribed preanalytical error related to the sampling site, and to identify the responsible non-compliant sampling site observed.

Principle of hemodiafiltration. Schematic representation of the extracorporeal circuit used during hemodialysis. Blood flows from the patient’s vascular access through the arterial line (inflow) to the dialyzer and returns via the venous line (outflow).

This analysis was conducted as case report, involving data from patients. The treatment has been carried out in Grenoble University Hospital according to French current regulation about case report publication and after consultation with our data protection officer. All subjects were informed about the processing of their data and their rights and have all signed a case report consent form in accordance with legislation and the institutional requirements. The raw data supporting the conclusions of this article will be made available by the authors within respect of General Data Protection Regulation, without undue reservation.

Laboratory analyses

We reported the case of an 89-year-old woman undergoing HDF for the management of end-stage renal disease, secondary to embolic thrombosis of the renal arteries. Blood samples were collected at the initiation and conclusion of a dialysis session for routine biochemical analysis, including electrolytes, total protein, calcium, phosphate, urea, uric acid, and creatinine. Samples were drawn into BD Vacutainer lithium heparin tubes with gel separators (Becton Dickinson, Franklin Lakes, USA). The specimens arrived at the laboratory within 30 minutes of collection and were processed immediately. Preanalytical handling was performed using our automated system Aptio Laboratory Automation System (Inpeco SA, Novazzano, Switzerland), distributed by Siemens Healthineers. Samples were centrifuged at 2500xg for 10 minutes at 22 °C and subsequently analyzed using our automated clinical chemistry platform Atellica Solution (Siemens Healthineers, Tarrytown, USA).

However, analysis of the post-dialysis sample was initially delayed due to an analyzer error related to the sample aspiration needle. Upon visual inspection, the laboratory technician identified an abnormal gel separation pattern in the post-dialysis tube (Figure 1, left tube): the separator gel had migrated to the topmost layer, while the plasma remained in the middle, and the packed blood cells at the bottom. After carefully recovering the plasma located beneath the separator gel, the prescribed post-dialysis biochemical analyses were performed. This issue recurred within the following month in two additional male patients, aged 75 and 77 years, undergoing HDF for diabetic nephropathy and idiopathic membranous glomerulonephritis, respectively. In all three cases, blood collection was performed by different nursing staff using different dialysis machines. Table 1 summarizes the biochemical results obtained from pre- and post-dialysis samples. All three patients exhibited marked hyperproteinemia in the post-dialysis samples, with unexplained elevations in total protein concentrations compared to pre-dialysis values. In addition to various electrolyte abnormalities, laboratory testing revealed severe hypercalcemia and hypokalemia, inconsistent with the patients’ asymptomatic clinical status. Blood urea nitrogen concentrations were undetectable, precluding the calculation of Kt/V. Following discussions with the treating physicians, and in light of these inconsistencies, none of the results from the affected samples were reported. Blood tests were repeated without urgency during the next dialysis session.

Lithium heparin plasma separator tubes following centrifugation. Left: abnormal flotation of the separator gel. Right: appropriate positioning of the separator gel following standard phase.

Comparative analysis of biochemical parameters pre- and post-dialysis in patients exhibiting abnormal separator gel flotation in post-dialysis blood samples.
Case 1 Case 2 Case 3
Parameter Pre-dialysis Post-dialysis Pre-dialysis Post-dialysis Pre-dialysis Post-dialysis
Sodium (mmol/L) 144 133 133 127 137 130
Potassium (mmol/L) 4.1 2.6 3.5 2.0 4.9 3.0
Chloride (mmol/L) 110 91 95 80 101 77
Bicarbonate (mmol/L) 26 26 23 27 21 26
Calcium (mmol/L) 2.1 3.8 1.9 3.8 2.2 3.3
Phosphate (mmol/L) 1.2 < 0.1 1.4 < 0.1 2.0 < 0.1
Total protein (g/L) 62.0 149.4 79.0 168.1 74.0 169.4
Creatinine (µmol/L) 295 47 443 77 799 159
Uric acid (mmol/L) 331 34 462 ND 386 45
Urea (mmol/L) 15.3 < 1.8 28.0 < 1.8 19.3 < 1.8
ND - Not determined.
Further investigations

To investigate potential sampling errors, a collaboration was established with the dialysis center (AGDUC – Association Grenobloise des Dialysés et Urémiques Chroniques). Following discussions with the medical team, we attempted to reproduce the gel migration anomaly associated with hyperproteinemia and hypercalcemia in four additional patients, distinct from those previously described, all of whom were undergoing hemodiafiltration. Pre-dialysis samples were collected from the arterial site. Post-dialysis blood tests were performed in these four patients using two distinct sampling sites on the extracorporeal circuit: (1) the arterial line upstream of the dialyzer, and (2) the venous line downstream of the dialyzer but upstream of the substitution fluid reinfusion port (Figure 2).

Results are presented as mean ± 95% confidence interval (CI) for each parameter in the pre-dialysis, post-dialysis venous, and post-dialysis arterial groups. Using Stata version 18.0 (College Station, Texas, USA), the mean difference between post-dialysis venous and arterial samples, along with its 95% CI, was computed accordingly.

What happened?

Following centrifugation of blood samples collected from both arterial and venous sites, a clear anomaly in the migration of the separator gel was consistently observed in tubes drawn from the venous site in all four patients. In contrast, samples collected from the arterial site exhibited normal gel migration, with the gel properly situated between the plasma and the pellet, as expected. Table 2 summarizes the biochemical results for each defined group. Venous blood samples demonstrated biochemical abnormalities consistent with our three initial cases, including marked hyperproteinemia (mean 147.3 g/L, 95% CI: 112.1 to 182.4) and severe hypercalcemia (mean 3.6 mmol/L, 95% CI: 3.2 to 3.9). The mean difference in plasma total protein was 70.5 g/L, with a 95% CI of 35.4 to 105.6 g/L, and the mean difference in plasma calcium was 1.1 mmol/L, with a 95% CI of 0.6 to 1.6 mmol/L. For all outcomes, the 95% CIs of the mean differences between the two sampling sites excluded zero, thus providing an argument for the presence of a signal for a difference.

Comparative study of biochemical parameters in predialysis and postdialysis according to the sampling site
Parameter Blood sampling
Pre-dialysis(arterial A)(N = 4) Post-dialysis(arterial A)(N = 4) Post-dialysis(venous V)(N = 4) Post-dialysis(V-A)(N = 4)
Sodium (mmol/L) 138(133 to 143) 137(134 to 139) 131(126 to 137) - 5(- 9 to - 1)
Potassium (mmol/L) 5.0(4.3 to 5.6) 3.5(3.0 to 4.0) 2.3(0.9 to 3.7) - 1.2(- 2.2 to - 0.1)
Chloride (mmol/L) 102.1(99.3 to 104.9) 97.5(94.2 to 100.9) 86.3(75.8 to 96.7) - 11.3(- 18.8 to - 3.8)
Calcium (mmol/L) 2.2(1.9 to 2.6) 2.5(2.2 to 2.7) 3.6(3.2 to 3.9) 1.1(0.6 to 1.6)
Phosphate (mmol/L) 1.7(0.2 to 3.1) 0.6(0.3 to 0.9) 0.1*(0.1 to 0.1) - 0.5(- 0.8 to - 0.2)
Total protein (g/L) 70.6(58.9 to 82.2) 76.8(61.7 to 91.9) 147.3(112.1 to 182.4) 70.5(35.4 to 105.6)
Creatinine (µmol/L) 644.5(458.3 to 834.3) 228.8(161.1 to 293.4) 77.5(65.9 to 90.4) - 151.3(- 245.9 to - 56.6)
Urea (mmol/L) 19.9(16.2 to 23.6) 6.8(2.0 to 3.6) 1.8*(1.8 to 1.8) - 5.0(- 8.1 to - 1.8)
*All measured values were below the lower threshold of detection. For statistical purpose the minimum value of detection was assigned. Data are expressed as mean (95% confidence intervals). The mean difference between post-dialysis venous and arterial samples was estimated with its 95% confidence interval.
Discussion

The results of our investigations confirm that the observed protein migration anomaly and hyperproteinemia were indeed of preanalytical origin: post-dialysis blood samples in our patients were collected from the venous line instead of the arterial line. A better understanding of the principles of HDF allowed us to hypothesize that the hyperproteinemia was secondary to hemoconcentration induced by ultrafiltration. This hemoconcentration was evident in the post-dialysis samples, notably in the sample from the left-hand tube (Figure 1), which showed abnormally enlarged red blood cells, consistent with elevated hematocrit values. The observed hyperproteinemia provided a plausible explanation for the flotation anomaly, as previously described by Fatás et al. in patients with multiple myeloma (11). Furthermore, Faught et al. observed abnormal flotation of the separator gel in clinical samples with total protein concentrations above 162 g/L in BD collection tubes (12). As described in our case report, Demir et al. also reported abnormal flotation of separator gel in blood collection tubes used in HD patients, with marked increases in protein concentrations exceeding 168 g/L in post-dialysis samples (13). However, in this study, upon reviewing medical records, it was found that all three patients exhibiting flotation anomalies were hypotensive following the dialysis session. The authors concluded that hyperproteinemia was due to hemoconcentration caused by hypovolemia. In contrast, our patients were entirely asymptomatic. Our study presents compelling evidence in favor of hemoconcentration and hyperproteinemia being of preanalytical origin, related to post-dialysis blood sampling from the venous (outflow) line instead of the arterial (inflow) line. The venous site is clearly identified as an inappropriate site for post-dialysis sampling in patients undergoing hemodiafiltration. Our findings could be strengthened by conducting a study with a larger patient cohort to achieve methodological conclusiveness. However, the benefit of including additional patients to obtain statistically significant results appears limited, particularly as the sampling method for pre- and post-dialysis urea measurement is clearly defined in the KDOQI guidelines: samples must be taken from the arterial line (2). Our case underscores the importance of strictly adhering to these recommendations and identifies three major risks. First, the Kt/V cannot be interpreted from samples drawn from the venous site, as the measured urea concentration falls below the quantification threshold. Alternatively, dialysis dose can be estimated using the urea reduction ratio (URR), calculated as: (pre-dialysis urea - post-dialysis urea) / pre-dialysis urea (14). The minimum recommended dialysis dose corresponds to a URR of 60%. In our four patients, the risk of overestimating the URR is easily understood if calculated using a detection threshold of 1.8 mmol/L. The same applies to the calculation of Kt/V. Second, the electrolyte disturbances observed in post-dialysis samples drawn from the venous site underscore the risk of inappropriate management of hypokalemia or hypercalcemia if these results were reported. Third, aspiration of the gel, when it is not properly positioned in the tube, may occur during sample processing by laboratory instrumentation, especially in highly automated laboratories where primary collection tubes are centrifuged and analyzed without direct visual inspection by personnel. The instrument’s needle can become partially or completely obstructed by the gel, potentially compromising the integrity of the device. Needle replacement may be required, which could lead to delays in result turnaround time.

In conclusion, our case highlights the critical importance of using the appropriate sampling site for post-dialysis blood testing, as well as the potential risks associated with not adhering to established guidelines. The arterial line was identified as the correct site for post-dialysis sample collection, whereas the venous line should be strictly reserved for infusion or reinjection purposes and must not be used for blood collection at the end of dialysis.

What you can do in your laboratory to prevent such errors

Continuous education of clinical teams on adherence to correct blood sampling protocols and their influence on laboratory results is essential. The critical risk associated by improper sampling site selection, especially for post-dialysis tubes, and its subsequent impact must be comprehensively managed by healthcare personnel.

Clinical laboratories must provide healthcare teams of the AGDUC with informational leaflets containing detailed and specific instructions addressing all aspects of the preanalytical phase.

Communication between the clinical laboratory and clinical departments must be strengthened.

If a non-conformity is identified, it should be documented and communicated to the prescribing physician in the results report. This practice will facilitate the assessment of deviations from sampling protocols and improve nurse training where necessary.

Potential conflict of interest

None declared.

Data availability statement

All data genered and analyzed in the presented study are included in this published article.

References CanaudBFouqueD. Recommandations européennes de bonnes pratiques (EBPG) en hémodialyse. Deuxième vague [European recommendations for good practice in hemodialysis. Part Two]. Nephrol Ther. 2008;4:115–24. 10.1016/j.nephro.2007.12.00218326481 National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. Am J Kidney Dis. 2015;66:884–930. 10.1053/j.ajkd.2015.07.01526498416 NodimarCChauveauP. Argumentaire justifiant le dosage des marqueurs biochimiques de routine en hémodialyse [Argument justifying the measurement of routine biochemical markers in hemodialysis]. Nephrol Ther. 2024;20:143–6. 10.1684/ndt.2024.7438742304 GendtLSzymanowiczA. Proposition pour la maîtrise de la phase pré-analytique selon la norme NF EN ISO 15189. Bio Trib Mag. 2010;36:50–8. 10.1007/s11834-010-0022-8 Lima-OliveiraGLippiGSalvagnoGLGelatiMBassiAControA Abnormal gel flotation caused by contrast media during adrenal vein sampling. Biochem Med (Zagreb). 2016;26:444–50. 10.11613/BM.2016.04727812311 Parra-RobertMRico-SantanaNAlcaraz-QuilesJSandalinasSFernándezEFalcónI Improvement in the stability of serum samples stored in an automated refrigerated module. Clin Biochem. 2016;49:1396–8. 10.1016/j.clinbiochem.2016.10.01227789213 van den OuwelandJMWChurchS. High total protein impairs appropriate gel barrier formation in BD Vacutainer blood collection tubes. Clin Chem. 2007;53:364–5. 10.1373/clinchem.2006.08165317259253 DavesMLippiGCosioGRaffagniniAPeerEDangellaA An unusual case of a primary blood collection tube with floating separator gel. J Clin Lab Anal. 2012;26:246–7. 10.1002/jcla.2151222811356 HannedoucheTBacheletTRoyFLCanaudB. Place de l’hémodiafiltration en ligne dans le traitement de suppléance rénale de l’insuffisance rénale chronique ultime en 2022 : situation actuelle et perspectives. [Place of on-line hemodiafiltration in renal replacement therapy for chronic end-stage renal disease in 2021: Current status and perspectives]. Nephrol Ther. 2022;17:3S5-17/3S11. 10.1016/S1769-7255(22)00033-5 CanaudBChénineLLeray-MoraguèsHPatrierLRodriguezAGontier-PicardA Hémodiafiltration en ligne : modalités pratiques, sécurité et efficacité de la méthode [Online hemodiafiltration: Practical aspects, safety and efficacy]. Nephrol Ther. 2017;13:189–201. 10.1016/j.nephro.2017.02.00728483384 FatásMFranqueloPFranqueloR. Anomalous flotation of separator gel: density or viscosity? Clin Chem. 2008;54:771–2. 10.1373/clinchem.2007.09371618375495 FaughtRCMarshallJBornhorstJ. Solution densities and estimated total protein contents associated with inappropriate flotation of separator gel in different blood collection tubes. Arch Pathol Lab Med. 2011;135:1081–4. 10.5858/2010-0488-OAR.121877989 DemirMOzlemSSarierM. Abnormal Flotation of Separator Gel in Blood Test Tubes in the Hemodialysis Patients. EJMI. 2019;3:280–4. 10.14744/ejmi.2019.82037 SchortgenF. Tolérance et efficacité des séances d’épuration extrarénale [Tolerance and efficacy of renal replacement therapy]. Reanimation. 2003;12:318–26. 10.1016/S1624-0693(03)00062-8
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "011001" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-011001" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.011001" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(152) "Unexpected abnormal flotation of gel separator in tube of post dialysis samples: a case report highlighting the critical role of sampling site selection" ["journals_article_author"]=> string(80) "Anne Croisonnier, Vincent Bois, Guillaume Vernin, Carole Chirica, Dorra Guergour" ["journals_article_author_country"]=> string(6) "France" ["journals_article_categories_heading"]=> string(23) "Preanalytical mysteries" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(99) "blood specimen collection, hemodiafiltration, renal dialysis, hyperproteinemia, preanalytical phase" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2625" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "14" ["meta_title"]=> string(152) "Unexpected abnormal flotation of gel separator in tube of post dialysis samples: a case report highlighting the critical role of sampling site selection" ["meta_desc"]=> string(152) "Unexpected abnormal flotation of gel separator in tube of post dialysis samples: a case report highlighting the critical role of sampling site selection" ["meta_keyw"]=> string(99) "blood specimen collection, hemodiafiltration, renal dialysis, hyperproteinemia, preanalytical phase" ["created"]=> string(19) "2025-12-09 12:00:12" ["modified"]=> string(19) "2026-02-17 09:23:07" } [38]=> object(stdClass)#87 (35) { ["journals_id"]=> string(4) "1218" ["journals_xml"]=> string(71969) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010708 10.11613/BM.2026.010708 Original articles Automated Aerospray Hematology PRO staining shows good agreement for mature leukocytes but limited diagnostic reliability for immature forms: comparison with manual May-Grünwald-Giemsa staining NiklerAna*1TomasMatea1SaračevićAndrea1Radišić BiljakVanja12 University Hospital Sveti Duh, Department of Medical Laboratory Diagnostics, Zagreb, Croatia University of Zagreb, Faculty of Kinesiology, Department of Sport and Exercise medicine, Zagreb, Croatia Corresponding author: ana.nikler@gmail.com

Author contributions

A Nikler: Conceptualization, Investigation, Methodology, Validation, Writing - original draft; M Tomas: Formal analysis, Methodology, Writing - review & editing; A Saračević: Investigation, Methodology, Writing - review & editing; V Radišić Biljak: Conceptualization, Data duration, Investigation, Methodology, Validation, Writing - original draft, Writing - review & editing.

15022026 15022026 36 1 010708 1109202508012026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Aerospray provided comparable staining to May-Grünwald-Giemsa (MGG) for mature white blood cells (WBCs)

• Manual MGG staining remains necessary for reliable evaluation of immature cells

• Diagnostic accuracy was unsatisfactory for atypical lymphocytes, immature granulocytes and blasts

• Immature WBCs had reduced granularity and lighter nuclear staining with Aerospray

• Erythrocyte and platelet morphology were unaffected by the staining method

Introduction

Microscopic examination of peripheral blood smears remains essential step in hematology diagnostics, requiring reliable and standardized staining techniques. This study evaluated performance of Aerospray Hematology PRO Slide Stainer (ELITechGroup Inc., Utah, USA) in comparison with manual May-Grünwald-Giemsa (MGG) technique.

Materials and methods

Forty K2EDTA-whole-blood smears were prepared in duplicate and stained using both methods. Hundred samples flagged by Siemens Advia 2120i for atypical lymphocytes (ATYPS), immature granulocytes (IG), blasts and nucleated red blood cells were analyzed for diagnostic accuracy. Precision was assessed using three K2EDTA-whole-blood samples, where 12 smears per sample were evaluated. Manual differential counts of 100 white blood cells (WBC) per slide were performed by experienced laboratory scientist. Data distribution was assessed using Kolmogorov-Smirnov test. Method comparison was performed using Bland-Altman and Passing-Bablok analyses, while sensitivity and specificity were calculated for ATYPS, IG and blasts.

Results

Precision results met acceptable criteria for all WBC subpopulations. No significant differences were observed for mature WBCs: intercept - 4.0 (- 13.8 to 3.0) slope 1.0 (0.9 to 1.2) for neutrophils; intercept - 1.5 (- 9.3 to 1.9), slope 1.1 (0.9 to 1.3) for lymphocytes; intercept 1.0 (- 2.0 to 1.6), slope 1.0 (0.9 to 1.4) for monocytes; intercept 0.0 (- 1.5 to 1.3), slope 1.0 (0.5 to 1.7) for eosinophils. Staining of mature WBCs was comparable, showing no significant differences in nuclear or cytoplasmic morphology. While immature WBCs, particularly myelocytes, displayed fewer granules and lighter nuclear staining with Aerospray. Diagnostic accuracy was unsatisfactory for classifying ATYPS (Se = 73%, Sp = 60%), IG (Se = 63%, Sp = 50%) and blasts (Se = 63%, Sp = 100%), whereas erythrocyte and platelet morphology were unaffected.

Conclusions

Aerospray Hematology PRO is suitable for mature WBC populations. However, manual MGG staining remains necessary for reliable evaluation of immature and pathological cells.

Keywords: Aerospray Hematology PRO Slide StainerverificationMay Grünwald Giemsamanual technique
Introduction

Microscopic examination of peripheral blood smears remains an essential step in laboratory hematology diagnostics despite the overgrowing laboratory automatization (1). Careful morphological assessment of blood cells provides critical information for the detection of hematological abnormalities, recognition of abnormal cell forms, and identification of immature or pathological cell populations, which may be crucial for establishing a diagnosis and monitoring disease progression or treatment response. Therefore, high-quality and standardized blood smear preparation and staining are indispensable for ensuring accurate microscopic interpretation and minimizing inter-laboratory variability.

Conventional manual preparation and staining of peripheral blood smears, most commonly performed using the May-Grünwald-Giemsa (MGG) technique, remains widely used in routine laboratory practice (2). However, manual smear preparation and staining are time-consuming procedures, highly dependent on the experience of laboratory professionals and susceptible to inter- and intra-operator variability. To address these limitations, automated smear stainers have been introduced to improve workflow efficiency, reduce human error, and ensure better reproducibility of staining quality. A wide range of commercially available automated smear stainers are integrated with hematology analyzers, facilitating more rapid and standardized preparation of peripheral blood smears. Numerous studies have investigated the performance of such integrated systems and their impact on morphological assessment (3-9).

The aim of this study was to compare the staining quality and diagnostic suitability of peripheral blood smears prepared using the Aerospray Hematology PRO Slide Stainer (ELITechGroup Inc., Utah, USA) and the standard manual laboratory procedure based on MGG technique. The evaluation was performed using routine complete blood count (CBC) samples, with a focus on cellular morphology visualization and the reliability of leukocyte differential analysis.

Materials and methods Study design

This verification study was performed in a clinical hematology laboratory following routine diagnostic workflow. The study was conducted in October 2023 at the Department of Medical Laboratory Diagnostics, University Hospital Sveti Duh (Zagreb, Croatia). It comprised assessment of staining precision, method comparison, and evaluation of diagnostic performance for selected leukocyte populations. The Institutional Ethics Committee approved the use of residual patient blood samples for the purposes of laboratory method evaluation and quality improvement (approval number 01-2013).

Sample selection

A total of 120 K2EDTA samples (Becton Dickinson, Franklin Lakes, USA, 2mL) were included in the study, out of which 40 of them previously analyzed on a Siemens Advia 2120i automated hematology analyzer (Siemens, Marburg, Germany), without differential abnormality, were selected for staining comparison. Additionally, 20 samples per each of the following flags were included in the study of diagnostic accuracy: atypical lymphocytes (ATYPS), immature granulocytes (IG), blasts and nucleated red blood cells (NRBCs) (N = 80). Also, three samples with different leukocyte differential counts (neutrophils > 70%, lymphocytes > 50%, monocytes > 12%) were selected for precision determination. Blood samples were obtained from both inpatient and outpatient populations, encompassing patients from various hospital departments, in order to reflect routine clinical hematology practice.

Blood smear preparation

Two blood smears from each of the selected samples were simultaneously prepared by inverting the sample tube 8-10 times before pipetting 25 microliters for each blood smear. The blood sample was dispensed on the slide approximately 5-7 millimetres from the frosted part of the slide. A spreading slide with frosted edges was lightly pressed on the slide at a 30° to 45° angle then moved backwards to contact the blood drop so that it spread along the width of the slide edge, and was moved forward in a motion so that insures the smear is not too thick not too thin. The smear was covering two thirds of the glass with a well rounded, bullet like edge. After drying at room temperature for 25-30 minutes the slides were stained both by MGG manual technique and by Aerospray Hematology PRO Slide Stainer.

Manual dip staining May-Grünwald Giemsa method

Manual MGG staining was performed using a dip-staining procedure according to the manufacturer’s instructions (Sigma-Aldrich), consisting of four sequential steps (10):

Slides are immersed in May-Grünwald eosin methylene blue solution by Merck (Darmstadt, Germany) for 5 minutes;

Smears are rinsed in pH 6.8 buffer for approximately 1-1.5 minutes;

Following, slides are placed in 5% buffered Giemsa azur eosin methylene blue solution by Merck for 20 minutes;

Final step includes rinsing in demineralised water and left to air dry before microscoping.

Staining by Aerospray Hematology PRO Slide Stainer

Aerospray staining instrument utilizes a controlled six-step staining process. The instrument has four operating possibilities: Rapid, Wright-Giemsa; May Grunwald Giemsa and Custom. Extensive modifications of the staining programs are possible in order to improve individual staining steps (11). After the initial setup of the Aerospray HematologyPRO Slide Stainer device, all solutions were prepared according to the manufacturer’s instructions. Aerospray uses four solutions, out of which two are ready to use, while two are prepared manually (ELITechGroup Inc, Logan, USA). The blood slides are sprayed directly by each solution thus reducing the risk of cross-contamination. Firstly, the slides were sprayed with the fixator, the intensity setting we chose for the fixation of the slides was level 3, afterwards the slides were sprayed simultaneously with Thyazine (ELITechGroup Inc, Logan, USA) and Eosin (ELITechGroup Inc, Logan, USA) in a concentrated staining cycle, the ratio of red/blue was 65/35. After a mid-rinse, the diluted staining cycle started. The diluted cycles ratio of red/blue was 60/40 with the dilution of stain/ buffer ratio of 30/70, dilute intensity was at a level 2, and end rinse intensity was at a level 6 to try to prevent staining the reverse side of the slides. The staining cycle comes to an end with a drying cycle. The slides were fully stained and ready for microscopic examination in less than 10 minutes after loading into the dying carousel. All of the used materials and ways of preparation are listed in Table 1.

Comparison of staines used for morphology staining between automated Aerospray Hematology PRO Slide Stainer and standard manual May Grünwald Giemsa technique
Staines Preparation
May-Grünwald Giemsa (MGG) manual technique May-Grünwald’s eosin-methylene blue solution Ready to use
Giemsa azur eosin methylene blue solution 10 mL of concentrated Giemsa solution is diluted in 190 mL of the pH 6.8 buffer
Buffer tablets pH 6.8 for preparing buffer solution The buffer pill is dissolved in 1 liter of demineralised water
Aerospray Hematology PRO Slide Stainer Aerospray Hematology Pro Reagent A, Buffer (pH 7.2) 3 mL of the Hematology Pro Reagent A, Buffer with 500 mL of distilled water
Hematology Reagent B: Thiazin Stain Ready to use
Aerospray Hematology Pro Reagent C, Eosin Ready to use
Hematology Reagent D - Aerofix Fixative with methanol Mix of 500 mL of methanol and 15 mL of a concentrate Aerofix

For descriptive purposes, selected workflow-related characteristics of manual MGG staining and the Aerospray Hematology PRO Slide Stainer are presented in Table 2. These characteristics include approximate slide preparation time, hands-on time, level of process standardization, and routine maintenance requirements.

Comparison of workflow-related characteristics of manual May-Grünwald-Giemsa staining and Aerospray Hematology PRO Slide Stainer
Parameter Manual May-Grünwald-Giemsa staining Aerospray Hematology PRO Slide Stainer
Staining principle Manual dip staining Automated spray-based staining
Total slide preparation time* Approximately 40-45 minutes Approximately 5-7 minutes
Hands-on time High (continuous manual handling) Low (automated process)
Throughput Limited High
Process standardization Operator-dependent High (automated reagent application)
Protocol flexibility Limited manual adjustment of staining steps Extensive programmable staining options
Routine maintenance Every-day reagent preparations and cleaning Daily and weekly maintenance according to manufacturer’s recommendations
*Approximate times recorded under routine diagnostic workflow; not derived from a formal time-motion study.
Verification procedure Precision

To avoid possible imprecision errors, prior the comparison studies a short precision study was performed. For three peripheral K2EDTA-whole blood samples, 12 smears were prepared from each sample. A complete 12-position carousel of the Aerospray Hematology PRO Slide was loaded and all smears were stained simultaneously under identical conditions. Each slide was subsequently examined microscopically, and the standard deviation (SD) and coefficient of variation (CV) were calculated for the main leukocyte (WBC) subpopulations: neutrophils, lymphocytes, monocytes, and eosinophils. Acceptability criteria were established according to biological variability defined by EFLM Biological Variation Database (12).

Method comparison

All 120 paired stained slides were independently evaluated by a single experienced medical laboratory scientist, blinded to the staining method, in order to minimize potential inter-observer variability. For each sample, a manual differential count of 100 leukocytes was performed on both manually stained MGG slides and Aerospray-stained slides, thereby simulating the usual routine laboratory practice. Digital microscopy using the CellaVision DC-60 system was used for illustrative documentation of selected representative blood smears in order to support visual comparison of morphological features. CellaVision was not available for routine use at the time of the study and was therefore not used for statistical evaluation.

Diagnostic accuracy

Diagnostic accuracy of Aerospray staining for ATYPS, IG and blasts was determined by comparison with manual microscopic evaluation of MGG-stained peripheral blood smears, which served as the reference (gold standard) method. Diagnostic performance was expressed as sensitivity and specificity. Acceptability criteria were defined according to Vis et al., with sensitivity > 80% and specificity > 95% for ATYPS, sensitivity > 90% and specificity > 70% for IG, and sensitivity and specificity > 95% for blasts (13).

Statistical analysis

The comparison of WBC differential counts in samples without morphological abnormalities was performed by using Bland-Altman and Passing Bablok statistical analyses. Prior to method comparison, data distribution normality was assessed using the Kolmogorov-Smirnov test. While the diagnostic accuracy in classifying ATYPS, IG and blasts was performed by a 2x2 diagnostic table out of which sensitivity and specificity were calculated. Statistical analysis was performed in MedCalc Statistical Software version 22.014 (MedCalc Software Ltd, Ostend, Belgium).

Results

The precision study results were satisfactory, with all WBC subpopulations meeting predefined acceptable criteria (Table 3). The RBCs stained by Aerospray were a rich red color and no effect on distinction of any RBC morphological abnormalities were observed.

Results of the precision study of WBC subpopulations in Aerospray-stained peripheral blood smears
Neutrophils Lymphocytes Monocytes Eosinophils
S1 S2 S3 S1 S2 S3 S1 S2 S3 S1 S2 S3
Mean (%) 75.3 37.3 66.7 10.6 53.2 16.5 7.0 6.4 15.5 1.9 3.4 1.3
SD 3.5 4.3 2.1 2.8 4.0 2.0 2.0 2.1 1.3 0.8 1.2 0.5
CV (%) 4.7 11.6 3.2 26.9 7.5 12.3 27.9 32.2 8.5 41.4 36.3 37.2
Acceptance criteria for CV* (%) 32.5 28.0 33.2 41.4
*acceptance criteria defined by EFLM Biological Variation Database (12). S1 - sample 1. S2 - sample 2. S3 - sample 3. SD - standard deviation. CV - coefficient of variation.

No statistically significant differences were observed between paired slides for WBC subpopulations, as determined by Bland Altman and Passing Bablok statistical analyses, with normal data distribution confirmed by the Kolmogorov Smirnov test (Figures 1-2). Data for basophils were not sufficient for Passing Bablok analysis due to low cell counts (2% as highest value). An unsatisfactory diagnostic accuracy was observed in classifying ATYPS (Se = 73%, Sp = 60%, SOTA > 80% / > 95%), immature granulocytes (Se = 63%, Sp = 50%, SOTA > 90% / > 70%) and blasts (Se = 63%, Sp = 100%, SOTA > 95% / > 95%) as presented in Table 4. Samples flagged for NRBCs by the hematology analyzer did not show erythroblasts on microscopic examination of peripheral blood smears and were therefore excluded from further analysis.

Bland-Altman plots comparing wgite blood cell differential counts obtained from manually stained May Grünwald Giemsa (MGG) and Aerospray-stained peripheral blood smears. Panels A and B represent absolute differences and relative bias, respectively, for neutrophils (1), lymphocytes (2), monocytes (3), and eosinophils (4).

Passing Bablok scatter plots of white blood cell differential counts obtained from manually stained May Grünwald Giemsa (MGG) and Aerospray-stained peripheral blood smears. A) neutrophils, B) lymphocytes, C) monocytes, D) eosinophils.

Diagnostic accuracy of Aerospray staining for atypical lymphocytes, blasts and immature granulocytes, compared with the May-Grünwald-Giemsa method
ATYPS (%) Acceptablecriteria* (%) BLAST (%) Acceptablecriteria* (%) IG (%) Acceptablecriteria* (%)
Sensitivity (Se) (95% CI) 73 (45-92) > 80 63 (25-91) > 95 63 (35-85) > 90
Specificity (Sp) (95% CI) 60 (15-94) > 95 100 (74-100) > 95 50 (7-93) > 70
*defined by Vis et al as State-of-the-art (SOTA) criteria (13). ATYPS - atypical lymphocytes. BLAST - blast cells. IG - immature granulocytes. CI - confidence interval.

There was no significant difference in mature WBCs as far as the color differential of the nuclei and cytoplasm. However, there was a slight difference in the coloring of the toxic granules found in some of the smear duplicates. Aerospray staining of toxic granules was more red than purple and less represented than in the MGG stained slides.

Immature WBCs were noticeably different. Although the cytoplasm was standardly stained, there were significantly fewer primary granules represented in the slides stained by Aerospray compared to the manual MGG technique. The MGG stained the immature WBCs with a nucleus a bit more intensely with a dark purple, but the primary granules were by comparison far more noticeable in color and in number unlike in the firstly mentioned method that especially goes as far as myelocytes differential (Figure 3). The differences in depiction of primary granules differed vastly between the two slides. There was no difference with staining atypical lymphocytes, the nucleus was a purple/light pink colour in both methods, with overwhelming clear cytoplasm, noticeable red granules were present and a darkened blue edge. There was slight difference with staining of the blasts. The MGG staining resulted in a darker purple colouring of the nucleus and a noticeable nucleolus discolouring, whereas Aerospray staining of the nucleus was lighter in color which made it slightly harder to notice the nucleoli, typically found in blasts (Figure 4). Cytoplasm was clear, a light blue color with a darkened blue edge on both staining methods.

The comparison of myelocyte morphology in a peripheral blood smear stained by standard manual May Grünwald Giemsa technique (left) and by Aerospray Hematology PRO Slide Stainer (right). Both depicted cells were taken from the same sample.

The comparison of blast morphology in a peripheral blood smear stained by standard manual May Grünwald Giemsa technique (left) and by Aerospray Hematology PRO Slide Stainer (right). Both depicted cells were taken from the same sample.

Although the main focus of the comparison study was on the WBC’s and RBC’s morphology, no major morphological differences were noticed on the platelets.

Discussion

An earlier publication of the Aerospray staining system in hematology was published by Duchayne and Aldebert in 2008 (14). In that study, the authors demonstrated that, after appropriate adjustment of staining parameters, Aerospray staining could produce peripheral blood and bone marrow smears with overall morphological appearance comparable to the conventional MGG method. However, their evaluation was primarily focused on qualitative assessment of staining characteristics and did not address diagnostic performance or the reliability of leukocyte differential assessment in routine clinical samples. In contrast, the present study provides a contemporary, clinically oriented re-evaluation of Aerospray Hematology PRO Slide Stainer using routine peripheral CBC samples selected based on analyzer flags. Unlike previous report, our study integrates statistical comparison, diagnostic accuracy analysis, and focused assessment of immature and pathological leukocyte populations according to current state-of-the-art performance criteria.

Our results demonstrate that, in samples without morphological abnormalities, Aerospray-stained slides showed good agreement with manually stained MGG slides for mature leukocyte populations. However, in samples flagged for potential morphological abnormalities, the automated staining method demonstrated limited diagnostic accuracy for the identification and differentiation of immature and pathological leukocyte forms. This distinction, which was not addressed in earlier studies, is particularly relevant in modern hematology laboratories where morphological review is increasingly triggered by analyzer flags and where accurate identification of immature cells is critical for clinical decision-making.

The main practical advantage of the Aerospray Hematology PRO Slide Stainer is undisputably its speed. While the standard manual MGG technique requires a minimum of 40-45 minutes to produce a quality stained slide, with Aerospray Hematology PRO Slide Stainer turnover time can be reduced to 5-7 minutes. Additionally, the uniform spreading of the dye enables better standardization of the whole process. Coupled with the automated microscopy analyzer, such as CellaVision, the analysis and classification of the stained slides also becomes standardized and consistent which leads to a clean, efficient, and smooth workflow with excellent results, as shown by Verdoes et al. (15). In their study, various Aerospray staining settings were assessed in combination with automated WBC classification using the CellaVision DM 1200. The authors predefined that a staining setting would be considered acceptable if the automated WBC classification achieved ≥ 95% accuracy as verified by an experienced laboratory technician. However, it is important to note that manual staining techniques were not included in their evaluation, nor were the smears reviewed manually under the microscope.

Beyond preparation time, the two staining methods differ in several workflow-related aspects that are relevant for routine laboratory practice. The main advantages of the Aerospray Hematology PRO Slide Stainer include a high degree of process standardization, reduced hands-on time, and suitability for high-throughput laboratories. Automated reagent application minimizes operator-dependent variability and facilitates integration into routine diagnostic workflows.

According to International Council for Standardization in Haematology (ICSH) guidelines, substantial differences may exist between digital microscopy systems that utilize manually prepared and stained blood smears and those employing automated slide makers and stainers (16). Although automated systems generally provide standardized smear preparation and staining, comparative studies evaluating differences in morphological details and color consistency between these two approaches remain limited. Previous reports have noted that blood smears prepared automatically may display cells that appear larger and thinner, with potential chromatic variations compared to cells stained using panoptical manual techniques (7, 17, 18). In the presence of abnormal cells or in pediatric samples rich in lymphocytes, such variations in cell size, thickness, and coloration may contribute to misclassification, often leading to an overestimation of blast cells (19). Our study observed significant differences in the staining of immature WBCs, particularly myelocytes, where Aerospray staining showed fewer and less distinct primary granules and lighter nuclear coloration compared to the manual MGG method. Furthermore, the diagnostic accuracy for atypical lymphocytes and blasts was unsatisfactory when using Aerospray, while the morphology of mature WBCs was comparable between the two methods, with no significant differences in nuclear or cytoplasmic staining. To enhance laboratory interpretation, the ICSH guidelines recommend that manufacturers provide high-quality reference images comparing manually and automatically prepared smears, along with clear explanations of expected morphological and chromatic differences (16).

Although a full digital morphology comparison was not performed, the observed staining-related differences in immature leukocyte populations are clinically relevant in the context of modern hematology workflows, where digital morphology systems are increasingly used as a decision-support tool (20, 21). Suboptimal visualization of primary granules and lighter nuclear staining may adversely affect both manual and digital classification, particularly in samples flagged for immature or pathological cells.

This study has several limitations. Digital morphology was not available for routine use at the time of the study and therefore could not be applied systematically or included in diagnostic performance analysis. Slide evaluation was performed by a single experienced laboratory scientist, reflecting routine laboratory practice but precluding assessment of inter-observer variability. Manual differential counts were limited to 100 WBCs per slide in order to simulate routine workflow and did not follow CLSI H20-A2 recommendations for evaluation of leukocyte differential counting methods (22). Additionally, NRBCs were not evaluated because samples flagged for nucleated red blood cells did not demonstrate erythroblasts upon microscopic review. Pediatric and neonatal samples were not analyzed separately, and no further optimization of staining parameters was attempted, which may limit the applicability of the results to other populations or staining conditions. Cost per sample was not systematically assessed as such analysis is highly dependent on local pricing, reagent contracts, workload, and laboratory organization. The coloring of the RBCs in manually stained slides with MGG technique was slightly grayish, than prefereably light pink, perhaps due to not so optimal buffer pH, which was not checked during the verification process. However, that did not influence the distinction of any RBC morphological abnormalities, as stated before.

Neverthless, under the applied staining protocol, Aerospray Hematology PRO Slide Stainer demonstrated comparable performance to manual MGG staining for samples with mature leukocyte populations. However, the automated staining method showed insufficient diagnostic accuracy for the reliable identification and classification of immature and pathological leukocyte forms. Consequently, manual MGG staining remains indispensable when evaluating samples in which immature or pathological cells are expected.

In conclusion, these findings define the practical scope and limitations of the automated staining method as applied in this study.

Acknowledgments

We wish to thank Mrs Iris Štrbat from Labena d.o.o. (Zagreb, Croatia) for technical assistance in the initial setup of the Aerospray HematologyPRO Slide Stainer and for providing the necessary consumables for the performed verification.

Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features. Int J Lab Hematol. 2015;37:287–303. 10.1111/ijlh.1232725728865 PiatonEFabreMGoubin-VersiniIBretz-GrenierMFCourtade-SaïdiMVincentS Recommandations techniques et règles de bonne pratique pour la coloration de May-Grünwald-Giemsa: revue de la littérature et apport de l’assurance qualité [Technical recommendations and best practice guidelines for May-Grünwald-Giemsa staining: literature review and insights from the quality assurance]. Ann Pathol. 2015;35:294–305. 10.1016/j.annpat.2015.05.01926188673 Saad AlbichrISottiauxJYHottonJDe LaveleyeMDupretPDetryG. Cross-evaluation of five slidemakers and three automated image analysis systems: The pitfalls of automation? Int J Lab Hematol. 2020;42:573–80. 10.1111/ijlh.1326432539225 KwakMSJeongIHChoSSWooKSHanJY. Performance Evaluation of the Abbott Alinity hs Blood Slide Maker/Stainer. Ann Lab Med. 2022;42:482–4. 10.3343/alm.2022.42.4.48235177570 KajjouneOSakhiARouhiSQuiddiWSayaghS. Performance evaluation of the Sysmex XN50 slide-maker-stainer. Saudi J Med. 2025;10:82–8. 10.36348/sjm.2025.v10i03.002 KimHNHurMKimHParkMKimSWMoonHW Comparison of three staining methods in the automated digital cell imaging analyzer Sysmex DI-60. Clin Chem Lab Med. 2018;56:e280–3. 10.1515/cclm-2018-053929924735 SimsonEGascon-LemaMGBrownDL. Performance of automated slidemakers and stainers in a working laboratory environment - routine operation and quality control. Int J Lab Hematol. 2010;32:e64–76. 10.1111/j.1751-553X.2009.01141.x19220552 LeeHTParkPWSeoYHKimKHSeoJYJeongJH Performance evaluation of Mindray CAL 8000(BC-6800 and SC-120) hematology analyzer and slidemaker/stainer. J Clin Lab Anal. 2017;31:e22065. 10.1002/jcla.2206527660110 HedleyBDKeeneyMChin-YeeIBrownW. Initial performance evaluation of the UniCel® DxH 800 Coulter® cellular analysis system. Int J Lab Hematol. 2011;33:45–56. 10.1111/j.1751-553X.2010.01239.x20491996 Sigma Aldrich Giemsa Stain. Procedure No. GS-10, Revised 2014-09. Available from: https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/187/333/procedure-gs-10-giemsa-stain-modified-mk.pdf. Accessed August 12th 2025. EliTechGroup Inc. Aerospray Hematology Pro Slide Stainer Applications Manual. Logan (UT): EliTechGroup Inc.; 2023. Document No.: 57-2001-01G. Aarsand AK, Fernandez-Calle P, Webster C, Coskun A, Gonzales-Lao E, Diaz-Garzon J, et al. The EFLM Biological Variation Database. Available from: https://biologicalvariation.eu/. Accessed January 15th 2025. VisJYHuismanA. Verification and quality control of routine hematology analyzers. Int J Lab Hematol. 2016;38:100–9. 10.1111/ijlh.1250327161194 DuchayneEAldebertC. Évaluation de l’automate de coloration Aerospray (Elitech) au laboratoire d’hématologie [Evaluation of a new staining automatic instrument Aerospray (Elitech) in an hematology laboratory]. Rev Francoph Lab. 2008;406:81–5. 10.1016/S1773-035X(08)74529-5 Verdoes A, Cowley R, Reeve A. Standardizing the Hematology Stain Workflow with Aerospray and CellaVision. ELITechGroup Inc. White Paper 2021. Available from: https://www.scribd.com/document/897610548/AreoSpray-White-Paper. Accessed February 5th 2024. KratzALeeSHZiniGRiedlJAHurMMachinS. International Council for Standardization in Haematology. Digital morphology analyzers in hematology: ICSH review and recommendations. Int J Lab Hematol. 2019;41:437–47. 10.1111/ijlh.1304231046197 ParkMHurMKimHKimHNKimSWMoonHW Detection of Plasmodium falciparum using automated digital cell morphology analyzer Sysmex DI-60. Clin Chem Lab Med. 2018;56:e284–7. 10.1515/cclm-2018-006529813024 PierreRV. Peripheral blood film review. The demise of the eyecount leukocyte differential. Clin Lab Med. 2002;22:279–97. 10.1016/S0272-2712(03)00075-111933579 EilertsenHHenrikssonCEHagveTA. The use of CellaVision DM96 in the verification of the presence of blasts in samples flagged by the Sysmex XE-5000. Int J Lab Hematol. 2017;39:423–8. 10.1111/ijlh.1264828333407 KimHHurMd’OnofrioGZiniG. Real-World Application of Digital Morphology Analyzers: Practical Issues and Challenges in Clinical Laboratories. Diagnostics (Basel). 2025;15:677. 10.3390/diagnostics1506067740150020 KimHKweonOJYoonSLimYKKimB. Performance of the automated digital cell image analyzer UIMD PBIA in white blood cell classification: a comparative study with Sysmex DI-60. Clin Chem Lab Med. 2025;63:1409–18. 10.1515/cclm-2024-132339837502 Clinical and Laboratory Standards Institute (CLSI). Reference Leukocyte (WBC) Differential Count (Proportional) and Evaluation of Instrumental Methods; Approved Guideline, 2nd ed. CLSI document H20-A2. Wayne: CLSI; 2007.
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010708" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010708" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010708" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(194) "Automated Aerospray Hematology PRO staining shows good agreement for mature leukocytes but limited diagnostic reliability for immature forms: comparison with manual May-Grünwald-Giemsa staining" ["journals_article_author"]=> string(67) "Ana Nikler, Matea Tomas, Andrea Saračević, Vanja Radišić Biljak" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(92) "Aerospray Hematology PRO Slide Stainer, verification, May Grünwald Giemsa, manual technique" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2689" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "13" ["meta_title"]=> string(86) "Automated Aerospray Hematology PRO staining shows good agreement for mature leukocytes" ["meta_desc"]=> string(86) "Automated Aerospray Hematology PRO staining shows good agreement for mature leukocytes" ["meta_keyw"]=> string(92) "Aerospray Hematology PRO Slide Stainer, verification, May Grünwald Giemsa, manual technique" ["created"]=> string(19) "2026-02-05 10:27:20" ["modified"]=> string(19) "2026-02-17 09:22:48" } [39]=> object(stdClass)#88 (35) { ["journals_id"]=> string(4) "1219" ["journals_xml"]=> string(108844) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010707 10.11613/BM.2026.010707 Original articles Orthopedic trauma is associated with higher serum concentrations of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 in mild traumatic brain injury with negative head computed tomography Osmić-HusniAlma*1JadrićRadivoj2 Department for Biochemistry, Polyclinic for Laboratory Diagnostics, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina Department of Medical Biochemistry, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina Corresponding author: husnialma@gmail.com

Author contributions

Alma Osmić-Husni: Conceptualization, Methodology, Investigation, Data curation, Formal analysis, Visualization, Writing – original draft, Writing – review & editing. Radivoj Jadrić: Methodology, Formal analysis, Supervision.

15022026 15022026 36 1 010707 1208202501012026 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Serum glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) concentrations were measured in computed tomography (CT) - negative mild traumatic brain injury (mTBI)

• GFAP and UCH-L1 concentrations were higher in mTBI with orthopedic trauma

• GFAP and UCH-L1 concentrations had reduced specificity in CT-negative mTBI

• Orthopedic trauma is associated with higher GFAP and UCH-L1 in CT-negative mTBI

• Clinical interpretation of biomarkers should be integrated with patient assessment

Introduction

Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) are increasingly used biomarkers in the evaluation of mild traumatic brain injury (mTBI), primarily to reduce the frequent overuse of head computed tomography (head CT). However, their specificity may be compromised by orthopedic trauma, which commonly accompanies mTBI. The aim of this study was to assess whether orthopedic trauma is associated with higher serum concentrations of GFAP and UCH-L1 in CT-negative mTBI patients, thereby potentially reducing their specificity for detecting CT-positive mTBI.

Materials and methods

This prospective observational study included 67 CT-negative mTBI patients, of whom 29 (0.43) had orthopedic trauma and 38 (0.57) had none. Blood samples were obtained within 12 hours of injury and serum concentrations of GFAP and UCH-L1 were measured using a chemiluminescent microparticle immunoassay (CMIA) on the Alinity analyzer, following the manufacturer’s instructions. Statistical analysis included Mann-Whitney U test, chi-square test, Kruskal-Wallis test, post-hoc Dunn’s test and logistic regression analysis with P < 0.05 considered significant.

Results

Serum GFAP concentrations were significantly higher in patients with orthopedic injuries (median (IQR): 70.0 (30.8 to 226.5) pg/mL) than in those without (24.95 (5.52 to 49.15) pg/mL; P < 0.001). Similarly, UCH-L1 concentrations were higher in the orthopedic injury group (median (IQR): 2494.3 (670.1 to 5708.1) pg/mL) compared with those without trauma (262.8 (153.8-595.3) pg/mL; P < 0.001).

Conclusions

Orthopedic trauma is associated with higher serum concentrations of GFAP and UCH-L1 in CT-negative mTBI patients, which may reduce the specificity of these biomarkers for ruling out intracranial injury.

Keywords: GFAPorthopedic injuriesUCH-L1head CT
Introduction

Mild traumatic brain injury (mTBI) is the most common form of traumatic brain injury, accounting for approximately 70-90% of all TBI cases globally (1). Although most patients recover within days or weeks, a significant proportion of experience persistent cognitive, emotional, and physical symptoms lasting months or even years (2).

Clinically, mTBI is defined by a Glasgow coma scale (GCS) score of 13-15, transient neurological symptoms, and frequently, a normal head computed tomography (CT) scan (3). Despite the availability of validated clinical decision rules, CT remains widely overused in patients with mTBI, exposing many individuals to unnecessary ionizing radiation and increasing health-care costs (4). At the same time, a recent systematic review confirmed that CT is indispensable in the acute evaluation of TBI for the rapid identification of life-threatening lesions such as intracranial hemorrhage and skull fractures, which understandably makes clinicians reluctant to omit CT in the emergency setting (5).

In a large trauma cohort, both markers were rapidly detectable in serum within hours after injury and showed good diagnostic accuracy for CT-defined intracranial lesions and the need for neurosurgical intervention (6). In severe TBI, higher serum GFAP and UCH-L1 concentrations correlated with lower GCS scores, abnormal CT findings and mortality (7). In the ALERT-TBI multicenter trial, a combined GFAP/UCH-L1 test performed within 12 hours of injury showed very high sensitivity and negative predictive value for ruling out CT-detectable intracranial injuries (8). A recent single-centre study in patients with suspected mTBI reported similar performance, supporting the potential clinical role of these biomarkers in safely reducing unnecessary head CT scans (9). To support clinicians in the early evaluation of suspected mTBI, laboratory assays have been developed for routine use. The Abbott Alinity i TBI test is an in vitro diagnostic chemiluminescent microparticle immunoassay (CMIA) that provides quantitative measurement of GFAP and UCH-L1 in serum and plasma, intended for adults (≥ 18 years) within 12 hours of injury (GCS 13–15), using cut-off values of 35 pg/mL for GFAP and 400 pg/mL for UCH-L1; combined interpretation of both markers improves diagnostic accuracy and supports reduction of unnecessary CT scans (10).

Recent reviews emphasized that GFAP and UCH-L1 are among the most extensively validated biomarkers of brain injury, highlighting their potential clinical application. These reviews also pointed to important challenges, including the need for assay standardization, establishment of clinically relevant cut-off values, and further validation before routine implementation (11). A systematic review and meta-analysis from 2025 reported diagnostic performances for the individual biomarkers in identifying CT-positive mTBI, showing that GFAP reached a sensitivity of 76% and a specificity of 74%, while UCH-L1 demonstrated a higher sensitivity (86%) but a lower specificity (51%). These values apply to single biomarker performance and do not directly reflect the combined GFAP/UCH-L1 assay employed in this study (12). A recent prospective study conducted in an emergency department setting evaluated the diagnostic performance of GFAP and UCH-L1 in patients with mild traumatic brain injury (mTBI). The authors reported that GFAP achieved a sensitivity of 83.3% and a specificity of 37.9%, while UCH-L1 showed a sensitivity of 50.0% and a specificity of 65.0%. These findings indicate that, although both biomarkers demonstrate potential for rapid triage of mTBI, further validation is required before their implementation as standard adjuncts to CT (13). A large European multicenter study further demonstrated that measurement of GFAP and UCH-L1 can effectively exclude intracranial lesions in patients with mTBI, supporting their diagnostic utility in clinical decision-making (14).

Despite promising sensitivity, the specificity of these biomarkers in real world scenarios remains uncertain, particularly in patients with extracranial injuries, such as orthopedic trauma. In a prospective two-center study, 73 patients with acute orthopedic trauma without head injury were compared to 93 patients with CT-negative mTBI. GFAP concentrations on admission were significantly higher in orthopedic trauma patients than in CT-negative mTBI, while UCH-L1 concentrations did not differ between the groups. Importantly, magnetic resonance imaging (MRI) performed in 71% of the orthopedic cohort revealed no acute traumatic lesions, confirming higher serum concentrations of GFAP and UCH-L1 despite the absence of brain injury (15). In a prospective cohort of adult trauma patients, GFAP showed higher accuracy than S100β for detecting traumatic intracranial lesions on CT and remained reliable even in the presence of extracranial fractures, whereas S100B concentrations were markedly influenced by extracranial injuries (16). Another study demonstrated that early serum concentrations of GFAP breakdown products (GFAP-BDP), measured within 4 hours after injury, reliably discriminated TBI patients from trauma and healthy controls and were associated with intracranial CT lesions as well as the need for neurosurgical intervention (17). A methodological article on TBI biomarker research stressed that many published studies are limited by small samples, heterogeneous patient cohorts and suboptimal timing and handling of blood samples, and that rigorous standardization is essential for correct interpretation of GFAP and UCH-L1 results (18). However, data on CT-negative mTBI with concomitant orthopedic trauma are still limited. Therefore, the aim of our prospective observational study was to assess whether orthopedic trauma is associated with higher concentrations of GFAP and UCH-L1 in CT-negative mTBI patients and whether this may affect the specificity of these biomarkers for detecting intracranial injury.

Materials and methods Study design

This prospective observational study was conducted at the University Clinical Center (UCC) Tuzla over an eight-month period (August 2024-March 2025). Adult patients (≥ 18 years) presenting with mTBI were screened for eligibility. Mild TBI was defined as head injury with a GCS score of 13–15 on admission, in accordance with a widely accepted definition of mild traumatic injury (19, 20). The study protocol was reviewed and approved by the Ethics Committee of UCC Tuzla (Approval No. 02-09/2-114/23) and written informed consent was obtained from all participants prior to inclusion.

Subjects

Inclusion criteria were age ≥ 18 years, hospital admission within 12 hours post-injury, GCS 13–15, availability of both serum biomarker testing (GFAP and UCH-L1) and head CT imaging performed on admission. Exclusion criteria included GCS < 13, penetrating head trauma, venous blood sampling conducted more than 12 hours after injury, and patients with acute intracranial findings on head CT (CT-positive mTBI). Patients with no acute findings on head CT were further categorized into two groups based on the presence or absence of orthopedic injuries, to assess whether such injuries contribute to elevated serum concentrations of GFAP and UCH-L1 in the absence of CT-positive findings.

Patients presenting with head injury were initially assessed in the emergency surgical department. Mild TBI was diagnosed in patients with aGCS score of 13-15 on admission and at least one of the following: transient loss of consciousness (< 30 min), post-traumatic amnesia (< 24 h), or transient confusion/disorientation, consistent with a widely accepted definition of mTBI (20). The decision to perform head CT was made by the on-duty surgeon according to the standard emergency department protocol, which considered clinical risk factors such as loss of consciousness, post-traumatic amnesia, repeated vomiting, severe headache, seizure, or signs of skull fracture. Computed tomography scans were performed by radiology engineers and interpreted by board-certified radiologists within one hour of imaging. A CT-positive finding was defined as the presence of intracranial hemorrhage (subarachnoid, subdural, epidural, or intracerebral), cerebral contusions, or skull fractures. Patients without acute intracranial findings were classified as CT-negative and were eligible for our study group. Orthopedic injuries were confirmed both radiologically (X-ray or CT) and by orthopedic specialists and included long bone fractures (femur, tibia, humerus, radius/ulna), pelvic fractures, and fractures of the upper and lower extremities such as clavicle, hand, or foot bones. The mechanism of injury was recorded for all patients.

Methods

Venous blood samples were collected upon hospital admission and in all cases within 12 hours of the traumatic event. Blood was drawn into 6 mL serum tubes with clot activator (Vacusera CAT Serum, Disera A.Ş., İzmir, Turkey) and immediately transported to the Department of Biochemistry at the UCC Tuzla Polyclinic for Laboratory Diagnostics for processing. In the laboratory, samples were allowed to clot for approximately 30 minutes at room temperature (total time from venipuncture to centrifugation ≈ 30 minutes), followed by centrifugation at 3000 rpm for 7 minutes (≈ 21 000 g-minutes) in accordance with the manufacturer’s instructions for the Alinity i TBI assay (Abbott diagnostics, Abbott Park, USA), to ensure complete separation of serum and removal of cellular components (10). Prior to analysis, all serum samples were visually inspected for hemolysis, lipemia, and icterus. Samples exhibiting visible discoloration or turbidity were excluded from testing to avoid analytical interference. The hemolysis, icterus and lipemia (HIL) index detection module was not enabled on the Alinity i analyzer, therefore visual inspection served as the preanalytical quality-control step. All biomarker analyses were performed within two hours after centrifugation.

Serum concentrations of GFAP and UCH-L1 were quantified using chemiluminescent microparticle immunoassay (CMIA) technology on the Alinity i analyzer (Abbott diagnostics, Abbott Park, USA). The analyses employed GFAP Reagent Kit (04W17) and UCH-L1 Reagent Kit (04W19). Calibration was performed using the respective GFAP Calibrators (04W1701) and UCH-L1 Calibrators (04W1910) and verified by two levels of internal control materials (GFAP Controls 04W1710; UCH-L1 Controls 04W1910). Calibration and control testing followed the Abbott assay protocol (10). External quality-control material was not applied, as the assay was conducted exclusively for research purposes and is not part of the routine diagnostic workflow of the laboratory. Analytical performance characteristics were consistent with manufacturer specifications: analytical measuring interval (AMI): 6.1-42 000 pg/mL (GFAP); 26.3-25 000 pg/mL (UCH-L1); limit of detection (LoD): 3.2 pg/mL (GFAP); 18.3 pg/mL (UCH-L1) and intra-assay CV < 6%; Inter-assay CV < 8%.

Values below the LoD were reported as “< LoD” and excluded from statistical analysis. Diagnostic cut-off values were 35 pg/mL for GFAP and 400 pg/mL for UCH-L1, as recommended in the Alinity i TBI assay documentation. Samples exceeding either threshold were interpreted as positive (10).

Statistical analysis

Descriptive statistics were reported as median with interquartile range (IQR; Q1-Q3) for non-normally distributed variables, as determined using the Shapiro-Wilk test, which was applied to assess the normality of data distribution. Categorical variables were presented as ratios. Group comparisons were performed using the Mann–Whitney U test for comparisons between two independent groups, and the Kruskal-Wallis test for comparisons involving three or more groups, as both tests are appropriate for continuous non-parametric data and do not assume normality. Differences in categorical variable frequencies were assessed using the χ2 (chi-square) test while all expected cell counts were sufficient (≥ 5), which allows efficient evaluation of associations between categorical variables in larger datasets. Post-hoc comparisons between injury subtypes were conducted using Dunn’s test, following significant Kruskal-Wallis results, to identify specific group differences while controlling for multiple comparisons. Adjusted P-values from Dunn’s post-hoc tests were reported using the Bonferroni correction method to control for the family-wise error rate across multiple subgroup comparisons. In addition to P-values, effect sizes were quantified by the Hodges–Lehmann median differences between groups, with corresponding 95% confidence intervals (95% CI), providing a robust measure of the magnitude and direction of observed differences. Multivariable linear regression on log-transformed biomarker concentrations was used to adjust for confounding factors. To assess independent effects, multivariable logistic regression models were applied. All statistical tests were two-tailed, and a P-value < 0.05 was considered statistically significant. Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 23.0 (IBM Corp., Armonk, USA).

Results

A total of 102 adult patients with mTBI were initially screened. Thirty four patients were excluded due to positive head CT findings, and one patient was excluded because of hemolysis, leaving 67 head CT-negative patients who met the inclusion criteria and were included in the final analysis. Of these, 29/67 had orthopedic injuries while the remaining 38/67 had no such injuries.

Serum biomarker, age and time from injury/blood draw analysis (Table 1) revealed significantly higher concentrations of both GFAP and UCH-L1 in the orthopedic injury group compared to the non-orthopedic group. GFAP concentrations had a median of 70.0 (30.80-226.45) pg/mL versus 24.95 (15.52-49.15) pg/mL (P = 0.001), while UCH-L1 concentrations were 2494.3 (670.05-5708.10) pg/mL versus 262.5 (153.75-595.27) pg/mL (P < 0.001). Age showed a significant difference between orthopedic injury group with median (min-max) 51 (18-77) years and the non-orthopedic group with median 33 (18-64) years, P = 0.017. Time from injury/blood draw (hours) did not show a significant difference between orthopedic injury group with median 3.0 (2.0-4.0) hours, and the non-orthopedic group with median 3.0 (2.0-3.5) hours, P = 0.155.

Differences in continuous variables between head CT-negative mild traumatic brain injury patients with and without orthopedic injuries
Parameter Injuries N Median Range P adjusted β(95% CI) P(adjusted)
Age (years) Non-Ort 38 33 18 64 0.017 / /
Orthopedic 29 51 18 77
Time (h) Non-Ort 38 3.0 2.0 4.0 0.155 / /
Orthopedic 29 3.0 2.0 3.5
GFAP (pg/mL) Non-Ort 38 24.95 15.52 49.15 0.001 1.80(1.20 to 2.40) < 0.001
Orthopedic 29 70.0 30.80 226.45
UCH-L1 (pg/mL) Non-Ort 38 262.50 153.75 595.27 < 0.001 1.90(1.30 to 2.50) < 0.001
Orthopedic 29 2494.30 670.05 5708.10
Age is presented as median (min-max). CT - computed tomography. Non-Ort - non orthopedic. Time - time from injury/blood draw. GFAP - glial fibrillary acidic protein. UCH-L1 - ubiquitin C-terminal hydrolase L1. CI - confidence interval. P < 0.05 was considered statistically significant.

In age-adjusted linear regression, orthopedic injury remained independently associated with higher GFAP (β 1.80, 95% CI 1.20-2.40; P < 0.001) and UCH-L1 concentrations (β 1.90, 95% CI 1.30-2.50; P < 0.001). Additional analyses showed no significant associations of sex, injury mechanism or time from injury with biomarker concentrations, and these variables were therefore not retained as confounders.

When patients were stratified according to injury type, biomarker values again differed across subgroups (Table 2). GFAP and UCH-L1 concentrations were lower in patients without additional injuries and higher in those with fractures, particularly rib, spine or pelvic fractures, and in patients with neck injuries (P = 0.004 for GFAP and P < 0.001 for UCH-L1). Post-hoc Dunn’s tests with Bonferroni correction (Table 3) showed that patients with rib/spine/pelvic fractures had significantly higher GFAP and UCH-L1 concentrations than those without additional injuries, with median differences and 95% CI presented as effect sizes.

Differences in biomarker values among head CT-negative mild traumatic brain injury (mTBI) patients according to injury type
Biomarker Group Type of injuries N Median IQR P
Non-Ort None 18 22.20 15.52 47.77
Wounds 8 30.40 17.47 40.97
GFAP(pg/mL) Neck 12 29.25 14.55 169.62 0.004
Orthopedic Extr. fract. 5 30.40 24.0 48.25
Other fract. 24 120.45 34.02 230.67
Non-Ort None 18 262.50 159.75 439.72
Wounds 8 425.55 164.47 1700.20
UCH-L1(pg/mL) Neck 12 204.20 138.52 594.97 < 0.001
Orthopedic Extr. fract. 5 645.80 471.55 947.45
Other fract. 24 3099.40 1270.32 6047.97
CT - computed tomography. Non-Ort - non orthopedic. None - no injuries. Extr.fract. - extremity fractures. Other fract. - fractures of ribs, spine or pelvic bones. Neck - neck injuries, whiplash. Time - time from injury/blood draw. GFAP - glial fibrillary acidic protein. UCH-L1 - ubiquitin C-terminal hydrolase L1. IQR - interquartile range. P < 0.05 was considered statistically significant.
<italic>Post-hoc</italic> Dunn’s test of GFAP and UCH-L1 differences between injury subgroups in head CT-negative mild traumatic brain injury patients
GFAP UCH-L1
Group pairs MD (HL) 95% CI P (Bonf) MD (HL) 95% CI P (Bonf)
None - Wounds - 3.604 - 20.01 to 12.80 1.000 - 7.889 - 22.06 to 7.12 1.000
None - Extr. fract. - 5.917 - 24.00 to 12.17 1.000 - 15.439 - 31.67 to 0.20 0.590
None - Neck - 6.208 - 22.56 to 13.53 1.000 - 2.014 -1 5.95 to 12.43 1.000
None - Other fract. - 22.146 - 38.33 to - 8.18 0.020 - 31.222 - 44.68 to - 18.70 < 0.010
Wounds -Extr. fract. 2.313 - 15.95 to 23.89 1.000 7.550 - 9.49 to 25.70 1.000
Wounds - Neck - 2.604 - 18.71 to 14.44 1.000 5.875 - 9.21 to 22.20 1.000
Wounds - Other fract. 18.542 4.29 to 34.18 0.200 23.333 9.19 to 36.43 0.030
Extr. fract. - Neck - 0.292 - 19.92 to 19.28 1.000 13.425 - 4.24 to 30.00 1.000
Extr. fract.- Other fract. - 16.229 - 34.36 to 2.76 1.000 - 15.783 - 32.32 to 1.32 0.590
Neck - Other fract. 15.938 3.26 to 31.72 0.210 29.208 15.03 to 44.60 < 0.010
CT - computed tomography. None - no injuries. Extr.fract. - extremity fractures. Other fract. - fractures of ribs, spine or pelvic bones. Neck - neck injuries, whiplash. MD(HL) - median difference (Hodges-Lehmann). P(Bonf) - Bonferroni adjusted P-value. Note: Bonferroni adjustment for 10 comparisons. GFAP - glial fibrillary acidic protein. UCH-L1 - ubiquitin C-terminal hydrolase L1. CI - confidence interval. P < 0.05 was considered statistically significant.

In adjusted logistic regression including GFAP, UCH-L1 and age, higher UCH-L1 concentrations (OR 1.001, 95% CI 1.000-1.002; P = 0.006) and higher age (OR 1.056, 95% CI 1.011-1.104; P = 0.015) were independently associated with orthopedic injury, whereas GFAP (OR 1.006, 95% CI 0.999-1.012; P = 0.088) did not retain statistical significance (Table 4).

Association of blood biomarkers with orthopedic trauma in head CT-negative mild traumatic brain injury patients
Predictor Adjusted logistic regression
OR 95% CI P
GFAP 1.006 0.999 to 1.012 0.088
UCH-L1 1.001 1.000 to 1.002 0.006
Age 1.056 1.011 to 1.104 0.015
CT - computed tomography. OR - odds ratio. GFAP - glial fibrillary acidic protein. UCH-L1 - ubiquitin C-terminal hydrolase L1. CI - confidence interval. P < 0.05 was considered statistically significant.

Among CT-negative mTBI patients, test specificity also varied by injury type (Table 5). GFAP specificity was higher in patients without additional injuries and in those with extremity fractures (72.2% and 80.0%, respectively), and lower in patients with other fractures (29.2%), wounds or neck injuries (both 50.0%). For UCH-L1, specificity was high in patients without additional injuries (77.8%) but markedly lower in those with extremity and other fractures (0% and 8.3%, respectively).

Test specificity among head CT-negative mild traumatic brain injury patients according to injury type
Test Orthopedic Non - Orthopedic
Extremity fractures Other fractures None Wounds Neck injury
Positive 1 17 5 4 6
Negative 4 7 13 4 6
GFAP Total 5 24 18 8 12
Specificity (%) 80 29.2 72.2 50 50
95% CI 37.6-96.4 14.9-49.2 49.1-87.5 21.5-78.5 25.4-74.6
Positive 5 22 4 4 5
Negative 0 2 14 4 7
UCH-L1 Total 5 24 18 8 12
Specificity (%) 0 8.3 77.8 50 58.3
95% CI 0.0-45.9 1.5-26.1 54.8-91.0 21.5-78.5 30.7-81.4
CT - computed tomography. None - no injuries. Other fract. - fractures of ribs, spine or pelvic bones. Neck - neck injuries, whiplash. GFAP - glial fibrillary acidic protein. UCH-L1 - ubiquitin C-terminal hydrolase L1. CI - confidence interval.
Discussion

In this prospective observational single-centre study, serum concentrations of GFAP and UCH-L1 in CT-negative patients with mild traumatic brain injury (mTBI) were significantly higher in those with concomitant orthopedic injuries than in those without such trauma. These findings suggest that orthopedic trauma may contribute to additional release of these biomarkers, even in the absence of intracranial pathology visible on CT imaging.

Participants in the orthopedic group were older, and the groups also differed in sex distribution; however, additional analyses showed no meaningful influence of sex, GCS score or time from injury to sampling on biomarker concentrations. In age-adjusted models, the presence of orthopedic trauma remained associated with higher GFAP and UCH-L1 concentrations, indicating that concomitant extracranial orthopedic injury, rather than demographic or procedural factors, is the main driver of biomarker elevation in CT-negative mTBI.

Within the CT-negative cohort, biomarker concentrations also varied according to injury type. Concentrations of GFAP and UCH-L1 were lowest in patients without extracranial injuries and tended to be higher in those with fractures, particularly rib, spine or pelvic fractures, consistent with the overall differences detected by non-parametric tests. Post-hoc Dunn’s tests with Bonferroni correction identified only a limited number of significant pairwise differences, for example between patients with rib/spine/pelvic fractures and those without extracranial injuries for GFAP, and for UCH-L1 also versus some non-orthopedic subgroups such as neck injuries and soft-tissue wounds. However, many comparisons between fracture and non-orthopedic subgroups did not reach statistical significance, so these patterns should be interpreted with caution. Overall, the data suggests a trend towards higher GFAP and UCH-L1 concentrations in patients with more extensive extracranial injury, rather than a uniform and statistically robust gradient across all injury subgroups.

The strong positive correlation between GFAP and UCH-L1 indicates that these biomarkers show a largely parallel response after trauma. However, only UCH-L1 retained an independent association with orthopedic trauma in multivariable logistic regression adjusted for age, whereas GFAP did not remain significant. Taken together, these findings suggest that UCH-L1 may represent a more robust marker of concomitant orthopedic injury in CT-negative mTBI, while GFAP appears to be more susceptible to confounding and to contribute less independently to the overall extracranial injury profile.

In our CT-negative mTBI cohort, both GFAP and UCH-L1 showed only moderate specificity, with pronounced variability across extracranial injury patterns. This pattern is broadly consistent with findings from a large prospective cohort study in a mixed trauma population, a systematic review and meta-analysis in patients with mild TBI, a multicentre observational study of mild TBI, an emergency department–based diagnostic study, and a European multicentre study, all of which reported high sensitivity and negative predictive value for CT-positive lesions but only moderate specificity (6, 8, 12-14). However, these studies rarely quantified specificity separately in CT-negative patients or according to the presence and type of extracranial trauma. Our data add to this evidence by showing that, within CT-negative mTBI, specificity is highest in patients without extracranial injuries (GFAP 72.2%, UCH-L1 77.8%) or with isolated extremity fractures (GFAP 80.0%), and drops markedly in those with fractures of the ribs, spine or pelvis (GFAP 29.2%, UCH-L1 8.3%), wounds, or neck injuries. These findings provide more granular estimates of how different extracranial injury patterns modify the diagnostic performance of these biomarkers in the CT-negative population that is most relevant for clinical decision-making.

Only a limited number of previous reports have directly examined how extracranial trauma influences glial biomarker concentrations. In a general trauma cohort with a high proportion of patients who sustained extracranial fractures involving the torso and extremities, these fractures substantially reduced the specificity of S100B, whereas GFAP maintained relatively good accuracy for detecting intracranial lesions on CT and was less affected by fractures (16). In our CT-negative mTBI cohort, GFAP specificity was likewise highest in patients without extracranial injuries and in those with isolated limb fractures, but decreased in patients with rib, spine or pelvic fractures, wounds and neck injuries, while UCH-L1 specificity dropped even more markedly across these orthopedic subgroups, particularly in those with rib, spine or pelvic fractures.

There is one prospective two-centre study that directly compared CT-negative mTBI patients with orthopedic trauma controls without head injury (15). In that study, serum GFAP and UCH-L1 were measured repeatedly from admission up to several months after injury and related to neuroimaging findings in 73 patients with acute orthopedic trauma and 93 patients with CT-negative mTBI. At admission, GFAP concentrations were higher in orthopedic trauma than in CT-negative mTBI, whereas UCH-L1 concentrations did not differ at any time point, and neither biomarker was able to distinguish CT-negative mTBI from orthopedic trauma; patients with orthopedic injuries and elevated GFAP or UCH-L1 were therefore considered at risk of being misclassified as having concomitant mTBI and of undergoing unnecessary brain imaging, and the authors questioned the diagnostic value of these markers for mild CT-negative TBI (15). A methodological commentary later pointed out that heterogeneous inclusion criteria, incomplete early sampling and possible misclassification of mild TBI cases within the orthopedic group may have contributed to these findings (18). By comparison, our study is restricted exclusively to CT-negative mTBI, using a single early blood sample obtained within 12 h of injury on one commercial platform, and stratifies patients according to the presence and pattern of orthopedic injuries rather than including trauma controls without head injury. We also found higher GFAP and UCH-L1 concentrations in patients with orthopedic injuries, and in age-adjusted models both biomarkers remained independently associated with orthopedic injury. These findings support the view that extracranial trauma is an important source of biomarker positivity in CT-negative mTBI and may explain part of the biomarker-positive/CT-negative cases reported in large diagnostic trials (6, 8, 12–15, 20).

Histological studies have demonstrated that GFAP is not confined to astrocytes but is also expressed in Schwann cells, satellite cells and enteric glia, as well as in fibroblasts, chondrocytes, bone marrow stromal cells, periosteum and cardiac valves, providing multiple potential extracranial sources after orthopedic trauma (21, 22). Our findings are consistent with these concerns, as we show that the presence and localization of orthopedic injuries substantially reduce the specificity of both GFAP and UCH-L1 in CT-negative mTBI, whereas specificity is highest in patients without extracranial injuries. Taken together with large-scale diagnostic and methodological work, our results support the use of GFAP/UCH-L1 primarily as high-sensitivity rule out tools and indicate that positive biomarker results should be interpreted with particular caution when major extracranial trauma is present (6, 8, 12–15, 20).

This study has several limitations that should be considered when interpreting specificity results. Biomarker concentrations were measured once during the acute phase, preventing assessment of temporal dynamics or delayed release patterns.
Lack of MRI correlation was another limitation, as MRI was not routinely performed, which limited verification of microstructural brain lesions in CT negative cases and may have led to misclassification of some biomarker positive patients. Small subgroup sizes also posed a limitation, as certain extracranial injury categories such as wounds and neck injuries included a limited number of participants, resulting in wider confidence intervals. Minor timing and analytical variations were also possible. Although all samples were collected within 12 hours post-injury, small differences in timing and assay sensitivity may have affected absolute concentration. Potential confounding factors such as age, medications, and comorbidities could have influenced biomarker concentrations independently of trauma. The absence of a control group and follow up outcomes further limits interpretation. Without healthy controls or long-term data, prognostic interpretation remains limited. A recent review summarized several unresolved issues concerning the clinical use of blood biomarkers in mild traumatic brain injury, including uncertainties related to biomarker kinetics, specificity, and extracerebral sources (23). The present study directly addresses some of these questions by demonstrating that extracranial injuries substantially affect serum GFAP and UCH-L1 concentrations, limiting their diagnostic specificity in CT-negative mTBI.

In conclusion, our study demonstrated that patients with CT-negative mTBI and concomitant orthopedic trauma exhibited significantly higher serum concentrations of GFAP and UCH-L1 compared to those with isolated mTBI. These findings indicate that these biomarkers lack sufficient specificity for identifying CNS injury in the presence of extracranial trauma and should therefore be interpreted within the broader clinical context.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request

References CarrollLJCassidyJDHolmLKrausJCoronadoVG. Methodological issues and research recommendations for mild traumatic brain injury: the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med. 2004; 43(Suppl):113–25. 10.1080/1650196041002387715083875 McMahonPHricikAYueJKPuccioAMInoueTLingsmaHF Symptomatology and functional outcome in mild traumatic brain injury: results from the prospective TRACK-TBI study. J Neurotrauma. 2014;31:26–33. 10.1089/neu.2013.298423952719 JagodaASBazarianJJBrunsJJJrCantrillSVGeanADHowardPK Clinical policy: neuroimaging and decisionmaking in adult mild traumatic brain injury in the acute setting. Ann Emerg Med. 2002;40:231–49. 10.1067/mem.2002.12578212140504 MelnickERSzlezakCMBentleySKDziuraJDKotlyarSPostLA. CT overuse for mild traumatic brain injury. Jt Comm J Qual Patient Saf. 2012;38:483–9. 10.1016/S1553-7250(12)38064-123173394 DabasMMAlameriADMohamedNMMahmoodRKimDHSamreenM Comparative efficacy of MRI and CT in traumatic brain injury: a systematic review. Cureus. 2024;16:e72086. 10.7759/cureus.7208639574979 PapaLBrophyGMWelchRDLewisLMBragaCFTanCN Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol. 2016;73:551–60. 10.1001/jamaneurol.2016.003927018834 MondelloSPapaLBukiABullockMRCzeiterETortellaFC Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case-control study. Crit Care. 2011;15:R156. 10.1186/cc1028621702960 BazarianJJBiberthalerPWelchRDLewisLMBarzoPBogner-FlatzV Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol. 2018;17:782–9. 10.1016/S1474-4422(18)30231-X30054151 LegramanteJMMinieriMBelliMGiovannelliAAgnoliABajoD Evaluation of GFAP/UCH-L1 biomarkers for computed tomography exclusion in mild traumatic brain injury (mTBI). Int J Emerg Med. 2024;17:164. 10.1186/s12245-024-00708-z39448905 Abbott Laboratories. Alinity i GFAP and UCH-L1 assay package insert. Available at: https://www.corelaboratory.abbott. Accessed July 23rd 2025. KrauszADKorleyFKBurnsMA. The current state of traumatic brain injury biomarker measurement methods. Biosensors (Basel). 2021;11:319. 10.3390/bios1109031934562909 KaramianAFarzanehHKhoshnoodiMMalekiNRohatgiSFordJN Accuracy of GFAP and UCH-L1 in predicting brain abnormalities on CT scans after mild traumatic brain injury: a systematic review and meta-analysis. Eur J Trauma Emerg Surg. 2025;51:68. 10.1007/s00068-024-02697-339856327 JalaliRBałuchMMalinowskaJZwiernikJKernABilJ GFAP/UCH-L1 as a biomarker for rapid assessment of mild TBI in emergency departments. Med Sci Monit. 2025;31:e948353. 10.12659/MSM.94835340498681 Milevoj KopčinovićLNikolac GabajNLapićIRogićDOpreaORDobreanuM Exclusion of intracranial lesions in mild traumatic brain injury using glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1: a European multicenter study. Eur J Emerg Med. 2025;32:351–8. 10.1097/MEJ.000000000000123440214300 PostiJPHossainITakalaRSKLiedesHNewcombeVOuttrimJ Glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 are not specific biomarkers for mild CT-negative traumatic brain injury. J Neurotrauma. 2017;34:1427–38. 10.1089/neu.2016.444227841729 PapaLSilvestriSBrophyGMGiordanoPFalkJLBragaCF GFAP out-performs S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. J Neurotrauma. 2014;31:1815–22. 10.1089/neu.2013.324524903744 PapaLLewisLMFalkJLZhangZSilvestriSGiordanoP Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med. 2012;59:471–83. 10.1016/j.annemergmed.2011.08.02122071014 PapaLWangKKW. Raising the bar for traumatic brain injury biomarker research: methods make a difference. J Neurotrauma. 2017;34:2187–9. 10.1089/neu.2017.503028322619 TeasdaleGJennettB. Assessment of coma and impaired consciousness: a practical scale. Lancet. 1974;2:81–4. 10.1016/S0140-6736(74)91639-04136544 KayTHarringtonDEAdamsRAndersonTBerrolSCiceroneK Definition of mild traumatic brain injury. J Head Trauma Rehabil. 1993;8:86–7. 10.1097/00001199-199309000-00010 JessenKRThorpeRMirskyR. Molecular identity, distribution and heterogeneity of glial fibrillary acidic protein: an immunoblotting and immunohistochemical study of Schwann cells, satellite cells, enteric glia and astrocytes. J Neurocytol. 1984;13:187–200. 10.1007/BF011481146726286 HainfellnerJAVoigtländerTStröbelTMazalPRMaddalenaASAguzziA Fibroblasts can express glial fibrillary acidic protein (GFAP) in vivo. J Neuropathol Exp Neurol. 2001;60:449–61. 10.1093/jnen/60.5.44911379820 HierDBObafemi-AjayiTThimganMSOlbrichtGRAziziSAllenB Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues. Biomark Res. 2021;9:70. 10.1186/s40364-021-00325-534530937
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010707" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010707" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010707" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(207) "Orthopedic trauma is associated with higher serum concentrations of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 in mild traumatic brain injury with negative head computed tomography" ["journals_article_author"]=> string(34) "Alma Osmić-Husni, Radivoj Jadrić" ["journals_article_author_country"]=> string(0) "" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(42) "GFAP, orthopedic injuries, UCH-L1, head CT" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1684" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "12" ["meta_title"]=> string(137) "Orthopedic trauma is associated with higher serum concentrations of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1" ["meta_desc"]=> string(137) "Orthopedic trauma is associated with higher serum concentrations of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1" ["meta_keyw"]=> string(42) "GFAP, orthopedic injuries, UCH-L1, head CT" ["created"]=> string(19) "2026-02-05 10:34:44" ["modified"]=> string(19) "2026-02-17 09:22:36" } [40]=> object(stdClass)#89 (35) { ["journals_id"]=> string(4) "1220" ["journals_xml"]=> string(88155) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010706 10.11613/BM.2026.010706 Original articles Indirect estimation of serum enzymes reference intervals in adults using the reflimR and refineR algorithms YıldızRaziye*ArslanFatma DemetKöseoğluMehmet Department of Medical Biochemistry, Faculty of Medicine, Bakırcay University, Izmir, Turkey Corresponding author: drraziyeyildiz@gmail.com

Author contributions

R Yıldız: Conceptualization, Data duration, Formal analysis, Investigation, Project administration, Resources, Visualisation, Writing – original draft; FD Arslan: Conceptualization, Data duration, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Writing – review & editing; M Köseoglu: Conceptualization, Project administration, Supervision, Writing – review & editing.

15022026 15022026 36 1 010706 2907202502122025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Reference intervals were estimated using an indirect method

• Eight serum enzymes were analyzed: ALP, ALT, AST, CK, GGT, LDH, amylase, lipase

• ReflimR and refineR showed high agreement (88.5%)

• Sex-specific reference intervals were needed for ALP, ALT, AST, CK, GGT

• ReflimR provides a practical tool for reference interval verification

Introduction

Many clinical laboratories rely on manufacturer-provided reference intervals (RIs) because of logistical and financial constraints of direct RI estimation. Indirect estimation methods offer a practical alternative for deriving RIs from laboratory data. This study aimed to estimate RIs for eight serum enzymes using the R-based algorithm reflimR, and to compare them with refineR, manufacturer’s instructions for use (IFU), and direct methods.

Materials and methods

Data from adult outpatients tested between January 2021 and May 2022 were retrospectively analyzed for alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), creatine kinase (CK), gamma-glutamyl transferase (GGT), lactate dehydrogenase and lipase. Reference intervals were estimated using reflimR and refineR, and compared with IFU and direct RIs. Overlap between lower and upper limits was evaluated using a color-coded scheme. Data distribution was tested with Shapiro–Wilk; and Mann–Whitney U and Spearman’s correlation tests were used for group comparisons and correlations.

Results

Sex-specific RIs were required for ALP, ALT, AST, CK and GGT. ReflimR generally produced wider intervals than refineR. Agreement of reflimR with refineR, parametric, and IFU-based RIs was 88.5%, 72.7%, and 62.5%, respectively. The lowest agreement was observed with the non-parametric method (55.0%).

Conclusions

ReflimR provides a practical approach for indirect RIs estimation from routine data. Its performance was comparable to refineR and parametric methods, supporting its use for verifying or updating local RIs, especially where population-specific RIs are unavailable. To our knowledge, this is the first study to apply reflimR to the Turkish population and directly compare its performance with refineR and IFUs.

Keywords: reference rangesbig dataclinical enzyme testslaboratory information systems
Introduction

Reference intervals (RIs), typically defined as the central 95% of laboratory test results obtained from a healthy population, are essential tools for the clinical interpretation of laboratory data (1). However, RIs can vary considerably depending on factors such as sex, age, ethnicity, geographic region, and lifestyle. Therefore, international guidelines recommend the use of population-specific RIs to ensure accurate clinical decision-making (1, 2).

Traditionally, RIs have been established using the direct method, which involves recruiting healthy volunteers and performing controlled measurements to define the reference distribution. Although this method is considered the gold standard, it is often limited by substantial logistical, financial, and time-related constraints, making it impractical for many laboratories (3, 4).

To address these limitations, indirect statistical methods have been developed to estimate RIs from existing patient data within laboratory information systems. These methods aim to isolate results that reflect non-pathological distributions, thereby enabling RI estimation without the need for dedicated sampling (3, 5). Notably, such methods benefit from large sample sizes and reflect the diversity observed in routine clinical data, which may better capture physiological variability (6, 7). International recommendations, including the Clinical and Laboratory Standards Institute guideline (EP28-A3c) and the International Federation of Clinical Chemistry and Laboratory Medicine Committee on Reference Intervals and Decision Limits (C-RIDL), also endorse indirect approaches as a practical alternative for establishing RIs (1, 3).

Among the available indirect estimation methods, refineR and reflimR are freely accessible R-based algorithms specifically designed for RI estimation. The refineR algorithm applies an inverse modelling approach, scanning data segments, identifying potential cut-off points, and applying Box-Cox transformation with parameter fitting to estimate the non-pathological distribution (8). In contrast, reflimR, assumes either a normal or log-normal distribution and employs a trimming strategy based on boxplot thresholds, from which reference limits are derived using a truncated quantile-quantile plot (6, 9).

Most laboratory test results, including enzyme activity assays, do not follow a normal distribution. Enzymes frequently exhibit right-skewed distributions due to their asymmetric physiological behavior, making them particularly suitable for modeling with indirect methods that accommodate non-Gaussian data structures (1, 7).

This study aimed to estimate adult RIs for eight commonly measured serum enzymes using the newly developed reflimR algorithm, and to compare its performance with refineR, manufacturer’s instructions for use (IFU), and previously published direct RI studies in the Turkish population. We hypothesized that reflimR would yield RIs comparable to those obtained by refineR and direct methods, while providing more population-representative values than IFUs.

Materials and methods

This retrospective study included routine laboratory test results analyzed from blood samples collected between 8 am and 10 am from adult outpatients (aged 18-65 years) at a University Hospital in Western Turkey between January 2021 and May 2022. The study protocol was approved by the Ethics Committee of Bakırçay University Faculty of Medicine (Approval No: 2151, dated March 19, 2025).

Serum enzyme measurements included alkaline phosphatase (ALP, U/L), alanine aminotransferase (ALT, U/L), amylase (U/L), aspartate aminotransferase (AST, U/L), creatine kinase (CK, U/L), gamma-glutamyl transferase (GGT, U/L), lactate dehydrogenase (LD, U/L), and lipase (U/L). All tests were performed on the Cobas 8000 c702 analyzer (Roche Diagnostics, Mannheim, Germany) using enzymatic colorimetric methods according to manufacturer protocols. The analytical limit of detection values provided by the manufacturer were as follows: ALT, AST, and ALP were 5 U/L; GGT, amylase, and lipase were 3 U/L; CK was 7 U/L; and LD was 10 U/L. Internal and external quality control (QC) procedures were implemented throughout the study period. Internal QC was performed daily using two levels of commercial control materials (PreciControl ClinChem Multi 1 and 2, Roche Diagnostics, Mannheim, Germany), and results were monitored according to Westgard rules. During the study period, the coefficients of variation were < 5% for all enzymes. External QC was ensured through participation in the Randox International Quality Assessment Scheme (RIQAS) program, with monthly proficiency testing, all of which were within acceptable limits.

Only the first test result per patient was included. Records with missing data or values outside the analytical limit of detection were excluded. Outliers were removed based on Tukey’s rule. Data distribution was assessed using the Shapiro–Wilk test and visual inspection of histograms. Because all enzyme activity values were not normally distributed, sex-based differences were assessed using the Mann–Whitney U test, and correlations between age and enzyme values were evaluated using Spearman’s rank correlation.

Reference intervals were estimated using two indirect methods: refineR (v1.6.2) and reflimR (v1.0.6), both implemented in R software version 4.3.3 (R Foundation for Statistical Computing, Vienna, Austria; https://www.r-project.org/). Following previous evaluations of indirect methods, a minimum sample size of > 200 was considered adequate for reflimR and > 1000 for refineR to ensure robust estimation (6). Estimates were compared with RIs provided in IFUs, based on Roche Diagnostics reagents. These values were also compared against parametric and non-parametric RIs reported in direct studies of the Turkish population (10).

The agreement between RI estimation methods for the lower limit (LL) and upper limit (UL) of each enzyme was assessed with the tolerance range approach using permissible uncertainty function from the reflimR package. The 95% confidence intervals (CIs) for LL and UL were estimated with precomputed Monte Carlo–based closed formulas the using conf_int95 function from the reflimR package (9). A traffic light visualization was used to illustrate agreement: green means the target value is within the reflimR tolerance range, yellow means the target value is outside but the tolerance ranges overlap, and red means the tolerance ranges are completely separate (6).

Results

Significant sex-related differences were observed for ALP, ALT, AST, CK, and GGT, whereas LD, amylase, and lipase showed no relevant differences; therefore, sex-specific RIs were estimated only for these analytes. Spearman’s correlation analyses revealed no relevant correlation between age and enzyme values. Although statistically significant due to the large sample size, all observed coefficients were negligible (r < 0.25, P < 0.001 for all).

Tables 1 and 2 summarize the RIs obtained from IFUs, direct methods (parametric and non-parametric), and indirect methods (reflimR and refineR). It also includes sample sizes and information regarding sex-specific partitioning. Figure 1 shows a graphical comparison between the RIs estimated by reflimR and those provided in the IFUs.

Reference intervals for enzymes with sex-specific partitioning
Reference range derived by reflimR Reference range derived by refineR Reference range given in IFU Parametric Non-parametric
Para-meters(U/L) Sex N LL(95% CI) UL(95% CI) LL(95% CI) UL(95% CI) LL UL LL(90% CI) UL(90% CI) LL(90% CI) UL(90% CI)
ALP M 3685 46.4(45.3-48.0) 126.3(122.1-129.4) 44.4†(39.1-47.8) 115†(90.7-131) 40† 129* 43†(40-46) 116†(113-120) 42†(41-44) 120*(116-123)
F 6615 37.0(36.1-38.2) 133.9(129.8-137.0) 37.2*(36.3-40.1) 132*(118-135) 35* 104‡ 35†(34-38) 105‡(102-111) 36*(34-37) 110‡(106-115)
ALT M 11799 7.8(7.61-8.06) 47.3(45.79-48.47) 7.85*(7.17-7.98) 46.3*(32.3-47.4) 5‡ 41† 9†(8.2-9.2) 57‡(53.3-61.9) 8*(8.0-9.0) 58‡(55.0-61.0)
F 22293 6.1(6.00-6.23) 31.4(30.7-31.91) 6.09*(4.81-6.18) 28.2†(20.6-30.7) 5† 33* 7†(6.8-7.2) 28†(26.0-29.2) 7†(6.0-7.0) 33*(29.0-35.1)
AST M 1247 10.8(10.4-11.5) 27.6(26.0-28.7) 9.25†(8.66-10.7) 25.1†(23.9-28.5) 5‡ 40‡ 13‡(12.6-13.3) 30†(29.7-31.7) 13‡(12.0-13.0) 36‡(34.0-38.0)
F 2591 9.4(9.15-9.77) 23.9(23.01- 24.55) 8.66†(8.34-9.45) 22.8†(20.9-25.8) 5‡ 32‡ 11‡(10.5-11.1) 25*(24.3-26.5) 11‡(10.0-11.0) 28‡(26.1-29.2)
CK M 902 40.6(37.4-46.2) 224.7(197.4-244.1) 39.3*(23.2-58.1) 209*(132-232) 39* 308‡ 48†(45-54) 227*(221-248) 47†(43-49) 252†(239-266)
F 1849 32.5(30.9-35.0) 146.9(136.3-154.6) 31.5*(28-34) 121†(106-143) 26† 192‡ 34*(30-36) 131†(116-139) 32*(27-34) 135†(126-151)
GGT M 3110 8.8(8.40-9.40) 52.2(48.88-54.70) 9.14*(7.87-9.33) 43.7‡(37.3-47.4) 8* 61† 11†(10.1-11.9) 70‡(68-77) 11†(10.0-11.0) 78‡(69-82)
F 5062 5.5(5.30-5.78) 31.9(30.4-33.08) 5.96*(5.4-6.1) 24.3‡(19.5-30.0) 5* 36† 7‡(7.0-7.7) 33*(31-37) 7‡(7.0-8.0) 39‡(36-44)
IFU - manufacturer’s instructions for use. Parametric and non-parametric - reference intervals from direct method studies in the literature. *The target limit is within the tolerance range of the limit estimated by reflimR. †The target limit is outside the tolerance range of the estimated limit, but the tolerance ranges of the target and estimated limits overlap. ‡The tolerance ranges of the target and estimated limits do not overlap. LL - lower reference limit. UL - upper reference limit. M - male. F - female. ALP - alkaline phosphatase. ALT - alanine aminotransferase. AST - aspartate aminotransferase. CK - creatine kinase. GGT - gamma-glutamyl transferase.
Reference intervals for enzymes with unified partitioning
Reference range derived by reflimR Reference range derived by refineR Reference range given in IFU Parametric Non-parametric
Parameters(U/L) N LL(95% CI) UL(95% CI) LL(95% CI) UL(95% CI) LL UL LL(90% CI) UL(90% CI) LL(90% CI) UL(90% CI)
Amylase 2121 29.8(28.5-31.9) 127.9(119.7-134.0) 29.2*(19.6-31.2) 114†(84.8-128) 28* 100‡ NA NA NA NA
LD 5540 118(116-120) 233(229-236) 118*(116-120) 222†(209-232) NA NA 126† (NA) 220† (NA) NA NA
Lipase 973 15.4(14.4-17.2) 68.3(61.3-73.2) 14.9*(12.1-19.9) 55.4‡(41.2-68) 13† 60† NA NA NA NA
IFU - manufacturer’s instructions for use. Parametric and non-parametric - reference intervals from direct method studies in the literature. *The target limit is within the tolerance range of the limit estimated by reflimR. †The target limit is outside the tolerance range of the estimated limit, but the tolerance ranges of the target and estimated limits overlap. ‡The tolerance ranges of the target and estimated limits do not overlap. LL - lower reference limit. UL - upper reference limit. LD - lactate dehydrogenase. NA - not available.

Comparison of reference intervals (Ris, IU/L) estimated by reflimR with manufacturer's instructions for use (IFU). The black and red dashed density curves represent the distributions of the assumed reference population and potential pathological outliers, respectively. The solid blue line indicates the fitted curve to the assumed distribution, and the background histogram represents the frequency distribution of routine data. Vertical dashed lines show the lower limit (LL) and upper limit (UL) estimated by reflimR, while vertical solid lines show IFU values. The shaded areas around the vertical lines represent tolerance ranges based on permissible uncertainty. Agreement is illustrated using a traffic-light color code: green indicates that the target limit is within the tolerance range of the limit estimated by reflimR; yellow indicates that the target limit is outside the tolerance range of the estimated limit, but the tolerance ranges of the target and estimated limits overlap; and red indicates that the tolerance ranges of the target and estimated limits do not overlap. ALP - alkaline phosphatase. ALT - alanine aminotransferase. AST - aspartate aminotransferase. CK - creatine kinase. GGT - gamma-glutamyl transferase.

Overlap between the RIs estimated by reflimR and refineR was observed for both sexes, except for the ULs of GGT and lipase. The agreement between refineR and reflimR, defined as the proportion of comparisons classified as green or yellow in the color-coded system, was 88.5% (23 out of 26) across all analytes. As shown in Tables 1 and 2, reflimR tended to yield higher ULs than refineR, which resulted in broader RIs in most analytes. The agreement between IFU-provided RIs and those estimated by reflimR was 62.5% (15 out of 24). Agreement with direct methods was 72.7% (16 out of 22) for the parametric method and 55.0% (11 out of 20) for the non-parametric method.

For ALP, although reflimR and refineR estimates showed close agreement in both sexes, reflimR produced slightly wider intervals. While the UL derived from reflimR was comparable across other methods in males, it substantially exceeded the ULs provided by IFU and direct methods in females.

For ALT and AST, reflimR produced similar RIs to those of refineR in both sexes. While reflimR in males yielded a higher but acceptable UL of ALT than IFU, the UL estimated by reflimR was significantly lower than those reported by direct methods. Instructions for use was notable for having the widest RI and highest UL for AST. While reflimR yielded a significantly lower UL for AST than that of non-parametric methods in both sexes, it was comparable to the values obtained using parametric methods.

For CK, reflimR and refineR produced similar RIs in both sexes. The IFU provided higher ULs compared to both indirect and direct methods. Notably, all methods revealed marked sex-related differences with higher ULs in males.

For GGT, indirect methods yielded lower ULs compared to IFU and direct methods. The UL estimated by reflimR was substantially higher than that of refineR in both sexes. Direct methods, especially non-parametric ones, yielded higher ULs, up to 78 U/L in males.

For amylase and lipase, reflimR estimated wider RIs than IFU. The UL tolerance limits for amylase did not overlap with those of IFU, whereas the ULs for lipase did. Since sex-based RIs for these tests were not estimated by reflimR, no comparison with direct methods was performed.

For LD, reflimR produced RIs similar to those obtained with refineR and parametric methods. Since the IFU presents sex-based RIs, they were not included in the comparison.

Discussion

In this study, we compared adult RIs estimated by indirect methods (reflimR and refineR), direct methods (parametric and non-parametric), and IFU values for eight commonly used serum enzymes activities. ReflimR demonstrated strong agreement with refineR (88.5%) and substantial agreement with parametric methods (72.7%). The lowest agreement was found for IFU values (62.5%) and non-parametric estimates (55.0%). These findings highlight the practical utility of indirect approaches, particularly reflimR, to verify and update local RIs using patient data.

The limited agreement with IFU values likely reflects that such intervals are often derived from restricted or non-representative populations, or even from literature values, and may therefore not capture local demographic and environmental characteristics, as also reported in C-RIDL studies (11, 12). In contrast, non-parametric estimates are highly sensitive to sample size and outliers; if the dataset is not sufficiently large and well-characterized, the resulting intervals may not represent the true population distribution (11). These methodological limitations can reduce concordance with indirect approaches. Consistent with our findings, recent multicenter and big data studies have shown that indirect and parametric methods yield more robust and comparable reference intervals, whereas IFU and non-parametric methods are more prone to variability (12, 13).

Overall, reflimR produced comparable or slightly wider RIs than refineR, depending on the analyte and sex. In our analysis, the broader intervals produced by reflimR compared to refineR may be attributed to its simpler assumption of normal or log-normal distributions, rather than the more complex statistical modeling of the pathological distribution used by refineR.

Agreement between reflimR and direct methods varied by analyte, with closer overlap for ALP (males), ALT (females), and CK (both sexes), and weaker concordance for AST and GGT. Such discrepancies may reflect methodological differences as well as population-specific factors. We did not compare the RIs of amylase and lipase with direct methods because we used sex-independent intervals for these analytes.

ReflimR estimated a higher UL for ALT in males and lower ULs for AST in both sexes compared to IFU. Similarly, Özarda et al. reported higher ALT values in males and lower AST ULs in both sexes compared to the Abbott Diagnostics IFU values (10). They also observed narrower RIs for ALT and AST in females than in males. Similar to our findings, Köseoğlu et al. reported markedly narrower RIs for AST compared to the Abbott Diagnostics IFU values (14). These findings suggest sex-specific variability in ALT and AST activities, as well as discrepancies between IFU values and population-based estimates (10, 14, 15).

For ALP, reflimR produced the widest interval across all methods, with female ULs markedly higher than both IFU and previous reports (10). These findings suggest that reflimR may better reflect physiological diversity, particularly in females, compared to IFU.

Creatine kinase exhibited the most pronounced sex-related differences, consistent with physiological determinants such as muscle mass, hormonal influences, and physical activity (16, 17). These findings reinforce the need for sex-specific RIs, while the high UL provided by the IFU may represent an overestimation relative to population-based values.

The lack of overlap between indirect and direct estimates suggests that GGT is sensitive to population-specific factors such as alcohol use and metabolic status. These results underscore the value of indirect methods in generating more conservative and population-representative intervals.

The higher ULs of amylase and lipase estimated by reflimR may more accurately reflect physiological variation. Similar findings have been reported in studies using the OPUS::L and modified Bhattacharya methods, which are both indirect methods that estimate RIs from large routine laboratory datasets. OPUS::L applies statistical models such as truncated maximum likelihood to extract non-pathological values, while the Bhattacharya method identifies the main (presumed healthy) population by fitting frequency distributions (4, 17). Both methods yielded higher ULs which raise concerns about misclassification or overdiagnosis when narrow IFUs are used.

Minimal sex-related variation across methods justifies the use of a unified RI for LD. Consistent with Ozarda et al. and Omuse et al., sex-related differences in LD activities were minimal, supporting the use of unified RIs for this analyte (10, 16).

Sex appears to be a critical determinant in enzyme distribution. Significant sex-based differences were observed for ALT, AST, ALP, GGT, and CK, reinforcing the need for sex-partitioned RIs in clinical interpretation. In contrast, LD, amylase, and lipase showed minor sex-related variability, making unified RIs feasible. These findings are consistent with previous reports (10, 14, 16).

Sun et al. identified a need for age partitioning only for GGT in males, while no such requirement was found for ALP or AST (18). Some studies reported significant age-related differences, particularly ALT and ALP in females (11, 15, 16). Taken together, these observations reinforce the notion that age-related variation in enzyme activity is generally modest and tends to manifest selectively in subgroups of certain analytes. This may justify our decision not to apply age-based partitioning in this study.

The indirect methods must be highly sensitive in distinguishing non-pathological distributions in laboratory databases with a high proportion of pathological values (8, 19). It has been reported that optimal performance is achieved when the pathological fraction is below 30%, with a dataset of more than 200 for reflimR and more than 1000 for refineR (7, 20, 21). In our study, all analytes, except CK in males (N = 902) and lipase (N = 973), met the recommended sample size. The pathological fraction was below 21% for all enzymes, supporting the robustness of the derived RIs.

To the best of our knowledge, this is the first study to establish enzyme RIs in the Turkish adult population using both refineR and the newly introduced R-based algorithm, reflimR. Nonetheless, several limitations should be acknowledged. The study population was limited to adults, excluding both pediatric and geriatric groups. Age-specific RIs were not established, since the correlation between age and enzyme activity was minimal. Slight increases in enzyme activities with advancing age may be confounded by factors such as medication use or increased body mass (22). Consequently, distinguishing between age-related pathological elevations and normal physiological changes remains a challenge in the interpretation of laboratory results. Finally, as the data were generated on a single analytical platform, the generalizability of these RIs to other platforms may be limited.

The observed discrepancies between IFU-based values and population-derived estimates emphasize the importance of establishing RIs tailored to the target population. Leveraging large-scale laboratory data to estimate population-specific RIs improves the interpretation of test results and may help reduce unnecessary clinical interventions. ReflimR may offer a practical solution for clinical laboratories with limited resources to conduct direct RI studies. In practice, laboratory specialists can verify or update their local RIs with reflimR by using routinely laboratory data, provided adequate sample size and data quality are ensured.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved Guideline - third Edition. CLSI document EP28-A3c. Wayne:CLSI;2010. International Organization for Standardization. ISO 15189:2022. Medical laboratories – Requirements for quality and competence. Geneva: ISO; 2022. JonesGRHaeckelRLohTPSikarisKStreichertTKatayevA Indirect methods for reference interval determination – review and recommendations. Clin Chem Lab Med. 2018;57:20–9. 10.1515/cclm-2018-007329672266 AmodeoBSchindlerASchachtUWahlH. Calculation of indirect reference intervals of plasma lipase activity of adults from existing laboratory data based on the Reference Limit Estimator integrated in the OPUS:L information system. J Lab Med. 2021;45:131–4. 10.1515/labmed-2021-0008 OzardaY. Establishing and using reference intervals. Turk J Biochem. 2020;45:1–10. 10.1515/tjb-2017-0299 MeyerAMüllerRHoffmannMSkadbergØLadangADieplingerB Comparison of three indirect methods for verification and validation of reference intervals at eight medical laboratories: a European multicenter study. J Lab Med. 2023;47:155–63. 10.1515/labmed-2023-0042 AmmerTSchützenmeisterAProkoschHUZierkJRankCMRauhM. RIbench: a proposed benchmark for the standardized evaluation of indirect methods for reference interval estimation. Clin Chem. 2022;68:1410–24. 10.1093/clinchem/hvac14236264679 AmmerTSchützenmeisterAProkoschHURauhMRankCMZierkJ. refineR: a novel algorithm for reference interval estimation from real-world data. Sci Rep. 2021;11:16023. 10.1038/s41598-021-95301-234362961 HoffmannGKlawitterSTrulsonIAdlerJHoldenriederSKlawonnF. A novel tool for the rapid and transparent verification of reference intervals in clinical laboratories. J Clin Med. 2024;13:4397. 10.3390/jcm1315439739124664 OzardaYIchiharaKAslanDAybekHAriZTaneliF A multicenter nationwide reference intervals study for common biochemical analytes in Turkey using Abbott analyzers. Clin Chem Lab Med. 2014;52:1823–33. 10.1515/cclm-2014-022825153598 ShahSAVIchiharaKDheraiAJAshavaidTF. Reference intervals for 33 biochemical analytes in healthy Indian population: C-RIDL IFCC initiative. Clin Chem Lab Med. 2018;56:2093–103. 10.1515/cclm-2018-015230074895 IchiharaKOzardaYBarthJHKleeGQiuLErasmusR A global multicenter study on reference values: 1. Assessment of methods for derivation and comparison of reference intervals. Clin Chim Acta. 2017;467:70–82. 10.1016/j.cca.2016.09.01627666761 ChenDZhouYFanLYangZYangD. Establishment of gender- and age-related reference intervals for serum uric acid in adults based on big data from Zhejiang Province in China. Clin Chem Lab Med. 2025;63:1199–207. 10.1515/cclm-2024-128839898807 DursunSCuhadarS. Determination of reference intervals of healthy adults aged between 20–50 years in Izmir. Turk J Biochem. 2010;35:215–24. MuRChenWPanBWangLHaoXHuangX First definition of reference intervals of liver function tests in China: a large-population-based multi-center study about healthy adults. PLoS One. 2013;8:e72916. 10.1371/journal.pone.007291624058449 OmuseGIchiharaKMainaDHoffmanMKagothoEKanyuaA Determination of reference intervals for common chemistry and immunoassay tests for Kenyan adults based on an internationally harmonized protocol and up-to-date statistical methods. PLoS One. 2020;15:e0235234. 10.1371/journal.pone.023523432645006 BakanEPolatHOzardaYOzturkNBaygutalpNKUmudumFZ A reference interval study for common biochemical analytes in Eastern Turkey: a comparison of a reference population with laboratory data mining. Biochem Med (Zagreb). 2016;26:210–23. 10.11613/BM.2016.02327346966 SunZChaiJZhouQXuJ. Establishment of gender- and age-specific reference intervals for serum liver function tests among the elderly population in northeast China: a retrospective study. Biochem Med (Zagreb). 2022;32:020707. 10.11613/BM.2022.02070735799982 AgaravattAKansaraGKhubchandaniASanghaniHPatelSParchwaniD. Verification of reference interval of thyroid hormones with manual and automated indirect approaches: comparison of Hoffman, KOSMIC and refineR methods. Cureus. 2023;15:e39066. 10.7759/cureus.3906637323364 AnkerSCMorgensternJAdlerJBruneMBringsSFlemingE Verification of sex- and age-specific reference intervals for 13 serum steroids determined by mass spectrometry: evaluation of an indirect statistical approach. Clin Chem Lab Med. 2022;61:452–63. 10.1515/cclm-2022-060336537103 ArzidehFBrandhorstGGurrEHinschKHoffTRoggenburckL An improved indirect approach for determining reference limits from intra-laboratory databases exemplified by concentrations of electrolytes. J Lab Med. 2009;33:52–66. 10.1515/JLM.2009.015 DanielssonJKangastupaPLaatikainenTAaltoMNiemeläO. Impacts of common factors of lifestyle on serum liver enzymes. World J Gastroenterol. 2014;20:11743–52. 10.3748/wjg.v20.i33.1174325206278
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010706" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010706" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010706" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(107) "Indirect estimation of serum enzymes reference intervals in adults using the reflimR and refineR algorithms" ["journals_article_author"]=> string(54) "Raziye Yıldız, Fatma Demet Arslan, Mehmet Köseoğlu" ["journals_article_author_country"]=> string(6) "Turkey" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(81) "reference ranges, big data, clinical enzyme tests, laboratory information systems" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1827" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "11" ["meta_title"]=> string(107) "Indirect estimation of serum enzymes reference intervals in adults using the reflimR and refineR algorithms" ["meta_desc"]=> string(107) "Indirect estimation of serum enzymes reference intervals in adults using the reflimR and refineR algorithms" ["meta_keyw"]=> string(81) "reference ranges, big data, clinical enzyme tests, laboratory information systems" ["created"]=> string(19) "2026-02-05 10:38:56" ["modified"]=> string(19) "2026-02-17 09:22:25" } [41]=> object(stdClass)#90 (35) { ["journals_id"]=> string(4) "1214" ["journals_xml"]=> string(88384) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010705 10.11613/BM.2026.010705 Original articles Maternal serum steroid hormones in vaginal delivery and caesarean section KadivnikMirta12MandićDario3WagnerJasenka4KralikKristina5ŠijanovićSiniša12PlečkoDeni4MullerAdrijana12BegolliGramos6DebeljakŽeljko*78 Department of Obstetrics and Gynecology, University Hospital Centre Osijek, Osijek, Croatia Department of Obstetrics and Gynecology, Faculty of Medicine, J. J. Strossmayer University, Osijek, Croatia Department of Laboratory Medicine and Pharmacy, Faculty of Medicine, J. J. Strossmayer University, Osijek, Croatia Department of Medical Biology and Genetics, Faculty of Medicine, J. J. Strossmayer University, Osijek, Croatia Department of Medical Statistics and Informatics, Faculty of Medicine, J. J. Strossmayer University, Osijek, Croatia Clinic of Medical Biochemistry, University Clinical Center of Kosovo, Pristina, Kosovo Clinical Institute of Laboratory Diagnostics, University Hospital Centre Osijek, Osijek, Croatia Department of Pharmacology, Faculty of Medicine, J. J. Strossmayer University, Osijek, Croatia Corresponding author: zeljko.debeljak@gmail.com

Author contributions

M Kadivnik: Writing – review & editing, Writing – original draft, Investigation, Formal analysis, Data curation, Conceptualization; Ž Debeljak: Writing – review & editing, Supervision, Project administration, Methodology, Funding acquisition, Conceptualization; D Mandić: Writing – review & editing, Supervision, Project administration, Conceptualization; J Wagner: Supervision, Project administration, Methodology, Funding acquisition, Conceptualization; K Kralik: Formal analysis, Methodology, Data curation; S Šijanović: Supervision, Conceptualization; A Muller: Supervision, Conceptualization. G Begolli: Project administration, Conceptualization; D Plečko: Project administration, Conceptualization. All co-authors reviewed the manuscript, provided a critique of the intellectual content, and approved the final version before submission.

15122025 15022026 36 1 010705 1104202523102025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• The process of labor involves several key endocrine mechanisms

• Maternal serum steroids and the mode of delivery are associated

• Low aldosterone is associated with the urgent caesarean section

Introduction

The hormonal interplay between the mother and the fetal-placental unit may influence the mode of delivery. This study aimed to investigate the association between maternal peripartal serum concentrations of sex hormone-binding globulin (SHBG) and 10 steroid hormones with delivery outcomes.

Materials and methods

This observational study included 171 healthy pregnant women with spontaneous onset of labor: 117 had vaginal delivery and 54 underwent urgent cesarean section (C-section). Serum concentrations of aldosterone, androstenedione, cortisol, cortisone, corticosterone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), 17-hydroxyprogesterone, progesterone, and total testosterone were determined by liquid chromatography–tandem mass spectrometry (LC-MS/MS), while free testosterone was calculated. Sex hormone-binding globulin was measured by chemiluminescent microparticle immunoassay. Group differences were tested with the Mann-Whitney U test, and associations with delivery mode were assessed by logistic regression and receiver operating characteristic (ROC) analysis.

Results

Compared with the vaginal delivery group, women who underwent urgent C-section had significantly lower serum concentrations of SHBG, corticosterone, cortisol, aldosterone, progesterone, 17-hydroxyprogesterone, DHEA, DHEAS, and free testosterone (all P < 0.001). In multivariate logistic regression, aldosterone (odds ratio, OR 0.11, 95% CI 0.04 to 0.27, P < 0.001) and DHEAS (OR 0.74, 95% CI 0.58 to 0.94, P = 0.011) were independently associated with delivery mode. ROC analysis showed that aldosterone > 0.9 nmol/L predicted vaginal delivery with AUC 0.874, sensitivity 88%, and specificity 77%.

Conclusions

Low maternal aldosterone concentrations showed the strongest association with urgent C-section, suggesting that aldosterone may play a protective role in successful vaginal delivery.

Keywords: aldosteronecesarean sectiondeliveryvaginalsteroids
Introduction

The onset of labor appears to be coordinated by complex factors related to the mother and the fetal-placental unit (1, 2). It is a complex interplay of immunologic and endocrine mechanisms modulated by ethnicity, gestational age, and etiology (3). It includes the progressive relaxation and dilatation of the cervix, rupture of the amniotic membranes, and the initiation and maintenance of effective uterine contractions, culminating in labor (4). Synthesis and metabolism of steroid hormones during pregnancy are the result of complex metabolic pathways involving activities in the fetus, placenta, and mother (5). In humans, steroid hormones, prostaglandins, cytokines, and nitric oxide stimulate cervical remodeling by altering the content of the extracellular matrix and collagen (6). Cervical remodeling is of paramount importance for normal labor and it depends on dehydroepiandrosterone sulfate (DHEAS) and dihydrotestosterone (DHT) concentrations (7, 8). Dehydroepiandrosterone sulfate impacts the activation of neutrophils and macrophages and the production of proteolytic enzymes in the uterine cervix needed for the vaginal delivery (8, 9). Additionally, DHEAS and DHT, along with progesterone (P4) and dehydroepiandrosterone (DHEA), play a role in the contractility of the uterus (10). The role of maternal adrenal steroids, together with estrogen (E2) and P4, is the regulation of the fetuses’ access to nutrients, electrolytes, and water that involves control of maternal volume expansion, uterine and placental blood flow, and substrate availability (11). Thus, adrenal steroids may, indirectly, impact the mode of delivery.

Mode of delivery makes an important impact on the postpartum status of mothers and the perinatal outcome of newborns, especially in the active phase of delivery. Delaying an urgent Caesarean section (C-section) during the active phase of delivery, when the cervix is dilated over 6 cm and contractions are strong, can lead to significant adverse outcomes for both the mother and the fetus. The interval between the decision to perform a C-section and the actual delivery, known as the decision-to-delivery interval (DDI), is a critical factor in these outcomes (12). The maternal consequences of prolonged DDI could be uterine atony and postpartum hemorrhage, and a higher risk of postpartum infections, while the fetal consequences could be more frequent admission to the neonatal intensive care unit and increased perinatal mortality (13).

The question arises whether steroid hormones could play a predictive role in the choice of delivery mode. To our knowledge, only the study by Adamcova et al. has examined the relationship between the serum steroid hormone panel and mode of delivery (5). However, several studies investigated associations of maternal serum concentrations of individual steroid hormones, particularly androgens and cortisol with the mode of delivery (14-18). The aim of this study was to investigate the relationship between the mode of delivery and peripartal, maternal serum concentrations of an extended steroid panel consisting of aldosterone, androstenedione, cortisol, cortisone, corticosterone, DHEA, DHEAS, 17-hydroxyprogesterone (17-OHP), P4, free and total testosterone, along with the sex hormone-binding globulin (SHBG).

Materials and methods Subjects

This observational study was conducted between November 2017 and April 2023 at the Department of Gynecology and Obstetrics and the Clinical Institute for Laboratory Diagnostics, Osijek University Hospital. Total of 171 healthy pregnant women whose delivery began with a regular spontaneous contraction of the uterus with or without premature membrane rupture, were included in the study. Inclusion criteria for our study involved a singleton pregnancy with a newborn in cephalic presentation: mothers were admitted in the first stage of delivery, and had regular contractions. Exclusion criteria were the use of drugs that influence steroidogenesis, hyper- or hypothyroidism, pregnancy complications (hyperemesis, bleeding, endometriosis, any previous operation on the uterus), and multiple pregnancies. Subjects were divided into 2 groups: the first group was composed of 54 woman whose labor started spontaneously, but ended with the urgent C-section due to indications that were not predictable before the onset of labor (e.g., cervical-corporal dystocia, fetal hypoxia, vaginal hemorrhage), while the second group was composed of 117 woman whose labor started spontaneously and ended with vaginal delivery. This study has been a part of a larger project: although it shares participants with the previous study, the study goals are different (19). Demographic data included the mothers’ age, body mass index (BMI), parity, and smoking status, together with the newborns’ gender and weight. Body mass index was categorized as normal (18.5-24.9), overweight (25-29.9), and obese (≥ 30) according to WHO criteria (20). Macrosomal newborns are defined as a birth weight of newborn relative to gestational age, specifically at or above the 90th percentile (21). The questionnaire collected information on maternal age, maternal medical history, maternal smoking status, newborns gender, and newborns weight. Demographics are given in Table 1.

Demographic characteristics of women undergoing urgent cesarean section and those with vaginal delivery
Urgent cesarean section(N = 54) Vaginal delivery(N = 117) P value
Mothers’ age (years)[Median (min - max)] 31 (20-41) 30 (18-44) 0.581†
BMI (kg/m2)[Median (IQR)] 26.8 (23.6-30.5) 26.4 (24.2-29.4) 0.673†
BMI [N (%)]
Normal weight 17 (31) 42 (36)
Overweight 22 (41) 47 (40) 0.807*
Obese 15 (28) 28 (24)
Parity [N (%)]
Primiparous 40 (74) 49 (42) < 0.001
Multiparous 14 (26) 68 (58)
Mothers smoking habit [N (%)] 18 (33) 32 (27,4) 0.42
RVP [N (%)] 17 (31) 38 (32,5) 0.89 *
Weeks of gestation[Median (IQR)] 38+6 (35+6 – 39 + 3) 38+5 (36+2 – 39+4) 0.944†
Newborns gender [N (%)]
Male 29 (54) 62 (53) 0.931*
Female 25 (46) 55 (47)
Newborns birth weight (g)Median (IQR) 2999(2151 - 3300) 3280(2795 - 3593) 0.009
Macrosomal newborns
No 54 (100) 107 (91.5) 0.03
Yes 0 10 (8.5)
Bold denotes statistically significant differences. *χ2 test; †Mann-Whitney U test. Percentages within each group, column totals sum to 100%. Macrosomal newborns are defined as a birth weight of newborn relative to gestational age, specifically at or above the 90th percentile (21). Gestational age is expressed as completed weeks of gestation + days (e.g., 38+6 = 38 weeks and 6 days). Values are presented as median (interquartile range). N - number of participants. BMI - body mass index; BMI categories defined according to WHO criteria (20). RVP – lat. ruptura velamentorum praetemporaria.

This study has been conducted in accordance with the World Medical Association Declaration of Helsinki (22). It was approved by the Ethical Committee of the University Hospital Osijek (approval number: R2: 12272-4/2017) and the Faculty of Medicine, Josip Juraj Strossmayer University of Osijek (approval number: class: 602-04/18-08/07; Reg. No: 2158-61-07-18-133). All participants signed an informed consent form and filled out a questionnaire requiring relevant medical history and socio-demograhic information. Participants´ anonymity was guaranteed.

Blood sampling and analysis

After the patients were admitted to the delivery room, venous blood was drawn in test tubes that did not contain anticoagulants. Blood samples were obtained during the first stage of labor, before the application of the oxytocin infusion, if needed, and predominantly in the supine position; however, variations in maternal posture could not be fully controlled and may have influenced aldosterone concentrations. Venous blood (5 mL) was collected in plain serum separator tubes (BD Vacutainer, Becton Dickinson, Franklin Lakes, USA) during the first stage of labor, before oxytocin infusion, if applicable. Samples were centrifuged at 3500 rpm for 10 minutes, aliquoted, and stored at - 70 °C until analysis.

A liquid chromatography-tandem mass spectrometry (LC-MS/MS) instrument, LCMS-8050 (Shimadzu, Kyoto, Japan) was used to determine of the serum concentration of 10 steroid hormones (aldosterone, androstenedione, cortisol, cortisone, corticosterone, DHEA, DHEAS, 17-OHP, P4 and testosterone). All serum samples for LC-MS/MS determination of steroid hormones were prepared using the same standardized procedure (ChromSystems kit), while SHBG concentration was determined separately by chemiluminescent immunoassay. The determination of hormone serum concentrations was preceded by a serum sample preparation using a commercially available kit (ChromSystems, Gräfelfing, Germany). Equation by Vermeulen et al. was used to calculate the serum concentration of free testosterone. The concentration of SHBG was measured using Abbott ARCHITECT i1000SR chemiluminescent microparticle immunoassay (Abbott Diagnostics, Lake Forest, USA).

Statistical analysis

Categorical variables were presented as counts and percentages, and compared using the chi-square test. Normality of continuous variables was assessed with the Shapiro–Wilk test. Continuous variables were summarized as medians with interquartile range or range (minimum-maximum) and compared between groups using the Mann–Whitney U test. In the bivariate logistic regression analysis, the following variables were considered as independent predictors: SHBG, corticosterone, cortisol, cortisone, aldosterone, progesterone (P4), 17-hydroxyprogesterone (17-OHP), DHEA, DHEAS, androstenedione, testosterone, and free testosterone. Associations between these variables and mode of delivery were examined with bivariate and multivariate logistic regression. Multivariate models were fitted using the stepwise method (entry P < 0.05, removal P > 0.2). Results were expressed as odds ratios (OR) with 95% confidence intervals. The goodness-of-fit of the model was assessed using the Hosmer–Lemeshow test. Receiver operating characteristic (ROC) curve analysis was applied to evaluate the diagnostic performance of significant predictors. All P values were two-sided, with the level of significance set at α = 0.05. Analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, USA) and MedCalc 23.3.7 (MedCalc Software Ltd, Ostend, Belgium).

Results

The baseline characteristics of all study participants and the difference in sociodemographic characteristics between the two groups of patients who had vaginal deliveries or C-sections are shown in Table 1.

A statistically significant difference between groups was found in serum concentrations of SHBG, corticosterone, cortisol, aldosterone, P4, 17-OHP, DHEA, DHEAS, and free testosterone (Figure 1). All of these serum concentrations were lower in the group of patients whose labor ended with an urgent cesarean section. Similar results were obtained by bivariate logistic regression, and the most important results were as follows: lower aldosterone (OR 0.09, 95% CI 0.04 to 0.23, P < 0.001) and lower DHEAS concentrations (OR 0.74, 95% CI 0.59 to 0.93, P = 0.009) were significantly associated with urgent C-section. Testosterone and cortisone, and free testosterone, did not demonstrate statistically significant differences between groups, while other steroid hormones and SHBG showed a modest association with urgent C-section. In the multivariate model adjusted for parity and fetal macrosomia, aldosterone, DHEAS, and SHBG remained independent predictors of urgent C-section. They were inversely associated with the C-section as a mode of delivery. Multivariate regression analysis (Table 2) was used to develop a fully statistically significant model (χ2 = 70.3, P = 0.001). The model accurately classified 85% of cases. Regression analysis was performed with correction for confounding factors (maternal parity and fetal macrosomy). Aldosterone and DHEAS have significantly contributed to the above model, demonstrating a protective role: the higher the serum concentration of aldosterone and DHEAS, the lower the likelihood of C-section (OR 0.11 and OR 0.74, respectively).

Box and whisker plot showing the differences in hormone concentrations between urgent C-section and vaginal delivery. The Mann-Whitney U test was used. SGBG - Sex Hormone Binding Globulin. P4 - progesterone. 17-OHP - 17-hydroxyprogesterone. DHEA - dehydroepiandrosterone. DHEAS - dehydroepiandrosterone sulfate. C-section - Caesarean section.

Multivariate logistic regression analyses predicting the probability of cesarean delivery
Variables *Multivariate regression analysis
β P value OR 95% CI
SHBG - 0.322 0.004 0.99 0.99 to 0.99
Aldosterone - 2.096 < 0.001 0.11 0.04 to 0.27
DHEAS - 0.322 0.020 0.74 0.58 to 0.94
Constant 4.787 < 0.001
*adjusted for fetal macrosomia and parity. Bold font denotes statistically significant differences. SGBG - sex hormone binding globulin. DHEAS - dehysdroepiandrostendion sulfate. OR - odds ratio. 95% CI - 95% confidence interval. β - regression coefficient.

Based on the ROC analysis, aldosterone proved to be the most important indicator of urgent C-section (Table 3 and Figure 2). Aldosterone concentration greater than 0.9 nmol/L was associated with vaginal delivery (area under the curve (AUC) = 0.874, sensitivity = 88%, specificity = 77%, P = 0.001), while the rest of the investigated steroids provided less pronounced differences between delivery modes.

Receiver operating characteristic (ROC) analysis of maternal hormone parameters in relation to mode of delivery (caesarean section <italic>vs</italic> vaginal delivery)
Parameters AUC 95% CI Sensitivity% Specificity% Cut-off* Youden P value
SHBG 0.673 0.598 to 0.743 50 80 ≤ 431.1 0.303 < 0.001
Cortisol 0.709 0.635 to 0.776 69 64 ≤ 1093 0.326 < 0.001
Aldosterone 0.874 0.814 to 0.920 88 77 ≤ 0.9 0.652 < 0.001
DHEAS 0.653 0.576 to 0.724 57 71 ≤ 1.7 0.284 0.001
Bold font denotes statistical significance. All concentrations are given as nmol/L. SHBG - sex hormone binding globulin. DHEAS - dehysdroepiandrostendion sulfate. AUC - area under the curve. 95% CI - 95% confidence interval.

Receiver operating characteristic (ROC) curves of maternal SHBG, cortisol, aldosterone, and DHEAS illustrating their association with mode of delivery (caesarean section vs. vaginal delivery). Aldosterone demonstrated the highest discriminatory accuracy among the analyzed hormones. SHBG - sex hormone binding globulin. DHEAS - dehydroepiandrosterone sulfate.

Additional analyses showed that newborns delivered by urgent C-section had significantly lower birth weight compared with those born vaginally (Table 1). Macrosomia occurred only in the vaginal delivery group (Table 1, 8.5% vs. 0%, Fisher’s exact test P = 0.03). In parity-stratified analyses, multiparous women had significantly higher concentrations of SHBG (OR 1.52, 95% CI 1.12 to 2.07, P = 0.007) and aldosterone (OR 1.38, 95% CI 1.07 to 1.79, P = 0.01), whereas primiparous women had higher androstenedione (OR 1.71, 95% CI 1.30 to 2.25, P < 0.001) and testosterone concentrations (OR 1.95, 95% CI 1.43 to 2.66, P < 0.001). No significant hormonal differences were observed according to the presence or absence of prelabor rupture of membranes (PROM).

Discussion

During pregnancy, P4, E2, androgens, and corticosteroids play an important role, and their concentrations vary depending on the type of delivery (5). In a spontaneous vaginal delivery, however, the concentrations change due to the onset of labor and the stress response to delivery (5). To our knowledge, no studies that analyze the possible link between serum concentrations of steroid hormones determined by LC-MS/MS and urgent C-section have been published. To bridge this gap, in the present study, the focus was on differences between serum concentrations of SHBG and 10 selected maternal steroid hormones between two groups of mothers divided by the mode of delivery and their connection with the mode of delivery. It was found that there was a significantly lower concentration of SHBG, corticosterone, cortisol, aldosterone, P4, 17-OHP, free testosterone, DHEA, and DHEAS in the group of patients whose birth ended with an urgent C-section. A similar study performed by Adamcova et al. also detected differences in maternal serum steroids between the modes of delivery (5). Still, in comparison to our study, aldosterone was not included in the study, and these authors compared serum concentrations of steroid hormones between groups of patients whose labor ended by vaginal delivery or by the elective C-section. There is an expected difference in the serum concentration of steroid hormones between urgent and elective C-sections: in urgent C-sections, there is a possibility that certain steroid serum concentrations are more consistent with serum concentrations of steroids in vaginal delivery.

The link between maternal serum androgens and the mode of delivery was also obtained by other groups (14-18). The only exception from the established link is represented in the study by Cawyer et al., these authors were unable to establish a clear correspondence between DHEAS concentrations and the mode of delivery, which may be attributed to the different analytical method used in this study (23).

Particularly interesting results from the study presented here came from the bivariate and multivariate logistic regression: aldosterone, but also DHEAS, provide a statistically significant contribution to regression models of a delivery mode. The ROC analysis revealed a cut-off value below which the C-section is expected. Among the given hormones, aldosterone, with an OR of 0.107 for the urgent C-section, stands out. Adrenal steroids may influence the type of birth via indirect control. For example, in response to the stress caused by labor and vaginal delivery, aldosterone concentration rises during vaginal delivery more than during urgent C-section (24). Jensen et al. demonstrated that adrenal steroid hormones, together with E2 and P4, regulate fetal access to nutrients, electrolytes, and water by regulating maternal volume expansion, uterine and placental perfusion (11). Aldosterone itself affects placental blood flow and development, as well as the transfer of oxygen and nutrients to the fetus (25-27). Uterine contractions could favor the occurrence of fetal asphyxia and/or hypoxia and termination of pregnancy by C-section, if angiogenesis and placental development are inadequate, which may be associated to the aldosterone concentration below 0.9 nmol/L. A significant influence of aldosterone on the course of labor could also lie in its influence on the expansion of plasma volume.

As presented in the Results section, we found significantly lower concentrations of SHBG, corticosterone, cortisol, aldosterone, progesterone, 17-OHP, free testosterone, DHEA, and DHEAS in women whose delivery ended with urgent C-section. These results suggest relative hypovolemia in pregnant women who underwent C-section, which may be a consequence of a lower serum concentration of aldosterone in the C-section group. Insufficient aldosterone production may lead to inadequate expansion of plasma volume, which may result in uteroplacental insufficiency. This condition can impair uterine contractility and cervical ripening and lead to dysfunctional labor patterns such as prolonged or stopped labor. As a result, the likelihood of interventions such as induction of labor or C-section increases (28). All presented results and explanations suggest a possible protective role of maternal serum aldosterone against the urgent C-section.

Possible influence of androgens, especially DHEAS, on the mode of labor can be explained by their effect on cervical remodeling and myometrial contractility (9, 27). The effect of DHEAS on cervical remodeling has been associated with increased levels of the cytokine IL-8, which is involved in the chemotaxis of neutrophils recruited to the cervix towards the end of pregnancy, and it stimulates the secretion of proteolytic enzymes (9, 28). In short, lower DHEAS concentrations (< 1.7 nmol/L) could lead to a lack of peripartum cervical remodeling and thus urgent C-section. Inversely, the increase of the DHEAS concentration lowers the risk of C-section (OR 0.76), suggesting a possible protective role of DHEAS against the urgent C-section. Remarkably, only 2 steroids in the group that underwent C-section had higher serum concentrations, namely testosterone and androstenedione. It is important to mention that these differences were not statistically significant. It could be due to a difference in renal function between the two groups of pregnant women, and this could be the basis for some future study. Although renal clearance differences could be one possible explanation, as suggested by recent evidence linking kidney function and female reproductive hormones, this parameter was not assessed in our study and should therefore be interpreted with caution (29).

In our cohort, primiparity was significantly more frequent in the urgent C-section group, which is consistent with its established role as a risk factor for cesarean delivery. To account for this potential bias, parity (together with fetal macrosomia) was included as a covariate in the multivariate regression analysis. Importantly, aldosterone, DHEAS, and SHBG remained independent predictors of urgent C-section even after adjustment, indicating that the observed associations were not explained by differences in parity.

Our finding of no significant differences in cortisol (or other steroid hormones) between women with and without rupture of membranes is noteworthy. Although cortisol has been shown to dramatically induce matrix metalloproteinase-7 (MMP-7) in the human amniotic tissue, leading to degradation of the extracellular matrix, and elevated MMP-9 expression has been associated with spontaneous rupture of fetal membranes, our data do not support a role for measurable systemic steroid hormone differences by RVP status in our cohort (30, 31). Local (membrane-level) expression/activity of MMPs may be a more sensitive indicator than circulating hormone concentrations.

There are some specific limitations and some strengths of the presented study. The timing of sampling could be seen as such limitation. Sampling took place at different stages of the first stage of delivery, depending on when the subjects were admitted to the delivery room. In addition, a C-section was performed shortly before the delivery, when the labor-induced hormonal changes had already started. Future research should be conducted over several weeks before delivery as a longitudinal study of hormonal changes. In addition, the limitations of this study include a relatively small number of women who underwent urgent C-section and the lack of follow-up measurements before delivery. Furthermore, another limitation of our study is the lack of strict control for maternal posture at the time of blood sampling. Postural changes are known to influence aldosterone concentrations, and although samples were generally collected in the supine position, variability cannot be fully excluded (32). At the end, one of the limitations could be the fact that some predictors in bivariate regression yielded narrow 95% confidence intervals, which may be related to the relatively low variability of the measurements. To improve interpretation, the results should be considered in the context of clinically relevant units of change.

The main strength of this study was the analytical method by which serum concentrations of steroids were determined. Measurements of the serum steroids by immunoassays were found to show a significant analytical bias (28). Due to chromatographic separation and the selectivity of mass spectrometry, LC-MS/MS is less susceptible to interference from related compounds that may be present in maternal serum (19, 28). No studies dealing with the association of free testosterone with the mode of delivery were found.

In conclusion, maternal serum concentrations of DHEAS and aldosterone are associated with mode of delivery. Low aldosterone concentrations were linked to an increased likelihood of urgent cesarean section, suggesting a possible protective role of aldosterone in successful vaginal delivery. Further multicentric studies are needed to confirm this role.

Acknowledgments

The authors would like to give special thanks to colleagues and nurses at the Clinic of Obstetrics and Gynecology at the University Hospital in Osijek, Croatia. Also, the authors would like to thank the patients for their participation and support in this study.

Potential conflict of interest

None declared.

Data availability statement

Data presented in this study is available on request from the corresponding author.

References NorwitzERRobinsonJNChallisJRG. The Control of Labor. N Engl J Med. 1999;341:660–6. 10.1056/NEJM19990826341090610460818 ChallisJRGMatthewsSGGibbW. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev. 2000;21:514–50. 10.1210/edrv.21.5.040711041447 KeelanJA. Intrauterine inflammatory activation, functional progesterone withdrawal, and the timing of term and preterm birth. J Reprod Immunol. 2018;125:89–99. 10.1016/j.jri.2017.12.00429329080 MenonR. Spontaneous preterm birth, a clinical dilemma: etiologic, pathophysiologic and genetic heterogeneities and racial disparity. Acta Obstet Gynecol Scand. 2008;87:590–600. 10.1080/0001634080200512618568457 AdamcováKKolátorováLŠkodováTŠimkováMPařízekAStárkaL Steroid hormone levels in the peripartum period—differences caused by fetal sex and delivery type. Physiol Res. 2018;67:S489–97. 10.33549/physiolres.93401930484675 SennströmMB. Human cervical ripening, an inflammatory process mediated by cytokines. Mol Hum Reprod. 2000;6:375–81. 10.1093/molehr/6.4.37510729321 GranströmLEkmanGMalmströmA. Insufficient remodelling of the uterine connective tissue in women with protracted labour. Br J Obstet Gynaecol. 1991;98:1212–6. 10.1111/j.1471-0528.1991.tb15391.x1777452 MaymonERomeroRPacoraPGomezRAthaydeNEdwinS Human neutrophil collagenase (matrix metalloproteinase 8) in parturition, premature rupture of the membranes, and intrauterine infection. Am J Obstet Gynecol. 2000;183:94–9. 10.1067/mob.2000.10765210920315 KanayamaNEl MaradnyEGotoJTeraoT. Effect of dehydroepiandrosterone sulfate on interleukin-8 receptor during cervical ripening. Eur J Endocrinol. 1998;138:587–93. 10.1530/eje.0.13805879625374 CoxSMCaseyMLMacDonaldPC. Accumulation of interleukin-1beta and interleukin-6 in amniotic fluid: a sequela of labour at term and preterm. Hum Reprod Update. 1997;3:517–27. 10.1093/humupd/3.5.5179528914 JensenEWoodCKeller-WoodM. The normal increase in adrenal secretion during pregnancy contributes to maternal volume expansion and fetal homeostasis. J Soc Gynecol Investig. 2002;9:362–71. 10.1016/S1071-5576(02)00179-X12445601 KitawTMLimenhSKChekoleFAGetieSAGemedaBNEngdaAS. Decision to delivery interval and associated factors for emergency cesarean section: a cross-sectional study. BMC Pregnancy Childbirth. 2021;21:224. 10.1186/s12884-021-03706-833743626 AbdulbakiMAliyuFOAyindeMIssaAAdeniranASIbrahimOR. Impact of ‘decision-to-delivery’ interval on maternal and perinatal outcomes: a retrospective study of emergency caesarean section from 2017 to 2021 at a secondary health facility in Nigeria. BMC Pregnancy Childbirth. 2024;24:493–8. 10.1186/s12884-024-06700-y39039486 HerczPSiklôsPUngârL. Serum dehydroepiandrosterone and cortisol concentration in the maternal-fetoplacental hormonal system in elective caesarean section and spontaneous vaginal delivery in the 28th to 36th and 40th weeks of pregnancy. Gynecol Obstet Invest. 1990;29:112–4. 10.1159/0002933142139860 OkunowoAAAdegbolaOAjayiGO. Evaluation of maternal serum levels of dehydroepiandrosterone sulphate and its association with successful labour outcome among parturients undergoing spontaneous labour at term. J Obstet Gynaecol. 2017;37:191–4. 10.1080/01443615.2016.122927827923285 DoğanayMErdemogluEAvşarAFAksakalOS. Maternal serum levels of dehydroepiandrosterone sulfate and labor induction in postterm pregnancies. Int J Gynaecol Obstet. 2004;85:245–9. 10.1016/j.ijgo.2003.10.00815145259 GoolsbyLSchlechtKRacowskyCGeletyTReedK. Maternal serum dehydroepiandrosterone sulfate levels and the efficiency of labor in young nulliparas. Obstet Gynecol. 1996;88:56–9. 10.1016/0029-7844(96)00081-68684762 MazorMGhezziFCohenJHershkovitzRTolosaJELevyJ Maternal plasma and amniotic fluid dehydroepiandrosterone-sulfate concentrations in preterm labor and delivery. Arch Gynecol Obstet. 1996;259:7–12. 10.1007/BF025053028933923 KadivnikMDebeljakŽMandićDWagnerJKralikKŠijanovićS Requirement for oxytocin augmentation in spontaneous parturition is associated with the maternal serum steroid hormones assessed by liquid chromatography coupled to the tandem mass spectrometry. J Obstet Gynaecol Res. 2021;47:2347–55. 10.1111/jog.1479233855759 UlijaszekSJ. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization; 2000. J Biosoc Sci. 2003;35:624–5. 10.1017/S0021932003245508 Macrosomia: ACOG practice bulletin summary, number 216. Obstet Gynecol. 2020;135:246–8. 10.1097/AOG.000000000000360731856119 World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4. 10.1001/jama.2013.28105324141714 CawyerCRLobashevksyECorley-TophamGAndersonSOwenJSubramaniamA. Association between maternal serum hormones along the maternal-fetal hypothalamic-pituitary-adrenal axis and successful vaginal delivery measured prior to labor induction. Am J Perinatol. 2020;37:1195–200. 10.1055/s-0040-170880132215880 BeitinsIZBayardFAncesIGKowarskiAMigeonCJ. The metabolic clearance rate, blood production, interconversion and transplacental passage of cortisol and cortisone in pregnancy near term. Pediatr Res. 1973;7:509–19. 10.1203/00006450-197305000-000044704743 Gennari-MoserCKhankinEVSchüllerSEscherGFreyBMPoetmannCB Regulation of placental growth by aldosterone and cortisol. Endocrinology. 2011;152:263–71. 10.1210/en.2010-052521068161 LumbersERPringleKG. Roles of the circulating renin-angiotensin-aldosterone system in human pregnancy. Am J Physiol Regul Integr Comp Physiol. 2014;306:R91–101. 10.1152/ajpregu.00034.201324089380 WalczakCGaignierFGiletAZouFThorntonSNRoparsA. Aldosterone increases VEGF-A production in human neutrophils through PI3K, ERK1/2 and p38 pathways. Biochim Biophys Acta. 2011;1813:2125–32. 10.1016/j.bbamcr.2011.07.01021803079 LuisiSPetragliaFBenedettoCNappiREBernardiFFadaltiM Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab. 2000;85:2429–33. 10.1210/jcem.85.7.667510902789 BhaduriMSarrisIHysiPNicolaidesKBairdFBramhamK. Impact of CKD on female reproductive hormones. Kidney Int Rep. 2025;10:2178–88. 10.1016/j.ekir.2025.05.00340677365 WangLYWangWSWangYWLuJWLuYZhangCY Drastic induction of MMP-7 by cortisol in the human amnion: implications for membrane rupture at parturition. FASEB J. 2019;33:2770–81. 10.1096/fj.201801216R30303742 AthaydeNEdwinSSRomeroRGomezRMaymanEPacoraP A role for matrix metalloproteinase-9 in spontaneous rupture of the fetal membranes. Am J Obstet Gynecol. 1998;179:1248–53. 10.1016/S0002-9378(98)70141-39822510 MinvaleevRSNozdrachevADKir’yanovaVVIvanovAI. Postural influences on the hormone level in healthy subjects: I. The cobra posture and steroid hormones. Hum Physiol. 2004;30:452–6. 10.1023/B:HUMP.0000036341.80214.28
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010705" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010705" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010705" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(73) "Maternal serum steroid hormones in vaginal delivery and caesarean section" ["journals_article_author"]=> string(148) "Mirta Kadivnik, Dario Mandić, Jasenka Wagner, Kristina Kralik, Siniša Šijanović, Deni Plečko, Adrijana Muller, Gramos Begolli, Željko Debeljak" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(58) "aldosterone, cesarean section, delivery, vaginal, steroids" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3350" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "10" ["meta_title"]=> string(73) "Maternal serum steroid hormones in vaginal delivery and caesarean section" ["meta_desc"]=> string(73) "Maternal serum steroid hormones in vaginal delivery and caesarean section" ["meta_keyw"]=> string(58) "aldosterone, cesarean section, delivery, vaginal, steroids" ["created"]=> string(19) "2025-12-09 11:57:09" ["modified"]=> string(19) "2026-02-17 09:23:18" } [42]=> object(stdClass)#91 (35) { ["journals_id"]=> string(4) "1213" ["journals_xml"]=> string(50478) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010704 10.11613/BM.2026.010704 Original articles First trimester of pregnancy TSH laboratory specific reference intervals established by an indirect method Sanz-FelisiMaría1Arbiol-RocaAriadna1Sánchez-GarcíaPaula2MadurgaAlicia*1 Clinical Laboratory, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain Institut Català de la Salut, Atenció a la salut sexual i reproductiva Torrassa, Barcelona, Spain Corresponding author: amadurga@bellvitgehospital.cat

Author contributions

M Sanz-Felisi: Conceptualization, methodology, validation, investigation, writing-revision & editing, visualization; A Arbiol-Roca: Conceptualization, methodology, validation, investigation, writing-revision & editing, visualization; P Sánchez-García: methodology, investigation; A Madurga: Conceptualization, methodology, validation, investigation, writing-revision & editing, visualization, supervision, project administration.

15122025 15022026 36 1 010704 0805202502112025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• The upper reference limit of the study for thyroid stimulating hormone (TSH) using the Roche Elecsys TSH reagent was 4.33 mIU/L

• The new reference intervals (RIs) are consistent with previous publications and the 2017 ATA guideline recommendation

• The RIs could reduce the risk of misdiagnosis and optimize thyroid management during pregnancy

Introduction

This study established laboratory and trimester specific indirect reference intervals (RIs) for thyroid stimulating hormone (TSH).

Materials and methods

A retrospective observational study was performed at a tertiary-care laboratory’s hospital during 12 months. Between February 2023 and February 2024, TSH results from 2166 women in their first trimester of pregnancy were retrieved. Only outpatients coming from primary care were included in the study. After applying exclusion and outlier criteria, TSH results from 1300 patients were analyzed to establish new RIs using the 2.5th and 97.5th percentiles by the non-parametric percentile method. These RIs were verified by an indirect method analyzing 486 TSH results from a cohort of pregnant women that were extracted from April to June 2024, and a direct prospective study of 28 pregnant women from a primary care center. All TSH tests were measured using a Cobas 8000 e801 system (Roche, Basel, Switzerland).

Results

The TSH RIs were 0.60-4.33 mIU/L. Both verification methods met the requirements of the CLSI guidelines.

Conclusions

The indirect method could be used to establish and verify local RIs for TSH in first trimester pregnant women. This may reduce misclassification of pregnant women undergoing thyroid function tests.

Keywords: indirect methodpregnant womenreference intervalsthyroid stimulating hormone
Introduction

Thyroid hormones play a vital role during pregnancy, influencing maternal wellbeing and fetal development. Maternal hypothyroidism is consistently associated with an increased risk of adverse pregnancy outcomes, including premature birth, low birth weight, pregnancy loss, and reduced intelligence quotient in offspring. Additionally, this condition can adversely affect the cognitive and neurological development of the fetus (1, 2). Hence, a precise evaluation of the thyroid function during pregnancy and prompt intervention when required are crucial for correct fetal development. Considering these premises, thyroid stimulating hormone (TSH) is necessary for diagnosing thyroid disorders.

During pregnancy, particularly in the first trimester, several physiological changes influence thyroid function. The structural similarity between human chorionic gonadotropin (hCG) and TSH causes hCG to stimulate thyroid hormone production, which can reduce TSH concentrations. Elevated estrogen concentrations also increase thyroid-binding globulin (TBG), which binds to thyroid hormones and reduces their blood concentrations. This in turn triggers the secretion of TSH and promotes further production of thyroid hormones. It is also important to consider that normal pregnancy is associated with an increased need for iodine and increased renal excretion of this element (1, 2).

Therefore, TSH results of healthy pregnant women differ from those of healthy non-pregnant women, and for this reason the American Thyroid Association (ATA) postulates the need for trimester specific reference intervals (RIs) for serum TSH based on the local population (3, 4). These RIs should be based on pregnant women with no known thyroid disease, optimal iodine intake, and negative anti-thyroperoxidase antibody (anti-TPO) status.

The establishment and verification of RIs using conventional direct methods are often complicated by resource limitations or specific patient demographics (5). Jones et al., from the working group of the IFCC Committee on Reference Intervals and Decision Limits (C-RIDL), aims to promote the adoption of indirect methods for establishing and validating RIs to support the development of improved statistical techniques for these studies (6).

Different laboratories may use different immunoassays to measure TSH, which can lead to discrepancies between TSH RIs. For these reasons, it is important to establish laboratory specific assay RIs to ensure consistency and reliability of test results (7, 9).

The aim of this study was to establish first trimester TSH RIs using an indirect method and the Elecsys TSH Roche Diagnostics reagent (Roche, Basel, Switzerland).

Materials and methods Study design

A retrospective observational study was conducted over 12 months (February 2023 to February 2024) at Bellvitge University Hospital. This 700-bed tertiary care teaching hospital is located in L’Hospitalet de Llobregat, Barcelona, Spain, and receives an average of 4000 laboratory requests per day.

Laboratory results for TSH of pregnant women on request for the first trimester protocol were obtained from the Laboratory Information System (LIS) (Modulab, Werfen, Barcelona, Spain). A total of 2166 TSH results were extracted from the LIS. Only outpatients coming from primary care were included in the study.

The analysis of the first trimester of pregnancy corresponds to a gestational age between 8 and 13 weeks and 6 days (10).

Exclusion criteria for this study included patients with recorded serum concentrations of free thyroxine (fT4), free triiodothyronine (fT3), anti-TPO, anti-thyroglobulin (anti-Tg) and/or anti-thyrotropin receptor (anti-TSHR) antibodies because our hospital’s laboratory protocols state that the LIS automatically adds free thyroid hormone and thyroid antibody measurements when TSH values fall outside the RIs.

Patients were also excluded from the study if they had follow-up thyroid function tests or a previous diagnosis related to thyroid function. The medical history and current treatment of all patients with TSH values outside the existing RIs were reviewed.

Data on TSH values, maternal age, ethnicity, weight, and type of pregnancy were extracted from the LIS and the SsdwLab program (SBP Soft, Girona, Spain).

The study protocol received approval from the institutional Clinical Research Ethics Committee (PR144/24). In regards to the direct verification study, each patient was given detailed information and provided written informed consent before blood sample collection. Patients’ clinical histories were reviewed using the hospital’s Physical Examination Information System (SAP GUI v.770, SAP SE, Walldorf, Germany).

To verify the RIs, two different studies were performed. The first one was a retrospective observational study based on the indirect method. A new cohort with the same characteristics as the population used to establish the RIs was selected. Another data export was performed from the LIS between April and June 2024. A total of 1391 TSH results were collected from the LIS, which were reduced to 486 after the exclusion criteria were applied. The RIs were verified using the same exclusion criteria as in the first study.

The direct method was used for the second verification of the study. A prospective study involving 28 first trimester pregnant patients recruited from a primary care women’s sexual and reproductive health center was performed. Patients were selected from the laboratory based on their medical history. A midwife nurse was responsible for recruitment and obtaining informed consent. Inclusion criteria for the selection of patients were healthy, pregnant women with normal pregnancies and no known complications. Exclusion criteria were a personal or family history of thyroid disease or other autoimmune diseases, previous treatment with thyroid medication or iodine irradiation, a history of recurrent miscarriage, and an age of over 37 years.

Methods

Each venous blood sample was collected into 8.5 mL serum tubes with separator gel and clot activator (Becton Dickinson (BD) Vacutainer SSTTM II Advance, Reference No. 366468). The time of blood collection was performed in the morning between 8 and 9 a.m. After 30 minutes of clotting time, the tubes were centrifuged at 1500xg for 10 minutes at 20-25 ºC and subsequently analysed.

All analytes were measured using the electrochemiluminescence immunoassay analyzer Cobas 8000 (Roche, Basel, Switzerland). TSH serum concentration was measured using the Elecsys TSH reagent (Roche, Basel, Switzerland). The laboratory is accredited to UNE/EN ISO 15189:2023. Internal and external quality control achieved the metrological requirements of the laboratory during the study period.

Statistical analysis

The distribution of TSH serum concentration was assessed for normality using the Shapiro-Wilk test, and a histogram was also used for the visual assessment. Logarithmic transformation was used to adjust for data distribution. To remove outliers, the interquartile range (IQR) was calculated using the first quartile Q1 (1.19) and the third quartile Q3 (2.65). After removing outliers using the ± 1.5 IQR method, RIs for TSH serum concentration were calculated by the non-parametric percentile method, using the original data, according to the CLSI guidelines C28-A3. Reference intervals with 90% of confidence intervals (CIs) were defined by the 2.5th and 97.5th percentiles of the distribution of TSH results in the cohort without outliers.

Data management and statistical analyses were conducted using the Stata Statistical Software: Release 14 (Stata Corp LP, College Station, TX, USA) and the Analyse-it software package for Excel 2016 (Analyse-it Software, Ltd., Leeds, UK).

Results

From the initial data of 2166 TSH results obtained from the LIS, 1375 TSH results were included after applying exclusion criteria (Figure 1). After removing the outliers and applying 1.5 IQR, the final data included 1300 TSH results. The data did not fit a Gaussian distribution for either raw or log-transformed data (Figure 2).

Flowchart for cohort selection and reference intervals verification using an indirect method. LIS - laboratory information system. TSH - thyroid stimulating hormone. fT4 - free thyroxin. fT3 - free triiodothyronine. anti-TPO - anti-thyroperoxidase antibodies. anti-Tg - anti-thyroglobulin antibodies. anti-TSHR - anti-thyrotropin receptor antibodies. RIs - reference intervals.

Histogram of the data distribution and normality Q-Q plot. TSH - thyroid stimulating hormone.

The median TSH serum concentration was 1.76 mIU/L (0.01-4.81 mIU/L) and the median maternal age was 32 years (16-38 years). The majority of patients were of Caucasian ethnicity (75%) and had a singleton pregnancy (98%). The median weight was 65 kg (31-157 kg).

The obtained TSH RIs with 90% CIs of first trimester pregnant women were: 0.60 (0.56 to 0.62)-4.33 (4.19 to 4.44) mIU/L.

The newly established RIs were validated using an indirect method. The data contained 486 results, and the median TSH serum concentration was 1.65 mIU/L (0.01-5.43 mIU/L). The verification was considered valid if less than 5% of the results fell outside the RIs. Only 17 patients (3.5%) had TSH results outside the new RIs that did not exceed the 5% requirement, confirming the validity of the new RIs (11).

Finally, the RIs were verified using a direct method (12). According to the CLSI EP28-A3 guideline, the RIs were deemed valid if no more than two of the 20 tested subjects’ values (or 10% of the test results) fell outside the reported RIs (11). A total of 28 healthy pregnant women were recruited from a primary care centre. The median TSH serum concentration was 2.16 mIU/L (0.23-4.71 mIU/L). Only two patients had a result below and above the interval limits (0.60-4.33 mIU/L). This means that 2/28 of the TSH results were outside the new RIs and therefore in compliance with the CLSI requirements (11).

Discussion

In this study, we estimated RIs for serum TSH (0.60-4.33 mIU/L) in pregnant women during the first trimester of pregnancy using an indirect approach. This method has been shown to be effective in identifying clinically significant changes in analyte concentrations that might otherwise go undetected (13-18).

According to the 2011 ATA guideline, the upper reference limit TSH serum concentration during pregnancy was established at 2.50 mIU/L for the first trimester of pregnancy (19). It has previously been reported that this universal cut-off is unhelpful and unrealistically low in many situations, creating a false sense of simplicity in a complex situation (3).

Following this publication, larger cohort studies have produced center specific and trimester specific RIs during pregnancy. Studies of pregnant women in Asia, India, and the Netherlands have shown significantly higher TSH RIs for each trimester of pregnancy (20-23). For instance, Marwaha et al., found that TSH RIs in a healthy Indian population were 0.60-5.00 mIU/L in the first trimester, using the direct method (21).

The ATA released an updated guideline in 2017 (4). This guideline recommends using an upper reference limit of approximately 4.00 mIU/L in the absence of internal or transferable pregnancy specific TSH RIs.

It should be noted that TSH RIs for different methods and reagent manufacturers might vary as they have been established using male and non-pregnant women and different antibodies. The decrease in serum TSH due to high concentrations of hCG during pregnancy should also be taken into consideration (23).

The manufacturer also provided RIs for pregnant women during their first trimester (0.33-4.59 mIU/L) and for females in different age groups (1.01-5.09 mIU/L for 11-20 years old; 0.44-3.63 mIU/L for 20-39 years old; and 0.16-3.94 mIU/L for 40-69 years old), based on various German studies (24, 25).

McNeil and Stanford claimed that a number of recent studies had shown that a more realistic RI was between 3.00 and 4.00 mIU/L, depending on the analytical method used (3). In their review, they also reported an average first trimester 97.5th percentile for TSH of 4.00 mIU/L when using Roche analysers (3).

Following the ATA recommendations we have established specific TSH RIs for pregnant women during the first trimester of pregnancy (4). The prior TSH RIs used in our laboratory were based on a national, cross-sectional, population survey of individual’s ≥ 18 years old (0.57-5.51 mUI/L) (26).

The results of this study are consistent with the aforementioned, as the upper RI is 4.33 mIU/L, very close to the 4 mIU/L proposed by McNeil and Stanford (3). These RIs are also in accordance with the RIs proposed by the manufacturer for pregnant women during the first trimester, and lower than the ones reported for non-pregnant women, which is consistent with the downward shift in TSH during the early stages of pregnancy (24).

In a 2025 study, Sun et al. used a Siemens ADVIA Centaur XP analyzer to calculate the TSH RIs for pregnant women in a Chinese population (27). Their results showed lower RIs in the first trimester of pregnancy (0.02-3.39 mIU/L) than those observed in this study. This exemplifies the influence of different populations and analytical methods, and the importance of establishing laboratory-specific TSH RIs.

Recently, Dorizzi et al., calculated TSH RIs (0.34-3.81 mIU/L) for pregnant women by the direct method (28). Their study was focused on a different time setting, since it was performed at 14-16 weeks of gestation, whereas ours was performed at 8-13 weeks. They also evaluated iodine intake by measuring urinary iodine excretion, concluding that mild and moderate iodine deficiencies did not affect the RIs (28).

Thus, this study incorporates and builds on previous recommendations in compliance with the CLSI guidelines to improve the accuracy and applicability of RIs using the indirect method (11, 13-18). This data is also consistent with reports using the direct method.

Furthermore, the RIs were also verified using a direct method that relies on a well-characterized reference population, as well as standardized sample collection and analysis. By contrast, the RIs were also verified using an indirect method involving retrospective data and statistical filtering, reflecting the actual analytical and pre-analytical conditions of the laboratory’s patient population. Consequently, both verification methods offer complementary value to the process (8).

Although it is presumed that our population’s iodine intake is adequate, and evaluating iodine status is not mandatory in areas without iodine deficiencies, a limitation of our study was that the subjects’ iodine status was not measured (29, 30).

Recently, Osinga et al. did a systematic revision and meta-analysis, and concluded that not excluding TPOAb-positive individuals led to an increase in the upper limit of TSH RI in all cohorts, with a mean increase of 0.65 (0.05-1.34) mIU/L in the first trimester of pregnancy (31). In this regard, indirect methods require robust statistical methods to differentiate between normal and pathological results. Another limitation of the present study is that we intentionally excluded all patients who had undergone more than one thyroid hormone and/or anti-thyroid antibody test. This was done to ensure consistency in the dataset and to prevent individuals with thyroid disease from being selected.

In conclusion, the results of this study highlight the importance of establishing accurate, population specific RIs for TSH in the first trimester of pregnancy. It is a robust and comprehensive approach that takes into account the population characteristics, the laboratory methodology, and preanalytical factors such as the time at which blood was collected.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are not publicly available due to preserve individuals’ privacy under the European General Data Protection Regulation, but are available from the corresponding author on request.

References CaseyBMDasheJSWellsCEMcIntireDByrdWLevenoKJ Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005;105:239–45. 10.1097/01.AOG.0000152345.99421.2215684146 SalazarPCisternasPMartinezMInestrosaNC. Hypothyroidism and cognitive disorders during development and adulthood: Implications in the central nervous system. Mol Neurobiol. 2019;56:2952–63. 10.1007/s12035-018-1270-y30073507 McNeilARStanfordPE. Reporting thyroid function tests in pregnancy. Clin Biochem Rev. 2015;36:109–26.26900190 AlexanderEKPearceENBrentGABrownRSChenHDosiouC 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27:315–89. 10.1089/thy.2016.045728056690 DoyleKBunchDR. Reference intervals: past, present, and future. Crit Rev Clin Lab Sci. 2023;60:466–82. 10.1080/10408363.2023.219674637036018 JonesGRDHaeckelRLohTPSikarisKStreichertTKatayevA Indirect methods for reference interval determination - review and recommendations. Clin Chem Lab Med. 2018;57:20–9. 10.1515/cclm-2018-007329672266 ThienpontLMVan UytfangheKBeastallGFaixJDIeiriTMillerWG Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 1: thyroid-stimulating hormone. Clin Chem. 2010;56:902–11. 10.1373/clinchem.2009.14017820395624 Martinez-SanchezLMarques-GarciaFOzardaYBlancoABrouwerNCanaliasF Big data and reference intervals: rationale, current practices, harmonization and standardization prerequisites and future perspectives of indirect determination of reference intervals using routine data. Adv Lab Med. 2020;2:9–25. 10.1515/almed-2020-003437359198 RitchieRFPalomakiG. Selecting clinically relevant populations for reference intervals. Clin Chem Lab Med. 2004;42:702–9. 10.1515/CCLM.2004.12015327003 Protocol de seguiment de l’embaràs a Catalunya. Tercera edició. Departament de Salut;Barcelona:2018. Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline − third Edition. CLSI document EP28-A3c. Wayne:CLSI;2013. TateJRYenTJonesGRD. Transference and validation of reference intervals. Clin Chem. 2015;61:1012–5. 10.1373/clinchem.2015.24305526089382 FarrellCLNguyenL. Indirect reference intervals: Harnessing the power of stored laboratory data. Clin Biochem Rev. 2019;40:99–111. 10.33176/AACB-19-0002231205377 HaeckelRWosniokWStreichertT. Review of potentials and limitations of indirect approaches for estimating reference limits/intervals of quantitative procedures in laboratory medicine. J Lab Med. 2021;45:35–53. 10.1515/labmed-2020-0131 MaCWangXWuJChengXXiaLXueF Real-world big-data studies in laboratory medicine: Current status, application, and future considerations. Clin Biochem. 2020;84:21–30. 10.1016/j.clinbiochem.2020.06.01432652094 MaSYuJQinXLiuJ. Current status and challenges in establishing reference intervals based on real-world data. Crit Rev Clin Lab Sci. 2023;60:427–41. 10.1080/10408363.2023.219549637038925 SikarisKA. Separating disease and health for indirect reference intervals. J Lab Med. 2021;45:55–68. 10.1515/labmed-2020-0157 MadurgaAArbiol-RocaANavarro-BadalMRde BaseaAC-BDot-BachD. Strategic use of Big Data: implementing reference intervals for serum folate and serum cobalamin. Biochem Med (Zagreb). 2025;35:010705. 10.11613/BM.2025.01070539974199 Stagnaro-GreenAAbalovichMAlexanderEAziziFMestmanJNegroR Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081–125. 10.1089/thy.2011.008721787128 YanYQDongZLDongLWangFRYangXMJinXY Trimester- and method-specific reference intervals for thyroid tests in pregnant Chinese women: methodology, euthyroid definition and iodine status can influence the setting of reference intervals: Reference intervals for thyroid tests in pregnant Chinese women. Clin Endocrinol (Oxf). 2011;74:262–9. 10.1111/j.1365-2265.2010.03910.x21044115 MarwahaRKChopraSGopalakrishnanSSharmaBKanwarRSSastryA Establishment of reference range for thyroid hormones in normal pregnant Indian women. BJOG. 2008;115:602–6. 10.1111/j.1471-0528.2008.01673.x18333941 KorevaarTIMSchalekamp-TimmermansSde RijkeYBVisserWEVisserWde Muinck Keizer-SchramaSMPF Hypothyroxinemia and TPO-antibody positivity are risk factors for premature delivery: the generation R study. J Clin Endocrinol Metab. 2013;98:4382–90. 10.1210/jc.2013-285524037884 MoonH-WChungH-JParkC-MHurMYunY-M. Establishment of trimester-specific reference intervals for thyroid hormones in Korean pregnant women. Ann Lab Med. 2015;35:198–204. 10.3343/alm.2015.35.2.19825729721 Reference Intervals for Children and Adults Elecsys® Thyroid Tests TSH, FT4, FT3, T4, T3, T-Uptake, FT4-Index, Anti-TPO, Anti-Tg, Anti-TSHR, Tg, hCT cobas e analyzers. CH-6343 Rotkreuz Switzerland: Roche Diagnostics International Ltd; 2020. RiegerKVogelMEngelCCeglarekUThieryJKratzschJ Referenzintervalle für eisenabhängige Blutparameter bei Kindern und Jugendlichen: Ergebnisse einer populationsgestützten Kohortenstudie (LIFE Child). J Lab Med. 2016;40:31–41. 10.1515/labmed-2015-0093 ValdésSMaldonado-AraqueCLago-SampedroALillo-MuñozJAGarcia-FuentesEPerez-ValeroV Reference values for TSH may be inadequate to define hypothyroidism in persons with morbid obesity: Di@bet.es study. Obesity (Silver Spring). 2017;25:788–93. 10.1002/oby.2179628276648 SunTLiuXYinC. Reference intervals for thyroid hormones in pregnant women. Endokrynol Pol. 2025;76:257–64. 10.5603/ep.10004940586409 DorizziRMSpiazziGRolliNMaltoniPMingollaLSgarzaniC Trimester-specific reference intervals for thyroid function parameters in pregnant Caucasian women using Roche platforms: a prospective study. J Endocrinol Invest. 2023;46:2459–69. 10.1007/s40618-023-02098-037095269 Bretón I, Díaz A, Gil Á, Recio MC, Vila L, Carlos MÁ. Informe del Comité Científico de la Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) en relación con la situación nutricional de la mujer en edad fértil, durante la gestación y la lactancia con respecto a la ingesta adecuada de yodo. Revista del Comité Científico de la AESAN. 2023;105-51. TorresMTFrancésLVilaLManresaJMFalguera-PuigGPrietoG Iodine nutritional status of women in their first trimester of pregnancy in Catalonia. BMC Pregnancy Childbirth. 2017;17(1):249. 10.1186/s12884-017-1423-428747228 OsingaJAJDerakhshanAPalomakiGEAshoorGMännistöTMarakaS TSH and FT4 Reference Intervals in Pregnancy: A Systematic Review and Individual Participant Data Meta-Analysis. J Clin Endocrinol Metab. 2022;107:2925–33. 10.1210/clinem/dgac42535861700
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010704" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010704" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010704" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(106) "First trimester of pregnancy TSH laboratory specific reference intervals established by an indirect method" ["journals_article_author"]=> string(79) "María Sanz-Felisi, Ariadna Arbiol-Roca, Paula Sánchez-García, Alicia Madurga" ["journals_article_author_country"]=> string(5) "Spain" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(81) "indirect method, pregnant women, reference intervals, thyroid stimulating hormone" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3366" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "9" ["meta_title"]=> string(106) "First trimester of pregnancy TSH laboratory specific reference intervals established by an indirect method" ["meta_desc"]=> string(106) "First trimester of pregnancy TSH laboratory specific reference intervals established by an indirect method" ["meta_keyw"]=> string(81) "indirect method, pregnant women, reference intervals, thyroid stimulating hormone" ["created"]=> string(19) "2025-12-09 11:52:28" ["modified"]=> string(19) "2026-02-17 09:23:30" } [43]=> object(stdClass)#92 (35) { ["journals_id"]=> string(4) "1212" ["journals_xml"]=> string(79775) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010703 10.11613/BM.2026.010703 Original articles The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods MorenoAna12SandúaAmaia12Ferrer-CostaRoser34Jacobs-CachaConxita34VaroNerea1Ancizu-MarckertJavier5RoblesJose Enrique5Pérez GraciaJose Luis26AlegreEstibaliz127GonzálezÁlvaro*127 Service of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain Laboratory of circulating biomarkers in cancer, Cancer Center Clínica Universidad de Navarra, Pamplona, Spain Clinical Biochemistry Department, Vall d’Hebron University Hospital, Barcelona, Spain Clinical Biochemistry, drug delivery and therapy Research Group, Vall d’Hebrón Research Institute (VHIR), Barcelona, Spain Department of Urology, Clínica Universidad De Navarra, Pamplona, Spain Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain IdiSNA, Navarra Institute for Health Research, Pamplona, Spain

The last two authors contributed equally to this work.

Corresponding author: agonzaleh@unav.es.

Author contributions

Ana Moreno: Investigation, Methodology, Visualisation, Formal analysis, Writing. Amaia Sandúa: Investigation, Methodology, Visualisation, Formal analysis, Writing. Roser Ferrer-Costa: Investigation, Methodology, Visualisation, Formal analysis, Writing. Conxita Jacobs-Cacha: Investigation, Methodology, Visualisation, Formal analysis, Writing. Nerea Varo: Investigation, Methodology, Visualisation, Formal analysis, Writing. Javier Ancizu-Marckert: Investigation, Resources. Jose Enrique Robles: Investigation, Resources. Estibaliz Alegre: Investigation, Methodology, Visualisation, Formal analysis, Writing, Formal análisis, Project administration, Supervision. Álvaro González: Investigation, Methodology, Visualisation, Formal analysis, Writing, Formal análisis, Project administration, Supervision.

15122025 15022026 36 1 010703 0304202516092025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• PSA International Standard has less extracellular vesicles and extracellular vesicles-PSA (ev-PSA) than serum samples

• PSA detection limit may impair ev-PSA quantification by some methods

• Ev-PSA concentrations differ between methods

• Ev-PSA can cause bias in serum PSA quantification between methods

Introduction

Prostate-specific antigen (PSA) can circulate bound to extracellular vesicles (EVs) and its measurement (ev-PSA) can be useful in prostate cancer. Although not designed with that purpose, total PSA assays react with ev-PSA. We evaluated the analytical performance of several total PSA assays in ev-PSA quantification and the impact of ev-PSA on total PSA measurement.

Materials and methods

Extracellular vesicles were isolated from 83 serum samples from prostate cancer patients by size exclusion chromatography or ultracentrifugation. PSA was quantified in serum, EVs, International Standard for PSA 17/100 from the World Health Organization (WHO IS 17/100) and exosomes from lymph node carcinoma of the prostate (LNCaP) cell line, using commercial immunoassays (Elecsys, Atellica, Immulite, Liaison and Kryptor).

Results

Nanoparticle tracking analysis showed that the WHO IS 17/100 contains significantly less EVs than serum (P < 0.001). The sensitivity to detect ev-PSA followed this order: Elecsys ~ Atellica > Immulite > Liaison > Kryptor. Ev-PSA could be detected in all serum samples with Elecsys and Atellica, but not with Immulite (87.8%), Liaison (58.5%) or Kryptor (48.8%). Bland-Altman analysis showed a proportional bias in ev-PSA quantification between Elecsys and other methods. Addition of ev-PSA to serum samples caused a proportional bias in PSA measurement between Elecsys and Immulite methods, with a relationship (r2 = 0.99; P < 0.001) between ev-PSA and the difference in total PSA concentration between both methods.

Conclusions

While ev-PSA can be measured using commercial kits, notable differences exist between methods, which could lead to potential discrepancies in serum total PSA results across various assays.

Keywords: prostate-specific antigenextracellular vesiclesimmunoassaysprostate cancerevaluation
Introduction

Prostate cancer is the most prevalent cancer in males and the second cause of cancer-related mortality (1). Approximately half of all males over the age of 70 will eventually be diagnosed with prostate cancer provoking high medical, psychological and economic costs for both patients and health systems. Prostate-specific antigen (PSA) plays a pivotal role in the diagnosis, prognosis, treatment selection, and follow-up of prostate cancer (2). Prostate-specific antigen circulates as: free PSA and PSA bound to either α1-antichymotrypsin (complexed PSA) or α2-macroglobulin (3). The latter is an immunologically hidden isoform, not recognized by routine analytical methods. Total PSA tests are designed to detect free PSA and complexed PSA with an equimolar response using antibodies that recognize both isoforms of the PSA molecule (4). These tests are calibrated with the International Standard from the World Health Organization (WHO IS) for PSA (first coded 96/670 and second coded 17/100), where the proportion of bound to free PSA is 90:10 (5). Despite these harmonization attempts, discrepancies between PSA concentrations quantified with different methodologies persist, thereby rendering the transfer of results challenging (6-8).

Extracellular vesicles (EVs) are small lipid membrane vesicles secreted by almost all cells into the extracellular space (9). Extracellular vesicles comprise exosomes (30-150 nm), originated as intraluminal vesicles within multivesicular bodies; microvesicles (100-1000 nm), formed by outward budding of the plasma membrane; and apoptotic bodies (500-2000 nm), released during programmed cell death (9).

Extracellular vesicles serve as carrier systems for parental cell-specific bioactive molecules, which modulate signaling pathways in recipient cells, regulating intercellular communication in a multitude of physiological and pathological processes (10-12). Active secretion of EVs is increased in cancer cells, contributing to tumor development (13). Present in accessible body fluids (blood, urine, semen, etc.), EVs are emerging as potentially clinically useful biomarkers (13, 14). Although a test kit based on nucleic acid analysis in EVs has been developed to diagnose prostate cancer, the application of EVs analysis in clinical laboratories is still a challenging issue (15). Some of the main problems are the use of complex technologies and the lack of standardized and reproducible methods that could be transferred between laboratories (16, 17).

Recent studies have demonstrated that PSA also circulates bound to EVs (ev-PSA) (18). Additionally, the proportion of ev-PSA is increased when serum total PSA is lower than 4 μg/L, differing significantly between prostate cancer patients and healthy controls or patients with benign hyperplasia (19, 20). Moreover, some commercial PSA kits, despite not being designed to react with this molecular form of PSA, do in fact recognize it (19). Total PSA assays use antibodies that may react differently, or even not react, with ev-PSA. Due to these reactivity differences, the presence of ev-PSA might cause a bias in the quantification of PSA, which can be quite relevant in some patients, as ev-PSA might account for more than 30% of serum total PSA (19).

Our aim was to evaluate the analytical performance of total PSA commercial methods in the quantification of ev-PSA, and to assess the impact of that ev-PSA on serum total PSA measurement.

Materials and methods Subjects

Blood samples were obtained from 83 prostate cancer patients, who attended the Medical Oncology Department of our institution between 2023 and 2024. Storage time was less than two years, which does not affect PSA stability (21). Samples were collected in 5 mL or 10 mL Vacutainer serum collection tubes (Becton Dickinson, Sunnyvale, USA). After clot formation, tubes were centrifuged at 2000xg for 10 min and serum samples were then aliquoted and stored at - 80°C in the collection C.0003132; 14/04/2014, of the National Biobank Registry. The study was approved by the Local Ethic Committee (2022.087), and all volunteers gave written informed consent for the study.

Commercial exosomes derived from the Lymph node carcinoma of the prostate (LNCaP) cell line were purchased from HansaBioMed Life Sciences (Tallinn, Estonia). The WHO IS PSA coded 17/100, was purchased from the National Institute for Biological Standards and Control (NISBC, South Mimms, UK) and reconstituted according to the manufacturer´s instructions. This standard replaces the exhausted stock 1st WHO IS coded 96/670.

Methods Extracellular vesicles isolation

Serum samples from 41 patients, randomly selected, were initially centrifuged at 16,000xg for 30 minutes to eliminate any residual cellular debris (Figure 1). Extracellular vesicles were then isolated using size exclusion chromatography (SEC) with the Exo-spin midi kit columns (Cell Guidance System, Cambridge, UK), in accordance with the manufacturer’s instructions.

Flowchart showing the distribution of 83 serum samples from prostate cancer patients across the different analyses performed. EVs - extracellular vesicles. PSA - prostate specific antigen.

To obtain both EVs-depleted serum and EVs from the same sample, 42 randomly selected serum samples were centrifuged at 16,000xg for 30 min and subsequently subjected to ultracentrifugation at 100,000xg for 90 min in a Hitachi CS150NX micro ultracentrifuge (Hitachi Koki Co., Tokyo, Japan). After centrifugation, the EVs-depleted serum (supernatant, sn) was carefully removed and the pellet containing the EVs was resuspended in female serum previously deprived of EVs by ultracentrifugation.

Additionally, the WHO IS 17/100 diluted (1:4) in phosphate buffered saline (PBS) was ultracentrifuged and resuspended in PBS.

Nanoparticle tracking analysis

The presence of EVs was analyzed in the WHO IS 17/100 and in a serum sample with a PSA concentration of 100.9 µg/L, used as a positive control, by Nanoparticle tracking analysis with a NanoSight LM20 (Malvern Panalytical, Malvern, UK). Particle size and concentration were determined and reported as nm and particles/mL, respectively.

Prostate specific antigen analysis

The concentrations of total PSA in serum (s-PSA), in serum-derived EVs (ev-PSA) and supernatants (sn-PSA) were measured using total PSA commercial assay kits with their respective analyzers: Elecsys (Cobas e602, Roche Diagnostics, Basel, Switzerland), Atellica (Atellica IM 1600, Siemens Healthineers, Erlangen, Germany), Immulite (Immulite 2000 XPi, Siemens Healthineers, Erlangen, Germany), Kryptor (Brahms Kryptor Compact Plus, Thermo Fisher, Waltham, USA), and Liaison (Liaison XL, Diasorin, Saluggia, Italy). All these methods are calibrated against the WHO IS PSA 96/670, but differ in the capture and tracer antibodies against different PSA epitopes and their declared limits of quantification (Table 1) (4).

Rate of ev-PSA detection and ev-PSA concentrations in 41 samples from prostate cancer patients quantified by different immunoassays
Assay Declared LOQ (µg/L) % of samples with detected ev-PSA ev-PSA(µg/L)
Elecsys 0.014 100 1.06 (0.43-3.68)
Atellica 0.02 100 0.92 (0.55-3.66)
Immulite 0.04 87.8 1.24 (0.34-2.68)
Kryptor 0.27 48.8 3.59 (1.85-5.91)
Liaison 0.09 58.5 3.44 (0.77-4.82)
ev-PSA - prostate specific antigen quantified in extracellular vesicles. LOQ - limit of quantification. ev-PSA is presented as median and interquartile range.
Linearity and detection limit analysis

Samples were prepared by serial dilutions of LNCaP exosomes using women´s EVs free serum supernatant. Linearity analysis was performed following the CLSI EP06 recommendations (22). The detection limit study was performed following the Spanish Society of Laboratory Medicine (SEQC-ML) recommendations (23).

Serum spiking with ev-PSA

A pool of women serum (400 µL) was spiked-in with 100 µL of five different concentrations of ev-PSA (0.529 to 6.93 µg/L) diluted in PBS or with 100 µL of PBS alone (Table 2). Prostate specific antigen was then quantified in duplicate using the Elecsys and Immulite assays.

Results from the spiking experiment with ev-PSA
Samples Spiking evPSA (µg/L) Dilution Expected evPSA (µg/L) PSA Elecsys(µg/L) PSA Immulite(µg/L) Δ PSA (Elecsys - Immulite)
1 0.529 1:5 0.106 0.106 0.077 0.029
2 0.979 1:5 0.196 0.189 0.160 0.029
3 1.61 1:5 0.322 0.322 0.271 0.051
4 2.66 1:5 0.532 0.535 0.444 0.091
5 6.93 1:5 1.386 1.380 1.195 0.185
A pool of women serum was spiked-in with five different concentrations of ev-PSA and total PSA was quantified in duplicate by Elecsys and Immulite assays. The PSA concentrations correspond to duplicates means. Δ PSA corresponds to the difference between PSA measured by Elecsys and PSA measured by Immulite. ev-PSA - prostate specific antigen quantified in extracellular vesicles. PSA - prostate specific antigen.
Statistical analysis

Sample size (N = 34) for each group was calculated based on an alpha of 0.05, a power of 0.8, and an expected effect size of 0.5. D’Agostino-Pearson normality test was used to study data distribution. Data was represented as median and interquartile range. Correlation was studied using Spearman correlation coefficient (r). When comparing the methods, ev-PSA results with the other immunoassays were referred to Elecsys results, as this was the method employed in a previous publication (19). For comparisons, Friedman test and Dunn’s multiple comparisons test were used. Regression analysis was performed with the Deming test and agreement between methods was assessed with Bland-Altman test (24). A two-tailed P-value of < 0.05 was considered statistically significant. Statistical analysis was performed using GraphPad Prism version 10.3 (GraphPad Software, Boston, USA).

Results Analysis of ev-PSA in the WHO International Standard 17/100 for total PSA

We observed that the mean particle concentration in the ultracentrifuged serum sample was 6.6 x108 ± 5.9 x107 particles/mL (101.5 ± 9.8 particles/frame) with a mean size of 115 ± 53 nm, and ev-PSA represented 0.66% of total PSA. However, the mean particle concentration in the WHO IS 17/100 was more than 10 times lower, 4.7 x107 ± 3.7 x106 particles/mL (7.8 ± 0.6 particles/frame) with a mean size of 135 ± 39 nm, and ev-PSA was only 0.2% of total PSA (P < 0.001).

Study of the ev-PSA reactivity to immunochemical methods

We previously observed that commercial exosomes from the LNCaP prostate cell line showed a total PSA concentration of 35.3 μg/g of exosomes using the Elecsys total PSA commercial assay (19). When serial dilutions were performed, all immunoassays showed a good linearity in the measuring range (dilution 1 corresponds to 2.48 µg/L of ev-PSA measured with Elecsys, Supplemental Figure 1), with a r2 > 0.97, and the 95% confidence intervals of the X- Y- intercepts containing the 0 value. The coefficient of variation at the concentrations of 0.2 and 0.1 µg/L was lower than 5% with all methods analyzed. However, the assays showed a very different analytical sensitivity, being higher for Elecsys and Atellica, which could detect a relative concentration of 0.016. Meanwhile, Immulite did not detect relative concentrations lower than 0.06, and Kryptor and Liaison lower than 0.16.

As the Elecsys method showed the best analytical sensitivity, we then studied its detection and quantification limits for ev-PSA, which were 0.01 µg/L and 0.02 µg/L, respectively. We replicated the study with the Immulite assay, which in comparison had higher detection and quantification limits: 0.04 µg/L and 0.11 µg/L, respectively. In both cases, the quantification limits were similar to those reported by the manufacturer for serum total PSA.

Circulating ev-PSA evaluation with different commercial immunoassays

We analyzed 41 samples with a median s-PSA concentration of 25.74 µg/L (12.16-72.32 µg/L), according to the Elecsys method (Figure 1). After EVs isolation by SEC, ev-PSA was detected in 100% of the samples when analyzed with the Elecsys and Atellica immunoassays but not with the other immunoassays (Table 1). In those samples (N = 20) where ev-PSA was measurable by all five methods, ev-PSA concentrations were significantly lower when measured with Immulite compared to Elecsys (P = 0.014) and Kryptor (P = 0.019) (Supplemental Figure 2). Concerning ev-PSA, Deming regression analysis showed that Atellica and Immulite immunoassays demonstrated the greatest concordance with the Elecsys immunoassay for ev-PSA. In contrast, Kryptor and Liaison significantly overestimated ev-PSA concentrations, with Kryptor showing the greatest deviation (Figure 2).

Deming regression analysis of ev-PSA measured with: (A) Elecsys and Atellica, (B) Immulite, (C) Kryptor, or (D) Liaison immunoassays.

We also assessed the agreement between Elecsys and the other methods to measure ev-PSA concentrations with Bland-Altman plots (Figure 3). We observed that the Elecsys assay showed a high agreement with Atellica assay, but there was a proportional bias compared to the other assays. For ev-PSA concentrations below 3 µg/L, the Elecsys assay reported higher concentrations than the Immulite, Kryptor or Liaison assays, and for ev-PSA concentrations below 1 µg/L, lower concentrations than the Atellica assay.

Bland-Altman plots of the ev-PSA ratio between (A) Elecsys and Atellica, (B) Immulite, (C) Liaison and (D) Kryptor assays against the mean value of the two assays. Dotted lines indicate the bias between the methods and the limits of agreement.

Comparison of the reactivity of ev-PSA and soluble total PSA

To assess whether the immunoreactivity differences were more relevant for ev-PSA than for the soluble forms present in the supernatant, we compared PSA concentrations in EVs and in EVs-free serum supernatant (sn-PSA) obtained by ultracentrifugation from 42 patients. Based on previous results, we focused on Elecsys and Immulite PSA methods (Figure 4 and Supplemental Table 1). Immulite/Elecsys ratio of sn-PSA was 0.96 (0.89 - 1.02), similar to that of serum (0.96 (0.86 - 1.05); P = 0.057), while in EVs the ratio decreased to 0.77 (0.66 - 0.83; P < 0.001). These results showed that ev-PSA exhibited different immunoreactivity compared to soluble sn-PSA when measured with Elecsys and with Immulite assays.

Comparison of the Immulite/Elecsys ratio of PSA concentrations measured in serum, extracellular vesicles (EV), and EV-free serum supernatant (SN). Lines and whiskers represent median and interquartile range. PSA - prostate specific antigen.

Impact of ev-PSA on discrepancies in total PSA results across immunoassays

The spiking experiment performed to study the impact of the different ev-PSA reactivity on serum total PSA measurement showed a relationship between the concentration of the added ev-PSA and the difference in total PSA concentration between Elecsys and Immulite (r2 = 0.99; Table 2 and Figure 5A). Furthermore, we observed that Elecsys produced significantly higher results than Immulite (P = 0.031; Figure 5B), with a mean bias of 18% ± 6%. To address that the difference was not due to matrix effect, we also measured samples to which only PBS was added and there was no significant difference between the two methods (P > 0.999).

(A) Relationship between the ev-PSA added and the difference between PSA measured with Elecsys and Immulite. (B) Comparison of the concentration measured with Elecsys and Immulite for different amounts of ev-PSA added to a woman serum sample. Horizontal lines represent median. PSA - prostate specific antigen.

Regarding the other methods, we analyzed the differences between s-PSA results related to ev-PSA measured in EVs obtained by SEC. We observed a significant correlation between the difference of s-PSA between Kryptor or Liaison and Elecsys in relation to ev-PSA measured with Elecsys (r = 0.59; P < 0.001) and (r = 0.49; P = 0.001) respectively. Of note, there was a poor but significant correlation between ev-PSA measured with Atellica and the differences in serum PSA between the two Siemens methods, Atellica and Immulite (r = 0.37; P = 0.019). This correlation was also observed when we analyzed the ev-PSA in EVs obtained by ultracentrifugation, which confirmed that this effect was not due to EVs extraction method.

Discussion

In this work, we evaluated the quantification of ev-PSA using different commercial methods designed for the analysis of serum PSA. These commercial kits were selected because they are routinely used in clinical laboratories, their antibodies reactivity has been described, and their harmonization has been analyzed in most of them (4, 6, 7). The possibility of using these PSA assays to determine the concentration of PSA in EVs was already established (19). However, these commercial methods were not designed to measure this circulating form of PSA, and their epitopes can be unexposed or hidden within these particles. Moreover, the methods analyzed here use antibodies that recognize different epitopes present in the PSA molecule and have different affinities (4). We observed that all of them reacted with ev-PSA, which means that the recognized epitopes are exposed to the antibodies. This suggests that ev-PSA is located at the surface of the EVs, either integrated or, more likely, associated with the membrane (25).

The concentration of ev-PSA is lower than the soluble circulating isoforms and, in most cases, close to the quantification limit (19). We observed that all the methods showed linearity in the response below 2.5 µg/L, which is the range of the ev-PSA concentration usually present in serum. The sensitivity to ev-PSA changed noticeably between the immunochemical methods studied, with Elecsys and Atellica being the most sensitive of the assays analyzed here. It is interesting to note that the sensitivity differs between the two Siemens methods, being lower in the Immulite assay than in the Atellica method. However, all of them presented a good reproducibility.

Most commercial PSA kits are calibrated using the WHO IS 96/670 for PSA, which allows equimolar reactivity with total and free PSA, thereby reducing interlaboratory coefficients of variation in the measurement of the major serum PSA isoforms (5). However, discordances among laboratories for serum PSA concentrations are approximately 15% (26). At the time this standard was developed, ev-PSA had not been described (27). This standard is obtained from seminal fluid, which is rich in EVs (28), but we have observed that it contains very low concentrations of EVs and ev-PSA. The low levels of ev-PSA in the WHO IS 17/100 and the use of antibodies not designed to recognize it in an equimolar way may also cause a bias in the comparison of the s-PSA reactivity between different methods. This can occur especially when the proportion of ev-PSA is high, which is more common when s-PSA is less than 4 µg/L (19). This bias can be quite relevant as in some patients, ev-PSA might account for more than 30% of serum total PSA, and even higher than the percentage of free PSA.

We have observed that ev-PSA reacts differently depending on the commercial method used. Hence, there was an important bias when comparing Immulite, Kryptor and Liaison with Elecsys assay. However, as expected, there was a strong agreement between these assays when analyzing s-PSA (7). Also, while the Elecsys and Atellica assays determined ev-PSA concentrations in all samples (some very close to the limit of quantification), Liaison and Kryptor failed to quantify most of them. The difference in the recognition of the soluble form of PSA and ev-PSA was also demonstrated with the higher correlation and agreement between methods for s-PSA and sn-PSA, compared to ev-PSA. This is especially relevant in the case of Kryptor assay, where although the limit of detection was higher than that of Elecsys and could not detect ev-PSA in most samples, there was an overestimation of ev-PSA concentration in the measured range. This could be due to the different epitopes recognized by the monoclonal antibodies that react distinctly with ev-PSA (4). Ferraro et al. showed a general tendency of the Roche assays to overestimate and of the Siemens assays to underestimate serum PSA concentrations (6). The observed overestimation also holds true for ev-PSA and even to a greater degree, but with a difference between Atellica and Immulite. It is interesting to note that the difference in serum total PSA between these two Siemens Healthineers methods correlates with the concentration of ev-PSA in the samples. Importantly, those differences in ev-PSA reactivity affecting PSA quantification, have been observed using two EVs isolation methods (SEC and ultracentrifugation), which suggests that our observations were not influenced by the EVs purification method (17). Considering all this, we can conclude that the different immunoreactivity of ev-PSA might cause a bias between serum PSA commercial methods.

Despite the efforts made for the harmonization of PSA measurement, it was observed that the bias was not within the analytical performance specifications (± 10.6%) based on biological variation, as previously described by the European Biological Variation Study (29). The type of antibody can contribute to the bias between different methods. However, if the concentration of ev-PSA is high in a serum sample, it could produce different serum total PSA results with different methods due to the distinct reactivity of ev-PSA, as shown here, and this could have implications for the transfer of serum results between laboratories that use different methods. The effect of ev-PSA is relevant at concentrations lower than 4 µg/L, where the percentage of this form can be higher than 10% and even reach 40% of total PSA (19). Probably, at high PSA concentrations, where the proportion of ev-PSA is usually much lower, the effect could be negligible. For this reason, in the standardization of the methodology, commercial kits should consider the presence of ev-PSA and design antibodies that also react equimolarly with ev-PSA. Further studies would be needed to address this relevant point.

Since observed changes in EVs should undoubtedly be attributed to changes in the clinical status of the patient and not to differences in the isolation and/or analysis process, the use of EVs as a liquid biopsy in clinical practice has been hampered by the lack of standardization of techniques for EVs isolation and subsequent analysis (9, 17). Furthermore, this lack of standardization also limits the reproducibility of the measurement, making it difficult to compare and share results between different research groups (18, 30). Many of the test protocols usually used are not commercially available and lack reference materials and experimental controls to be reliably used for standardization of experiments between laboratories. We have previously shown that using the Elecsys total PSA assay, the ev-PSA/s-PSA ratio can differentiate prostate cancer patients from both benign prostatic hyperplasia patients and healthy controls (19). For this reason, the use of standardized commercial kits could facilitate comparison between laboratories. However, a methodological analysis of commercial kits for use with EVs, as shown here, is necessary to facilitate interlaboratory comparisons and multicenter studies.

The reactivity of the method used against ev-PSA can lead to over- or underestimation of total PSA depending on the assay used. At s-PSA concentrations lower than 4 µg/L, where the ratio ev-PSA/s-PSA is higher, is probably where ev-PSA has a more significant effect on the bias between methods (19). This bias can cause relevant clinical implications, as the proportion of ev-PSA to total PSA is higher in patients with benign prostatic hyperplasia compared to cancer patients (19). In addition, it could affect patient follow-up with total PSA when ev-PSA concentrations change during the course of the disease. In addition, it could explain the discrepancy in total PSA results obtained with certain measurement systems in specific patient subsets, impairing the interchangeability of methods.

Our study has two main limitations. First, we focused on technical performance rather than clinical performance. However, our results suggest that, at least, the ev-PSA could influence the use of different commercial kits for the monitoring of cancer patients. Second, we evaluated only a subset of commercially available PSA assays. Further studies would be needed with more commercial methods and performing an in-depth analysis of the s-PSA range where the effect of ev-PSA would have more impact. In summary, here we show that ev-PSA can be measured using commercial kits such as Elecsys, Atellica, Immulite, Kryptor and Liaison, not designed for this form of PSA. It should be considered that ev-PSA measurement is method-dependent and that the detection limit for ev-PSA could impair its detection and quantification (8). Finally, ev-PSA can be a source of discrepancies in the routine serum total PSA results obtained with different commercial PSA assays and should be considered when transferring results between laboratories.

Acknowledgements

This work was supported by a José Luis Castaño-SEQC-ML Foundation Grant. We would like to thank Dra. María Romero for her support in the preparation of the manuscript.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalA Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. 10.3322/caac.2166033538338 FerraroSBussettiMPanteghiniM. Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice. Clin Chem. 2021;67:602–9. 10.1093/clinchem/hvab00233619518 BeckerCLiljaH. Individual prostate-specific antigen (PSA) forms as prostate tumor markers. Clin Chim Acta. 1997;257:117–32. 10.1016/S0009-8981(96)06437-69028629 StenmanUHPausEAllardWJAnderssonIAndresCBarnettTR Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. Tumour Biol. 1999;20:1–12. 10.1159/00005652310628402 RaffertyBRigsbyPRoseMStameyTGaines DasR. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem. 2000;46:1310–7. 10.1093/clinchem/46.9.131010973859 FerraroSBussettiMRizzardiSBragaFPanteghiniM. Verification of Harmonization of Serum Total and Free Prostate-Specific Antigen (PSA) Measurements and Implications for Medical Decisions. Clin Chem. 2021;67:543–53. 10.1093/clinchem/hvaa26833674839 van RossumHHHoldenriederSBallieuxBBadrickTCYunYMZhangC Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study. Clin Chem. 2024;70:669–79. 10.1093/clinchem/hvae00538385453 StephanCKlaasMMullerCSchnorrDLoeningSAJungK. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006;52:59–64. 10.1373/clinchem.2005.05917016391327 GonzálezÁLópez-BorregoSSandúaAVales-GomezMAlegreE. Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories. Crit Rev Clin Lab Sci. 2024;61:435–57. 10.1080/10408363.2024.230993538361287 AlegreESanmamedMFRodriguezCCarranzaOMartin-AlgarraSGonzalezA. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med. 2014;138:828–32. 10.5858/arpa.2013-0134-OA24878024 ChenGHuangACZhangWZhangGWuMXuW Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382–6. 10.1038/s41586-018-0392-830089911 ValadiHEkstromKBossiosASjostrandMLeeJJLotvallJO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9. 10.1038/ncb159617486113 LogozziMMizzoniDCapassoCDel PreteSDi RaimoRFalchiM Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH. J Enzyme Inhib Med Chem. 2020;35:280–8. 10.1080/14756366.2019.169724931790614 DuijveszDVersluisCYvan der FelsCAVredenbregt-van den BergMSLeivoJPeltolaMT Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer. Int J Cancer. 2015;137:2869–78. 10.1002/ijc.2966426139298 McKiernanJDonovanMJO’NeillVBentinkSNoerholmMBelzerS A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016;2:882–9. 10.1001/jamaoncol.2016.009727032035 WelshJAGoberdhanDCIO’DriscollLBuzasEIBlenkironCBussolatiB Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404. 10.1002/jev2.1240438326288 MacíasMRebmannVMateosBVaroNPerez-GraciaJLAlegreE Comparison of six commercial serum exosome isolation methods suitable for clinical laboratories. Effect in cytokine analysis. Clin Chem Lab Med. 2019;57:1539–45. 10.1515/cclm-2018-129730990781 LogozziMAngeliniDFIessiEMizzoniDDi RaimoRFedericiC Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. Cancer Lett. 2017;403:318–29. 10.1016/j.canlet.2017.06.03628694142 SandúaASanmamedMFRodriguezMAncizu-MarckertJGurpideAPerez-GraciaJL PSA reactivity in extracellular microvesicles to commercial immunoassays. Clin Chim Acta. 2023;543:117303. 10.1016/j.cca.2023.11730336948237 LogozziMAngeliniDFGiulianiAMizzoniDDi RaimoRMaggiM Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study. Cancers (Basel). 2019;11:1449. 10.3390/cancers1110144931569672 AlegreEVaroNFernandez-CallePCallejaSGonzalezA. Impact of ultra-low temperature long-term storage on the preanalytical variability of twenty-one common biochemical analytes. Clin Chem Lab Med. 2022;60:1003–10. 10.1515/cclm-2022-006335470640 Clinical and Laboratory Standards Institute (CLSI). Evaluation of Linearity of Quantitative Measurement Procedures. 2nd ed. CLSI guideline EP06. Wayne: CLSI; 2020. Sánchez ManriqueMGella TomásFJ. Recomendaciones para el estudio de la capacidad de detección de los procedimientos de medida en el laboratorio clínico. Química Clínica. 2004;23:439–41. [in Spanish] BlandJMAltmanDG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135–60. 10.1177/09622802990080020410501650 JungALMoller JorgensenMBaekRGrissKHanMAuf Dem BrinkeK Surface Proteome of Plasma Extracellular Vesicles as Biomarkers for Pneumonia and Acute Exacerbation of Chronic Obstructive Pulmonary Disease. J Infect Dis. 2020;221:325–35. 10.1093/infdis/jiz46031617573 BoegemannMArsovCHadaschikBHerkommerKImkampFNoferJR Discordant prostate specific antigen test results despite WHO assay standardization. Int J Biol Markers. 2018;33:275–82. 10.1177/172460081875475029734838 GabrielKIngramAAustinRKapoorATangDMajeedF Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS One. 2013;8:e70047. 10.1371/journal.pone.007004723936141 AalbertsMStoutTAStoorvogelW. Prostasomes: extracellular vesicles from the prostate. Reproduction. 2013;147:R1–14. 10.1530/REP-13-035824149515 CarobeneAGuerraELocatelliMCucchiaraVBrigantiAAarsandAK Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer. Clin Chim Acta. 2018;486:185–91. 10.1016/j.cca.2018.07.04330063887 PangBZhuYNiJRuanJThompsonJMaloufD Quality Assessment and Comparison of Plasma-Derived Extracellular Vesicles Separated by Three Commercial Kits for Prostate Cancer Diagnosis. Int J Nanomedicine. 2020;15:10241–56. 10.2147/IJN.S28310633364756
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010703" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010703" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010703" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(105) "The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods" ["journals_article_author"]=> string(186) "Ana Moreno, Amaia Sandúa, Roser Ferrer-Costa, Conxita Jacobs-Cacha, Nerea Varo, Javier Ancizu-Marckert, Jose Enrique Robles, Jose Luis Pérez Gracia, Estibaliz Alegre, Álvaro González" ["journals_article_author_country"]=> string(5) "Spain" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(92) "prostate-specific antigen, extracellular vesicles, immunoassays, prostate cancer, evaluation" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3930" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "8" ["meta_title"]=> string(105) "The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods" ["meta_desc"]=> string(105) "The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods" ["meta_keyw"]=> string(92) "prostate-specific antigen, extracellular vesicles, immunoassays, prostate cancer, evaluation" ["created"]=> string(19) "2025-12-09 11:45:07" ["modified"]=> string(19) "2026-02-17 09:23:44" } [44]=> object(stdClass)#93 (35) { ["journals_id"]=> string(4) "1211" ["journals_xml"]=> string(131914) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010702 10.11613/BM.2026.010702 Original articles Serum lipoprotein(a) concentrations in presumably healthy Polish subjects in relation to age, sex, and cardiometabolic risk factors StefańskaAnna*1BergmannKatarzyna1SzternelŁukasz1SiódmiakJoanna1WolskaAleksandra1DwojacznyBlanka2KrintusMagdalena1PanteghiniMauro1 Department of Laboratory Medicine, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, Poland Department of Human Physiology, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, Poland Corresponding author: zuzanna@cm.umk.pl

Author contributions

A Stefańska: Conceptualization, Methodology, Formal analysis, Investigation, Resources, Data curation, Writing – Original Draft, Visualization; K Bergmann: Methodology, Formal analysis, Investigation, Resources, Writing – Original Draft, Visualization; Ł Szternel: Methodology, Investigation, Resources; J Siódmiak: Methodology, Investigation, Resources; A Wolska: Methodology, Investigation, Resources; B Dwojaczny: Methodology, Investigation, Resources; M Krintus: Methodology, Resources, Writing - Review & Editing; M Panteghini: Conceptualization, Writing - Review & Editing, Supervision. All authors revised the manuscript and approved its final version.

15122025 15022026 36 1 010702 0504202516092025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• The first Polish study evaluating lipoprotein(a) (Lp(a)) concentrations in both adults and children

• The first Polish study including Lp(a)-dependent lipid indices: %Lp(a)/apoB and %Lp(a)-C/LDL-C

• We evaluate the association of Lp(a) with age, sex and cardiometabolic risk factors

• We found a significant impact of age and LDL-C on Lp(a) concentration

Introduction

Lipoprotein(a) (Lp(a)) is an independent cardiovascular risk factor, primarily determined by genetic factors. This study assessed Lp(a) concentrations in presumably healthy subjects and evaluated its association with age, sex, and cardiometabolic risk factors.

Materials and methods

The study included presumably healthy 1046 adults and 276 children. Laboratory parameters: lipid profile, Lp(a), apolipoprotein B (apoB), glucose, HbA1c, C-reactive protein and creatinine were measured. Contributions of Lp(a)-apoB to apoB (%Lp(a)/apoB) and of Lp(a)-cholesterol to LDL-cholesterol (%Lp(a)-C/LDL-C) were calculated.

Results

Lipoprotein(a) concentrations were significantly higher in adults than in children (P = 0.014) and in women than in girls (P = 0.003), but showed no overall sex differences. In women, Lp(a) was higher after age 50, while in men a slight rise occurred after age 60. Lipid indices %Lp(a)/apoB and %Lp(a)-C/LDL-C declined in men until their 40s and was higher after 50 in both sexes. In a multivariable logistic regression model increased LDL-C concentration was a significant predictor of Lp(a) ≥ 0.30 g/L in women (odds ratio, OR = 1.77; P = 0.021) and children (OR = 2.83; P = 0.009). Boys had twofold higher probability of Lp(a) ≥ 0.30 g/L than girls (OR = 2.17; P = 0.024).

Conclusions

Lipoprotein(a) concentrations increase with age, especially after 50 in women and 60 in men, and are significantly associated with LDL-C. Rising %Lp(a)/apoB and %Lp(a)-C/LDL-C alongside falling apoB and LDL-C suggest greater atherogenicity in older individuals, particularly men. These findings support including Lp(a) in lipid profile for better cardiovascular risk assessment.

Keywords: lipoprotein(a)cardiovascular risklipoproteinsdyslipidemiaepidemiology
Introduction

Lipoprotein(a) (Lp(a)), a low-density lipoprotein (LDL)-like lipoprotein containing apolipoprotein(a), is an independent risk factor for cardiovascular disease (CVD), including coronary artery disease (CAD), myocardial infarction, stroke and peripheral arterial disease (1). Guidelines have classified serum Lp(a) concentrations for cardiovascular risk assessment as low (< 0.30 g/L; < 75 nmol/L), moderate (0.30-0.50 g/L; 75-125 nmol/L), high (0.50-1.80 g/L; 125-450 nmol/L), and very high (> 1.80 g/L; > 450 nmol/L), respectively (1, 2). They advocate for a single lifetime Lp(a) measurement as part of comprehensive CVD risk evaluation, emphasizing its role in identifying individuals at underestimated risk, particularly those with high and very high concentrations. Lipoprotein(a) measurement is strongly recommended in subjects with a personal or family history of premature cardiovascular events (1, 2). Currently, no approved pharmacologic therapies specifically target Lp(a) reduction. Some lipid-lowering agents, e.g. proprotein convertase subtilisin/kexin 9 inhibitors and cholesteryl ester transfer protein inhibitors, demonstrate only modest Lp(a) lowering effects (1).

More than 90% of the variation in Lp(a) concentrations in blood is determined by genetic factors, with significant differences observed between ethnic groups and among European populations (3, 4). Studies suggest that Lp(a) concentrations may increase with age, particularly in postmenopausal women (5, 6). Additionally, various non-genetic factors, including kidney, liver, and thyroid diseases, inflammation and certain medications, can influence Lp(a) concentrations. Accordingly, current guidelines recommend interpreting Lp(a) values with caution in individuals with these conditions (1, 2).

To date, only a few studies have examined the distribution of Lp(a) values in the Polish adult population (7-9). However, data on Lp(a) distribution in Polish children are still lacking. Beyond the adult population, there is growing recognition of the need to assess Lp(a) concentrations in children. Pediatric guidelines recommend lipid screening at two key time points, i.e., between 9-11 and 17-21 years, to identify individuals at risk for early-onset atherosclerotic cardiovascular disease (ASCVD) (10). Incorporating Lp(a) measurements into pediatric ASCVD risk assessment is also desirable (11). Nevertheless, no study has evaluated Lp(a) concentrations in Polish adults and children at the same time. Therefore, this study aims to assess Lp(a) concentrations in the Polish population, encompassing both adults and children, while considering age, sex, and selected non-genetic factors. It also examines the prevalence of elevated Lp(a) values and the association with cardiometabolic risk factors.

Materials and methods Study design

This cross-sectional study included a total number of 1322 presumably healthy Polish subjects, selected based on defined inclusion and exclusion criteria (Figure 1S, supplementary data). Between 2011 and 2019, adults were recruited through workplaces, website announcements, and wall posters in public places, while children were recruited from primary schools. All individuals (parents for children) provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and approved by the Bioethics Committee of Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland (approval no. KB 507/2024, 10.12.2024).

Distribution of serum Lp(a) concentrations in adults (A) and children (B). Lp(a) - lipoprotein(a).

Exclusion criteria included pregnancy, growth hormone replacement therapy, a history of chronic or acute inflammation or serum C-reactive protein (CRP) concentrations ≥ 10 mg/L, an estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73 m2, and thyroid disorders. Thyroid-related exclusion criteria encompassed thyrostatic treatment, radioactive iodine therapy, thyroid hormone replacement therapy, or thyroid-stimulating hormone (TSH) concentrations in serum outside the previously published reference ranges (12, 13). Individuals with serum LDL-cholesterol (LDL-C) concentrations ≥ 4.91 mmol/L (≥ 190 mg/dL), as well as with chronic liver disease or alanine aminotransferase (ALT) activity in serum exceeding two times the sex-specific upper reference limits: 0.82 µkat/L (49 U/L) for men and 0.55 µkat/L (33 U/L) for women were also excluded.

Definition of subject characteristics and cardiometabolic parameters

Subject characteristics were determined based on demographic, clinical and laboratory parameters. Age, smoking habits, medical history and medication use were collected through a medical questionnaire, conducted by trained medical staff: general practitioners and laboratory specialists. Height (cm) and weight (kg) were measured using standard methods, and body mass index (BMI) derived. In adult, overweight was defined as a BMI between 25 and 29.9 kg/m2, while obesity was classified as a BMI of ≥ 30 kg/m2. In children, overweight was defined as BMI ranging from 85th to less than the 95th percentile, while obesity was defined as BMI ≥ 95th percentile, based on the Centers for Disease Control and Prevention’s sex-specific BMI-for-age growth charts (14). Systolic and diastolic blood pressure were measured twice in a seated position after at least 10 min of rest, following standard procedures. Hypertension was defined in adults as blood pressure ≥ 140/90 mmHg or use of antihypertensive treatment, and in children as blood pressure ≥ 95th percentile, based on the sex and height-specific charts from the Polish Hypertension Society recommendations (15). Smoking status was categorized as: current smoker, ex-smoker, or non-smoker. Dyslipidemia in adults was characterized by at least one of the following findings: serum triglycerides (TG) ≥ 1.7 mmol/L (≥ 150 mg/dL), total cholesterol (TC) ≥ 5.0 mmol/L (≥ 190 mg/dL), LDL-C ≥ 3.0 mmol/L (≥ 115 mg/dL), non-high density lipoprotein (HDL) cholesterol (non-HDL-C) ≥ 3.4 mmol/L (≥130 mg/dL), apolipoprotein B (apoB) > 1.00 g/L, HDL-cholesterol (HDL-C) ≤ 1.2 mmol/L (≤ 45 mg/dL) for women and ≤ 1.0 mmol/L (≤ 40 mg/dL) for men, respectively, or use of lipid-lowering medications (2). In children, dyslipidemia was defined by at least one abnormal serum lipid parameter as follows: TC ≥ 4.4 mmol/L (≥ 170 mg/dL), TG ≥ 0.85 mmol/L (≥ 75 mg/dL) for children < 10 years old and ≥ 1.02 mmol/L (≥ 90 mg/dL) for those aged 10-11 years, respectively; LDL-C ≥ 2.85 mmol/L (≥ 110 mg/dL), HDL-C ≤ 1.17 mmol/L (≤ 45 mg/dL), and non-HDL-C ≥ 3.1 mmol/L (≥ 120 mg/dL) (2). Impaired fasting glucose and type 2 diabetes were diagnosed according to the American Diabetes Association criteria (16). Serum CRP concentrations of 3.0 to 9.9 mg/L were considered as low-grade inflammation. A postmenopausal status was assigned to women aged ≥ 52 years (17). Cardiovascular risk thresholds for Lp(a) were set at < 0.30 g/L (< 75 nmol/L) for low, 0.30-0.50 g/L (75-125 nmol/L) for intermediate, and > 0.50 g/L (> 125 nmol/L) for high/very high risk (2). The study considered hypertension, prediabetes/diabetes, smoking, dyslipidemia, low-grade inflammation, overweight/obesity, and postmenopausal status as cardiometabolic risk factors.

Laboratory measurements

Fasting venous blood samples were collected from each participant at 7.00-9.00 a.m. using disposable Vacutainer system (Becton Dickinson, Franklin Lakes, USA) into a 6-mL tube with clot activator to obtain serum for biochemical measurements, two 2-mL tubes containing EDTA for HbA1c and sodium fluoride for glucose measurements, respectively. Samples with clot activator were left for 30 minutes at room temperature to clot completely and then centrifuged at 3000 rpm for 15 minutes. Samples for glucose testing were centrifuged immediately after collection at 3000 rpm for 15 minutes at 4 °C. Concentrations of plasma glucose and HbA1c in the whole blood were measured in fresh samples, while TC, HDL-C, TG, apoB, Lp(a), creatinine, CRP, TSH, ALT, aspartate aminotransferase (AST), and γ-glutamyltransferase (GGT) were assayed in deep-frozen (− 80 °C) serum samples. Samples were stored for a maximum of 2 years.

All basic biochemical measurements were performed on the Alinity platform (Abbott Laboratories, Chicago, USA). Reagents for measuring apoB and Lp(a), using immunoturbidimetric methods, were supplied by Randox Laboratories Ltd. (Crumlin, Northern Ireland, UK). Lipoprotein(a) and apoB measurements were performed using the ABX Pentra 400 analyzer (Horiba ABX, Montpellier, France). The apoB assay is traceable to the IFCC/WHO reference material SP3-08. The Lp(a) assay, licensed from Denka Seiken, is based on an antigen-antibody reaction between Lp(a) in a sample and anti-Lp(a) (rabbit) polyclonal antibodies adsorbed to latex particles. This assay utilizes a five-point calibration (analytical measurement range 0.03-0.90 g/L) and is traceable to the WHO/IFCC reference material SRM 2B. Lipoprotein(a) measurements showed a between-run imprecision (as coefficient of variation, CV) < 6.1%, with a limit of detection (LoD) of 0.03 g/L. Low density lipoprotein-C was calculated using the Sampson formula, while non-HDL-C was determined by subtracting HDL-C from TC (18). An estimated glomerular filtration rate was assessed using the 2021 CKD-EPI equation for adults and the Schwartz formula for children, based on serum creatinine concentration measured by the enzymatic method. Non-Lp(a) apoB was calculated after converting Lp(a) and apoB concentrations from g/L to nmol/L. The conversion factors used were 0.00055 for apoB from nmol/L to g/L, and 1818 for apoB from g/L to nmol/L. For Lp(a), to convert g/L to nmol/L results were multiplied by 215 (19). The number of non-Lp(a) apoB-containing particles was determined by subtracting Lp(a) particle count (in nmol/L) from the total apoB particle count (in nmol/L) and then converting this value to g/L by multiplying by 0.00055. Lipoprotein(a)-cholesterol (Lp(a)-C) was estimated using the Rosenson-Marcovina formula as: Lp(a) (nmol/L) x 0.077 = Lp(a)-C (mg/dL). The calculated Lp(a)-C was then subtracted from LDL-C to obtain LDL-CLp(a)corr (20). This formula was selected because studies on large cohorts have shown that the conventional method, which assumes Lp(a)-C comprising 30% of Lp(a) mass, overestimates Lp(a)-C at higher Lp(a) concentrations, leading to an underestimation of LDL-CLp(a)corr. The Rosenson-Marcovina formula estimates Lp(a)-C as 16.6% of Lp(a) mass, providing a more accurate correction.

Statistical analysis

Statistical analysis was performed using Statistica 13.3 software (StatSoft Inc., Tulsa, USA). Normality was assessed using the Shapiro-Wilk test and data presented as median with Q1-Q3 ranges (25th-75th percentile) for non-Gaussian distributions. Lipoprotein(a) values < LoD (0.03 g/L) were recorded as 0.03 for calculations. Comparisons between two groups were performed using the Student’s t-test (Gaussian) or the Mann–Whitney U test (non-Gaussian data distribution), while multiple-group comparisons were performed using the Kruskal–Wallis test. Fisher’s exact test or the Chi-squared test were used to compare categorical variables. Two-way ANOVA models were used to evaluate median values and 95% confidence interval (CI) for medians by increasing age. Statistical significance (P) for age by sex interaction was calculated with tests of between-subject effects. Spearman rank correlation coefficients were calculated between Lp(a) and cardiometabolic risk factors. Multivariable linear regression was used to assess the relationship between Lp(a) (dependent variable) and cardiometabolic risk factors (independent variables), with adjusted R2 reported. Logistic regression examined associations between high Lp(a) concentrations and cardiometabolic risk factors, with odds ratios calculated per unit increase in risk factor occurrence. For multivariable analyses, non-Gaussian variables were log-transformed. A P-value < 0.05 was considered statistically significant.

Results General characteristics of studied population and lipid profile analysis

The study included 1046 Caucasian adults (54% women), aged 18-99 years, and 276 prepubertal Caucasian children (aged 9-11 years). Participants originated from both urban and rural areas of the Kuyavian-Pomeranian Voivodeship, a region in north-central Poland (Figure 2S, supplementary data). Table 1 summarizes the characteristics of studied subjects. In adults, the prevalence of overweight and dyslipidemia, characterized by elevated LDL-C, TG, apoB, non-HDL-C, and/or lower HDL-C, was significantly higher in men than in women. Among children, overweight was significantly more frequent in boys than in girls (16.4% vs. 8.1%; P = 0.034). The prevalence of hypertension was almost 3-times higher in girls than in boys, even if with a borderline statistical significance (P = 0.055).

Serum lipoprotein(a) concentrations across age categories. Data are expressed as medians, with vertical bars indicating 95% confidence intervals. Age categories (x-axis): 0: 9-11 years, 1: 18-29 years, 2: 30-39 years, 3: 40-49 years, 4: 50-59 years, 5: 60-69 years, 6: 70-99 years. Lp(a) - lipoprotein(a).

Characteristics of recruited subjects
Total adults(N = 1046) Adult women(N = 562) Adult men(N = 484) P-value women vs. men Total children(N = 276) Girls(N = 148) Boys(N = 128) P-value girls vs. boys
Age, years* 42 (18-99) 42 (33-56) 42 (32-54) 0.230 10 (9-11) 10 (9-11) 10 (9-11) 0.522
Menopause - 32.7% - - - - - -
Risk factors
Overweight 34.4% 26.2% 44.0% < 0.001 12.0% 8.1% 16.4% 0.034
Obesity 16.0% 15.2% 17.2% 0.381 12.3% 10.1% 14.8% 0.236
CRP 3-9.9 mg/L 13.6% 15.0% 11.9% 0.144 9.1% 9.5% 8.6% 0.795
Prediabetes 19.8% 17.9% 21.9% 0.105 11.4% 10.2% 12.8% 0.499
Type 2 diabetes 5.6% 4.9% 6.3% 0.324 0 0 0 -
TC≥ 5.0 mmol/L (adults),≥ 4.4 mmol/L (children) 56.2% 57.1% 55.2% 0.537 50.7% 52.7% 48.4% 0.477
LDL-C≥ 3.0 mmol/L (adults),≥ 2.85 mmol/L (children) 52.1% 48.9% 55.8% 0.026 28.3% 29.1% 27.3% 0.741
ApoB> 1.00 g/L 36.5% 49.1% 58.1% 0.004 12.3% 13.5% 10.9% 0.513
TG≥ 1.7 mmol/L (adults),≥ 0.85/≥ 1.02 mmol/L (children) 19.6% 12.8% 27.5% <0.001 33.3% 31.8% 35.2% 0.513
HDL-C≤ 1.2/≤ 1.0 mmol/L (women/men),≤ 1.17 mmol/L (children) 13.0% 7.1% 19.9% <0.001 10.5% 10.8% 10.2% 0.872
Non-HDL-C≥ 3.4 mmol/L (adults),≥ 3.1 mmol/L (children) 58.8% 52.9% 65.7% <0.001 37.3% 39.2% 35.2% 0.494
eGFR 60-89mL/min/1.73m2 24.9% 24.6% 25.3% 0.794 3.3% 3.1% 3.5% 0.853
Hypertension 22.3% 21.1% 23.7% 0.314 6.2% 8.8% 3.2% 0.055
Current smoker 19.3% 19.9% 18.5% 0.567 0 0 0 -
Ex-smokers 16.0% 11.0% 21.0% <0.001 0 0 0 -
*Median (min-max). ApoB - apolipoprotein B. CRP - C-reactive protein. eGRF - estimated glomerular filtration rate. HDL-C - high-density lipoprotein cholesterol. LDL-C - low-density lipoprotein cholesterol. non-HDL-C - non-high density lipoprotein cholesterol. TC - total cholesterol. TG - triglycerides.

Adults had significantly higher concentrations of TC, TG, non-HDL-C, LDL-C, and apoB, and lower HDL-C concentrations than children, with similar differences observed between women and girls, and men and boys (Table 2). While Lp(a) concentrations did not differ by sex, they were significantly higher in adults than children, and in women than girls, a pattern also seen for Lp(a)-C. The percentage contributions of Lp(a)-apoB to total apoB (%Lp(a)/apoB) and Lp(a)-C to LDL-C (%Lp(a)-C/LDL-C) were significantly higher in boys when compared to girls, with simultaneously lower values of the percentage contribution of Lp(a)-apoB to total apoB in boys compared to men. Moreover, non-Lp(a) apoB and LDL-CLp(a)corr were significantly higher in adults than in children in both sexes.

Lipid parameters in studied subjects.
Parameter All adults(N = 1046) Adult women(N = 562) Adult men (N = 484) Women vs. men All children (N = 276) Girls (N = 148) Boys (N = 128) Girls vs.boys Adults vs. children Women vs. girls Men vs. boys
TC, mmol/L 5.04(4.42-5.74) 5.04(4.45-5.69) 4.99(4.40-5.79) 0.482 4.40(3.85-4.86) 4.45(3.93-4.84) 4.34(3.80-4.91) 0.612 < 0.001 < 0.001 < 0.001
TG, mmol/L 1.09(0.79-1.52) 0.95(0.71-1.31) 1.26(0.96-1.78) < 0.001 0.79(0.60-1.08) 0.82(0.62-1.02) 0.73(0.56-1.09) 0.240 < 0.001 < 0.001 < 0.001
HDL-C, mmol/L 1.42(1.21-1.68) 1.58(1.37-1.86) 1.27(1.09-1.47) < 0.001 1.50(1.32-1.73) 1.52(1.32-1.71) 1.47(1.29-1.76) 0.551 0.001 0.028 < 0.001
Non-HDL-C, mmol/L 3.54(2.92-4.29) 3.39(2.84-4.16) 3.77(3.08-4.45) < 0.001 2.82(2.38-3.28) 2.89(2.43-3.31) 2.74(2.35-3.26) 0.595 < 0.001 < 0.001 < 0.001
LDL-C, mmol/L 3.05(2.46-3.72) 2.95(2.40-3.65) 3.15(2.53-3.77) 0.022 2.46(2.02-2.90) 2.48(1.99-2.90) 2.40(1.99-2.87) 0.613 < 0.001 < 0.001 < 0.001
ApoB, g/L 0.90(0.76-1.07) 0.85(0.72-1.02) 0.97(0.80-1.14) < 0.001 0.77(0.65-0.92) 0.78(0.65-0.92) 0.77(0.64-0.89) 0.406 < 0.001 < 0.001 < 0.001
Lp(a),g/Lnmol/L* 0.09(0.06-0.26)19.3 (12.9-55.9) 0.10(0.06-0.27)21.5 (12.9-58.0) 0.09(0.06-0.26)19.3 (12.9-55.9) 0.465 0.09(0.05-0.15)19.3 (10.7-32.2) 0.09(0.05-0.13)19.3 (10.7-27.9) 0.09(0.06-0.24)19.3 (12.9-51.6) 0.155 0.014 0.003 0.708
Lp(a) (%):> 0.30 g/L0.30-0.50 g/L> 0.50 g/L 22913 22913 221012 1.0000.5820.626 18135 15114 22166 0.1330.2230.444 0.1480.047< 0.001 0.0610.4590.002 1.0000.0560.050
Non-Lp(a) apoB, g/L 0.87(0.73-1.05) 0.83(0.70-0.99) 0.95(0.78-1.11) < 0.001 0.77(0.64-0.89) 0.77(0.64-0.90) 0.75(0.63-0.86) 0.276 < 0.001 < 0.001 < 0.001
%Lp(a)/apoB 1.39(0.74-3.34) 1.46(0.78-3.46) 1.31(0.70-3.24) 0.055 1.74(0.76-3.10) 1.36(0.71-2.32) 1.67(1.00-4.09) 0.034 0.947 0.069 0.044
Lp(a)-C, mg/dL 1.53(0.99- 4.33) 1.61(0.99-4.42) 1.49(0.99- 4.29) 0.466 1.50(0.74-2.48) 1.47(0.74-2.11) 1.56(1.04-3.96) 0.051 0.014 0.003 0.708
LDL-CLp(a)corr, mg/dL 113(92-139) 110(91-136) 118(95-143) 0.015 91(76-109) 94(77-110) 90(75-107) 0.708 < 0.001 < 0.001 < 0.001
%Lp(a)-C/LDL-C 1.53(0.81-3.69) 1.59(0.84-3.69) 1.43(0.79-3.80) 0.952 1.70(0.91-3.08) 1.69(0.82-2.60) 1.75(1.12-3.71) < 0.001 0.711 0.371 0.127
Data are expressed as medians (25th – 75th percentile); *conversion factor from g/L to nmol/L: 215. ApoB - apolipoprotein B. HDL-C - high-density lipoprotein cholesterol. LDL-C - low-density lipoprotein cholesterol. Lp(a) - lipoprotein(a). Lp(a)-C - lipoprotein(a) cholesterol. %Lp(a)/apoB - contribution of Lp(a)-apoB to total apoB in %. %Lp(a)-C/LDL-C - contribution of Lp(a)-C to LDL-C in %. non-HDL-C - non-high density lipoprotein cholesterol. TC - total cholesterol. TG - triglycerides.
Distribution of Lp(a) across age categories

Figure 1 illustrates the distribution of Lp(a) concentrations in serum of adults and children in the studied population. Lipoprotein(a) concentrations were undetectable (i.e., < 0.03 g/L) in 7% of adults and 10% of children. Lipoprotein(a) > 0.30 g/L was observed in 22% of adults and 18% of children, with no significant sex difference. However, Lp(a) > 0.50 g/L was significantly more frequent in adults (13%) than children (5%) (P < 0.001) (Table 2).

Figure 2 depicts the association of Lp(a) concentrations with age and sex in the studied population. Lipoprotein(a) concentrations were significantly higher only in females after the age of 50 (P for trend, 0.0008). On the contrary, the slight increase of Lp(a) concentrations in males after the age of 60 was not significant (P for trend, 0.157). Similar models were applied to evaluate the association of apoB concentrations in serum and the contribution of Lp(a)-apoB to total apoB (%Lp(a)/apoB) with age and sex (Figure 3). In men, apoB concentrations were significantly higher, reaching a plateau in the fourth decade, then decreasing after age 50 (P for trend, < 0.0001). In women, the increase was late, with a plateau around the fifth decade (P for trend, < 0.0001). The contribution of Lp(a)-apoB to total apoB did not change significantly with age in women (P = 0.064), whereas in men there were lower values until the fourth decade and then an increase in later years (P = 0.002). The dynamics of apoB changes and the percentage contribution of Lp(a)-apoB to apoB differed significantly between males and females (P for apoB, < 0.0001, P for %Lp(a)/apoB, 0.044). By analyzing LDL-C and the contribution of Lp(a)-C to LDL-C (Figure 4), we found that LDL-C concentrations were significantly higher until the fourth decade of life in males and the fifth decade in females, followed by a gradual decline in later years (P for trend, < 0.0001). The dynamics of LDL-C changes differed significantly between males and females (P < 0.0001). In males, the percentage contribution of Lp(a)-C to LDL-C was slightly lower until the fourth decade and then gradually higher in later years (P for trend, 0.0018). In females, %Lp(a)-C/LDL-C changes were less evident, with a modest significant increase after the fifth decade (P for trend, 0.047). The dynamics of %Lp(a)-C/LDL-C changes did not differ significantly between sexes (P = 0.345).

Serum apoB concentrations (A) and %Lp(a)/apoB values (B) across age categories. Data are expressed as medians, with vertical bars indicating 95% confidence intervals. Age categories (x-axis): 0: 9-11 years, 1: 18-29 years, 2: 30-39 years, 3: 40-49 years, 4: 50-59 years, 5: 60-69 years, 6: 70-99 years. ApoB - apolipoprotein B. %Lp(a)/apoB - contribution of Lp(a)-apoB to total apoB in %.

Changes in serum LDL-C (A) and %Lp(a)-C/LDL-C values (B) across age categories. Data are expressed as medians, with vertical bars indicating 95% confidence intervals. Age categories (x-axis): 0: 9-11 years, 1: 18-29 years, 2: 30-39 years, 3: 40-49 years, 4: 50-59 years, 5: 60-69 years, 6: 70-99 years. LDL-C - low-density lipoprotein cholesterol. %Lp(a)-C/LDL-C - contribution of Lp(a)-C to LDL-C in %.

Correlations between Lp(a) and cardiometabolic parameters, and multivariable logistic regression models assessing independent predictors of high Lp(a) concentrations

In adults, no correlations between Lp(a) concentration and cardiometabolic parameters exceeded r = 0.25. In children, Lp(a) showed weak correlations with non-HDL-C (r = 0.26, P < 0.001) and LDL-C (r = 0.27, P < 0.001).

A multivariable logistic regression model was used to assess independent predictors of high Lp(a) concentrations (≥ 0.30 g/L; Table 3). Among the analyzed variables, only increased LDL-C remained a significant predictor both in women and children, with an approximately two-fold increased likelihood of elevated Lp(a) in adult women (odds ratio, OR = 1.77; 95%CI: 1.10-2.86; P = 0.021) and tripling the probability of the occurrence of high Lp(a) concentrations in children (OR = 2.83; 95%CI: 1.24-6.44; P = 0.009). Additionally, boys had an approximately twofold higher probability of Lp(a) concentrations ≥ 0.30 g/L than girls (OR = 2.17; 95%CI: 1.05-4.46; P = 0.024).

Predictors of high Lp(a) concentrations in serum by the multivariable logistic regression model.
All adults Adult women Adult men Children
Lp(a), g/L ≥ 0.30 ≥ 0.50 ≥ 0.30 ≥ 0.50 ≥ 0.30 ≥ 0.50 ≥ 0.30
Overall model statistics Chi2=10.9P=0.143NR2=0.017 Chi2=10.8P=0.148NR2=0.021 Chi2=8.5P=0.204NR2=0.024 Chi2=12.1P=0.055NR2=0.043 Chi2=4.53P=0.606NR2=0.015 Chi2=4.19P=0.651NR2=0.019 Chi2=16.4P=0.012NR2=0.110
Odds ratio (95% confidence intervals)
LDL-C,≥ 3.0 mmol/L (adults)≥ 2.85 mmol/L (children) 1.51(1.05-2.16) 1.42(0.91-2.23) 1.77(1.10-2.86) 2.03(1.11-3.69) 1.15(0.66-2.00) 0.79(0.38-1.63) 2.83(1.24-6.44)
ApoB,≥ 1.0 g/L 1.08(0.74-1.56) 1.28(0.81-2.04) 0.99(0.59-1.67) 1.06(0.57-1.97) 1.32(0.76-2.28) 1.75(0.85-3.60) 1.45(0.52-4.08)
eGFR,60-89 mL/min/1.73 m2 0.99(0.98-1.00) 0.99(0.98-1.01) 1.28(0.75-2.17) 1.23(0.66-2.31) 1.28(0.74-2.21) 1.04(0.51-2.14) 1.00(0.99-1.01)
Low-grade inflammation(CRP ≥ 3.0 mg/L) 1.05(0.67-1.66) 1.10(0.64-1.89) 0.87(0.46-1.61) 1.21(0.60-2.44) 1.32(0.67-2.58) 1.07(0.44-2.61) 1.75(0.52-5.94)
BMI,≥ 30 kg/m2 (adults)> 95th percentile (children) 1.02(0.66-1.58) 1.32(0.80-2.17) 1.22(0.66-2.27) 1.13(0.55-2.31) 0.87(0.47-1.63) 1.42(0.70-2.90) 0.37(0.10-1.40)
Menopause - - 0.86(0.50-1.46) 1.22(0.65-2.29) - - -
Age ≥ 50 years 0.84(0.57-1.23) 1.03(0.64-1.64) - - 0.78(0.46-1.33) 0.71 (0.361.40) -
Sex (male) 0.94(0.69-1.29) 0.86(0.58-1.27) - - - - 2.17(1.05-4.46)
Values in bold denote statistical significance of odds ratio (P < 0.05). ApoB - apolipoprotein B. BMI - body mass index. CRP - C-reactive protein. eGFR - estimated glomerular filtration rate. LDL-C - low-density lipoprotein cholesterol. Lp(a) - lipoprotein(a). NR2 - Nagelkerke R2.
Discussion

Understanding the distribution of Lp(a) concentrations in relation to age, sex, and cardiometabolic risk factors may allow for a more accurate assessment of cardiovascular risk. Given that Lp(a) contributes to both apoB and LDL-C concentrations, its impact should be considered in routine lipid profiling to avoid potential misclassification of risk (1, 2).

Our findings indicate that approximately one-fifth of both adults and children had Lp(a) ≥ 0.30 g/L. However, Lp(a) > 0.50 g/L was significantly more prevalent in adults than in children. While no significant sex differences were observed, median Lp(a) concentrations tended to be lower in girls. Interestingly, Lp(a) concentrations were significantly higher in women after the age of 40, whereas in men only a slight rise was observed after age of 60. Despite these variations, the overall age-related dynamics of Lp(a) were similar in both sexes. In contrast, the analysis of %Lp(a)/apoB and %Lp(a)-C/LDL-C ratios showed lower values in men up to their 40s and higher values in both sexes after the age of 50, indicating that the contribution of Lp(a) to apoB and LDL-C measurements is influenced by both age and sex. Several studies have reported higher Lp(a) concentrations in women. For example, the MESA study demonstrated that women consistently had higher Lp(a) concentrations across all ethnic groups (21). Other studies have indicated that the prevalence of Lp(a) > 0.30 g/L varies depending on the presence of dyslipidemia, with higher concentrations observed in women than in men (22). A recent study by Yurtseven et al. confirmed that Lp(a) concentrations were significantly higher in women over 50 years of age, suggesting the need for sex-specific Lp(a) thresholds in cardiovascular risk assessment (23). Data from the Copenhagen General Population Study showed that Lp(a) concentrations increased around age 50 in women, irrespective of use of hormone replacement therapy (5). However, when examining the association between Lp(a) > 0.40 g/L and CVD mortality, no significant sex differences were noted. In contrast, the Lp(a)HERITAGE study demonstrated that individuals < 65 years old, particularly women, tend to have higher Lp(a) and LDL-C concentrations, potentially increasing their risk of premature CVD (24). Evidence suggests that sex differences in lipoprotein production result from a combination of genetic factors, sex chromosomes, and sex hormones. Lipoprotein(a) production is highly regulated by the LPA gene, with variations in its expression and in the activity of proteins, such as sortilin, involved in Lp(a) production and clearance, potentially contributing to higher Lp(a) concentrations in women compared to men (21). However, the exact mechanisms behind these differences remain unclear.

Few studies have examined Lp(a) concentrations in Polish population. The EUROASPIRE V survey, conducted on 200 subjects without diagnosed CVD, found that 30% of participants had Lp(a) concentration > 0.30 g/L, and 22.5% had Lp(a) > 0.50 g/L (7). In the Malopolska CAD Prophylactic Program, enrolling 800 middle-aged individuals, 17.8% of participants had Lp(a) > 0.50 g/L, with a higher proportion of women in this group (8). The STAR-Lp(a) study, including 2475 outpatient cardiology clinic patients, reported that Lp(a) ≥ 0.30 g/L was present in 21.5% of participants, while Lp(a) ≥ 0.50 g/L was found in 13.5% of individuals (9). However, none of these studies analyzed Lp(a) variations across different age groups. In a previous study, we examined the association between Lp(a) and lipid biomarkers of cardiovascular risk in relation to age and sex in 422 apparently healthy individuals aged 19-84 years (25). We found that women aged ≤ 40 years with LDL-C ≤ 100 mg/dL and elevated Lp(a) (≥ 0.40 g/L) had higher apoB and small dense LDL-C concentrations compared to those with Lp(a) < 0.40 g/L. This pattern was not observed in men. These findings suggested that younger women with elevated Lp(a) may have an increased CVD risk related to higher apoB concentrations, despite having desirable LDL-C concentrations.

Data on Lp(a) in Polish children are very limited. Research in pediatric endocrinology suggested that children with type 1 diabetes have significantly higher Lp(a) concentrations than healthy controls (26). Additionally, Lp(a) was linked to a family history of CVD in Polish children with diabetes, obesity, and hypertension (27). In young Finns, Raitakari et al. found an increase in Lp(a) concentrations and prevalence of elevated Lp(a) (> 0.30 g/L) with age (11). Elevated Lp(a) in youth, particularly when combined with high LDL-C, was associated with a significantly higher CVD risk. Finally, the prospective “LIFE Child” study, performed in a German children cohort, found that Lp(a) concentrations remained stable over 4 years, unaffected by age, sex, or BMI, but strongly associated with LDL-C (28).

To our knowledge, the present study is the first evaluating the Lp(a)-dependent lipid biomarkers in the Polish population, considering both sex and age. It should be noted that total apoB measurements primarily reflect the sum of LDL-apoB and Lp(a)-apoB, while LDL-C measurements can be influenced by the cholesterol content of Lp(a) (Lp(a)-C). Recent studies have suggested that Lp(a)-apoB is more strongly associated with ASCVD risk than LDL-apoB (29). The proatherogenic properties of Lp(a) arise from its apoB and cholesterol content, oxidized phospholipids, proinflammatory and antifibrinolytic characteristics, and denser structure compared to LDL particles. However, the overall contribution of Lp(a) to CVD risk is smaller than that of LDL particles, particularly in individuals with low Lp(a) concentrations (30). In our study, the median Lp(a)/apoB was 1.39% in adults and 1.74% in children, respectively. A UK Biobank study reported a median of 0.9% in primary prevention subjects (29). Furthermore, the median Lp(a)-C/LDL-C in our study was 1.53% in adults and 1.70% in children, ~5% lower than that reported in a meta-analysis of 18,043 individuals, which however used an overestimating Lp(a)-C calculation. We applied the Rosenson-Marcovina formula (considering Lp(a)-C as 16.6% of Lp(a) mass) for our exploratory analysis, though it requires further validation. Given such inaccuracies, currently LDL-C correction based on Lp(a)-C is not recommend.

Ratio %Lp(a)/apoB remained stable with age in women but declined in men until the fourth decade before increasing significantly. Ratio %Lp(a)-C/LDL-C was lower in men until the fourth decade, then increasing, as in women, after 50 years of age. This trend coincided with decreasing apoB and LDL-C concentrations and rising of Lp(a), suggesting greater lipid profile atherogenicity in older men. Interestingly, in our population the highest %Lp(a)/apoB and %Lp(a)-C/LDL-C were seen in boys aged 9-11, despite relatively low LDL-C and apoB concentrations. As no previous studies have assessed these relationships, our results cannot be directly compared with those of other authors.

The variability in Lp(a) concentrations is primarily determined by genetic factors. However, recent studies suggest that Lp(a) is also interrelated with other cardiovascular risk factors, such as apoB, CRP, and oxidized phospholipids, which may influence cardiovascular risk assessment (31, 32). In our study, weak correlations between Lp(a) and LDL-C or non-HDL-C concentrations were observed only in children. Moreover, an LDL-C concentration ≥ 110 mg/dL was the strongest predictor of high Lp(a) concentrations, increasing approximately three-fold the likelihood to detect this condition. Additionally, in women, an LDL-C concentration ≥ 115 mg/dL was a significant predictor of high Lp(a) concentrations, approximately doubling the likelihood of detecting elevated Lp(a). These findings align with our previous observations that LDL-C is a stronger predictor of high Lp(a) concentrations in women than in men (25). Similarly, Burzyńska et al. reported that individuals with elevated Lp(a) were more likely to be females having hyperlipidemia (9).

The findings of our study are especially relevant considering that Poland is classified as a high-risk country for cardiovascular mortality and shows a relatively high prevalence of elevated Lp(a) concentrations. Moreover, atherogenic isoforms of apo(a), characterized by smaller apo(a) size, fewer KIV-2 repeats, and the presence of the rs10455872 variant, are more frequently observed in Central and Western Europe (e.g., Poland, Germany, the United Kingdom) as well as in the Balkan region (Southeastern Europe, e.g., Bulgaria, Romania), compared to Northern and Southern Europe (e.g., Finland, Italy, Greece, Spain). Therefore, Lp(a) characteristics could be region-specific (8, 33).

Some study strengths and limitations should be further acknowledged. To our knowledge, it is the first study to evaluate Lp(a)-dependent lipid biomarkers in the Polish population while considering both sex and age. Although multiple studies have explored the distribution of Lp(a) concentrations in relation to cardiometabolic risk factors, comparisons are often difficult due to ethnic variability and confounding factors affecting Lp(a) concentrations. In our study, we minimized confounding factors by recruiting a group of presumably healthy individuals without acute or chronic diseases. Furthermore, a key strength of our study is the parallel analysis of Lp(a) concentrations in both adults and children from the same population, using the same Lp(a) assay method. Harmonization of Lp(a) results obtained with different immunoassays remains indeed a major challenge due to the potential impact of the heterogeneity of apo(a) isoforms and the variability in kringle IV number in Lp(a) quantification. In our study, Lp(a) measurements were performed using the Randox assay, that shows minimum apo(a) size related influence (34).

However, we recruited a relatively small number of study participants from a single region in north-central Poland; therefore, this group is not fully representative of the overall Polish population. It should be also noted that reporting Lp(a) results in nmol/L is considered more methodologically accurate, as it reflects the number of apo(a) molecules. However, assays that accurately measure Lp(a) in nmol/L are not commercially available. Commercial immunoturbidimetric and nephelometric assays use polyclonal antibodies that may recognize a variable number of kringle IV repeats, potentially leading to underestimation or overestimation of Lp(a) mass due to apo(a) size polymorphism (1, 35). Among the available immunossays, the Randox Lp(a) assay (using Denka reagents) calibrated in mass units is considered to approximate molar measurements closely (21). Accordingly, Randox offers the possibility, for a limited number of analyzers, to convert instrument-specific Lp(a) calibrator values in nmol/L; however, this option is not available for the analyzer used in this study (Horiba ABX Pentra 400). Alternatively, conversion factors to convert Lp(a) in mass units to nmol/L that are available in the literature may be used. However, since an assay-specific conversion factor should be determined for each calibrator, the use of a single conversion factor may be not sufficiently accurate. For these reasons, we used mass units (g/L) to report Lp(a) results throughout the paper, and a single conversion factor 2.15 (widely accepted in the literature for the Randox method) was applied only for the calculation of non–Lp(a) apoB and for providing Lp(a) values in nmol/L (in parentheses) to allow comparison with mass units. These data should be however interpreted with consideration of potential inaccuracies (19, 36, 37).

In conclusion, this study reveals key age- and sex-related patterns in Lp(a) concentrations and their contribution to apoB and LDL-C concentrations. Approximately 20% of both adults and children had elevated Lp(a), with slightly lower concentrations observed in girls and a notable increase in women after age 40 and in men after age 60. Elevated LDL-C emerged as the strongest predictor of high Lp(a) concentrations in both women and children, underscoring its relevance in Lp(a)-related risk assessment. The %Lp(a)/apoB and %Lp(a)-C/LDL-C ratios increased in both sexes after age 50, accompanied by declining apoB and LDL-C concentrations and rising Lp(a) concentrations. This pattern suggests greater atherogenicity in older individuals, particularly in men. Notably, the highest relative Lp(a) contributions were observed in boys aged 9-11, despite low absolute lipid concentrations, indicating a potential early cardiovascular risk.

Potential conflict of interest

None declared.

Data availability statement

The data will be shared on reasonable request to the corresponding author.

References KronenbergFMoraSStroesESGFerenceBAArsenaultBJBerglundL Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925–46. 10.1093/eurheartj/ehac36136036785 SolnicaBSygitowiczGSitkiewiczDJóźwiakJKasperczykSBroncelM 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2024;20:357–74. 10.5114/aoms/18619138757022 NordestgaardBGChapmanMJRayKBorénJBorénJAndreottiF Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–53. 10.1093/eurheartj/ehq38620965889 ParéGÇakuAMcQueenMAnandSSEnasEClarkeR Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation. 2019;139:1472–82. 10.1161/CIRCULATIONAHA.118.03431130667276 SimonySBMortensenMBLangstedAAfzalSKamstrupPRNordestgaardBG. Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study. Atherosclerosis. 2022;355:76–82. 10.1016/j.atherosclerosis.2022.06.102335803767 KimCJKimTHRyuWSRyooUH. Influence of menopause on high density lipoprotein-cholesterol and lipids. J Korean Med Sci. 2000;15:380–6. 10.3346/jkms.2000.15.4.38010983684 RatajczakJKubicaAPietrzykowskiŁMichalskiPKosobucka-OzdobaABuczkowskiK Lipoprotein (a) and the Occurrence of Lipid Disorders and Other Cardiovascular Risk Factors in Patients without Diagnosed Cardiovascular Disease. J Clin Med. 2024;13:4649. 10.3390/jcm1316464939200791 KonieczyńskaMNowakKPudłoJZasadaMTlałkaMWypasekE Elevated lipoprotein(a) in the middle-aged Polish population: Preliminary data on the genetic background. Kardiol Pol. 2023;81:1279–81. 10.33963/v.kp.9766037823755 BurzyńskaMJankowskiPBabickiMBanachMChudzikM. Prevalence of hyperlipoproteinemia(a) in individuals of European ancestry treated at outpatient cardiology clinics: results from a cross-sectional STAR-Lp(a) study. Pol Arch Intern Med. 2024;134:16860. 10.20452/pamw.1686039352310 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and AdolescentsNational Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128:S213–56. 10.1542/peds.2009-2107C22084329 RaitakariOKartiosuoNPahkalaKHutri-KähönenNBazzanoLAChenW Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood. Circulation. 2023;147:23–31. 10.1161/CIRCULATIONAHA.122.06066736440577 StefanskaAKrintusMSiodmiakJWolskaASzternelLGackowskaL Adult reference intervals for serum thyroid-stimulating hormone using Abbott Alinity i measuring system. Clin Chem Lab Med. 2024;63:e104–7. 10.1515/cclm-2024-101939377213 FerraroSLuconiECalcaterraVCordaroEBianchiACeredaC Reference intervals for thyroid biomarkers to enhance the assessment of thyroid status in childhood and adolescence. Clin Chem Lab Med. 2023;61:1309–18. 10.1515/cclm-2022-105336704909 Centers for Disease Control and Prevention. Defining child BMI categories: BMI and BMI categories for children and teens. Available at: https://www.cdc.gov/obesity/basics/childhood-defining.html. Accessed on February 13, 2025. TykarskiAFilipiakKJanuszewiczALitwinMNarkiewiczKPrejbiszA Zasady postępowania w nadciśnieniu tętniczym - 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019;5:99–151. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S15–33. 10.2337/dc21-S00233298413 KaczmarekM. The timing of natural menopause in Poland and associated factors. Maturitas. 2007;57:139–53. 10.1016/j.maturitas.2006.12.00117307314 SampsonMLingCSunQHarbRAshmaigMWarnickR A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020;5:540–8. 10.1001/jamacardio.2020.001332101259 PatelAPWangMPirruccelloJPEllinorPTNgKKathiresanS Lp(a) (Lipoprotein(a)) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol. 2021;41:465–74. 10.1161/ATVBAHA.120.31529133115266 RosensonRSLópezJAGMonsalvoMLWuYWangHMarcovinaSM. Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a). Cardiovasc Drugs Ther. 2024;38:191–7. 10.1007/s10557-022-07407-y36435949 ForbangNICriquiMHAllisonMAIxJHSteffenBTCushmanM Sex and ethnic differences in the associations between lipoprotein(a) and peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis. J Vasc Surg. 2016;63:453–8. 10.1016/j.jvs.2015.08.11426518096 PinoBDGoriniFGagginiMLandiPPingitoreAVassalleC. Lipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience. J Clin Med. 2023;12:764. 10.3390/jcm1203076436769413 YurtsevenEUralDGursoyECunediogluBOGulerOUBaysalK Is There a Need for Sex-Tailored Lipoprotein(a) Cut-Off Values for Coronary Artery Disease Risk Stratification? Clin Cardiol. 2024;47:e70012. 10.1002/clc.7001239263966 NissenSEWolskiKChoLNichollsSJKasteleinJLeitersdorfE Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart. 2022;9:e002060. 10.1136/openhrt-2022-00206036252994 BergmannKStefanskaAKrintusMSypniewskaG. Discordance between lipoprotein (a) and LDL-cholesterol levels in cardiovascular risk assessment in apparently healthy subjects. Nutr Metab Cardiovasc Dis. 2023;33:1429–36. 10.1016/j.numecd.2023.04.01037169665 Pac-KożuchowskaEPiekarskiRMroczkowska-JuchkiewiczASzewczykL. The Evaluation of Lipid Profile and Thrombomoduline Concentration in Children with Newly Diagnosed and Longterm Type 1 Diabetes Mellitus. Pediatric Endocrinology. 2010;9(3):39–46. GlowinskaBUrbanMKoputA. Cardiovascular risk factors in children with obesity, hypertension and diabetes: lipoprotein(a) levels and body mass index correlate with family history of cardiovascular disease. Eur J Pediatr. 2002;161:511–8. 10.1007/s00431-002-1040-712297895 StürzebecherPEUttingerKLVogelMSchlingmannMCeglarekUIsermannB Lipoprotein(a) serum concentrations in children in relation to body mass index, age and sex. Pediatr Res. 2024;96:177–83. 10.1038/s41390-024-03108-438418593 MarstonNAMelloniGEMMurphySAMorzeJKamanuFKEllinorPT Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins. J Am Coll Cardiol. 2024;83:470–2. 10.1016/j.jacc.2023.09.83638233021 TsimikasSBittnerV. Particle Number and Characteristics of Lipoprotein(a), LDL, and apoB: Perspectives on Contributions to ASCVD. J Am Coll Cardiol. 2024;83:396–400. 10.1016/j.jacc.2023.11.00838233013 ArnoldNBlaumCGoßlingABrunnerFJBayBFerrarioMM C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project. Eur Heart J. 2024;45:1043–54. 10.1093/eurheartj/ehad86738240386 RaderDJBajajA. Lipoprotein(a) and Oxidized Phospholipids: Partners in Crime or Individual Perpetrators in Cardiovascular Disease? J Am Coll Cardiol. 2023;81:1793–6. 10.1016/j.jacc.2023.02.05137137589 TsimikasSFazioSFerdinandKCGinsbergHNKoschinskyMLMarcovinaSM NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol. 2018;71:177–92. 10.1016/j.jacc.2017.11.01429325642 ScharnaglHStojakovicTDieplingerBDieplingerHErhartGKostnerGM Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis. 2019;289:206–13. 10.1016/j.atherosclerosis.2019.08.01531493849 KronenbergF. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Atherosclerosis. 2022;349:123–35. 10.1016/j.atherosclerosis.2022.04.00835606072 KheraAVEverettBMCaulfieldMPHantashFMWohlgemuthJRidkerPM Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129:635–42. 10.1161/CIRCULATIONAHA.113.00440624243886 Mohammadi-ShemiraniPChongMNarulaSPerrotNConenDRobertsJD Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study. J Am Coll Cardiol. 2022;79:1579–90. 10.1016/j.jacc.2022.02.01835450575
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010702" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010702" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010702" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(131) "Serum lipoprotein(a) concentrations in presumably healthy Polish subjects in relation to age, sex, and cardiometabolic risk factors" ["journals_article_author"]=> string(145) "Anna Stefańska, Katarzyna Bergmann, Łukasz Szternel, Joanna Siódmiak, Aleksandra Wolska, Blanka Dwojaczny, Magdalena Krintus, Mauro Panteghini" ["journals_article_author_country"]=> string(6) "Poland" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(77) "lipoprotein(a), cardiovascular risk, lipoproteins, dyslipidemia, epidemiology" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3220" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "7" ["meta_title"]=> string(131) "Serum lipoprotein(a) concentrations in presumably healthy Polish subjects in relation to age, sex, and cardiometabolic risk factors" ["meta_desc"]=> string(131) "Serum lipoprotein(a) concentrations in presumably healthy Polish subjects in relation to age, sex, and cardiometabolic risk factors" ["meta_keyw"]=> string(77) "lipoprotein(a), cardiovascular risk, lipoproteins, dyslipidemia, epidemiology" ["created"]=> string(19) "2025-12-09 11:40:25" ["modified"]=> string(19) "2026-02-17 09:23:56" } [45]=> object(stdClass)#94 (35) { ["journals_id"]=> string(4) "1216" ["journals_xml"]=> string(123818) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010701 10.11613/BM.2026.010701 Original articles Key incidents identified by the Royal College of Pathologists of Australasia Quality Assurance Programs Key Incident Monitoring and Management EQA program JayanettiAnushkaRoxbyDavidBadrickTony Royal College of Pathologists of Australasia Quality Assurance Programs, Sydney, Australia Molecular Medicine and Pathology, College of Medicine and Public Health, Flinders Medical Centre, Adelaide, Australia Corresponding author: tony.badrick@rcpaqap.com.au

Author contributions

T Badrick: Conceptualization, Methodology, Writing, original draft - review & editing; A Jayanetti: Investigation, formal analysis, Project administration, review & editing; D Roxby: review & editing.

15122025 15022026 36 1 010701 1605202516092025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Key Incident Monitoring and Management EQA Program data from 2024 surveys was 55,329,998 episodes recorded, and 1,496,708 incidents identified

•“No specimen received” appears to have the highest 80th percentile across the patient sources

• The commonest site of error is the Emergency Department

Introduction

The Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) Key Incident Monitoring and Management EQA Program (KIMMS) aims to monitor the laboratory quality system’s pre- and post-analytical phases. The purpose of this paper is to describe the most common incidents from 2024.

Materials and methods

The KIMMS program has four surveys a year, collecting data from the previous three months, with preanalytical and postanalytical incident reporting of 35 incident types. Participants are asked to capture the number of episodes and the number of incidents per quarter of the year.

Results

The four 2024 surveys received an average of 111 responses, with 55,329,998 episodes recorded and 1,496,708 incidents identified. The findings from the 2024 program are that the incident “No specimen received” appears to have the highest 80th percentile across the patient sources. The commonest site of error is the Emergency Department (ED), with an 80th percentile overall.

Conclusions

The KIMMS data provide valuable, regular and reproducible benchmarking data for the pre- and post-analytical phases of the total testing cycle.

Keywords: preanalytical phaseincident reportingrisks managementquality improvementsBenchmarking
Introduction

Pre- and postanalytical errors represent most errors in the total testing cycle leading to increased risk of misdiagnosis and treatment of patients (1-3). Identification, phlebotomy, collection tube and sample preservation and transport related errors are common sources of error, particularly when the specimen collection staff are not laboratory-controlled (4). Postanalytical errors mainly involve delayed or incomplete delivery of results to referring doctors. Despite this, few benchmarking EQA programs are available for medical laboratories to assess these error rates objectively (5, 6). Indicators of the extra-analytical phases of the Total Testing Process (TTP) have been developed in several countries, such as Australia and New Zealand, The US Brazil, and Spain/Catalonia, and other surveys and programs have been promoted in the UK, China and Croatia (7-14). In 2008, the IFCC launched a Working Group named “Laboratory Errors and Patient Safety” (WG: LEPS) to identify Quality Indicators (QIs) and related quality specifications that (i) produce benchmarks from comparing laboratories, (ii) promote error reduction and (iii) increase patient safety. The IFCC has developed QIs, which laboratories in several countries have evaluated, and the WG: LEPS has reported preliminary results (15-17).

To reduce pre- and post-analytical error, laboratories need to focus on these phases of the total testing cycle with relevant QIs and benchmarks from external sources (18-20). As with any form of benchmarking, laboratories must collect and track their QIs and then compare them against the relevant peer group. Initially, this ensures they collect the same data as their peers, then compare their performance. If there are significant differences after data collection error has been eliminated, then a review of the process is warranted. To ensure there is confidence in this comparison, a sufficiently large peer group collecting the same QIs needs to be available, and the data collection needs to be regular enough to detect trends (21).

But collecting QI data in pathology can be tedious. Benchmarking processes are far more difficult than standard analytical EQA because measurement may be complex and not standardised, data collection may not be easy, and targets are unavailable. As with many benchmarking exercises, there have been problems with the definitions and robustness of the QIs. Key Incident Monitoring and Management EQA Program has tried to ensure that participants collect and submit the same data for each of the QIs. While progress has been made in this direction, the data is still not always homogeneous. One of the aims of the KIMMS program is to produce a list of key incidents that should be tracked by an LIS. Also, changing a process is more difficult than identifying an error in an assay system.

The Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) Key Incident Monitoring and Management EQA Program (KIMMS) started in 2011 and aims to monitor the pre- and post-analytical phase of the laboratory quality system (7). Key Incident Monitoring and Management EQA Program measures risks from incidents recorded by participant laboratories and compares these to those of peer organisations. Incidents and risks are related but not equal (22). The program assesses risk based on the consequences to the patient, the probability that the event will occur, and how easy it is to detect the incident. A reduction in probability or an increase in detectability can reduce the risk. A two-phase risk calculation is used in KIMMS, where a harm factor equals consequences multiplied by likelihood (21). The risk score equals harm times detectability (23).

As an example of this risk score process, we present this case where the overall performance summary highlights any “incident” that recorded a rate greater than 80% of all participants. This is presented in a table, which includes columns for the consequence, probability and detectability rating (Tables 1-3). The KIMMS Advisory Committee has pre-determined the consequence rating, so this field is pre-populated.

Example risk score table from the KIMMS report
Parameter out of allowable limits Consequence rating Probability rating Detectability rating Risk score Organisational response
Inpatient - hemolysis rate = 400 2 5 1 10 Example: Although this is a low-risk incident, high compared to peers and to our collectors (0.2). Meeting with hospital organised 7/10/22
KIMMS consequence scale
Scale Name Definition
1 Negligible/Minimal Minimal, delay, inconvenience
2 Marginal/Minor Recollect required
3 Significant/Moderate Delayed management (non-malignant) and/or medical treatment
4 Serious/Major Delayed diagnosis (malignant) and/or surgical treatment
5 Critical/Catastrophic Serious harm to multiple patients and/or patient death
KIMMS probability scale
Scale Name Example Definition
1 Rare < 1/year
2 Unlikely 1 per year
3 Occasional 1 per month
4 Likely 1 per week
5 Frequent 1 per day or more
Results review

It is recommended that participants review their results by applying the probability and detectability rating to determine the risk score (Tables 2-4). The risk score is calculated by multiplying the three ratings (consequence rating x probability rating x detectability rating). The risk score can be used as a guide to organisational risk; from that, a decision is made as to the next step(s).

KIMMS detectability scale
Scale Name Definition
1 Detected > 95%
2 Most detected 75-95%
3 Half detected 25-75%
4 Most not detected < 5-25%
5 Not detected < 5%

In the above example, the consequence, probability and detectability rating give a risk score of 10. This would be considered low risk. Apart from flagging that the risk is higher than other participants’ inpatient collections, it is unlikely that any further immediate action is required. This incident should be monitored closely to ensure it does not deteriorate.

Risk score

The score is calculated by multiplying the consequences (Table 1) x probability (Table 2) x detectability (Table 3).

The purpose of this paper is to report the most common incidents that have been detected in the 2024 KIMMS program.

Materials and methods

The KIMMS program has four surveys a year, collecting data from the previous three months, with preanalytical and postanalytical incident reporting of 35 incident types that have been pre-determined by the RCPAQAP KIMMS Advisory Committee. Data is submitted via the RCPAQAP myQAP portal, where result entry instructions are included. Participants are asked to capture the number of episodes and the number of incidents per quarter of the year.

Data is then analysed using RCPAQAP in-house data analysis software, where each specific incident reported to KIMMS is calculated per 100,000 episodes (number of incidents divided by the number of episodes, multiplied by 100,000), known as the rate. Incident rates are compared to peer groups and flagged red if outside the best performers, which is set at 80% of all results. This summary will focus on 2024 data.

A single request usually covers an episode and may contain one or more samples. It may include more than one request, but the samples are collected simultaneously, i.e., samples received together in a bag with a request form equal one episode.

Participants range from small to large pathology laboratories, where size is determined by the number of episodes per quarter (small: < 100,000, medium: 100,000-500,000, large: > 500,000). This data is also collected for each submission. The participants include a mix of public and private organisations from across Australia and a couple of international sites.

Patient sources

The KIMMS program was renewed in 2023 to allow for further comparison by separating data into categories such as the patient source (Inpatient/Outpatient/Community/Emergency Department (ED)).

The Inpatient patient source refers to pathology testing performed on an admitted hospital patient (public or private hospital). The Outpatient source includes pathology requests and specimens that are collected while a patient attends a clinic run by a hospital. This includes day patients and cancer treatment centres. The Emergency Department patient source refers to pathology testing performed on a patient attending an Emergency Department (ED)/Emergency Room (ER)/Accident and Emergency (A&E)/Casualty ward/department. The community patient source is for when the pathology request is generated anywhere, but the specimens are collected in settings other than the previously mentioned patient sources. This includes doctors’ surgeries, designated collection centres (even within a hospital), nursing homes, home visits, and workplace collections.

The KIMMS program also offers a Mixed patient source option for those organisations that are unable to differentiate their data between patient sources. In the final calculations, these are analysed with a total of all results.

Results

The four 2024 surveys received an average of 111 responses, with 55,329,998 episodes recorded and 1,496,708 incidents identified.

Table 5 summarises the total episodes and incidents reported per survey. Table 6 summarises the key results for the top three incidents from all sites, and Table 7 shows the key results per size of organisation. Tables 8-10 display the average 80th percentile cut-off rates and standard deviations (SDs) per patient source and the Mixed/Total category for the Test Request/Collection incident categories, as well as the Test Registration/Analytical/Postanalytical incident categories from the four 2024 KIMMS surveys.

The total number of episodes and incidents reported in each 2024 KIMMS survey
Total episodes Total incidents
Survey 1 11,930,241 274,277
Survey 2 13,123,033 295,720
Survey 3 14,832,081 484,514
Survey 4 15,444,643 442,197
The top three incidents with the highest incident rates in 2024, <italic>per</italic> the source of the patient
Inpatient Outpatient Community Emergency Department Mixed/Total
Incorrect specimen type or container or acid (200) Incorrect specimen type or container or acid (160) No specimen received (272) Incorrect specimen type or container or acid (344) No specimen received (271)
Specimen clotted or other clotting issue (250) Essential clinical indication for a test is not provided (227) Essential clinical indication for the test is not provided (130) Specimen clotted or other clotting issue (428) Insufficient specimen (126)
Specimen hemolysed (230) No specimen received (320) Insufficient specimen (92) Specimen hemolysed (711) Specimen hemolysed (127)
Values in brackets represent the rates.
The top three incidents with the highest incident rates in 2024, <italic>per</italic> the size of the organisation (episodes <italic>per</italic> quarter)
Small organisation(< 100,000 episodes)N = 89 Medium organisation (100,000-500,000 episodes)N = 13 Large organisation(> 500,000 episodes)N = 9
Essential collection date/time not provided or discrepant between specimen and request (401) No specimen received (407) No specimen received (528)
Incorrect specimen type or container or acid (589) Insufficient specimen (322) Essential clinical indication for the test is not provided (331)
Specimen clotted or other clotting issue (466) Specimen clotted or other clotting issue (411) Specimen hemolysed (280)
The “N” value refers to the average number of submissions per survey in 2024 that selected that particular size of organisation.
Average 80th percentile cut-off rates <italic>per</italic> patient source for the Test Request/Collection incident categories from the four 2024 KIMMS surveys
Inpatient Outpatient Community ED
Clarification of tests required 109.4 140.2 0.9 263.6
Insufficient requester details or signature missing 3.2 0.0 7.5 8.1
Unlabelled specimen or request 210.4 247.5 128.6 272.2
Insufficient patient ID on specimen and/or request 113.4 91.3 85.2 100.4
ID mismatch between specimen and/or request 161.8 100.9 61.9 200.6
Specimens from wrong patient (WSIT) 35.5 24.1 1.6 44.8
Essential collection date/time not provided or discrepant between specimen and request 14.1 9.3 2.3 34.3
Essential signature missing or discrepant on transfusion sample and/or request 113.6 83.0 17.9 185.6
Essential clinical indication for test not provided 41.7 78.8 40.3 18.5
Essential specimen type/site not provided 6.0 0.0 10.9 3.3
Incorrect patient preparation 8.2 0.0 12.2 9.0
Incorrect specimen type or container or acid 228.7 158.0 75.5 208.3
No specimen received 421.4 521.7 378.5 589.4
Insufficient specimen 335.5 252.6 147.8 458.2
Specimen incorrect fill leading to incorrect specimen:additive ratio 153.7 88.8 42.0 199.3
Specimen clotted or other clotting issue 385.4 161.6 51.1 679.7
Specimen contaminated - non-microbiological 40.7 17.8 4.6 33.6
Specimen contaminated - microbiological 0.0 0.0 0.1 1.8
Specimen hemolysed 75.1 37.1 44.1 416.0
Specimen leaking 0.0 0.0 3.8 13.1
Incorrect transport / storage temperature / handling 46.5 65.2 50.9 33.0
Transport delay leading to specimen being too old to test 109.7 135.1 45.8 82.6
Average 80th percentile cut-off rates for the Mixed/Total patient source for the Test Request/Collection incident categories from the four 2024 KIMMS surveys
Mixed/Total
Clarification of tests required 44.3
Insufficient requester details or signature missing 9.1
Unlabelled specimen or request 227.2
Insufficient patient ID on specimen and/or request 78.0
ID mismatch between specimen and/or request 120.5
Specimens from wrong patient (WSIT) 28.0
Essential collection date/time not provided or discrepant between specimen and request 12.9
Essential signature missing or discrepant on transfusion sample and/or request 102.4
Essential clinical indication for test not provided 53.1
Essential specimen type/site not provided 11.1
Incorrect patient preparation 11.0
Incorrect specimen type or container or acid 178.7
No specimen received 425.7
Insufficient specimen 290.4
Specimen incorrect fill leading to incorrect specimen: additive ratio 129.4
Specimen clotted or other clotting issue 359.8
Specimen contaminated - non-microbiological 26.7
Specimen contaminated - microbiological 0.0
Specimen hanalytemolysed 83.9
Specimen leaking 8.6
Incorrect transport / storage temperature / handling 49.4
Transport delay leading to specimen being too old to test 94.9
Average 80th percentile cut-off rates for all results for the Test Registration/Analytical/Postanalytical incident categories from the four 2024 KIMMS surveys
Total
Incorrect unique specimen identifier 8.4
Patient ID - wrong patient 7.1
Errors in transcription of patient demographic information 31.7
Incorrect or missed tests 183.1
Incorrect or missing specimen type, site, collection time 26.0
Incorrect requesting or copy doctor 131.7
Internal laboratory process incident - unfixable 43.0
Within laboratory ID error 6.4
Intra or inter-laboratory specimen lost or misplaced - irreplaceable 0.2
Intra or inter-laboratory specimen lost or misplaced - replaceable 10.0
Failures of clinical handover high-risk (critical) results 0.1
Failures of clinical handover non-critical results 0.1
Amended reports, significant patient impact 47.7

Figures 1-3 are bar graphs highlighting the average 80th percentile cut-off rates per patient source and the Mixed/Total category for the Test Request/Collection incident categories, as well as the Test Registration/Analytical/Postanalytical incident categories from the four 2024 KIMMS surveys.

Average 80th percentile cut-off rates per patient source for the Test Request/Collection incident categories from the four 2024 KIMMS surveys.

Average 80th percentile cut-off rates for the Mixed/Total patient source for the Test Request/Collection incident categories from the four 2024 KIMMS surveys.

Average 80th percentile cut-off rates for all results for the Test Registration/Analytical/Post-Analytical incident categories from the four 2024 KIMMS surveys.

Discussion

The findings from the 2024 program are that the incident “No specimen received” appears to have the highest 80th percentile across the patient sources. The cost of a recollection is significant, both in organisational cost and patient time (24). More importantly, it is an error that can be reduced once identified. Suggested mechanisms to reduce this incident would be computer-generated, or manual checklists of collection tubes required for a given set of requested tests.

The commonest site of error is the ED, with an 80th percentile overall. The primary cause is the non-professional collector and the collection process (4, 25-27). The solution could include better training of nursing and medical staff in the ED, though this has had poor long-term effects (25). The issue may be costly enough for the organisation to place phlebotomists in ED (28).

The 80th percentiles are consistent for all incidents throughout the year, meaning the occurrence of incidents is also consistent, validating the data collection process. The 80th percentiles are greater overall for incidents that fall under the Collection incident category, such as “No specimen received”, “Insufficient specimen”, “Specimen clotted” and “Specimen hemolysed”. Sites that perform greater than the 80th percentile have the incidents flagged for review. It is then up to the participants to calculate the risk of the incident to their organisation by referring to our KIMMS Matrix Table (https://rcpaqap.com.au/kimms-matrix-table/), which comprises consequence, probability and detectability. Specific incidences, such as WSIT, may have lower rates reported than the actual values, as the detectability of such incidences is low. This is why in the KIMMS risk matrix table, a higher value for detectability can be assigned to increase the overall risk score and severity of these incidents.

The KIMMS program has been operating since 2011 with several improvements (7, 21, 23). Significant findings and trends have been separately published (21, 29). This experience of participants reporting using standardised definitions of incidents has led to consistent data collections as can be seen from year-on-year results. It has taken some years for this to occur, as there is much variation in what laboratories call episodes and what their capability is to accurately collect these data. The QIs used are relevant to Australian laboratory practice and share commonality with the IFCC set. It is difficult to compare results from different publications as many are one-off surveys rather than a system of regular data collection.

The limitations of this program’s data collection process include some manual data collection processes and likely missing data for some QIs, such as WSIT, because the laboratory is unable to identify these errors (30).

In conclusion, the KIMMS data provide valuable, regular and reproducible benchmarking data for the pre- and post-analytical phases of the total testing cycle. The incidents represent areas where the risk to patients can be reduced.

All incidents measured in the KIMMS program and explanation of each incident
Categories Incident Explanation of incident
Test request Clarification of tests required Collector or laboratory required to contact requestor to confirm test(s) requested as information not clear or illegible on request
Insufficient requester details or signature missing This occurs when the information supplied is not sufficient to know which doctor should receive the report, or the request is not signed when a signature is required
Unlabelled specimen and/or request This is when sample or request has no patient identifiers
Collection: Identification Insufficient patient ID specimen and/or request Minimum identifiers are full name and DOB. Three identifiers may be required e.g., transfusion samples
ID mismatch between specimen and/or request ID on specimen label does not match accompanying request form or electronic order
Specimen from wrong patient (WSIT) Labelling of specimen and request are concordant, but the actual sample in the container is from a different patient
Essential collection date and/or time not provided or discrepant between specimen and request Specimen and form must align especially essential for a Transfusion request
Collection: Documentation Essential signature missing or discrepant on transfusion sample and/or request This refers to collector and patient signature
Essential clinical indication for test not provided Collector fails to record the clinical indication for the test that is required by the laboratory to aid in the interpretation of results
Essential specimen type/site not provided Specimen type and/or site not provided when information is required to aid in appropriate testing and interpretation of results by the laboratory
Incorrect patient preparation Patient not fasting, medication taken instead of being withheld, preparation procedure for test not followed
Incorrect specimen type or container or acid Incorrect specimen type collected/submitted for test request
No specimen received No sample received to do the test
Insufficient specimen Insufficient specimen to do any or all tests requested
Collection: Specimen Specimen incorrect fill leading to incorrect specimen: additive ratio Under or overfilled Citrate (COAG) tubes
Specimen clotted or other clotting issue Most commonly EDTA tubes, but any tube with anti-coagulant may be clotted
Specimen contaminated - non microbiological E.g. diluted from IV drip; or order of draw incorrect
Specimen contaminated - microbiological Contaminated microbiology samples that require a recollection
Specimen hemolysed Hemolysis should be counted if the sample is deemed unsuitable for one or more tests due to the level of hemolysis
Specimen leaking Any leakage should be recorded, even if there is still sufficient specimen to do the test
Collection: Transport, storage and handling Incorrect transport/storage temperature/handling Stored and/or transported at wrong temperature or handling not in accordance with documented procedure
Transport delay leading to specimen being too old to test Any delay in transport
Incorrect unique specimen identifier Also known as episode; laboratory or accession number. It is the unique identifier for that specimen from that patient collected/submitted on that date/time
Patient ID wrong patient This occurs when the wrong patient is chosen at data entry from a list of patients with the same, or similar name. Request associated to incorrect patient demographics
Test registration Error in transcription of patient demographic information This occurs when information is incorrectly entered from a request. Registration data manually entered
Incorrect or missed tests Test on request form not added at registration or incorrect test added
Incorrect or missing specimen type, site, collection time This is when the information is available on the request form or electronic order but is not entered into the LIS
Incorrect requesting or copy doctor Referring clinician or copy to clinician not registered to receive copy of the report
Internal laboratory process incident - unfixable This refers to any incident that happens after the sample has arrived at the laboratory that is not directly related to performing the test
Analytical Within laboratory ID error Error transferring patient Identification within the laboratory
Intra or inter-laboratory specimen lost or misplaced - irreplaceable Specimens lost during intra and inter-laboratory transfer that are irreplaceable
Intra or inter-laboratory specimen lost or misplaced - replaceable Specimens lost during intra and inter-laboratory transfer that can be recollected
Failure of clinical handover high-risk (critical) results Failure to communicate high-risk results to the relevant party within agreed guidelines as documented within your organisation
Postanalytical Failure of clinical handover non-critical results Requests to re-send copy of report due to non-receipt by the requestor, including referring laboratories
Amended report. Significant patient impact This is amended report due to a diagnostic error or incorrect result being released
DOB - date of birth. LIS - laboratory information system.

Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References PlebaniM. Errors in laboratory medicine and patient safety: The road ahead. Clin Chem Lab Med. 2007;45:700–7. 10.1515/CCLM.2007.17017579520 CarraroPPlebaniM. Errors in a stat laboratory: types and frequencies 10 years later. Clin Chem. 2007;53:1338–42. 10.1373/clinchem.2007.08834417525103 PlebaniM. Exploring the iceberg of errors in laboratory medicine. Clin Chim Acta. 2009;404:16–23. 10.1016/j.cca.2009.03.02219302995 McCaugheyEJEJVecellioELakeRLiLBurnettLChesherD Key factors influencing the incidence of hemolysis: A critical appraisal of current evidence. Crit Rev Clin Lab Sci. 2017;54:59–72. 10.1080/10408363.2016.125024728013559 SciacovelliLPlebaniM. The IFCC Working Group on laboratory errors and patient safety. Clin Chim Acta. 2009;404:79–85. 10.1016/j.cca.2009.03.02519328194 KristensenGBBAakreKMKristoffersenAHSandbergS. How to conduct External Quality Assessment Schemes for the pre-analytical phase? Biochem Med (Zagreb). 2014;24:114–22. 10.11613/BM.2014.01324627720 BadrickTGaySMackayMSikarisK. The key incident monitoring and management system - History and role in quality improvement. Clin Chem Lab Med. 2018;56:264–72. 10.1515/cclm-2017-021928771429 NakhlehRESouersRJBashlebenCPTalbertMLKarcherDSMeierFA Fifteen years’ experience of a college of American pathologists program for continuous monitoring and improvement. Arch Pathol Lab Med. 2014;138:1150–5. 10.5858/arpa.2014-0148-OA25171697 MeierFASouersRJHowanitzPJTworekJAPerrottaPLNakhlehRE Seven Q-Tracks monitors of laboratory quality drive general performance improvement: Experience from the College of American Pathologists Q-Tracks program 1999-2011. Arch Pathol Lab Med. 2015;139:762–75. 10.5858/arpa.2014-0090-CP26030245 ShcolnikWDe OliveiraCADe São JoséASDe Oliveira GaloroCAPlebaniMBurnettD. Brazilian laboratory indicators program. Clin Chem Lab Med. 2012;50:1923–34. 10.1515/cclm-2012-035723096110 KirchnerMJFunesVAAdzetCBClarMVDEscuerMIGironaJM Quality indicators and specifications for key processes in clinical laboratories: A preliminary experience. Clin Chem Lab Med. 2007;45:672–7. 10.1515/CCLM.2007.12217484633 BarthJH. Clinical quality indicators in laboratory medicine: A survey of current practice in the UK. Ann Clin Biochem. 2011;48:238–40. 10.1258/acb.2010.01023421367882 BarthJH. Clinical quality indicators in laboratory medicine. Ann Clin Biochem. 2012;49:9–16. 10.1258/acb.2011.01112622042979 SimundicAMTopicE. Quality Indicators. Biochem Med (Zagreb). 2008;18:311–9. 10.11613/BM.2008.027 SciacovelliLPadoanAAitaABassoDPlebaniM. Quality indicators in laboratory medicine: State-of-the-art, quality specifications and future strategies. Clin Chem Lab Med. 2023;61:688–95. 10.1515/cclm-2022-114336660807 PlebaniM. Quality indicators to detect pre-analytical errors in laboratory testing. Clin Biochem Rev. 2012;33:85–8.22930602 SciacovelliLLippiGSumaracZWestJGarcia Del Pino CastroIFurtado VieiraK Quality Indicators in Laboratory Medicine: The status of the progress of IFCC Working Group “laboratory Errors and Patient Safety” project. Clin Chem Lab Med. 2017;55:348–57. 10.1515/cclm-2016-092927988505 AitaASciacovelliLPlebaniM. Extra-analytical quality indicators - where to now? Clin Chem Lab Med. 2018;57:127–33. 10.1515/cclm-2017-096429252191 PlebaniMSciacovelliLAitaAPadoanAChiozzaML. Quality indicators to detect pre-analytical errors in laboratory testing. Clin Chim Acta. 2014;432:44–8. 10.1016/j.cca.2013.07.03324012653 SciacovelliLPadoanAAitaABassoDPlebaniM. Quality indicators in laboratory medicine: State-of-the-art, quality specifications and future strategies. Clin Chem Lab Med. 2023;61:688–95. 10.1515/cclm-2022-114336660807 GaySBadrickT. Changes in error rates in the Australian key incident monitoring and management system program. Biochem Med (Zagreb). 2020;30:020704. 10.11613/BM.2020.02070432292282 BadrickTGaySMcCaugheyEJEJGeorgiouA. External quality assessment beyond the analytical phase: An Australian perspective. Biochem Med (Zagreb). 2017;27:73–80. 10.11613/BM.2017.00928392728 GaySPopeBBadrickTWhileyM. Review of current incidents and risk calculations used in the Royal College of Australasian Pathologists Key Incident Management and Monitoring Systems - a system that could be used by all Australasian medical laboratories, and easily adapted to worldwide use. Biochem Med (Zagreb). 2022;32:010702. 10.11613/BM.2022.01070234955670 GreenSF. The cost of poor blood specimen quality and errors in preanalytical processes. Clin Biochem. 2013;46:1175–9. 10.1016/j.clinbiochem.2013.06.00123769816 HowanitzPJLehmanCMJonesBAMeierFAHorowitzGL. Clinical laboratory quality practices when hemolysis occurs. Arch Pathol Lab Med. 2015;139:901–6. 10.5858/arpa.2014-0252-CP26125430 HeyerNJDerzonJHWingesLShawCMassDSnyderSR Effectiveness of practices to reduce blood sample hemolysis in EDs: A laboratory medicine best practices systematic review and meta-analysis. Clin Biochem. 2012;45:1012–32. 10.1016/j.clinbiochem.2012.08.00222968086 LeeHLeeHKimCShinHLeeIKimY. Hemolysis Control in the Emergency Department by Interventional Blood Sampling. J Pers Med. 2023;13:651. 10.3390/jpm1304065137109037 BurnsERYoshikawaN. Hemolysis in Serum Samples Drawn by Emergency Department Personnel versus Laboratory Phlebotomists. Lab Med. 2002;5:378–80. 10.1309/PGM4-4F8L-2P1M-LKPB GaySSikarisK. Badrick. Tony. Reporting Critical Pathology Results - what is the current state of play in Australian Laboratories? An opinion based on findings of a KIMMS audit. Australian Journal of Medical Science. 2019;40:126–30. DunbarNMKaufmanRM. Factors associated with wrong blood in tube errors: An international case series – The BEST collaborative study. ransfusion. 2022;62:44–50. 10.1111/trf.1671634726274
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010701" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010701" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010701" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(154) "Key incidents identified by the Royal College of Pathologists of Australasia Quality Assurance Programs Key Incident Monitoring and Management EQA program" ["journals_article_author"]=> string(44) "Anushka Jayanetti, David Roxby, Tony Badrick" ["journals_article_author_country"]=> string(9) "Australia" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(93) "preanalytical phase, incident reporting, risks management, quality improvements, Benchmarking" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3160" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "6" ["meta_title"]=> string(154) "Key incidents identified by the Royal College of Pathologists of Australasia Quality Assurance Programs Key Incident Monitoring and Management EQA program" ["meta_desc"]=> string(154) "Key incidents identified by the Royal College of Pathologists of Australasia Quality Assurance Programs Key Incident Monitoring and Management EQA program" ["meta_keyw"]=> string(93) "preanalytical phase, incident reporting, risks management, quality improvements, Benchmarking" ["created"]=> string(19) "2025-12-12 09:50:38" ["modified"]=> string(19) "2026-02-17 09:24:39" } [46]=> object(stdClass)#95 (35) { ["journals_id"]=> string(4) "1224" ["journals_xml"]=> string(63846) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010503 10.11613/BM.2026.010503 Reviews National recommendations of the Working Group for Postanalytics of the Croatian Society of Medical Biochemistry and Laboratory Medicine: Quality indicators of the postanalytical phase PodolarSonja1Vlašić TanaskovićJelena2JokićAnja*3HonovićLorena2RimacVladimira4Leniček KrležaJasna5 Medical Biochemistry Laboratory, General Hospital “Dr. Tomislav Bardek”, Koprivnica, Croatia Department of Laboratory Diagnostics, General Hospital Pula, Pula, Croatia Department of Medical Biochemical Diagnostics, University Hospital for Infectious Diseases “Dr. Fran Mihaljević”, Zagreb, Croatia Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Zagreb, Croatia Department of Laboratory Diagnostics, Children’s Hospital Zagreb, Zagreb, Croatia Corresponding author: anja.jokic@gmail.com

Author contributions

S Podolar: Writing - original draft - Preparation, creation and/or presentation of the published work, specifically writing the initial draft (including substantive translation), Conceptualization - Ideas; formulation or evolution of overarching research goals and aims; J Vlašić Tanasković, A Jokić, L Honović, V Rimac: Writing - review & editing - Preparation, creation and/or presentation of the published work by those from the original research group, specifically critical review, commentary or revision - including pre- or post-publication stages; J Leniček Krleža: Writing - review & editing - Preparation, creation and/or presentation of the published work by those from the original research group, specifically critical review, commentary or revision - including pre- or post-publication stages, Project administration - Management and coordination responsibility for the research activity planning and execution.

15022026 15022026 36 1 010503 0106202522122025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2026 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Quality indicators describe the efficiency of the laboratory process

• Quality indicator framework: planning, measuring data, analysing data, implementing improvements

• Recommended quality indicators in the postanalytical phase: turnaround time, errors withdrawn or retracted laboratory test reports, and notification of critical results

• Recommended quality indicators in the post-postanalytical phase: monitoring issuance of laboratory test reports and monitoring user satisfaction

Considering the concept of quality as a degree of excellence, the term quality of laboratory work tells us how excellent our results are in all areas of laboratory work. Therefore, quality indicators have been introduced with the aim of monitoring and measuring quality. Quality indicators describe the efficiency of the laboratory process in the form of a numerical value, providing objective evidence of the conformity of the specified laboratory process with respect to predefined criteria. The Working Group for Postanalytics of the Croatian Society of Medical Biochemistry and Laboratory Medicine has decided to describe the necessary steps in designing and monitoring quality indicators, with an emphasis on the quality of the postanalytical and post-postanalytical phase. The main purpose of these recommendations is to facilitate the incorporation of quality indicators into laboratories’ daily routines. Laboratories in the Republic of Croatia are recommended to monitor three quality indicators in the postanalytical phase of laboratory work: turnaround time, withdrawn or retracted laboratory test reports, and notification of critical results. Additionally, two indicators are recommended in the post-postanalytical phase: monitoring issuance of laboratory test reports and monitoring user satisfaction. Harmonising acceptable performance limits and monitoring of the most commonly used quality indicators opens up the possibility of comparisons between laboratories and a uniform quality of laboratory services throughout the healthcare system.

Keywords: quality indicatorspostanalytical phaseturnaround timecritical resultsquality management
Introduction

Designing an error prevention mechanism and assessing the quality of laboratory work are priorities for all laboratory professionals. However, ensuring accurate laboratory test results are delivered on time, ultimately leading to correct diagnoses and effective patient treatment, remains a significant challenge. As technological solutions advance in all areas of laboratory work, the demand for effective quality control of laboratory processes has also increased. Quality indicators have been introduced for this purpose. These indicators play an important part in assessing the quality of the total laboratory work (1).

Quality indicators describe the efficiency of the laboratory process in the form of a numerical value and provide objective evidence of the conformity of the specified laboratory process with respect to predefined criteria (2). Although the result of the quality indicators is an exact value, the procedure of implementing and monitoring the quality indicators can be a challenging task in itself. The lack of time and clear quality objectives often puts laboratory personnel in a situation where they feel responsible for processes that are out of their control, or where monitoring quality indicators does not necessarily lead to quality improvement (3). This is particularly evident in the postanalytical phase, such as the reporting of critical results, which extend beyond the laboratory and involve personnel not directly involved in the laboratory work (4).

In 2008, the Working Group on Laboratory Errors and Patient Safety (WG-LEPS) of the International Federation of Clinical Chemistry and Laboratory Medicine started a project aimed at creating a list of key quality indicators for the entire laboratory process, enabling laboratories to report their own measured results, modelled on external quality control schemes (5). Participation in this program enabled laboratories to measure the quality of their performance in a standardised manner and compare their results with acceptance criteria calculated based on the results reported by all participating laboratories.

Guided by this, the Working Group for Postanalytics of the Croatian Society of Medical Biochemistry and Laboratory Medicine has decided to describe the necessary steps in designing and monitoring quality indicators, with a particular emphasis on the quality of the postanalytical phase. These recommendations aim to make it easier for laboratories to introduce quality indicators into their daily routine. With careful and systematic planning, quality indicators serve as a valuable tool for developing and maintaining the quality of laboratory processes.

Establishing quality indicators

Quality indicators should be established to assess and monitor the compliance of laboratory processes that require additional attention due to their complexity or processes critical to patient safety. The implementation and monitoring of quality indicators for key laboratory processes are mandatory for every laboratory, in accordance with the standards set by the Croatian Chamber of Medical Biochemists and the ISO 15189 accreditation requirements (6, 7). It is the responsibility of the laboratory manager to decide on the introduction of quality indicators. The further steps of implementation and monitoring, which usually include planning quality indicators, data collection, and analysis, can be delegated to all laboratory personnel (Figure1) (6, 7).

Necessary steps in the implementation of quality indicators.

Planning the implementation of quality indicators

To effectively document all steps involved in planning the implementation of quality indicators, it is recommended to create a planning form. This form should include the following essential elements: a) a name of the quality indicator, b) a laboratory process being monitored, c) a description of the quality indicator, d) individuals responsible for monitoring, e) the data to be collected and the methods for data collection, f) the time interval during which the quality indicator will be monitored, g) the frequency of data evaluations, h) acceptance criteria for the quality indicator with the source mentioned and, i) the propositions of the actions to be taken if the acceptance criteria are not met (Table 1) (8, 9).

Example of planning of quality indicator: turnaround time for STAT potassium
Name of quality indicator Turnaround time for stat potassium
Monitored processes Preparation of the STAT sample for analysis, transportation of the sample to the analyzer, analysis, review of the test results, additional procedures such as retesting, and release of the laboratory test report
Description of quality indicator Time elapsed from confirmation of the request from the laboratory to the release of the report for stat potassium
Responsible personnel Data record: all personnel with LIS authorisationData assessment: medical biochemist (name)
Time frame of monitoring Continuously
Data to be recorded/methodof recording 1. Time of confirmation of request/LIS2. Time of report release/LIS3. Time frame from 1. to 2. in minutes/LIS report
Frequency of reports Reports: monthly
Acceptable criteria Time frame: 60 minutes (13)Number of reports released after 60 minutes: < 18% (11)
Recommended correctiveaction if applicable 1. Separate place of sample acceptance2. Mark the sample for visibility during sample preparation3. Use of the STAT position on the analyzer
LIS - laboratory information system. STAT - position for urgent samples.

For quality indicators that are continuously monitored in the laboratories, such as turnaround time (TAT), the frequency of data analysis and reporting must be defined. For indicators implemented to obtain specific information about the process (e.g., TAT for manual/semi-automated test analysis to confirm the need for automation of the analysis), a time frame must be established in which specific data is collected, analysed, and reported (7, 8).

It is essential to establish the criteria that quality indicators should meet (10). These criteria can be determined based on literature reviews, recommendations from relevant professional societies, standards from interlaboratory comparisons, requirements from laboratory users, or suggestions from equipment and reagent manufacturers.

As previously mentioned, the WG-LEPS criteria define current standards for acceptable laboratory performance limits. Similar to criteria based on biological variability, the 25th percentile indicates high-performance quality, while the 75th percentile reflects a lower level of quality (11). Due to the lack of national programs, all Croatian laboratories are invited to use the published criteria as a source of acceptance criteria and participate in this project as the next step in the improvement phase (Table 2). Designing quality indicators according to external quality control schemes or interlaboratory comparisons is the most objective evidence of the quality of laboratory work. However, this approach also has drawbacks. These include the frequent need for manual data collection due to insufficient information systems, the additional workload caused by data entry and report analysis, and, in some cases, the absence of suitable schemes or the use of inadequate criteria (12).

Overview of recommended quality indicators for key processes of the postanalytical phase of laboratory work by Working Group on “Laboratory Errors and Patient Safety”
Percentage of laboratory reports released outside the specified time frame
TAT TAT for STAT potassium results
TAT for STAT PT-INR results
TAT for STAT total blood count results
TAT for STAT troponin (TnI or TnT) results
Percentage of STAT potassium results (released after 1h)
Laboratory report Percentage of revoked laboratory reports
Notification of critical results Percentage of delayed inpatient critical results
Percentage of delayed outpatient critical results
TAT - turnaround time. STAT - position for urgent samples. PT-INR - prothrombin time - international normalized ratio. TnI - troponin I. TnT - troponin T.
Monitoring of quality indicators

The approach to data collection must be adapted to the laboratory’s capabilities, especially to the available functionalities of the information systems or equipment, as well as to the time commitment of the laboratory personnel involved in the data collection. The person in charge of planning the quality indicators is responsible for creating forms for data collection, training all personnel involved in data collection, and carrying out all other procedures, such as modifying the laboratory information system (LIS) (9). Data can be collected manually, where data is collected on a form designed for monitoring quality indicators, or automatically, where data is collected using information systems: LIS, other information systems (e.g., hospital or corporate information systems), or middleware that connects LIS to analyzers.

Using information systems for data collection allows the generation of various reports, and filters can be applied to test results or patient data. Automated data filtering saves time and lessens personnel burden, and the results are often less prone to errors. Data for quality indicators can be collected retrospectively (by filtering data recorded independently of quality indicators monitoring) or prospectively (data collection starts with the introduction of quality indicators) (8).

Creation and evaluation of reports

The report should clearly indicate whether the measured data meet the preset criteria. For easier interpretation, it is recommended to present the results in a table or graph. The interpretation should include a possible explanation for any deviation from the criteria, as well as trend monitoring or comparison with previous results for continuous quality indicators (8).

The evaluation of the obtained results is conducted by the laboratory manager and should be included in the laboratory management review (7). The laboratory manager decides whether to continue, change, or terminate quality monitoring. Based on the report on the quality indicators, necessary corrective actions can be requested, personnel training can be introduced, or the replacement of laboratory equipment can be planned (7).

Quality indicators of the postanalytical phase

Laboratories are recommended to monitor three quality indicators in the postanalytical phase of laboratory work: TAT, withdrawn or retracted laboratory test reports, and notification of critical results (13).

Turnaround time

Turnaround time is the most frequently monitored quality indicator in laboratories as it most comprehensively describes the laboratory process (14). It is also a key quality indicator that physicians and patients, as users of laboratory services, frequently rely on to evaluate the quality of those services (15). For most Croatian laboratories, TAT includes the time from confirmation of the laboratory test request in the LIS to the release of the laboratory test report (16). Assuming that confirmation of the test request began after the laboratory received the sample, the processes included in this time are preparation of the sample for analysis, transportation of the sample to the analyzer, analysis, interpretation of the test results, additional procedures such as sample dilution or retesting, and release of the laboratory test report. If the confirmation of the test request is followed by sampling in the laboratory, this interval also includes the process of preparing the patient for sampling and the sampling itself.

When monitoring the TAT, a model with two approaches is possible. Laboratories may choose to record the time interval between confirmation of the test request for laboratory tests in the LIS and the release of the laboratory test report. The second approach involves monitoring the number of reports not released within the specified time interval, and the quality indicator is expressed as a percentage of the total number of laboratory reports released (5, 17).

When defining the goals and acceptance criteria for TAT, it is important to evaluate data for emergency and routine samples separately (18). For emergency samples, TAT could be monitored for sample or specific tests, as proposed by the WG-LEPS (5). The chosen test should best describe all involved laboratory processes. The recommended TAT for emergency testing is up to one hour from the confirmation of the test request to the release of the laboratory test report or test result of the chosen test (13).

The turnaround time for routine tests depends on the laboratory’s capabilities, including equipment and personnel, the complexity of the analysis, the test’s cost, and user expectations. Although the TAT of routine tests is rarely the focus of quality assessment of laboratory work, its monitoring better describes the processes that are often skipped for urgent samples, such as non-emergency transportation of samples, either to or within the laboratory, or the storage of samples for tests that are not performed immediately.

The data for the TAT should be recorded daily, including the time of request confirmation and the time of release of the laboratory test report. The recording itself is done automatically if the information systems are used in the laboratory. It is also desirable to customise or upgrade the information systems used to provide the ability to generate reports on the TAT quality indicators. The frequency of recorded data analysis and reports should be adapted to the size and needs of the laboratory. It is recommended that TAT results be analyzed monthly (6, 7). Any deviation from the set criteria should be analyzed, and the cause of the delay in laboratory test reports should be identified. Exceeding the TAT should not always be considered an indicator of compromised quality, but rather the opposite. For example, this may be due to additional tests that must be performed to clarify the results of the first-line tests. However, when evaluating the results and making decisions about further steps, the main goal should be timely patient care (17).

Withdrawn or retracted laboratory test reports

A laboratory test report with incorrect test results can have profound consequences for the patient (18). The report with the incorrect result must be withdrawn immediately, and the reason for the error should be identified. If possible, a new sample should be analyzed and the new report with the correct test results should be released. It is necessary to inform the responsible physician about the withdrawal of the report. Both the revoked report and the corrected report must be clearly labelled. Each such adverse event must be recorded and evaluated in the form of a quality indicator (13).

The source of error for an incorrectly released laboratory test report can lie in any phase of the laboratory work, including the pre-preanalytical and post-postanalytical phases that take place outside the laboratory (19, 20). Automation of the analytical phase, autovalidation, and the introduction of information systems are just some of the solutions that have helped prevent errors in the laboratory. Regardless, dealing with incorrectly released reports requires the attention of laboratory experts. The minimum data collected for analyzing quality indicators is the total number of incorrectly released test results or the percentage of incorrectly released reports relative to the total number of all released reports (6). The records may also include the source of error, which can provide additional information, such as the percentage of each source of error (21). The recording of data for this quality indicator should be continuous, with data analysis and reporting of results at least once a year (6, 7).

Notification of critical results

A critical result is any result that indicates a patient’s health condition is life-threatening or requires immediate medical intervention. Laboratories must have established procedures to report such laboratory test results to the physician as soon as possible (22).

A precondition for an efficient reporting of critical results includes a list of tests with associated critical values. Such a list can be based on literature data, as well as on agreed medical decision limits adapted to the patient population or the requirements of the physicians using the laboratory (23, 24). The effectiveness of the process itself depends on the method of reporting. In most cases, critical results are reported by telephone to a healthcare professional involved in the patient’s care, preferably a physician (13). Considering the security of medical data and confirmation of receipt, other communication channels can also be used, such as printing laboratory test reports on a designated printer and sending e-mails or messages (25).

It is recommended to set an acceptable time frame of 30 minutes for reporting critical results, with the start time implying the time of release of the laboratory test report (13). Critical limits can be implemented in information systems to ensure that such results are clearly and timely visible to laboratory personnel. Each laboratory must keep records of reported critical results (6, 7). Records of reported critical results should include the first and last name of the patient whose result is reported, the test with a critical result, the name of the healthcare professional to whom the result was reported, the date and time of the report, and the name of the person who reported the critical result. Records of special notes, such as the impossibility of reporting due to the unavailability of the responsible physician, should also be kept (7).

The effectiveness of the notification of the critical results can be assessed by introducing a quality indicator. The data that best describe this quality indicator include: a) the time required to report the critical result, taking the time of release of the laboratory test report as the starting point, or b) the percentage of critical results reported outside the specified time, with the time of release of the laboratory test report as the starting point, or c) percentage of successfully reported results (14, 26).

It is recommended to analyze generated data on critical results and produce a report at least once a year (7).

Quality indicators in the post-postanalytical phase

In addition to those already mentioned, the quality indicators can also refer to other important parameters of the post-postanalytical phase that ensure the principle of comprehensive laboratory management and monitoring the quality of laboratory work.

Monitoring issuance of laboratory test reports

Although the delivery of laboratory test reports to the client in most laboratories in the Republic of Croatia is ensured by the Central Health Information System, due to problems with system availability and the patient’s personal need to receive laboratory test reports directly from the laboratory, the laboratory reports can be personally collected by patients or sent to the patient’s e-mail. For the latter, a valid consent form must be designed and made easily accessible for patients.

Monitoring the frequency of issuance of laboratory test reports personally collected in the laboratory or the percentage of securely received e-mail reports, including laboratory test reports from referral and collaborative laboratories, as quality indicators, adds value to the quality of the laboratory’s communication with its users. The data obtained can be helpful to the laboratory manager in organizing the work of laboratory personnel, as well as identifying the need to provide additional information to laboratory users. The time intervals for reporting on the proposed quality indicators should be adapted to the size and needs of the laboratory and could be monthly, semi-annually, or annually.

Monitoring user satisfaction

The basic method of monitoring user satisfaction involves recording compliments, complaints, and suggestions from all users of the laboratory, including patients, clinic personnel, and laboratory personnel (6, 7). The forms for suggestions, compliments, and complaints must be created, made visible, and easily accessible to all users of the laboratory. This quality indicator reflects the mutual communication between the provider and the user and is one of the most important quality indicators. It is therefore recommended that user satisfaction be continuously recorded with a regular monthly report on the above points. The report should also include a record of corrective actions required.

Additionally, laboratory management is required to conduct a user satisfaction survey at least once a year and report the results back to the laboratory staff (7). The survey should include both patients and physicians, and should assess user satisfaction with all critical laboratory processes (27). The aforementioned processes may include phlebotomy services, TAT, issuance of laboratory test reports, or advisory activities (Table 3). In this way, it significantly contributes to ensuring recognition of and trust in the laboratory’s work results.

Proposed quality indicators in the post-postanalytical phase
Monitoring issuance of laboratory test reports Percentage of securely received laboratory test reports by e-mail
Percentage of issuance of laboratory test reports personally collected in the laboratory
Monitoring user satisfaction Number of user compliments, complaints, and suggestions
User satisfaction survey
Conclusion

Medical biochemical laboratories in the Republic of Croatia are advised to use these recommendations, which provide minimum quality requirements to facilitate the use of quality indicators for certain crucial postanalytical processes. Harmonising the definition and monitoring of the most used quality indicators opens the possibility of comparisons between laboratories, a uniform quality of laboratory services throughout the healthcare system, and setting national goals related to the quality of laboratory work.

To minimise the burden of managing extensive documentation, laboratories should require upgrades from their information system providers that allow for the automatic recording of data monitored in the quality indicator in a standardised manner, while enabling the creation of reports and the ability to evaluate this data through reporting. Ideally, the acceptance criteria for individual quality indicators should be adapted to the needs and requirements of laboratory users. However, it should represent added value and complement the benchmark set by national and international medical group recommendations.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References PlebaniM. Quality in laboratory medicine: 50 years on. Clin Biochem. 2017;50:101–4. 10.1016/j.clinbiochem.2016.10.00727760306 SimundicAMTopićE. Quality indicators. Biochem Med (Zagreb). 2008;18:311–9. 10.11613/BM.2008.027 LapićIRogićDIvićMTomičevićMKardum ParoMMĐerekL Laboratory professionals’ attitudes towards ISO 15189:2012 accreditation: an anonymous survey of three Croatian accredited medical laboratories. Biochem Med (Zagreb). 2021;31:020712. 10.11613/BM.2021.02071234140835 PlebaniM. Harmonizing the post-analytical phase: focus on the laboratory report. Clin Chem Lab Med. 2024;62:1053–62. 10.1515/cclm-2023-140238176022 SciacovelliLPanteghiniMLippiGSumaracZCadamuroJGaloroCAO Defining a roadmap for harmonizing quality indicators in Laboratory Medicine: a consensus statement on behalf of the IFCC Working Group “Laboratory Error and Patient Safety” and EFLM Task and Finish Group “Performance specifications for the extra-analytical phases”. Clin Chem Lab Med. 2017;55:1478–88. 10.1515/cclm-2017-041228688224 Upitnik o samoprocjeni. Povjerenstvo za stručni nadzor, Hrvatska komora medicinskih biokemičara, 2017. (In Croatian) International Organization for Standardization (ISO). ISO 15189:2022 - Medical laboratories - Requirements for quality and competence. ISO;2022. Clinical and Laboratory Standards Institute (CLSI). Developing and Using Quality Indicators for Laboratory Improvement; Approved Guideline. CLSI document QMS12-Ed2. 2nd ed. Wayne:CLSI;2019. CadamuroJGakschMMrazekCHaschke-BecherEPlebaniM. How do we use the data from pre-analytical quality indicators and how should we? J Lab Precis Med. 2018;3:1–9. 10.21037/jlpm.2018.04.04 SciacovelliLSonntagOPadoanAZambonCCarraroPPlebaniM. Monitoring quality indicators in laboratory medicine does not automatically result in quality improvement. Clin Chem Lab Med. 2011;50:463–9. 10.1515/cclm.2011.80922149744 SciacovelliLPadoanAAitaABassoDPlebaniM. Quality indicators in laboratory medicine: state-of-the-art, quality specifications and future strategies. Clin Chem Lab Med. 2023;61:688–95. 10.1515/cclm-2022-114336660807 PlebaniM. The quality indicator paradox. Clin Chem Lab Med. 2016;54:1119–22. 10.1515/cclm-2015-108026641971 Lenicek KrlezaJHonovicLVlasic TanaskovicJPodolarSRimacVJokicA. Post-analytical laboratory work: national recommendations from the Working Group for Post-analytics on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Biochem Med (Zagreb). 2019;29:020502. 10.11613/BM.2019.02050231223256 HawkinsRC. Laboratory turnaround time. Clin Biochem Rev. 2007;28:179–94.18392122 TsaiERTintuANDemirtasDBoucherieRJde JongeRde RijkeYB. A critical review of laboratory performance indicators. Crit Rev Clin Lab Sci. 2019;56:458–71. 10.1080/10408363.2019.164178931393193 JokicARimacVVlasic TanaskovicJPodolarSHonovicLLenicek KrlezaJ. The concurrence of the current postanalytical phase management with the national recommendations: a survey of the Working Group for Postanalytics of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Biochem Med (Zagreb). 2021;31:030704. 10.11613/BM.2021.03070434658645 McKillopDJAuldP. National turnaround time survey: professional consensus standards for optimal performance and thresholds considered to compromise efficient and effective clinical management. Ann Clin Biochem. 2017;54:158–64. 10.1177/000456321665188727166313 PlebaniM. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med. 2006;44:750–9. 10.1515/CCLM.2006.12316729864 JohnGKFavaloroEJAustinSIslamMZSanthakumarAB. From errors to excellence: the pre-analytical journey to improved quality in diagnostics. A scoping review. Clin Chem Lab Med. 2025;63(7):1243–59. 10.1515/cclm-2024-127739868979 KaltDA. A Retrospective Analysis of Corrected Laboratory Results in a Large Academic Medical Center. Am J Clin Pathol. 2019;152:200–6. 10.1093/ajcp/aqz03630985883 MrazekCLippiGKeppelMHFelderTKOberkoflerHHaschke-BecherE Errors within the total laboratory testing process, from test selection to medical decision-making - A review of causes, consequences, surveillance and solutions. Biochem Med (Zagreb). 2020;30:020502. 10.11613/BM.2020.02050232550813 CampbellCCaldwellGCoatesPFlatmanRGeorgiouAHorvathAR Consensus Statement for the Management and Communication of High Risk Laboratory Results. Clin Biochem Rev. 2015;36:97–105.26900189 Don-WauchopeACWangLGreyV. Pediatric critical values: laboratory-pediatrician discourse. Clin Biochem. 2009;42:1658–61. 10.1016/j.clinbiochem.2009.06.02919615355 ŠonjićPNiklerAVuljanićDDukićLŠimundićAM. Clinician’s opinion about critical risk results proposed by the Croatian Chamber of Medical Biochemists: a survey in one Croatian tertiary hospital. Biochem Med (Zagreb). 2019;29:030711. 10.11613/BM.2019.03071131624464 KopcinovicLMTrifunovićJPavosevicTNikolacN. Croatian survey on critical results reporting. Biochem Med (Zagreb). 2015;25:193–202. 10.11613/BM.2015.01926110031 SciacovelliLAitaAPadoanAPellosoMAntonelliGPivaE Performance criteria and quality indicators for the post-analytical phase. Clin Chem Lab Med. 2016;54:1169–76. 10.1515/cclm-2015-089726656613 RuizRLlopisMBioscaCTrujilloGLlovetMTarrésE Indicators and quality specifications for strategic and support processes related to the clinical laboratory: four years’ experience. Clin Chem Lab Med. 2010;48:1015–9. 10.1515/CCLM.2010.22920491599
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010503" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010503" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010503" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(183) "National recommendations of the Working Group for Postanalytics of the Croatian Society of Medical Biochemistry and Laboratory Medicine: Quality indicators of the postanalytical phase" ["journals_article_author"]=> string(113) "Sonja Podolar, Jelena Vlašić Tanasković, Anja Jokić, Lorena Honović, Vladimira Rimac, Jasna Leniček Krleža" ["journals_article_author_country"]=> string(7) "Croatia" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(95) "quality indicators, postanalytical phase, turnaround time, critical results, quality management" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2454" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "5" ["meta_title"]=> string(183) "National recommendations of the Working Group for Postanalytics of the Croatian Society of Medical Biochemistry and Laboratory Medicine: Quality indicators of the postanalytical phase" ["meta_desc"]=> string(63) "National recommendations of the Working Group for Postanalytics" ["meta_keyw"]=> string(95) "quality indicators, postanalytical phase, turnaround time, critical results, quality management" ["created"]=> string(19) "2026-02-17 08:32:16" ["modified"]=> string(19) "2026-02-17 09:21:49" } [47]=> object(stdClass)#96 (35) { ["journals_id"]=> string(4) "1209" ["journals_xml"]=> string(72678) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010502 10.11613/BM.2026.010502 Reviews The cancer ratio plus in the differential diagnosis of pleural effusions: a scoping review of current evidence BendimradYasmine*12MellahLamia12SnoussiMalak23El BakkouriJalila24 Mohammed VI Faculty of Pharmacy, Mohammed VI University of Sciences and Health, Casablanca, Morocco Laboratory Medicine, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health, Casablanca, Morocco Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca, Morocco Immunopathology-Immunotherapy-Immunomonitoring Laboratory, Mohammed VI University of Sciences and Health, Casablanca, Morocco Corresponding author: ybendimrad@um6ss.ma

Author contributions

Y Bendimrad: Conceptualization, Investigation, Methodology, Writing – original draft; L Mellah: Investigation, Writing – original draft; M Snoussi: Writing – review & editing, Validation; J El Bakkouri: Supervision.

15122025 15022026 36 1 010502 1808202506112025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• The calculated cancer ratio plus (CR+) appears promising for differentiating malignant from tuberculous pleural effusions

• This review maps available evidence and identifies gaps in clinical practice

• The composite nature of CR+ (using three routine parameters) offers a potential advantage over single conventional markers

Findings support future research to validate CR+

Introduction

Differentiating between malignant pleural effusion (MPE) and tuberculous pleural effusion (TPE) remains challenging in clinical practice. The cancer ratio plus (CR+), a potential diagnostic tool calculated as serum lactate dehydrogenase/(pleural adenosine deaminase x pleural lymphocyte percentage) has emerged to address this diagnostic challenge. This scoping review maps the available evidence on its diagnostic performance.

Materials and methods

We conducted a systematic search of PubMed, Scopus, and Web of Science databases from inception to April 2025. Eligible studies assessed the accuracy of CR+ in distinguishing MPE from TPE. Data on study design, cut-off values, sensitivity, specificity, area under the curve (AUC), and likelihood ratios were extracted and synthesized narratively.

Results

Six studies comprising 881 patients were included. Reported cut-off values varied widely (5.7 - 41.0), as did sensitivity (74.3 - 97.6%) and specificity (36.6 - 94.1%). Most studies, however, reported good discriminatory power with AUC values generally above 0.80. The highest diagnostic accuracy was observed in one study, which reported a sensitivity of 97.6%, a specificity of 94.1%, and an AUC of 0.86. Differences in cut-off thresholds, study populations, local tuberculosis epidemiology, and laboratory methodology (particularly lymphocyte quantification) likely contributed to this heterogeneity.

Conclusions

The CR+ appears promising as a non-invasive tool using routine parameters for differentiating MPE from TPE, but diagnostic performance varies across settings. The heterogeneity in optimal cut-off values highlights the need for local validation before clinical adoption. Future research should standardize methodology and assess its impact on decision-making and patient outcomes.

Keywords: cancer ratio plusmalignant pleural effusiontuberculous pleural effusiondifferential diagnosis
Introduction

Pleural effusion is a common clinical condition characterized by the abnormal accumulation of fluid within the pleural space (1). It represents a significant diagnostic challenge in clinical practice globally, particularly in regions with high tuberculosis (TB) prevalence (2). Among its diverse etiologies, malignant pleural effusion (MPE) and tuberculous pleural effusion (TPE) are of particular clinical importance due to their vastly different management strategies and prognostic implications (3, 4). Accurate and timely differentiation between these two conditions is particularly challenging because both typically present as lymphocyte-predominant exudative effusions with similar gross appearance and overlapping biochemical profiles on initial laboratory analysis, making clinical distinction difficult without additional specialized testing (5). Misdiagnosis can lead to delays in appropriate cancer treatment for MPE or unnecessary prolonged anti-TB therapy for TPE, both of which can negatively impact patient outcomes (6).

The diagnosis of pleural effusion typically involves thoracentesis followed by pleural fluid analysis, including cytological examination and microbiological tests (7, 8). While cytology is crucial for identifying malignant cells, its sensitivity is limited, particularly in effusions with low cellularity or specific cancer types (9). Similarly, the prolonged turnaround time for microbiological cultures, essential for confirming tuberculous etiology, can lead to clinically significant diagnostic delays (10). Moreover, the diagnostic challenge for TPE is compounded because tuberculous pleuritis typically involves a paucibacillary process where only a scant number of bacilli are present in the pleural fluid, resulting in the low sensitivity of standard microbiological tests and frequent negative culture results (11). These inherent limitations underscore the urgent need for rapid and accurate complementary diagnostic tools.

Classical biomarkers in pleural fluid have been commonly used to aid in the differentiation of MPE and TPE (12). Pleural fluid adenosine deaminase (ADA) activities are typically higher in TPE, while lactate dehydrogenase (LD) tends to be higher in MPE (13, 14). Adenosine deaminase is an intracellular enzyme involved in purine metabolism and is released predominantly by activated T lymphocytes and macrophages during cellular immune responses (15, 16). Higher ADA in TPE reflects the intense T-cell-mediated immune activation within the pleural space (17). However, higher ADA is not specific, as MPE can also exhibit moderately higher ADA due to increased lymphocyte turnover in the tumor microenvironment and by the tumor cells themselves, thus decreasing its specificity for TPE (18). Lactate dehydrogenase, on the other hand, is a cytoplasmic enzyme present in virtually all tissues and released into circulation following cellular injury or necrosis (19). Higher serum LD activities are commonly observed in malignancy, reflecting both the high metabolic activity of tumor cells and the extensive cellular turnover associated with cancer progression (20). Conversely, in tuberculous pleurisy, serum LD is generally lower, as the process is dominated by localized immune activation rather than widespread tissue destruction. Other biochemical parameters, such as protein concentrations, glucose, and differential cell counts, are also frequently employed to enhance diagnostic accuracy (14). However, despite their clinical usefulness, all these conventional biomarkers suffer from limited sensitivity and specificity.

To overcome these diagnostic limitations and improve diagnostic accuracy, the cancer ratio - defined as the ratio of serum LD to pleural fluid ADA - was introduced as a composite diagnostic index (21). Studies suggest that a high cancer ratio may effectively indicate MPE, although diagnostic accuracy varies in the literature. Building upon this approach, the Cancer ratio plus (CR+) was developed to further enhance differentiation. This modified index integrates three routinely measured laboratory parameters - serum LD, pleural ADA, and pleural lymphocyte percentage - to improve discrimination between malignant and tuberculous effusions. It is calculated according to the following formula: CR+ = serum LD/(pleural ADA x pleural lymphocyte percentage) (22). The rationale behind this modification is that pleural lymphocyte percentages are usually lower in malignant effusions compared to tuberculous effusions, thus potentially improving diagnostic differentiation (22).

However, despite growing interest, the available evidence remains limited and inconsistent across studies. To date, no comprehensive synthesis has specifically focused on evaluating the diagnostic value of the CR+. The objective of this scoping review is therefore to systematically map the existing evidence on the diagnostic performance of the CR+ in differentiating malignant from tuberculous pleural effusions. Specifically, we aim to summarize reported cut-off values and diagnostic accuracy metrics, and to highlight gaps in current literature that warrant further research.

Materials and methods Protocol and registration

This scoping review was conducted following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines, a framework designed to ensure transparent and comprehensive reporting of scoping reviews (23). The protocol was prospectively registered on the Open Science Framework (https://doi.org/10.17605/OSF.IO/VBG8Y) on April 16. 2025.

Search strategy

A comprehensive literature search was performed across three electronic databases: PubMed, Scopus, and Web of Science, from inception to April 2025. The search strategy combined terms related to pleural effusions, malignancy, tuberculosis, and the CR+. Specifically, keywords included combinations of “pleural effusion,” “malignant pleural effusion,” “tuberculous pleural effusion,” “Cancer Ratio Plus,” “serum LDH,” “pleural ADA,” “lymphocyte percentage,” and diagnostic accuracy terms such as “diagnosis,” “sensitivity,” and “specificity.” Additionally, a manual search of reference lists was performed, which identified one additional article published in 2025.

Eligibility criteria

Studies were eligible for inclusion if they met the following criteria:

Reported on the diagnostic performance of the CR+ for differentiating between MPE and TPE.

Provided at least one diagnostic accuracy metric. The following diagnostic accuracy metrics were considered: sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). Positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were also included when available.

Were original research articles published in English.

Case reports, reviews, editorials, and studies focusing solely on cancer ratio (without the “Plus” modification) were excluded, as they did not provide original data on the diagnostic performance of the specific diagnostic tool of interest.

Selection process

Duplicate records were identified and removed using Microsoft Excel. Titles and abstracts were screened independently by a single reviewer, followed by full-text review. Any uncertainties were resolved through discussion with a senior supervisor. The study selection process is illustrated in the PRISMA flowchart (Figure 1). During the screening phase, we noted a limited number of published articles specifically evaluating the CR+, highlighting the novelty of this diagnostic tool and the relevance of conducting this scoping review.

PRISMA 2020 flow diagram illustrating the study selection process for the scoping review.

Data extraction and charting

A standardized data extraction form was used to collect the following data: first author, year of publication, and country, study design, characteristics of the study population and comparator groups (MPE vs. TPE cases), reported cut-off value for the CR+, diagnostic performance metrics: sensitivity, specificity, AUC, PLR, and NLR values (if available) and whether the individual components (serum LD, pleural ADA, lymphocyte percentage) were reported separately.

Data synthesis

The extracted data were synthesized narratively and presented in tables. No meta-analysis was performed due to the anticipated heterogeneity across study designs, populations, and diagnostic thresholds. This approach allows for a comprehensive description of the available evidence while acknowledging the limitations of combining the data statistically. Key findings, including reported cut-off values and diagnostic accuracy metrics, were summarized to provide an overview of the current evidence regarding the CR+.

Results Study selection and characteristics

A total of six studies met the inclusion criteria and were included in this scoping review. This relatively small number of studies highlights the limited current evidence on the CR+. The selection process is detailed in the PRISMA-ScR flow diagram (Figure 1). The included studies were published between 2016 and 2025.

Most studies employed a prospective observational design, which generally provides stronger evidence than retrospective studies, while two were retrospective. The studies were conducted across various geographic regions, including Asia (Singapore, China, India), Africa (Egypt), and Europe (Turkey), indicating a reasonable geographic distribution. Sample sizes varied considerably across studies, ranging from 78 to 220 participants (estimated median sample size: 132). The comparator groups also differed, with some studies comparing only MPE vs. TPE, while others included additional diagnostic categories such as parapneumonic effusions, which may contribute to heterogeneity in the results.

Data extraction and diagnostic performance

The key findings related to cut-off thresholds and diagnostic performance are summarized below and presented in detail in Table 1. Cut-off thresholds for the CR+ showed a substantial variation across included studies, ranging from 5.65 to 41.00. Sensitivity values varied considerably, ranging from 74.3% to 97.6%, while specificity also showed marked variation, ranging from 36.6% to 94.1%. The area under the receiver operating characteristic curve, a measure of the test’s overall discriminatory ability, was reported in all studies, with values ranging from 0.58 to 0.98, indicating generally good to excellent discrimination. Positive likelihood ratio and NLR were also available for most studies, although some did not report these metrics explicitly.

Diagnostic performance of cancer ratio plus in included studies
Study Country Study design N Comparator group Cut-off (CR+) Sensitivity (%) Specificity (%) AUC PLR NLR
Verma et al., 2016 (22) Singapore Prospective 118 MPE vs. TPE > 30 97.6 94.1 0.86 41 0.06
Hussein and Elhefnawy, 2020 (29) Egypt Prospective 78 MPE vs. TPE vs others ≥ 41 93.6 91.7 0.98 NR NR
Ren and Xu, 2021 (30) China Retrospective 219 MPE vs. TPE > 22.6 (for > 50 years) 86.8 84.6 0.84 5.64 0.16
Zhou et al., 2022 (31) China Prospective 220 MPE vs. TPE ≤ 34.74* 81.5 80.0 0.87 4.06 0.23
Gayaf et al., 2021 (32) Turkey Retrospective 146 MPE vs. TPE vs. PPE > 36.88 74.3 88.9 0.69 6.68 0.29
Parida et al., 2025 (33) India Prospective 100 MPE vs. TPE vs. PPE > 5.65 89.7 36.6 0.58 1.41 0.28
*For the Zhou et al. (2022) study, the CR+ was evaluated as a negative predictive factor for TPE. Thus, a cut-off of ≤ 34.74 indicates TPE, implying that values > 34.74 suggest MPE. N - sample size. MPE - malignant pleural effusion. TPE - tuberculous pleural effusion. PPE - parapneumonic effusion. CR+ - cancer ratio plus. PLR - positive likelihood ratio. NLR - negative likelihood ratio. AUC -area under the curve. NR - not reported.
Discussion

This scoping review mapped current evidence on the diagnostic utility of the CR+ for distinguishing MPE from TPE. Across six studies encompassing 881 patients from diverse geographic settings, the CR+ consistently demonstrated promising diagnostic performance. Most studies reported AUC values above 0.80, indicating good to excellent discriminatory power. However, considerable heterogeneity was observed in cut-off thresholds, which ranged from 5.7 to 41.0, as well as in sensitivity (74.3-97.6%) and specificity (36.6-94.1%).

This variability likely reflects differences in study populations, laboratory protocols, clinical settings, and disease prevalence, thereby limiting the generalizability of a universal threshold. Nevertheless, the consistent trend toward improved diagnostic discrimination compared to conventional markers highlights the CR+ as a promising tool warranting further validation.

The CR+ builds upon two widely accessible biomarkers - serum LD and pleural ADA - by incorporating pleural lymphocyte percentage, a marker typically elevated in TPE. This composite approach captures multiple pathophysiological dimensions and appears to enhance diagnostic accuracy. In several studies, the CR+ outperformed both ADA alone and the original Cancer Ratio (serum LD/pleural ADA). Notably, Verma et al. and Zhou et al. found that CR+ provided superior performance when integrated with traditional markers.

This multi-parameter model may reduce false positives in settings where ADA activities are higher in non-tuberculous conditions or where LD alone lacks specificity (24). The addition of lymphocyte percentage may also be particularly useful in borderline cases, increasing clinician confidence in differential diagnosis.

Several factors may explain the substantial heterogeneity observed across studies. Geographic differences play a significant role, as the prevalence of TB and malignancies varies widely between countries and influences the pre-test probability of each condition (25). Patient selection criteria also differed between studies: some included only lymphocytic exudates, while others assessed a broader spectrum of pleural effusions, including parapneumonic or indeterminate causes.

A notable source of heterogeneity arises from the study by Parida et al. (2025), which reported the lowest specificity (36.6%) and a poor discriminatory performance (AUC = 0.58), which the authors themselves reported as non-significant (P = 0.171). This contrasts with all other studies, which demonstrated AUC values ranging from 0.69 to 0.98. This outlier pattern can be explained by both statistical and epidemiological factors.

From a statistical perspective, the authors used an exceptionally low cut-off threshold (5.7) compared with other studies (ranging from 22.6 to 41.0). Lower thresholds classify more patients as test-positive, which mathematically increases sensitivity (detecting nearly all true positives, 89.7%) but inevitably lowers specificity, because more false positives are inevitably captured - specifically, TPE or parapneumonic pleural effusion misclassified as malignant. This sensitivity-specificity trade-off is a well-established principle in diagnostic testing and fully accounts for the pattern observed in this study (26).

From an epidemiological standpoint, the research was conducted in Odisha, India - a region within a country with one of the world’s highest TB burdens (27). In this context, almost half of the cohort (48%) presented TPE, while malignant effusions represented only 29%. Such a high TB prevalence fundamentally shifts the pre-test probability and can reduce the discriminative capacity of the CR+. Additionally, regional differences in TB strains, patient characteristics (including comorbidity profiles, nutritional status, and age distributions), local disease spectrum, cancer types, and possibly pleural fluid handling or laboratory measurement protocols may all have contributed to the observed discrepancies. The inclusion of parapneumonic pleural effusions (23% of cases) as a third diagnostic category may have further complicated the diagnostic landscape.

Analytical and methodological variability represents another major source of heterogeneity. While ADA and LD assays are generally well-standardized, pleural fluid cell differential reporting remains far more variable across laboratories. In particular, the quantification of pleural fluid lymphocytes, a key denominator component of the CR+ formula, lacks standardization. While all included studies reported "lymphocyte percentage", none provided sufficient detail regarding differential cell counting methodology (manual vs. automated) or specific morphological criteria used to distinguish lymphocytes from monocytes or reactive macrophages. These methodological differences in lymphocyte identification and counting could introduce systematic variation in CR+ values across laboratories and contribute to the observed heterogeneity in optimal cut-off thresholds.

Age demographics are another important variable. For example, Ren et al. highlighted that age-specific thresholds may be necessary, especially since the prevalence of malignancy increases with advancing age (28).

Overall, these findings suggest that local epidemiology significantly influences the diagnostic relevance of CR+, with substantially reduced or negligible utility possible in certain high TB-burden settings. Rather than undermining previous studies, the discordant result from Parida et al. reinforces their validity by highlighting the crucial importance of interpreting CR+ within its specific clinical, methodological, and epidemiological context. These factors collectively underscore that no universal CR+ threshold can be applied across all clinical contexts, and that rigorous local validation aligned with population characteristics and clinical priorities is essential for successful implementation in routine practice. Future systematic reviews and meta-analyses should therefore stratify results by TB prevalence, geographic region, and population characteristics rather than pooling heterogeneous data.

Despite its limitations, the CR+ offers several pragmatic advantages. It is based entirely on laboratory parameters that are already measured as part of standard pleural fluid analysis, requiring no specialized equipment or additional cost. This makes it particularly attractive in resource-limited settings, where advanced diagnostic techniques such as thoracoscopy may be inaccessible. The test also provides rapid results, potentially expediting decision-making and avoiding unnecessary treatment delays.

However, the lack of standardized cut-off values remains a key obstacle to clinical implementation. Applying thresholds derived from dissimilar populations or methods could lead to misclassification and inappropriate clinical decisions. Therefore, the CR+ should always be interpreted within its local epidemiological and laboratory context. Furthermore, this diagnostic tool should not be used in isolation, but rather as part of an integrated diagnostic approach that includes clinical assessment, radiological findings, and conventional microbiological or cytological testing.

Its optimal use may lie in serving as a triage tool or adjunct within diagnostic algorithms, particularly in patients with indeterminate cytology or equivocal ADA results. Incorporating the CR+ into clinical pathways may ultimately reduce the need for invasive procedures and facilitate earlier initiation of appropriate therapy.

This review is, to our knowledge, the first synthesis focused exclusively on the CR+. By aggregating results from diverse clinical and geographic contexts, it offers a comprehensive view of current evidence and identifies key knowledge gaps.

Nevertheless, several limitations must be acknowledged. First, the relatively small number of included studies (N = 6) limits the generalizability of our findings and precludes robust statistical synthesis. Second, our restriction to English-language publications may have led to the exclusion of relevant data from high TB burden regions such as parts of Eastern Europe, Central Asia, and the former Soviet Union countries, where valuable experience may not be published in English.

Third, stratified analyses by TB prevalence or regional epidemiology were not feasible. Notably, Parida et al. reported poor discriminatory ability in high TB-burden India (AUC 0.58), contrasting sharply with excellent performance elsewhere (AUC 0.69-0.98). This suggests CR+ may have limited utility in certain high-burden contexts. Inconsistent reporting across studies prevented further subgroup analyses.

Fourth, no formal assessment of study quality was conducted, and the heterogeneity in design and reporting prevented a meta-analytic approach. Importantly, most studies did not assess the real-world clinical impact of CR+, such as changes in diagnostic yield, decision-making, or patient outcomes. These limitations should inform the design of future research efforts.

To fully realize the potential of the CR+, future research should prioritize methodological standardization and context-specific validation. Specifically, studies should aim to harmonize ADA and LD assay protocols and establish robust, population-specific cut-off values tailored to local epidemiology and clinical priorities. Large-scale, prospective, multicenter trials are needed that deliberately recruit populations from both high and low TB-burden settings, with stratified analyses by TB prevalence, age groups, and cancer types. Additionally, efforts should be made to standardize lymphocyte counting methodology across laboratories to improve the reproducibility and comparability of CR+ values.

Equally important is the need to evaluate how CR+ influences clinical outcomes, including diagnostic efficiency, time to appropriate therapy, treatment decisions, and patient prognosis. The integration of CR+ into comprehensive diagnostic algorithms - alongside clinical, imaging, and potentially molecular biomarkers - may further refine its utility and contribute to a more personalized approach to pleural effusion management.

In conclusion, the CR+ emerges as a promising, accessible, and cost-effective diagnostic tool for distinguishing MPE from TPE. It offers diagnostic value beyond conventional markers, particularly in settings with limited diagnostic resources. However, its clinical use should be guided by locally validated thresholds and integrated into broader diagnostic frameworks. Rigorous prospective research is required to address existing limitations and to optimize its implementation in clinical practice.

Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References Krishna R, Antoine MH, Alahmadi MH, Rudrappa M. Pleural Effusion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Apr 29]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK448189/ LightRW. Update on tuberculous pleural effusion. Respirology. 2010;15:451–8. 10.1111/j.1440-1843.2010.01723.x20345583 ValdésLAlvarezDValleJMPoseAJoséES. The Etiology of Pleural Effusions in an Area With High Incidence of Tuberculosis. Chest. 1996;109:158–62. 10.1378/chest.109.1.1588549179 HusseinMThomasMAl-TikrityMHameedMRazaTAlkhateebE Etiology of exudative pleural effusion among adults: differentiating between tuberculous and other causes, a multicenter prospective cohort study. IJID Reg. 2024;12:100425. 10.1016/j.ijregi.2024.10042539281191 DarooeiRSanadgolGGh-NatajAAlmasniaMDarivishiAEslaminejadA Discriminating Tuberculous Pleural Effusion from Malignant Pleural Effusion Based on Routine Pleural Fluid Biomarkers, Using Mathematical Methods. Tanaffos. 2017;16:157–65.29308081 PorcelJM. Biomarkers in the diagnosis of pleural diseases: a 2018 update. Ther Adv Respir Dis. 2018;12:1753466618808660. 10.1177/175346661880866030354850 KarkhanisVSJoshiJM. Pleural effusion: diagnosis, treatment, and management. Open Access Emerg Med. 2012;4:31–52. 10.2147/OAEM.S2994227147861 NicholsonMJManleyCAhmadD. Thoracentesis for the Diagnosis and Management of Pleural Effusions: The Current State of a Centuries-Old Procedure. J Respir. 2023;3:208–22. 10.3390/jor3040020 PairmanLBeckertLELDaggerMMazeMJ. Evaluation of pleural fluid cytology for the diagnosis of malignant pleural effusion: a retrospective cohort study. Intern Med J. 2022;52:1154–9. 10.1111/imj.1572535191191 Vongthilath-MoeungRPoncetARenziGSchrenzelJJanssensJP. Time to Detection of Growth for Mycobacterium tuberculosis in a Low Incidence Area. Front Cell Infect Microbiol. 2021;11:704169. 10.3389/fcimb.2021.70416934490143 Lo CascioCMKaulVDhooriaSAgrawalAChaddhaU. Diagnosis of tuberculous pleural effusions: A review. Respir Med. 2021;188:106607. 10.1016/j.rmed.2021.10660734536698 FeiGYijunMWeijiangJHuiminCFangL. Biomarkers for distinguishing tuberculous pleural effusion from non-tuberculosis effusion: a retrospective study. BMC Infect Dis. 2023;23:771. 10.1186/s12879-023-08781-037940883 AggarwalANAgarwalRSehgalISDhooriaS. Adenosine deaminase for diagnosis of tuberculous pleural effusion: A systematic review and meta-analysis. PLoS One. 2019;14:e0213728. 10.1371/journal.pone.021372830913213 MercerRMCorcoranJPPorcelJMRahmanNMPsallidasI. Interpreting pleural fluid results. Clin Med (Lond). 2019;19:213–7. 10.7861/clinmedicine.19-3-21331092513 SauerAVBrigidaICarriglioNAiutiA. Autoimmune Dysregulation and Purine Metabolism in Adenosine Deaminase Deficiency. Front Immunol. 2012;3:265. 10.3389/fimmu.2012.0026522969765 Martinez-NavioJMCasanovaVPachecoRNaval-MacabuhayIClimentNGarciaF Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. J Leukoc Biol. 2011;89:127–36. 10.1189/jlb.100969620959412 AggarwalANAgarwalRSehgalISDhooriaS. Adenosine deaminase for diagnosis of tuberculous pleural effusion: A systematic review and meta-analysis. PLoS One. 2019;14:e0213728. 10.1371/journal.pone.021372830913213 LeeJParkJLimJKParkJELeeYHChoiSH Tuberculous and Malignant Pleural Effusions With Adenosine Deaminase Levels of 40-70 IU/L: Trends in New Cases Over Time and Differentiation Between Groups. J Korean Med Sci. 2025;40:e35. 10.3346/jkms.2025.40.e3540195924 ChanFKMMoriwakiKDe RosaMJ. Detection of Necrosis by Release of Lactate Dehydrogenase (LDH) Activity. Methods Mol Biol. 2013;979:65–70. 10.1007/978-1-62703-290-2_723397389 ZhangJLuQLiuWZhouN. The metabolic role of lactate dehydrogenase in the growth of diffuse large B cell lymphoma. Ann Hematol. 2025;104:545–58. 10.1007/s00277-025-06321-139500758 VermaAAbisheganadenJLightRW. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio). Lung. 2016;194:147–53. 10.1007/s00408-015-9831-626678281 VermaADagaonkarRSMarshallDAbisheganadenJLightRW. Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count). Can Respir J. 2016;2016:7348239. 10.1155/2016/734823928070157 TriccoACLillieEZarinWO’BrienKKColquhounHLevacD PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–73. 10.7326/M18-085030178033 Sai BRC, Rao R. Adarsha G K et al. Utility of Cancer Ratio (Serum LDH/Pleural Fluid ADA) and Cancer Plus Ratio (Cancer Ratio/Pleural Fluid Lymphocytic Percentage) in Differentiating Malignant Pleural Effusion and Tubercular Pleural Effusion: A Prospective Observational Study. Research Square [Preprint]. 2025 [cited 2025 Nov 3]. Available from: https://www.researchsquare.com/article/rs-7264543/v1 World health organization. Global tuberculosis report. 1.1 TB incidence. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024/tb-disease-burden/1-1-tb-incidence. Accessed November 3rd, 2025. VachWGerkeOHøilund-CarlsenPF. Three principles to define the success of a diagnostic study could be identified. J Clin Epidemiol. 2012;65:293–300. 10.1016/j.jclinepi.2011.07.00421995974 DasDSatapathyPMurmuB. First Line Anti-TB Drug Resistance in an Urban Area of Odisha, India. J Clin Diagn Res. 2016;10:DC04–06. 10.7860/JCDR/2016/20289.884628050363 Czarnecka-KujawaKKrahnMDWuFStanbrookMTomlinsonGYasufukuK Understanding the Growing Burden of Malignant Pleural Effusion – Epidemiology, Healthcare Utilization, and Cost: A Canadian Perspective. Respiration. 2025;104:421–33. 10.1159/00054352239837310 HusseinSAElhefnawyMY. Relations between serum and pleural fluid biomarkers: a new look of an old concept. Egypt J Bronchol. 2020;14:4. 10.1186/s43168-020-00004-3 RenZXuL. Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion. Clinics (Sao Paulo). 2021;76:e2515. 10.6061/clinics/2021/e251533909825 ZhouJYangYZhangYLiuHDouQ. Age : pleural fluid ADA ratio and other indicators for differentiating between tubercular and malignant pleural effusions. Medicine (Baltimore). 2022;101:e29788. 10.1097/MD.000000000002978835777003 GayafMAnarCCanbazMTatarDGüldavalF. Value of Cancer Ratio plus and Cancer Ratio Formulation in Distinguishing Malignant Pleural Effusion from Tuberculosis and Parapneumonic Effusion. Tanaffos. 2021;20:221–31.35382086 ParidaDRathJSahooS. Diagnostic role of Cancer Ratio and Cancer Ratio Plus differentiability of Tubercular PLEF and Malignant pleural effusion in Tertiary care Hospital, Odisha. CME J Geriatr Med. 2025;17:13–9.
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010502" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010502" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010502" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(110) "The cancer ratio plus in the differential diagnosis of pleural effusions: a scoping review of current evidence" ["journals_article_author"]=> string(66) "Yasmine Bendimrad, Lamia Mellah, Malak Snoussi, Jalila El Bakkouri" ["journals_article_author_country"]=> string(7) "Morocco" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(99) "cancer ratio plus, malignant pleural effusion, tuberculous pleural effusion, differential diagnosis" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2351" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "4" ["meta_title"]=> string(110) "The cancer ratio plus in the differential diagnosis of pleural effusions: a scoping review of current evidence" ["meta_desc"]=> string(110) "The cancer ratio plus in the differential diagnosis of pleural effusions: a scoping review of current evidence" ["meta_keyw"]=> string(99) "cancer ratio plus, malignant pleural effusion, tuberculous pleural effusion, differential diagnosis" ["created"]=> string(19) "2025-12-09 11:34:40" ["modified"]=> string(19) "2026-02-17 09:24:06" } [48]=> object(stdClass)#97 (35) { ["journals_id"]=> string(4) "1208" ["journals_xml"]=> string(123987) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010501 10.11613/BM.2026.010501 Reviews Claudins proteins in brain tumors: expression patterns and therapeutic target RomanowiczAdrianna*12Łukaszewicz-ZającMarta1MroczkoBarbara12 Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland Corresponding author: adrianna.romanowicz@sd.umb.edu.pl, Submitted: February 26, 2025 Accepted: October 23, 2025

Author contributions

A Romanowicz: Conceptualization, Visualization, Writing – original draft; M Łukaszewicz-Zając: Investigation, Conceptualization, Writing – review & editing; B Mroczko: Conceptualization, Formal analysis, Writing – review & editing.

15122025 15022026 36 1 010501 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Claudins contribute to the aggressive growth and metastasis of gliomas

• Claudin-3 and claudin-4 overexpression promotes glioblastoma progression

• Reduced claudin-1, claudin-5, and claudin-6 expressions are observed in advanced gliomas

• Claudin-4 is linked to larger tumor size and may serve as a prognostic marker

• Claudins hold potential as diagnostic biomarkers and therapeutic targets for central nervous system tumors

Tight junctions (TJs) are essential for preserving cell polarity and controlling permeability. It has been disclosed that TJ proteins, especially specific claudins (CLDNs), are linked to inflammation and contribute to the emergence of diverse cancers, including brain malignancies. Aggressive gliomas, including glioblastoma multiforme (GBM), remain among the most common and deadly central nervous system (CNS) tumors worldwide, despite considerable advances in diagnostic and therapeutic approaches. These types of tumors are characterized by high rates of recurrence and metastasis, resulting in poor outcomes and prognosis. The pathophysiology of brain cancer is closely linked to CLDNs, as these specific proteins play critical roles in tumor cell proliferation, invasion, and disruption of the blood-brain barrier (BBB). Some studies reported the potential role of CLDNs in glioma progression and other neurological disorders. The purpose of this review is to highlight the significance of CLDNs in CNS tumors, especially their participation in the formation of malignant gliomas. Additionally, the diagnostic and prognostic importance of selected CLDNs has been assessed. Selected CLDNs, such as CLDN3 and CLDN4 promote GBM growth, proliferation and migration. Moreover, overexpression of CLDN3 support progression and metastasis of these malignancies, while reduced expression of CLDN1 and CLDN5 is observed in advanced gliomas. Presented results suggest that CLDNs may serve as biomarkers for diagnosis and prognosis as well as therapeutic targets in CNS tumors. Further investigation is essential to clarify their clinical relevance and therapeutic potential.

Keywords: claudinsbiomarkersglioblastomacentral nervous system neoplasmsblood-brain barrier
Introduction

The significance of selected claudins (CLDNs) that play a crucial role in regulating the paracellular permeability and maintaining the polarity of epithelial cells has been studied extensively in many malignancies, including tumors of the central nervous system (CNS) (1-3). Certain researchers propose that these proteins could serve as promising biochemical indicators in the development of CNS tumors. Consequently, this review aims to provide an in-depth analysis of the expression patterns, functional significance, and biomarker potential of selected CLDNs in CNS malignancies, with particular emphasis on glioblastoma (GBM), the most prevalent and aggressive form of glioma. The paper highlights the emerging role of claudins in tumor progression, invasion, and therapeutic resistance, emphasizing their biological relevance in CNS tumor development. As a narrative review, it outlines the expression profiles of selected CLDNs in various CNS tumors and explores their potential as biochemical biomarkers for diagnosis and prognosis. A more comprehensive understanding of CLDN activity in brain tumors could thus provide critical insights into the molecular mechanisms driving CNS malignancies and guide the development of more effective therapeutic strategies. Moreover, the therapeutic implications of targeting CLDNs are also discussed. Numerous clinical studies have demonstrated that disruptions in tight junctions (TJs), primarily composed of claudins, are closely associated with malignant transformation. Claudins play a pivotal role in regulating tumor invasiveness, proliferation, and metastasis, positioning them as key elements in brain cancer pathophysiology and as promising therapeutic targets (2, 3).

Methods of literature search

In preparing this review, a comprehensive literature search was conducted using PubMed, Scopus, and Web of Science databases. Only peer-reviewed articles published in English were considered. The key terms used in the literature search included “Claudins”; “Biomarkers”; “Glioblastoma”; “Central Nervous System Neoplasms”; “Blood-Brain Barrier”; “Tight Junctions”. The primary focus was on literature published between 2010 and 2024. Nevertheless, due to the limited number of recent original studies addressing general characteristics of claudins, older publications were also included where relevant and scientifically valuable. In line with the principles of the San Francisco Declaration on Research Assessment (DORA), an effort was made to cite primarily original research articles to emphasize the value of primary scientific data. However, selected review articles were also included to provide broader context, summarize current understanding, and support the interpretation of original findings.

Basic molecular features of the claudins protein family

Claudins constitute a family of transmembrane proteins comprising 26 members in humans and 27 in rodents, with molecular weights ranging from approximately 20 to 34 kDa (4). These proteins are grouped into two categories based on their sequence similarity: classic claudins (CLDNs1-10, CLDN14, CLDN15, CLDN17, CLDN19) and non-classic claudins (CLDNs11-13, CLDN16, CLDN18, CLDNs20-24) (1-5). Claudins are part of a multi-gene family, with several closely related pairs of CLDN genes located near each other in the human genome. Functionally, these proteins can be further categorized into barrier-forming claudins (such as CLDN1 and CLDN5) and pore-forming claudins (like CLDN2, CLDN10, and CLDN15) (1-4). Chromosomal localization and functional roles of classic and non-classic claudins have been presented in Table 1.

Chromosomal localization and functional roles of classic and non-classic claudins
Category Claudin Chromosome location of the gene General function References
CLDN1 3q22.3
CLDN2 Xq22.3
CLDN3 7q11.23
CLDN4 7q11.23
Classic claudins CLDN5 22q11.21 Classical claudins are a family of tight junction proteins primarily involved in maintaining the integrity and selective permeability of epithelial and endothelial barriers (1-9)
CLDN6 16p13.3
CLDN7 17p13.1
CLDN8 21q22.11
CLDN9 16p13.3
CLDN10 13q32.2
CLDN11 3q26.2
CLDN12 7q21.11
CLDN13 8q22.1
CLDN14 21q22.3
CLDN15 7q21.11
CLDN16 3q28
CLDN17 21q22.11
Non-classic claudins CLDN18 3q22.3 Non-classical claudins differ from their classical counterparts in that they often exhibit more diverse and specialized functions beyond the formation of tight junctions. Their primary roles include: modulation of tumor microenvironment, tissue-specific expression, regulation of signaling pathways (1-9,46-49)
CLDN19 1p34.2
CLDN20 6q25.3
CLDN21 4q35.1
CLDN22 4q35.1
CLDN23 8p23.1
CLDN24 4q35.1
CLDN25 11q23.1
CLDN26 8q24.3
CLDN27 21q22.11

Claudins play a crucial role in regulating the paracellular permeability and maintaining the polarity of epithelial cells by forming TJs (2-4). Tight junctions consists of integral transmembrane (TM) proteins and peripheral membrane proteins that engage in intricate protein-protein interactions. They include endogenous transmembrane proteins such as CLDNs and occludin, as well as cytoplasmic proteins like zonula occludens, which connect the actin cytoskeleton and signaling proteins (3). Claudins are made up of an N-terminal segment in the cytoplasm, four transmembrane regions, two extracellular loops, and a C-terminal cytoplasmic tail (1-4, 6). These proteins exhibit a structural pattern that includes four predicted TM regions, with one larger extracellular loop containing a conserved sequence motif, and a second, shorter extracellular loop (1-4, 6). Claudins also create channels that selectively allow certain ions to pass between cells, while the shorter extracellular loop displays a helix-turn-helix configuration (7). Figure 1 illustrates the structure of claudin. Additionally, two cysteine residues form internal disulfide bonds, playing a key role in maintaining the protein’s stability (6). The C-terminal tail of claudins shows variability in both sequence and length, and it includes a PDZ-domain-binding motif (PSD95 - postsynaptic density protein; Dlg1 - Drosophila disc large tumor suppressor; ZO-1 - zonula occludens-1 protein), which enables direct interactions with cytoplasmic components of TJs. The positioning and role of CLDNs are also controlled by the phosphorylation of the C-terminal, which is a target of serine, threonine, and tyrosine kinases (6).

Structure of claudin proteins. Claudins consist of an N-terminal cytoplasmic segment, four transmembrane (TM) regions, two extracellular loops (ECL-1 and ECL-2), and a C-terminal cytoplasmic tail. They form channels that selectively allow ions to pass between cells, with the shorter extracellular loop adopting a helix-turn-helix configuration. Two cysteine residues form internal disulfide bonds, maintaining protein stability. The C-terminal tail contains a PDZ-domain-binding motif, enabling interactions with cytoplasmic tight junction components. Positioning and function of claudins are also regulated by phosphorylation. COOH terminal - carboxy-terminal domain. NH2 terminal - amino-terminal domain. ECL-1 - extracellular loop 1. ECL-2 - extracellular loop 2. TM1-4 - transmembrane domains 1 to 4. Figure was modified and adopted from reference (3).

Claudins modulate the functional alterations of TJ protein through post-translational changes. Processes like phosphorylation, ubiquitination, palmitoylation, and glycosylation as post-translational modifications impact CLDNs structure, stability, transport, and function (8). Research by Suzuki et al. has demonstrated that the transmembrane segments of mammalian claudin 15 (mCLDN15) create a characteristic left-handed four-helix bundle (9). Moreover, significant portions of the two extracellular segments form a distinct β-sheet fold, encompassing two extracellular segments. These findings suggest that the linear arrangement of mCLDN15 protomers observed in the lipidic cubic phase (LCP) crystals might be indicative of linear claudin polymers that are formed in TJs. The authors conclude that understanding the crystal structure of CLDNs, which are the building blocks of TJ strands, will enhance our molecular understanding of the paracellular barriers between epithelial cells in multicellular organisms (9). The primary role of most members of the CLDN is to establish paracellular barriers, regulate intramembranous diffusion, and maintain cellular polarity (10, 11). These proteins are predominantly localized in the apical membrane region, where they contribute to the formation of TJ complexes, essential for preserving both cell polarity and intercellular adhesion. Consequently, CLDNs are found to be critical for the proper functioning of the intercellular barriers formed by TJs, underscoring their significance in cell–cell junction integrity and tissue homeostasis (11).

Claudins and cancer pathogenesis

In addition to forming the structural backbone of tight junctions, claudins play pivotal physiological roles in regulating paracellular permeability and maintaining epithelial cell polarity. Their characteristic structure enables them to function both as barriers and selective pores. Moreover, claudins can directly modulate signaling pathways or indirectly influence cell growth, survival, proliferation, and differentiation through interactions with other proteins. Their expression is tightly regulated and varies across tissues, with additional diversity introduced by alternative splicing. In cancer, the disruption of normal epithelial architecture compromises tight junction integrity, affecting the function and localization of claudins (12). While these proteins are vital for maintaining the epithelial barrier, their significance in neoplasia is not fully understood (12). The loss of claudins disrupts the integrity of cell connections, one of the characteristics of epithelial-mesenchymal transition (EMT). In cancer, the loss of cell polarity and differentiation is closely tied to metastasis, with EMT serving as a crucial mechanism in this progression (12). The process of EMT starts with the disintegration of the connection among epithelial cells, including adherens junctions, TJs, desmosomes, and gap junctions, which can lead to a disruption of cell polarity and reorganization of the cytoskeleton. Claudins, as the proteins associated with TJs, have been found to contribute to various stages of cancer progression (12). An increasing amount of research indicates that tumor growth is influenced not only by intrinsic mechanisms but also by paracrine signals, including specific growth factors secreted by the TM. Such signaling molecules are typically produced as transmembrane proteins and get released through a process of limited proteolysis known as ectodomain shedding (13). Claudins expression and localization are frequently altered in a variety of tumors, which can facilitate cancer progression by impairing cell polarity and increasing cellular migration. Claudin-1 has been shown to be highly expressed in gastric cancer tissues, particularly in intestinal-type tumors and CLDN1 overexpression was positively associated with more advanced TNM stages, the presence of lymph node metastasis and well-differentiated tumors. Its elevated expression also appears to be negative prognostic factor, especially in the intestinal-type of gastric cancer (14). Claudin-1 primarily acts as a tumor promoter by enhancing the invasive and motility capabilities of cancer cells. This effect is mediated through its role in altering cell adhesion, disrupting epithelial barrier integrity EMT, a key process in cancer metastasis. Additionally, CLDN1 has been implicated in modulating signaling pathways, such as Wnt/β-catenin, further contributing to intestinal-type gastric cancer progression and the spread of malignant cells (14). Quantitative real-time polymerase chain reaction (qRT-PCR) analysis revealed that CLDN1 mRNA expression was significantly elevated in non-small cell lung cancer (NSCLC) tissues compared to adjacent normal tissues. In addition, CLDN1 mRNA expression was significantly higher in the tissue of NSCLC patients in advanced TNM stages (III–IV) and with the presence of lymph node metastases in comparison to subjects without lymph node metastasis and at stages I and II, what indicate the role for CLDN1 in the progression and metastasis of NSCL (15). Additionally, CLDN2 displays elevated expression in human lung adenocarcinoma cells and contributes to enhanced cell proliferation, while its knockdown has been shown to increase paracellular permeability and intracellular accumulation of doxorubicin in tumor spheroids. These findings suggest that loss of CLDN2 expression may enhance the sensitivity of lung adenocarcinoma cells to anticancer agents (16). In the study of Okui et al. several clonal populations representing aggressive and non-aggressive phenotypes from a human pancreatic cancer cell line were isolated and subsequently authors identified CLDN7 as a gene specifically expressed in the clonal population with aggressive phenotypes. DNA microarray analysis revealed a high expression of CLDN7 in the human pancreatic cell lines MIA PaCa-2-A (cells with an epithelial morphology) compared to low expression of CLDN7 in the MIA PaCa-2-R cells (with a non-epithelial morphology), while the knockdown of CLDN7 in the MIA PaCa-2-A cells induced a marked inhibition of proliferation (17). Authors conclude that CLDN7 is expressed in the rapidly proliferating and dominant cell population of pancreatic cancer tissues and represents a potential molecular target for pancreatic cancer treatment (17).

Classification of central nervous system tumors

Central nervous system tumors account for roughly 2% of all cancer cases globally (18). Such tumors belong to a highly diverse category of growth, characterized by distinct disease progressions and varying patient outlooks. According to the 2021 World Health Organization (WHO) classification, tumors of the CNS are now categorized based on a combination of histological grading (grades 1 to 4) and molecular characteristics, such as isocitrate dehydrogenase (IDH) mutation status, 1p/19q co-deletion, and telomerase reverse transcriptase (TERT) promoter mutations (18). Gliomas, tumors of glial origin, are the most common primary malignant CNS tumors, accounting for over 40% of cases. Glioblastoma multiforme, which accounts for 55% of all neuroepithelial tumors in adults, remains the most lethal CNS malignancy. The pathogenesis of CNS tumors, including gliomas, involves a combination of genetic and epigenetic alterations. Advances in understanding these processes have paved the way for novel therapies targeting cancer stem cells and epigenetic regulators. Several environmental factors, such as alcohol and tobacco use, mobile phone usage, contact with chemical substances, head trauma, infections, injuries, N-nitroso compounds, and low-frequency electromagnetic fields, have been reported to be potentially associated with the development of brain tumors (19-21). However, the only well-established risk factor for these neoplasms is prior exposure to high-dose ionizing radiation (19-21).

Diagnosis of central nervous system tumors

Imaging modalities play a crucial role in the diagnostic evaluation of CNS tumors (20, 21). Despite significant advancements in both structural and functional neuroimaging techniques, the survival rates for patients remain unsatisfactory. Unfortunately, current neuroimaging methods lack the specificity required for effective differentiation between various types of brain tumors. Extensive research efforts have yielded minimal progress, necessitating that tumor grading and classification should be performed through histopathological analysis of tissue specimens, which inherently involve surgical procedures (20, 21). Future diagnostic strategies should focus on integrating molecular biomarkers with histopathological analysis to improve the accuracy and personalization of tumor classification. The continued advancement of molecular diagnostic tools is expected to significantly enhance the early detection, and prognosis of malignant CNS neoplasms, potentially reducing the need for invasive surgical procedures in the future. The introduction of readily available biochemical markers could greatly enhance the diagnostic process for these tumors, facilitating disease monitoring, differential diagnosis, and surgical planning, especially in the early stages of the disease (22). In standard clinical practice, the determination of the concentrations of the alpha-fetoprotein (AFP) and beta subunit of human chorionic gonadotropin (β-HCG) are the primary biochemical tumor markers utilized for diagnosing rare pediatric germ cell tumors. Moreover, numerous researchers have investigated the plasma concentrations of various biomarkers in plasma, e.g. glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), glial fibrillary acidic protein (GFAP), neuropeptide Y (NPY, placental growth factor (PlGF), S100B, and interleukin 8 (IL-8) in patients diagnosed with diverse forms of CNS tumors (22). The investigators determined that the plasma concentrations of these biomarkers showed significant correlation with neuropathological classifications and characteristics. Central nervous system tumor markers are valuable, however have several limitations, such as lack of specificity, e.g. these substances are not unique to cancer and can be elevated in non-cancerous conditions, leading to false-positive results and unnecessary diagnostic procedures or treatment. Another limitation is lack of sensitivity, e.g. might not be elevated in all individuals with cancer or not for all types of cancer, causing false negatives in early stages and missed diagnosis. For example, GFAP which is considered as a prototype glial-specific biomarker, lacks tumor specificity. Elevated GFAP concentration in serum is also observed following stroke or traumatic brain injury, reflecting general brain damage rather than neoplastic transformation (23, 24). Notably, increased serum GFAP concentration after surgical resection occur regardless of glioma grade, confirming its low specificity for tumor burden. Thus, while GFAP may support differential diagnosis or complement imaging findings, its standalone diagnostic value remains limited (23, 24). Similarly, angiogenesis-related proteins have garnered interest due to the role of vascular proliferation in glioblastoma pathogenesis. Vascular endothelial growth factor (VEGF), often elevated in the serum of glioblastoma patients and targeted by therapeutic agents like bevacizumab, is not tumor-specific. Clinical trials evaluating antiangiogenic therapies, such as thalidomide and cediranib, revealed that circulating VEGF concentration neither correlated with overall survival nor reliably reflected disease recurrence (25, 26). This limits its utility as a prognostic or monitoring biomarker in GBM. Epidermal growth factor receptor (EGFR), often amplified or mutated in GBM, showed elevated serum concentration in patients compared to healthy individuals (26). However, postoperative concentration did not significantly decline, indicating poor sensitivity to tumor burden changes. Hence, while EGFR alterations are valuable for molecular classification and targeted therapy stratification, serum EGFR concentration alone is not reliable indicators of tumor dynamics (27). In summary, while several proteins demonstrate potential as glioma biomarkers, most suffer from limited specificity, inconsistent correlation with tumor progression, and variability due to non-neoplastic brain conditions. Furthermore, comparative evaluation with claudins and other methods like imaging or biopsies, may help to establish more precise diagnostic and prognostic tools in CNS neoplasms. As a result, there is an urgent need for the development of novel biochemical tumor markers. In this context, claudins, owing to their distinct expression patterns and biological functions, have gained attention as potential diagnostic and prognostic biomarkers in CNS malignancies. To provide a concise overview, Table 2 summarizes their expression patterns, functional roles, and clinical significance. The significance of selected CLDNs has also been presented in Table 2.

The importance of some claudins as potential biomarkers for CNS tumors
Claudins(references) Expression Association with cancer Possible diagnostic/prognostic marker Possible therapeutic target
CLDN1(30-33) Reduced in high-grade gliomas (3 and 4); higher in low-grade gliomas (1 and 2) Linked to cancer progression and invasiveness Possible prognostic marker for cancer grading -
CLDN3(36,37) Significantly upregulated in GBM Supports tumor cell growth and epithelial-mesenchymal transition - Potential target via TGF-β inhibitors (e.g., ITD-1)
CLDN4(38-41) Increased with glioma progression Enhances glioma cell proliferation and migration; correlates with tumor size Potential biomarker for gliomas Monoclonal antibody (e.g. KM3900) targeting CLDN4 induces cytotoxicity and disrupts tumor tight junctions, enhancing therapy efficacy.
CLDN - claudin. CNS - central nervous system. GBM - glioblastoma multiforme. TGF-β - transforming growth factor-β.
Classic claudins in central nervous system malignancies

Claudin-1, the first identified member of the CLDNs, weighing 22 kDa, is highly expressed in organs such as the brain, kidney, liver and spleen (28, 29). In various cancers, CLDN1 shows an altered role; its reduced expression has been linked to cancer progression, increased invasiveness, and the development of metastatic characteristics (30, 31). Investigation highlights CLDN1 as one of the most deregulated claudins in human cancers, acting as either a tumor promoter or suppressor depending on the specific cancer type (32). Karnati et al. observed a significant reduction in CLDN1 expression in glioblastoma (grade 4) and anaplastic astrocytoma (grade 3) tumor samples, compared to pilocytic astrocytoma (grade 1) and diffuse astrocytoma (grade 2) samples, in which CLDN1 expression was elevated (33).

Claudin-3, a member of the transmembrane TJ protein family, serves as a key structural component within TJs (34, 35). Sun et al. have reported that CLDN3 is upregulated in GBM and contributes to tumor cell growth and epithelial-mesenchymal transition in both in vitro and in vivo models (36). Their findings suggest that CLDN3 expression can be activated by transforming growth factor-β (TGF-β), while specific inhibitors of the TGF-β signaling pathway, such as inhibitor of TGF-β receptor type I (ALK5) degradation 1 (ITD-1), reduce CLDN3 levels. Further studies showed that elevated CLDN3 levels amplify TGF-β-induced growth and EMT in GBM cells, whereas decreasing CLDN3 diminishes these effects. This research highlights CLDN3 role in supporting GBM growth and metastasis, linking it to the tumor-promoting functions of TGF-β. As a result, targeting CLDN3 with specific inhibitors could offer a promising strategy for treating this aggressive cancer (36, 37).

Claudin-4, a transmembrane protein, is found within the TJs of intestinal epithelial cells and on the surface of M cells in both humans and mice. In microfold cells, CLDN4 functions as a TNF receptor for Clostridium perfringens enterotoxin (CPE), interacting specifically with the toxin’s C-terminal 30 amino acids through direct binding (38). Elevated CLDN4 expression in glioma tissues are associated with poor clinical outcomes, and Yang et al. further demonstrated a positive correlation between CLDN4 expression and the more advanced clinical stages of glioma patients, what was assessed using immunohistochemical staining (IHC) (38). In vitro investigations demonstrate that elevated CLDN4 expression significantly enhances glioma cell proliferation and migration. Moreover, overexpression of CLDN4 is associated with increased tumor sizes in glioma xenograft models. Additionally, CLDN4 influences glioma progression by modulating the NNAT/Wnt signaling pathway. The tumor-promoting role of the CLDN4/NNAT axis has been further confirmed in glioma organoids. Collectively, these findings suggest that CLDN4 holds promise as a valuable biomarker and a potential therapeutic target for glioma treatment (38). Yan et al. have found that CLDN4 expression was upregulated in GBM tissues and cell lines compared to paired adjacent normal tissues and normal human astrocytes (NHAs) (39). Furthermore, elevated CLDN4 expression were correlated with shorter overall survival in GBM patients. Suppression of CLDN4 expression was shown to reduce mesenchymal transformation, as well as inhibit GBM cell invasion, migration, and tumor growth both in vitro and in vivo. Functional analyses revealed that CLDN4 is involved in modulating the tumor necrosis factor alpha (TNF-α) signaling pathway. Additionally, the TGF-β pathway was found to upregulate CLDN4 expression and enhance GBM cell invasiveness, while its inhibition by ITD-1 reduced CLDN4 levels and suppressed invasion. TGF-β also promoted the nuclear translocation of CLDN4. Collectively, these results suggest that the TGF-β/CLDN4/TNF-α/NF-κB signaling axis plays a critical role in glioma progression, and its disruption may offer a promising therapeutic strategy for GBM (39). Targeting of CLDN4 is expected to provide multi-layered effects by enabling direct attacks on CLDN4-overexpressing cancer cells, disrupting the intratumoral microenvironment, and facilitating drug delivery by impairing TJs. It is also expected to inhibit tumor-promoting signals generated by non-TJ CLDN4. Some clinical investigations generated a monoclonal antibody (KM3900) that targets CLDN4 extracellular loop 2 and induces antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in vitro (40). Claudin-4 is expressed in a several normal tissues, and off-target effects of anti-CLDN4 drugs other than antibodies should also be determined (41).

Claudin-5 plays a crucial role in regulating the permeability of the blood-brain barrier (BBB) during lung cancer brain metastasis by modulating the proliferation, migration, and permeability of human brain vascular endothelial (hCMEC/D3) cells. This regulation, primarily mediated through the cell adhesion molecule signaling pathway, enhances tight junction integrity and contributes to the suppression of lung cancer brain metastasis formation (42). The expression profile of CLDN5 closely corresponded to that of CLDN1, exhibiting similar patterns in both high-grade (3, 4) and low-grade (1, 2) samples (33). The main conclusion of the present study is that reduced expression CLDN1 and CLDN5 are linked to the advancement of malignant gliomas, with this effect becoming more evident as the grade of glioma increases. Liebner and colleagues found a frequent reduction in CLDN1 expression in GBM tissue compared to normal brain tissue, without any significant downregulation of CLDN5 (43). Likewise, Ishihara and colleagues analyzed 24 cases of both low- and high-grade gliomas and reported a loss of CLDN1 expression in high-grade tumors (44). Reduced CLDN1 expression was observed in glioma cell lines derived from high-grade (grade 3 and 4) tumors, compared to low-grade pilocytic astrocytomas (grade 1), diffuse astrocytomas (grade 2), and non-neoplastic control tissues (43, 44).

Claudin-6 shares homology with classical claudins, specifically CLDNs 1–5, 7–10, 14, 15, 17, and 19, distinguishing it from the less homologous non-classical CLDN (45). This protein was first identified in 2001 through differential display analysis during the differentiation process of embryoid bodies (EBs) (46). Claudin-6 expression is subject to dynamic regulation by multiple factors. It is present in fetal tissues such as the kidneys, pancreas, stomach and, lungs, but notably absent in these tissues in adults (47). Claudin-6 also emerges as one of the first proteins expressed during embryonic development in cells as they commit to an epithelial lineage and serves as a surface-specific marker for human pluripotent stem cells (hPSCs) (48). The expression profiles of claudins differ across various cancer types, with CLDN6 undergoing extensive investigation through pan-cancer analyses. Claudin-6 was notably upregulated in 20 different cancers; however, its expression was significantly reduced in GBM tissues, chromophobe renal cell carcinoma (KICH), acute myeloid leukemia (LAML), clear cell renal cell carcinoma (KIRC and LGG) (49). Moreover, based on research conducted by Zhuang et al., it can be concluded that CLDN10 expression levels vary significantly across cell types (50). Claudin-10 is highly expressed in brain endothelial cells, where it contributes to the formation of TJ strands and maintains the integrity and selective permeability of the BBB. Knockdown of CLDN10 in brain endothelial cells significantly reduces transendothelial resistance and increases barrier permeability, facilitating both drug delivery and the transendothelial invasion of breast cancer cells. Importantly, breast cancer cells with low CLDN10 expression showed enhanced ability to cross the brain endothelial barrier, suggesting that CLDN10 downregulation may promote brain metastasis. These findings provide a foundation for further research into potential biomarkers for brain-related diseases (50).

Methodology and technologies applicable to clinical chemistry and laboratory medicine for the evaluation of the claudins

New omics technologies, including proteomics, metabolomics, and lipidomics, enable the identification of biomarkers with high sensitivity, even at the single-cell level (51-53). In addition, recent advances such as artificial intelligence support the analysis of large heterogeneous datasets, improving diagnostic accuracy by recognizing subtle molecular patterns (54). A growing body of evidence indicates that several claudins may serve as potential biomarkers in cancer, although contradictory results have been reported. This suggests that CLDNs can act both as promoters and suppressors of tumor growth depending on context (55). The variability in results may arise from differences in sampling strategies and from the lack of standardized approaches for assessing CLDN immunoreactivity and subcellular localization (55). Since both the expression level and localization of claudins are critical for maintaining epithelial function, their altered synthesis or mislocalization is characteristic of malignant transformation (55). In cancer research, immunochemistry-based methods have been most widely applied to evaluate CLDN expression. Immunohistochemistry (IHC) has been extensively used to assess tissue expression and localization patterns (14, 30). Western blotting has been performed to validate protein concentrations in both tissues and glioma cell lines (33). More recently, enzyme-linked immunoassays (ELISA) have been employed to measure circulating CLDN concentrations in patient sera, offering a minimally invasive and cost-effective approach for biomarker evaluation (56). For the analysis of mRNA expression, several methods have been used, including real-time RT-PCR to quantify CLDN transcripts in normal and malignant tissues, Northern blotting to assess gene expression profiles, and data mining of the public SAGE database to visualize differential expression (28, 29). Quantitative PCR studies further demonstrated downregulation of CLDN1 and CLDN5 in gliomas of all four grades and in glioma model cell lines (33). Finally, DNA-based methods, such as cDNA cloning and sequencing, have been applied to characterize CLDN gene sequences and variants in normal and cancerous tissues (29). These approaches provide complementary insights into the genomic basis of altered CLDN expression observed in cancer.

The new omics technologies, including proteomics, metabolomics, and lipidomics are able to identify biomarkers with high sensitivity, even up to individual cell (51, 52). Innovative technologies have been discovered to improve overcome problems, reliability, and enhance the user experience (53). Furthermore, artificial intelligence, recently the most investigating issue, is able to evaluate large amounts of heterogeneous data and recognize subtle patterns to answer diagnostic questions (54).

Growing body of evidence indicate the role of several claudins as potential biomarkers of cancer disease and reported contradictory results, which demonstrate that these proteins play dual role as promoters as well as tumor-growth suppressors in carcinogenesis (55). Some authors indicated that main possible cause of discrepancies in CLDNs levels during neoplastic process is a considerable variability of sampling and the absence of a consistent approach to the evaluation of the immune reactivity of CLDNs and to the differential analysis of subcellular localization of these proteins (55). Based on literature data, investigators conclude that only an optimal expression and localization of claudins is important for maintaining the normal physiological function of the epithelium, and any imbalance may have pathological consequences. The synthesis of CLDN in malignant cells as well as their aberrant localization are characteristic for formation of a malignant phenotype (55). Therefore, in our present review we presented the investigations, where the levels of CLDNs were assessed mainly by immunohistochemical methods (14, 30). Moreover, we demonstrated the original findings, where authors identified all the human CLDN genes and corresponding proteins sequences from GenBank, while to visualize the results the public SAGE database was used to ascertain the gene expression of all CLDNs in normal and malignant tissues. In addition, real-time RT-PCR method was employed to explore a subset of CLDN genes in normal and cancerous tissues (28). Other methods reported in the study concerning the measurement of CLDNs levels were: Northern Blotting, cDNA Cloning and Sequencing (29). Using quantitative PCR and Western blot methods the mRNA and protein status of selected CLDNs genes were studied in human gliomas. Quantitative analysis of the transcript and protein expression data showed that CLDN1, and CLDN5 were significantly down regulated glioma of all four grades, what was also reported in the malignant glioma model cell lines (33). Recently, many authors use high sensitivity and specificity, ease of use, and relatively cost-effective enzyme-linked immunoassay (ELISA) method to assess serum concentrations of selected CLDNs in the patients with malignancies as promising biomarkers for predicting the development, proliferative ability, and prognosis of cancer, because blood is easy to obtain and can be obtained repeatedly (56).

Claudins as therapeutic targets in cancer

Two criteria are characteristic for an ideal molecule for targeted therapy in malignancy. Its expression should be restricted in certain tissues, with no expression or inaccessibility to targeting strategies in other normal tissues to avoid adverse effects; as well as the expression of this ideal molecule should be positive, and its epitopes should be exposed in corresponding malignant tissues, rendering them targeted (57). Claudins have been discovered to meet the two criteria and as promising targets for the treatment of cancer (56). Some clinical investigations proved that normal epithelial cells also express these proteins, but claudin expression has tissue specificity, and some claudins are only expressed in very few tissue types (56). Based on this specific expression profile and difference between normal and tumor cells, CLDNs are attractive targets that can theoretically enable selective drug delivery with minimal adverse events. Claudins have been a focus of the biotechnology and pharmaceutical industries as potential therapeutic targets. Moreover, a number of investigations concerning pharmacogenomics allows for assessment of genetic polymorphisms that predict a response to chemotherapeutic agents and reported an idea of personalized or precision medicine by determining susceptibility to certain drugs through identification of genetic variants (58). The localization of CLDN1 as a transmembrane protein cause that this chemokine is perfect target for the enhanced drug absorption for preventing infection and treating cancer (31). Recently, CLDN1 was successfully targeted with anti-CLDN1 near-infrared fluorophore to track the CRC cells, and it may provide a novel way for fluorescence-guided surgery of tumor. In the future, a similar approach can be applied to CLDN1 by preparation of CLDN1 targeting molecule and can be tested for cytotoxicity to normal cells (57). In addition, a chimeric anti-CLDN18.2 monoclonal antibody (mAb) – Zolbetuximab is currently under FDA review that has undergone phase 1, 2, and 3 explorations in advanced CLDN18.2 positive gastric adenocarcinoma tumors (59-61). Investigators suggest that it may emerge as the first CLDN targeted therapy approved. Other CLDN agents targeting CLDN6 and CLDN4 are ongoing in solid tumors, including mAbs, C-CPE or mAb-drug/material conjugates, bispecific T cell engagers (BiTEs) and chimeric antigen receptor (CAR) T cells are under intensive investigation.

Conclusions

Numerous clinical studies suggest that selected CLDNs, such as CLDN3 and CLDN4 promote GBM growth, proliferation and migration. Moreover, overexpression of CLDN3 support progression and metastasis of these malignancies, while reduced expression of CLDN1 and CLDN5 is observed in advanced gliomas. The heightened expression of CLDN4 is linked to larger glioma sizes and this claudin might be a promising biomarker and potential therapeutic target of patients with glioma. Moreover, expression of CLDN6 was significantly decreased among others in GBM and LGG. In conclusion, several claudins have the potential to act as prognostic and diagnostic biomarkers, as well as therapeutic targets for CNS tumors. Moreover, further study is necessary to explore innovative approaches that assess the usefulness of these proteins in diagnosing CNS tumors and predicting patient outcomes. Such studies should focus on the varying expression profiles of CLDNs across different tumor histology and disease stages.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References KwonMJ. Emerging roles of claudins in human cancer. Int J Mol Sci. 2013;14:18148–80. 10.3390/ijms14091814824009024 KaufmannRPiontekJGrüllFFrommMKrugSMGünzelD Visualization and quantitative analysis of reconstituted tight junctions using localization microscopy. PLoS One. 2012;7:e31128. 10.1371/journal.pone.003112822319608 KrauseGWinklerLMuellerSLHaseloffRFPiontekJBlasigIE. Structure and function of claudins. Biochim Biophys Acta. 2008;1778:631–45. 10.1016/j.bbamem.2007.10.01818036336 GünzelDYuAS. Claudins and the modulation of tight junction permeability. Physiol Rev. 2013;93:525–69. 10.1152/physrev.00019.201223589827 National Center for Biotechnology Information. Available from: http://www.ncbi.nlm.nih.gov/. Accessed January 14th 2025. LiJAngelowSLingeALiangJYuAS. Claudin-2 pore function requires an intramolecular disulfide bond between two conserved extracellular cysteines. Am J Physiol Cell Physiol. 2013;305:C190–6. 10.1152/ajpcell.00074.201323677799 MeoliLGünzelD. Channel functions of claudins in the organization of biological systems. Biochim Biophys Acta Biomembr. 2020;1862:183344. 10.1016/j.bbamem.2020.18334432442419 WangCWuNPeiBMaXYangW. Claudin and pancreatic cancer. Front Oncol. 2023;13:1136227. 10.3389/fonc.2023.113622736959784 SuzukiHNishizawaTTaniKYamazakiYTamuraAIshitaniR Crystal structure of a claudin provides insight into the architecture of tight junctions. Science. 2014;344:304–7. 10.1126/science.124857124744376 LamouilleSXuJDerynckR. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96. 10.1038/nrm375824556840 ShangXLinXManorekGHowelSB. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Mol Pharmacol. 2013;83:85–94. 10.1124/mol.112.07979823053666 LiJ. Context-dependent roles of claudins in tumorigenesis. Front Oncol. 2021;11:676781. 10.3389/fonc.2021.67678134354941 HashimotoIOshimaT. Claudins and gastric cancer: An overview. Cancers (Basel). 2022;14:290. 10.3390/cancers1402029035053454 HuangJLiJQuYZhangJZhangLChenX The expression of claudin 1 correlates with β-catenin and is a prognostic factor of poor outcome in gastric cancer. Int J Oncol. 2014;44:1293–301. 10.3892/ijo.2014.229824535143 ZhaoZFanHHigginsTQiJHuoXLiuY CLDN1 increases drug resistance of non-small cell lung cancer by activating autophagy via up-regulation of ULK1 phosphorylation. Med Sci Monit. 2017;23:2906–16. 10.12659/MSM.90417728614291 MaruhashiRNagasakaAKishimotoSOshimaTSatoMNakanishiH. Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models. Biochim Biophys Acta Mol Cell Res. 2018;1865:470–9. 10.1016/j.bbamcr.2017.12.00529247669 OkuiNKamataYSagawaYKuharaAHayashiKUwagawaT Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer. Pancreatology. 2019;19:88–96. 10.1016/j.pan.2018.10.00930416041 LouisDNPerryAWesselingPBratDJCreeIAFigarella-BrangerD The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-oncol. 2021;23:1231–51. 10.1093/neuonc/noab10634185076 SchaffLRMellinghoffIK. Glioblastoma and other primary brain malignancies in adults: A review. JAMA. 2023;329:574–87. 10.1001/jama.2023.002336809318 ChandanaSRMovvaSAroraMSinghT. Primary brain tumors in adults. Am Fam Physician. 2008;77:1423–30.18533376 FisherJLSchwartzbaumJAWrenschMBergerMS. Evaluation of epidemiologic evidence for primary adult brain tumor risk factors using evidence-based medicine. Prog Neurol Surg. 2006;19:54–79. 10.1159/00009517917033147 Ilhan-MutluAWagnerLWidhalmGWoehrerATraunwieserTCzechT Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg Rev. 2013;36:45–55. 10.1007/s10143-012-0401-622763625 JungCSFoerchCSchanzerAHeckAPlateKHSeifertV Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007;130:3336–41. 10.1093/brain/awm26317998256 HusainHSavageWGrossmanSAYeXBurgerPCEverettA Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neurooncol. 2012;109:123–7. 10.1007/s11060-012-0874-822492246 KesariSSchiffDHensonJWMuzikanskyAGigasDCDohertyL Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-oncol. 2008;10:300–8. 10.1215/15228517-2008-00518403492 GrovesMDPuduvalliVKChangSMConradCAGilbertMRTremont-LukatsIW A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007;81:271–7. 10.1007/s11060-006-9225-y17031561 QuarantaMDivellaRDanieleADi TardoSVenneriMTLolliI Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori. 2007;93:275–80. 10.1177/03008916070930030817679463 HewittKJAgarwalRMorinPJ. The claudin gene family: Expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186. 10.1186/1471-2407-6-18616836752 MoritaKFuruseMFujimotoKTsukitaS. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA. 1999;96:511–6. 10.1073/pnas.96.2.5119892664 CohnMLGoncharukVNDiwanAHZhangPSShenSSPrietoVG. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. J Cutan Pathol. 2005;32:533–6. 10.1111/j.0303-6987.2005.00324.x16115050 MorohashiSKusumiTSatoFOdagiriHChibaHYoshiharaS Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med. 2007;20:139–43. 10.3892/ijmm.20.2.13917611630 BhatAASyedNTherachiyilLNisarSHashemSMachaMA Claudin-1, a double-edged sword in cancer. Int J Mol Sci. 2020;21:569. 10.3390/ijms2102056931952355 KarnatiHKPanigrahiMShaikNAGreigNHBagadiARKamalMA Downregulated expression of claudin-1 and claudin-5 and upregulation of β-catenin: Association with human glioma progression. CNS Neurol Disord Drug Targets. 2014;13:1413–26. 10.2174/187152731366614102312155025345514 LeiNChengYWanJBlasigRLiABaiY Claudin-3 inhibits tumor-induced lymphangiogenesis via regulating the PI3K signaling pathway in lymphatic endothelial cells. Sci Rep. 2022;12:17440. 10.1038/s41598-022-22156-636261482 WangZZhao HanWLiCLiuSWangXChenY Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease. Clin Res Hepatol Gastroenterol. 2019;43:410–6. 10.1016/j.clinre.2018.11.01431053499 SunZYanTJiangHCaiJZhuXChenQ. Claudin-3 facilitates the progression and mediates the tumorigenic effects of TGF-β in glioblastoma multiforme. Med Oncol. 2023;40:268. 10.1007/s12032-023-02136-037578554 XuYShresthaNPréatVBeloquiA. Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. J Control Release. 2020;322:486–508. 10.1016/j.jconrel.2020.04.00632276004 YangFXuWTangXLiQHouXHuiX. Claudin 4 enhances the malignancy of glioma cells via NNAT/Wnt signaling. Am J Cancer Res. 2023;13:2530–9.37424817 YanTTanYDengGSunZLiuBWangY TGF-β induces GBM mesenchymal transition through upregulation of CLDN4 and nuclear translocation to activate TNF-α/NF-κB signal pathway. Cell Death Dis. 2022;13:339. 10.1038/s41419-022-04788-835418179 SuzukiMKato-NakanoMKawamotoSFuruyaAAbeYMisakaH Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Sci. 2009;100:1623–30. 10.1111/j.1349-7006.2009.01239.x19555390 Fujiwara-TaniRMoriSOgataRSasakiRIkemotoAKishiS Claudin-4: A new molecular target for epithelial cancer therapy. Int J Mol Sci. 2023;24:5494. 10.3390/ijms2406549436982569 MaSCLiQPengJYZhouwenJLDiaoJFNiuJ Claudin-5 regulates blood-brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis. CNS Neurosci Ther. 2017;23:947–60. 10.1111/cns.1276428961379 LiebnerSFischmannARascherGDuffnerFGroteEHKalbacherH Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000;100:323–31. 10.1007/s00401000018010965803 IshiharaHKubotaHLindbergRLLeppertDGloorSMErredeM Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor-β2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol. 2008;67:435–48. 10.1097/NEN.0b013e31816fd62218431253 GünzelDFrommM. Claudins and other tight junction proteins. Compr Physiol. 2012;2:1819–52. 10.1002/j.2040-4603.2012.tb00450.x23723025 TurksenKTroyTC. Claudin-6: A novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Dev Dyn. 2001;222:292–300. 10.1002/dvdy.117411668606 ReinhardKRengstlBOehmPMichelKBillmeierAHaydukN An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367:446–53. 10.1126/science.aay596731896660 Ben-DavidUNudelNBenvenistyN. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nat Commun. 2013;4:1992. 10.1038/ncomms299223778593 ZhangCGuoCLiYLiuKZhaoQOuyangL. Identification of Claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis. Front Cell Dev Biol. 2021;9:726656. 10.3389/fcell.2021.72665634409042 ZhuangXJiWFangZYangYRugeFDouQP Claudin-10 in the blood brain barrier function of cerebral endothelial cells and transendothelial invasion of breast cancer cells. Anticancer Res. 2023;43:3923–34. 10.21873/anticanres.1658037648330 MisraBBLangefeldCOlivierMCoxLA. Integrated omics: tools, advances and future approaches. J Mol Endocrinol. 2019;62:R21–45. 10.1530/JME-18-005530006342 EidenMChristinatNChakrabartiASonnaySMirozJPCuenoudB Discovery and validation of temporal patterns involved in human brain ketometabolism in cerebral microdialysis fluids of traumatic brain injury patients. EBioMedicine. 2019;44:607–17. 10.1016/j.ebiom.2019.05.05431202815 NaglerMNiliusHMichielinGMasoodiMLargiadèrCR. New diagnostic technologies in laboratory medicine: potential benefits and challenges. Pol Arch Intern Med. 2024;134:16772. 10.20452/pamw.1677238884596 NiliusHTsoukaSNaglerMMasoodiM. Machine learning applications in precision medicine: from metabolic phenotyping to clinical practice. Trends Analyt Chem. 2024;179:117872. 10.1016/j.trac.2024.117872 PopovaOPKuznetsovaAVBogomazovaSYIvanovAA. Claudins as biomarkers of differential diagnosis and prognosis of tumors. J Cancer Res Clin Oncol. 2021;147:2803–17. 10.1007/s00432-021-03725-034241653 UthayananLEl-BahrawyM. Potential roles of claudin-3 and claudin-4 ovarian cancer management. J Egypt Natl Canc Inst. 2022;34:24. 10.1186/s43046-022-00125-435665865 LiJ. Targeting claudins in cancer: diagnosis, prognosis and therapy. Am J Cancer Res. 2021;11:3406–24.34354852 HollandsworthHMLwinTMAmirfakhriSFilemoniFBatraSKHoffmanRM Anti-claudin-1 conjugated to a near-infrared fluorophore targets colon cancer in PDxO mouse models. J Surg Res. 2019;242:145–50. 10.1016/j.jss.2019.04.04831077946 RogersJEAjaniJA. State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies. Curr Opin Oncol. 2024;36:308–12. 10.1097/CCO.000000000000104138726797 ShitaraKLordickFBangYJEnzingerPIlsonDShahMA Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER-2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomized, double-blind, phase 3 trial. Lancet. 2023;401:1655–68. 10.1016/S0140-6736(23)00620-737068504 ShahMAShitaraKAjaniJABangYJEnzingerPIlsonD Zolbetuximab plus CapeOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133–41. 10.1038/s41591-023-02465-737524953
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010501" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010501" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010501" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(77) "Claudins proteins in brain tumors: expression patterns and therapeutic target" ["journals_article_author"]=> string(63) "Adrianna Romanowicz, Marta Łukaszewicz-Zając, Barbara Mroczko" ["journals_article_author_country"]=> string(6) "Poland" ["journals_article_categories_heading"]=> string(7) "Reviews" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(89) "claudins, biomarkers, glioblastoma, central nervous system neoplasms, blood-brain barrier" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2800" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "3" ["meta_title"]=> string(77) "Claudins proteins in brain tumors: expression patterns and therapeutic target" ["meta_desc"]=> string(77) "Claudins proteins in brain tumors: expression patterns and therapeutic target" ["meta_keyw"]=> string(89) "claudins, biomarkers, glioblastoma, central nervous system neoplasms, blood-brain barrier" ["created"]=> string(19) "2025-12-09 11:33:00" ["modified"]=> string(19) "2026-02-17 09:24:14" } [49]=> object(stdClass)#98 (35) { ["journals_id"]=> string(4) "1207" ["journals_xml"]=> string(14499) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010401 10.11613/BM.2026.010401 Letter to the Editor/Reply Telomere length and oxidative stress in small-cell lung cancer: commentary on prognostic value VarikasuvuSeshadri Reddy* Department of Biochemistry, All India Institute of Medical Sciences, Deoghar, India Corresponding author: lifeschemistry@live.com

Author contributions

SR Varikasuvu: Conceptualization, Formal analysis, Investigation, Methodology, Investigation, Data, Writing and review, Validation, Supervision and Final approval.

15122025 15022026 36 1 010401 1107202516112025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• The letter contextualizes the prognostic role of leukocyte telomere length and paraoxonase-1 activity in small-cell lung cancer (SCLC), in response to recent findings by Guzonjić et al.

• It highlights the influence of oxidative stress, lifestyle factors (obesity and smoking), treatment regimens, and genetic background on telomere dynamics and clinical outcomes

• The commentary underscores the importance of integrating telomere biology with clinical variables and molecular markers for improved prognostication in SCLC

• It encourages future research incorporating platinum sensitivity, genetic polymorphisms, and larger cohorts to enhance clinical applicability

This commentary discusses the prognostic relevance of leukocyte telomere length and paraoxonase-1 activity in small-cell lung cancer (SCLC) patients undergoing chemotherapy. It emphasizes the importance of integrating telomere biology and oxidative stress assessment in prognostic modeling. The discussion also considers the modifying effects of lifestyle, treatment regimens, and genetic background, advocating for research that combines clinical, biochemical, and molecular data to enhance prognostication in SCLC.

Keywords: chemotherapyoxidative stressparaoxonase-1small-cell lung cancertelomere length
Dear Editor,

I read with great interest the recent article by Guzonjić et al., which examined leukocyte telomere length (LTL) and paraoxonase-1 (PON1) activity in patients with small-cell lung cancer (SCLC), providing insights into their prognostic significance using Kaplan–Meier and Cox regression models (1). The study makes an important contribution to understanding how telomere biology and oxidative stress may influence cancer outcomes. The inclusion of LTL and redox markers across three treatment time points offers valuable information on chemotherapy-induced changes in systemic oxidative stress and survival. Obesity and smoking are recognized sources of oxidative stress and telomere attrition. Adjusting for these factors, as performed by Guzonjić et al., strengthens the validity of the reported associations between LTL, PON1, and survival (1). The reported hazard ratios (HR = 1.747 for LTL and HR = 1.710 for PON1) were directionally consistent with prior evidence, underscoring the importance of considering lifestyle-related confounders in biomarker-based prognostication models.

Emerging data suggest that clinical outcomes in SCLC are influenced not only by baseline redox status and telomere dynamics but also by treatment regimens and genetic background. For instance, platinum-based chemotherapy has been shown to induce oxidative DNA damage and affect telomere dynamics in experimental models. Chemotherapy-induced oxidative damage and genetic background may further modulate survival in SCLC. Platinum-based regimens can affect telomere dynamics, while polymorphisms in DNA repair or telomere-maintenance genes influence treatment response (2). Although the study by Guzonjić et al. do not stratify outcomes by platinum sensitivity or DNA damage response markers, such analyses would enhance future investigations.

Findings from meta-analyses further contextualize the present results. Studies aggregating telomere length data across multiple cancer types support a consistent association between shorter LTL and poor prognosis, although variability remains due to methodological and population differences (3, 4). Similarly, reduced PON1 activity has been linked to poor outcomes in SCLC and may interact with telomere attrition in a synergistic fashion (3).

Evidence from Mendelian randomization studies reveals a complex interplay between genetically determined telomere length and cancer risk. While shorter telomeres are generally associated with genomic instability and increased susceptibility to cancer, longer telomeres in certain contexts may facilitate unchecked proliferation and tumor progression (5). These nuances emphasize that LTL may function as both a biomarker and potential mediator in SCLC biology, requiring careful interpretation.

The hazard ratios (HRs) were derived from multivariate Cox models adjusted for age, body mass index, smoking status, disease stage, performance status, chemotherapy cycle, and baseline redox and telomere values. Although not statistically significant, the HRs were directionally consistent with prior evidence, underscoring the robustness of the analysis (1). Notably, the survival curves for both LTL and PON1 began to diverge after the median survival time, suggesting a potential late effect that might be clarified with larger cohorts or longer follow-up.

Overall, the study by Guzonjić et al. provides meaningful insight into telomere-redox dynamics in SCLC. Future research integrating telomere biology, oxidative stress markers, and genetic modifiers could further enhance prognostic clinical utility and therapeutic strategies.

Acknowledgments

Dr. S.R. Varikasuvu specially acknowledges Bhairavi Sisters (Sahasra and Aagneya) for the time he could not give them during the preparation of this letter.

Potential conflict of interest

None declared.

Data availability statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

References GuzonjićAJovanovićDSimićIĆeriman KrstićVSamardzićNOstanekB Telomere length and oxidative stress in small cell lung cancer patients: changes through chemotherapy cycles compared to healthy controls. Biochem Med (Zagreb). 2025;35:020705. 10.11613/BM.2025.02070540469570 JangSHWientjesMGLuDAuJL. Drug delivery and transport to solid tumors. Pharm Res. 2003;20:1337–50. 10.1023/A:102578550597714567626 ZhangCChenXLiLZhouYWangCHouS. The Association between Telomere Length and Cancer Prognosis: Evidence from a Meta-Analysis. PLoS One. 2015;10:e0133174. 10.1371/journal.pone.013317426177192 MundstockESarriaEEZattiHMattos LouzadaFKich GrunLHerbert JonesM Effect of obesity on telomere length: Systematic review and meta-analysis. Obesity (Silver Spring). 2015;23:2165–74. 10.1002/oby.2118326407932 Telomeres Mendelian Randomization CollaborationHaycockPCBurgessSNounuAZhengJOkoliGNBowdenJ. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncol. 2017;3:636–51. 10.1001/jamaoncol.2017.231628241208
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010401" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010401" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010401" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(94) "Telomere length and oxidative stress in small-cell lung cancer: commentary on prognostic value" ["journals_article_author"]=> string(25) "Seshadri Reddy Varikasuvu" ["journals_article_author_country"]=> string(5) "India" ["journals_article_categories_heading"]=> string(26) "Letter to the Editor/Reply" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(86) "chemotherapy, oxidative stress, paraoxonase-1, small-cell lung cancer, telomere length" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "1539" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "2" ["meta_title"]=> string(94) "Telomere length and oxidative stress in small-cell lung cancer: commentary on prognostic value" ["meta_desc"]=> string(94) "Telomere length and oxidative stress in small-cell lung cancer: commentary on prognostic value" ["meta_keyw"]=> string(86) "chemotherapy, oxidative stress, paraoxonase-1, small-cell lung cancer, telomere length" ["created"]=> string(19) "2025-12-09 11:28:13" ["modified"]=> string(19) "2026-02-17 09:24:24" } [50]=> object(stdClass)#99 (35) { ["journals_id"]=> string(4) "1206" ["journals_xml"]=> string(95741) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-36-1-010101 10.11613/BM.2026.010101 Lessons in biostatistics Effect sizes for nonparametric tests Fiel PeresFernanda* Independent researcher, São Paulo, Brazil Corresponding author: fernandafperes@hotmail.com

Author contributions

F Fiel Peres: Conceptualization, Writing – original draft, Writing – review & editing.

15122025 15022026 36 1 010101 0505202523092025 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Reporting effect sizes is essential to complement P values

• The article reviews effect size measures for four nonparametric tests

• Guidance is given on how to classify the magnitude of effect sizes

• Practical examples illustrate how to calculate and interpret effect sizes

Effect size measures are important complements to P values, providing information about the magnitude and practical relevance of research findings. While widely discussed in the context of parametric tests, effect size estimation for nonparametric tests remains less explored. This article reviews standardized effect size measures applicable to four common nonparametric tests: Mann-Whitney, Wilcoxon signed-rank, Kruskal-Wallis, and Friedman. Commonly suggested classifications for these effect sizes are also discussed. This article aims to support researchers in reporting and interpreting effect sizes more effectively in nonparametric contexts.

Keywords: biostatisticseffect sizenonparametric statisticswriting in science
Why report effect sizes?

Scientific findings are often evaluated solely based on P values, despite the well-known limitations of this metric (1, 2). A major concern is that P values do not convey the magnitude of an observed effect and are highly sensitive to sample size (3, 4). For example, when comparing fasting glucose between sedentary and active individuals, a mean difference of 0.3 mmol/L is not statistically significant with 10 participants per group (P value = 0.278), but becomes significant when the group size is increased to 50 (P value = 0.014) - even though the means and standard deviation (0.6 mmol/L) remain identical (Table 1). This demonstrates that statistically significant results may correspond to trivial effects, whereas non-significant findings may hide potentially relevant differences. To address these limitations, it is widely recommended that effect sizes be reported alongside P values (1, 2, 5).

Example of P value dependence on sample size
Scenario N per group Mean fasting glucose (mmol/L), sedentary group Mean fasting glucose (mmol/L), exercise group Pooled standard deviation (mmol/L) Mean difference (mmol/L) P
1 10 5.8 5.5 0.6 0.3 0.278
2 50 5.8 5.5 0.6 0.3 0.014

Effect sizes quantify the magnitude of an effect - in the example above, the difference between group means (0.3 mmol/L) is an unstandardized effect size, expressed in physical units (mmol/L). Such measures allow researchers to judge whether an observed difference is of practical or clinical importance. Standardized effect sizes, in contrast, have no units and facilitate comparisons across studies that use different measurement scales (1). A common standardized effect size for comparing two independent groups is Cohen’s d, calculated as the difference between group means divided by the pooled standard deviation (6). In the fasting glucose example (Table 1), Cohen’s d would be 0.50, conventionally classified as a medium effect (7). For nonparametric analyses, standardized effect sizes such as the probability of superiority, ordinal eta-squared, or Kendall’s W can be used to convey the magnitude of the effect without relying on units. These measures provide a way to quantify effect size when assumptions of parametric tests are not met.

Although reporting standardized effect sizes is relatively common in clinical research, it remains less frequent in basic science studies, including cell culture and animal experiments (8, 9). In these fields, statistical analyses still rely heavily on P values, and the omission of effect size measures makes it difficult to determine whether non-significant results truly indicate absence of an effect or are instead a consequence of insufficient statistical power.

While standardized effect size measures for parametric tests are well documented in the literature, their application in nonparametric analyses has received comparatively limited attention (6, 10, 11). This paper addresses this gap by presenting effect size measures for four widely used nonparametric tests - Mann-Whitney U, Wilcoxon signed-rank, Kruskal-Wallis, and Friedman - and by reviewing suggested classification thresholds. It should be emphasized that such classifications are only heuristics; statistical descriptors such as “small,” “medium,” or “large” do not necessarily align with clinical or practical relevance (12, 13). For instance, conventional guidelines consider a Cohen’s d of 0.8 a large effect (7). Yet this value may correspond to a mere 0.2 mmol/L difference in fasting glucose between groups when the pooled standard deviation is 0.25 mmol/L - a difference that might appear statistically impressive but be clinically negligible in many contexts.

Mann-Whitney U test

The Mann-Whitney U test - also known as the Wilcoxon-Mann-Whitney test or Wilcoxon rank-sum test - compares the distributions of two independent groups. It is used when the independent variable (i.e., the grouping variable) has two categories. The dependent variable may be either numerical or ordinal in nature (14).

Effect size r

The most reported effect size after conducting a Mann-Whitney U test is the effect size r. Its calculation is straightforward and requires only the values of z and N. Here, z is the standardized test statistic from the Mann-Whitney U test, which is provided by most statistical software packages. If unavailable, the z value can be calculated manually using the equation (Eq.) provided below (15).

In this formula, U is the Mann-Whitney U statistic, and n1 and n2 are the sample sizes of the two independent groups. This version does not include continuity correction or tie adjustments. For details on applying these in the z calculation, see Zar (16).

Once the z value is obtained, the effect size r is calculated as (Eq. 2):

where N = n1 + n2 is the total sample size.

The absolute value of r is commonly classified as small (≥ 0.1), medium (≥ 0.3), or large (≥ 0.5), following Cohen’s thresholds (7, 17). Other classifications with finer gradations have also been proposed (18, 19).

For example, consider two groups with n1 = n2 = 10 and a Mann-Whitney test yielding U = 35. From the formula above, this corresponds to z = - 1.13 and hence r = - 0.25. According to Cohen’s thresholds (7), this represents a small effect size.

Table 2 lists the R functions used to compute r and other effect sizes (20). In addition, an Excel spreadsheet is provided as a supplementary tool to facilitate their calculation.

Summary of effect size measures for nonparametric tests with corresponding R functions
Test Corresponding parametric test* Effect size Formula/ Method R function / Package Suggested classification†
Mann-Whitney U test Independent t-test r wilcoxonR() from rcompanion Small: |r| ≥ 0.1Medium: |r| ≥ 0.3Large: |r| ≥ 0.5Ranges from -1 to 1, with 0 indicating no difference between groups.
Mann-Whitney U test Independent t-test Vargha and Delaney’s A (VDA) vda() from rcompanion Small: VDA ≥ 0.56Medium: VDA ≥ 0.64Large: VDA ≥ 0.71Ranges from 0 to 1, with 0.5 indicating no difference between groups.
Mann-Whitney U test Independent t-test Rank-biserial correlation coefficient (rg) = Cliff’s delta (δ) wilcoxonRG() from rcompanionrank_biserial() from effectsize Small: |rg| ≥ 0.11Medium: |rg| ≥ 0.28Large: |rg| ≥ 0.43Ranges from -1 to 1, with 0 indicating no difference between groups.
Wilcoxon signed-rank test Paired t-test r wilcoxonPairedR() from rcompanion Small: |r| ≥ 0.1Medium: |r| ≥ 0.3Large: |r| ≥ 0.5Ranges from -1 to 1, with 0 indicating no difference between groups.
Test Corresponding parametric test* Effect size Formula/ Method R function / Package Suggested classification†
Wilcoxon signed-rank test Paired t-test Matched-pairs rank biserial correlation coefficient (rc) wilcoxonPairedRC() from rcompanionrank_biserial(paired = TRUE) from effectsize Small: |rc| ≥ 0.11Medium: |rc| ≥ 0.28Large: |rc| ≥ 0.43Ranges from -1 to 1, with 0 indicating no difference between groups.
Wilcoxon signed-rank test Paired t-test Probability of superiority for dependent groups (PSdep) Versions that account for ties are discussed in the main text. / Small: PSdep ≥ 0.56Medium: PSdep ≥ 0.64Large: PSdep ≥ 0.71Ranges from 0 to 1, with 0.5 indicating no difference between groups.
Kruskal-Wallis test One-way ANOVA Ordinal eta-squared (η2H) ordinalEtaSquared() from rcompanionrank_eta_squared() from effectsize Small: η2H ≥ 0.01Medium: η2H ≥ 0.06Large: η2H ≥ 0.14Ranges from 0 to 1, with higher values indicating a larger effect.
Kruskal-Wallis test One-way ANOVA Ordinal epsilon-squared (ε2R) epsilonSquared() from rcompanionrank_epsilon_squared() from effectsize Small: ε2R ≥ 0.01Medium: ε2R ≥ 0.06Large: ε2R ≥ 0.14Ranges from 0 to 1, with higher values indicating a larger effect.
Kruskal-Wallis test One-way ANOVA Vargha and Delaney’s A (VDA) Should be calculated from the Mann-Whitney U test for each pairwise comparison. multiVDA() from rcompanion Small: VDA ≥ 0.56Medium: VDA ≥ 0.64Large: VDA ≥ 0.71Ranges from 0 to 1, with 0.5 indicating no difference between groups.
Friedman test Repeated-measures ANOVA Kendall’s W kendallW() from rcompanionkendalls_w() from effectsizefriedman_effsize() from rstatix Small: W ≥ 0.1Medium: W ≥ 0.3Large: W ≥ 0.5Ranges from 0 to 1, with higher values indicating a larger effect.
*The parametric tests shown are not exact counterparts of the nonparametric tests, as their null hypotheses differ: the parametric tests assess mean differences, while the nonparametric tests assess differences in overall distributions. †References for each of these classifications, as well as alternative classification criteria, are provided in the main text.
Vargha and Delaney’s A effect size or probability of superiority

After conducting a Mann-Whitney U test, researchers can compute Vargha and Delaney’s A (VDA) statistics, a variant of the Common Language Effect Size (CLES), also known as the probability of superiority (21, 22). This metric offers an intuitive interpretation: it represents the probability that a randomly selected subject from one group will have a higher observed value than a randomly selected subject from the other group.

Vargha and Delaney’s A is calculated using the formula below (Eq. 3), where U is the Mann-Whitney U statistic, and n1 and n2 are the sample sizes of groups 1 and 2, respectively (22):

Vargha and Delaney’s A ranges from 0 to 1, with 0.5 indicating no difference between groups. Values closer to 1 (or 0) indicate stronger superiority of one group over the other. According to Vargha and Delaney, VDA values can be classified as small (VDA ≥ 0.56), medium (VDA ≥ 0.64), or large (VDA ≥ 0.71) (21). The corresponding R function for computing VDA is shown in Table 2.

For the fasting glucose example presented earlier, consider two groups of 10 participants each, with a Mann-Whitney test yielding U = 35. In this case, the corresponding VDA is 0.35. Because this value is below 0.5, we interpret it as 1 − 0.35 = 0.65. This indicates a 65% probability that a randomly selected sedentary individual has a higher glucose concentration than a randomly selected physically active individual. This interpretation offers a more intuitive understanding of the group difference, complementing the information provided by P values.

Rank-biserial correlation coefficient or Cliff’s delta

The rank-biserial correlation coefficient (also referred to as Glass’ rank-biserial correlation) is commonly abbreviated as r or rg (23). In the context of the Mann–Whitney U test, rg is equivalent to Cliff’s delta (δ) effect size (24). These effect sizes are linear transformations of VDA statistics and extend the range of possible values from −1 to 1.

A value of 0 for either rg or δ indicates no difference between the two groups. A value of 1 signifies that all observations in Group 1 exceed those in Group 2, whereas a value of −1 indicates that all observations in Group 2 exceed those in Group 1 (23). According to Vargha and Delaney, the absolute value of δ can be interpreted as small (≥ 0.11), medium (≥ 0.28), or large (≥ 0.43) (21). However, this classification is not universally accepted. Tomczak and Tomczak, for instance, recommend applying the thresholds proposed by Cohen for Pearson’s r: small (≥ 0.1), medium (≥ 0.3), and large (≥ 0.5) (7, 25).

The formula used to calculate rg (or δ) is presented below (Eq. 4 and Eq. 5), where U denotes the Mann-Whitney U statistic, and n1 and n2 represent the sample sizes of groups 1 and 2, respectively (21). The R function used to compute rg is provided in Table 2.

rg = δ = 2 × VDA – 1

For the same fasting glucose example, with a VDA of 0.65, the corresponding rank-biserial correlation (rg) is 0.30, indicating a moderate (medium) effect and a tendency for higher glucose concentrations in the sedentary group compared with the physically active group.

Wilcoxon signed-rank test

Wilcoxon signed-rank test compares the scores of two dependent (paired) groups. It is appropriate when the independent variable has two categories referring to related groups, such as before and after an intervention.

The procedure begins by calculating, for each subject, the difference between the two paired measurements. These differences are then ranked according to their absolute values, and the test statistic is obtained by comparing the sum of the positive ranks with the sum of the negative ranks (for a detailed explanation of the manual computation, see King et al.) (14).

The Wilcoxon signed-rank test is often described as suitable for either numeric or ordinal dependent variables. However, King et al. caution that applying it to ordinal data requires assumptions that are frequently unrealistic (14). Specifically, it assumes that the differences between pairs of scores can be meaningfully ranked and that the scale intervals are consistent. For example, in a pain scale from 1 to 10 (ordinal), the test assumes that the difference between pain levels 4 and 5 is equivalent to the difference between levels 8 and 9 - an assumption that may not always hold (14).

Effect size r

The calculation of the r effect size for the Wilcoxon signed-rank test follows the same formula as for the Mann-Whitney test (17). In this context, z is the standardized test statistic from the Wilcoxon signed-rank test, usually reported by statistical software but also obtainable through manual calculation (14, 15). The standardized z can be computed as:

where T is the smaller of the sums of positive ranks (R+) and negative ranks (R-), and n is the number of non-zero differences. This formula for z does not include continuity correction or tie adjustments (see Zar for these versions) (16). Once the z value is obtained, the effect size r is calculated using the formula below (Eq. 7) (17).

According to Cohen’s guidelines, the absolute values of r can be interpreted as small (≥ 0.10), medium (≥ 0.30), or large (≥ 0.50), as also noted by Fritz et al. (7, 17). The R function used to compute r is provided in Table 2.

Probability of superiority for dependent groups

The probability of superiority for dependent groups (PSdep) follows the same interpretative framework as the probability of superiority for independent groups (VDA). Probability of superiority for dependent groups represents the probability that a randomly selected experimental subject exhibits a positive (or negative, depending on the direction of interest) difference between paired observations. Its values range from 0 to 1, where 0.5 indicates no difference between groups (22).

The calculation of PSdep depends on the presence of ties - cases in which experimental subjects have identical values in both conditions, resulting in a difference of zero. When no ties are present, PSdep can be computed using the formula below (Eq. 8) where w denotes the count of differences in the direction of interest (positive or negative), and N is the sample size (number of paired observations) (22).

In the presence of ties, the calculation of PSdep must be adjusted. According to Grissom and Kim, two approaches are possible: (1) exclude ties from the calculation; or (2) include half the number of ties in the numerator (22). The authors recommend reporting both calculations in articles (22).

First option (excluding ties):

where n is number of pairs without ties.

Second option (including ties):

where t is the number of pairs with ties, and N is the total number of pairs.

The VDA, explained earlier in relation to independent groups, corresponds to the probability of superiority with adjustment for ties (21). Therefore, the classification thresholds for PSdep, whether ties are absent or corrected for, can follow those suggested for VDA: small effect (PSdep ≥ 0.56), medium effect (PSdep ≥ 0.64), and large effect (PSdep ≥ 0.71) (21).

It is important to note that the term probability of superiority for dependent samples and its notation PSdep are not universally standardized; different authors may refer to the same effect size using different terms.

Matched-pairs rank biserial correlation coefficient

The matched-pairs rank biserial correlation coefficient is abbreviated as r or rc (14, 23). As with the version for independent samples (rg), rc ranges from -1 to 1. A value of 1 indicates that all differences between groups 1 and 2 are positive (group 2 > group 1), whereas a value of −1 indicates that all differences are negative (group 1 > group 2) (23). The paired rank-biserial correlation coefficient can be calculated using the formula below (Eq. 11) (14):

where R+ represents the sum of positive ranks, R- the sum of negative ranks, T the smallest value between R+ and R-, and N = sample size (number of pairs).

Tomczak and Tomczak recommend interpreting the absolute values of rc using the same thresholds as Pearson’s correlation coefficient, as discussed above (25). Alternatively, it can be classified according to Vargha and Delaney’s guidelines for the independent-samples rank-biserial correlation: small (rc ≥ 0.11), medium (rc ≥ 0.28), or large (rc ≥ 0.43) (21). The R function used to compute rc is provided in Table 2.

As an illustration, based on the fasting glucose data (mmol/L) in Table 3, the Wilcoxon signed-rank test yielded T = 21.0 with N = 10 pairs. The standardized statistic was z = - 0.66, which corresponds to the following effect sizes: r = - 0.209 and rc = 0.236, both interpreted as small effects. The PSdep, computed using the number of negative differences, was 60%. This indicates a 60% probability that a randomly selected individual from this sample shows a decrease from before to after.

Intermediate Calculations for Effect Size Estimation in the Wilcoxon Signed-Rank Test (Fasting Glucose, mg/dL).
ID Before (mmol/L) After (mmol/L) Difference (After - Before) |Difference| Rank of |Difference|*
A 5.8 5.6 -0.2 0.2 5.5
B 5.5 5.6 0.1 0.1 2
C 7.2 6.8 -0.4 0.4 9
D 6.2 6.1 -0.1 0.1 2
E 6.9 7.1 0.2 0.2 5.5
F 5.8 5.6 -0.2 0.2 5.5
G 6.2 5.4 -0.8 0.8 10
H 7.4 7.7 0.3 0.3 8
I 5.7 5.6 -0.1 0.1 2
J 5.4 5.6 0.2 0.2 5.5
Sum of positive ranks = 21Sum of negative ranks = 34T = 21Number of positive differences = 4Number of negative differences = 6Number of ties = 0
* In case of ties, average ranks are assigned. For example, the smallest absolute difference is 2, which occurs four times; thus, each observation receives the average of ranks 1, 2, and 3, resulting in a rank of 2.
Effect sizes for Kruskal-Wallis test

The Kruskal-Wallis test is an extension of the Mann-Whitney U test for situations involving more than two groups. The Kruskal-Wallis test is appropriate when the independent variable is nominal with more than two categories, and the dependent variable is either numerical or ordinal (14).

Ordinal eta-squared (η<sup>2</sup><sub>H</sub>)

An effect size commonly used for the Kruskal-Wallis test is the eta-squared calculated from the test statistic H, often referred to as ordinal eta-squared (η2H). This effect size is computed using the following formula (25, 26):

where H represents the Kruskal-Wallis test statistic, k is the number of groups and N the total number of observations across all groups.

Ordinal eta-squared should not be confused with the eta-squared effect size (η2) derived from ANOVA (6). The ANOVA eta-squared is calculated from the F-statistic and degrees of freedom and represents the proportion of variance in the dependent variable explained by the independent variable (6). In contrast, ordinal eta-squared is based on the H-statistic from the Kruskal-Wallis test. To distinguish it from the ANOVA version, it is termed ordinal eta-squared and denoted as η2H, following Cohen’s notation (26).

Values of ordinal eta-squared range between 0 and 1. According to Cohen and Tomczak and Tomczak, when multiplied by 100, η2H can be interpreted as the percentage of variance in the dependent variable explained by the independent variable (25, 26). However, this interpretation has been criticized because the concept of variance does not strictly apply to rank-based analyses such as the Kruskal-Wallis test (27). To illustrate, consider three independent samples: Sample 1 = 10, 11, 12; Sample 2 = 10, 50, 51; Sample 3 = 10, 200, 201. While the original variances differ greatly (1, 547, and 12097, respectively), ranking the values within each sample results in identical ranks (1-3) with the same mean and variance for all three samples. This demonstrates that rank-based variance captures relative order rather than absolute differences. Consequently, interpreting η2H percentage of variance explained may be misleading, as it ignores the magnitude of differences in the original measurements.

The conventional classification of η2H effect sizes follows the same thresholds used for ANOVA eta-squared (η2): small effect (≥ 0.01), medium effect (≥ 0.06), and large effect (≥ 0.14) (7, 28). Functions in R for calculating ordinal eta-squared are listed in Table 2.

Ordinal epsilon-squared (ε<sup>2</sup><sub>R</sub>)

Epsilon-squared calculated from the Kruskal-Wallis test statistic H - referred to as ordinal epsilon-squared (ε2R) - is another suggested effect size for this test. This measure can be calculated using the following formula (Eq. 13), simplified by the author (14, 25):

Similar to ordinal eta-squared, ordinal epsilon-squared ranges from 0 to 1. Values near zero indicate no association between the dependent and independent variables, while values equal to 1 represent a perfect association (14).

It is important to avoid confusing ordinal epsilon-squared-denoted as ε2R, following King et al. - with the non-ordinal epsilon-squared (ε2) calculated from ANOVA F-values and degrees of freedom (6, 14). The ANOVA epsilon-squared (ε2) is a bias-corrected version of eta-squared (η2) (29).

There is no consensus regarding the classification thresholds for ordinal epsilon-squared. Since epsilon-squared is an adjusted version of eta-squared, some authors recommend using the same classification criteria as for eta-squared (30). Alternatively, based on its equivalence to the effect size r, another suggested classification is small effect (ε2R ≥ 0.01), medium effect (ε2R ≥ 0.08), or large effect (ε2R ≥ 0.26) (31). Functions in R for calculating ordinal epsilon-squared are also presented in Table 2.

To illustrate, consider fasting glucose concentrations in three groups (N = 10 each): sedentary, moderately active, and highly active. The Kruskal–Wallis test yields H = 8.4. Applying the above formulas gives η2H = 0.237 and ε2R = 0.290, both interpreted as large effects.

Ordinal epsilon-squared versus ordinal eta-squared

As explained in the previous section, the classical epsilon-squared effect size (ε2) from ANOVA is a bias-corrected version of the eta-squared effect size (η2) (29). In parametric one-way ANOVA models, η2 corresponds to the R2 value of the model, while ε2 corresponds to the adjusted R2 (30). However, this direct relationship does not apply to their ordinal counterparts, η2H and ε2R, which are calculated from ranked data.

There is currently no empirical research directly comparing η2H and ε2R. Notably, Tao raised the possibility - in a discussion forum - that the formulas for these two effect sizes may have been inadvertently switched in the literature (32). This hypothesis arises from the observation that, when conducting an ANOVA on ranked data, the unadjusted R2 aligns with ε2R, whereas the adjusted R2 corresponds to η2H.

This correspondence can be demonstrated mathematically. In a one-way ANOVA with k groups and N observations, the linear model on ranked data includes an intercept and p = k−1 predictors. Consider the formula for the adjusted R2 (R2adj):

Substituting p = k−1, we have:

Replacing R2 with the ε2R formula presented in the previous section, we obtain:

Thus, under these assumptions, if ε2R = R2, then η2H = R2adj. The mathematical equivalence between R2 in a regression on ranked data and ε2R is shown in (33).

It is important to stress that this inversion is speculative and has not been formally validated. Therefore, researchers should continue to apply the formulas established in the current literature and outlined in previous sections. To reduce ambiguity, it is recommended that authors explicitly report the exact formula used for calculating the effect size.

Moreover, because η2H and ε2R are calculated from ranked data, their interpretation as proportions of explained variance is conceptually debatable and has been subject to criticism (27). This limitation complicates their practical use. As a result, alternative effect size measures - such as VDA - may provide a more robust interpretation for ordinal data and will be discussed in the subsequent section.

VDA effect size (probability of superiority)

As discussed earlier in relation to the VDA effect size for the Mann-Whitney U test, the VDA corresponds to the probability of superiority when comparing two groups (21, 22). When performing a Kruskal-Wallis test, one option is to calculate the VDA effect size for all possible pairwise comparisons between groups (31). To manually calculate these VDA effect sizes, the researcher must conduct Mann-Whitney U tests for each pair of groups and then compute the VDA value using the formula previously described for the Mann-Whitney U test. The “multiVDA” function from the “rcompanion” package enables the calculation of VDA effect sizes for all pairwise comparisons simultaneously, streamlining the analysis process (34). This function is included in Table 2.

Friedman test

The Friedman test is a non-parametric method used to detect differences in treatments across multiple related groups or repeated measurements on the same subjects. It is commonly regarded as the nonparametric alternative to the repeated measures ANOVA (14). This test is appropriate when the independent variable involves related groups with more than two categories, and the dependent variable is either numeric or ordinal (14, 15).

Kendall’s W effect size

For the Friedman test, Kendall’s W coefficient (also known as the coefficient of concordance) is the primary effect size measure recommended (14, 25). Kendall’s W can be calculated using the following formula (14, 25):

where χw2 is the chi-square statistic from the Friedman test, k the number of related groups or conditions and N the total sample size.

The value of W ranges from 0 to 1, with higher values indicating a stronger effect. There is no universal consensus on the classification of Kendall’s W effect size. Some authors recommend applying Cohen’s guidelines for w, with thresholds for small (W ≥ 0.1), medium (W ≥ 0.3), or large (W ≥ 0.5) effects (7, 35). Alternatively, Mangiafico proposes classifications that depend on the number of related groups (k) (31). Ben-Shachar suggests adopting the same classification system used for the kappa concordance coefficient, with the most widely used scale being that of Landis and Koch, which defines slight agreement (W ≥ 0.0), fair (W ≥ 0.2), moderate (W ≥ 0.4), substantial (W ≥ 0.6), and almost perfect agreement (W ≥ 0.8) (30, 36).

To illustrate, consider fasting glucose measured across three conditions in the same 10 participants: morning, afternoon, and evening. The Friedman test yields χw2 = 6.5. Given the study design with N = 10 and k = 3, the corresponding W = 0.325, which is classified as a medium effect.

Effect sizes <italic>versus</italic> sample size

The sample size required in a study depends, among other factors, on the effect size that one aims to detect. Smaller effects generally require larger samples to achieve adequate statistical power, whereas larger effects can be detected with fewer observations. For instance, to detect a mean difference of 0.3 mmol/L in fasting glucose between two groups (assuming a standard deviation of 0.6 mmol/L, 80% power, and a 5% significance level), 64 participants per group would be needed. In contrast, detecting a 0.6 mmol/L difference under the same conditions requires 17 participants per group (7).

Calculating the required sample size for nonparametric tests is generally less straightforward than for parametric tests, as it depends on the characteristics of the distribution of the underlying data (37). Some guidelines suggest using the sample size calculated for the corresponding parametric test and increasing it by 15% - but this rule-of-thumb is based on practical considerations rather than a formal consensus (38). A more robust and reproducible alternative is to use software such as the open-source G*Power, which can perform power analyses tailored to specific nonparametric scenarios, considering standardized effect sizes, significance level, and desired power (see 37 for detailed guidance) (39).

Although effect sizes are theoretically independent of sample size, there is ongoing debate about this assumption. Recent evidence indicates that observed effect sizes tend to be larger in studies with smaller samples, potentially reflecting publication bias favoring significant results (40, 41). This highlights the importance of reporting effect sizes alongside p-values and considering both the effect magnitude and the sample size when interpreting study findings. Researchers should exercise caution when comparing effect sizes across studies with very different sample sizes, as apparent differences may reflect methodological or reporting biases rather than true differences in effects.

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing is not applicable to this article.

References SullivanGMFeinnR. Using effect size - or why the p value is not enough. J Grad Med Educ. 2012;4:279–82. 10.4300/JGME-D-12-00156.123997866 CohenJ. The earth is round (p<. 05). Am Psychol. 1994;49:997. 10.1037/0003-066X.49.12.997 Kline RB. Becoming a behavioral science researcher: A guide to producing research that matters. 1st ed. New York: The Guilford Press; 2008. ZhuW. Sadly, the earth is still round (p< 0.05). J Sport Health Sci. 2012;1:9–11. 10.1016/j.jshs.2012.02.002 HalseyLG. The reign of the p-value is over: What alternative analyses could we employ to fill the power vacuum? Biol Lett. 2019;15:20190174. 10.1098/rsbl.2019.017431113309 LakensD. Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:863. 10.3389/fpsyg.2013.0086324324449 Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988. HawkinsDGallacherEGammellM. Statistical power, effect size and animal welfare: Recommendations for good practice. Anim Welf. 2013;22:339–44. 10.7120/09627286.22.3.339 MorganJL. Alternative to the statistical mass confusion of testing for ‘no effect’. J Cell Biol. 2025;224:e202403034. 10.1083/jcb.20240303440699150 Espírito SantoHDanielF. Calculating and reporting effect sizes on scientific papers (1): P< 0.05 limitations in the analysis of mean differences of two groups. Revista Portuguesa de Investigação Comportamental e Social. 2017;1:3–16. (in Portuguese) 10.7342/ismt.rpics.2015.1.1.14 Espírito SantoHDanielF. Calculating and reporting effect sizes on scientific papers (3): Guide to report regression models and ANOVA effect sizes. Revista Portuguesa de Investigação Comportamental e Social. 2018;4:43–60. (in Portuguese) 10.31211/rpics.2018.4.1.72 ThompsonB. Effect sizes, confidence intervals, and confidence intervals for effect sizes. Psychol Sch. 2007;44:423–32. 10.1002/pits.20234 SchäferTSchwarzMA. The meaningfulness of effect sizes in psychological research: Differences between sub-disciplines and the impact of potential biases. Front Psychol. 2019;10:813. 10.3389/fpsyg.2019.0081331031679 King BM, Rosopa PJ, Minium EW. Statistical reasoning in the behavioral sciences. 7th ed. Hoboken: John Wiley & Sons; 2018. Siegel S. Nonparametric statistics for the behavioral sciences. 1st ed. Columbus: McGraw-Hill Book Company; 1956. Zar J. Biostatistical analysis. 5th ed. Hoboken: Prentice-Hall/Pearson; 2010. FritzCOMorrisPERichlerJJ. Effect size estimates: Current use, calculations, and interpretation. J Exp Psychol Gen. 2012;141:2. 10.1037/a002433821823805 FunderDCOzerDJ. Evaluating effect size in psychological research: Sense and nonsense. Adv Methods Pract Psychol Sci. 2019;2:156–68. 10.1177/2515245919847202 LovakovAAgadullinaER. Empirically derived guidelines for effect size interpretation in social psychology. Eur J Soc Psychol. 2021;51:485–504. 10.1002/ejsp.2752 R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2025. Available from: https://www.R-project.org/. Accessed May 20th, 2025. VarghaADelaneyHD. A critique and improvement of the CL common language effect size statistics of McGraw and Wong. J Educ Behav Stat. 2000;25:101–32. 10.3102/10769986025002101 Grissom RJ, Kim JJ. Effect sizes for research: Univariate and multivariate applications. 2nd ed. New York: Routledge; 2012. 10.4324/9780203803233 KerbyDS. The simple difference formula: An approach to teaching nonparametric correlation. Comprehensive Psychology. 2014;3:11–IT. 10.2466/11.IT.3.1 CliffN. Dominance statistics: Ordinal analyses to answer ordinal questions. Psychol Bull. 1993;114:494. 10.1037/0033-2909.114.3.494 TomczakETomczakM. The need to report effect size estimates revisited. An overview of some recommended measures of effect size. Trends Sport Sci. 2014;21. Cohen BH. Explaining psychological statistics. 3rd ed. Hoboken: John Wiley & Sons; 2008. Mangiafico SS. Eta-squared from Kruskal-Wallis in R. Available from: https://stats.stackexchange.com/q/433091. Accessed May 20th, 2025. KirkRE. Practical significance: A concept whose time has come. Educ Psychol Meas. 1996;56:746–59. 10.1177/0013164496056005002 OkadaK. Is omega squared less biased? A comparison of three major effect size indices in one-way ANOVA. Behaviormetrika. 2013;40:129–47. 10.2333/bhmk.40.129 Ben-ShacharMSLüdeckeDMakowskiD. effectsize: Estimation of effect size indices and standardized parameters. J Open Source Softw. 2020;5:2815. 10.21105/joss.02815 Mangiafico SS. Summary and analysis of extension program evaluation in R, version 1.23.0, revised 2025. Available from: https://rcompanion.org/handbook. Accessed May 20th, 2025. Tao J. Anyone know how to calculate eta squared for a Kruskal-Wallis analysis? Available from: https://www.researchgate.net/post/Anyone-know-how-to-calculate-eta-squared-for-a-Kruskal-Wallis-analysis. Accessed May 20th, 2025. Skitter P. Epsilon squared Kruskal-Wallis = eta squared regular. Available from: https://drive.google.com/file/d/0B3VsxBCbBYAKb1kxNDZsWWJNcVE/. Accessed May 20th, 2025. Mangiafico SS. rcompanion: Functions to support extension education program evaluation. Available from: https://CRAN.R-project.org/package=rcompanion/. Accessed May 20th, 2025. Kassambara A. Rstatix: Pipe-friendly framework for basic statistical tests. Available from: https://doi.org/10.32614/CRAN.package.rstatix. Accessed May 20th, 2025. LandisJRKochGG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977;33:363–74. 10.2307/2529786884196 Faul F, Erdfelder E, Buchner A, Lang AGG. *power 3.1 manual. Düsseldorf, Germany: Heinrich-Heine-Universität Düsseldorf; 2023. Available from: https://www.psychologie.hhu.de/fileadmin/redaktion/Fakultaeten/Mathematisch-Naturwissenschaftliche_Fakultaet/Psychologie/AAP/gpower/GPowerManual.pdf. Accessed May 20th, 2025. GraphPad Software. Sample size for nonparametric tests. GraphPad Prism; Available from: https://www.graphpad.com/guides/prism/latest/statistics/stat_sample_size_for_nonparametric_.htm. Accessed August 14th, 2025. FaulFErdfelderELangAGBuchnerAG. * power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91. 10.3758/BF0319314617695343 KühbergerAFritzAScherndlT. Publication bias in psychology: A diagnosis based on the correlation between effect size and sample size. PLoS One. 2014;9:e105825. 10.1371/journal.pone.010582525192357 LindenAHPolletTVHönekoppJ. Publication bias in psychology: A closer look at the correlation between sample size and effect size. PLoS One. 2024;19:e0297075. 10.1371/journal.pone.029707538359021
" ["journals_volume"]=> string(2) "36" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "010101" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-36-1-010101" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2026.010101" ["journals_article_pubdate"]=> string(10) "2026-02-15" ["journals_article_title"]=> string(36) "Effect sizes for nonparametric tests" ["journals_article_author"]=> string(19) "Fernanda Fiel Peres" ["journals_article_author_country"]=> string(6) "Brazil" ["journals_article_categories_heading"]=> string(24) "Lessons in biostatistics" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(72) "biostatistics, effect size, nonparametric statistics, writing in science" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(5) "38899" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "1" ["meta_title"]=> string(36) "Effect sizes for nonparametric tests" ["meta_desc"]=> string(36) "Effect sizes for nonparametric tests" ["meta_keyw"]=> string(72) "biostatistics, effect size, nonparametric statistics, writing in science" ["created"]=> string(19) "2025-12-09 10:54:06" ["modified"]=> string(19) "2026-02-17 09:24:30" } [51]=> object(stdClass)#100 (35) { ["journals_id"]=> string(4) "1166" ["journals_xml"]=> string(0) "" ["journals_volume"]=> string(2) "35" ["journals_issue"]=> string(1) "1" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(0) "" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(7) "bm-35-r" ["journals_article_id_doi"]=> string(4) "none" ["journals_article_pubdate"]=> string(10) "2025-02-15" ["journals_article_title"]=> string(16) "Index of authors" ["journals_article_author"]=> string(0) "" ["journals_article_author_country"]=> string(0) "" ["journals_article_categories_heading"]=> string(38) "Index of authors and list of reviewers" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(0) "" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3218" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(35123) "

Index of authors in Biochemia Medica journal in 2024

 

 

 

A

Aertgeerts M Biochem Med (Zagreb) 2024;34(3):031002

Ahmad F Biochem Med (Zagreb) 2024;34(1):010503

Akturk M Biochem Med (Zagreb) 2024;34(1):010802

Aleric I Biochem Med (Zagreb) 2024;34(3):030802

Antipov VA Biochem Med (Zagreb) 2024;34(3):030503

Antončić D Biochem Med (Zagreb) 2024;34(3):030504

Aparicio-Pelaz D Biochem Med (Zagreb) 2024;34(2):020706

 

B

Bakula D Biochem Med (Zagreb) 2024;34(1):010502

Balos Toruner F Biochem Med (Zagreb) 2024;34(1):010802

Barlas T Biochem Med (Zagreb) 2024;34(1):010802

Baršić Lapić I Biochem Med (Zagreb) 2024;34(1):010703

Batra DR Biochem Med (Zagreb) 2024;34(1):010503

Beljan A Biochem Med (Zagreb) 2024;34(2):021001

Bilić-Ćurčić I Biochem Med (Zagreb) 2024;34(1):010803

Bishara S Biochem Med (Zagreb) 2024;34(1):010101

Blagec V Biochem Med (Zagreb) 2024;34(2):021001

Blazevic N Biochem Med (Zagreb) 2024;34(1):010502

Böckenhauer D Biochem Med (Zagreb) 2024;34(3):031002

Bogut A Biochem Med (Zagreb) 2024;34(2):020801

Bolat S Biochem Med (Zagreb) 2024;34(2):020701

Boreyko J Biochem Med (Zagreb) 2024;34(3):030703

Božina T Biochem Med (Zagreb) 2024;34(2):020703

Bransfield A Biochem Med (Zagreb) 2024;34(1):011001

Brkić Barbarić D Biochem Med (Zagreb) 2024;34(3):031001

Bronic A Biochem Med (Zagreb) 2024;34(2):021001

Broz P Biochem Med (Zagreb) 2024;34(2):020802

Brunel V Biochem Med (Zagreb) 2024;34(3):030702

Bulat S Biochem Med (Zagreb) 2024;34(3):030704

Bulum J Biochem Med (Zagreb) 2024;34(2):020703

Buljanović V Biochem Med (Zagreb) 2024;34(3):031001

Buljubašić R Biochem Med (Zagreb) 2024;34(3):030501

Butorac D Biochem Med (Zagreb) 2024;34(1):010701

 

C

Cadamuro J Biochem Med (Zagreb) 2024;34(1):010401

Cahill MR Biochem Med (Zagreb) 2024;34(1):011001

Canecki-Varžić S Biochem Med (Zagreb) 2024;34(1):010803

Chen J Biochem Med (Zagreb) 2024;34(3):030801

Cheng X Biochem Med (Zagreb) 2024;34(3):030705

Cigrovski Berković M Biochem Med (Zagreb) 2024;34(3):030501

Cigula Kurajica V Biochem Med (Zagreb) 2024;34(1):010702

Çolak Samsum E Biochem Med (Zagreb) 2024;34(2):020701

Contini ME Biochem Med (Zagreb) 2024;34(3):030101

Coskun A Biochem Med (Zagreb) 2024;34(2):020101

Costelloe SJ Biochem Med (Zagreb) 2024;34(1):011001

Cvetković I Biochem Med (Zagreb) 2024;34(3):030701

 

Č

Čepelak I Biochem Med (Zagreb) 2024;34(2):020504

Čičak H Biochem Med (Zagreb) 2024;34(3):030704

Čolak T Biochem Med (Zagreb) 2024;34(2):020801

 

Ć

Ćelap I Biochem Med (Zagreb) 2024;34(1):010701, 2024;34(3):030706, 2024;34(3):030901

Ćuk A Biochem Med (Zagreb) 2024;34(2):020801, 2024;34(3):030701

 

D

Denimal D Biochem Med (Zagreb) 2024;34(1):010801

Dodig S Biochem Med (Zagreb) 2024;34(2):020504

Dong X Biochem Med (Zagreb) 2024;34(2):020707

Duc ACE Biochem Med (Zagreb) 2024;34(3):030502

Dukić L Biochem Med (Zagreb) 2024;34(3):030704

Dunđerović Ž Biochem Med (Zagreb) 2024;34(2):020801

 

Đ

Đerek L Biochem Med (Zagreb) 2024;34(3):030501

 

 

E

E. Duc AC Biochem Med (Zagreb) 2024;34(3):030502

Eroglu Altinova A Biochem Med (Zagreb) 2024;34(1):010802

 

F

Fabre M Biochem Med (Zagreb) 2024;34(2):020706

Felder TK Biochem Med (Zagreb) 2024;34(1):010401

Ferrer R Biochem Med (Zagreb) 2024;34(2):020704

Fettig J Biochem Med (Zagreb) 2024;34(3):030702

Fraissinet F Biochem Med (Zagreb) 2024;34(3):030702

Frans G Biochem Med (Zagreb) 2024;34(3):031002

Friščić I Biochem Med (Zagreb) 2024;34(2):020705 

 

G

Gabrilchak AI Biochem Med (Zagreb) 2024;34(3):030503

Gaćina P Biochem Med (Zagreb) 2024;34(3):030706

Galić S Biochem Med (Zagreb) 2024;34(1):010702

Ganoci L Biochem Med (Zagreb) 2024;34(2):020703

Gao R Biochem Med (Zagreb) 2024;34(3):030705

García-Osuna Á Biochem Med (Zagreb) 2024;34(2):020704

Gillibert A Biochem Med (Zagreb) 2024;34(3):030702

Girot H Biochem Med (Zagreb) 2024;34(3):030702

Glavcic G Biochem Med (Zagreb) 2024;34(1):010502

Grdić Rajković M Biochem Med (Zagreb) 2024;34(1):010701, 2024;34(1):010703

Grubišić B Biochem Med (Zagreb) 2024;34(1):010803

Guiñón L Biochem Med (Zagreb) 2024;34(2):020704

Gulbahar O Biochem Med (Zagreb) 2024;34(1):010802

Guo X Biochem Med (Zagreb) 2024;34(1):010705

Gusyakova OA Biochem Med (Zagreb) 2024;34(3):030503

 

H

Hanić M Biochem Med (Zagreb) 2024;34(2):020708

Hanžek A Biochem Med (Zagreb) 2024;34(3):030502

Hanžek M Biochem Med (Zagreb) 2024;34(3):030706

He DH Biochem Med (Zagreb) 2024;34(1):010901

Hehenwarter L Biochem Med (Zagreb) 2024;34(1):010401

Hołyńska-Iwan I Biochem Med (Zagreb) 2024;34(2):020502

Horvat M Biochem Med (Zagreb) 2024;34(2):020803

Hrabar D Biochem Med (Zagreb) 2024;34(1):010502

Hu Y Biochem Med (Zagreb) 2024;34(3):030705

Huang M Biochem Med (Zagreb) 2024;34(3):030801

Huang Y Biochem Med (Zagreb) 2024;34(1):010704

Huber-Schönauer U Biochem Med (Zagreb) 2024;34(1):010401

Hulina Tomašković A Biochem Med (Zagreb) 2024;34(1):010701

 

I

Ialongo C Biochem Med (Zagreb) 2024;34(1):010501

Illana FJ Biochem Med (Zagreb) 2024;34(2):020704

Ivanko I Biochem Med (Zagreb) 2024;34(3):030706

Ivica J Biochem Med (Zagreb) 2024;34(3):030703

Ivković A Biochem Med (Zagreb) 2024;34(3):030704

 

J

Janković M Biochem Med (Zagreb) 2024;34(2):020503

Janković T Biochem Med (Zagreb) 2024;34(2):020503

Jankowiak M Biochem Med (Zagreb) 2024;34(2):020502

Jeličić J Biochem Med (Zagreb) 2024;34(3):030704

Josipović J Biochem Med (Zagreb) 2024;34(3):030706

Joyce CM Biochem Med (Zagreb) 2024;34(1):011001

Jureša V Biochem Med (Zagreb) 2024;34(2):020803

Juričić G Biochem Med (Zagreb) 2024;34(3):030504

 

 

K

Kačkov Maslać S Biochem Med (Zagreb) 2024;34(1):010701

Karakoc MA Biochem Med (Zagreb) 2024;34(1):010802

Kardum Paro MM Biochem Med (Zagreb) 2024;34(2):020705

Katalinic D Biochem Med (Zagreb) 2024;34(3):030802

Kattner E Biochem Med (Zagreb) 2024;34(3):030802

Kipman U Biochem Med (Zagreb) 2024;34(1):01040

1 Kirin M Biochem Med (Zagreb) 2024;34(3):031001

Kolduskova K Biochem Med (Zagreb) 2024;34(2):020802

Kong LR Biochem Med (Zagreb) 2024;34(1):010901

Krešić B Biochem Med (Zagreb) 2024;34(2):020803

Kukralova S Biochem Med (Zagreb) 2024;34(2):020802

Kuštro M Biochem Med (Zagreb) 2024;34(1):010703

 

L

La Grasta Sabolić L Biochem Med (Zagreb) 2024;34(2):020709

Lan M Biochem Med (Zagreb) 2024;34(1):010705

Lapić I Biochem Med (Zagreb) 2024;34(2):020803, 2024;34(3):030504

Lauc G Biochem Med (Zagreb) 2024;34(2):020708

Leleu D Biochem Med (Zagreb) 2024;34(1):010801

Li B Biochem Med (Zagreb) 2024;34(2):020707

Li G Biochem Med (Zagreb) 2024;34(3):030801

Liang S Biochem Med (Zagreb) 2024;34(1):010705

Lišnjić D Biochem Med (Zagreb) 2024;34(1):010803

Llorente E Biochem Med (Zagreb) 2024;34(2):020706

López-Triguero S Biochem Med (Zagreb) 2024;34(2):020706

Lukić I Biochem Med (Zagreb) 2024;34(3):031001 

 

LJ

Ljubić K Biochem Med (Zagreb) 2024;34(2):020801, 2024;34(3):030701

 

M

Ma C Biochem Med (Zagreb) 2024;34(3):030705

Ma H Biochem Med (Zagreb) 2024;34(1):010704

Maćkowiak K Biochem Med (Zagreb) 2024;34(2):020502

Mandić S Biochem Med (Zagreb) 2024;34(1):010803

Marević S Biochem Med (Zagreb) 2024;34(3):030501

Margetić S Biochem Med (Zagreb) 2024;34(3):030706

Marijančević D Biochem Med (Zagreb) 2024;34(3):030501, 2024;34(3):030706

Martínez-Brú C Biochem Med (Zagreb) 2024;34(2):020704

Maštrović Radončić K Biochem Med (Zagreb) 2024;34(3):030704

Matanović L Biochem Med (Zagreb) 2024;34(3):030501

Medvedeva EA Biochem Med (Zagreb) 2024;34(3):030503

Melin A Biochem Med (Zagreb) 2024;34(3):030702

Meng X Biochem Med (Zagreb) 2024;34(2):020707

Mikulić I Biochem Med (Zagreb) 2024;34(2):020801, 2024;34(3):030701

Mikulić V Biochem Med (Zagreb) 2024;34(2):020801, 2024;34(3):030701

Miler M Biochem Med (Zagreb) 2024;34(1):010502, 2024;34(2):020709

Miletić T Biochem Med (Zagreb) 2024;34(1):010701

Milevoj Kopčinović L Biochem Med (Zagreb) 2024;34(1):010703, 2024;34(3):030504

Milić M Biochem Med (Zagreb) 2024;34(3):031001 Mrazek C Biochem Med (Zagreb) 2024;34(1):010401

 

N

Nikolac Gabaj N Biochem Med (Zagreb) 2024;34(3):030901

Novokmet M Biochem Med (Zagreb) 2024;34(2):020708

 

O

O’Shaughnessy M Biochem Med (Zagreb) 2024;34(1):011001

Osmanov Z Biochem Med (Zagreb) 2024;34(1):010802

 

P

Palatova J Biochem Med (Zagreb) 2024;34(2):020802

Palić J Biochem Med (Zagreb) 2024;34(2):020703

Pavic T Biochem Med (Zagreb) 2024;34(1):010502

Pavić M Biochem Med (Zagreb) 2024;34(2):021001

Pelajic S Biochem Med (Zagreb) 2024;34(1):010502

Penava N Biochem Med (Zagreb) 2024;34(3):030701

Perales-Afán JJ Biochem Med (Zagreb) 2024;34(2):020706

Perkov S Biochem Med (Zagreb) 2024;34(2):020705

Perović A Biochem Med (Zagreb) 2024;34(3):030501

Petrović J Biochem Med (Zagreb) 2024;34(2):020801

Pirich C Biochem Med (Zagreb) 2024;34(1):010401

Plavša B Biochem Med (Zagreb) 2024;34(2):020708

Prce A Biochem Med (Zagreb) 2024;34(2):020801

Puente-Lanzarote JJ Biochem Med (Zagreb) 2024;34(2):020706

Pušić A Biochem Med (Zagreb) 2024;34(3):030701

 

Q

Qi Z Biochem Med (Zagreb) 2024;34(3):030705

Qiang Y Biochem Med (Zagreb) 2024;34(1):010705

 

 

R

Racek J Biochem Med (Zagreb) 2024;34(2):020802

Radeljak A Biochem Med (Zagreb) 2024;34(2):020705

Radišić Biljak V Biochem Med (Zagreb) 2024;34(2):020803, 2024;34(3):030501, 2024;34(3):030504, 2024;34(3):030704

Raguž F Biochem Med (Zagreb) 2024;34(2):020801

Rajdl D Biochem Med (Zagreb) 2024;34(2):020802

Rajesh K Biochem Med (Zagreb) 2024;34(1):010503

Rapčan B Biochem Med (Zagreb) 2024;34(2):020708

Rašić D Biochem Med (Zagreb) 2024;34(1):010701

Ratkajec V Biochem Med (Zagreb) 2024;34(1):010502

Ravi S Biochem Med (Zagreb) 2024;34(1):010503

Razdorov G Biochem Med (Zagreb) 2024;34(2):020708

Rico Ríos N Biochem Med (Zagreb) 2024;34(1):011001

Rogic D Biochem Med (Zagreb) 2024;34(1):010502

Ruljančić N Biochem Med (Zagreb) 2024;34(1):010703

Rumora L Biochem Med (Zagreb) 2024;34(3):030701

Rymen D Biochem Med (Zagreb) 2024;34(3):031002

 

S

Sabadi D Biochem Med (Zagreb) 2024;34(1):010803

Schonberger E Biochem Med (Zagreb) 2024;34(1):010803

Şeneş M Biochem Med (Zagreb) 2024;34(2):020701

Siatka C Biochem Med (Zagreb) 2024;34(3):030502

Skrlec I Biochem Med (Zagreb) 2024;34(3):030802

Slišković AM Biochem Med (Zagreb) 2024;34(2):020703

Smaić F Biochem Med (Zagreb) 2024;34(2):020803, 2024;34(3):030504

Sospedra M Biochem Med (Zagreb) 2024;34(2):020704

Spence JR Biochem Med (Zagreb) 2024;34(3):030101

Stanley DJ Biochem Med (Zagreb) 2024;34(3):030101

Stejskal D Biochem Med (Zagreb) 2024;34(2):021002

Stipanović-Kastelić J Biochem Med (Zagreb) 2024;34(2):020705

Stojanović I Biochem Med (Zagreb) 2024;34(1):010701

Stonys R Biochem Med (Zagreb) 2024;34(2):020702

Sultania A Biochem Med (Zagreb) 2024;34(1):010503

Sürer H Biochem Med (Zagreb) 2024;34(2):020701

Szewczyk-Golec K Biochem Med (Zagreb) 2024;34(2):020502 

 

Š

Šálek T Biochem Med (Zagreb) 2024;34(2):021002

Šamija I Biochem Med (Zagreb) 2024;34(2):020709

Šerić V Biochem Med (Zagreb) 2024;34(3):031001

Šimac B Biochem Med (Zagreb) 2024;34(2):020803. 2024;34(3):030501, 2024;34(3):030504

Šimičević L Biochem Med (Zagreb) 2024;34(2):020703

Šimundić AM Biochem Med (Zagreb) 2024;34(3):030704

Šimunović J Biochem Med (Zagreb) 2024;34(2):020708

Štambuk J Biochem Med (Zagreb) 2024;34(2):020708

Švitek L Biochem Med (Zagreb) 2024;34(1):010803

 

T

Talapko J Biochem Med (Zagreb) 2024;34(3):030802

Tentor D Biochem Med (Zagreb) 2024;34(3):030802

Tomić F Biochem Med (Zagreb) 2024;34(2):020803

Tomić V Biochem Med (Zagreb) 2024;34(3):030701

Trbojević-Akmačić I Biochem Med (Zagreb) 2024;34(2):020708

Trkulja V Biochem Med (Zagreb) 2024;34(2):020703

Tukshumskaya LL Biochem Med (Zagreb) 2024;34(3):030503

Turčić A Biochem Med (Zagreb) 2024;34(1):010702

Turčić P Biochem Med (Zagreb) 2024;34(1):010701

 

U

Unić A Biochem Med (Zagreb) 2024;34(2):020709

 

V

Valent Morić B Biochem Med (Zagreb) 2024;34(2):020709

Vanhove T Biochem Med (Zagreb) 2024;34(3):031002

Vashishth R Biochem Med (Zagreb) 2024;34(1):010503

Vcev A Biochem Med (Zagreb) 2024;34(3):030802

Venkatesan S Biochem Med (Zagreb) 2024;34(1):01050

3 Vermeersch P Biochem Med (Zagreb) 2024;34(3):031002

Vidranski V Biochem Med (Zagreb) 2024;34(2):020803

Vitkus D Biochem Med (Zagreb) 2024;34(2):020702

Vogrinc Ž Biochem Med (Zagreb) 2024;34(1):010702

Volarić M Biochem Med (Zagreb) 2024;34(2):020801

Vrkić Kirhmajer M Biochem Med (Zagreb) 2024;34(2):020703

Vrkljan N Biochem Med (Zagreb) 2024;34(1):010502

Vrtarić A Biochem Med (Zagreb) 2024;34(3):030901

Vučković F Biochem Med (Zagreb) 2024;34(2):020708

Vuga I Biochem Med (Zagreb) 2024;34(2):020803

 

W

Wang HL Biochem Med (Zagreb) 2024;34(1):010901

Wen D Biochem Med (Zagreb) 2024;34(2):020707

Witters P Biochem Med (Zagreb) 2024;34(3):031002

Wu H Biochem Med (Zagreb) 2024;34(1):010705

 

 

X

Xia L Biochem Med (Zagreb) 2024;34(3):030705

Xie YH Biochem Med (Zagreb) 2024;34(1):010901

Xu Y Biochem Med (Zagreb) 2024;34(1):010704

 

Y

Yalcin MM Biochem Med (Zagreb) 2024;34(1):010802

Yetkin I Biochem Med (Zagreb) 2024;34(1):010802

Yücel D Biochem Med (Zagreb) 2024;34(2):020701

 

 

Z

Zendjabil M Biochem Med (Zagreb) 2024;34(2):020501

Zeng XF Biochem Med (Zagreb) 2024;34(2):020707

Zenkova J Biochem Med (Zagreb) 2024;34(2):020802

Zhang C Biochem Med (Zagreb) 2024;34(3):030801

Zhang D Biochem Med (Zagreb) 2024;34(1):010705

Zhang J Biochem Med (Zagreb) 2024;34(1):010704

Zhang X Biochem Med (Zagreb) 2024;34(1):010704

Zhang Y Biochem Med (Zagreb) 2024;34(1):010901

Zhao C Biochem Med (Zagreb) 2024;34(1):010705

Zhao F Biochem Med (Zagreb) 2024;34(3):030705

Zhao J Biochem Med (Zagreb) 2024;34(1):010705

Zhao X Biochem Med (Zagreb) 2024;34(1):010705

Zhao Z Biochem Med (Zagreb) 2024;34(1):010704

Zhou CQ Biochem Med (Zagreb) 2024;34(1):010901

Zlosa M Biochem Med (Zagreb) 2024;34(1):010803

 

Ž

Žarak M Biochem Med (Zagreb) 2024;34(3):030501

" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "16" ["meta_title"]=> string(0) "" ["meta_desc"]=> string(0) "" ["meta_keyw"]=> string(0) "" ["created"]=> string(19) "2025-02-20 09:14:56" ["modified"]=> string(19) "2025-02-20 10:24:39" } [52]=> object(stdClass)#101 (35) { ["journals_id"]=> string(4) "1198" ["journals_xml"]=> string(26279) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-35-3-031002 10.11613/BM.2025.031002 Preanalytical mysteries Preanalytical mystery: falsely elevated intact parathyroid hormone due to sampling from a grafted forearm TsengYu-Wei1YehChun-Chieh2ChouChe-Yi3ChenSi-Yu1ErTze-Kiong*14 Division of Laboratory Medicine, Asia University Hospital, Asia University, Taichung, Taiwan Department of Surgery, Asia University Hospital, Taichung, Taiwan Division of Nephrology, Asia University Hospital, Taichung, Taiwan Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan Corresponding author: tzekiong92@gmail.com, Submitted: April 19, 2025 Accepted: August 27, 2025

Author contributions

Y-W Tseng: Conceptualization, Investigation, Formal analysis, Writing - review and editing; C-C Yeh: Conceptualization, Investigation, Formal analysis, Finding acquisition, Writing - review and editing; C-Y Chou: Conceptualization, Investigation, Formal analysis, Finding acquisition, Writing - review and editing; S-Y Chen: Conceptualization, Investigation, Formal analysis, Writing - review and editing; T-K Er: Conceptualization, Investigation, Formal analysis, Writing - review and editing.

15102025 15102025 35 3 031002 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Falsely elevated intact parathyroid hormone (iPTH) concentrations due to sampling from autotransplanted parathyroid site

• Misleading iPTH results raising concern for recurrent hyperparathyroidism

• Normalized iPTH upon contralateral arm sampling confirming sampling-site artifact

• Implementation of LIS-based alerts and staff training for proper sampling

• Emphasizes the importance of long-term documentation of sampling sites after parathyroidectomy

Spurious elevations in intact parathyroid hormone (iPTH) can lead to unnecessary interventions. We describe a dialysis patient who developed unexpectedly high iPTH concentrations months after total parathyroidectomy with forearm autotransplantation (TPTX-AT). Blood samples had been collected from the grafted forearm, resulting in falsely elevated iPTH values. Once the sample was collected from the non-grafted arm, iPTH concentrations normalized. This case highlights the importance of sampling site awareness in laboratory diagnostics and demonstrates how implementing a simple laboratory information system (LIS)-based protocol can prevent misinterpretation.

Keywords: case reportpreanalytical erroriPTH, sampling siteparathyroid autotransplantation
Introduction

Secondary hyperparathyroidism (SHPT) is a frequent complication among patients with end-stage renal disease (ESRD). Secondary hyperparathyroidism is marked by excessive production and release of parathyroid hormone (PTH), accompanied by progressive enlargement and hyperplasia of the parathyroid glands (1). In some cases, elevated parathyroid hormone concentrations may persist even after successful kidney transplantation, despite normalization of standard biochemical markers (2). Nowadays, total parathyroidectomy with forearm autotransplantation (TPTX-AT) is a well-established treatment for secondary hyperparathyroidism (3).

Monitoring PTH concentrations is essential in managing patients with ESRD, particularly those undergoing chronic hemodialysis.

Previously, Khalil et al. reported that blood samples collected from the forearm with parathyroid autografts can yield spuriously elevated PTH concentrations due to localized hormone secretion. Although this preanalytical artifact is recognized in the immediate postoperative period, its potential to mislead results during long-term follow-up is often underappreciated (4). Consistent with these observations, Başcı et al. also described falsely elevated intact parathyroid hormone (iPTH) concentrations when blood was drawn from a forearm graft following total parathyroidectomy with TPTX-AT (5). We present a case demonstrating this issue and the quality improvement measures implemented. This case is aligned with Biochemia Medica’s emphasis on uncovering practical preanalytical challenges and educating laboratory professionals (6).

Laboratory analyses

This case expands upon prior findings by demonstrating that sampling-site errors can have a delayed yet clinically significant impact on patient management in the dialysis setting. A 61-year-old male patient with ESRD on regular hemodialysis underwent TPTX-AT in October 2024, with autograft placement in his right forearm. Postoperatively, iPTH concentrations drawn from the left (non-grafted) arm declined sharply from 1037.0 ng/L preoperatively to 9.2 ng/L within 7 days. The surgical outcome was initially interpreted as successful. Blood samples were collected using serum separator tubes (SST) and processed within 2 hours of collection. Intact PTH concentrations were measured using a two-site immunoenzymatic (“sandwich”) chemiluminescent immunoassay (Beckman Coulter Access, UniCel DxI 800 platform, Brea, USA), with an analytical sensitivity of 1 ng/L.

During routine iPTH monitoring in February 2025, a blood sample was inadvertently drawn from the right forearm, where the parathyroid graft was located, yielding an iPTH concentration of 2869.4 ng/L and raising concern for recurrent hyperparathyroidism. A repeated test on March 14, also collected from the grafted arm, showed a persistently elevated iPTH concentration of 1936.0 ng/L. Despite these markedly elevated values, the patient’s serum calcium was 1.95 mmol/L (reference range: 2.15-2.58 mmol/L), and phosphorus was 1.84 mmol/L (reference range: 0.81-1.61 mmol/L), with no clinical signs or symptoms suggestive of recurrence. In April, a sample obtained from the non-grafted left arm revealed a normalized iPTH concentration of 51.2 ng/L. Table 1 demonstrates the chronological fluctuation of iPTH values in relation to blood sampling sites, highlighting the impact of graft-site collection.

Intact parathyroid hormone (iPTH) concentrations and sampling sites in the patient over time
Date iPTH (ng/L) Arm (Site)
2024-01-03 1037.2 Left (AVF)
2024-04-03 1037.0 Left (AVF)
2024-06-07 1989.4 Left (AVF)
2024-07-04 1879.1 Left (AVF)
2024-09-02 1925.2 Left (AVF)
2024-10-03 1772.7 Left (AVF)
2024-11-01 13.4 Left (AVF)
2024-11-06 9.2 Left (AVF)
2025-01-01 55.8 Left (AVF)
2025-02-25 2869.4 Right (Graft)
2025-03-14 1936.0 Right (Graft)
2025-04-02 51.2 Left (AVF)
AVF - arteriovenous fistula.
Further investigation

Recurrent secondary hyperparathyroidism was initially suspected due to the markedly elevated iPTH concentrations. Hyperplasia or increased activity of the autotransplanted parathyroid tissue was considered, and forearm ultrasound was contemplated to assess graft function. However, imaging was ultimately not pursued, as a repeated iPTH test using a sample drawn from the contralateral (non-grafted) arm yielded normalized results. This finding confirmed that the initial elevation was due to a sampling-site artifact rather than true graft hyperfunction, thereby resolving the diagnostic uncertainty without the need for further imaging.

Solution

During routine iPTH surveillance in February 2025, a markedly elevated value (2869.4 ng/L) was reported from a sample collected in the right forearm. A second elevated result was observed in March, again from the same site. Despite the abnormal results, the patient exhibited no clinical signs or symptoms, and serum calcium and phosphorus were not significantly elevated. Upon chart review, it was noted that the parathyroid autograft had been placed in the right arm following TPTX-AT. A repeat iPTH sample was obtained from the left (non-grafted) arm, revealing a normalized value of 51.2 ng/L. This confirmed the spuriously high readings were due to localized secretion at the graft site.

Discussion

Preanalytical variables are responsible for the majority of laboratory diagnostic errors, including issues such as mislabeling, improper sample collection, and inadequate transport or storage conditions (7, 8). This highlights the need for careful attention to preanalytical factors, particularly the sampling site, in the interpretation of iPTH values. Our case adds to existing evidence by demonstrating that sampling-site errors can lead to spuriously elevated iPTH concentrations even months after parathyroidectomy. Notably, in our patient, falsely elevated iPTH concentrations were observed approximately five months after autotransplantation, suggesting that this preanalytical artifact may persist over the long term. This issue is particularly significant in dialysis settings, where routine laboratory testing may not consistently account for forearm graft sites. Persistent iPTH elevation due to localized secretion from the grafted arm highlights the importance of sampling from the non-grafted site and reinforces the need for long-term awareness of sampling locations to avoid diagnostic errors. Implementing standardized sampling protocols may prevent misinterpretation and reduce unnecessary diagnostic procedures.

What YOU should / can do in your laboratory to prevent such errors

To minimize the risk of sampling-site–related errors in iPTH measurement, laboratories should ensure that the presence and location of parathyroid autografts are clearly documented within the Laboratory Information System (LIS). This allows staff to verify proper sampling sites during routine blood collection. Additionally, phlebotomy and nursing personnel should receive targeted training to avoid drawing samples from grafted forearms. Institutions are encouraged to establish standard operating procedures (SOPs) that define appropriate sampling practices for iPTH. When unexpectedly high iPTH concentrations are encountered, laboratories should consider retesting using a sample from the contralateral (non-grafted) arm to rule out localized secretion artifacts.

Acknowledgements:

This study was supported by grants from Asia University Hospital (ASIA-113-51018 and ASIA-114-51017).

Potential conflict of interest

None declared.

Data availability statement

No data was generated during this study, so data sharing statement is not applicable to this article.

References XuYEvansMSoroMBaranyPCarreroJJ. Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clin Kidney J. 2021;14:2213–20. 10.1093/ckj/sfab00634603697 IvarssonKMAkaberiSIsakssonEReihnerERylanceRPrutzKG The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dial Transplant. 2015;30:2027–33. 10.1093/ndt/gfv33426374600 ZhouBZhuLXiangCChengFZhuXZhouY Total parathyroidectomy with forearm autotransplantation in secondary hyperparathyroidism patients: analysis of muscle, subcutaneous and muscle + subcutaneous method. BMC Surg. 2021;21:226. 10.1186/s12893-021-01222-233933053 KhalilDKerrPD. PTH monitoring after total parathyroidectomy with forearm auto-transplantation: potential for spuriously high levels from grafted forearm. J Otolaryngol Head Neck Surg. 2017;46:49. 10.1186/s40463-017-0226-y28645310 BaşcıKKNErsoyYBekarM. Spuriously high levels in a patient after total parathyroidectomy with forearm auto-transplantation. Bosphorus Med J. 2023;10:54–8. SimundicAMCadamuroJCornesM. Biochemia Medica introduces new section: Pre-analytical mysteries. Biochem Med (Zagreb). 2017;27:418–20. 10.11613/BM.2017.04428694732 PlebaniM. Quality indicators to detect pre-analytical errors in laboratory testing. Clin Biochem Rev. 2012;33:85–8.22930602 LippiGChanceJJChurchSDazziPFontanaRGiavarinaD Preanalytical quality improvement: from dream to reality. Clin Chem Lab Med. 2011;49:1113–26. 10.1515/CCLM.2011.60021517699
" ["journals_volume"]=> string(2) "35" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "031002" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-35-3-031002" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2025.031002" ["journals_article_pubdate"]=> string(10) "2025-10-15" ["journals_article_title"]=> string(105) "Preanalytical mystery: falsely elevated intact parathyroid hormone due to sampling from a grafted forearm" ["journals_article_author"]=> string(67) "Yu-Wei Tseng, Chun-Chieh Yeh, Che-Yi Chou, Si-Yu Chen, Tze-Kiong Er" ["journals_article_author_country"]=> string(6) "Taiwan" ["journals_article_categories_heading"]=> string(23) "Preanalytical mysteries" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(86) "case report, preanalytical error, iPTH, sampling site, parathyroid autotransplantation" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2249" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "14" ["meta_title"]=> string(105) "Preanalytical mystery: falsely elevated intact parathyroid hormone due to sampling from a grafted forearm" ["meta_desc"]=> string(105) "Preanalytical mystery: falsely elevated intact parathyroid hormone due to sampling from a grafted forearm" ["meta_keyw"]=> string(86) "case report, preanalytical error, iPTH, sampling site, parathyroid autotransplantation" ["created"]=> string(19) "2025-10-08 10:19:59" ["modified"]=> string(19) "2025-10-15 10:19:17" } [53]=> object(stdClass)#102 (35) { ["journals_id"]=> string(4) "1188" ["journals_xml"]=> string(38905) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-35-3-031001 10.11613/BM.2025.031001 Case reports What is uric acid concentration in urine in patients with uric acid kidney stones? - a case study ŠálekTomáš*12MusilPavel1ZlatníkováIrena1 Department of Clinical Biochemistry and Pharmacology, Tomas Bata Hospital in Zlín, Zlín, Czech Republic Department of Health Care Sciences, Faculty of Humanities, Tomas Bata University in Zlín, Zlín, Czech Republic Corresponding author: tsalek@seznam.cz

Author contributions

T Šálek: draft of the article, editing, final approval, and is accountable for all aspects of work; P Musil: critical review and editing, data collection,final approval, and is accountable for all aspects of work; I Zlatníková: critical review and editing, data collection, final approval, and is accountable for all aspects of work.

15082025 15102025 35 3 031001 1504202519062025 ©Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• The uric acid dissociation constant (pKa) is 5.35 at 37 °C

• Uric acid crystals are formed in overly acidic urine

• Stone compositional analysis is the definitive diagnostic tool and should be attempted in all patients

• Sample alkalization is needed for urine uric acid measurement

• 24-hour collected urine or second-morning spot sample could have been used for treatment decisions in this patient

This case report describes a patient with uric acid kidney stones. Alkalization therapy using mainly potassium citrate is the first-choice treatment. When hyperuricosuria > 4 mmol/24 hours is present, xanthine oxidase inhibitors are added. It implies that accurate urine uric acid measurement is of high importance. Uric acid was measured in a 24-hour collection and a second-morning sample. Urine uric acid was measured after sample alkalization to pH > 6.5 and heating to 56 °C for 10 minutes, and for educational reasons without sample treatment. The uric acid excretion in the sample without alkalization in the 24-hour collection was 2.436 mmol, after alkalization, the excretion was 4.650 mmol/24 hours. Sample alkalization led to a prescription for xanthine oxidase inhibitor medication that is indicated as the second-line therapy when hyperuricosuria > 4 mmol/24 hours is present. This case study shows how the correct preanalytical phase is essential for medical decision-making.

Keywords: nephrolithiasisuric acidurine specimen collectionurinespecimen preservation
Introduction

Kidney stone disease is highly prevalent worldwide, with the prevalence in North America at 7-13%. The prevalence in Europe is 5-9% (1). The first steps in diagnosis include evaluation of detailed medical and dietary history, kidney stone analysis, and measurement of urine and serum kidney stone risk factors. At least one 24-hour urine collection is recommended to identify the risk factors. Therapy aims to avoid recurrent disease by decreasing urine saturation and concentrations of lithogenic substances and increasing levels of kidney stone inhibitors (2).

Uric acid nephrolithiasis is a systemic metabolic disorder and the third most common type of kidney stone in the industrialized world, accounting for about 10% of all stone formers (3). The uric acid dissociation constant (pKa) is 5.35 at 37 °C. The overly acidic urine promotes the protonation of water-soluble urate to the poorly soluble uric acid (4).

The local Ethics Committee approved the publication of case study No. 2024/18. The patient signed the informed consent regarding the publication of his case study.

This case study presents a patient with a uric acid kidney stone with falsely low urine uric concentration when measured without alkalization due to crystal formation in an acidic environment.

A 55-year-old male has suffered from kidney stones since March 2023. The infrared spectroscopy revealed a 100% uric acid kidney stone composition. In November 2024, the next stone passed with the same composition. In January 2025, he was referred to the Metabolic Clinic for kidney stone prevention. His medical history included obesity, hypercholesterolemia, hypertension, type 2 diabetes mellitus, and reflux esophagitis. His medication included atorvastatin 20 mg, perindopril 5 mg, bisoprolol 5 mg, metformin 1700 mg, and esomeprazole 40mg daily. Ha had no allergy. The physical examination showed a blood pressure of 131/95 mmHg, a height of 187 cm, and a body weight of 127 kg (body mass index of 36 kg/m2). Metabolic evaluation of serum and urine kidney stone risk factors was performed.

Laboratory analyses

The results of basic serum chemistry tests are shown in Table 1. Urine kidney stone risk factors were analyzed in the 24-hour collection sample and spot second-morning urine. Results from both urine samples are shown in Table 2. In addition, for educational reasons, uric acid concentrations were measured before alkalization, and the results are shown in a separate row.

Serum laboratory test results (selected methods)
Serum laboratory test (unit) Result Reference range
Sodium (mmol/L) 140 136-144
Potassium (mmol/L) 4.3 3.8-5.1
Chloride (mmol/L) 108 95-107
Total calcium (mmol/L) 2.21 2.10-2.55
Magnesium (mmol/L) 0.83 0.80-0.94
Inorganic phosphate (mmol/L) 0.99 0.81-1.45
Urea (mmol/L) 4.8 3.0-8.0
Creatinine (µmol/L) 87 64-104
eGFR (CKD-EPI equation) from serum creatinine (mL/min/1.73m2) 86 90-150
Uric acid (µmol/L) 366 140-360
Serum HCO3- (mmol/L) 19.8 22.0-28.0
eGFR - estimated glomerular filtration rate. CKD-EPI - Chronic Kidney Disease Epidemiology Collaboration.
Urine laboratory test results (selected methods)
Urine laboratory test (unit) 24 hour collected urine result Second-morning spot sample result Reference range
Volume (L) 1.2 – 1.5-3.0
pH 4.96 4.84 –
Uric acid before alkalization (mmol) 2.436 – –
Uric acid to creatinine ratio, alkalized test – 0.31 0.10-0.30
Uric acid, alkalized test (mmol) 4.650 – 2.0-4.0
Citrate to creatinine ratio – 0.18 > 0.15
Citrate (mmol) 5.1 – > 2.5
Sodium (mmol) 178 – 0-87
Calcium (mmol) 5.19 – 2.0-5.0
Magnesium (mmol) 3.9 3.0-5.0
Inorganic phosphate (mmol) 30 – 13-34
Oxalate (mmol) 0.336 – 0.00-0.50
Ammonium (mmol) 34 – 15-50
Sulfate (mmol) 21 – 7-47
Urea (mmol) 401 – 330-580

Urine was collected in a 5-liter polyethylene container with 2.5 g of thymol added in advance at the laboratory (1 g/L urine, diluted from a stock of 10% thymol w/v in isopropanol). The 24-hour urine collection was delivered to the laboratory within two hours after collection, the container was properly mixed, urine volume was measured, and the specimen was divided into the aliquots in 10 mL polypropylene tubes without additives (FL Medical, Padua, Italy). Without further additives, the first 1 mL aliquot was used to immediately measure pH, osmolality, sodium, ammonium, urea, and creatinine. Tthe second 1 mL aliquot was acidified by 10 µL of 6M hydrochloric acid to decrease its pH below two and heated at 56 °C for 10 minutes for calcium, magnesium, and inorganic phosphate measurements. The third 1 mL aliquot was acidified by 20 µL 7M H3PO4 to measure citrate, oxalate, and sulfate. Before measurement, the sample was heated in a water bath at 56 °C for 30 min to solubilize possible crystals. The fourth 1mL aliquot was alkalized by 10 µL 6M NaOH to pH > 6.5 and heated at 56 °C for 10 minutes for uric acid measurement. This analytical approach (alkalization + heating) was recommended by the Working Group Preanalytical Phase (WG-PRE) and Task and Finish Group Urinalysis (TFG-U) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) (5).

When bringing their 24-hour specimen to the laboratory, second-morning urine was collected under a fluid restriction to a maximum of 2 dL before voiding at the laboratory. Thymol was added to the second-morning specimen at the same concentration as in the 24-hour collections of urine. In the laboratory, the same analyses were performed in the spot second-morning urine as in the collected sample.

Calcium, magnesium, inorganic phosphate, uric acid, sodium, potassium, chloride, and creatinine were measured on the Abbott Architect ci16200 analyzer (Abbott Laboratories, Abbott Park, USA). The analytical performance characteristics of the urine uric acid method, which is based on the uricase spectrophotometric principle, are: relative bias of 3.70%, intermediate precision of 1.87%, post-alkalization recovery of 96.31%, and linearity range of 0.12-15.42 mmol/L. Oxalate, citrate, and sulfate measurements were carried out by capillary electrophoresis on Lumex CAPEL–205 analyzer (Lumex Instruments Canada, Mission, Canada).

Urine pH was measured by a glass pH electrode using a pH meter (Perphect Meter Model 330, Canton, USA).

What happened?

The patient had falsely low uric acid concentrations in urine due to acidic pH without sample alkalization.

After urine alkalization, the urine uric acid concentrations markedly increased. Uric acid crystals were formed in acidic urine, leading to lower uric acid concentrations.

Discussion

This case study shows falsely low urine uric acid concentrations due to the formation of uric acid crystals in acidic urine.

Low urine pH (below 5.5), low urine volume, and hyperuricosuria are key risk factors for uric acid crystal formation. Stone compositional analysis is the definitive diagnostic tool and should be attempted in all patients. Urine pH plays a central role in the diagnosis and monitoring of this type of nephrolithiasis (6). Our patient had all these risk factors. Kidney stone analysis was performed by infrared spectroscopy, and his urine pH was measured by pH meter.

Sakhaee et al. reported that low urine pH is the most important factor in uric acid kidney stone development. Insulin plays an important role in renal ammonium synthesis. Insulin resistance leads to impaired renal ammonia synthesis and excretion. Decreased urine ammonium excretion in those patients leaves protons in urine unbuffered, leading to lower pH (7). Our patient had urine pH even below 5.0 in both the collected and the second-morning samples. The morning sample had a lower pH compared to the 24-hour collected sample. The morning samples are generally more concentrated than the 24-hour collections. It shows that morning urine samples may also be useful for monitoring this type of kidney stone. The reason may also be that 24-hour collections are not popular among patients and are frequently incomplete. In our patient, based on second-morning urine sample results, the patient may also be advised to eat a more plant-based alkaline diet, less acid-producing animal products, and prescribed citrate treatment. Monitoring by imaging techniques like sonography is also needed to evidence the dissolution.

Wiederkehr and Moe reported that urine uric acid concentrations also play a role in uric acid crystal precipitation (3). It implies that correct uric acid concentration measurement is important.

Sakhaee also reported that uric acid kidney stones are more frequent in patients with obesity and type 2 diabetes mellitus (8). The same clinical features are present in our case study.

The first-line therapy in uric acid kidney stone patients is citrate alkalization to a urine pH of 6.5 (9). Citrate alkalization therapy can be prescribed based on uric acid kidney stone composition and acidic urine pH. Xanthine oxidase inhibitors are used in the second step when hyperuricosuria > 4 mmol/24 hours is present (10). This case study showed that sample alkalization led to two times higher 24-hour uric acid excretion results. A similar situation was in the spot second-morning sample. It is the reason why urine alkalization is recommended before uric acid measurement.

Many urine constituents change in concentration when the rate of water excretion alters due to variations in fluid intake and diet. Diagnostic decisions should not be based on a single measurement due to this variability, especially in borderlines of diagnostic categories (11). All our kidney stone patients are regularly monitored. The more results we have, the better.

What YOU should /can do in your laboratory to prevent such errors

Alkalization to pH > 6.5 and heating to 56 °C for 10 minutes is needed before urine uric acid measurement.

Acknowledgments

MgA. Jiří Balát contributed to the graphical abstract technical editing.

Potential conflicts of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References SorokinIMamoulakisCMiyazawaKRodgersATalatiJLotanY. Epidemiology of stone disease across the world. World J Urol. 2017;35:1301–20. 10.1007/s00345-017-2008-628213860 Kidney Stones: Medical Mangement Guideline - American Urological Association. Available from: https://www.auanet.org/guidelines-and-quality/guidelines/kidney-stones-medical-mangement-guideline. Accessed February 10th 2025. WiederkehrMRMoeOW. Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder. Clin Rev Bone Miner Metab. 2011;9:207–17. 10.1007/s12018-011-9106-625045326 BobulescuIAParkSKXuLHRBlancoFPoindexterJAdams-HuetB Net Acid Excretion and Urinary Organic Anions in Idiopathic Uric Acid Nephrolithiasis. Clin J Am Soc Nephrol. 2019;14:411–20. 10.2215/CJN.1042081830745301 ŠálekTMusilPVermeerschPMarringtonRDikmenZGPoláchováR Preservation of urine specimens for metabolic evaluation of recurrent urinary stone formers. Clin Chem Lab Med. 2024;63:129–38. 10.1515/cclm-2024-077339072394 ShastriSPatelJSambandamKKLedererED. Kidney Stone Pathophysiology, Evaluation and Management: Core Curriculum 2023. Am J Kidney Dis. 2023;82:617–34. 10.1053/j.ajkd.2023.03.01737565942 SakhaeeKAdams-HuetBMoeOWPakCYC. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62:971–9. 10.1046/j.1523-1755.2002.00508.x12164880 SakhaeeK. Epidemiology and Clinical Pathophysiology of Uric Acid Kidney Stones. J Nephrol. 2014;27:241–5. 10.1007/s40620-013-0034-z24497296 BhojaniNBjazevicJWallaceBLeeLKalerKSDionM Update - 2022 Canadian Urological Association guideline: Evaluation and medical management of the kidney stone patient. Can Urol Assoc J. 2022;16:175–88. 10.5489/cuaj.787235623003 EAU Guidelines on Urolithiasis - Uroweb. Available from: https://uroweb.org/guidelines/urolithiasis/chapter/metabolic-evaluation-and-recurrence-prevention. Accessed February 18th 2025. KouriTTHofmannWFalboROyaertMSchubertSGertsenJB The EFLM European Urinalysis Guideline 2023. Clin Chem Lab Med. 2024;62:1653–786. 10.1515/cclm-2024-007038534005
" ["journals_volume"]=> string(2) "35" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "031001" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-35-3-031001" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2025.031001" ["journals_article_pubdate"]=> string(10) "2025-10-15" ["journals_article_title"]=> string(97) "What is uric acid concentration in urine in patients with uric acid kidney stones? - a case study" ["journals_article_author"]=> string(48) "Tomáš Šálek, Pavel Musil, Irena Zlatníková" ["journals_article_author_country"]=> string(14) "Czech Republic" ["journals_article_categories_heading"]=> string(12) "Case reports" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(83) "nephrolithiasis, uric acid, urine specimen collection, urine, specimen preservation" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "6273" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "13" ["meta_title"]=> string(97) "What is uric acid concentration in urine in patients with uric acid kidney stones? - a case study" ["meta_desc"]=> string(97) "What is uric acid concentration in urine in patients with uric acid kidney stones? - a case study" ["meta_keyw"]=> string(83) "nephrolithiasis, uric acid, urine specimen collection, urine, specimen preservation" ["created"]=> string(19) "2025-08-04 20:40:51" ["modified"]=> string(19) "2025-10-15 10:18:58" } [54]=> object(stdClass)#103 (35) { ["journals_id"]=> string(4) "1187" ["journals_xml"]=> string(49372) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-35-3-030902 10.11613/BM.2025.030902 Case reports Cystatin C for gentamicin dosing - a case study ŠálekTomáš*12KlhůfekJosef3VodičkaMartin3PšenčíkMarek1 Department of Clinical Biochemistry and Pharmacology, Tomas Bata Hospital in Zlín, Zlín, Czech Republic Institute of Clinical Biochemistry and Diagnostics, Medical Faculty in Hradec Králové, Charles University in Prague, Prague, Czech Republic Department of Clinical Pharmacy, Tomas Bata Hospital in Zlín, Zlín, Czech Republic Corresponding author: tsalek@seznam.cz

Author contributions

T Šálek: writing the draft article, editing, data interpretation, approval of the final version, and taking full responsibility; M Vodička and J Klhůfek: critical review of the article, data interpretation, approval of the final version, and taking full responsibility; M Pšenčík: critical review of the article, data analysis, approval of the final version, and taking full responsibility.

15082025 15102025 35 3 030902 1902202529052025 ©Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Serum creatinine concentration strongly depends on muscle mass

• Low muscle mass leads to glomerular filtration rate (GFR) overestimation from serum creatinine

• Cystatin C does not depend on muscle mass

• Cystatin C is needed for dosing of drugs that are excreted by GFR

The study aims to present a case study of a patient with supratherapeutic serum gentamicin concentration. An 83-year-old male was admitted to the Department of Internal Medicine for persistent loss of appetite, decompensated heart failure, and pneumonia. He was treated with 240 mg gentamicin daily alongside ampicillin/sulbactam penicillin antibiotic. The trough gentamicin concentrations and estimated glomerular filtration rate from creatinine (eGFRcrea) and cystatin C (eGFRcys) were performed. The patient had the supratherapeutic trough gentamicin concentration of 2.5 mg/L. eGFRcrea was 62 mL/min/1.73m2 and eGFRcys was 25 mL/min/1.73m2. The difference between eGFRcrea and eGFRcys was 148%. Falsely high eGFRcrea in elderly patient led to the supratherapeutic gentamicin concentration even after the standard 240 mg gentamicin dose.

Keywords: gentamicinscreatininecystatin Cglomerular filtration ratedrug overdose
Introduction

The glomerular filtration rate (GFR) is a key factor for dosing drugs excreted by the kidney. The kidneys excrete aminoglycoside antibiotics, which are nephrotoxic and can lead to kidney failure in overdosed patients. Once-daily dosing of gentamicin is also recommended based on GFR and body weight (1).

Traditionally, plasma creatinine has been used to estimate GFR. Unfortunately, low muscle mass, which is common in elderly, chronically ill patients, affects plasma creatinine. Cystatin C is another marker of GFR, that is not affected by low muscle mass and predicts mortality (2).

Patient safety is the reason we are presenting a case study with a significant discrepancy between the estimated glomerular filtration rate from serum creatinine (eGFRcrea) and cystatin C (eGFRcys) that would impact gentamicin dosing.

Case report

An 83-year-old male was admitted to the Department of Internal Medicine for decompensated heart failure, persistent loss of appetite, and pneumonia. His body weight was 70 kg, height was 170 cm, and his body mass index was 22 kg/m2. He lost 5 kg last month and underwent a nutritional specialist consultation. He suffered from chronic heart failure, paroxysmal atrial fibrillation, hypercholesterolemia, hypertension, and chronic kidney disease stage G3a based on eGFRcrea. His regular daily medication included atorvastatin 80 mg, ezetimibe 10 mg, ramipril 1.25 mg, nebivolol 5 mg-0-2.5 mg, rivaroxaban 20 mg, empagliflozin 10 mg, 25-hydroxyvitamin D3, and spironolactone 12.5 mg.

During this hospitalization, he was administered 240 mg of gentamicin daily along with ampicillin/sulbactam penicillin antibiotic. The target trough concentration is below 1 mg/L to reduce nephrotoxicity (1). Almost all patients taking gentamicin are monitored for trough concentrations. Clinical pharmacologists (who graduated from a Medical faculty and specialized in Clinical pharmacology) or clinical pharmacists (who graduated from a Faculty of pharmacy and specialized in Clinical pharmacy) manually enter interpretative comments recommending the next gentamicin dosing into the laboratory information system. Fasting blood samples were collected in 5 mL VACUETTE tubes with red top and separator aktivator for clotting (Greiner Bio-One Gmbh, Kremsmünster, Austria), at 6 a.m. Centrifugation at 1500xg for 10 minutes was performed within one hour after sample collection.

Both creatinine and cystatin C were measured using standardized methods traceable to international standards NIST SRM 967 and DA ERM 471, respectively (3, 4). Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations were used to calculate eGFRcrea, eGFRcys, and eGFR from both markers (eGFRcrea+cys) (5, 6). These equations are among the validated formulas according to KDIGO 2024 guidelines (7). For our patient, the following equations were used: CKD-EPI creatinine 2009 equation: eGFRcrea = 141 x (creatinine/79.6)-1.209 x 0.993Age, CKD-EPI cystatin C 2012 equation: eGFRcys = 133 x (cystatin C/0,8)-1.328 x 0.996Age, CKD-EPI creatinine-cystatin C 2012 combined equation: eGFRcrea+cys = 135 x (creatinine/79.6)-0.601 x (cystatin C/0.8)-0.711 x 0.995Age.

All laboratory tests, including thyroid-stimulating hormone (TSH) and albumin, were measured on an Abbott Architect ci 16200 automated analyzer (Abbott Laboratories, Abbott Park, USA). Albumin was measured using a bromocresol green photometric method. TSH was measured using a chemiluminescent microparticle immunoassay calibrated against WHO TSH 80/558 reference material.

All dosing data were used to interpret serum gentamicin concentrations, including the initial dose date, dosing time, 240 mg gentamicin dose, dosing interval, and intravenous route of administration (8). Before the fourth dose, his trough concentration had increased to 2.5 mg/L. Gentamicin concentrations before the second and third doses were not ordered. The modeling program MwPharm++ 1.7.14.0 version (Mediware, Groningen, The Nederlands) also supported dosing using a population pharmacokinetic two-compartment model for gentamicin. Based on this model, gentamicin concentrations were best fitted when eGFRcys was used to estimate renal function. The interpretative comment on the laboratory report recommended extending the dosing interval to 36 hours and reducing the dose to 160 mg/L, which resulted in a trough concentration of 1.0 mg/L. Laboratory test results are shown in Table 1.

Laboratory fasting serum test results in the patient with supratherapeutic gentamicin concentrations, monitoring of inflammation and renal function
Serum laboratory test (unit) ResultAugust 14th ResultAugust 18th ResultAugust 28th Reference range
Sodium (mmol/L) 137 138 142 136-144
Potassium (mmol/L) 4.7 4.7 4.1 3.8-5.1
Chloride (mmol/L) 104 107 104 95-107
Glucose (mmol/L) 4.9 4.8 4.9 3.9-5.5
Gentamicin (mg/L) 2.5 1.0 - < 1.00
Serum urea (mmol/L) 9.0 9.0 14.4 3.0-8.0
Creatinine (µmol/L) 96 112 138 49-90
eGFRcrea (mL/min/1.73m2) 62 52 40 90-150
Cystatin C (mg/L) 2.21 2.41 - < 0.96
eGFRcys (mL/min/1.73m2) 25 22 - 90-150
eGFRcrea+cys (mL/min/1.73m2) 38 33 - 90-150
Albumin (g/L) 26.5 25.1 26.6 36.0-45.0
C-reactive protein (mg/L) 136 91 23 0-2
Thyroid stimulating hormone (mU/L) 0.725 - - 0.350-4.940
eGFRcrea - estimated glomerular filtration rate from serum creatinine. eGFRcys - estimated glomerular filtration rate from serum cystatin C. eGFRcrea+cys - estimated glomerular filtration rate from serum creatinine and cystatin C.

After successful antibiotic treatment, the patient was discharged home on August 28th.

The patient signed the informed consent for the publication of his case report. The local Ethics Committee approved the publication of case study No.2024/18.

Discussion

The patient with supratherapeutic gentamicin concentration and a significant difference between eGFRcrea and eGFRcys was presented. Gentamicin concentrations were best fitted when eGFRcys was used to estimate renal function.

Groothof et al. in their large study involving over 13,000 patients, reported that serum creatinine is an unreliable marker of GFR due to its dependence on muscle mass (9). Our elderly patient likely had a falsely overestimated eGFRcrea due to low muscle mass.

Hanna et al. analyzed a cohort of 1869 adults with cancer. Their mean age was 66 years. A total of 543 patients who had more than 30% lower eGFRcys compared with eGFRcrea had more commonly trough supratherapeutic concentrations of vancomycin and digoxin, hyperkalemia related to trimethoprim-sulfamethoxazol, and toxic effects of baclofen (10). Our patient also had more than 30% lower eGFRcys and supratherapeutic trough concentrations of drug excreted by kidneys.

Rebollo and Cepeda-Piorno presented a case study of a 78-year-old male patient with supratherapeutic trough amikacin concentrations which can lead to nephrotoxicity and ototoxicity. His body mass index was 29 kg/m2. They concluded that eGFRcys, based on the CKD-EPI 2012 equation, is better for dosing amikacin and aminoglycosides than eGFRcrea (11). This is consistent with our findings of supratherapeutic gentamicin trough concentrations, and gentamicin concentrations were best fitted when eGFRcys was used to estimate renal function.

Chin et al. found that eGFRcrea+cys calculated using the CKD-EPI 2012 equation provided the best estimate of gentamicin clearance. Their study group included 260 patients with a median age of 67 years (12). The disadvantage of this study is that creatinine was not measured using a standardized enzyme method traceable to international standards NIST SRM 967. Creatinine was measured by a modified Jaffe reaction.

Karimzadeh et al. conducted a systematic review on toxicity in patients receiving repeated doses of aminoglycosides and once-daily dosing. Once-daily dosing was found to be safer in terms of nephrotoxicity (13), which is why we also used safer once-daily dosing.

The KDIGO 2024 guidelines recommended the eGFRcrea+cys equation to confirm for chronic kidney disease, determine the stage, and adjust medication dosing for renally excreted drugs with a narrow therapeutic index (7). The reason for using the combined equation is that cystatin C may be affected by variables such as thyroid disease, corticosteroid use, and cancer. We did not have these non-renal variables in our patient.

Chen et al. analyzed the UK Biobank and found that older age and male gender were strong predictors for the group with lower eGFRcys compared to the group with eGFRcrea. The group with lower eGFRcys had a 3-fold higher prevalence of diabetes and current smoking and a 2-fold higher prevalence of cardiovascular disease compared to the group with lower eGFRcrea (14). This is consistent with the case of our patient, who had cardiovascular disease including heart failure.

Wang et al. reported that cystatin C was positively associated with cardiovascular and all-cause mortality (15). This finding also highlights the role of cystatin C in clinical diagnostics for prognostic purposes.

Šálek et al. reported that measuring cystatin C would avoid supratherapeutic concentrations of gentamicin and digoxin. The median difference between eGFRcrea and eGFRcys in patients in the Intensive Care Unit was 19 mL/min/1.73m2 (46%) (16, 17). Our patient also had trough supratherapeutic gentamicin concentrations and a significant difference between eGFRcrea and eGFRcys. Muscle wasting in critically ill patients is common. Our patient had pneumonia, which is also an acute and potentially fatal diagnosis. These manuscripts emphasize that this situation is quite common among elderly patients.

Hu et al. demonstrated that cystatin C was positively associated with inflammatory markers CRP and procalcitonin in patients with sepsis (18). Our patient also had high CRP concentrations. On the other hand, his gentamicin concentrations were best fitted when eGFRcys was used to estimate renal function.

A limitation of this case study is that we did not measure GFR using the gold-standard exogenous marker method like inulin clearance. It could show true biases between inulin clearance and eGFRcrea, eGFRcys, and eGFRcrea+cys. On the other hand, cystatin C is a newly emerging global standard for eGFR (19).

The results of this case study can be interpreted as follows: low muscle mass likely led to low serum creatinine with falsely high eGFRcrea, resulting in supratherapeutic gentamicin concentrations. This situation could have been prevented by measuring cystatin C. Figure 1 shows the total incorrect dosing process.

The overall incorrect dosing process of gentamicin. Low muscle mass probably led to low serum creatinine with falsely high estimated glomerular filtration rate (eGFRcrea) from serum creatinine, which resulted in supratherapeutic gentamicin concentrations. The estimated glomerular filtration rate from serum cystatin C (eGFRcys) was less than half that of eGFRcrea. The supratherapeutic gentamicin concentrations could have been prevented by measuring cystatin C.

We can conclude that eGFRcys plays a key role in the care of patients taking drugs eliminated by the kidneys. Estimating GFR without cystatin C would lead to supratherapeutic concentrations and could affect patient safety.

Acknowledgments

MgA. Jiří Balát contributed to the graphical abstract technical editing.

Potential conflicts of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References HodiamontCJvan den BroekAKde VroomSLPrinsJMMathôtRAAvan HestRM. Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review. Clin Pharmacokinet. 2022;61:1075–94. 10.1007/s40262-022-01143-035754071 CerezoICanchoBRodriguez SabillonJAJorgeAAlvarez LopezAValladaresJ Comparative Prognostic Value of Glomerular Filtration Rate, Serum Cystatin C, Beta-2-Microglobulin and Albuminuria for Death and Chronic Kidney Disease Progression. J Clin Lab Anal. 2025;39:e25139. 10.1002/jcla.2513939713962 DodderNGTaiSSCSniegoskiLTZhangNFWelchMJ. Certification of Creatinine in a Human Serum Reference Material by GC-MS and LC-MS. Clin Chem. 2007;53:1694–9. 10.1373/clinchem.2007.09002717660272 GrubbABlirup-JensenSLindströmVSchmidtCAlthausHZegersI First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med. 2010;48:1619–21. 10.1515/CCLM.2010.31821034257 LeveyASStevensLASchmidCHZhangYLCastroAF3rdFeldmanHI A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. 10.7326/0003-4819-150-9-200905050-0000619414839 InkerLASchmidCHTighiouartHEckfeldtJHFeldmanHIGreeneT Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. N Engl J Med. 2012;367:20–9. 10.1056/NEJMoa111424822762315 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105 4S:S117–314. 10.1016/j.kint.2023.10.01838490803 ŠálekTŠálekTSchneiderkaPStudenáBVotroubkováM. Survey on request form content and result reporting in therapeutic drug monitoring service among laboratories in Czechia and Slovakia. Biochem Med (Zagreb). 2020;30:020706. 10.11613/BM.2020.02070632550814 GroothofDShehabNBNErlerNSPostAKremerDPolinder-BosHA Creatinine, cystatin C, muscle mass, and mortality: Findings from a primary and replication population-based cohort. J Cachexia Sarcopenia Muscle. 2024;15:1528–38. 10.1002/jcsm.1351138898741 HannaPEWangQStrohbehnIAMorenoDHardenDOuyangT Medication-Related Adverse Events and Discordancies in Cystatin C–Based vs Serum Creatinine–Based Estimated Glomerular Filtration Rate in Patients With Cancer. JAMA Netw Open. 2023;6:e2321715. 10.1001/jamanetworkopen.2023.2171537405775 RebolloNCepeda-PiornoFJ. Cystatin C for therapeutic drug monitoring. Clin Chem. 2015;61:804–7. 10.1373/clinchem.2014.22584726025947 ChinPKLChew-HarrisJSCFlorkowskiCMBeggEJ. The performance of contemporary cystatin C-based GFR equations in predicting gentamicin clearance. Br J Clin Pharmacol. 2015;79:268–77. 10.1111/bcp.1250125155642 KarimzadehIAbdollahpour-AlitappehMGhaffariSMahi-BirjandMBarkhordariAAlemzadehE. Aminoglycosides: Single- or Multiple-daily Dosing? An Updated Qualitative Systematic Review of Randomized Trials on Toxicity and Efficacy. Curr Mol Med. 2024;24:1358–73. 10.2174/156652402366623080116045237533241 ChenDCLuKScherzerRLeesJSRutherfordEMarkPB Cystatin C- and Creatinine-based Estimated GFR Differences: Prevalence and Predictors in the UK Biobank. Kidney Med. 2024;6:100796. 10.1016/j.xkme.2024.10079638567244 WangTZhuYLiuXZhangYZhangZWuJ Cystatin C and sarcopenia index are associated with cardiovascular and all-cause death among adults in the United States. BMC Public Health. 2024;24:1972. 10.1186/s12889-024-19137-x39044229 ŠálekTVodičkaMGabrhelíkT. Estimated glomerular filtration rate in patients overdosed with gentamicin. J Lab Med. 2020;44:35–9. 10.1515/labmed-2019-0124 ŠálekTVodičkaMGřivaM. Cystatin C may be better than creatinine for digoxin dosing in older adults with atrial fibrillation. J Clin Lab Anal. 2020;34:e23427. 10.1002/jcla.2342732716587 HuCZhangZHouBXueHPuXYeJ. Prognostic value of serum cystatin C in patients with sepsis. Indian J Pathol Microbiol. 2023;66:573–6. 10.4103/ijpm.ijpm_804_2137530342 HundemerGLSoodMMAkbariA. Beyond Creatinine: Is Cystatin C the New Global Standard for Estimated Glomerular Filtration Rate Evaluation? Kidney Med. 2024;6:100806. 10.1016/j.xkme.2024.10080638495598
" ["journals_volume"]=> string(2) "35" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030902" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-35-3-030902" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2025.030902" ["journals_article_pubdate"]=> string(10) "2025-10-15" ["journals_article_title"]=> string(47) "Cystatin C for gentamicin dosing - a case study" ["journals_article_author"]=> string(66) "Tomáš Šálek, Josef Klhůfek, Martin Vodička, Marek Pšenčík" ["journals_article_author_country"]=> string(14) "Czech Republic" ["journals_article_categories_heading"]=> string(12) "Case reports" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(78) "gentamicins, creatinine, cystatin C, glomerular filtration rate, drug overdose" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "4966" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "12" ["meta_title"]=> string(47) "Cystatin C for gentamicin dosing - a case study" ["meta_desc"]=> string(47) "Cystatin C for gentamicin dosing - a case study" ["meta_keyw"]=> string(78) "gentamicins, creatinine, cystatin C, glomerular filtration rate, drug overdose" ["created"]=> string(19) "2025-08-04 20:38:01" ["modified"]=> string(19) "2025-10-15 10:18:47" } [55]=> object(stdClass)#104 (35) { ["journals_id"]=> string(4) "1191" ["journals_xml"]=> string(55971) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-35-3-030901 10.11613/BM.2025.030901 Case reports Perspective and consideration in the application of personalized reference intervals based on biological variation: a four-month observation of a woman with SARS-CoV-2 reinfection HuGaofeng1XuLei12GuoKai13LiChenbin*1 National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing, PR China Department of Clinical Laboratory, Peking University First Hospital, Beijing, PR China Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, Genetics and Birth Defects Control Center, National Center for Children’s Health, MOE Key Laboratory of Major Diseases in Children, Beijing Children’s Hospital, Capital Medical University, Beijing, P. R. China Corresponding author: cbli@nccl.org.cn

Author contributions

Gaofeng Hu: Conceptualization, Formal analysis, Investigation, Methodology, Validation, Visualisation, Writing – original draft. Lei Xu: Formal analysis, Investigation, Methodology, Validation. Kai Guo: Conceptualization, Investigation, Methodology, Validation, Visualisation, Writing – review & editing. Chenbin Li: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing – review & editing.

15082025 15102025 35 3 030901 1802202515052025 ©Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Personalized reference intervals offer substantial clinical value and utility

• Recommended to use published biological variation data for the calculation

• The reference change value can be effectively employed as a supplementary method

This study aimed to investigate potential benefit of personalized reference intervals (prRIs) by conducting a four-month observation of a woman with SARS-CoV-2 reinfection. Two types of prRIs were calculated: one derived from the population biological variation (BV) data provided by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) biological variation database (prRIs_pop.), and the other derived from individual variation data (prRIs_ind.). These were subsequently compared. A total of 110 test results encompassing complete blood count (CBC) and leukocyte differential counts from the case were assessed according to the limits of prRIs_pop., reference change values (RCVs_pop.) and the population-based reference intervals (popRIs). In instances where limited historical health data are available (N ≤ 3), the application of prRIs_pop. was recommended over prRIs_ind. The prRIs_pop. and RCVs_pop. identified a greater number of potential clinical pathological change compared to popRIs (the ratio of potential abnormal values to total test values: prRIs_pop. 22/110, RCVs_pop. 25/110, popRIs 2/110, respectively). The findings suggest that the use of prRIs can be advantageous in clinical settings and is worthy of broader adoption. However, it is essential to choose an appropriate calculation method tailored to the specific clinical context.

Keywords: biological variationhematologypersonalized reference intervalsbiological variationreference change valuereference intervals
Introduction

The interpretation of laboratory data relies on reliable reference data for comparison, which are typically derived from population-based data statistics but applied to individuals. However, using population-based reference intervals to interpret test results for individual patients presents significant limitations in diagnosing, monitoring, and treating single individuals. To address this issue, Coşkun and colleagues developed a novel method for calculating personalized reference intervals (prRIs) based on biological variation (BV) (1-3). This approach allows patients’ test results to be compared against their own individualized reference intervals, offering potential benefits in diagnosis and patient follow-up. Despite its promise, the adoption of individualized reference intervals has not yet received adequate attention in the field. In this study, we present a representative case study conducted over a four-month period to assess the advantages of utilizing prRIs for monitoring patients in real-world clinical practice.

Case presentation Patient

A 33-year-old woman presented with fever (38 °C), dry cough, sore throat, and myalgia. She tested positive for SARS-CoV-2 antigen using two different kits on 2 consecutive days. After taking antipyretic drugs, her body temperature returned to normal by Day 3, and her remaining symptoms resolved within one week. Prior to this episode, she had received three doses of COVID-19 vaccine (Sinopharm Beijing) and had experienced her first SARS-CoV-2 infection 9 months earlier. The study was conducted in compliance with the ethical guidelines established by the Institutional Review Board of Beijing Hospital (Approval Letter No. 2023BJYYEC-194-01). Written informed consent was obtained from the case presented in this report.

Laboratory work-up

We collected complete blood count (CBC) results, including leukocytes, erythrocyte, hematocrit, hemoglobin and platelets, as well as and leukocyte differential counts, including neutrophils, lymphocytes, monocytes, eosinophils and basophils, at 11 time points from Day - 10 to Day 115 (with Day 0 was defined as the day of symptom onset) before and after the SARS-CoV-2 reinfection. All laboratory tests were conducted at the National Center for Clinical Laboratories (NCCL), Beijing Hospital.

The population-based reference intervals (popRIs) were derived from the China national health standard WS/T 405 (available at http://www.nhc.gov.cn/ewebeditor/uploadfile/2013/01/20130109171100186.pdf). Personalized reference intervals (prRIs) and reference change values (RCVs) were calculated using the equations proposed by Coşkun and colleagues (1, 2). The homeostatic set point (HSP) was estimated based on results from her three previous physical examinations conducted between 3 years and 5 months previously (N = 3). Due to the limited number of data points available for HSP calculation, two distinct methods were employed to determine the prRIs and RCVs: one derived from population BV data (prRIs_pop. and RCVs_pop.), and the derived from individual variation data (prRIs_ind. and RCVs_ind.). The formulas for these calculation (Equations (Eq.) 1-8) are provided below.

Note: z = 1.96 for 95% probability; is the t-table value with n−1 freedom (two-side); UL, upper limit; LL, lower limit; N/A, not applicable; TVset, the total variation around the true homeostatic set point.

The within-subject biological variation (CVI) and between-subject biological variation (CVG) data were sourced from European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) BV database (4). The analytical variation (CVA) data were obtained from NCCL. The “total variation” of the results (CVT) is the combination of within-person variation (CVP) and CVA and calculated from the HSP data of the case with SARS-CoV-2 reinfection (3).

The calculated parameters are summarized in Table 1. The index of individuality (II), defined as the ratio of CVI to CVG based on data form the EFLM BV database, ranged from 0.24 to 0.65 (1, 4). The range of the prRIs_pop. (upper limit - lower limit) for all 10 tested parameters were narrower compared to the popRIs. However, the prRIs_ind. for only 5 of the tested parameters (leukocytes, neutrophils, lymphocytes, eosinophils, and basophils) were narrower than the popRIs (Table 1 and Figure 1-A). Additionally, the RCVs_pop. of 6 of the tested parameters were lower than RCVs_ind. (Table 1 and Figure 1-B).

Summary of calculated parameters for complete blood count and leukocyte differential count
HSP CVI (%) CVA (%) CVT (%) II popRIs prRIs_pop. RCVs_pop. (%) prRIs_ind. RCVs_ind. (%)
Leukocytes(x 109/L) 4.8 ± 0.5 11.10 1.26 9.45 0.65 3.5 ~ 9.5 3.7 ~ 6.0 30.96 2.5 ~ 7.0 26.20
Neutrophils(x 109/L) 3.0 ± 0.3 14.10 1.46 9.83 0.58 1.8 ~ 6.3 2.0 ~ 3.9 39.29 1.5 ~ 4.4 27.25
Lymphocytes(x 109/L) 1.4 ± 0.1 10.80 3.55 6.62 0.48 1.1 ~ 3.2 1.0 ~ 1.7 31.51 0.9 ~ 1.8 18.34
Monocytes(x 109/L) 0.3 ± 0.1 13.30 7.08 24.24 0.60 0.1 ~ 0.6 0.2 ~ 0.4 41.77 - 0.1 ~ 0.7 67.20
Eosinophils(x 109/L) 0.1 ± 0.0 15.00 16.70 37.50 0.24 0.02 ~ 0.52 0.04 ~ 0.12 62.23 - 0.1 ~ 0.2 103.94
Basophils(x 109/L) 0.04 ± 0.0 12.40 14.35 0.00 0.44 0 ~ 0.06 0.02 ~ 0.06 52.56 0.0 ~ 0.04 0.00
Erythrocytes(x 1012/L) 4.45 ± 0.17 2.80 0.67 3.82 0.40 3.8 ~ 5.1 4.16 ~ 4.74 7.98 3.61 ~ 5.30 10.59
Hematocrit(L/L) 0.420 ± 0.020 2.80 0.54 4.76 0.50 0.35 ~ 0.45 0.390 ~ 0.450 7.90 0.320 ~ 0.520 13.20
Hemoglobin (g/L) 141 ± 5 2.70 0.25 3.36 0.44 115 ~ 150 132 ~ 149 7.52 117 ~ 164 9.32
Platelets(x 109/L) 217 ± 25 6.40 0.17 11.43 0.47 125 ~ 350 185 ~ 249 18.06 94 ~ 341 31.69
HSP - homeostatic set point presented as mean and standard deviation. CVI – within-subject biological variation. CVA – analytical variation. CVT – total variation. II - index of individuality, i.e. CVI/CVG. popRIs - population-based reference intervals. prRIs_pop. – personalized reference intervals derived from population biological variation data. RCVs_pop. - reference change values derived from population biological variation data. prRIs_ind. - personalized reference intervals derived from individual variation data. RCVs_ind. - reference change values derived from individual variation data. Reference intervals are presented as lower to upper limit.

The test results evaluated against the limits of prRIs_pop., RCVs_pop. and popRIs. Data identified as potential anomalies using, prRIs_pop., RCVs_pop. and popRIs criteria were marked with red, blue, and green boxes, respectively. prRIs_pop. - personalized reference intervals derived from the population biological variation data provided by the EFLM. RCVs_pop. - reference change values derived from the population biological variation data provided by the EFLM. popRIs - population-based reference intervals.

A total of 110 test results were evaluated against the limits of prRIs_pop., RCVs_pop. and popRIs, as detailed in Figure 2 and Supplementary Table 1. The analysis revealed that prRIs_pop. and RCVs_pop. identified a great number of potential clinical pathological change compared to popRIs. Specifically, the ratios of potential abnormal values to the total number of test values were as follows: prRIs_pop. 22/110, RCVs_pop. 25/110, and popRIs 2/110 (Figure 2 and Supplementary Table 1).

The comparison of calculated parameters. prRIs_pop. - personalized reference intervals derived from the population biological variation data provided by the EFLM. RCVs_pop. - reference change values derived from the population biological variation data provided by the EFLM. popRIs - population-based reference intervals. RCVs_ind. - reference change values derived from individual variation data. RCVs_pop. - reference change values derived from population biological variation data.

Discussion

In the pursuit of precision medicine, the development of the new prRIs algorithm based on the homeostatic model represents a significant advancement in the field of clinical laboratory medicine. Mathematically, the upper and lower limits of prRIs are determined by HSP and the total variation around the true HSP (TVset) (1-3). However, one of the primary challenges in calculating prRIs is the availability of reliable and sufficient steady-state data (5, 6). The critical factor lies in accurately identifying steady-state condition, which are not synonymous with healthy condition. In chronic diseases such as diabetes, asymptomatic hyperuricemia, and malnutrition-related anemia, which may have been present for years before diagnosis, previous test results may not necessarily reflect the true HSP. Therefore, it is essential to implemented both prRIs and popRIs in tandem. Additionally, outlier and trend analysis are indispensable tools in this process. However, we have reservations about automatically excluding data that fall outside the popRIs limits when calculating prRIs. In some cases, an individual may be in a steady-state condition, yet their test results may lie outside the popRIs limits. We recommended using RCVs or other robust method to determine whether such data should be excluded. RCVs, calculated based on 2 consecutive results from an individual, are independent of analyte’s HSP. Nevertheless, it is important to note that a single test result cannot definitively indicate whether a recovery from a pathological state or a new pathological change has occurred. When reliable HSP data are available, prRIs offer the highest sensitivity for interpreting test results and are most conductive to facilitating prompt clinical decision-making among the three types of intervals (prRIs, RCVs, and popRIs). In summary, the clinical application of prRIs requires a long-term awareness of health management and imposes higher quality control requirements for both the pre-analytical and post-analytical phases of the testing process. This underlines the importance of close collaboration between clinicians and laboratory professionals. This approach ensures the accurate and effective use of prRIs in advancing personalized patient care.

The estimation of TVset can be performed using two equations based on CVI or CVP, which rely on either the normal distribution or t-distribution (see Eq. 2 and 5). The EFLM Biological Variation Database provides freely accessible CVI estimates derived from global published BV studies and meta-analysis (4). However, for CBC and leukocyte differential counts, the specimens are analyzed immediately after collection due to their instability. Consequently, the calculated CVI data may be confounded by between-run analytical variation (7). Although newer statistical methods, such as CV-ANOVA, the Bayesian approach, and big data mining, offer more scientific and efficient tools for reliable BV estimation, they do not fundamentally resolve this issue (8). Coşkun and colleagues advocate for the use of CVP over CVI when deriving prRIs, as CVP more accurately reflects the BV of a single individual, whereas CVI represents the “average” BV of a population (9). In this study, we estimated two types of prRIs: prRIs_pop. and prRIs_ind.. When historical health data are limited, such as with a sample size of N = 3, the range of prRIs_ind. can become excessively wide, potentially exceeding that of popRI. This diminished the advantages of using prRIs. As recommended by Coşkun, at least 5 previous test results from a steady-state condition are needed. The widespread use of laboratory information system has made more data accessible to laboratory professionals. While, accumulating sufficient data to calculate CVP for all patients is both time-consuming and often impractical for most laboratories. Therefore, it may be more feasible to calculate and utilize prRIs_pop. and RCVs_pop. in clinical practice. Additionally, the CVI estimates of CBC and leukocyte differential counts in EFLM BV database are derived from meta-analysis. Given the rapid advancements and innovation in detection technology, we recommend prioritizing CVI estimates from studies with higher Biological Variation Data Critical Appraisal Checklist (BIVAC) grades over meta-analysis results. This approach ensures more accurate BV estimates tailored to specific populations and detection technologies.

Most clinical laboratories rely on published CVI data and their own laboratory’s CVA data to calculate prRIs. It is widely accepted that CVA should be less than or equal to half of CVI (CVA ≤ 0.5CVI) when estimating BV, and measurands with CVI > 30% are generally considered unsuitable for prRIs calculations (3, 7). This implies that the CVA of a measurand should ideally be less than 15%. However, due to limitations in measurement methods, the CVA for eosinophils and basophils in our laboratory were 16.7% and 14.4%, respectively. In such case, RCVs may be a more suitable alternative. In fact, each laboratory should establish its own analytical performance specifications (APS) for measurands. Importantly, prRIs are not only individualized but also laboratory-specific, which adds complexity to the standardization and harmonization efforts in laboratory medicine.

The index of individuality (II) is commonly used to evaluate the applicability popRIs (1). Two equations are typically used for II calculation: II = CVI/ CVG and (10). While there is no- consensus on which formula is preferable, the former is more frequently used. The II values for CBC and leukocyte differential counts, calculated using data from the EFLM ranged from 0.24 to 0.65 (4). This indicates that conventional popRIs have very limited utility in identifying abnormal results for a specific individual (7). Ideally, clinical laboratories should reansition to using prRIs rather than popRIs. The findings in this case revealed that the popRIs criterion could only identify a limited number of potential outliers, whereas the prRIs_pop. and RCVs_pop. criteria demonstrate broader applicability by identifying more potential abnormal values across different disease phases including the incubation and recovery periods. While these results are derived from a single case observation, they imply that the employment of more sensitive criteria (prRIs_pop. and RCVs_pop.) could enhance the detection of clinically significant variations in future cohort studies and may help uncover additional patterns in disease progression. Nevertheless, the preponderance of extant evidence corroborates the indispensability of population-based reference intervals (popRIs) for parameters exhibiting an index of individuality greater than 0.6. Consequently, emphasis is placed on the necessity of selecting popRIs, prRIs, or a combination, for the interpretation of results, with this selection being based on each parameter’s intrinsic biological characteristics.

In summary, this case study demonstrates the significant potential of population biological variation-based prRIs in improving clinical decision-making. The limitations of this study are the data from only one woman with SARS-CoV-2 reinfection and the serial measurements of blood cells, but this study provides unique contributions: (1) a comprehensively documented longitudinal dataset spanning the entire disease course (incubation, disease, and recovery phases); and (2) rigorously standardized laboratory procedures ensuring exceptional comparability across all tests, including the three HSP measurements. Despite the considerable challenges that still need to be overcome for the widespread implementation of prRIs - and full integration into routine clinical practice remains a long-term goal - the ongoing discussion and critical evaluation of the utility and importance of laboratory measurements remain valuable.

Acknowledgements

The authors gratefully acknowledge Dr. Peng Mingting from the National Center for Clinical Laboratories for her valuable scientific guidance throughout this study and her insightful suggestions on manuscript preparation.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References CoşkunASandbergSUnsalICavusogluCSerteserMKilercikM Personalized Reference Intervals in Laboratory Medicine: A New Model Based on Within-Subject Biological Variation. Clin Chem. 2021;67:374–84. 10.1093/clinchem/hvaa23333188412 CoşkunASandbergSUnsalIYavuzFGCavusogluCSerteserM Personalized reference intervals - statistical approaches and considerations. Clin Chem Lab Med. 2021;60:629–35. 10.1515/cclm-2021-106634894385 CoşkunASandbergSUnsalICavusogluCSerteserMKilercikM Personalized and Population-Based Reference Intervals for 48 Common Clinical Chemistry and Hematology Measurands: A Comparative Study. Clin Chem. 2023;69:1009–30. 10.1093/clinchem/hvad11337525518 Aarsand AK, Fernandez-Calle P, Webster C, Coşkun A, Gonzales-Lao E, Diaz-Garzon J, et al. The EFLM Biological Variation Database. Available at: https://biologicalvariation.eu/. Accessed: August 23, 2024. CoşkunASandbergSUnsalICavusogluCSerteserMKilercikM Personalized reference intervals: Using estimates of within-subject or within-person biological variation requires different statistical approaches. Clin Chim Acta. 2022;524:201–2. 10.1016/j.cca.2021.10.03434743811 CarobeneABanfiGLocatelliMVidaliM. Personalized reference intervals: From the statistical significance to the clinical usefulness. Clin Chim Acta. 2022;524:203–4. 10.1016/j.cca.2021.10.03634743810 FraserCGHarrisEK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci. 1989;27:409–37. 10.3109/104083689091065952679660 SandbergSCarobeneABartlettBCoşkunAFernandez-CallePJonkerN Biological variation: recent development and future challenges. Clin Chem Lab Med. 2022;61:741–50. 10.1515/cclm-2022-125536537071 CoşkunASandbergSUnsalISerteserMAarsandAK. Personalized reference intervals: from theory to practice. Crit Rev Clin Lab Sci. 2022;59:501–16. 10.1080/10408363.2022.207090535579539 PlebaniMPadoanALippiG. Biological variation: back to basics. Clin Chem Lab Med. 2015;53:155–6. 10.1515/cclm-2014-118225568984
" ["journals_volume"]=> string(2) "35" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030901" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-35-3-030901" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2025.030901" ["journals_article_pubdate"]=> string(10) "2025-10-15" ["journals_article_title"]=> string(179) "Perspective and consideration in the application of personalized reference intervals based on biological variation: a four-month observation of a woman with SARS-CoV-2 reinfection" ["journals_article_author"]=> string(39) "Gaofeng Hu, Lei Xu, Kai Guo, Chenbin Li" ["journals_article_author_country"]=> string(18) "China, P. R. China" ["journals_article_categories_heading"]=> string(12) "Case reports" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(133) "biological variation, hematology, personalized reference intervals, biological variation, reference change value, reference intervals" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "7567" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "11" ["meta_title"]=> string(114) "Perspective and consideration in the application of personalized reference intervals based on biological variation" ["meta_desc"]=> string(114) "Perspective and consideration in the application of personalized reference intervals based on biological variation" ["meta_keyw"]=> string(88) "biological variation, hematology, personalized reference intervals, biological variation" ["created"]=> string(19) "2025-08-06 09:03:04" ["modified"]=> string(19) "2025-10-15 10:18:32" } [56]=> object(stdClass)#105 (35) { ["journals_id"]=> string(4) "1202" ["journals_xml"]=> string(150475) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-35-3-030704 10.11613/BM.2025.030704 Original articles Refining quality control strategies in highly automated laboratories: experience in the integration of multistage statistical designs and risk management Costa-PallarueloMaría*12García-OsunaÁlvaro12CanyellesMarina12Martínez-BruCecília2NanNicoleta1Ferrer-PerezRosa12Blanco-VacaFrancisco1GuiñónLeonor123 Biochemistry Department, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain Core Laboratory, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Quality Department Laboratories, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Corresponding author: mcostap@santpau.cat, Received: January 31, 2025 Accepted: September 5, 2025

Author contributions

MCT: Conceptualization, Data duration, Methodology, Investigation, Writing - original draft. AGO: Writing - review & editing. MC: Writing - review & editing. CMB: Writing - review & editing. NN: Writing - review & editing. RF: Writing - review & editing. FBV: Writing - review & editing. LG: Conceptualization, Methodology, Supervision, Writing - original draft.

15102025 15102025 35 3 030704 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• We present a practical approach integrating multistage quality control (QC) design and run size requirements

• Two of the 7 QC plans initially designed were implemented across all analyzers

• Only 4 individualized QC plans were required for specific parameters

Introduction

The ISO 15189:2022 standard considers both the robustness of analytical methods and the risk of erroneous results in the quality control plan (QCP) design. Westgard et al.’s nomogram recommends quality control (QC) rules based on sample run size to ensure that the maximum expected number of unreliable patient results remains below one. This study aimed to implement a standardized, risk-based QC strategy across multiple analyzers without integrated on board QC, ensuring practical quality assurance.

Material and methods

Thirty-two biochemistry parameters on Alinity c systems and three on Cobas Pro systems were included. The analytical performance of each parameter on each analyzer was assessed using sigma metric. Workload requirements were considered to determine the desired run size. Based on the “sigma metric statistical QC run size nomogram” proposed by Westgard et al., a multistage bracketed QCP was designed for each parameter. When multiple designs were available, the simplest QC rule was prioritized.

Results

Seven QCPs were initially established for 35 parameters. In the absence of automation, practical adaptations based on sigma metrics were implemented. Additionally, to streamline management, the QCP covering the greatest number of parameters per analyzer was prioritized, which ultimately resulted in the adoption of only two general QCP. Only 4 individualized QCP were required to cover 10 parameters with lower sigma values.

Conclusions

This approach demonstrates the feasibility of implementing a refined QC strategy for parameters with sigma ≥ 4 in a highly automated laboratory, ensuring consistent quality assurance and efficient resource allocation for higher-risk tests.

Keywords: laboratory automationMax E(Nuf) QC modelmultistage QCrisk managementrun size
Introduction

Highly automated laboratories operate in continuous mode, with uninterrupted data collection ensuring a steady flow of samples through analytical systems. This mode is characterized by real-time monitoring, where sample measurements are continuously performed, providing instant data. Continuous performance can be evaluated through a bracketed internal quality control (IQC), in which the results are not reported until the next scheduled IQC event is passed, ensuring that only reliable data are used for decision-making (1).

Proper quality control (QC) plans are essential to ensure reliable results for clinical decision-making, since these decisions have a direct impact on patient safety. However, despite the well-established principle that QC strategies should be tailored to analytical performance, many highly automated laboratories still apply a uniform QC rule and a fixed number of control measurements across all parameters, without accounting for the specific performance of each measurement procedure in each of the available analyzers (1-4). Notably, approximately 59% of laboratories worldwide continue to use the 12s rule for all measurands, without considering it to the performance characteristics of individual tests (2). Moreover, QC is usually managed with a one-stage approach, which means that all QC events are treated equally throughout the daily workload. Concerning this, Westgard et al. introduced the concept of multistage bracketed statistical QC combining a “startup” design for the initial phase of operation with a “monitor” design to maintain quality standards during the continuous reporting of patient test results (1). Starting the process is a critical control point where the probability of error is high so a more demanding QC design with a high probability of error detection (preferably > 90%) is applied. After the performance is assured by the “startup” QC and testing patient samples is initiated, then a less demanding “monitor” design with a lower probability of false rejection (< 5%) is applied.

Analytical performance is usually evaluated using the sigma metric; the higher the sigma, the better the performance, and vice versa (3, 5). Nevertheless, based solely on analytical performance, the absence of errors during analysis cannot be guaranteed, so that erroneous patient results can be reported. In this regard, the ISO 15189:2022 standard (section 7.3.7.2.) requires considering not only the robustness and stability of the analytical method but also the risk of reporting erroneous results when designing QC plans (6). Additionally, the Clinical and Laboratory Standards Institute (CLSI) issued practice guidelines (C24-Ed4) to assist the implementation of risk management within QC plans (7).

In this regard, Parvin et al. introduced the concept of the number of unreliable final patient results (Nuf), referring to erroneous results that, once released, are unlikely to be identified and corrected. Building on this, the Max E(Nuf) value represents the maximum expected number of such unreliable results yielded between two QC events. A value of Max E(Nuf) below one indicates that, on average, fewer than one erroneous result is expected before error detection, thus ensuring acceptable analytical risk. Although it assumes normally distributed errors and consistent system performance - conditions that may not always hold in practice - this concept provides a standardized method for designing QC strategies, introducing sample run size as a key factor in QC plans (8, 9). Defining an appropriate sample run size, the detection of errors is improved, thereby minimizing the reporting of erroneous patient results. To facilitate practical implementation, Westgard et al. developed a sigma-metric run size nomogram, which, based on the sample run size, recommends the appropriate QC rules, as well as the number of control measurements that are needed to maintain Max E(Nuf) below one (1).

This study is based on the hypothesis that a QC plan integrating multistage statistical designs and risk management can be effectively applied across multiple analyzers in the same laboratory, leading to a standardized and improved analytical control. The aim of this study was to integrate this optimized QC strategy in the absence of automated QC tools in a practical and feasible way in our laboratory, thus enhancing quality assurance.

Materials and methods Materials

This study was conducted in the core laboratory of a tertiary hospital in Catalonia, Spain. This laboratory is dedicated to high-throughput automated testing and operates continuously - 24 hours a day, 365 days a year - processing both urgent and routine analyses. It is equipped with a track system that integrates the preanalytical, analytical, and postanalytical phases, and employs spectrophotometric and immunoassay platforms. Most tests (more than 75%) are performed within the biochemistry area, accounting for approximately 1000 orders daily.

Annually, the biochemistry area of the core laboratory performs more than 3,375,528 determinations (less than 0.5% from outpatients), covering a catalogue of over 177 tests. The facility is equipped with nine clinical chemistry analyzers and staffed by 11 specialists in biochemistry.

Internal quality control data were collected over a six-month period (September 2023 to March 2024). The IQC materials used included Multichem S Plus and Multichem U (Technopath Clinical Diagnostics, Ballina, Ireland), as well as PreciControl CARD, PreciControl PCT, and PreciControl TN (Roche Diagnostics GmbH, Mannheim, Germany). The same lot of IQC materials was used throughout the study, selected based on the availability of extensive historical performance data. Calibrators and reagents also remained consistent, supported by long shelf-life supplies.

Methods

Twenty-eight biochemistry parameters in serum and seven in urine (U) were included in the study. Thirty-two parameters were measured in Alinity c systems (Abbott Laboratories, Chicago, USA). Three parameters were measured in Cobas Pro systems (Roche Diagnostics, Mannheim, Germany). Table 1 shows the distribution of the parameters based on the number of analyzers in which the measurement procedure was available.

Distribution of measurement procedures across the analyzers in the laboratory
One analyzer Two analyzers Three analyzers Four analyzers
Albumin UCalcium UGlucose UHDLPhosphorus U AmylaseCreatinine UDirect BilirubinPotassium UNT-proBNPProcalcitoninSodium UTroponin TUrea UUric Acid ASTChlorideCholesterolCKLDMagnesiumPotassiumSodiumTriglyceride AlbuminAPALTCalciumCreatinineGGTGlucoseCRPTotal BilirubinTotal ProteinUrea
HDL - high density lipoprotein. AP - alkaline phosphatase. ALT - alanine aminotransferase. AST - aspartate aminotransferase. CK - creatine kinase. LD - lactate dehydrogenase. GGT - gamma-glutamyl transferase. CRP - C-reactive protein. NT-proBNP - N-terminal pro brain natriuretic peptide. U - urine.

To select an appropriate strategy, the first step was to evaluate the analytical performance of the measurement procedures using sigma metric. Thus, for each parameter imprecision and analytical bias were calculated for each concentration of the quality control levels and for each analyzer. Imprecision was expressed as coefficient variation (CV). Analytical bias, expressed as systematic error (SE), was determined as SE (%) = ((Mean value - Target value) / Target value) x100. Allowable total error (TEa) was obtained from the updated quality specifications and was adjusted according to the analytical performance of each measurement procedure (10-12). The most demanding TEa that ensured good analytical performance (sigma ≥ 4) was selected (13, 14). Whenever specifications based on biological variation were unavailable, state-of-the-art specifications were adopted (15). Allowable total error and the source of the analytical performance specifications selected are detailed in Supplementary Tables 1 and 2. For each quality control level on each analyzer, the sigma value was calculated using the following equation: Sigma (σ) = (TEa - SE) / CV (1). Next, the mean sigma value for each analyzer was estimated, provided that no measurement procedure had a sigma value below 4 on any analyzer. As an exception, it was accepted that at low concentrations the sigma value could be between 3 and 4, since analytical performance is usually poorer in these concentration ranges and, for the parameters of the study, there are not concentration-dependent quality specifications that allow obtaining a more reliable sigma.

Once the analytical performance of each parameter was calculated, the workload requirements were considered to establish the appropriate run size for each measurement procedure. First, we established five categories considering different daily workloads and their corresponding sample run size, understood as the number of patient samples between two QC events, according to the model proposed by Westgard et al. (1). To simplify the quality control strategy, the sample run size was defined as a quarter of the daily workload, ensuring manageable monitoring. Based on the workload data, each parameter was assigned to one of the following run size categories (maximum of samples is in the brackets): A (100), B (75), C (50), D (25), and E (12). Thereafter, for each parameter a multistage QC plan was designed on the basis of the “sigma metric statistical QC run size nomogram” proposed by Westgard et al. (1).

The “startup” stage was designed considering a number of patient samples greater than or equal to the daily workload. Additionally, the selected QC rule should have had a probability of error detection (Ped) ≥ 0.9 to ensure the detection of the majority of analytical errors.

The “monitor” stage was designed considering a number of patient samples greater than or equal to the sample run size. In this case, the QC rule selected should have had a probability of false rejection (Pfr) ≤ 0.05, to ensure that quality remained acceptable by regularly reporting results.

When multiple designs were available for a parameter, priority was given to the simplest rule, even if it resulted in an increase in the number of control measurements, as long as this increase was manageable.

Results

The mean sigma values obtained for each parameter in each of the analyzers are shown in Tables 2 and 3, respectively. All Alinity systems showed 6-10 parameters with sigma values ≥ 6, 5-9 parameters with sigma between 5 and 6, 1-5 parameters with sigma between 4 and 5 and up to 3 parameters with sigma < 4. Both Cobas Pro systems showed 1-2 tests reaching sigma values ≥ 6 and 1-2 parameters with sigma between 4 and 5. Based on these performance metrics and the workload category requirements, tailored QC plans combining “startup” and “monitor” QC rules were developed, as shown in Table 4, along with an explanation of the selected QC rules. Figure 1 illustrates how these QC plans were selected, using as an example of Category C parameter with a sigma value of 5. It outlines the development of appropriate QC rules for both the “startup” and “monitor” phases using the Westgard nomogram, and their validation through power function graphs to ensure compliance with predefined Ped and Pfr thresholds. Tables 5 and 6 illustrate the QC plan obtained for each parameter and analyzer, along with their appropriate workload management.

Mean sigma values for the parameters measured on Alinity c systems
Parameter σ, mean
Alinity c1 Alinity c2 Alinity c3 Alinity c4
Albumin ≥ 6 ≥ 6 5.74 ≥ 6
AP ≥ 6 5.26 ≥ 6 5.66
ALT ≥ 6 ≥ 6 ≥ 6 ≥ 6
Amylase na 5.39 5.90 na
AST ≥ 6 na 4.38 5.52
Calcium ≥ 6 5.82 5.14 5.82
Cholesterol na 5.24 4.92 5.65
Chloride 4.14 3.31 4.63 na
CK na ≥ 6 ≥ 6 ≥ 6
Creatinine ≥ 6 5.00 5.42 5.45
Direct Bilirubin 5.15 na 5.03 na
GGT ≥ 6 4.19 ≥ 6 ≥ 6
Glucose 5.20 ≥ 6 ≥ 6 ≥ 6
HDL na na na 4.43
LD 3.69 na 3.93 5.58
Magnesium 3.39 na 4.36 4.68
CRP 5.00 5.83 5.27 5.86
Potassium 5.94 5.91 ≥ 6 na
Sodium 3.16 3.66 3.48 na
Total Bilirubin ≥ 6 ≥ 6 ≥ 6 ≥ 6
Total Protein 5.89 4.05 3.74 5.39
Triglyceride ≥6 na 5.59 4.51
Urea ≥ 6 ≥ 6 5.11 5.94
Uric Acid na 5.18 4.47 na
Albumin U na ≥ 6 na na
Calcium U na ≥ 6 na na
Creatinine U ≥ 6 ≥ 6 na na
Glucose U na ≥ 6 na na
Phosphorus U na 5.23 na na
Potassium U ≥ 6 ≥ 6 na na
Sodium U ≥ 6 5.55 na na
Urea U 5.68 5.63 na na
σ - sigma. AP - alkaline phosphatase. ALT - alanine aminotransferase. AST - aspartate aminotransferase. CK - creatine kinase. HDL - high density lipoprotein. LD - lactate dehydrogenase. GGT - gamma-glutamyl transferase. CRP - C-reactive protein. U - urine. na - parameter not available.
Mean sigma values for the parameters measured in Cobas Pro systems
Parameter σ, mean
Cobas 1 Cobas 2
NT-proBNP 4.97 4.21
Procalcitonin ≥ 6 4.91
Troponin T ≥ 6 ≥ 6
σ - sigma. NT-proBNP - N-terminal pro brain natriuretic peptide.
Quality control plans developed according to the “sigma metric statistical QC run size nomogram”
QC plan “Startup” QC rule “Monitor” QC rule
1 12.5s N1 13s N1
2 13s N2 13s N1
3 12s N1 13s N1
4 MR N4 13s N2
5 13s N4 12.5s N1
6 MR N4 13s N4
7 13s N4 13s N1
QC - quality control. N - number of quality control measurements. MR N4 represents a 13s/22s/R4s/41s multirule with 4 control measurements per QC event. 12.5s N1 is a 12.5s single rule with 1 control per QC event. 13s N2 is a 13s single rule with 2 control measurements per QC event. 12s N1 is a 12s single rule with 1 control per QC event; 13s N4 is a 13s single-rule procedure with 4 control measurements per QC event. 13s N1 is a 13s single rule with 1 control measurement per QC event.

Application of Westgard nomogram: example for a category C parameter with 5-Sigma level. A and B illustrate the “startup” phase: (A) Intersection of workload (200 samples, Category C) and sigma determines the QC rule. (B) The power function graph confirms that this rule, at a sigma level of 5, achieves Ped ≥ 90%. C and D illustrate the “monitor” phase: (C) Intersection of sample run size (50 samples, Category C) and sigma determines the QC rule. (D) The power function graph confirms that this rule, at a sigma level of 5, achieves Pfr ≤ 5%. Adapted with permission from (1). Ped - probability of error detection. Pfr - probability of false rejection. QC - quality control. SE - systematic error. σ - sigma.

Quality control plans for the parameters measured in Alinity c systems
Parameter Alinity c1 Alinity c2 Alinity c3 Alinity c4
QCP Category QCP Category QCP Category QCP Category
Albumin 1 B 1 C 1 C 1 D
AP 1 B 1 C 1 C 1 D
ALT 1 B 1 B 1 C 1 D
Amylase na na 1 D 1 E na na
AST 1 C na na 4 C 1 D
Calcium 1 B 1 C 3 C 1 D
Cholesterol na na 1 C 3 E 1 D
Chloride 4 E - E 7 E na na
CK na na 1 D 1 E 1 E
Creatinine 1 A 5 B 1 C 1 C
D Bil 2 E na na 3 E na na
GGT 1 B 6 C 1 C 1 D
Glucose 1 B 1 B 1 C 1 D
HDL na na na na na na 4 D
LD - C na na - E 1 E
Magnesium - C na na 4 E 7 E
CRP 3 C 1 C 2 C 1 D
Potassium 1 B 1 B 1 A na na
Sodium - B - B - A na na
T Bil 1 B 1 C 1 C 1 D
Total Protein 1 C 6 C - C 2 D
Triglyceride 1 C na na 1 E 4 D
Urea 1 A 1 A 3 C 1 C
Uric Acid na na 2 E 7 E na na
Albumin U na na 1 D na na na na
Calcium U na na 1 E na na na na
Creatinine U 1 E 1 E na na na na
Glucose U na na 1 E na na na na
Phos U na na 1 E na na na na
Potassium U 1 E 1 E na na na na
Sodium U 1 E 1 E na na na na
Urea U 1 E 1 E na na na na
AP - alkaline phosphatase. ALT - alanine aminotransferase. AST - aspartate aminotransferase. CK - creatine kinase. D Bil - direct bilirubin. HDL - high density lipoprotein. LD - lactate dehydrogenase. GGT - gamma-glutamyl transferase. CRP - C reactive protein. Phos – phosphorus. QCP - quality control plan. T Bil - total bilirubin. U - urine. na - not available. “-“ - sigma < 4.
Quality control plans for the parameters measured in Cobas Pro systems
Parameter Cobas 1 Cobas 2
QCP Category QCP Category
NT-proBNP 3 D 4 D
Procalcitonin 1 E 3 E
Troponin T 1 D 1 D
QCP - quality control plan. NT-proBNP - N-terminal pro brain natriuretic peptide.

To demonstrate the feasibility of implementing QC plans integrating multistage designs and risk-based criteria across multiple analyzers, several practical adjustments were necessary in our setting due to the absence of automated tools. In the “startup” phase, although the 13s N1 rule could have been applied to parameters with sigma values ≥ 6 and daily workloads below 350, a unified approach was preferred (16). Therefore, the 12.5s N1 rule was selected for all such parameters, balancing simplicity and performance. During the “monitor” phase, the selection of QC rules was primarily based on the sample run size, followed by evaluation of the Pfr. The 12s N1 rule was excluded from this stage, given its relatively high Pfr (about 0.05), which may compromise routine efficiency. In both phases, when multiple rule options were available, the simplest rule achieving Ped ≥ 0.9 was consistently prioritized. These decisions, summarized in Table 7, illustrate how harmonized, analyzer-spanning QC strategies can be constructed in a practical and scalable manner while maintaining analytical rigor. To further simplify implementation across the six analyzers, and in line with the proposed harmonized QC strategy, the QC plan covering the greatest number of parameters per analyzer was selected. This resulted in the adoption of only two QC plans (QCP 2 and 3) out of the seven initially defined. As shown in Table 8, only ten parameters with lower sigma values required individualized QC plans due to their need for stricter QC rules. These ten parameters were effectively covered by four individual QCPs.

Framework for selecting a quality control plan based on the sigma level of measurement procedures
Sigma level “Startup” stage “Monitor” stage
≥ 6 12.5s N1 QC rules could be selected based on the desired run size*
5-6 QC rules could be selected based on the desired run size* QC rules could be selected based on the desired run size*
4-5 MR N4 QC rules could be selected based on the desired run size*
< 4 na† na†
*QC rule could be selected based on the “sigma metric statistical QC run size nomogram” proposed by Westgard et al (1). †No QC strategy is available, as no “startup” QC rule achieves a Ped ≥ 0.9. Improvement of the analytical performance is needed. QC - quality control. N - number of quality control measurements per QC event.
Quality control plan implemented by analyzer and individualized quality control plans for specific parameters
Analyzer QCP Individualized QCP, parameter
Alinity1 c1 3 4, chloride
Alinity1 c2 2 5, creatinine; 6, GGT and total protein
Alinity2 c3 3 4, AST and magnesium; 7, chloride and uric acid
Alinity3 c4 2 7, magnesium; 4, triglyceride and HDL
Cobas Pro1 3 -
Cobas Pro2 3 4, NT-proBNP
AST - aspartate aminotransferase. HDL - high density lipoprotein. NT-proBNP - N-terminal pro brain natriuretic peptide. QCP - quality control plan.
Discussion

Multistage bracketed statistical QC strategies, which integrate analytical performance metrics and workload requirements, offer a promising approach to optimize patient safety in clinical laboratories. This strategy allowed us to tailor QC plans, to achieve a balance between quality assurance and operational efficiency.

Several general concepts helped us implement the new QC strategies. First, to control a measurement procedure with a sigma value ≥ 6, simple QC rules with Ped ≥ 0.9 could be employed, resulting in Max E(Nuf) values from 0.3-0.4, which means that 250-333 patient samples could be analyzed between two QC events, ensuring that no more than one erroneous result would be reported (16). Second, for measurement procedures with sigma values between 5 and 6, QC rules can be selected based on the desired run size, while maintaining an acceptable Max E(Nuf). For measurement procedures with sigma values between 4 and 5, achieving an acceptable Max E(Nuf) requires applying more complex QC rules, such as multiple control rules 13s/22s/R4s/41s (MR N4), in the “startup” stage to reach an appropriate Ped, regardless of the desired run size. Finally, for sigma values below 4, no “startup” QC rule achieves a Ped ≥ 0.9, indicating poor performance and the need for improvements to ensure the quality of these measurement procedures to achieve a Max E(Nuf) <1 (1, 17). These principles formed the basis for the selection and standardization of QC plans across the analyzers.

Some of the advantages of such a QC strategy are related to its scalability and long-term efficiency. While the initial implementation effort increases with the number of analytes and analytical platforms, once established, the addition of new parameters or analyzers requires considerably less effort. This is because key components of the strategy, such as the QC plan categories derived from a risk-based classification model, along with the QC rule selection criteria, are already standardized and can be systematically applied across different systems (1). Moreover, free QC calculators available on the Westgard website offer a user-friendly tool to facilitate the application of risk-based QC rule selection and performance evaluation (18). Although these calculators were not used in our study, they may help other laboratories in integrating risk-based QC strategies. Additionally, by allocating more demanding QC plans only to parameters with lower sigma values, the strategy ensures optimal use of resources without compromising analytical quality (1, 19).

Despite these advantages, several limitations must be acknowledged. The lack of automated tools constituted the major limitation for the implementation of this QC strategy in our laboratory. Automated measurement of on-board controls based on the category assigned at each parameter and analyzer, along with the management of rules for accepting or rejecting control results, would enable us an individualized management of each parameter (20). Performing these functions manually requires specialized laboratory personnel and entails considerable effort. In our setting, we addressed this in Alinity systems by configuring the middleware AlinIQ AMS (Abbott Laboratories, Chicago, USA) to withhold sample results once the predefined number of measurements per category was performed for each parameter and analyzer. These rules enabled us to lock the corresponding test until the required QC plan was completed, ensuring compliance with established QC plan. Furthermore, as our hospital does not provide primary care services, sample flow remains generally consistent, with predictable peak times throughout the day, facilitating the timely execution of QC procedures. For the Cobas Pro systems, where no middleware is available, this procedure was performed manually by laboratory staff according to the same predefined rules.

While the lack of automation was a primary constraint, additional factors may impact the broader applicability of our findings. Although the sigma metric remains a useful tool for QC design, its reliability depends on the veracity of imprecision and bias estimates, that changes constantly, as well as, on the appropriate selection of the TEa. These variables can significantly affect sigma values and, consequently, influence the selection of QC plan (19, 21).

Other authors have demonstrated the practical applicability of a multistage bracketed statistical QC model in their laboratories. Nevertheless, these studies were predominantly focused on the optimization of the QC plan for an isolated parameter or for a set of parameters within a single analyzer (22, 23). To date, no study has been published showing the implementation of this QC strategy across multiple parameters and the several analytical systems of a highly automated laboratory.

Future work should focus on the development or adaptation of middleware tools that support dynamic QC plan assignment based on real-time performance metrics. Moreover, integrating economic evaluations, such as cost-effectiveness or cost-benefit analyses, into the model could strengthen its practical value and support decision-making in resource-limited settings. Finally, the implementation of this approach in similar laboratories with diverse analytical platforms and operational context would provide valuable information to confirm the model’s applicability and guide further refinement.

This pragmatic approach demonstrates the feasibility of implementing a refined QC strategy in a highly automated laboratory for all parameters with a sigma level ≥ 4. It offers a practical framework for optimizing laboratory performance by ensuring consistent quality assurance and enabling focused allocation of resources to parameters with higher analytical risk. Further validation across diverse laboratory settings will help confirm its broader applicability and inform future enhancements.

Potential conflict of interest

None declared.

Data availability statement

The datasets generated during the current study are available from the corresponding author on reasonable request.

References WestgardJOBayatHWestgardSA. Planning risk-based SQC schedules for bracketed operation of continuous production analyzers. Clin Chem. 2018;64:289–96. 10.1373/clinchem.2017.27829129097516 RicósCFernandez-CallePPerichCWestgardJ. Internal quality control – past, present and future trends. Advances in Laboratory Medicine/Avances en Medicina de Laboratorio. 2022;3:243–62. 10.1515/almed-2022-002937362142 Armbruster D, Westgard JO, Westgard SA, editors. Risk, error and uncertainty: laboratory quality management in the age of metrology. Philadelphia: Elsevier; 2017. 10.1016/S0272-2712(16)30120-2 RosenbaumMWFloodJGMelansonSEFBaumannNAMarzinkeMARaiAJ Quality control practices for chemistry and immunochemistry in a cohort of 21 large academic medical centers. Am J Clin Pathol. 2018;150:96–104. 10.1093/ajcp/aqy03329850771 FeldhammerMBrownMColbyJBryksinJMilstidBNicholsJH. A survey of sigma metrics across three academic medical centers. J Appl Lab Med. 2021;6:1264–75. 10.1093/jalm/jfab02834060592 International Organization for Standardization (ISO). Medical laboratories – Particular requirements for quality and competence. EN ISO 15189:2022. Geneva: ISO; 2022. Clinical and Laboratory Standards Institute (CLSI). Statistical quality control for quantitative measurement procedures: principles and definitions. 4th ed. CLSI document C24-Ed4. Wayne: CLSI; 2016. ParvinCA. Assessing the impact of the frequency of quality control testing on the quality of reported patient results. Clin Chem. 2008;54:2049–54. 10.1373/clinchem.2008.11363918927244 Yundt-PachecoJParvinCA. Validating the performance of QC procedures. Clin Lab Med. 2013;33:75–88. 10.1016/j.cll.2012.11.00623331730 Aarsand AK, Fernandez-Calle P, Webster C, Coskun A, Gonzales-Lao E, Diaz-Garzon J, et al. The EFLM biological variation database. Available from: https://biologicalvariation.eu/. Accessed March 3th 2024. Minchinela J, Ricós C, Perich C, Fernández-Calle P, Alvarez V, Domenech M, et al. Biological variation database and quality specifications for imprecision, bias and total error (desirable and minimum). The 2014 update. Available from: https://www.westgard.com/biodatabase-2014-update.htm. Accessed May 5th 2024. Prada de MedioEMolina BorrásAAlcaraz QuilesJBatista CastellvíJRamón BauzáFSalas GarcíaA Especificaciones mínimas de consenso de calidad analítica en España. Comparación con valores previos, preceptivos y de variabilidad biológica. Rev Med Lab. 2020;1:93–107. [in Spanish] BayatHWestgardSAWestgardJO. Planning risk-based statistical quality control strategies: graphical tools to support the new Clinical and Laboratory Standards Institute C24-Ed4 guidance. J Appl Lab Med. 2017;2:211–21. 10.1373/jalm.2017.02319232630969 Westgard JO, Armbruster D, Westgard S. Risk, Error and Uncertainty: Laboratory Quality Management in the Age of Metrology. Clinics in Laboratory Medicine, Vol. 37. New York: Elsevier, 2017. 10.1016/S0272-2712(16)30120-2 SandbergSFraserCGHorvathARJansenRJonesGOosterhuisW Defining analytical performance specifications: consensus statement from the 1st strategic conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med. 2015;53:833–5. 10.1515/cclm-2015-006725719329 YagoMAlcoverS. Selecting statistical procedures for quality control planning based on risk management. Clin Chem. 2016;62:959–65. 10.1373/clinchem.2015.25409427197677 WestgardJOBayatHWestgardSA. Planning SQC strategies and adapting QC frequency for patient risk. Clin Chim Acta. 2021;523:1–5. 10.1016/j.cca.2021.08.02834464612 Westgard. JO, Schilling. P. Westgard QC Calculator. Available from: https://tools.westgard.com/qccalculator.html. Accessed May 5th 2024. WestgardSBayatHWestgardJO. Analytical Sigma metrics: A review of Six Sigma implementation tools for medical laboratories. Biochem Med (Zagreb). 2018;28:020502. 10.11613/BM.2018.02050230022879 LippiGDa RinG. Advantages and limitations of total laboratory automation: a personal overview. Clin Chem Lab Med. 2019;57:802–11. 10.1515/cclm-2018-132330710480 HensKBerthMArmbrusterDWestgardS. Sigma metrics used to assess analytical quality of clinical chemistry assays: importance of the allowable total error (TEa) target. Clin Chem Lab Med. 2014;52:973–80. 10.1515/cclm-2013-109024615486 IlardoC. Application of SQC model to optimize an internal quality control schedule for Haemoglobin A1c measurement on the Capillarys analyzer. Int J Med Biochem. 2022;5:107–12. 10.14744/ijmb.2022.63496 ZengYHeHQinKZhangMAnZHuangH. Practical application of the sigma-metric run size nomogram for multistage bracketed statistical quality control analysis of eight enzymes. Clin Chim Acta. 2019;492:57–61. 10.1016/j.cca.2019.02.00630738955
" ["journals_volume"]=> string(2) "35" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030704" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-35-3-030704" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2025.030704" ["journals_article_pubdate"]=> string(10) "2025-10-15" ["journals_article_title"]=> string(153) "Refining quality control strategies in highly automated laboratories: experience in the integration of multistage statistical designs and risk management" ["journals_article_author"]=> string(161) "María Costa-Pallaruelo, Álvaro García-Osuna, Marina Canyelles, Cecília Martínez-Bru, Nicoleta Nan, Rosa Ferrer-Perez, Francisco Blanco-Vaca, Leonor Guiñón" ["journals_article_author_country"]=> string(5) "Spain" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(84) "laboratory automation, Max E(Nuf) QC model, multistage QC, risk management, run size" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "3223" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(2) "10" ["meta_title"]=> string(153) "Refining quality control strategies in highly automated laboratories: experience in the integration of multistage statistical designs and risk management" ["meta_desc"]=> string(153) "Refining quality control strategies in highly automated laboratories: experience in the integration of multistage statistical designs and risk management" ["meta_keyw"]=> string(84) "laboratory automation, Max E(Nuf) QC model, multistage QC, risk management, run size" ["created"]=> string(19) "2025-10-14 08:51:21" ["modified"]=> string(19) "2025-10-15 10:18:19" } [57]=> object(stdClass)#106 (35) { ["journals_id"]=> string(4) "1196" ["journals_xml"]=> string(78810) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-35-3-030703 10.11613/BM.2025.030703 Original articles Serum hepcidin concentration is lower in advanced stages of sporadic colorectal cancer RolićTara12MandićSanja*13YazdaniMazyar4Ferenac KišMarina15DistanteSonia4BanjariInes6 Faculty of Medicine, University of Osijek, Osijek, Croatia Institute of Clinical Laboratory Diagnostics, Osijek University Hospital Centre, Osijek, Croatia Medical-biochemistry laboratory, Policlinic LabPlus, Osijek, Croatia Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Clinical Institute for Transfusion Medicine, Osijek University Hospital Centre, Osijek, Croatia Faculty of Food Technology Osijek, University of Osijek, Osijek, Croatia Corresponding author: mandic.sanja@gmail.com, Submitted: March 20, 2025 Accepted: August 8, 2025

Author contributions

Conceptualization - TR, SM, IB. Writing original draft - TR, SM, MY, SD, IB. Writing and editing - TR, MY, SD, SM, IB, MFK.

15102025 15102025 35 3 030703 Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• CRC patients show lower hepcidin concentration than controls

• Hepcidin is moderately linked to ferritin, reflecting iron dysregulation in colorectal cancer

• Colorectal cancer patients have lower ferritin than controls

• Hepcidin is lower in advanced tumor stage (T3 vs. T0)

• C-reactive protein and interleukin-6 correlate weakly with hepcidin, suggesting other tumor effects

Introduction

Hepcidin (Hep), a key regulatory hormone of iron (Fe) homeostasis, governs its absorption and storage, and is influenced by inflammation and Fe status. This study investigated serum Hep concentrations and their associations with Fe markers and inflammation in patients with sporadic colorectal cancer (CRC).

Materials and methods

We compared serum concentrations of Hep, Fe, unsaturated and total iron binding capacity, transferrin, transferrin saturation, ferritin, C-reactive protein (CRP), interleukin-6 (IL-6) and tumor markers in 82 CRC patients and 58 controls. Statistically significant differences were tested using the Mann-Whitney U test and Student’s t test. Additionally, Hep were analyzed according to tumor stage. Colorectal cancer was confirmed histopathologically after colonoscopy with biopsy (TNM staging).

Results

Colorectal cancer patients exhibited significantly lower Hep concentrations than controls (8.1 vs. 19.7 ng/mL, P = 0.020). Ferritin was also lower in CRC (109 vs. 250 µg/L, P = 0.002). Hepcidin showed the strongest positive correlation with ferritin in CRC. Inflammatory markers (CRP and IL-6) correlated moderately to weakly with hepcidin in both groups (controls: rho = 0.52 (P < 0.001); CRC: rho = 0.26 (P = 0.022) for CRP and CRC: rho = 0.30 (P = 0.033) for IL-6). Notably, Hep concentrations were lower in patients with advanced tumor stage (T0 vs. T3, P = 0.043).

Conclusion

These findings suggest that CRC is associated with lower hepcidin and ferritin concentrations, potentially reflecting complex and cancer-specific dysregulation in Fe metabolism beyond inflammation alone.

Keywords: anemiacolorectal cancerhepcidinhomeostasisiron
Introduction

Iron metabolism plays a crucial role in health and disease, requiring tight regulation to avoid iron deficiency or overload. Excess iron promotes oxidative stress, while deficiency impairs cellular function (1). Hepcidin (Hep), a liver-derived peptide hormone, is the master regulator of systemic iron homeostasis (2). It inhibits iron export by binding to ferroportin, the only known iron exporter, leading to its degradation and lower serum iron concentrations (2, 3). Hepcidin expression is influenced by iron stores, erythropoietic demand, and inflammation (4). It is often elevated in chronic inflammation and certain cancers, contributing to anemia of inflammation (5). Anemia of chronic disease (or anemia of inflammation) is increasingly prevalent in chronic conditions where reduced iron recycling from macrophages is observed (6). Inflammatory response and the release of inflammation-induced cytokines, such as interleukin-6 (IL-6), triggers Hep synthesis. Hepcidin, upregulated by IL-6, binds to ferroportin and limits iron availability in the plasma, leading to hypoferremia and anemia of chronic disease or anemia of inflammation (7). However, different measuring methods, whether mass spectrometry or immunochemical principles, have produced varying results and challenges in methodological standardization, complicating clinical interpretation (8).

In colorectal cancer (CRC), disturbances in iron metabolism are common and often manifest as anemia of inflammation or iron-deficiency anemia (9). Previous studies have shown conflicting results regarding Hep concentrations in CRC, presenting a more complex scenario, where iron loss by bleeding, inflammation, and tumor-associated iron demand coexist. Evidence suggests both, upregulation due to inflammation and downregulation related to tumor-specific iron demands. While altered iron biomarkers and anemia are common in CRC, the role of Hep remains unclear, with conflicting reports on its expression and clinical relevance (9, 10). Overall, a better understanding of iron metabolism in cancer cells may also aid in the understanding of chemotherapy resistance (11).

Colorectal cancer is a major global health burden, and understanding its metabolic profile may aid early detection and treatment stratification (12, 13). Mechanistically, unabsorbed dietary iron that remains in the gastrointestinal tract may have potentially carcinogenic effect (14). Despite its central role in iron regulation, Hep has not been extensively studied as a potential biomarker in sporadic, non-metastatic CRC.

The aim of this study was to investigate whether Hep serum concentrations are altered in a prospective cohort of CRC patients. We explored Hep correlation with iron metabolism, inflammation (C-reactive protein, CRP), tumor markers (carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA), tumor stage and anemia-related indices to better understand its role in CRC-related iron dysregulation and examined its potential as a biomarker of CRC. We hypothesized that Hep is dysregulated in CRC and reflects disease stage and systemic iron imbalance.

Materials and methods Materials

A prospective cohort study was conducted in non-metastatic CRC patients and in a control group. Study participants were referred to the University Hospital Centre Osijek between August 2020 and August 2023. Blood sampling and completion of a food frequency questionnaire (FFQ) were performed after participants provided written informed consent, in accordance with ethical guidelines. Patients were recruited at the Department of Radiotherapy and Oncology, University Hospital Centre Osijek, following colonoscopy (the reference method for diagnosing CRC) and biopsy with histopathological confirmation of CRC. Tumor staging was classified as stage T0-T3 (N0-N3, M0) according to the tumor node metastasis (TNM) classification system of the American Joint Committee on Cancer: T0 – no histopathological evidence of a primary tumor (no tumor cells were detected in the sample), T1 – tumor invades the submucosa, T2 - tumor invades the muscularis propria, T3 - tumor invades through the muscularis propria into the pericolorectal tissues, Tx – primary tumor cannot be assessed due to insufficient information (eg., poorly preserved tissue, incomplete biopsy, technical issues, or missing clinical/radiological data). Patients underwent colonoscopy due to clinical symptoms and/or positive guaiac fecal occult blood test (HemoGnost, BioGnost, Zagreb, Croatia) manually preformed at referring institutions or as part of the Croatian National CRC screening program.

Inclusion criteria for the CRC group included: confirmed diagnosis of sporadic colorectal cancer, male and female participants, aged between 40 and 80 years with a body mass index (BMI) of less than 35 kg/m2 and following a diet that included both animal- and plant-based foods. Patients with BMI > 35 kg/m2 were not excluded, as only one in the CRC group and two in the control group met this criterion. A structured FFQ was used to obtain information on diet type and supplement intake. These criteria ensured that the study population was both representative and homogenous, focusing on early-stage colorectal cancer patients with specific demographic and lifestyle characteristics. Exclusion criteria for the CRC group included the diagnosis of hereditary colorectal cancer (such as Lynch syndrome), colorectal cancer classified as an advanced stage (T4), additional cancer diagnoses, acromegaly, ulcerative colitis, Crohn’s disease, irritable bowel syndrome, parasitic or other infectious diseases, diverticulosis, or cystic fibrosis, transplant recipients, patients undergoing immunosuppressive therapy, or had type 1 or type 2 diabetes, active Helicobacter pylori infection, ongoing therapy with antacids, and the chronic use of non-steroid anti-inflammatory drugs (NSAIDs), participants receiving iron supplementation therapy or regularly used dietary supplements containing iron, vitamin B12, folic acid, vitamin D, or calcium, had a clinically significant weight loss (> 5% of body mass in the last 6 to 12 months), and a diet that excluded meat consumption. The control group inclusion criteria were male and female participants aged between 40 and 80 years, with a BMI less than 35 kg/m2 and adhering to a diet consisting of both animal- and plant-based foods. Exclusion criteria for the control group matched those of the colorectal cancer group. The control group was recruited during routine blood testing at the Institute of Clinical Laboratory Diagnostics, Osijek University Hospital Centre, meeting the inclusion and exclusion criteria.

This research was approved by the Ethical Committee of the University Hospital Centre Osijek, No. R2-8262/2020. and was conducted in accordance with the Declaration of Helsinki.

Methods

All laboratory analyses were measured at the Institute of Clinical Laboratory Diagnostics, University Hospital Centre Osijek. Venipuncture was performed in the morning between 7:00 and 9:00 AM, while patients were fasting, in accordance with international recommendations (15). Blood was collected in K2EDTA coagulant tubes and anticoagulant-free tubes (Becton, Dickinson and Company, USA) which were centrifuged at 2000xg for 10 minutes. Afterwards, hemoglobin was measured from full blood sample, and serum samples were used for the determination of iron metabolism parameters including iron, unsaturated iron binding capacity (UIBC), transferrin, ferritin, CRP, CEA and CA19-9. Total iron binding capacity (TIBC) and transferrin saturation were calculated using the following formulas: TIBC = iron + UIBC; transferrin saturation (%Trf = iron / (TIBC x 100)). A Beckman Coulter AU680 analyzer (Beckman Coulter, Inc., Brea, USA) was used to measure iron and UIBC spectrophotometrically, while Trf, ferritin, and CRP were measured by immunoturbidimetry. Hepcidin concentrations were measured by enzyme-linked immunoassay (ELISA) using the HybridXL DRG analyzer (DRG Instruments GmbH, Marburg, Germany). The fully automated immunoassay has intra- (CVi) and interindividual (CVg) coefficients of variations provided by manufacturer of CVi = 2.55% and CVg = 13.68%, which were verified by our laboratory; linearity 1.67-81.00 ng/mL, limit of detection 1.67 ng/mL and limit of quantification 2.62 ng/mL with proposed reference ranges by manufacturer for males 1.67-49.75 ng/mL and females 1.67-56.70 ng/mL (16). Internal quality control at two levels provided by the manufacturer was used before the measurement of the samples and external quality control was not available. The immunoassay method on Roche Cobas e801 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) was used to measure CEA, CA19-9 and IL-6. Hemoglobin concentrations were measured using Sysmex XN-2000 automatic analyzer (Sysmex Corporation, Kobe, Japan). While routine biomarkers were analyzed immediately upon sampling, aliquots for Hep determination were stored at - 20 ºC and analyzed after 6 months. According to the manufacturer, hepcidin remains stable under this storage conditions.

Statistical analysis

Statistical analysis of data was performed using the MedCalc statistical program (MedCalc for Windows, version 12.4.0.0.; MedCalcSoftware, Mariakerke, Belgium). The D’Agostino-Pearson test was conducted to assess normality of data distribution. Results are presented as absolute counts for sex (male vs. female), age (range), and TNM stage for the colorectal cancer group; as median values and interquartile ranges (25th-75th percentile) for parameters following non-normal distribution (Fe, TIBC_CRC, ferritin, %Trf, CRP, CEA, CA19-9); and as means and standard deviations for parameters following a normal distribution (UIBC, transferrin, TIBC_CONTROL). Spearman’s rank correlation coefficient (rho) was used for non-normally distributed variables, and Pearson’s correlation coefficient (r) was used to for normally distributed variables. The Mann-Whitney U test and t-test was used for the comparison of Hep, CRP, iron, UIBC, TIBC, ferritin, transferrin and %Trf values in the CRC group versus the control group. The Kruskal-Wallis test was used to differentiate Hep concentrations in the CRC group across TNM stages. P-values less than 0.05 (P < 0.05) were considered statistically significant.

Results

A total of 82 patients with sporadic, non-metastatic colorectal cancer were included in the study, comprising 22 females and 60 males. The median age of the participants was 65 years, ranging from 46 to 79 years. According to TNM staging, stage T3 was predominant (38/82), followed by an unknown stage (Tx) in 18/82 and less frequent cases of stage T2 (14/82). A total of 58 participants were included as the control group, consisting of 5 females and 53 males, with a median age of 58 years (range: 55-61).

The CRC group was significantly older (P < 0.001) and had a higher proportion of females (P = 0.013) compared to the control group.

Iron metabolism parameters are summarized in Table 1. Significant differences in Hep, ferritin, UIBC, TIBC, transferrin and hemoglobin concentrations between the CRC and control groups were found.

Laboratory results of iron metabolism parameters including hepcidin, inflammation and tumor markers
Analyte (unit) Control groupN = 58 CRCN = 82 P
Hepcidin (ng/mL) 19.7 (12.1-26.8) 8.1 (5.5-14.0) 0.020
CRP (mg/L) 5.3 (2.2-33.2) 3.0 (2.3-4.8) 0.106
Iron (µmol/L) 13.8 (10.8-15.8) 13.6 (10.6-15.8) 0.443
UIBC (µmol/L) 38.3 (± 15) 49.1 (± 16) < 0.001
TIBC (µmol/L) 51.4 (± 15) 63.8 (59.4-66.2) < 0.001
Ferritin (µg/L) 250 (130-485) 109 (78-140) 0.002
Transferrin (g/L) 2.3 (± 0.8) 2.9 (± 0.7) < 0.001
Transferrin saturation (%) 24 (20-27) 21 (18-26) 0.334
CEA (µg/L) N/A 2.9 (2.6-5.3) N/A
CA19-9 (kIU/L) N/A 11.4 (8.3-18.3) N/A
IL-6 (ng/L) N/A 9.1 (5.8-15.6) N/A
Hemoglobin (g/L) 137 (118-153) 126 (114-138) 0.022
Results are presented as median (25th-75th percentile) and as mean and standard deviation. Data were compared using the Mann-Whitney U test for non-normally distributed data and student t-test for normally distributed data. CRC - colorectal cancer group. CA19-9 - carbohydrate antigen 19-9. CEA - carcinoembryonic antigen. CRP - C-reactive protein. IL-6 - interleukin-6. N/A - not applicable. TIBC - total iron binding capacity. UIBC - unsaturated iron binding capacity. P < 0.05 was considered statistically significant.

In the control group, the strongest positive correlation was observed between Hep and ferritin (rho = 0.84 (P < 0.001)). Total iron binding capacity, transferrin and UIBC exhibited moderate negative correlation with ferritin (rho = - 0.72, - 0.72 and - 0.66 respectively, all P < 0.001). Iron showed a weak negative correlation with Hep in the control group (rho = - 0.38 (P = 0.004)). Hepcidin showed a moderate positive correlation with CRP in the control group (rho = 0.52 (P < 0.001)), while in the CRC group the correlation was weaker (rho = 0.26 (P = 0.022)). In the CRC group, Hep was moderately positively correlated with ferritin (rho = 0.62 (P < 0.001)), weakly negatively correlated with transferrin (rho = - 0.43 (P < 0.001)), TIBC ((rho = - 0.37 (P < 0.001)) and UIBC ((rho = - 0.45 (P < 0.001)), and weakly positively correlated with CRP ((rho = 0.26 (P = 0.022)). All correlation coefficients are shown in Table 2.

Correlation of hepcidin-25 with selected parameters of iron metabolism, inflammation (CRP) and tumor markers in colorectal cancer and control groups
CRCN = 82 Control groupN = 58
Hepcidin
Correlation coefficient (P) Correlation coefficient (P)
Iron 0.22 (0.045) - 0.38 (0.004)
UIBC - 0.45 (< 0.001) - 0.66 (< 0.001)
TIBC -0.37 (< 0.001) - 0.724 (< 0.001)
Ferritin 0.62 (< 0.001) 0.84 (< 0.001)
Transferrin - 0.43 (< 0.001) - 0.72 (< 0.001)
Transferrin saturation 0.37 (< 0.001) - 0.09 (0.53)
CRP 0.26 (0.022) 0.52 (< 0.001)
CEA 0.16 (0.270) N/A
CA19-9 0.10 (0.470) N/A
IL-6 0.30 (0.033) N/A
Hemoglobin 0.15 (0.180) - 0.17 (0.248)
Correlation data are presented as Spearman’s rho coefficients for non-normally distributed data and Pearson r coefficients for normally distributed data. CA19-9 - carbohydrate antigen 19-9. CRC - colorectal cancer group. CEA - carcinoembryonic antigen. CRP - C-reactive protein. IL-6 - interleukin-6. N/A - not applicable. TIBC - total iron binding capacity. UIBC - unsaturated iron binding capacity. P < 0.05 was considered statistically significant.

In the CRC group, median Hep concentrations were lower in advanced stages, with the lowest concentrations observed in stage T3 (4.00 ng/mL (2.8-9.0). A statistically significant difference in hepcidin concentration was found between stage T0 and T3 (P = 0.043). These findings are summarized in Table 3. Tumor markers (CEA and CA19-9) did not exceed the established cut-off values.

TNM staging of colorectal cancer and hepcidin serum concentrations
TNM N of subjects with CRC Hepcidin (ng/mL) P
T0 9 33.0 (13.8-42.0) 0.043*
T1 3 48.3 (33.2-120.2)
T2 14 12.8 (7.2-36.7)
T3 38 4.0 (2.8-9.0)
Tx 18 18.1 (5.4-30.4)
Hepcidin concentrations are presented as median (25th-75th percentile). CRC - colorectal cancer group. TNM - tumor node metastasis. *T0 vs. T3 (Kruskal-Wallis test, P = 0.001). P < 0.05 was considered statistically significant.
Discussion

Our findings indicate altered iron metabolism in patients with sporadic CRC and a multifactorial alteration in iron metabolism in CRC. The significantly lower serum Hep concentrations between the CRC and control group further supports this observation. Although Hep concentrations varied considerably with both groups, the control group exhibited a higher median value and a wider interquartile range (25th-75th percentile) than the CRC group.

To the best of our knowledge, this is the first study to specifically evaluate serum Hep concentrations in patients with sporadic CRC, compare them to a control group and examine Hep as an iron-related marker in relation to iron metabolism analytes, inflammation marker and tumor markers. Additionally, this is the first study to analyze Hep concentrations by tumor stage.

Iron plays a crucial role in carcinogenesis, and CRC is particularly notable in the context of intestinal iron absorption (10). Patients diagnosed with CRC often present with anemia (17). The inflammatory cytokine IL-6 triggers the production of Hep, which inhibits erythropoiesis, leading to anemia (18). Interestingly, in our study, IL-6 showed a minimal correlation with Hep. However, concentration was above the cut off (9.1 ng/L; 25th-75th percentile: 5.8-15.6) suggesting the role of inflammation in CRC. C-reactive protein showed a moderate positive correlation with Hep in the control group and a weak correlation in the CRC group. This suggests that factors beyond inflammation, such as occult blood loss, may contribute to anemia in CRC. Our study revealed significant correlations between iron metabolism parameters and Hep, supporting the multifactorial nature of altered iron metabolism in cancer. A limited number of studies have investigated the role of Hep in CRC, primarily using cell lines (11, 19). For instance, increased expression of Hep and ferritin heavy chain has been reported in CRC biopsies (11). Although comparison with cell lines studies is not possible, in some way this aligns with our findings of significantly different Hep and ferritin concentrations between CRC and control groups.

Further, the correlations between Hep and iron parameters were statistically significant, they were generally weak, but a notable trend in intergroup differences was observed. Particularly, the moderate correlation between Hep and ferritin is consistent with previous reports (20).

While ferritin has been explored as a tumor marker in several cancers, no consensus exists due to methodological variability (13, 21, 22). Some studies, such as Ramirez Cormona et al., reported lower ferritin concentrations in CRC patients, a finding supported by our results (22). Di Grazia et al. observed an association between high Hep concentrations and poor prognosis in metastatic CRC (23). Since we had a non-metastatic CRC cohort, these data are not comparable, but it is important to note that our results showed lower Hep concentrations with advancing tumor stage, particularly in T3, indicating a possible link between tumor progression and Hep suppression. Our data showed that the main difference in Hep concentrations was between the earliest (T0) and more advanced (T3) tumor stages, with T3 showing notably lower serum hepcidin concentrations. Lower Hep concentrations observed in advanced tumor stages may reflect dysregulated iron metabolism and a potential role for Hep in advancing disease.

Hepcidin is abnormally secreted by CRC cells, promoting cancer growth and survival (22). Disrupted local hepcidin-ferroportin signaling is crucial for cancer growth, as alterations in this pathway contribute to cancer cell proliferation (24). The local production of Hep by cancer cells suggests that targeting this process could serve as a potential therapeutic strategy in cancer treatment. While all cells require iron for metabolism, cancer cells exhibit a heightened demand for iron due to its essential role in synthesizing deoxyribonucleotides for DNA replication and sustaining rapid proliferation (25). The iron-dependent enzyme ribonucleotide reductase catalyzes the rate-limiting step in DNA synthesis, making intracellular iron availability essential for enhanced cellular proliferation and DNA replication. Cancer cells demonstrate an increased ability to absorb iron, reduce iron export and bypass ferroptosis (iron-depended cell death), distinguishing them from non-malignant cells (10, 26). This ability to evade ferroptosis contributes to their resistance to chemotherapy (10). Overall, higher Hep concentrations have been observed in various carcinomas, including CRC (19, 23, 27). In our study we report lower serum Hep concentrations in advanced stages of CRC. The results indicate that in the advanced stages of CRC, Hep production may be reduced. Such reduction likely allows undisturbed iron absorption, creating favorable conditions for cancer progression. A potential reason for discrepancies with previous findings may be differences in study design, particularly the use of cell lines or including metastatic CRC in other studies, whereas our cohort included patients with sporadic CRC.

Some studies have found no significant differences in Hep concentrations or iron metabolism parameters between CRC patients and controls, while others have observed slightly decreased Hep concentrations (18, 28, 29). Our findings suggest significant differences, but it is important to note that not all parameters are statistically significant. Differences in methods used to assess iron metabolism parameters are also important factors to consider when interpreting contradictory results. The analytical methods applied in our study have not been used in any previous research to our knowledge.

However, the present study has several limitations, including a relatively small sample size, particularly the low number of the female participants in the control group, lack of stratification by sex and age, especially among anemic patients, and no gender-based stratification for iron parameters. The immunoassay method used to detect Hep has limitations such as cross-reactivity between different Hep isoforms and high intra- and inter-individual variability. Additionally, the low number of female controls makes comparisons difficult. Nevertheless, hemoglobin concentration in the control group were above anemia cut off values, regardless of sex. It would be beneficial to increase the sample size to validate these findings and further explore the potential value of Hep as a biomarker for monitoring and managing colorectal cancer. Ideally, controls should include patients with positive occult blood test but no cancer. Furthermore, other conditions such as autoimmune and kidney diseases which can affect Hep expression, were not assessed in either group, which may have impacted the results. Finally, the study lacked power analysis, and the sample was underpowered within individual T-stage subgroups, especially T1 and T2. Nevertheless, the nature of a prospective cohort study, patients were selected independently of staging criteria.

In conclusion, our results suggest that Hep concentrations are lower in advanced stages of sporadic, non-metastatic CRC and could serve as a valuable biomarker reflecting tumor stage. Hepcidin shows a moderate correlation with ferritin and like ferritin, may have potential as a tumor marker in the future research. The observed pattern of lower Hep concentrations across tumor stages may also reveal a potential relationship between tumor stage and Hep regulation, which could have implications for understanding disease and identifying new therapeutic approaches. Evaluating Hep as a potential therapeutic target in CRC represents an important direction for future research.

Acknowledgments

The study was supported by the research scholarship prof. Elizabeta Topić, provided by the Croatian Society of Medical Biochemistry and Laboratory Medicine.

Potential conflict of interest

None declared.

Data availability statement

All data generated and analyzed in the presented study are included in this published article.

References CharleboisEPantopoulosK. Nutritional Aspects of Iron in Health and Disease. Nutrients. 2023;15:2441. 10.3390/nu1511244137299408 GanzTNemethE. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology (Am Soc Hematol Educ Program). 2011;2011:538–42. 10.1182/asheducation-2011.1.53822160086 CamaschellaCNaiASilvestriL. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105:260–72. 10.3324/haematol.2019.23212431949017 NemethEGanzT. Hepcidin and Iron in Health and Disease. Annu Rev Med. 2023;74:261–77. 10.1146/annurev-med-043021-03281635905974 TehMRArmitageAEDrakesmithH. Why cells need iron: a compendium of iron utilisation. Trends Endocrinol Metab. 2024;35:1026–49. 10.1016/j.tem.2024.04.01538760200 YiannikouridesALatunde-DadaGO. A Short Review of Iron Metabolism and Pathophysiology of Iron Disorders. Medicines (Basel). 2019;6:85. 10.3390/medicines603008531387234 WardDGRobertsKBrookesMJJoyHMartinAIsmailT Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol. 2008;14:1339–45. 10.3748/wjg.14.133918322945 DiepeveenLELaarakkersCMMMartosGPawlakMEUguzFFVerberneK Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material. Clin Chem Lab Med. 2019;57:864–72. 10.1515/cclm-2018-078330485171 HuangYCaoDChenZChenBLiJWangR Iron intake and multiple health outcomes: Umbrella review. Crit Rev Food Sci Nutr. 2023;63:2910–27. 10.1080/10408398.2021.198286134583608 EstêvãoDda Cruz-RibeiroMCardosoAPCostaAMOliveiraMJDuarteTL Iron metabolism in colorectal cancer: a balancing act. Cell Oncol (Dordr). 2023;46:1545–58. 10.1007/s13402-023-00828-337273145 SornjaiWNguyen Van LongFPionNPasquerASaurinJCMarcelV Iron and hepcidin mediate human colorectal cancer cell growth. Chem Biol Interact. 2020;319:109021. 10.1016/j.cbi.2020.10902132092301 World Health Organization. GLOBOCAN Cancer Today Data 2022. Available from: https://gco.iarc.fr/today/home. Accessed December 6th, 2024. GaoYWangJZhouYShengSQianSYHuoX. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Sci Rep. 2018;8:2732. 10.1038/s41598-018-21048-y29426902 BanjariIHjartakerA. Dietary sources of iron and vitamin B12: Is this the missing link in colorectal carcinogenesis? Med Hypotheses. 2018;116:105–10. 10.1016/j.mehy.2018.05.00329857891 SimundicAMBoleniusKCadamuroJChurchSCornesMPvan Dongen-LasesEC Joint EFLM-COLABIOCLI Recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56:2015–38. 10.1515/cclm-2018-060230004902 RolicTMandicSLukicIHorvatVBanjariI. Verification of the Automated ELISA Assay for Hepcidin-25 in Human Serum. SEEMEJED. 2023;7:36–41. 10.26332/seemedj.v7i1.266 GvirtzmanRLivovskyDMTahoverEGoldinEKoslowskyB. Anemia can predict the prognosis of colorectal cancer in the pre-operative stage: a retrospective analysis. World J Surg Oncol. 2021;19:341. 10.1186/s12957-021-02452-734876136 WeissGGanzTGoodnoughLT. Anemia of inflammation. Blood. 2019;133:40–50. 10.1182/blood-2018-06-85650030401705 PusatciogluCKNemethEFantuzziGLlorXFreelsSTussing-HumphreysL Systemic and tumor level iron regulation in men with colorectal cancer: a case control study. Nutr Metab (Lond). 2014;11:21. 10.1186/1743-7075-11-2124872837 GalettiVStoffelNUSieberCZederCMorettiDZimmermannMB. Threshold ferritin and hepcidin concentrations indicating early iron deficiency in young women based on upregulation of iron absorption. EClinicalMedicine. 2021;39:101052. 10.1016/j.eclinm.2021.10105234401687 GackowskiDKruszewskMBanaszkiewiczZJawienAOlinskiR. Lymphocyte labile iron pool, plasma iron, transferrin saturation and ferritin levels in colon cancer patients. Acta Biochim Pol. 2002;49:269–72. 10.18388/abp.2002_384512136950 Ramírez-CarmonaWDiaz-FabregatBYuri YoshigaeAMusa de AquinoAScaranoWRde Souza CastilhoAC Are Serum Ferritin Levels a Reliable Cancer Biomarker? A Systematic Review and Meta-Analysis. Nutr Cancer. 2022;74:1917–26. 10.1080/01635581.2021.198299634607491 Di GraziaADi FuscoDFranzeEColellaMStrimpakosGSalvatoriS Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial-Mesenchymal Transition and Correlates with Progression of the Disease. Cancers (Basel). 2022;14: 10.3390/cancers1421529436358713 SchwartzAJGoyertJWSolankiSKerkSAChenBCastilloC Hepcidin sequesters iron to sustain nucleotide metabolism and mitochondrial function in colorectal cancer epithelial cells. Nat Metab. 2021;3:969–82. 10.1038/s42255-021-00406-734155415 TortiSVManzDHPaulBTBlanchette-FarraNTortiFM. Iron and Cancer. Annu Rev Nutr. 2018;38:97–125. 10.1146/annurev-nutr-082117-05173230130469 AksanAFarragKAksanSSchroederOSteinJ. Flipside of the Coin: Iron Deficiency and Colorectal Cancer. Front Immunol. 2021;12:635899. 10.3389/fimmu.2021.63589933777027 LinFTuffourAHaoGPeprahFAHuangAZhouY Distinctive modulation of hepcidin in cancer and its therapeutic relevance. Front Oncol. 2023;13:1141603. 10.3389/fonc.2023.114160336895478 CaoHWangCChaiRDongQTuS. Iron intake, serum iron indices and risk of colorectal adenomas: a meta-analysis of observational studies. Eur J Cancer Care (Engl). 2017;26: 10.1111/ecc.1248626956572 PhillipsEHorniblowRDPooleVBedfordMWardDGKirkhamAJ A potential role for hepcidin in obesity-driven colorectal tumorigenesis. Oncol Rep. 2018;39:392–400. 10.3892/or.2017.606229115635
" ["journals_volume"]=> string(2) "35" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030703" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-35-3-030703" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2025.030703" ["journals_article_pubdate"]=> string(10) "2025-10-15" ["journals_article_title"]=> string(86) "Serum hepcidin concentration is lower in advanced stages of sporadic colorectal cancer" ["journals_article_author"]=> string(93) "Tara Rolić, Sanja Mandić, Mazyar Yazdani, Marina Ferenac Kiš, Sonia Distante, Ines Banjari" ["journals_article_author_country"]=> string(15) "Croatia, Norway" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(54) "anemia, colorectal cancer, hepcidin, homeostasis, iron" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "2396" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "9" ["meta_title"]=> string(86) "Serum hepcidin concentration is lower in advanced stages of sporadic colorectal cancer" ["meta_desc"]=> string(86) "Serum hepcidin concentration is lower in advanced stages of sporadic colorectal cancer" ["meta_keyw"]=> string(54) "anemia, colorectal cancer, hepcidin, homeostasis, iron" ["created"]=> string(19) "2025-10-08 10:15:32" ["modified"]=> string(19) "2025-10-15 10:18:03" } [58]=> object(stdClass)#107 (35) { ["journals_id"]=> string(4) "1190" ["journals_xml"]=> string(75456) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-35-3-030702 10.11613/BM.2025.030702 Original articles Cardiac biomarkers in term newborns with common pathological conditions during the first 24 hours postpartum KarlovićHelena*1Jerković RagužMarjana23MikulićIvanka45MikulićVinka45TomićVajdana36 Clinic for Children Diseases, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina Department of Neonatology, Clinic for Children Diseases, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina Department of Laboratory Diagnostics, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina Faculty of Pharmacy, University of Mostar, Mostar, Bosnia and Herzegovina Department of Obstetrics and Gynecology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina Corresponding author: helena.karlovic@hotmail.com

Author contributions

H Karlović: Conceptualization, Data duration, Investigation, Writing; M Jerković Raguž: Conceptualization, Data duration, Resources, Supervision, Validation; I Mikulić: Investigation, Resources, Supervision, Methodology; Mikulić: Investigation, Resources, Supervision, Methodology; V Tomić: Resources, Project administration, Validation.

15082025 15102025 35 3 030702 2609202413062025 ©Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• Creatine-kinase (CK) activity was higher in healthy newborns than in those with jaundice, infection, or both

• CK was lower in neonates with infection than in those with neurological abnormalities

• N-terminal pro b-type natriuretic peptide (NT-proBNP), high sensitivity troponin I (hs-TnI) concentrations, and CK- myocardial band activity showed no differences between the study groups

• No biomarkers differences were found by gender or heart ultrasound in the first day

Introduction

Cardiac biomarkers may help diagnose and monitor different neonatal conditions, but their concentrations are still underexplored in common pathologies diagnosed within the first day. This study compared N-terminal pro b-type natriuretic peptide (NT-proBNP), high sensitivity troponin I (hs-TnI), creatine kinase (CK), and its isoenzyme creatine kinase-myocardial band (CK-MB) concentrations and activities, measured within the first 24 hours (h) postpartum, between the healthy term neonates and those with jaundice, perinatal infection, transient neurological abnormalities (TNA), and heart ultrasound abnormalities.

Materials and methods

The study included 100 term newborns, whose cardiac biomarkers’ concentrations were determined from the serum within 24 h postpartum on the Alinity ci analyzer (Abbott, Chicago, USA). The Mann-Whitney and Kruskal-Wallis tests, performed in SPSS Statistics v. 25.0 (IBM Corp., Armonk, USA), were used to test the significance of differences between the study groups, with P < 0.05 indicating significance.

Results

Within first 24 h postpartum healthy newborns had significantly higher CK activities compared to those with jaundice (P = 0.047), perinatal infection (P = 0.012), or combination of both (P = 0.017). Lower CK activities were demonstrated in perinatal infection compared to TNA (P = 0.041). Other biomarkers’ concentrations did not differ between the study groups. No significant differences were found in cardiac biomarkers’ concentrations regarding gender or heart ultrasound findings.

Conclusions

During the first 24 h postpartum, only CK activities differed between healthy newborns and those with the common pathologic conditions, being lower in the newborns with jaundice and/or infection. Analogous differences were present between newborns with infection and those with TNA.

Keywords: cardiac biomarkersneonatal jaundiceperinatal infectionterm neonatetransient neurological abnormalities
Introduction

In neonates, the transition from fetal to the neonatal hemodynamics involves unique physiological changes: closure of natural heart shunts, a decrease in pulmonary artery pressure, and an increase in systemic circulatory pressure (1). The transition in perinatal circulation and the shift of blood flow from the placenta to the lungs elevate ventricular volume and pressure load. As B-type natriuretic peptide (BNP) and its inactive by-product, N-terminal pro b-type natriuretic peptide (NT-proBNP) are indicators of cardiac volume expansion and pressure overload, they are consequently synthesized and released from myocardial cells into the circulation after birth (2, 3). Therefore, within the first 24 hours (h) of life, NT-proBNP concentration may be elevated, with a tendency for a rapid decline during the first week, with gradual decrease over time and stabilization during childhood (4).

High sensitivity troponin I (hs-TnI), creatine kinase (CK), and its isoenzyme creatine kinase-myocardial band (CK-MB) are well known markers of myocardial damage. The concentrations of these cardiac biomarkers are commonly elevated at birth, which can be attributed to possible transient hypoxia associated with the process of delivery, combined with the transition of the cardiorespiratory system to postnatal life. The decline in hs-TnI, CK, and CK-MB concentrations and activities over time follows a pattern similar to NT-proBNP, with their concentrations decreasing in the first days of life until they reach stable lower concentrations that persist throughout adult life (4, 5).

In most healthy newborns, the transition from fetal to neonatal circulation, as described above, along with the closure of the ductus arteriosus and foramen ovale (FO), is expected within the first 48 h of life (6). However, in some newborns, these openings remain persistently open, resulting in patent foramen ovale (PFO) and patent ductus arteriosus (PDA) (7). Neonates with PDA have tendency to have significantly higher NT-proBNP and troponin concentrations which is associated with an increase in oxygen demand of the cardiac cells and positively correlates to hemodynamic severity of PDA (4, 8). It was observed that low NT-proBNP concentration or a decrease in its concentration, could indicate closure of the ductus arteriousus, while higher concentrations were associated with later PDA (4).

As previous research shows, various pathological conditions of the neonatal age are proven to influence the values ​​of neonatal cardiac biomarkers. It has been shown that perinatal asphyxia (PA) and its complications, such as hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia, and persistent pulmonary hypertension of the newborn, lead to a significant increase in NT-proBNP concentrations. Cardiovascular dysfunction is a common outcome in term infants following PA, as it causes injury of many organs, including the heart (9). As it is known, hs-TnI, CK and CK-MB are indicators of cardiac injury, and higher concentrations of these biomarkers have been also established in neonates with HIE (10, 11). Studies have shown a tendency for NT-proBNP concentrations to increase in neonates with pulmonary hypertension or cardiomyopathies, neonatal sepsis, and those with various forms of congenital heart disease (CHD) (4, 12-15).

The role of hs-TnI in the diagnosis and monitoring of CHD remains conflicting based on current research findings. However, it has been observed that hs-TnI concentrations are significantly higher in severe cases of respiratory distress compared to healthy groups. No significant differences between healthy neonates and those with CHD or among different CHD groups have been established when it comes to CK-MB activities. However, CK-MB activities were notably higher in CHD neonates who underwent surgical correction during the neonatal hospitalization period compared to those who didn’t (4). Furthermore, there is evidence suggesting that CK-MB could serve as a predictor of mortality in neonatal shock (16). While existing literature describes variations in cardiac biomarker values concerning pathological conditions in neonates, gender-based differences have generally not been significant in prior studies (3, 17).

As it’s seen above, current knowledge indicates that cardiac biomarkers could be utilized to diagnose and monitor certain cardiac and non-cardiac pathological conditions (16, 18, 19). However, the available literature does not sufficiently address the relationship between cardiac biomarkers’ concentrations and certain pathological conditions commonly encountered within the 24 h postpartum, such as neonatal jaundice, perinatal infection, transient neurological abnormalities (TNA), and heart ultrasound abnormalities (2, 10, 20, 21). Considering the aforementioned, and described variations in cardiac biomarkers’ concentrations in the early neonatal age, determining their concentrations during this period seemed necessary in order to make a distinction between expected cardiac biomarkers’ concentrations in the mentioned pathological conditions, and the concentrations that could be potentially associated with more serious pathological conditions in neonate within the first 24 h postpartum (4, 5, 9, 10, 12-16). This study compared NT-proBNP, hs-TnI, CK, and CK-MB concentrations and activities, measured within the first 24 h postpartum, between the healthy term neonates and those with jaundice, perinatal infection, TNA, and heart ultrasound abnormalities. We consider that term neonates diagnosed with described neonatal pathologies tend to have higher cardiac biomarkers’ concentrations compared to healthy term neonates in the first 24 h of life.

Materials and methods Subjects

This study was conducted in University Clinical Hospital Mostar (UCHM) from January 2023 to March 2024. The study encompassed term neonates in first 24 h of life who were born at a gestational age (GA) from 37+0/7 to 41+6/7 weeks at the Clinic for Gynecology and Obstetrics of UCHM. Preterm newborns, newborns with chromosomal abnormalities, and resuscitated newborns with poor Apgar scores (< 8) were excluded from this study. A preterm newborn is considered to be a newborn GA less than 37+0/7 weeks. It involved only neonates whose parents consented to participate in the research, confirmed by signing a written informed consent. In addition to healthy neonates, the study included those with various pathological conditions, with diagnoses made based on clearly defined guidelines. The diagnosis of neonatal jaundice was defined according to the National Institute for Health and Care Excellence (NICE) guidelines from 2016, which implied a total serum bilirubin concentration > 100 µmol/l in neonates immediately after birth, > 125 µmol/L at 6 h, > 150 µmol/L at 12 h, > 175 µmol/L at 18 h, and > 200 µmol/L at 24 h of life (22). Transient neurological abnormalities considered transient deviations in newborns’ muscle tone, such as hypertonia, hypotonia, and variable tone (23). Minor physical malformations included preauricular appendages, syndactyly, and low-set ears (24). Exclusion criteria for pregnant women were any pathological conditions that have been proven to affect fetal growth and development such as hypertension, diabetes mellitus, autoimmune disease, etc. (25). Mothers’ and newborns’ data were taken from the hospital information system and delivery register.

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Commission University Clinical Hospital Mostar (call number 1071/22, dated 03.07.2022).

Methods

In this study venous blood samples were used for laboratory analysis, as they are previously taken for routine laboratory tests (required by a neonatologist during the first 24 h of a newborn’s life), as part of the post-delivery examination. After the routine analyses requested by neonatologists were completed, the remaining serum was used for the analysis of cardiac biomarkers in this study. No additional blood samples were taken for analyses during the study. Median cubital vein or dorsal hand veins were most frequently used for venipuncture. Venous blood samples were collected in Micro sample tubes with gel (Sarstedt, Nümbrecht, Germany; volume 1.3 mL) with Micro needles 23 G (Sarstedt, Nümbrecht, Germany). The collected samples were centrifuged at 2320xg for 10 minutes on Eppendorf Centrifuge 5804R (Germany) and stored at - 80 °C until analysis. Concentrations of NT-proBNP and hs-TnI, as well as CK and CK-MB activities were measured on Alinity ci analyzer (Abbott, Chicago, USA). The chemiluminescent microparticle immunoassay (CMIA) was used to determine NT-proBNP and hs-TnI concentrations. Activity of CK was determined using a kinetic ultraviolet (UV) test, and CK-MB using an enzyme immunoinhibition test.

Echocardiography was performed during the first 24 h of the newborn’s life, when the neonatologist observed a heart murmur or any other clinical sign that could indicate the presence of cardiac pathology (26, 27). A specified examination has been performed on the General Electric Vivid T8 (GE HealthCare, Chicago, USA).

Statistical analysis

The Mann-Whitney and Kruskal-Wallis tests, performed in SPSS Statistics v. 25.0 (IBM Corp., Armonk, USA), were used to test the significance of differences between the study groups, with P < 0.05 indicating significance. Post-hoc testing included pairwise comparisons using Dunn’s method with Bonferroni correction. Results are expressed as absolute frequency, median, minimum and maximum.

Results

This study included total of 100 term newborns, encompassing 26 healthy newborns, and 74 newborns with pathological conditions, primarily jaundice or perinatal infection (Table 1). Heart ultrasound was performed on 71 newborns, and abnormalities were established in 55 of them, most commonly FO (Table 1). Regarding heart ultrasound, the category “other diagnoses” included newborns with diagnoses of ventricular septal defect (VSD) and atrial septal defect (ASD).

Distribution of participants based on pathological conditions and heart ultrasound findings.
N*
Pathological conditions
Neonatal jaundice 26
Perinatal infection 19
Neonatal jaundice and perinatal infection 16
TNA 7
Minor physical malformations 6
Heart ultrasound
Normal 16
FO 37
FO and PDA 14
Other diagnoses 4
*absolute frequency. TNA - transient neurological abnormalities. FO - foramen ovale. PDA - patent ductus arteriousus.

Regarding laboratory findings, a significant difference was observed for CK activities (Table 2). Healthy newborns had significantly higher CK activities compared to those with jaundice (P = 0.047), perinatal infection (P = 0.012), and neonates who had both jaundice and perinatal infection (P = 0.017) within the first 24 h postpartum. Additionally, it was found that neonates with perinatal infection have significantly lower CK activities compared to neonates with TNA (P = 0.041) in the first day of life. Other biomarkers’ concentrations did not differ between the study groups. Differences based on gender, as well as heart ultrasound findings within the first 24 h of neonatal life, were not significant for any biomarker (Table 2).

Neonatal cardiac biomarkers’ concentrations and activities ​​according to gender, pathological conditions and heart ultrasound findings in the first 24 h postpartum
N* NT-proBNP(ng/L) hs-TnI(ng/L) CK-MB(U/L) CK(U/L)
Gender
Male 59 3181(621-16,359) 13(2-230) 41(41-16) 397(140-2661)
Female 41 3040(889-10,114) 18(1-222) 39(39-21) 437(133-2502)
P value 0.372 0.360 0.599 0.866
Pathological condition
Healthy newborns 26 3376(1018-10,395) 17(3-95) 49(21-123) 569(151-2502)
Neonatal jaundice 26 3622(621-16,359) 13(3-222) 40(16-176) 383(137-1523)
Perinatal infection 19 2985(1015-12,663) 14(1-41) 35(18-118) 292(140-1347)
Neonatal jaundice and perinatal infection 16 2162(889-12,993) 20(3-230) 42(19-108) 359(133-1302)
TNA 7 3882(1738-8760) 11(3-18) 41(22-61) 552(341-2661)
Minor physical malformations 6 2548(729-8099) 25(9-74) 44(27-76) 337(246-1460)
P value 0.847 0.369 0.858 0.033
Heart ultrasound
Normal 16 3902(1263-10,395) 14(1-52) 44(16-176) 515(164-1460)
FO 37 2211(621-12,663) 17(3-230) 36(21-97) 338(133-1615)
FO and PDA 14 4075(1914-16,359) 14(3-222) 40(18-108) 510(164-2661)
Other diagnoses 4 5949(2559-8698) 7(4-37) 48(19-90) 365(328-1103)
P value 0.087 0.514 0.719 0.227
*absolute frequency. Result are shown as median (min-max), P value is assessed by Mann-Whitney (gender) or Kruskal-Wallis test. TNA - transient neurological abnormalities. NT-proBNP - N-terminal pro b-type natriuretic peptide. hs-TnI - high sensitivity troponin I. CK - creatine kinase. CK-MB - creatine kinase-myocardial band. FO - foramen ovale. PDA - patent ductus arteriousus.
Discussion

Overall, this study emphasizes that healthy neonates have higher CK activities compared to neonates with jaundice, perinatal infection, or both jaundice and perinatal infection within the first 24 h postpartum. At the same time, neonates with perinatal infection have lower CK activities compared to those with TNA in the first day of life. Concentrations of NT-proBNP, hs-TnI, and CK-MB activity did not differ between the neonates with different pathologic conditions or in comparison with the healthy neonates. Additionally, there was no difference in the concentrations of any cardiac biomarker based on gender or heart ultrasound findings within the first 24 h of neonatal life.

Liu et al. reported significantly increased serum CK activities in neonatal jaundice patients within the bacterial infection group, with a positive correlation to inflammatory markers (20). Their study included only newborns with jaundice and compared those with and without infection, ultimately suggesting that bacterial infection might contribute to myocardial dysfunction in this population. In contrast, our results did not show a significant difference in CK activities between jaundiced newborns with or without perinatal infection. These differing outcomes may be attributed to several factors, including the larger sample size and the broader age range (up to 28 days) in the study by Liu et al., compared to our study, which was limited to the first 24 h postpartum.

Elevated concentrations of unconjugated bilirubin may contribute to myocardial injury in neonates through multiple mechanisms, including alterations in membrane permeability, direct interference with mitochondrial function, oxidative stress, and tissue hypoxia (28). Despite these potential effects of hyperbilirubinemia on cardiac muscle, no increase in NT-proBNP, hs-TnI, CK, or CK-MB concentrations was observed in this study group. Regarding hs-TnI, our findings are consistent with those of Taksande et al., who observed no significant difference in troponin I concentrations or cardiac structure between healthy neonates and those with unconjugated hyperbilirubinemia (21). Although the age range in their study was broader, the comparable results may indicate that neonatal jaundice is not necessarily associated with myocardial injury in the early postnatal period.

Conducted study also demonstrates higher CK activities in healthy newborns compared to those with perinatal infection. Unfortunately, the relationship between this cardiac biomarker and perinatal infection has not yet been investigated, which opens up opportunities for further research.

The recent studies have shown that NT-proBNP production is enhanced by inflammatory and endothelial mediators as part of cardiovascular dysfunction occurrence in neonatal sepsis (15). As such, they suggest that NT-proBNP could find its purpose as an indicator of neonatal sepsis and its outcome (2, 13-15). However, in neonates with perinatal infection, higher NT-proBNP concentrations were not observed in this study. During the early stages, inflammation associated with sepsis causes a slight rise in NT-proBNP concentrations, likely as a result of the release of small amounts of BNP stored in granules. However, if the condition progresses to septic shock and myocardial dysfunction, this increase becomes more pronounced due to the de novo synthesis of the peptide and rapid gene expression (14). Since NT-proBNP concentrations in this study were measured within the first 24 h of life, this could potentially explain the absence of a marked increase in NT-proBNP in examined neonates.

Although this study found that neonates with perinatal infection have lower CK activities compared to neonates with TNA within the first 24 h of life, comparable results have not been documented in previous studies. However, it has been shown that neonates with neurological deviations may have elevated CK activities, especially in first days of life (10). Numerous studies have also obtained that neonates with neurological deficits also tend to have elevated NT-proBNP, hs-TnI, and CK-MB concentrations (9, 11, 29). Conversely, this study did not detect elevated concentrations of the mentioned biomarkers during the first day of life in newborns with neurological deficits.

Contrary to previous findings, conducted study did not reveal differences in cardiac biomarkers’ concentrations between neonates with normal heart ultrasound and those with ultrasound abnormalities (FO, PDA, VSD, ASD). According to many other studies, including meta-analysis by Teixeira et al., higher NT-proBNP concentrations were recorded in neonates with PDA compared to the group in which PDA was naturally closed, including positive correlation to hemodynamic severity of PDA (2, 4, 18). Vaisbourd et al. also demonstrated higher troponin concentrations in preterm neonates who have hemodynamically significant PDA compared with nonsignificant PDA (8).​Nevertheless, the lack of differences in cardiac biomarkers’ concentrations presented in the conducted study are not uncommon. Even studies that used the same research kits obtained somewhat different results. Although, such an occurrence has not been fully explained, it is believed that the age of newborns after birth plays a crucial role in the diagnosis of neonatal CHD and that it can be attributed to significant changes in NT-proBNP concentrations within the first few days of life (2). Additional studies are needed to better clarify the role of neonatal NT-proBNP concentrations in assessing the presence and severity of CHD.

Furthermore, the study indicates that there were no differences in cardiac biomarkers’ concentrations between genders, whether or not pathological conditions or heart ultrasound abnormalities were present. Similar results are shown in the existing literature, with the emphasis that these studies often used broader timeframes within the neonatal period for measuring biomarker values or included fewer participants compared to this study (3, 17).

A key limitation of the study is the overall small sample size, particularly when compared to previous studies involving larger number of neonates (2-4, 6, 21, 30). This limitation is further emphasized by the very small number of participants in certain subgroups, which should be taken into account when interpreting the results.

In conclusion, this study suggest that, within the first 24 h of life, CK activities may vary depending on neonatal health status, being lower in newborns with jaundice, perinatal infection, or both, compared to healthy controls, as well in newborns with infection compared to those with TNA, while other cardiac biomarkers remained consistent across the study groups. These results emphasize the importance of timing in cardiac biomarkers’ evaluation and highlight the need for further studies to clarify the early postnatal dynamics of cardiac biomarkers in various neonatal conditions.

Acknowledgments

We would like to express our gratitude to all those who helped us during the writing of this manuscript. Thanks to all the peer reviewers for their opinions and suggestions.

Potential conflict of interest

None declared.

Data availability statement

The data generated and analyzed in the presented study are available from the corresponding author on request.

References ChakkarapaniAARoehrCCHooperSBte PasABGuptaS. Transitional circulation and hemodynamic monitoring in newborn infants. Pediatr Res. 2024;96:595–603. 10.1038/s41390-022-02427-836593283 XieHHuoYChenQHouX. Application of B-Type Natriuretic Peptide in Neonatal Diseases. Front Pediatr. 2021;9:767173. [cited 2024 July 20] Available from https://pmc.ncbi.nlm.nih.gov/articles/PMC8689063/ [Internet]10.3389/fped.2021.76717334950618 ChristouEIliodromitiZPouliakisASokouRZantiotouMPetropoulouC NT-proBNP Concentrations in the Umbilical Cord and Serum of Term Neonates: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2022;12:1416. 10.3390/diagnostics1206141635741227 TeixeiraRNevesAGuimarãesH. Cardiac biomarkers in neonatology: BNP/NTproBNP, troponin I/T, CK-MB and myoglobin – a systematic review. J Pediatr Neonat Individual Med [Internet]. 2017;6:e060219. [cited 2024 July 20] Available from https://jpnim.com/index.php/jpnim/article/view/060219/456 KarlénJKarlssonMEliassonHBonamyAEHalvorsenCP. Cardiac Troponin T in Healthy Full-Term Infants. Pediatr Cardiol. 2019;40:1645–54. 10.1007/s00246-019-02199-931489446 YuanZZhangLZLiBChungHTJiangJXChiangJY Investigation of echocardiographic characteristics and predictors for persistent defects of patent foramen ovale or patent ductus arteriosus in Chinese newborns. Biomed J. 2021;44:209–16. 10.1016/j.bj.2019.12.00733867286 ConnuckDSunJPSuperDMKirchnerHLFradleyLGHarcar-SevcikRA Incidence of patent ductus arteriosus and patent foramen ovale in normal infants. Am J Cardiol. 2002;89:244–7. 10.1016/S0002-9149(01)02214-711792356 VaisbourdYSharifDRiskinAYanivLDinurGAmenK The effect of patent ductus arteriosus on coronary artery blood flow in premature infants: a prospective observational pilot study. J Perinatol. 2020;40:1366–74. 10.1038/s41372-020-0622-432080335 SweetmanDArmstrongKMurphyJFAMolloyEJ. Cardiac biomarkers in neonatal hypoxic ischaemia. Acta Paediatr. 2012;101:338–43. 10.1111/j.1651-2227.2011.02539.x22118561 Sandoval KaramianAGMercimek-AndrewsSMohammadKMolloyEJChangTChauV Neonatal encephalopathy: Etiologies other than hypoxic-ischemic encephalopathy. Semin Fetal Neonatal Med. 2021;26:101272. [cited 2024 July 20] Available from https://www.sciencedirect.com/science/article/abs/pii/S1744165X21000809 [Internet]10.1016/j.siny.2021.10127234417137 WojnarowiczOBaumertM. Selected cardiac biomarkers in newborns with perinatal asphyxia symptoms. Pediatr Med Rodz. 2022;18:130–3. 10.15557/PiMR.2022.0018 ClausenHNorénEValtonenSKoivuASairanenMLiubaP. Evaluation of Circulating Cardiovascular Biomarker Levels for Early Detection of Congenital Heart Disease in Newborns in Sweden. JAMA Netw Open. 2020;3:e2027561. [cited 2024 July 20] Available from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2773467 [Internet]10.1001/jamanetworkopen.2020.2756133263763 DegerİCeylanA. Diagnostic and Prognostic Value of Serum NT-ProBNP in the Diagnosis of Neonatal Sepsis. East J Med. 2022;27:47–52. 10.5505/ejm.2022.88156 OkurNBuyuktiryakiMUraşNOncelMYHalilHIşıkŞ Role of N-Terminal Pro-brain Natriuretic Peptide in the Early Diagnosis of Neonatal Sepsis. J Pediatr Infect Dis. 2019;14:228–34. 10.1055/s-0039-1692341 YangCMaJGuoLLiBWangLLiM NT-Pro-BNP and echocardiography for the early assessment of cardiovascular dysfunction in neonates with sepsis. Medicine (Baltimore). 2022;101:e30439. 10.1097/MD.000000000003043936123906 ThakkarTSoodKSodhiM. Creatine kinase-myocardial band (CK-MB) in neonatal shock and its correlation with inotropic support and outcome. J Cardiovasc Dis Res. 2023;14:1252–8. DongKXingJDaiYSongXLiuJFuM Age- and sex-specific upper reference limits for cardiac biomarkers in Chinese children and adolescents: a prospective study. Sci Rep. 2024;14:28295. [cited 2025 January 07] Available from https://www.nature.com/articles/s41598-024-77153-8 [Internet]10.1038/s41598-024-77153-839550417 FritzA-SKellerTKribsAHünselerC. Diseases associated with prematurity in correlation with N-terminal pro-brain natriuretic peptide levels during the early postnatal life. Eur J Pediatr. 2023;182:3075–82. 10.1007/s00431-023-04973-737072630 de Freitas NakataKCda Silva PereiraPPSalgado RiverosB. Creatine kinase test diagnostic accuracy in neonatal screening for Duchenne Muscular Dystrophy: A systematic review. Clin Biochem. 2021;98:1–9. 10.1016/j.clinbiochem.2021.09.01034626608 LiuYSunXWangYXingCLiLZhouS. Evaluation of Associated Markers of Neonatal Pathological Jaundice Due to Bacterial Infection. Iran J Public Health. 2021;50:333–40. 10.18502/ijph.v50i2.539433747997 Taksande AM, Pujari D. Evaluation of cardiac function in neonates with unconjugated hyperbilirubinemia. Pediatr Neonat Individ Med [Internet]. 2022 [cited 2024 july 20];11:e110103. Available from: https://jpnim.com/index.php/jpnim/article/view/e110103. AmosRCJacobHLeithW. Jaundice in newborn babies under 28 days: NICE guideline 2016 (CG98). Arch Dis Child Educ Pract Ed. 2017;102:207–9. 10.1136/archdischild-2016-31155628179382 StraathofEJMHeinemanKRHamerEGHadders-AlgraM. Patterns of atypical muscle tone in the general infant population: prevalence and associations with perinatal risk and neurodevelopmental status. Early Hum Dev. 2021;152:105276. [cited 2024 July 20] Available from https://www.sciencedirect.com/science/article/pii/S0378378220307805 [Internet]10.1016/j.earlhumdev.2020.10527633220644 Grubeša RagužSJerković RagužMBrzicaJDžidaSMikulićSKolobarićA Meaning and clinical interest of minor malformations and normal variants in neonatology. Balkan J Med Genet. 2024;27:37–42. 10.2478/bjmg-2024-001039263644 TsikourasPAntsaklisPNikolettosKKotanidouSKritsotakiNBothouA Diagnosis, Prevention, and Management of Fetal Growth Restriction (FGR). J Pers Med. 2024;14:698. 10.3390/jpm1407069839063953 McNamaraPJJainAEl-KhuffashAGiesingerRWeiszDFreudL Guidelines and Recommendations for Targeted Neonatal Echocardiography and Cardiac Point-of-Care Ultrasound in the Neonatal Intensive Care Unit: An Update from the American Society of Echocardiography. J Am Soc Echocardiogr. 2024;37:171–215. 10.1016/j.echo.2023.11.01638309835 YoonSAHongWHChoHJ. Congenital heart disease diagnosed with echocardiogram in newborns with asymptomatic cardiac murmurs: a systematic review. BMC Pediatr. 2020;20:322. 10.1186/s12887-020-02212-832605548 ChenZZhangSFangAShaoJShenHSunB Early changes in left ventricular myocardial function by 2D speckle tracking layer-specific technique in neonates with hyperbilirubinemia. Quant Imaging Med Surg. 2022;12:796–809. 10.21037/qims-21-19734993119 VijlbriefDCBendersMJNLKempermanHvan BelFde VriesWB. Use of cardiac biomarkers in neonatology. Pediatr Res. 2012;72:337–43. 10.1038/pr.2012.8822797141 TranKHVo-VanNLNguyen-ThiKHLe-ThiPANguyenHS. Neonatal Morbidity and Mortality in a Neonatal Unit in a Vietnamese Hospital. Iran J Neonatol. 2022;13:65–71.
" ["journals_volume"]=> string(2) "35" ["journals_issue"]=> string(1) "3" ["journals_fpage"]=> string(1) "0" ["journals_lpage"]=> string(1) "0" ["journals_elocationID"]=> string(6) "030702" ["journals_title"]=> string(16) "Biochemia Medica" ["journals_article_id_publisher_id"]=> string(14) "bm-35-3-030702" ["journals_article_id_doi"]=> string(23) "10.11613/BM.2025.030702" ["journals_article_pubdate"]=> string(10) "2025-10-15" ["journals_article_title"]=> string(108) "Cardiac biomarkers in term newborns with common pathological conditions during the first 24 hours postpartum" ["journals_article_author"]=> string(91) "Helena Karlović, Marjana Jerković Raguž, Ivanka Mikulić, Vinka Mikulić, Vajdana Tomić" ["journals_article_author_country"]=> string(0) "" ["journals_article_categories_heading"]=> string(17) "Original articles" ["journals_article_categories_subheading"]=> string(0) "" ["journals_article_kwd"]=> string(110) "cardiac biomarkers, neonatal jaundice, perinatal infection, term neonate, transient neurological abnormalities" ["journals_article_active"]=> string(1) "1" ["journals_article_view_count"]=> string(4) "5434" ["journals_article_ahead_of_print"]=> string(1) "0" ["journals_article_received"]=> string(10) "0000-00-00" ["journals_article_accepted"]=> string(10) "0000-00-00" ["journals_article_html_author_notes"]=> string(0) "" ["journals_article_html_author_email"]=> string(0) "" ["journals_article_html_abstract"]=> string(0) "" ["journals_article_html_content"]=> string(0) "" ["journals_article_html_notes"]=> string(0) "" ["journals_article_html_references"]=> string(0) "" ["journals_article_html_licence"]=> string(0) "" ["vrstni"]=> string(1) "8" ["meta_title"]=> string(108) "Cardiac biomarkers in term newborns with common pathological conditions during the first 24 hours postpartum" ["meta_desc"]=> string(108) "Cardiac biomarkers in term newborns with common pathological conditions during the first 24 hours postpartum" ["meta_keyw"]=> string(110) "cardiac biomarkers, neonatal jaundice, perinatal infection, term neonate, transient neurological abnormalities" ["created"]=> string(19) "2025-08-06 09:00:18" ["modified"]=> string(19) "2025-10-15 10:17:51" } [59]=> object(stdClass)#108 (35) { ["journals_id"]=> string(4) "1189" ["journals_xml"]=> string(127121) "
BM Biochem Med (Zagreb) Biochemia Medica Biochem. Med. (Zagreb) 1330-0962 1846-7482 Croatian Society of Medical Biochemistry and Laboratory Medicine bm-35-3-030701 10.11613/BM.2025.030701 Original articles Association of inflammatory markers with depression and anxiety in female patients with primary Sjögren’s syndrome MrsićFanika*1VukasovićInes23Tešija KunaAndrea23Ladika DavidovićBlaženka4MarkeljevićJasenka15 Department of Clinical Immunology and Rheumatology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia Department of Clinical Chemistry, Sestre milosrdnice University Hospital Center, Zagreb, Croatia School of Medicine, Catholic University of Croatia, Zagreb, Croatia Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia School of Medicine, University of Zagreb, Zagreb, Croatia Corresponding author: fmrsic@yahoo.com

Author contributions

F Mrsić: Conceptualization, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing. A Tešija Kuna: Formal analysis, Investigation, Validation, Visualization, Writing – review & editing. I Vukasović: Formal analysis, Investigation, Validation, Visualization, Writing – review & editing. B Ladika Davidović: Investigation, Validation, Writing – original draft. J Markeljević: Conceptualization, Methodology, Supervision.

15082025 15102025 35 3 030701 0902202529052025 ©Croatian Society of Medical Biochemistry and Laboratory Medicine. 2025 Croatian Society of Medical Biochemistry This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Graphical abstract

Highlights

• More than half of patients with primary Sjögren’s syndrome have depression and anxiety

• Interleukin 6 concentration is higher in primary Sjögren’s syndrome patients with either depression or anxiety

• Interleukin 6 may be a predictor of depression in patients with primary Sjögren’s syndrome

• European League Against Rheumatism Sjögren’s Syndrome Patient Reported Index (ESSPRI) for fatigue may be a predictor of anxiety in patients with primary Sjögren’s syndrome

Introduction

Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease affecting exocrine glands and is frequently accompanied by depression and anxiety. Proinflammatory cytokines, particularly interleukin 6 (IL-6), have been implicated in the pathogenesis of both pSS and mood disorders. This study aimed to assess the association between inflammatory markers, disease activity, and psychological symptoms in patients with pSS.

Materials and methods

A cross-sectional study was conducted on 60 female patients diagnosed with pSS at Sestre milosrdnice University Hospital Center between 2019 and 2021. Depression and anxiety were evaluated using the Hospital Anxiety and Depression Scale. Inflammatory biomarkers (erythrocyte sedimentation rate, rheumatoid factor, ferritin, fibrinogen, CRP, C3, C4, IL-6) and disease activity indices (ESSDAI, ESSPRI) were analyzed. Statistical analyses, including logistic regression, were applied to determine independent predictors of depression and anxiety.

Results

Depression was detected in 39/60 of patients, while 34/60 exhibited anxiety symptoms. Patients with either depression or anxiety had significantly higher IL-6 concentration (P < 0.001 and P = 0.002, respectively). Logistic regression identified IL-6 as an independent predictor of depression (OR = 3.23, 95%CI: 1.07 - 9.80, P = 0.038), while ESSPRI fatigue was a significant predictor of anxiety (OR = 2.01, 95%CI: 1.13 – 3.58, P = 0.018).

Conclusions

The findings suggest that IL-6 could be a predictor of pSS-related depression, potentially serving as a biomarker for this extraglandular manifestation and ESSPRI fatigue as a predictor for anxiety.

Keywords: anxietydepressioninflammationinterleukin 6primary Sjögren’s syndrome
Introduction

Sjögren’s syndrome (SS) is a chronic systemic, autoimmune, lymphoproliferative disease affecting exocrine glands and internal organs (1). The female-to-male ratio of SS is 9:1. It is clinically manifested as primary SS (pSS), with glandular and systemic manifestations, or secondary SS (sSS) associated with other autoimmune diseases (1). It is characterized by dryness of the mouth and eyes with the production of various autoantibodies in the blood (2). In addition to the symptoms associated with functional impairment of the glands with exocrine secretion and extraglandular symptoms, patients with pSS may also have general symptoms such as depression (3). Although the exact etiopathogenetic mechanism of SS is not known, it is believed that disturbed neuroendocrine-humoral regulation of the immune system in genetically predisposed individuals exposed to provocative factors plays a role in the development of pSS (4). Despite evidence of a strong genetic component, the interaction of the immune, endocrine and nervous systems, mediated by hormones, neurotransmitters, neuropeptides, cytokines and their receptors, is key in the development of SS (4). It is believed that the imbalance of cytokines in pSS causes gland dysfunction and systemic manifestations, which results in decreased secretory function of gland (5). In addition to symptoms associated with gland dysfunction, interleukin 6 (IL-6) may play a role in the development of depression (6). Its overexpression represents a potential biological pathway by which inflammation may contribute to symptoms of depression. There are several proposed mechanisms by which cytokines could influence the development of depression. Cytokines can activate the hypothalamic-pituitary-adrenal (HPA) axis, directly, via corticotropin-releasing hormone (CRH) or via cytokine-induced resistance of glucocorticoid receptors (7). This causes hyperactivity of the HPA axis due to impaired negative feedback. Furthermore, proinflammatory cytokines can alter monoamine neurotransmitters in different regions of the brain leading to an increase in acute phase proteins and serum concentration of IL-6 (7). This leads to a reduced availability of L-tryptophan, which is known to reduce the availability of serotonin in the central nervous system. Interleukin 6 is a proinflammatory cytokine that is activated in response to tissue injury and infection. It contributes to host defense by stimulating acute phase reactants such as C-reactive protein (CRP), ceruloplasmin, haptoglobin and ferritin. Its increased concentration was found in the saliva, tears and serum of patients with SS. Also, it was shown that concentration of IL-6 correlates with dryness of the eyes and mucous membranes, with the degree of lymphocytic infiltration of the salivary glands and with the number of extraglandular symptoms (8). Interleukin 6 mediates its biological effects through the IL-6 receptor (IL-6R). Activation of IL-6R leads to the maturation of B cells, which favors their hyperplasia and increased concentration of inflammatory reactants, which explains the proinflammatory state visible in SS (6, 9).

The most recent studies have shown an increased concentration of IL-6 in the blood of patients with depression and a positive correlation between the concentration of cytokines in the cerebrospinal fluid with disease activity in depressed patients (10, 11). Considering the above, a potential therapeutic goal could be to block IL-6 or its receptor in pSS, which would reduce systemic and local inflammation, reduce the activation of B cells and autoantibodies, and thus have a favorable effect on the local inflammatory process and systemic autoimmunity in pSS.

Depression and anxiety are common comorbidities in patients with pSS. We hypothesized that certain inflammatory markers or indicators of disease activity could potentially serve as predictors for developing these psychological symptoms. The aim of this study was to determine the association of inflammatory markers, and activity of disease with depression and anxiety in patients with pSS.

Materials and methods Subjects

This cross-sectional study included 60 female patients diagnosed with pSS. The patients were recruited from the population of patients with pSS treated at the Department of Clinical Immunology and Rheumatology, Sestre milosrdnice University Hospital Center during two years of research (from 2019 to 2021). The diagnosis of pSS was made based on the classification criteria for pSS: American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) (12). All patients with pSS fulfilled the classification criteria for pSS, which requires the presence of either anti-Ro60/SS-A and/or a positive biopsy finding of the minor labial salivary glands (focus score ≥ 1). An exclusion factor was the association or overlapping of pSS with another autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, primary biliary cirrhosis, chronic active hepatitis, Hashimoto’s thyroiditis), other acute and chronic inflammatory diseases, patients with a psychiatric diagnosis before the diagnosis of SS, patients treated with anti-inflammatory drugs, corticosteroids, antidepressants, antipsychotics, hormone replacement therapy within 6 weeks before inclusion in the trial. Disease activity and subjective complaints of patients were measured using two indices defined and validated in clinical practice; European League Against Rheumatism - EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) and EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) (13, 14). ESSDAI is a standardized instrument for the homogenous evaluation of systemic activity in order to be used as outcome criteria to evaluate primary SS in clinical trials as well in daily practice. It includes 12 different domains (i.e. organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system (PNS), central nervous system (CNS), hematological, glandular, constitutional, lymphadenopathic, biological). Disease activity is classified as low (ESSDAI < 5), moderate activity (ESSDAI 5 - 13), and high activity (ESSDAI ≥ 14). The ESSPRI scale consists of three individual 0-10 cm scales and includes a domain representing the patient’s symptoms: dryness, pain and fatigue. The total maximum score is 30, with a higher score reflecting more severe complaints. A test that can objectivize dry eye is called the Schirmer test. It measures the 5-minute wetting of standardized filter paper placed in the lower lateral part of the fornix of the eyelid and serves as an indicator of basal (anesthetized) or stimulated (non-anesthetized) tear flow. The speed of movement along the test strip is proportional to the rate of tear secretion. Schirmer test value without anesthesia of 5 mm or less in both eyes is one of the classification criteria for SS. Salivary flow measurement (sialometry) is used for assessment of dry mouth. It is used to measure the amount of saliva produced. Sialometry in SS, as one of the diagnostic criteria, collects unstimulated saliva for 15 minutes and a 5-minute saliva collection after chewing paraffin to ensure salivary stimulation. An unstimulated whole saliva flow rate of less than 0.1 mL/min is considered abnormal and is included in the criteria for SS. As a screening for the presence of clinically significant symptoms of anxiety and depression, patients completed the Hospital Anxiety and Depression Scale (HADS) (15). It is a self-report rating scale of 14 items (range 0-3) that consists of 7 items for anxiety and 7 items for depression. The score may range between 0 and 21 per subscale (0-7 absence of depression/anxiety, 8-10 mild, 11-14 moderate and 15-21 severe depression/anxiety). Before the very beginning, the research received the consent of the Ethics Committee of Sestre milosrdnice University Hospital Center (EP-18647/18-5) and the informed consent of all participants. The research was conducted in accordance with the Declaration of Helsinki.

Methods

For patients with pSS following analysis were performed: complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), antinuclear antibodies (ANA), anti-Ro60/SS-A and anti-La/SS-B antibodies, complement components (C3, C4), ferritin, fibrinogen and IL-6. Analysis was conducted in Department of Clinical Chemistry and Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center. Blood samples were collected during morning hours between 7 and 9 in standardized collection tubes: with clot activator for biochemistry, K2EDTA for complete blood count, 3.8% Na-citrate (1:5) for ESR, and 3.2% Na-citrate (1:10) for fibrinogen (all Vaccuette, Greiner Bio-One, Kremsmünster, Austria). Complete blood count was analyzed on the Sysmex XN1000 hematology analyzer (Sysmex Corp., Kobe, Japan), ESR manually with modified Westergren method and fibrinogen assay was performed on the BCS XP System hemostasis analyzer (Siemens Healthineers, Erlangen, Germany). Rheumatoid factor, CRP, C3, C4 and ferritin were measured on the Abbott Architect c8000 analyzer (Abbott Laboratories, Abbott Park, USA). Detection of ANA was performed using indirect immunofluorescence test (IIF) on Human Epithelial Type 2 cells substrate (HEp-2) (Euroimmun, Luebeck, Germany) using Olympus BX43 fluorescence microscope (Olympus, Tokyo, Japan), anti-Ro60/SS-A and anti-La/SS-B autoantibodies by chemiluminescence immunoassay (CMIA) on Bio-FLASH analyzer (Inova Diagnostics, San Diego, USA).

Interleukin 6 was determined by the electrochemiluminescence method (ECLIA) on a Cobas e601 analyzer (Roche Diagnostics, Basel, Switzerland). The specified measurement range is 1.5 to 5000 pg/mL.

Statistical analysis

In the analysis of the normality of the distribution of continuous data, the Smirnov-Kolmogorov test was used. The data were presented as median and interquartile range (IQR), with minimum and maximum if applicable. According to the obtained results, in the further analysis, appropriate non-parametric tests were used.

Antibody positivity, ESSDAI, and HADS categories were presented as the number of patients out of the total number.

Differences in continuous variables between groups were analyzed by the Mann-Whitney U test. Logistic regression analysis was done and presented with odds ratio (OD), corresponding 95% confidence interval (OR, 95%CI), and P values. All values that in univariate analysis had statistical significance for the OR were entered into a multivariate regression prediction model. Multivariate model was used for the prediction of depression and anxiety and additionally was adjusted for age.

P values less than 0.05 were considered significant. For statistical analysis, MedCalc Statistical Software version 20.008 (MedCalc Software, Ostend, Belgium) was used.

Results

The study included 60 patients diagnosed with pSS. All participants were female, with an average age of 58 years in the range of 21-75 years. Fifty-nine out of 60 patients had a positive Schirmer test, while 45/60 had an unstimulated salivary flow ≤ 0.1 mL/min. Salivary gland biopsy (≥ 1 focus/4 mm2) was positive in 26/60 patients. Descriptive statistics of examined clinical and laboratory values in patients are shown in Table 1.

Descriptive statistics of examined clinical and laboratory values in pSS patients (N = 60)
Min Max
Age (years) 58 (51-64) 21 75
ESSDAI 4 (2-7) 0 15
Duration of the disease from the onset of symptoms (years) 9 (5-13) 2 21
Duration of disease since diagnosis (years) 7 (3-10) 1 20
ESSPRI total 21 (17-23) 6 28